<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38587239</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>390</Volume><Issue>15</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>1382</StartPage><EndPage>1393</EndPage><MedlinePgn>1382-1393</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2312572</ELocationID><Abstract><AbstractText Label="BACKGROUND">The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock remains unclear.</AbstractText><AbstractText Label="METHODS">In an international, multicenter, randomized trial, we assigned patients with STEMI and cardiogenic shock to receive a microaxial flow pump (Impella CP) plus standard care or standard care alone. The primary end point was death from any cause at 180 days. A composite safety end point was severe bleeding, limb ischemia, hemolysis, device failure, or worsening aortic regurgitation.</AbstractText><AbstractText Label="RESULTS">A total of 360 patients underwent randomization, of whom 355 were included in the final analysis (179 in the microaxial-flow-pump group and 176 in the standard-care group). The median age of the patients was 67 years, and 79.2% were men. Death from any cause occurred in 82 of 179 patients (45.8%) in the microaxial-flow-pump group and in 103 of 176 patients (58.5%) in the standard-care group (hazard ratio, 0.74; 95% confidence interval [CI], 0.55 to 0.99; P&#x2009;=&#x2009;0.04). A composite safety end-point event occurred in 43 patients (24.0%) in the microaxial-flow-pump group and in 11 (6.2%) in the standard-care group (relative risk, 4.74; 95% CI, 2.36 to 9.55). Renal-replacement therapy was administered to 75 patients (41.9%) in the microaxial-flow-pump group and to 47 patients (26.7%) in the standard-care group (relative risk, 1.98; 95% CI, 1.27 to 3.09).</AbstractText><AbstractText Label="CONCLUSIONS">The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The incidence of a composite of adverse events was higher with the use of the microaxial flow pump. (Funded by the Danish Heart Foundation and Abiomed; DanGer Shock ClinicalTrials.gov number, NCT01633502.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0003-2873-5845</Identifier><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engstr&#xf8;m</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Lisette O</ForeName><Initials>LO</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiskj&#xe6;r</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangner</LastName><ForeName>Norman</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0793-7923</Identifier><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polzin</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulze</LastName><ForeName>P Christian</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemmensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panoulas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3206-6162</Identifier><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Nikos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frydland</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmvang</LastName><ForeName>Lene</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kj&#xe6;rgaard</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Rikke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf8;nborg</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Matias G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udesen</LastName><ForeName>Nanna L J</ForeName><Initials>NLJ</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junker</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terkelsen</LastName><ForeName>Christian J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Evald H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linke</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woitek</LastName><ForeName>Felix J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westenfeld</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf6;bius-Winkler</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wachtell</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravn</LastName><ForeName>Hanne B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassen</LastName><ForeName>Jens F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boesgaard</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerke</LastName><ForeName>Oke</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassager</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet (J.E.M., T.E., M.F., L.H., J.K., R.S., J.L., S.B., C.H.), and the Department of Clinical Medicine, University of Copenhagen (T.E., L.H., C.H.), Copenhagen, the Departments of Cardiology (J.E.M., L.O.J., N.L.J.U., A.J., J.F.L.), Anesthesiology and Intensive Care (H.S., H.B.R.), and Nuclear Medicine (O.G.), Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark (J.E.M., L.O.J., H.B.R., J.F.L.), Odense, the Departments of Cardiology (H.E., C.J.T., E.H.C.) and Anesthesiology and Intensive Care Medicine (S.C.), Aarhus University Hospital, Aarhus, and the Department of Cardiology, Zealand University Hospital, Roskilde (P.C., M.G.L.) - all in Denmark; the Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden (N.M., A.L., F.J.W.), the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, and the Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf (A.P., R.W.), the Department of Internal Medicine I, Cardiology, Angiology, and Intensive Medical Care, University Hospital Jena, Jena (P.C.S., S.M.-W.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, and Deutsches Zentrum f&#xfc;r Herz Kreislauf Forschung, Berlin (C.S.), the Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg (P.N.), the Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Hamburg (P.C.), the Department of Cardiology, University Hospital Bonn, Bonn (S.Z.), the Department of Cardiology and Angiology, Hannover Medical School, Hannover (A.S.), and the Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier (N.W.) - all in Germany; the Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom (V.P.); and the Greenberg Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York (K.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DanGer Shock Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01633502</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>12-04-R90-A3960-22700</GrantID><Agency>Hjerteforeningen</Agency><Country/></Grant><Grant><GrantID>Research Grant received 2018</GrantID><Agency>Abiomed</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Cardiol. 2024 Jun;21(6):355. doi: 10.1038/s41569-024-01035-9.</RefSource><PMID Version="1">38654088</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jun 27;390(24):2325-2326. doi: 10.1056/NEJMc2406255.</RefSource><PMID Version="1">38924738</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jun 27;390(24):2326-2327. doi: 10.1056/NEJMc2406255.</RefSource><PMID Version="1">38924739</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jun 27;390(24):2327. doi: 10.1056/NEJMc2406255.</RefSource><PMID Version="1">38924740</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jun 27;390(24):2327. doi: 10.1056/NEJMc2406255.</RefSource><PMID Version="1">38924741</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jun 27;390(24):2328. doi: 10.1056/NEJMc2406255.</RefSource><PMID Version="1">38924742</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jun 27;390(24):2328. doi: 10.1056/NEJMc2406255.</RefSource><PMID Version="1">38924743</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jun 27;390(24):2328-2330. doi: 10.1056/NEJMc2406255.</RefSource><PMID Version="1">38924744</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001243" MajorTopicYN="N">Assisted Circulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Jacob Eifer</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okkels Jensen</LastName><ForeName>Lisette</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Junker</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tange Veien</LastName><ForeName>Karsten</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Junker Udesen</LastName><ForeName>Nanna Louise</ForeName><Initials>NL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassager</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engstr&#xf8;m</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmvang</LastName><ForeName>Lene</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kjaergaard</LastName><ForeName>Jesper</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Rikke</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf8;nborg</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fryldand</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paulin Beske</LastName><ForeName>Rasmus</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boesgaard</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eiskj&#xe6;r</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christensen</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Evald H&#xf8;j</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terkelsen</LastName><ForeName>Christian Juhl</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linke</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woitek</LastName><ForeName>Felix J</ForeName><Initials>FJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hommel</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangner</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polzin</LastName><ForeName>Amin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Westenfeld</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulze</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moebius-Winkler</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clemmensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Westermann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panoulas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werner</LastName><ForeName>Nicos</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wachtell</LastName><ForeName>Kristian</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg Ravn</LastName><ForeName>Hanne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flensted Lassen</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Haas</LastName><ForeName>Inge</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerke</LastName><ForeName>Oke</ForeName><Initials>O</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38587239</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2312572</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37634145</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>389</Volume><Issue>14</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>1286</StartPage><EndPage>1297</EndPage><MedlinePgn>1286-1297</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2307227</ELocationID><Abstract><AbstractText Label="BACKGROUND">Extracorporeal life support (ECLS) is increasingly used in the treatment of infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality.</AbstractText><AbstractText Label="METHODS">In this multicenter trial, patients with acute myocardial infarction complicated by cardiogenic shock for whom early revascularization was planned were randomly assigned to receive early ECLS plus usual medical treatment (ECLS group) or usual medical treatment alone (control group). The primary outcome was death from any cause at 30 days. Safety outcomes included bleeding, stroke, and peripheral vascular complications warranting interventional or surgical therapy.</AbstractText><AbstractText Label="RESULTS">A total of 420 patients underwent randomization, and 417 patients were included in final analyses. At 30 days, death from any cause had occurred in 100 of 209 patients (47.8%) in the ECLS group and in 102 of 208 patients (49.0%) in the control group (relative risk, 0.98; 95% confidence interval [CI], 0.80 to 1.19; P&#x2009;=&#x2009;0.81). The median duration of mechanical ventilation was 7 days (interquartile range, 4 to 12) in the ECLS group and 5 days (interquartile range, 3 to 9) in the control group (median difference, 1 day; 95% CI, 0 to 2). The safety outcome consisting of moderate or severe bleeding occurred in 23.4% of the patients in the ECLS group and in 9.6% of those in the control group (relative risk, 2.44; 95% CI, 1.50 to 3.95); peripheral vascular complications warranting intervention occurred in 11.0% and 3.8%, respectively (relative risk, 2.86; 95% CI, 1.31 to 6.25).</AbstractText><AbstractText Label="CONCLUSIONS">In patients with acute myocardial infarction complicated by cardiogenic shock with planned early revascularization, the risk of death from any cause at the 30-day follow-up was not lower among the patients who received ECLS therapy than among those who received medical therapy alone. (Funded by the Else Kr&#xf6;ner Fresenius Foundation and others; ECLS-SHOCK ClinicalTrials.gov number, NCT03637205.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-0169-998X</Identifier><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeymer</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akin</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behnes</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassaf</LastName><ForeName>Tienush</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahabadi</LastName><ForeName>Amir Abbas</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graf</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4038-147X</Identifier><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seidler</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuster</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duerschmied</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemmensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennersdorf</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fichtlscherer</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voigt</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfarth</LastName><ForeName>Melchior</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewen</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linke</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tigges</LastName><ForeName>Eike</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruch</LastName><ForeName>Leonhard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8325-250X</Identifier><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franz</LastName><ForeName>Jutta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauten</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goslar</LastName><ForeName>Tomaz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feistritzer</LastName><ForeName>Hans-Josef</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xf6;ss</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchhof</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouarrak</LastName><ForeName>Taoufik</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desch</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From Heart Center Leipzig at University of Leipzig (H.T., H.-J.F., J.P., S.D., A.F.) and Helios Health Institute (E.K.), Leipzig, Institut f&#xfc;r Herzinfarktforschung (U.Z., T.O., S.S.) and Klinikum Ludwigshafen (U.Z.), Ludwigshafen, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim (I.A., M.B., D.D.), the West German Heart and Vascular Center, University Hospital Essen (T.R., A.A.M.), and Contilia Elisabeth-Krankenhaus, Essen (I.V.), Essen, Asklepios Clinic Langen, Langen (R.L.), University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck (I.E., T. Graf), Heart Center G&#xf6;ttingen, University Medicine G&#xf6;ttingen, G&#xf6;ttingen (T.S., A.S.), Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine (C.S.), and Unfallkrankenhaus Berlin (L.B.), Berlin, University Heart and Vascular Center Hamburg (P.C.) and Asklepios Clinic St. Georg (E.T.), Hamburg, SLK Kliniken Heilbronn, Heilbronn (M.H.), University Heart and Vascular Center Frankfurt, Frankfurt (S.F.), Heart Center Wuppertal, Witten-Herdecke University, Wuppertal (M.S.), Paracelsus Private University, Clinic Nuremberg South, Nuremberg (S.J.), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg (S.E.), Technische Universit&#xe4;t Dresden, Heart Center, Dresden (A.L.), University Clinic W&#xfc;rzburg, W&#xfc;rzburg (P.N.), University Clinic D&#xfc;sseldorf, D&#xfc;sseldorf (C.J.), Clinic Winnenden, Winnenden (J.F.), and Zentralklinik Bad Berka, Bad Berka (P.L.) - all in Germany; and University Medical Center Ljubljana, Ljubljana, Slovenia (T. Goslar).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ECLS-SHOCK Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03637205</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>Nr. 2018_A102</GrantID><Agency>Else Kr&#xf6;ner-Fresenius-Stiftung</Agency><Country/></Grant><Grant><GrantID>F/10/18</GrantID><Agency>Deutsche Herzstiftung</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2023 Dec;176(12):JC135. doi: 10.7326/J23-0093.</RefSource><PMID Version="1">38048577</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jan 11;390(2):189-190. doi: 10.1056/NEJMc2312854.</RefSource><PMID Version="1">38197832</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jan 11;390(2):190. doi: 10.1056/NEJMc2312854.</RefSource><PMID Version="1">38197833</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jan 11;390(2):190. doi: 10.1056/NEJMc2312854.</RefSource><PMID Version="1">38197834</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2024 Jan 11;390(2):190-191. doi: 10.1056/NEJMc2312854.</RefSource><PMID Version="1">38197835</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Respir Crit Care Med. 2024 Oct 1;210(7):931. doi: 10.1164/rccm.202401-0087RR.</RefSource><PMID Version="1">39133507</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009204" MajorTopicYN="N">Myocardial Revascularization</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desch</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeymer</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freund</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirchhof</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouarrak</LastName><ForeName>Taoufik</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huber</LastName><ForeName>Kurt</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werdan</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friede</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akin</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behnes</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duerschmied</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xf6;ss</LastName><ForeName>Janine</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feistritzer</LastName><ForeName>Hans-Josef</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rassaf</LastName><ForeName>Tienush</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahabadi</LastName><ForeName>Amir Abbas</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mittag</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graf</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuernau</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraei</LastName><ForeName>Roza</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seidler</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuster</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landmesser</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clemmensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schrage</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blankenberg</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hennersdorf</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharpf</LastName><ForeName>Dominik</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fichtlscherer</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyl</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voigt</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seyfarth</LastName><ForeName>Melchior</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vorpahl</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>John</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauschinger</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ewen</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahfoud</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xf6;hm</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linke</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woitek</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangner</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tigges</LastName><ForeName>Eike</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meincke</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willems</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessner</LastName><ForeName>Nele</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakmi</LastName><ForeName>Samer</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frantz</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruch</LastName><ForeName>Leonhard</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zahn</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jung</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelm</LastName><ForeName>Malte</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franz</LastName><ForeName>Jutta</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapp</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lauten</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nef</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doerr</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wengenmeyer</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Staudacher</LastName><ForeName>Dawid</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Westermann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rottbauer</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulze</LastName><ForeName>P Christian</ForeName><Initials>PC</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xf6;bius-Winkler</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldus</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adler</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laufs</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lenk</LastName><ForeName>Karsten</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lauten</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xf6;llmann</LastName><ForeName>Helge</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blumenstein</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felix</LastName><ForeName>Stephan B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abel</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xd6;ner</LastName><ForeName>Alper</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ince</LastName><ForeName>H&#xfc;seyin</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schempf</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadel</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bock</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weferling</LastName><ForeName>Maren</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamm</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noc</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goslar</LastName><ForeName>Tomaz</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boekstegers</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maier</LastName><ForeName>Lars S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sedding</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dutzmann</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tongers</LastName><ForeName>J&#xf6;rn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bufe</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baumanns</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kersten</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marx</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preusch</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>7</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>27</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>27</Day><Hour>14</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37634145</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2307227</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37231510</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Diagnostic accuracy of point-of-care ultrasound for shock: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>200</StartPage><MedlinePgn>200</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">200</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-023-04495-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Circulatory failure is classified into four types of shock (obstructive, cardiogenic, distributive, and hypovolemic) that must be distinguished as each requires a different treatment. Point-of-care ultrasound (POCUS) is widely used in clinical practice for acute conditions, and several diagnostic protocols using POCUS for shock have been developed. This study aimed to evaluate the diagnostic accuracy of POCUS in identifying the etiology of shock.</AbstractText><AbstractText Label="METHODS">We conducted a systematic literature search of MEDLINE, Cochrane Central Register of Controlled Trials, Embase, Web of Science, Clinicaltrial.gov, European Union Clinical Trials Register, WHO International Clinical Trials Registry Platform, and University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) until June 15, 2022. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and assessed study quality using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Meta-analysis was conducted to pool the diagnostic accuracy of POCUS for each type of shock. The study protocol was prospectively registered in UMIN-CTR (UMIN 000048025).</AbstractText><AbstractText Label="RESULTS">Of the 1553 studies identified, 36 studies were full-text reviewed, and 12 studies with 1132 patients were included in the meta-analysis. Pooled sensitivity and specificity were 0.82 [95% confidence interval (CI) 0.68-0.91] and 0.98 [95% CI 0.92-0.99] for obstructive shock, 0.78 [95% CI 0.56-0.91] and 0.96 [95% CI 0.92-0.98] for cardiogenic shock, 0.90 [95% CI 0.84-0.94] and 0.92 [95% CI 0.88-0.95] for hypovolemic shock, and 0.79 [95% CI 0.71-0.85] and 0.96 [95% CI 0.91-0.98] for distributive shock, respectively. The area under the receiver operating characteristic curve for each type of shock was approximately 0.95. The positive likelihood ratios for each type of shock were all greater than 10, especially 40 [95% CI 11-105] for obstructive shock. The negative likelihood ratio for each type of shock was approximately 0.2.</AbstractText><AbstractText Label="CONCLUSIONS">The identification of the etiology for each type of shock using POCUS was characterized by high sensitivity and positive likelihood ratios, especially for obstructive shock.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Takuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Health Data Science, Graduate School of Data Science, Yokohama City University, 22-2 Seto, Kanazawa, Yokohama, 236-0027, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Jikei University School of Medicine, Minato-ku, 105-8471, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Health Data Science, Graduate School of Data Science, Yokohama City University, 22-2 Seto, Kanazawa, Yokohama, 236-0027, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noma</LastName><ForeName>Hisashi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Data Science, The Institute of Statistical Mathematics, Tachikawa, 190-8562, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomura</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Perioperative Medical Support, Tokushukai Medical Corporation, Chiyoda-ku, 102-0074, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Jichi Medical University, Shimotsuke, 329-0498, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihara</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Health Data Science, Graduate School of Data Science, Yokohama City University, 22-2 Seto, Kanazawa, Yokohama, 236-0027, Japan. meta.analysis.r@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan. meta.analysis.r@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019095" MajorTopicYN="Y">Point-of-Care Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067716" MajorTopicYN="N">Point-of-Care Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="Y">Shock</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Circulatory failure</Keyword><Keyword MajorTopicYN="N">Diagnostic accuracy</Keyword><Keyword MajorTopicYN="N">Early diagnosis</Keyword><Keyword MajorTopicYN="N">Obstructive shock</Keyword><Keyword MajorTopicYN="N">Point-of-care ultrasound</Keyword><Keyword MajorTopicYN="N">Shock</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>26</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37231510</ArticleId><ArticleId IdType="pmc">PMC10214599</ArticleId><ArticleId IdType="doi">10.1186/s13054-023-04495-6</ArticleId><ArticleId IdType="pii">10.1186/s13054-023-04495-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vincent J-L, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726&#x2013;1734. doi: 10.1056/NEJMra1208943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1208943</ArticleId><ArticleId IdType="pubmed">24171518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacker DA, Winters ME. Shock. Emerg Med Clin North Am. 2014;32(4):747&#x2013;758. doi: 10.1016/j.emc.2014.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.emc.2014.07.003</ArticleId><ArticleId IdType="pubmed">25441032</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AE, Aborn LS, Kline JA. Severity of emergency department hypotension predicts adverse hospital outcome. Shock. 2004;22(5):410&#x2013;414. doi: 10.1097/01.shk.0000142186.95718.82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000142186.95718.82</ArticleId><ArticleId IdType="pubmed">15489632</ArticleId></ArticleIdList></Reference><Reference><Citation>Marbach JA, Almufleh A, Di Santo P, Simard T, Jung R, Diemer G, et al. A shifting paradigm: the role of focused cardiac ultrasound in bedside patient assessment. Chest. 2020;158(5):2107&#x2013;2118. doi: 10.1016/j.chest.2020.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.07.021</ArticleId><ArticleId IdType="pubmed">32707179</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieillard-Baron A, Millington SJ, Sanfilippo F, Chew M, Diaz-Gomez J, McLean A, et al. A decade of progress in critical care echocardiography: a narrative review. Intensive Care Med. 2019;45(6):770&#x2013;788. doi: 10.1007/s00134-019-05604-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-019-05604-2</ArticleId><ArticleId IdType="pubmed">30911808</ArticleId></ArticleIdList></Reference><Reference><Citation>Labovitz AJ, Noble VE, Bierig M, Goldstein SA, Jones R, Kort S, et al. Focused cardiac ultrasound in the emergent setting: a consensus statement of the American Society of Echocardiography and American College of Emergency Physicians. J Am Soc Echocardiogr. 2010;23(12):1225&#x2013;1230. doi: 10.1016/j.echo.2010.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2010.10.005</ArticleId><ArticleId IdType="pubmed">21111923</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-G&#xf3;mez JL, Mayo PH, Koenig SJ. Point-of-care ultrasonography. N Engl J Med. 2021;385(17):1593&#x2013;1602. doi: 10.1056/NEJMra1916062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1916062</ArticleId><ArticleId IdType="pubmed">34670045</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AE, Tayal VS, Sullivan DM, Kline JA. Randomized, controlled trial of immediate versus delayed goal-directed ultrasound to identify the cause of nontraumatic hypotension in emergency department patients. Crit Care Med. 2004;32(8):1703&#x2013;1708. doi: 10.1097/01.CCM.0000133017.34137.82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000133017.34137.82</ArticleId><ArticleId IdType="pubmed">15286547</ArticleId></ArticleIdList></Reference><Reference><Citation>Pershad J, Myers S, Plouman C, Rosson C, Elam K, Wan J, et al. Bedside limited echocardiography by the emergency physician is accurate during evaluation of the critically ill patient. Pediatrics. 2004;114(6):e667&#x2013;e671. doi: 10.1542/peds.2004-0881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2004-0881</ArticleId><ArticleId IdType="pubmed">15545620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo P, Arntfield R, Balik M, Kory P, Mathis G, Schmidt G, et al. The ICM research agenda on critical care ultrasonography. Intensive Care Med. 2017;43(9):1257&#x2013;1269. doi: 10.1007/s00134-017-4734-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-017-4734-z</ArticleId><ArticleId IdType="pubmed">28271320</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitson MR, Mayo PH. Ultrasonography in the emergency department. Crit Care. 2016;20(1):227. doi: 10.1186/s13054-016-1399-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1399-x</ArticleId><ArticleId IdType="pmc">PMC4983783</ArticleId><ArticleId IdType="pubmed">27523885</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen CA, Holden S, Vela J, Rathleff MS, Jensen MB. Point-of-care ultrasound in general practice: a systematic review. Ann Fam Med. 2019;17(1):61&#x2013;69. doi: 10.1370/afm.2330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.2330</ArticleId><ArticleId IdType="pmc">PMC6342599</ArticleId><ArticleId IdType="pubmed">30670398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier-Jean A, Albert M, Shiloh AL, Eisen LA, Williamson D, Beaulieu Y. The diagnostic and therapeutic impact of point-of-care ultrasonography in the intensive care unit. J Intensive Care Med. 2017;32(3):197&#x2013;203. doi: 10.1177/0885066615606682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066615606682</ArticleId><ArticleId IdType="pubmed">26423745</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera P, Mailhot T, Riley D, Mandavia D. The RUSH exam: Rapid Ultrasound in SHock in the evaluation of the critically lll. Emerg Med Clin North Am. 2010;28(1):29&#x2013;56, vii. doi: 10.1016/j.emc.2009.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.emc.2009.09.010</ArticleId><ArticleId IdType="pubmed">19945597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein DA. BLUE-protocol and FALLS-protocol: two applications of lung ultrasound in the critically ill. Chest. 2015;147(6):1659&#x2013;1670. doi: 10.1378/chest.14-1313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.14-1313</ArticleId><ArticleId IdType="pubmed">26033127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V, Fletcher SN. A review of echocardiography in anaesthetic and peri-operative practice. Part 2: training and accreditation. Anaesthesia. 2014;69(8):919&#x2013;927. doi: 10.1111/anae.12709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.12709</ArticleId><ArticleId IdType="pubmed">24801304</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen MB, Sloth E, Larsen KM, Schmidt MB. Transthoracic echocardiography for cardiopulmonary monitoring in intensive care. Eur J Anaesthesiol. 2004;21(9):700&#x2013;707. doi: 10.1097/00003643-200409000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003643-200409000-00006</ArticleId><ArticleId IdType="pubmed">15595582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo PH, Beaulieu Y, Doelken P, Feller-Kopman D, Harrod C, Kaplan A, et al. American College of Chest Physicians/La Soci&#xe9;t&#xe9; de R&#xe9;animation de Langue Fran&#xe7;aise statement on competence in critical care ultrasonography. Chest. 2009;135(4):1050&#x2013;1060. doi: 10.1378/chest.08-2305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.08-2305</ArticleId><ArticleId IdType="pubmed">19188546</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer KT, Kimura BJ, Korcarz CE, Pellikka PA, Rahko PS, Siegel RJ. Focused cardiac ultrasound: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2013;26(6):567&#x2013;581. doi: 10.1016/j.echo.2013.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2013.04.001</ArticleId><ArticleId IdType="pubmed">23711341</ArticleId></ArticleIdList></Reference><Reference><Citation>Stickles SP, Carpenter CR, Gekle R, Kraus CK, Scoville C, Theodoro D, et al. The diagnostic accuracy of a point-of-care ultrasound protocol for shock etiology: a systematic review and meta-analysis. CJEM. 2019;21(3):406&#x2013;417. doi: 10.1017/cem.2018.498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cem.2018.498</ArticleId><ArticleId IdType="pubmed">30696496</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera P, Mailhot T, Riley D, Mandavia D. The RUSH exam 2012: rapid ultrasound in shock in the evaluation of the critically ill patient. Ultrasound Clin. 2012;7(2):255&#x2013;278. doi: 10.1016/j.cult.2011.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cult.2011.12.010</ArticleId><ArticleId IdType="pubmed">19945597</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y. Cochrane handbook for systematic reviews of diagnostic test accuracy. Version 2.0. The Cochrane Collaboration; 2022. https://training.cochrane.org/handbook-diagnostic-test-accuracy Accessed 9 Apr 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10408284</ArticleId><ArticleId IdType="pubmed">37470764</ArticleId></ArticleIdList></Reference><Reference><Citation>Salameh JP, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370:m2632. doi: 10.1136/bmj.m2632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2632</ArticleId><ArticleId IdType="pubmed">32816740</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, PRISMA-DTA Group et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388&#x2013;396. doi: 10.1001/jama.2017.19163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.19163</ArticleId><ArticleId IdType="pubmed">29362800</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529&#x2013;536. doi: 10.7326/0003-4819-155-8-201110180-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-155-8-201110180-00009</ArticleId><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982&#x2013;990. doi: 10.1016/j.jclinepi.2005.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2005.02.022</ArticleId><ArticleId IdType="pubmed">16168343</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865&#x2013;2884. doi: 10.1002/sim.942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.942</ArticleId><ArticleId IdType="pubmed">11568945</ArticleId></ArticleIdList></Reference><Reference><Citation>Noma H, Matsushima Y, Ishii R. Confidence interval for the AUC of SROC curve and some related methods using bootstrap for meta-analysis of diagnostic accuracy studies. Commun Stat Case Stud Data Anal Appl. 2021;7(3):344&#x2013;358.</Citation></Reference><Reference><Citation>McInnes MDF, Bossuyt PMM. Pitfalls of systematic reviews and meta-analyses in imaging research. Radiology. 2015;277(1):13&#x2013;21. doi: 10.1148/radiol.2015142779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2015142779</ArticleId><ArticleId IdType="pubmed">26402491</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):882&#x2013;893. doi: 10.1016/j.jclinepi.2005.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2005.01.016</ArticleId><ArticleId IdType="pubmed">16085191</ArticleId></ArticleIdList></Reference><Reference><Citation>van Enst WA, Ochodo E, Scholten RJPM, Hooft L, Leeflang MM. Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC Med Res Methodol. 2014;14:70. doi: 10.1186/1471-2288-14-70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-70</ArticleId><ArticleId IdType="pmc">PMC4035673</ArticleId><ArticleId IdType="pubmed">24884381</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefer S, Atkinson P, Chandra K, Henneberry RJ, Olszynski PA, Peach M, et al. Sonographic findings of left ventricular dysfunction to predict shock type in undifferentiated hypotensive patients: an analysis from the sonography in hypotension and cardiac arrest in the emergency department (SHoC-ED) study. Cureus. 2021;13(7):e16360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8360322</ArticleId><ArticleId IdType="pubmed">34395137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghane MR, Gharib MH, Ebrahimi A, Samimi K, Rezaee M, Rasouli HR, et al. Accuracy of rapid ultrasound in shock (RUSH) exam for diagnosis of shock in critically ill patients. Trauma Mon. 2015;20(1):e20095. doi: 10.5812/traumamon.20095.</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/traumamon.20095</ArticleId><ArticleId IdType="pmc">PMC4362031</ArticleId><ArticleId IdType="pubmed">25825696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zieleskiewicz L, Lopez A, Hraiech S, Baumstarck K, Pastene B, Di Bisceglie M, et al. Bedside POCUS during ward emergencies is associated with improved diagnosis and outcome: an observational, prospective, controlled study. Crit Care. 2021;25(1):34. doi: 10.1186/s13054-021-03466-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03466-z</ArticleId><ArticleId IdType="pmc">PMC7825196</ArticleId><ArticleId IdType="pubmed">33482873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazerian P, Volpicelli G, Gigli C, Lamorte A, Grifoni S, Vanni S. Diagnostic accuracy of focused cardiac and venous ultrasound examinations in patients with shock and suspected pulmonary embolism. Intern Emerg Med. 2018;13(4):567&#x2013;574. doi: 10.1007/s11739-017-1681-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-017-1681-1</ArticleId><ArticleId IdType="pubmed">28540661</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahulkumar HH, Bhavin PR, Shreyas KP, Krunalkumar HP, Atulkumar S, Bansari C. Utility of point-of-care ultrasound in differentiating causes of shock in resource-limited setup. J Emerg Trauma Shock. 2019;12(1):10&#x2013;17. doi: 10.4103/JETS.JETS_61_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/JETS.JETS_61_18</ArticleId><ArticleId IdType="pmc">PMC6496999</ArticleId><ArticleId IdType="pubmed">31057278</ArticleId></ArticleIdList></Reference><Reference><Citation>Daley JI, Dwyer KH, Grunwald Z, Shaw DL, Stone MB, Schick A, et al. Increased sensitivity of focused cardiac ultrasound for pulmonary embolism in emergency department patients with abnormal vital signs. Acad Emerg Med. 2019;26(11):1211&#x2013;1220. doi: 10.1111/acem.13774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acem.13774</ArticleId><ArticleId IdType="pubmed">31562679</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaih AH, Housseini AM, Khalifa MEM. Accuracy and outcome of rapid ultrasound in shock and hypotension (RUSH) in Egyptian polytrauma patients. Chin J Traumatol. 2018;21(3):156&#x2013;162. doi: 10.1016/j.cjtee.2017.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjtee.2017.06.009</ArticleId><ArticleId IdType="pmc">PMC6033727</ArticleId><ArticleId IdType="pubmed">29784591</ArticleId></ArticleIdList></Reference><Reference><Citation>Javali RH, Loganathan A, Srinivasarangan M, Patil A, Siddappa GB, Satyanarayana N, et al. Reliability of emergency department diagnosis in identifying the etiology of nontraumatic undifferentiated hypotension. Indian J Crit Care Med. 2020;24(5):313&#x2013;320. doi: 10.5005/jp-journals-10071-23429.</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-10071-23429</ArticleId><ArticleId IdType="pmc">PMC7358855</ArticleId><ArticleId IdType="pubmed">32728321</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagheri-Hariri S, Yekesadat M, Farahmand S, Arbab M, Sedaghat M, Shahlafar N, et al. The impact of using RUSH protocol for diagnosing the type of unknown shock in the emergency department. Emerg Radiol. 2015;22(5):517&#x2013;520. doi: 10.1007/s10140-015-1311-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10140-015-1311-z</ArticleId><ArticleId IdType="pubmed">25794785</ArticleId></ArticleIdList></Reference><Reference><Citation>Agmy G, Ahmed R, Mohamed A, Hamed S, Saad M. Implication of transthoracic sonography in assessment of circulatory failure: Fayoum experience with falls protocol. Chest. 2017;152(4):A618. doi: 10.1016/j.chest.2017.08.650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2017.08.650</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesfaye E, Zewude T. Rapid ultrasonographic assessment of undifferentiated shock in hypotensive patients. Crit Care. 2018;22.</Citation></Reference><Reference><Citation>Shokoohi H, Boniface KS, Pourmand A, Liu YT, Davison DL, Hawkins KD, et al. Bedside ultrasound reduces diagnostic uncertainty and guides resuscitation in patients with undifferentiated hypotension. Crit Care Med. 2015;43(12):2562&#x2013;2569. doi: 10.1097/CCM.0000000000001285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001285</ArticleId><ArticleId IdType="pubmed">26575653</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Liu L, Chang W, Wu Z, Huang L, Chao Y, et al. Diagnosis Accuracy of lung ultrasound for arf in critically ill patients: a systematic review and meta-analysis. Front Med. 2021;8:705960. doi: 10.3389/fmed.2021.705960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.705960</ArticleId><ArticleId IdType="pmc">PMC8383297</ArticleId><ArticleId IdType="pubmed">34447767</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel D, Leisterer J, Ferrada P, Ekkernkamp A, Mutze S, Hoenning A. Point-of-care ultrasonography for diagnosing thoracoabdominal injuries in patients with blunt trauma. Cochrane Database Syst Rev. 2018;12(12):CD012669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517180</ArticleId><ArticleId IdType="pubmed">30548249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W, Shen Y, Yang J, He X, Zhang M. Diagnosis of pneumothorax by radiography and ultrasonography: a meta-analysis. Chest. 2011;140(4):859&#x2013;866. doi: 10.1378/chest.10-2946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.10-2946</ArticleId><ArticleId IdType="pubmed">21546439</ArticleId></ArticleIdList></Reference><Reference><Citation>Robba C, Wong A, Poole D, Al Tayar A, Arntfield RT, Chew MS, et al. Basic ultrasound head-to-toe skills for intensivists in the general and neuro intensive care unit population: consensus and expert recommendations of the European Society of Intensive Care Medicine. Intensive Care Med. 2021;47(12):1347&#x2013;1367. doi: 10.1007/s00134-021-06486-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06486-z</ArticleId><ArticleId IdType="pmc">PMC8596353</ArticleId><ArticleId IdType="pubmed">34787687</ArticleId></ArticleIdList></Reference><Reference><Citation>Blans MJ, Bosch FH, van der Hoeven JG. A practical approach to critical care ultrasound. J Crit Care. 2019;51:156&#x2013;164. doi: 10.1016/j.jcrc.2019.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2019.01.002</ArticleId><ArticleId IdType="pubmed">30826611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanks CW, Correa V. Advantages of cardiopulmonary ultrasound in post-cardiopulmonary resuscitation tension pneumothorax. J Ultrasound Med. 2018;37(4):819&#x2013;822. doi: 10.1002/jum.14437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jum.14437</ArticleId><ArticleId IdType="pubmed">28960428</ArticleId></ArticleIdList></Reference><Reference><Citation>Haskings EM, Eissa M, Allard RV, MirGhassemi A, McFaul CM, Miller EC. Point-of-care ultrasound use in emergencies: what every anaesthetist should know. Anaesthesia. 2023;78(1):105&#x2013;118. doi: 10.1111/anae.15910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15910</ArticleId><ArticleId IdType="pubmed">36449358</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli G, Lamorte A, Tullio M, Cardinale L, Giraudo M, Stefanone V, et al. Point-of-care multiorgan ultrasonography for the evaluation of undifferentiated hypotension in the emergency department. Intensive Care Med. 2013;39(7):1290&#x2013;1298. doi: 10.1007/s00134-013-2919-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-013-2919-7</ArticleId><ArticleId IdType="pubmed">23584471</ArticleId></ArticleIdList></Reference><Reference><Citation>Inocencio M, Childs J, Chilstrom ML, Berona K. Ultrasound findings in tension pneumothorax: a case report. J Emerg Med. 2017;52(6):e217&#x2013;e220. doi: 10.1016/j.jemermed.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jemermed.2017.02.008</ArticleId><ArticleId IdType="pubmed">28342574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearns MJ, Walley KR. Tamponade: hemodynamic and echocardiographic diagnosis. Chest. 2018;153(5):1266&#x2013;1275. doi: 10.1016/j.chest.2017.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2017.11.003</ArticleId><ArticleId IdType="pubmed">29137910</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29976291</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of the American College of Cardiology</Title><ISOAbbreviation>J Am Coll Cardiol</ISOAbbreviation></Journal><ArticleTitle>Epinephrine Versus Norepinephrine for&#xa0;Cardiogenic Shock After Acute&#xa0;Myocardial Infarction.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>182</EndPage><MedlinePgn>173-182</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacc.2018.04.051</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-1097(18)34749-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking.</AbstractText><AbstractText Label="OBJECTIVES">The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction.</AbstractText><AbstractText Label="METHODS">The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was the occurrence of refractory CS. Refractory CS was defined as CS with sustained hypotension, end-organ hypoperfusion and hyperlactatemia, and high inotrope and vasopressor doses.</AbstractText><AbstractText Label="RESULTS">Fifty-seven patients were randomized into 2 study arms, epinephrine and norepinephrine. For the primary efficacy endpoint, cardiac index evolution was similar between the 2 groups (p&#xa0;=&#xa0;0.43) from baseline (H0) to H72. For the main safety endpoint, the observed higher incidence of refractory shock in the epinephrine group (10 of 27 [37%] vs. norepinephrine 2 of 30 [7%]; p&#xa0;=&#xa0;0.008) led to early termination of the study. Heart rate increased significantly with epinephrine from H2 to H24 while remaining unchanged with norepinephrine (p&#xa0;&lt; 0.0001). Several metabolic changes were unfavorable to epinephrine compared with norepinephrine, including an increase in cardiac double product (p&#xa0;=&#xa0;0.0002) and lactic acidosis from H2 to H24 (p&#xa0;&lt; 0.0001).</AbstractText><AbstractText Label="CONCLUSIONS">In patients with CS secondary to acute myocardial infarction, the use of epinephrine compared with&#xa0;norepinephrine was associated with similar effects on arterial pressure and cardiac index and a higher incidence of refractory shock. (Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock [OptimaCC]; NCT01367743).</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale Brabois, CHRU Nancy, P&#xf4;le Cardio-M&#xe9;dico-Chirurgical, Vandoeuvre-les-Nancy, INSERM U1116, Facult&#xe9; de M&#xe9;decine, Vandoeuvre-les-Nancy, and Universit&#xe9; de Lorraine, Nancy, France. Electronic address: blevy5463@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clere-Jehl</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Strasbourg (UNISTRA), Facult&#xe9; de m&#xe9;decine, H&#xf4;pitaux Universitaires de Strasbourg, Service de r&#xe9;animation, Nouvel H&#xf4;pital Civil, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legras</LastName><ForeName>Annick</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>M&#xe9;decine Intensive R&#xe9;animation, CHRU Bretonneau, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morichau-Beauchant</LastName><ForeName>Tristan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medical ICU, Cochin University Hospital (APHP), Paris, France, and Paris Descartes University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leone</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Surgical ICU, H&#xf4;pital Nord, AP-HM, Aix Marseille Universit&#xe9;, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frederique</LastName><ForeName>Ganster</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, Groupement Hospitalier Mulhouse Sud Alsace-H&#xf4;pital Emile Muller, Mulhouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quenot</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Fran&#xe7;ois Mitterrand University Hospital, Dijon, Lipness Team, INSERM Research Center LNC-UMR1231 and LabExLipSTIC, University of Burgundy, Dijon, and INSERM CIC 1432, Clinical Epidemiology, University of Burgundy, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmoun</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale Brabois, CHRU Nancy, P&#xf4;le Cardio-M&#xe9;dico-Chirurgical, Vandoeuvre-les-Nancy, INSERM U1116, Facult&#xe9; de M&#xe9;decine, Vandoeuvre-les-Nancy, and Universit&#xe9; de Lorraine, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cariou</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical ICU, Cochin University Hospital (APHP), Paris, France, and Paris Descartes University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassus</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Heart and Lung Center, Cardiology, Helsinki University and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harjola</LastName><ForeName>Veli-Pekka</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Heart and Lung Center, Cardiology, Helsinki University and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meziani</LastName><ForeName>Ferhat</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Strasbourg (UNISTRA), Facult&#xe9; de m&#xe9;decine, H&#xf4;pitaux Universitaires de Strasbourg, Service de r&#xe9;animation, Nouvel H&#xf4;pital Civil, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louis</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation, H&#xf4;pital Mercy, Metz, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossignol</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM CIC1433, Nancy University Hospital, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>INSERM CIC1433, Nancy University Hospital, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girerd</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>INSERM CIC1433, Nancy University Hospital, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm UMR-S 942, H&#xf4;pital Lariboisi&#xe8;re, Paris, Department of Anaesthesiology and Intensive Care, Lariboisi&#xe8;re Hospital, and Universit&#xe9; Paris Diderot-Sorbonne Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vignon</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical-Surgical Intensive Care Unit, Teaching Hospital of Limoges, Limoges, and INSERM CIC 1435, Teaching Hospital of Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Collaborators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01367743</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Cardiol</MedlineTA><NlmUniqueID>8301365</NlmUniqueID><ISSNLinking>0735-1097</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YKH834O4BH</RegistryNumber><NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Am Coll Cardiol. 2018 Jul 10;72(2):183-186. doi: 10.1016/j.jacc.2018.04.052.</RefSource><PMID Version="1">29976292</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Am Coll Cardiol. 2018 Nov 6;72(19):2412. doi: 10.1016/j.jacc.2018.07.100.</RefSource><PMID Version="1">30384900</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Am Coll Cardiol. 2018 Nov 6;72(19):2413. doi: 10.1016/j.jacc.2018.09.008.</RefSource><PMID Version="1">30384901</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004837" MajorTopicYN="N">Epinephrine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">epinephrine</Keyword><Keyword MajorTopicYN="N">norepinephrine</Keyword><Keyword MajorTopicYN="N">vasopressor</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Mattei</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thivilier</LastName><ForeName>Carine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auchet</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fritz</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boisrame-Helme</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mercier</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garot</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perny</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gette</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hammad</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vigne</LastName><ForeName>Coralie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dargent</LastName><ForeName>Auguste</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andreu</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guiot</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29976291</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2018.04.051</ArticleId><ArticleId IdType="pii">S0735-1097(18)34749-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22920912</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>367</Volume><Issue>14</Issue><PubDate><Year>2012</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Intraaortic balloon support for myocardial infarction with cardiogenic shock.</ArticleTitle><Pagination><StartPage>1287</StartPage><EndPage>1296</EndPage><MedlinePgn>1287-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1208410</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In current international guidelines, intraaortic balloon counterpulsation is considered to be a class I treatment for cardiogenic shock complicating acute myocardial infarction. However, evidence is based mainly on registry data, and there is a paucity of randomized clinical trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this randomized, prospective, open-label, multicenter trial, we randomly assigned 600 patients with cardiogenic shock complicating acute myocardial infarction to intraaortic balloon counterpulsation (IABP group, 301 patients) or no intraaortic balloon counterpulsation (control group, 299 patients). All patients were expected to undergo early revascularization (by means of percutaneous coronary intervention or bypass surgery) and to receive the best available medical therapy. The primary efficacy end point was 30-day all-cause mortality. Safety assessments included major bleeding, peripheral ischemic complications, sepsis, and stroke.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 300 patients in the IABP group and 298 in the control group were included in the analysis of the primary end point. At 30 days, 119 patients in the IABP group (39.7%) and 123 patients in the control group (41.3%) had died (relative risk with IABP, 0.96; 95% confidence interval, 0.79 to 1.17; P=0.69). There were no significant differences in secondary end points or in process-of-care measures, including the time to hemodynamic stabilization, the length of stay in the intensive care unit, serum lactate levels, the dose and duration of catecholamine therapy, and renal function. The IABP group and the control group did not differ significantly with respect to the rates of major bleeding (3.3% and 4.4%, respectively; P=0.51), peripheral ischemic complications (4.3% and 3.4%, P=0.53), sepsis (15.7% and 20.5%, P=0.15), and stroke (0.7% and 1.7%, P=0.28).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of intraaortic balloon counterpulsation did not significantly reduce 30-day mortality in patients with cardiogenic shock complicating acute myocardial infarction for whom an early revascularization strategy was planned. (Funded by the German Research Foundation and others; IABP-SHOCK II ClinicalTrials.gov number, NCT00491036.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Leipzig-Heart Center, Department of Internal Medicine/Cardiology, Leipzig, Germany. thielh@medizin.uni-leipzig.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeymer</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Franz-Josef</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Ferenc</LastName><ForeName>Miroslaw</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Olbrich</LastName><ForeName>Hans-Georg</ForeName><Initials>HG</Initials></Author><Author ValidYN="Y"><LastName>Hausleiter</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Richardt</LastName><ForeName>Gert</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hennersdorf</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Empen</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fuernau</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Desch</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Hambrecht</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fuhrmann</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>B&#xf6;hm</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ebelt</LastName><ForeName>Henning</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schuler</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Werdan</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><CollectiveName>IABP-SHOCK II Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00491036</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Oct 4;367(14):1349-50. doi: 10.1056/NEJMe1209601.</RefSource><PMID Version="1">22920913</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Cardiol. 2012 Oct;9(10):551. doi: 10.1038/nrcardio.2012.132.</RefSource><PMID Version="1">22965109</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Med Klin Intensivmed Notfmed. 2012 Oct;107(7):567-70. doi: 10.1007/s00063-012-0168-0.</RefSource><PMID Version="1">23052992</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2012 Dec 18;157(12):JC6-11. doi: 10.7326/0003-4819-157-12-201212180-02011.</RefSource><PMID Version="1">23247960</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 3;368(1):81. doi: 10.1056/NEJMc1213513.</RefSource><PMID Version="1">23281982</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 3;368(1):80. doi: 10.1056/NEJMc1213513.</RefSource><PMID Version="1">23281983</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 3;368(1):80-1. doi: 10.1056/NEJMc1213513.</RefSource><PMID Version="1">23281984</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Expert Rev Cardiovasc Ther. 2013 Feb;11(2):147-9. doi: 10.1586/erc.12.185.</RefSource><PMID Version="1">23405835</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care. 2013 Mar 06;17(2):307. doi: 10.1186/cc12520.</RefSource><PMID Version="1">23472937</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015906" MajorTopicYN="N">Angioplasty, Balloon, Coronary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="N">Coronary Artery Bypass</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="Y">Intra-Aortic Balloon Pumping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015607" MajorTopicYN="N">Stents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Schuler</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werdan</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeymer</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeymer</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vonderschmitt</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messemer</LastName><ForeName>Beate</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alkisoglu</LastName><ForeName>Zehra</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vonderschmitt</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ourrak</LastName><ForeName>Taoufik</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haerting</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huber</LastName><ForeName>Kurt</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maisch</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Follath</LastName><ForeName>Ferenc</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desch</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuernau</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuler</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leuschner</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Waha</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wetzel</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pausewang</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neumann</LastName><ForeName>Franz-Josef</ForeName><Initials>FJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferenc</LastName><ForeName>Miroslaw</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olbrich</LastName><ForeName>Hans-Gerd</ForeName><Initials>HG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hopf</LastName><ForeName>Hans-Bernd</ForeName><Initials>HB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hausleiter</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Waha</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orban</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lennerz</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seyfarth</LastName><ForeName>Melchior</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardt</LastName><ForeName>Gert</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Bettina</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdel-Wahab</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toelg</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geist</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bahnsen-Maa&#xdf;</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hennersdorf</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graf</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riemann</LastName><ForeName>Urs</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharpf</LastName><ForeName>Dominik</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Empen</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felix</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werdan</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ebelt</LastName><ForeName>Henning</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buerke</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlitt</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hambrecht</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fach</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fiehn</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeymer</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gitt</LastName><ForeName>Anselm K</ForeName><Initials>AK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mark</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winkler</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lauer</LastName><ForeName>Bernward</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuhrmann</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xf6;hm</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Link</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figulla</LastName><ForeName>Hans-Reiner</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jung</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Utschig</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurowski</LastName><ForeName>Volkhard</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfrum</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radke</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schunkert</LastName><ForeName>Heribert</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minden</LastName><ForeName>Hans-Heinrich</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Braun-Dullaeus</LastName><ForeName>R&#xfc;diger C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmei&#xdf;er</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walz</LastName><ForeName>Friederike</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kr&#xfc;lls-M&#xfc;nch</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rochor</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strasser</LastName><ForeName>Ruth H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simonis</LastName><ForeName>Gregor</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maier</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ertl</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudra</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hug</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sick</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bomba</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultheiss</LastName><ForeName>Hans-Peter</ForeName><Initials>HP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsch&#xf6;pe</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andresen</LastName><ForeName>Dietrich</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kr&#xfc;lls-M&#xfc;nch</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurek</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nienaber</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ince</LastName><ForeName>H&#xfc;seyin</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Hendrick</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamm</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xf6;llmann</LastName><ForeName>Helge</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapp</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baumann</LastName><ForeName>Gert</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knebel</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franz</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xfc;hlen</LastName><ForeName>Helmut</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stracke</LastName><ForeName>Lars U</ForeName><Initials>LU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwinger</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xe4;uml</LastName><ForeName>Herrmann</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xe4;chinger</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gie&#xdf;mann</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtenberg</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prondzinsky</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tebbe</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birkemeyer</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1208410</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34347952</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>385</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>516</StartPage><EndPage>525</EndPage><MedlinePgn>516-525</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2026845</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the selection of inotropic agents in clinical practice.</AbstractText><AbstractText Label="METHODS">We randomly assigned patients with cardiogenic shock to receive milrinone or dobutamine in a double-blind fashion. The primary outcome was a composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke diagnosed by a neurologist, or initiation of renal replacement therapy. Secondary outcomes included the individual components of the primary composite outcome.</AbstractText><AbstractText Label="RESULTS">A total of 192 participants (96 in each group) were enrolled. The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants (49%) in the milrinone group and in 52 participants (54%) in the dobutamine group (relative risk, 0.90; 95% confidence interval [CI], 0.69 to 1.19; P&#x2009;=&#x2009;0.47). There were also no significant differences between the groups with respect to secondary outcomes, including in-hospital death (37% and 43% of the participants, respectively; relative risk, 0.85; 95% CI, 0.60 to 1.21), resuscitated cardiac arrest (7% and 9%; hazard ratio, 0.78; 95% CI, 0.29 to 2.07), receipt of mechanical circulatory support (12% and 15%; hazard ratio, 0.78; 95% CI, 0.36 to 1.71), or initiation of renal replacement therapy (22% and 17%; hazard ratio, 1.39; 95% CI, 0.73 to 2.67).</AbstractText><AbstractText Label="CONCLUSIONS">In patients with cardiogenic shock, no significant difference between milrinone and dobutamine was found with respect to the primary composite outcome or important secondary outcomes. (Funded by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario; ClinicalTrials.gov number, NCT03207165.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Santo</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Richard G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marbach</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutson</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Trevor</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9465-8150</Identifier><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>F Daniel</ForeName><Initials>FD</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harnett</LastName><ForeName>David T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merdad</LastName><ForeName>Anas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almufleh</LastName><ForeName>Aws</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Willy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Razek</LastName><ForeName>Omar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-4123-6004</Identifier><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernando</LastName><ForeName>Shannon M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-4549-4289</Identifier><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyeremanteng</LastName><ForeName>Kwadwo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernick</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>George A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froeschl</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labinaz</LastName><ForeName>Marino</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le May</LastName><ForeName>Michel R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hibbert</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Mod&#xe9;lisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03207165</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D065007">Pragmatic Clinical Trial</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000318">Adrenergic beta-Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058987">Phosphodiesterase 3 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>3S12J47372</RegistryNumber><NameOfSubstance UI="D004280">Dobutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>JU9YAX04C7</RegistryNumber><NameOfSubstance UI="D020105">Milrinone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2021 Nov 25;385(22):2107-2108. doi: 10.1056/NEJMc2114890.</RefSource><PMID Version="1">34818493</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2021 Nov 25;385(22):2108. doi: 10.1056/NEJMc2114890.</RefSource><PMID Version="1">34818494</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Respir Crit Care Med. 2024 May 15;209(10):1255-1257. doi: 10.1164/rccm.202303-0604RR.</RefSource><PMID Version="1">38498852</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000318" MajorTopicYN="N">Adrenergic beta-Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004280" MajorTopicYN="N">Dobutamine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020105" MajorTopicYN="N">Milrinone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058987" MajorTopicYN="N">Phosphodiesterase 3 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>4</Day><Hour>17</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34347952</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2026845</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33152122</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.</ArticleTitle><Pagination><StartPage>CD009669</StartPage><MedlinePgn>CD009669</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD009669</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD009669.pub4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) are potentially life-threatening complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery. While there is solid evidence for the treatment of other cardiovascular diseases of acute onset, treatment strategies in haemodynamic instability due to CS and LCOS remains less robustly supported by the given scientific literature. Therefore, we have analysed the current body of evidence for the treatment of CS or LCOS with inotropic and/or vasodilating agents. This is the second update of a Cochrane review originally published in 2014.</AbstractText><AbstractText Label="OBJECTIVES">Assessment of efficacy and safety of cardiac care with positive inotropic agents and vasodilator agents in CS or LCOS due to AMI, HF or after cardiac surgery.</AbstractText><AbstractText Label="SEARCH METHODS">We conducted a search in CENTRAL, MEDLINE, Embase and CPCI-S Web of Science in October 2019. We also searched four registers of ongoing trials and scanned reference lists and contacted experts in the field to obtain further information. No language restrictions were applied.</AbstractText><AbstractText Label="SELECTION CRITERIA">Randomised controlled trials (RCTs) enrolling patients with AMI, HF or cardiac surgery complicated by CS or LCOS.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS">We used standard methodological procedures according to Cochrane standards.</AbstractText><AbstractText Label="MAIN RESULTS">We identified 19 eligible studies including 2385 individuals (mean or median age range 56 to 73 years) and three ongoing studies. We categorised studies into 11 comparisons, all against standard cardiac care and additional other drugs or placebo. These comparisons investigated the efficacy of levosimendan versus dobutamine, enoximone or placebo; enoximone versus dobutamine, piroximone or epinephrine-nitroglycerine; epinephrine versus norepinephrine or norepinephrine-dobutamine; dopexamine versus dopamine; milrinone versus dobutamine and dopamine-milrinone versus dopamine-dobutamine. All trials were published in peer-reviewed journals, and analyses were done by the intention-to-treat (ITT) principle. Eighteen of 19 trials were small with only a few included participants. An acknowledgement of funding by the pharmaceutical industry or missing conflict of interest statements occurred in nine of 19 trials. In general, confidence in the results of analysed studies was reduced due to relevant study limitations (risk of bias), imprecision or indirectness. Domains of concern, which showed a high risk in more than 50% of included studies, encompassed performance bias (blinding of participants and personnel) and bias affecting the quality of evidence on adverse events. All comparisons revealed uncertainty on the effect of inotropic/vasodilating drugs on all-cause mortality with a low to very low quality of evidence. In detail, the findings were: levosimendan versus dobutamine (short-term mortality: RR 0.60, 95% CI 0.36 to 1.03; participants = 1701; low-quality evidence; long-term mortality: RR 0.84, 95% CI 0.63 to 1.13; participants = 1591; low-quality evidence); levosimendan versus placebo (short-term mortality: no data available; long-term mortality: RR 0.55, 95% CI 0.16 to 1.90; participants = 55; very low-quality evidence); levosimendan versus enoximone (short-term mortality: RR 0.50, 0.22 to 1.14; participants = 32; very low-quality evidence; long-term mortality: no data available); epinephrine versus norepinephrine-dobutamine (short-term mortality: RR 1.25; 95% CI 0.41 to 3.77; participants = 30; very low-quality evidence; long-term mortality: no data available); dopexamine versus dopamine (short-term mortality: no deaths in either intervention arm; participants = 70; very low-quality evidence; long-term mortality: no data available); enoximone versus dobutamine (short-term mortality RR 0.21; 95% CI 0.01 to 4.11; participants = 27; very low-quality evidence; long-term mortality: no data available); epinephrine versus norepinephrine (short-term mortality: RR 1.81, 0.89 to 3.68; participants = 57; very low-quality evidence; long-term mortality: no data available); and dopamine-milrinone versus dopamine-dobutamine (short-term mortality: RR 1.0, 95% CI 0.34 to 2.93; participants = 20; very low-quality evidence; long-term mortality: no data available). No information regarding all-cause mortality were available for the comparisons milrinone versus dobutamine, enoximone versus piroximone and enoximone versus epinephrine-nitroglycerine.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS">At present, there are no convincing data supporting any specific inotropic or vasodilating therapy to reduce mortality in haemodynamically unstable patients with CS or LCOS. Considering the limited evidence derived from the present data due to a high risk of bias and imprecision, it should be emphasised that there is an unmet need for large-scale, well-designed randomised trials on this topic to close the gap between daily practice in critical care of cardiovascular patients and the available evidence. In light of the uncertainties in the field, partially due to the underlying methodological flaws in existing studies, future RCTs should be carefully designed to potentially overcome given limitations and ultimately define the role of inotropic agents and vasodilator strategies in CS and LCOS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uhlig</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Surgical Intensive Care, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Efremov</LastName><ForeName>Ljupcho</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Center for Health Sciences, Medical School of the Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tongers</LastName><ForeName>J&#xf6;rn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology, Angiology and Intensive Care Medicine, University Hospital Halle (Saale), Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frantz</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikolajczyk</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Center for Health Sciences, Medical School of the Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedding</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiology, Angiology and Intensive Care Medicine, University Hospital Halle (Saale), Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schumann</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Surgical Intensive Care, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006835">Hydrazones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical><Chemical><RegistryNumber>3S12J47372</RegistryNumber><NameOfSubstance UI="D004280">Dobutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>C7Z4ITI7L7</RegistryNumber><NameOfSubstance UI="D017335">Enoximone</NameOfSubstance></Chemical><Chemical><RegistryNumber>YKH834O4BH</RegistryNumber><NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2018 Jan 29;1:CD009669. doi: 10.1002/14651858.CD009669.pub3.</RefSource><PMID Version="1">29376560</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002303" MajorTopicYN="N">Cardiac Output, Low</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004280" MajorTopicYN="N">Dobutamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017335" MajorTopicYN="N">Enoximone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004837" MajorTopicYN="N">Epinephrine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006835" MajorTopicYN="N">Hydrazones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Konstantin Uhlig:</b> no relevant conflicts of interests&#x2028;<b>Ljupcho Efremov:</b> no relevant conflicts of interests&#x2028;<b>J&#xf6;rn Tongers:</b> lecture honoraria and travel support from Orion Pharma&#x2028;<b>Stefan Frantz:</b> advisory boards, lectures, and study support from AMGEN Europe, AstraZeneca, Bayer Vital, Boehringer Ingelheim, Bristol Myers Squibb GmbH, Daiichi Sankyo, MSD, Novartis, Pfizer, Sanofi, Servier, Vifor&#x2028;<b>Rafael Mikolajczyk:</b> no relevant conflicts of interests&#x2028;<b>Daniel Sedding:</b> no relevant conflicts of interests&#x2028;<b>Julia Schumann:</b> no relevant conflicts of interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>5</Day><Hour>17</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33152122</ArticleId><ArticleId IdType="pmc">PMC8094388</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD009669.pub4</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Adamopoulos 2006 {published data only}</Title><Reference><Citation>Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology 2006;98:102-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16784930</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Alvarez 2006 {published data only}</Title><Reference><Citation>Alvarez J, Bouzada M, Fernandez AL, Caruezo V, Taboada M, Rodriguez J, et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia 2006;59(4):338-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709386</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Atallah 1990 {published data only}</Title><Reference><Citation>Atallah G, George M, Lehot JJ, Bastien O, Bejuit R, Durand PG, et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux 1990;83(3):63-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2147837</ArticleId></ArticleIdList></Reference><Reference><Citation>George M, Atallah G, Lehot JJ, Bastien O, Durand PG, Estanove S. Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse 1990;83(Spec 3):57-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">2147836</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Feneck 2001 {published data only}</Title><Reference><Citation>Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A, European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 2001;15(3):306-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426360</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Follath (LIDO) 2002 {published data only}</Title><Reference><Citation>Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.</Citation><ArticleIdList><ArticleId IdType="pubmed">12133653</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fuhrmann 2008 {published data only}</Title><Reference><Citation>Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine 2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181809846</ArticleId><ArticleId IdType="pubmed">18664782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Galinier 1990 {published data only}</Title><Reference><Citation>Galinier M, Rochiccioli JP, Edouard P, Fourcade J, Massabuau P, Puel J, et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse 1990;83(SPEC 3):27-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">2147831</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Garc&#x3af;a&#x2010;Gonz&#xe1;lez 2006 {published data only}</Title><Reference><Citation>Garc&#xed;a-Gonz&#xe1;lez MJ, Dominguez-Rodr&#xed;guez A, Ferrer-Hita JJ, Abreu-Gonz&#xe1;lez P, Mu&#x148;oz MB. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure 2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejheart.2006.01.007</ArticleId><ArticleId IdType="pubmed">16492404</ArticleId></ArticleIdList></Reference><Reference><Citation>Samini-Fard S, Garc&#xed;a-Gonz&#xe1;lez MJ, Dom&#xed;nguez-Rodr&#xed;guez A, Abreu-Gonz&#xe1;lez P. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology 2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2007.04.143</ArticleId><ArticleId IdType="pubmed">17643519</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Husebye 2013 {published and unpublished data}</Title><Reference><Citation>Husebye T, Eritsland J, Muller C, Sandvik L, Arnesen H, Seljeflot I, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure 2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfs215</ArticleId><ArticleId IdType="pubmed">23288914</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lancon 1990 {published data only}</Title><Reference><Citation>Lancon JP, Caillard B, Volot F, Obadia JF, Bock F. Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation 1990;9(3):289-94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2142589</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levin 2008 {published data only}</Title><Reference><Citation>Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espa&#x148;ola de Cardiolog&#xed;a 2008;61(5):471-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18462650</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levy 2011 {published data only}</Title><Reference><Citation>Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine 2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181ffe0eb</ArticleId><ArticleId IdType="pubmed">21037469</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levy 2018 {published data only}</Title><Reference><Citation>Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology 2018;72(2):173-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29976291</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy B, Meziani F, Leone M, Guiot P, Quenot JP, Louis G, &#xa0;et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care 2018;8(Suppl 1):13.</Citation></Reference></ReferenceList><ReferenceList><Title>Mebazaa (SURVIVE) 2007 {published data only}</Title><Reference><Citation>Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007;297(17):1883-91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17473298</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meissner 1996 {published data only}</Title><Reference><Citation>Meissner A, Schmelzle T, Simon R. Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie 1996;85(11):839-46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9064946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Patel 1993 {published data only}</Title><Reference><Citation>Patel A, Caldicott LD, Skoyles JR, Das P, Sherry KM. Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia 1993;71(6):869-72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8280556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rosseel 1997 {published data only}</Title><Reference><Citation>Rosseel PM, Santman FW, Bouter H, Dott CS. Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine? Intensive Care Medicine 1997;23:962-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9347368</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Slawsky 2000 {published data only}</Title><Reference><Citation>Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102(18):2222-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11056096</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zw&#xf6;lfer 1995 {published data only}</Title><Reference><Citation>Zwolfer W, Dressler HT, Keznickl P, Dieterich HA. Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology 1995;18(3):145-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7743685</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Al&#x2010;Shawaf 2006 {published data only}</Title><Reference><Citation>Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R. Levosimendan or milrinone in the type 2 diabetes patient with low ejection fraction undergoing elective coronary artery surgery. Journal of Cardiothoracic and Vascular Anesthesia 2006;20:353-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16750735</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dupuis 1992 {published data only}</Title><Reference><Citation>Dupuis JY, Bondy R, Cattran C, Nathan HJ, Wynands JE. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery. Journal of Cardiothoracic and Vascular Anesthesia 1992;6(5):542-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">1421065</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>El Mokhtari 2007 {published data only}</Title><Reference><Citation>El Mokhtari Nour Eddine, Arlt A, Meissner A, Lins M. Inotropic therapy for cardiac low output syndrome. European Journal of Medical Research 2007;12(11):563-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18024265</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pomer 1986 {published data only}</Title><Reference><Citation>Pomer S, Elert O, Sarai K, Satter P. Comparative effects of combined dopamine and nitroprusside versus dobutamine and nitroprusside infusions for computer-controlled management of low-output cardiac failure after open heart surgery. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1986;24(2):77-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">3957495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rychter 1985 {published data only}</Title><Reference><Citation>Rychter J, Iwaszkiewicz A, Golanski R, Rybinski L, Kesiak J, Tomaszewska L. Nitroglycerin and dobutamine in the treatment of low cardiac output syndrome after direct myocardial revascularization. Wplyw Glukagonu na Uklad Krazenia 1985;40(5):135-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">3920646</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Seino 1996 {published data only}</Title><Reference><Citation>Seino Y, Momomura S, Takano T, Hayakawa H, Katoh K, Japan Intravenous Milrinone Investigators. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Intensive Care Medicine 1996;24(9):1490-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797620</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to ongoing studies</Title><ReferenceList><Title>NCT03207165 {published data only}</Title><Reference><Citation>NCT03207165. Milrinone versus dobutamine in critically ill patients. clinicaltrials.gov/show/NCT03207165 (first received 2 July 2017).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT03340779 {published data only}</Title><Reference><Citation>NCT03340779. Norepinephrine vs norepinephrine and dobutamine in cardiogenic shock. clinicaltrials.gov/show/NCT03340779 (first received 14 November 2017).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT04020263 {published data only}</Title><Reference><Citation>NCT04020263. Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. clinicaltrials.gov/show/NCT04020263 (first received 16 July 2019).</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Alexander 2001</Title><Reference><Citation>Alexander RW, Pratt CM, Ryan TJ, Roberts R. Diagnosis and management of patients with acute myocardial infarction. In: Fuster V, Alexander RW, O&#x2019;Rourke RA, editors(s). Hurst&#x2019;s The Heart. 10th edition. New York: McGraw-Hill Company, 2001:1275&#x2013;359.</Citation></Reference></ReferenceList><ReferenceList><Title>Balshem 2011</Title><Reference><Citation>Balshem H, Helfand M, Sch&#xfc;nemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of&#xa0;Clinical Epidemiology 2011;64(4):401-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208779</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Belletti 2015</Title><Reference><Citation>Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L, et al. The effect of inotropes and vasopressors on mortality. British Journal of Anaesthesia 2015;115(5):656-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">26475799</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Benjamin 2019</Title><Reference><Citation>Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics: 2019 update: a report from the American Heart Association. Circulation 2019;139(10):E56-E528.</Citation><ArticleIdList><ArticleId IdType="pubmed">30700139</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>CDC 2019</Title><Reference><Citation>Centers for Disease Control and Prevention. Heart Disease and Stroke Prevention. www.cdc.gov/chronicdisease/resources/publications/aag.htm (accessed 23 December 2019).</Citation></Reference></ReferenceList><ReferenceList><Title>Chioncel 2020</Title><Reference><Citation>Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure 2020;22(8):1315-41. [DOI: 10.1002/ejhf.1922]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1922</ArticleId><ArticleId IdType="pubmed">32469155</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cholley 2019</Title><Reference><Citation>Cholley B, Levy B, Fellahi J-L, Longrois D, Amour J, Ouattara A, et al. Levosimendan in the light of the results of the recent randomized controlled trials. An expert opinion paper. Critical Care 2019;23(385):1-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6883606</ArticleId><ArticleId IdType="pubmed">31783891</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Delaney 2010</Title><Reference><Citation>Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. International Journal of Cardiology 2010;138:281-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18817994</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>De Luca 2004</Title><Reference><Citation>De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction - every minute of delay counts. Circulation 2004;109(10):1223&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15007008</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>De Luca 2015</Title><Reference><Citation>De Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, et al. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. European Journal of Heart Failure 2015;17(11):1124-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26339723</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Den Uil 2009a</Title><Reference><Citation>Den Uil CA, Caliskan K, Lagrand WK, Van der Ent M, Jewbali LS, Van Kuijk JP, et al. Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure. Intensive Care Medicine 2009;35(11):1893-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19639300</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Den Uil 2009b</Title><Reference><Citation>Den Uil CA, Lagrand WK, Van der Ent M, Nieman K, Struijs A, Jewbali LSD, et al. Conventional hemodynamic resuscitation may fail to optimize tissue perfusion: an observational study on the effects of dobutamine, enoximone, and norepinephrine in patients with acute myocardial infarction complicated by cardiogenic shock. PLOS&#xa0;One 2014;9(8):e103978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4118994</ArticleId><ArticleId IdType="pubmed">25084171</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Den Uil 2019</Title><Reference><Citation>Den Uil CA, Van Mieghem NM, Bastos MB, Jewbali LS, Lenzen MJ, Engstrom AE, et al. Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: a randomised trial. EuroIntervention 2019;15(7):586-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">31147306</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Elbadawi 2019</Title><Reference><Citation>Elbadawi A, Elgendy IY, Mahmoud K, Barakat AF, Mentias A, Mohamed AH, &#xa0;et al. Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. Journal of the American College of Cardiology, Cardiovascular Interventions 2019;12(18):1825&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">31537282</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fang 2018</Title><Reference><Citation>Fang M, Cao H, Wang Z. Levosimendan in patients with cardiogenic shock complicating myocardial infarction. Medicina&#xa0;Intensiva 2018;42(7):409-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">29126662</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gamper 2016</Title><Reference><Citation>Gamper G, Havel C, Arrich J, Losert H, Pace NL, M&#xfc;llner M, et al. Vasopressors for hypotensive shock. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No: CD003709. [DOI: 10.1002/14651858.CD003709.pub4]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003709.pub4</ArticleId><ArticleId IdType="pmc">PMC6516856</ArticleId><ArticleId IdType="pubmed">26878401</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>GRADEpro GDT 2015 [Computer program]</Title><Reference><Citation>GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011a</Title><Reference><Citation>Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.</Citation><ArticleIdList><ArticleId IdType="pubmed">21195583</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011b</Title><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839614</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011c</Title><Reference><Citation>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21247734</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011d</Title><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302.</Citation><ArticleIdList><ArticleId IdType="pubmed">21803546</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011e</Title><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21802903</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011f</Title><Reference><Citation>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21802904</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2013</Title><Reference><Citation>Guyatt GH, Oxman AD, Santesso N, Hefland M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609141</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harjola 2010</Title><Reference><Citation>Harjola VP, Costa S, Sund R, Ylikangas S, Siiril&#xe4;-Waris K, Melin J, et al, FINN-AKVA Study Group. The type of acute heart failure and the costs of hospitalization. International Journal of Cardiology 2010;145(1):103-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19560830</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harrison 2013</Title><Reference><Citation>Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia 2013;27(6):1224-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">24050857</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>HFMA 2010</Title><Reference><Citation>Healthcare Financial Management Association. National average costs by department for heart failure and shock. Healthcare Financial Management 2010;64(3):122-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">20214117</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2002</Title><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2011a</Title><Reference><Citation>Higgins JP, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Hochman 1999</Title><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularisation in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New England Journal of Medicine 1999;341:625-34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hochman 2003</Title><Reference><Citation>Hochman&#xa0;JS. Cardiogenic shock complicating acute myocardial infarction - expanding the paradigm. Circulation 2003;107(24):2998&#x2013;3002.</Citation><ArticleIdList><ArticleId IdType="pubmed">12821585</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hollenberg 2007</Title><Reference><Citation>Hollenberg SM. Vasodilators in acute heart failure. Heart Failure Reviews 2007;12(2):143-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17447137</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>How 2010</Title><Reference><Citation>How OJ, R&#xf8;sner A, Kildal AB, Stenberg TA, Gjessing PF, Hermansen SE, et al. Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock. Translational Research 2010;156(5):273-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20970750</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Huang 2013</Title><Reference><Citation>Huang X, Lei S, Zhu M, Jiang R, Huang L, Xia G, et al. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. Journal of Zhejiang University - SCIENCE B 2013;14(5):400-15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3650454</ArticleId><ArticleId IdType="pubmed">23645177</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jeger 2008</Title><Reference><Citation>Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer J-C, Erne P, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Annals of Internal Medicine 2008;149(9):618-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">18981487</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Karami 2020</Title><Reference><Citation>Karami M, Hemradj VV, Ouweneel DM, Den Uil CA, Limpens J, Otterspoor LC, et al. Vasopressors and inotropes in acute myocardial infarction related cardiogenic shock: a systematic review and meta-analysis. Journal of Clinical Medicine 2020;9(7):e2051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7408805</ArticleId><ArticleId IdType="pubmed">32629772</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Koster 2015</Title><Reference><Citation>Koster G, Wetterslev J, Gluud C, Zijlstra JG, Scheeren TWL, Van der Horst ICC, et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine 2015;41:203-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25518953</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Landoni 2010a</Title><Reference><Citation>Landoni G, Mizzi A, Biondi-Zoccai G, Bruno G, Bignami E, Corno L, et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. Journal of Cardiothoracic and Vascular Anesthesia 2010;24(1):51-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19700350</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Landoni 2010b</Title><Reference><Citation>Landoni G, Mizzi A, Biondi-Zoccai A, Bignami E, Prati P, Ajello V, et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiologica 2010;76(4):276-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">20332741</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Landoni 2012</Title><Reference><Citation>Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Critical Care Medicine 2012;40(2):634-46.</Citation><ArticleIdList><ArticleId IdType="pubmed">21963578</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lefebvre 2011</Title><Reference><Citation>Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Leopold 2018</Title><Reference><Citation>Leopold V, Gayat E, Pirracchio R, Spinar J, Parenica J, Tarvasmaki T, et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Medicine 2018;44(6):847-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">29858926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Maharaj 2011</Title><Reference><Citation>Maharaj R, Metaxa V. Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Critical Care 2011;15:R140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219012</ArticleId><ArticleId IdType="pubmed">21651806</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Moher 2009</Title><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 2009;6(7):1-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mozaffarian 2016</Title><Reference><Citation>Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al, American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Executive summary: Heart disease and stroke statistics - 2016 Update: a report from the American Heart Association. Circulation 2016;133(4):447-54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26811276</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nativi&#x2010;Nicolau 2014</Title><Reference><Citation>Nativi-Nicolau J, Selzman CH, Fang JC, Stehlik J. Pharmacologic therapies for acute cardiogenic shock. Current Opinion in Cardiology 2014;29(3):250-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24686400</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nieminen 2014</Title><Reference><Citation>Nieminen MS, Altenberger J, Ben-Gal T, Boehmer A, Comin-Colet J, Dickstein K, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure. International Journal of Cardiology 2014;174(2):360-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24780540</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nieminen 2016</Title><Reference><Citation>Nieminen MS, Buerke M, Cohen-Solal A, Costa S, Edes I, Erlikh A, et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. International Journal of Cardiology 2016;218:150&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27232927</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>O'Gara 2013</Title><Reference><Citation>O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127(4):e362&#x2013;e425.</Citation><ArticleIdList><ArticleId IdType="pubmed">23247304</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pietrangelo 2010</Title><Reference><Citation>Pietrangelo T, Giampietro L, De Filippis B, La Rovere R, Fulle S, Amoroso R. Effect of milrinone analogues on intracellular calcium increase in single living H9C2 cardiac cells. European Journal of Medicinal Chemistry 2010;45(11):4928-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">20801556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ponikowski 2016</Title><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure 2016;18(8):891&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">27207191</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Reyentovich 2016</Title><Reference><Citation>Reyentovich A, Barghash MH, Hochman JS. Management of refractory cardiogenic shock. Nature Reviews Cardiology 2016;13(8):481-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">27356877</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Reynolds 2008</Title><Reference><Citation>Reynolds HR, Hochman JS. Cardiogenic shock - current concepts and improving outcomes. Circulation 2008;117(5):686-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">18250279</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ribeiro 2010</Title><Reference><Citation>Ribeiro RA, Rohde LEP, Polanczyk CA. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arquivos Brasileiros de Cardiologia 2010;95(2):230-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20549133</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rognoni 2011</Title><Reference><Citation>Rognoni A, Lupi A, Lazzero M, Bongo AS, Rognoni G. Levosimendan: from basic science to clinical trials. Recent Patents on Cardiovascular Drug Discovery 2011;6(1):9-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208157</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>R&#xfc;cker 2008</Title><Reference><Citation>R&#xfc;cker G, Schwarzer G, Schumacher M. Heterogeneity in meta-analysis: misconceiving I2. Evidenz, Fortbildung und Qualit&#xe4;t im Gesundheitswesen 2008;Suppl VI:20.</Citation></Reference></ReferenceList><ReferenceList><Title>Samimi&#x2010;Fard 2008</Title><Reference><Citation>Samimi-Fard S, Garc&#xed;a-Gonz&#xe1;lez MJ, Dom&#xed;nguez-Rodr&#xed;guez A, Abreu-Gonz&#xe1;lez P. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology 2008;127(2):284-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17643519</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sanfilippo 2017</Title><Reference><Citation>Sanfilippo&#xa0;F, Knight JB, Scolletta&#xa0;S, &#xa0;Santonocito C, &#xa0;Pastore F, &#xa0;Lorini FL, et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Critical Care 2017;21(1):252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648477</ArticleId><ArticleId IdType="pubmed">29047417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Santesso 2016</Title><Reference><Citation>Santesso N, Carrasco-Labra A, Langendam M, Brignardello-Petersen R, Mustafa RA, Heus P, et al. Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. Journal of&#xa0;Clinical&#xa0;Epidemiology 2016;74:28-39.</Citation><ArticleIdList><ArticleId IdType="pubmed">26796947</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shea 2009</Title><Reference><Citation>Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. Journal of Clinical Epidemiology 2009;62(10):1013-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19230606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Silvetti 2014</Title><Reference><Citation>Silvetti S, Greco T, Di Prima AL, Mucchetti M, Lurdes Castro M, Pasin L, et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients. Clinical Research in Cardiology 2014;103(7):505-13.</Citation><ArticleIdList><ArticleId IdType="pubmed">24368740</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Singh 2007</Title><Reference><Citation>Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, et al. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock. Journal of the American College of Cardiology 2007;50(18):1752&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17964038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Steg 2012</Title><Reference><Citation>Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kaab S, et al, CLARIFY Registry Investigators. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. European Heart Journal 2012;33(22):2831-40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498005</ArticleId><ArticleId IdType="pubmed">22922505</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thackray 2002</Title><Reference><Citation>Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. European Journal of Heart Failure 2002;4(4):515-29.</Citation><ArticleIdList><ArticleId IdType="pubmed">12167393</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thiele 2019</Title><Reference><Citation>Thiele H, Ohman EM, DeWaha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. European Heart Journal 2019;40(32):2671-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Triposkiadis 2009</Title><Reference><Citation>Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. Journal of the American College of Cardiology 2009;54(19):1747-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">19874988</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Werdan 2019</Title><Reference><Citation>Werdan K, Ru&#xdf; M, Boeken U, Buerke M, Briegel J, Delle-Karth G, et al. Deutsch-&#xf6;sterreichische S3 Leitlinie &#x201e;Infarktbedingter kardiogener Schock - Diagnose, Monitoring und Therapie&#x201c;. leitlinien.dgk.org/2020/deutsch-oesterreichische-s3-leitlinie-infarktbedingter-kardiogener-schock-diagnose-monitoring-und-therapie/ (accessed prior to 29 October 2020).</Citation></Reference></ReferenceList><ReferenceList><Title>Windecker 2013</Title><Reference><Citation>Windecker S, Bax JJ, Myat A, Stone GW, Marber MS. Future treatment strategies in ST-segment elevation myocardial infarction. Lancet 2013;382(9892):644&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">23953388</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yeh 2010</Title><Reference><Citation>Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. New England Journal of Medicine 2010;362(23):2155&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">20558366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yusuf 2004</Title><Reference><Citation>Yusuf S, Hawken S, &#xd4;unpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364185</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zheng 2009</Title><Reference><Citation>Zheng J, Ma J, Zhang P, Hu L, Fan X, Tang Q. Milrinone inhibits hypoxia or hydrogen dioxide-induced persistent sodium current in ventricular myocytes. European Journal of Pharmacology 2009;616(1-3):206-12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19549513</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>Schumann 2018</Title><Reference><Citation>Schumann J, Henrich EC, Strobl H, Prondzinsky R, Weiche S, Thiele H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No: CD009669. [DOI: 10.1002/14651858.CD009669.pub3]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009669.pub3</ArticleId><ArticleId IdType="pmc">PMC6491099</ArticleId><ArticleId IdType="pubmed">29376560</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Unverzagt 2014</Title><Reference><Citation>Unverzagt S, Wachsmuth L, Hirsch K, Thiele H, Buerke M, Haerting J, et al. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No: CD009669. [DOI: 10.1002/14651858.CD009669.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009669.pub2</ArticleId><ArticleId IdType="pubmed">24385385</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36471408</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Parameters associated with successful weaning of veno-arterial extracorporeal membrane oxygenation: a systematic review.</ArticleTitle><Pagination><StartPage>375</StartPage><MedlinePgn>375</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">375</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-022-04249-w</ELocationID><Abstract><AbstractText Label="PURPOSE">Veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) can be used to restore organ perfusion in patients with cardiogenic shock until native heart recovery occurs. It may be challenging, however, to determine when patients can be weaned successfully from ECMO-surviving without requiring further mechanical support or heart transplant. We aimed to systematically review the medical literature to determine the biomarkers, hemodynamic and echocardiographic parameters associated with successful weaning of VA-ECMO in adults with cardiogenic shock and to present an evidence-based weaning algorithm incorporating key findings.</AbstractText><AbstractText Label="METHOD">We systematically searched PubMed, Embase, ProQuest, Google Scholars, Web of Science and the Grey literature for pertinent original research reports. We excluded studies limited to extracorporeal cardiopulmonary resuscitation (ECPR) as the neurological prognosis may significantly alter the decision-making process surrounding the device removal in this patient population. Studies with a mixed population of VA-ECMO for cardiogenic shock or cardiac arrest were included. We excluded studies limited to patients in which ECMO was only used as a bridge to VAD or heart transplant, as such patients are, by definition, never "successfully weaned." We used the Risk of Bias Assessment tool for Non-Randomized Studies. The study was registered on the International prospective register of systematic reviews (PROSPERO CRD42020178641).</AbstractText><AbstractText Label="RESULTS">We screened 14,578 records and included 47 that met our pre-specified criteria. Signs of lower initial severity of shock and myocardial injury, early recovery of systemic perfusion, left and right ventricular recovery, hemodynamic and echocardiographic stability during flow reduction trial and/or pump-controlled retrograde trial off predicted successful weaning. The most widely used parameter was the left ventricular outflow tract velocity time integral, an indicator of stroke volume. Most studies had a moderate or high risk of bias. Heterogeneity in methods, timing, and conditions of measurements precluded any meta-analysis.</AbstractText><AbstractText Label="CONCLUSIONS">In adult patients on VA-ECMO for cardiogenic shock, multiple biomarkers, hemodynamic and echocardiographic parameters may be used to track resolution of systemic hypoperfusion and myocardial recovery in order to identify patients that can be successfully weaned.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charbonneau</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chahinian</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bebawi</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavigueur</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe9;vesque</LastName><ForeName>&#xc9;milie</ForeName><Initials>&#xc9;</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Surgery, Montreal Heart Institute, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamarche</LastName><ForeName>Yoan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Surgery, Montreal Heart Institute, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serri</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Surgery, Montreal Heart Institute, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Surgery, Montreal Heart Institute, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noly</LastName><ForeName>Pierre-Emmanuel</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Surgery, Montreal Heart Institute, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cournoyer</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavayas</LastName><ForeName>Yiorgos Alexandros</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, H&#xf4;pital du Sacr&#xe9;-C&#x153;ur de Montr&#xe9;al, 5400 Boulevard Gouin Ouest, Montreal, QC, H4J 1C5, Canada. yiorgos.alexandros.cavayas@umontreal.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Surgery, Montreal Heart Institute, Montreal, Canada. yiorgos.alexandros.cavayas@umontreal.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016887" MajorTopicYN="Y">Cardiopulmonary Resuscitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="Y">Heart Arrest</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adults</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Echocardiography</Keyword><Keyword MajorTopicYN="N">Extracorporeal life support</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Hemodynamic parameters</Keyword><Keyword MajorTopicYN="N">Left ventricular function</Keyword><Keyword MajorTopicYN="N">Right ventricular function</Keyword><Keyword MajorTopicYN="N">VA-ECMO</Keyword></KeywordList><CoiStatement>On behalf of all authors, the corresponding authors state that there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>5</Day><Hour>23</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36471408</ArticleId><ArticleId IdType="pmc">PMC9724323</ArticleId><ArticleId IdType="doi">10.1186/s13054-022-04249-w</ArticleId><ArticleId IdType="pii">10.1186/s13054-022-04249-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abrams D, Garan AR, Abdelbary A, et al. Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Med. 2018;44:717&#x2013;729. doi: 10.1007/s00134-018-5064-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-018-5064-5</ArticleId><ArticleId IdType="pubmed">29450594</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiser SM, Tribble CG, Kaza AK, et al. When to discontinue extracorporeal membrane oxygenation for postcardiotomy support. Ann Thorac Surg. 2001 doi: 10.1016/S0003-4975(00)02340-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(00)02340-7</ArticleId><ArticleId IdType="pubmed">11216748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A, Combes A, van Diepen S, et al. Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med. 2018;44:760&#x2013;773. doi: 10.1007/s00134-018-5214-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-018-5214-9</ArticleId><ArticleId IdType="pubmed">29767322</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousse N, Juthier F, Pin&#xe7;on C, et al. ECMO as a bridge to decision: recovery, VAD, or heart transplantation? Int J Cardiol. 2015;187:620&#x2013;627. doi: 10.1016/j.ijcard.2015.03.283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.03.283</ArticleId><ArticleId IdType="pubmed">25863737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-S, Chao A, Yu H-Y, et al. Analysis and results of prolonged resuscitation in cardiac arrest patients rescued by extracorporeal membrane oxygenation. J Am Coll Cardiol. 2003;41:197&#x2013;203. doi: 10.1016/S0735-1097(02)02716-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(02)02716-X</ArticleId><ArticleId IdType="pubmed">12535808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W-W, Tsai F-C, Tsai T-Y, et al. Predictors of mortality in patients successfully weaned from extracorporeal membrane oxygenation. PLoS ONE. 2012 doi: 10.1371/journal.pone.0042687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042687</ArticleId><ArticleId IdType="pmc">PMC3411657</ArticleId><ArticleId IdType="pubmed">22870340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavarocchi NC, Pitcher HT, Yang Q, et al. Weaning of extracorporeal membrane oxygenation using continuous hemodynamic transesophageal echocardiography. J Thorac Cardiovasc Surg. 2013;146:1474&#x2013;1479. doi: 10.1016/j.jtcvs.2013.06.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2013.06.055</ArticleId><ArticleId IdType="pubmed">23993027</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso S, Matsui H, Fushimi K, Yasunaga H. In-hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a national inpatient database in Japan. Crit Care Lond Engl. 2016;20:80&#x2013;80. doi: 10.1186/s13054-016-1261-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1261-1</ArticleId><ArticleId IdType="pmc">PMC4820970</ArticleId><ArticleId IdType="pubmed">27044572</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Pieri M, Arnaez Corada B, et al. Timing and strategy for weaning from venoarterial ECMO are complex issues. J Cardiothorac Vasc Anesth. 2015;29:906&#x2013;911. doi: 10.1053/j.jvca.2014.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2014.12.011</ArticleId><ArticleId IdType="pubmed">25836952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangrillo A. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc. 2013;15:7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23944202</ArticleId></ArticleIdList></Reference><Reference><Citation>Omar HR, Mirsaeidi M, Mangar D, Camporesi EM. Duration of ECMO is an independent predictor of intracranial hemorrhage occurring during ECMO support. ASAIO J. 2016;62:634&#x2013;636. doi: 10.1097/MAT.0000000000000368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000368</ArticleId><ArticleId IdType="pubmed">26978708</ArticleId></ArticleIdList></Reference><Reference><Citation>Extracorporal Life Support Organisation (ELSO). Guidelines for adult cardiac failure. https://www.elso.org/Portals/0/IGD/Archive/FileManager/e76ef78eabcusersshyerdocumentselsoguidelinesforadultcardiacfailure1.3.pdf. Accessed 19 Aug 2019</Citation></Reference><Reference><Citation>Extracorporal Life Support Organisation (ELSO). Guidelines for ECPR cases. https://www.elso.org/Portals/0/IGD/Archive/FileManager/6713186745cusersshyerdocumentselsoguidelinesforecprcases1.3.pdf. Accessed 19 Aug 2019</Citation></Reference><Reference><Citation>Lorusso R, Shekar K, MacLaren G, et al. ELSO interim guidelines for venoarterial extracorporeal membrane oxygenation in adult cardiac patients. ASAIO J. 2021;67:827&#x2013;844. doi: 10.1097/MAT.0000000000001510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001510</ArticleId><ArticleId IdType="pubmed">34339398</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, Luyt C-E, Leprince P, et al. Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med. 2011;37:1738&#x2013;1745. doi: 10.1007/s00134-011-2358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-011-2358-2</ArticleId><ArticleId IdType="pubmed">21965097</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C-L, Wang H, Jia M, et al. The early dynamic behavior of lactate is linked to mortality in postcardiotomy patients with extracorporeal membrane oxygenation support: a retrospective observational study. J Thorac Cardiovasc Surg. 2015;149:1445&#x2013;1450. doi: 10.1016/j.jtcvs.2014.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.11.052</ArticleId><ArticleId IdType="pubmed">25534305</ArticleId></ArticleIdList></Reference><Reference><Citation>Park B-W, Seo D-C, Moon I-K, et al. Pulse pressure as a prognostic marker in patients receiving extracorporeal life support. Resuscitation. 2013;84:1404&#x2013;1408. doi: 10.1016/j.resuscitation.2013.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2013.04.009</ArticleId><ArticleId IdType="pubmed">23603288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortuno S, Delmas C, Diehl J-L, et al. Weaning from veno-arterial extra-corporeal membrane oxygenation: which strategy to use? Ann Cardiothorac Surg. 2019;8:E1&#x2013;E8. doi: 10.21037/acs.2018.08.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs.2018.08.05</ArticleId><ArticleId IdType="pmc">PMC6379199</ArticleId><ArticleId IdType="pubmed">30854330</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, El-Banayosy A, Combes A. How to wean a patient from veno-arterial extracorporeal membrane oxygenation. Intensive Care Med. 2015;41:902&#x2013;905. doi: 10.1007/s00134-015-3663-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-3663-y</ArticleId><ArticleId IdType="pubmed">25619488</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk of Bias Assessment tool for Non-randomized Studies (RoBANS). Development and validation of a new instrument|Colloquium Abstracts. https://abstracts.cochrane.org/2011-madrid/risk-bias-assessment-tool-non-randomized-studies-robans-development-and-validation-new. Accessed 6 Sept 2021</Citation></Reference><Reference><Citation>Colombo CNJ, Dammassa V, Pozzi M, et al. Echocardiographic predictors of VA ECMO weaning in patients with cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2019;8(Supplement 1):144&#x2013;145. doi: 10.1177/2048872619829424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872619829424</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyt C-E, Landivier A, Leprince P, et al. Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock. J Crit Care. 2012;27:524.e7&#x2013;524.e14. doi: 10.1016/j.jcrc.2011.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2011.12.009</ArticleId><ArticleId IdType="pubmed">22386227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazet C, Conil JM, Georges B, et al. How to predict weaning success during ECLS support? Ann Intensive Care. 2017;7(1 Supplement 1):160. doi: 10.1186/s13613-016-0224-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-016-0224-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Mork SR, Frederiksen CA, Nielsen RR, et al. A systematic approach to weaning from extracorporeal membrane oxygenation in patients with refractory cardiac failure. Acta Anaesthesiol Scand. 2021;17:17. doi: 10.1111/aas.13814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.13814</ArticleId><ArticleId IdType="pubmed">33728635</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T, Watanabe M, Murakami M, et al. End-tidal carbon dioxide monitoring indicates recovery from cardiogenic shock in patients receiving percutaneous cardiopulmonary support. J Artif Organs. 2005;8:63&#x2013;66. doi: 10.1007/s10047-004-0279-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10047-004-0279-3</ArticleId><ArticleId IdType="pubmed">15951983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez Martin J, Alonso-Fernandez-Gatta M, Merchan Gomez S, et al. Echocardiographic recovery changes in patients supported with veno-arterial extracorporeal membrane oxygenator and weaning success. Eur Heart J. 2021;42:ehab724 1060. doi: 10.1093/eurheartj/ehab724.1060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab724.1060</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Liu N, Dong D, et al. Pulmonary artery flotation catheter (PAFC) combined with pump-controlled retrograde trial off (PCRTO) as a trial for weaning VA-ECMO patients: a retrospective study. Perfusion. 2022 doi: 10.1177/02676591211054976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02676591211054976</ArticleId><ArticleId IdType="pubmed">35191337</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaumi Y, Yasuda S, Morii I, et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J. 2005;26:2185&#x2013;2192. doi: 10.1093/eurheartj/ehi411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehi411</ArticleId><ArticleId IdType="pubmed">16014643</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto M, Asaumi Y, Nakamura Y, et al. Clinical determinants of successful weaning from extracorporeal membrane oxygenation in patients with fulminant myocarditis. ESC Heart Fail. 2018;5:675&#x2013;684. doi: 10.1002/ehf2.12291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12291</ArticleId><ArticleId IdType="pmc">PMC6073023</ArticleId><ArticleId IdType="pubmed">29757498</ArticleId></ArticleIdList></Reference><Reference><Citation>North M, Eckman P, Samara M, et al. Peak troponin predicts successful weaning from VA ECMO in patients with acute myocardial infarction complicated by cardiogenic shock. Int J Artif Organs. 2022;45:68&#x2013;74. doi: 10.1177/0391398821991155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0391398821991155</ArticleId><ArticleId IdType="pubmed">33530814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiura A, Abe R, Nakayama T, et al. Predictors of successful weaning from veno-arterial extracorporeal membrane oxygenation after coronary revascularization for acute myocardial infarction complicated by cardiac arrest: a retrospective multicenter study. Shock. 2019;51:690&#x2013;697. doi: 10.1097/SHK.0000000000001220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001220</ArticleId><ArticleId IdType="pubmed">30080744</ArticleId></ArticleIdList></Reference><Reference><Citation>Omar HR, Handshoe JW, Tribble T, Guglin M. Survival on venoarterial extracorporeal membrane oxygenation in cardiogenic shock: which lactate is most useful? ASAIO J. 2022;68:41&#x2013;45. doi: 10.1097/MAT.0000000000001413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001413</ArticleId><ArticleId IdType="pubmed">33769350</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhr L, Djordjevic I, Ivanov B, et al. Concomitant IABP Improves ECMO Weaning: A Single-Center Experience. Thorac Cardiovasc Surg. 2022;70(S 01):S1&#x2013;S61. doi: 10.1055/s-0042-1742931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0042-1742931</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshima K, Morishita Y, Hinohara H, et al. Factors for weaning from a percutaneous cardiopulmonary support system (PCPS) in patients with severe cardiac failure: a comparative study in weaned and nonweaned patients. Int Heart J. 2006;47:575&#x2013;584. doi: 10.1536/ihj.47.575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1536/ihj.47.575</ArticleId><ArticleId IdType="pubmed">16960412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongkolpun W, Bakos P, Peluso L, et al. Cutaneous blood flow as a predictor of successful weaning from VA-ECMO. Crit Care. 2019 doi: 10.1186/s13054-019-2358-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2358-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried JA, Griffin JM, Masoumi A, et al. Predictors of survival and ventricular recovery following acute myocardial infarction requiring extracorporeal membrane oxygenation therapy. ASAIO J. 2022;68:800&#x2013;807. doi: 10.1097/MAT.0000000000001570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001570</ArticleId><ArticleId IdType="pubmed">35380184</ArticleId></ArticleIdList></Reference><Reference><Citation>Morisawa D, Higuchi Y, Iwakura K, et al. Predictive factors for successful weaning from percutaneous cardiopulmonary support in patients with cardiogenic shock complicating acute myocardial infarction. J Cardiol. 2012;60:350&#x2013;354. doi: 10.1016/j.jjcc.2012.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2012.06.005</ArticleId><ArticleId IdType="pubmed">22819038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu J. Clinical parameters for successful weaning from venous-arterial extracorporeal membrane oxygenation after cardiogenic shock. J Am Coll Cardiol. 2012;59:E1022. doi: 10.1016/S0735-1097(12)61023-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(12)61023-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada K, Kawakami S, Murata S, et al. Predicting parameters for successful weaning from veno-arterial extracorporeal membrane oxygenation in cardiogenic shock. ESC Heart Fail. 2021;8:471&#x2013;480. doi: 10.1002/ehf2.13097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13097</ArticleId><ArticleId IdType="pmc">PMC7835592</ArticleId><ArticleId IdType="pubmed">33264500</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi R, Guo J, Zhou Q, et al. Effect evaluation of bedside ultrasound monitoring of left ventricular functional parameters combined with clinical indicators on veno-arterial extracorporeal membrane oxygenation. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021;33:329&#x2013;333. doi: 10.3760/cma.j.cn121430-20201023-00684.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn121430-20201023-00684</ArticleId><ArticleId IdType="pubmed">33834975</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruke T, Inomata T, Kawaguchi T, et al. Prognostic impact of dramatic alteration of mixed venous oxygen saturation on the hemodynamic recovery from veno-arterial extracorporeal membrane oxygenation. Eur Heart J. 2012;33:69. doi: 10.1093/eurheartj/ehs281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawamura A, Okumura T, Hirakawa A, et al. Early prediction model for successful bridge to recovery in patients with fulminant myocarditis supported with percutaneous venoarterial extracorporeal membrane oxygenation&#x2014;insights from the change pump study. Circ J. 2018;82:699&#x2013;707. doi: 10.1253/circj.CJ-17-0549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-17-0549</ArticleId><ArticleId IdType="pubmed">29081472</ArticleId></ArticleIdList></Reference><Reference><Citation>Chommeloux J, Montero S, Franchineau G, et al. Microcirculation evolution in patients on venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med. 2020;48:e9&#x2013;e17. doi: 10.1097/CCM.0000000000004072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004072</ArticleId><ArticleId IdType="pubmed">31634235</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin S, dos Reis MD, Caliskan K, et al. Functional evaluation of sublingual microcirculation indicates successful weaning from VA-ECMO in cardiogenic shock. Crit Care. 2017;21:265. doi: 10.1186/s13054-017-1855-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-017-1855-2</ArticleId><ArticleId IdType="pmc">PMC5658964</ArticleId><ArticleId IdType="pubmed">29073930</ArticleId></ArticleIdList></Reference><Reference><Citation>North M, Wilson K, Hryniewicz K. Swan-Ganz catheter guided VA ECMO wean leads to successful decannulation. ASAIO J. 2018;64(Supplement 2):44. doi: 10.1097/MAT.0000000000000882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MY, Lin PJ, Tsai FC, et al. (2009) Postcardiotomy extracorporeal life support in adults: the optimal duration of bridging to recovery. ASAIO J Am Soc Artif Intern Organs. 1992;55:608&#x2013;613. doi: 10.1097/mat.0b013e3181b899c0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mat.0b013e3181b899c0</ArticleId><ArticleId IdType="pubmed">19770638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim JY, Jung JS. Predictors of successful weaning from veno-arterial extracorporeal membrane oxygenation support. Perfus Ger. 2019;34(1 Supplement):88&#x2013;89. doi: 10.1177/0267659119829686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659119829686</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph A, Venturini J, Blair JEA, et al. Prognostic value of right ventricular function in percutaneous veno-arterial extracorporeal membrane oxygenation. BMC Cardiovasc Disord. 2019;19:1&#x2013;16. doi: 10.1186/s12872-018-0978-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0978-y</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruke T, Inomata T, Imai H, et al. End-tidal carbon dioxide concentration can estimate the appropriate timing for weaning off from extracorporeal membrane oxygenation for refractory circulatory failure. Int Heart J. 2010;51:116&#x2013;120. doi: 10.1536/ihj.51.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1536/ihj.51.116</ArticleId><ArticleId IdType="pubmed">20379045</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaney C, Vuthoori R, Lima B, et al. Assessment of cardiac recovery using a formal stepwise weaning protocol in patients supported with venoarterial extracorporeal membrane oxygenation. Artif Organs. 2020;44(3):E97. doi: 10.1111/aor.13651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.13651</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, Guerot E, Combes A, et al. Two-dimensional strain rate and doppler tissue myocardial velocities: analysis by echocardiography of hemodynamic and functional changes of the failed left ventricle during different degrees of extracorporeal life support. J Am Soc Echocardiogr. 2012;25:632&#x2013;640. doi: 10.1016/j.echo.2012.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2012.02.009</ArticleId><ArticleId IdType="pubmed">22421027</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo CNJ, Dammassa V, Pozzi M, et al. Echocardiographic predictors of VA-ECMO weaning in patients with cardiogenic shock. Intensive Care Med Exp. 2019 doi: 10.1186/s40635-019-0265-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40635-019-0265-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouazani N, Shudo Y, Hill C, et al. The interest of tissue doppler imaging in the weaning of venoarterial extracorporeal membrane oxygenation. BMC Cardiovasc Disord. 2019;19:1&#x2013;16. doi: 10.1186/s12872-018-0978-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0978-y</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, Caudron J, Leprince P, et al. Right&#x2013;left ventricular interdependence: a promising predictor of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med. 2017;43:592&#x2013;594. doi: 10.1007/s00134-016-4657-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4657-0</ArticleId><ArticleId IdType="pubmed">28011989</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederiksen CA, Nielsen R, Frederiksen AS, et al. Echocardiographic predictors for successful weaning from veno-arterial extracorporeal membrane oxygenation. Eur Heart J. 2018;39(Supplement 1):1200. doi: 10.1093/eurheartj/ehy566.P5689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy566.P5689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambaro A, Vazir A, Galiatsou E, et al. Can speckle tracking help to guide VA-ECMO weaning? Provisional results of a pilot study. Perfusion. 2020;35(1 SUPPL):110. doi: 10.1177/0267659120909723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659120909723</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Jang WJ, Park TK, et al. Echocardiographic predictors of successful extracorporeal membrane oxygenation weaning after refractory cardiogenic shock. J Am Soc Echocardiogr. 2021 doi: 10.1016/j.echo.2020.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2020.12.002</ArticleId><ArticleId IdType="pubmed">33321165</ArticleId></ArticleIdList></Reference><Reference><Citation>Elena Puerto E, Guido Tavazzi G, Alessia Gambaro A, et al. Interaction between veno-arterial extracorporeal membrane oxygenation and the right ventricle. Eur Heart J Acute Cardiovasc Care. 2021;10(zuab020):173. doi: 10.1093/ehjacc/zuab020.173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuab020.173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Park Y, Choi KH, et al. Prognostic implication of RV coupling to pulmonary circulation for successful weaning from extracorporeal membrane oxygenation. JACC Cardiovasc Imaging. 2021;14:1523&#x2013;1531. doi: 10.1016/j.jcmg.2021.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2021.02.018</ArticleId><ArticleId IdType="pubmed">33865793</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-C, Lin L-Y, Chen Y-S, et al. Three-dimensional echocardiography-derived right ventricular ejection fraction correlates with success of decannulation and prognosis in patients stabilized by venoarterial extracorporeal life support. J Am Soc Echocardiogr. 2018;31:169&#x2013;179. doi: 10.1016/j.echo.2017.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2017.09.004</ArticleId><ArticleId IdType="pubmed">29079045</ArticleId></ArticleIdList></Reference><Reference><Citation>Westrope C, Harvey C, Robinson S, et al. Pump controlled retrograde trial off from VA-ECMO. ASAIO J. 2013;59:517&#x2013;519. doi: 10.1097/MAT.0b013e31829f5e9f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0b013e31829f5e9f</ArticleId><ArticleId IdType="pubmed">23995993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling L, Chan KM. Weaning adult patients with cardiogenic shock on veno-arterial extracorporeal membrane oxygenation by pump-controlled retrograde trial off. Perfusion. 2018;33:339&#x2013;345. doi: 10.1177/0267659118755888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659118755888</ArticleId><ArticleId IdType="pubmed">29409389</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh Y-C, Lee C-T, Wang C-H, et al. Investigation of microcirculation in patients with venoarterial extracorporeal membrane oxygenation life support. Crit Care Lond Engl. 2018;22:200. doi: 10.1186/s13054-018-2081-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-2081-2</ArticleId><ArticleId IdType="pmc">PMC6098836</ArticleId><ArticleId IdType="pubmed">30121090</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara A, Akin S, dos Reis MD, et al. Microcirculatory assessment of patients under VA-ECMO. Crit Care. 2016 doi: 10.1186/s13054-016-1519-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1519-7</ArticleId><ArticleId IdType="pmc">PMC5078964</ArticleId><ArticleId IdType="pubmed">27776535</ArticleId></ArticleIdList></Reference><Reference><Citation>Abali G, Tokg&#xf6;zo&#x11f;lu L, &#xd6;zcebe OI, et al. Which Doppler parameters are load independent? A study in normal volunteers after blood donation. J Am Soc Echocardiogr. 2005;18:1260&#x2013;1265. doi: 10.1016/j.echo.2005.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2005.06.012</ArticleId><ArticleId IdType="pubmed">16376752</ArticleId></ArticleIdList></Reference><Reference><Citation>Yal&#xe7;in F, Kaftan A, Muderriso&#x11f;lu H, et al. Is Doppler tissue velocity during early left ventricular filling preload independent? Heart. 2002;87:336&#x2013;339. doi: 10.1136/heart.87.4.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.87.4.336</ArticleId><ArticleId IdType="pmc">PMC1767062</ArticleId><ArticleId IdType="pubmed">11907005</ArticleId></ArticleIdList></Reference><Reference><Citation>Moury PH, Zunarelli R, Bailly S, et al. Diaphragm Thickening during venoarterial extracorporeal membrane oxygenation weaning: an observational prospective study. J Cardiothorac Vasc Anesth. 2021;35:1981&#x2013;1988. doi: 10.1053/j.jvca.2020.10.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.10.047</ArticleId><ArticleId IdType="pubmed">33218955</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35037618</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1866-0452</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Deutsches Arzteblatt international</Title><ISOAbbreviation>Dtsch Arztebl Int</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal Membrane Oxygenation.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>244</EndPage><MedlinePgn>235-244</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3238/arztebl.m2022.0068</ELocationID><ELocationID EIdType="pii" ValidYN="Y">arztebl.m2022.0068</ELocationID><Abstract><AbstractText Label="BACKGROUND">Veno-venous extracorporeal membrane oxygenation (VV-ECMO) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO), also known as extracorporeal life support (ECLS), can both be used to treat patients with acute pulmonary or cardiovascular failure.</AbstractText><AbstractText Label="METHODS">This review is based on publications retrieved by a selective search in PubMed on the topics of cardiogenic shock and acute pulmonary failure, also known as the acute respiratory distress syndrome (ARDS), as well as on ECMO. Attention was given chiefly to randomized, controlled trials and guidelines.</AbstractText><AbstractText Label="RESULTS">Initial findings from prospective, randomized trials of VV-ECMO are now available. Trials of ECLS therapy are now in progress or planned. A meta-analysis of two randomized, controlled trials of VV-ECMO for ARDS revealed more frequent survival 90 days after randomization among patients treated with VV-ECMO, compared to the control groups (36% vs. 48%; RR = 0.75 [95% confidence interval 0.6; 0.94]). For selected patients, after evaluation of the benefit-risk profile, VV-ECMO is a good treatment method for severe pulmonary failure, and ECLS for cardiogenic shock and resuscitation. The goal is to secure the circulation so that native heart function can be stabilized in the patient's further course or a permanent left-heart support system can be implanted, or else to support lung function until recovery.</AbstractText><AbstractText Label="CONCLUSION">ECMO is a valid option in selected patients when conservative treatment has failed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bernhardt</LastName><ForeName>Alexander M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department for Cardiovascular Surgery, University Heart &amp; Vascular Center Hamburg; Department of Cardiology, University Heart &amp; Vascular Center Hamburg; Department of Anaesthesiology, LMU Hospital Munich; Department of Cardiovascular Surgery, Heart Center, Faculty of Medicine, University of Freiburg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schrage</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Ines</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Trummer</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Westermann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Reichenspurner</LastName><ForeName>Hermann</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Dtsch Arztebl Int</MedlineTA><NlmUniqueID>101475967</NlmUniqueID><ISSNLinking>1866-0452</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Arztebl Int. 2022 Oct 7;119(40):685. doi: 10.3238/arztebl.m2022.0236.</RefSource><PMID Version="1">36594342</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Arztebl Int. 2022 Oct 7;119(40):685-686. doi: 10.3238/arztebl.m2022.0237.</RefSource><PMID Version="1">36594343</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>17</Day><Hour>8</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35037618</ArticleId><ArticleId IdType="pmc">PMC9342119</ArticleId><ArticleId IdType="doi">10.3238/arztebl.m2022.0068</ArticleId><ArticleId IdType="pii">arztebl.m2022.0068</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374:1351&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762075</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. Engl J Med. 2018;378:1965&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">29791822</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintel M, Busana M, Gattinoni L. Breathing and ventilation during extracorporeal membrane oxygenation: how to find the balance between rest and load. Am J Respir Crit Care Med. 2019;200:954&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794105</ArticleId><ArticleId IdType="pubmed">31216180</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Peek GJ, Hajage D, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Med. 2020;46:2048&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537368</ArticleId><ArticleId IdType="pubmed">33021684</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher EC, Tomlinson G, Hajage D, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc bayesian analysis of a randomized clinical trial. JAMA. 2018;320:2251&#x2013;2259.</Citation><ArticleIdList><ArticleId IdType="pubmed">30347031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fichtner F, Moerer O, Weber-Carstens S, Nothacker M, Kaisers U, Laudi S. Clinical guideline for treating acute respiratory insufficiency with invasive ventilation and extracorporeal membrane oxygenation: evidence-based recommendations for choosing modes and setting parameters of mechanical ventilation. Respiration. 2019;98:357&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">31505511</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher PM, Schrage B, Sinning CR, et al. Venoarterial extracorporeal membrane oxygenation for cardiopulmonary support. Circulation. 2018;138:2298&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pubmed">30571518</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, De Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40:2671&#x2013;2683.</Citation><ArticleIdList><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Westermann D. Mechanical circulatory support devices in cardiogenic shock and acute heart failure. Curr Opin Crit Care. 2019;25:391&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">31135393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson-Smith AR, Bogdanova Y, Roydhouse S, et al. Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: systematic review and meta-analysis. Ann Cardiothorac Surg. 2019;8:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379189</ArticleId><ArticleId IdType="pubmed">30854307</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Freund A, Gimenez MR, et al. Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - design and rationale of the ECLS-SHOCK trial. Am Heart J. 2021;234:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">33428901</ArticleId></ArticleIdList></Reference><Reference><Citation>Banning AS, Adriaenssens T, Berry C, et al. Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial. EuroIntervention. 2021;16:e1227&#x2013;e1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9725005</ArticleId><ArticleId IdType="pubmed">33106225</ArticleId></ArticleIdList></Reference><Reference><Citation>Michels G, Wengenmayer T, Hagl C, et al. Recommendations for extracorporeal cardiopulmonary resuscitation (eCPR): consensus statement of DGIIN, DGK, DGTHG, DGfK, DGNI, DGAI, DIVI and GRC. Clin Res Cardiol. 2019;108:455&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">30361819</ArticleId></ArticleIdList></Reference><Reference><Citation>Yannopoulos D, Bartos J, Raveendran G, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet. 2020;396:1807&#x2013;1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7856571</ArticleId><ArticleId IdType="pubmed">33197396</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff D, Sayer G, Doshi D, Uriel N. Hemodynamics of mechanical circulatory support. J Am Coll Cardiol. 2015;66:2663&#x2013;2674.</Citation><ArticleIdList><ArticleId IdType="pubmed">26670067</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Becher PM, Bernhardt A, et al. Left ventricular unloading is associated with lower mortality in cardiogenic shock patients treated with veno-arterial extracorporeal membrane oxygenation: results from an international, multicenter cohort study. Circulation. 2020;142:2095&#x2013;2106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688081</ArticleId><ArticleId IdType="pubmed">33032450</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher PM, Go&#xdf;ling A, Schrage B, et al. Procedural volume and outcomes in patients undergoing VA-ECMO support. Crit Care. 2020;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275456</ArticleId><ArticleId IdType="pubmed">32503646</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao P, Khalpey Z, Smith R, Burkhoff D, Kociol RD. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. Circ Heart Fail. 2018;11 e004905.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Whitman G, Milojevic M, et al. 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. Ann Thorac Surg. 2021;111:327&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">33036737</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffa GM, Kowalewski M, Brodie D, et al. Meta-analysis of peripheral or central extracorporeal membrane oxygenation in postcardiotomy and non-postcardiotomy shock. Ann Thorac Surg. 2019;107:311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">29959943</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirnberger D, Fiser R, Harvey C, et al.  Extracorporeal Life Support Organisation Guidelines for ECMO transport. ELSO Guidelines ( 
 www.elso.org/resources/guidelines.aspx
. (2015)</Citation></Reference><Reference><Citation>Gehron J, Buchwald D, Klak K, Benk C, Bauer A. Aufgabengebiete der Kardiotechnik - ein Update. Kardiotechnik. 2017;26:64&#x2013;69.</Citation></Reference><Reference><Citation>Trummer G, M&#xfc;ller T, Muellenbach RM, et al. Education module extracorporeal life support (ECLS): Consensus statement of DIVI, DGTHG, DGfK, DGAI, DGIIN, DGF, GRC and DGK. Med Klin Intensivmed Notfmed. 2021;116:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">33792739</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis C, Brodie D, Strassmann S, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med. 2016;42:889&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">26942446</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies D, Jones D, et al. Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009;302:1888&#x2013;1895.</Citation><ArticleIdList><ArticleId IdType="pubmed">19822628</ArticleId></ArticleIdList></Reference><Reference><Citation>Patroniti N, Zangrillo A, Pappalardo F, et al. The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks. Intensive Care Med. 2011;37:1447&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080128</ArticleId><ArticleId IdType="pubmed">21732167</ArticleId></ArticleIdList></Reference><Reference><Citation>S3-Leitlinie 011/021. Einsatz der extrakorporalen Zirkulation (ECLS/ECMO) bei Herz- und Kreislaufversagen. 
 www.awmf.org/uploads/tx_szleitlinien/011-021l_S3_Einsatz-der-extrakorporalen-Zirkulation-ECLS-ECMO-bei-Herz-Kreislaufversagen_2021-02.pdf
. (2020)</Citation></Reference><Reference><Citation>Krishnan S, Schmidt GA. Hemodynamic monitoring in the extracorporeal membrane oxygenation patient. Curr Opin Crit Care. 2019;25:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">30865613</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JK, Smith TN, Pitcher HT, Hirose H, Cavarocchi NC. Cerebral and lower limb near-infrared spectroscopy in adults on extracorporeal membrane oxygenation. Artif Organs. 2012;36:659&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">22817780</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman LM, Malfertheiner MV, Montisci A, Pappalardo F. Weaning from veno-venous extracorporeal membrane oxygenation: how I do it. J Thorac Dis. 2018;10:692&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911556</ArticleId><ArticleId IdType="pubmed">29732188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross-Hardt S, Hesselmann F, Arens J, et al. Low-flow assessment of current ECMO/ECCO2R rotary blood pumps and the potential effect on hemocompatibility. Crit Care. 2019;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836552</ArticleId><ArticleId IdType="pubmed">31694688</ArticleId></ArticleIdList></Reference><Reference><Citation>Swol J, Shekar K, Protti A, et al. Extubate before VV ECMO decannulation or decannulate while remaining on the ventilator? The EuroELSO 2019 weaning survey. ASAIO J. 2021;67:e86&#x2013;e89.</Citation><ArticleIdList><ArticleId IdType="pubmed">32701622</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiumello D, Coppola S, Froio S, Colombo A, Del Sorbo L. Extracorporeal life support as bridge to lung transplantation: a systematic review. Crit Care. 2015;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302424</ArticleId><ArticleId IdType="pubmed">25774818</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiouris A, Budev MM, Yun JJ. Extracorporeal membrane oxygenation as a bridge to lung transplantation in the United States: a multicenter survey. ASAIO J. 2018;64:689&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">29251631</ArticleId></ArticleIdList></Reference><Reference><Citation>Weig T, Irlbeck M, Frey L, et al. Parameters associated with short- and midterm survival in bridging to lung transplantation with extracorporeal membrane oxygenation. Clin Transplant. 2013;27:E563&#x2013;E570.</Citation><ArticleIdList><ArticleId IdType="pubmed">23898897</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M, Kreibich M, Beyersdorf F, Benk C, Maier S, Trummer G. Standardized weaning from temporary extracorporeal life support in cardiovascular patients. Thorac Cardiovasc Surg. 2020;68:425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">31207648</ArticleId></ArticleIdList></Reference><Reference><Citation>Potapov E, Loforte A, Pappalardo F, et al. Impact of a surgical approach for implantation of durable left ventricular assist devices in patients on extracorporeal life support. J Card Surg. 2021;36:1344&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">33547707</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhardt AM, Zipfel S, Reiter B, et al. Impella 50. therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes. Eur J Cardiothorac Surg. 2019;56:1031&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">31038672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoldi LF, Pappalardo F, Lubos E, et al. Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 50 : de-escalate and ambulate. J Crit Care. 2020;57:259&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">32061461</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R, Hachamovitch R, Kittleson M, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014;97:610&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">24210621</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquer S, De Haro C, Peruga P, Oliva JC, Artigas A. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. Ann Intensive Care. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429319</ArticleId><ArticleId IdType="pubmed">28500585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36722581</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">0974-5181</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Annals of cardiac anaesthesia</Title><ISOAbbreviation>Ann Card Anaesth</ISOAbbreviation></Journal><ArticleTitle>Multiparameters associated to successful weaning from VA ECMO in adult patients with cardiogenic shock or cardiac arrest: Systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>4</StartPage><EndPage>11</EndPage><MedlinePgn>4-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/aca.aca_79_22</ELocationID><Abstract><AbstractText>Venoarterial extracorporeal membrane oxygenation (VA ECMO) is a form of temporary mechanical circulatory support and simultaneous extracorporeal gas exchange for acute cardiorespiratory failure, including refractory cardiogenic shock (CS) and cardiac arrest (CA). Few studies have assessed predictors of successful weaning (SW) from VA ECMO. This systematic review and meta-analysis aimed to identify a multiparameter strategy associated with SW from VA ECMO. PubMed and the Cochrane Library and the International Clinical Trials Registry Platform were searched. Studies reporting adult patients with CS or CA treated with VA ECMO published from the year 2000 onwards were included. Primary outcomes were hemodynamic, laboratory, and echocardiography parameters associated with a VA ECMO SW. A total of 11 studies (n=653) were included in this review. Pooled VA ECMO SW was 45% (95%CI: 39-50%, I2 7%) and in-hospital mortality rate was 46.6% (95%CI: 33-60%; I2 36%). In the SW group, pulse pressure [MD 12.7 (95%CI: 7.3-18) I2 = 0%] and mean blood pressure [MD 20.15 (95%CI: 13.8-26.4 I2 = 0) were higher. They also had lower values of creatinine [MD -0.59 (95%CI: -0.9 to -0.2) I2 = 7%], lactate [MD -3.1 (95%CI: -5.4 to -0.7) I2 = 89%], and creatine kinase [-2779.5 (95%CI: -5387 to -171) I2 = 38%]. And higher left and right ventricular ejection fraction, MD 17.9% (95%CI: -0.2-36.2) I2 = 91%, and MD 15.9% (95%CI 11.9-20) I2 = 0%, respectively. Different hemodynamic, laboratory, and echocardiographic parameters were associated with successful device removal. This systematic review demonstrated the relationship of multiparametric assessment on VA ECMO SW.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burgos</LastName><ForeName>Lucrecia Mar&#xed;a</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Heart Failure, Pulmonary Hypertension and Transplant Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seoane</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Critical care Cardiology Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos, Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez</LastName><ForeName>Mirta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Heart Failure, Pulmonary Hypertension and Transplant Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baro Vila</LastName><ForeName>Roc&#xed;o Consuelo</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Heart Failure, Pulmonary Hypertension and Transplant Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furmento</LastName><ForeName>Juan Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Critical care Cardiology Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos, Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrancic</LastName><ForeName>Mariano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos, Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aissaoui</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Penn State Heart and Vascular Institute (HVI), Critical Care Unit, Penn State Health Milton S. Hershey Medical Center (HMC) and Penn State University. Hershey, USA and INSERM 970, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Ann Card Anaesth</MedlineTA><NlmUniqueID>9815987</NlmUniqueID><ISSNLinking>0971-9784</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016278" MajorTopicYN="N">Ventricular Function, Right</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="Y">Heart Arrest</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac arrest</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">echocardiogram</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">weaning</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>1</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36722581</ArticleId><ArticleId IdType="pmc">PMC9997464</ArticleId><ArticleId IdType="doi">10.4103/aca.aca_79_22</ArticleId><ArticleId IdType="pii">AnnCardAnaesth_2023_26_1_4_367026</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Napp LC, K&#xfc;hn C, Bauersachs J. ECMO in cardiac arrest and cardiogenic shock. Herz. 2017;42:27&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5306351</ArticleId><ArticleId IdType="pubmed">28127638</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am CollCardiol. 2014;63:2769&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">24814488</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Brodie D, Chen YS, Fan E, Henriques JPS, Hodgson C, et al. The ICM research agenda on extracorporeal life support. Intensive Care Med. 2017;43:1306&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">28470346</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams D, Garan AR, Abdelbary A, Bacchetta M, Bartlett RH, Beck J, et al. Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Med. 2018;44:717&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">29450594</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall A, Follin A, Cholley B, Mantz J, Aissaoui N, Pirracchio R. Veno-arterial-ECMO in the intensive care unit: From technical aspects to clinical practice. AnaesthCrit Care Pain Med. 2018;37:259&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">29033360</ArticleId></ArticleIdList></Reference><Reference><Citation>Barge-Caballero E, Almenar-Bonet L, Gonzalez-Vilchez F, Lambert-Rodriguez JL, Gonzalez-Costello J, Segovia-Cubero J, et al. Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry. Eur J Heart Fail. 2018;20:178&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">28949079</ArticleId></ArticleIdList></Reference><Reference><Citation>Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B. Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ. 2008;17:S41&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18964254</ArticleId></ArticleIdList></Reference><Reference><Citation>Keebler ME, Haddad EV, Choi CW, McGrane S, Zalawadiya S, Schlendorf KH, et al. Venoarterialextracorporeal membrane oxygenation in cardiogenic shock. JACC Heart Fail. 2018;6:503&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">29655828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortuno S, Delmas C, Diehl JL, Bailleul C, Lancelot A, Naili M, et al. Weaning from veno-arterial extra-corporeal membrane oxygenation: Which strategy to use? Ann CardiothoracSurg. 2019;8:E1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379199</ArticleId><ArticleId IdType="pubmed">30854330</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow SY, Hwang NC. Update on anesthesia management for explantation of veno-arterial extracorporeal membrane oxygenation in adult patients. Ann Card Anaesth. 2019;22:422&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813703</ArticleId><ArticleId IdType="pubmed">31621679</ArticleId></ArticleIdList></Reference><Reference><Citation>ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support Extracorporeal Life Support Organization, Version 1.3 November 2013 Ann Arbor, MI, USA.  [Last accesed on 2021 Nov 01].  Available from: http://www.elsonet.org .</Citation></Reference><Reference><Citation>Liberati A1, Altman DG, Tetzlaff J, Mulrow C, G&#xf8;tzsche PC, Ioannidis JP. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009;6:e1000100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707010</ArticleId><ArticleId IdType="pubmed">19621070</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, Gotzsche PC, J&#xfc;ni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells A, Shea B, O&#x2019;Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis.  [Last accesed on 2021 Nov 01].  Available from:http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp .</Citation></Reference><Reference><Citation>Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: Step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296675</ArticleId><ArticleId IdType="pubmed">22264277</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002;31:88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan &#x2014; A web and mobile app for systematic reviews. Syst Rev. 2016;5:210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Kofidis T, Kamiya H, Shrestha M, Tessmann R, Haverich A, et al. Creatine kinase isoenzyme MB relative index as predictor of mortality on extracorporeal membrane oxygenation support for postcardiotomy cardiogenic shock in adult patients. Eur J Cardiothorac Surg. 2006;30:617&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16934992</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, Luyt CE, Leprince P, Trouillet JL, L&#xe9;ger P, Pavie A, et al. Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med. 2011;37:1738&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21965097</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyt CE, Landivier A, Leprince P, Bernard M, Pavie A, Chastre J, et al. Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock. JCritCare. 2012;27:524.e7&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">22386227</ArticleId></ArticleIdList></Reference><Reference><Citation>Park BW, Seo DC, Moon IK, Chung JW, Bang DW, Hyon MS, et al. Pulse pressure as a prognostic marker in patients receiving extracorporeal life support. Resuscitation. 2013;84:1404&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23603288</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CL, Wang H, Jia M, Ma N, Meng X, Hou XT. The early dynamic behavior of lactate is linked to mortality in postcardiotomy patients with extracorporeal membrane oxygenation support: A retrospective observational study. JThoracCardiovascSurg. 2015;149:1445&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">25534305</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, Caudron J, Leprince P, Fagon JY, Lebreton G, Combes A, et al. Right-left ventricular interdependence: A promising predictor of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med. 2017;43:592&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">28011989</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin S, Dos Reis Miranda D, Caliskan K, Soliman OI, Guven G, Struijs A, et al. Functional evaluation of sublingual microcirculation indicates successful weaning from VA ECMO in cardiogenic shock. CritCare (London, England) 2017;21:265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5658964</ArticleId><ArticleId IdType="pubmed">29073930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W, Kim Y, Choi H, Kim H, Lee S, Lee H, et al. Advanced age as a predictor of survival and weaning in venoarterial extracorporeal oxygenation: A retrospective observational study. Biomed Res Int. 2017;2017:3505784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5397620</ArticleId><ArticleId IdType="pubmed">28484710</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KC, Lin LY, Chen YS, Lai CH, Hwang JJ, Lin LC. Three-dimensional echocardiography-derived RVEF correlates with success of decannulation and prognosis in patients stabilized by venoarterial extracorporeal life support. J Am Soc Echocardiogr. 2018;31:169&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">29079045</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto M, Asaumi Y, Nakamura Y, Nakatani T, Nagai T, Kanaya T, et al. Clinical determinants of successful weaning from extracorporeal membrane oxygenation in patients with fulminant myocarditis. ESC Heart failure. 2018;5:675&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6073023</ArticleId><ArticleId IdType="pubmed">29757498</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiura A, Abe R, Nakayama T, Hattori N, Fujimoto Y, Himi T, et al. Predictors of successful weaning from veno-arterial extracorporeal membrane oxygenation after coronary revascularization for acute myocardial infarction complicated by cardiac arrest: A retrospective multicenter study. Shock (Augusta, Ga) 2019;51:690&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30080744</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh TC, Chang HH, Ger LP, Wang JO, Kao S, Ho ST. Clinical risk factors of extracorporeal membrane oxygenation support in older adults. PLoSOne. 2018;13:e0195445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889174</ArticleId><ArticleId IdType="pubmed">29624620</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancari F, Perrotti A, Dal&#xe9;n M, Guerrieri M, Fiore A, Reichart D, et al. Meta-analysis of the outcome after postcardiotomyvenoarterial extracorporeal membrane oxygenation in adult patients. J CardiothoracVascAnesth. 2018;32:1175&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29158060</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso S, Matsui H, Fushimi K, Yasunaga H. In-hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: Analysis of 5,263 patients using a national inpatient database in Japan. Crit Care. 2016;20:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820970</ArticleId><ArticleId IdType="pubmed">27044572</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YS, Chao A, Yu HY, Ko WJ, Wu IH, Chen RJ, et al. Analysis and results of prolonged resuscitation in cardiac arrest patients rescued by extracorporeal membrane oxygenation. J Am CollCardiol. 2003;41:197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">12535808</ArticleId></ArticleIdList></Reference><Reference><Citation>International summary. ECLS registry report. 2019. Jul,  [Last accesed on 2021 Nov 01].  Available from: https://www.elso.org/Registry/Statistics/InternationalSummary.aspx .</Citation></Reference><Reference><Citation>Aissaoui N, El-Banayosy A, Combes A. How to wean a patient from veno-arterial extracorporeal membrane oxygenation. Intensive Care Med. 2015;41:902&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25619488</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, Guerot E, Combes A, Delouche A, Chastre J, Leprince P, et al. Two-dimensional strain rate and Doppler tissue myocardial velocities: analysis by echocardiography of hemodynamic and functional changes of the failed left ventricle during different degrees of extracorporeal life support. J Am Soc Echocardiogr. 2012;25:632&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22421027</ArticleId></ArticleIdList></Reference><Reference><Citation>Platts DG, Sedgwick JF, Burstow DJ, Mullany DV, Fraser JF. The role of echocardiography in the management of patients supported by extracorporeal membrane oxygenation. J Am Soc Echocardiogr. 2012;25:131&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22169046</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Pieri M, Arnaez Corada B, Ajello S, Melisurgo G, De Bonis M, et al. Timing and strategy for weaning from venoarterial ECMO are complex issues. J Cardiothorac Vasc Aanesth. 2015;29:906&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">25836952</ArticleId></ArticleIdList></Reference><Reference><Citation>Santise G, Panarello G, Ruperto C, Turrisi M, Pilato Gm Giunta A, et al. Extracorporeal membrane oxygenation for graft failure after heart transplantation: a multidisciplinary approach to maximize weaning rate. Int J Artif Organs. 2016;37:706&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25262630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavarocchi NC, Pitcher HT, Yang Q, Karbowski P, Miessau J, Hastings HM, et al. Weaning of extracorporeal membrane oxygenation using continuous hemodynamic transesophageal echocardiography. J Thorac Cardiovasc Surg. 2013;146:1474&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23993027</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32828186</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>396</Volume><Issue>10250</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>552</EndPage><MedlinePgn>545-552</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(20)30733-9</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(20)30733-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with sepsis-induced cardiomyopathy with cardiogenic shock have a high mortality. This study assessed venoarterial extracorporeal membrane oxygenation (VA-ECMO) support for sepsis-induced cardiogenic shock refractory to conventional treatments.</AbstractText><AbstractText Label="METHODS">In this retrospective, multicentre, international cohort study, we compared outcomes of 82 patients (aged &#x2265;18 years) with septic shock who received VA-ECMO at five academic ECMO centres, with 130 controls (not receiving ECMO) obtained from three large databases of septic shock. All patients had severe myocardial dysfunction (cardiac index 3 L/min per m<sup>2</sup> or less or left ventricular ejection fraction [LVEF] 35% or less) and severe haemodynamic compromise (inotrope score at least 75 &#x3bc;g/kg per min or lactic acidaemia at least 4 mmol/L) at time of inclusion. The primary endpoint was survival at 90 days. A propensity score-weighted analysis was done to control for confounders.</AbstractText><AbstractText Label="FINDINGS">At baseline, patients treated with VA-ECMO had more severe myocardial dysfunction (mean cardiac index 1&#xb7;5 L/min per m<sup>2</sup>vs 2&#xb7;2 L/min per m<sup>2</sup>, LVEF 17% vs 27%), more severe haemodynamic impairment (inotrope score 279 &#x3bc;g/kg per min vs 145 &#x3bc;g/kg per min, lactataemia 8&#xb7;9 mmol/L vs 6&#xb7;5 mmol/L), and more severe organ failure (Sequential Organ Failure Assessment score 17 vs 13) than did controls, with p&lt;0&#xb7;0001 for each comparison. Survival at 90 days for patients treated with VA-ECMO was significantly higher than for controls (60% vs 25%, risk ratio [RR] for mortality 0&#xb7;54, 95% CI [0&#xb7;40-0&#xb7;70]; p&lt;0&#xb7;0001). After propensity score weighting, ECMO remained associated with improved survival (51% vs 14%, adjusted RR for mortality 0&#xb7;57, 95% CI [0&#xb7;35-0&#xb7;93]; p=0&#xb7;0029). Lactate and catecholamine clearance were also significantly enhanced in patients treated with ECMO. Among the 49 survivors treated with ECMO, 32 who had been treated at the largest centre reported satisfactory Short Form-36 evaluated health-related quality of life at 1-year follow-up.</AbstractText><AbstractText Label="INTERPRETATION">Patients with severe sepsis-induced cardiogenic shock treated with VA-ECMO had a large and significant improvement in survival compared with controls not receiving ECMO. However, despite the careful propensity-weighted analysis, we cannot rule out unmeasured confounders.</AbstractText><AbstractText Label="FUNDING">None.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Br&#xe9;chot</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, Assistance Publique-H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France; Coll&#xe8;ge de France, Centre of Interdisciplinary Research in Biology, CNRS UMR7241, INSERM U1050, Paris, France. Electronic address: nicolas.brechot@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajage</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, AP-HP, H&#xf4;pitaux Universitaires Piti&#xe9; Salp&#xea;tri&#xe8;re-Charles Foix, D&#xe9;partement Biostatistique Sant&#xe9; Publique et Information M&#xe9;dicale, Centre de Pharmaco&#xe9;pid&#xe9;miologie (Cephepi), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmoun</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Centre Hospitalier Universitaire de Nancy and INSERM U1116, Universit&#xe9; de Lorraine, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demiselle</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Centre Hospitalier Universitaire Angers, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agerstrand</LastName><ForeName>Cara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Centre, and New York-Presbyterian Hospital, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montero</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, Assistance Publique-H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France; Acute Cardiovascular Care Unit, Cardiology, Hospital Germans Trias i Pujol, Barcelona, Spain; Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, Assistance Publique-H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France; Sorbonne Universit&#xe9; INSERM-UMRS 1166, Institute of Cardiometabolism and Nutrition, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luyt</LastName><ForeName>Charles-Edouard</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, Assistance Publique-H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France; Sorbonne Universit&#xe9; INSERM-UMRS 1166, Institute of Cardiometabolism and Nutrition, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebreton</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de Chirurgie Cardiaque et Cardiovasculaire, Institut de Cardiologie, Assistance Publique-H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France; Sorbonne Universit&#xe9; INSERM-UMRS 1166, Institute of Cardiometabolism and Nutrition, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe9;kimian</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, Assistance Publique-H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flecher</LastName><ForeName>Erwan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service de Chirurgie Cardiaque, Centre Hospitalier Universitaire de Rennes, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zogheib</LastName><ForeName>Elie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Critical Care Department, Amiens University Hospital, Picardy Jules Verne University, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Centre Hospitalier Universitaire de Nancy and INSERM U1116, Universit&#xe9; de Lorraine, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slutsky</LastName><ForeName>Arthur S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Interdepartmental Division of Critical Care Medicine, Departments of Medicine, Surgery and Biomedical Engineering, University of Toronto, Toronto, ON, Canada; Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodie</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Centre, and New York-Presbyterian Hospital, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asfar</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Centre Hospitalier Universitaire Angers, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Combes</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, Assistance Publique-H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France; Sorbonne Universit&#xe9; INSERM-UMRS 1166, Institute of Cardiometabolism and Nutrition, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International ECMO Network</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2020 Aug 22;396(10250):515-517. doi: 10.1016/S0140-6736(20)30762-5.</RefSource><PMID Version="1">32828179</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Cardiol. 2020 Nov;17(11):680. doi: 10.1038/s41569-020-00450-y.</RefSource><PMID Version="1">32913307</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Anaesthesist. 2021 Oct;70(10):888-894. doi: 10.1007/s00101-021-00976-x.</RefSource><PMID Version="1">34324037</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Respir Crit Care Med. 2023 Jul 15;208(2):196-198. doi: 10.1164/rccm.202206-1165RR.</RefSource><PMID Version="1">37141107</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32828186</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30733-9</ArticleId><ArticleId IdType="pii">S0140-6736(20)30733-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27520452</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>The value of blood lactate kinetics in critically ill patients: a systematic review.</ArticleTitle><Pagination><StartPage>257</StartPage><MedlinePgn>257</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">257</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-016-1403-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The time course of blood lactate levels could be helpful to assess a patient's response to therapy. Although the focus of published studies has been largely on septic patients, many other studies have reported serial blood lactate levels in different groups of acutely ill patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a systematic search of PubMed, Science Direct, and Embase until the end of February 2016 plus reference lists of relevant publications. We selected all observational and interventional studies that evaluated the capacity of serial blood lactate concentrations to predict outcome. There was no restriction based on language. We excluded studies in pediatric populations, experimental studies, and studies that did not report changes in lactate values or all-cause mortality rates. We separated studies according to the type of patients included. We collected data on the number of patients, timing of lactate measurements, minimum lactate level needed for inclusion if present, and suggested time interval for predictive use.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 96 studies met our criteria: 14 in general ICU populations, five in general surgical ICU populations, five in patients post cardiac surgery, 14 in trauma patients, 39 in patients with sepsis, four in patients with cardiogenic shock, eight in patients after cardiac arrest, three in patients with respiratory failure, and four in other conditions. A decrease in lactate levels over time was consistently associated with lower mortality rates in all subgroups of patients. Most studies reported changes over 6, 12 or 24&#xa0;hrs, fewer used shorter time intervals. Lactate kinetics did not appear very different in patients with sepsis and other types of patients. A few studies suggested that therapy could be guided by these measurements.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The observation of a better outcome associated with decreasing blood lactate concentrations was consistent throughout the clinical studies, and was not limited to septic patients. In all groups, the changes are relatively slow, so that lactate measurements every 1-2 hrs are probably sufficient in most acute conditions. The value of lactate kinetics appears to be valid regardless of the initial value.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Erasme Hospital, Universit&#xe9; Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. jlvincent@intensive.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintairos E Silva</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Erasme Hospital, Universit&#xe9; Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couto</LastName><ForeName>L&#xfa;cio</ForeName><Initials>L</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Intensive Care, Erasme Hospital, Universit&#xe9; Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taccone</LastName><ForeName>Fabio S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Erasme Hospital, Universit&#xe9; Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27520452</ArticleId><ArticleId IdType="pmc">PMC4983759</ArticleId><ArticleId IdType="doi">10.1186/s13054-016-1403-5</ArticleId><ArticleId IdType="pii">10.1186/s13054-016-1403-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Broder G, Weil MH. Excess lactate: an index of reversibility of shock in human patients. Science. 1964;143:1457&#x2013;9. doi: 10.1126/science.143.3613.1457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.143.3613.1457</ArticleId><ArticleId IdType="pubmed">14107454</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil MH, Afifi AA. Experimental and clinical studies on lactate and pyruvate as indicators of the severity of acute circulatory failure (shock) Circulation. 1970;41:989&#x2013;1001. doi: 10.1161/01.CIR.41.6.989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.41.6.989</ArticleId><ArticleId IdType="pubmed">5482913</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretz DI, McGregor M, Dossetor JB. Lactic acidosis: a clinically significant aspect of shock. Can Med Assoc J. 1964;90:673&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1922420</ArticleId><ArticleId IdType="pubmed">14127378</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369:1726&#x2013;34. doi: 10.1056/NEJMra1208943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1208943</ArticleId><ArticleId IdType="pubmed">24171518</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy B. Lactate and shock state: the metabolic view. Curr Opin Crit Care. 2006;12:315&#x2013;21. doi: 10.1097/01.ccx.0000235208.77450.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ccx.0000235208.77450.15</ArticleId><ArticleId IdType="pubmed">16810041</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichol AD, Egi M, Pettila V, Bellomo R, French C, Hart G, et al. Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multi-centre study. Crit Care. 2010;14:R25. doi: 10.1186/cc8888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8888</ArticleId><ArticleId IdType="pmc">PMC2875540</ArticleId><ArticleId IdType="pubmed">20181242</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801&#x2013;10. doi: 10.1001/jama.2016.0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraut JA, Madias NE. Lactic acidosis. N Engl J Med. 2014;371:2309&#x2013;19. doi: 10.1056/NEJMra1309483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1309483</ArticleId><ArticleId IdType="pubmed">25494270</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40:1795&#x2013;815. doi: 10.1007/s00134-014-3525-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-014-3525-z</ArticleId><ArticleId IdType="pmc">PMC4239778</ArticleId><ArticleId IdType="pubmed">25392034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichol A, Bailey M, Egi M, Pettila V, French C, Stachowski E, et al. Dynamic lactate indices as predictors of outcome in critically ill patients. Crit Care. 2011;15:R242. doi: 10.1186/cc10497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc10497</ArticleId><ArticleId IdType="pmc">PMC3334793</ArticleId><ArticleId IdType="pubmed">22014216</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas SA, Lange T, Saugel B, Petzoldt M, Fuhrmann V, Metschke M, et al. Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients. Intensive Care Med. 2016;42:202&#x2013;10. doi: 10.1007/s00134-015-4127-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-4127-0</ArticleId><ArticleId IdType="pubmed">26556617</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Dufaye P, Berre J, Leeman M, Degaute JP, Kahn RJ. Serial lactate determinations during circulatory shock. Crit Care Med. 1983;11:449&#x2013;51. doi: 10.1097/00003246-198306000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-198306000-00012</ArticleId><ArticleId IdType="pubmed">6406145</ArticleId></ArticleIdList></Reference><Reference><Citation>Orringer CE, Eustace JC, Wunsch CD, Gardner LB. Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia. N Engl J Med. 1977;297:796&#x2013;9. doi: 10.1056/NEJM197710132971502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197710132971502</ArticleId><ArticleId IdType="pubmed">19702</ArticleId></ArticleIdList></Reference><Reference><Citation>Polonen P, Ruokonen E, Hippelainen M, Poyhonen M, Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. Anesth Analg. 2000;90:1052&#x2013;9. doi: 10.1097/00000539-200005000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-200005000-00010</ArticleId><ArticleId IdType="pubmed">10781452</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010;182:752&#x2013;61. doi: 10.1164/rccm.200912-1918OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200912-1918OC</ArticleId><ArticleId IdType="pubmed">20463176</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303:739&#x2013;46. doi: 10.1001/jama.2010.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.158</ArticleId><ArticleId IdType="pmc">PMC2918907</ArticleId><ArticleId IdType="pubmed">20179283</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer M, Holthaus CV, Fuller BM. The impact of serial lactate monitoring on emergency department resuscitation interventions and clinical outcomes in severe sepsis and septic shock: an observational cohort study. Shock. 2015;43:55&#x2013;61. doi: 10.1097/SHK.0000000000000260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000260</ArticleId><ArticleId IdType="pmc">PMC4269567</ArticleId><ArticleId IdType="pubmed">25186838</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HB, Kuan WS, Batech M, Shrikhande P, Mahadevan M, Li CH, et al. Outcome effectiveness of the severe sepsis resuscitation bundle with addition of lactate clearance as a bundle item: a multi-national evaluation. Crit Care. 2011;15:R229. doi: 10.1186/cc10469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc10469</ArticleId><ArticleId IdType="pmc">PMC3334775</ArticleId><ArticleId IdType="pubmed">21951322</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL. Serial blood lactate levels reflect both lactate production and clearance. Crit Care Med. 2015;43:e209. doi: 10.1097/CCM.0000000000000906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000906</ArticleId><ArticleId IdType="pubmed">25978172</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL. Lactic acidosis. N Engl J Med. 2015;372:1077&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25760371</ArticleId></ArticleIdList></Reference><Reference><Citation>Levraut J, Ciebiera JP, Chave S, Rabary O, Jambou P, Carles M, et al. Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Respir Crit Care Med. 1998;157:1021&#x2013;6. doi: 10.1164/ajrccm.157.4.9705037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.157.4.9705037</ArticleId><ArticleId IdType="pubmed">9563714</ArticleId></ArticleIdList></Reference><Reference><Citation>Revelly JP, Tappy L, Martinez A, Bollmann M, Cayeux MC, Berger MM, et al. Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Crit Care Med. 2005;33:2235&#x2013;40. doi: 10.1097/01.CCM.0000181525.99295.8F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000181525.99295.8F</ArticleId><ArticleId IdType="pubmed">16215376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowan BN, Burns HJ, Boyle P, Ledingham IM. The relative prognostic value of lactate and haemodynamic measurements in early shock. Anaesthesia. 1984;39:750&#x2013;5. doi: 10.1111/j.1365-2044.1984.tb06516.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2044.1984.tb06516.x</ArticleId><ArticleId IdType="pubmed">6476309</ArticleId></ArticleIdList></Reference><Reference><Citation>Suistomaa M, Ruokonen E, Kari A, Takala J. Time-pattern of lactate and lactate to pyruvate ratio in the first 24&#xa0;hrs of intensive care emergency admissions. Shock. 2000;14:8&#x2013;12. doi: 10.1097/00024382-200014010-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-200014010-00002</ArticleId><ArticleId IdType="pubmed">10909886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Wu DW, Chen XM, Li C, Ding SF, Zhai Q, et al. Relationship between blood lactic level, lactic clearance, duration of lacticemia and prognosis of critically ill patients in intensive care unit. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2009;21:357&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19570343</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen TC, van Bommel J, Mulder PG, Lima AP, van der Hoven B, Rommes JH, et al. Prognostic value of blood lactate levels: does the clinical diagnosis at admission matter? J Trauma. 2009;66:377&#x2013;85. doi: 10.1097/TA.0b013e3181648e2f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181648e2f</ArticleId><ArticleId IdType="pubmed">19204510</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna U, Joshi SP, Modh M. An evaluation of serial blood lactate measurement as an early predictor of shock and its outcome in patients of trauma or sepsis. Indian J Crit Care Med. 2009;13:66&#x2013;73. doi: 10.4103/0972-5229.56051.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-5229.56051</ArticleId><ArticleId IdType="pmc">PMC2772249</ArticleId><ArticleId IdType="pubmed">19881186</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman HM, Vincent JL. Prognostic value of admission serum lactate concentrations in intensive care unit patients. Acta Clin Belg. 2010;65:176&#x2013;81. doi: 10.1179/acb.2010.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/acb.2010.037</ArticleId><ArticleId IdType="pubmed">20669785</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beest PA, Brander L, Jansen SP, Rommes JH, Kuiper MA, Spronk PE. Cumulative lactate and hospital mortality in ICU patients. Ann Intensive Care. 2013;3:6. doi: 10.1186/2110-5820-3-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2110-5820-3-6</ArticleId><ArticleId IdType="pmc">PMC3599274</ArticleId><ArticleId IdType="pubmed">23446002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Chen K, Ni H, Fan H. Predictive value of lactate in unselected critically ill patients: an analysis using fractional polynomials. J Thorac Dis. 2014;6:995&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120171</ArticleId><ArticleId IdType="pubmed">25093098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen TC, van Bommel J, Mulder PG, Rommes JH, Schieveld SJ, Bakker J. The prognostic value of blood lactate levels relative to that of vital signs in the pre-hospital setting: a pilot study. Crit Care. 2008;12:R160. doi: 10.1186/cc7159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7159</ArticleId><ArticleId IdType="pmc">PMC2646325</ArticleId><ArticleId IdType="pubmed">19091118</ArticleId></ArticleIdList></Reference><Reference><Citation>McNelis J, Marini CP, Jurkiewicz A, Szomstein S, Simms HH, Ritter G, et al. Prolonged lactate clearance is associated with increased mortality in the surgical intensive care unit. Am J Surg. 2001;182:481&#x2013;5. doi: 10.1016/S0002-9610(01)00755-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(01)00755-3</ArticleId><ArticleId IdType="pubmed">11754855</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain FA, Martin MJ, Mullenix PS, Steele SR, Elliott DC. Serum lactate and base deficit as predictors of mortality and morbidity. Am J Surg. 2003;185:485&#x2013;91. doi: 10.1016/S0002-9610(03)00044-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(03)00044-8</ArticleId><ArticleId IdType="pubmed">12727572</ArticleId></ArticleIdList></Reference><Reference><Citation>Meregalli A, Oliveira RP, Friedman G. Occult hypoperfusion is associated with increased mortality in hemodynamically stable, high-risk, surgical patients. Crit Care. 2004;8:R60&#x2013;5. doi: 10.1186/cc2423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc2423</ArticleId><ArticleId IdType="pmc">PMC420024</ArticleId><ArticleId IdType="pubmed">15025779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinal Fernandez PA, Olano E, Acosta C, Bertullo H, Albornoz H, Bagnulo H. Prognostic value of lactate clearance in the first 6&#xa0;hrs of intensive medicine course. Med Intensiva. 2009;33:166&#x2013;70. doi: 10.1016/S0210-5691(09)71212-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0210-5691(09)71212-4</ArticleId><ArticleId IdType="pubmed">19558937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim WA, Ahmed AS. Serial estimations of blood lactate predict postoperative outcome in cancer patients undergoing head and neck surgeries. Egyptian J Anaesth. 2013;29:149&#x2013;54. doi: 10.1016/j.egja.2012.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.egja.2012.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay AJ, Xu M, Sessler DI, Blackstone EH, Bashr CA. Lactate clearance time and concentration linked to morbidity and death in cardiac surgical patients. Ann Thorac Surg. 2013;95:486&#x2013;92. doi: 10.1016/j.athoracsur.2012.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2012.07.020</ArticleId><ArticleId IdType="pubmed">22959571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar LA, Almeida JP, Fukushima JT, Rhodes A, Vincent JL, Osawa EA, et al. High lactate levels are predictors of major complications after cardiac surgery. J Thorac Cardiovasc Surg. 2013;146:455&#x2013;60. doi: 10.1016/j.jtcvs.2013.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2013.02.003</ArticleId><ArticleId IdType="pubmed">23507124</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, Kim SP, Kim JB, Jung SH, Choo SJ, Chung CH, et al. Blood lactate level during extracorporeal life support as a surrogate marker for survival. J Thorac Cardiovasc Surg. 2014;148:714&#x2013;20. doi: 10.1016/j.jtcvs.2014.02.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.02.078</ArticleId><ArticleId IdType="pubmed">24685378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Delgado JC, Esteve F, Javierre C, Torrado H, Rodriguez-Castro D, Carrio ML, et al. Evaluation of serial arterial lactate levels as a predictor of hospital and long-term mortality in patients after cardiac surgery. J Cardiothorac Vasc Anesth. 2015;29:1441&#x2013;53. doi: 10.1053/j.jvca.2015.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2015.04.024</ArticleId><ArticleId IdType="pubmed">26321121</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CL, Wang H, Jia M, Ma N, Meng X, Hou XT. The early dynamic behavior of lactate is linked to mortality in postcardiotomy patients with extracorporeal membrane oxygenation support: A retrospective observational study. J Thorac Cardiovasc Surg. 2015;149:1445&#x2013;50. doi: 10.1016/j.jtcvs.2014.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.11.052</ArticleId><ArticleId IdType="pubmed">25534305</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson D, Scalea TM, Hitchcock R, Trooskin SZ, Henry SM, Greenspan J. Lactate clearance and survival following injury. J Trauma. 1993;35:584&#x2013;8. doi: 10.1097/00005373-199310000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199310000-00014</ArticleId><ArticleId IdType="pubmed">8411283</ArticleId></ArticleIdList></Reference><Reference><Citation>Manikis P, Jankowski S, Zhang H, Kahn RJ, Vincent JL. Correlation of serial blood lactate levels to organ failure and mortality after trauma. Am J Emerg Med. 1995;13:619&#x2013;22. doi: 10.1016/0735-6757(95)90043-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-6757(95)90043-8</ArticleId><ArticleId IdType="pubmed">7575797</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm C, Melcer B, Horbrand F, Worl HH, von Donnersmarck GH, Muhlbauer W. Haemodynamic and oxygen transport responses in survivors and non-survivors following thermal injury. Burns. 2000;26:25&#x2013;33. doi: 10.1016/S0305-4179(99)00095-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0305-4179(99)00095-9</ArticleId><ArticleId IdType="pubmed">10630316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerovic O, Golubovic V, Spec-Marn A, Kremzar B, Vidmar G. Relationship between injury severity and lactate levels in severely injured patients. Intensive Care Med. 2003;29:1300&#x2013;5. doi: 10.1007/s00134-003-1753-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-003-1753-8</ArticleId><ArticleId IdType="pubmed">12904861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamolz LP, Andel H, Schramm W, Meissl G, Herndon DN, Frey M. Lactate: early predictor of morbidity and mortality in patients with severe burns. Burns. 2005;31:986&#x2013;90. doi: 10.1016/j.burns.2005.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2005.06.019</ArticleId><ArticleId IdType="pubmed">16274931</ArticleId></ArticleIdList></Reference><Reference><Citation>Billeter A, Turina M, Seifert B, Mica L, Stocker R, Keel M. Early serum procalcitonin, interleukin-6, and 24-hr lactate clearance: useful indicators of septic infections in severely traumatized patients. World J Surg. 2009;33:558&#x2013;66. doi: 10.1007/s00268-008-9896-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-008-9896-y</ArticleId><ArticleId IdType="pubmed">19148699</ArticleId></ArticleIdList></Reference><Reference><Citation>Regnier MA, Raux M, Le MY, Asencio Y, Gaillard J, Devilliers C, et al. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology. 2012;117:1276&#x2013;88. doi: 10.1097/ALN.0b013e318273349d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e318273349d</ArticleId><ArticleId IdType="pubmed">23168430</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubendorfer C, Billeter AT, Seifert B, Keel M, Turina M. Serial lactate and admission SOFA scores in trauma: an analysis of predictive value in 724 patients with and without traumatic brain injury. Eur J Trauma Emerg Surg. 2013;39:25&#x2013;34. doi: 10.1007/s00068-012-0212-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-012-0212-z</ArticleId><ArticleId IdType="pubmed">26814920</ArticleId></ArticleIdList></Reference><Reference><Citation>Odom SR, Howell MD, Silva GS, Nielsen VM, Gupta A, Shapiro NI, et al. Lactate clearance as a predictor of mortality in trauma patients. J Trauma Acute Care Surg. 2013;74:999&#x2013;1004. doi: 10.1097/TA.0b013e3182858a3e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3182858a3e</ArticleId><ArticleId IdType="pubmed">23511137</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinonen E, Hardcastle TC, Barle H, Muckart DJ. Lactate clearance predicts outcome after major trauma. Afr J Emerg Med. 2014;4:61&#x2013;5. doi: 10.1016/j.afjem.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.afjem.2013.11.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas AD, Franzon O. Lactate as predictor of mortality in polytrauma. Arq Bras Cir Dig. 2015;28:163&#x2013;6. doi: 10.1590/S0102-67202015000300004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0102-67202015000300004</ArticleId><ArticleId IdType="pmc">PMC4737353</ArticleId><ArticleId IdType="pubmed">26537138</ArticleId></ArticleIdList></Reference><Reference><Citation>Dezman ZD, Comer AC, Smith GS, Narayan M, Scalea TM, Hirshon JM. Failure to clear elevated lactate predicts 24-hr mortality in trauma patients. J Trauma Acute Care Surg. 2015;79:580&#x2013;5. doi: 10.1097/TA.0000000000000810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000810</ArticleId><ArticleId IdType="pmc">PMC4586044</ArticleId><ArticleId IdType="pubmed">26402531</ArticleId></ArticleIdList></Reference><Reference><Citation>Roumen RM, Redl H, Schlag G, Sandtner W, Koller W, Goris RJ. Scoring systems and blood lactate concentrations in relation to the development of adult respiratory distress syndrome and multiple organ failure in severely traumatized patients. J Trauma. 1993;35:349&#x2013;55. doi: 10.1097/00005373-199309000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199309000-00004</ArticleId><ArticleId IdType="pubmed">8371291</ArticleId></ArticleIdList></Reference><Reference><Citation>Blow O, Magliore L, Claridge JA, Butler K, Young JS. The golden hr and the silver day: detection and correction of occult hypoperfusion within 24&#xa0;hrs improves outcome from major trauma. J Trauma. 1999;47:964&#x2013;9. doi: 10.1097/00005373-199911000-00028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199911000-00028</ArticleId><ArticleId IdType="pubmed">10568731</ArticleId></ArticleIdList></Reference><Reference><Citation>Claridge JA, Crabtree TD, Pelletier SJ, Butler K, Sawyer RG, Young JS. Persistent occult hypoperfusion is associated with a significant increase in infection rate and mortality in major trauma patients. J Trauma. 2000;48:8&#x2013;14. doi: 10.1097/00005373-200001000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200001000-00003</ArticleId><ArticleId IdType="pubmed">10647559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker J, Coffernils M, Leon M, Gris P, Vincent JL. Blood lactate levels are superior to oxygen-derived variables in predicting outcome in human septic shock. Chest. 1991;99:956&#x2013;62. doi: 10.1378/chest.99.4.956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.99.4.956</ArticleId><ArticleId IdType="pubmed">2009802</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman G, Berlot G, Kahn RJ, Vincent JL. Combined measurements of blood lactate concentrations and gastric intramucosal pH in patients with severe sepsis. Crit Care Med. 1995;23:1184&#x2013;93. doi: 10.1097/00003246-199507000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199507000-00006</ArticleId><ArticleId IdType="pubmed">7600825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardin G, Pradier C, Tiger F, Deloffre P, Mattei M. Blood pressure and arterial lactate level are early indicators of short-term survival in human septic shock. Intensive Care Med. 1996;22:17&#x2013;25. doi: 10.1007/BF01728326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01728326</ArticleId><ArticleId IdType="pubmed">8857433</ArticleId></ArticleIdList></Reference><Reference><Citation>Marecaux G, Pinsky MR, Dupont E, Kahn RJ, Vincent JL. Blood lactate levels are better prognostic indicators than TNF and IL-6 levels in patients with septic shock. Intensive Care Med. 1996;22:404&#x2013;8. doi: 10.1007/BF01712155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01712155</ArticleId><ArticleId IdType="pubmed">8796390</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker J, Gris P, Coffernils M, Kahn RJ, Vincent JL. Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg. 1996;171:221&#x2013;6. doi: 10.1016/S0002-9610(97)89552-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(97)89552-9</ArticleId><ArticleId IdType="pubmed">8619454</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Gando S, Morimoto Y, Nanzaki S, Kemmotsu O. Serial measurement of arterial lactate concentrations as a prognostic indicator in relation to the incidence of disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Surg Today. 2001;31:853&#x2013;9. doi: 10.1007/s005950170022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s005950170022</ArticleId><ArticleId IdType="pubmed">11759877</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 2004;32:1637&#x2013;42. doi: 10.1097/01.CCM.0000132904.35713.A7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000132904.35713.A7</ArticleId><ArticleId IdType="pubmed">15286537</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HB, Corbett SW, Steele R, Banta J, Clark RT, Hayes SR, et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med. 2007;35:1105&#x2013;12. doi: 10.1097/01.CCM.0000259463.33848.3D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000259463.33848.3D</ArticleId><ArticleId IdType="pubmed">17334251</ArticleId></ArticleIdList></Reference><Reference><Citation>Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock. 2008;29:328&#x2013;33. doi: 10.1097/SHK.0b013e318150716b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318150716b</ArticleId><ArticleId IdType="pubmed">18277855</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CS, Qiu HB, Huang YZ, Xie JF, Mo M, Liu SQ, et al. Prospective research on the prognosis of septic shock based on the change of lactate concentration in arterial blood. Zhonghua Wai Ke Za Zhi. 2009;47:685&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19615239</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold RC, Shapiro NI, Jones AE, Schorr C, Pope J, Casner E, et al. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock. 2009;32:35&#x2013;9. doi: 10.1097/SHK.0b013e3181971d47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181971d47</ArticleId><ArticleId IdType="pubmed">19533847</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HB, Loomba M, Yang JJ, Jacobsen G, Shah K, Otero RM, et al. Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. J Inflamm (Lond) 2010;7:6. doi: 10.1186/1476-9255-7-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-9255-7-6</ArticleId><ArticleId IdType="pmc">PMC2837000</ArticleId><ArticleId IdType="pubmed">20181046</ArticleId></ArticleIdList></Reference><Reference><Citation>Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Heffner AC, Kline JA, et al. Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation. Acad Emerg Med. 2012;19:252&#x2013;8. doi: 10.1111/j.1553-2712.2012.01292.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1553-2712.2012.01292.x</ArticleId><ArticleId IdType="pmc">PMC3313083</ArticleId><ArticleId IdType="pubmed">22435856</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanaty OM, Megahed M, Demerdash H, Swelem R. Delta neutrophil index versus lactate clearance: early markers for outcome prediction in septic shock patients. Alex J Med. 2012;48:327&#x2013;33. doi: 10.1016/j.ajme.2012.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajme.2012.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Puskarich MA, Trzeciak S, Shapiro NI, Albers AB, Heffner AC, Kline JA, et al. Whole blood lactate kinetics in patients undergoing quantitative resuscitation for severe sepsis and septic shock. Chest. 2013;143:1548&#x2013;53. doi: 10.1378/chest.12-0878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.12-0878</ArticleId><ArticleId IdType="pmc">PMC3673659</ArticleId><ArticleId IdType="pubmed">23740148</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker CA, Griffith DM, Gray AJ, Datta D, Hay AW. Early lactate clearance in septic patients with elevated lactate levels admitted from the emergency department to intensive care: time to aim higher? J Crit Care. 2013;28:832&#x2013;7. doi: 10.1016/j.jcrc.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2013.02.004</ArticleId><ArticleId IdType="pubmed">23602032</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu V, Morehouse JW, Soule J, Whippy A, Escobar GJ. Fluid volume, lactate values, and mortality in sepsis patients with intermediate lactate values. Ann Am Thorac Soc. 2013;10:466&#x2013;73. doi: 10.1513/AnnalsATS.201304-099OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.201304-099OC</ArticleId><ArticleId IdType="pmc">PMC5475420</ArticleId><ArticleId IdType="pubmed">24004068</ArticleId></ArticleIdList></Reference><Reference><Citation>Marty P, Roquilly A, Vallee F, Luzi A, Ferre F, Fourcade O, et al. Lactate clearance for death prediction in severe sepsis or septic shock patients during the first 24&#xa0;hrs in intensive care unit: an observational study. Ann Intensive Care. 2013;3:3. doi: 10.1186/2110-5820-3-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2110-5820-3-3</ArticleId><ArticleId IdType="pmc">PMC3614435</ArticleId><ArticleId IdType="pubmed">23398782</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Lee J, Park YS, Lee CH, Lee SM, Yim JJ, et al. Prognostic value of central venous oxygen saturation and blood lactate levels measured simultaneously in the same patients with severe systemic inflammatory response syndrome and severe sepsis. Lung. 2014;192:435&#x2013;40. doi: 10.1007/s00408-014-9564-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-014-9564-y</ArticleId><ArticleId IdType="pubmed">24549333</ArticleId></ArticleIdList></Reference><Reference><Citation>Permpikul C, Sringam P, Tongyoo S. Therapeutic goal achievements during severe sepsis and septic shock resuscitation and their association with patients' outcomes. J Med Assoc Thai. 2014;97(Suppl 3):S176&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">24772596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Zhang M, Yan P, Wu X, Shao J, Zheng R. Retrospective analysis of the value of arterial blood lactate level and its clearance rate on the prognosis of septic shock patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27:38&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25591435</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbois A, Bige N, Pichereau C, Boelle PY, Baudel JL, Bourcier S, et al. Exploration of skin perfusion in cirrhotic patients with septic shock. J Hepatol. 2015;62:549&#x2013;55. doi: 10.1016/j.jhep.2014.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2014.10.012</ArticleId><ArticleId IdType="pubmed">25457199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SM, Kim SE, Kim EB, Jeong HJ, Son YK, An WS. Lactate clearance and vasopressor seem to be predictors for mortality in severe sepsis patients with lactic acidosis supplementing sodium bicarbonate: a retrospective analysis. PLoS One. 2015;10:e0145181. doi: 10.1371/journal.pone.0145181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0145181</ArticleId><ArticleId IdType="pmc">PMC4686961</ArticleId><ArticleId IdType="pubmed">26692209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokhandwala S, Moskowitz A, Lawniczak R, Giberson T, Cocchi MN, Donnino MW. Disease heterogeneity and risk stratification in sepsis-related occult hypoperfusion: a retrospective cohort study. J Crit Care. 2015;30:531&#x2013;6. doi: 10.1016/j.jcrc.2015.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2015.01.009</ArticleId><ArticleId IdType="pmc">PMC4414712</ArticleId><ArticleId IdType="pubmed">25708119</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li Z, Yin M, Chen XM, Ding SF, Li C, et al. Combination of Acute Physiology and Chronic Health Evaluation II score, early lactate area, and N-terminal prohormone of brain natriuretic peptide levels as a predictor of mortality in geriatric patients with septic shock. J Crit Care. 2015;30:304&#x2013;9. doi: 10.1016/j.jcrc.2014.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2014.11.013</ArticleId><ArticleId IdType="pubmed">25499413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat SR, Swenson KE, Francis MW, Wira CR. Lactate clearance predicts survival among patients in the emergency department with severe sepsis. West J Emerg Med. 2015;16:1118&#x2013;26. doi: 10.5811/westjem.2015.10.27577.</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/westjem.2015.10.27577</ArticleId><ArticleId IdType="pmc">PMC4703153</ArticleId><ArticleId IdType="pubmed">26759665</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertoff J, Chisum M, Simmons L, King B, Walker M, Lascano J. Prognostic utility of plasma lactate measured between 24 and 48&#xa0;h after initiation of early goal-directed therapy in the management of sepsis, severe sepsis, and septic shock. J Intensive Care. 2016;4:13. doi: 10.1186/s40560-016-0142-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-016-0142-7</ArticleId><ArticleId IdType="pmc">PMC4751685</ArticleId><ArticleId IdType="pubmed">26877875</ArticleId></ArticleIdList></Reference><Reference><Citation>Drumheller BC, Agarwal A, Mikkelsen ME, Sante SC, Weber AL, Goyal M, et al. Risk factors for mortality despite early protocolized resuscitation for severe sepsis and septic shock in the emergency department. J Crit Care. 2016;31:13&#x2013;20. doi: 10.1016/j.jcrc.2015.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2015.10.015</ArticleId><ArticleId IdType="pubmed">26611382</ArticleId></ArticleIdList></Reference><Reference><Citation>He HW, Liu DW, Long Y, Wang XT. High central venous-to-arterial CO2 difference/arterial-central venous O2 difference ratio is associated with poor lactate clearance in septic patients after resuscitation. J Crit Care. 2016;31:76&#x2013;81. doi: 10.1016/j.jcrc.2015.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2015.10.017</ArticleId><ArticleId IdType="pubmed">26640138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha TS, Shin TG, Jo IJ, Hwang SY, Chung CR, Suh GY et al. Lactate clearance and mortality in septic patients with hepatic dysfunction. Am J Emerg Med. 2016;34:1011&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26976769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolvardi E, Malmir J, Reihani H, Hashemian AM, Bahramian M, Khademhosseini P, et al. The role of lactate clearance as a predictor of organ dysfunction and mortality in patients with severe sepsis. Mater Sociomed. 2016;28:57&#x2013;60. doi: 10.5455/msm.2016.28.57-60.</Citation><ArticleIdList><ArticleId IdType="doi">10.5455/msm.2016.28.57-60</ArticleId><ArticleId IdType="pmc">PMC4789646</ArticleId><ArticleId IdType="pubmed">27047270</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir A, Saulters KJ, Olum S, Pitts K, Parsons A, Churchill C et al. Outcomes of patients with severe sepsis after the first 6 hrs of resuscitation at a regional referral hospital in Uganda. J Crit Care. 2016;33:78&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">26994777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian HH, Han SS, Lv CJ, Wang T, Li Z, Hao D, et al. The effect of early goal lactate clearance rate on the outcome of septic shock patients with severe pneumonia. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012;24:42&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22248751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Tian HY, Hu ZJ, Zhao C, Liu LX, Zhang Y, et al. Comparison of the effect of fluid resuscitation as guided either by lactate clearance rate or by central venous oxygen saturation in patients with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013;25:578&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu X, Xu Q, Cai G, Yan J, Yan M. Efficacies of fluid resuscitation as guided by lactate clearance rate and central venous oxygen saturation in patients with septic shock. Zhonghua Yi Xue Za Zhi. 2015;95:496&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">25916923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan WS, Ibrahim I, Leong BS, Jain S, Lu Q, Cheung YB, et al. Emergency department management of sepsis patients: a randomized, goal-oriented, noninvasive sepsis trial. Ann Emerg Med. 2016;67:367&#x2013;78. doi: 10.1016/j.annemergmed.2015.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2015.09.010</ArticleId><ArticleId IdType="pubmed">26475246</ArticleId></ArticleIdList></Reference><Reference><Citation>Attana P, Lazzeri C, Chiostri M, Picariello C, Gensini GF, Valente S. Lactate clearance in cardiogenic shock following ST elevation myocardial infarction: a pilot study. Acute Card Care. 2012;14:20&#x2013;6. doi: 10.3109/17482941.2011.655293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482941.2011.655293</ArticleId><ArticleId IdType="pubmed">22356569</ArticleId></ArticleIdList></Reference><Reference><Citation>Attana P, Lazzeri C, Chiostri M, Picariello C, Gensini GF, Valente S. Strong-ion gap approach in patients with cardiogenic shock following ST-elevation myocardial infarction. Acute Card Care. 2013;15:58&#x2013;62. doi: 10.3109/17482941.2013.776691.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482941.2013.776691</ArticleId><ArticleId IdType="pubmed">23806089</ArticleId></ArticleIdList></Reference><Reference><Citation>Park TK, Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, et al. Clinical outcomes of patients with acute myocardial infarction complicated by severe refractory cardiogenic shock assisted with percutaneous cardiopulmonary support. Yonsei Med J. 2014;55:920&#x2013;7. doi: 10.3349/ymj.2014.55.4.920.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2014.55.4.920</ArticleId><ArticleId IdType="pmc">PMC4075395</ArticleId><ArticleId IdType="pubmed">24954319</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther S, Theiss HD, Fischer M, Sattler S, Peterss S, Born F, et al. Percutaneous extracorporeal life support for patients in therapy refractory cardiogenic shock: initial results of an interdisciplinary team. Interact Cardiovasc Thorac Surg. 2014;18:283&#x2013;91. doi: 10.1093/icvts/ivt505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivt505</ArticleId><ArticleId IdType="pmc">PMC3930215</ArticleId><ArticleId IdType="pubmed">24336784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kliegel A, Losert H, Sterz F, Holzer M, Zeiner A, Havel C, et al. Serial lactate determinations for prediction of outcome after cardiac arrest. Medicine (Baltimore) 2004;83:274&#x2013;9. doi: 10.1097/01.md.0000141098.46118.4c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000141098.46118.4c</ArticleId><ArticleId IdType="pubmed">15342971</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnino MW, Miller J, Goyal N, Loomba M, Sankey SS, Dolcourt B, et al. Effective lactate clearance is associated with improved outcome in post-cardiac arrest patients. Resuscitation. 2007;75:229&#x2013;34. doi: 10.1016/j.resuscitation.2007.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2007.03.021</ArticleId><ArticleId IdType="pubmed">17583412</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnalich F, Menendez M, Lagos V, Ciria E, Quesada A, Codoceo R, et al. Prognostic value of cell-free plasma DNA in patients with cardiac arrest outside the hospital: an observational cohort study. Crit Care. 2010;14:R47. doi: 10.1186/cc8934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8934</ArticleId><ArticleId IdType="pmc">PMC2887159</ArticleId><ArticleId IdType="pubmed">20350299</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guen M, Nicolas-Robin A, Carreira S, Raux M, Leprince P, Riou B, et al. Extracorporeal life support following out-of-hospital refractory cardiac arrest. Crit Care. 2011;15:R29. doi: 10.1186/cc9976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9976</ArticleId><ArticleId IdType="pmc">PMC3222065</ArticleId><ArticleId IdType="pubmed">21244674</ArticleId></ArticleIdList></Reference><Reference><Citation>Starodub R, Abella BS, Grossestreuer AV, Shofer FS, Perman SM, Leary M, et al. Association of serum lactate and survival outcomes in patients undergoing therapeutic hypothermia after cardiac arrest. Resuscitation. 2013;84:1078&#x2013;82. doi: 10.1016/j.resuscitation.2013.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2013.02.001</ArticleId><ArticleId IdType="pubmed">23402966</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnino MW, Andersen LW, Giberson T, Gaieski DF, Abella BS, Peberdy MA, et al. Initial lactate and lactate change in post-cardiac arrest: a multicenter validation study. Crit Care Med. 2014;42:1804&#x2013;11. doi: 10.1097/CCM.0000000000000332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000332</ArticleId><ArticleId IdType="pmc">PMC4154535</ArticleId><ArticleId IdType="pubmed">24776606</ArticleId></ArticleIdList></Reference><Reference><Citation>Riveiro DF, de Oliveira VM, Braunner JS, Vieira SR. Evaluation of serum lactate, central venous saturation, and venous-arterial carbon dioxide difference in the prediction of mortality in postcardiac arrest syndrome. J Intensive Care Med. 2015. [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">26112759</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TA, Martin R, Celenza A, Bremner A, Fatovich D, Krause J, et al. Use of serum lactate levels to predict survival for patients with out-of-hospital cardiac arrest: a cohort study. Emerg Med Australas. 2016;28:171&#x2013;8. doi: 10.1111/1742-6723.12560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1742-6723.12560</ArticleId><ArticleId IdType="pubmed">26929190</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YF, Lin Y, Zhu XL. Clinical significance of early lactate clearance rate in patients with respiratory failure. Zhonghua Jie He He Hu Xi Za Zhi. 2010;33:183&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20450636</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu WH, Niu YY, Zhang CR, Xiao LB, Ye HS, Pan DM, et al. Combined APACH II score and arterial blood lactate clearance rate to predict the prognosis of ARDS patients. Asian Pac J Trop Med. 2012;5:656&#x2013;60. doi: 10.1016/S1995-7645(12)60134-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1995-7645(12)60134-5</ArticleId><ArticleId IdType="pubmed">22840456</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang Z, Xu H, Dong L, Gao F, Yan J. Prognostic significance of early lactate clearance rate for severe acute respiratory failure patients on extracorporeal membrane oxygenation. Zhonghua Jie He He Hu Xi Za Zhi. 2014;37:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">24809711</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XW, Ma T, Qu B, Ji Y, Liu Z. Prognostic value of initial arterial lactate level and lactate metabolic clearance rate in patients with acute paraquat poisoning. Am J Emerg Med. 2013;31:1230&#x2013;5. doi: 10.1016/j.ajem.2013.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2013.04.019</ArticleId><ArticleId IdType="pubmed">23706581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JF, Wu RY, Chen J, Ou-Yang B, Chen MY, Guan XD. Early lactate clearance as a reliable predictor of initial poor graft function after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int. 2011;10:587&#x2013;92. doi: 10.1016/S1499-3872(11)60100-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1499-3872(11)60100-8</ArticleId><ArticleId IdType="pubmed">22146621</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, Antonaglia V, Guiotto G, Paladino F, Schiraldi F. Two-hr lactate clearance predicts negative outcome in patients with cardiorespiratory insufficiency. Crit Care Res Pract. 2010;2010:917053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958677</ArticleId><ArticleId IdType="pubmed">20981271</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed KAE, Ahmed DAE. Prognostic value of lactate clearance in severe community-acquired pneumonia. Egypt J Chest Dis Tuberc. 2014;63:1053&#x2013;8. doi: 10.1016/j.ejcdt.2014.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcdt.2014.05.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TR, Kang MJ, Cha WC, Shin TG, Sim MS, Jo IJ, et al. Better lactate clearance associated with good neurologic outcome in survivors who treated with therapeutic hypothermia after out-of-hospital cardiac arrest. Crit Care. 2013;17:R260. doi: 10.1186/cc13090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc13090</ArticleId><ArticleId IdType="pmc">PMC4057293</ArticleId><ArticleId IdType="pubmed">24172276</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto H, Nihei S, Endo T, Kanazawa A, Arai H, Nagata K, et al. Examination of relationship between lactate clearance and neurologic outcome in cardiac arrest induced by ventricular fibrillation. J UOEH. 2014;36:11&#x2013;6. doi: 10.7888/juoeh.36.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.7888/juoeh.36.11</ArticleId><ArticleId IdType="pubmed">24633180</ArticleId></ArticleIdList></Reference><Reference><Citation>Qvisth V, Hagstrom-Toft E, Enoksson S, Bolinder J. Catecholamine regulation of local lactate production in vivo in skeletal muscle and adipose tissue: role of -adrenoreceptor subtypes. J Clin Endocrinol Metab. 2008;93:240&#x2013;6. doi: 10.1210/jc.2007-1313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2007-1313</ArticleId><ArticleId IdType="pubmed">17986640</ArticleId></ArticleIdList></Reference><Reference><Citation>Contenti J, Occelli C, Corraze H, Lemoel F, Levraut J. Long-term beta-blocker therapy decreases blood lactate concentration in severely septic patients. Crit Care Med. 2015;43:2616&#x2013;22. doi: 10.1097/CCM.0000000000001308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001308</ArticleId><ArticleId IdType="pubmed">26427590</ArticleId></ArticleIdList></Reference><Reference><Citation>Orbegozo Cortes D, Rayo Bonor A, Vincent JL. Isotonic crystalloid solutions: a structured review of the literature. Br J Anaesth. 2014;112:968&#x2013;81. doi: 10.1093/bja/aeu047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeu047</ArticleId><ArticleId IdType="pubmed">24736393</ArticleId></ArticleIdList></Reference><Reference><Citation>Didwania A, Miller J, Kassel D, Jackson EV, Jr, Chernow B. Effect of intravenous lactated Ringer's solution infusion on the circulating lactate concentration: Part 3. Results of a prospective, randomized, double-blind, placebo-controlled trial. Crit Care Med. 1997;25:1851&#x2013;4. doi: 10.1097/00003246-199711000-00024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199711000-00024</ArticleId><ArticleId IdType="pubmed">9366769</ArticleId></ArticleIdList></Reference><Reference><Citation>Dezman ZD, Comer AC, Narayan M, Scalea TM, Hirshon JM, Smith GS. Alcohol consumption decreases lactate clearance in acutely injured patients. Injury. 2016. [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482221</ArticleId><ArticleId IdType="pubmed">27025567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse JA, Zaidi SA, Carlson RW. Significance of blood lactate levels in critically ill patients with liver disease. Am J Med. 1987;83:77&#x2013;82. doi: 10.1016/0002-9343(87)90500-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(87)90500-6</ArticleId><ArticleId IdType="pubmed">3605185</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiolero R, Tappy L, Gillet M, Revelly JP, Roth H, Cayeux C, et al. Effect of major hepatectomy on glucose and lactate metabolism. Ann Surg. 1999;229:505&#x2013;13. doi: 10.1097/00000658-199904000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199904000-00009</ArticleId><ArticleId IdType="pmc">PMC1191736</ArticleId><ArticleId IdType="pubmed">10203083</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia P, Soto D, Bruhn A, Alegria L, Jarufe N, Luengo C, et al. Impairment of exogenous lactate clearance in experimental hyperdynamic septic shock is not related to total liver hypoperfusion. Crit Care. 2015;19:188. doi: 10.1186/s13054-015-0928-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0928-3</ArticleId><ArticleId IdType="pmc">PMC4432956</ArticleId><ArticleId IdType="pubmed">25898244</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt LE, Larsen FS. Prognostic implications of hyperlactatemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminophen-induced acute liver failure. Crit Care Med. 2006;34:337&#x2013;43. doi: 10.1097/01.CCM.0000194724.70031.B6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000194724.70031.B6</ArticleId><ArticleId IdType="pubmed">16424712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez G, Luengo C, Bruhn A, Kattan E, Friedman G, Ospina-Tascon GA, et al. When to stop septic shock resuscitation: clues from a dynamic perfusion monitoring. Ann Intensive Care. 2014;4:30. doi: 10.1186/s13613-014-0030-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-014-0030-z</ArticleId><ArticleId IdType="pmc">PMC4273696</ArticleId><ArticleId IdType="pubmed">25593746</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34327527</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2048-8734</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>European heart journal. Acute cardiovascular care</Title><ISOAbbreviation>Eur Heart J Acute Cardiovasc Care</ISOAbbreviation></Journal><ArticleTitle>Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction.</ArticleTitle><Pagination><StartPage>1009</StartPage><EndPage>1015</EndPage><MedlinePgn>1009-1015</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjacc/zuab060</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To assess differences in long-term outcome and functional status of patients with cardiogenic shock (CS) treated by percutaneous mechanical circulatory support (pMCS) and intra-aortic balloon pump (IABP).</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Long-term follow-up of the multicentre, randomized IMPRESS in Severe Shock trial (NTR3450) was performed 5-year after initial randomization. Between 2012 and 2015, a total of 48 patients with severe CS from acute myocardial infarction (AMI) with ST-segment elevation undergoing immediate revascularization were randomized to pMCS by Impella CP (n&#x2009;=&#x2009;24) or IABP (n&#x2009;=&#x2009;24). For the 5-year assessment, all-cause mortality, functional status, and occurrence of major adverse cardiac and cerebrovascular event (MACCE) were assessed. MACCE consisted of death, myocardial re-infarction, repeat percutaneous coronary intervention, coronary artery bypass grafting, and stroke. Five-year mortality was 50% (n&#x2009;=&#x2009;12/24) in pMCS patients and 63% (n&#x2009;=&#x2009;15/24) in IABP patients (relative risk 0.87, 95% confidence interval 0.47-1.59, P&#x2009;=&#x2009;0.65). MACCE occurred in 12/24 (50%) of the pMCS patients vs. 19/24 (79%) of the IABP patients (P&#x2009;=&#x2009;0.07). All survivors except for one were in New York Heart Association Class I/II [pMCS n&#x2009;=&#x2009;10 (91%) and IABP n&#x2009;=&#x2009;7 (100%), P&#x2009;=&#x2009;1.00] and none of the patients had residual angina. There were no differences in left ventricular ejection fraction between the groups (pMCS 52&#x2009;&#xb1;&#x2009;11% vs. IABP 48&#x2009;&#xb1;&#x2009;10%, P&#x2009;=&#x2009;0.53).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this explorative randomized trial of patients with severe CS after AMI, there was no difference in long-term 5-year mortality between pMCS and IABP-treated patients, supporting previously published short-term data and in accordance with other long-term CS trials.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karami</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksen</LastName><ForeName>Erlend</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Heart Disease, Haukeland University Hospital, Jonas Lies vei 65, 5021 Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouweneel</LastName><ForeName>Dagmar M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claessen</LastName><ForeName>Bimmer E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0002-1703-7921</Identifier><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vis</LastName><ForeName>M Marije</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baan</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beijk</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Packer</LastName><ForeName>Erik J S</ForeName><Initials>EJS</Initials><AffiliationInfo><Affiliation>Department of Heart Disease, Haukeland University Hospital, Jonas Lies vei 65, 5021 Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sjauw</LastName><ForeName>Krischan D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engstrom</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlaar</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagrand</LastName><ForeName>Wim K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Jose P S</ForeName><Initials>JPS</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Acute Cardiovasc Care</MedlineTA><NlmUniqueID>101591369</NlmUniqueID><ISSNLinking>2048-8726</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Intra-aortic balloon pump</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34327527</ArticleId><ArticleId IdType="pmc">PMC8648392</ArticleId><ArticleId IdType="doi">10.1093/ehjacc/zuab060</ArticleId><ArticleId IdType="pii">6330850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schramm R, Morshuis M, Schoenbrodt M, Boergermann J, Hakim-Meibodi K, Hata M, Gummert JF.. Current perspectives on mechanical circulatory support. Eur J Cardiothorac Surg 2019;55:i31&#x2013;i37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526098</ArticleId><ArticleId IdType="pubmed">30608535</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Price S, Slutsky AS, Brodie D.. Temporary circulatory support for cardiogenic shock. Lancet 2020;396:199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">32682486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Seyfarth M, Henriques JPS.. Percutaneous mechanical circulatory support versus intra-aortic balloon pump for treating cardiogenic shock: meta-analysis. J Am Coll Cardiol 2017;69:358&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">27810348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD; SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006;295:2511&#x2013;2515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782030</ArticleId><ArticleId IdType="pubmed">16757723</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, Eitel I, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Jobs A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Hunziker L, Savonitto S, Torremante P, Vrints C, Schneider S, Zeymer U, Desch S; CULPRIT-SHOCK Investigators. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med 2018;379:1699&#x2013;1710.</Citation><ArticleIdList><ArticleId IdType="pubmed">30145971</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M, Meyer-Saraei R, Fuernau G, Eitel I, Hambrecht R, B&#xf6;hm M, Werdan K, Felix SB, Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S; IABPSHOCK II Trial (Intraaortic Balloon Pump in Cardiogenic Shock II) Investigators. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II trial.Circulation. 2019;139:395&#x2013;403</Citation><ArticleIdList><ArticleId IdType="pubmed">30586721</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera D, Stables R, Clayton T, De Silva K, Lumley M, Clack L, Thomas M, Redwood S.. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation 2013;127:207&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">23224207</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Ibrahim K, Loehn T, Werner N, Sinning J-M, Pappalardo F, Pieri M, Skurk C, Lauten A, Landmesser U, Westenfeld R, Horn P, Pauschinger M, Eckner D, Twerenbold R, Nordbeck P, Salinger T, Abel P, Empen K, Busch MC, Felix SB, Sieweke J-T, M&#xf8;ller JE, Pareek N, Hill J, MacCarthy P, Bergmann MW, Henriques JPS, M&#xf6;bius-Winkler S, Schulze PC, Ouarrak T, Zeymer U, Schneider S, Blankenberg S, Thiele H, Sch&#xe4;fer A, Westermann D.. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation 2019;139:1249&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">30586755</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemradj VV, Karami M, Sjauw KD, Engstr&#xf6;m AE, Ouweneel DM, de Brabander J, Vis MM, Wykrzykowska JJ, Beijk MA, Koch KT, Baan J, de Winter RJ, Piek JJ, Driessen AHG, Lagrand WK, Vlaar APJ, Ottervanger JP, Henriques JPS.. Pre-PCI versus immediate post-PCI Impella initiation in acute myocardial infarction complicated by cardiogenic shock. PLoS One 2020;15:e0235762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371192</ArticleId><ArticleId IdType="pubmed">32687502</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone M, Albani S, Giannini F, Colangelo S, Boccuzzi GG, Garbo R, Brilakis ES, D'ascenzo F, de Ferrari GM, Colombo A.. Short term outcomes of Impella in cardiogenic shock: a review and meta-analysis of observational studies. Int J Cardiol 2021;324:44&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">32971148</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Fish K, Kovacic JC, Bikou O, Leonardson L, Nomoto K, Aguero J, Kapur NK, Hajjar RJ, Ishikawa K.. Left ventricular unloading using an Impella CP improves coronary flow and infarct zone perfusion in ischemic heart failure. J Am Heart Assoc 2018;7:e006462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5907535</ArticleId><ArticleId IdType="pubmed">29514806</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur NK, Esposito ML.. Door to unload: a new paradigm for the management of cardiogenic shock. Curr Cardiovasc Risk Rep 2016;10:41.</Citation></Reference><Reference><Citation>Udesen NJ, M&#xf8;ller JE, Lindholm MG, Eiskj&#xe6;r H, Sch&#xe4;fer A, Werner N, Holmvang L, Terkelsen CJ, Jensen LO, Junker A, Schmidt H, Wachtell K, Thiele H, Engstr&#xf8;m T, Hassager C; DanGer Shock investigators. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J 2019;214:60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">31176289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33032450</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4539</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>22</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Circulation</Title><ISOAbbreviation>Circulation</ISOAbbreviation></Journal><ArticleTitle>Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study.</ArticleTitle><Pagination><StartPage>2095</StartPage><EndPage>2106</EndPage><MedlinePgn>2095-2106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCULATIONAHA.120.048792</ELocationID><Abstract><AbstractText Label="BACKGROUND">Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used to treat cardiogenic shock. However, VA-ECMO might hamper myocardial recovery. The Impella unloads the left ventricle. This study aimed to evaluate whether left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO was associated with lower mortality.</AbstractText><AbstractText Label="METHODS">Data from 686 consecutive patients with cardiogenic shock treated with VA-ECMO with or without left ventricular unloading using an Impella at 16 tertiary care centers in 4 countries were collected. The association between left ventricular unloading and 30-day mortality was assessed by Cox regression models in a 1:1 propensity score-matched cohort.</AbstractText><AbstractText Label="RESULTS">Left ventricular unloading was used in 337 of the 686 patients (49%). After matching, 255 patients with left ventricular unloading were compared with 255 patients without left ventricular unloading. In the matched cohort, left ventricular unloading was associated with lower 30-day mortality (hazard ratio, 0.79 [95% CI, 0.63-0.98]; <i>P</i>=0.03) without differences in various subgroups. Complications occurred more frequently in patients with left ventricular unloading: severe bleeding in 98 (38.4%) versus 45 (17.9%), access site-related ischemia in 55 (21.6%) versus 31 (12.3%), abdominal compartment in 23 (9.4%) versus 9 (3.7%), and renal replacement therapy in 148 (58.5%) versus 99 (39.1%).</AbstractText><AbstractText Label="CONCLUSIONS">In this international, multicenter cohort study, left ventricular unloading was associated with lower mortality in patients with cardiogenic shock treated with VA-ECMO, despite higher complication rates. These findings support use of left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO and call for further validation, ideally in a randomized, controlled trial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schrage</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departments of Cardiology (B.S., P.M.B., S. Blankenberg, S.D., A.G., P.K., D.W.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becher</LastName><ForeName>Peter Moritz</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Departments of Cardiology (B.S., P.M.B., S. Blankenberg, S.D., A.G., P.K., D.W.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernhardt</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery (A.B., H.R.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezerra</LastName><ForeName>Hiram</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tampa General Hospital, University of South Florida (H.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blankenberg</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Cardiology (B.S., P.M.B., S. Blankenberg, S.D., A.G., P.K., D.W.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medizinische Klinik und Poliklinik I (S. Brunner, D.K., M.O.), LMU Klinikum, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colson</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, CHU Montpellier, University Montpellier, France (P.C., M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudemus Deseda</LastName><ForeName>Gaston</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Anesthesia, Critical Care and Pain Medicine (G.C.D.), Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabboura</LastName><ForeName>Salim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Cardiology (B.S., P.M.B., S. Blankenberg, S.D., A.G., P.K., D.W.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckner</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Paracelsus Medical University N&#xfc;rnberg, Germany (D.E., M.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eden</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany(M.E., D.F., N.F., C.N.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Heart Center L&#xfc;beck, University Hospital Schleswig-Holstein, Germany (I.E., T.G.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Derk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany(M.E., D.F., N.F., C.N.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany(M.E., D.F., N.F., C.N.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funamoto</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery (M.F., D.M.), Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Go&#xdf;ling</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Cardiology (B.S., P.M.B., S. Blankenberg, S.D., A.G., P.K., D.W.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graf</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Heart Center L&#xfc;beck, University Hospital Schleswig-Holstein, Germany (I.E., T.G.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagl</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Herzchirurgische Klinik und Poliklinik (C.H.), LMU Klinikum, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchhof</LastName><ForeName>Paulus</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departments of Cardiology (B.S., P.M.B., S. Blankenberg, S.D., A.G., P.K., D.W.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Sciences, University of Birmingham and University Hospitals Birmingham and Sandwell and West Birmingham National Health ServiceTrusts, United Kingdom (P.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departments of Cardiology (B.S., P.M.B., S. Blankenberg, S.D., A.G., P.K., D.W.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medizinische Klinik und Poliklinik I (S. Brunner, D.K., M.O.), LMU Klinikum, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landmesser</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Campus Benjamin, Charit&#xe9; Universit&#xe4;tsmedizin Berlin, Germany (U.L., C.S.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Franklin/German Centre for Cardiovascular Research (DZHK), partner site Berlin/Institute of Health (BIH), Germany (U.L., C.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipinski</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of California, San Diego (J.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.L., D.A.M., A.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majunke</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Germany (N.M., M.S., L.S., H.T., F.T.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maniuc</LastName><ForeName>Octavian</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Medizinische Klinik und Poliklinik I (S. Brunner, D.K., M.O.), LMU Klinikum, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital W&#xfc;rzburg, Germany (O.M., P.N.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery (M.F., D.M.), Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf6;bius-Winkler</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Jena, Germany (S.M.-W., P.C.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrow</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.L., D.A.M., A.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mourad</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, CHU Montpellier, University Montpellier, France (P.C., M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noel</LastName><ForeName>Curt</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany(M.E., D.F., N.F., C.N.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital W&#xfc;rzburg, Germany (O.M., P.N.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orban</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Advanced Heart Failure and Mechanical Circulatory Support Program, Vita Salute University, Milan, Italy (F.P., V.P.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) ISMETT (Istituto Mediterraneo trapianti e terapie avanzate), UPMC (University of Pittsburgh Medical Center)Italy, Palermo, Italy (F.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Sandeep M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, St. Rita's Medical Center, Lima, OH (S.M.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pauschinger</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Paracelsus Medical University N&#xfc;rnberg, Germany (D.E., M.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazzanese</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Advanced Heart Failure and Mechanical Circulatory Support Program, Vita Salute University, Milan, Italy (F.P., V.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichenspurner</LastName><ForeName>Hermann</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery (A.B., H.R.), University Heart and Vascular Center Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandri</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Germany (N.M., M.S., L.S., H.T., F.T.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulze</LastName><ForeName>P Christian</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Jena, Germany (S.M.-W., P.C.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H G Schwinger</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medizinische Klinik II, Klinikum Weiden, Germany (R.H.G.S., L.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinning</LastName><ForeName>Jan-Malte</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>University Heart Center Bonn, Department of Cardiology, Germany (J.-M.S., A.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksoy</LastName><ForeName>Adem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Heart Center Bonn, Department of Cardiology, Germany (J.-M.S., A.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Campus Benjamin, Charit&#xe9; Universit&#xe4;tsmedizin Berlin, Germany (U.L., C.S.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Franklin/German Centre for Cardiovascular Research (DZHK), partner site Berlin/Institute of Health (BIH), Germany (U.L., C.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szczanowicz</LastName><ForeName>Lukasz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Germany (N.M., M.S., L.S., H.T., F.T.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Germany (N.M., M.S., L.S., H.T., F.T.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tietz</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Germany (N.M., M.S., L.S., H.T., F.T.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varshney</LastName><ForeName>Anubodh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.L., D.A.M., A.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wechsler</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medizinische Klinik II, Klinikum Weiden, Germany (R.H.G.S., L.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westermann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Hamburg/L&#xfc;beck/Kiel, Germany (B.S., P.M.B., A.B., S. Blankenberg, S.D., M.E., I.E., D.F., N.F., T.G., P.K., C.N., D.W.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circulation</MedlineTA><NlmUniqueID>0147763</NlmUniqueID><ISSNLinking>0009-7322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2020 Dec;142(22):2107-2109. doi: 10.1161/CIRCULATIONAHA.120.050847.</RefSource><PMID Version="1">33252999</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2021 Jun 8;143(23):e1021. doi: 10.1161/CIRCULATIONAHA.120.052111.</RefSource><PMID Version="1">34097445</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2021 Jun 8;143(23):e1024. doi: 10.1161/CIRCULATIONAHA.121.053992.</RefSource><PMID Version="1">34097447</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2021 Jun 8;143(23):e1022-e1023. doi: 10.1161/CIRCULATIONAHA.120.053263.</RefSource><PMID Version="1">34097450</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="Y">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">shock, cardiogenic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33032450</ArticleId><ArticleId IdType="pmc">PMC7688081</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048792</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz&#xe1;lez-Juanatey JR, Harjola VP, Jankowska EA, et al. ; ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129&#x2013;2200. doi: 10.1093/eurheartj/ehw128</Citation><ArticleIdList><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher PM, Schrage B, Sinning CR, Schmack B, Fluschnik N, Schwarzl M, Waldeyer C, Lindner D, Seiffert M, Neumann JT, et al. Venoarterial extracorporeal membrane oxygenation for cardiopulmonary support. Circulation. 2018;138:2298&#x2013;2300. doi: 10.1161/CIRCULATIONAHA.118.036691</Citation><ArticleIdList><ArticleId IdType="pubmed">30571518</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40:2671&#x2013;2683. doi: 10.1093/eurheartj/ehz363</Citation><ArticleIdList><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner S, Guenther SPW, Lackermair K, Peterss S, Orban M, Boulesteix AL, Michel S, Hausleiter J, Massberg S, Hagl C. Extracorporeal life support in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 2019;73:2355&#x2013;2357. doi: 10.1016/j.jacc.2019.02.044</Citation><ArticleIdList><ArticleId IdType="pubmed">31072581</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Burkhoff D, R&#xfc;bsamen N, Becher PM, Schwarzl M, Bernhardt A, Grahn H, Lubos E, S&#xf6;ffker G, Clemmensen P, et al. Unloading of the left ventricle during venoarterial extracorporeal membrane oxygenation therapy in cardiogenic shock. JACC Heart Fail. 2018;6:1035&#x2013;1043. doi: 10.1016/j.jchf.2018.09.009</Citation><ArticleIdList><ArticleId IdType="pubmed">30497643</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo JJ, Aleksova N, Pitcher I, Couture E, Parlow S, Faraz M, Visintini S, Simard T, Di Santo P, Mathew R, et al. Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol. 2019;73:654&#x2013;662. doi: 10.1016/j.jacc.2018.10.085</Citation><ArticleIdList><ArticleId IdType="pubmed">30765031</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, Greco T, Lembo R, M&#xfc;llerleile K, Colombo A, et al. Concomitant implantation of Impella&#xae; on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19:404&#x2013;412. doi: 10.1002/ejhf.668</Citation><ArticleIdList><ArticleId IdType="pubmed">27709750</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SM, Lipinski J, Al-Kindi SG, Patel T, Saric P, Li J, Nadeem F, Ladas T, Alaiti A, Phillips A, et al. Simultaneous venoarterial extracorporeal membrane oxygenation and percutaneous left ventricular decompression therapy with Impella is associated with improved outcomes in refractory cardiogenic shock. ASAIO J. 2019;65:21&#x2013;28. doi: 10.1097/MAT.0000000000000767</Citation><ArticleIdList><ArticleId IdType="pubmed">29489461</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Westermann D. Mechanical circulatory support devices in cardiogenic shock and acute heart failure: current evidence. Curr Opin Crit Care. 2019;25:391&#x2013;396. doi: 10.1097/MCC.0000000000000629</Citation><ArticleIdList><ArticleId IdType="pubmed">31135393</ArticleId></ArticleIdList></Reference><Reference><Citation>Tongers J, Sieweke JT, K&#xfc;hn C, Napp LC, Flierl U, R&#xf6;ntgen P, Schmitto JD, Sedding DG, Haverich A, Bauersachs J, et al. Early escalation of mechanical circulatory support stabilizes and potentially rescues patients in refractory cardiogenic shock. Circ Heart Fail. 2020;13:e005853.doi: 10.1161/CIRCHEARTFAILURE.118.005853</Citation><ArticleIdList><ArticleId IdType="pubmed">32164431</ArticleId></ArticleIdList></Reference><Reference><Citation>Buuren SV, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J. Stat. Software. 2011;45:1&#x2013;67. doi: 10.18637/jss.v045.i03</Citation></Reference><Reference><Citation>R: A language and environment for statistical computing [computer program]. 2010. Vienna, Austria: R Foundation for Statistical Computing</Citation></Reference><Reference><Citation>Uriel N, Sayer G, Annamalai S, Kapur NK, Burkhoff D. Mechanical unloading in heart failure. J Am Coll Cardiol. 2018;72:569&#x2013;580. doi: 10.1016/j.jacc.2018.05.038</Citation><ArticleIdList><ArticleId IdType="pubmed">30056830</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, Hollenberg SM, Kapur NK, O&#x2019;Neill W, Ornato JP, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv. 2019;94:29&#x2013;37. doi: 10.1002/ccd.28329</Citation><ArticleIdList><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Schreiber TL, Grines CL, Dixon SR, Moses JW, Maini BS, Khandelwal AK, Ohman EM, O&#x2019;Neill WW. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol. 2017;119:845&#x2013;851. doi: 10.1016/j.amjcard.2016.11.037</Citation><ArticleIdList><ArticleId IdType="pubmed">28040188</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, O&#x2019;Horo JC, Antharam P, Ananthaneni S, Vallabhajosyula S, Stulak JM, Dunlay SM, Holmes DR, Jr, Barsness GW. Venoarterial extracorporeal membrane oxygenation with concomitant Impella versus venoarterial extracorporeal membrane oxygenation for cardiogenic shock. ASAIO J. 2020;66:497&#x2013;503. doi: 10.1097/MAT.0000000000001039</Citation><ArticleIdList><ArticleId IdType="pubmed">31335363</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird-Zars VM, Barnett CF, Barsness GW, Burke JA, Cremer PC, et al. Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes. 2019;12:e005618.doi: 10.1161/CIRCOUTCOMES.119.005618</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11032172</ArticleId><ArticleId IdType="pubmed">30879324</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Weimann J, Dabboura S, Yan I, Hilal R, Becher PM, Seiffert M, Bernhardt AM, Kluge S, Reichenspurner H, et al. Patient characteristics, treatment and outcome in non-ischemic vs. ischemic cardiogenic shock. J Clin Med. 2020;9:931.doi: 10.3390/jcm9040931</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7230560</ArticleId><ArticleId IdType="pubmed">32231121</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, Eitel I, Nordbeck P, Geisler T, Landmesser U, et al. ; CULPRIT-SHOCK Investigators. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018;379:1699&#x2013;1710. doi: 10.1056/NEJMoa1808788</Citation><ArticleIdList><ArticleId IdType="pubmed">30145971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK investigators: should we emergently revascularize occluded coronaries for cardiogenic shock?. N Engl J Med. 1999;341:625&#x2013;634. doi: 10.1056/NEJM199908263410901</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, et al. ; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287&#x2013;1296. doi: 10.1056/NEJMoa1208410</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldetti L, Gramegna M, Beneduce A, Melillo F, Moroni F, Calvo F, Melisurgo G, Ajello S, Fominskiy E, Pappalardo F, et al. Strategies of left ventricular unloading during VA-ECMO support: a network meta-analysis. Int J Cardiol. 2020;312:16&#x2013;21. doi: 10.1016/j.ijcard.2020.02.004</Citation><ArticleIdList><ArticleId IdType="pubmed">32057479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, Esmailian F, Azarbal B. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014;97:610&#x2013;616. doi: 10.1016/j.athoracsur.2013.09.008</Citation><ArticleIdList><ArticleId IdType="pubmed">24210621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino S, Nguyen P, Salerno N, Polimeni A, Sabatino J, Makris A, Hennessy A, Giustino G, Spaccarotella C, Mongiardo A, et al. Standard versus ultrasound-guided cannulation of the femoral artery in patients undergoing invasive procedures: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9:677.doi: 10.3390/jcm9030677</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141204</ArticleId><ArticleId IdType="pubmed">32138283</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, Pieri M, Skurk C, Lauten A, Landmesser U, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139:1249&#x2013;1258. doi: 10.1161/CIRCULATIONAHA.118.036614</Citation><ArticleIdList><ArticleId IdType="pubmed">30586755</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2020;323:734&#x2013;745. doi: 10.1001/jama.2020.0254</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042879</ArticleId><ArticleId IdType="pubmed">32040163</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin AP, Spertus JA, Curtis JP, Desai N, Masoudi FA, Bach RG, McNeely C, Al-Badarin F, House JA, Kulkarni H, et al. The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. 2020;141:273&#x2013;284. doi: 10.1161/CIRCULATIONAHA.119.044007</Citation><ArticleIdList><ArticleId IdType="pubmed">31735078</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito ML, Morine KJ, Annamalai SK, O&#x2019;Kelly R, Aghili N, Pedicini R, Breton C, Mullin A, Hamadeh A, Kiernan MS, et al. Increased plasma-free hemoglobin levels identify hemolysis in patients with cardiogenic shock and a trans valvular micro-axial flow pump. Artif Organs. 2019;43:125&#x2013;131. doi: 10.1111/aor.13319</Citation><ArticleIdList><ArticleId IdType="pubmed">30216467</ArticleId></ArticleIdList></Reference><Reference><Citation>Koerner MM, Harper MD, Gordon CK, Horstmanshof D, Long JW, Sasevich MJ, Neel JD, El Banayosy A. Adult cardiac veno-arterial extracorporeal life support (VA-ECMO): prevention and management of acute complications. Ann Cardiothorac Surg. 2019;8:66&#x2013;75. doi: 10.21037/acs.2018.12.09</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379202</ArticleId><ArticleId IdType="pubmed">30854314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufeld T, Beckmann E, Ius F, Koigeldiev N, Sommer W, Mashaqi B, Fleissner FN, Siemeni T, Puntigam JO, Kaufeld J, et al. Risk factors for critical limb ischemia in patients undergoing femoral cannulation for venoarterial extracorporeal membrane oxygenation: is distal limb perfusion a mandatory approach?. Perfusion. 2019;34:453&#x2013;459. doi: 10.1177/0267659119827231</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6732820</ArticleId><ArticleId IdType="pubmed">30736721</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein ML. The starling relationship and veno-arterial ECMO: ventricular distension explained. ASAIO J. 2018;64:497&#x2013;501. doi: 10.1097/MAT.0000000000000660</Citation><ArticleIdList><ArticleId IdType="pubmed">29076945</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35103766</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>442</StartPage><EndPage>453</EndPage><MedlinePgn>442-453</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2021.24776</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The optimal approach to the use of venoarterial extracorporeal membrane oxygenation (ECMO) during cardiogenic shock is uncertain.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether early use of moderate hypothermia (33-34 &#xb0;C) compared with strict normothermia (36-37 &#xb0;C) improves mortality in patients with cardiogenic shock receiving venoarterial ECMO.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Randomized clinical trial of patients (who were eligible if they had been endotracheally intubated and were receiving venoarterial ECMO for cardiogenic shock for &lt;6 hours) conducted in the intensive care units at 20 French cardiac shock care centers between October 2016 and July 2019. Of 786 eligible patients, 374 were randomized. Final follow-up occurred in November 2019.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Early moderate hypothermia (33-34 &#xb0;C; n&#x2009;=&#x2009;168) for 24 hours or strict normothermia (36-37 &#xb0;C; n&#x2009;=&#x2009;166).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The primary outcome was mortality at 30 days. There were 31 secondary outcomes including mortality at days 7, 60, and 180; a composite outcome of death, heart transplant, escalation to left ventricular assist device implantation, or stroke at days 30, 60, and 180; and days without requiring a ventilator or kidney replacement therapy at days 30, 60, and 180. Adverse events included rates of severe bleeding, sepsis, and number of units of packed red blood cells transfused during venoarterial ECMO.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 374 patients who were randomized, 334 completed the trial (mean age, 58 [SD, 12] years; 24% women) and were included in the primary analysis. At 30 days, 71 patients (42%) in the moderate hypothermia group had died vs 84 patients (51%) in the normothermia group (adjusted odds ratio, 0.71 [95% CI, 0.45 to 1.13], P&#x2009;=&#x2009;.15; risk difference, -8.3% [95% CI, -16.3% to -0.3%]). For the composite outcome of death, heart transplant, escalation to left ventricular assist device implantation, or stroke at day 30, the adjusted odds ratio was 0.61 (95% CI, 0.39 to 0.96; P&#x2009;=&#x2009;.03) for the moderate hypothermia group compared with the normothermia group and the risk difference was -11.5% (95% CI, -23.2% to 0.2%). Of the 31 secondary outcomes, 30 were inconclusive. The incidence of moderate or severe bleeding was 41% in the moderate hypothermia group vs 42% in the normothermia group. The incidence of infections was 52% in both groups. The incidence of bacteremia was 20% in the moderate hypothermia group vs 30% in the normothermia group.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In this randomized clinical trial involving patients with refractory cardiogenic shock treated with venoarterial ECMO, early application of moderate hypothermia for 24 hours did not significantly increase survival compared with normothermia. However, because the 95% CI was wide and included a potentially important effect size, these findings should be considered inconclusive.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov Identifier: NCT02754193.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>M&#xe9;decine Intensive et R&#xe9;animation, CHRU Nancy, P&#xf4;le Cardio-M&#xe9;dico-Chirurgical, Vandoeuvre-les-Nancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1116, Facult&#xe9; de M&#xe9;decine, Vandoeuvre-les-Nancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; de Lorraine, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girerd</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lorraine, INSERM, Centre d'Investigations Cliniques Plurith&#xe9;matique, INSERM 1433, CHRU de Nancy, Institut Lorrain du Coeur et des Vaisseaux, Nancy, Frances.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amour</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut de Perfusion, de R&#xe9;animation et d'Anesth&#xe9;sie de Chirurgie Cardiaque Paris Sud, H&#xf4;pital Priv&#xe9; Jacques Cartier, Massy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besnier</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandie University, UNIROUEN, INSERM U1096, EnVi, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nesseler</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, Rennes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Rennes, CHU de Rennes, Inra, INSERM, Institut NUMECAN - UMR_A 1341, UMR_S 1241, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helms</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Strasbourg, Facult&#xe9; de M&#xe9;decine, H&#xf4;pitaux Universitaires de Strasbourg, Service de M&#xe9;decine Intensive-R&#xe9;animation, Nouvel H&#xf4;pital Civil, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmas</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonneville</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>AP-HP, Bichat Hospital, Medical and infectious diseases ICU, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guidon</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>P&#xf4;le Anesth&#xe9;sie-R&#xe9;animation, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozec</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service d'Anesth&#xe9;sie-R&#xe9;animation, H&#xf4;pital G&amp;R Laennec CHU de Nantes, Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>L'institut du Thorax INSERM, CNRS, CHU Nantes, UNIV Nantes, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Hel&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montpellier University, INSERM, CNRS, PhyMedExp, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bougon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation, Centre Hospitalier Annecy, Genevois, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaouch</LastName><ForeName>Oussama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>H&#xf4;pital Europ&#xe9;en Georges Pompidou, AP-HP, Department of Anesthesiology and Critical Care Medicine, Universit&#xe9; Paris Descartes, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walid</LastName><ForeName>Oulehri</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Service d'Anesth&#xe9;sie-R&#xe9;animation et M&#xe9;decine p&#xe9;ri-Op&#xe9;ratoire, Nouvel H&#xf4;pital Civil, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herv&#xe9;</LastName><ForeName>Dupont</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>R&#xe9;animation M&#xe9;dico-Chirurgicale Cardio-Thoracique, Vasculaire et Respiratoire, CHU Amiens Picardie, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belin</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, CHU Besan&#xe7;on, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaide-Chevronnay</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de R&#xe9;animation Cardiovasculaire et Thoracique, P&#xf4;le Anesth&#xe9;sie R&#xe9;animation, CHU de Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossignol</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation, Centre Hospitalier Annecy, Genevois, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmoun</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>M&#xe9;decine Intensive et R&#xe9;animation, CHRU Nancy, P&#xf4;le Cardio-M&#xe9;dico-Chirurgical, Vandoeuvre-les-Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lorraine, Centre d'Investigations Cliniques Plurith&#xe9;matique, INSERM 1433, CHRU de Nancy, Institut Lorrain du Coeur et des Vaisseaux, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slutsky</LastName><ForeName>Arthur S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Keenan Research Center, Li Ka Shing Knowledge Institute, St Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Surgery, and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodie</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, College of Physicians and Surgeons, Columbia University, and the Center for Acute Respiratory Failure, New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fellahi</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Service d'Anesth&#xe9;sie-R&#xe9;animation, H&#xf4;pital Louis Pradel, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire CarMeN, INSERM 1060, Universit&#xe9; Lyon 1 Claude Bernard, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouattara</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CHU Bordeaux, Department of Anaesthesia and Critical Care, Magellan Medico-Surgical Centre, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Bordeaux, INSERM, UMR 1034, Biology of Cardiovascular Diseases, Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Combes</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, APHP Sorbonne Universit&#xe9; H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HYPO-ECMO Trial Group and the International ECMO Network (ECMONet)</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02754193</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2022 May 17;327(19):1927-1928. doi: 10.1001/jama.2022.5043.</RefSource><PMID Version="1">35579646</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2022 May 17;327(19):1928. doi: 10.1001/jama.2022.5040.</RefSource><PMID Version="1">35579647</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA. 2023 Apr 11;329(14):1226. doi: 10.1001/jama.2023.3806.</RefSource><PMID Version="1">37039807</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Respir Crit Care Med. 2023 Jul 15;208(2):196-198. doi: 10.1164/rccm.202206-1165RR.</RefSource><PMID Version="1">37141107</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001831" MajorTopicYN="Y">Body Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016027" MajorTopicYN="N">Heart Transplantation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007036" MajorTopicYN="N">Hypothermia, Induced</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007442" MajorTopicYN="N">Intubation, Intratracheal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="N">Renal Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Levy reported receiving personal fees from Abiomed, Gettinge, Baxter, Novartis, Sanofi, Amomed, and Orion. Dr Girerd reported receiving personal fees from Novartis, Bayer, AstraZeneca, Lilly, Boehringer, and Vifor. Dr Besnier reported receiving personal fees from Amomed Pharma, Orion Pharma, and the Laboratoire Fran&#xe7;ais du Fractionnement et des Biotechnologies (LFB). Dr Delmas reported receiving personal fees from Abiomed and Abbott Laboratories. Dr Sonneville reported receiving grants from the French Ministry of Health, the European Society of Intensive Care Medicine, and the French Society of Anesthesiology and Intensive Care Medicine. Dr Rozec reported receiving personal fees from Baxter, Aguettant, LFB, Institut Sup&#xe9;rieur d'&#xe9;lectronique de Paris (ISEP), Nordic Pharma, Amomed, Haemonetics, Aspen, Boston Scientific, Ethypharm, and Medtronic and nonfinancial support from ISEP. Dr Gaide-Chevronnay reported receiving personal fees from LFB. Dr Rossignol reported receiving personal fees from Idorsia, G3P, CinCor, AstraZeneca, Bayer, Grunenthal, CVRx, Novartis, Novo Nordisk, Relypsa, Roche, Servier, Stealth Peptides, and Vifor Fresenius Medical Care Renal Pharma; receiving grants from AstraZeneca, Bayer, CVRx, Novartis, and Vifor Fresenius Medical Care Renal Pharma; and being the co-founder of CardioRenal. Dr Kimmoun reported receiving personal fees from Aspen and Aguettant. Dr Slutsky reported receiving personal fees from Baxter, Xenios, and Fresenius Medical Care and being the chair of the scientific committee of the International ECMO Network. Dr Brodie reported receiving grants from ALung Technologies; serving on medical advisory boards and receiving personal fees from Abiomed, Xenios, Medtronic, and Cellenkos; and being the president-elect of the Extracorporeal Life Support Organization and the chair of the executive committee of the International ECMO Network. Dr Ouattara reported receiving personal fees from Abiomed, Nordic Pharma, LFB, VifOR Pharma, Orion Pharma, ISEP, Masimo, and Medtronic. Dr Combes reported receiving personal fees from Getinge, Baxter, and Fresenius-Xenios. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Mattei</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thivillier</LastName><ForeName>Carine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auchet</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Pierrre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fritz</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maureira</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hubert</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Yihua</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meziani</LastName><ForeName>Ferhat</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merdji</LastName><ForeName>Hamid</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monnier</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clere-Jehl</LastName><ForeName>Rapha&#xeb;l</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieszkowska</LastName><ForeName>Ania</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pineton</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chommeloux</LastName><ForeName>Juliette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xe9;kimian</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebreton</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quessard</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Imbault</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>R&#xe9;my</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pernot</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joseph</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scollo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escudier</LastName><ForeName>&#xc9;tienne</ForeName><Initials>&#xc9;</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muller</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorez</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirodot</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doguet</LastName><ForeName>Fabien</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scherrer</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aludaat</LastName><ForeName>Chadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernasinski</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zogheib</LastName><ForeName>Elie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caus</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bizouarn</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Mickael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roussel</LastName><ForeName>Jean-Christian</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senage</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flecher</LastName><ForeName>Erwan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verhoye</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roisne</LastName><ForeName>Antoine</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biedermann</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vardon-Bounes</LastName><ForeName>Fanny</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crognier</LastName><ForeName>Laure</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porterie</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colson</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaudard</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rouviere</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouadma</LastName><ForeName>Lila</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinnah</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nataf</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Para</LastName><ForeName>Marylou</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dureau</LastName><ForeName>Pauline</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djavidi</LastName><ForeName>Nima</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bougl&#xe9;</LastName><ForeName>Adrien</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leprince</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dessertaine</LastName><ForeName>G&#xe9;raldine</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durand</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albaladejo</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Cecile</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belon</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piton</LastName><ForeName>Gael</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winiszewski</LastName><ForeName>Hadrien</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perroti</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tonon</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholley</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zlotnik</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Achouh</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nougue</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collange</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mertes</LastName><ForeName>Paul Michel</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kindo</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35103766</ArticleId><ArticleId IdType="pmc">PMC8808325</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.24776</ArticleId><ArticleId IdType="pii">2788527</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rao P, Khalpey Z, Smith R, Burkhoff D, Kociol RD. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. Circ Heart Fail. 2018;11(9):e004905. doi:10.1161/CIRCHEARTFAILURE.118.004905</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.118.004905</ArticleId><ArticleId IdType="pubmed">30354364</ArticleId></ArticleIdList></Reference><Reference><Citation>Chioncel O, Parissis J, Mebazaa A, et al. . Epidemiology, pathophysiology and contemporary management of cardiogenic shock&#x2014;a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(8):1315-1341. doi:10.1002/ejhf.1922</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1922</ArticleId><ArticleId IdType="pubmed">32469155</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Price S, Slutsky AS, Brodie D. Temporary circulatory support for cardiogenic shock. Lancet. 2020;396(10245):199-212. doi:10.1016/S0140-6736(20)31047-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31047-3</ArticleId><ArticleId IdType="pubmed">32682486</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiagarajan RR, Barbaro RP, Rycus PT, et al. ; ELSO member centers . Extracorporeal Life Support Organization registry international report 2016. ASAIO J. 2017;63(1):60-67. doi:10.1097/MAT.0000000000000475</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000475</ArticleId><ArticleId IdType="pubmed">27984321</ArticleId></ArticleIdList></Reference><Reference><Citation>Prondzinsky R, Unverzagt S, Lemm H, et al. . Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol. 2012;101(5):375-384. doi:10.1007/s00392-011-0403-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-011-0403-3</ArticleId><ArticleId IdType="pubmed">22212516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107(24):2998-3002. doi:10.1161/01.CIR.0000075927.67673.F2</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000075927.67673.F2</ArticleId><ArticleId IdType="pubmed">12821585</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671-2683. doi:10.1093/eurheartj/ehz363</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz363</ArticleId><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference><Reference><Citation>Dankiewicz J, Cronberg T, Lilja G, et al. ; TTM2 Trial Investigators . Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384(24):2283-2294. doi:10.1056/NEJMoa2100591</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100591</ArticleId><ArticleId IdType="pubmed">34133859</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquot A, Lepage X, Merckle L, Girerd N, Levy B. Protocol for a multicentre randomised controlled trial evaluating the effects of moderate hypothermia versus normothermia on mortality in patients with refractory cardiogenic shock rescued by venoarterial extracorporeal membrane oxygenation (VA-ECMO) (HYPO-ECMO study). BMJ Open. 2019;9(10):e031697. doi:10.1136/bmjopen-2019-031697</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-031697</ArticleId><ArticleId IdType="pmc">PMC6797322</ArticleId><ArticleId IdType="pubmed">31615800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rab T, Ratanapo S, Kern KB, et al. . Cardiac shock care centers: JACC review topic of the week. J Am Coll Cardiol. 2018;72(16):1972-1980. doi:10.1016/j.jacc.2018.07.074</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.07.074</ArticleId><ArticleId IdType="pubmed">30309475</ArticleId></ArticleIdList></Reference><Reference><Citation>Noyes AM, Lundbye JB. Managing the complications of mild therapeutic hypothermia in the cardiac arrest patient. J Intensive Care Med. 2015;30(5):259-269. doi:10.1177/0885066613516416</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066613516416</ArticleId><ArticleId IdType="pubmed">24371249</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Leprince P, Luyt CE, et al. . Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med. 2008;36(5):1404-1411. doi:10.1097/CCM.0b013e31816f7cf7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31816f7cf7</ArticleId><ArticleId IdType="pubmed">18434909</ArticleId></ArticleIdList></Reference><Reference><Citation>Landoni G, Comis M, Conte M, et al. . Mortality in multicenter critical care trials: an analysis of interventions with a significant effect. Crit Care Med. 2015;43(8):1559-1568. doi:10.1097/CCM.0000000000000974</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000974</ArticleId><ArticleId IdType="pubmed">25821918</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen N, Wetterslev J, Cronberg T, et al. ; TTM Trial Investigators . Targeted temperature management at 33&#xb0;C versus 36&#xb0;C after cardiac arrest. N Engl J Med. 2013;369(23):2197-2206. doi:10.1056/NEJMoa1310519</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1310519</ArticleId><ArticleId IdType="pubmed">24237006</ArticleId></ArticleIdList></Reference><Reference><Citation>Dmitrienko A, Tamhane A, Bretz F. Multiple Testing Problems in Pharmaceutical Statistics. CRC/Taylor &amp; Francis; 2010.</Citation></Reference><Reference><Citation>Pedroza C, Truong VT. Performance of models for estimating absolute risk difference in multicenter trials with binary outcome. BMC Med Res Methodol. 2016;16(1):113. doi:10.1186/s12874-016-0217-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-016-0217-0</ArticleId><ArticleId IdType="pmc">PMC5006411</ArticleId><ArticleId IdType="pubmed">27576307</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher EC, Tomlinson G, Hajage D, et al. . Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc bayesian analysis of a randomized clinical trial. JAMA. 2018;320(21):2251-2259. doi:10.1001/jama.2018.14276</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.14276</ArticleId><ArticleId IdType="pubmed">30347031</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Br&#xe9;chot N, Hariri S, et al. . Nosocomial infections in adult cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation. Clin Infect Dis. 2012;55(12):1633-1641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888098</ArticleId><ArticleId IdType="pubmed">22990851</ArticleId></ArticleIdList></Reference><Reference><Citation>Villablanca PA, Rao G, Briceno DF, et al. . Therapeutic hypothermia in ST elevation myocardial infarction: a systematic review and meta-analysis of randomised control trials. Heart. 2016;102(9):712-719. doi:10.1136/heartjnl-2015-308559</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2015-308559</ArticleId><ArticleId IdType="pubmed">26864673</ArticleId></ArticleIdList></Reference><Reference><Citation>Annoni F, Peluso L, Fiore M, et al. . Impact of therapeutic hypothermia during cardiopulmonary resuscitation on neurologic outcome: a systematic review and meta-analysis. Resuscitation. 2021;162:365-371. doi:10.1016/j.resuscitation.2021.01.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2021.01.029</ArticleId><ArticleId IdType="pubmed">33545107</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Zhen Z, Na J, Wang Q, Gao L, Yuan Y. Associations of therapeutic hypothermia with clinical outcomes in patients receiving ECPR after cardiac arrest: systematic review with meta-analysis. Scand J Trauma Resusc Emerg Med. 2020;28(1):3. doi:10.1186/s13049-019-0698-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13049-019-0698-z</ArticleId><ArticleId IdType="pmc">PMC6961259</ArticleId><ArticleId IdType="pubmed">31937354</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegman B, Aggarwal B, Senapati A, Shao M, Menon V. Serial hemodynamic measurements in post-cardiac arrest cardiogenic shock treated with therapeutic hypothermia. Eur Heart J Acute Cardiovasc Care. 2015;4(3):263-269. doi:10.1177/2048872614547688</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872614547688</ArticleId><ArticleId IdType="pubmed">25114327</ArticleId></ArticleIdList></Reference><Reference><Citation>Zobel C, Adler C, Kranz A, et al. . Mild therapeutic hypothermia in cardiogenic shock syndrome. Crit Care Med. 2012;40(6):1715-1723. doi:10.1097/CCM.0b013e318246b820</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318246b820</ArticleId><ArticleId IdType="pubmed">22487996</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegman BM, Newby LK, Hochman JS, Ohman EM. Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment: is therapeutic hypothermia one possibility? J Am Coll Cardiol. 2012;59(7):644-647. doi:10.1016/j.jacc.2011.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.11.010</ArticleId><ArticleId IdType="pubmed">22322079</ArticleId></ArticleIdList></Reference><Reference><Citation>Soar J, Berg KM, Andersen LW, et al. ; Adult Advanced Life Support Collaborators . Adult advanced life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation. 2020;156:A80-A119. doi:10.1016/j.resuscitation.2020.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2020.09.012</ArticleId><ArticleId IdType="pmc">PMC7576326</ArticleId><ArticleId IdType="pubmed">33099419</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando SM, Di Santo P, Sadeghirad B, et al. . Targeted temperature management following out-of-hospital cardiac arrest: a systematic review and network meta-analysis of temperature targets. Intensive Care Med. 2021;47(10):1078-1088. doi:10.1007/s00134-021-06505-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06505-z</ArticleId><ArticleId IdType="pubmed">34389870</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tberg M, van der Pals J, Olivecrona GK, G&#xf6;tberg M, Koul S, Erlinge D. Mild hypothermia reduces acute mortality and improves hemodynamic outcome in a cardiogenic shock pig model. Resuscitation. 2010;81(9):1190-1196. doi:10.1016/j.resuscitation.2010.04.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2010.04.033</ArticleId><ArticleId IdType="pubmed">20627520</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuernau G, Beck J, Desch S, et al. . Mild hypothermia in cardiogenic shock complicating myocardial infarction. Circulation. 2019;139(4):448-457. doi:10.1161/CIRCULATIONAHA.117.032722</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.032722</ArticleId><ArticleId IdType="pubmed">30026282</ArticleId></ArticleIdList></Reference><Reference><Citation>Alushi B, Ndrepepa G, Lauten A, et al. . Hypothermia in patients with acute myocardial infarction: a meta-analysis of randomized trials. Clin Res Cardiol. 2021;110(1):84-92. doi:10.1007/s00392-020-01652-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01652-7</ArticleId><ArticleId IdType="pubmed">32303830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard H, S&#xf8;reide E, de Haas I, et al. . Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital cardiac arrest: a randomized clinical trial. JAMA. 2017;318(4):341-350. doi:10.1001/jama.2017.8978</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.8978</ArticleId><ArticleId IdType="pmc">PMC5541324</ArticleId><ArticleId IdType="pubmed">28742911</ArticleId></ArticleIdList></Reference><Reference><Citation>Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009;37(7)(suppl):S186-S202. doi:10.1097/CCM.0b013e3181aa5241</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181aa5241</ArticleId><ArticleId IdType="pubmed">19535947</ArticleId></ArticleIdList></Reference><Reference><Citation>Polderman KH. Application of therapeutic hypothermia in the intensive care unit: opportunities and pitfalls of a promising treatment modality&#x2014;part 2: practical aspects and side effects. Intensive Care Med. 2004;30(5):757-769. doi:10.1007/s00134-003-2151-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-003-2151-y</ArticleId><ArticleId IdType="pubmed">14767590</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan J, Ma Q, Zhu C, Shi Y, Duan B. eCPR combined with therapeutic hypothermia could improve survival and neurologic outcomes for patients with cardiac arrest: a meta-analysis. Front Cardiovasc Med. 2021;8:703567. doi:10.3389/fcvm.2021.703567</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.703567</ArticleId><ArticleId IdType="pmc">PMC8414549</ArticleId><ArticleId IdType="pubmed">34485403</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhuyse F, Ducrocq N, Louis H, et al. . Moderate hypothermia improves cardiac and vascular function in a pig model of ischemic cardiogenic shock treated with veno-arterial ECMO. Shock. 2017;47(2):236-241. doi:10.1097/SHK.0000000000000712</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000712</ArticleId><ArticleId IdType="pubmed">27488087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19007597</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>19</Issue><PubDate><Year>2008</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Journal of the American College of Cardiology</Title><ISOAbbreviation>J Am Coll Cardiol</ISOAbbreviation></Journal><ArticleTitle>A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction.</ArticleTitle><Pagination><StartPage>1584</StartPage><EndPage>1588</EndPage><MedlinePgn>1584-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacc.2008.05.065</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to test whether the left ventricular assist device (LVAD) Impella LP2.5 (Abiomed Europe GmbH, Aachen, Germany) provides superior hemodynamic support compared with the intra-aortic balloon pump (IABP).</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiogenic shock caused by left ventricular failure is associated with high mortality in patients with acute myocardial infarction (AMI). An LVAD may help to bridge patients to recovery from left ventricular failure.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a prospective, randomized study, 26 patients with cardiogenic shock were studied. The primary end point was the change of the cardiac index (CI) from baseline to 30 min after implantation. Secondary end points included lactic acidosis, hemolysis, and mortality after 30 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 25 patients the allocated device (n = 13 IABP, n = 12 Impella LP2.5) could be safely placed. One patient died before implantation. The CI after 30 min of support was significantly increased in patients with the Impella LP2.5 compared with patients with IABP (Impella: DeltaCI = 0.49 +/- 0.46 l/min/m(2); IABP: DeltaCI = 0.11 +/- 0.31 l/min/m(2); p = 0.02). Overall 30-day mortality was 46% in both groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients presenting with cardiogenic shock caused by AMI, the use of a percutaneously placed LVAD (Impella LP 2.5) is feasible and safe, and provides superior hemodynamic support compared with standard treatment using an intra-aortic balloon pump. (Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock [ISAR-SHOCK]; NCT00417378).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seyfarth</LastName><ForeName>Melchior</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t, Munich, Germany. seyfarth@dhm.mhn.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sibbing</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Iris</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Fr&#xf6;hlich</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bott-Fl&#xfc;gel</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dirschinger</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kastrati</LastName><ForeName>Adnan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sch&#xf6;mig</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00417378</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Cardiol</MedlineTA><NlmUniqueID>8301365</NlmUniqueID><ISSNLinking>0735-1097</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004869" MajorTopicYN="N">Equipment Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="Y">Intra-Aortic Balloon Pumping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19007597</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2008.05.065</ArticleId><ArticleId IdType="pii">S0735-1097(08)02826-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25787196</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>20</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of the American College of Cardiology</Title><ISOAbbreviation>J Am Coll Cardiol</ISOAbbreviation></Journal><ArticleTitle>Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>2184</StartPage><EndPage>2194</EndPage><MedlinePgn>2184-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacc.2015.03.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-1097(15)00819-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Transcatheter aortic valve replacement (TAVR) is an option in certain high-risk surgical patients with severe aortic valve stenosis. It is unknown whether TAVR can be safely introduced to lower-risk patients.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The NOTION (Nordic Aortic Valve Intervention Trial) randomized clinical trial compared TAVR with surgical aortic valve replacement (SAVR) in an all-comers patient cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients &#x2265; 70 years old with severe aortic valve stenosis and no significant coronary artery disease were randomized 1:1 to TAVR using a self-expanding bioprosthesis versus SAVR. The primary outcome was the composite rate of death from any cause, stroke, or myocardial infarction (MI) at 1 year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 280 patients were randomized at 3 Nordic centers. Mean age was 79.1 years, and 81.8% were considered low-risk patients. In the intention-to-treat population, no significant difference in the primary endpoint was found (13.1% vs. 16.3%; p = 0.43 for superiority). The result did not change in the as-treated population. No difference in the rate of cardiovascular death or prosthesis reintervention was found. Compared with SAVR-treated patients, TAVR-treated patients had more conduction abnormalities requiring pacemaker implantation, larger improvement in effective orifice area, more total aortic valve regurgitation, and higher New York Heart Association functional class at 1 year. SAVR-treated patients had more major or life-threatening bleeding, cardiogenic shock, acute kidney injury (stage II or III), and new-onset or worsening atrial fibrillation at 30 days than did TAVR-treated patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the NOTION trial, no significant difference between TAVR and SAVR was found for the composite rate of death from any cause, stroke, or MI after 1 year. (Nordic Aortic Valve Intervention Trial [NOTION]; NCT01057173).</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thyregod</LastName><ForeName>Hans Gustav H&#xf8;rsted</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: hans.gustav.thyregod@regionh.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinbr&#xfc;chel</LastName><ForeName>Daniel Andreas</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ihlemann</LastName><ForeName>Nikolaj</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nissen</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kjeldsen</LastName><ForeName>Bo Juel</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petursson</LastName><ForeName>Petur</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yanping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Statistics, Medtronic Inc., Mounds View, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzen</LastName><ForeName>Olaf Walter</ForeName><Initials>OW</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engstr&#xf8;m</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemmensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Peter Bo</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesia, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Lars Willy</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesia, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Peter Skov</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;ndergaard</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01057173</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Cardiol</MedlineTA><NlmUniqueID>8301365</NlmUniqueID><ISSNLinking>0735-1097</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Am Coll Cardiol. 2015 May 26;65(20):2195-7. doi: 10.1016/j.jacc.2015.03.560.</RefSource><PMID Version="1">25998665</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Am Coll Cardiol. 2015 Aug 25;66(8):979-80. doi: 10.1016/j.jacc.2015.04.084.</RefSource><PMID Version="1">26293772</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Am Coll Cardiol. 2015 Aug 25;66(8):979. doi: 10.1016/j.jacc.2015.05.075.</RefSource><PMID Version="1">26293773</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Am Coll Cardiol. 2015 Oct 6;66(14):1638-1639. doi: 10.1016/j.jacc.2015.06.1345.</RefSource><PMID Version="1">26429094</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Am Coll Cardiol. 2015 Oct 6;66(14):1638. doi: 10.1016/j.jacc.2015.06.1346.</RefSource><PMID Version="1">26429095</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Thorac Surg. 2015 Nov;100(5):1976. doi: 10.1016/j.athoracsur.2015.05.076.</RefSource><PMID Version="1">26522570</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="N">Aortic Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="N">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006350" MajorTopicYN="N">Heart Valve Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="N">Transcatheter Aortic Valve Replacement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aortic valve prosthesis</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25787196</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2015.03.014</ArticleId><ArticleId IdType="pii">S0735-1097(15)00819-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40162941</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>16</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Journal of the American College of Cardiology</Title><ISOAbbreviation>J Am Coll Cardiol</ISOAbbreviation></Journal><ArticleTitle>Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>1587</StartPage><EndPage>1597</EndPage><MedlinePgn>1587-1597</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacc.2025.03.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-1097(25)05334-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The impact of intra-aortic balloon pump (IABP) on survival and successful bridging to heart replacement therapies (HRT) in patients with heart failure-cardiogenic shock (HF-CS) remains unclear.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The purpose of this study was to evaluate the effect of early IABP use vs standard care on 60-day survival or successful bridging to HRT.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the multicenter, prospective Altshock-2 (Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart&#xa0;Failure Complicated by Cardiogenic Shock), patients with Society for Cardiovascular Angiography and Interventions stage B, C, or D HF-CS and suitable for HRT were randomized to receive early IABP plus standard care (IABP group) or standard care (control group). The primary endpoint was survival or successful bridge to HRT at 60&#xa0;days. Secondary endpoints included overall survival, maximum inotropic score, and maximum sequential organ failure assessment score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 53 patients were randomized to IABP and 48 to standard care. Patients were Society for Cardiovascular Angiography and Interventions stage B (28%, n&#xa0;=&#xa0;28), C (57%, n&#xa0;=&#xa0;56), and D (15%, n&#xa0;=&#xa0;16). At the prespecified interim analysis, the trial was stopped because of futility. The primary endpoint was reached in 43 patients (81%) in the IABP group and 36 patients (75%) in the control group (HR: 0.72; 95%&#xa0;CI: 0.31-1.68; P&#xa0;=&#xa0;0.45). A total of 37 patients (37%) underwent HRT within the 60-day follow-up. Four patients were escalated in the study group (7.5%) vs 2 in the control group (4.2%). Additionally, 6 patients (13%) initially assigned to standard care crossed over to IABP. Complications were comparable between groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Routine early IABP plus standard care, compared with standard care, did not significantly improve survival or successful bridging to HRT in patients with HF-CS. (Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart&#xa0;Failure Complicated by Cardiogenic Shock [Altshock-2]; NCT04369573).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morici</LastName><ForeName>Nuccia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Gnocchi, ONLUS, Santa Maria Nascente, Milan, Italy. Electronic address: nmorici@dongnocchi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frea</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rota</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Units of Biostatistics and Biomathematics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villanova</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravinese</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dini</LastName><ForeName>Carlotta Sorini</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ettore</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Anesthesia and Intensive Care, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maj</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Anesthesia and Intensive Care, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Lio</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potena</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Heart Failure and Transplant Unit-IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Serafina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabatino</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Heart Failure and Transplant Unit-IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viola</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garatti</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavecchia</LastName><ForeName>Giovanni Amedeo</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoldi</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Humanitas Research Hospital, IRCCS Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliva</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapur</LastName><ForeName>Navin K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine Section, Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavazzi</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical-Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy; Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS, Anestesia e Rianimazione I, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Ferrari</LastName><ForeName>Gaetano Maria</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Kore University, Enna and Centro Cuore GB Morgagni, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Altshock-2 Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04369573</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Cardiol</MedlineTA><NlmUniqueID>8301365</NlmUniqueID><ISSNLinking>0735-1097</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="Y">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">heart failure-cardiogenic shock</Keyword><Keyword MajorTopicYN="N">heart replacement therapies</Keyword><Keyword MajorTopicYN="N">intra-aortic balloon pump</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The trial was supported by an unrestricted grant provided by Getinge Global US. Representatives of the funders did not take part in the trial design and did not participate in the analysis or interpretation of data or in the writing of the paper. Dr Kapur has been appointed as Global Chief Medical and scientific officer at Johnson and Johnson MedTech, Heart Recovery; has received institutional research grants from Abbott, Abiomed, Boston Scientific, Getinge, LivaNova, and Teleflex; and has received consulting/speaking honoraria from Abbott, Abiomed, Boston Scientific, Getinge, LivaNova, Teleflex, Zoll, and Edwards. Dr Pappalardo is a consultant for Abiomed and Carmat. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>31</Day><Hour>21</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>31</Day><Hour>10</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40162941</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2025.03.003</ArticleId><ArticleId IdType="pii">S0735-1097(25)05334-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">21477402</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-8526</ISSN><JournalIssue CitedMedium="Internet"><Volume>2011</Volume><PubDate><Year>2011</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>BMJ clinical evidence</Title><ISOAbbreviation>BMJ Clin Evid</ISOAbbreviation></Journal><ArticleTitle>Myocardial infarction (ST-elevation).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">0202</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">About one quarter of people having an acute myocardial infarction (MI) in the USA will die of it, half of them within 1 hour of the onset of symptoms. Cardiogenic shock develops in over 5% of people surviving the first hour after an acute MI, with a mortality of 50% to 80% in the first 48 hours.</AbstractText><AbstractText Label="METHODS AND OUTCOMES" NlmCategory="METHODS">We conducted a systematic review and aimed to answer the following clinical questions: Which treatments improve outcomes in acute MI? Which treatments improve outcomes for cardiogenic shock after MI? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found 52 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this systematic review we present information relating to the effectiveness and safety of the following interventions: angiotensin-converting enzyme (ACE) inhibitors, aspirin, beta-blockers, calcium channel blockers, early cardiac surgery, early invasive cardiac revascularisation, glycoprotein IIb/IIIa inhibitors, intra-aortic balloon counterpulsation, nitrates (with or without thrombolysis), positive inotropes, primary percutaneous transluminal coronary angioplasty (PTCA), pulmonary artery catheterisation, thrombolysis (with or without low molecular weight heparin, with or without unfractionated heparin), vasodilators, and ventricular assistance devices and cardiac transplantation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wakai</LastName><ForeName>Abel P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Emergency Care Research Unit (ECRU), Midland Regional Hospital, Tullamore, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Clin Evid</MedlineTA><NlmUniqueID>101294314</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019039">Platelet Glycoprotein GPIIb-IIIa Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015906" MajorTopicYN="N">Angioplasty, Balloon, Coronary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="Y">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019039" MajorTopicYN="N">Platelet Glycoprotein GPIIb-IIIa Complex</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21477402</ArticleId><ArticleId IdType="pmc">PMC3217814</ArticleId><ArticleId IdType="pii">0202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994;330:1724&#x2013;1730.</Citation><ArticleIdList><ArticleId IdType="pubmed">8190135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, et al, for the SHOCK investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban P, Stauffer JC, Khatchatrian N, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock&#xa0;&#x2014;&#xa0;(S)MASH. Eur Heart J 1999;20:1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383377</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray C, Lopez A. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pubmed">9142060</ArticleId></ArticleIdList></Reference><Reference><Citation>National Heart, Lung, and Blood Institute. Morbidity and mortality: chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; May 1992.</Citation></Reference><Reference><Citation>Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999;340:1162&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasdai D, Califf RM, Thompson TD, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2000;35:136&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">10636271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction&#xa0;&#x2014;&#xa0;etiology, management and outcome: a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36(3 suppl A):1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985706</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban P, Bernstein M, Costanza M, et al. An internet-based registry of acute myocardial infarction in Switzerland. Kardiovasc Med 2000;3:430&#x2013;441.</Citation></Reference><Reference><Citation>Berger PB, Tuttle RH, Holmes DR, et al. One year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularisation: results of the GUSTO-1 trial. Circulation 1999;99:873&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027808</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of people. BMJ 1994;308:81&#x2013;106. Search date 1990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2539220</ArticleId><ArticleId IdType="pubmed">8298418</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC370209</ArticleId><ArticleId IdType="pubmed">7045161</ArticleId></ArticleIdList></Reference><Reference><Citation>Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">2899772</ArticleId></ArticleIdList></Reference><Reference><Citation>Baigent BM, Collins R. ISIS-2: four year mortality of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction study. Circulation 1993;88(suppl I):I-291&#x2013;I-292.</Citation></Reference><Reference><Citation>Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results of all randomized trials of more than 1000 patients. Lancet 1994;343:311&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">7905143</ArticleId></ArticleIdList></Reference><Reference><Citation>French JK, Hyde TA, Patel H, et al. Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. J Am Coll Cardiol 1999;34:62&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399993</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins R, Peto R, Baigent BM, et al. Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">9062095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruppo Italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI). GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">1975321</ArticleId></ArticleIdList></Reference><Reference><Citation>Third International Study of Infarct Survival (ISIS-3) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">1347801</ArticleId></ArticleIdList></Reference><Reference><Citation>The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">8204123</ArticleId></ArticleIdList></Reference><Reference><Citation>The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">9340503</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) investigators. Single bolus tenecteplase compared to front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">10475182</ArticleId></ArticleIdList></Reference><Reference><Citation>InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">11102251</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoons MI, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 1993;342:1523&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pubmed">7902905</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore JM, Granger CB, Simoons MI, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-1 trial. Circulation 1995;92:2811&#x2013;2818.</Citation><ArticleIdList><ArticleId IdType="pubmed">7586246</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation 1997;95:2508&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pubmed">9184581</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoons M, Krzeminska-Pakula M, Alonso A, et al. for the AMI-SK Investigators. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23:1282&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">12175665</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca G, Marino P. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J 2007;154:1085.e1&#x2212;e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035079</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Bahekar A, Molnar J, et al. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Clin Cardiol 2009;32:358&#x2212;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6653358</ArticleId><ArticleId IdType="pubmed">19609890</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega JL, Morrow DA, Ostor E, et al. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation 2007;115:2822&#x2013;2828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17515461</ArticleId></ArticleIdList></Reference><Reference><Citation>The GUSTO V investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905&#x2013;1914.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandzari DE, Hasselblad V, Tcheng JE, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 2004;147:457&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">14999194</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007;28:443&#x2212;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251257</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004;292:362&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107:1497&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654606</ArticleId></ArticleIdList></Reference><Reference><Citation>van 't Hof AW, Ernst N, de Boer MJ, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004;25:837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutlip DE, Ricciardi MJ, Ling FS, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003;92:977&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorman S, Zorman D, Noc M, et al. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:533&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12208418</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Peto R, Lewis S, et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335&#x2013;371. Search date not reported.</Citation><ArticleIdList><ArticleId IdType="pubmed">2858114</ArticleId></ArticleIdList></Reference><Reference><Citation>Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730&#x2013;1737. Search date 1997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31101</ArticleId><ArticleId IdType="pubmed">10381708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271643</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation 1991;83:422&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671346</ArticleId></ArticleIdList></Reference><Reference><Citation>Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598&#x2013;604. Search date 1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">10080457</ArticleId></ArticleIdList></Reference><Reference><Citation>ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomised trials. Circulation 1998;97:2202&#x2013;2212. Search date not reported.</Citation><ArticleIdList><ArticleId IdType="pubmed">9631869</ArticleId></ArticleIdList></Reference><Reference><Citation>Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Systematic overview of individual data from 96,712 randomized patients. J Am Coll Cardiol 2000;35:1801&#x2013;1807. Search date not reported.</Citation><ArticleIdList><ArticleId IdType="pubmed">10841227</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58&#xa0;050 patients with suspected acute myocardial infarction. Lancet 1995;345:669&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">7661937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruppo Italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">7910229</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988;1:1088&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">2896919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox RG, Hampton JR, Banks DC, et al. Early nifedipine in acute myocardial infarction: the TRENT study. BMJ 1986;293:1204&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1341981</ArticleId><ArticleId IdType="pubmed">3096431</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">8285927</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998;21:633&#x2013;641. Search date 1997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655547</ArticleId><ArticleId IdType="pubmed">9755379</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Furberg CD. Effects of calcium channel blockers on survival after myocardial infarction. Cardiovasc Drugs Ther 1987;1:343&#x2013;344. Search date not reported.</Citation><ArticleIdList><ArticleId IdType="pubmed">3154669</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993;270:1589&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">8371471</ArticleId></ArticleIdList></Reference><Reference><Citation>The Multicenter Diltiazem Post Infarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">2899840</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">12517460</ArticleId></ArticleIdList></Reference><Reference><Citation>Boersma E. The Primary Coronary Angioplasty vs.Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">16513663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Pogue J. Primary angioplasty compared to thrombolytic therapy for acute myocardial infarction [editorial]. JAMA 1997;278:2110&#x2013;2111.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403429</ArticleId></ArticleIdList></Reference><Reference><Citation>The GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173270</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Werf F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial. JAMA 1995;273:1586&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pubmed">7745771</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, White HD, et al. One year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176812</ArticleId></ArticleIdList></Reference><Reference><Citation>GISSI-1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">2868337</ArticleId></ArticleIdList></Reference><Reference><Citation>French, JK, Feldman, HA, Assmann SF, et al. Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J 2003; 146: 804&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">14597928</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert P, Tinker J. Inotropic drugs in acute circulatory failure. Intensive Care Med 1980;6:101&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">6102579</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Int Med 1999;131:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR, Sopko G, Cerra F, et al. Pulmonary artery catheterization and clinical outcomes. JAMA 2000;283:2568&#x2013;2572.</Citation><ArticleIdList><ArticleId IdType="pubmed">10815121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Hoyt J. Pulmonary artery catheters in cardiovascular disease. New Horiz 1977;5:207&#x2013;213. Search date 1996.</Citation><ArticleIdList><ArticleId IdType="pubmed">9259332</ArticleId></ArticleIdList></Reference><Reference><Citation>Participants. Pulmonary artery catheter consensus conference: consensus statement. Crit Care Med 1997;25:910&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">9201042</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Rourke MF, Norris RM, Campbell TJ, et al. Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure. Am J Cardiol 1981;47:815&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">7010976</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty JT, Becker LC, Weiss JL, et al. Results of a randomized prospective trial of intraaortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarction. J Am Coll Cardiol 1985;6:434&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">3926848</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier OH. Future directions of cardiac assistance. Semin Thorac Cardiovasc Surg 2000;12:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052193</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani FD, Lynch W, Swaniker F, et al. Extracorporeal life support to left ventricular assist device bridge to cardiac transplantation. Circulation 1999;100(suppl 19):II-206&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavroidis D, Sun BC, Pae WE. Bridge to transplantation: the Penn State experience. Ann Thorac Surg 1999;68:684&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">10475471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">19445779</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-8526</ISSN><JournalIssue CitedMedium="Internet"><Volume>2009</Volume><PubDate><Year>2009</Year><Month>Jan</Month><Day>09</Day></PubDate></JournalIssue><Title>BMJ clinical evidence</Title><ISOAbbreviation>BMJ Clin Evid</ISOAbbreviation></Journal><ArticleTitle>Myocardial infarction (ST-elevation).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">0202</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">About a quarter of people having an acute myocardial infarction (MI) in the USA will die of it, half of them within 1 hour of the onset of symptoms. Cardiogenic shock develops in over 5% of people surviving the first hour after an acute MI, with a mortality of 50-80% in the first 48 hours.</AbstractText><AbstractText Label="METHODS AND OUTCOMES" NlmCategory="METHODS">We conducted a systematic review and aimed to answer the following clinical questions: Which treatments improve outcomes in acute MI? Which treatments improve outcomes for cardiogenic shock after MI? We searched: Medline, Embase, The Cochrane Library, and other important databases up to August 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found 50 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this systematic review we present information relating to the effectiveness and safety of the following interventions: angiotensin-converting enzyme (ACE) inhibitors, aspirin, beta-blockers, calcium channel blockers, early cardiac surgery, early invasive cardiac revascularisation, glycoprotein IIb/IIIa inhibitors, intra-aortic balloon counterpulsation, nitrates (with or without thrombolysis), positive inotropes, primary percutaneous transluminal coronary angioplasty (PTCA), pulmonary artery catheterisation, thrombolysis (with or without low molecular weight heparin, with or without unfractionated heparin), vasodilators, and ventricular assistance devices and cardiac transplantation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wakai</LastName><ForeName>Abel P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Clin Evid</MedlineTA><NlmUniqueID>101294314</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019039">Platelet Glycoprotein GPIIb-IIIa Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015906" MajorTopicYN="N">Angioplasty, Balloon, Coronary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="Y">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019039" MajorTopicYN="N">Platelet Glycoprotein GPIIb-IIIa Complex</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19445779</ArticleId><ArticleId IdType="pmc">PMC2907827</ArticleId><ArticleId IdType="pii">0202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994;330:1724&#x2013;1730.</Citation><ArticleIdList><ArticleId IdType="pubmed">8190135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, et al, for the SHOCK investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban P, Stauffer JC, Khatchatrian N, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock&#xa0;&#x2014;&#xa0;(S)MASH. Eur Heart J 1999;20:1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383377</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray C, Lopez A. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pubmed">9142060</ArticleId></ArticleIdList></Reference><Reference><Citation>National Heart, Lung, and Blood Institute. Morbidity and mortality: chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; May 1992.</Citation></Reference><Reference><Citation>Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999;340:1162&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasdai D, Califf RM, Thompson TD, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2000;35:136&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">10636271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction&#xa0;&#x2014;&#xa0;etiology, management and outcome: a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36(3 suppl A):1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985706</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban P, Bernstein M, Costanza M, et al. An internet-based registry of acute myocardial infarction in Switzerland. Kardiovasc Med 2000;3:430&#x2013;441.</Citation></Reference><Reference><Citation>Berger PB, Tuttle RH, Holmes DR, et al. One year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularisation: results of the GUSTO-1 trial. Circulation 1999;99:873&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027808</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of people. BMJ 1994;308:81&#x2013;106. Search date 1990; primary sources Medline and Current Contents.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2539220</ArticleId><ArticleId IdType="pubmed">8298418</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC370209</ArticleId><ArticleId IdType="pubmed">7045161</ArticleId></ArticleIdList></Reference><Reference><Citation>Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;ii:349&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">2899772</ArticleId></ArticleIdList></Reference><Reference><Citation>Baigent BM, Collins R. ISIS-2: four year mortality of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction study [abstract]. Circulation 1993;88(suppl I):I-291&#x2013;I-292.</Citation></Reference><Reference><Citation>Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results of all randomized trials of more than 1000 patients. Lancet 1994;343:311&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">7905143</ArticleId></ArticleIdList></Reference><Reference><Citation>French JK, Hyde TA, Patel H, et al. Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. J Am Coll Cardiol 1999;34:62&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399993</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins R, Peto R, Baigent BM, et al. Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">9062095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruppo Italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI). GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">1975321</ArticleId></ArticleIdList></Reference><Reference><Citation>Third International Study of Infarct Survival (ISIS-3) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">1347801</ArticleId></ArticleIdList></Reference><Reference><Citation>The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">8204123</ArticleId></ArticleIdList></Reference><Reference><Citation>The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">9340503</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) investigators. Single bolus tenecteplase compared to front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">10475182</ArticleId></ArticleIdList></Reference><Reference><Citation>InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">11102251</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoons MI, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 1993;342:1523&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pubmed">7902905</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore JM, Granger CB, Simoons MI, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-1 trial. Circulation 1995;92:2811&#x2013;2818.</Citation><ArticleIdList><ArticleId IdType="pubmed">7586246</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation 1997;95:2508&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pubmed">9184581</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoons M, Krzeminska-Pakula M, Alonso A, et al. for the AMI-SK Investigators. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23:1282&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">12175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;roux P, Welsh RC. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol 2003;91:860&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667572</ArticleId></ArticleIdList></Reference><Reference><Citation>Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Eng J Med 2006;354:1477&#x2013;1488.</Citation><ArticleIdList><ArticleId IdType="pubmed">16537665</ArticleId></ArticleIdList></Reference><Reference><Citation>The Assessment of the Safety and Efficacy of a New Thrombolytic regimen (ASSENT) 3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">11530146</ArticleId></ArticleIdList></Reference><Reference><Citation>Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642&#x2013;1649.</Citation><ArticleIdList><ArticleId IdType="pubmed">11940541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega JL, Morrow DA, Ostor E, et al. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation 2007;115:2822&#x2013;2828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17515461</ArticleId></ArticleIdList></Reference><Reference><Citation>The GUSTO V investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905&#x2013;1914.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandzari DE, Hasselblad V, Tcheng JE, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 2004;147:457&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">14999194</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003;42:1879&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pubmed">14662245</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: A meta-analysis. J Am Med Assoc 2004;292:362&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107:1497&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654606</ArticleId></ArticleIdList></Reference><Reference><Citation>van 't Hof AW, Ernst N, de Boer MJ, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004;25:837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutlip DE, Ricciardi MJ, Ling FS, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003;92:977&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorman S, Zorman D, Noc M, et al. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:533&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12208418</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Peto R, Lewis S, et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335&#x2013;371. Search date not stated; primary sources computer-aided search of the literature, manual search of reference lists, and enquiries to colleagues about relevant papers.</Citation><ArticleIdList><ArticleId IdType="pubmed">2858114</ArticleId></ArticleIdList></Reference><Reference><Citation>Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730&#x2013;1737. Search date 1997; primary sources Medline, Embase, Biosis, Healthstar, Sigle, IHTA, Derwent drug file, dissertation abstracts, Pascal, international pharmaceutical abstracts, Science Citation Index, and hand searches of reference lists.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31101</ArticleId><ArticleId IdType="pubmed">10381708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271643</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation 1991;83:422&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671346</ArticleId></ArticleIdList></Reference><Reference><Citation>Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598&#x2013;604. Search date 1997; primary sources Medline and hand searches of reference lists.</Citation><ArticleIdList><ArticleId IdType="pubmed">10080457</ArticleId></ArticleIdList></Reference><Reference><Citation>ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomised trials. Circulation 1998;97:2202&#x2013;2212. Search date not stated; primary source collaboration group of principal investigators of all randomised trials who collated individual patient data.</Citation><ArticleIdList><ArticleId IdType="pubmed">9631869</ArticleId></ArticleIdList></Reference><Reference><Citation>Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Systematic overview of individual data from 96,712 randomized patients. J Am Coll Cardiol 2000;35:1801&#x2013;1807. Search date not stated; primary source individual patient data on all trials involving more than 1000 patients.</Citation><ArticleIdList><ArticleId IdType="pubmed">10841227</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58&#xa0;050 patients with suspected acute myocardial infarction. Lancet 1995;345:669&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">7661937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruppo Italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">7910229</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988;1:1088&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">2896919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox RG, Hampton JR, Banks DC, et al. Early nifedipine in acute myocardial infarction: the TRENT study. BMJ 1986;293:1204&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1341981</ArticleId><ArticleId IdType="pubmed">3096431</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">8285927</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998;21:633&#x2013;641. Search date 1997; primary sources Medline, Science Citation Index, Current Contents, and hand searches of reference lists.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655547</ArticleId><ArticleId IdType="pubmed">9755379</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Furberg CD. Effects of calcium channel blockers on survival after myocardial infarction. Cardiovasc Drugs Ther 1987;1:343&#x2013;344. Search dates and primary sources not reported.</Citation><ArticleIdList><ArticleId IdType="pubmed">3154669</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993;270:1589&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">8371471</ArticleId></ArticleIdList></Reference><Reference><Citation>The Multicenter Diltiazem Post Infarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">2899840</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">12517460</ArticleId></ArticleIdList></Reference><Reference><Citation>Boersma E. The Primary Coronary Angioplasty vs.Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">16513663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Pogue J. Primary angioplasty compared to thrombolytic therapy for acute myocardial infarction [editorial]. JAMA 1997;278:2110&#x2013;2111.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403429</ArticleId></ArticleIdList></Reference><Reference><Citation>The GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173270</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Werf F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial. JAMA 1995;273:1586&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pubmed">7745771</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, White HD, et al. One year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176812</ArticleId></ArticleIdList></Reference><Reference><Citation>GISSI-1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">2868337</ArticleId></ArticleIdList></Reference><Reference><Citation>French, JK, Feldman, HA, Assmann SF, et al. Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J 2003; 146: 804&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">14597928</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert P, Tinker J. Inotropic drugs in acute circulatory failure. Intensive Care Med 1980;6:101&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">6102579</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Int Med 1999;131:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR, Sopko G, Cerra F, et al. Pulmonary artery catheterization and clinical outcomes. JAMA 2000;283:2568&#x2013;2572.</Citation><ArticleIdList><ArticleId IdType="pubmed">10815121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Hoyt J. Pulmonary artery catheters in cardiovascular disease. New Horiz 1977;5:207&#x2013;213. Search date 1996; primary sources not stated.</Citation><ArticleIdList><ArticleId IdType="pubmed">9259332</ArticleId></ArticleIdList></Reference><Reference><Citation>Participants. Pulmonary artery catheter consensus conference: consensus statement. Crit Care Med 1997;25:910&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">9201042</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Rourke MF, Norris RM, Campbell TJ, et al. Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure. Am J Cardiol 1981;47:815&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">7010976</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty JT, Becker LC, Weiss JL, et al. Results of a randomized prospective trial of intraaortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarction. J Am Coll Cardiol 1985;6:434&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">3926848</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier OH. Future directions of cardiac assistance. Semin Thorac Cardiovasc Surg 2000;12:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052193</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani FD, Lynch W, Swaniker F, et al. Extracorporeal life support to left ventricular assist device bridge to cardiac transplantation. Circulation 1999;100(suppl 19):II-206&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavroidis D, Sun BC, Pae WE. Bridge to transplantation: the Penn State experience. Ann Thorac Surg 1999;68:684&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">10475471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39982182</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Society of Critical Care Medicine Guidelines on Adult Critical Care Ultrasonography: Focused Update 2024.</ArticleTitle><Pagination><StartPage>e447</StartPage><EndPage>e458</EndPage><MedlinePgn>e447-e458</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0000000000006530</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Critical care ultrasonography (CCUS) is rapidly evolving with new evidence being published since the prior 2016 guideline.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To identify and assess the best evidence regarding the clinical outcomes associated with five CCUS applications in adult patients since the publication of the previous guidelines.</AbstractText><AbstractText Label="PANEL DESIGN" NlmCategory="UNASSIGNED">An interprofessional, multidisciplinary, and diverse expert panel of 36 individuals including two patient/family representatives was assembled via an intentional approach. Conflict-of-interest policies were strictly followed in all phases of the guidelines, including task force selection and voting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Focused research questions based on Population, Intervention, Control, and Outcomes (PICO) for adult CCUS application were developed. Panelists applied the guidelines revision process described in the Standard Operating Procedures Manual to analyze supporting literature and to develop evidence-based recommendations as a focused update. The evidence was statistically summarized and assessed for quality using the Grading of Recommendations, Assessment, Development, and Evaluation approach. The evidence-to-decision framework was used to formulate recommendations as strong or conditional.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The Adult CCUS Focused Update Guidelines panel aimed to understand the current impact of CCUS on patient important outcomes as they related to five PICO questions in critically ill adults. A rigorous systematic review of evidence to date informed the panel's recommendations. In adult patients with septic shock, acute dyspnea/respiratory failure, or cardiogenic shock, we suggest using CCUS to guide management. Given evidence supporting an improvement in mortality, we suggest the use of CCUS for targeted volume management as opposed to usual care without CCUS. Last, there was insufficient data to determine if CCUS should be used over standard care without CCUS in the management of patients with cardiac arrest.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The guidelines panel achieved strong agreement regarding the recommendations for CCUS to improve patient outcomes. These recommendations are intended for consideration along with the patient's existing clinical status.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 by the Society of Critical Care Medicine. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D&#xed;az-G&#xf3;mez</LastName><ForeName>Jos&#xe9; L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Integrated Hospital Care Institute (Divisions of Anesthesiology, Critical Care Medicine, Emergency Medicine, Hospital Medicine, Infectious Disease, and Pulmonary Medicine), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Emergency Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ablordeppey</LastName><ForeName>Enyo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Emergency Medicine, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanspa</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Intermountain Medical Center, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basmaji</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carver</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medical College of Wisconsin, Milwaukee, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Jayne Chirdo</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Baylor College of Medicine, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargani</LastName><ForeName>Luna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goffi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto, St. Michael's Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Knowledge Institute, Keenan Research Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hynes</LastName><ForeName>Allyson M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of New Mexico School of Medicine, Albuquerque, NM.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology Critical Care Medicine, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasal</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Division of Critical Care, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koratala</LastName><ForeName>Abhilash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kort</LastName><ForeName>Smadar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stony Brook Medicine, Stony Brook, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindbloom</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>North Memorial Health Hospital, Robbinsdale, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livezey</LastName><ForeName>Pete</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Integrated Hospital Care Institute (Divisions of Anesthesiology, Critical Care Medicine, Emergency Medicine, Hospital Medicine, Infectious Disease, and Pulmonary Medicine), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Emergency Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Emergency Medicine, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intermountain Medical Center, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical College of Wisconsin, Milwaukee, WI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor College of Medicine, Houston, TX.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto, St. Michael's Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Knowledge Institute, Keenan Research Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of New Mexico School of Medicine, Albuquerque, NM.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology Critical Care Medicine, Nashville, TN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Division of Critical Care, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stony Brook Medicine, Stony Brook, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>North Memorial Health Hospital, Robbinsdale, MN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Stanford University, Palo Alto, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care, and Sleep Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wake Forest University School of Medicine, Winston Salem, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Anesthesia and Intensive Care, Istituto Cardiocentro Ticino, EOC, Lugano, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Versailles St Quentin, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Carolinas Medical Center at Atrium Health, Charlotte, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keck School of Medicine of USC, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology &amp; Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobo</LastName><ForeName>Viveta</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Stanford University, Palo Alto, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Integrated Hospital Care Institute (Divisions of Anesthesiology, Critical Care Medicine, Emergency Medicine, Hospital Medicine, Infectious Disease, and Pulmonary Medicine), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Emergency Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Emergency Medicine, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intermountain Medical Center, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical College of Wisconsin, Milwaukee, WI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor College of Medicine, Houston, TX.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto, St. Michael's Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Knowledge Institute, Keenan Research Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of New Mexico School of Medicine, Albuquerque, NM.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology Critical Care Medicine, Nashville, TN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Division of Critical Care, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stony Brook Medicine, Stony Brook, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>North Memorial Health Hospital, Robbinsdale, MN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Stanford University, Palo Alto, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care, and Sleep Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wake Forest University School of Medicine, Winston Salem, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Anesthesia and Intensive Care, Istituto Cardiocentro Ticino, EOC, Lugano, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Versailles St Quentin, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Carolinas Medical Center at Atrium Health, Charlotte, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keck School of Medicine of USC, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology &amp; Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care, and Sleep Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Ng</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panebianco</LastName><ForeName>Nova</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parekh</LastName><ForeName>Madhavi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarwal</LastName><ForeName>Aarti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wake Forest University School of Medicine, Winston Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teran</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Via</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesia and Intensive Care, Istituto Cardiocentro Ticino, EOC, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieillard-Baron</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Versailles St Quentin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weekes</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Carolinas Medical Center at Atrium Health, Charlotte, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiley</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Keck School of Medicine of USC, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikravan</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2895-8571</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology &amp; Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="Y">Critical Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Sharif received funding from McMaster University, Department of Medicine Early Career Award. Dr. Carver received funding from Cytovale and Innovital. Drs. Gargani and Goffi received funding from Philips Healthcare. Drs. Gargani and Liu received funding from Caption Health. Dr. Gargani received funding from EchoNous and Sanofi. Dr, Goffi received funding from the Butterfly Network. Dr. Kort received funding from Medtronics and AISAP. Dr. Liu disclosed she is on the Medical Advisory Board of PocusPro and is an examination writer for the American Board of Emergency Medicine. Dr. Mitchell received funding from Davies Publishing, Elsevier, and Acoustic Range Estimates; their institution received funding from W.L. Gore &amp; Associates. Dr. Sarwal received funding from Stimdia; they disclosed loan of devices from ImageMonitoring and Butterfly. Dr. Teran received funding from Fujifilm Sonosite; they disclosed they are course director and founder of The Resuscitative Transesophageal Echocardiography Workshop. Dr. Via disclosed they are co-founder of eMedical Academy. Dr. Vieillard-Baron received funding from Air Liquide Healthcare. Dr. Weekes received funding from the Agency for Healthcare Research and Quality (R01HS025979) and Scanwell Health. Dr. Nikravan received funding from Verathon and Philips. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39982182</ArticleId><ArticleId IdType="doi">10.1097/CCM.0000000000006530</ArticleId><ArticleId IdType="pii">00003246-202502000-00018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>D&#xed;az-G&#xf3;mez JL, Mayo PH, Koenig SJ: Point-of-care ultrasonography. N Engl J Med. 2021; 385:1593&#x2013;1602</Citation></Reference><Reference><Citation>Frankel HL, Kirkpatrick AW, Elbarbary M, et al.: Guidelines for the appropriate use of bedside general and cardiac ultrasonography in the evaluation of critically ill patients&#x2014;part I: General ultrasonography. Crit Care Med. 2015; 43:2479&#x2013;2502</Citation></Reference><Reference><Citation>Levitov A, Frankel HL, Blaivas M, et al.: Guidelines for the appropriate use of bedside general and cardiac ultrasonography in the evaluation of critically ill patients&#x2014;part II: Cardiac ultrasonography. Crit Care Med. 2016; 44:1206&#x2013;1227</Citation></Reference><Reference><Citation>Persaud N, Ally M, Woods H, et al.: Racialised people in clinical guideline panels. Lancet (London, England). 2022; 399:139&#x2013;140</Citation></Reference><Reference><Citation>Welch VA, Akl EA, Guyatt G, et al.: GRADE equity guidelines 1: Considering health equity in GRADE guideline development: Introduction and rationale. J Clin Epidemiol. 2017; 90:59&#x2013;67</Citation></Reference><Reference><Citation>Nikravan S, Lanspa MJ, Ablordeppey E, et al.: An approach to diversifying the selection of a guideline panel&#x2014;the process utilized for the updated adult critical care ultrasound guidelines. Crit Care Med. 2024; 52:1251&#x2013;1257</Citation></Reference><Reference><Citation>Ferrada P, Evans D, Wolfe L, et al.: Findings of a randomized controlled trial using limited transthoracic echocardiogram (LTTE) as a hemodynamic monitoring tool in the trauma bay. J Trauma Acute Care Surg. 2014; 76:31&#x2013;37; discussion 37&#x2013;38</Citation></Reference><Reference><Citation>Virani SS, Alonso A, Benjamin EJ, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics&#x2014;2020 update: A report from the American Heart Association. Circulation. 2020; 141:e139&#x2013;e596</Citation></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, et al.; Cochrane Bias Methods Group: The Cochrane collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928</Citation></Reference><Reference><Citation>Atkinson PR, Beckett N, French J, et al.: Does point-of-care ultrasound use impact resuscitation length, rates of intervention, and clinical outcomes during cardiac arrest? A study from the sonography in hypotension and cardiac arrest in the emergency department (SHoC-ED) investigators. Cureus. 2019; 11:e4456</Citation></Reference><Reference><Citation>Mojtaba C, Farhad H, Helaleh R, et al.: Echocardiography integrated ACLS protocol versus conventional cardiopulmonary resuscitation in patients with pulseless electrical activity cardiac arrest. Chin J Traumatol. 2012; 15:284&#x2013;287</Citation></Reference><Reference><Citation>Chou EH, Wang C-H, Monfort R, et al.: Association of ultrasound-related interruption during cardiopulmonary resuscitation with adult cardiac arrest outcomes: A video-reviewed retrospective study. Resuscitation. 2020; 149:74&#x2013;80</Citation></Reference><Reference><Citation>Clattenburg EJ, Wroe P, Brown S, et al.: Point-of-care ultrasound use in patients with cardiac arrest is associated prolonged cardiopulmonary resuscitation pauses: A prospective cohort study. Resuscitation. 2018; 122:65&#x2013;68</Citation></Reference><Reference><Citation>Fair J 3rd, Mallin MP, Adler A, et al.: Transesophageal echocardiography during cardiopulmonary resuscitation is associated with shorter compression pauses compared with transthoracic echocardiography. Ann Emerg Med. 2019; 73:610&#x2013;616</Citation></Reference><Reference><Citation>In&#x2019;t Veld MAH, Allison MG, Bostick DS, et al.: Ultrasound use during cardiopulmonary resuscitation is associated with delays in chest compressions. Resuscitation. 2017; 119:95&#x2013;98</Citation></Reference><Reference><Citation>Kang SY, Jo IJ, Lee G, et al.: Point-of-care ultrasound compression of the carotid artery for pulse determination in cardiopulmonary resuscitation. Resuscitation. 2022; 179:206&#x2013;213</Citation></Reference><Reference><Citation>Lien W-C, Chong K-M, Chang C-H, et al.: Impact of ultrasonography on chest compression fraction and survival in patients with out-of-hospital cardiac arrest. West J Emerg Med. 2023; 24:322&#x2013;330</Citation></Reference><Reference><Citation>McCarville P, Payette C, Rahimi-Saber A, et al.: Improving ultrasound use in CPR to minimize duration of pulse checks. Chest. 2019; 156:A1569</Citation></Reference><Reference><Citation>Prosen G, Grmec S, Kupnik D, et al.: Focused echocardiography and capnography during resuscitation from pulseless electrical activity after out-of-hospital cardiac arrest. Crit Care. 2009; 13:PP61</Citation></Reference><Reference><Citation>Schwartz BE, Gandhi P, Najafali D, et al.: Manual palpation vs. femoral arterial Doppler ultrasound for comparison of pulse check time during cardiopulmonary resuscitation in the emergency department: A pilot study. J Emerg Med. 2021; 61:720&#x2013;730</Citation></Reference><Reference><Citation>Wagner B, Chinn E, Lorenzen B, et al.: 337 Duration of pulse checks using point-of-care transthoracic echocardiography versus point-of-care transesophageal echocardiography versus palpation. Ann Emerg Med. 2020; 76:S130</Citation></Reference><Reference><Citation>Zengin S, G&#xfc;m&#xfc;&#x15f;bo&#x11f;a H, Sabak M, et al.: Comparison of manual pulse palpation, cardiac ultrasonography and Doppler ultrasonography to check the pulse in cardiopulmonary arrest patients. Resuscitation. 2018; 133:59&#x2013;64</Citation></Reference><Reference><Citation>Evans D, Doraiswamy V, Prosciak M, et al.: Complications associated with pulmonary artery catheters: A comprehensive clinical review. Scand J Surg. 2009; 98:199&#x2013;208</Citation></Reference><Reference><Citation>Lanspa MJ, Burk RE, Wilson EL, et al.: Echocardiogram-guided resuscitation versus early goal-directed therapy in the treatment of septic shock: A randomized, controlled, feasibility trial. J Intensive Care. 2018; 6:50</Citation></Reference><Reference><Citation>Alhabashy WS, Shalaby OM, Elgebaly AS, et al.: Echocardiography-guided hemodynamic management of severe sepsis and septic shock in adults: A randomized controlled trial. Anaesth Pain Intensive Care. 2021; 25:722&#x2013;732</Citation></Reference><Reference><Citation>Yoshida T, Yoshida T, Noma H, et al.: Diagnostic accuracy of point-of-care ultrasound for shock: A systematic review and meta-analysis. Crit Care. 2023; 27:200</Citation></Reference><Reference><Citation>Vignon P, Repesse X, Begot E, et al.: Comparison of echocardiographic indices used to predict fluid responsiveness in ventilated patients. Am J Respir Crit Care Med. 2017; 195:1022&#x2013;1032</Citation></Reference><Reference><Citation>Elsayed Afandy M, El Sharkawy SI, Omara AF: Transthoracic echocardiographic versus cardiometry derived indices in management of septic patients. Egypt J Anaesth. 2020; 36:312&#x2013;318</Citation></Reference><Reference><Citation>Garg M, Sen J, Goyal S, et al.: Comparative evaluation of central venous pressure and sonographic inferior vena cava variability in assessing fluid responsiveness in septic shock. Indian J Crit Care Med. 2016; 20:708&#x2013;713</Citation></Reference><Reference><Citation>Ismail RM, Dahroug AH, Zaytoun TM: Determination of end point of fluid resuscitation using simplified lung ultrasound protocol in patients with septic shock. Egypt J Chest Dis Tuberc. 2019; 68:102&#x2013;107</Citation></Reference><Reference><Citation>Li L, Ai Y, Wang X, et al.: Effect of focused cardiopulmonary ultrasonography on clinical outcome of septic shock: A randomized study. J Int Med Res. 2021; 49:03000605211013176</Citation></Reference><Reference><Citation>Musikatavorn K, Plitawanon P, Lumlertgul S, et al.: Randomized controlled trial of ultrasound-guided fluid resuscitation of sepsis-induced hypoperfusion and septic shock. West J Emerg Med. 2021; 22:369&#x2013;378</Citation></Reference><Reference><Citation>Sricharoenchai T, Saisirivechakun P: Effects of dynamic versus static parameter-guided fluid resuscitation in patients with sepsis: A randomized controlled trial. F1000Res. 2024; 13:528</Citation></Reference><Reference><Citation>Wang X, Liu D, Zhang H, et al.: Impact of extended focus assessed transthoracic echocardiography protocol in septic shock patients. Zhonghua yi xue za zhi. 2011; 91:1879&#x2013;1883</Citation></Reference><Reference><Citation>Yu K, Zhang S, Chen N, et al.; CCUGDT Study Group: Critical care ultrasound goal-directed versus early goal-directed therapy in septic shock. Intensive Care Med. 2022; 48:121&#x2013;123</Citation></Reference><Reference><Citation>Zhuang Y, Dai L, Cheng L, et al.: Inferior vena cava diameter combined with lung ultrasound B-line score to guide fluid resuscitation in patients with septic shock. Zhonghua wei Zhong Bing ji jiu yi xue. 2020; 32:1356&#x2013;1360</Citation></Reference><Reference><Citation>Baker K, Brierley S, Kinnear F, et al.: Implementation study reporting diagnostic accuracy, outcomes and costs in a multicentre randomised controlled trial of non&#x2010;expert lung ultrasound to detect pulmonary oedema. Emerg Med Australas. 2020; 32:45&#x2013;53</Citation></Reference><Reference><Citation>Golan YB-B, Sadeh R, Mizrakli Y, et al.: Early point-of-care ultrasound assessment for medical patients reduces time to appropriate treatment: A pilot randomized controlled trial. Ultrasound Medi Biol. 2020; 46:1908&#x2013;1915</Citation></Reference><Reference><Citation>Cid-Serra X, Royse A, Canty D, et al.: Effect of a multiorgan focused clinical ultrasonography on length of stay in patients admitted with a cardiopulmonary diagnosis: A randomized clinical trial. JAMA Netw Open. 2021; 4:e2138228</Citation></Reference><Reference><Citation>Colclough A, Nihoyannopoulos P: Pocket-sized point-of-care cardiac ultrasound devices. Herz. 2017; 42:255&#x2013;261</Citation></Reference><Reference><Citation>Drapkina O, Dzhioeva O, Kuzub A, et al.: Experience in using focused cardiac ultrasound in patients with acute heart failure in the intensive care unit. Russian J Cardiol. 2020; 25:4082</Citation></Reference><Reference><Citation>Kaur A, Oyiengo D, Minami T, et al.: Ultrasound measures of diaphragm thickness and liberation from mechanical ventilation. Chest. 2016; 150:467A</Citation></Reference><Reference><Citation>Kudenchuk PJ, Hosenpud JD, McDonald RW, et al.: Immediate echocardiography in the management of acute respiratory exacerbations of cardiopulmonary disease: A prospective study. Chest. 1990; 97:782&#x2013;787</Citation></Reference><Reference><Citation>Laursen CB, Sloth E, Lassen AT, et al.: Point-of-care ultrasonography in patients admitted with respiratory symptoms: A single-blind, randomised controlled trial. Lancet Respir Med. 2014; 2:638&#x2013;646</Citation></Reference><Reference><Citation>Li X, Chen J, Gu C, et al.: The impact on 30-day mortality from a brief focused ultrasound-guided management protocol immediately before emergency noncardiac surgery in critically ill patients: A multicenter randomized controlled trial. J Cardiothorac Vasc Anesth. 2022; 36:1100&#x2013;1110</Citation></Reference><Reference><Citation>Pang PS, Russell FM, Ehrman R, et al.: Lung ultrasound-guided emergency department management of acute heart failure (BLUSHED-AHF): A randomized controlled pilot trial. Heart Fail. 2021; 9:638&#x2013;648</Citation></Reference><Reference><Citation>Pivetta E, Goffi A, Nazerian P, et al.; Study Group on Lung Ultrasound from the Molinette and Careggi Hospitals: Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: A randomized controlled trial. Eur J Heart Fail. 2019; 21:754&#x2013;766</Citation></Reference><Reference><Citation>Pontis E, Claret P-G, Markarian T, et al.: Integration of lung ultrasound in the diagnostic reasoning in acute dyspneic patients: A prospective randomized study. Am J Emerg Med. 2018; 36:1597&#x2013;1602</Citation></Reference><Reference><Citation>Pradhan S, Shrestha PS, Shrestha GS, et al.: Clinical impact of lung ultrasound monitoring for diagnosis of ventilator associated pneumonia: A diagnostic randomized controlled trial. J Crit Care. 2020; 58:65&#x2013;71</Citation></Reference><Reference><Citation>Ricci J-E, Aguilhon S, Occean B-V, et al.: Impact of daily bedside echocardiographic assessment on readmissions in acute heart failure: A randomized clinical trial. J Clin Med. 2022; 11:2047</Citation></Reference><Reference><Citation>Riishede M, Lassen A, Baatrup G, et al.: Point-of-care ultrasound of the heart and lungs in patients with respiratory failure: A pragmatic randomized controlled multicenter trial. Scand J Trauma Resusc Emerg Med. 2021; 29:60</Citation></Reference><Reference><Citation>Salem MS, Eltatawy HS, Abdelhafez AA, et al.: Lung ultrasound-versus FiO2-guided PEEP in ARDS patients. Egypt J Anaesth. 2020; 36:31&#x2013;37</Citation></Reference><Reference><Citation>Wang X-T, Liu D-W, Zhang H-M, et al.: Integrated cardiopulmonary sonography: A useful tool for assessment of acute pulmonary edema in the intensive care unit. J Ultrasound Med. 2014; 33:1231&#x2013;1239</Citation></Reference><Reference><Citation>Xia L, Ma J, Hu L, et al.: Application of visual artificial airway in patients with ARDS assisted by pulmonary ultrasound. Biomed Res Int. 2022; 2022:2719016</Citation></Reference><Reference><Citation>Volpicelli G, Gargani L, Perlini S, et al.; on behalf of the International Multicenter Study Group on LUS in COVID-19: Lung ultrasound for the early diagnosis of COVID-19 pneumonia: An international multicenter study. Intensive Care Med. 2021; 47:444&#x2013;454</Citation></Reference><Reference><Citation>Beye SA, Diallo B, Keita M, et al.: Assessment of lung injury severity using ultrasound in critically ill COVID-19 patients in resource limited settings. Ann Intensive Care. 2023; 13:33</Citation></Reference><Reference><Citation>Atkinson PR, Milne J, Diegelmann L, et al.: Does point-of-care ultrasonography improve clinical outcomes in emergency department patients with undifferentiated hypotension? An international randomized controlled trial from the SHoC-ED investigators. Ann Emerg Med. 2018; 72:478&#x2013;489</Citation></Reference><Reference><Citation>Chytra I, Pradl R, Bosman R, et al.: Esophageal Doppler-guided fluid management decreases blood lactate levels in multiple-trauma patients: A randomized controlled trial. Crit Care. 2007; 11:1&#x2013;9</Citation></Reference><Reference><Citation>Effat H, Alsayed IA, Alhusseiny R, et al.: Fluid management in critically ill patients with acute kidney injury: Role of noninvasive assessment of stroke volume. Egypt J Crit Care Med. 2021; 8:9&#x2013;19</Citation></Reference><Reference><Citation>Lan P, Wang T-T, Li H-Y, et al.: Utilization of echocardiography during septic shock was associated with a decreased 28-day mortality: A propensity score-matched analysis of the MIMIC-III database. Ann Transl Med. 2019; 7:662</Citation></Reference><Reference><Citation>Li G, Wei F, Zhang G, et al.: Clinical value of early liquid resuscitation guided by passive leg-raising test combined with transthoracic echocardiography in patients with septic shock. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019; 31:413&#x2013;417</Citation></Reference><Reference><Citation>Qi B, Yang W, Zhang H, et al.: Clinical application of inferior vena cava inspiratory collapsibility in early goal-directed therapy of septic shock. Chin J Resp Crit Care Med. 2020; 19:246&#x2013;250</Citation></Reference><Reference><Citation>Qin Y, Yin W-H, Zeng X-Y, et al.: Influence of critical care ultrasound oriented fluid management in different stages of shock to the outcome. Sichuan Da Xue Xue Bao Yi Xue Ban. 2019; 50:803&#x2013;807</Citation></Reference><Reference><Citation>Rusu D, Siriopol I, Lungu O, et al.: Lung ultrasound as a bedside tool for postoperative fluid management in surgical ICU patients: A randomized study. Chest. 2020; 157:A135</Citation></Reference><Reference><Citation>Meyhoff TS, Hjortrup PB, Wetterslev J, et al.; CLASSIC Trial Group: Restriction of intravenous fluid in ICU patients with septic shock. N Engl J Med. 2022; 386:2459&#x2013;2470</Citation></Reference><Reference><Citation>Shapiro NI, Douglas IS, Brower RG, et al.; National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network: Early restrictive or liberal fluid management for sepsis-induced hypotension. N Engl J Med. 2023; 388:499&#x2013;510</Citation></Reference><Reference><Citation>Boyd JH, Forbes J, Nakada T-a, et al.: Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011; 39:259&#x2013;265</Citation></Reference><Reference><Citation>Kelm DJ, Perrin JT, Cartin-Ceba R, et al.: Fluid overload in patients with severe sepsis and septic shock treated with early goal-directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death. Shock. 2015; 43:68&#x2013;73</Citation></Reference><Reference><Citation>Chen Y, Shlofmitz E, Khalid N, et al.: Right heart catheterization-related complications: A review of the literature and best practices. Cardiol Rev. 2020; 28:36&#x2013;41</Citation></Reference><Reference><Citation>Hemamid H, Nabil M, Hakimi A: Does echocardiography improve clinical outcomes in shock states? Ann Intensive Care. 2020; 10</Citation></Reference><Reference><Citation>Atkinson P, Hunter S, Banerjee A, et al.: Does point-of-care ultrasonography change emergency department care delivered to hypotensive patients when categorized by shock type? A post-hoc analysis of an international randomized controlled trial from the SHoC-ED investigators. Cureus. 2019; 11:e6058</Citation></Reference><Reference><Citation>Chen J-T, Roberts RJ, Sevransky J, et al.; VOLUME-CHASER Study Group: Volume-Chaser: Use of critical care ultrasound and physiologic parameter assessments for fluid resuscitation is not associated with survival in patients with shock. Dallas, TX, American Thoracic Society 2019 International Conference, May 17-19, 2019, p A5996</Citation></Reference><Reference><Citation>Kanji HD, McCallum J, Sirounis D, et al.: Limited echocardiography&#x2013;guided therapy in subacute shock is associated with change in management and improved outcomes. J Crit Care. 2014; 29:700&#x2013;705</Citation></Reference><Reference><Citation>Merz TM, Cioccari L, Frey PM, et al.: Continual hemodynamic monitoring with a single-use transesophageal echocardiography probe in critically ill patients with shock: A randomized controlled clinical trial. Intensive Care Med. 2019; 45:1093&#x2013;1102</Citation></Reference><Reference><Citation>Harvey S, Stevens K, Harrison D, et al.: An evaluation of the clinical and cost-effectiveness of pulmonary artery catheters in patient management in intensive care: A systematic review and a randomised controlled trial. Health Technol Assess (Winchester, England). 2006; 10: iii&#x2013;iv, ix&#x2013;xi, 1&#x2013;133</Citation></Reference><Reference><Citation>Hadian M, Pinsky MR: Evidence-based review of the use of the pulmonary artery catheter: Impact data and complications. Crit Care. 2006; 10:1&#x2013;11</Citation></Reference><Reference><Citation>Parviainen I, Jakob S, Suistomaa M, et al.: Practical sources of error in measuring pulmonary artery occlusion pressure: A study in participants of a special intensivist training program of The Scandinavian Society of Anaesthesiology and Intensive Care Medicine (SSAI). Acta Anaesthesiol Scand. 2006; 50:600&#x2013;603</Citation></Reference><Reference><Citation>Hasnie AA, Parcha V, Hawi R, et al.: Complications associated with transesophageal echocardiography in transcatheter structural cardiac interventions. J Am Soc Echocardiogr. 2023; 36:381&#x2013;390</Citation></Reference><Reference><Citation>Freitas-Ferraz AB, Bernier M, Vaillancourt R, et al.: Safety of transesophageal echocardiography to guide structural cardiac interventions. J Am Coll Cardiol. 2020; 75:3164&#x2013;3173</Citation></Reference><Reference><Citation>Iriarte F, Riquelme GA, Sorensen P, et al.: Esophageal perforation after transesophageal echocardiography: A case report. Int J Surg Case Rep. 2020; 66:21&#x2013;24</Citation></Reference><Reference><Citation>Piercy M, McNicol L, Dinh DT, et al.: Major complications related to the use of transesophageal echocardiography in cardiac surgery. J Cardiothorac Vasc Anesth. 2009; 23:62&#x2013;65</Citation></Reference><Reference><Citation>Prager R, Bowdridge J, Pratte M, et al.: Indications, clinical impact, and complications of critical care transesophageal echocardiography: A scoping review. J Intensive Care Med. 2023; 38:245&#x2013;272</Citation></Reference><Reference><Citation>Kadosh BS, Berg DD, Bohula EA, et al.: Pulmonary artery catheter use and mortality in the cardiac intensive care unit. Heart Failure. 2023; 11:903&#x2013;914</Citation></Reference><Reference><Citation>Saxena A, Garan AR, Kapur NK, et al.: Value of hemodynamic monitoring in patients with cardiogenic shock undergoing mechanical circulatory support. Circulation. 2020; 141:1184&#x2013;1197</Citation></Reference><Reference><Citation>Garan AR, Kanwar M, Thayer KL, et al.: Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in-hospital mortality. JACC Heart Fail. 2020; 8:903&#x2013;913</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36753927</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8171</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of emergency medicine</Title><ISOAbbreviation>Am J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review.</ArticleTitle><Pagination><StartPage>124</StartPage><EndPage>128</EndPage><MedlinePgn>124-128</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajem.2023.01.050</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-6757(23)00054-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cardiogenic shock (CS) is associated with high morbidity and mortality. In recent times, there is increasing interest in the role of angiotensin II in CS. We sought to systematically review the current literature on the use of angiotensin II in CS.</AbstractText><AbstractText Label="METHODS">PubMed, EMBASE, Medline, Web of Science, PubMed Central, and CINAHL databases were systematically searched for studies that evaluated the efficacy of angiotensin II in patients with CS during 01/01/2010-07/07/2022. Outcomes of interest included change in mean arterial pressure (MAP), vasoactive medication requirements (percent change in norepinephrine equivalent [NEE] dose), all-cause mortality, and adverse events.</AbstractText><AbstractText Label="RESULTS">Of the total 2,402 search results, 15 studies comprising 195 patients were included of which 156 (80%) received angiotensin II. Eleven patients (84.6%) in case reports and case series with reported MAP data at hour 12 noted an increase in MAP. Two studies noted a positive hemodynamic response (defined a priori) in eight (88.9%) and five (35.7%) patients. Eight studies reported a reduction in NEE dose at hour 12 after angiotensin II administration and one study noted a 100% reduction in NEE dose. Out of 47 patients with documented information, 13 patients had adverse outcomes which included hepatic injury (2), digital ischemia (1), ischemic optic neuropathy (1), ischemic colitis (2), agitated delirium (1), and thrombotic events (2).</AbstractText><AbstractText Label="CONCLUSIONS">In this first systematic review of angiotensin II in CS, we note the early clinical experience. Angiotensin II was associated with improvements in MAP, decrease in vasopressor requirements, and minimal reported adverse events.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Mridul</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Aryan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieruszewski</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Departments of Anesthesiology and Pharmacy, Mayo Clinic, Rochester, MN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belford</LastName><ForeName>P Matthew</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America; Perioperative Outcomes and Informatics Collaborative (POIC), Wake Forest University School of Medicine, Winston-Salem, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>David X</ForeName><Initials>DX</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanna</LastName><ForeName>Ashish K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Perioperative Outcomes and Informatics Collaborative (POIC), Wake Forest University School of Medicine, Winston-Salem, NC, United States of America; Section on Critical Care Medicine, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America; Outcomes Research Consortium, Cleveland, OH, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saraschandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America; Perioperative Outcomes and Informatics Collaborative (POIC), Wake Forest University School of Medicine, Winston-Salem, NC, United States of America; Department of Implementation Science, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America. Electronic address: svallabh@wakehealth.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Emerg Med</MedlineTA><NlmUniqueID>8309942</NlmUniqueID><ISSNLinking>0735-6757</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>11128-99-7</RegistryNumber><NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036361">Peptide Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000804" MajorTopicYN="N">Angiotensin II</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062186" MajorTopicYN="N">Arterial Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036361" MajorTopicYN="Y">Peptide Hormones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="Y">Shock</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin II</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Critical care cardiology</Keyword><Keyword MajorTopicYN="N">Post-cardiotomy</Keyword><Keyword MajorTopicYN="N">Vasoplegia</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest PMW previously served as a consultant for La Jolla Pharmaceutical Company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>18</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36753927</ArticleId><ArticleId IdType="doi">10.1016/j.ajem.2023.01.050</ArticleId><ArticleId IdType="pii">S0735-6757(23)00054-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29683753</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0966-0461</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>British journal of nursing (Mark Allen Publishing)</Title><ISOAbbreviation>Br J Nurs</ISOAbbreviation></Journal><ArticleTitle>Fluid therapy and shock: an integrative literature review.</ArticleTitle><Pagination><StartPage>449</StartPage><EndPage>454</EndPage><MedlinePgn>449-454</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12968/bjon.2018.27.8.449</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">shock refers to a physiological situation that puts life at risk. Its early identification and the timely institution of therapeutic measures can avoid death. Despite the frequent administration of fluid therapy as a treatment for shock, the type and dose of fluids to be delivered remain undetermined.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">to determine the type of fluids to be administered and the type of approach to be performed in the different types of shock.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">integrative literature review.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">data about fluid therapy in hypovolaemic and distributive shock were obtained, specifically in the haemorrhagic and the septic types. None of the articles addressed cardiogenic shock.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">hypotensive resuscitation, with blood, is the most appropriate approach in haemorrhagic shock. There remains a question regarding the best approach in septic shock. However, conservative fluid therapy seems to be appropriate, with preference given to the administration of balanced crystalloids or albumin as an alternative.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Joana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical-Surgical Nursing Specialist, Cardiac Intensive Care Unit, Professor Doutor Fernando Fonseca Hospital, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gon&#xe7;alves</LastName><ForeName>Lu&#xed;s</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical-Surgical Nursing Specialist, Emergency and Resuscitation Medical Vehicle of Cascais, near Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sousa</LastName><ForeName>Patr&#xed;cia Pont&#xed;fice</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Assistant Teacher, Portuguese Catholic University, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Nurs</MedlineTA><NlmUniqueID>9212059</NlmUniqueID><ISSNLinking>0966-0461</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077324">Crystalloid Solutions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077324" MajorTopicYN="N">Crystalloid Solutions</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="Y">Fluid Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057184" MajorTopicYN="N">Practice Patterns, Nurses'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013222" MajorTopicYN="N">State Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Evidence-based practice</Keyword><Keyword MajorTopicYN="N">Fluid therapy</Keyword><Keyword MajorTopicYN="N">Haemorrhagic shock</Keyword><Keyword MajorTopicYN="N">Septic shock</Keyword><Keyword MajorTopicYN="N">Shock</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29683753</ArticleId><ArticleId IdType="doi">10.12968/bjon.2018.27.8.449</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35152887</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2261</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>13</Day></PubDate></JournalIssue><Title>BMC cardiovascular disorders</Title><ISOAbbreviation>BMC Cardiovasc Disord</ISOAbbreviation></Journal><ArticleTitle>Mortality in cardiogenic shock patients receiving mechanical circulatory support: a network meta-analysis.</ArticleTitle><Pagination><StartPage>48</StartPage><MedlinePgn>48</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">48</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12872-022-02493-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Mechanical circulatory support (MCS) devices are widely used for cardiogenic shock (CS). This network meta-analysis aims to evaluate which MCS strategy offers advantages.</AbstractText><AbstractText Label="METHODS">A systemic search of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials was performed. Studies included double-blind, randomized controlled, and observational trials, with 30-day follow-ups. Paired independent researchers conducted the screening, data extraction, quality assessment, and consistency and heterogeneity assessment.</AbstractText><AbstractText Label="RESULTS">We included 39 studies (1 report). No significant difference in 30-day mortality was noted between venoarterial extracorporeal membrane oxygenation (VA-ECMO) and VA-ECMO plus Impella, Impella, and medical therapy. According to the surface under the cumulative ranking curve, the optimal ranking of the interventions was surgical venting plus VA-ECMO, medical therapy, VA-ECMO plus Impella, intra-aortic balloon pump (IABP), Impella, Tandem Heart, VA-ECMO, and Impella plus IABP. Regarding in-hospital mortality and 30-day mortality, the forest plot showed low heterogeneity. The results of the node-splitting approach showed that direct and indirect comparisons had a relatively high consistency.</AbstractText><AbstractText Label="CONCLUSIONS">IABP more effectively reduce the incidence of 30-day mortality compared with VA-ECMO and Impella for the treatment of CS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Emergency and Chest Pain Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, NO. 107, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Emergency and Critical Care Medicine of Shandong Province, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences; The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency and Chest Pain Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, NO. 107, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Emergency and Critical Care Medicine of Shandong Province, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences; The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Shukun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency and Chest Pain Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, NO. 107, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Emergency and Critical Care Medicine of Shandong Province, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences; The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chuanxin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Emergency and Chest Pain Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, NO. 107, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Emergency and Critical Care Medicine of Shandong Province, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences; The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency and Chest Pain Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, NO. 107, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Emergency and Critical Care Medicine of Shandong Province, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences; The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bailu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Trial Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Shujian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency and Chest Pain Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, NO. 107, Jinan, 250012, Shandong, China. weishujian@sdu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Emergency and Critical Care Medicine of Shandong Province, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China. weishujian@sdu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China. weishujian@sdu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences; The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China. weishujian@sdu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cardiovasc Disord</MedlineTA><NlmUniqueID>100968539</NlmUniqueID><ISSNLinking>1471-2261</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006354" MajorTopicYN="Y">Heart, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Intra-aortic balloon pump</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">Tandem heart</Keyword><Keyword MajorTopicYN="N">Venoarterial extracorporeal membrane oxygenation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>14</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35152887</ArticleId><ArticleId IdType="pmc">PMC8842943</ArticleId><ArticleId IdType="doi">10.1186/s12872-022-02493-0</ArticleId><ArticleId IdType="pii">10.1186/s12872-022-02493-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232&#x2013;e268.</Citation><ArticleIdList><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, Kern M, Garratt KN, Goldstein JA, Dimas V, et al. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. J Am Coll Cardiol. 2015;65(19):e7&#x2013;e26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25861963</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Dunlay SM, Prasad A, Kashani K, Sakhuja A, Gersh BJ, Jaffe AS, Holmes DR, Jr, Barsness GW. Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock. J Am Coll Cardiol. 2019;73(14):1781&#x2013;1791.</Citation><ArticleIdList><ArticleId IdType="pubmed">30975295</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Arora S, Lahewala S, Kumar V, Shantha GPS, Jentzer JC, Stulak JM, Gersh BJ, Gulati R, Rihal CS, et al. Temporary mechanical circulatory support for refractory cardiogenic shock before left ventricular assist device surgery. J Am Heart Assoc. 2018;7(22):e010193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6404446</ArticleId><ArticleId IdType="pubmed">30571481</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Arora S, Sakhuja A, Lahewala S, Kumar V, Shantha GPS, Egbe AC, Stulak JM, Gersh BJ, Gulati R, et al. Trends, predictors, and outcomes of temporary mechanical circulatory support for postcardiac surgery cardiogenic shock. Am J Cardiol. 2019;123(3):489&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">30473325</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Patlolla SH, Sandhyavenu H, Vallabhajosyula S, Barsness GW, Dunlay SM, Greason KL, Holmes DR, Jr., Eleid MF. Periprocedural cardiopulmonary bypass or venoarterial extracorporeal membrane oxygenation during transcatheter aortic valve replacement: a systematic review. J Am Heart Assoc. 2018, 7(14).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6064861</ArticleId><ArticleId IdType="pubmed">29987125</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall A, Follin A, Cholley B, Mantz J, Aissaoui N, Pirracchio R. Veno-arterial-ECMO in the intensive care unit: From technical aspects to clinical practice. Anaesthesia Crit Care Pain Med. 2018;37(3):259&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">29033360</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D, Khera S, Aronow WS, Mujib M, Palaniswamy C, Sule S, Jain D, Gotsis W, Ahmed A, Frishman WH, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014;3(1):e000590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959706</ArticleId><ArticleId IdType="pubmed">24419737</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird-Zars VM, Barnett CF, Barsness GW, Burke JA, Cremer PC, et al. Epidemiology of shock in contemporary cardiac intensive care units. Circul Cardiovasc Quality Outcomes. 2019;12(3):e005618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11032172</ArticleId><ArticleId IdType="pubmed">30879324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunziker L, Radovanovic D, Jeger R, Pedrazzini G, Cuculi F, Urban P, Erne P, Rickli H, Pilgrim T. Twenty-year trends in the incidence and outcome of cardiogenic shock in AMIS plus registry. Circ Cardiovasc Interv. 2019;12(4):e007293.</Citation><ArticleIdList><ArticleId IdType="pubmed">30943781</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, Nordbeck P, Geisler T, Landmesser U, Skurk C, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419&#x2013;2432.</Citation><ArticleIdList><ArticleId IdType="pubmed">29083953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341(9):625&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J. 2015;36(20):1223&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">25732762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsangaris A, Alexy T, Kalra R, Kosmopoulos M, Elliott A, Bartos JA, Yannopoulos D. Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) support for the management of cardiogenic shock. Front Cardiovasc Med. 2021;8:686558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8292640</ArticleId><ArticleId IdType="pubmed">34307500</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;cker G, Petropoulou M, Schwarzer G. Network meta-analysis of multicomponent interventions. Biometrical J Biometrische Zeitschrift. 2020;62(3):808&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217213</ArticleId><ArticleId IdType="pubmed">31021449</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Systematic Rev. 10:Ed000142</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9(7):e99682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084629</ArticleId><ArticleId IdType="pubmed">24992266</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro L, Zipfel S, Braunsteiner J, Schaefer A, Sill B, S&#xf6;ffker G, Kluge S, Lubos E, Rybczinski M, Grahn H, et al. Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support. J Crit Care. 2020;57:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">32423622</ArticleId></ArticleIdList></Reference><Reference><Citation>Park TK, Yang JH, Choi S-H, Song YB, Hahn J-Y, Choi J-H, Sung K, Lee YT, Gwon H-C. Clinical impact of intra-aortic balloon pump during extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock. BMC Anesthesiol. 2014;14(1):27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003289</ArticleId><ArticleId IdType="pubmed">24725532</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Hu W, Xiao H, Feng X, Chen Y, Zhang D. Intra-aortic balloon pump improves clinical prognosis and attenuates C-reactive protein level in acute STEMI complicated by cardiogenic shock. Cardiology. 2010;117(1):75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">20924182</ArticleId></ArticleIdList></Reference><Reference><Citation>Prondzinsky R, Lemm H, Swyter M, Wegener N, Unverzagt S, Carter JM, Russ M, Schlitt A, Buerke U, Christoph A, et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: The prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome*. Crit Care Med. 2010;38(1):152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">19770739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheu J-J, Tsai T-H, Lee F-Y, Fang H-Y, Sun C-K, Leu S, Yang C-H, Chen S-M, Hang C-L, Hsieh Y-K, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med. 2010;38(9):1810&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pubmed">20543669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagawa E, Dote K, Kato M, Sasaki S, Nakano Y, Kajikawa M, Higashi A, Itakura K, Sera A, Inoue I, et al. Should we emergently revascularize occluded coronaries for cardiac arrest? Circulation. 2012;126(13):1605&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pubmed">22899771</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Schneider S, Zeymer U, Thiele H, Westermann D. Response by Schrage et al to Letter Regarding Article, "Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Matched-Pair IABP-SHOCK II Trial 30-Day Mortality Analysis". Circulation. 2019;140(11):e559&#x2013;e560.</Citation><ArticleIdList><ArticleId IdType="pubmed">31498699</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Becher PM, Bernhardt A, Bezerra H, Blankenberg S, Brunner S, Colson P, Cudemus Deseda G, Dabboura S, Eckner D, et al. Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation. Circulation. 2020;142(22):2095&#x2013;2106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688081</ArticleId><ArticleId IdType="pubmed">33032450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourad M, Gaudard P, De La Arena P, Eliet J, Zeroual N, Rouvi&#xe8;re P, Roubille F, Albat B, Colson PH. Circulatory support with extracorporeal membrane oxygenation and/or impella for cardiogenic shock during myocardial infarction. ASAIO J. 2018;64(6):708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">29240628</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz. Treating refractory cardiogenic shock with the tandemheart and Impella devices: a single center experience. Cardiol Res. 2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358142</ArticleId><ArticleId IdType="pubmed">28348673</ArticleId></ArticleIdList></Reference><Reference><Citation>Akanni OJ, Takeda K, Truby LK, Kurlansky PA, Chiuzan C, Han J, Topkara VK, Yuzefpolskaya M, Colombo PC, Karmpaliotis D, et al. EC-VAD: combined use of extracorporeal membrane oxygenation and percutaneous microaxial pump left ventricular assist device. ASAIO J. 2019;65(3):219&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">29734259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernly B, Karami M, Engstr&#xf6;m AE, Windecker S, Hunziker L, L&#xfc;scher TF, Henriques JP, Ferrari MW, Binneb&#xf6;&#xdf;el S, Masyuk M, et al. Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis. ESC Heart Failure. 2021;8(2):953&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8006691</ArticleId><ArticleId IdType="pubmed">33560591</ArticleId></ArticleIdList></Reference><Reference><Citation>Karami M, den Uil CA, Ouweneel DM, Scholte NTB, Engstr&#xf6;m AE, Akin S, Lagrand WK, Vlaar APJ, Jewbali LS, Henriques JPS. Mechanical circulatory support in cardiogenic shock from acute myocardial infarction: Impella CP/5.0 versus ECMO. Eur Heart J: Acute Cardiovasc Care. 2019;9(2):164&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">31353918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, Greco T, Lembo R, M&#xfc;llerleile K, Colombo A, et al. Concomitant implantation of Impella&#xae;on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19(3):404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">27709750</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Sick P, Boudriot E, Diederich K-W, Hambrecht R, Niebauer J, Schuler G. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26(13):1276&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochaton T, Huot L, Elbaz M, Delmas C, Aissaoui N, Farhat F, Mewton N, Bonnefoy E. Mechanical circulatory support with the Impella&#xae; LP5.0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: The IMPELLA-STIC randomized study. Arch Cardiovasc Diseases. 2020;113(4):237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">31740272</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152(3):469.e461&#x2013;469.e468.</Citation><ArticleIdList><ArticleId IdType="pubmed">16923414</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper S, Masood MF, Baltazar Garcia M, Pisani M, Ewald GA, Lasala JM, Bach RG, Singh J, Balsara KR, Itoh A. Left Ventricular Unloading by Impella Device Versus Surgical Vent During Extracorporeal Life Support. Ann Thorac Surg. 2017;104(3):861&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">28347536</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah R, Thomson A, Atianzar K, Somma K, Mehra A, Clavijo L, Matthews RV, Shavelle DM. Percutaneous left ventricular support for high-risk PCI and cardiogenic shock: Who gets what? Cardiovasc Revascul Med. 2012;13(2):101&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">22406055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemor A, Hosseini Dehkordi SH, Basir MB, Villablanca PA, Jain T, Koenig GC, Alaswad K, Moses JW, Kapur NK, O'Neill W. Impella versus extracorporeal membrane oxygenation for acute myocardial infarction cardiogenic shock. Cardiovasc Revasc Med. 2020;21(12):1465&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pubmed">32605901</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, Fr&#xf6;hlich G, Bott-Fl&#xfc;gel L, Byrne R, Dirschinger J, Kastrati A, Sch&#xf6;mig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJS, Vis MM, Wykrzykowska JJ, Koch KT, Baan J, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69(3):278&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner S, Guenther SPW, Lackermair K, Peterss S, Orban M, Boulesteix A-L, Michel S, Hausleiter J, Massberg S, Hagl C. Extracorporeal life support in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 2019;73(18):2355&#x2013;2357.</Citation><ArticleIdList><ArticleId IdType="pubmed">31072581</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao N-W, Shih C-M, Yeh J-S, Kao Y-T, Hsieh M-H, Ou K-L, Chen J-W, Shyu K-G, Weng Z-C, Chang N-C, et al. Extracorporeal membrane oxygenation&#x2013;assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock. J Crit Care. 2012;27(5):530.e531&#x2013;530.e511.</Citation><ArticleIdList><ArticleId IdType="pubmed">22591567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HK, Jeong MH, Ahn Y, Sim DS, Chae SC, Kim YJ, Hur SH, Seong IW, Hong TJ, Choi DH, et al. Clinical outcomes of the intra-aortic balloon pump for resuscitated patients with acute myocardial infarction complicated by cardiac arrest. J Cardiol. 2016;67(1):57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">25982668</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarche Y, Cheung A, Ignaszewski A, Higgins J, Kaan A, Griesdale DEG, Moss R. Comparative outcomes in cardiogenic shock patients managed with Impella microaxial pump or extracorporeal life support. J Thorac Cardiovasc Surg. 2011;142(1):60&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">20880553</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo-Silberman S, Fichet J, Mathonnet A, Varenne O, Ricome S, Chaib A, Zuber B, Spaulding C, Cariou A. Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5. Resuscitation. 2013;84(5):609&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">23069592</ArticleId></ArticleIdList></Reference><Reference><Citation>Feistritzer H-J, Desch S, Freund A, Poess J, Zeymer U, Ouarrak T, Schneider S, de Waha-Thiele S, Fuernau G, Eitel I, et al. Prognostic impact of active mechanical circulatory support in cardiogenic shock complicating acute myocardial infarction, results from the culprit-shock trial. J Clin Med. 2020;9(6):1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356113</ArticleId><ArticleId IdType="pubmed">32599815</ArticleId></ArticleIdList></Reference><Reference><Citation>Karatolios K, Chatzis G, Markus B, Luesebrink U, Ahrens H, Divchev D, Syntila S, Jerrentrup A, Schieffer B. Comparison of mechanical circulatory support with venoarterial extracorporeal membrane oxygenation or Impella for patients with cardiogenic shock: a propensity-matched analysis. Clin Res Cardiol. 2020;110:1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8405518</ArticleId><ArticleId IdType="pubmed">33185749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung ES, Lim C, Lee H-Y, Choi J-H, Lee J-S, Park K-H. Results of Extracorporeal Membrane Oxygenation (ECMO) support before coronary reperfusion in cardiogenic shock with acute myocardial infarction. Korean J Thorac Cardiovasc Surg. 2011;44(4):273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249319</ArticleId><ArticleId IdType="pubmed">22263168</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SM, Lipinski J, Al-Kindi SG, Patel T, Saric P, Li J, Nadeem F, Ladas T, Alaiti A, Phillips A, et al. Simultaneous venoarterial extracorporeal membrane oxygenation and percutaneous left ventricular decompression therapy with impella is associated with improved outcomes in refractory cardiogenic shock. ASAIO J. 2019;65(1):21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">29489461</ArticleId></ArticleIdList></Reference><Reference><Citation>Barron HV, Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, Chou TM. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J. 2001;141(6):933&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">11376306</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziewierz A, Siudak Z, Rakowski T, Kleczy&#x144;ski P, Zasada W, Dudek D. Impact of intra-aortic balloon pump on long-term mortality of unselected patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock. Adv Interv Cardiol. 2014;3:175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252308</ArticleId><ArticleId IdType="pubmed">25489303</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeymer U, Hochadel M, Hauptmann K-E, Wiegand K, Schuhmacher B, Brachmann J, Gitt A, Zahn R. Intra-aortic balloon pump in patients with acute myocardial infarction complicated by cardiogenic shock: results of the ALKK-PCI registry. Clin Res Cardiol. 2012;102(3):223&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">23179136</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanborn TA, Sleeper LA, Bates ER, Jacobs AK, Boland J, French JK, Dens J, Dzavik V, Palmeri ST, Webb JG, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000;36(3):1123&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985715</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RD, Ohman EM, Holmes DR, Jr, Col I, Stebbins AL, Bates ER, Stomel RJ, Granger CB, Topol EJ, Califf RM. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30(3):708&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">9283530</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyama N, Imai H, Kurosawa T, Fukuda N, Moriguchi M, Nishinari M, Nishii M, Kono K, Soma K, Izumi T. Therapeutic strategy using extracorporeal life support, including appropriate indication, management, limitation and timing of switch to ventricular assist device in patients with acute myocardial infarction. J Artif Organs. 2013;17(1):33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">24162152</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, Greco T, Lembo R, M&#xfc;llerleile K, Colombo A, et al. Concomitant implantation of Impella(&#xae;) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19(3):404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">27709750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemor A, Hosseini Dehkordi SH, Basir MB, Villablanca PA, Jain T, Koenig GC, Alaswad K, Moses JW, Kapur NK, O'Neill W. Impella versus extracorporeal membrane oxygenation for acute myocardial infarction cardiogenic shock. Cardiovasc Revascul Med. 2020;21(12):1465&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pubmed">32605901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochaton T, Huot L, Elbaz M, Delmas C, Aissaoui N, Farhat F, Mewton N, Bonnefoy E. Mechanical circulatory support with the Impella&#xae; LP5.0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: The IMPELLA-STIC randomized study. Arch Cardiovasc Dis. 2020;113(4):237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">31740272</ArticleId></ArticleIdList></Reference><Reference><Citation>Telukuntla KS, Estep JD. Acute mechanical circulatory support for cardiogenic shock. Methodist Debakey Cardiovasc J. 2020;16(1):27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7137625</ArticleId><ArticleId IdType="pubmed">32280415</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, O'Horo JC, Antharam P, Ananthaneni S, Vallabhajosyula S, Stulak JM, Dunlay SM, Holmes DR, Jr, Barsness GW. Venoarterial extracorporeal membrane oxygenation with concomitant impella versus venoarterial extracorporeal membrane oxygenation for cardiogenic shock. ASAIO J. 2020;66(5):497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">31335363</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo JJ, Aleksova N, Pitcher I, Couture E, Parlow S, Faraz M, Visintini S, Simard T, Di Santo P, Mathew R, et al. Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol. 2019;73(6):654&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">30765031</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad SA, Grier LR, Scott LK, Green R, Jordan M. Percutaneous cannulation for extracorporeal membrane oxygenation by intensivists: a retrospective single-institution case series. Crit Care Med. 2015;43(5):1010&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">25746749</ArticleId></ArticleIdList></Reference><Reference><Citation>Keebler ME, Haddad EV, Choi CW, McGrane S, Zalawadiya S, Schlendorf KH, Brinkley DM, Danter MR, Wigger M, Menachem JN, et al. Venoarterial extracorporeal membrane oxygenation in cardiogenic shock. JACC Heart failure. 2018;6(6):503&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">29655828</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff D, Sayer G, Doshi D, Uriel N. Hemodynamics of mechanical circulatory support. J Am Coll Cardiol. 2015;66(23):2663&#x2013;2674.</Citation><ArticleIdList><ArticleId IdType="pubmed">26670067</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena A, Garan AR, Kapur NK, O'Neill WW, Lindenfeld J, Pinney SP, Uriel N, Burkhoff D, Kern M. Value of hemodynamic monitoring in patients with cardiogenic shock undergoing mechanical circulatory support. Circulation. 2020;141(14):1184&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">32250695</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2020;323(8):734&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042879</ArticleId><ArticleId IdType="pubmed">32040163</ArticleId></ArticleIdList></Reference><Reference><Citation>Squiers JJ, Lima B, DiMaio JM. Contemporary extracorporeal membrane oxygenation therapy in adults: Fundamental principles and systematic review of the evidence. J Thorac Cardiovasc Surg. 2016;152(1):20&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">27060027</ArticleId></ArticleIdList></Reference><Reference><Citation>Truby LK, Takeda K, Mauro C, Yuzefpolskaya M, Garan AR, Kirtane AJ, Topkara VK, Abrams D, Brodie D, Colombo PC, et al. Incidence and implications of left ventricular distention during venoarterial extracorporeal membrane oxygenation support. ASAIO J. 2017;63(3):257&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">28422817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostadal P, Mlcek M, Kruger A, Hala P, Lacko S, Mates M, Vondrakova D, Svoboda T, Hrachovina M, Janotka M, et al. Increasing venoarterial extracorporeal membrane oxygenation flow negatively affects left ventricular performance in a porcine model of cardiogenic shock. J Transl Med. 2015;13:266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537539</ArticleId><ArticleId IdType="pubmed">26275717</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xe9;chot N, Demondion P, Santi F, Lebreton G, Pham T, Dalakidis A, Gambotti L, Luyt CE, Schmidt M, Hekimian G, et al. Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. Eur Heart J Acute Cardiovasc Care. 2018;7(1):62&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">28574276</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R, Hachamovitch R, Makkar R, Ramzy D, Moriguchi JD, Arabia FA, Esmailian F, Azarbal B. Lack of survival benefit found with use of intraaortic balloon pump in extracorporeal membrane oxygenation: a pooled experience of 1517 patients. J Invasive Cardiol. 2015;27(10):453&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">26208379</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, O'Horo JC, Antharam P, Ananthaneni S, Vallabhajosyula S, Stulak JM, Eleid MF, Dunlay SM, Gersh BJ, Rihal CS, et al. Concomitant intra-aortic balloon pump use in cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation. Circ Cardiovasc Interv. 2018;11(9):e006930.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354593</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito ML, Kapur NK. Acute mechanical circulatory support for cardiogenic shock: the "door to support" time. F1000Research. 2017;6:737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5443341</ArticleId><ArticleId IdType="pubmed">28580136</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, Eitel I, P&#xf6;ss J, Fuernau G, de Waha S. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J. 2017;38(47):3523&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">29020341</ArticleId></ArticleIdList></Reference><Reference><Citation>Badiye AP, Hernandez GA, Novoa I, Chaparro SV. Incidence of hemolysis in patients with cardiogenic shock treated with Impella Percutaneous left ventricular assist device. ASAIO J (Am Soc Artif Internal Organs : 1992). 2016;62(1):11&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">26418208</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandawat A, Rao SV. Percutaneous mechanical circulatory support devices in cardiogenic shock. Circ Cardiovasc Interv. 2017; 10(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578718</ArticleId><ArticleId IdType="pubmed">28500136</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Zhang J, Kareem K, Tran D, Conway RG, Arias K, Griffith BP, Wu ZJ. Device-induced platelet dysfunction in mechanically assisted circulation increases the risks of thrombosis and bleeding. Artif Organs. 2019;43(8):745&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687529</ArticleId><ArticleId IdType="pubmed">30805954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sy E, Sklar MC, Lequier L, Fan E, Kanji HD. Anticoagulation practices and the prevalence of major bleeding, thromboembolic events, and mortality in venoarterial extracorporeal membrane oxygenation: a systematic review and meta-analysis. J Crit Care. 2017;39:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28237895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30116917</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1534-3170</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>Current cardiology reports</Title><ISOAbbreviation>Curr Cardiol Rep</ISOAbbreviation></Journal><ArticleTitle>ECMO and Short-term Support for Cardiogenic Shock in Heart Failure.</ArticleTitle><Pagination><StartPage>87</StartPage><MedlinePgn>87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11886-018-1041-4</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">This review aims to discuss the role of ECMO in the treatment of cardiogenic shock in heart failure.</AbstractText><AbstractText Label="RECENT FINDINGS">Trials done previously have shown that IABP does not improve survival in cardiogenic shock compared to medical treatment, and that neither Impella 2.5 nor TandemHeart improves survival compared to IABP. The "IMPRESS in severe shock" trial compared Impella CP with IABP and found no difference in survival. A meta-analysis of cohort studies comparing ECMO with IABP showed 33% improved 30-day survival with ECMO (risk difference 33%; 95% CI 14-52%; p&#xa0;=&#x2009;0.0008; NNT 3). ECMO is indicated in medically refractory cardiogenic shock. ECMO can be considered in cardiogenic shock patients with estimated mortality of more than 50%. ECMO is probably the MCS of choice in cardiogenic shock with; biventricular failure, respiratory failure, life-threatening arrhythmias and cardiac arrest.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chakaramakkil</LastName><ForeName>Mathew Jose</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Level 12, National Heart Centre Singapore, 5 Hospital Drive, Singapore, 169609, Singapore. mathew.jose.c@singhealth.com.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivathasan</LastName><ForeName>Cumaraswamy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Level 12, National Heart Centre Singapore, 5 Hospital Drive, Singapore, 169609, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Cardiol Rep</MedlineTA><NlmUniqueID>100888969</NlmUniqueID><ISSNLinking>1523-3782</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30116917</ArticleId><ArticleId IdType="doi">10.1007/s11886-018-1041-4</ArticleId><ArticleId IdType="pii">10.1007/s11886-018-1041-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ann Intensive Care. 2016 Dec;6(1):97</Citation><ArticleIdList><ArticleId IdType="pubmed">27714705</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Cardiovasc Surg. 2015 May;149(5):1428-33</Citation><ArticleIdList><ArticleId IdType="pubmed">25746030</ArticleId></ArticleIdList></Reference><Reference><Citation>Resuscitation. 2006 Sep;70(3):381-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16828957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2008 Nov 4;52(19):1584-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Heart Fail. 2015 May;17(5):501-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25820680</ArticleId></ArticleIdList></Reference><Reference><Citation>Artif Organs. 1998 Apr;22(4):326-36</Citation><ArticleIdList><ArticleId IdType="pubmed">9555964</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2015 Dec 15;66(23):2663-2674</Citation><ArticleIdList><ArticleId IdType="pubmed">26670067</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2009 Sep;30(17):2102-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19617601</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2017 Apr 18;69(15):1913-1920</Citation><ArticleIdList><ArticleId IdType="pubmed">28408020</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 1999 Apr;15(4):508-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10371130</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2005 Jul;26(13):1276-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Cardiovasc Surg. 2015 Aug;150(2):333-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25869084</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2016 Jul 14;37(27):2129-2200</Citation><ArticleIdList><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2009 Mar 10;119(9):1211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19237658</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2010 Sep;38(9):1810-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20543669</ArticleId></ArticleIdList></Reference><Reference><Citation>ASAIO J. 2015 Jan-Feb;61(1):31-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25303799</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2007 Jul;35(7):1673-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17507822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 2014 Feb;97(2):610-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24210621</ArticleId></ArticleIdList></Reference><Reference><Citation>J Card Fail. 2018 Mar;24(3):148-156</Citation><ArticleIdList><ArticleId IdType="pubmed">29032225</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2016 Nov;44(11):1974-1979</Citation><ArticleIdList><ArticleId IdType="pubmed">27322361</ArticleId></ArticleIdList></Reference><Reference><Citation>Interv Cardiol Clin. 2017 Jul;6(3):359-371</Citation><ArticleIdList><ArticleId IdType="pubmed">28600090</ArticleId></ArticleIdList></Reference><Reference><Citation>ASAIO J. 2005 May-Jun;51(3):281-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15968960</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2014 Apr;68(4):529-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24674706</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Oct 4;367(14):1287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2006 Sep;152(3):469.e1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16923414</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2017 Jan 24;69(3):278-287</Citation><ArticleIdList><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2003 Apr 16;41(8):1273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12706920</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2017 Aug;45(8):1359-1366</Citation><ArticleIdList><ArticleId IdType="pubmed">28471885</ArticleId></ArticleIdList></Reference><Reference><Citation>Artif Organs. 2001 Aug;25(8):599-602</Citation><ArticleIdList><ArticleId IdType="pubmed">11531708</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Thorac Cardiovasc Surg. 2015 Summer;27(2):81-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26686427</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2016 Dec;42(12):1922-1934</Citation><ArticleIdList><ArticleId IdType="pubmed">27647331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 2016 Mar;101(3):919-26</Citation><ArticleIdList><ArticleId IdType="pubmed">26518372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 2012 Jul;94(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22429669</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2016 Mar;42(3):370-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26825953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiothorac Surg. 2017 Jul 17;12(1):55</Citation><ArticleIdList><ArticleId IdType="pubmed">28716039</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Heart Fail. 2017 Mar;19(3):404-412</Citation><ArticleIdList><ArticleId IdType="pubmed">27709750</ArticleId></ArticleIdList></Reference><Reference><Citation>Artif Organs. 2017 Nov;41(11):E263-E273</Citation><ArticleIdList><ArticleId IdType="pubmed">28762511</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2001 May 15;87(10):1184-8; A4</Citation><ArticleIdList><ArticleId IdType="pubmed">11356395</ArticleId></ArticleIdList></Reference><Reference><Citation>ASAIO J. 2017 May/Jun;63(3):257-265</Citation><ArticleIdList><ArticleId IdType="pubmed">28422817</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2017 Oct 17;136(16):e232-e268</Citation><ArticleIdList><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Transplant. 2012 May-Jun;26(3):484-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21919969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 2010 Nov;90(5):1541-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20971259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intensive Care. 2017 May 22;5:27</Citation><ArticleIdList><ArticleId IdType="pubmed">28546860</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2017 Jan 24;69(3):358-360</Citation><ArticleIdList><ArticleId IdType="pubmed">27810348</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 1999 Sep;16(3):342-50</Citation><ArticleIdList><ArticleId IdType="pubmed">10554855</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2015 Sep 1;36(33):2246-56</Citation><ArticleIdList><ArticleId IdType="pubmed">26033984</ArticleId></ArticleIdList></Reference><Reference><Citation>Resuscitation. 2013 Nov;84(11):1525-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23827888</ArticleId></ArticleIdList></Reference><Reference><Citation>Interact Cardiovasc Thorac Surg. 2012 Sep;15(3):420-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22659268</ArticleId></ArticleIdList></Reference><Reference><Citation>Artif Organs. 2017 Mar;41(3):224-232</Citation><ArticleIdList><ArticleId IdType="pubmed">27658844</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2013 Jan;34(2):112-20</Citation><ArticleIdList><ArticleId IdType="pubmed">22513777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31611428</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-2501</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of invasive cardiology</Title><ISOAbbreviation>J Invasive Cardiol</ISOAbbreviation></Journal><ArticleTitle>Systematic Review and Meta-Analysis of Interventional Emergency Treatment of Decompensated Severe Aortic Stenosis.</ArticleTitle><Pagination><StartPage>30</StartPage><EndPage>36</EndPage><MedlinePgn>30-36</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">JIC20191015-3</ELocationID><Abstract><AbstractText Label="AIMS">Patients in cardiogenic shock (CS) due to decompensated aortic stenosis (AS) evidence poor prognosis. Both emergency transcatheter aortic valve replacement (eTAVR) and emergency balloon aortic valvuloplasty (eBAV) have been reported in CS patients. We aimed to summarize and compare available studies on eBAV and eTAVR in patients suffering from CS due to decompensated AS with regard to safety and efficacy.</AbstractText><AbstractText Label="METHODS AND RESULTS">Study-level data were analyzed. Heterogeneity was assessed using the I2 statistic. Pooled proportions, ie, event rates, were calculated and obtained using a random-effects model (DerSimonian and Laird). Eight studies were found suitable for the final analysis, including 311 patients. Primary endpoint was mortality at 30 days. For eBAV (n = 238), 30-day mortality rate was 46.2% (95% confidence interval [CI], 30.3%-62.5%; I&#xb2;=74%), major bleeding rate was 10% (95% CI, 5.4%-15.7%; I&#xb2;=13%), and stroke rate was 0.7% (95% CI, 0.0%-2.7%; I&#xb2;=0%). Aortic regurgitation (AR) &#x2265;II was present in 8.6% (95% CI, 0.4%-23.5%; I&#xb2;=86%). For eTAVR (n = 73), 30-day mortality rate was 22.6% (95% CI, 12.0%-35.2%; I&#xb2;=26%), major bleeding rate was 5.8% (95% CI, 0.5%-14.7%; I&#xb2;=0%), and stroke rate was 5.8% (95% CI, 0.5%-14.7%; I&#xb2;=0%). AR &#x2265;II was present in 4% (95% CI, 0.0%-12.1%; I&#xb2;=0%).</AbstractText><AbstractText Label="CONCLUSION">Mortality in CS patients due to decompensated severe AS is high, regardless of interventional treatment strategy. Both eBAV and eTAVR seem feasible. As eTAVR is associated with better initial improvements in hemodynamics and simultaneously avoids sequential interventions, it might be favorable to eBAV in select patients. If eTAVR is not available, eBAV might serve as a "bridge" to elective TAVR.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wernly</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Jirak</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lichtenauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Veulemans</LastName><ForeName>Verena</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Zeus</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Piayda</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hoppe</LastName><ForeName>Uta C</ForeName><Initials>UC</Initials></Author><Author ValidYN="Y"><LastName>Lauten</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Frerker</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Hospital D&#xfc;sseldorf, Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, 40225 D&#xfc;sseldorf, Germany. Christian.Jung@med.uni-duesseldorf.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Invasive Cardiol</MedlineTA><NlmUniqueID>8917477</NlmUniqueID><ISSNLinking>1042-3931</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="Y">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063126" MajorTopicYN="Y">Balloon Valvuloplasty</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004638" MajorTopicYN="N">Emergency Treatment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010043" MajorTopicYN="N">Outcome and Process Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="Y">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">balloon valvuloplasty</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">emergency treatment</Keyword><Keyword MajorTopicYN="N">severe AS</Keyword><Keyword MajorTopicYN="N">transcatheter aortic valve replacement</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31611428</ArticleId><ArticleId IdType="doi">10.25270/jic/19.00003</ArticleId><ArticleId IdType="pii">JIC20191015-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38202071</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal Membrane Oxygenation for Pulmonary Embolism: A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">64</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13010064</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The use of extracorporeal membrane oxygenation (ECMO) for high-risk pulmonary embolism (HRPE) with haemodynamic instability or profound cardiogenic shock has been reported. Guidelines currently support the use of ECMO only in patients with cardiac arrest or circulatory collapse and in conjunction with other curative therapies. We aimed to characterise the mortality of adults with HRPE treated with ECMO, identify factors associated with mortality, and compare different adjunct curative therapies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review and meta-analysis, searching four international databases from their inception until 25 June 2023 for studies reporting on more than five patients receiving ECMO for HRPE. Random-effects meta-analyses were conducted. The primary outcome was in-hospital mortality. A subgroup analysis investigating the outcomes with curative treatment for HRPE was also performed. The intra-study risk of bias and the certainty of evidence were also assessed. This study was registered with PROSPERO (CRD42022297518).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 39 observational studies involving 6409 patients receiving ECMO for HRPE were included in the meta-analysis. The pooled mortality was 42.8% (95% confidence interval [CI]: 37.2% to 48.7%, moderate certainty). Patients treated with ECMO and catheter-directed therapy (28.6%) had significantly lower mortality (<i>p</i> &lt; 0.0001) compared to those treated with ECMO and systemic thrombolysis (57.0%). Cardiac arrest prior to ECMO initiation (regression coefficient [B]: 1.77, 95%-CI: 0.29 to 3.25, <i>p</i> = 0.018) and pre-ECMO heart rate (B: -0.076, 95%-CI: -0.12 to 0.035, <i>p</i> = 0.0003) were significantly associated with mortality. The pooled risk ratio when comparing mortality between patients on ECMO and those not on ECMO was 1.51 (95%-CI: 1.07 to 2.14, <i>p</i> &lt; 0.01) in favour of ECMO. The pooled mortality was 55.2% (95%-CI: 47.7% to 62.6%), using trim-and-fill analysis to account for the significant publication bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">More than 50% of patients receiving ECMO for HRPE survive. While outcomes may vary based on the curative therapy used, early ECMO should be considered as a stabilising measure when treating patients with HRPE. Patients treated concurrently with systemic thrombolysis have higher mortality than those receiving ECMO alone or with other curative therapies, particularly catheter-directed therapies. Further studies are required to explore ECMO vs. non-ECMO therapies in view of currently heterogenous datasets.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boey</LastName><ForeName>Jonathan Jia En</ForeName><Initials>JJE</Initials><Identifier Source="ORCID">0000-0002-2763-3241</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Western Sydney Clinical Campuses, University of New South Wales, Sydney, NSW 2170, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhundi</LastName><ForeName>Ujwal</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Singapore 119074, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Ryan Ruiyang</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0002-8335-7640</Identifier><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore 119228, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiew</LastName><ForeName>John Keong</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore 119228, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Nicole Chui-Jiet</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Royal College of Surgeons in Ireland (RCSI), University College Dublin (UCD) Malaysia Campus, D02 YN77 Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7876-4877</Identifier><AffiliationInfo><Affiliation>Agency for Science, Technology and Research (A*STaR), Singapore 138632, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hobohm</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4312-0366</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Cardiology I and Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, St. Vincent's Hospital Sydney, Darlinghurst, NSW 2010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1777-2045</Identifier><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, 6229 HX Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht, 6229 ER Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacLaren</LastName><ForeName>Graeme</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1307-4274</Identifier><AffiliationInfo><Affiliation>Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Singapore 119074, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore 119228, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>Kollengode</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1822-9455</Identifier><AffiliationInfo><Affiliation>Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Singapore 119074, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore 119228, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList><CoiStatement>R.R.L. acknowledges research support outside of this work from the Clinician Scientist Development Unit, Yong Loo Lin School of Medicine, National University of Singapore. R.L. is a consultant for LivaNova, Medtronic, Abiomed, and Getinge (all honoraria are paid to the University to support research activities) and is a member of the medical advisory board of Eurosets, Xenios, and Hemocue. He is a member of the ELSO steering committee and chairs the research committee. G.M. is the president of the Extracorporeal Life Support Organisation (ELSO). K.R. is a member of the ELSO steering committee and chairs the publications committee. He has received honoraria from Xenios for educational lectures on ECMO. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38202071</ArticleId><ArticleId IdType="pmc">PMC10779708</ArticleId><ArticleId IdType="doi">10.3390/jcm13010064</ArticleId><ArticleId IdType="pii">jcm13010064</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Horlander K.T., Mannino D.M., Leeper K.V. Pulmonary embolism mortality in the United States, 1979-1998: An analysis using multiple-cause mortality data. Arch. Intern. Med. 2003;163:1711&#x2013;1717. doi: 10.1001/archinte.163.14.1711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.163.14.1711</ArticleId><ArticleId IdType="pubmed">12885687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassila R., Jula A., Pitk&#xe4;niemi J., Haukka J. The association of statin use with reduced incidence of venous thromboembolism: A population-based cohort study. BMJ Open. 2014;4:e005862. doi: 10.1136/bmjopen-2014-005862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2014-005862</ArticleId><ArticleId IdType="pmc">PMC4225235</ArticleId><ArticleId IdType="pubmed">25377011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N., Rossi E., De Rosa M., Goldhaber S.Z. Massive pulmonary embolism. Circulation. 2006;113:577&#x2013;582. doi: 10.1161/CIRCULATIONAHA.105.592592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.592592</ArticleId><ArticleId IdType="pubmed">16432055</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasrija C., Kronfli A., George P., Raithel M., Boulos F., Herr D.L., Gammie J.S., Pham S.M., Griffith B.P., Kon Z.N. Utilization of veno-arterial extracorporeal membrane oxygenation for massive pulmonary embolism. Ann. Thorac. Surg. 2018;105:498&#x2013;504. doi: 10.1016/j.athoracsur.2017.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.08.033</ArticleId><ArticleId IdType="pubmed">29174781</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.-J., Harjola V.-P., Huisman M.V., Humbert M., Jennings C.S., Jim&#xe9;nez D. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Eur. Heart J. 2020;41:543&#x2013;603. doi: 10.1093/eurheartj/ehz405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz405</ArticleId><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference><Reference><Citation>Alba A.C., Foroutan F., Buchan T.A., Alvarez J., Kinsella A., Clark K., Zhu A., Lau K., McGuinty C., Aleksova N., et al. Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients. J. Heart Lung Transplant. 2021;40:260&#x2013;268. doi: 10.1016/j.healun.2021.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2021.01.009</ArticleId><ArticleId IdType="pubmed">33551227</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsi F., Lebreton G., Br&#xe9;chot N., Hekimian G., Nieszkowska A., Trouillet J.L., Luyt C.E., Leprince P., Chastre J., Combes A., et al. Life-threatening massive pulmonary embolism rescued by venoarterial-extracorporeal membrane oxygenation. Crit. Care. 2017;21:76. doi: 10.1186/s13054-017-1655-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-017-1655-8</ArticleId><ArticleId IdType="pmc">PMC5369216</ArticleId><ArticleId IdType="pubmed">28347320</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuff H., Zochios V., Vuylsteke A. Extracorporeal membrane oxygenation in acute massive pulmonary embolism: A systematic review. Perfusion. 2015;30:611&#x2013;616. doi: 10.1177/0267659115583377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659115583377</ArticleId><ArticleId IdType="pubmed">25910837</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh Y.N., Oh D.K., Koh Y., Lim C.-M., Huh J.-W., Lee J.S., Jung S.-H., Kang P.-J., Hong S.-B. Use of extracorporeal membrane oxygenation in patients with acute high-risk pulmonary embolism: A case series with literature review. Acute Crit. Care. 2019;34:148&#x2013;154. doi: 10.4266/acc.2019.00500.</Citation><ArticleIdList><ArticleId IdType="doi">10.4266/acc.2019.00500</ArticleId><ArticleId IdType="pmc">PMC6786667</ArticleId><ArticleId IdType="pubmed">31723920</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggio P., Hemmila M., Haft J., Bartlett R. Extracorporeal Life Support for Massive Pulmonary Embolism. J. Trauma Acute Care Surg. 2007;62:570&#x2013;576. doi: 10.1097/TA.0b013e318031cd0c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318031cd0c</ArticleId><ArticleId IdType="pubmed">17414330</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia D., Yang I.X., Ling R.R., Syn N., Poon W.H., Murughan K., Tan C.S., Choong A.M.T.L., MacLaren G., Ramanathan K. Vascular Complications of Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Regression Analysis. Crit. Care Med. 2020;48:e1269&#x2013;e1277. doi: 10.1097/CCM.0000000000004688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004688</ArticleId><ArticleId IdType="pubmed">33105148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra S., Ling R.R., Yang I.X., Poon W.H., Tan C.S., Monagle P., MacLaren G., Ramanathan K. Severe COVID-19 and coagulopathy: A systematic review and meta-analysis. Ann. Acad. Med. Singap. 2021;50:325&#x2013;335. doi: 10.47102/annals-acadmedsg.2020420.</Citation><ArticleIdList><ArticleId IdType="doi">10.47102/annals-acadmedsg.2020420</ArticleId><ArticleId IdType="pubmed">33990820</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldetti L., Beneduce A., Cianfanelli L., Falasconi G., Pannone L., Moroni F., Venuti A., Sacchi S., Gramegna M., Pazzanese V., et al. Use of extracorporeal membrane oxygenation in high-risk acute pulmonary embolism: A systematic review and meta-analysis. Artif. Organs. 2021;45:569&#x2013;576. doi: 10.1111/aor.13876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.13876</ArticleId><ArticleId IdType="pubmed">33277695</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott J.H., Gordon M., Vender R., Pettigrew S., Desai P., Marchetti N., Mamary A.J., Panaro J., Cohen G., Bashir R., et al. Venoarterial Extracorporeal Membrane Oxygenation in Massive Pulmonary Embolism-Related Cardiac Arrest: A Systematic Review. Crit. Care Med. 2021;49:760&#x2013;769. doi: 10.1097/CCM.0000000000004828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004828</ArticleId><ArticleId IdType="pubmed">33590996</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopard R., Nielsen P., Ius F., Cebotari S., Ecarnot F., Pilichowski H., Schmidt M., Kjaergaard B., Sousa-Casasnovas I., Ghoreishi M., et al. Optimal reperfusion strategy in acute high-risk pulmonary embolism requiring extracorporeal membrane oxygenation support: A systematic review and meta-analysis. Eur. Respir. J. 2022;60:2102977. doi: 10.1183/13993003.02977-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02977-2021</ArticleId><ArticleId IdType="pubmed">35487534</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters M.D., Godfrey C.M., Khalil H., McInerney P., Parker D., Soares C.B. Guidance for conducting systematic scoping reviews. Int. J. Evid. Based Healthc. 2015;13:141&#x2013;146. doi: 10.1097/XEB.0000000000000050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/XEB.0000000000000050</ArticleId><ArticleId IdType="pubmed">26134548</ArticleId></ArticleIdList></Reference><Reference><Citation>Santesso N., Glenton C., Dahm P., Garner P., Akl E.A., Alper B., Brignardello-Petersen R., Carrasco-Labra A., De Beer H., Hultcrantz M., et al. GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions. J. Clin. Epidemiol. 2020;119:126&#x2013;135. doi: 10.1016/j.jclinepi.2019.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2019.10.014</ArticleId><ArticleId IdType="pubmed">31711912</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials. 1986;7:177&#x2013;188. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Clopper C.J., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404&#x2013;413. doi: 10.1093/biomet/26.4.404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/26.4.404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyaga V.N., Arbyn M., Aerts M. Metaprop: A Stata command to perform meta-analysis of binomial data. Arch. Public Health. 2014;72:39. doi: 10.1186/2049-3258-72-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2049-3258-72-39</ArticleId><ArticleId IdType="pmc">PMC4373114</ArticleId><ArticleId IdType="pubmed">25810908</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzer G., Chemaitelly H., Abu-Raddad L.J., R&#xfc;cker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res. Synth. Methods. 2019;10:476&#x2013;483. doi: 10.1002/jrsm.1348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1348</ArticleId><ArticleId IdType="pmc">PMC6767151</ArticleId><ArticleId IdType="pubmed">30945438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X., Wang W., Liu J., Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G.H., Oxman A.D., Kunz R., Woodcock J., Brozek J., Helfand M., Alonso-Coello P., Glasziou P., Jaeschke R., Akl E.A. GRADE guidelines: 7. Rating the quality of evidence&#x2014;Inconsistency. J. Clin. Epidemiol. 2011;64:1294&#x2013;1302. doi: 10.1016/j.jclinepi.2011.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2011.03.017</ArticleId><ArticleId IdType="pubmed">21803546</ArticleId></ArticleIdList></Reference><Reference><Citation>Iorio A., Spencer F.A., Falavigna M., Alba C., Lang E., Burnand B., McGinn T., Hayden J., Williams K., Shea B. Use of GRADE for assessment of evidence about prognosis: Rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350:h870. doi: 10.1136/bmj.h870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h870</ArticleId><ArticleId IdType="pubmed">25775931</ArticleId></ArticleIdList></Reference><Reference><Citation>Danial P., Olivier M.E., Br&#xe9;chot N., Ponnaiah M., Schoell T., D&#x2019;Alessandro C., Demondion P., Cl&#xe9;ment M., Juvin C., Carillion A., et al. Association Between Shock Etiology and 5-Year Outcomes After Venoarterial Extracorporeal Membrane Oxygenation. J. Am. Coll. Cardiol. 2023;81:897&#x2013;909. doi: 10.1016/j.jacc.2022.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.12.018</ArticleId><ArticleId IdType="pubmed">36858709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T., Araki T., Imaizumi T., Sumita Y., Nakai M., Tanaka A., Okumura T., Butt J.H., Petrie M.C., McMurray J.J.V., et al. Prognosis in Patients with Cardiogenic Shock Who Received Temporary Mechanical Circulatory Support. JACC Asia. 2023;3:122&#x2013;134. doi: 10.1016/j.jacasi.2022.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacasi.2022.10.004</ArticleId><ArticleId IdType="pmc">PMC9982290</ArticleId><ArticleId IdType="pubmed">36873766</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Chen J., Xu X., Lan F., He M., Shao C., Xu Y., Han P., Chen Y., Zhu Y., et al. Extracorporeal Membrane Oxygenation-First Strategy for Acute Life-Threatening Pulmonary Embolism. Front. Cardiovasc. Med. 2022;9:875021. doi: 10.3389/fcvm.2022.875021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.875021</ArticleId><ArticleId IdType="pmc">PMC9203845</ArticleId><ArticleId IdType="pubmed">35722115</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser M.F., Jabri A., Sharma S., Alhuneafat L., Omar Y.A., Krishnan V., Cameron S.J. Outcomes with use of extra-corporeal membrane oxygenation in high-risk pulmonary embolism: A national database perspective. J. Thromb. Thrombolysis. 2023;55:499&#x2013;505. doi: 10.1007/s11239-023-02773-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-023-02773-2</ArticleId><ArticleId IdType="pubmed">36662443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto Y., Ohbe H., Matsui H., Nakajima M., Sasabuchi Y., Sato Y., Watanabe T., Yamada T., Fukunami M., Yasunaga H. Effectiveness of systemic thrombolysis on clinical outcomes in high-risk pulmonary embolism patients with venoarterial extracorporeal membrane oxygenation: A nationwide inpatient database study. J. Intensive Care. 2023;11:4. doi: 10.1186/s40560-023-00651-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-023-00651-w</ArticleId><ArticleId IdType="pmc">PMC9901114</ArticleId><ArticleId IdType="pubmed">36740697</ArticleId></ArticleIdList></Reference><Reference><Citation>Panholzer B., Gravert H., Borzikowsky C., Huenges K., Schoettler J., Schoeneich F., Attmann T., Haneya A., Frank D., Cremer J., et al. Outcome after surgical embolectomy for acute pulmonary embolism. J. Cardiovasc. Med. 2022;23:519&#x2013;523. doi: 10.2459/JCM.0000000000001349.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001349</ArticleId><ArticleId IdType="pubmed">35905002</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid C., Zietlow S., Wagner T.O., Laas J., Borst H.G. Fulminant pulmonary embolism: Symptoms, diagnostics, operative technique, and results. Ann. Thorac. Surg. 1991;52:1102&#x2013;1105; discussion 1105&#x2013;1107. doi: 10.1016/0003-4975(91)91288-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-4975(91)91288-7</ArticleId><ArticleId IdType="pubmed">1953130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahito K., Murata S., Adachi H., Ino T., Fuse K. Resuscitation and circulatory support using extracorporeal membrane oxygenation for fulminant pulmonary embolism. Artif. Organs. 2000;24:427&#x2013;430. doi: 10.1046/j.1525-1594.2000.06590.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1594.2000.06590.x</ArticleId><ArticleId IdType="pubmed">10886059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiba K., Okuda J., Maejima N., Iwahashi N., Tsukahara K., Tahara Y., Hibi K., Kosuge M., Ebina T., Endo T. Percutaneous cardiopulmonary support in pulmonary embolism with cardiac arrest. Resuscitation. 2012;83:183&#x2013;187. doi: 10.1016/j.resuscitation.2011.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2011.10.019</ArticleId><ArticleId IdType="pubmed">22062683</ArticleId></ArticleIdList></Reference><Reference><Citation>Munakata R., Yamamoto T., Hosokawa Y., Tokita Y., Akutsu K., Sato N., Murata S., Tajima H., Mizuno K., Tanaka K. Massive pulmonary embolism requiring extracorporeal life support treated with catheter-based interventions. Int. Heart J. 2012;53:370&#x2013;374. doi: 10.1536/ihj.53.370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1536/ihj.53.370</ArticleId><ArticleId IdType="pubmed">23258138</ArticleId></ArticleIdList></Reference><Reference><Citation>George B., Parazino M., Omar H.R., Davis G., Guglin M., Gurley J., Smyth S. A retrospective comparison of survivors and non-survivors of massive pulmonary embolism receiving veno-arterial extracorporeal membrane oxygenation support. Resuscitation. 2018;122:1&#x2013;5. doi: 10.1016/j.resuscitation.2017.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2017.11.034</ArticleId><ArticleId IdType="pubmed">29128608</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneveau N., Guillon B., Planquette B., Piton G., Kimmoun A., Gaide-Chevronnay L., Aissaoui N., Neuschwander A., Zogheib E., Dupont H., et al. Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: A multicentre series of 52 cases. Eur. Heart J. 2018;39:4196&#x2013;4204. doi: 10.1093/eurheartj/ehy464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy464</ArticleId><ArticleId IdType="pubmed">30137303</ArticleId></ArticleIdList></Reference><Reference><Citation>Minakawa M., Fukuda I., Miyata H., Motomura N., Takamoto S., Taniguchi S., Daitoku K., Kondo N. Outcomes of Pulmonary Embolectomy for Acute Pulmonary Embolism. Circ. J. 2018;82:2184&#x2013;2190. doi: 10.1253/circj.CJ-18-0371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-18-0371</ArticleId><ArticleId IdType="pubmed">29952349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ius F., Hoeper M.M., Fegbeutel C., K&#xfc;hn C., Olsson K., Koigeldiyev N., Tudorache I., Warnecke G., Optenh&#xf6;fel J., Puntigam J.O. Extracorporeal membrane oxygenation and surgical embolectomy for high-risk pulmonary embolism. Eur. Respir. J. 2019;53:1801773. doi: 10.1183/13993003.01773-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01773-2018</ArticleId><ArticleId IdType="pubmed">30728206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjaergaard B., Kristensen J.H., Sindby J.E., de Neergaard S., Rasmussen B.S. Extracorporeal membrane oxygenation in life-threatening massive pulmonary embolism. Perfusion. 2019;34:467&#x2013;474. doi: 10.1177/0267659119830014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659119830014</ArticleId><ArticleId IdType="pubmed">30773127</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandigers L., Scholten E., Rietdijk W.J.R., den Uil C.A., van Thiel R.J., Rigter S., Heijnen B., Gommers D., Dos Reis Miranda D. Survival and neurological outcome with extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest caused by massive pulmonary embolism: A two center observational study. Resuscitation. 2019;136:8&#x2013;13. doi: 10.1016/j.resuscitation.2018.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2018.12.008</ArticleId><ArticleId IdType="pubmed">30572065</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K., Hikone M., Kuwahara Y., Ishida T., Sugiyama K., Hamabe Y. Extracorporeal CPR for massive pulmonary embolism in a &#x201c;hybrid 2136 emergency department&#x201d;. Am. J. Emerg. Med. 2019;37:2132&#x2013;2135. doi: 10.1016/j.ajem.2019.01.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2019.01.039</ArticleId><ArticleId IdType="pubmed">30691862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaese S., Lebiedz P. Extracorporeal life support after failure of thrombolysis in pulmonary embolism. Adv. Respir. Med. 2020;88:13&#x2013;17. doi: 10.5603/ARM.a2020.0073.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/ARM.a2020.0073</ArticleId><ArticleId IdType="pubmed">32153003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sertic F., Diagne D., Chavez L., Richards T., Berg A., Acker M., Giri J.S., Szeto W.Y., Khandhar S., Gutsche J., et al. Mid-term outcomes with the use of extracorporeal membrane oxygenation for cardiopulmonary failure secondary to massive pulmonary embolism. Eur. J. Cardiothorac. Surg. 2020;58:923&#x2013;931. doi: 10.1093/ejcts/ezaa189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezaa189</ArticleId><ArticleId IdType="pubmed">32725134</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraud R., Laurencet M., Assouline B., De Charri&#xe8;re A., Banfi C., Bendjelid K. Can VA-ECMO be used as an adequate treatment in massive pulmonary embolism? J. Clin. Med. 2021;10:3376. doi: 10.3390/jcm10153376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10153376</ArticleId><ArticleId IdType="pmc">PMC8348430</ArticleId><ArticleId IdType="pubmed">34362159</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg J.B., Spevack D.M., Ahsan S., Rochlani Y., Ohira S., Spencer P., Kai M., Malekan R., Spielvogel D., Lansman S. Comparison of Surgical Embolectomy and Veno-arterial Extracorporeal Membrane Oxygenation for Massive Pulmonary Embolism. Semin. Thorac. Cardiovasc. Surg. 2021;34:934&#x2013;942. doi: 10.1053/j.semtcvs.2021.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semtcvs.2021.06.011</ArticleId><ArticleId IdType="pubmed">34157383</ArticleId></ArticleIdList></Reference><Reference><Citation>Guliani S., Das Gupta J., Osofsky R., Kraai E.P., Mitchell J.A., Dettmer T.S., Wray T.C., Tawil I., Rana M.A., Marinaro J. Venoarterial extracorporeal membrane oxygenation is an effective management strategy for massive pulmonary embolism patients. J. Vasc. Surg. Venous. Lymphat. Disord. 2021;9:307&#x2013;314. doi: 10.1016/j.jvsv.2020.04.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2020.04.033</ArticleId><ArticleId IdType="pubmed">32505687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobohm L., Sagoschen I., Habertheuer A., Barco S., Valerio L., Wild J., Schmidt F.P., Gori T., M&#xfc;nzel T., Konstantinides S., et al. Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolism. Resuscitation. 2021;170:285&#x2013;292. doi: 10.1016/j.resuscitation.2021.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2021.10.007</ArticleId><ArticleId IdType="pubmed">34653550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hockstein M.A., Creel-Bulos C., Appelstein J., Jabaley C.S., Stentz M.J. Institutional Experience With Venoarterial Extracorporeal Membrane Oxygenation for Massive Pulmonary Embolism: A Retrospective Case Series. J. Cardiothorac. Vasc. Anesth. 2021;35:2681&#x2013;2685. doi: 10.1053/j.jvca.2020.12.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.12.045</ArticleId><ArticleId IdType="pubmed">33531193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.W., Tsai M.T., Hu Y.N., Wang Y.C., Wen J.S., Wu H.Y., Luo C.Y., Roan J.N. Simultaneous Thrombolysis and Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Emboli. Ann. Thorac. Surg. 2021;111:923&#x2013;929. doi: 10.1016/j.athoracsur.2020.05.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2020.05.155</ArticleId><ArticleId IdType="pubmed">32738223</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Solano J., Sousa-Casasnovas I., Bell&#xf3;n-Cano J.M., Garc&#xed;a-Carre&#xf1;o J., Ju&#xe1;rez-Fern&#xe1;ndez M., D&#xed;ez-Delhoyo F., Sanz-Ruiz R., Devesa-Cordero C., El&#xed;zaga-Corrales J., Fern&#xe1;ndez-Avil&#xe9;s F., et al. Lactate levels as a prognostic predict in cardiogenic shock under venoarterial extracorporeal membrane oxygenation support. Rev. Esp. Cardiol. 2021;75:595&#x2013;603. doi: 10.1016/j.recesp.2021.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2021.08.007</ArticleId><ArticleId IdType="pubmed">34810119</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad N.K., Boyajian G., Tran D., Shah A., Jones K.M., Madathil R.J., Deatrick K.B., Cires-Drouet R., Kaczorowski D.J. Veno-Arterial Extracorporeal Membrane Oxygenation for Pulmonary Embolism after Systemic Thrombolysis. Semin. Thorac. Cardiovasc. Surg. 2021;34:549&#x2013;557. doi: 10.1053/j.semtcvs.2021.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semtcvs.2021.04.004</ArticleId><ArticleId IdType="pubmed">33974966</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumantepe M., Ozturk C. Acoustic pulse thrombolysis complemented by ECMO improved survival in patients with high-risk pulmonary embolism. J. Card. Surg. 2022;37:492&#x2013;500. doi: 10.1111/jocs.16222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.16222</ArticleId><ArticleId IdType="pubmed">35020205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang J., Koo S.M., Kim K.U., Kim Y.K., Uh S.T., Jang G.E., Chang W., Lee B.Y. Clinical experiences of high-risk pulmonary thromboembolism receiving extracorporeal membrane oxygenation in single institution. Tuberc. Respir. Dis. 2022;85:249&#x2013;255. doi: 10.4046/trd.2022.0004.</Citation><ArticleIdList><ArticleId IdType="doi">10.4046/trd.2022.0004</ArticleId><ArticleId IdType="pmc">PMC9263344</ArticleId><ArticleId IdType="pubmed">35645168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ltaief Z., Lupieri E., Bonnemain J., Ben-Hamouda N., Rancati V., Kobbe S.S., Kirsch M., Chiche J.-D., Liaudet L. Venoarterial Extracorporeal Membrane Oxygenation in High-Risk Pulmonary Embolism: A Case Series and Literature Review. Rev. Cardiovasc. Med. 2022;23:193. doi: 10.31083/j.rcm2306193.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm2306193</ArticleId><ArticleId IdType="pmc">PMC11273876</ArticleId><ArticleId IdType="pubmed">39077191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mously H., Hajjari J., Chami T., Hammad T., Schilz R., Carman T., Elgudin Y., Abu-Omar Y., Pelletier M.P., Shishehbor M.H., et al. Percutaneous mechanical thrombectomy and extracorporeal membranous oxygenation: A case series. Catheter. Cardiovasc. Interv. 2022;100:274&#x2013;278. doi: 10.1002/ccd.30295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.30295</ArticleId><ArticleId IdType="pubmed">35686535</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadlbauer A., Philipp A., Blecha S., Lubnow M., Lunz D., Li J., Terrazas A., Schmid C., Lange T.J., Camboni D. Long-term follow-up and quality of life in patients receiving extracorporeal membrane oxygenation for pulmonary embolism and cardiogenic shock. Ann. Intensive Care. 2021;11:181. doi: 10.1186/s13613-021-00975-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00975-6</ArticleId><ArticleId IdType="pmc">PMC8709804</ArticleId><ArticleId IdType="pubmed">34951692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai H.Y., Wang Y.T., Lee W.C., Yen H.T., Lo C.M., Wu C.C., Huang K.R., Chen Y.C., Sheu J.J., Chen Y.Y. Efficacy and Safety of Veno-Arterial Extracorporeal Membrane Oxygenation in the Treatment of High-Risk Pulmonary Embolism: A Retrospective Cohort Study. Front. Cardiovasc. Med. 2022;9:799488. doi: 10.3389/fcvm.2022.799488.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.799488</ArticleId><ArticleId IdType="pmc">PMC8924067</ArticleId><ArticleId IdType="pubmed">35310966</ArticleId></ArticleIdList></Reference><Reference><Citation>George T.J., Sheasby J., Sawhney R., DiMaio J.M., Afzal A., Gable D., Sayfo S. Extracorporeal membrane oxygenation for large pulmonary emboli. Bayl. Univ. Med. Cent. Proc. 2023;36:314&#x2013;317. doi: 10.1080/08998280.2023.2171699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08998280.2023.2171699</ArticleId><ArticleId IdType="pmc">PMC10120470</ArticleId><ArticleId IdType="pubmed">37091759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelty C.E., Berjaoui W., Shrestha N.K., Fitch S., Jovinge S.M., Rendon R.L. Veno-Arterial Extracorporeal Membrane Oxygenation versus Standard Medical Management for Massive Pulmonary Embolism. Perfusion. 2023. online ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02676591231182247</ArticleId><ArticleId IdType="pubmed">37283140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N., Ouda A., Voci D., Barco S., Micieli E., M&#xfc;nger M., Pleming W., Grigorean A., Sromicki J., Schmiady M.O., et al. Percutaneous large-bore aspiration embolectomy with veno-arterial extracorporal membrane oxygenation support or standby in patients with high-risk pulmonary embolism and contraindications to thrombolysis: A preliminary single centre experience. Eur. Heart J. Acute Cardiovasc. Care. 2023;12:232&#x2013;236. doi: 10.1093/ehjacc/zuad014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuad014</ArticleId><ArticleId IdType="pubmed">36825861</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim H.T., Jo M.S., Chang Y.J., Cho D.G., Kim J.W. Outcome of Massive Pulmonary Embolism Treated Only with Extracorporeal Membrane Oxygenation and Anticoagulation without Thrombolytic Therapy or Surgical Embolectomy. Perfusion. 2023. online ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02676591231164878</ArticleId><ArticleId IdType="pubmed">37083034</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat. Med. 2007;26:4544&#x2013;4562. doi: 10.1002/sim.2889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2889</ArticleId><ArticleId IdType="pubmed">17476644</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanimoto A., Sugiyama K., Tanabe M., Kitagawa K., Kawakami A., Hamabe Y. Out-of-hospital cardiac arrest patients with an initial non-shockable rhythm could be candidates for extracorporeal cardiopulmonary resuscitation: A retrospective study. Scand. J. Trauma Resusc. Emerg. Med. 2020;28:101. doi: 10.1186/s13049-020-00800-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13049-020-00800-2</ArticleId><ArticleId IdType="pmc">PMC7559626</ArticleId><ArticleId IdType="pubmed">33054829</ArticleId></ArticleIdList></Reference><Reference><Citation>Belohlavek J., Rohn V., Jansa P., Tosovsky J., Kunstyr J., Semrad M., Horak J., Lips M., Mlejnsky F., Balik M., et al.  Veno-arterial ECMO in severe acute right ventricular failure with pulmonary obstructive hemodynamic pattern.  [(accessed on 29 October 2023)];J. Invasive Cardiol. 2010 22:365&#x2013;369. Available online:  https://pubmed.ncbi.nlm.nih.gov/20679672/</Citation><ArticleIdList><ArticleId IdType="pubmed">20679672</ArticleId></ArticleIdList></Reference><Reference><Citation>Kmiec L., Philipp A., Floerchinger B., Lubnow M., Unterbuchner C., Creutzenberg M., Lunz D., Mueller T., Schmid C., Camboni D. Extracorporeal membrane oxygenation for massive pulmonary embolism as bridge to therapy. ASAIO J. 2020;66:146&#x2013;152. doi: 10.1097/MAT.0000000000000953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000953</ArticleId><ArticleId IdType="pubmed">30720492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangaraju R., Klok F.A. Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism. Hematol. Am. Soc. Hematol. Educ. Program. 2020;2020:195&#x2013;200. doi: 10.1182/hematology.2020000167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/hematology.2020000167</ArticleId><ArticleId IdType="pmc">PMC7727511</ArticleId><ArticleId IdType="pubmed">33275707</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg J.B., Giri J., Kobayashi T., Ruel M., Mittnacht A.J.C., Rivera-Lebron B., DeAnda A., Jr., Moriarty J.M., MacGillivray T.E. Surgical Management and Mechanical Circulatory Support in High-Risk Pulmonary Embolisms: Historical Context, Current Status, and Future Directions: A Scientific Statement from the American Heart Association. Circulation. 2023;147:e628&#x2013;e647. doi: 10.1161/CIR.0000000000001117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001117</ArticleId><ArticleId IdType="pubmed">36688837</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrer M., Cuijpers P., Furukawa T.A., Ebert D.D. Doing Meta-Analysis with R: A Hands-On Guide. Chapman and Hall/CRC; Boca Raton, FL, USA: 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1201/9781003107347</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36691820</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1594</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Artificial organs</Title><ISOAbbreviation>Artif Organs</ISOAbbreviation></Journal><ArticleTitle>Microaxial circulatory support for percutaneous coronary intervention: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>934</StartPage><EndPage>942</EndPage><MedlinePgn>934-942</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/aor.14494</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Microaxial circulatory support devices have been used to support patients treated with percutaneous coronary intervention (PCI) for acute myocardial infarction complicated by cardiogenic shock (AMICS). The purpose of this systematic review and meta-analysis was to pool and analyze the existing evidence on the baseline characteristics, periprocedural data, and outcomes of microaxial support before and after PCI in AMICS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An electronic database search was performed to identify all cohort studies on Impella and PCI for cardiogenic shock in the English language. A total of five articles comprising 543 patients were included. These patients received microaxial support either before (pre-PCI) or after (post-PCI) undergoing PCI. Comparative analyses were done between both groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean patient age was 66&#x2009;years [95% Confidence Interval (58-74)], and 22% (89/396) of patients were female. ST-elevation myocardial infarctions (MI)&#xa0;comprised&#xa0;64% (44-80) of MIs and 50% (44-56) of MIs involved the left anterior descending artery. The mean number of diseased vessels was 2.21 (1.62-2.80). The mean left ventricular ejection fraction was 31% (23.4-38.6). The mean arterial pressure was 66.3&#x2009;mm&#x2009;Hg (54.1-78.5). Mean serum lactate [6.1&#x2009;mmol/L (3.3-8.9)] and serum creatinine [1.4&#xa0;mg/dl (1.0-1.7)] were similar between groups. 30-day mortality was lower in the pre-PCI group [41% (34%-49%)] compared to the post-PCI group [61% (42%-77%), p&#xa0;&lt;&#x2009;0.01]. Pooled Kaplan-Meier analysis showed better early survival in the pre-PCI group (p&#xa0;&lt;&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients presenting with AMICS were similar at baseline in both pre-PCI and post-PCI groups. Nevertheless, pre-PCI group showed better early survival compared to post-PCI group.</AbstractText><CopyrightInformation>&#xa9; 2023 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>Sophie A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-2450-3222</Identifier><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Jake L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Danial</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-7876-3962</Identifier><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vishnevsky</LastName><ForeName>Alec</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Thomas Jefferson University, Pennsylvania, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajapreyar</LastName><ForeName>Indranee N</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Thomas Jefferson University, Pennsylvania, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggiero</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Thomas Jefferson University, Pennsylvania, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rame</LastName><ForeName>J Eduardo</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Thomas Jefferson University, Pennsylvania, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Entwistle</LastName><ForeName>John W</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-1492-6483</Identifier><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massey</LastName><ForeName>Howard T</ForeName><Initials>HT</Initials><Identifier Source="ORCID">0000-0003-4682-5203</Identifier><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchantchaleishvili</LastName><ForeName>Vakhtang</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4357-3533</Identifier><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Artif Organs</MedlineTA><NlmUniqueID>7802778</NlmUniqueID><ISSNLinking>0160-564X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36691820</ArticleId><ArticleId IdType="doi">10.1111/aor.14494</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153-639.</Citation></Reference><Reference><Citation>Kosaraju A, Pendela VS, Hai O. Cardiogenic shock. Treasure Island, FL: StatPearls Publishing LLC; 2022.</Citation></Reference><Reference><Citation>Kimman JR, Van Mieghem NM, Endeman H, Brugts JJ, Constantinescu AA, Manintveld OC, et al. Mechanical support in early cardiogenic shock: what is the role of intra-aortic balloon counterpulsation? Curr Heart Fail Rep. 2020;17(5):247-60.</Citation></Reference><Reference><Citation>O'Neill WW, Grines C, Schreiber T, Moses J, Maini B, Dixon SR, et al. Analysis of outcomes for 15&#x2009;259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. Am Heart J. 2018;202:33-8.</Citation></Reference><Reference><Citation>Stretch R, Sauer CM, Yuh DD, Bonde P. National trends in the utilization of short-term mechanical circulatory support. J Am Coll Cardiol. 2014;64(14):1407-15.</Citation></Reference><Reference><Citation>Basir MB, Schreiber TL, Grines CL, Dixon SR, Moses JW, Maini BS, et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol. 2017;119(6):845-51.</Citation></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287-96.</Citation></Reference><Reference><Citation>Unverzagt S, Buerke M, de Waha A, Haerting J, Pietzner D, Seyfarth M, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev. 2015;3:CD007398.</Citation></Reference><Reference><Citation>Zeymer U, Hochadel M, Hauptmann K-E, Wiegand K, Schuhmacher B, Brachmann J, et al. Intra-aortic balloon pump in patients with acute myocardial infarction complicated by cardiogenic shock: results of the ALKK-PCI registry. Clin Res Cardiol. 2013;102(3):223-7.</Citation></Reference><Reference><Citation>Thiele H, Zeymer U, Thelemann N, Neumann F-J, Hausleiter J, Abdel-Wahab M, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction. Circulation. 2019;139(3):395-403.</Citation></Reference><Reference><Citation>Miller PE, Bromfield SG, Ma Q, Crawford G, Whitney J, DeVries A, et al. Clinical outcomes and cost associated with an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump in patients presenting with acute myocardial infarction complicated by cardiogenic shock. JAMA Intern Med. 2022;182(9):926-33.</Citation></Reference><Reference><Citation>Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, et al. Use of mechanical circulatory support devices among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA Netw Open. 2021;4(2):e2037748.</Citation></Reference><Reference><Citation>O'Neill WW, Anderson M, Burkhoff D, Grines CL, Kapur NK, Lansky AJ, et al. Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices. Am Heart J. 2022;248:139-49.</Citation></Reference><Reference><Citation>O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126(14):1717-27.</Citation></Reference><Reference><Citation>Joseph SM, Brisco MA, Colvin M, Grady KL, Walsh MN, Cook JL, et al. Women with cardiogenic shock derive greater benefit from early mechanical circulatory support: an update from the cVAD registry. J Interv Cardiol. 2016;29(3):248-56.</Citation></Reference><Reference><Citation>Meraj PM, Doshi R, Schreiber T, Maini B, O'Neill WW. Impella 2.5 initiated prior to unprotected left main PCI in acute myocardial infarction complicated by cardiogenic shock improves early survival. J Interv Cardiol. 2017;30(3):256-63.</Citation></Reference><Reference><Citation>Sch&#xe4;fer A, Werner N, Burkhoff D, Sieweke J-T, Zietzer A, Masyuk M, et al. Influence of timing and predicted risk on mortality in Impella-treated infarct-related cardiogenic shock patients. Front Cardiovasc Med. 2020;7:74.</Citation></Reference><Reference><Citation>Lazkani M, Murarka S, Kobayashi A, Seibolt L, Yang T, Pershad A. A retrospective analysis of Impella use in all-comers: 1-year outcomes. J Interv Cardiol. 2017;30(6):577-83.</Citation></Reference><Reference><Citation>Loehn T, O'Neill WW, Lange B, Pfluecke C, Schweigler T, Mierke J, et al. Long term survival after early unloading with Impella CP&#xae; in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2020;9(2):149-57.</Citation></Reference><Reference><Citation>Tarantini G, Masiero G, Burzotta F, Pazzanese V, Briguori C, Trani C, et al. Timing of Impella implantation and outcomes in cardiogenic shock or high-risk percutaneous coronary revascularization. Catheter Cardiovasc Interv. 2021;98(2):E222-34.</Citation></Reference><Reference><Citation>Chatzis G, Markus B, Luesebrink U, Ahrens H, Divchev D, Syntila S, et al. Early Impella support in postcardiac arrest cardiogenic shock complicating acute myocardial infarction improves short- and long-term survival. Crit Care Med. 2021;49(6):943-55.</Citation></Reference><Reference><Citation>Hemradj VV, Karami M, Sjauw KD, Engstr&#xf6;m AE, Ouweneel DM, de Brabander J, et al. Pre-PCI versus immediate post-PCI Impella initiation in acute myocardial infarction complicated by cardiogenic shock. PLoS ONE. 2020;15(7):e0235762.</Citation></Reference><Reference><Citation>O'Neill WW, Schreiber T, DHW W, Rihal C, Naidu SS, Civitello AB, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella registry. J Interv Cardiol. 2014;27(1):1-11.</Citation></Reference><Reference><Citation>Kwon D, Reis IM. Simulation-based estimation of mean and standard deviation for meta-analysis via approximate Bayesian computation (ABC). BMC Med Res Methodol. 2015;15:61.</Citation></Reference><Reference><Citation>Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.</Citation></Reference><Reference><Citation>Menees DS, Peterson ED, Wang Y, Curtis JP, Messenger JC, Rumsfeld JS, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med. 2013;369(10):901-9.</Citation></Reference><Reference><Citation>Kapur NK, Davila CD. Timing, timing, timing: the emerging concept of the &#x2018;door to support&#x2019; time for cardiogenic shock. Eur Heart J. 2017;38(47):3532-4.</Citation></Reference><Reference><Citation>Fuernau G, Ledwoch J, Desch S, Eitel I, Thelemann N, Jung C, et al. Impact of timing of intraaortic balloon counterpulsation on mortality in cardiogenic shock-a subanalysis of the IABP-SHOCK II trial. Eur Heart J Acute Cardiovasc Care. 2020;10(1):54-61.</Citation></Reference><Reference><Citation>Cheng JM, van Leeuwen MAH, de Boer SPM, Wai MCGTJ, den Uil CA, Jewbali LSD, et al. Impact of intra-aortic balloon pump support initiated before versus after primary percutaneous coronary intervention in patients with cardiogenic shock from acute myocardial infarction. Int J Cardiol. 2013;168(4):3758-63.</Citation></Reference><Reference><Citation>Sjauw KD, Engstr&#xf6;m AE, Vis MM, Boom W, Baan J, de Winter RJ, et al. Efficacy and timing of intra-aortic counterpulsation in patients with ST-elevation myocardial infarction complicated by cardiogenic shock. Neth Heart J. 2012;20(10):402-9.</Citation></Reference><Reference><Citation>Helgestad OKL, Josiassen J, Hassager C, Jensen LO, Holmvang L, Udesen NLJ, et al. Contemporary trends in use of mechanical circulatory support in patients with acute MI and cardiogenic shock. Open Heart. 2020;7(1):e001214.</Citation></Reference><Reference><Citation>Abdel-Wahab M, Saad M, Kynast J, Geist V, Sherif MA, Richardt G, et al. Comparison of hospital mortality with intra-aortic balloon counterpulsation insertion before versus after primary percutaneous coronary intervention for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2010;105(7):967-71.</Citation></Reference><Reference><Citation>Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2020;323(8):734-45.</Citation></Reference><Reference><Citation>Manian N, Thakker J, Nair A. The use of mechanical circulatory assist devices for ACS patients with cardiogenic shock and high-risk PCI. Curr Cardiol Rep. 2022;24(6):699-709.</Citation></Reference><Reference><Citation>Tehrani BN, Truesdell AG, Sherwood MW, Desai S, Tran HA, Epps KC, et al. Standardized team-based care for cardiogenic shock. J Am Coll Cardiol. 2019;73(13):1659-69.</Citation></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, Fr&#xf6;hlich G, Bott-Fl&#xfc;gel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584-8.</Citation></Reference><Reference><Citation>Vargas KG, J&#xe4;ger B, Kaufmann CC, Biagioli A, Watremez S, Gatto F, et al. Impella in cardiogenic shock following acute myocardial infarction: a systematic review and meta-analysis. Wien Klin Wochenschr. 2020;132(23):716-25.</Citation></Reference><Reference><Citation>Amin AP, Spertus JA, Curtis JP, Desai N, Masoudi FA, Bach RG, et al. The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. 2020;141(4):273-84.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32397890</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1477-111X</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>1_suppl</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Perfusion</Title><ISOAbbreviation>Perfusion</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal life support for phaeochromocytoma-induced cardiogenic shock: a systematic review.</ArticleTitle><Pagination><StartPage>20</StartPage><EndPage>28</EndPage><MedlinePgn>20-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0267659120908413</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Phaeochromocytoma is a catecholamine-secreting tumour associated with clinical presentation ranging from paroxysmal hypertension to intractable cardiogenic shock. Extracorporeal life support, in veno-arterial mode, application in refractory acute heart dysfunction is sharply increasing worldwide. However, its clinical utility in phaeochromocytoma-induced cardiogenic shock remains still unclear.</AbstractText><AbstractText Label="METHODS">A systematic review of published reports was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement. Searches were accomplished on PubMed, Embase and Google Scholar to identify articles describing the use of extracorporeal life support in the setting of phaeochromocytoma-induced cardiogenic shock (PROSPERO: CRD42019125225).</AbstractText><AbstractText Label="RESULTS">Thirty-five reports, including 62 patients supported with extracorporeal life support because of intractable phaeochromocytoma crisis, were included for the analysis. Almost all the subjects underwent peripheral cannulation for extracorporeal life support. The median duration of the mechanical circulatory support was 5&#x2009;days, and most of the patients recovered normal myocardial function (left ventricular ejection fraction &#x2a7e;50%). In-hospital survival was 87%. Phaeochromocytoma was removed surgically during extracorporeal life support in 10 patients (16%), while in the remaining after haemodynamic stabilization and weaning from the mechanical support.</AbstractText><AbstractText Label="CONCLUSION">Successful management of phaeochromocytoma-induced cardiogenic shock depends on prompt recognition and immediate treatment of shock. In this scenario, extracorporeal life support may play a significant role allowing cardiac and end-organ recovery and giving time for accurate diagnosis and specific treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matteucci</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0694-2747</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Circolo Hospital, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalewski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fina</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Policlinico San Donato, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiritano</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University Magna Graecia of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meani</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raffa</LastName><ForeName>Giuseppe M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0001-7141-2561</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, Department of Anesthesia and Intensive Care, Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldobayyan</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beghi</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Circolo Hospital, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maessen</LastName><ForeName>Jos</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1777-2045</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Perfusion</MedlineTA><NlmUniqueID>8700166</NlmUniqueID><ISSNLinking>0267-6591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Perfusion. 2020 May;35(1_suppl):18-19. doi: 10.1177/0267659120909770.</RefSource><PMID Version="1">32397889</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Perfusion. 2021 Jan;36(1):103-104. doi: 10.1177/0267659120963930.</RefSource><PMID Version="1">33021142</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Perfusion. 2021 Jan;36(1):105-106. doi: 10.1177/0267659120966916.</RefSource><PMID Version="1">33084509</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000310" MajorTopicYN="N">Adrenal Gland Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010673" MajorTopicYN="N">Pheochromocytoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal life support</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">phaeochromocytoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32397890</ArticleId><ArticleId IdType="doi">10.1177/0267659120908413</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40451596</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</Title><ISOAbbreviation>J Heart Lung Transplant</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy intravenous istaroxime up to 60&#xa0;hours for patients with pre-cardiogenic shock.</ArticleTitle><Pagination><StartPage>1569</StartPage><EndPage>1580</EndPage><MedlinePgn>1569-1580</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.healun.2025.05.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-2498(25)01977-1</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">A drug that improves blood pressure and cardiac output (CO) while reducing pulmonary wedge pressure safely is needed for patients with cardiogenic shock (CS) due to acute heart failure (AHF).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a randomized, double-blind, placebo-controlled trial, istaroxime 0.5 to 1.5&#xa0;&#xb5;g/kg/min for 24-60&#xa0;hours was administered to 48 patients, and placebo to 42 patients, with pre-CS due to AHF under hemodynamic monitoring. Echocardiographic and Holter monitoring were done in both parts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients randomized to istaroxime had a greater increase in systolic blood pressure (SBP) during the first 6&#xa0;hours (primary endpoint), ls-mean (SE) 62.0 (6.59) mmHg*hour vs 36.4 (7.11) in the placebo arm (LS mean difference of 25.6&#xa0;mmHg*hour, 95% CI 7.2-44.0&#xa0;mmHg*h, P&#xa0;=&#xa0;0.007). In patients administered istaroxime for at least 48&#xa0;hours, SBP increase persisted for 60&#xa0;hours. Istaroxime led to a greater increase in CO (0.66&#xa0;L/min, P&#xa0;=&#xa0;0.017) and decrease in wedge pressure (3.8&#xa0;mmHg, P&#xa0;=&#xa0;0.0017). Relative to average baselines of 3.6&#xa0;L/min for CO and 22.5&#xa0;mmHg for wedge pressure, this translates into improvements of 18.3% and 16.9%, respectively. Echocardiographic assessments showed improvements in E/A, TAPSE, and LA volume at 24&#xa0;hours. There were improvements in eGFR at 24-72&#xa0;hours and NYHA class to 72&#xa0;hours. NT-proBNP increased more in istaroxime-treated patients. Heart rate decreased more in the first 24&#xa0;hours in istaroxime-treated patients. No significant malignant arrhythmias were detected in patients treated with istaroxime on Holter monitoring.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this small study, istaroxime doses of up to 1.0&#xa0;&#xb5;g/kg/min for up to 60&#xa0;hours were associated with improvements in SBP, CO and reductions in wedge pressure and heart rate without increases in arrhythmias.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Biegus</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Heart Diseases, Wroclaw Medical University, Wroc&#x142;aw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis and Lariboisi&#xe8;re Hospitals, FHU PROMICE, DMU Parabol, APHP Nord, Paris, France; Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metra</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagnesi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chioncel</LastName><ForeName>Ovidiu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania; University of Medicine Carol Davila, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davison</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Universit&#xe9; Paris Cit&#xe9;, Paris, France; Momentum Research, Inc., Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Momentum Research, Inc., Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Momentum Research, Inc., Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippatos</LastName><ForeName>Gerasimos</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyci&#x144;ska</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Intensive Cardiac Care, Medical University of Bia&#x142;ystok, Bia&#x142;ystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novosadova</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Momentum Research, Inc., Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulati</LastName><ForeName>Gaurav</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CardioVascular Center, Tufts Medical Center, Boston, MA 02111.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barros</LastName><ForeName>Marianela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Momentum Research, Inc., Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Maria Luz</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>ECLA international, Rosario, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guardia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Windtree Therapeutics, Inc., Warrington, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zymli&#x144;ski</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Heart Diseases, Wroclaw Medical University, Wroc&#x142;aw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gajewski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Heart Diseases, Wroclaw Medical University, Wroc&#x142;aw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponikowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Heart Diseases, Wroclaw Medical University, Wroc&#x142;aw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Phillip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Windtree Therapeutics, Inc., Warrington, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonson</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Windtree Therapeutics, Inc., Warrington, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Gad</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Universit&#xe9; Paris Cit&#xe9;, Paris, France; Momentum Research, Inc., Durham, NC. Electronic address: gadcotter@momentum-research.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Heart Lung Transplant</MedlineTA><NlmUniqueID>9102703</NlmUniqueID><ISSNLinking>1053-2498</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002302" MajorTopicYN="N">Cardiac Output</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011669" MajorTopicYN="N">Pulmonary Wedge Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute heart failure</Keyword><Keyword MajorTopicYN="N">Cardiac calcitrope</Keyword><Keyword MajorTopicYN="N">Central hemodynamics</Keyword><Keyword MajorTopicYN="N">Intravenous therapy</Keyword><Keyword MajorTopicYN="N">Istaroxime</Keyword><Keyword MajorTopicYN="N">Pre-cardiogenic shock</Keyword></KeywordList><CoiStatement>Conflicts of Interest statement MM received personal fees of minimal amounts in the last three years from Amgen, Livanova, and Vifor pharma as member of Executive or Data Monitoring Committees of sponsored clinical trials; from Astra-Zeneca, Abbott vascular, Bayer, Boheringer Ingelhelm, and Edwards Therapeutics for participation to advisory boards and/or speeches at sponsored meetings. MP received personal fees from Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics, and Vifor Pharma. OC is a member of the Boehringer Ingelheim Advisory Board. BD, GC, CE, MN, MB, and KT are employees of Momentum Research, which has received grants for research from the Heart Initiative, Corteria, Windtree, Echosens, and 4teen4. GF reports lecture fees and/and or advisor and/or trial committee membership from Bayer, Boehringer Ingelheim, Servier, Novartis, Impulse Dynamics, Vifor, Medtronic, Cardior, and Novo Nordisk; Research Grants from the European Union. AM reports personal fees from Orion, Roche, Adrenomed and Fire 1, and grants and personal fees from 4TEEN4, Abbott, Roche, and Sphyngotec. PP reports other from Trevena, during the conduct of the study; reports grants and personal fees from Amgen, Inc., grants and personal fees from Servier, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Vifor Pharma, grants and personal fees from Novartis, grants and personal fees from Bayer, grants and personal fees from Cibiem, grants and personal fees from AstraZeneca, grants and personal fees from BMS, grants and personal fees from Renal Guard Solutions, grants and personal fees from Impulse Dynamics, grants and personal fees from Abbott Vascular, personal fees from Berlin Chemie, outside the submitted work. PS, CG, and SS are employees of Windtree Therapeutics, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>3</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>1</Day><Hour>21</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40451596</ArticleId><ArticleId IdType="doi">10.1016/j.healun.2025.05.013</ArticleId><ArticleId IdType="pii">S1053-2498(25)01977-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39102873</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1752-8062</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical and translational science</Title><ISOAbbreviation>Clin Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Early administration of ketorolac after cardiac surgery and postoperative complications: Analysis of the MIMIC-IV database.</ArticleTitle><Pagination><StartPage>e13907</StartPage><MedlinePgn>e13907</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13907</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/cts.13907</ELocationID><Abstract><AbstractText>Inflammation may contribute to postoperative cardiac complications and ketorolac, an anti-inflammatory agent inhibiting cyclooxygenase (COX), shows promise in enhancing cardiac graft patency by suppressing endothelial cell proliferation in animal studies. However, the safety of postoperative ketorolac use remains controversial. This study investigates the association between early ketorolac application and complications following cardiac surgery. Data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database fueled this retrospective cohort study. The primary outcome is a composite of mortality, pulmonary insufficiency, severe acute kidney injury (AKI), hemorrhage or hematoma, infection, cardiogenic shock, and cerebrovascular infarction postcardiac surgery. Propensity score matching (PSM; 1:1 match, caliper 0.2), multivariate logistic regression, interaction stratification analysis, pairwise algorithmic, and overlap weight model analyses were employed. Following inclusion and exclusion criteria, 7143 patients who underwent valvular surgery or coronary artery bypass grafting (CABG) were included. PSM created a balanced cohort of 3270 individuals (1635 in the ketorolac group). The matched cohort exhibited an 8.1% overall rate of postoperative complications, with a lower composite outcome rate in patients receiving ketorolac within 48&#x2009;h of surgery compared with those without (PSM, OR 0.70 [95% CI, 0.54-0.90]). Consistent associations were observed in total cohort analyses, sensitivity, and subgroup analyses. Early ketorolac use within 48&#x2009;h post-CABG or valvular procedures in adults is independently associated with a lower incidence of composite postoperative adverse events. Prospective trials are warranted to assess causality.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9929-3856</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Shanghai Cancer Center, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Bo</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5173-3285</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Shanghai Cancer Center, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5680-349X</Identifier><AffiliationInfo><Affiliation>Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3197-0427</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Shanghai Cancer Center, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Sci</MedlineTA><NlmUniqueID>101474067</NlmUniqueID><ISSNLinking>1752-8054</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YZI5105V0L</RegistryNumber><NameOfSubstance UI="D020910">Ketorolac</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020910" MajorTopicYN="Y">Ketorolac</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="N">Coronary Artery Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declared no competing interests for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>5</Day><Hour>19</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39102873</ArticleId><ArticleId IdType="pmc">PMC11299995</ArticleId><ArticleId IdType="doi">10.1111/cts.13907</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown JR, Cochran RP, Leavitt BJ, et&#xa0;al. Multivariable prediction of renal insufficiency developing after cardiac surgery. Circulation. 2007;116:I139&#x2010;I143.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846294</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyanka P, Zarbock A, Izawa J, Gleason TG, Renfurm RW, Kellum JA. The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients. J Thorac Cardiovasc Surg. 2021;162:143&#x2010;151.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32033818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra PK, Luckraz H, Nandi J, et&#xa0;al. Long&#x2010;term quality of life postacute kidney injury in cardiac surgery patients. Ann Card Anaesth. 2018;21:41&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5791486</ArticleId><ArticleId IdType="pubmed">29336390</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford TC, Magruder JT, Grimm JC, et&#xa0;al. Complications after cardiac operations: all are not created equal. Ann Thorac Surg. 2017;103:32&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">27884410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Bellomo R. Cardiac surgery&#x2010;associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol. 2017;13:697&#x2010;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">28869251</ArticleId></ArticleIdList></Reference><Reference><Citation>Moonesinghe SR, Mythen MG, Grocott MPW. High&#x2010;risk surgery: epidemiology and outcomes. Anesth Analg. 2011;112:891&#x2010;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">20495138</ArticleId></ArticleIdList></Reference><Reference><Citation>Spickler W. Ketorolac (Toradol): a new analgesic or an old NSAID? Can Med Assoc J. 1993;148:1693&#x2010;1695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1485584</ArticleId><ArticleId IdType="pubmed">8485673</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou R, Gordon DB, de Leon&#x2010;Casasola OA, et&#xa0;al. Management of postoperative pain: a clinical practice guideline from the American pain society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' committee on regional anesthesia, executive committee, and administrative council. J Pain. 2016;17:131&#x2010;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">26827847</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Lamberts M, Olsen AMS, et&#xa0;al. Cardiovascular safety of non&#x2010;aspirin non&#x2010;steroidal anti&#x2010;inflammatory drugs: review and position paper by the working group for cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37:1015&#x2010;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">26984863</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya M, Dunning J. Does the use of non&#x2010;steroidal anti&#x2010;inflammatory drugs after cardiac surgery increase the risk of renal failure? Interact Cardiovasc Thorac Surg. 2010;11:461&#x2010;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">20639308</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue M, Caldarone CA, Frndova H, et&#xa0;al. Safety and efficacy of ketorolac in children after cardiac surgery. Intensive Care Med. 2009;35:1584&#x2010;1592.</Citation><ArticleIdList><ArticleId IdType="pubmed">19562323</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Daggett C, Drant S, Rivero N, Lewis A. Prospective randomized trial of ketorolac after congenital heart surgery. J Cardiothorac Vasc Anesth. 2004;18:454&#x2010;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">15365927</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AEW, Bulgarelli L, Shen L, et&#xa0;al. MIMIC&#x2010;IV, a freely accessible electronic health record dataset. Sci Data. 2023;10:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9810617</ArticleId><ArticleId IdType="pubmed">36596836</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke JP, von Elm E, Altman DG, et&#xa0;al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2020496</ArticleId><ArticleId IdType="pubmed">17941715</ArticleId></ArticleIdList></Reference><Reference><Citation>Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289:2554&#x2010;2559.</Citation><ArticleIdList><ArticleId IdType="pubmed">12759327</ArticleId></ArticleIdList></Reference><Reference><Citation>Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: composite end points. J Card Fail. 2005;11:567&#x2010;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">16230258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott E, Nussmeier NA, Duke PC, et&#xa0;al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481&#x2010;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12830070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussmeier NA, Whelton AA, Brown MT, et&#xa0;al. Complications of the COX&#x2010;2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081&#x2010;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bainbridge D, Cheng DC, Martin JE, Novick R, the evidence&#x2010;based perioperative clinical outcomes research (EPiCOR) group . NSAID&#x2010;analgesia, pain control and morbidity in cardiothoracic surgery. Can J Anesth/J Can Anesth. 2006;53:46&#x2010;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulik A, Ruel M, Bourke ME, et&#xa0;al. Postoperative naproxen after coronary artery bypass surgery: a double&#x2010;blind randomized controlled trial. Eur J Cardiothorac Surg. 2004;26:694&#x2010;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450559</ArticleId></ArticleIdList></Reference><Reference><Citation>Coxib and traditional NSAID Trialists' (CNT) Collaboration , Bhala N, Emberson J, et&#xa0;al. Vascular and upper gastrointestinal effects of non&#x2010;steroidal anti&#x2010;inflammatory drugs: meta&#x2010;analyses of individual participant data from randomised trials. Lancet. 2013;382:769&#x2010;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778977</ArticleId><ArticleId IdType="pubmed">23726390</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mahmoodi AN, Kim PY. Ketorolac. StatPearls. StatPearls Publishing; 2023. 
http://www.ncbi.nlm.nih.gov/books/NBK545172/
</Citation><ArticleIdList><ArticleId IdType="pubmed">31424756</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveri L, Jerzewski K, Kulik A. Black box warning: is ketorolac safe for use after cardiac surgery? J Cardiothorac Vasc Anesth. 2014;28:274&#x2010;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">24231193</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard M, Warhurst R, Sheehan C. Safety of continuous infusion ketorolac in postoperative coronary artery bypass graft surgery patients. Pharmacy. 2016;4:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419367</ArticleId><ArticleId IdType="pubmed">28970395</ArticleId></ArticleIdList></Reference><Reference><Citation>Engoren MC, Habib RH, Zacharias A, et&#xa0;al. Postoperative analgesia with ketorolac is associated with decreased mortality after isolated coronary artery bypass graft surgery in patients already receiving aspirin: a propensity&#x2010;matched study. J Cardiothorac Vasc Anesth. 2007;21:820&#x2010;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">18068059</ArticleId></ArticleIdList></Reference><Reference><Citation>Warltier DC, Laffey JG, Boylan JF, Cheng DCH. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology. 2002;97:215&#x2010;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">12131125</ArticleId></ArticleIdList></Reference><Reference><Citation>Canet J, Gallart L. Postoperative respiratory failure: pathogenesis, prediction, and prevention. Curr Opin Crit Care. 2014;20:56&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24240985</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Cooper MG, Craig JC, Knight JF, Keneally JP. Effects of nonsteroidal anti&#x2010;inflammatory drugs on postoperative renal function in adults with normal renal function. Cochrane Database Syst Rev. 2007;2017:CD002765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6516878</ArticleId><ArticleId IdType="pubmed">17443518</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan TJ, Singla N, Daniels SE, et&#xa0;al. Cardiovascular safety of hydroxypropyl&#x2010;&#x3b2;&#x2010;cyclodextrin&#x2010;diclofenac in the management of acute postsurgical pain: a pooled analysis of 2 randomized, double&#x2010;blind, placebo&#x2010; and active comparator&#x2010;controlled phase III clinical trials. J Clin Anesth. 2016;31:249&#x2010;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27185721</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas KE, Fortes TA, Flom P, Manasseh DM, Andaz C, Borgen P. Intraoperative ketorolac use does not increase the risk of bleeding in breast surgery. Ann Surg Oncol. 2019;26:3368&#x2010;3373.</Citation><ArticleIdList><ArticleId IdType="pubmed">31342387</ArticleId></ArticleIdList></Reference><Reference><Citation>Naseem H&#x2010;U&#x2010;R, Dorman RM, Ventro G, Rothstein DH, Vali K. Safety of perioperative ketorolac administration in pediatric appendectomy. J Surg Res. 2017;218:232&#x2010;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">28985855</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J&#x2010;Y, Ko TL, Wen YR, et&#xa0;al. Opioid&#x2010;sparing effects of ketorolac and its correlation with the recovery of postoperative bowel function in colorectal surgery patients: a prospective randomized double&#x2010;blinded study. Clin J Pain. 2009;25:485&#x2010;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">19542795</ArticleId></ArticleIdList></Reference><Reference><Citation>Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN. Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Pharmacotherapy. 2015;35:520&#x2010;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">25940579</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase&#x2010;2. N Engl J Med. 2001;345:433&#x2010;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">11496855</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo&#x2010;oxygenase&#x2010;1 rather than cyclo&#x2010;oxygenase&#x2010;2 are associated with human gastrointestinal toxicity: a full in&#xa0;vitro analysis. Proc Natl Acad Sci. 1999;96:7563&#x2010;7568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22126</ArticleId><ArticleId IdType="pubmed">10377455</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzo J, Escolar G, Hern&#xe1;ndez M&#x2010;R, Gal&#xe1;n A&#x2010;M, Ordinas A. Prohemorrhagic potential of dipyrone, ibuprofen, ketorolac, and aspirin: mechanisms associated with blood flow and erythrocyte deformability. J Cardiovasc Pharmacol. 2001;38:183&#x2010;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483867</ArticleId></ArticleIdList></Reference><Reference><Citation>Shufflebarger JV, Doyle J, Roth T, Maguire K, Rothkopf DM. The effect of ketorolac on microvascular thrombosis in an experimental rabbit model. Plast Reconstr Surg. 1996;98:140&#x2010;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">8657765</ArticleId></ArticleIdList></Reference><Reference><Citation>Engoren M, Hadaway J, Schwann TA, Habib RH. Ketorolac improves graft patency after coronary artery bypass grafting: a propensity&#x2010;matched analysis. Ann Thorac Surg. 2011;92:603&#x2010;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">21801915</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker CSR, Hall RJC, Evans TJ, et&#xa0;al. Cyclooxygenase&#x2010;2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646&#x2010;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">10073969</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotfis K, Szyli&#x144;ska A, Listewnik M, et&#xa0;al. Balancing intubation time with postoperative risk in cardiac surgery patients&#x2014;A retrospective cohort analysis. TCRM. 2018;14:2203&#x2010;2212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6225847</ArticleId><ArticleId IdType="pubmed">30464493</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey ML, Richter SM, Mullany DV, Tesar PJ, Fraser JF. Risk factors and survival in patients with respiratory failure after cardiac operations. Ann Thorac Surg. 2011;92:1573&#x2010;1579.</Citation><ArticleIdList><ArticleId IdType="pubmed">21855851</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Jia Y, Wu X, et&#xa0;al. Early postoperative acetaminophen administration and severe acute kidney injury after cardiac surgery. Am J Kidney Dis. 2023;81:675.e1&#x2010;683.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">36586561</ArticleId></ArticleIdList></Reference><Reference><Citation>Demir T, Ergenoglu MU, Demir HB, et&#xa0;al. Pretreatment with methylprednisolone improves myocardial protection during on&#x2010;pump coronary artery bypass surgery. Heart Surg Forum. 2015;18:E171&#x2010;E177.</Citation><ArticleIdList><ArticleId IdType="pubmed">26334856</ArticleId></ArticleIdList></Reference><Reference><Citation>Polderman JA, Farhang&#x2010;Razi V, Van Dieren S, et&#xa0;al. Adverse side effects of dexamethasone in surgical patients. Cochrane Database Syst Rev. 2018;2019:CD011940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513495</ArticleId><ArticleId IdType="pubmed">30152137</ArticleId></ArticleIdList></Reference><Reference><Citation>Toner AJ, Ganeshanathan V, Chan MT, Ho KM, Corcoran TB. Safety of perioperative glucocorticoids in elective noncardiac surgery: a systematic review and meta&#x2010;analysis. Anesthesiology. 2017;126:234&#x2010;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">27922839</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34677198</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2308-3425</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Journal of cardiovascular development and disease</Title><ISOAbbreviation>J Cardiovasc Dev Dis</ISOAbbreviation></Journal><ArticleTitle>Meta-Analysis of Placebo-Controlled Trials of Levosimendan in Acute Myocardial Infarction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">129</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcdd8100129</ELocationID><Abstract><AbstractText>The treatment of acute myocardial infarction is early revascularization. Heart failure and cardiogenic shock may complicate acute myocardial infarction despite applying the best available strategy. Levosimendan is a relatively new drug to treat heart failure with a peculiar mechanism of action: calcium sensitization of myocardial fibres. Levosimendan has a direct inotropic effect but also pleiotropic effects; through the K+ATP channel's opening, it also has a vasodilator effect which may participate concretely in the global effects of the drug. The focus of the literature is on the anti-heart failure and anti-cardiogenic shock properties of Levosimendan, but it may have effects also preventing the development of myocardial insufficiency in acute myocardial infarction. The aim of the meta-analysis is to evaluate the effect of Levosimendan on acute myocardial infarction in placebo-controlled trials. Based on the eight studies selected, we found a beneficial effect of Levosimendan on acute and long-term mortality of patients affected by acute myocardial infarction. With caution in interpreting the results of this meta-analysis, our data support the idea that Levosimendan may already have a role in the treatment of acute ischemic heart disease. Further studies specifically designed to investigate the early role in the treatment of ischemic heart failure are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tumminello</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3121-8400</Identifier><AffiliationInfo><Affiliation>Cardiology Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cereda</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbieri</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8982-4898</Identifier><AffiliationInfo><Affiliation>Fondazione IRCCS C&#xe0; Granda Ospedale Maggiore Policlinico, Division of Cardiology, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biondi-Zoccai</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6103-8510</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mediterranea Cardiocentro, 80138 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucreziotti</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mafrici</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1941-9963</Identifier><AffiliationInfo><Affiliation>Cardiology Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carugo</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5166-0899</Identifier><AffiliationInfo><Affiliation>Fondazione IRCCS C&#xe0; Granda Ospedale Maggiore Policlinico, Division of Cardiology, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Cardiovasc Dev Dis</MedlineTA><NlmUniqueID>101651414</NlmUniqueID><ISSNLinking>2308-3425</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Levosimendan</Keyword><Keyword MajorTopicYN="N">acute heart failure</Keyword><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>22</Day><Hour>12</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34677198</ArticleId><ArticleId IdType="pmc">PMC8539734</ArticleId><ArticleId IdType="doi">10.3390/jcdd8100129</ArticleId><ArticleId IdType="pii">jcdd8100129</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2018;39:119&#x2013;177. doi: 10.1093/eurheartj/ehx393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx393</ArticleId><ArticleId IdType="pubmed">29198432</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Neumann F.J., Ferenc M., Olbrich H.G., Hausleiter J., Richardt G., Hennersdorf M., Empen K., Fuernau G., et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N. Engl. J. Med. 2012;367:1287&#x2013;1296. doi: 10.1056/NEJMoa1208410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208410</ArticleId><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Musial R., Moncznik P., Smialek P., Stolinski J., Sadowski J., Drwila R. Experience in application of therapies VA ECMO as short-term mechanical support of circulatory system of adult patients in cardiogenic shock. Kardiol. Pol. 2016;74:1477&#x2013;1484. doi: 10.5603/KP.a2016.0087.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/KP.a2016.0087</ArticleId><ArticleId IdType="pubmed">27221960</ArticleId></ArticleIdList></Reference><Reference><Citation>Metra M., Eichhorn E., Abraham W.T., Linseman J., B&#xf6;hm M., Corbalan R., DeMets D., De Marco T., Elkayam U., Gerber M., et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: The randomized, doubleblind, placebo-controlled, parallel group ESSENTIAL trials. Eur. Heart J. 2009;30:3015&#x2013;3026. doi: 10.1093/eurheartj/ehp338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehp338</ArticleId><ArticleId IdType="pmc">PMC2792716</ArticleId><ArticleId IdType="pubmed">19700774</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham W.T., Adams K.F., Fonarow G.C., Costanzo M.R., Berkowitz R.L., LeJemtel T.H., Cheng M.L., Wynne J., ADHERE Study Group In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J. Am. Coll. Cardiol. 2005;46:57&#x2013;64. doi: 10.1016/j.jacc.2005.03.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2005.03.051</ArticleId><ArticleId IdType="pubmed">15992636</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A., Parissis J., Porcher R., Gayat E., Nikolaou M., Boas F.V., Follath F. Short-term survival by treatment among patients hospitalized with acute heart failure: The global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37:290&#x2013;301. doi: 10.1007/s00134-010-2073-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-2073-4</ArticleId><ArticleId IdType="pubmed">21086112</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp I.&#xc9;.Z., De Hert S.G., Salmenper&#xe4; M., Leppikangas H., Follath F. Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. Int. J. Cardiol. 2012;159:82&#x2013;87. doi: 10.1016/j.ijcard.2011.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2011.07.022</ArticleId><ArticleId IdType="pubmed">21784540</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca L., Sardella G., Proietti P., Battagliese A., Benedetti G., Di Roma A., Fedele F. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: A Doppler echocardiographic study. J. Am. Soc. Echocardiogr. 2006;19:172&#x2013;177. doi: 10.1016/j.echo.2005.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2005.08.016</ArticleId><ArticleId IdType="pubmed">16455421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahit M.C., Kochar A., Granger C.B. Post-Myocardial Infarction Heart Failure. JACC Heart Fail. 2018;6:179&#x2013;186. doi: 10.1016/j.jchf.2017.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2017.09.015</ArticleId><ArticleId IdType="pubmed">29496021</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A., Altman D.G., Tetzlaff J., Mulrow C., G&#xf8;tzsche P.C., Ioannidis J.P. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136/bmj.b2700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Husebye T., Eritsland J., M&#xfc;ller C., Sandvik L., Arnesen H., Seljeflot I., Bj&#xf8;rnerheim R., Andersen G.&#xd8;. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: A randomized, placebo-controlled study. Eur. J. Heart Fail. 2013;15:565&#x2013;572. doi: 10.1093/eurjhf/hfs215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfs215</ArticleId><ArticleId IdType="pubmed">23288914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Wu J., Yan X., Zhang Y. Enhancement of myocardial function and reduction of injury with Levosimendan after percutaneous coronary intervention for acute myocardial infarction: A pilot study. Cardiology. 2014;128:202&#x2013;208. doi: 10.1159/000360933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000360933</ArticleId><ArticleId IdType="pubmed">24751502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonntag S., Sundberg S., Lehtonen L.A., Kleber F.X. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J. Am. Coll. Cardiol. 2004;43:2177&#x2013;2182. doi: 10.1016/j.jacc.2004.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2004.02.052</ArticleId><ArticleId IdType="pubmed">15193677</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiseyev V.S., P&#xf5;der P., Andrejevs N., Ruda M.Y., Golikov A.P., Lazebnik L.B., Kobalava Z.D., Lehtonen L.A., Laine T., Nieminen M.S., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur. Heart J. 2002;23:1422&#x2013;1432. doi: 10.1053/euhj.2001.3158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/euhj.2001.3158</ArticleId><ArticleId IdType="pubmed">12208222</ArticleId></ArticleIdList></Reference><Reference><Citation>Omerovic E., R&#xe5;munddal T., Albertsson P., Holmberg M., Hallgren P., Boren J., Grip L., Matejka G. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction. Vasc. Health Risk Manag. 2010;6:657&#x2013;663. doi: 10.2147/VHRM.S8856.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VHRM.S8856</ArticleId><ArticleId IdType="pmc">PMC2941779</ArticleId><ArticleId IdType="pubmed">20859537</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca L., Proietti P., Celotto A., Bucciarelli-Ducci C., Benedetti G., Di Roma A., Sardella G., Genuini I., Fedele F. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am. Heart J. 2005;150:563&#x2013;568. doi: 10.1016/j.ahj.2004.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2004.10.013</ArticleId><ArticleId IdType="pubmed">16169341</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Z., Guo M., Zhang Y.Q., Liang H.Q., Zhang L.Y., Song Y. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology. 2014;128:195&#x2013;201. doi: 10.1159/000357864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000357864</ArticleId><ArticleId IdType="pubmed">24751462</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo-Silberman S. Percutaneous coronary intervention in women: Is sex still an issue? Minerva Cardioangiol. 2020;68:393&#x2013;404. doi: 10.23736/S0026-4725.20.05203-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0026-4725.20.05203-2</ArticleId><ArticleId IdType="pubmed">32326680</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger C.B., Goldberg R.J., Dabbous O.M., Pieper K.S., Eagle K.A., Cannon C.P. Predictors of hospital mortality in the global registry of acute coronary events. Arch. Intern. Med. 2003;163:2345&#x2013;2353. doi: 10.1001/archinte.163.19.2345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.163.19.2345</ArticleId><ArticleId IdType="pubmed">14581255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadic M., Cuspidi C., Versaci F., Calcagno S. Right ventricular infarction: Can we still use old tricks? Minerva Cardioangiol. 2020 doi: 10.23736/S0026-4725.20.05412-2. Ahead of Print.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0026-4725.20.05412-2</ArticleId><ArticleId IdType="pubmed">33146483</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Huu A., Shum-Tim D. Intra-aortic balloon pump: Current evidence &amp; future perspectives. Future Cardiol. 2018;14:319&#x2013;328. doi: 10.2217/fca-2017-0070.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fca-2017-0070</ArticleId><ArticleId IdType="pubmed">29953264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingman L.V., Alekseev A.E., Hodgson-Zingman D.M., Terzic A. ATP-sensitive potassium channels: Metabolic sensing and cardioprotection. J. Appl. Physiol. (1985) 2007;103:1888&#x2013;1893. doi: 10.1152/japplphysiol.00747.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00747.2007</ArticleId><ArticleId IdType="pubmed">17641217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkia M., Stark C., Haavisto M., Kentala R., V&#xe4;h&#xe4;silta T., Savunen T. Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion. Heart. 2016;102:465&#x2013;471. doi: 10.1136/heartjnl-2015-308137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2015-308137</ArticleId><ArticleId IdType="pubmed">26762238</ArticleId></ArticleIdList></Reference><Reference><Citation>Levijoki J., Pollesello P., Kaheinen P., Haikala H. Improved survival with simendan after experimental myocardial infarction in rats. Eur. J. Pharmacol. 2001;419:243&#x2013;248. doi: 10.1016/S0014-2999(01)00997-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(01)00997-9</ArticleId><ArticleId IdType="pubmed">11426847</ArticleId></ArticleIdList></Reference><Reference><Citation>Louhelainen M., Vahtola E., Kaheinen P., Leskinen H., Merasto S., Kyt&#xf6; V. Effects of levosimendan on cardiac remodelling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br. J. Pharmacol. 2007;150:851&#x2013;861. doi: 10.1038/sj.bjp.0707157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0707157</ArticleId><ArticleId IdType="pmc">PMC2013885</ArticleId><ArticleId IdType="pubmed">17325658</ArticleId></ArticleIdList></Reference><Reference><Citation>Maytin M., Colucci W.S. Cardioprotection: A new paradigm in the management of acute heart failure syndromes. Am. J. Cardiol. 2005;96:26G&#x2013;31G. doi: 10.1016/j.amjcard.2005.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2005.07.018</ArticleId><ArticleId IdType="pubmed">16181820</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff D., Garan A.R., Kapur N.K.J. The SCAI Cardiogenic Shock Staging System Gets Taken for a Test Drive. Am. Coll. Cardiol. 2019;74:2129&#x2013;2131. doi: 10.1016/j.jacc.2019.08.1020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.08.1020</ArticleId><ArticleId IdType="pubmed">31548098</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34463361</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8191</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of cardiac surgery</Title><ISOAbbreviation>J Card Surg</ISOAbbreviation></Journal><ArticleTitle>Cardiogenic shock and machine learning: A systematic review on prediction through clinical decision support softwares.</ArticleTitle><Pagination><StartPage>4153</StartPage><EndPage>4159</EndPage><MedlinePgn>4153-4159</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.15934</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Cardiogenic shock (CS) withholds a significantly high mortality rate between 40% and 60% despite advances in diagnosis and medical/surgical intervention. To date, machine learning (ML) is being implemented to integrate numerous data to optimize early diagnostic predictions and suggest clinical courses. This systematic review summarizes the area under the curve (AUC) receiver operating characteristics (ROCs) accuracy for the early prediction of CS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review was conducted within databases of PubMed, ScienceDirect, Clinical Key/MEDLINE, Embase, GoogleScholar, and Cochrane. Cohort studies that assessed the accuracy of early detection of CS using ML software were included. Data extraction was focused on AUC-ROC values directed towards the early detection of CS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 943 studies were included for systematic review. From the reviewed studies, 2.2% (N&#x2009;=&#x2009;21) evaluated patient outcomes, of which 14.3% (N&#x2009;=&#x2009;3) were assessed. The collective patient cohort (N&#x2009;=&#x2009;698) consisted of 314 (45.0%) females, with an average age and body mass index of 64.1 years and 28.1&#x2009;kg/m<sup>2</sup> , respectively. Collectively, 159 (22.8%) mortalities were reported following early CS detection. Altogether, the AUC-ROC value was 0.82 (&#x3b1;&#x2009;=&#x2009;.05), deeming it of superb sensitivity and specificity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">From the present comprehensively gathered data, this study accounts the use of ML software for the early detection of CS in a clinical setting as a valid tool to predict patients at risk of CS. The complexity of ML and its parallel lack of clinical evidence implies that further prospective randomized control trials are needed to draw definitive conclusions before standardizing the use of these technologies.</AbstractText><AbstractText Label="BRIEF SUMMARY" NlmCategory="METHODS">The catastrophic risk of developing CS continues to be a concern in the management of critical cardiac care. The use of ML predictive models have the potential to provide the accurate and necessary feedback for the early detection and proper management of CS. This systematic review summarizes the AUC-ROCs accuracy for the early prediction of CS.</AbstractText><CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aleman</LastName><ForeName>Rene</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Florida, Weston, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Sinal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Florida, Weston, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleiman</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cleveland Clinic Florida, Weston, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navia</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Florida, Weston, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheffield</LastName><ForeName>Cedric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Florida, Weston, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brozzi</LastName><ForeName>Nicolas A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0003-2570-324X</Identifier><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Florida, Weston, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Surg</MedlineTA><NlmUniqueID>8908809</NlmUniqueID><ISSNLinking>0886-0440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020000" MajorTopicYN="Y">Decision Support Systems, Clinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">area under the curve</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">early detection</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">receiving operating characteristics</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34463361</ArticleId><ArticleId IdType="doi">10.1111/jocs.15934</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>de Waha S, Fuernau G, Desch S, et al. Long-term prognosis after extracorporeal life support in refractory cardiogenic shock: results from a real-world cohort. EuroIntervention. 2016;11(12):1363-1371. https://doi.org/10.4244/EIJV11I12A265</Citation></Reference><Reference><Citation>Kunadian V, Qiu W, Ludman P, et al. Outcomes in patients with cardiogenic shock following percutaneous coronary intervention in the contemporary era: an analysis from the BCIS database (British Cardiovascular Intervention Society). JACC Cardiovasc Interv. 2014;7(12):1374-1385. https://doi.org/10.1016/j.jcin.2014.06.017</Citation></Reference><Reference><Citation>Li X, Sousa-Casasnovas I, Devesa C, Ju&#xe1;rez M, Fern&#xe1;ndez-Avil&#xe9;s F, Mart&#xed;nez-Sell&#xe9;s M. Predictors of in-hospital mortality among cardiogenic shock patients. Prognostic and therapeutic implications. Int J Cardiol. 2016;224:114-118. https://doi.org/10.1016/j.ijcard.2016.09.019</Citation></Reference><Reference><Citation>Schiller P, Vikholm P, Hellgren L. The Impella&#xae; Recover mechanical assist device in acute cardiogenic shock: a single-centre experience of 66 patients. Interact Cardiovasc Thorac Surg. 2016;22(4):452-458. https://doi.org/10.1093/icvts/ivv305</Citation></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann F-J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287-1296. https://doi.org/10.1056/NEJMoa1208410</Citation></Reference><Reference><Citation>Tomcikova D, Felsoci M, Spinar J, et al. Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: classification tree analysis on data from the Acute Heart Failure Database-Main registry. J Crit Care. 2013;28(3):250-258. https://doi.org/10.1016/j.jcrc.2012.09.014</Citation></Reference><Reference><Citation>Puymirat E, Fagon JY, Aegerter P, et al. Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997-2012. Eur J Heart Fail. 2017;19(2):192-200. https://doi.org/10.1002/ejhf.646</Citation></Reference><Reference><Citation>Munir MB, Sharbaugh MS, Thoma FW, et al. Trends in hospitalization for congestive heart failure, 1996-2009. Clin Cardiol. 2017;40(2):109-119. https://doi.org/10.1002/clc.22638</Citation></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. https://doi.org/10.1136/bmj.g7647</Citation></Reference><Reference><Citation>Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8(4):283-298. https://doi.org/10.1016/s0001-2998(78)80014-2</Citation></Reference><Reference><Citation>Hosmer DW Jr., Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. Wiley; 2013.</Citation></Reference><Reference><Citation>What types of studies are there? In: Institute for Quality and Efficiency in Health Care (IQWiG); 2016. Accessed July 27, 2021. https://www.ncbi.nlm.nih.gov/books/NBK390304/</Citation></Reference><Reference><Citation>Silcox C, Dentzer S, Bates DW. AI-enabled clinical decision support software: a &#x201c;trust and value checklist&#x201d; for clinicians. NEJM Catalyst. 2020;1(6). 1-14. https://doi.org/10.1056/cat.20.0212</Citation></Reference><Reference><Citation>Ganguli I, Gordon WJ, Lupo C, et al. Machine learning and the pursuit of high-value health care. NEJM Catalyst. 2020;1(6). 1-14. https://doi.org/10.1056/cat.20.0094</Citation></Reference><Reference><Citation>Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347-1358. https://doi.org/10.1056/nejmra1814259</Citation></Reference><Reference><Citation>Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317-1318. https://doi.org/10.1001/jama.2017.18391</Citation></Reference><Reference><Citation>Ohno-Machado L. Realizing the full potential of electronic health records: the role of natural language processing. J Am Med Inform Assoc. 2011;18(5):539. https://doi.org/10.1136/amiajnl-2011-000501</Citation></Reference><Reference><Citation>Demner-Fushman D, Chapman WW, McDonald CJ. What can natural language processing do for clinical decision support? J Biomed Inf. 2009;42(5):760-772. https://doi.org/10.1016/j.jbi.2009.08.007</Citation></Reference><Reference><Citation>Morse KE, Bagley SC, Shah NH. Author correction: estimate the hidden deployment cost of predictive models to improve patient care. Nat Med. 2020;26(5):803. https://doi.org/10.1038/s41591-020-0862-z</Citation></Reference><Reference><Citation>Heaven WD. Google's medical AI was super accurate in a lab. Real life was a different story. MIT Technology Review; 2020. Accessed July 28, 2021. https://www.technologyreview.com/2020/04/27/1000658/google-medical-ai-accurate-lab-real-life-clinic-covid-diabetes-retina-disease/</Citation></Reference><Reference><Citation>Basir MB, Kapur NK, Patel K, et al. Improved outcomes associated with the use of shock protocols: updates from the National Cardiogenic Shock initiative. Catheter Cardiovasc Interv. 2019;93(7):1173-1183. https://doi.org/10.1002/ccd.28307</Citation></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv. 2019;94(1):29-37. https://doi.org/10.1002/ccd.28329</Citation></Reference><Reference><Citation>Rahman F, Finkelstein N, Alyakin A, et al. Using machine learning for early prediction of cardiogenic shock in patients with acute heart failure; 2021. https://doi.org/10.21203/rs.3.rs-453102/v1. Accessed July 13, 2021.</Citation></Reference><Reference><Citation>Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree analysis. ACC Curr J Rev. 2005;14(4):34. https://doi.org/10.1016/j.accreview.2005.02.073</Citation></Reference><Reference><Citation>Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010;3(1):25-32. https://doi.org/10.1161/CIRCOUTCOMES.109.854877</Citation></Reference><Reference><Citation>Spinar J, Parenica J, Vitovec J, et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care. 2011;15(6):R291. https://doi.org/10.1186/cc10584</Citation></Reference><Reference><Citation>Lagu T, Pekow PS, Shieh M-S, et al. Validation and comparison of seven mortality prediction models for hospitalized patients with acute decompensated heart failure. Circ Heart Fail. 2016;9(8). 1-10. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002912</Citation></Reference><Reference><Citation>Pickering BW, Dong Y, Ahmed A, et al. The implementation of clinician designed, human-centered electronic medical record viewer in the intensive care unit: a pilot step-wedge cluster randomized trial. Int J Med Inform. 2015;84(5):299-307. https://doi.org/10.1016/j.ijmedinf.2015.01.017</Citation></Reference><Reference><Citation>Pinevich Y, Amos-Binks A, Burris CS, et al. Validation of a Machine Learning Model for early shock detection. Mil Med. Published online May 29; 2021. https://doi.org/10.1093/milmed/usab220</Citation></Reference><Reference><Citation>Calvillo-Arg&#xfc;elles O, Sierra-Fern&#xe1;ndez CR, Padilla-Ibarra J, et al. Integrating the STOP-BANG Score and clinical data to predict cardiovascular events after infarction: a machine learning study. Chest. 2020;158(4):1669-1679. https://doi.org/10.1016/j.chest.2020.03.074</Citation></Reference><Reference><Citation>Chung F, Abdullah HR, Liao P. STOP-Bang Questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149(3):631-638. https://doi.org/10.1378/chest.15-0903</Citation></Reference><Reference><Citation>Meune C, Drexler B, Haaf P, et al. The GRACE score's performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. Heart. 2011;97(18):1479-1483. https://doi.org/10.1136/hrt.2010.220988</Citation></Reference><Reference><Citation>Eagle KA, Lim MJ, Dabbous OH. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-Aug postdischarge death in an international registry. ACC Curr J Rev. 2004;13(8):9. https://doi.org/10.1016/j.accreview.2004.07.119</Citation></Reference><Reference><Citation>Juarez-Orozco LE, Knol RJJ, Sanchez-Catasus CA, Martinez-Manzanera O, van der Zant FM, Knuuti J. Machine learning in the integration of simple variables for identifying patients with myocardial ischemia. J Nucl Cardiol. 2020;27(1):147-155. https://doi.org/10.1007/s12350-018-1304-x</Citation></Reference><Reference><Citation>Motwani M, Dey D, Berman DS, et al. Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis. Eur Heart J. 2017;38(7):500-507. https://doi.org/10.1093/eurheartj/ehw188</Citation></Reference><Reference><Citation>Arsanjani R, Xu Y, Dey D, et al. Improved accuracy of myocardial perfusion SPECT for detection of coronary artery disease by machine learning in a large population. J Nucl Cardiol. 2013;20(4):553-562. https://doi.org/10.1007/s12350-013-9706-2</Citation></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295(21):2511-2515. https://doi.org/10.1001/jama.295.21.2511</Citation></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341(9):625-634. https://doi.org/10.1056/NEJM199908263410901</Citation></Reference><Reference><Citation>Mao Q, Jay M, Hoffman JL, et al. Multicentre validation of a sepsis prediction algorithm using only vital sign data in the emergency department, general ward and ICU. BMJ Open. 2018;8(1):e017833. https://doi.org/10.1136/bmjopen-2017-017833</Citation></Reference><Reference><Citation>Brown SM, Jones J, Kuttler KG, Keddington RK, Allen TL, Haug P. Prospective evaluation of an automated method to identify patients with severe sepsis or septic shock in the emergency department. BMC Emerg Med. 2016;16(1):31. https://doi.org/10.1186/s12873-016-0095-0</Citation></Reference><Reference><Citation>Hyland SL, Faltys M, H&#xfc;ser M, et al. Early prediction of circulatory failure in the intensive care unit using machine learning. Nat Med. 2020;26(3):364-373. https://doi.org/10.1038/s41591-020-0789-4</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29126662</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5727</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Medicina intensiva</Title><ISOAbbreviation>Med Intensiva (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis.</ArticleTitle><Pagination><StartPage>409</StartPage><EndPage>415</EndPage><MedlinePgn>409-415</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medin.2017.08.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5691(17)30283-8</ELocationID><Abstract><AbstractText Label="PURPOSE">Cardiac shock is the leading cause of death in patients with acute myocardial infarction. The objective of this systematic review and meta-analysis was to evaluate whether levosimendan, compared to any type of control, is associated with improved clinical outcomes in patients with cardiogenic shock complicating myocardial infarction.</AbstractText><AbstractText Label="MATERIALS AND METHODS">The PubMed, EMBASE, Cochrane Central Register, and China National Knowledge Information databases were searched for pertinent studies published up until 1 May 2016. Randomized and non-randomized clinical trials comparing levosimendan to standard therapy or placebo, in adult patients with cardiogenic shock complicating myocardial infarction, and reporting at least one outcome of interest were included. The primary outcome was mortality, whereas secondary outcomes were length of ICU stay, SOFA score, cardiac index (CI), cardiac power index (CPI), ejection fraction (EF), end-systolic volume (ESV), mean blood pressure (MBP), pulmonary arterial pressure (PAP), mixed venous oxygen saturation (SvO<sub>2</sub>), pulmonary artery occlusion pressure (PAOP) and glomerular filtration rate (GFR). We pooled risk ratio (RR) and 95% confidence interval (CI) using fixed and random effects models.</AbstractText><AbstractText Label="RESULTS">Thirteen studies comprising a total of 648 patients were included in the analysis. There was a nonsignificant reduction in mortality with levosimendan compared to the controls (RR=0.82 [0.65-1.01], P for effect=0.07, I<sup>2</sup>=0%). In the levosimendan group PAP and ESV were significantly reduced, while CI, CPI, EF, MBP and SvO<sub>2</sub> were significantly increased. No differences in SOFA score, ICU days, PAOP or GFR were noted.</AbstractText><AbstractText Label="CONCLUSIONS">Levosimendan can improve hemodynamic parameters and cardiac function when compared with a control group, with no evidence of benefit in terms of survival.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Espa&#xf1;a, S.L.U. y SEMICYUC. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, 3rd Hospital of HeBei Medical University, Shi Jiazhuang, China; Department of Anaesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, 3rd Hospital of HeBei Medical University, Shi Jiazhuang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, 3rd Hospital of HeBei Medical University, Shi Jiazhuang, China. Electronic address: 18533112993@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Intensiva (Engl Ed)</MedlineTA><NlmUniqueID>101717568</NlmUniqueID><ISSNLinking>2173-5727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Choque cardiog&#xe9;nico</Keyword><Keyword MajorTopicYN="N">Infarto de miocardio</Keyword><Keyword MajorTopicYN="N">Levosimendan</Keyword><Keyword MajorTopicYN="N">Levosimend&#xe1;n</Keyword><Keyword MajorTopicYN="N">Mortalidad</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29126662</ArticleId><ArticleId IdType="doi">10.1016/j.medin.2017.08.009</ArticleId><ArticleId IdType="pii">S0210-5691(17)30283-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38631341</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1940-5596</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Seminars in cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>Semin Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>Noteworthy in Cardiothoracic Surgery 2023.</ArticleTitle><Pagination><StartPage>100</StartPage><EndPage>105</EndPage><MedlinePgn>100-105</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/10892532241246037</ELocationID><Abstract><AbstractText>Noteworthy in Cardiothoracic Surgery 2023 summarizes a few of the most high-impact trials and provocative trends in cardiothoracic surgery and transplantation this past year. Transplantation using organs procured from donation after circulatory death (DCD) continues to increase, and the American Society of Transplant Surgeons released recommendations on best practices in 2023. We review a summary of data on the impact of DCD on heart and lung transplantation. There has been increased interest in extracorporeal life support (ECLS), particularly after the COVID-19 pandemic, and we review the results of the highly discussed ECLS-SHOCK trial, which randomized patients in cardiogenic shock with planned revascularization to ECLS vs usual care. With improving survival outcomes in complex aortic surgery, there is a need for higher-quality evidence to guide which cooling and cerebral perfusion strategies may optimize cognitive outcomes in these patients. We review the short-term outcomes of the GOT ICE trial (Cognitive Effects of Body Temperature During Hypothermic Circulatory Arrest), a multicenter, randomized controlled trial of three different nadir temperatures, evaluating outcomes in cognition and associated changes in functional magnetic resonance imaging. Finally, both the Society of Thoracic Surgeons (STS) and the American College of Cardiology, American Heart Association, American College of Chest Physicians and Heart Rhythm Society (ACC/AHA/ACCP/HRS) updated atrial fibrillation guidelines in 2023, and we review surgically relevant updates to the guidelines and the evidence behind them.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rove</LastName><ForeName>Jessica Y</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0009-0005-9930-7583</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation><Identifier Source="RINGGOLD">129263</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cain</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation><Identifier Source="RINGGOLD">129263</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>Jordan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation><Identifier Source="RINGGOLD">129263</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reece</LastName><ForeName>T Brett</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation><Identifier Source="RINGGOLD">129263</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9807630</NlmUniqueID><ISSNLinking>1089-2532</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019616" MajorTopicYN="N">Thoracic Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016027" MajorTopicYN="N">Heart Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016040" MajorTopicYN="N">Lung Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac surgery</Keyword><Keyword MajorTopicYN="N">cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">circulatory arrest</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">thoracic surgery</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>11</Day><Hour>19</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>18</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>17</Day><Hour>18</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38631341</ArticleId><ArticleId IdType="doi">10.1177/10892532241246037</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23944202</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1441-2772</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine</Title><ISOAbbreviation>Crit Care Resusc</ISOAbbreviation></Journal><ArticleTitle>A meta-analysis of complications and mortality of extracorporeal membrane oxygenation.</ArticleTitle><Pagination><StartPage>172</StartPage><EndPage>178</EndPage><MedlinePgn>172-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To comprehensively assess published peer-reviewed studies related to extracorporeal membrane oxygenation (ECMO), focusing on outcomes and complications of ECMO in adult patients.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Systematic review and meta-analysis.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">MEDLINE/PubMed was searched for articles on complications and mortality occurring during or after ECMO.</AbstractText><AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">Included studies had more than 100 patients receiving ECMO and reported in detail fatal or nonfatal complications occurring during or after ECMO. Primary outcome was mortality at the longest follow-up available; secondary outcomes were fatal and non-fatal complications.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Twelve studies were included (1763 patients), mostly reporting on venoarterial ECMO. Criteria for applying ECMO were variable, but usually comprised acute respiratory failure, cardiogenic shock or both. After a median follow-up of 30 days (1st-3rd quartile, 30-68 days), overall mortality was 54% (95% CI, 47%-61%), with 45% (95% CI, 42%-48%) of fatal events occurring during ECMO and 13% (95% CI, 11%-15%) after it. The most common complications associated with ECMO were: renal failure requiring continuous venovenous haemofiltration (occurring in 52%), bacterial pneumonia (33%), any bleeding (33%), oxygenator dysfunction requiring replacement (29%), sepsis (26%), haemolysis (18%), liver dysfunction (16%), leg ischaemia (10%), venous thrombosis (10%), central nervous system complications (8%), gastrointestinal bleeding (7%), aspiration pneumonia (5%), and disseminated intravascular coagulation (5%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Even with conditions usually associated with a high chance of death, almost 50% of patients receiving ECMO survive up to discharge. Complications are frequent and most often comprise renal failure, pneumonia or sepsis, and bleeding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zangrillo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Biondi-Zoccai</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Frati</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Patroniti</LastName><ForeName>Nicol&#xf2;</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pesenti</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Crit Care Resusc</MedlineTA><NlmUniqueID>100888170</NlmUniqueID><ISSNLinking>1441-2772</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23944202</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30142110</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1559-0879</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Season>Jul/Aug</Season></PubDate></JournalIssue><Title>Innovations (Philadelphia, Pa.)</Title><ISOAbbreviation>Innovations (Phila)</ISOAbbreviation></Journal><ArticleTitle>Outcomes of Impella 5.0 in Cardiogenic Shock: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>254</StartPage><EndPage>260</EndPage><MedlinePgn>254-260</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/IMI.0000000000000535</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the study was to comprehensively summarize the survival outcomes and complications of Impella 5.0 (Abiomed Inc, Danvers, MA USA) use in patients with cardiogenic shock (CS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a literature review for relevant studies by searching in Medline, Medline In-Process, EMBASE, and the CENTRAL bibliographic databases on April 30, 2017. Nonoverlapping studies with 10 patients or more supported for cardiogenic shock with Impella 5.0 or Impella left direct were included. Data on patient characteristics, indication of support, and outcomes were extracted. A random effect was used to pool the various outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This meta-analysis included six studies totaling 163 patients (mean &#xb1; SD age = 56.3 &#xb1; 12.0, male 81%). Indications for support included 88 (54.0%) for acute on chronic decompensated heart failure, 35 (21.5%) for postcardiotomy cardiogenic shock, 27 (16.6%) for acute myocardial infarction complicated by cardiogenic shock, and, 13 (8.0%) for cardiogenic shock due to other reasons. Survival to next therapy was 73.5% in patients supported for acute on chronic decompensated heart failure. The survival to device explant among patients supported for postcardiotomy cardiogenic shock or acute myocardial infarction complicated by cardiogenic shock was 90.2%, and of those, myocardial recovery was achieved in 73.8%. The overall estimated survival to discharge, 30, 180, and 365 days was 73.5%, 72.6%, 62.7%, and 58.4%, respectively. Patients supported for postcardiotomy cardiogenic shock had the highest heart recovery among survivors to explant (92.1%) and highest survival at 30 (89.5%) and 365 days (69.5%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Impella 5.0/LD is associated with favorable survival outcomes and higher rate of myocardial recovery in patients with cardiogenic shock.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Batsides</LastName><ForeName>George</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Massaro</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Anson</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Saint Paul's Hospital, University of British Columbia, Vancouver, BC Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltesz</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramzy</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Division of Cardiothoracic Surgery, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Innovations (Phila)</MedlineTA><NlmUniqueID>101257528</NlmUniqueID><ISSNLinking>1556-9845</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30142110</ArticleId><ArticleId IdType="doi">10.1097/IMI.0000000000000535</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35144785</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1876-7605</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>JACC. Cardiovascular interventions</Title><ISOAbbreviation>JACC Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Comparative Analysis of Patient Characteristics in Cardiogenic Shock Studies: Differences Between Trials and Registries.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>304</EndPage><MedlinePgn>297-304</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcin.2021.11.036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1936-8798(21)02143-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES">This study sought to evaluate the differences in cardiogenic shock patient characteristics in trial patients and real-life patients.</AbstractText><AbstractText Label="BACKGROUND">Cardiogenic shock (CS) is a leading cause of mortality in patients presenting with acute myocardial infarction (AMI). However, the enrollment of patients into clinical trials is challenging and may not be representative of real-world patients.</AbstractText><AbstractText Label="METHODS">We performed a systematic review of studies in patients presenting with AMI-related CS and compared patient characteristics of those enrolled into randomized controlled trials (RCTs) with those in registries.</AbstractText><AbstractText Label="RESULTS">We included 14 RCTs (n&#xa0;=&#xa0;2,154) and 12 registries (n&#xa0;=&#xa0;133,617). RCTs included more men (73% vs 67.7%, P&#xa0;&lt;&#xa0;0.001) compared with registries. Patients enrolled in RCTs had fewer comorbidities, including less hypertension (61.6% vs 65.9%, P&#xa0;&lt; 0.001), dyslipidemia (36.4% vs 53.6%, P&#xa0;&lt; 0.001), a history of stroke or transient ischemic attack (7.1% vs 10.7%, P&#xa0;&lt; 0.001), and prior coronary artery bypass graft surgery (5.4% vs 7.5%, P&#xa0;&lt; 0.001). Patients enrolled in RCTs also had lower lactate levels (4.7 &#xb1; 2.3 mmol/L vs 5.9 &#xb1; 1.9&#xa0;mmol/L, P&#xa0;&lt; 0.001) and higher mean arterial pressure (73.0 &#xb1; 8.8 mm Hg vs 62.5 &#xb1; 12.2&#xa0;mm&#xa0;Hg, P&#xa0;&lt; 0.001). Percutaneous coronary intervention (97.5% vs 58.4%, P&#xa0;&lt; 0.001) and extracorporeal membrane oxygenation (11.6% vs 3.4%, P&#xa0;&lt; 0.001) were used more often in RCTs. The&#xa0;in-hospital mortality (23.9% vs 38.4%, P&#xa0;&lt; 0.001) and 30-day mortality (39.9% vs 45.9%, P&#xa0;&lt; 0.001) were lower in&#xa0;RCT patients.</AbstractText><AbstractText Label="CONCLUSIONS">RCTs in AMI-related CS tend to enroll fewer women and lower-risk patients compared with registries. Patients enrolled in RCTs are more likely to receive aggressive treatment with percutaneous coronary intervention and extracorporeal membrane oxygenation and have lower in-hospital and 30-day mortality.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Megaly</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Henry Ford Hospital, Detroit, Michigan, USA. Electronic address: michaelmegaly3@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buda</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alaswad</LastName><ForeName>Khaldoon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Henry Ford Hospital, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brilakis</LastName><ForeName>Emmanouil S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupont</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Northside Hospital, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>Srihari</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Westchester Medical Center, Valhalla, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohman</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Duke Medical Center, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napp</LastName><ForeName>L Christian</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Henry Ford Hospital, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basir</LastName><ForeName>Mir B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Henry Ford Hospital, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Cardiovasc Interv</MedlineTA><NlmUniqueID>101467004</NlmUniqueID><ISSNLinking>1936-8798</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JACC Cardiovasc Interv. 2022 Feb 14;15(3):305-307. doi: 10.1016/j.jcin.2021.12.016.</RefSource><PMID Version="1">35144786</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">real-world data</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures Dr Basir is a consultant/speaker for Abbott Vascular, Abiomed, Cardiovascular Systems, Chiesi, Procyrion, and Zoll. Dr Alaswad has received honoraria for consulting/speaking from Boston Scientific, Cardiovascular Systems Inc, LivaNova, and Teleflex. Dr Brilakis has received honoraria for consulting/speaking from Abbott Vascular, American Heart Association (associate editor Circulation), Amgen, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, Cardiovascular Systems Inc, Ebix, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder of MHI Ventures. Dr Napp has received honoraria for lecturing/consulting and has received research support from Cytosorbents; has received honoraria for lecturing from Abbott and Maquet; and has received&#xa0;honoraria for lecturing/proctoring/consulting and research funding from Abiomed. Dr O&#x2019;Neill is a consultant/speaker for Abbott Vascular, Abiomed, Boston Scientific, Edwards, and Zoll. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35144785</ArticleId><ArticleId IdType="doi">10.1016/j.jcin.2021.11.036</ArticleId><ArticleId IdType="pii">S1936-8798(21)02143-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34713720</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8298</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Future cardiology</Title><ISOAbbreviation>Future Cardiol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of Impella 5.0 in cardiogenic shock: an updated systematic review.</ArticleTitle><Pagination><StartPage>253</StartPage><EndPage>264</EndPage><MedlinePgn>253-264</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/fca-2021-0046</ELocationID><Abstract><AbstractText><b>Aim:</b> The impact on safety and efficacy outcomes of Impella 5.0 in cardiogenic shock (CS) has not been systematically assessed. <b>Materials &amp; methods:</b> We conducted a systematic review of the literature (PROSPERO protocol: CRD42020164680) to critically appraise available evidence on Impella 5.0 comparative safety, efficacy and effectiveness. <b>Results:</b> Of 244 retrieved citations, 17 original articles met the <i>a priori</i> defined inclusion criteria. All included studies had a retrospective study design and, overall, reported on, respectively, 52 and 67 different safety and efficacy/effectiveness outcomes. Thirty-day survival rates ranged from 40 to 94%, myocardial recovery from 18 to 93%. <b>Conclusion:</b> Impella 5.0 provides a full cardiac support, it is associated with a lower rate of vascular complications, it represents a valuable bridge-to-decision and allows for resolution of intercurrent clinical conditions. As available data suggest Impella 5.0 good performance in CS of various etiologies, more solid evidence will come from much-needed large-scale all-comer registries and prospective multicenter randomized trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bossi</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7421-6053</Identifier><AffiliationInfo><Affiliation>HTA Committee, Health Directorate, IRCCS San Raffaele Hospital, Milan, 20132, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Vita-Salute San Raffaele University, Milan, 20132, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7511-9012</Identifier><AffiliationInfo><Affiliation>Advanced Heart Failure &amp; Mechanical Circulatory Support Program, IRCCS San Raffaele Hospital, Milan, 20132, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of&#xa0;Cardiovascular, ASST Santi Paolo e Carlo, Milan, 20142, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaetti</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5464-5822</Identifier><AffiliationInfo><Affiliation>HTA Committee, Health Directorate, IRCCS San Raffaele Hospital, Milan, 20132, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Vita-Salute San Raffaele University, Milan, 20132, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamanti</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>HTA Committee, Health Directorate, IRCCS San Raffaele Hospital, Milan, 20132, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alessio</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>HTA Committee, Health Directorate, IRCCS San Raffaele Hospital, Milan, 20132, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoldi</LastName><ForeName>Letizia Fausta</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Advanced Heart Failure &amp; Mechanical Circulatory Support Program, IRCCS San Raffaele Hospital, Milan, 20132, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of&#xa0;Cardiovascular, Humanitas Clinical &amp; Research Center IRCCS, Rozzano, 20089, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9129-833X</Identifier><AffiliationInfo><Affiliation>Advanced Heart Failure &amp; Mechanical Circulatory Support Program, IRCCS San Raffaele Hospital, Milan, 20132, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic &amp; Vascular Anesthesia &amp; Intensive Care, AO SS Antonio e Biagio e Cesare Arrigo, 15121, Alessandria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odone</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5657-9774</Identifier><AffiliationInfo><Affiliation>HTA Committee, Health Directorate, IRCCS San Raffaele Hospital, Milan, 20132, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, Experimental &amp; Forensic Medicine, University of Pavia, Pavia, 27100, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Future Cardiol</MedlineTA><NlmUniqueID>101239345</NlmUniqueID><ISSNLinking>1479-6678</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Cardiogenic shock (CS) is a life-threatening condition in which the heart cannot pump enough blood to meet&#xa0;the body's needs. Despite advances in biomedical research and technology, CS is still associated with high mortality. Some devices (Intra-aortic balloon pump (IABP), Impella, Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO), placed through vascular accesses, can support the heart in the failing phase. The aim of this systematic review of the scientific literature is to evaluate safety, efficacy and effectiveness of Impella 5.0 in CS.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">INTERMACS 1</Keyword><Keyword MajorTopicYN="N">Impella 5.0</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>8</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34713720</ArticleId><ArticleId IdType="doi">10.2217/fca-2021-0046</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26683930</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>50</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: A Systematic Analytical Review.</ArticleTitle><Pagination><StartPage>e2198</StartPage><MedlinePgn>e2198</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2198</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000002198</ELocationID><Abstract><AbstractText>Pheochromocytoma and paraganglioma (PPG) are rare and late-diagnosed catecholamine secreting tumors, which may be associated with unrecognized and/or severe cardiomyopathies. We performed a computer-assisted systematic search of the electronic Medline databases using the MESH terms "myocarditis," "myocardial infarction," "Takotsubo," "stress cardiomyopathy," "cardiogenic shock", or "dilated cardiomyopathy," and "pheochromocytoma" or "paraganglioma" from 1961 to August 2012. All detailed case reports of cardiomyopathy due to a PPG, without coronary stenosis, and revealed by acute symptoms were included and analyzed. A total of 145 cases reports were collected (49 Takotsubo Cardiomyopathies [TTC] and 96 other Catecholamine Cardiomyopathies [CC]). At initial presentation, prevalence of high blood pressure (87.7%), chest pain (49.0%), headaches (47.6%), palpitations (46.9%), sweating (39.3%), and shock (51.0%) were comparable between CC and TTC. Acute pulmonary edema (58.3% vs 38.8%, P&#x200a;=&#x200a;0.03) was more frequent in CC. There was no difference in proportion of patients with severe left ventricular systolic dysfunction (LV Ejection Fraction [LVEF]&#x200a;&lt;&#x200a;30%) at initial presentation between both groups (P&#x200a;=&#x200a;0.15). LVEF recovery before (64.9% vs 40.8%, P&#x200a;=&#x200a;0.005) and after surgical resection (97.7% vs 73.3%, P&#x200a;=&#x200a;0.001) was higher in the TTC group. Death occurred in 11 cases (7.6%). In multivariate analysis, only TTC was associated with a better LV recovery (0.15 [0.03-0.67], P&#x200a;=&#x200a;0.03). Pheochromocytoma and paraganglioma can lead to different cardiomyopathies with the same brutal and life-threatening initial clinical presentation but with a different recovery rate. Diagnosis of unexplained dilated cardiomyopathy or TTC should lead clinicians to a specific search for PPG.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Batisse-Lignier</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the CHU Clermont-Ferrand, Endocrinology Department, Clermont-Ferrand, France (MB-L, CB, SM, BR, FD, IT); CNRS UMR 6293, Inserm GReD, Clermont-Ferrand, France (MB-L, SM, IT); CHU Clermont-Ferrand, Biostatistics unit (Clinical Research and Innovation Direction), Clermont-Ferrand, France (BP); and Clermont Universit&#xe9;, Universit&#xe9; d'Auvergne, Cardio Vascular Interventional Therapy and Imaging (CaVITI), Image Science for Interventional Techniques (ISIT), UMR6284, and CHU Clermont-Ferrand, Cardiology Department, Clermont-Ferrand, France (PM, RP, CV, GC, BC, J-RL, RE).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Motreff</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pierrard</LastName><ForeName>Romain</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Burnot</LastName><ForeName>Christelle</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vorilhon</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Maqdasy</LastName><ForeName>Salwan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Roche</LastName><ForeName>B&#xe9;atrice</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Desbiez</LastName><ForeName>Francoise</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Clerfond</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Citron</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lusson</LastName><ForeName>Jean-Ren&#xe9;</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Tauveron</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Eschalier</LastName><ForeName>Romain</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Cardiol. 2016 Mar 15;207:132-3. doi: 10.1016/j.ijcard.2016.01.127.</RefSource><PMID Version="1">26800136</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000310" MajorTopicYN="N">Adrenal Gland Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="N">Cardiomyopathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010673" MajorTopicYN="N">Pheochromocytoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26683930</ArticleId><ArticleId IdType="pmc">PMC5058902</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000002198</ArticleId><ArticleId IdType="pii">00005792-201512150-00025</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lenders JWM, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet 2005; 366:665&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">16112304</ArticleId></ArticleIdList></Reference><Reference><Citation>Amar L, Servais A, Gimenez-Roqueplo A-P, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90:2110&#x2013;2116.</Citation><ArticleIdList><ArticleId IdType="pubmed">15644401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JA, Duh Q-Y. Sporadic paraganglioma. World J Surg 2008; 32:683&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">18224469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjuric M, Gleeson M. Consensus statement and guidelines on the management of paragangliomas of the head and neck. Skull Base 2009; 19:109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637566</ArticleId><ArticleId IdType="pubmed">19568348</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca F, Holl N, Vinzio S, et al. Manifestations cardiaques des ph&#xe9;ochromocytomes. Ann Endocrinol 2009; 70:43&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">19150713</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelinka T, Petr&#xe1;k O, Turkov&#xe1; H, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res 2012; 44:379&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">22517556</ArticleId></ArticleIdList></Reference><Reference><Citation>Coupez E, Eschalier R, Pereira B, et al. A single pathophysiological pathway in Takotsubo cardiomyopathy: catecholaminergic stress. Arch Cardiovasc Dis 2014; 107:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">24796853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittstein IS, Thiemann DR, Lima JAC, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005; 352:539&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittstein IS. Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? Cell Mol Neurobiol 2012; 32:847&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11498407</ArticleId><ArticleId IdType="pubmed">22297544</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilgrim TM, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: a systematic review. Int J Cardiol 2008; 124:283&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">17651841</ArticleId></ArticleIdList></Reference><Reference><Citation>Milinis K, Fisher M. Takotsubo cardiomyopathy: pathophysiology and treatment. Postgrad Med J 2012; 88:530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">22647668</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V, Kant G, Hans N, et al. Takotsubo-like cardiomyopathy in pheochromocytoma. Int J Cardiol 2011; 153:241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">21474192</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J-H, Kim KS, Sul J-Y, et al. Prevalence and patterns of left ventricular dysfunction in patients with pheochromocytoma. J Cardiovasc Ultrasound 2011; 19:76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150700</ArticleId><ArticleId IdType="pubmed">21860721</ArticleId></ArticleIdList></Reference><Reference><Citation>Giavarini A, Chedid A, Bobrie G, et al. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart Br Card Soc 2013; 99:1438&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pubmed">23837998</ArticleId></ArticleIdList></Reference><Reference><Citation>Galetta F, Franzoni F, Bernini G, et al. Cardiovascular complications in patients with pheochromocytoma: a mini-review. Biomed Pharmacother 2010; 64:505&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">20580187</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 2009; 6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Madias JE. Why the current diagnostic criteria of Takotsubo syndrome are outmoded: a proposal for new criteria. Int J Cardiol 2014; 174:468&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">24820748</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinning C, Keller T, Abegunewardene N, et al. Tako-Tsubo syndrome: dying of a broken heart? Clin Res Cardiol 2010; 99:771&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">20848112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai S, Kitabatake A, Tomoike H. Takotsubo Cardiomyopathy Group. Guidelines for diagnosis of takotsubo (ampulla) cardiomyopathy. Circ J 2007; 71:990&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">17527002</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao WB, Liu CF, Chiang CW, et al. Cardiovascular manifestations of pheochromocytoma. Am J Emerg Med 2000; 18:622&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">10999582</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vliet PD, Burchell HB, Titus JL. Focal myocarditis associated with pheochromocytoma. N Engl J Med 1966; 274:1102&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">5932021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiswell JG, Crago RM. Reversible cardiomyopathy with pheochromocytoma. Trans Am Clin Climatol Assoc 1969; 80:185&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2440986</ArticleId><ArticleId IdType="pubmed">4240971</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sayed AM, Brinjikji W, Salka S. Demographic and co-morbid predictors of stress (takotsubo) cardiomyopathy. Am J Cardiol 2012; 110:1368&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">22819424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol 2010; 55:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">20117439</ArticleId></ArticleIdList></Reference><Reference><Citation>Redfors B, Ali A, Shao Y, et al. Different catecholamines induce different patterns of takotsubo-like cardiac dysfunction in an apparently afterload dependent manner. Int J Cardiol 2014; 174:330&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">24794965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Ungprasert P, Ratanapo S, et al. Clinical characteristics of takotsubo cardiomyopathy in North America. North Am J Med Sci 2013; 5:77&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624723</ArticleId><ArticleId IdType="pubmed">23641366</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh NK, Rumman S, Mikell FL, et al. Stress cardiomyopathy: clinical and ventriculographic characteristics in 107 North American subjects. Int J Cardiol 2010; 141:297&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">19155079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu CN, Aguilar-Lopez CA, Sakr AE, et al. Long-term outcome of Tako-tsubo cardiomyopathy. Heart Lung Circ 2010; 19:601&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655278</ArticleId></ArticleIdList></Reference><Reference><Citation>Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 2013; 113:739&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843360</ArticleId><ArticleId IdType="pubmed">23989716</ArticleId></ArticleIdList></Reference><Reference><Citation>Elesber A, Lerman A, Bybee KA, et al. Myocardial perfusion in apical ballooning syndrome correlate of myocardial injury. Am Heart J 2006; 152:469.e9&#x2013;469.e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">16923415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, Rees PSC, Prasad S, et al. Stress (Takotsubo) cardiomyopathy&#x2014;a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008; 5:22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18094670</ArticleId></ArticleIdList></Reference><Reference><Citation>Santulli G, Campanile A, Spinelli L, et al. G protein-coupled receptor kinase 2 in patients with acute myocardial infarction. Am J Cardiol 2011; 107:1125&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296320</ArticleId></ArticleIdList></Reference><Reference><Citation>Santulli G. Adrenal signaling in heart failure: something more than a distant ship's smoke on the horizon. Hypertension 2014; 63:215&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">24218430</ArticleId></ArticleIdList></Reference><Reference><Citation>Perino A, Ghigo A, Ferrero E, et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110 &#x3b3;. Mol Cell 2011; 42:84&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265115</ArticleId><ArticleId IdType="pubmed">21474070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassim TA, Clarke DD, Mai VQ, et al. Catecholamine-induced cardiomyopathy. Endocr Pract 2008; 14:1137&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">19158054</ArticleId></ArticleIdList></Reference><Reference><Citation>W M, M I, S F, et al. Irreversible dilated cardiomyopathy after surgical resection of pheochromocytomas associated with von Hippel&#x2013;Lindau disease. Int J Cardiol 2009; e95&#x2013;e96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17942173</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalby MC, Burke M, Radley-Smith R, et al. Pheochromocytoma presenting after cardiac transplantation for dilated cardiomyopathy. J Heart Lung Transplant 2001; 20:773&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pubmed">11448809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkenfeld C, Cohen M, Lansman SL, et al. Heart transplantation for end-stage cardiomyopathy caused by an occult pheochromocytoma. J Heart Lung Transplant 1992; 11:363&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">1576142</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcovitz PA, Czako P, Rosenblatt S, et al. Pheochromocytoma presenting with Takotsubo syndrome. J Intervent Cardiol 2010; 23:437&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">21029177</ArticleId></ArticleIdList></Reference><Reference><Citation>Saddoud N, Turki I, Chammakhi R, et al. Malignant paraganglioma with vertebral and skull metastasis. J Radiol 2006; 87:1887&#x2013;1890.</Citation><ArticleIdList><ArticleId IdType="pubmed">17213774</ArticleId></ArticleIdList></Reference><Reference><Citation>Plouin P-F, Chatellier G, Fofol I, et al. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 29:1133&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">9149678</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholten A, Vriens MR, Cromheecke GJE, et al. Hemodynamic instability during resection of pheochromocytoma in MEN versus non-MEN patients. Eur J Endocrinol 2011; 165:91&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">21498631</ArticleId></ArticleIdList></Reference><Reference><Citation>Miskulin J, Shulkin BL, Doherty GM, et al. Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 2003; 134:918&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">14668723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Yu A, Filippone LA, et al. Inverted-takotsubo pattern cardiomyopathy secondary to pheochromocytoma: a clinical case and literature review. Clin Cardiol 2010; 33:200&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6653389</ArticleId><ArticleId IdType="pubmed">20394039</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi AP, Bing-You RG, Thomas LR. Recurrent takotsubo cardiomyopathy associated with pheochromocytoma. Endocr Pract 2009; 15:560&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">19491077</ArticleId></ArticleIdList></Reference><Reference><Citation>Frhlich GM, Schoch B, Schmid F, et al. Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy. Int J Cardiol 2012; 154:328&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">22044675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32473281</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2020</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Mechanical circulatory support for Takotsubo syndrome: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>31</StartPage><EndPage>39</EndPage><MedlinePgn>31-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2020.05.033</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(20)31840-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cardiogenic shock occurs in 10%-15% of patients with Takotsubo syndrome (TS). For several reasons catecholamines, and especially inotropes, should be avoided in TS. Temporary mechanical circulatory support (MCS) appears attractive as bridge-to-recovery, but prospective studies are lacking. Here we analyze the available literature on MCS use in patients with TS.</AbstractText><AbstractText Label="METHODS AND RESULTS">PubMed/Medline was systematically screened until December 2019. 18 studies reporting pooled data of 5629 TS patients, of whom 227 had received MCS, were considered for a qualitative synthesis. 81 articles from 2003 through 2019 reporting individual data of 93 MCS cases were included in a meta-analysis. Median age was 57 (IQR: 43-68) years, 83.9% were women, and a physical trigger could be identified in 74.1% of cases. Median left ventricular ejection fraction (LVEF) before MCS was 20% (IQR: 15-25) and comparable between groups defined by MCS device. An apical TS type was present in 76.1% of cases. The overall number of publications on MCS for TS increased over time, as did those using veno-arterial extracorporeal membrane oxygenation (V-A ECMO) and Impella, while those using intra-aortic balloon pump declined. MCS-related complications were not regularly reported. Median time on MCS was 3 (IQR: 2-7) days, with an overall survival of 94.6%.</AbstractText><AbstractText Label="CONCLUSIONS">MCS for TS-related shock is increasingly reported, with a growing use of V-A ECMO and Impella. Currently available clinical data support this approach. Prospective studies are needed to evaluate safety and efficacy of different devices as well as timing of MCS in this special patient population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Jannik</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiac Arrest Center, Advanced Heart Failure Unit, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS ISMETT, UPMC Italy, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#x11b;lohl&#xe1;vek</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitto</LastName><ForeName>Jan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauersachs</LastName><ForeName>Johann</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiac Arrest Center, Advanced Heart Failure Unit, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napp</LastName><ForeName>L Christian</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Cardiac Arrest Center, Advanced Heart Failure Unit, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. Electronic address: napp.christian@mh-hannover.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054549" MajorTopicYN="Y">Takotsubo Cardiomyopathy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac arrest</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">ECLS</Keyword><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Silvia Mariani, Jannik Richter, and Jan B&#x11b;lohl&#xe1;vek have nothing to disclose. Jan Dieter Schmitto received consultant honoraria from Medtronic and Abbott. Federico Pappalardo received speakers fee from Abiomed. Roberto Lorusso is consultant for Medtronic and LivaNova, and Advisory Board Member of Eurosets: all honoraria are paid to the University for research support. Johann Bauersachs received lecture honoraria and research support from Abiomed, outside the submitted work. L. Christian Napp received consultant, proctoring and lecture honoraria from Abiomed and lecture honoraria from Abbott, Maquet and Orion, all outside the submitted work. Other relationships outside the present work exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32473281</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2020.05.033</ArticleId><ArticleId IdType="pii">S0167-5273(20)31840-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36343565</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3288</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><PubDate><Year>2023</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Heart &amp; lung : the journal of critical care</Title><ISOAbbreviation>Heart Lung</ISOAbbreviation></Journal><ArticleTitle>Pulmonary hypertension and associated outcomes in noncardiac surgery: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>21</StartPage><EndPage>27</EndPage><MedlinePgn>21-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hrtlng.2022.10.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0147-9563(22)00252-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Some studies suggest that patients with pulmonary hypertension (PH) may be at higher risk of complications and death after noncardiac surgery. However, the magnitude of these associations is unclear.</AbstractText><AbstractText Label="OBJECTIVES">To determine the associations between PH and adverse outcomes after noncardiac surgery.</AbstractText><AbstractText Label="METHODS">We searched PUBMED and EMBASE for studies published from January 1970 to April 2022. We included studies that reported the association between PH and one or more outcomes of interest occurring after noncardiac surgery. Data were pooled using random-effects models and reported as summary odds ratios (ORs) with 95% confidence intervals (CIs).</AbstractText><AbstractText Label="RESULTS">Eighteen studies met eligibility criteria (n=18,214,760). PH was independently associated with mortality (adjusted odds ratio [OR] 2.09; 95% CI, 1.51-2.90; I<sup>2</sup>=98%; 8 studies). PH was associated with a higher unadjusted risk of deep venous thrombosis (OR 4.02; 95% CI, 2.14-7.54; I<sup>2</sup>=85%; 3 studies), pulmonary embolism (OR 4.16; 95% CI, 3.23-5.36; I<sup>2</sup>=69%; 7 studies), myocardial infarction (OR 1.49; 95% CI, 1.44-1.54; I<sup>2</sup>=0%; 5 studies), congestive heart failure or cardiogenic shock (OR 3.37; 95% CI, 1.73-6.60; I<sup>2</sup>=34%; 5 studies), length of hospital stay (mean difference 1.97 days; 95% CI, 0.81-3.12; I<sup>2</sup>=99%; 5 studies), and delayed extubation (OR 5.98; 95% CI, 1.70-21.02; I<sup>2</sup>=3%; 3 studies). PH was associated with lower unadjusted risk of postoperative stroke (OR 0.93; 95% CI, 0.88-0.98; I<sup>2</sup>=0%; 3 studies).</AbstractText><AbstractText Label="CONCLUSION">PH is a predictor of morbidity and mortality after noncardiac surgery. High quality studies are needed to determine effective strategies for reducing postoperative complications in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Binbraik</LastName><ForeName>Yasser</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Cardiac Sciences Department, King Saud University, Riyadh, Saudi Arabia.. Electronic address: yasser.binbraik@medportal.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Michael Ke</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.; Population Health Research Institute, Hamilton, Ontario, Canada.. Electronic address: wangm7@mcmaster.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riekki</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conen</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.; Population Health Research Institute, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcucci</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.; Population Health Research Institute, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borges</LastName><ForeName>Flavia Kessler</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.; Population Health Research Institute, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hambly</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devereaux</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.; Population Health Research Institute, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Lung</MedlineTA><NlmUniqueID>0330057</NlmUniqueID><ISSNLinking>0147-9563</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Noncardiac surgery</Keyword><Keyword MajorTopicYN="N">Postoperative morbidity</Keyword><Keyword MajorTopicYN="N">Postoperative mortality</Keyword><Keyword MajorTopicYN="N">Pulmonary hypertension</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The author declare no conflicts of interest with the contents of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>7</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36343565</ArticleId><ArticleId IdType="doi">10.1016/j.hrtlng.2022.10.015</ArticleId><ArticleId IdType="pii">S0147-9563(22)00252-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27060027</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-685X</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of thoracic and cardiovascular surgery</Title><ISOAbbreviation>J Thorac Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Contemporary extracorporeal membrane oxygenation therapy in adults: Fundamental principles and systematic review of the evidence.</ArticleTitle><Pagination><StartPage>20</StartPage><EndPage>32</EndPage><MedlinePgn>20-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtcvs.2016.02.067</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5223(16)00424-4</ELocationID><Abstract><AbstractText>Extracorporeal membrane oxygenation (ECMO) provides days to weeks of support for patients with respiratory, cardiac, or combined cardiopulmonary failure. Since ECMO was first reported in 1974, nearly 70,000 runs of ECMO have been implemented, and the use of ECMO in adults increased by more than 400% from 2006 to 2011 in the United States. A variety of factors, including the 2009 influenza A epidemic, results from recent clinical trials, and improvements in ECMO technology, have motivated this increased use in adults. Because ECMO is increasingly becoming available to a diverse population of critically ill patients, we provide an overview of its fundamental principles and a systematic review of the evidence basis of this treatment modality for a variety of indications in adults.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Squiers</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Baylor Research Institute, Baylor Scott &amp; White Health, Dallas, Tex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac and Thoracic Surgery, Baylor University Medical Center, Baylor Healthcare System, Dallas, Tex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiMaio</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Baylor Research Institute, Baylor Scott &amp; White Health, Dallas, Tex; Department of Cardiac and Thoracic Surgery, Baylor University Medical Center, Baylor Healthcare System, Dallas, Tex. Electronic address: jmdimaio@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Cardiovasc Surg</MedlineTA><NlmUniqueID>0376343</NlmUniqueID><ISSNLinking>0022-5223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Thorac Cardiovasc Surg. 2016 Jul;152(1):32-3. doi: 10.1016/j.jtcvs.2016.03.040.</RefSource><PMID Version="1">27087192</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal cardiopulmonary resuscitation</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27060027</ArticleId><ArticleId IdType="doi">10.1016/j.jtcvs.2016.02.067</ArticleId><ArticleId IdType="pii">S0022-5223(16)00424-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37752999</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Surgical Outcomes of Post-myocardial Infarction Ventricular Septal Defect/Rupture: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>e44135</StartPage><MedlinePgn>e44135</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e44135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.44135</ELocationID><Abstract><AbstractText>Ventricular septal defect (VSD) is a catastrophic acute myocardial infarction (MI) complication. Despite a significant reduction in the prevalence of post-MI VSD with the advancement of surgical techniques, it is still considered fatal with a high mortality rate. The trends in the clinical outcomes of patients with post-MI VSD show discretion due to the complexity of the disease. Therefore, the present analysis aimed to evaluate the surgical outcomes and associated risks in the patients of post-MI VSD. A thorough literature survey resulted in 40 studies of our interest. The pooled proportion of differential variables, including the incidence of cardiogenic shock, 30-day survival, and overall mortality, were estimated using Bayesian hierarchical models. The risk difference was estimated for the location of MI and VSD and mortality in patients with coronary artery bypass graft (CABG). In addition, the heterogeneity tests for inconsistency and publication biases using Egger's and Begg's tests were also estimated. The analysis revealed a significant risk difference of 0.23 and 0.27 for the anterior vs. posterior location of MI and VSD, respectively. Further, the pooled proportion of 30-day survival and mortality was found to be 54.43% (95% credible interval (CI): 52.88-55.98%) and 48.22% (95% CI: 4-12.3%), respectively. Moreover, the heterogeneity test revealed significant inconsistencies in all the datasets with&#xa0;<i>an I2&#xa0;</i>index of &gt;90% (<i>p</i>&lt;0.0001). Lastly, the publication bias results suggested no evidence of asymmetry and small-study effects. Conclusively, the surgical management of post-MI VSD patients is considered beneficial; however, the outcomes signify its fatal behavior.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, Ghosh et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Soumitra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology, Post Graduate Institute of Medical Education &amp; Research, Chandigarh, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halder</LastName><ForeName>Vikram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, U. N. Mehta Institute of Cardiology &amp; Research Centre, Ahmedabad, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, U. N. Mehta Institute of Cardiology &amp; Research Centre, Ahmedabad, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haranal</LastName><ForeName>Maruti</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, U. N. Mehta Institute of Cardiology &amp; Research Centre, Ahmedabad, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barwad</LastName><ForeName>Parag</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Harkant</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thingnam</LastName><ForeName>Shyam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Vidur</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">surgical outcomes</Keyword><Keyword MajorTopicYN="N">ventricular septal defect</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>3</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37752999</ArticleId><ArticleId IdType="pmc">PMC10518374</ArticleId><ArticleId IdType="doi">10.7759/cureus.44135</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Non-surgical repair of ventricular septal rupture after acute myocardial infarction. Tang L, Fang Z, Hu X, et al. Int J Cardiol. 2015;185:328&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">25828675</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-infarction ventricular septal defect: the importance of site of infarction and cardiogenic shock on outcome. Anderson DR, Adams S, Bhat A, Pepper JR. https://pubmed.ncbi.nlm.nih.gov/2635944/ Eur J Cardiothorac Surg. 1989:554&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">2635944</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery for post infarction ventricular septal defect (VSD): risk factors for hospital death and long term results. Labrousse L, Choukroun E, Chevalier JM, et al. Eur J Cardiothorac Surg. 2002;21:725&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932175</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Crenshaw BS, Granger CB, Birnbaum Y, et al. Circulation. 2000;101:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10618300</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factors and outcome analysis after surgical management of ventricular septal rupture complicating acute myocardial infarction: a retrospective analysis. Huang SM, Huang SC, Wang CH, et al. J Cardiothorac Surg. 2015;10:66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4426168</ArticleId><ArticleId IdType="pubmed">25935413</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-infarction ventricular septal defect: risk factors and early outcomes. Serpytis P, Karvelyte N, Serpytis R, et al.  https://www.hellenicjcardiol.org/archive/full_text/2015/1/2015_1_66.pdf. Hellenic J Cardiol. 2015;56:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">25701974</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery for post-myocardial infarct ventricular septal defect. Daggett WM, Guyton RA, Mundth ED, et al. Ann Surg. 1977;186:260&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1396347</ArticleId><ArticleId IdType="pubmed">302110</ArticleId></ArticleIdList></Reference><Reference><Citation>A modified infarct exclusion technique for a post-infarction ventricular septal defect. Hirotani T, Nakamichi T. http://www.atcs.jp/pdf/2002_8_5/281.pdf. Ann Thorac Cardiovasc Surg. 2002;8:281&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472410</ArticleId></ArticleIdList></Reference><Reference><Citation>Modified infarct exclusion technique for repair of postinfarction ventricular septal rupture. Parachuri VR, Tripathy AK, Gaikwad NM, Singh AP, Mahajan V, Niranjan S. Ann Thorac Surg. 2019;107:0&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">30403981</ArticleId></ArticleIdList></Reference><Reference><Citation>A modified infarct exclusion technique for repair of anteroapical postinfarction ventricular septal defect. Bayezid O, Turkay C, Golbasi I. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1336699/ Tex Heart Inst J. 2005;32:299&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1336699</ArticleId><ArticleId IdType="pubmed">16392209</ArticleId></ArticleIdList></Reference><Reference><Citation>Perioperative use of TandemHeart percutaneous ventricular assist device in surgical repair of postinfarction ventricular septal defect. Gregoric ID, Kar B, Mesar T, Nathan S, Radovancevic R, Patel M, Loyalka P. ASAIO J. 2014;60:529&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">25010911</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgical treatment of ventricular septal defect complicating acute myocardial infarction. experience of a north Italian referral hospital. Cerin G, Di Donato M, Dimulescu D, et al. Cardiovasc Surg. 2003;11:149&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">12664051</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgical repair of post infarction ventricular septal defects: a national experience. Jeppsson A, Liden H, Johnsson P, Hartford M, R&#xe5;degran K. Eur J Cardiothorac Surg. 2005;27:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">15691673</ArticleId></ArticleIdList></Reference><Reference><Citation>Midterm results of the "sandwich technique" via a right ventricle incision to repair post-infarction ventricular septal defect. Isoda S, Osako M, Kimura T, Mashiko Y, Yamanaka N, Nakamura S, Maehara T. Ann Thorac Cardiovasc Surg. 2012;18:318&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510795</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence and predictors of 30-day mortality in patients with ventricular septal rupture complicating acute myocardial infarction. Pradhan A, Jain N, Cassese S, et al. Heart Asia. 2018;10:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6109810</ArticleId><ArticleId IdType="pubmed">30166998</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S. Higgins JPT, Green S. Chichester (UK): John Wiley &amp; Sons; 2011. Cochrane Handbook for Systematic Reviews of Interventions.</Citation></Reference><Reference><Citation>The in vivo morphology of post-infarct ventricular septal defect and the implications for closure. Hamilton MC, Rodrigues JC, Martin RP, Manghat NE, Turner MS. JACC Cardiovasc Interv. 2017;10:1233&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">28641844</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitfalls for the "Sandwich technique" via a right ventricular incision to repair post-infarction ventricular septal defects. Isoda S, Imoto K, Uchida K, et al. Gen Thorac Cardiovasc Surg. 2017;65:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">27744610</ArticleId></ArticleIdList></Reference><Reference><Citation>Myocardial rupture after acute myocardial infarction. ten year review. Feneley MP, Chang VP, O'Rourke MF. Br Heart J. 1983;49:550&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC481348</ArticleId><ArticleId IdType="pubmed">6849717</ArticleId></ArticleIdList></Reference><Reference><Citation>Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. Elbadawi A, Elgendy IY, Mahmoud K, et al. JACC Cardiovasc Interv. 2019;12:1825&#x2013;1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">31537282</ArticleId></ArticleIdList></Reference><Reference><Citation>Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. Menon V, Webb JG, Hillis LD, et al. J Am Coll Cardiol. 2000;1110:6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985713</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanical circulatory support for early surgical repair of postinfarction ventricular septal defect with cardiogenic shock. Vondran M, Wehbe MS, Etz C, Ghazy T, Rastan AJ, Borger MA, Schroeter T. Artif Organs. 2021;45:244&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">32857884</ArticleId></ArticleIdList></Reference><Reference><Citation>Longitudinal outcomes after surgical repair of postinfarction ventricular septal defect in the Medicare population. Arnaoutakis GJ, Kilic A, Conte JV, et al. Ann Thorac Surg. 2020;109:1243&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">31562839</ArticleId></ArticleIdList></Reference><Reference><Citation>Immediate primary transcatheter closure of postinfarction ventricular septal defects. Thiele H, Kaulfersch C, Daehnert I, Schoenauer M, Eitel I, Borger M, Schuler G. Eur Heart J. 2009;30:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">19036747</ArticleId></ArticleIdList></Reference><Reference><Citation>Transcatheter closure of postmyocardial infarction, iatrogenic, and postoperative ventricular septal defects: the Mayo clinic experience. Egbe AC, Poterucha JT, Rihal CS, et al. Catheter Cardiovasc Interv. 2015;86:1264&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">26033272</ArticleId></ArticleIdList></Reference><Reference><Citation>Outcomes of early versus delayed transcatheter closure of post-myocardial infarction ventricular septal defect. Heckle MR, Brooksbank JA, Agarwal MA, Ibebuogu UN. Cardiovasc Revasc Med. 2020;21:1093&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">32089512</ArticleId></ArticleIdList></Reference><Reference><Citation>Management and midterm outcomes of post-infarction ventricular septal defect. Wiemers P, Harvey R, Khatun M, Mundy J, Peters P, Shah P. Asian Cardiovasc Thorac Ann. 2012;20:663&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">23284107</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-infarction ventricular septal defect: surgical outcomes in the last decade. Yam N, Au TW, Cheng LC. Asian Cardiovasc Thorac Ann. 2013;21:539&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">24570555</ArticleId></ArticleIdList></Reference><Reference><Citation>Techniques, timing &amp; prognosis of post infarct ventricular septal repair: a re-look at old dogmas. Malhotra A, Patel K, Sharma P, et al. Braz J Cardiovasc Surg. 2017;32:147&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570397</ArticleId><ArticleId IdType="pubmed">28832791</ArticleId></ArticleIdList></Reference><Reference><Citation>Post infarction ventricular septal defect - can we do better? Deja MA, Szostek J, Widenka K, et al. Eur J Cardiothorac Surg. 2000;18:194&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">10925229</ArticleId></ArticleIdList></Reference><Reference><Citation>Repair of post-infarct ventricular septal defect with or without coronary artery bypass grafting in the northwest of England: a 5-year multi-institutional experience. Barker TA, Ramnarine IR, Woo EB, et al. Eur J Cardiothorac Surg. 2003;24:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643812</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgical repair of post-infarction ventricular septal defect - findings from a Japanese national database. Sakaguchi G, Miyata H, Motomura N, et al. Circ J. 2019;83:2229&#x2013;2235.</Citation><ArticleIdList><ArticleId IdType="pubmed">31511450</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends in incidence and mortality rates of ventricular septal rupture during acute myocardial infarction. Moreyra AE, Huang MS, Wilson AC, Deng Y, Cosgrove NM, Kostis JB. Am J Cardiol. 2010;106:1095&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">20920645</ArticleId></ArticleIdList></Reference><Reference><Citation>Primary transcatheter closure of post-myocardial infarction ventricular septal rupture using amplatzer atrial septal occlusion device: a study from tertiary care in South India. Aggarwal M, Natarajan K, Vijayakumar M, et al. Indian Heart J. 2018;70:519&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6116725</ArticleId><ArticleId IdType="pubmed">30170647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventricular septal defect after myocardial infarction: diagnosis by two-dimensional contrast echocardiography. Drobac M, Gilbert B, Howard R, Baigrie R, Rakowski H. Circulation. 1983;67:335&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">6848222</ArticleId></ArticleIdList></Reference><Reference><Citation>Percutaneous Closure of post-infarction ventricular septal defects-an over decade-long experience. Sabiniewicz R, Huczek Z, Zbro&#x144;ski K, et al. J Interv Cardiol. 2017;30:63&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">28078714</ArticleId></ArticleIdList></Reference><Reference><Citation>Influence of thrombolytic therapy on the patterns of ventricular septal rupture after acute myocardial infarction. Rhydwen GR, Charman S, Schofield PM. Postgrad Med J. 2002;78:408&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1742442</ArticleId><ArticleId IdType="pubmed">12151656</ArticleId></ArticleIdList></Reference><Reference><Citation>Transcatheter management of ventricular septal rupture after myocardial infarction. Landzberg MJ, Lock JE. Semin Thorac Cardiovasc Surg. 1998;10:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620460</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the thrombolysis and thrombin inhibition in myocardial infarction 9 study. Becker RC, Hochman JS, Cannon CP, et al. J Am Coll Cardiol. 1999;33:479&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">9973029</ArticleId></ArticleIdList></Reference><Reference><Citation>Sequential management of post-myocardial infarction ventricular septal defects. Trivedi KR, Aldebert P, Riberi A, et al. Arch Cardiovasc Dis. 2015;108:321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">25754906</ArticleId></ArticleIdList></Reference><Reference><Citation>In-hospital outcomes and long-term follow-up after percutaneous transcatheter closure of postinfarction ventricular septal defects. Zhang R, Sun Y, Sun M, Zhang H, Hou J, Yu B. Biomed Res Int. 2017;2017:7971027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5448058</ArticleId><ArticleId IdType="pubmed">28593177</ArticleId></ArticleIdList></Reference><Reference><Citation>A modified infarct exclusion technique: triple-patch technique for postinfarction ventricular septal perforation. Sugimoto T, Yoshii S, Yamamoto K, et al. J Thorac Cardiovasc Surg. 2008;135:702&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329503</ArticleId></ArticleIdList></Reference><Reference><Citation>Percutaneous closure of postinfarction ventricular septal defect: in-hospital outcomes and long-term follow-up of UK experience. Calvert PA, Cockburn J, Wynne D, et al. Circulation. 2014;129:2395&#x2013;2402.</Citation><ArticleIdList><ArticleId IdType="pubmed">24668286</ArticleId></ArticleIdList></Reference><Reference><Citation>Management and outcome of ventricular septal rupture complicating acute myocardial infarction: what is new in the era of percutaneous intervention? Tai S, Tang JJ, Tang L, et al. Cardiology. 2018;141:226&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">30852569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39895893</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2211-4122</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Journal of cardiovascular echography</Title><ISOAbbreviation>J Cardiovasc Echogr</ISOAbbreviation></Journal><ArticleTitle>Pancreatitis-associated Myocarditis: Systematic Review and Meta-analysis of a Deadly Duo.</ArticleTitle><Pagination><StartPage>160</StartPage><EndPage>169</EndPage><MedlinePgn>160-169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/jcecho.jcecho_59_24</ELocationID><Abstract><AbstractText>Myocardial injury is a recognized complication of acute pancreatitis, whereas myocarditis has only been occasionally reported and has not been systematically evaluated. We systematically reviewed PubMed literature published up to January 2024 for studies including both "myocarditis" and "pancreatitis" as keywords. Relevant data regarding patient characteristics and outcomes were collected and analyzed. A total of 31 patients from 31 independent studies were included. The etiology of pancreatitis was viral in 52%, bacterial in 20%, toxic in 16%, autoimmune in 9%, and idiopathic in 3%. 23% of patients were immunocompromised. Median high sensitivity-cardiac troponin T was 342 (IQR 73-890) ng/L and N-terminus-pro-brain natriuretic peptide was 11053 (IQR 1397-26150) pg/mL. The average left ventricular ejection fraction was 33&#xb1;13%. Fulminant myocarditis, presenting with cardiogenic shock and/or malignant ventricular arrhythmias occurred in 48% of patients, more frequently in men than in women (<i>P</i>=0.026). Severe myocarditis occurred in 42% of edematous and 60% of necrotizing pancreatitis (<i>P</i>=0.56). No association was found between the severity of myocarditis and plasma levels of amylase (<i>P</i>=0.98) and lipase (<i>P</i>=0.83). The relative frequency of severe myocarditis was 80% in pancreatitis due to Leptospirosis, and 40% in pancreatitis due to viral infections. The mortality rate was 22%: 13% died during hospitalization and 9% after. Myocarditis is a potentially lethal complication of pancreatitis and is more frequently associated with viral etiology in immunocompromised individuals. Based on such findings, cardiac troponin measurements and an electrocardiogram are advisable to exclude myocardial involvement in selected patients. Confirmatory diagnosis and prognostic assessments should be based on cardiac magnetic resonance imaging.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Journal of Cardiovascular Echography.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Alberti</LastName><ForeName>Mattia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Marcucci</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Radiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biondi</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiusolo</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masini</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faggioni</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Radiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cioni</LastName><ForeName>Dania</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Radiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrone</LastName><ForeName>Doralisa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Caterina</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neri</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Radiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aquaro</LastName><ForeName>Giovanni Donato</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Area, Radiology Division, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Cardiovasc Echogr</MedlineTA><NlmUniqueID>101562228</NlmUniqueID><ISSNLinking>2211-4122</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arrhythmias</Keyword><Keyword MajorTopicYN="N">cardiac magnetic resonance</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword><Keyword MajorTopicYN="N">pancreatitis</Keyword><Keyword MajorTopicYN="N">shock</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>3</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>3</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39895893</ArticleId><ArticleId IdType="pmc">PMC11784726</ArticleId><ArticleId IdType="doi">10.4103/jcecho.jcecho_59_24</ArticleId><ArticleId IdType="pii">JCE-34-160</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh VK, Wu BU, Bollen TL, Repas K, Maurer R, Mortele KJ, et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol. 2009;7:1247&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">19686869</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaubitz J, Asgarbeik S, Lange R, Mazloum H, Elsheikh H, Weiss FU, et al. Immune response mechanisms in acute and chronic pancreatitis: Strategies for therapeutic intervention. Front Immunol. 2023;14:1279539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10595029</ArticleId><ArticleId IdType="pubmed">37881430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappell MS. Acute pancreatitis: Etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am. 2008;92:889&#x2013;923. ix-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">18570947</ArticleId></ArticleIdList></Reference><Reference><Citation>Beger HG, Rau B, Mayer J, Pralle U. Natural course of acute pancreatitis. World J Surg. 1997;21:130&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8995067</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis &#x2013; 2012: Revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23100216</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppaniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E, Kirkpatrick AW, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6567462</ArticleId><ArticleId IdType="pubmed">31210778</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Moin A, Virk HU, Jneid H, Virani SS, Krittanawong C. Association of cardiovascular disease and pancreatitis: What came first, the chicken or the egg? J Clin Med. 2023;12:7101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10672425</ArticleId><ArticleId IdType="pubmed">38002718</ArticleId></ArticleIdList></Reference><Reference><Citation>Chac&#xf3;n-Portillo MA, Payr&#xf3;-Ram&#xed;rez G, Pel&#xe1;ez-Luna MC, Uscanga-Dom&#xed;nguez LF, Vasqu&#xe9;z-Ortiz Z, Orihuela C, et al. Abnormal cardiovascular findings in acute pancreatitis: Are they associated with disease severity? Rev Invest Clin. 2017;69:314&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29265116</ArticleId></ArticleIdList></Reference><Reference><Citation>Thandassery RB, Choudhary N, Bahl A, Kochhar R. Characterization of cardiac dysfunction by echocardiography in early severe acute pancreatitis. Pancreas. 2017;46:626&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">28398922</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan U, Petrechko O, Sagheer S, Majeed H, Zaidi SH, Wasty N, et al. Acute pancreatitis and myocardial infarction: A narrative review. Cardiology. 2023;148:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">36592617</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu ES, Lange JJ, Broor A, Kutty K. Acute pancreatitis masquerading as inferior wall myocardial infarction: A review. Case Rep Gastroenterol. 2019;13:321&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6738212</ArticleId><ArticleId IdType="pubmed">31543754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni N, Bhasin DK, Rana SS, Bahl A, Sinha SK, Rao C, et al. Diastolic dysfunction, prolonged QTc interval and pericardial effusion as predictors of mortality in acute pancreatitis. J Gastroenterol Hepatol. 2012;27:1576&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22849657</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna T, Patel J, Singh I, Kalra S, Dhiman M, Kohli I, et al. The impact of type 2 myocardial infarction in acute pancreatitis: Analysis of 1.1 million hospitalizations and review of the literature. Cureus. 2023;15:e44113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10518190</ArticleId><ArticleId IdType="pubmed">37750110</ArticleId></ArticleIdList></Reference><Reference><Citation>Awan RU, Iyer A, Khan UA, Majeed H, Nabeel A, Zaidi SH, et al. Insights into clinical outcomes of acute pancreatitis with concomitant acute myocardial infarction using the national inpatient sample database. Am J Cardiol. 2023;203:295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">37517123</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Li Z, Ge P, Guo H, Li L, Zhang G, et al. Comprehensive mechanism, novel markers and multidisciplinary treatment of severe acute pancreatitis-associated cardiac injury &#x2013; A narrative review. J Inflamm Res. 2021;14:3145&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286248</ArticleId><ArticleId IdType="pubmed">34285540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar S, Liu PP, Cooper LT., Jr Myocarditis. Lancet. 2012;379:738&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814111</ArticleId><ArticleId IdType="pubmed">22185868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: An expert consensus document. Circ Heart Fail. 2020;13:e007405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673642</ArticleId><ArticleId IdType="pubmed">33176455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampejo T, Durkin SM, Bhatt N, Guttmann O. Acute myocarditis: Aetiology, diagnosis and management. Clin Med (Lond) 2021;21:e505&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8439515</ArticleId><ArticleId IdType="pubmed">34507935</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimarchi G, Teresi L, Licordari R, Pingitore A, Pizzino F, Grimaldi P, et al. Transient left ventricular dysfunction from cardiomyopathies to myocardial viability: When and why cardiac function recovers. Biomedicines. 2024;12:1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11117605</ArticleId><ArticleId IdType="pubmed">38791012</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2024;13:55&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">37740496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawla P, Bandaru SS, Vellipuram AR. Review of infectious etiology of acute pancreatitis. Gastroenterology Res. 2017;10:153&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505279</ArticleId><ArticleId IdType="pubmed">28725301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar L, Naik SK, Agarwal SS, Bastia BK. Autopsy diagnosis of a death due to scorpion stinging &#x2013; A case report. J Forensic Leg Med. 2012;19:494&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23084316</ArticleId></ArticleIdList></Reference><Reference><Citation>Persichino J, Garrison R, Krishnan R, Sutjita M. Effusive-constrictive pericarditis, hepatitis, and pancreatitis in a patient with possible Coxsackievirus B infection: Acase report. BMC Infect Dis. 2016;16:375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977840</ArticleId><ArticleId IdType="pubmed">27503532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayburn D, Gerke S. Supraventricular tachycardia as the initial presentation of new-onset lupus: A case report. Pediatr Emerg Care. 2021;37:e565&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34406996</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R, Gurtoo A, Prakash A, Jose R, Bansal P. Leptospiral myocarditis and pancreatitis. Trop Doct. 2023;53:329&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">36597661</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins KA, Abdou MH, Hadi MA. Coxsackie B2 virus infection causing multiorgan failure and cardiogenic shock in a 42-year-old man. Tex Heart Inst J. 2019;46:32&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378994</ArticleId><ArticleId IdType="pubmed">30833835</ArticleId></ArticleIdList></Reference><Reference><Citation>Yogendranathan N, Herath HM, Sivasundaram T, Constantine R, Kulatunga A. A case report of zinc phosphide poisoning: Complicated by acute renal failure and tubulo interstitial nephritis. BMC Pharmacol Toxicol. 2017;18:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5445288</ArticleId><ArticleId IdType="pubmed">28545504</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Lazo V, Abdelmottaleb W, Popescu-Martinez A. Pembrolizumab-induced myocarditis and pancreatitis in a patient with colon cancer: A case report. Cureus. 2022;14:e26034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9205379</ArticleId><ArticleId IdType="pubmed">35734025</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang GM, Hu P, Wu Y. Simultaneous pancreatitis and myocarditis in childhood-onset systemic lupus erythematous. Arch Rheumatol. 2018;33:381&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6328225</ArticleId><ArticleId IdType="pubmed">30632541</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagopoulos P, Terzi I, Karanikas M, Galanopoulos N, Maltezos E. Myocarditis, pancreatitis, polyarthritis, mononeuritis multiplex and vasculitis with symmetrical peripheral gangrene of the lower extremities as a rare presentation of leptospirosis: A case report and review of the literature. J Med Case Rep. 2014;8:150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038076</ArticleId><ArticleId IdType="pubmed">24885926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampropoulos K, Bazoukis G, Kolyviras A, Tse G, Saplaouras A, Iliopoulos T. Pancreatitis and myocarditis coexistence due to infection by Coxsackie B1 and B4 viruses. Clin Case Rep. 2018;6:23&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5771903</ArticleId><ArticleId IdType="pubmed">29375831</ArticleId></ArticleIdList></Reference><Reference><Citation>Akuzawa N, Harada N, Hatori T, Imai K, Kitahara Y, Sakurai S, et al. Myocarditis, hepatitis, and pancreatitis in a patient with coxsackievirus A4 infection: A case report. Virol J. 2014;11:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895747</ArticleId><ArticleId IdType="pubmed">24410962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranawaka N, Jeevagan V, Karunanayake P, Jayasinghe S. Pancreatitis and myocarditis followed by pulmonary hemorrhage, a rare presentation of leptospirosis- a case report and literature survey. BMC Infect Dis. 2013;13:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560203</ArticleId><ArticleId IdType="pubmed">23347428</ArticleId></ArticleIdList></Reference><Reference><Citation>Egashira F, Kawashima M, Morikawa A, Kosuda M, Ishihara H, Watanabe K. A rare case of fulminant type 1 diabetes mellitus accompanied by both acute pancreatitis and myocarditis - Case report. BMC Endocr Disord. 2020;20:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437161</ArticleId><ArticleId IdType="pubmed">32811476</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmeyer RB, Padosch SA, Madea B. Lethal enterovirus-induced myocarditis and pancreatitis in a 4-month-old boy. Forensic Sci Int. 2006;156:51&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh J. Typhoid pancreatitis presenting as hemorrhagic pleural effusion complicated by myocarditis: Correspondence. Indian J Pediatr. 2023;90:740.</Citation><ArticleIdList><ArticleId IdType="pubmed">37184714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland JH. Mumps complicated by myocarditis, meningoencephalitis and pancreatitis; review of the literature and report of a case. N Engl J Med. 1949;240:417&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18112679</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas M, T&#xf6;rnhage CJ. Family transmission of COVID-19 including a child with MIS-C and acute pancreatitis. Int Med Case Rep J. 2021;14:55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7872935</ArticleId><ArticleId IdType="pubmed">33574714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yew KL, San Go C, Razali F. Pancreatitis and myopericarditis complication in leptospirosis infection. J Formos Med Assoc. 2015;114:785&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24630490</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun J, SieperJ, SchwarzA, Hiepe F, Lenz T, Keller F, et al. Widespread vasculopathy with hemolytic uremic syndrome, perimyocarditis and cystic pancreatitis in a young woman with mixed connective tissue disease. Case report and review of the literature. Rheumatol Int. 1993;13:31&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8516621</ArticleId></ArticleIdList></Reference><Reference><Citation>Philipponnet C, Michel PA, Daudon M, Brocheriou I, Boffa JJ. Intravascular foscarnet crystal precipitation causing multiorgan failure. Am J Kidney Dis. 2015;65:152&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25301103</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretagostini R, Lai Q, Pettorini L, Garofalo M, Poli L, Melandro F, et al. Multiple organ failure associated with Coxsackie virus in a kidney transplant patient: Case report. Transplant Proc. 2016;48:438&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">27109973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni&#xf1;o-Taravilla C, Espinosa-Vielma YP, Otaola-Arca H, Poli-Harlowe C, Tapia LI, Ortiz-Fritz P. Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 treated with tocilizumab. Pediatr Rep. 2020;12:142&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7768469</ArticleId><ArticleId IdType="pubmed">33291619</ArticleId></ArticleIdList></Reference><Reference><Citation>Pa&#xf1;o-Pardo JR, Alcaide ML, Abbo L, Dickinson G. Primary HIV infection with multisystemic presentation. Int J Infect Dis. 2009;13:e177&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">19028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarawgi S, Gupta AK, Arora DS, Jasuja S. Acute renal failure associated with nonfulminant acute viral hepatitis A. Indian J Nephrol. 2008;18:77&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813126</ArticleId><ArticleId IdType="pubmed">20142908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladisch R, Hofmann W, Waldherr R. Myocarditis and insulitis following coxsackie virus infection. Z Kardiol. 1976;65:837&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">793225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchner GI, Krug N, Bleck JS, Fliser D, Manns MP, Wagner S. Fulminant course of leptospirosis complicated by multiple organ failure. Z Gastroenterol. 2001;39:587&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11558063</ArticleId></ArticleIdList></Reference><Reference><Citation>Young EJ, Killam AP, Greene JF, Jr Disseminated herpesvirus infection. Association with primary genital herpes in pregnancy. JAMA. 1976;235:2731&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">178938</ArticleId></ArticleIdList></Reference><Reference><Citation>Teniente Urbina ME, Casas Casta&#xf1;eda J, Jos&#xe9; P, Saavedra O. Pancreatitis, miocarditis y nefritis intersticial asociadas a infecci&#xf3;n aguda por el virus de epstein barr. Rev Gastroenterol del Per&#xfa;. 2009;29:367&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20066023</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma SK, Ahmad S, Shirazi N, Barthwal SP, Khurana D, Chugh M, et al. Acute pancreatitis: A lesser-known complication of aluminum phosphide poisoning. Hum Exp Toxicol. 2007;26:979&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">18375644</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhi NS, Dutta U, Sathyanarayana G, Singh K. Acute pancreatitis: Presenting manifestation of varicella infection. Trop Gastroenterol. 2004;25:82&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">15471323</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose NR. Myocarditis: Infection versus autoimmunity. J Clin Immunol. 2009;29:730&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19826933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsingh AI, Lee WT, Collins DN, Armstrong LE. Differential recruitment of B and T cells in coxsackievirus B4-induced pancreatitis is influenced by a capsid protein. J Virol. 1997;71:8690&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192333</ArticleId><ArticleId IdType="pubmed">9343227</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore M, Kaplan MH, McPhee J, Bregman DJ, Klein SW. Epidemiologic, clinical, and laboratory features of Coxsackie B1-B5 infections in the United States, 1970-79. Public Health Rep. 1984;99:515&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1424625</ArticleId><ArticleId IdType="pubmed">6091168</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WG. Coxsackie B myopericarditis in adults. Am Heart J. 1970;80:34&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">5426837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayatpour M, Zbitnew A, Dempster G, Miller KR. Role of coxsackievirus B4 in the pathogenesis of acute glomerulonephritis. Can Med Assoc J. 1973;109:873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1946988</ArticleId><ArticleId IdType="pubmed">4750301</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaoutis T, Klein JD. Enterovirus infections. Pediatr Rev. 1998;19:183&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9613170</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodili F, van Bommel EF. Severe rhabdomyolysis and acute renal failure following recent Coxsackie B virus infection. Neth J Med. 2003;61:177&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12916546</ArticleId></ArticleIdList></Reference><Reference><Citation>Papachristou F, Printza N. Acute nephritis complicating Coxsackie B infection. Indian Pediatr. 2005;42:838&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau G. Acute fulminant, fatal Coxsackie B virus infection: A report of two cases. Ann Acad Med Singap. 1994;23:917&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7741514</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorenbeyn A, Smally AJ. A rare case of concomitant viral myocarditis and pericarditis in a 44-year-old patient. J Emerg Med. 2004;27:355&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15498615</ArticleId></ArticleIdList></Reference><Reference><Citation>Coplan NL, Atallah V, Mediratta S, Bruno MS, DePasquale NP. Cardiac, pancreatic, and liver abnormalities in a patient with coxsackie-B infection. Am J Med. 1996;101:325&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8873496</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaheeruddin S, Bade NA, Jani S, Srichai MB. A case of Coxsackie B virus infection leading to multi-organ inflammation: Myopericarditis and acute liver failure. Case Rep Intern Med. 2014;1:45.</Citation></Reference><Reference><Citation>Edwards CN, Evarard CO. Hyperamylasemia and pancreatitis in leptospirosis. Am J Gastroenterol. 1991;86:1665&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1719805</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolze E, Schaad JD, Bool PH. Weil&#x2018;s disease associated with pancreatic necrosis; report on a case. Trop Geogr Med. 1959;11:93&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">13659588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakumara J, Prasath T, Samarajiwa G, Priyadarshani S, Perera N, Indrakumar J. Myocarditis causing severe heart failure &#x2013;An unusual early manifestation of leptospirosis: A case report. BMC Res Notes. 2015;8:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371810</ArticleId><ArticleId IdType="pubmed">25884600</ArticleId></ArticleIdList></Reference><Reference><Citation>Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14:296&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88975</ArticleId><ArticleId IdType="pubmed">11292640</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118652</ArticleId><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221:1762&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184346</ArticleId><ArticleId IdType="pubmed">32227123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. 2020;324:294&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7281352</ArticleId><ArticleId IdType="pubmed">32511676</ArticleId></ArticleIdList></Reference><Reference><Citation>Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet. 2020;395:1771&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220177</ArticleId><ArticleId IdType="pubmed">32410760</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324:259&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7281356</ArticleId><ArticleId IdType="pubmed">32511692</ArticleId></ArticleIdList></Reference><Reference><Citation>Badui E, Garcia-Rubi D, Robles E, Jimenez J, Juan L, Deleze M, et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology. 1985;36:431&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">4025948</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Singh S, Minz RW, Radotra BD, Ahluwalia J, Grover A. Lupus myocarditis in children. Ann Rheum Dis. 2004;63:745&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1755022</ArticleId><ArticleId IdType="pubmed">15140786</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoodi I. The simultaneous incidence of acute pancreatitis and autoimmune hemolytic anemia: A rare duo in a patient with SLE. Ger Med Sci. 2014;12:Doc12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178942</ArticleId><ArticleId IdType="pubmed">25276114</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Dima A, Balaban DV, Jurcut C, Jinga M. Systemic lupus erythematosus-related acute pancreatitis. Lupus. 2021;30:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">33307986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian XP, Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: Insight into pathogenesis, diagnosis and treatment. World J Gastroenterol. 2010;16:2971&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890936</ArticleId><ArticleId IdType="pubmed">20572299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Ahlawat SK. Aluminum phosphide poisoning &#x2013; A review. J Toxicol Clin Toxicol. 1995;33:19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">7837309</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamoon Z, Peterfy RJ, Hammoud S, Khazaeni B. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Scorpion toxicity.</Citation><ArticleIdList><ArticleId IdType="pubmed">28613678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bumbrah GS, Krishan K, Kanchan T, Sharma M, Sodhi GS. Phosphide poisoning: A review of literature. Forensic Sci Int. 2012;214:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763089</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Gaddam S, Wang N, Xie Y, Deng Z, Zhou Z, et al. Multiparametric mapping magnetic resonance imaging of pancreatic disease. Front Physiol. 2020;11:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047169</ArticleId><ArticleId IdType="pubmed">32153416</ArticleId></ArticleIdList></Reference><Reference><Citation>Bele&#xf9; A, Canonico D, Morana G. T1 and T2-mapping in pancreatic MRI: Current evidence and future perspectives. Eur J Radiol Open. 2024;12:100572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11170358</ArticleId><ArticleId IdType="pubmed">38872711</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36704455</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Takotsubo cardiomyopathy after cardiac surgery: A case-series and systematic review of literature.</ArticleTitle><Pagination><StartPage>1067444</StartPage><MedlinePgn>1067444</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1067444</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2022.1067444</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Takotsubo cardiomyopathy (TTC) is a rare entity after cardiac surgery.</AbstractText><AbstractText Label="AIMS" NlmCategory="UNASSIGNED">To describe patients' profile who developed postoperative TTC after cardiac surgery, management, and outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a systematic literature search to extract cases of TTC after adult cardiac surgery (from 1990 to 2021). Additionally, we extracted all cases of TTC in a prospective single-center cohort database of 10,000+ patients (from 2007 to 2019). We then combined all cases in a single cohort to describe its clinical features.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">From 694 screened articles, we retained 71 individual cases published in 20 distinct articles (19 cases reports and 1 case-series). We combined these to 10 cases extracted from our cohort [among 10,682 patients (0.09%)]. Overall, we included 81 cases. Patients were aged 68 &#xb1; 10 years-old and 64/81 (79%) were women. Surgery procedures included mitral valve and/or tricuspid valve surgery in 70/81, 86%. TTC was diagnosed in the first days after surgery [median 4 (1-4) days]. Incidence of cardiogenic shock, defined as requirement of vasopressor and/or inotropic support was 24/29, 83% (data available on 29/81 patients). Refractory cardiogenic appeared in 5/81, 6% who required implantation of arterio-venous extra-corporeal membrane oxygenation, and 6/81, 7%, intra-aortic balloon pump. In-hospital mortality was 5/81, 6%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This systematic review, based on case reports and case series, showed that postoperative TTC appears as a rare complication after cardiac surgery and mainly occurred after mitral and/or tricuspid valve repair procedures. In this population, TTC is associated with high rate of cardiogenic shock.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Laghlam, Touboul, Herry, Estagnasi&#xe9;, Dib, Baccouche, Brusset, Nguyen and Squara.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laghlam</LastName><ForeName>Driss</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touboul</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herry</LastName><ForeName>Morgane</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estagnasi&#xe9;</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dib</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baccouche</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brusset</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Lee S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squara</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Critical Care, Clinique Ambroise Par&#xe9;, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac surgery</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mitral valve surgery</Keyword><Keyword MajorTopicYN="N">takotsubo cardiomyopathy</Keyword><Keyword MajorTopicYN="N">tricuspid valve surgery</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>27</Day><Hour>2</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36704455</ArticleId><ArticleId IdType="pmc">PMC9871635</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.1067444</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Satoh HT, Uchida T. Takotsubo-type cardiomyopathy due to multivessel spasm. In: Kodama K, Haze K, Hon M. editors. Clinical Aspects of Myocardial Injury: From Ischemia to Heart Failure. Tokyo: Kagakuyouronsya Co; (1990). p. 56&#x2013;64.</Citation></Reference><Reference><Citation>Ghadri J, Wittstein I, Prasad A, Sharkey S, Dote K, Akashi Y, et al. International expert consensus document on takotsubo syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. (2018) 39:2032&#x2013;46. 10.1093/eurheartj/ehy076</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy076</ArticleId><ArticleId IdType="pmc">PMC5991216</ArticleId><ArticleId IdType="pubmed">29850871</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Lerman A, Rihal C. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. (2008) 155:408&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">18294473</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh K, Carson K, Shah R, Sawhney G, Singh B, Parsaik A, et al. Meta-analysis of clinical correlates of acute mortality in takotsubo cardiomyopathy. Am J Cardiol. (2014) 113:1420&#x2013;8. 10.1016/j.amjcard.2014.01.419</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2014.01.419</ArticleId><ArticleId IdType="pubmed">24685327</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. (2015) 350:g7647.</Citation><ArticleIdList><ArticleId IdType="pubmed">25555855</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh H, Miyake Y, Hioki I, Tanaka S, Okabe M. Report of takotsubo cardiomyopathy occurring during cardiopulmonary bypass. J Extra Corpor Technol. (2007) 39:109&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4680663</ArticleId><ArticleId IdType="pubmed">17672194</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogan A, Ghosh P, Schwammenthal E, Raanani E. Takotsubo syndrome after cardiac surgery. Ann Thorac Surg. (2008) 85:1439&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18355549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bl&#xe1;zquez J, Gonz&#xe1;lez J, Dalmau M, L&#xf3;pez J. Takotsubo cardiomyopathy after elective mitral valve replacement. Interact Cardiovasc Thorac Surg. (2010) 11:117&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20395252</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamane K, Hirose H, Reeves G, Marhefka G, Silvestry S. Left ventricular dysfunction mimicking takotsubo cardiomyopathy following cardiac surgery. J Heart Valve Dis. (2011) 20:471&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21863664</ArticleId></ArticleIdList></Reference><Reference><Citation>Gariboldi V, Jop B, Grisoli D, Jaussaud N, Kerbaul F, Collart F. Takotsubo syndrome after mitral valve replacement for acute endocarditis. Ann Thorac Surg. (2011) 91:e31&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">21352964</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xe4;rber G, M&#xfc;hle A, Doenst T, Borger M, Mohr F. Late onset takotsubo cardiomyopathy after mitral valve replacement. Thorac Cardiovasc Surg. (2011) 59:500&#x2013;3. 10.1055/s-0030-1270798</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0030-1270798</ArticleId><ArticleId IdType="pubmed">21442586</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernick W, Hargrove W, Augoustides J, Horak J. Takotsubo cardiomyopathy associated with cardiac arrest following cardiac surgery: new variants of an unusual syndrome. J Card Surg. (2010) 25:679&#x2013;83. 10.1111/j.1540-8191.2010.01135.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1540-8191.2010.01135.x</ArticleId><ArticleId IdType="pubmed">21039858</ArticleId></ArticleIdList></Reference><Reference><Citation>Attisani M, Campanella A, Boffini M, Rinaldi M. Takotsubo cardiomyopathy after minimally invasive mitral valve surgery: clinical case and review. J Heart Valve Dis. (2013) 22:675&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">24383380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Jansz P, Baron D. Delirium and takotsubo cardiomyopathy following cardiac surgery. Anaesth Intensive Care. (2013) 41:437&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23659417</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Koerner M, El-Banayosy A, Soleimani B, Pae W, Leuenberger U. Takotsubo&#x2019;s syndrome after mitral valve repair and rescue with extracorporeal membrane oxygenation. Ann Thorac Surg. (2014) 97:1777&#x2013;8. 10.1016/j.athoracsur.2013.08.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2013.08.032</ArticleId><ArticleId IdType="pubmed">24792263</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorca R, Callejo F, Pun F, Mart&#xed;n M, Corros C, Alperi A, et al. Takotsubo syndrome after heart valve surgery. Int J Cardiol. (2015) 197:254&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26148767</ArticleId></ArticleIdList></Reference><Reference><Citation>Pergolini A, Zampi G, Casali G, Madeo A, Visconti C, Cipullo P, et al. Takotsubo syndrome after mitral valve replacement: case report and brief review of the literature. J Cardiothorac Vasc Anesth. (2015) 29:431&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24365714</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiariello G, Bruno P, Colizzi C, Crea F, Massetti M. Takotsubo cardiomyopathy following cardiac surgery. J Card Surg. (2016) 31:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">26661572</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Delgado M, Garc&#xed;a-Huertas D, Navarrete-S&#xe1;nchez I, Olivencia-Pe&#xf1;a L, Garrido J. Extracorporeal membrane oxygenation support for takotsubo syndrome and long QT after cardiac surgery. Med Intensiva. (2017) 41:441&#x2013;3. 10.1016/j.medin.2016.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medin.2016.07.007</ArticleId><ArticleId IdType="pubmed">27650460</ArticleId></ArticleIdList></Reference><Reference><Citation>Elikowski W, Ma&#x142;ek-Elikowska M, Greberski K, Rzymski S, Ko&#x142;owrotkiewicz A, Furmaniuk J, et al. Takotsubo syndrome following mitral valve replacement and left anterior descending coronary artery bypass grafting. Pol Merkur Lekarski. (2019) 46:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">30810114</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Oh I, Shin E, Lee S, Jeon J, Kim H, et al. Extracorporeal membrane oxygenation for takotsubo cardiomyopathy that developed after mitral valve replacement. Acute Crit Care. (2020) 35:51&#x2013;5. 10.4266/acc.2018.00304</Citation><ArticleIdList><ArticleId IdType="doi">10.4266/acc.2018.00304</ArticleId><ArticleId IdType="pmc">PMC7056952</ArticleId><ArticleId IdType="pubmed">31743637</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazhev Z, Stoev H. Takotsubo cardiomyopathy after elective aortic and mitral valve replacement. Folia Med (Plovdiv). (2020) 62:204&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32337907</ArticleId></ArticleIdList></Reference><Reference><Citation>Totaro P, Triolo O, Argano V. Rare but real: takotsubo syndrome following mitral valve surgery. J Card Surg. (2020) 35:721&#x2013;4. 10.1111/jocs.14453</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.14453</ArticleId><ArticleId IdType="pubmed">32027403</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Lim J. Risk factors for takotsubo syndrome following cardiac surgery: a case-control study. J Card Surg. (2021) 36:2767&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">33993525</ArticleId></ArticleIdList></Reference><Reference><Citation>Devesa A, Hernandez-Estefania R, Tunon J, Acena A. Takotsubo syndrome after mitral valve surgery: a case report. Eur Heart J Case Rep. (2020) 4:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793183</ArticleId><ArticleId IdType="pubmed">33442643</ArticleId></ArticleIdList></Reference><Reference><Citation>Akashi Y, Nakazawa K, Sakakibara M, Miyake F, Musha H, Sasaka K. 123I-MIBG myocardial scintigraphy in patients with &#x201c;takotsubo&#x201d; cardiomyopathy. J Nucl Med. (2004) 45:1121&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15235057</ArticleId></ArticleIdList></Reference><Reference><Citation>Abehsira G, Bachelot A, Badilini F, Koehl L, Lebot M, Favet C, et al. complex influence of gonadotropins and sex steroid hormones on QT interval duration. J Clin Endocrinol Metab. (2016) 101:2776&#x2013;84. 10.1210/jc.2016-1877</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2016-1877</ArticleId><ArticleId IdType="pubmed">27167057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancona F, Bertoldi L, Ruggieri F, Cerri M, Magnoni M, Beretta L, et al. Takotsubo cardiomyopathy and neurogenic stunned myocardium: similar albeit different. Eur Heart J. (2016) 37:2830&#x2013;2. 10.1093/eurheartj/ehw035</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw035</ArticleId><ArticleId IdType="pubmed">26922810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu M, Gao Z, Zhang X, Liao D, Pu D, Brennan T, et al. Impact of mitral regurgitation on left ventricular anatomic and molecular remodeling and systolic function: implication for outcome. Am J Physiol Heart Circ Physiol. (2009) 296:H1727&#x2013;32. 10.1152/ajpheart.00882.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00882.2008</ArticleId><ArticleId IdType="pubmed">19329766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehat I, Molkentin J. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. (2010) 122:2727&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076218</ArticleId><ArticleId IdType="pubmed">21173361</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell B, Motlagh D, Ashley W. Form follows function: how muscle shape is regulated by work. J Appl Physiol (1985). (2000) 88:1127&#x2013;32. 10.1152/jappl.2000.88.3.1127</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.2000.88.3.1127</ArticleId><ArticleId IdType="pubmed">10710412</ArticleId></ArticleIdList></Reference><Reference><Citation>Walmsley J, Squara P, Wolfhard U, Cornelussen R, Lumens J. Impact of abrupt versus gradual correction of mitral and tricuspid regurgitation: a modelling study. EuroIntervention. (2019) 15:902&#x2013;11. 10.4244/EIJ-D-19-00598</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-D-19-00598</ArticleId><ArticleId IdType="pubmed">31746755</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Wakeel N, Fernandes J, Amiri A, Siniawski H, Goubergrits L, Berger F, et al. Hemodynamic and energetic aspects of the left ventricle in patients with mitral regurgitation before and after mitral valve surgery. J Magn Reson Imaging. (2015) 42:1705&#x2013;12. 10.002/jmri.24926</Citation><ArticleIdList><ArticleId IdType="doi">10.002/jmri.24926</ArticleId><ArticleId IdType="pubmed">25918860</ArticleId></ArticleIdList></Reference><Reference><Citation>Scally C, Abbas H, Ahearn T, Srinivasan J, Mezincescu A, Rudd A, et al. Myocardial and systemic inflammation in acute stress-induced (takotsubo) cardiomyopathy. Circulation. (2019) 139:1581&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438459</ArticleId><ArticleId IdType="pubmed">30586731</ArticleId></ArticleIdList></Reference><Reference><Citation>Wehlin L, Vedin J, Vaage J, Lundahl J. Peripheral blood monocyte activation during coronary artery bypass grafting with or without cardiopulmonary bypass. Scand Cardiovasc J. (2005) 39:78&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16097419</ArticleId></ArticleIdList></Reference><Reference><Citation>Halter J, Steinberg J, Fink G, Lutz C, Picone A, Maybury R, et al. Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass. J Extra Corpor Technol. (2005) 37:272&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4680784</ArticleId><ArticleId IdType="pubmed">16350379</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Martinez J, Shen J. Lamotrigine-induced hemophagocytic lymphohistiocytosis with takotsubo cardiomyopathy: a case report. J Med Case Rep. (2019) 13:345. 10.1186/s13256-019-2295-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-019-2295-1</ArticleId><ArticleId IdType="pmc">PMC6878683</ArticleId><ArticleId IdType="pubmed">31767022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah W, Hamid M, Grover H, Figueredo V, Inayat F. Takotsubo cardiomyopathy secondary to haemophagocytic lymphohistiocytosis in HIV patients: a comprehensive review. BMJ Case Rep. (2019) 12:e226599. 10.1136/bcr-2018-226599</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2018-226599</ArticleId><ArticleId IdType="pmc">PMC6510155</ArticleId><ArticleId IdType="pubmed">31015233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortuno S, Jozwiak M, Mira J, Nguyen L. Case report: takotsubo syndrome associated with novel coronavirus disease 2019. Front Cardiovasc Med. (2021) 8:614562. 10.3389/fcvm.2021.614562</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.614562</ArticleId><ArticleId IdType="pmc">PMC7937625</ArticleId><ArticleId IdType="pubmed">33693034</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Barsness G, Herrmann J, Anavekar N, Gulati R, Prasad A. Comparison of complications and in-hospital mortality in takotsubo (apical ballooning/stress) cardiomyopathy versus acute myocardial infarction. Am J Cardiol. (2020) 132:29&#x2013;35. 10.1016/j.amjcard.2020.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.07.015</ArticleId><ArticleId IdType="pubmed">32762963</ArticleId></ArticleIdList></Reference><Reference><Citation>Redfors B, Vedad R, Anger&#xe5;s O, R&#xe5;munddal T, Petursson P, Haraldsson I, et al. Mortality in takotsubo syndrome is similar to mortality in myocardial infarction&#x2013;a report from the SWEDEHEART registry. Int J Cardiol. (2015) 185:282&#x2013;9. 10.1016/j.ijcard.2015.03.162</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.03.162</ArticleId><ArticleId IdType="pubmed">25818540</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Dunlay S, Murphree D, Jr., Barsness G, Sandhu G, Lerman A, et al. Cardiogenic shock in takotsubo cardiomyopathy versus acute myocardial infarction: an 8-year national perspective on clinical characteristics, management, and outcomes. JACC Heart Fail. (2019) 7:469&#x2013;76. 10.1016/j.jchf.2018.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2018.12.007</ArticleId><ArticleId IdType="pubmed">31078481</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvin E, Stern D, Goldstein D. Mechanical support for postcardiotomy cardiogenic shock: has progress been made? J Card Surg. (2010) 25:442&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">20487107</ArticleId></ArticleIdList></Reference><Reference><Citation>Landoni G, Lomivorotov V, Alvaro G, Lobreglio R, Pisano A, Guarracino F, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. (2017) 376:2021&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28320259</ArticleId></ArticleIdList></Reference><Reference><Citation>Madias J. Pathophysiology of takotsubo syndrome: do not forsake coronary vasospasm! Int J Cardiol. (2018) 266:42.</Citation><ArticleIdList><ArticleId IdType="pubmed">29887470</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuura T, Ueno M, Iwanaga Y, Miyazaki S. Importance of sympathetic nervous system activity during left ventricular functional recovery and its association with in-hospital complications in takotsubo syndrome. Heart Vessels. (2019) 34:1317&#x2013;24. 10.1007/s00380-019-01359-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-019-01359-4</ArticleId><ArticleId IdType="pubmed">30796565</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa M, Ferraz P, Escobar R, Martins W, de Araujo e Sa F, Lustosa P, et al. Preservation versus non-preservation of mitral valve apparatus during mitral valve replacement: a meta-analysis of 3835 patients. Interact Cardiovasc Thorac Surg. (2012) 15:1033&#x2013;9. 10.1093/icvts/ivs379</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivs379</ArticleId><ArticleId IdType="pmc">PMC3501301</ArticleId><ArticleId IdType="pubmed">23027596</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36195825</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1496-8975</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Canadian journal of anaesthesia = Journal canadien d'anesthesie</Title><ISOAbbreviation>Can J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis.</ArticleTitle><Pagination><StartPage>1537</StartPage><EndPage>1553</EndPage><MedlinePgn>1537-1553</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12630-022-02337-7</ELocationID><Abstract><AbstractText Label="PURPOSE">To compare the relative efficacy of supportive therapies (inotropes, vasopressors, and mechanical circulatory support [MCS]) for adult patients with cardiogenic shock complicating acute myocardial infarction.</AbstractText><AbstractText Label="SOURCE">We conducted a systematic review and network meta-analysis and searched six databases from inception to December 2021 for randomized clinical trials (RCTs). We evaluated inotropes, vasopressors, and MCS in separate networks. Two reviewers performed screening, full-text review, and extraction. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework to rate the certainty in findings. The critical outcome of interest was 30-day all-cause mortality.</AbstractText><AbstractText Label="PRINCIPAL FINDINGS">We included 17 RCTs. Among inotropes (seven RCTs, 1,145 patients), levosimendan probably reduces mortality compared with placebo (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.33 to 0.87; moderate certainty), but primarily in lower severity shock. Milrinone (OR, 0.52; 95% CI, 0.19 to 1.39; low certainty) and dobutamine (OR, 0.67, 95% CI, 0.30 to 1.49; low certainty) may have no effect on mortality compared with placebo. With regard to MCS (eight RCTs, 856 patients), there may be no effect on mortality with an intra-aortic balloon pump (IABP) (OR, 0.94; 95% CI, 0.69 to 1.28; low certainty) or percutaneous MCS (pMCS) (OR, 0.96; 95% CI, 0.47 to 1.98; low certainty), compared with a strategy involving no MCS. Intra-aortic balloon pump use was associated with less major bleeding compared with pMCS. We found only two RCTs evaluating vasopressors, yielding insufficient data for meta-analysis.</AbstractText><AbstractText Label="CONCLUSION">The results of this systematic review and network meta-analysis indicate that levosimendan reduces mortality compared with placebo among patients with low severity cardiogenic shock. Intra-aortic balloon pump and pMCS had no effect on mortality compared with a strategy of no MCS, but pMCS was associated with higher rates of major bleeding.</AbstractText><AbstractText Label="STUDY REGISTRATION">Center for Open Science ( https://osf.io/ky2gr ); registered 10 November 2020.</AbstractText><CopyrightInformation>&#xa9; 2022. Canadian Anesthesiologists' Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernando</LastName><ForeName>Shannon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada. sfernando@qmed.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. sfernando@qmed.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Critical Care, Lakeridge Health Corporation, Oshawa, ON, Canada. sfernando@qmed.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghirad</LastName><ForeName>Behnam</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodie</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belley-C&#xf4;t&#xe9;</LastName><ForeName>Emilie P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Research Institute, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Diepen</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Eddy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Santo</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Trevor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe9;vy</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale Brabois, CHRU Nancy, P&#xf4;le Cardio-M&#xe9;dico-Chirurgical, Nancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NSERM U1116, Facult&#xe9; de M&#xe9;decine, Universit&#xe9; de Lorraine, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Combes</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition, Sorbonne Universit&#xe9;, INSERM Unite Mixte de Recherche (UMRS) 1166, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, Assistance Publique-H&#xf4;pitaux de Paris (APHP), H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hibbert</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rochwerg</LastName><ForeName>Bram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><VernacularTitle>Inotropes, vasopresseurs et assistance circulatoire m&#xe9;canique pour le traitement de choc cardiog&#xe9;nique compliquant un infarctus du myocarde : une revue syst&#xe9;matique et une m&#xe9;ta-analyse en r&#xe9;seau.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Anaesth</MedlineTA><NlmUniqueID>8701709</NlmUniqueID><ISSNLinking>0832-610X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="UNLABELLED">R&#xe9;SUM&#xe9;: OBJECTIF: Comparer l&#x2019;efficacit&#xe9; relative des th&#xe9;rapies de soutien (inotropes, vasopresseurs et assistance circulatoire m&#xe9;canique [ACM]) chez les patients adultes atteints d&#x2019;un choc cardiog&#xe9;nique compliquant un infarctus aigu du myocarde.</AbstractText><AbstractText Label="SOURCES" NlmCategory="METHODS">Nous avons r&#xe9;alis&#xe9; une revue syst&#xe9;matique et une m&#xe9;ta-analyse en r&#xe9;seau et effectu&#xe9; des recherches dans six bases de donn&#xe9;es depuis leur cr&#xe9;ation jusqu&#x2019;&#xe0; d&#xe9;cembre 2021 pour en tirer les &#xe9;tudes randomis&#xe9;es contr&#xf4;l&#xe9;es (ERC). Nous avons &#xe9;valu&#xe9; les inotropes, les vasopresseurs et les ACM dans des r&#xe9;seaux distincts. Deux r&#xe9;viseurs ont effectu&#xe9; la recherche, l&#x2019;&#xe9;valuation du texte int&#xe9;gral et l&#x2019;extraction. Nous avons utilis&#xe9; le syst&#xe8;me de notation GRADE (Grading of Recommendations Assessment, Development, and Evaluation) pour &#xe9;valuer la certitude des r&#xe9;sultats. Le crit&#xe8;re d&#x2019;&#xe9;valuation d&#x2019;int&#xe9;r&#xea;t &#xe9;tait la mortalit&#xe9; toutes causes confondues &#xe0; 30 jours.</AbstractText><AbstractText Label="CONSTATATIONS PRINCIPALES" NlmCategory="UNASSIGNED">Nous avons inclus 17 ERC. Parmi les inotropes (sept ERC, 1145 patients), le l&#xe9;vosimendan a probablement r&#xe9;duit la mortalit&#xe9; par rapport au placebo (rapport de cotes [RC], 0,53; intervalle de confiance [IC] &#xe0; 95 %, 0,33 &#xe0; 0,87; certitude mod&#xe9;r&#xe9;e), mais principalement en cas de choc de s&#xe9;v&#xe9;rit&#xe9; moindre. La milrinone (RC, 0,52; IC 95 %, 0,19 &#xe0; 1,39; certitude faible) et la dobutamine (RC, 0,67, IC 95 %, 0,30 &#xe0; 1,49; certitude faible) pourraient n&#x2019;avoir aucun effet sur la mortalit&#xe9; par rapport au placebo. En ce qui concerne l&#x2019;ACM (huit ERC, 856 patients), il pourrait n&#x2019;y avoir aucun effet sur la mortalit&#xe9; avec un ballon intra-aortique (IABP) (RC, 0,94; IC 95 %, 0,69 &#xe0; 1,28; certitude faible) ou un ACM percutan&#xe9; (ACMp) (RC, 0,96; IC 95 %, 0,47 &#xe0; 1,98; certitude faible), par rapport &#xe0; une strat&#xe9;gie sans ACM. L&#x2019;utilisation d&#x2019;un ballon intra-aortique &#xe9;tait associ&#xe9;e &#xe0; moins de saignements majeurs par rapport &#xe0; une ACMp. Nous n&#x2019;avons trouv&#xe9; que deux ERC &#xe9;valuant les vasopresseurs, ce qui n&#x2019;a pas fourni suffisamment de donn&#xe9;es pour la m&#xe9;ta-analyse.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Les r&#xe9;sultats de cette revue syst&#xe9;matique et de la m&#xe9;ta-analyse en r&#xe9;seau indiquent que le l&#xe9;vosimendan r&#xe9;duit la mortalit&#xe9; par rapport au placebo chez les patients pr&#xe9;sentant un choc cardiog&#xe9;nique de faible gravit&#xe9;. Le ballon intra-aortique et l&#x2019;ACMp n&#x2019;ont eu aucun effet sur la mortalit&#xe9; par rapport &#xe0; une strat&#xe9;gie sans ACM, mais l&#x2019;ACMp &#xe9;tait associ&#xe9;e &#xe0; des taux plus &#xe9;lev&#xe9;s de saignements majeurs. ENREGISTREMENT DE L&#x2019;&#xe9;TUDE: Center for Open Science ( https://osf.io/ky2gr ); enregistr&#xe9;e le 10 novembre 2020.</AbstractText><CopyrightInformation>&#xa9; 2022. Canadian Anesthesiologists' Society.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">cardiology</Keyword><Keyword MajorTopicYN="N">critical care medicine</Keyword><Keyword MajorTopicYN="N">inotropes</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">vasopressors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>4</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36195825</ArticleId><ArticleId IdType="doi">10.1007/s12630-022-02337-7</ArticleId><ArticleId IdType="pii">10.1007/s12630-022-02337-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017; 136: e232&#x2013;68. https://doi.org/10.1161/cir.0000000000000525</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000525</ArticleId><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A, Combes A, van Diepen S, et al. Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med 2018; 44: 760&#x2013;73. https://doi.org/10.1007/s00134-018-5214-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-018-5214-9</ArticleId><ArticleId IdType="pubmed">29767322</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J 2019; 40: 2671&#x2013;83. https://doi.org/10.1093/eurheartj/ehz363</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz363</ArticleId><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340: 1162&#x2013;8. https://doi.org/10.1056/nejm199904153401504</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199904153401504</ArticleId><ArticleId IdType="pubmed">10202167</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung RG, Di Santo P, Mathew R, et al. Implications of myocardial infarction on management and outcome in cardiogenic shock. J Am Heart Assoc 2021; 10: e021570. https://doi.org/10.1161/jaha.121.021570</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/jaha.121.021570</ArticleId><ArticleId IdType="pubmed">34713704</ArticleId><ArticleId IdType="pmc">8751815</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, Puymirat E, Delmas C, et al. Trends in cardiogenic shock complicating acute myocardial infarction. Eur J Heart Fail 2020; 22: 664&#x2013;72. https://doi.org/10.1002/ejhf.1750</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1750</ArticleId><ArticleId IdType="pubmed">32078218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999; 341: 625&#x2013;34. https://doi.org/10.1056/nejm199908263410901</Citation></Reference><Reference><Citation>Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017; 377: 2419&#x2013;32. https://doi.org/10.1056/nejmoa1710261</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1710261</ArticleId><ArticleId IdType="pubmed">29083953</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry TD, Tomey MI, Tamis-Holland JE, et al. Invasive management of acute myocardial infarction complicated by cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2021; 143: e815&#x2013;29. https://doi.org/10.1161/cir.0000000000000959</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000959</ArticleId><ArticleId IdType="pubmed">33657830</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy B, Buzon J, Kimmoun A. Inotropes and vasopressors use in cardiogenic shock: when, which and how much? Curr Opin Crit Care 2019; 25: 384&#x2013;90. https://doi.org/10.1097/mcc.0000000000000632</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mcc.0000000000000632</ArticleId><ArticleId IdType="pubmed">31166204</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheeren TW, Bakker J, Kaufmann T, et al. Current use of inotropes in circulatory shock. Ann Intensive Care 2021; 11: 21. https://doi.org/10.1186/s13613-021-00806-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00806-8</ArticleId><ArticleId IdType="pubmed">33512597</ArticleId><ArticleId IdType="pmc">7846624</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Price S, Slutsky AS, Brodie D. Temporary circulatory support for cardiogenic shock. Lancet 2020; 396: 199&#x2013;212. https://doi.org/10.1016/s0140-6736(20)31047-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)31047-3</ArticleId><ArticleId IdType="pubmed">32682486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni hici T, Boardman HM, Baig K, et al. Mechanical assist devices for acute cardiogenic shock. Cochrane Database Syst Rev 2020; 6: CD013002. https://doi.org/10.1002/14651858.cd013002.pub2</Citation></Reference><Reference><Citation>Uhlig K, Efremov L, Tongers J, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 2020; 11: CD009669. https://doi.org/10.1002/14651858.cd009669.pub4</Citation></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 2019; 94: 29&#x2013;37. https://doi.org/10.1002/ccd.28329</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28329</ArticleId><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. https://doi.org/10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777&#x2013;84. https://doi.org/10.7326/m14-2385</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Savovi&#x107;, Page MJ, Sterne JA. Revised Cochrane risk of bias tool for randomized trials (ROB 2.0), 2016. Available from URL: https://www.unisa.edu.au/contentassets/72bf75606a2b4abcaf7f17404af374ad/rob2-0_indiv_main_guidance.pdf (accessed July 2022).</Citation></Reference><Reference><Citation>DerSimonian R, La&#xec;rd N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177&#x2013;88. https://doi.org/10.1016/0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012; 3: 98&#x2013;110. https://doi.org/10.1002/jrsm.1044</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1044</ArticleId><ArticleId IdType="pubmed">26062084</ArticleId><ArticleId IdType="pmc">4433772</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557&#x2013;60. https://doi.org/10.1136/bmj.327.7414.557</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId><ArticleId IdType="pmc">192859</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012; 3: 111&#x2013;25. https://doi.org/10.1002/jrsm.1045</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1045</ArticleId><ArticleId IdType="pubmed">26062085</ArticleId><ArticleId IdType="pmc">4433771</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR. Network meta-analysis. Stata J 2015; 15: 951&#x2013;85.</Citation></Reference><Reference><Citation>Fernando SM, Di Santo P, Sadeghirad B, et al. Targeted temperature management following out-of-hospital cardiac arrest: a systematic review and network meta-analysis of temperature targets. Intensive Care Med 2021; 47: 1078&#x2013;88. https://doi.org/10.1007/s00134-021-06505-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06505-z</ArticleId><ArticleId IdType="pubmed">34389870</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando SM, Tran A, Sadeghirad B, et al. Noninvasive respiratory support following extubation in critically ill adults: a systematic review and network meta-analysis. Intensive Care Med 2022; 48: 137&#x2013;47. https://doi.org/10.1007/s00134-021-06581-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06581-1</ArticleId><ArticleId IdType="pubmed">34825256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006; 101: 447&#x2013;59. https://doi.org/10.1198/016214505000001302</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/016214505000001302</ArticleId></ArticleIdList></Reference><Reference><Citation>Yepes-Nu&#xf1;ez JJ, Li SA, Guyatt G, et al. Development of the summary of findings table for network meta-analysis. J Clin Epidemiol 2019; 115: 1&#x2013;13. https://doi.org/10.1016/j.jclinepi.2019.04.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2019.04.018</ArticleId><ArticleId IdType="pubmed">31055177</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from&#xa0;a network meta-analysis. J Clin Epidemiol 2018; 93: 36&#x2013;44. https://doi.org/10.1016/j.jclinepi.2017.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2017.10.005</ArticleId><ArticleId IdType="pubmed">29051107</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020; 371: m3900. https://doi.org/10.1136/bmj.m3900</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3900</ArticleId><ArticleId IdType="pubmed">33177059</ArticleId></ArticleIdList></Reference><Reference><Citation>Santesso N, Glenton C, Dahm P, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 2020; 119: 126&#x2013;35. https://doi.org/10.1016/j.jclinepi.2019.10.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2019.10.014</ArticleId><ArticleId IdType="pubmed">31711912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochaton T, Huot L, Elbaz M, et al. Mechanical circulatory support with the Impella&#xae; LP5.0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: the IMPELLA-STIC randomized study. Arch Cardiovasc Dis 2020; 113: 237&#x2013;43. https://doi.org/10.1016/j.acvd.2019.10.005</Citation></Reference><Reference><Citation>Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW, TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006; 152: e1&#x2013;8. https://doi.org/10.1016/j.ahj.2006.05.031</Citation></Reference><Reference><Citation>Caldicott LD, Hawley K, Heppell R, Woodmansey PA, Channer KS. Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double-blind trial. Eur Heart J 1993; 14: 696&#x2013;700. https://doi.org/10.1093/eurheartj/14.5.696</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/14.5.696</ArticleId><ArticleId IdType="pubmed">8508864</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779&#x2013;89. https://doi.org/10.1056/nejmoa0907118</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa0907118</ArticleId><ArticleId IdType="pubmed">20200382</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann JT, Schmeisser A, Schulze MR, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008; 36: 2257&#x2013;66. https://doi.org/10.1097/ccm.0b013e3181809846</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ccm.0b013e3181809846</ArticleId><ArticleId IdType="pubmed">18664782</ArticleId></ArticleIdList></Reference><Reference><Citation>Husebye T, Eritsland J, M&#xfc;ller C, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail 2013; 15: 565&#x2013;72. https://doi.org/10.1093/eurjhf/hfs215</Citation></Reference><Reference><Citation>Jia Z, Guo M, Zhang YQ, Liang HQ, Zhang LY, Song Y. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology 2014; 128: 195-201. https://doi.org/10.1159/000357864</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000357864</ArticleId><ArticleId IdType="pubmed">24751462</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy B, Clere-Jehl R, Legras A, et al. Epinephrine versus norepinephrine for&#xa0;cardiogenic shock after acute&#xa0;myocardial infarction. J Am Coll Cardiol 2018; 72: 173&#x2013;82. https://doi.org/10.1016/j.jacc.2018.04.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.04.051</ArticleId><ArticleId IdType="pubmed">29976291</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew R, Di Santo P, Jung RG, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med 2021; 385: 516&#x2013;25. https://doi.org/10.1056/nejmoa2026845</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2026845</ArticleId><ArticleId IdType="pubmed">34347952</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297: 1883&#x2013;91. https://doi.org/10.1001/jama.297.17.1883</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.297.17.1883</ArticleId><ArticleId IdType="pubmed">17473298</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiseyev VS, P&#xf5;der P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422&#x2013;32. https://doi.org/10.1053/euhj.2001.3158</Citation></Reference><Reference><Citation>Ohman EM, Nanas J, Stomel RJ, et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis 2005; 19: 33&#x2013;9. https://doi.org/10.1007/s11239-005-0938-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-005-0938-0</ArticleId><ArticleId IdType="pubmed">15976965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump&#xa0;in cardiogenic shock after acute&#xa0;myocardial infarction. J Am Coll Cardiol 2017; 69: 278&#x2013;87. https://doi.org/10.1016/j.jacc.2016.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.10.022</ArticleId><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Prondzinsky R, Lemm H, Swyter M, et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010; 38: 152&#x2013;60. https://doi.org/10.1097/ccm.0b013e3181b78671</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ccm.0b013e3181b78671</ArticleId><ArticleId IdType="pubmed">19770739</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008; 52: 1584&#x2013;8. https://doi.org/10.1016/j.jacc.2008.05.065</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2008.05.065</ArticleId><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26: 1276&#x2013;83. https://doi.org/10.1093/eurheartj/ehi161</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehi161</ArticleId><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287&#x2013;96. https://doi.org/10.1056/nejmoa1208410</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1208410</ArticleId><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022; 145: e895&#x2013;1032. https://doi.org/10.1161/cir.0000000000001063</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000001063</ArticleId><ArticleId IdType="pubmed">35363499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholley B, Levy B, Fellahi JL, et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care 2019; 23: 385. https://doi.org/10.1186/s13054-019-2674-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2674-4</ArticleId><ArticleId IdType="pubmed">31783891</ArticleId><ArticleId IdType="pmc">6883606</ArticleId></ArticleIdList></Reference><Reference><Citation>Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997&#x2013;1003. https://doi.org/10.1016/s0735-1097(02)02968-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(02)02968-6</ArticleId><ArticleId IdType="pubmed">12651048</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002; 144: 1102&#x2013;8. https://doi.org/10.1067/mhj.2002.125620</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mhj.2002.125620</ArticleId><ArticleId IdType="pubmed">12486437</ArticleId></ArticleIdList></Reference><Reference><Citation>Squara P, Hollenberg S, Payen D. Reconsidering vasopressors for cardiogenic shock: everything should be made as simple as possible, but not simpler. Chest 2019; 156: 392&#x2013;401. https://doi.org/10.1016/j.chest.2019.03.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2019.03.020</ArticleId><ArticleId IdType="pubmed">30935893</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017; 38: 3523&#x2013;31. https://doi.org/10.1093/eurheartj/ehx363</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx363</ArticleId><ArticleId IdType="pubmed">29020341</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando SM, Qureshi D, Tanuseputro P, et al. Mortality and costs following extracorporeal membrane oxygenation in critically ill adults: a population-based cohort study. Intensive Care Med 2019; 45: 1580&#x2013;9. https://doi.org/10.1007/s00134-019-05766-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-019-05766-z</ArticleId><ArticleId IdType="pubmed">31529353</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando SM, Qureshi D, Tanuseputro P, et al. Long-term mortality and costs following use of Impella&#xae; for mechanical circulatory support: a population-based cohort study. Can J Anesth 2020; 67: 1728&#x2013;37. https://doi.org/10.1007/s12630-020-01755-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-020-01755-9</ArticleId><ArticleId IdType="pubmed">32671805</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35122776</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3763</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Indian heart journal</Title><ISOAbbreviation>Indian Heart J</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis of incidence and outcomes of life-threatening arrhythmias in takotsubo cardiomyopathy.</ArticleTitle><Pagination><StartPage>110</StartPage><EndPage>119</EndPage><MedlinePgn>110-119</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ihj.2022.01.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0019-4832(22)00024-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Takotsubo cardiomyopathy (TC) or stress-induced cardiomyopathy is a transient heart condition that clinically resembles an acute coronary syndrome. This study aims to assess the incidence of life-threatening arrhythmias in patients with Takotsubo cardiomyopathy and evaluate the outcomes of patients with life-threatening arrhythmias (LTAs) in Takotsubo cardiomyopathy compared with those without LTA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We comprehensively searched the PubMed, Google Scholar, and Embase databases from inception to February 2021. The primary aim of the study was to determine the incidence of LTAs in TC patients. Other outcomes of interest were the odds of in-hospital, long-term mortality, and cardiogenic shock (CS) in TC patients with LTAs versus those without LTAs. For all statistical analyses, ReviewManager and MedCalc were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen studies were included in this study involving 55,557 participants (2,185 with LTAs and 53,372 without LTAs). The pooled incidence of LTAs in the patients of TC was found to be 6.29% (CI: 4.70-8.08%; I2&#xa0;=&#xa0;94.67%). There was a statistically significant increased risk of in-hospital mortality (OR&#xa0;=&#xa0;4.74; CI: 2.24-10.04; I2&#xa0;=&#xa0;77%, p&#xa0;&lt;&#xa0;0.0001) and cardiogenic shock (OR&#xa0;=&#xa0;5.60; CI: 3.51-8.95; I2&#xa0;=&#xa0;0%, p&#xa0;&lt;&#xa0;0.00001) in the LTA group versus the non-LTA group. LTA was not associated with long-term mortality (OR&#xa0;=&#xa0;2.23; CI: 0.94-5.28; I2&#xa0;=&#xa0;53%, p&#xa0;=&#xa0;0.07).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The pooled incidence of life-threatening arrhythmias in the patients of TC was found to be 6.29%. In the group of TC patients with LTAs, the odds of in-hospital mortality and CS, was higher than in the TC patients without LTAs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rathore</LastName><ForeName>Sawai Singh</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Kinza</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafqat</LastName><ForeName>Shameel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariq</LastName><ForeName>Eleze</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tousif</LastName><ForeName>Sohaib</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ziauddin University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>UlHaq</LastName><ForeName>Zain Ghufran</ForeName><Initials>ZG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ziauddin University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-S&#xe1;nchez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Universidad Del Norte, Barranquilla, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Woodbine</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Universidad Del Norte, Barranquilla, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granados-Mendoza</LastName><ForeName>Sofia Carolina</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Universidad Del Norte, Barranquilla, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacouture-C&#xe1;rdenas</LastName><ForeName>Natalia Andrea</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Universidad Del Norte, Barranquilla, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avenda&#xf1;o-Capriles</LastName><ForeName>Camilo Andr&#xe9;s</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Universidad Del Norte, Barranquilla, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maheshwari</LastName><ForeName>Chanchal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Karachi Medical College and Hospital, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Aimen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bahria University Medical and Dental College, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahalwar</LastName><ForeName>Gauranga</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shariff</LastName><ForeName>Mariam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA; Section of Cardiovascular Research, Heart, Vascular and Thoracic Department, Cleveland Clinic Akron General, Akron, OH, USA. Electronic address: drashishkumar.u@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian Heart J</MedlineTA><NlmUniqueID>0374675</NlmUniqueID><ISSNLinking>0019-4832</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054549" MajorTopicYN="Y">Takotsubo Cardiomyopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Life-threatening arrhythmias</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Takotsubo cardiomyopathy</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>5</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35122776</ArticleId><ArticleId IdType="pmc">PMC9039676</ArticleId><ArticleId IdType="doi">10.1016/j.ihj.2022.01.005</ArticleId><ArticleId IdType="pii">S0019-4832(22)00024-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gianni M., Dentali F., Grandi A.M., Sumner G., Hiralal R., Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J. 2006;27:1523&#x2013;1529. doi: 10.1093/eurheartj/ehl032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehl032</ArticleId><ArticleId IdType="pubmed">16720686</ArticleId></ArticleIdList></Reference><Reference><Citation>Akashi Y.J., Nef H.M., Lyon A.R. Epidemiology and pathophysiology of Takotsubo syndrome. Nat Rev Cardiol. 2015;12:387&#x2013;397. doi: 10.1038/nrcardio.2015.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2015.39</ArticleId><ArticleId IdType="pubmed">25855605</ArticleId></ArticleIdList></Reference><Reference><Citation>Veillet-Chowdhury M., Hassan S.F., Stergiopoulos K. Takotsubo cardiomyopathy: a review. Acute Card Care. 2014;16:15&#x2013;22. doi: 10.3109/17482941.2013.869346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482941.2013.869346</ArticleId><ArticleId IdType="pubmed">24552225</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin H.Z., Amin L.Z., Pradipta A. Takotsubo cardiomyopathy: a brief review. J&#xa0;Med Life. 2020;13:3&#x2013;7. doi: 10.25122/jml-2018-0067.</Citation><ArticleIdList><ArticleId IdType="doi">10.25122/jml-2018-0067</ArticleId><ArticleId IdType="pmc">PMC7175432</ArticleId><ArticleId IdType="pubmed">32341693</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown K.H., Trohman R.G., Madias C. Arrhythmias in takotsubo cardiomyopathy. Card Electrophysiol Clin. 2015;7:331&#x2013;340. doi: 10.1016/j.ccep.2015.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccep.2015.03.015</ArticleId><ArticleId IdType="pubmed">26002397</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesel L., Berthon C., Messas N., et al. Atrial arrhythmias in Takotsubo cardiomyopathy: incidence, predictive factors, and prognosis. Eur Eur Pacing, Arrhythmias, Card Electrophysiol J Work Groups Card Pacing, Arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:298&#x2013;305. doi: 10.1093/europace/euy147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euy147</ArticleId><ArticleId IdType="pubmed">30007327</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Lerman A., Rihal C.S. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155:408&#x2013;417. doi: 10.1016/j.ahj.2007.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2007.11.008</ArticleId><ArticleId IdType="pubmed">18294473</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore F., Zorzi A., Peruzza F., et al. Incidence and management of life-threatening arrhythmias in Takotsubo syndrome. Int J Cardiol. 2013;166:261&#x2013;263. doi: 10.1016/j.ijcard.2012.09.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2012.09.107</ArticleId><ArticleId IdType="pubmed">23098850</ArticleId></ArticleIdList></Reference><Reference><Citation>Malanchini G., Del Corral M.P., De Filippo P., Ferrari P., Solomon A., Krepp J. Cardiac arrhythmias and In-hospital mortality amongst patients with takotsubo cardiomyopathy: a retrospective study in an Italian population. Int J Cardiol Hear Vasc. 2020;31:100608. doi: 10.1016/j.ijcha.2020.100608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2020.100608</ArticleId><ArticleId IdType="pmc">PMC7475186</ArticleId><ArticleId IdType="pubmed">32923578</ArticleId></ArticleIdList></Reference><Reference><Citation>Templin C., Ghadri J.R., Diekmann J., et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N&#xa0;Engl J Med. 2015;373:929&#x2013;938. doi: 10.1056/NEJMoa1406761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1406761</ArticleId><ArticleId IdType="pubmed">26332547</ArticleId></ArticleIdList></Reference><Reference><Citation>Madias C., Fitzgibbons T.P., Alsheikh-Ali A.A., et al. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Heart Rhythm. 2011;8:555&#x2013;561. doi: 10.1016/j.hrthm.2010.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2010.12.012</ArticleId><ArticleId IdType="pubmed">21146632</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiermaier T., Eitel C., Denef S., et al. Prevalence and clinical significance of life-threatening arrhythmias in takotsubo cardiomyopathy. J&#xa0;Am Coll Cardiol. 2015;65:2148&#x2013;2150. doi: 10.1016/j.jacc.2015.02.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.02.062</ArticleId><ArticleId IdType="pubmed">25975480</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Battrawy I., Lang S., Ansari U., et al. Impact of concomitant atrial fibrillation on the prognosis of Takotsubo cardiomyopathy. Eur Eur Pacing, Arrhythmias, Card Electrophysiol J Work Groups Card Pacing, Arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol. 2017;19:1288&#x2013;1292. doi: 10.1093/europace/euw293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euw293</ArticleId><ArticleId IdType="pubmed">27702871</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tulder M., Furlan A., Bombardier C., Bouter L. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine (Phila Pa. 1976;28:1290&#x2013;1299. doi: 10.1097/01.BRS.0000065484.95996.AF. 2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.BRS.0000065484.95996.AF</ArticleId><ArticleId IdType="pubmed">12811274</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136/bmj.b2700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo C.K.L., Mertz D., Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014;14:1&#x2013;5. doi: 10.1186/1471-2288-14-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-45</ArticleId><ArticleId IdType="pmc">PMC4021422</ArticleId><ArticleId IdType="pubmed">24690082</ArticleId></ArticleIdList></Reference><Reference><Citation>Auzel O., Mustafic H., Pilli&#xe8;re R., El Mahmoud R., Dubourg O., Mansencal N. Incidence, characteristics, risk factors, and outcomes of takotsubo cardiomyopathy with and without ventricular arrhythmia. Am J Cardiol. 2016;117:1242&#x2013;1247. doi: 10.1016/j.amjcard.2016.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2016.01.017</ArticleId><ArticleId IdType="pubmed">26874546</ArticleId></ArticleIdList></Reference><Reference><Citation>Dib C., Prasad A., Friedman P.A., et al. Malignant arrhythmia in apical ballooning syndrome: risk factors and outcomes. Indian Pacing Electrophysiol J. 2008;8:182&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2490812</ArticleId><ArticleId IdType="pubmed">18679529</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesel L., Berthon C., Messas N., et al. Ventricular arrhythmias and sudden cardiac arrest in Takotsubo cardiomyopathy: incidence, predictive factors, and clinical implications. Heart Rhythm. 2018;15:1171&#x2013;1178. doi: 10.1016/j.hrthm.2018.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2018.04.002</ArticleId><ArticleId IdType="pubmed">29627435</ArticleId></ArticleIdList></Reference><Reference><Citation>Song B.G., Hahn J.-Y., Cho S.J., et al. Clinical characteristics, ballooning pattern, and long-term prognosis of transient left ventricular ballooning syndrome. Heart Lung. 2010;39:188&#x2013;195. doi: 10.1016/j.hrtlng.2009.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2009.07.006</ArticleId><ArticleId IdType="pubmed">20457338</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharkey S.W., Pink V.R., Lesser J.R., Garberich R.F., Maron M.S., Maron B.J. Clinical profile of patients with high-risk tako-tsubo cardiomyopathy. Am J Cardiol. 2015;116:765&#x2013;772. doi: 10.1016/j.amjcard.2015.05.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2015.05.054</ArticleId><ArticleId IdType="pubmed">26144453</ArticleId></ArticleIdList></Reference><Reference><Citation>Regnante R.A., Zuzek R.W., Weinsier S.B., et al. Clinical characteristics and four-year outcomes of patients in the Rhode Island Takotsubo Cardiomyopathy Registry. Am J Cardiol. 2009;103:1015&#x2013;1019. doi: 10.1016/j.amjcard.2008.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2008.12.020</ArticleId><ArticleId IdType="pubmed">19327433</ArticleId></ArticleIdList></Reference><Reference><Citation>Bento D., Azevedo O., Santos R., et al. Short- and medium-term prognosis of Takotsubo syndrome in a Portuguese population. Rev Port Cardiol. 2019;38:349&#x2013;357. doi: 10.1016/j.repc.2018.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.repc.2018.07.010</ArticleId><ArticleId IdType="pubmed">31221486</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchihashi K., Ueshima K., Uchida T., et al. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J&#xa0;Am Coll Cardiol. 2001;38:11&#x2013;18. doi: 10.1016/s0735-1097(01)01316-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(01)01316-x</ArticleId><ArticleId IdType="pubmed">11451258</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant S., Deshmukh A., Mehta K., et al. Burden of arrhythmias in patients with Takotsubo cardiomyopathy (apical ballooning syndrome) Int J Cardiol. 2013;170:64&#x2013;68. doi: 10.1016/j.ijcard.2013.10.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2013.10.041</ArticleId><ArticleId IdType="pubmed">24207072</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T., Yoshikawa T., Maekawa Y., et al. Characterization of predictors of in-hospital cardiac complications of takotsubo cardiomyopathy: multi-center registry from Tokyo CCU Network. J&#xa0;Cardiol. 2014;63:269&#x2013;273. doi: 10.1016/j.jjcc.2013.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2013.09.003</ArticleId><ArticleId IdType="pubmed">24139869</ArticleId></ArticleIdList></Reference><Reference><Citation>Citro R., Rigo F., Previtali M., et al. Differences in clinical features and in-hospital outcomes of older adults with tako-tsubo cardiomyopathy. J&#xa0;Am Geriatr Soc. 2012;60:93&#x2013;98. doi: 10.1111/j.1532-5415.2011.03730.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2011.03730.x</ArticleId><ArticleId IdType="pubmed">22092251</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharkey S.W., Windenburg D.C., Lesser J.R., et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J&#xa0;Am Coll Cardiol. 2010;55:333&#x2013;341. doi: 10.1016/j.jacc.2009.08.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.08.057</ArticleId><ArticleId IdType="pubmed">20117439</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Battrawy I., Santoro F., Stiermaier T., et al. Prevalence, management, and outcome of adverse rhythm disorders in takotsubo syndrome: insights from the international multicenter GEIST registry. Heart Fail Rev. 2020;25:505&#x2013;511. doi: 10.1007/s10741-019-09856-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-019-09856-4</ArticleId><ArticleId IdType="pubmed">31713085</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinjikji W., El-Sayed A.M., Salka S. In-hospital mortality among patients with takotsubo cardiomyopathy: a study of the National Inpatient Sample 2008 to 2009. Am Heart J. 2012;164:215&#x2013;221. doi: 10.1016/j.ahj.2012.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2012.04.010</ArticleId><ArticleId IdType="pubmed">22877807</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelargonio G., La Rosa G., Di Stasio E., et al. Ventricular arrhythmias in Takotsubo Syndrome: incidence, predictors and clinical outcomes. J&#xa0;Cardiovasc Med. 2021;22:180&#x2013;189. doi: 10.2459/JCM.0000000000001106.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001106</ArticleId><ArticleId IdType="pubmed">32890232</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ller C., Eitel C., Thiele H., Eitel I., Stiermaier T. Ventricular arrhythmias in patients with Takotsubo syndrome. J&#xa0;Arrhythmia. 2018;34:369&#x2013;375. doi: 10.1002/joa3.12029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/joa3.12029</ArticleId><ArticleId IdType="pmc">PMC6111471</ArticleId><ArticleId IdType="pubmed">30167007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena Escobar J.A., Aung M., Amin S., Gulraiz A., Gandhi F.R., Malik B.H. Pathogenesis of ventricular arrhythmias and its effect on long-term prognosis in patients with takotsubo cardiomyopathy. Cureus. 2020;12:e11171. doi: 10.7759/cureus.11171.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.11171</ArticleId><ArticleId IdType="pmc">PMC7689872</ArticleId><ArticleId IdType="pubmed">33262908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes L.R., Vinhas H., Cordeiro P., et al. Five cases of transient left ventricular apical ballooning--the experience of a Portuguese center. Rev Port Cardiol Orgao Of Da Soc Port Cardiol&#xa0;= Port J Cardiol an Off J Port Soc Cardiol. 2008;27:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">18605068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharkey S.W., Lesser J.R., Zenovich A.G., et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005;111:472&#x2013;479. doi: 10.1161/01.CIR.0000153801.51470.EB.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000153801.51470.EB</ArticleId><ArticleId IdType="pubmed">15687136</ArticleId></ArticleIdList></Reference><Reference><Citation>Nault M.A., Baranchuk A., Simpson C.S., Redfearn D.P. Takotsubo cardiomyopathy: a novel &#x201c;proarrhythmic&#x201d; disease. Anadolu Kardiyol Derg. 2007;7(Suppl 1):101&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">17584696</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakul N.F.N., Shrestha S., Balabbigari N., Talati S. Complete heart block: a rare complication of takotsubo syndrome. Case Reports Cardiol. 2019;2019:1&#x2013;5. doi: 10.1155/2019/2576373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/2576373</ArticleId><ArticleId IdType="pmc">PMC6803752</ArticleId><ArticleId IdType="pubmed">31687216</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodi G., Bellandi B., Del Pace S., et al. Natural history of tako-tsubo cardiomyopathy. Chest. 2011;139:887&#x2013;892. doi: 10.1378/chest.10-1041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.10-1041</ArticleId><ArticleId IdType="pubmed">20884730</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez-Gil I.J., Molina M., Bernardo E., et al. Tako-tsubo syndrome and heart failure: long-term follow-up. Rev Esp Cardiol. 2012;65:996&#x2013;1002. doi: 10.1016/j.recesp.2012.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2012.04.016</ArticleId><ArticleId IdType="pubmed">22819220</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriz O., Brosolo G., Martina S., et al. In-hospital and long-term mortality in Takotsubo cardiomyopathy: a community hospital experience. J&#xa0;Community Hosp Intern Med Perspect. 2016;6:31082. doi: 10.3402/jchimp.v6.31082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jchimp.v6.31082</ArticleId><ArticleId IdType="pmc">PMC4942542</ArticleId><ArticleId IdType="pubmed">27406446</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelliccia F., Pasceri V., Patti G., et al. Long-term prognosis and outcome predictors in takotsubo syndrome: a systematic review and meta-regression study. JACC Heart Fail. 2019;7:143&#x2013;154. doi: 10.1016/j.jchf.2018.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2018.10.009</ArticleId><ArticleId IdType="pubmed">30611720</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelliccia F., Parodi G., Greco C., et al. Comorbidities frequency in Takotsubo syndrome: an international collaborative systematic review including 1109 patients. Am J Med. 2015;128 doi: 10.1016/j.amjmed.2015.01.016. 654.e11-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2015.01.016</ArticleId><ArticleId IdType="pubmed">25660245</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiermaier T., Moeller C., Oehler K., et al. Long-term excess mortality in takotsubo cardiomyopathy: predictors, causes and clinical consequences. Eur J Heart Fail. 2016;18:650&#x2013;656. doi: 10.1002/ejhf.494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.494</ArticleId><ArticleId IdType="pubmed">26990821</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiermaier T., Eitel C., Desch S., et al. Incidence, determinants and prognostic relevance of cardiogenic shock in patients with Takotsubo cardiomyopathy. Eur Hear Journal Acute Cardiovasc Care. 2016;5:489&#x2013;496. doi: 10.1177/2048872615612456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872615612456</ArticleId><ArticleId IdType="pubmed">26474843</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider B., Athanasiadis A., Schwab J., et al. Complications in the clinical course of tako-tsubo cardiomyopathy. Int J Cardiol. 2014;176:199&#x2013;205. doi: 10.1016/j.ijcard.2014.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2014.07.002</ArticleId><ArticleId IdType="pubmed">25049018</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S., Dunlay S.M., Murphree D.H.J., et al. Cardiogenic shock in takotsubo cardiomyopathy versus acute myocardial infarction: an 8-year national perspective on clinical characteristics, management, and outcomes. JACC Heart Fail. 2019;7:469&#x2013;476. doi: 10.1016/j.jchf.2018.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2018.12.007</ArticleId><ArticleId IdType="pubmed">31078481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36195759</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2110-5820</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Annals of intensive care</Title><ISOAbbreviation>Ann Intensive Care</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications.</ArticleTitle><Pagination><StartPage>93</StartPage><MedlinePgn>93</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">93</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13613-022-01067-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Venoarterial extracorporeal membrane oxygenation (va-ECMO) is an advanced life support for critically ill patients with refractory cardiogenic shock. This temporary support bridges time for recovery, permanent assist, or transplantation in patients with high risk of mortality. However, the benefit of this modality is still subject of discussion and despite the continuous development of critical care medicine, severe cardiogenic shock remains associated with high mortality. Therefore, this work aims to analyze the current literature regarding in-hospital mortality and complication rates of va-ECMO in patients with cardiogenic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review and meta-analysis of the most recent literature to analyze the outcomes of va-ECMO support. Using the PRISMA guidelines, Medline (PubMed) and Scopus (Elsevier) databases were systematically searched up to May 2022. Meta-analytic pooled estimation of publications variables was performed using a weighted random effects model for study size.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-two studies comprising 12756 patients were included in the final analysis. Between 1994 and 2019, 62% (pooled estimate, 8493/12756) of patients died in the hospital. More than one-third of patients died during ECMO support. The most frequent complications were renal failure (51%, 693/1351) with the need for renal replacement therapy (44%, 4879/11186) and bleeding (49%, 1971/4523), bearing the potential for permanent injury or death. Univariate meta-regression analyses identified age over 60&#xa0;years, shorter ECMO duration and presence of infection as variables associated with in-hospital mortality, while the studies reporting a higher incidence of cannulation site bleeding were unexpectedly associated with a reduced in-hospital mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Extracorporeal membrane oxygenation is an invasive life support with a high risk of complications. We identified a pooled in-hospital mortality of 62% with patient age, infection and ECMO support duration being associated with a higher mortality. Protocols and techniques must be developed to reduce the rate of adverse events. Finally, randomized trials are necessary to demonstrate the effectiveness of va-ECMO in cardiogenic shock.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Rajsic</LastName><ForeName>Sasa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Medical University Innsbruck, 6020, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Treml</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Medical University Innsbruck, 6020, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jadzic</LastName><ForeName>Dragana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Anesthesia and Intensive Care Department, Pain Therapy Service, Cagliari University, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breitkopf</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Medical University Innsbruck, 6020, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberleitner</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Medical University Innsbruck, 6020, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popovic Krneta</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukumiric</LastName><ForeName>Zoran</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-6193-3662</Identifier><AffiliationInfo><Affiliation>Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000, Belgrade, Serbia. zoran.bukumiric@med.bg.ac.rs.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Intensive Care</MedlineTA><NlmUniqueID>101562873</NlmUniqueID><ISSNLinking>2110-5820</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">Extracorporeal life support</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Venoarterial extracorporeal membrane oxygenation</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>4</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36195759</ArticleId><ArticleId IdType="pmc">PMC9532225</ArticleId><ArticleId IdType="doi">10.1186/s13613-022-01067-9</ArticleId><ArticleId IdType="pii">10.1186/s13613-022-01067-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Featherstone PJ, Ball CM. The early history of extracorporeal membrane oxygenation. Anaesth Intensive Care. 2018;46(6):555&#x2013;557. doi: 10.1177/0310057X1804600601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0310057X1804600601</ArticleId><ArticleId IdType="pubmed">30447660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill JD, O'Brien TG, Murray JJ, Dontigny L, Bramson ML, Osborn JJ, et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome) use of the Bramson membrane lung. New Engl J Med. 1972;286(12):629&#x2013;634. doi: 10.1056/NEJM197203232861204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197203232861204</ArticleId><ArticleId IdType="pubmed">5060491</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasseur A, Scolletta S, Lorusso R, Taccone FS. Hybrid extracorporeal membrane oxygenation. J Thorac Dis. 2018;10(Suppl 5):S707&#x2013;S715. doi: 10.21037/jtd.2018.03.84.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2018.03.84</ArticleId><ArticleId IdType="pmc">PMC5911562</ArticleId><ArticleId IdType="pubmed">29732190</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogan TV, Lequier L, Lorusso R, MacLaren G, Peek GJ. Extracorporeal life support: the ELSO red book. 5th edition. ed. Ann Arbor, Michigan: Extracorporeal Life Support Organization; 2017. 831 p.</Citation></Reference><Reference><Citation>Extracorporeal Life Support Organization (ELSO). Registry Report on Extracorporeal Life Support, International Summary. 2022. https://www.elso.org/Registry/InternationalSummaryandReports/InternationalSummary.aspx.</Citation></Reference><Reference><Citation>Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction. Circulation. 2009;119(9):1211&#x2013;1219. doi: 10.1161/CIRCULATIONAHA.108.814947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.814947</ArticleId><ArticleId IdType="pmc">PMC2730832</ArticleId><ArticleId IdType="pubmed">19237658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson-Smith AR, Bogdanova Y, Roydhouse S, Phan K, Tian DH, Yan TD, et al. Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: systematic review and meta-analysis. Annals Cardiothorac Surg. 2019;8(1):1&#x2013;8. doi: 10.21037/acs.2018.11.09.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs.2018.11.09</ArticleId><ArticleId IdType="pmc">PMC6379189</ArticleId><ArticleId IdType="pubmed">30854307</ArticleId></ArticleIdList></Reference><Reference><Citation>Napp LC, K&#xfc;hn C, Bauersachs J. ECMO in cardiac arrest and cardiogenic shock. Herz. 2017;42(1):27&#x2013;44. doi: 10.1007/s00059-016-4523-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00059-016-4523-4</ArticleId><ArticleId IdType="pmc">PMC5306351</ArticleId><ArticleId IdType="pubmed">28127638</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayer GT, Baker JN, Parks KA. Heart rescue: the role of mechanical circulatory support in the management of severe refractory cardiogenic shock. Curr Opin Crit Care. 2012;18(5):409&#x2013;416. doi: 10.1097/MCC.0b013e328357f1e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0b013e328357f1e6</ArticleId><ArticleId IdType="pubmed">22895213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014;97(2):610&#x2013;616. doi: 10.1016/j.athoracsur.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2013.09.008</ArticleId><ArticleId IdType="pubmed">24210621</ArticleId></ArticleIdList></Reference><Reference><Citation>El Sibai R, Bachir R, El Sayed M. Outcomes in cardiogenic shock patients with extracorporeal membrane oxygenation use: a matched cohort study in hospitals across the United States. Biomed Res Int. 2018;2018:2428648. doi: 10.1155/2018/2428648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/2428648</ArticleId><ArticleId IdType="pmc">PMC5896328</ArticleId><ArticleId IdType="pubmed">29789779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar LA, Teboul JL. Mechanical circulatory support devices for cardiogenic shock: state of the art. Crit Care. 2019;23(1):76. doi: 10.1186/s13054-019-2368-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2368-y</ArticleId><ArticleId IdType="pmc">PMC6408785</ArticleId><ArticleId IdType="pubmed">30850001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavalichi MA, Nistor I, Nedelcu AE, Zavalichi SD, Georgescu CMA, St&#x103;tescu C, et al. Extracorporeal membrane oxygenation in cardiogenic shock due to acute myocardial infarction: a systematic review. Biomed Res Int. 2020;2020:6126534. doi: 10.1155/2020/6126534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/6126534</ArticleId><ArticleId IdType="pmc">PMC7193268</ArticleId><ArticleId IdType="pubmed">32382560</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Critic Care Resusc. 2013;15(3):172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">23944202</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, Shea B, OConnell D, Peterson J, Welch V, Losos M, , et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. New York: Oxford; 2000.</Citation></Reference><Reference><Citation>Baujat B, Mah&#xe9; C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21(18):2641&#x2013;2652. doi: 10.1002/sim.1221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1221</ArticleId><ArticleId IdType="pubmed">12228882</ArticleId></ArticleIdList></Reference><Reference><Citation>Olkin I, Dahabreh IJ, Trikalinos TA. GOSH - a graphical display of study heterogeneity. Res Synth Methods. 2012;3(3):214&#x2013;223. doi: 10.1002/jrsm.1053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1053</ArticleId><ArticleId IdType="pubmed">26062164</ArticleId></ArticleIdList></Reference><Reference><Citation>Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455&#x2013;463. doi: 10.1111/j.0006-341X.2000.00455.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0006-341X.2000.00455.x</ArticleId><ArticleId IdType="pubmed">10877304</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991&#x2013;996. doi: 10.1016/j.jclinepi.2007.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2007.11.010</ArticleId><ArticleId IdType="pubmed">18538991</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso S, Matsui H, Fushimi K, Yasunaga H. In-hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a national inpatient database in Japan. Crit Care. 2016;20:80. doi: 10.1186/s13054-016-1261-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1261-1</ArticleId><ArticleId IdType="pmc">PMC4820970</ArticleId><ArticleId IdType="pubmed">27044572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunz D, Philipp A, M&#xfc;ller T, Pfister K, Foltan M, Rupprecht L, et al. Ischemia-related vascular complications of percutaneously initiated venoarterial extracorporeal membrane oxygenation: indication setting, risk factors, manifestation and outcome. J Crit Care. 2019;52:58&#x2013;62. doi: 10.1016/j.jcrc.2019.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2019.04.002</ArticleId><ArticleId IdType="pubmed">30978566</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhigalov K, S&#xe1; MPBO, Safonov D, Zagitov I, Alofesh A, Pavlova V, et al. Clinical outcomes of venoarterial extracorporeal life support in 462 patients: single-center experience. Artif Organs. 2020;44(6):620&#x2013;627. doi: 10.1111/aor.13625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.13625</ArticleId><ArticleId IdType="pubmed">31876312</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Cheng Z, Wang L, Li B, Huang W, Wen J, et al. Vascular complications of lower limb ischemia in patients with femoral venoarterial extracorporeal membrane oxygenation. Heart Surg Forum. 2020;23(3):E305&#x2013;E309. doi: 10.1532/hsf.2969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1532/hsf.2969</ArticleId><ArticleId IdType="pubmed">32524974</ArticleId></ArticleIdList></Reference><Reference><Citation>Loforte A, Marinelli G, Musumeci F, Folesani G, Pilato E, Martin Suarez S, et al. Extracorporeal membrane oxygenation support in refractory cardiogenic shock: treatment strategies and analysis of risk factors. Artif Organs. 2014;38(7):E129&#x2013;E141. doi: 10.1111/aor.12317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12317</ArticleId><ArticleId IdType="pubmed">24841637</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie A, Phan K, Tsai YC, Yan TD, Forrest P. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest: a meta-analysis. J Cardiothorac Vasc Anesth. 2015;29(3):637&#x2013;645. doi: 10.1053/j.jvca.2014.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2014.09.005</ArticleId><ArticleId IdType="pubmed">25543217</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandin EW, Nunez JI, Willar B, Kennedy K, Rycus P, Tonna JE, et al. Mechanical left ventricular unloading in patients undergoing venoarterial extracorporeal membrane oxygenation. J Am Coll Cardiol. 2022;79(13):1239&#x2013;1250. doi: 10.1016/j.jacc.2022.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.01.032</ArticleId><ArticleId IdType="pmc">PMC9187498</ArticleId><ArticleId IdType="pubmed">35361346</ArticleId></ArticleIdList></Reference><Reference><Citation>Yannopoulos D, Bartos J, Raveendran G, Walser E, Connett J, Murray TA, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet. 2020;396(10265):1807&#x2013;1816. doi: 10.1016/S0140-6736(20)32338-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32338-2</ArticleId><ArticleId IdType="pmc">PMC7856571</ArticleId><ArticleId IdType="pubmed">33197396</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavazzi G, Rossello X, Grand J, Gierlotka M, Sionis A, Ahrens I, et al. Epidemiology, monitoring, and treatment strategy in cardiogenic shock a multinational cross-sectional survey of ESC-acute cardiovascular care association research section. Eur Heart J Acute Cardiovasc Care. 2022 doi: 10.1093/ehjacc/zuac087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuac087</ArticleId><ArticleId IdType="pubmed">35941730</ArticleId></ArticleIdList></Reference><Reference><Citation>Diepen SV, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: a scientific statement from the American heart association. Circulation. 2017;136(16):232&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr, Ganiats TG, Holmes DR, Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139&#x2013;e228. doi: 10.1016/j.jacc.2014.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.09.017</ArticleId><ArticleId IdType="pubmed">25260718</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubron C, DePuydt J, Belon F, Bailey M, Schmidt M, Sheldrake J, et al. Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. Ann Intensive Care. 2016;6(1):97. doi: 10.1186/s13613-016-0196-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-016-0196-7</ArticleId><ArticleId IdType="pmc">PMC5053950</ArticleId><ArticleId IdType="pubmed">27714705</ArticleId></ArticleIdList></Reference><Reference><Citation>Oude Lansink-Hartgring A, de Vries AJ, Droogh JM, van den Bergh WM. Hemorrhagic complications during extracorporeal membrane oxygenation&#x2014;the role of anticoagulation and platelets. J Crit Care. 2019;54:239&#x2013;243. doi: 10.1016/j.jcrc.2019.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2019.09.013</ArticleId><ArticleId IdType="pubmed">31630073</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajsic S, Breitkopf R, Oezpeker UC, Bukumiri&#x107; Z, Dobesberger M, Treml B. The role of excessive anticoagulation and missing hyperinflammation in ECMO-associated bleeding. J Clin Med. 2022;11(9):2314. doi: 10.3390/jcm11092314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11092314</ArticleId><ArticleId IdType="pmc">PMC9102211</ArticleId><ArticleId IdType="pubmed">35566439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cakici M, Ozcinar E, Baran C, Bermede AO, Sar&#x131;caoglu MC, Inan MB, et al. A retrospective cohort analysis of percutaneous versus side-graft perfusion techniques for veno-arterial extracorporeal membrane oxygenation in patients with refractory cardiogenic shock. Perfusion. 2017;32(5):363&#x2013;371. doi: 10.1177/0267659116683792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659116683792</ArticleId><ArticleId IdType="pubmed">28553783</ArticleId></ArticleIdList></Reference><Reference><Citation>Masha L, Peerbhai S, Boone D, Shobayo F, Ghotra A, Akkanti B, et al. Yellow means caution: correlations between liver injury and mortality with the use of VA-ECMO. ASAIO J. 2019;65(8):812&#x2013;818. doi: 10.1097/MAT.0000000000000895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000895</ArticleId><ArticleId IdType="pubmed">30312207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino A, Costanzo D, Stanszus D, Valchanov K, Jenkins D, Sertic F, et al. Central Veno-arterial extracorporeal membrane oxygenation (C-VA-ECMO) after cardiothoracic surgery: a single-center experience. J Cardiothorac Vasc Anesth. 2018;32(3):1169&#x2013;1174. doi: 10.1053/j.jvca.2017.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2017.12.003</ArticleId><ArticleId IdType="pubmed">29428358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonacchi M, Cabrucci F, Bugetti M, Dokollari A, Parise O, Sani G, et al. Outcomes' predictors in post-cardiac surgery extracorporeal life support. An observational prospective cohort study. International J Surg. 2020;82:56&#x2013;63. doi: 10.1016/j.ijsu.2020.07.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2020.07.063</ArticleId><ArticleId IdType="pubmed">32828981</ArticleId></ArticleIdList></Reference><Reference><Citation>Laimoud M, Alanazi M. The clinical significance of blood lactate levels in evaluation of adult patients with veno-arterial extracorporeal membrane oxygenation. The Egyptian Heart J. 2020;72(1):74. doi: 10.1186/s43044-020-00108-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43044-020-00108-7</ArticleId><ArticleId IdType="pmc">PMC7588953</ArticleId><ArticleId IdType="pubmed">33108534</ArticleId></ArticleIdList></Reference><Reference><Citation>Liem S, Cavarocchi NC, Hirose H. Comparing in-patient extracorporeal cardiopulmonary resuscitation to standard cardiac treatment group of extracorporeal membrane oxygenation patients: 8 years of experience at a single institution. Perfusion. 2020;35(1):73&#x2013;81. doi: 10.1177/0267659119860735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659119860735</ArticleId><ArticleId IdType="pubmed">31296118</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan AJ, Lachmann N, Walther T, Doll N, Gradistanac T, Gommert JF, et al. Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO) Int J Artif Organs. 2006;29(12):1121&#x2013;1131. doi: 10.1177/039139880602901205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039139880602901205</ArticleId><ArticleId IdType="pubmed">17219352</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonna JE, Abrams D, Brodie D, Greenwood JC, Mateo-Sidron RUBIOJA, Usman A, et al. Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the extracorporeal life support organization (ELSO) ASAIO J. 2021;67(6):601&#x2013;610. doi: 10.1097/MAT.0000000000001432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001432</ArticleId><ArticleId IdType="pmc">PMC8315725</ArticleId><ArticleId IdType="pubmed">33965970</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekar K, Badulak J, Peek G, Boeken U, Dalton HJ, Arora L, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. ASAIO J. 2020;66(7):707&#x2013;721. doi: 10.1097/MAT.0000000000001193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001193</ArticleId><ArticleId IdType="pmc">PMC7228451</ArticleId><ArticleId IdType="pubmed">32604322</ArticleId></ArticleIdList></Reference><Reference><Citation>Treml B, Breitkopf R, Bukumiri&#x107; Z, Bachler M, Boesch J, Rajsic S. ECMO predictors of mortality: a 10-year referral centre experience. J Clin Med. 2022;11(5):1224. doi: 10.3390/jcm11051224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11051224</ArticleId><ArticleId IdType="pmc">PMC8911127</ArticleId><ArticleId IdType="pubmed">35268314</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Fernandez-Gatta M, Merchan-Gomez S, Toranzo-Nieto I, Gonzalez-Cebrian M, Diego-Nieto A, Barrio A, et al. Short-term mechanical circulatory support in elderly patients. Artif Organs. 2022;46(5):867&#x2013;877. doi: 10.1111/aor.14117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.14117</ArticleId><ArticleId IdType="pubmed">34780090</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KG, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med. 2009;37(11):2939&#x2013;2945. doi: 10.1097/CCM.0b013e3181b7fbbb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181b7fbbb</ArticleId><ArticleId IdType="pmc">PMC3365557</ArticleId><ArticleId IdType="pubmed">19770737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan K, Shekar K, Ling RR, Barbaro RP, Wong SN, Tan CS, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Critic Care. 2021;25(1):211. doi: 10.1186/s13054-021-03634-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03634-1</ArticleId><ArticleId IdType="pmc">PMC8201440</ArticleId><ArticleId IdType="pubmed">34127027</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi S, Di Bella S, Scaravilli V, Peri AM, Grasselli G, Alagna L, et al. Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention. Int J Antimicrob Agents. 2017;50(1):9&#x2013;16. doi: 10.1016/j.ijantimicag.2017.02.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2017.02.025</ArticleId><ArticleId IdType="pubmed">28528989</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel AM, Lew DF, Kao LS, Lally KP. Defining risk for infectious complications on extracorporeal life support. J Pediatr Surg. 2011;46(12):2260&#x2013;2264. doi: 10.1016/j.jpedsurg.2011.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpedsurg.2011.09.013</ArticleId><ArticleId IdType="pubmed">22152861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Critic Care Med. 2011;12(3):277&#x2013;281. doi: 10.1097/PCC.0b013e3181e28894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181e28894</ArticleId><ArticleId IdType="pubmed">20495508</ArticleId></ArticleIdList></Reference><Reference><Citation>Extracorporeal Life Support Organization (ELSO). Become A Member of Extracorporeal Life Support Organization. 2022. https://www.elso.org/AboutUs/JoinELSO.aspx. Accessed 15 Aug 2022.</Citation></Reference><Reference><Citation>Grover FL, Shroyer AL, Hammermeister K, Edwards FH, Ferguson TB, Jr, Dziuban SW, Jr, et al. A decade's experience with quality improvement in cardiac surgery using the Veterans Affairs and Society of Thoracic Surgeons national databases. Ann Surg. 2001;234(4):464&#x2013;472. doi: 10.1097/00000658-200110000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-200110000-00006</ArticleId><ArticleId IdType="pmc">PMC1422070</ArticleId><ArticleId IdType="pubmed">11573040</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis RC, Arrowsmith JE, Baker RA, de Somer F, Dobkowski WB, Fisher G, et al. Consensus statement: defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum. 2008;11(5):E316&#x2013;E322. doi: 10.1532/HSF98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1532/HSF98</ArticleId><ArticleId IdType="pubmed">19131308</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubin H, Petrov G, Dalyanoglu H, Richter M, Saeed D, Akhyari P, et al. Four-year experience of providing mobile extracorporeal life support to out-of-center patients within a suprainstitutional network-outcome of 160 consecutively treated patients. Resuscitation. 2017;121:151&#x2013;157. doi: 10.1016/j.resuscitation.2017.08.237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2017.08.237</ArticleId><ArticleId IdType="pubmed">28870718</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi KH, Yang JH, Hong D, Park TK, Lee JM, Song YB, et al. Optimal timing of venoarterial-extracorporeal membrane oxygenation in acute myocardial infarction patients suffering from refractory cardiogenic shock. Circ J. 2020;84(9):1502&#x2013;1510. doi: 10.1253/circj.CJ-20-0259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-20-0259</ArticleId><ArticleId IdType="pubmed">32684541</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsharkawy HA, Li L, Esa WA, Sessler DI, Bashour CA. Outcome in patients who require venoarterial extracorporeal membrane oxygenation support after cardiac surgery. J Cardiothorac Vasc Anesth. 2010;24(6):946&#x2013;951. doi: 10.1053/j.jvca.2010.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2010.03.020</ArticleId><ArticleId IdType="pubmed">20599396</ArticleId></ArticleIdList></Reference><Reference><Citation>Fux T, Holm M, Corbascio M, Lund LH, van der Linden J. Venoarterial extracorporeal membrane oxygenation for postcardiotomy shock: risk factors for mortality. J Thorac Cardiovasc Surg. 2018;156(5):1894&#x2013;902.e3. doi: 10.1016/j.jtcvs.2018.05.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2018.05.061</ArticleId><ArticleId IdType="pubmed">30343699</ArticleId></ArticleIdList></Reference><Reference><Citation>Karatolios K, Chatzis G, Markus B, Luesebrink U, Ahrens H, Divchev D, et al. Comparison of mechanical circulatory support with venoarterial extracorporeal membrane oxygenation or Impella for patients with cardiogenic shock: a propensity-matched analysis. Clin Res Cardiol. 2021;110(9):1404&#x2013;1411. doi: 10.1007/s00392-020-01777-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01777-9</ArticleId><ArticleId IdType="pmc">PMC8405518</ArticleId><ArticleId IdType="pubmed">33185749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan C, Tsai PR, Chen YS, Ko WJ. Prognostic factors for adult patients receiving extracorporeal membrane oxygenation as mechanical circulatory support&#x2013;a 14-year experience at a medical center. Artif Organs. 2010;34(2):E59&#x2013;64. doi: 10.1111/j.1525-1594.2009.00909.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1594.2009.00909.x</ArticleId><ArticleId IdType="pubmed">20420591</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CL, Wang H, Jia M, Ma N, Meng X, Hou XT. The early dynamic behavior of lactate is linked to mortality in postcardiotomy patients with extracorporeal membrane oxygenation support: a retrospective observational study. J Thorac Cardiovasc Surg. 2015;149(5):1445&#x2013;1450. doi: 10.1016/j.jtcvs.2014.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.11.052</ArticleId><ArticleId IdType="pubmed">25534305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzeffi MA, Tanaka K, Roberts A, Rector R, Menaker J, Kon Z, et al. Bleeding, thrombosis, and transfusion with two heparin anticoagulation protocols in venoarterial ECMO patients. J Cardiothorac Vasc Anesth. 2019;33(5):1216&#x2013;1220. doi: 10.1053/j.jvca.2018.07.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2018.07.045</ArticleId><ArticleId IdType="pubmed">30181084</ArticleId></ArticleIdList></Reference><Reference><Citation>McCloskey CG, Engoren MC. Transfusion and its association with mortality in patients receiving veno-arterial extracorporeal membrane oxygenation. J Crit Care. 2022;68:42&#x2013;47. doi: 10.1016/j.jcrc.2021.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2021.11.012</ArticleId><ArticleId IdType="pubmed">34896794</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos N, Marinos S, El-Sayed Ahmad A, Keller H, Meybohm P, Zacharowski K, et al. Risk factors associated with adverse outcome following extracorporeal life support: analysis from 360 consecutive patients. Perfusion. 2015;30(4):284&#x2013;290. doi: 10.1177/0267659114542458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659114542458</ArticleId><ArticleId IdType="pubmed">25049285</ArticleId></ArticleIdList></Reference><Reference><Citation>Radakovic D, Hamouda K, Penov K, Bening C, Sayed S, Gietzen C, et al. Central versus peripheral arterial cannulation for veno-arterial extracorporeal membrane oxygenation in post-cardiotomy patients. ASAIO J. 2021;67(1):67&#x2013;73. doi: 10.1097/MAT.0000000000001202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001202</ArticleId><ArticleId IdType="pubmed">33346992</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan AJ, Dege A, Mohr M, Doll N, Falk V, Walther T, et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg. 2010;139(2):302&#x2013;311. doi: 10.1016/j.jtcvs.2009.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.10.043</ArticleId><ArticleId IdType="pubmed">20106393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ro SK, Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW. Extracorporeal life support for cardiogenic shock: influence of concomitant intra-aortic balloon counterpulsation. Eur J Cardio Thorac Surg. 2014;46(2):186&#x2013;192. doi: 10.1093/ejcts/ezu005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezu005</ArticleId><ArticleId IdType="pubmed">24510911</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth S, Jansen C, M'Pembele R, Stroda A, Boeken U, Akhyari P, et al. Fibrinogen-albumin-ratio is an independent predictor of thromboembolic complications in patients undergoing VA-ECMO. Sci Rep. 2021;11(1):16648. doi: 10.1038/s41598-021-95689-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95689-x</ArticleId><ArticleId IdType="pmc">PMC8371004</ArticleId><ArticleId IdType="pubmed">34404824</ArticleId></ArticleIdList></Reference><Reference><Citation>Salna M, Fried J, Kaku Y, Brodie D, Sayer G, Uriel N, et al. Obesity is not a contraindication to veno-arterial extracorporeal life support. Eur J Cardio Thorac Surg. 2021;60(4):831&#x2013;838. doi: 10.1093/ejcts/ezab165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezab165</ArticleId><ArticleId IdType="pubmed">33969398</ArticleId></ArticleIdList></Reference><Reference><Citation>Son AY, Khanh LN, Joung HS, Guerra A, Karim AS, McGregor R, et al. Limb ischemia and bleeding in patients requiring venoarterial extracorporeal membrane oxygenation. J Vasc Surg. 2021;73(2):593&#x2013;600. doi: 10.1016/j.jvs.2020.05.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2020.05.071</ArticleId><ArticleId IdType="pubmed">32623105</ArticleId></ArticleIdList></Reference><Reference><Citation>Toivonen F, Biancari F, Dal&#xe9;n M, Dell'Aquila AM, J&#xf3;nsson K, Fiore A, et al. Neurologic injury in patients treated with extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock. J Cardiothorac Vasc Anesth. 2021;35(9):2669&#x2013;2680. doi: 10.1053/j.jvca.2020.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.11.004</ArticleId><ArticleId IdType="pubmed">33262035</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigneshwar NG, Kohtz PD, Lucas MT, Bronsert M, JW M, FM M, et al. Clinical predictors of in-hospital mortality in venoarterial extracorporeal membrane oxygenation. J Cardiac Surg. 2020;35(10):2512&#x2013;2521. doi: 10.1111/jocs.14758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.14758</ArticleId><ArticleId IdType="pubmed">32789912</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood KL, Ayers B, Gosev I, Kumar N, Melvin AL, Barrus B, et al. Venoarterial-extracorporeal membrane oxygenation without routine systemic anticoagulation decreases adverse events. Ann Thorac Surg. 2020;109(5):1458&#x2013;1466. doi: 10.1016/j.athoracsur.2019.08.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2019.08.040</ArticleId><ArticleId IdType="pubmed">31563493</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MY, Lin PJ, Lee MY, Tsai FC, Chu JJ, Chang YS, et al. Using extracorporeal life support to resuscitate adult postcardiotomy cardiogenic shock: treatment strategies and predictors of short-term and midterm survival. Resuscitation. 2010;81(9):1111&#x2013;1116. doi: 10.1016/j.resuscitation.2010.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2010.04.031</ArticleId><ArticleId IdType="pubmed">20627521</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau P, Xia Y, Shariff S, Jakobleff WA, Forest S, Lipsitz EC, et al. Factors associated with ipsilateral limb ischemia in patients undergoing femoral cannulation extracorporeal membrane oxygenation. Ann Vasc Surg. 2019;54:60&#x2013;65. doi: 10.1016/j.avsg.2018.08.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.avsg.2018.08.073</ArticleId><ArticleId IdType="pubmed">30217709</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26882190</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>209</Volume><PubDate><Year>2016</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Levosimendan meta-analyses: Is there a pattern in the effect on mortality?</ArticleTitle><Pagination><StartPage>77</StartPage><EndPage>83</EndPage><MedlinePgn>77-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2016.02.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(16)30227-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Levosimendan is an inodilator developed for treatment of acute heart failure and other cardiac conditions where the use of an inodilator is considered appropriate. Levosimendan has been studied in different therapeutic settings including acutely decompensated chronic heart failure, advanced heart failure, right ventricular failure, cardiogenic shock, septic shock, and cardiac and non-cardiac surgery. This variety of data has been re-analysed in 25 meta-analyses from 15 different international research groups, based on different rationales to select the studies included.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We here review all previously published meta-analyses on levosimendan to determine any common denominators for its effects on patient mortality. In addition, we also perform a comparative meta-analysis of the six phase II and III randomized double-blind trials which were taken into consideration by the regulatory authorities for the purpose of introducing levosimendan into the market.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Irrespective of clinical setting or comparator, all meta-analyses consistently show benefits for levosimendan, with lower relative risk (or odds ratio) for patient mortality. In 3/25 of the meta-analyses these beneficial trends did not reach statistical significance, while in 22/25 significance was reached. The relative risk is consistent overall, and very similar to that obtained in our own meta-analysis that considered only the 'regulatory' studies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The existing meta-analyses, now based on a population of over 6000 patients, provide the general message of significant benefits for levosimendan in terms of patient mortality. The weight of evidence is now clearly in favour of usefulness/efficacy of levosimendan, with data from multiple randomized trials and meta-analyses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pollesello</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Critical Care Proprietary Products, Orion Pharma, Espoo, Finland. Electronic address: piero.pollesello@orionpharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parissis</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Second Department of Cardiology and Heart Failure Unit, University of Athens Medical School, Attikon University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivikko</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Critical Care Proprietary Products, Orion Pharma, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harjola</LastName><ForeName>V-P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Emergency Medicine, Helsinki University, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006835">Hydrazones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006835" MajorTopicYN="N">Hydrazones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute cardiac care</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Inodilator</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26882190</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2016.02.014</ArticleId><ArticleId IdType="pii">S0167-5273(16)30227-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35089264</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-943X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>ASAIO journal (American Society for Artificial Internal Organs : 1992)</Title><ISOAbbreviation>ASAIO J</ISOAbbreviation></Journal><ArticleTitle>Axillary or Subclavian Impella 5.0 Support in Cardiogenic Shock: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>233</StartPage><EndPage>238</EndPage><MedlinePgn>233-238</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MAT.0000000000001452</ELocationID><Abstract><AbstractText>data around survival and adverse events of cardiogenic shock (CS) patients supported with axillary or subclavian artery 5.0 Impella are presently unavailable. We performed a systematic search of studies reporting the outcomes of axillary or subclavian access 5.0 Impella for refractory CS in PubMed, EMBASE, and the Cochrane Library. The primary outcome was 30-day survival. Secondary outcomes included survival to next therapy and adverse events on support. Proportional meta-analysis was used to pool across studies. Of the 795 potential studies identified, 13 studies were included in the meta-analysis (n&#x2009;=&#x2009;256 patients). The average age of patients across studies was 56&#x2009;&#xb1;&#x2009;5 years. Thirty-day survival for the overall cohort was 66% (95% CI: 59-73). Survival to the next therapy was 68% (95% CI: 60-76). The occurrence of adverse events over an average of 13 (95% CI: 12-14) days of support was the following: stroke 5.9%, hemolysis 27%, pump thrombosis 4.4%, limb ischemia 0.1%, major bleeding 5.4%, device malfunction 10.6%, exchange 6.6%, and infection 14%. In this systematic review and meta-analysis, we report survival and adverse event rates of axillary or subclavian access 5.0 Impella for CS. Such summary data can inform clinician decision-making.</AbstractText><CopyrightInformation>Copyright &#xa9; ASAIO 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duval</LastName><ForeName>Sue</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1025-8665</Identifier><AffiliationInfo><Affiliation>From the Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaffer</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Ranjit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexy</LastName><ForeName>Tamas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8381-6299</Identifier><AffiliationInfo><Affiliation>From the Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Cindy M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>From the Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cogswell</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ASAIO J</MedlineTA><NlmUniqueID>9204109</NlmUniqueID><ISSNLinking>1058-2916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: Dr. John has received research grants from Abbott Lab and serves as a speakers bureau. Dr. Cogswell has received employment from Medtronic&#x2014;husband&#x2019;s employment and Heart Failure Advisory Board&#x2014;and is speakers bureau of Abbott Lab. The other authors have no conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>28</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35089264</ArticleId><ArticleId IdType="doi">10.1097/MAT.0000000000001452</ArticleId><ArticleId IdType="pii">00002480-202202000-00015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pozzi M, Quessard A, Nguyen A, et al.: Using the Impella 5.0 with a right axillary artery approach as bridge to long-term mechanical circulatory assistance. Int J Artif Organs 2013.36: 605&#x2013;611</Citation></Reference><Reference><Citation>Bertoglio L, Katsarou M, Scandroglio M, Bertoldi L, Chiesa R, Pappalardo F: Surgical transaxillary placement of the Impella 5.0 ventricular assist device. J Card Surg 2019.34: 92&#x2013;98</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009.151: 264&#x2013;9, W64</Citation></Reference><Reference><Citation>Santos WMD, Secoli SR, P&#xfc;schel VAA: The Joanna Briggs Institute approach for systematic reviews. Rev Lat Am Enfermagem 2018.26: e3074</Citation></Reference><Reference><Citation>Moola S, Munn Z, Sears K, et al.: Conducting systematic reviews of association (etiology): The Joanna Briggs Institute&#x2019;s approach. Int J Evid Based Healthc 2015.13: 163&#x2013;169</Citation></Reference><Reference><Citation>Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000.56: 455&#x2013;463</Citation></Reference><Reference><Citation>Lam K, Sjauw KD, van der Meulen J, et al.: A combined surgical and percutaneous approach through the axillary artery to introduce the Impella LP5.0 for short-term circulatory support. Int J Cardiol 2009.134: 277&#x2013;279</Citation></Reference><Reference><Citation>Bresson D, Sibellas F, Farhat F, Jegaden O, Kirkorian G, Bonnefoy E: Preliminary experience with Impella Recover(&#xae;) LP5.0 in nine patients with cardiogenic shock: A new circulatory support system in the intensive cardiac care unit. Arch Cardiovasc Dis 2011.104: 458&#x2013;464</Citation></Reference><Reference><Citation>Schibilsky D, Lausberg H, Haller C, et al.: Impella 5.0 support in INTERMACS II cardiogenic shock patients using right and left axillary artery access. Artif Organs 2015.39: 660&#x2013;663</Citation></Reference><Reference><Citation>Schibilsky D, Kruger T, Lausberg HF, et al.: Impella 5.0 as a second-line mechanical circulatory support strategy after extracorporeal life support. Artif Organs 2016.40: 909&#x2013;916</Citation></Reference><Reference><Citation>Bansal A, Bhama JK, Patel R, et al.: Using the minimally invasive Impella 5.0 via the right subclavian artery cutdown for acute on chronic decompensated heart failure as a bridge to decision. Ochsner J 2016.16: 210&#x2013;216</Citation></Reference><Reference><Citation>Mastroianni C, Bouabdallaoui N, Leprince P, Lebreton G: Short-term mechanical circulatory support with the Impella 5.0 device for cardiogenic shock at La Piti&#xe9;-Salp&#xea;tri&#xe8;re. Eur Heart J Acute Cardiovasc Care 2017.6: 87&#x2013;92</Citation></Reference><Reference><Citation>Esposito ML, Jablonski J, Kras A, Krasney S, Kapur NK: Maximum level of mobility with axillary deployment of the Impella 5.0 is associated with improved survival. Int J Artif Organs 2018.41: 236&#x2013;239</Citation></Reference><Reference><Citation>Boll G, Fischer A, Kapur NK, Salehi P: Right axillary artery conduit is a safe and reliable access for implantation of Impella 5.0 microaxial pump. Ann Vasc Surg 2019.54: 54&#x2013;59</Citation></Reference><Reference><Citation>Bernhardt AM, Zipfel S, Reiter B, et al.: Impella 5.0 therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes. Eur J Cardiothorac Surg 2019.56: 1031&#x2013;1036</Citation></Reference><Reference><Citation>Chung JS, Emerson D, Ramzy D, et al.: A new paradigm in mechanical circulatory support: 100-patient experience. Ann Thorac Surg 2020.109: 1370&#x2013;1377</Citation></Reference><Reference><Citation>Doersch KM, Tong CW, Gongora E, Konda S, Sareyyupoglu B: Temporary left ventricular assist device through an axillary access is a promising approach to improve outcomes in refractory cardiogenic shock patients. ASAIO J 2015.61: 253&#x2013;258</Citation></Reference><Reference><Citation>Slaughter MS: UNOS status of heart transplant patients supported with a left ventricular assist device: Is it time to reconsider the status criteria? Tex Heart Inst J 2011.38: 549&#x2013;551</Citation></Reference><Reference><Citation>Cogswell R, John R, Estep JD, et al.: An early investigation of outcomes with the new 2018 donor heart allocation system in the United States. J Heart Lung Transplant 2020.39: 1&#x2013;4</Citation></Reference><Reference><Citation>Wilson-Smith AR, Bogdanova Y, Roydhouse S, et al.: Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: Systematic review and meta-analysis. Ann Cardiothorac Surg 2019.8: 1&#x2013;8</Citation></Reference><Reference><Citation>Russo JJ, Aleksova N, Pitcher I, et al.: Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol 2019.73: 654&#x2013;662</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34405356</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1496-8975</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Canadian journal of anaesthesia = Journal canadien d'anesthesie</Title><ISOAbbreviation>Can J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Pulmonary artery catheterization in patients with cardiogenic shock: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1611</StartPage><EndPage>1629</EndPage><MedlinePgn>1611-1629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12630-021-02083-2</ELocationID><Abstract><AbstractText Label="PURPOSE">Cardiogenic shock carries high morbidity and mortality. The purpose of this review was to determine the safety and efficacy of pulmonary artery catheterization (PAC) in adult patients hospitalized with cardiogenic shock.</AbstractText><AbstractText Label="SOURCE">We performed a systematic review and meta-analysis of observational studies and randomized controlled trials comparing PAC vs no PAC in cardiogenic shock. We searched MEDLINE, EMBASE, Cochrane CENTRAL, and grey literature. We screened articles, abstracted data, and evaluated risk of bias in duplicate. We pooled data using a random-effects model and evaluated the quality of evidence using the GRADE framework. Outcomes of interest were mortality, length of stay, and procedural complications.</AbstractText><AbstractText Label="PRINCIPAL FINDINGS">We identified 19 eligible observational studies (&#x2265; 2,716,287 patients) and no randomized controlled trials; 14 studies were at high risk of bias (lack of adjustment for prognostic variables and/or co-interventions). When pooling adjusted results, PAC was associated with improved survival to hospital discharge (relative risk [RR], 0.77; 95% confidence interval [CI], 0.64 to 0.91, I<sup>2</sup> = 98%; very low-quality evidence) and at longest available follow-up (RR, 0.72; 95% CI, 0.60 to 0.87; I<sup>2</sup> = 99%; very low-quality evidence). Unadjusted length of stay was 3.5 days longer (95% CI, 1.49 to 5.54; I<sup>2</sup> = 100%; very low-quality evidence) with PAC. Procedural complications were inconsistently reported.</AbstractText><AbstractText Label="CONCLUSIONS">Very low-quality observational evidence suggests PAC use in patients with cardiogenic shock is associated with lower mortality. Overall, these results support consideration of PAC for hemodynamic assessment in cardiogenic shock. Prospective randomized clinical trials are needed to further characterize the role of PAC in this population.</AbstractText><CopyrightInformation>&#xa9; 2021. Canadian Anesthesiologists' Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Justin Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vadakken</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitlock</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiac Surgery, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Research, Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koziarz</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Health Research, Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ainsworth</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Faizan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>William F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Research Institute, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demers</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belley-C&#xf4;t&#xe9;</LastName><ForeName>Emilie P</ForeName><Initials>EP</Initials><Identifier Source="ORCID">0000-0002-5071-076X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, McMaster University, Hamilton, ON, Canada. ebelleycote@me.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Research Institute, Hamilton, ON, Canada. ebelleycote@me.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada. ebelleycote@me.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><VernacularTitle>Cath&#xe9;t&#xe9;risme de l&#x2019;art&#xe8;re pulmonaire chez des patients en choc cardiog&#xe9;nique : une revue syst&#xe9;matique et une m&#xe9;ta-analyse.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Anaesth</MedlineTA><NlmUniqueID>8701709</NlmUniqueID><ISSNLinking>0832-610X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Can J Anaesth. 2021 Nov;68(11):1592-1596. doi: 10.1007/s12630-021-02084-1.</RefSource><PMID Version="1">34405360</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002407" MajorTopicYN="Y">Catheterization, Swan-Ganz</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="UNLABELLED">R&#xe9;SUM&#xe9;: OBJECTIF: Le choc cardiog&#xe9;nique entra&#xee;ne une morbidit&#xe9; et une mortalit&#xe9; &#xe9;lev&#xe9;es. Le but de cette revue &#xe9;tait de d&#xe9;terminer la s&#xe9;curit&#xe9; et l&#x2019;efficacit&#xe9; de l&#x2019;utilisation d&#x2019;un cath&#xe9;t&#xe9;risme de l&#x2019;art&#xe8;re pulmonaire (CAP) chez des patients adultes hospitalis&#xe9;s en choc cardiog&#xe9;nique.</AbstractText><AbstractText Label="SOURCES" NlmCategory="METHODS">Nous avons r&#xe9;alis&#xe9; une revue syst&#xe9;matique et une m&#xe9;ta-analyse d&#x2019;&#xe9;tudes observationnelles et d&#x2019;&#xe9;tudes randomis&#xe9;es contr&#xf4;l&#xe9;es comparant l&#x2019;utilisation vs la non-utilisation de CAP pour le traitement d&#x2019;un choc cardiog&#xe9;nique. Nous avons effectu&#xe9; des recherches dans les bases de donn&#xe9;es MEDLINE, EMBASE, Cochrane CENTRAL et dans la litt&#xe9;rature grise. Nous avons examin&#xe9; les articles, r&#xe9;sum&#xe9; les donn&#xe9;es et &#xe9;valu&#xe9; le risque de biais &#xe0; deux reprises. Nous avons regroup&#xe9; les donn&#xe9;es &#xe0; l&#x2019;aide d&#x2019;un mod&#xe8;le &#xe0; effets al&#xe9;atoires et &#xe9;valu&#xe9; la qualit&#xe9; des donn&#xe9;es probantes en nous appuyant sur le syst&#xe8;me GRADE. Les issues d&#x2019;int&#xe9;r&#xea;t &#xe9;taient la mortalit&#xe9;, la dur&#xe9;e de s&#xe9;jour et les complications proc&#xe9;durales.</AbstractText><AbstractText Label="CONSTATATIONS PRINCIPALES" NlmCategory="UNASSIGNED">Nous avons identifi&#xe9; 19 &#xe9;tudes observationnelles admissibles (&#x2265; 2 716 287 patients) et aucune &#xe9;tude randomis&#xe9;e contr&#xf4;l&#xe9;e; 14 &#xe9;tudes comportaient un risque &#xe9;lev&#xe9; de biais (absence d&#x2019;ajustement sur les variables pronostiques et/ou les interventions concomitantes). En regroupant les r&#xe9;sultats ajust&#xe9;s, le CAP a &#xe9;t&#xe9; associ&#xe9; &#xe0; une meilleure survie jusqu&#x2019;au cong&#xe9; de l&#x2019;h&#xf4;pital (risque relatif [RR], 0,77; intervalle de confiance [IC] &#xe0; 95 %, 0,64 &#xe0; 0,91, I2 = 98 %; donn&#xe9;es probantes de tr&#xe8;s faible qualit&#xe9;) et jusqu&#x2019;au point de suivi disponible rapport&#xe9; le plus lointain dans le temps (RR, 0,72; IC 95 %, 0,60 &#xe0; 0,87; I2 = 99 %; donn&#xe9;es probantes de tr&#xe8;s faible qualit&#xe9;). La dur&#xe9;e de s&#xe9;jour non ajust&#xe9;e &#xe9;tait 3,5 jours plus longue (IC 95 %, 1,49 &#xe0; 5,54; I2 = 100 %; donn&#xe9;es probantes de tr&#xe8;s faible qualit&#xe9;) avec un CAP. Les complications proc&#xe9;durales n&#x2019;&#xe9;taient par rapport&#xe9;es de mani&#xe8;re uniforme.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Des donn&#xe9;es observationnelles de tr&#xe8;s faible qualit&#xe9; sugg&#xe8;rent que l&#x2019;utilisation d&#x2019;un CAP chez des patients en choc cardiog&#xe9;nique est associ&#xe9;e &#xe0; une r&#xe9;duction de la mortalit&#xe9;. Dans l&#x2019;ensemble, ces r&#xe9;sultats sugg&#xe8;rent de consid&#xe9;rer le CAP pour l&#x2019;&#xe9;valuation h&#xe9;modynamique en cas de choc cardiog&#xe9;nique. Des &#xe9;tudes cliniques randomis&#xe9;es prospectives sont n&#xe9;cessaires pour mieux caract&#xe9;riser le r&#xf4;le du CAP dans cette population.</AbstractText><CopyrightInformation>&#xa9; 2021. Canadian Anesthesiologists' Society.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">acute heart failure</Keyword><Keyword MajorTopicYN="N">hemodynamic assessment</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary artery catheterization</Keyword><Keyword MajorTopicYN="N">right heart catheterization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34405356</ArticleId><ArticleId IdType="doi">10.1007/s12630-021-02083-2</ArticleId><ArticleId IdType="pii">10.1007/s12630-021-02083-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc 2014; DOI: https://doi.org/10.1161/JAHA.113.000590 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.113.000590</ArticleId><ArticleId IdType="pubmed">25074695</ArticleId><ArticleId IdType="pmc">4310389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D, Khera S, Dabhadkar KC, et al. Trends in coronary angiography, revascularization, and outcomes of cardiogenic shock complicating non-st-elevation myocardial infarction. Am J Cardiol 2016; 117: 1-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2015.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D. Is there a role for invasive hemodynamic monitoring in acute heart failure management? Curr Heart Fail Rep 2015; 12: 197-204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11897-015-0256-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348: 5-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa021108</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey S, Harrison DA, Singer M, et al; PAC-Man study collaboration. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366: 472-7.</Citation></Reference><Reference><Citation>National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network;&#xa0;Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354: 2213-24.</Citation></Reference><Reference><Citation>Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005; 294: 1625-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.294.13.1625</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajaram SS, Desai NK, Kalra A, et al. Pulmonary artery catheters for adult patients in intensive care. Cochrane Database Syst Rev 2013; DOI: https://doi.org/10.1002/14651858.CD003408.pub3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003408.pub3</ArticleId><ArticleId IdType="pubmed">23450539</ArticleId><ArticleId IdType="pmc">6517063</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem R, Vallee F, Rusca M, Mebazaa A. Hemodynamic monitoring by echocardiography in the ICU: the role of the new echo techniques. Curr Opin Crit Care 2008; 14: 561-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0b013e32830e6d81</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikuta K, Wang Y, Robinson A, Ahmad T, Krumholz HM, Desai NR. National trends in use and outcomes of pulmonary artery catheters among Medicare beneficiaries, 1999-2013. JAMA Cardiol 2017; 2: 908-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2017.1670</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017; 136: 232-68.</Citation></Reference><Reference><Citation>Ezekowitz JA, O&#x2019;Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society Guidelines for the management of heart failure. Can J Cardiol 2017; 33: 1342-433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2017.08.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) ceveloped with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw128</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 2019; DOI: https://doi.org/10.1002/ccd.28329 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28329</ArticleId><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; DOI: https://doi.org/10.7326/0003-4819-151-4-200908180-00136 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00136</ArticleId><ArticleId IdType="pubmed">19622512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999; 341: 625-34.</Citation></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287-96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208410</ArticleId></ArticleIdList></Reference><Reference><Citation>CLARITY Group at McMaster University. Tool to Assess Risk of Bias in Cohort Studies. 2017; Available from URL: https://www.evidencepartners.com/wp-content/uploads/2017/09/Tool-to-Assess-Risk-of-Bias-in-Cohort-Studies.pdf (accessed July 2021).</Citation></Reference><Reference><Citation>Guyatt GH, Oxman AD, Sch&#xfc;nemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein M, Hedges L V., Higgins JP, Rothstein HR. Introduction to Meta-Analysis. Chichester, UK: John Wiley &amp; Sons, Ltd; 2009.</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoomi R, Dawn B, Gupta K. Contemporary trends in pulmonary artery catheterization use in congestive heart failure: results from the United States national inpatient sample database. Eur Heart J 2016; 37: 119 (abstract).</Citation></Reference><Reference><Citation>Isseh IN, Gorgis S, Dagher C, Sharma S, Basir MB, Parikh S. Escalating temporary mechanical circulatory support in worsening cardiogenic shock: feasibility in advanced heart failure therapy candidates. J Cardiac Fail 2020; DOI: https://doi.org/10.1016/j.cardfail.2020.09.162 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2020.09.162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MG, Kelly RV, Kong DF, et al. Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. Am J Med 2005; 118: 482-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2004.12.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi R, Patel K, Patel P, Meraj PM. Trends in the utilization and in-hospital mortality associated with pulmonary artery catheter use for cardiogenic shock hospitalizations. Indian Heart J 2018; 70 Suppl 3: S496-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ihj.2018.08.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore JM, Goldberg RJ, Spodick DH, Alpert JS, Dalen JE. A community-wide assessment of the use of pulmonary artery catheters in patients with acute myocardial infarction. Chest 1987; 92: 721-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.92.4.721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez GA, Lemor A, Blumer V, et al. Trends in utilization and outcomes of pulmonary artery catheterization in heart failure with and without cardiogenic shock. J Card Fail 2019; 25: 364-71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2019.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill WW, Grines C, Schreiber T, et al. Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. Am Heart J 2018; 202: 33-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2018.03.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossello X, Vila M, Rivas-Lasarte M, et al. Impact of pulmonary artery catheter use on short- and long-term mortality in patients with cardiogenic shock. Cardiology 2016; 136: 61-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000448110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sionis A, Rivas-Lasarte M, Mebazaa A, et al. Current use and impact on 30-day mortality of pulmonary artery catheter in cardiogenic shock patients: results from the CardShock Study. J Intensive Care Med 2019; DOI: https://doi.org/10.1177/0885066619828959 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066619828959</ArticleId><ArticleId IdType="pubmed">30732522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotomi Y, Sato N, Kajimoto K, et al. Impact of pulmonary artery catheter on outcome in patients with acute heart failure syndromes with hypotension or receiving inotropes: from the ATTEND Registry. Int J Cardiol 2014; 172: 165-72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2013.12.174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zion MM, Balkin J, Rosenmann D, et al. Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT registry. Chest 1990; 98: 1331-5.</Citation></Reference><Reference><Citation>Vallabhajosyula S, Shankar A, Patlolla SH, et al. Pulmonary artery catheter use in acute myocardial infarction&#x2010;cardiogenic shock. ESC Hear Fail 2020; 7: 1234-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12652</ArticleId></ArticleIdList></Reference><Reference><Citation>Garan AR, Kanwar M, Thayer KL, et al. Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in-hospital mortality. JACC Hear Fail 2020; 8: 903-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2020.08.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha LD, Ogunbayo G, Misumida N, et al. Contemporary outcomes of pulmonary artery catheter use in the management of cardiogenic shock due to acute myocardial infarction. J Am Coll Cardiol 2018; DOI: https://doi.org/10.1016/S0735-1097(18)31704-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(18)31704-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu G, Pancholy S, Bajaj A, et al. TCT-511 does pulmonary artery catheterization improve in-hospital outcomes in patients with cardiogenic shock: analysis from National Inpatient Sample (NIS). J Am Coll Cardiol 2017; DOI: https://doi.org/10.1016/j.jacc.2017.09.627 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.09.627</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez J, Marino G, Selas S, et al. Pulmonary artery catheter might reduce risk of death in patients with low cardiac output after cardiac surgery. Intensive Care Med 2013; 39: S416 (abstract).</Citation></Reference><Reference><Citation>Ashraf S, Ando T, Adegbala O, et al. Incidence and implications of pulmonary artery catheter use in revascularized patients with myocardial infarction and cardiogenic shock: insights from large US national database. J Am Coll Cardiol 2020; DOI: https://doi.org/10.1016/S0735-1097(20)31539-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(20)31539-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveros E, Suboc TM, Rao A, Marinescu K, Aggarwal N, Volgman A. National inpatient sample database reveals pulmonary artery catheter use decreases outcomes but underused in women. J Am Coll Cardiol 2020; DOI: https://doi.org/10.1016/S0735-1097(20)31429-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(20)31429-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranka S, Mastoris I, Dalia T, et al. Right heart catheterization/pulmonary artery catheterization use in cardiogenic shock: a friend or a foe? Insights from the Nationwide Readmissions Database. J Card Fail 2020; DOI: https://doi.org/10.1016/j.cardfail.2020.09.366 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2020.09.366</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality. Overview of the National (Nationwide) Inpatient Sample (NIS); 2021. Available from: https://www.hcup-us.ahrq.gov/nisoverview.jsp#about (accessed July 2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37850383</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4539</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>20</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>Circulation</Title><ISOAbbreviation>Circulation</ISOAbbreviation></Journal><ArticleTitle>Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>1570</StartPage><EndPage>1581</EndPage><MedlinePgn>1570-1581</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCULATIONAHA.123.066179</ELocationID><Abstract><AbstractText Label="BACKGROUND">Although venoarterial extracorporeal membrane oxygenation (VA-ECMO) is beneficial for the treatment of profound cardiogenic shock, peripheral VA-ECMO cannulation can increase left ventricular afterload, thus compromising myocardial recovery. We investigated whether early routine left ventricular unloading can reduce 30-day mortality compared with the conventional approach in patients with cardiogenic shock undergoing VA-ECMO.</AbstractText><AbstractText Label="METHODS">This randomized clinical trial involved 116 patients with cardiogenic shock undergoing VA-ECMO from March 2021 to September 2022 at Chonnam National University Hospital, Gwangju, South Korea. The patients were randomly assigned to undergo either early routine left ventricular unloading with transseptal left atrial cannulation within 12 hours after randomization (n=58) or the conventional approach, which permitted rescue transseptal left atrial cannulation in case of an increased left ventricular afterload (n=58). The primary outcome was all-cause mortality within 30 days.</AbstractText><AbstractText Label="RESULTS">All 116 randomized patients (mean age, 67.6&#xb1;13.5 years; 34 [29.3%] women) completed the trial. At 30 days, all-cause death had occurred in 27 (46.6%) patients in the early group and 26 (44.8%) patients in the conventional group (hazard ratio, 1.02 [95% CI, 0.59-1.74]; <i>P</i>=0.942). Crossover to rescue transseptal left atrial cannulation occurred in 29 patients (50%) in the conventional group according to a clear indication. Time to rescue transseptal cannulation in the conventional group was a median of 21.8 (interquartile range, 12.4-52.2) hours after randomization. There were no significant differences in other secondary outcomes between the 2 groups except for a shorter time to disappearance of pulmonary congestion in the early group (median, 3 [interquartile range, 2-6] versus 5 [interquartile range, 3-7] days; <i>P</i>=0.027).</AbstractText><AbstractText Label="CONCLUSIONS">Among patients with cardiogenic shock undergoing VA-ECMO, early routine left ventricular unloading with transseptal left atrial cannulation did not reduce 30-day mortality compared with the conventional strategy, which permitted rescue transseptal left atrial cannulation. These findings should be cautiously interpreted until the results of multicenter trials using other unloading modalities become available.</AbstractText><AbstractText Label="REGISTRATION">URL: https://www.</AbstractText><AbstractText Label="CLINICALTRIALS">gov; Unique identifier: NCT04775472.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min Chul</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-6026-1702</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yongwhan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2405-1676</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung Hun</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-2337-7826</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Yoonmin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Joon Ho</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyun</LastName><ForeName>Dae Young</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-0038-0125</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Kyung Hoon</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-0377-6352</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sim</LastName><ForeName>Doo Sun</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0003-4162-7902</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Young Joon</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0003-0192-8161</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ju Han</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Myung Ho</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-7319-8562</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Yong Hun</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine (Y.H.J.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>In-Seok</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery (I.-S.J.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Youngkeun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2022-9366</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine (M.C.K., Y.L., S.H.L., Y.S., J.H.A., D.Y.H., K.H.C., D.S.S., Y.J.H., J.H.K., M.H.K., Y.A.), Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04775472</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circulation</MedlineTA><NlmUniqueID>0147763</NlmUniqueID><ISSNLinking>0009-7322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006325" MajorTopicYN="N">Heart Atria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">shock</Keyword></KeywordList><CoiStatement><b>Disclosures</b> None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37850383</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.066179</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31254171</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>Prognostic factors of mortality after surgery in infective endocarditis: systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>879</StartPage><EndPage>895</EndPage><MedlinePgn>879-895</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-019-01338-x</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">There is a lack of consensus about which endocarditis-specific preoperative characteristics have an actual impact over postoperative mortality. Our objective was the identification and quantification of these factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a systematic review of all the studies which reported factors related to in-hospital mortality after surgery for acute infective endocarditis, conducted according to PRISMA recommendations. A search string was constructed and applied on three different databases. Two investigators independently reviewed the retrieved references. Quality assessment was performed for identification of potential biases. All the variables that were included in at least two validated risk scores were meta-analyzed independently, and the pooled estimates were expressed as odds ratios (OR) with their confidence intervals (CI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The final sample consisted on 16 studies, comprising a total of 7484 patients. The overall pooled OR were statistically significant (p&#x2009;&lt;&#x2009;0.05) for: age (OR 1.03, 95% CI 1.00-1.05), female sex (OR 1.56, 95% CI 1.35-1.81), urgent or emergency surgery (OR 2.39 95% CI 1.91-3.00), previous cardiac surgery (OR 2.19, 95% CI 1.84-2.61), NYHA&#x2009;&#x2265;&#x2009;III (OR 1.84, 95% CI 1.33-2.55), cardiogenic shock (OR 4.15, 95% CI 3.06-5.64), prosthetic valve (OR 1.98, 95% CI 1.68-2.33), multivalvular affection (OR 1.35, 95% CI 1.01-1.82), renal failure (OR 2.57, 95% CI 2.15-3.06), paravalvular abscess (OR 2.39, 95% CI 1.77-3.22) and S. aureus infection (OR 2.27, 95% CI 1.89-2.73).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After a systematic review, we identified 11 preoperative factors related to an increased postoperative mortality. The meta-analysis of each of these factors showed a significant association with an increased in-hospital mortality after surgery for active infective endocarditis. Graph summary of the Pooled Odds Ratios of the 11 preoperative factors analyzed after the systematic review and meta-analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varela Barca</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4605-8801</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Ctra. Colmenar Viejo, km. 9.100, 28034, Madrid, Spain. lauravarela21089@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navas Elorza</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectology, University Hospital Ramon y Cajal, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Hidalgo</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University Hospital Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moya Mur</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muriel Garc&#xed;a</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Biostatistics Unit, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Felix</LastName><ForeName>B M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Clinical Biostatistics Unit, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miguelena Hycka</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Ctra. Colmenar Viejo, km. 9.100, 28034, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Roda</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Ctra. Colmenar Viejo, km. 9.100, 28034, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Men&#xe9;ndez</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Ctra. Colmenar Viejo, km. 9.100, 28034, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Infection. 2019 Dec;47(6):897. doi: 10.1007/s15010-019-01357-8.</RefSource><PMID Version="1">31552602</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004696" MajorTopicYN="N">Endocarditis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Infective endocarditis</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Prognostic factors</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31254171</ArticleId><ArticleId IdType="doi">10.1007/s15010-019-01338-x</ArticleId><ArticleId IdType="pii">10.1007/s15010-019-01338-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Infect Dis. 2018 Mar;68:102-107</Citation><ArticleIdList><ArticleId IdType="pubmed">29382606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Cardiovasc Surg. 2012;18(3):216-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22790993</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2015 Jan 13;131(2):131-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25480814</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Esp Cardiol (Engl Ed). 2013 May;66(5):384-90</Citation><ArticleIdList><ArticleId IdType="pubmed">24775821</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2011 Jun 16;149(3):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20178888</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2009 Mar 9;169(5):463-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19273776</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2016 Mar 7;37(10):840-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26685134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 2008 Apr;85(4):1490-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18355567</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart. 2017 Sep;103(18):1435-1442</Citation><ArticleIdList><ArticleId IdType="pubmed">28432158</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2004 Feb;25(3):267-76</Citation><ArticleIdList><ArticleId IdType="pubmed">14972429</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2010 Mar 9;121(9):1141-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20212293</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Cardiovasc Surg. 2007 Jan;133(1):144-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17198801</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 2007 Jan;31(1):43-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17140802</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Cardiovasc Thorac Ann. 2018 Sep;26(7):517-523</Citation><ArticleIdList><ArticleId IdType="pubmed">30185074</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2009 Jul 21;6(7):e1000097</Citation><ArticleIdList><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiol J. 2010;17(6):566-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21154258</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine (Baltimore). 2015 Dec;94(49):e2000</Citation><ArticleIdList><ArticleId IdType="pubmed">26656328</ArticleId></ArticleIdList></Reference><Reference><Citation>J Heart Valve Dis. 2011 Mar;20(2):223-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21560826</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorac Cardiovasc Surg. 2017 Apr;65(3):166-173</Citation><ArticleIdList><ArticleId IdType="pubmed">27074494</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Vessels. 2015 Mar;30(2):227-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24463846</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellenic J Cardiol. 2019 Jan 26;:</Citation><ArticleIdList><ArticleId IdType="pubmed">30690140</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2016 Jul 14;37(27):2129-2200</Citation><ArticleIdList><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2019 May 1;282:24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">30718134</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Surg. 1999 Jun;7(4):402-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10430521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 2012 Oct;94(4):1204-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22771489</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2016 Nov 1;222:1001-1002</Citation><ArticleIdList><ArticleId IdType="pubmed">27526384</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2010 Oct;29(10):1203-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20549531</ArticleId></ArticleIdList></Reference><Reference><Citation>Interact Cardiovasc Thorac Surg. 2014 Feb;18(2):169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">24174123</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ J. 2008 Dec;72(12):2062-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18981596</ArticleId></ArticleIdList></Reference><Reference><Citation>Enferm Infecc Microbiol Clin. 2019 Aug - Sep;37(7):435-440</Citation><ArticleIdList><ArticleId IdType="pubmed">30470460</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiol Clin. 2003 May;21(2):273-82, vii-viii</Citation><ArticleIdList><ArticleId IdType="pubmed">12874898</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 2018 May 1;53(5):1049-1054</Citation><ArticleIdList><ArticleId IdType="pubmed">29228242</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellenic J Cardiol. 2014 Nov-Dec;55(6):462-74</Citation><ArticleIdList><ArticleId IdType="pubmed">25432198</ArticleId></ArticleIdList></Reference><Reference><Citation>ScientificWorldJournal. 2012;2012:307571</Citation><ArticleIdList><ArticleId IdType="pubmed">22536134</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 2007 Apr;120(4):369.e1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17398233</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1997 Sep 13;315(7109):629-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2014 Jul 15;175(1):133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24852838</ArticleId></ArticleIdList></Reference><Reference><Citation>QJM. 2015 Mar;108(3):219-29</Citation><ArticleIdList><ArticleId IdType="pubmed">25223570</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Cir Cardiovasc. 2007 Apr-Jun;22(2):192-200</Citation><ArticleIdList><ArticleId IdType="pubmed">17992324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Cardiovasc Surg. 2011 Jan;141(1):98-106.e1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">21168017</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Heart Assoc. 2017 Jul 20;6(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">28729412</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2018 Sep;24(9):985-991</Citation><ArticleIdList><ArticleId IdType="pubmed">29269091</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2000 Apr 19;283(15):2008-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2000 Apr;6(4):207-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11168109</ArticleId></ArticleIdList></Reference><Reference><Citation>J Microbiol Immunol Infect. 2001 Jun;34(2):119-24</Citation><ArticleIdList><ArticleId IdType="pubmed">11456357</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Cardiovasc Surg. 2014 Sep;148(3):981-8.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">25026898</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Feb 10;342:d549</Citation><ArticleIdList><ArticleId IdType="pubmed">21310794</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Oct 18;343:d5928</Citation><ArticleIdList><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Mal Coeur Vaiss. 1993 Dec;86(12 Suppl):1825-35</Citation><ArticleIdList><ArticleId IdType="pubmed">8024388</ArticleId></ArticleIdList></Reference><Reference><Citation>Interact Cardiovasc Thorac Surg. 2018 Sep 1;27(3):317-321</Citation><ArticleIdList><ArticleId IdType="pubmed">29868857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2013 Feb 19;158(4):280-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23420236</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Dis. 2018 Jun;10(6):3679-3688</Citation><ArticleIdList><ArticleId IdType="pubmed">30069366</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2017 Jan 5;356:i6460</Citation><ArticleIdList><ArticleId IdType="pubmed">28057641</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2018 Oct;24(10):1102.e7-1102.e15</Citation><ArticleIdList><ArticleId IdType="pubmed">29408350</ArticleId></ArticleIdList></Reference><Reference><Citation>Tex Heart Inst J. 2011;38(6):667-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22199430</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Sci Monit. 2017 Jul 25;23:3617-3626</Citation><ArticleIdList><ArticleId IdType="pubmed">28740070</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 2018 Dec 1;54(6):1060-1066</Citation><ArticleIdList><ArticleId IdType="pubmed">29873701</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 2007 Aug;32(2):281-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17548201</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2017 Aug 15;241:97-102</Citation><ArticleIdList><ArticleId IdType="pubmed">28390740</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Jul 22;343:d4002</Citation><ArticleIdList><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 1996 Sep;62(3):932-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8784045</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1999 Jul 6;131(1):47-59</Citation><ArticleIdList><ArticleId IdType="pubmed">10391815</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2010 Jul 1;106(1):92-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20609654</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38697884</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0938</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cardiovascular revascularization medicine : including molecular interventions</Title><ISOAbbreviation>Cardiovasc Revasc Med</ISOAbbreviation></Journal><ArticleTitle>Combined use of intra-aortic balloon pump and impella in cardiogenic shock: A systematic review.</ArticleTitle><Pagination><StartPage>96</StartPage><EndPage>102</EndPage><MedlinePgn>96-102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.carrev.2024.04.296</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1553-8389(24)00448-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Use of Intra-Aortic Balloon Pump (IABP) in combination with Impella has been described as an alternative strategy for mechanical circulatory support (MCS) in patients with cardiogenic shock (CS). We provide a systematic review aimed to explore the effectiveness of this paired MCS approach.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a comprehensive systematic search in MEDLINE, Scopus, and Cochrane databases to identify all studies that investigated dual MCS with IABP and Impella.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our search strategy identified 12 articles, including 1 randomized controlled trial, 1 retrospective study, 1 case series, 7 case report and 2 animal studies. Rationale for this combined MCS strategy stems from an observed reduction in myocardial oxygen demand/supply ratio compared to the use of each device alone, without determining significant variations in left ventricular work. Nonetheless, this combined approach also leads to a 30-40&#xa0;% decline in Impella flow, increasing the risk of bleeding, Impella displacement, as well as triggering positioning and pressure alarms. Additionally, hemolytic risk data yielded inconclusive results. Importantly, there were no notable disparities in mortality rates when comparing the combined strategy to the use of each device individually.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">At the current state-of-the-art, there are no conclusive data demonstrating net clinical benefits of combining Impella with IABP. Considering the substantial risks of morbidity associated, we recommend against its use in clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farina</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy. Electronic address: farina.jacopo10@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erriquez</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campo</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biscaglia</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuin</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casella</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Ospedale Maggiore, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capecchi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Ospedale Maggiore, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobile</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Ospedale Maggiore, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Anesthesia and Intensive Care, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy and AOU Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Revasc Med</MedlineTA><NlmUniqueID>101238551</NlmUniqueID><ISSNLinking>1878-0938</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="Y">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="Y">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="Y">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Dual mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Intra-aortic balloon pump</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jacopo Farina reports administrative support was provided by University Hospital Arcispedale Sant'Anna of Ferrara Department of Cardiology. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>0</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>2</Day><Hour>21</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38697884</ArticleId><ArticleId IdType="doi">10.1016/j.carrev.2024.04.296</ArticleId><ArticleId IdType="pii">S1553-8389(24)00448-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27994255</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1058</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The journal of extra-corporeal technology</Title><ISOAbbreviation>J Extra Corpor Technol</ISOAbbreviation></Journal><ArticleTitle>Review of Venoarterial Extracorporeal Membrane Oxygenation and Development of Intracardiac Thrombosis in Adult Cardiothoracic Patients.</ArticleTitle><Pagination><StartPage>162</StartPage><EndPage>167</EndPage><MedlinePgn>162-167</MedlinePgn></Pagination><Abstract><AbstractText>Venoarterial extracorporeal membrane oxygenation (VA ECMO) has become an indispensable treatment option for adult cardiothoracic patients experiencing acute refractory cardiogenic shock. VA ECMO is not without inherent complications as in-hospital mortality has ranged from 45% to 65% (1-3). Intracardiac thrombosis (ICT) is a rare but life-threatening complication associated with VA ECMO. VA ECMO cases complicated by ICT were searched for using the MEDLINE (PubMed and OVID), Society of Cardiovascular Anesthesiology Headquarters, and Google Scholar databases. Twelve cases of VA ECMO-associated ICT were discovered for review. Indications for VA ECMO were postcardiotomy cardiogenic shock and heart failure. The primary location of thrombus was the left ventricle and aortic root. Majority of the cases did not report subtherapeutic systemic anticoagulation. Two patients survived after the development of ICT. VA ECMO-associated ICT is a devastating consequence with high mortality. The majority of ICT occurred in cases with perceived adequate anticoagulation, but this may not result in complete suppression of the coagulation response. Continued exposure to procoagulant stimuli and worsening ventricular function and intracardiac stasis can shift the balance toward a hypercoagulable state and development of thrombosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Brittney</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>J Extra Corpor Technol</MedlineTA><NlmUniqueID>0267637</NlmUniqueID><ISSNLinking>0022-1058</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiothoracic</Keyword><Keyword MajorTopicYN="N">coagulation</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword><Keyword MajorTopicYN="N">venoarterial extracorporeal membrane oxygenation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27994255</ArticleId><ArticleId IdType="pmc">PMC5153301</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Elsharkawy H. A., Li L., Esa W. A., et al. . Outcome in patients who require venoarterial extracorporeal membrane oxygenation support after cardiac surgery. J Cardiothorac Vasc Anesth. 2010;24:946&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20599396</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan A. J., Dege A., Mohr M., et al. . Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg. 2010;139(2):302&#x2013;11, 311.e301.</Citation><ArticleIdList><ArticleId IdType="pubmed">20106393</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams D., Combes A., Brodie D.. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63(25 Pt A):2769&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">24814488</ArticleId></ArticleIdList></Reference><Reference><Citation>Beiras-Fernandez A., Deutsch M. A., Kainzinger S., et al. . Extracorporeal membrane oxygenation in 108 patients with low cardiac output: A single-center experience. Int J Artif Organs. 2011;34:365&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">21534247</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan A. J., Lachmann N., Walther T., et al. . Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs. 2006;29:1121&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219352</ArticleId></ArticleIdList></Reference><Reference><Citation>Moubarak G., Weiss N., Leprince P., et al. . Massive intraventricular thrombus complicating extracorporeal membrane oxygenation support. Can J Cardiol. 2008;24:e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631260</ArticleId><ArticleId IdType="pubmed">18209764</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis F., Beiras-Fernandez A., Bruegger D., et al. . Huge intracardiac thrombosis in a patient on veno-arterial extracorporeal membrane oxygenation support. Interact Cardiovasc Thorac Surg. 2009;8:247&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19008325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajj-Chahine J., Tomasi J., Lanquetot H., et al. . Ascending aortic thrombosis in a patient on extra-corporeal membrane oxygenation. Eur J Cardiothorac Surg. 2010;37:953.</Citation><ArticleIdList><ArticleId IdType="pubmed">19913437</ArticleId></ArticleIdList></Reference><Reference><Citation>Leontiadis E., Koertke H., Bairaktaris A., et al. . Thrombosis of the ascending aorta during mechanical circulatory support in a patient with cardiogenic shock. Interact Cardiovasc Thorac Surg. 2010;11:510&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">20656800</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N., Hakim-Meibodi K., Morshuis M., et al. . Recurrent thrombosis after mechanical circulatory support. Interact Cardiovasc Thorac Surg. 2012;14:668&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329300</ArticleId><ArticleId IdType="pubmed">22350773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaide-Chevronnay L., Durand M., Rossi-Blancher M., et al. . Cardiac thrombosis in a patient during extracorporeal life support. J Cardiothorac Vasc Anesth. 2012;26:664&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21872491</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaide-Chevronnay L., Durand M., Rossi-Blancher M., et al. . Cardiac thrombosis in a patient during extracorporeal life support. J Cardiothorac Vasc Anesth. 2012;26:664&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21872491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramjee V., Shreenivas S., Rame J. E., et al. . Complete spontaneous left heart and aortic thromboses on extracorporeal membrane oxygenation support. Echocardiography. 2013;30:E342&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">23889597</ArticleId></ArticleIdList></Reference><Reference><Citation>Madershahian N., Weber C., Scherner M., et al. . Thrombosis of the aortic root and ascending aorta during extracorporeal membrane oxygenation. Intensive Care Med. 2014;40:432.</Citation><ArticleIdList><ArticleId IdType="pubmed">24306084</ArticleId></ArticleIdList></Reference><Reference><Citation>Doufl&#xe9; G., Facchin F., Anwar S., et al. . Severe hypercoagulable state on veno-arterial extracorporeal membrane oxygenation. Intensive Care Med. 2016;42(3):443.</Citation><ArticleIdList><ArticleId IdType="pubmed">26362953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangalli F., Greco G., Galbiati L., et al. . Regional thrombolysis with tenecteplase during extracorporeal membrane oxygenation: A new approach for left ventricular thrombosis. J Card Surg. 2015;30:541&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">25940057</ArticleId></ArticleIdList></Reference><Reference><Citation>Makdisi G., Hashmi Z. A., Wozniak T. C., et al. . Left ventricular thrombus associated with arteriovenous extra corporeal membrane oxygenation. J Thorac Dis. 2015;7:E552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4669293</ArticleId><ArticleId IdType="pubmed">26716054</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisclair M. D., Lane D. A., Philippou H., et al. . Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood. 1993;82:3350&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8241505</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmunds L. H., Colman R. W.. Thrombin during cardiopulmonary bypass. Ann Thorac Surg. 2006;82:2315&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17126170</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLaren G., Combes A., Bartlett R. H.. Contemporary extracorporeal membrane oxygenation for adult respiratory failure: Life support in the new era. Intensive Care Med. 2012;38:210&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22147116</ArticleId></ArticleIdList></Reference><Reference><Citation>Protti A., L'Acqua C., Panigada M.. The delicate balance between pro- (risk of thrombosis) and anti- (risk of bleeding) coagulation during extracorporeal membrane oxygenation. Ann Transl Med. 2016;4:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842390</ArticleId><ArticleId IdType="pubmed">27162789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievert A. N., Shackelford A. G., McCall M. M.. Trends and emerging technologies in extracorporeal life support: Results of the 2006 ECLS survey. J Extra Corpor Technol. 2009;41:73&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4680209</ArticleId><ArticleId IdType="pubmed">19681303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendel H. P., Ziemer G.. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg. 1999;16:342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10554855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarche Y., Chow B., B&#xe9;dard A., et al. . Thromboembolic events in patients on extracorporeal membrane oxygenation without anticoagulation. Innovations. Innovations (Phila). 2010;5:424&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22437638</ArticleId></ArticleIdList></Reference><Reference><Citation>Magovern G. J., Magovern J. A., Benckart D. H., et al. . Extracorporeal membrane oxygenation versus the biopump: Preliminary results in patients with postcardiotomy cardiogenic shock. Ann Thorac Surg. 1994;57:1462&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">8010788</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehrcke D. D., McCarthy P. M., Stewart R. W., et al. . Complications of extracorporeal life support systems using heparin-bound surfaces. The risk of intracardiac clot formation. J Thorac Cardiovasc Surg. 1995;110:843&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7564454</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M., Ditta A., Boncilli A., et al. . Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass. Perfusion. 2004;19:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15072255</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno M. N., Dentali F., Lupoli R., et al. . Mild antithrombin deficiency and risk of recurrent venous thromboembolism: A prospective cohort study. Circulation. 2014;129:497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">24146249</ArticleId></ArticleIdList></Reference><Reference><Citation>Despotis G. J., Levine V., Joist J. H., et al. . Antithrombin III during cardiac surgery: Effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg. 1997;85:498&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">9296400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman C., Rettmann J., Wilson L., Markewitz B.. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. Am J Clin Pathol. 2006;126:416&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16880140</ArticleId></ArticleIdList></Reference><Reference><Citation>Irby K., Swearingen C., Byrnes J., et al. . Unfractionated heparin activity measured by anti-factor Xa levels is associated with the need for extracorporeal membrane oxygenation circuit/membrane oxygenator change: A retrospective pediatric study. Pediatr Crit Care Med. 2014;15:e175&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013211</ArticleId><ArticleId IdType="pubmed">24622165</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Meara LC, Alten J. A., Goldberg K. G., et al. . Anti-Xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. ASAIO J. 2015;61:339&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">25710768</ArticleId></ArticleIdList></Reference><Reference><Citation>Delewi R., Zijlstra F., Piek J. J.. Left ventricular thrombus formation after acute myocardial infarction. Heart. 2012;98:1743&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3505867</ArticleId><ArticleId IdType="pubmed">23151669</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong T. H., Byun J. H., Yoo B. H., et al. . Successful left-heart decompression during extracorporeal membrane oxygenation in an adult patient by percutaneous transaortic catheter venting. Korean J Thorac Cardiovasc Surg. 2015;48:210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463232</ArticleId><ArticleId IdType="pubmed">26078930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon S. R., Henriques J. P., Mauri L., et al. . A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): Initial US experience. JACC Cardiovasc Interv. 2009;2:91&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19463408</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemoto C. M., Streiff M. B., Shermock K. M., et al. . Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring. Am J Clin Pathol. 2013;139:450&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23525615</ArticleId></ArticleIdList></Reference><Reference><Citation>Liveris A., Bello R. A., Friedmann P., et al. . Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2014;15:e72&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24335992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M., Ballotta A., Kandil H., et al. . Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15:R275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388709</ArticleId><ArticleId IdType="pubmed">22099212</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M., Agracheva N., Bonaveglio E., et al. . Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: A case-control study. J Cardiothorac Vasc Anesth. 2013;27:30&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23036625</ArticleId></ArticleIdList></Reference><Reference><Citation>Beiderlinden M., Treschan T., G&#xf6;rlinger K., et al. . Argatroban in extracorporeal membrane oxygenation. Artif Organs. 2007;31:461&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17537058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa S., Richardson J. E., Sakai T., et al. . High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass. J Anesth. 2012;26:9&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">22005756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwischenberger J. B., Nguyen T. T., Upp J. R., et al. . Complications of neonatal extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 1994;107:838&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8127113</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford M. A., Gauvreau K., McMullan D. M., et al. . Factors associated with mortality in neonates requiring extracorporeal membrane oxygenation for cardiac indications: Analysis of the extracorporeal life support organization registry data. Pediatr Crit Care Med. 2016;17:860&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">27355824</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36940708</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-1902</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Thoracic and cardiovascular surgeon</Title><ISOAbbreviation>Thorac Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal Membrane Oxygenation in Intoxication and Overdoses: A Systematic Review.</ArticleTitle><Pagination><StartPage>288</StartPage><EndPage>295</EndPage><MedlinePgn>288-295</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0043-1764160</ELocationID><Abstract><AbstractText>Extracorporeal membrane oxygenation (ECMO) has been increasingly applied over recent decades to treat severe cardiogenic shock and acute lung failure and cardiac arrest of various causes. Acute intoxication with therapeutic substances or other chemical substances can cause severe cardiogenic shock or even cardiac arrest. The purpose of this study was to conduct a qualitative systematic review of ECMO use in intoxication and poisoning. We searched the PubMed, Medline, and Web of Science databases from January 1971 to December 2021 and selected appropriate studies according to our inclusion and exclusion criteria to evaluate the role of ECMO in intoxication and poisoning systematically. Survival at hospital discharge was examined to describe the outcome. The search resulted in 365 publications after removing duplicates. In total, 190 full-text articles were assessed for eligibility. A total of 145 articles from 1985 to 2021 were examined in our final qualitative analysis. A total of 539 (100%) patients were included (mean age: 30.9&#x2009;&#xb1;&#x2009;16.6 years), with a distribution of <i>n</i>&#x2009;=&#x2009;64 (11.9%) cases with venovenous (vv) ECMO, <i>n</i>&#x2009;=&#x2009;218 (40.4%) cases with venoarterial (va) ECMO, and <i>n</i>&#x2009;=&#x2009;257 (47.7%) cases with cardiac arrest and extracorporeal cardiopulmonary resuscitation. Survival at hospital discharge was 61.0% for all patients, 68.8% for vaECMO, 75% for vvECMO, and 50.9% for extracorporeal cardiopulmonary resuscitation. When used and reported, ECMO seems to be a valid tool for adult and pediatric patients suffering intoxication from various pharmaceutical and nonpharmaceutical substances due to a high survival rate at hospital discharge.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Sven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4118-948X</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center-University of Freiburg, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Freiburg Faculty of Medicine, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf6;sner</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center-University of Freiburg, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Freiburg Faculty of Medicine, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saemann</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University Hospital Halle, Halle, Sachsen-Anhalt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sogl</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center-University of Freiburg, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Freiburg Faculty of Medicine, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beyersdorf</LastName><ForeName>Friedhelm</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center-University of Freiburg, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Freiburg Faculty of Medicine, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trummer</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center-University of Freiburg, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Freiburg Faculty of Medicine, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czerny</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center-University of Freiburg, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Freiburg Faculty of Medicine, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benk</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center-University of Freiburg, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Freiburg Faculty of Medicine, Freiburg, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Thorac Cardiovasc Surg</MedlineTA><NlmUniqueID>7903387</NlmUniqueID><ISSNLinking>0171-6425</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062787" MajorTopicYN="Y">Drug Overdose</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011041" MajorTopicYN="N">Poisoning</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="N">Heart Arrest</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>F.B., C.B. and G.T. are shareholders of ResuSciTec GmbH, Freiburg, Germany. C.B. and G.T. are part-time employees of ResuSciTec GmbH, Freiburg, Germany. The other authors report no conflict of interest regarding this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>4</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>19</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36940708</ArticleId><ArticleId IdType="doi">10.1055/s-0043-1764160</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39768971</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Anti-Platelet Therapy with Cangrelor in Cardiogenic Shock Patients: A Systematic Review and Single-Arm Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2092</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina60122092</ELocationID><Abstract><AbstractText><i>Background and Objectives:</i> Percutaneous coronary intervention (PCI) is a proven therapy for acute myocardial infarction (AMI) cardiogenic shock (CS). Dual anti-platelet therapy (i.e., aspirin plus an oral P2Y12 inhibitor) is recommended in patients treated with PCI. However, CS patients present severe hemodynamic instability, deranged hemostatic balance, and the need for invasive mechanical circulatory support (MCS) alongside invasive procedures, resulting in an increased risk of both bleeding and thrombotic complications, leaving uncertainty about the best anti-thrombotic treatment. Recently, the parenteral short-acting P2Y12 inhibitor has been increasingly used in the acute cardiac care setting, mainly in light of its favourable pharmacokinetic profile and organ-independent metabolism. <i>Materials and Methods:</i> In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review and single-arm meta-analysis of the safety and efficacy outcomes (i.e., rates of major bleeding, occurrence of stent/any thrombosis, and hospital survival) of all existing original studies reporting on the intravenous administration of cangrelor in AMI-CS patients. <i>Results:</i> Ten studies (678 patients with CS) published between 2017 and 2023 were included in the present review: nine were observational and one had a randomized design. Percutaneous revascularization was performed in &gt;80% of patients across the studies. Moreover, 26% of patients were treated with temporary MCS, and in all studies, concomitant systemic anticoagulation was performed. Cangrelor was administered intravenously at the dosage of 4 mcg/kg/min in 57% of patients, 0.75 mcg/kg/min in 37% of patients, and &lt;0.75 mcg/kg/min in 6%. The pooled rate of major bleeding was 17% (11-23%, confidence interval [CI]), and the pooled rate of stent thrombosis and any thrombosis were 1% (0.3-2.3% CI) and 3% (0.4-7% CI), respectively. Pooled hospital survival was 66% (59-73% CI). <i>Conclusions:</i> Cangrelor administration in AMI-CS patients was feasible and safe with a low rate of thromboembolic complications. Haemorrhagic complications were more frequent than thrombotic events. Nevertheless, to date, the optimal dosage of cangrelor in this clinical context still remains not universally recognized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Andria Ursoleo</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6313-9160</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldetti</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5986-049X</Identifier><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieri</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardelli</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0407-9871</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altizio</LastName><ForeName>Savino</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0002-6430-8963</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajello</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scandroglio</LastName><ForeName>Anna Mara</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6AQ1Y404U7</RegistryNumber><NameOfSubstance UI="C117446">cangrelor</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="Y">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="Y">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">VA-ECMO</Keyword><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">cangrelor</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword></KeywordList><CoiStatement>M.P., L.B., P.N., S.A. (Silvia Ajello), and A.M.S. received speaker fees from Abiomed Europe GmbH; M.P. received consultancy fees from Abiomed Europe GmbH.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39768971</ArticleId><ArticleId IdType="pmc">PMC11678342</ArticleId><ArticleId IdType="doi">10.3390/medicina60122092</ArticleId><ArticleId IdType="pii">medicina60122092</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., B&#xf6;hm M., Burri H., Butler J., &#x10c;elutkien&#x117; J., Chioncel O., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42:3599&#x2013;3726. doi: 10.1093/eurheartj/ehab368. Erratum in Eur. Heart J. 2021, 42, 4901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab368</ArticleId><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich P.A., Bozkurt B., Aguilar D., Allen L.A., Byun J.J., Colvin M.M., Deswal A., Drazner M.H., Dunlay S.M., Evers L.R., et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e876&#x2013;e894. doi: 10.1161/CIR.0000000000001062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001062</ArticleId><ArticleId IdType="pubmed">35363500</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D.D., Bohula E.A., van Diepen S., Katz J.N., Alviar C.L., Baird-Zars V.M., Barnett C.F., Barsness G.W., Burke J.A., Cremer P.C., et al. Epidemiology of Shock in Contemporary Cardiac Intensive Care Units. Circ. Cardiovasc. Qual. Outcomes. 2019;12:e005618. doi: 10.1161/CIRCOUTCOMES.119.005618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.119.005618</ArticleId><ArticleId IdType="pmc">PMC11032172</ArticleId><ArticleId IdType="pubmed">30879324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman J.S., Sleeper L.A., Webb J.G., Sanborn T.A., White H.D., Talley J.D., Christopher E.B., Jacobs A.K., Slater J.N., Col J., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N. Engl. J. Med. 1999;341:625&#x2013;634. doi: 10.1056/NEJM199908263410901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199908263410901</ArticleId><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller J.E., Engstr&#xf8;m T., Jensen L.O., Eiskj&#xe6;r H., Mangner N., Polzin A., Schulze P.C., Skurk C., Nordbeck P., Clemmensen P., et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N. Engl. J. Med. 2024;390:1382&#x2013;1393. doi: 10.1056/NEJMoa2312572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2312572</ArticleId><ArticleId IdType="pubmed">38587239</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Akin I., Behnes M., Rassaf T., Mahabadi A.A., Lehmann R., Eitel I., Graf T., Seidler T., et al. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N. Engl. J. Med. 2023;389:1286&#x2013;1297. doi: 10.1056/NEJMoa2307227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2307227</ArticleId><ArticleId IdType="pubmed">37634145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostadal P., Rokyta R., Karasek J., Kruger A., Vondrakova D., Janotka M., Naar J., Smalcova J., Hubatova M., Hromadka M., et al. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. Circulation. 2023;147:454&#x2013;464. doi: 10.1161/CIRCULATIONAHA.122.062949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.062949</ArticleId><ArticleId IdType="pubmed">36335478</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks P.A., Sieg A., Paruthi C., Rajapreyar I. Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation. J. Cardiovasc. Pharmacol. Ther. 2015;20:370&#x2013;377. doi: 10.1177/1074248415571456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248415571456</ArticleId><ArticleId IdType="pubmed">25665880</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M., Qamar A., Badreldin H.A., Faxon D.P., Bhatt D.L. Cangrelor Use in Cardiogenic Shock: A Single-Center Real-World Experience. JACC Cardiovasc. Interv. 2017;10:1712&#x2013;1714. doi: 10.1016/j.jcin.2017.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2017.07.009</ArticleId><ArticleId IdType="pubmed">28838482</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquis-Gravel G., Zeitouni M., Kochar A., Jones W.S., Sketch M.H., Rao S.V., Patel M.R., Ohman E.M. Technical consideration in acute myocardial infarction with cardiogenic shock: A review of antithrombotic and PCI therapies. Catheter. Cardiovasc. Interv. 2020;95:924&#x2013;931. doi: 10.1002/ccd.28455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28455</ArticleId><ArticleId IdType="pubmed">31435999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim K., Christoph M., Schmeinck S., Schmieder K., Steiding K., Schoener L., Pfluecke C., Quick S., Mues C., Jellinghaus S., et al. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2014;85:649&#x2013;656. doi: 10.1016/j.resuscitation.2014.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2014.02.004</ArticleId><ArticleId IdType="pubmed">24555950</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodi G., Bellandi B., Xanthopoulou I., Capranzano P., Capodanno D., Valenti R., Stavrou K., Migliorini A., Antoniucci D., Tamburino C., et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ. Cardiovasc. Interv. 2014;8:e001593. doi: 10.1161/CIRCINTERVENTIONS.114.001593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.114.001593</ArticleId><ArticleId IdType="pubmed">25552565</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubica J., Kozinski M., Navarese E.P., Tantry U., Kubica A., Siller-Matula J.M., Jeong Y.-H., Fabiszak T., Andruszkiewicz A., Gurbel P.A. Cangrelor: An emerging therapeutic option for patients with coronary artery disease. Curr. Med. Res. Opin. 2014;30:813&#x2013;828. doi: 10.1185/03007995.2014.880050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007995.2014.880050</ArticleId><ArticleId IdType="pubmed">24393016</ArticleId></ArticleIdList></Reference><Reference><Citation>Akers W.S., Oh J.J., Oestreich J.H., Ferraris S., Wethington M., Steinhubl S.R. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist. J. Clin. Pharmacol. 2010;50:27&#x2013;35. doi: 10.1177/0091270009344986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270009344986</ArticleId><ArticleId IdType="pubmed">19779037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorog D.A., Price S., Sibbing D., Baumbach A., Capodanno D., Gigante B., Halvorsen S., Huber K., Lettino M., Leonardi S., et al. Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: A joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur. Heart J. Cardiovasc. Pharmacother. 2021;7:125&#x2013;140. doi: 10.1093/ehjcvp/pvaa009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvaa009</ArticleId><ArticleId IdType="pubmed">32049278</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossini R., Masiero G., Fruttero C., Passamonti E., Calvaruso E., Cecconi M., Carlucci C., Mojoli M., Guido P., Talanas G., et al. Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience. TH Open. 2020;4:e437&#x2013;e445. doi: 10.1055/s-0040-1721504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1721504</ArticleId><ArticleId IdType="pmc">PMC7758156</ArticleId><ArticleId IdType="pubmed">33376943</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington R.A., Stone G.W., McNulty S., White H.D., Lincoff A.M., Gibson C.M., Pollack C.V.J., Montalescot G., Mahaffey K.W., Kleiman N.S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 2009;361:2318&#x2013;2329. doi: 10.1056/NEJMoa0908628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908628</ArticleId><ArticleId IdType="pubmed">19915221</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt D.L., Stone G.W., Mahaffey K.W., Gibson C.M., Steg P.G., Hamm C.W., Price M.J., Leonardi S., Gallup D., Bramucci E., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 2013;368:1303&#x2013;1313. doi: 10.1056/NEJMoa1300815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1300815</ArticleId><ArticleId IdType="pubmed">23473369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt D.L., Lincoff A.M., Gibson C.M., Stone G.W., McNulty S., Montalescot G., Kleiman N.S., Goodman S.G., White H.D., Mahaffey K.W., et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 2009;361:2330&#x2013;2341. doi: 10.1056/NEJMoa0908629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908629</ArticleId><ArticleId IdType="pubmed">19915222</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiolillo D.J., Firstenberg M.S., Price M.J., Tummala P.E., Hutyra M., Welsby I.J., Voeltz M.D., Chandna H., Ramaiah C., Brtko M., et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial. JAMA. 2012;307:265&#x2013;274. doi: 10.1001/jama.2011.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.2002</ArticleId><ArticleId IdType="pmc">PMC3774162</ArticleId><ArticleId IdType="pubmed">22253393</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldetti L., Nardelli P., Ajello S., Melisurgo G., Calabr&#xf2; M.G., Pieri M., Scandroglio A.M. Anti-thrombotic Therapy With Cangrelor and Bivalirudin in Venoarterial Extracorporeal Membrane Oxygenation Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Experience. ASAIO J. 2023;69:e346&#x2013;e350. doi: 10.1097/MAT.0000000000001871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001871</ArticleId><ArticleId IdType="pubmed">36490373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman S., Gass J., Weeks P. Antiplatelet Therapy Bridging with Cangrelor in Patients with Coronary Stents: A Case Series. Ann. Pharmacother. 2019;53:171&#x2013;177. doi: 10.1177/1060028018795840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1060028018795840</ArticleId><ArticleId IdType="pubmed">30132336</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557&#x2013;560. doi: 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohan D., Uricchio M.N., Konopka C.I., Montepara C.A., Verlinden N.J. Comparison of clinical outcomes with cangrelor plus aspirin versus oral dual antiplatelet therapy in patients supported with venoarterial extracorporeal membrane oxygenation. Artif. Organs. 2023;47:1672&#x2013;1677. doi: 10.1111/aor.14590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.14590</ArticleId><ArticleId IdType="pubmed">37203212</ArticleId></ArticleIdList></Reference><Reference><Citation>Droppa M., Vaduganathan M., Venkateswaran R.V., Singh A., Szumita P.M., Roberts R.J., Qamar A., Hack L., Rath D., Gawaz M., et al. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation. 2019;137:205&#x2013;212. doi: 10.1016/j.resuscitation.2019.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2019.02.008</ArticleId><ArticleId IdType="pubmed">30790690</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz A., Lewis T.C., Arnouk S., Altshuler D., Papadopoulos J., Toy B., Smith D.E., Merchan C. Clinical Use of Cangrelor After Percutaneous Coronary Intervention in Patients Requiring Mechanical Circulatory Support. Ann. Pharmacother. 2021;55:1215&#x2013;1222. doi: 10.1177/1060028021994621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1060028021994621</ArticleId><ArticleId IdType="pubmed">33567855</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B., Horton E., Domenico C., Nathan A., Fanaroff A., Acker M., Kolansky D. Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study. J. Invasive Cardiol. 2021;33:E998&#x2013;E1003. doi: 10.25270/jic/21.00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.25270/jic/21.00013</ArticleId><ArticleId IdType="pubmed">34817395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeymer U., Lober C., Richter S., Olivier C.B., Huber K., Haring B., Schwimmbeck P., Andrassy M., Akin I., Cuneo A., et al. Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and/or with cardiogenic shock. Eur. Heart J. Acute Cardiovasc. Care. 2023;12:462&#x2013;463. doi: 10.1093/ehjacc/zuad041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuad041</ArticleId><ArticleId IdType="pubmed">37042356</ArticleId></ArticleIdList></Reference><Reference><Citation>Droppa M., Borst O., Rath D., M&#xfc;ller K., Gawaz M., Bhatt D.L., Geisler T. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock&#x2014;A Case Series. Cell Physiol. Biochem. 2017;42:1336&#x2013;1341. doi: 10.1159/000478962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000478962</ArticleId><ArticleId IdType="pubmed">28700987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideo-Kajita A., Rogers T., Buchanan K., Iantorno M., Gajanana D., Ozaki Y., Dan K., Kolm P., Brathwaite E., Beyene S., et al. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention. Am. J. Cardiol. 2019;123:1228&#x2013;1238. doi: 10.1016/j.amjcard.2019.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.01.031</ArticleId><ArticleId IdType="pubmed">30738570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordis P., Bozic Mijovski M., Berden J., Steblovnik K., Blinc A., Noc M. Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: The CANGRELOR-OHCA study. EuroIntervention. 2023;18:1269&#x2013;1271. doi: 10.4244/EIJ-D-22-00675.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-D-22-00675</ArticleId><ArticleId IdType="pmc">PMC10015287</ArticleId><ArticleId IdType="pubmed">36484623</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiolillo D.J., Schneider D.J., Bhatt D.L., French W.J., Price M.J., Saucedo J.F., Shaburishvili T., Huber K., Prats J., Liu T., et al. Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J. Thromb. Thrombolysis. 2012;34:44&#x2013;55. doi: 10.1007/s11239-012-0737-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-012-0737-3</ArticleId><ArticleId IdType="pubmed">22569899</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos D., Xanthopoulou I., Gkizas V., Kassimis G., Theodoropoulos K.C., Makris G., Koutsogiannis N., Damelou A., Tsigkas G., Davlouros P., et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 2012;5:797&#x2013;804. doi: 10.1161/CIRCINTERVENTIONS.112.972323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.112.972323</ArticleId><ArticleId IdType="pubmed">23169985</ArticleId></ArticleIdList></Reference><Reference><Citation>Radu R.I., Ben Gal T., Abdelhamid M., Antohi E., Adamo M., Ambrosy A.P., Geavlete O., Lopatin Y., Lyon A., Miro O., et al. Antithrombotic and anticoagulation therapies in cardiogenic shock: A critical review of the published literature. ESC Heart Fail. 2021;8:4717&#x2013;4736. doi: 10.1002/ehf2.13643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13643</ArticleId><ArticleId IdType="pmc">PMC8712803</ArticleId><ArticleId IdType="pubmed">34664409</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Edom C.J., Gramegna M., Baldetti L., Beneduce A., Castelein T., Dauwe D., Frederiks P., Giustino G., Jacquemin M., Janssens S.P., et al. Management of Bleeding and Hemolysis During Percutaneous Microaxial Flow Pump Support: A Practical Approach. JACC Cardiovasc. Interv. 2023;16:1707&#x2013;1720. doi: 10.1016/j.jcin.2023.05.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2023.05.043</ArticleId><ArticleId IdType="pubmed">37495347</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33677732</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7322</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Heart failure reviews</Title><ISOAbbreviation>Heart Fail Rev</ISOAbbreviation></Journal><ArticleTitle>Mechanical circulatory support in patients with cardiogenic shock not secondary to cardiotomy: a network meta-analysis.</ArticleTitle><Pagination><StartPage>927</StartPage><EndPage>934</EndPage><MedlinePgn>927-934</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10741-021-10092-y</ELocationID><Abstract><AbstractText>To compare the efficacy and safety of different mechanical circulatory support (MCS) devices in CS. A total of 24 studies (7 randomized controlled trials-RCTs-and 17 non-RCTs) involving 11,117 patients were entered in a Bayesian network meta-analysis. The primary endpoint was 30-day mortality. Secondary endpoints were stroke and bleeding (requiring transfusion and/or intracranial and/or fatal). Compared with no MCS, extra-corporeal membrane oxygenation (ECMO) reduced 30-day mortality when used both alone (OR 0.37, 95% CrI 0.15-0.90) and together with the micro-axial pump Impella (OR 0.13, 95% CrI 0.02-0.80) or intra-aortic balloon pump (IABP) (OR 0.19, 95% CrI 0.05-0.63), although the relevant articles were affected by significant publication bias. Consistent results were obtained in a sensitivity analysis including only studies of CS due to myocardial infarction. After halving the weight of studies with a non-RCT design, only the benefit of ECMO&#x2009;+&#x2009;IABP on 30-day mortality was maintained (OR 0.22, 95% CI 0.057-0.76). The risk of bleeding was increased by TandemHeart (OR 13, 95% CrI 3.50-59), Impella (OR 5, 95% CrI 1.60-18), and IABP (OR 2.2, 95% CrI 1.10-4.4). No significant differences were found across MCS strategies regarding stroke. Although limited by important quality issues, the studies performed so far indicate that ECMO, especially if combined with Impella or IABP, reduces short-term mortality in CS. MCS increases the hazard of bleeding.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benenati</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Genoa, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toma</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Genoa, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canale</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Genoa, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergallo</LastName><ForeName>Rocco</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bona</LastName><ForeName>Roberta Della</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrated Surgical and Diagnostic Sciences, University of Genova, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canepa</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Genoa, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crimi</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santini</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrated Surgical and Diagnostic Sciences, University of Genova, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ameri</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7167-7287</Identifier><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy. pietroameri@unige.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Genoa, Genova, Italy. pietroameri@unige.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porto</LastName><ForeName>Italo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Genoa, Genova, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Fail Rev</MedlineTA><NlmUniqueID>9612481</NlmUniqueID><ISSNLinking>1382-4147</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Intra-aortic balloon pump</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">TandemHeart</Keyword></KeywordList><CoiStatement>Dr. Ameri reports personal fees from Novartis, personal fees from Astra Zeneca, personal fees from Vifor, personal fees from Daiichi-Sankyo, personal fees from Boehringer Ingelheim, personal fees from Janssen, personal fees from Merck Sharp &amp; Dohme, and personal fees from GlaxoSmithKline, outside the submitted work; Dr. Porto reports grants and personal fees from AstraZeneca, personal fees from Daiichi Sankyo, personal fees from Terumo Corporation, personal fees from Biotronik, personal fees from Bayer, personal fees from Amgen, and personal fees and non-financial support from Abiomed, outside the submitted work; Dr. Canepa reports grants and personal fees from Pfizer, personal fees from Novartis, personal fees from Akcea Therapeutics, and personal fees from Sanofi Genzyme, outside the submitted work; Dr. Crimi reports personal fees from Philips healthcare, outside the submitted work; other authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>7</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33677732</ArticleId><ArticleId IdType="pmc">PMC9033692</ArticleId><ArticleId IdType="doi">10.1007/s10741-021-10092-y</ArticleId><ArticleId IdType="pii">10.1007/s10741-021-10092-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lauridsen MD, R&#xf8;rth R, Lindholm MG, et al. Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction&#x2013;related cardiogenic shock from 2005 to 2017: a nationwide cohort study. Am Heart J. 2020;28(229):127&#x2013;137. doi: 10.1016/j.ahj.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.08.012</ArticleId><ArticleId IdType="pubmed">32861678</ArticleId></ArticleIdList></Reference><Reference><Citation>van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232&#x2013;e268.</Citation><ArticleIdList><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG et al&#xa0;(1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 341(9):625&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J. 1999;138(1 Pt 1):78&#x2013;86. doi: 10.1016/S0002-8703(99)70250-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-8703(99)70250-4</ArticleId><ArticleId IdType="pubmed">10385768</ArticleId></ArticleIdList></Reference><Reference><Citation>Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. J Am Coll Cardiol. 2015;65(19):e7&#x2013;e26. doi: 10.1016/j.jacc.2015.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.03.036</ArticleId><ArticleId IdType="pubmed">25861963</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, O&#x2019;Horo JC, Antharam P, et al. Concomitant intra-aortic balloon pump use in cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2018;11(9):e006930. doi: 10.1161/CIRCINTERVENTIONS.118.006930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.118.006930</ArticleId><ArticleId IdType="pubmed">30354593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios SA, Bravo CA, Weinreich M, et al. Meta-analysis and trial sequential analysis comparing percutaneous ventricular assist devices versus intra-aortic balloon pump during high-risk percutaneous coronary intervention or cardiogenic shock. Am J Cardiol. 2018;122(8):1330&#x2013;1338. doi: 10.1016/j.amjcard.2018.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2018.07.011</ArticleId><ArticleId IdType="pubmed">30146099</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Fares AA, Randhawa VK, Englesakis M, et al. Optimal strategy and timing of left ventricular venting during veno-arterial extracorporeal life support for adults in cardiogenic shock: a systematic review and meta-Analysis. Circ Heart Fail. 2019;12(11):e006486. doi: 10.1161/CIRCHEARTFAILURE.119.006486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.119.006486</ArticleId><ArticleId IdType="pubmed">31718322</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Yan S, Gao S, et al. Effect of an intra-aortic balloon pump with venoarterial extracorporeal membrane oxygenation on mortality of patients with cardiogenic shock: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2019;55(3):395&#x2013;404. doi: 10.1093/ejcts/ezy304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezy304</ArticleId><ArticleId IdType="pubmed">30252028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson-Smith AR, Bogdanova Y, Roydhouse S, et al. Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: systematic review and meta-analysis. Ann Cardiothorac Surg. 2019;8(1):1&#x2013;8. doi: 10.21037/acs.2018.11.09.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs.2018.11.09</ArticleId><ArticleId IdType="pmc">PMC6379189</ArticleId><ArticleId IdType="pubmed">30854307</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo JJ, Aleksova N, Pitcher I, et al. Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol. 2019;73(6):654&#x2013;662. doi: 10.1016/j.jacc.2018.10.085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.10.085</ArticleId><ArticleId IdType="pubmed">30765031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Sjauw KD et al&#xa0;(2017) Percutaneous mechanical circulatory support versus intra-aortic balloon pump&#xa0;in cardiogenic shock after acute&#xa0;myocardial infarction J Am Coll Cardiol 24;69(3):278&#x2013;287</Citation><ArticleIdList><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777&#x2013;784. doi: 10.7326/M14-2385.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Altman DG, G&#xf8;tzsche PC, et al. The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011;18(343):d5928. doi: 10.1136/bmj.d5928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Hern&#xe1;n MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;12(355):i4919. doi: 10.1136/bmj.i4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, Altman DG&#xa0;(2003) Measuring inconsistency in meta-analyses. British Medical Journal 327(7414):557&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavridis D, Giannatsi M, Cipriani A, Salanti G. A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health. 2015;18(2):40&#x2013;46. doi: 10.1136/eb-2015-102088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/eb-2015-102088</ArticleId><ArticleId IdType="pmc">PMC11234956</ArticleId><ArticleId IdType="pubmed">25908686</ArticleId></ArticleIdList></Reference><Reference><Citation>van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods. 2016;7(1):80&#x2013;93. doi: 10.1002/jrsm.1167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1167</ArticleId><ArticleId IdType="pmc">PMC5057346</ArticleId><ArticleId IdType="pubmed">26461181</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff D, Sayer G, Doshi D, Uriel N. Hemodynamics of mechanical circulatory support. J Am Coll Cardiol. 2015;66(23):2663&#x2013;2674. doi: 10.1016/j.jacc.2015.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.10.017</ArticleId><ArticleId IdType="pubmed">26670067</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287&#x2013;1296. doi: 10.1056/NEJMoa1208410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208410</ArticleId><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff D, Cohen H, Brunckhorst C, O&#x2019;Neill WW. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152(3):469.e1&#x2013;8. doi: 10.1016/j.ahj.2006.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2006.05.031</ArticleId><ArticleId IdType="pubmed">16923414</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584&#x2013;1588. doi: 10.1016/j.jacc.2008.05.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2008.05.065</ArticleId><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(4):e78&#x2013;e140. doi: 10.1016/j.jacc.2012.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.11.019</ArticleId><ArticleId IdType="pubmed">23256914</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87&#x2013;165. doi: 10.1093/eurheartj/ehy394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy394</ArticleId><ArticleId IdType="pubmed">30615155</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendjelid K. IABP and cardiogenic shock: a heartbreaking story. Am Heart J. 2018;199:178&#x2013;180. doi: 10.1016/j.ahj.2017.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2017.12.009</ArticleId><ArticleId IdType="pubmed">29754659</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Schreiber TL, Grines CL, et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol. 2017;119(6):845&#x2013;851. doi: 10.1016/j.amjcard.2016.11.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2016.11.037</ArticleId><ArticleId IdType="pubmed">28040188</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, De Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671&#x2013;2683. doi: 10.1093/eurheartj/ehz363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz363</ArticleId><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan J, Shi Y, Luo G, et al. Short-term efficacy and safety of different mechanical hemodynamic support devices for cardiogenic shock or high-risk Pci: a network meta-analysis of thirty-seven trials. Shock. 2021;55(1):5&#x2013;13. doi: 10.1097/SHK.0000000000001611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001611</ArticleId><ArticleId IdType="pubmed">33337786</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglin M, Zucker MJ, Bazan VM, et al. Venoarterial ECMO for adults: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(6):698&#x2013;716. doi: 10.1016/j.jacc.2018.11.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.11.038</ArticleId><ArticleId IdType="pubmed">30765037</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Burkhoff D, R&#xfc;bsamen N, et al. Unloading of the left ventricle during venoarterial extracorporeal membrane oxygenation therapy in cardiogenic shock. JACC Hear Fail. 2018;6(12):1035&#x2013;1043. doi: 10.1016/j.jchf.2018.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2018.09.009</ArticleId><ArticleId IdType="pubmed">30497643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper S, Masood MF, Baltazar Garcia M, et al. Left ventricular unloading by impella device versus surgical vent during extracorporeal life support. Ann Thorac Surg. 2017;104(3):861&#x2013;867. doi: 10.1016/j.athoracsur.2016.12.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.12.049</ArticleId><ArticleId IdType="pubmed">28347536</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Schulte C, Pieri M, et al. Concomitant implantation of Impella&#xae; on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19(3):404&#x2013;412. doi: 10.1002/ejhf.668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.668</ArticleId><ArticleId IdType="pubmed">27709750</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiller P, Hellgren L, Vikholm P. Survival after refractory cardiogenic shock is comparable in patients with Impella and veno-arterial extracorporeal membrane oxygenation when adjusted for SAVE score. Eur Hear J Acute Cardiovasc Care. 2019;8(4):329&#x2013;337. doi: 10.1177/2048872618799745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872618799745</ArticleId><ArticleId IdType="pubmed">30406678</ArticleId></ArticleIdList></Reference><Reference><Citation>Udesen NJ, M&#xf8;ller JE, Lindholm MG, et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J. 2019;214:60&#x2013;68. doi: 10.1016/j.ahj.2019.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2019.04.019</ArticleId><ArticleId IdType="pubmed">31176289</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubron C, DePuydt J, Belon F, et al. Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. Ann Intensive Care. 2016;6(1):97. doi: 10.1186/s13613-016-0196-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-016-0196-7</ArticleId><ArticleId IdType="pmc">PMC5053950</ArticleId><ArticleId IdType="pubmed">27714705</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R, Hachamovitch R, Kittleson M, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014;97(2):610&#x2013;616. doi: 10.1016/j.athoracsur.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2013.09.008</ArticleId><ArticleId IdType="pubmed">24210621</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteagudo-Vela M, Simon A, Riesgo Gil F, et al. Clinical indications of IMPELLA short-term mechanical circulatory support in a tertiary Centre. Cardiovasc Revascularization Med. 2019;S1553&#x2013;8389(19):30806&#x2013;30811.</Citation><ArticleIdList><ArticleId IdType="pubmed">31859100</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandawat A, Rao SV. Percutaneous mechanical circulatory support devices in cardiogenic shock. Circ Cardiovasc Interv. 2017;10(5):e004337. doi: 10.1161/CIRCINTERVENTIONS.116.004337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.116.004337</ArticleId><ArticleId IdType="pmc">PMC5578718</ArticleId><ArticleId IdType="pubmed">28500136</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35687316</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2724-5772</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Minerva cardiology and angiology</Title><ISOAbbreviation>Minerva Cardiol Angiol</ISOAbbreviation></Journal><ArticleTitle>Beneficial effects of levosimendan to wean patients from VA-ECMO: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>564</StartPage><EndPage>574</EndPage><MedlinePgn>564-574</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.23736/S2724-5683.22.06054-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients with refractory cardiogenic shock can benefit from veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The use of levosimendan in VA-ECMO patients may facilitate weaning and enhance survival.</AbstractText><AbstractText Label="EVIDENCE ACQUISITION" NlmCategory="METHODS">MEDLINE, Scopus, Web of Science, and Cochrane were searched from inception to October 10<sup>th</sup>, 2021. Eligible clinical trials and observational studies reporting the use of levosimendan in VA-ECMO were searched. Two reviewers extracted data and independently assessed the risk of bias. To integrate the data, a random-effect model was applied. The success of weaning from VA-ECMO was the primary outcome.</AbstractText><AbstractText Label="EVIDENCE SYNTHESIS" NlmCategory="RESULTS">Ten observational studies, including a total of 987 patients, were identified. Levosimendan was associated with successful weaning (362/448) compared with controls (328/539) (OR 2.37, 95% CI 1.71-3.28; P=0.01) and reduced mortality (144/433 vs. 258/507) (nine studies, OR 0.53, 95% CI 0.36-0.78; P=0.01) compared with control.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Levosimendan was associated with successful weaning and increased survival in VA-ECMO patients. Randomized trials should confirm these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertini</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy - pietro.bertini@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paternoster</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiac Resuscitation, Cardiovascular Anesthesia and Intensive Care, San Carlo Hospital, Potenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Disease Unit, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nocci</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Anesthesia and Critical Care, Department of Anesthesia and Critical Care, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costanzo</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brizzi</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romani</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit of Vascular Surgery, San Carlo Hospital, Potenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarracino</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Minerva Cardiol Angiol</MedlineTA><NlmUniqueID>101776555</NlmUniqueID><ISSNLinking>2724-5683</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35687316</ArticleId><ArticleId IdType="doi">10.23736/S2724-5683.22.06054-9</ArticleId><ArticleId IdType="pii">S2724-5683.22.06054-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40884710</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7322</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Heart failure reviews</Title><ISOAbbreviation>Heart Fail Rev</ISOAbbreviation></Journal><ArticleTitle>Infective endocarditis complicated by shock: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10741-025-10556-5</ELocationID><Abstract><AbstractText>Infective endocarditis (IE) complicated by septic or cardiogenic shock is linked to a marked increase in morbidity and mortality rates. This systematic review and meta-analysis sought to evaluate clinical outcomes, identify prognostic factors, and assess the effects of valve surgical intervention in patients with infective endocarditis complicated by shock. Systematic searches were performed in PubMed, Cochrane Library, and Google Scholar databases, following PRISMA and MOOSE guidelines. Included were observational studies published from January 2015 to May 2025 that reported on adult patients with infective endocarditis complicated by septic or cardiogenic shock. A random-effects model was utilized for data synthesis (restricted maximum likelihood with Hartung-Knapp adjustment), and meta-regression was conducted to assess sources of heterogeneity. Seven observational studies were included (n&#x2009;=&#x2009;183-255,838). In-hospital mortality among patients with shock was 62.3% (95% CI 48.3-74.5%). Compared with IE without shock, the pooled odds ratio for in-hospital mortality (HK-REML) was 5.83 (95% CI 1.35-25.23; 95% prediction interval 0.26-129.69), with substantial heterogeneity (I<sup>2</sup>&#x2009;=&#x2009;90.3%). Valve surgical intervention was associated with reduced mortality, particularly in cardiogenic shock. Staphylococcus aureus was the most common pathogen in available microbiological data. Shock was frequently accompanied by acute kidney injury, neurological complications, and multiorgan dysfunction. Infective endocarditis complicated by shock carries an extremely poor prognosis, with pooled mortality exceeding 60%. Prompt recognition of shock, timely initiation of appropriate antimicrobial therapy, hemodynamic stabilization, and early valve surgery are crucial to improve outcomes in this high-risk population. SYSTEMATIC REVIEW REGISTRATION: PROSPERO: CRD420250652570.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>P&#xee;r&#xee;ianu-Masgras</LastName><ForeName>Roxana-Bianca</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd, 050474, Bucharest, Romania. roxana-bianca.masgras@drd.umfcd.ro.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesia &amp; Critical Care, Lariboisi&#xe8;re Hospital, AP-HP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savarese</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoica</LastName><ForeName>Emanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1, Department of Cardiology, Emergency Institute for Cardiovascular Diseases "C.C.Iliescu", 258 Fundeni St, 022328, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geavlete</LastName><ForeName>Oliviana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd, 050474, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1, Department of Cardiology, Emergency Institute for Cardiovascular Diseases "C.C.Iliescu", 258 Fundeni St, 022328, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambrosy</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antohi</LastName><ForeName>Elena-Laura</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd, 050474, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1, Department of Cardiology, Emergency Institute for Cardiovascular Diseases "C.C.Iliescu", 258 Fundeni St, 022328, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>Mehmet Birhan</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Dokuz Eyl&#xfc;l University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radu</LastName><ForeName>Razvan-Ilie</ForeName><Initials>RI</Initials><AffiliationInfo><Affiliation>University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd, 050474, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1, Department of Cardiology, Emergency Institute for Cardiovascular Diseases "C.C.Iliescu", 258 Fundeni St, 022328, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamo</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Cardiology, ASST Spedali Civili, Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davison</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>UMR-S 942 (MASCOT), Universit&#xe9; Paris Cit&#xe9;, INSERM, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Momentum Research Inc, Durham, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heart Initiative, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biegus</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Clinical Department of Intensive Cardiac Care, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Gad</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UMR-S 942 (MASCOT), Universit&#xe9; Paris Cit&#xe9;, INSERM, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Momentum Research Inc, Durham, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heart Initiative, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Javed</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Baylor Scott and White Research Institute, Dallas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Sean P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chioncel</LastName><ForeName>Ovidiu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd, 050474, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1, Department of Cardiology, Emergency Institute for Cardiovascular Diseases "C.C.Iliescu", 258 Fundeni St, 022328, Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Fail Rev</MedlineTA><NlmUniqueID>9612481</NlmUniqueID><ISSNLinking>1382-4147</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Clinical outcomes</Keyword><Keyword MajorTopicYN="N">Infective endocarditis</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Septic shock</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval: This article does not contain any studies with human participants or animals performed by any of the authors. Consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40884710</ArticleId><ArticleId IdType="doi">10.1007/s10741-025-10556-5</ArticleId><ArticleId IdType="pii">10.1007/s10741-025-10556-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075&#x2013;128.</Citation></Reference><Reference><Citation>Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, Hirsch GA, Mehta JL (2015) Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol 65(19):2070&#x2013;2076</Citation><ArticleIdList><ArticleId IdType="pubmed">25975469</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlton EW, Cullen L, Than M, Gamble J, Khattab A, Greaves K (2015) A novel diagnostic protocol to identify patients suitable for discharge after a single high-sensitivity troponin. Heart 101(13):1041&#x2013;1046</Citation><ArticleIdList><ArticleId IdType="pubmed">25691511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir T, Uddin M, Qureshi WT, Regmi N, Tleyjeh IM, Saydain G (2022) Predictors of complications secondary to infective endocarditis and their associated outcomes: a large cohort study from the National Emergency Database (2016&#x2013;2018). Infect Dis Ther 11(1):305&#x2013;321</Citation><ArticleIdList><ArticleId IdType="pubmed">34817839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostaghim AS, Lo HYA, Khardori N (2017) A retrospective epidemiologic study to define risk factors, microbiology, and clinical outcomes of infective endocarditis in a large tertiary-care teaching hospital. SAGE Open Med 5:2050312117741772</Citation><ArticleIdList><ArticleId IdType="pubmed">29163950</ArticleId><ArticleId IdType="pmc">5692128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajani R, Klein JL (2020) Infective endocarditis: a contemporary update. Clin Med (Lond) 20(1):31&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">31941729</ArticleId></ArticleIdList></Reference><Reference><Citation>Krajinovic V, Ivancic S, Gezman P, Barsic B (2018) Association between cardiac surgery and mortality among patients with infective endocarditis complicated by sepsis and septic shock. Shock 49(5):536&#x2013;542</Citation><ArticleIdList><ArticleId IdType="pubmed">28991051</ArticleId></ArticleIdList></Reference><Reference><Citation>Peric&#xe0;s JM, Hern&#xe1;ndez-Meneses M, Mu&#xf1;oz P, Mart&#xed;nez-Sell&#xe9;s M, &#xc1;lvarez-Uria A, de Alarc&#xf3;n A, Guti&#xe9;rrez-Carretero E, Goenaga MA, Zarauza MJ, Falces C, Rodr&#xed;guez-Esteban M, Hidalgo-Tenorio C, Hern&#xe1;ndez-Cabrera M, Mir&#xf3; JM (2021) Characteristics and outcome of acute heart failure in infective endocarditis: focus on cardiogenic shock. Clin Infect Dis 73(5):765&#x2013;774</Citation><ArticleIdList><ArticleId IdType="pubmed">33560404</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos C, Vilacosta I, Fern&#xe1;ndez C, L&#xf3;pez J, Sarri&#xe1; C, Ferrera C, Revilla A, Silva J, Vivas D, Gonz&#xe1;lez I, San Rom&#xe1;n JA (2013) Contemporary epidemiology and prognosis of septic shock in infective endocarditis. Eur Heart J 34(26):1999&#x2013;2006</Citation><ArticleIdList><ArticleId IdType="pubmed">23060453</ArticleId></ArticleIdList></Reference><Reference><Citation>Peric&#xe0;s JM, Hern&#xe1;ndez-Meneses M, Mu&#xf1;oz P, &#xc1;lvarez-Ur&#xed;a A, Pinilla-Llorente B, de Alarc&#xf3;n A, Reviejo K, Fari&#xf1;as MC, Falces C, Goikoetxea-Agirre J, G&#xe1;lvez-Acebal J, Hidalgo-Tenorio C, G&#xf3;mez-Nebreda E, Miro JM (2021) Outcomes and risk factors of septic shock in patients with infective endocarditis: a prospective cohort study. Open Forum Infect Dis 8(6):ofab119</Citation><ArticleIdList><ArticleId IdType="pubmed">34189153</ArticleId><ArticleId IdType="pmc">8232381</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzi L, Sperandeo L, Forzano I, et al (2024) Contemporary evidence and practice on right heart catheterization in patients with acute or chronic heart failure. Diagnostics (Basel) 14(2):136. https://doi.org/10.3390/diagnostics14020136</Citation></Reference><Reference><Citation>Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS (2005) Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293(24):3012&#x2013;3021</Citation><ArticleIdList><ArticleId IdType="pubmed">15972563</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques A, Cruz I, Caldeira D, Alegria S, Gomes AC, Broa AL, Jo&#xe3;o I, Pereira H (2020) Risk factors for in-hospital mortality in infective endocarditis. Arq Bras Cardiol 114(1):1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">31751437</ArticleId><ArticleId IdType="pmc">7025303</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelsomino S, Maessen JG, van der Veen F, Livi U, Renzulli A, Luc&#xe0; F, Carella R, Crudeli E, Rubino A, Rostagno C, Russo C, Borghetti V, Beghi C, De Bonis M, Gensini GF, Lorusso R (2012) Emergency surgery for native mitral valve endocarditis: the impact of septic and cardiogenic shock. Ann Thorac Surg 93(5):1469&#x2013;1476</Citation><ArticleIdList><ArticleId IdType="pubmed">22342063</ArticleId></ArticleIdList></Reference><Reference><Citation>Handa K, Yoshioka D, Toda K, Yokoyama JY, Samura T, Suzuki K, Miyagawa S, Matsumiya G, Sakaguchi T, Fukuda H, Sawa Y (2020) Surgical results for infective endocarditis complicated with cardiogenic shock. Circ J 84(6):926&#x2013;934</Citation><ArticleIdList><ArticleId IdType="pubmed">32295976</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#xf3;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71</Citation><ArticleIdList><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2024) Cochrane handbook for systematic reviews of interventions version 6.5. Cochrane 2024. Available from https://www.cochrane.org/handbook</Citation></Reference><Reference><Citation>Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603&#x2013;605</Citation><ArticleIdList><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, Britten N, Roen K, Duffy S (2006) Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC methods programme Version 1(1):b92</Citation></Reference><Reference><Citation>Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1&#x2013;48</Citation></Reference><Reference><Citation>Hartung J, Knapp G (2001) On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat Med 20(12):1771&#x2013;1782</Citation><ArticleIdList><ArticleId IdType="pubmed">11406840</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, Higgins JP, Deeks JJ (2011) Interpretation of random effects meta-analyses. Bmj 342:d549</Citation><ArticleIdList><ArticleId IdType="pubmed">21310794</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557&#x2013;560</Citation><ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId><ArticleId IdType="pmc">192859</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W, Cheung MW (2010) Outlier and influence diagnostics for meta-analysis. Res Synth Methods 1(2):112&#x2013;125</Citation><ArticleIdList><ArticleId IdType="pubmed">26061377</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11):1559&#x2013;1573</Citation><ArticleIdList><ArticleId IdType="pubmed">12111920</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54(10):1046&#x2013;1055</Citation><ArticleIdList><ArticleId IdType="pubmed">11576817</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting . Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283(15):2008&#x2013;2012</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, Shea B, O&#x2019;Connell D, Peterson J, Welch V, Losos M, Tugwell P (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.</Citation></Reference><Reference><Citation>Motoc A, Kessels J, Roosens B, Lacor P, Van de Veire N, De Sutter J, Magne J, Droogmans S, Cosyns B (2023) Impact of the initial clinical presentation on the outcome of patients with infective endocarditis. Cardiol J 30(3):385&#x2013;390</Citation><ArticleIdList><ArticleId IdType="pubmed">34240402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lnu S, Jamal A, Raza MA, Umar Z, Ahmad S, Alvi W, Khattak LZ, Ajmal A, Ullah N, Khan K (2025) Infective endocarditis in septic shock: results from an observational multicenter study. Cureus 17(2):e78927</Citation><ArticleIdList><ArticleId IdType="pubmed">40092000</ArticleId><ArticleId IdType="pmc">11909614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chioncel O, Vinereanu D, Datcu M, Ionescu DD, Capalneanu R, Brukner I, Dorobantu M, Ambrosy A, Macarie C, Gheorghiade M (2011) The Romanian acute heart failure syndromes (RO-AHFS) registry. Am Heart journal. 162(1):142&#x2013;153 (e1)</Citation></Reference><Reference><Citation>Becher PM, Go&#xdf;ling A, Fluschnik N, Schrage B, Seiffert M, Schofer N, Blankenberg S, Kirchhof P, Westermann D, Kalbacher D (2024) Temporal trends in incidence, patient characteristics, microbiology and in-hospital mortality in patients with infective endocarditis: a contemporary analysis of 86,469 cases between 2007 and 2019. Clin Res Cardiol 113(2):205&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pubmed">36094574</ArticleId></ArticleIdList></Reference><Reference><Citation>Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, D&#x2019;Aiello I, Picchi A, De Sensi F, Habib G (2017) Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. Cardiovasc Diagn Ther 7(1):27&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">28164010</ArticleId><ArticleId IdType="pmc">5253443</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P (2011) Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system. BMC Infect Dis 11(1):48</Citation><ArticleIdList><ArticleId IdType="pubmed">21345185</ArticleId><ArticleId IdType="pmc">3051911</ArticleId></ArticleIdList></Reference><Reference><Citation>Abegaz TM, Bhagavathula AS, Gebreyohannes EA, Mekonnen AB, Abebe TB (2017) Short- and long-term outcomes in infective endocarditis patients: a systematic review and meta-analysis. BMC Cardiovasc Disord 17(1):291</Citation><ArticleIdList><ArticleId IdType="pubmed">29233094</ArticleId><ArticleId IdType="pmc">5728061</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, Caselli S, Doenst T, Ederhy S, Erba PA, Foldager D, Fosb&#xf8;l EL, Kovac J, Mestres CA, Miller OI, Miro JM, Pazdernik M, Pizzi MN, Quintana E, Rasmussen TB, Risti&#x107; AD, Rod&#xe9;s-Cabau J, Sionis A, Z&#xfc;hlke LJ, Borger MA (2023) 2023 ESC Guidelines for the management of endocarditis. Eur Heart J 44(39):3948&#x2013;4042</Citation><ArticleIdList><ArticleId IdType="pubmed">37622656</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvindi PG, Luthra S, Zingale A, Bifulco O, Berretta P, Pierri MD, Ohri SK, Di Eusanio M (2024) Surgical repair and replacement for native mitral valve infective endocarditis. J Cardiovasc Med (Hagerstown) 25(4):334&#x2013;341</Citation><ArticleIdList><ArticleId IdType="pubmed">38407841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj A, Kumar S, Salas de Armas IA, Nascimbene A, Nathan S, Kar B, Gregoric ID (2022) Pre- and post-operative mechanical circulatory support in surgical repair of post-acute myocardial infarction mechanical complications. Ann Cardiothorac Surg 11(3):304&#x2013;309</Citation><ArticleIdList><ArticleId IdType="pubmed">35733711</ArticleId><ArticleId IdType="pmc">9207699</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilotra NA, Stevens GR (2014) Temporary mechanical circulatory support: a review of the options, indications, and outcomes. Clin Med Insights Cardiol 8(Suppl 1):75&#x2013;85</Citation><ArticleIdList><ArticleId IdType="pubmed">25674024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Lo Coco V, Ravaux JM, Mariani S (2022) The use of mechanical circulatory support in post-acute myocardial infarction mechanical complications. Ann Cardiothorac Surg 11(3):325&#x2013;327</Citation><ArticleIdList><ArticleId IdType="pubmed">35733721</ArticleId><ArticleId IdType="pmc">9207683</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobreiro DI, Sampaio RO, Siciliano RF, Brazil CV, Branco CE, Lopes AS, Tarasoutchi F, Strabelli TM (2019) Early diagnosis and treatment in infective endocarditis: challenges for a better prognosis. Arquivos Brasileiros de Cardiologia 112(2):201&#x2013;3</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40254303</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Iron deficiency in patients with cardiogenic shock: protocol for a scoping review.</ArticleTitle><Pagination><StartPage>e092891</StartPage><MedlinePgn>e092891</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e092891</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-092891</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cardiogenic shock (CS) is a severe condition characterised by low cardiac output and often hypotension, which results in organ hypoperfusion due to cardiac failure. As a form of acute heart failure, this condition seems to share similar underlying pathological mechanisms. It is well established that iron deficiency is correlated with chronic and acute heart failure, causing worsening of the symptoms, reduction of quality of life and survival and simultaneously increasing the rehospitalisation rates for all causes in these patients. It remains unclear whether there is an association between iron deficiency and CS. The objective of this scoping review will be to determine the actual state of the art regarding the significance of iron deficiency in patients affected by CS.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">We will conduct a systematic review of the literature using MEDLINE and EMBASE via 'Ovid' (Elsevier) and Web of Science (2024 Clarivate). The goal is to analyse the incidence and clinical significance of iron deficiency in patients affected by cardiogenic shock. To gain a deeper insight into the underlying pathophysiological mechanisms, the review will include basic research conducted on both human subjects and on animal models as well as observational, randomised controlled studies and systematic reviews and meta-analysis. To maximise the identification of relevant reports and reduce loss of information, a systematic search of the literature will be performed from inception until January 2025 using the terms "iron deficiency" as well as "iron", "ferritin", "transferrin", "transferrin saturation", "hepcidin" and "soluble transferrin receptor" matching these terms with the keywords "cardiogenic shock", "acute heart failure", "advanced heart failure", "decompensated heart failure", "lvad", "left ventricular assist device", "mechanical circulatory support", "VA-ECMO" and "Extracorporeal Life Support". We will also use the corresponding MeSH and Emtree terms. In order to find grey literature, we will use the OADT.org internet-based database.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">No additional ethics approval is required, as this review is based on existing research without new data collection. Only studies with ethics approval will be included. We plan to publish our findings in a peer-reviewed journal and present them at international conferences on cardiology, intensive and acute cardiovascular care, cardiac surgery and cardioanaesthesiology.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Germinario</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0003-6230-4923</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9; - Medical Heart Center of Charit&#xe9; and German Heart Institute Berlin, Berlin, Germany lorenzo.germinario@dhzc-charite.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catena</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9; - Medical Heart Center of Charit&#xe9; and German Heart Institute Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ott</LastName><ForeName>Sascha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9; - Medical Heart Center of Charit&#xe9; and German Heart Institute Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Outcomes Research Consortium, Cleveland Clinic, Cleveland, OH 44195, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roeschl</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9; - Medical Heart Center of Charit&#xe9; and German Heart Institute Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health, Berlin, Germany; Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Institute of Medical Informatics, Invalidenstra&#xdf;e 90, 10115, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghamri</LastName><ForeName>Yassine</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9; - Medical Heart Center of Charit&#xe9; and German Heart Institute Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9; - Medical Heart Center of Charit&#xe9; and German Heart Institute Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health, Berlin, Germany; Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Institute of Medical Informatics, Invalidenstra&#xdf;e 90, 10115, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9; - Medical Heart Center of Charit&#xe9; and German Heart Institute Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Perioperative Medicine, St Bartholomew's Hospital and Barts Heart Centre, London EC1A 7BE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoenrath</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9; - Medical Heart Center of Charit&#xe9; and German Heart Institute Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018798" MajorTopicYN="Y">Anemia, Iron-Deficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090463" MajorTopicYN="Y">Iron Deficiencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098584" MajorTopicYN="N">Scoping Review as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult intensive &amp; critical care</Keyword><Keyword MajorTopicYN="N">Coronary heart disease</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Other metabolic, e.g. iron, porphyria</Keyword></KeywordList><CoiStatement>Competing interests: SO received institutional research and study funds from Novartis Pharma GmbH and institutional research, study and educational grants, speaker fees and advisory board fees from Abiomed. TR is a participant in the BIH Charit&#xe9; Digital Clinician Scientist Program funded by the Charit&#xe9;&#x2013;Universit&#xe4;tsmedizin Berlin, and the Berlin Institute of Health at Charit&#xe9; (BIH). BO: British Heart Foundation for Tight K: The role of Potassium in AFACS prevention (Grant number CS/18/3/34063). National Institute for Health Research (NIHR) for Predicting AF after Cardiac Surgery-the PARADISE Scores. A Clinical Prediction Rule for AFACS (Grant number NIHR131227). FS received institutional grants from Novartis, Abbott, non-financial support from Medtronic and institutional fees (speaker honoraria) from Abbott, Bayer, Novartis and Abiomed outside of the submitted work. All other authors have no completing interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>21</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>21</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>20</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40254303</ArticleId><ArticleId IdType="pmc">PMC12010308</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-092891</ArticleId><ArticleId IdType="pii">bmjopen-2024-092891</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aromataris E, Lockwood C, Porritt K.  JBI manual for evidence synthesis. JBI eBooks. 2024. https://jbi-global-wiki.refined.site/space/MANUAL Available.</Citation></Reference><Reference><Citation>Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467&#x2013;73. doi: 10.7326/M18-0850.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-0850</ArticleId><ArticleId IdType="pubmed">30178033</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds HR, Hochman JS. Cardiogenic shock. Circulation. 2008;117:686&#x2013;97. doi: 10.1161/CIRCULATIONAHA.106.613596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.613596</ArticleId><ArticleId IdType="pubmed">18250279</ArticleId></ArticleIdList></Reference><Reference><Citation>van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the american heart association. Circulation. 2017;136:e232&#x2013;68. doi: 10.1161/CIR.0000000000000525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000525</ArticleId><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann F-J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382:1638&#x2013;45. doi: 10.1016/S0140-6736(13)61783-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61783-3</ArticleId><ArticleId IdType="pubmed">24011548</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Akin I, Sandri M, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017;377:2419&#x2013;32. doi: 10.1056/NEJMoa1710261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1710261</ArticleId><ArticleId IdType="pubmed">29083953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129&#x2013;200. doi: 10.1093/eurheartj/ehw128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw128</ArticleId><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock. Cathet Cardio Intervent. 2019;94:29&#x2013;37. doi: 10.1002/ccd.28329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28329</ArticleId><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer JC, van Diepen S, Barsness GW, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol. 2019;74:2117&#x2013;28. doi: 10.1016/j.jacc.2019.07.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.07.077</ArticleId><ArticleId IdType="pubmed">31548097</ArticleId></ArticleIdList></Reference><Reference><Citation>Roeschl T, Hinrichs N, Hommel M, et al. Systematic assessment of shock severity in postoperative cardiac surgery patients. J Am Coll Cardiol. 2023;82:1691&#x2013;706. doi: 10.1016/j.jacc.2023.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.08.031</ArticleId><ArticleId IdType="pubmed">37852698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014;3:e000590. doi: 10.1161/JAHA.113.000590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.113.000590</ArticleId><ArticleId IdType="pmc">PMC3959706</ArticleId><ArticleId IdType="pubmed">24419737</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahuja M, Adegbala O, Mishra T, et al. Trends in the incidence of in-hospital mortality, cardiogenic shock, and utilization of mechanical circulatory support devices in myocarditis (analysis of national inpatient sample data, 2005-2014) J Card Fail. 2019;25:457&#x2013;67. doi: 10.1016/j.cardfail.2019.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2019.04.012</ArticleId><ArticleId IdType="pubmed">31035007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yandrapalli S, Sanaani A, Harikrishnan P, et al. Cardiogenic shock during heart failure hospitalizations: age-, sex-, and race-stratified trends in incidence and outcomes. Am Heart J. 2019;213:18&#x2013;29. doi: 10.1016/j.ahj.2019.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2019.03.015</ArticleId><ArticleId IdType="pubmed">31078113</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller JE, Engstr&#xf8;m T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390:1382&#x2013;93. doi: 10.1056/NEJMoa2312572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2312572</ArticleId><ArticleId IdType="pubmed">38587239</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg DD, Bohula EA, van Diepen S, et al. Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes. 2019;12:e005618. doi: 10.1161/CIRCOUTCOMES.119.005618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.119.005618</ArticleId><ArticleId IdType="pmc">PMC11032172</ArticleId><ArticleId IdType="pubmed">30879324</ArticleId></ArticleIdList></Reference><Reference><Citation>Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165:575&#x2013;82. doi: 10.1016/j.ahj.2013.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2013.01.017</ArticleId><ArticleId IdType="pubmed">23537975</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonko DO, Mandal AKJ, Missouris CG, et al. Disordered iron homeostasis in chronic heart failure. J Am Coll Cardiol. 2011;58:1241&#x2013;51. doi: 10.1016/j.jacc.2011.04.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.04.040</ArticleId><ArticleId IdType="pubmed">21903058</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowska EA, Kasztura M, Sokolski M, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35:2468&#x2013;76. doi: 10.1093/eurheartj/ehu235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu235</ArticleId><ArticleId IdType="pubmed">24927731</ArticleId></ArticleIdList></Reference><Reference><Citation>Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol. 2014;174:268&#x2013;75. doi: 10.1016/j.ijcard.2014.03.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2014.03.169</ArticleId><ArticleId IdType="pubmed">24768464</ArticleId></ArticleIdList></Reference><Reference><Citation>Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail. 2009;11:1084&#x2013;91. doi: 10.1093/eurjhf/hfp140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfp140</ArticleId><ArticleId IdType="pmc">PMC2770581</ArticleId><ArticleId IdType="pubmed">19875408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency&#x2020;. Eur Heart J. 2015;36:657&#x2013;68. doi: 10.1093/eurheartj/ehu385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu385</ArticleId><ArticleId IdType="pmc">PMC4359359</ArticleId><ArticleId IdType="pubmed">25176939</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136:1374&#x2013;83. doi: 10.1161/CIRCULATIONAHA.117.027497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.027497</ArticleId><ArticleId IdType="pmc">PMC5642327</ArticleId><ArticleId IdType="pubmed">28701470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Kirwan B-A, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. The Lancet. 2020;396:1895&#x2013;904. doi: 10.1016/S0140-6736(20)32339-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32339-4</ArticleId><ArticleId IdType="pubmed">33197395</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo TJ, Yeo PSD, Hadi FA, et al. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF) ESC Heart Fail. 2018;5:344&#x2013;53. doi: 10.1002/ehf2.12250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12250</ArticleId><ArticleId IdType="pmc">PMC5880664</ArticleId><ArticleId IdType="pubmed">29345426</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e895&#x2013;1032. doi: 10.1161/CIR.0000000000001063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001063</ArticleId><ArticleId IdType="pubmed">35363499</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddaway NR, Grainger M. citationchaser: An R package and Shiny app for forward and backward citations chasing in academic searching. 2021.</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark J, Glasziou P, Del Mar C, et al. A full systematic review was completed in 2 weeks using automation tools: a case study. J Clin Epidemiol. 2020;121:81&#x2013;90. doi: 10.1016/j.jclinepi.2020.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.01.008</ArticleId><ArticleId IdType="pubmed">32004673</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes C, Greenwood H, Carter M, et al. Automation of duplicate record detection for systematic reviews: Deduplicator. Syst Rev. 2024;13:206. doi: 10.1186/s13643-024-02619-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-024-02619-9</ArticleId><ArticleId IdType="pmc">PMC11295717</ArticleId><ArticleId IdType="pubmed">39095913</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock D, Peters MDJ, Khalil H, et al. Recommendations for the extraction, analysis, and presentation of results in scoping reviews. JBI Evid Synth . 2023;21:520&#x2013;32. doi: 10.11124/JBIES-22-00123.</Citation><ArticleIdList><ArticleId IdType="doi">10.11124/JBIES-22-00123</ArticleId><ArticleId IdType="pubmed">36081365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Hern&#xe1;n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Morgan RL, Rooney AA, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E) Environ Int. 2024;186:108602. doi: 10.1016/j.envint.2024.108602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envint.2024.108602</ArticleId><ArticleId IdType="pmc">PMC11098530</ArticleId><ArticleId IdType="pubmed">38555664</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooijmans CR, Rovers MM, de Vries RBM, et al. SYRCLE&#x2019;s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43. doi: 10.1186/1471-2288-14-43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-43</ArticleId><ArticleId IdType="pmc">PMC4230647</ArticleId><ArticleId IdType="pubmed">24667063</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. doi: 10.1136/bmj.j4008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j4008</ArticleId><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30220420</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1913</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>The American journal of cardiology</Title><ISOAbbreviation>Am J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>1661</StartPage><EndPage>1669</EndPage><MedlinePgn>1661-1669</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjcard.2018.08.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9149(18)31631-X</ELocationID><Abstract><AbstractText>The optimal strategy for patients with an acute myocardial infarction (MI) and multivessel (MV) coronary artery disease complicated by cardiogenic shock (CS) remains unknown. We conducted a meta-analysis of all randomized controlled trials and observational studies that reported adjusted effect measures to evaluate the association of MV-PCI (percutaneous coronary intervention), compared with culprit only (C)-PCI, with cardiovascular events in patients admitted for CS and MV disease. We identified 12 studies (n&#x202f;=&#x202f;1 randomized controlled trials, n&#x202f;=&#x202f;11 observational) that included 7,417 patients (n&#x202f;=&#x202f;1,809 treated with MV-PCI and n&#x202f;=&#x202f;5,608 with C-PCI). When compared with C-PCI, MV-PCI was not associated with an increased risk of short-term death (odds ratio [OR] 1.14, 95% confidence interval [CI] 0.87 to 1.48, p&#x202f;=&#x202f;0.35 and adjusted OR [OR<sub>adj</sub>] 1.00, 95% CI 0.70 to 1.43, p&#x202f;=&#x202f;1.00). In-hospital and/or short-term mortality tended to be higher with MV-PCI, when compared with C-PCI, for CS patients needing dialysis (&#xdf; 0.12, 95% CI from 0.049 to 0.198; p= 0.001), whereas MV-PCI was associated with lower in-hospital and/or short-term mortality in patients with an anterior MI (&#xdf; -0.022, 95% CI -0.03 to -0.01; p &lt;0.001). MV-PCI strategy was associated with a more frequent need for dialysis or contrast-induced nephropathy after revascularization (OR 1.36, 95% CI 1.06 to 1.75, p&#x202f;=&#x202f;0.02). In conclusion, MV-PCI seems not to increase risk of death during short- or long-term follow-up when compared with C-PCI in patients admitted for MV coronary artery disease and MI complicated by CS. Furthermore, it appears a more favorable strategy in patients with anterior MI, whereas the increased risk for AKI and its negative prognostic impact should be considered in decision-making process. Further studies are needed to confirm our hypothesis on in these subpopulations of CS patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertaina</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy. Electronic address: maurizio.bertaina@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferraro</LastName><ForeName>Ilenia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omed&#xe8;</LastName><ForeName>Pierlugi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrotto</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saint-Hilary</LastName><ForeName>Gaelle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Mathematical Sciences "G. L. Lagrange," Politecnico di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavender</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, University of North Carolina, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claessen</LastName><ForeName>Bimmer E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Jos&#xe9; P S</ForeName><Initials>JPS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frea</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usmiani</LastName><ForeName>Tullio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosso Marra</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pennone</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moretti</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amico</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ascenzo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Cardiol</MedlineTA><NlmUniqueID>0207277</NlmUniqueID><ISSNLinking>0002-9149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="N">Coronary Vessels</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009204" MajorTopicYN="N">Myocardial Revascularization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30220420</ArticleId><ArticleId IdType="doi">10.1016/j.amjcard.2018.08.003</ArticleId><ArticleId IdType="pii">S0002-9149(18)31631-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35430192</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1916-7075</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Canadian journal of cardiology</Title><ISOAbbreviation>Can J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Significant Valvular Dysfunction and Outcomes in Cardiogenic Shock: Insights From the Randomized DOREMI&#xa0;Trial.</ArticleTitle><Pagination><StartPage>1211</StartPage><EndPage>1219</EndPage><MedlinePgn>1211-1219</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cjca.2022.04.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0828-282X(22)00220-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with cardiogenic shock (CS) suffer high rates of in-hospital mortality, with little evidence guiding management. The impact of valvular heart disease in patients with CS remains unclear. We therefore conducted a post hoc analysis of the randomized Dobutamine Compared to Milrinone (DOREMI) trial to determine the impact of valvular disease on outcomes in patients with CS.</AbstractText><AbstractText Label="METHODS">We defined significant valvular disease as moderate to severe or greater valvular stenosis or regurgitation and divided participants into a group of those with significant valvular disease and those without. Our primary outcome was all-cause in-hospital mortality. Secondary endpoints included resuscitated cardiac arrest; cardiac transplantation or mechanical circulatory support; nonfatal myocardial infarction; stroke; initiation of renal replacement therapy; as well as changes in renal function, perfusion, and hemodynamics over time.</AbstractText><AbstractText Label="RESULTS">One hundred eighty-nine (98.4%) participants from the DOREMI trial were included in our analysis, and 74 (39.2%) had significant valvular dysfunction. Thirty-six (48.7%) patients with valvular disease died in hospital, compared with 37 (32.2%) in the comparator group (relative risk, 1.5; 95% confidence interval 1.06-2.15; P&#xa0;= 0.02). Patients with aortic stenosis (2.42, 1.56-3.75; P &lt; 0.01) and patients with mitral regurgitation (1.63, 1.1-2.43; P&#xa0;= 0.02) also had increased incidence of in-hospital mortality. There was no significant difference in any secondary outcomes among groups, apart from variances in mean arterial pressure observed in patients with valvular disease (P &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSIONS">Significant valvular dysfunction is associated with increased in-hospital mortality in patients with CS. Randomized clinical trial data are needed to further elucidate the role of transcatheter valvular interventions as a therapeutic target in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parlow</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Willy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Santo</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Richard G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lepage-Ratte</LastName><ForeName>Melissa Fay</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motazedian</LastName><ForeName>Pouya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prosperi-Porta</LastName><ForeName>Graeme</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Razek</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Trevor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labinaz</LastName><ForeName>Marino</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froeschl</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hibbert</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: bhibbert@ottawaheart.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CAPITAL DOREMI Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Cardiol</MedlineTA><NlmUniqueID>8510280</NlmUniqueID><ISSNLinking>0828-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="Y">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006349" MajorTopicYN="Y">Heart Valve Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="Y">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>17</Day><Hour>20</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35430192</ArticleId><ArticleId IdType="doi">10.1016/j.cjca.2022.04.004</ArticleId><ArticleId IdType="pii">S0828-282X(22)00220-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25453403</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>179</Volume><PubDate><Year>2015</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Management of multivessel coronary disease in STEMI patients: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>552</StartPage><EndPage>557</EndPage><MedlinePgn>552-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2014.10.035</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(14)01972-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Appropriate management for patients with multivessel coronary disease presenting with ST segment Elevation Myocardial Infarction (STEMI) remains to be defined.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Medline and Cochrane Library were searched for randomized controlled trials (RCTs) or observational studies adjusted with multivariate analysis, reporting about STEMI patients with multivessel coronary disease treated with either a culprit only or complete revascularization strategy, excluding patients in cardiogenic shock. Prespecified analysis was performed according to the strategy of complete revascularization, either during the same procedure of primary percutaneous coronary intervention (PCI) or during the index hospitalization. MACE (a composite and mutually exclusive end point of death or myocardial infarction or revascularization) at follow-up of at least one year was the primary end point. 9 studies with 4686 patients compared culprit only versus complete PCI performed during the primary PCI. Rates of MACE did not differ at 90 days (OR 0.70 [0.38, 1.27], I(2)=0%) or at 1 year (1-2.5) (OR 0.70 [0.47, 1.03], I(2)=0%). No significant difference was found for the components of the primary outcome, apart from a reduction in repeated revascularization for patients undergoing complete PCI during the STEMI procedure (OR 0.62 [0.39, 0.98], I(2)=0%). 6 studies (1 RCT) with 5855 patients compared culprit only lesions versus complete PCI performed during index hospitalization. 90 day risk of MACE did not differ nor 1 year (1-2.5) MACE (OR 0.86 [0.62, 1.08], I(2)=0%), with a similar reduction in repeated revascularization (0.60 [0.40, 0.90], I(2)=0%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Complete revascularization performed during primary PCI or index hospitalizations for patients presenting with STEMI appears safe at short term follow-up and offers a reduction in repeated revascularization at one year.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moretti</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ascenzo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy. Electronic address: fabrizio.dascenzo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quadri</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omed&#xe8;</LastName><ForeName>Pierluigi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montefusco</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taha</LastName><ForeName>Salma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerrato</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colaci</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shao-Liang</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biondi-Zoccai</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Piazzale Aldo Moro, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaita</LastName><ForeName>Fiorenzo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Citt&#xe0; Della Salute e Della Scienza, University of Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003327" MajorTopicYN="N">Coronary Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009204" MajorTopicYN="N">Myocardial Revascularization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complete revascularization</Keyword><Keyword MajorTopicYN="N">Multivessel disease</Keyword><Keyword MajorTopicYN="N">STEMI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25453403</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2014.10.035</ArticleId><ArticleId IdType="pii">S0167-5273(14)01972-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31469037</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-111X</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Perfusion</Title><ISOAbbreviation>Perfusion</ISOAbbreviation></Journal><ArticleTitle>Baseline surgical status and short-term mortality after extracorporeal membrane oxygenation for post-cardiotomy shock: a meta-analysis.</ArticleTitle><Pagination><StartPage>246</StartPage><EndPage>254</EndPage><MedlinePgn>246-254</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0267659119865122</ELocationID><Abstract><AbstractText Label="OBJECTIVE">While reported mortality rates on post-cardiotomy extracorporeal membrane oxygenation vary from center to center, impact of baseline surgical status (elective/urgent/emergency/salvage) on mortality is still unknown.</AbstractText><AbstractText Label="METHODS">A systematic search was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement using PubMed/Medline databases until March 2018 using the keywords "postcardiotomy," "cardiogenic shock," "extracorporeal membrane oxygenation," and "extracorporeal life support." Relevant articles were scrutinized and included in the meta-analysis only if reporting in-hospital/30-day mortality and baseline surgical status. The correlations between mortality and percentage of elective/urgent/emergency cases were investigated. Inference analysis of baseline status and extracorporeal membrane oxygenation complications was conducted as well.</AbstractText><AbstractText Label="RESULTS">Twenty-two studies (conducted between 1993 and 2017) enrolling N = 2,235 post-cardiotomy extracorporeal membrane oxygenation patients were found. Patients were mostly of non-emergency status (65.2%). Overall in-hospital/30-day mortality event rate (95% confidence intervals) was 66.7% (63.3-69.9%). There were no differences in in-hospital/30-day mortality with respect to baseline surgical status in the subgroup analysis (test for subgroup differences; p = 0.406). Similarly, no differences between mortality in studies enrolling &lt;50 versus &#x2a7e;50% of emergency/salvage cases was found: respective event rates were 66.9% (63.1-70.4%) versus 64.4% (57.3-70.8%); p = 0.525. Yet, there was a significant positive association between increasing percentage of emergency/salvage cases and rates of neurological complications (p &lt; 0.001), limb complications (p &lt; 0.001), and bleeding (p = 0.051). Incidence of brain death (p = 0.099) and sepsis (p = 0.134) was increased as well.</AbstractText><AbstractText Label="CONCLUSION">Other factors than baseline surgical status may, to a higher degree, influence the mortality in patients treated with extracorporeal membrane oxygenation for post-cardiotomy cardiogenic shock. Baseline status, however, strongly influences the complication occurrence while on extracorporeal membrane oxygenation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kowalewski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5478-3245</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior, Centre of Postgraduate Medical Education, Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiothoracic Research Centre, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raffa</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7141-2561</Identifier><AffiliationInfo><Affiliation>Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, ISMETT-IRCCS, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zieli&#x144;ski</LastName><ForeName>Kamil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meani</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7356-9036</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alanazi</LastName><ForeName>Musab</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbers</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuts</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natour</LastName><ForeName>Ehsan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bidar</LastName><ForeName>Elham</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreurs</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delnoij</LastName><ForeName>Thijs</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driessen</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sels</LastName><ForeName>Jan Willem</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Poll</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roekaerts</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maessen</LastName><ForeName>Jos</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwalski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior, Centre of Postgraduate Medical Education, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1777-2045</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Perfusion</MedlineTA><NlmUniqueID>8700166</NlmUniqueID><ISSNLinking>0267-6591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal life support</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">post-cardiotomy shock</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31469037</ArticleId><ArticleId IdType="doi">10.1177/0267659119865122</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32643847</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8191</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of cardiac surgery</Title><ISOAbbreviation>J Card Surg</ISOAbbreviation></Journal><ArticleTitle>On-pump beating-heart coronary artery bypass grafting in high-risk patients: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1958</StartPage><EndPage>1978</EndPage><MedlinePgn>1958-1978</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.14780</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Operative technique for surgical myocardial revascularization in high-risk patients remains an argument of debate. On-pump coronary artery bypass graft (CABG) with cardioplegic arrest and off-pump CABG have intrinsic limitations. The hybrid approach of on-pump beating-heart CABG (OPBHC) has been proposed over the years with conflicting results. This systematic review and meta-analysis intends to summarize the contemporary literature.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A literature search was conducted through major electronic databases. The systematic review provided a total of 279 articles, of those 17 studies were included in the present study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with on-pump CABG, OPBHC patients showed a preoperative higher risk profile but had reduced early mortality (risk ratio [RR], 0.59, 95% CI, 0.36-0.97) and reduced postoperative stroke (RR, 0.60, 95% CI, 0.39-0.91). Also, interesting trends towards reduced postoperative intra-aortic balloon pump use (RR, 0.56, 95% CI, 0.31-1.01) and myocardial infarction (RR, 0.48, 95% CI, 0.22-1.07) were observed. Baseline characteristics and postoperative complications were similar between OPBHC and off-pump CABG, but limited data are available. The risk of incomplete revascularization in OPBHC is lower than off-pump CABG (RR, 0.53, 95% CI, 0.33-0.87) but higher than conventional on-pump CABG (RR, 1.71, 95% CI, 1.23-2.39).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">OPBHC is an effective technique to perform surgical revascularization in high-risk patients as preventing haemodynamic deterioration and guaranteeing adequate end-organ perfusion. OPBHC represents an alternative technique to on-pump and off-pump CABG, in those cases in which complications deriving from cardioplegic arrest or manipulation of the heart are more likely. For these reasons, OPBHC might be useful in patients with recent myocardial infarction or with left ventricular dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dominici</LastName><ForeName>Carmelo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2028-2124</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Universit&#xe0; Campus Bio-Medico di Roma, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salsano</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nenna</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4069-6781</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Universit&#xe0; Campus Bio-Medico di Roma, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spadaccio</LastName><ForeName>Cristiano</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1672-7576</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Golden Jubilee National Hospital, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariscalco</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8200-2269</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Glenfield Hospital, University Hospitals of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santini</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chello</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Universit&#xe0; Campus Bio-Medico di Roma, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Surg</MedlineTA><NlmUniqueID>8908809</NlmUniqueID><ISSNLinking>0886-0440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="N">Coronary Artery Bypass</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047549" MajorTopicYN="N">Coronary Artery Bypass, Off-Pump</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="N">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">coronary artery bypass grafting</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">myocardial revascularization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32643847</ArticleId><ArticleId IdType="doi">10.1111/jocs.14780</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Neumann FJ, Sousa-Uva M, Ahlsson A, et al. Group ESCSD. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165.</Citation></Reference><Reference><Citation>Knuuti J, Wijns W, Saraste A, et al. Group ESCSD. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.</Citation></Reference><Reference><Citation>Gaudino M, Angelini GD, Antoniades C, et al. Off-pump coronary artery bypass grafting: 30 years of debate. J Am Heart Assoc. 2018;7:e009934.</Citation></Reference><Reference><Citation>Gaudino M, Angiolillo DJ, Di Franco A, et al. Stroke after coronary artery bypass grafting and percutaneous coronary intervention: incidence, pathogenesis, and outcomes. J Am Heart Assoc. 2019;8:e013032.</Citation></Reference><Reference><Citation>Gaudino M, Rahouma M, Di Mauro M, et al. Early versus delayed stroke after cardiac surgery: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8:e012447.</Citation></Reference><Reference><Citation>Lorusso R, Moscarelli M, Di Franco A, et al. Association between coronary artery bypass surgical techniques and postoperative stroke. J Am Heart Assoc. 2019;8:e013650.</Citation></Reference><Reference><Citation>Kim HJ, Oh YN, Ju MH, et al. On-pump beating heart versus conventional coronary artery bypass grafting: comparative study on early and long-term clinical outcomes. J Thorac Dis. 2018;10:2656-2665.</Citation></Reference><Reference><Citation>Perrault LP, Menasche P, Peynet J, et al. On-pump, beating-heart coronary artery operations in high-risk patients: an acceptable trade-off? Ann Thorac Surg. 1997;64:1368-1373.</Citation></Reference><Reference><Citation>Edgerton JR, Herbert MA, Jones KK, et al. On-pump beating heart surgery offers an alternative for unstable patients undergoing coronary artery bypass grafting. Heart Surg Forum. 2004;7:8-15.</Citation></Reference><Reference><Citation>Wang W, Wang Y, Piao H, et al. Early and medium outcomes of on-pump beating-heart versus off-pump CABG in patients with moderate left ventricular dysfunction. Braz J Cardiovasc Surg. 2019;34:62-69.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.</Citation></Reference><Reference><Citation>Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35.</Citation></Reference><Reference><Citation>Zhu MZL, Huq MM, Billah BM, et al. On-pump beating heart versus conventional coronary artery bypass grafting early after myocardial infarction: a propensity-score matched analysis from the ANZSCTS database. Heart Lung Circ. 2019;28:1267-1276.</Citation></Reference><Reference><Citation>Masuda M, Okumura M, Doki Y, et al. Thoracic and cardiovascular surgery in Japan during 2014: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2016;64:665-697.</Citation></Reference><Reference><Citation>Mizutani S, Matsuura A, Miyahara K, et al. On-pump beating-heart coronary artery bypass: a propensity matched analysis. Ann Thorac Surg. 2007;83:1368-1373.</Citation></Reference><Reference><Citation>Miyahara K, Matsuura A, Takemura H, et al. On-pump beating-heart coronary artery bypass grafting after acute myocardial infarction has lower mortality and morbidity. J Thorac Cardiovasc Surg. 2008;135:521-526.</Citation></Reference><Reference><Citation>Izumi Y, Magishi K, Ishikawa N, Kimura F. On-pump beating-heart coronary artery bypass grafting for acute myocardial infarction. Ann Thorac Surg. 2006;81:573-576.</Citation></Reference><Reference><Citation>Xia L, Ji Q, Song K, et al. Early clinical outcomes of on-pump beating-heart versus off-pump technique for surgical revascularization in patients with severe left ventricular dysfunction: the experience of a single center. J Cardiothorac Surg. 2017;12:11.</Citation></Reference><Reference><Citation>Antunes PE, Ferrao de Oliveira J, Prieto D, et al. Coronary artery bypass surgery without cardioplegia: hospital results in 8515 patientsdagger. Eur J Cardiothorac Surg. 2016;49:918-925.</Citation></Reference><Reference><Citation>Erkut B, Dag O, Kaygin MA, et al. On-pump beating-heart versus conventional coronary artery bypass grafting for revascularization in patients with severe left ventricular dysfunction: early outcomes. Can J Surg. 2013;56:398-404.</Citation></Reference><Reference><Citation>Tsai YT, Lin FY, Lai CH, Lin YC, Lin CY, Tsai CS. On-pump beating-heart coronary artery bypass provides efficacious short- and long-term outcomes in hemodialysis patients. Nephrol Dial Transplant. 2012;27:2059-2065.</Citation></Reference><Reference><Citation>Munos E, Calderon J, Pillois X, et al. Beating-heart coronary artery bypass surgery with the help of mini extracorporeal circulation for very high-risk patients. Perfusion. 2011;26:123-131.</Citation></Reference><Reference><Citation>Narayan P, Rogers CA, Bayliss KM, et al. On-pump coronary surgery with and without cardioplegic arrest: comparison of inflammation, myocardial, cerebral and renal injury and early and late health outcome in a single-centre randomised controlled trial. Eur J Cardiothorac Surg. 2011;39:675-683.</Citation></Reference><Reference><Citation>Darwazah AK, Bader V, Isleem I, Helwa K. Myocardial revascularization using on-pump beating heart among patients with left ventricular dysfunction. J Cardiothorac Surg. 2010;5:109.</Citation></Reference><Reference><Citation>Prifti E, Bonacchi M, Giunti G, et al. Does on-pump/beating-heart coronary artery bypass grafting offer better outcome in end-stage coronary artery disease patients? J Card Surg. 2000;15:403-410.</Citation></Reference><Reference><Citation>Pegg TJ, Selvanayagam JB, Francis JM, et al. A randomized trial of on-pump beating heart and conventional cardioplegic arrest in coronary artery bypass surgery patients with impaired left ventricular function using cardiac magnetic resonance imaging and biochemical markers. Circulation. 2008;118:2130-2138.</Citation></Reference><Reference><Citation>Ferrari E, Stalder N, von Segesser LK. On-pump beating heart coronary surgery for high risk patients requiring emergency multiple coronary artery bypass grafting. J Cardiothorac Surg. 2008;3:38.</Citation></Reference><Reference><Citation>Rastan AJ, Eckenstein JI, Hentschel B, et al. Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies. Circulation. 2006;114:I477-I485.</Citation></Reference><Reference><Citation>Ueki C, Sakaguchi G, Akimoto T, Ohashi Y, Sato H. On-pump beating-heart technique is associated with lower morbidity and mortality following coronary artery bypass grafting: a meta-analysis. Eur J Cardiothorac Surg. 2016;50:813-821.</Citation></Reference><Reference><Citation>Chaudhry UA, Harling L, Sepehripour AH, et al. Beating-heart versus conventional on-pump coronary artery bypass grafting: a meta-analysis of clinical outcomes. Ann Thorac Surg. 2015;100:2251-2260.</Citation></Reference><Reference><Citation>Liakopoulos OJ, Schlachtenberger G, Wendt D, et al. Early clinical outcomes of surgical myocardial revascularization for acute coronary syndromes complicated by cardiogenic shock: a report from the North-Rhine-Westphalia Surgical Myocardial Infarction Registry. J Am Heart Assoc. 2019;8:e012049.</Citation></Reference><Reference><Citation>Weiss ES, Chang DD, Joyce DL, Nwakanma LU, Yuh DD. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. J Thorac Cardiovasc Surg. 2008;135:503-511.</Citation></Reference><Reference><Citation>Mukherjee D, Ashrafian H, Kourliouros A, Ahmed K, Darzi A, Athanasiou T. Intra-operative conversion is a cause of masked mortality in off-pump coronary artery bypass: a meta-analysis. Eur J Cardiothorac Surg. 2012;41:291-299.</Citation></Reference><Reference><Citation>Borowski A, Korb H. Myocardial infarction in coronary bypass surgery using on-pump, beating heart technique with pressure- and volume-controlled coronary perfusion. J Card Surg. 2002;17:272-278.</Citation></Reference><Reference><Citation>Moscarelli M, Harling L, Attaran S, Ashrafian H, Casula RP, Athanasiou T. Surgical revascularisation of the acute coronary artery syndrome. Expert Rev Cardiovasc Ther. 2014;12:393-402.</Citation></Reference><Reference><Citation>White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the should we emergently revascularize occluded coronaries for cardiogenic shock (SHOCK) trial. Circulation. 2005;112:1992-2001.</Citation></Reference><Reference><Citation>Mehta RH, Lopes RD, Ballotta A, et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? Am Heart J. 2010;159:141-147.</Citation></Reference><Reference><Citation>Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014;3:e000590.</Citation></Reference><Reference><Citation>Andersen ND, Hart SA, Devendra GP, et al. Atheromatous disease of the aorta and perioperative stroke. J Thorac Cardiovasc Surg. 2018;155:508-516.</Citation></Reference><Reference><Citation>Dominici C, Salsano A, Nenna A, et al. Neurological outcomes after on-pump vs off-pump CABG in patients with cerebrovascular disease. J Card Surg. 2019;34:941-947.</Citation></Reference><Reference><Citation>Amabile A, Torregrossa G, Williams E, Puskas J. Mastering off-pump, total arterial coronary artery bypass grafting: a step-by-step approach [published online ahead of print January 17, 2020]. Multimed Man Cardiothorac Surg. 2020. https://doi.org/10.1510/mmcts.2020.003</Citation></Reference><Reference><Citation>Prapas S, Calafiore AM, Katsavrias KP, et al. Anaortic coronary surgery using the Pi-circuit is associated with a low incidence of perioperative neurological complications. Eur J Cardiothorac Surg. 2018;54:884-888.</Citation></Reference><Reference><Citation>Gaudino M, Bakaeen F, Benedetto U, et al. Use rate and outcome in bilateral internal thoracic artery grafting: insights from a systematic review and meta-analysis. J Am Heart Assoc. 2018;7:7.</Citation></Reference><Reference><Citation>Gaudino M, Lorusso R, Rahouma M, et al. Radial artery versus right internal thoracic artery versus saphenous vein as the second conduit for coronary artery bypass surgery: a network meta-analysis of clinical outcomes. J Am Heart Assoc. 2019;8:e010839.</Citation></Reference><Reference><Citation>Gutacker N, Bloor K, Cookson R, et al. Hospital surgical volumes and mortality after coronary artery bypass grafting: using international comparisons to determine a safe threshold. Health Serv Res. 2017;52:863-878.</Citation></Reference><Reference><Citation>Reichart D, Rosato S, Nammas W, et al. Clinical frailty scale and outcome after coronary artery bypass grafting. Eur J Cardiothorac Surg. 2018;54:1102-1109.</Citation></Reference><Reference><Citation>Chieffo A, Burzotta F, Pappalardo F, et al. Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCI: Italian Society of Interventional Cardiology Working Group endorsed by Spanish and Portuguese Interventional Cardiology Societies. Int J Cardiol. 2019;293:84-90.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37386548</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2731-3786</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of anesthesia, analgesia and critical care</Title><ISOAbbreviation>J Anesth Analg Crit Care</ISOAbbreviation></Journal><ArticleTitle>Cardiac complications in patients with COVID-19: a systematic review.</ArticleTitle><Pagination><StartPage>18</StartPage><MedlinePgn>18</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">18</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s44158-022-00046-7</ELocationID><Abstract><AbstractText>Cardiac complications in patients with COVID-19 have been described in the literature with an important impact on outcome. The primary objective of our systematic review was to describe the kind of cardiac complications observed in COVID-19 patients and to identify potential predictors of cardiovascular events. The secondary aim was to analyze the effect of cardiac complications on outcome.We performed this systematic review according to PRISMA guidelines using several databases for studies evaluating the type of cardiac complications and risk factors in COVID-19 patients. We also calculated the risk ratio (RR) and 95% CI. A random-effects model was applied to analyze the data. The heterogeneity of the retrieved trials was evaluated through the I<sup>2</sup> statistic. Our systematic review included 49 studies. Acute cardiac injury was evaluated in 20 articles. Heart failure and cardiogenic shock were reported in 10 articles. Myocardial infarction was evaluated in seven of the papers retrieved. Takotsubo, myocarditis, and pericardial effusion were reported in six, twelve, and five articles, respectively. Arrhythmic complications were evaluated in thirteen studies. Right ventricular dysfunction was evaluated in six articles. We included 7 studies investigating 2115 patients in the meta-analysis. The RR was 0.20 (95% CI: 0.17 to 0.24; P &lt; 0.00001, I<sup>2</sup> = 0.75). Acute cardiac injury represented the prevalent cardiac complications observed in COVID-19 patients (from 20 to 45% of the patients). Patients with acute cardiac injury seemed to be significantly older, with comorbidities, more likely to develop complications, and with higher mortality rates. Acute cardiac injury was found to be an independent risk factor for severe forms of SARS-CoV-2 infection and an independent predictor of mortality. Due to the scarce evidence, it was not possible to draw any conclusion regarding Takotsubo, myocarditis, pleural effusion, and right ventricular dysfunction in COVID-19 patients. Noteworthy, possible arrhythmic alterations (incidence rate of arrhythmia from 3 to 60%) in COVID-19 patients have to be taken into account for the possible complications and the consequent hemodynamic instabilities. Hypertension seemed to represent the most common comorbidities in COVID-19 patients (from 30 to 59.8%). The prevalence of cardiovascular disease (CVD) was high in this group of patients (up to 57%), with coronary artery disease in around 10% of the cases. In the majority of the studies retrieved, patients with CVD had a higher prevalence of severe form, ICU admission, and higher mortality rates.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brogi</LastName><ForeName>E</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9010-7941</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, Azienda Ospedaliero Universitaria Pisana, Via Paradisa 2, 56124, Pisa, Italy. etruscabrogi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marino</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency-Covid Intensive Care, Azienda Ospedaliera Universitaria di Bologna - Policlinico "S. Orsola Malpighi", Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertini</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care Medicine, Azienda Ospedaliero Universitaria Pisana, Via Roma n&#xb0; 67, 56126, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavazzi</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical-Surgical, Diagnostic and pediatric Sciences, University of Pavia, Via Alessandro Brambilla, 74, 27100, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anesthesia and Intensive Care, Fondazione Policlinico San Matteo IRCCS, Viale Camillo Golgi, 19, 27100, Pavia, PV, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corradi</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, Ente Ospedaliero Ospedali Galliera, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forfori</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Anesth Analg Crit Care</MedlineTA><NlmUniqueID>9918591885906676</NlmUniqueID><ISSNLinking>2731-3786</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute cardiac injury</Keyword><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Acute myocardial injury</Keyword><Keyword MajorTopicYN="N">Arrhythmia</Keyword><Keyword MajorTopicYN="N">Cardiac complications</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Coronavirus infection</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37386548</ArticleId><ArticleId IdType="pmc">PMC9043888</ArticleId><ArticleId IdType="doi">10.1186/s44158-022-00046-7</ArticleId><ArticleId IdType="pii">10.1186/s44158-022-00046-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265&#x2013;269. doi: 10.1038/s41586-020-2008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo E, Brogi E, Gamberini E, Agnoletti V. COVID-19: a clinical and organizational crisis. Intern Emerg Med. 2020;15:897&#x2013;899. doi: 10.1007/s11739-020-02410-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-020-02410-3</ArticleId><ArticleId IdType="pmc">PMC7309684</ArticleId><ArticleId IdType="pubmed">32577909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolondi G, Russo E, Gamberini E, Circelli A, Meca MCC, Brogi E, Viola L, Bissoni L, Poletti V, Agnoletti V. Iron metabolism and lymphocyte characterisation during Covid-19 infection in ICU patients: an observational cohort study. World J Emerg Surg. 2020;15(1):41. doi: 10.1186/s13017-020-00323-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13017-020-00323-2</ArticleId><ArticleId IdType="pmc">PMC7324776</ArticleId><ArticleId IdType="pubmed">32605582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiacchini G, Tric&#xf2; D, Ribechini A, Forfori F, Brogi E, Lucchi M, Berrettini S, Bertini P, Guarracino F, Bruschini L. Evaluation of the incidence and potential mechanisms of tracheal complications in patients with COVID-19. JAMA Otolaryngol Head Neck Surg. 2021;147(1):70&#x2013;76. doi: 10.1001/jamaoto.2020.4148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2020.4148</ArticleId><ArticleId IdType="pmc">PMC7677875</ArticleId><ArticleId IdType="pubmed">33211087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertini P, Forfori F, Bruschini L, Corradi F, Ribechini A, Brogi E, Guarracino F. Percutaneous tracheostomy in COVID-19 critically ill patients: experience from 30 consecutive procedures. Int Arch Otorhinolaryngol. 2021;25(1):e135&#x2013;e140. doi: 10.1055/s-0040-1718528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1718528</ArticleId><ArticleId IdType="pmc">PMC7851370</ArticleId><ArticleId IdType="pubmed">33552294</ArticleId></ArticleIdList></Reference><Reference><Citation>Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan M, Easton A, Breen G, Zandi M, Coles JP, Manji H, al-Shahi Salman R, Menon DK, Nicholson TR, Benjamin LA, Carson A, Smith C, Turner MR, Solomon T, Kneen R, Pett SL, Galea I, Thomas RH, Michael BD, Allen C, Archibald N, Arkell J, Arthur-Farraj P, Baker M, Ball H, Bradley-Barker V, Brown Z, Bruno S, Carey L, Carswell C, Chakrabarti A, Choulerton J, Daher M, Davies R, di Marco Barros R, Dima S, Dunley R, Dutta D, Ellis R, Everitt A, Fady J, Fearon P, Fisniku L, Gbinigie I, Gemski A, Gillies E, Gkrania-Klotsas E, Grigg J, Hamdalla H, Hubbett J, Hunter N, Huys AC, Ihmoda I, Ispoglou S, Jha A, Joussi R, Kalladka D, Khalifeh H, Kooij S, Kumar G, Kyaw S, Li L, Littleton E, Macleod M, Macleod MJ, Madigan B, Mahadasa V, Manoharan M, Marigold R, Marks I, Matthews P, Mccormick M, Mcinnes C, Metastasio A, Milburn-McNulty P, Mitchell C, Mitchell D, Morgans C, Morris H, Morrow J, Mubarak Mohamed A, Mulvenna P, Murphy L, Namushi R, Newman E, Phillips W, Pinto A, Price DA, Proschel H, Quinn T, Ramsey D, Roffe C, Ross Russell A, Samarasekera N, Sawcer S, Sayed W, Sekaran L, Serra-Mestres J, Snowdon V, Strike G, Sun J, Tang C, Vrana M, Wade R, Wharton C, Wiblin L, Boubriak I, Herman K, Plant G. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatr. 2020;7(10):875&#x2013;882. doi: 10.1016/S2215-0366(20)30287-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30287-X</ArticleId><ArticleId IdType="pmc">PMC7316461</ArticleId><ArticleId IdType="pubmed">32593341</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, Long B, Holladay D, Gottlieb M. Thrombotic complications of COVID-19. Am J Emerg Med. 2021;39:213&#x2013;218. doi: 10.1016/j.ajem.2020.09.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.09.065</ArticleId><ArticleId IdType="pmc">PMC7528743</ArticleId><ArticleId IdType="pubmed">33036855</ArticleId></ArticleIdList></Reference><Reference><Citation>Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020;253:117723. doi: 10.1016/j.lfs.2020.117723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117723</ArticleId><ArticleId IdType="pmc">PMC7194533</ArticleId><ArticleId IdType="pubmed">32360126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259&#x2013;260. doi: 10.1038/s41569-020-0360-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0360-5</ArticleId><ArticleId IdType="pmc">PMC7095524</ArticleId><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, G&#xf8;tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi: 10.1371/journal.pmed.1000100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000100</ArticleId><ArticleId IdType="pmc">PMC2707010</ArticleId><ArticleId IdType="pubmed">19621070</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaratunga EA, Corwin DS, Moran L, Snyder R (2020) Bradycardia in patients with COVID-19: a calm before the storm? Cureus 12(6):e8599. 10.7759/cureus.8599</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294893</ArticleId><ArticleId IdType="pubmed">32550090</ArticleId></ArticleIdList></Reference><Reference><Citation>Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. Jama. 2020;323(16):1612&#x2013;1614. doi: 10.1001/jama.2020.4326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4326</ArticleId><ArticleId IdType="pmc">PMC7082763</ArticleId><ArticleId IdType="pubmed">32191259</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, Ibrahim H, Friedman GH, Thompson C, Alviar CL, et al. ST-segment elevation in patients with Covid-19 - a case series. N Engl J Med. 2020;482:2478&#x2013;2480. doi: 10.1056/NEJMc2009020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2009020</ArticleId><ArticleId IdType="pmc">PMC7182015</ArticleId><ArticleId IdType="pubmed">32302081</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153(6):725&#x2013;733. doi: 10.1093/ajcp/aqaa062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqaa062</ArticleId><ArticleId IdType="pmc">PMC7184436</ArticleId><ArticleId IdType="pubmed">32275742</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Hu X, Cheng W, Yu L, Tu WJ, Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intens Care Med. 2020;46:851&#x2013;853. doi: 10.1007/s00134-020-05987-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05987-7</ArticleId><ArticleId IdType="pmc">PMC7079866</ArticleId><ArticleId IdType="pubmed">32123993</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Xu L, Dai Y, Ling Y, Mao J, Qian J, Zhu W, Di W, Ge J. Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol. 2020;43(7):796&#x2013;802. doi: 10.1002/clc.23384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23384</ArticleId><ArticleId IdType="pmc">PMC7323347</ArticleId><ArticleId IdType="pubmed">32562427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj. 2020;368:m1091. doi: 10.1136/bmj.m1091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1091</ArticleId><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabbagh MF, Aurora L, D'Souza P, Weinmann AJ, Bhargava P, Basir MB. Cardiac tamponade secondary to COVID-19. JACC Case Rep. 2020;2:1326&#x2013;1330. doi: 10.1016/j.jaccas.2020.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccas.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7177077</ArticleId><ArticleId IdType="pubmed">32328588</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, Cheng Y, Yan J, Ping H, Zhou Q. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. Int J Cardiol. 2020;311:116&#x2013;121. doi: 10.1016/j.ijcard.2020.03.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.03.087</ArticleId><ArticleId IdType="pmc">PMC7141178</ArticleId><ArticleId IdType="pubmed">32291207</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Erquicia P, Dobarro D, Raposeiras-Roub&#xed;n S, Bastos-Fernandez G, I&#xf1;iguez-Romo A. Multivessel coronary thrombosis in a patient with COVID-19 pneumonia. Eur Heart J. 2020;41(22):2132. doi: 10.1093/eurheartj/ehaa393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa393</ArticleId><ArticleId IdType="pmc">PMC7239221</ArticleId><ArticleId IdType="pubmed">32374373</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020;395(10235):1516. doi: 10.1016/S0140-6736(20)30912-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30912-0</ArticleId><ArticleId IdType="pmc">PMC7180035</ArticleId><ArticleId IdType="pubmed">32334650</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, Wang X, Hu C, Ping R, Hu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372&#x2013;1379. doi: 10.1164/rccm.202003-0543OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0543OC</ArticleId><ArticleId IdType="pmc">PMC7258652</ArticleId><ArticleId IdType="pubmed">32242738</ArticleId></ArticleIdList></Reference><Reference><Citation>Du RH, Liu LM, Yin W, Wang W, Guan LL, Yuan ML, Li YL, Hu Y, Li XY, Sun B, et al. Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan, China. Ann Am Thorac Soc. 2020;17(7):839&#x2013;846. doi: 10.1513/AnnalsATS.202003-225OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202003-225OC</ArticleId><ArticleId IdType="pmc">PMC7328178</ArticleId><ArticleId IdType="pubmed">32255382</ArticleId></ArticleIdList></Reference><Reference><Citation>Dweck MR, Bularga A, Hahn RT, Bing R, Lee KK, Chapman AR, White A, Salvo GD, Sade LE, Pearce K. Global evaluation of echocardiography in patients with COVID-19. Eur Heart J Cardiovasc Imag. 2020;21(9):949&#x2013;958. doi: 10.1093/ehjci/jeaa178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jeaa178</ArticleId><ArticleId IdType="pmc">PMC7337658</ArticleId><ArticleId IdType="pubmed">32556199</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(7):811&#x2013;818. doi: 10.1001/jamacardio.2020.1017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;42(2):206. doi: 10.1093/eurheartj/ehaa190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa190</ArticleId><ArticleId IdType="pmc">PMC7184348</ArticleId><ArticleId IdType="pubmed">32176300</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain H, Fadel A, Alwaeli H, Guardiola V. Coronavirus (COVID-19) fulminant myopericarditis and acute respiratory distress syndrome (ARDS) in a middle-aged male patient. Cureus. 2020;12(6):e8808. doi: 10.7759/cureus.8808.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.8808</ArticleId><ArticleId IdType="pmc">PMC7320646</ArticleId><ArticleId IdType="pubmed">32607304</ArticleId></ArticleIdList></Reference><Reference><Citation>Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(7):819&#x2013;824. doi: 10.1001/jamacardio.2020.1096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1096</ArticleId><ArticleId IdType="pmc">PMC7364333</ArticleId><ArticleId IdType="pubmed">32219357</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HN, Lee JH, Park HS, Yang DH, Jang SY, Bae MH, Cho Y, Chae SC, Lee YH. A case of COVID-19 with acute myocardial infarction and cardiogenic shock. J Korean Med Sci. 2020;35:e258. doi: 10.3346/jkms.2020.35.e258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e258</ArticleId><ArticleId IdType="pmc">PMC7358062</ArticleId><ArticleId IdType="pubmed">32657091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim IC, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J. 2020;41(19):1859. doi: 10.1093/eurheartj/ehaa288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa288</ArticleId><ArticleId IdType="pmc">PMC7184491</ArticleId><ArticleId IdType="pubmed">32282027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunal S, Sharma SM, Sharma SK, Gautam D, Bhatia H, Mahla H, Sharma S, Bhandari S. Cardiovascular complications and its impact on outcomes in COVID-19. Indian Heart J. 2020;72(6):593&#x2013;598. doi: 10.1016/j.ihj.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ihj.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC7609238</ArticleId><ArticleId IdType="pubmed">33357651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno T, Takahashi M, Obata R, Maeda T. Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York City. Am Heart J. 2020;226:24&#x2013;25. doi: 10.1016/j.ahj.2020.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.05.005</ArticleId><ArticleId IdType="pmc">PMC7227573</ArticleId><ArticleId IdType="pubmed">32425197</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer P, Degrauwe S, Van Delden C, Ghadri JR, Templin C. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J. 2020;41(19):1860. doi: 10.1093/eurheartj/ehaa306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa306</ArticleId><ArticleId IdType="pmc">PMC7184501</ArticleId><ArticleId IdType="pubmed">32285915</ArticleId></ArticleIdList></Reference><Reference><Citation>Monmeneu JV, Mafe ED, Soler JA, Perez BV, Caravaca JS, Torres RB, Garc&#xed;a-Gonzalez P, Ortega LH, Lopez-Lereu MP, Maceira AM. Subacute perimyocarditis in a young patient with COVID-19 infection. Eur Heart J Case Rep. 2020;4(FI1):1&#x2013;3. doi: 10.1093/ehjcr/ytaa157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytaa157</ArticleId><ArticleId IdType="pmc">PMC7314082</ArticleId><ArticleId IdType="pubmed">33089043</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascariello G, Cimino G, Calvi E, Bernardi N, Grigolato M, Garyfallidis P, Fabbricatore D, Pezzola E, Lombardi CM, Metra M. Cardiogenic shock due to COVID-19-related myocarditis in a 19-year-old autistic patient. J Med Cases. 2020;11(7):207&#x2013;210. doi: 10.14740/jmc3517.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jmc3517</ArticleId><ArticleId IdType="pmc">PMC8040434</ArticleId><ArticleId IdType="pubmed">33984092</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul JF, Charles P, Richaud C, Caussin C, Diakov C. Myocarditis revealing COVID-19 infection in a young patient. Eur Heart J Cardiovasc Imaging. 2020;21(7):776. doi: 10.1093/ehjci/jeaa107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jeaa107</ArticleId><ArticleId IdType="pmc">PMC7197601</ArticleId><ArticleId IdType="pubmed">32338706</ArticleId></ArticleIdList></Reference><Reference><Citation>Peigh G, Leya MV, Baman JR, Cantey EP, Knight BP, Flaherty JD. Novel coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series. Eur Heart J Case Rep. 2020;4(FI1):1&#x2013;6. doi: 10.1093/ehjcr/ytaa132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytaa132</ArticleId><ArticleId IdType="pmc">PMC7239209</ArticleId><ArticleId IdType="pubmed">33089039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens Care Med. 2020;46(5):846&#x2013;848. doi: 10.1007/s00134-020-05991-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D, De Cobelli F, Tresoldi M, Cappelletti AM, Basso C, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861&#x2013;1862. doi: 10.1093/eurheartj/ehaa286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa286</ArticleId><ArticleId IdType="pmc">PMC7184339</ArticleId><ArticleId IdType="pubmed">32267502</ArticleId></ArticleIdList></Reference><Reference><Citation>Seecheran R, Narayansingh R, Giddings S, Rampaul M, Furlonge K, Abdool K, Bhagwandass N, Seecheran NA. Atrial arrhythmias in a patient presenting with coronavirus disease-2019 (COVID-19) infection. J Investig Med High Impact Case Rep. 2020;8:2324709620925571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218462</ArticleId><ArticleId IdType="pubmed">32370558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao L, Li X, Zhou Y, Yu Y, Liu Y, Liu M, Zhang R, Zhang H, Wang X, Zhou F. Novel insights into illness progression and risk profiles for mortality in non-survivors of COVID-19. Front Med (Lausanne) 2020;7:246. doi: 10.3389/fmed.2020.00246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00246</ArticleId><ArticleId IdType="pmc">PMC7256183</ArticleId><ArticleId IdType="pubmed">32574334</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802&#x2013;810. doi: 10.1001/jamacardio.2020.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, Huang H, Yang B, Huang C. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41(22):2070&#x2013;2079. doi: 10.1093/eurheartj/ehaa408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa408</ArticleId><ArticleId IdType="pmc">PMC7239100</ArticleId><ArticleId IdType="pubmed">32391877</ArticleId></ArticleIdList></Reference><Reference><Citation>Solano-L&#xf3;pez J, S&#xe1;nchez-Recalde A, Zamorano JL. SARS-CoV-2, a novel virus with an unusual cardiac feature: inverted takotsubo syndrome. Eur Heart J. 2020;41(32):3106. doi: 10.1093/eurheartj/ehaa390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa390</ArticleId><ArticleId IdType="pmc">PMC7239192</ArticleId><ArticleId IdType="pubmed">32391885</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, Metra M, Curello S, Maffeo D, Pero G, Cacucci M, Assanelli E, Bellini B, Russo F, Ielasi A, Tespili M, Danzi GB, Vandoni P, Bollati M, Barbieri L, Oreglia J, Lettieri C, Cremonesi A, Carugo S, Reimers B, Condorelli G, Chieffo A. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020;141(25):2113&#x2013;2116. doi: 10.1161/CIRCULATIONAHA.120.047525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047525</ArticleId><ArticleId IdType="pmc">PMC7302062</ArticleId><ArticleId IdType="pubmed">32352306</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, Gal Oz A, Rothschild E, Baruch G, Peri Y, Arbel Y, Topilsky Y. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation. 2020;142(4):342&#x2013;353. doi: 10.1161/CIRCULATIONAHA.120.047971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047971</ArticleId><ArticleId IdType="pmc">PMC7382541</ArticleId><ArticleId IdType="pubmed">32469253</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, Sepe PA, Resasco T, Camporotondo R, Bruno R. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911&#x2013;915. doi: 10.1002/ejhf.1828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1828</ArticleId><ArticleId IdType="pmc">PMC7262276</ArticleId><ArticleId IdType="pubmed">32275347</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva DH, Lusby HP, Islam SP, Gupte AA, Beatty NL. Heart failure exacerbation as only presenting sign of COVID-19. IDCases. 2020;21:e00870. doi: 10.1016/j.idcr.2020.e00870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2020.e00870</ArticleId><ArticleId IdType="pmc">PMC7294254</ArticleId><ArticleId IdType="pubmed">32607310</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y, Huang X, Lv J, Luo Y, Shen L, Yang H, Huang G, Yang R. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797&#x2013;806. doi: 10.1002/jmv.25783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25783</ArticleId><ArticleId IdType="pmc">PMC7228368</ArticleId><ArticleId IdType="pubmed">32198776</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, You Q, Wu C, Cao S, Qu G, Yan X, Han X, Wang C, Zhang H. Impact of cardiovascular disease on clinical characteristics and outcomes of coronavirus disease 2019 (COVID-19) Circ J. 2020;84(8):1277&#x2013;1283. doi: 10.1253/circj.CJ-20-0348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-20-0348</ArticleId><ArticleId IdType="pubmed">32536672</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong S, Liu L, Lin F, Shi J, Han L, Liu H, He L, Jiang Q, Wang Z, Fu W, Li Z, Lu Q, Chen Z, Ding S. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study. BMC Infect Dis. 2020;20(1):787. doi: 10.1186/s12879-020-05452-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05452-2</ArticleId><ArticleId IdType="pmc">PMC7578439</ArticleId><ArticleId IdType="pubmed">33092539</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475&#x2013;481. doi: 10.1016/S2213-2600(20)30079-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30079-5</ArticleId><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Xu D, Fu S, Zhang J, Yang X, Xu L, Xu J, Wu Y, Huang C, Ouyang Y, Yang L, Fang M, Xiao H, Ma J, Zhu W, Hu S, Hu Q, Ding D, Hu M, Zhu G, Xu W, Guo J, Xu J, Yuan H, Zhang B, Yu Z, Chen D, Yuan S, Shang Y. Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study. Crit Care. 2020;24(1):219. doi: 10.1186/s13054-020-02939-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02939-x</ArticleId><ArticleId IdType="pmc">PMC7223395</ArticleId><ArticleId IdType="pubmed">32410714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J-H, Liu Y-X, Yuan J, Wang F-X, Wu W-B, Li J-X, Wang L-F, Gao H, Wang Y, Dong C-F. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020;48(5):1. doi: 10.1007/s15010-020-01424-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-020-01424-5</ArticleId><ArticleId IdType="pmc">PMC7146072</ArticleId><ArticleId IdType="pubmed">32277408</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, Peng Z, Pan H. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. doi: 10.1016/j.jcv.2020.104364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104364</ArticleId><ArticleId IdType="pmc">PMC7194884</ArticleId><ArticleId IdType="pubmed">32311650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, Yang AY, Yu BP, Huang ZP. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020;20(1):311. doi: 10.1186/s12879-020-05010-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05010-w</ArticleId><ArticleId IdType="pmc">PMC7188494</ArticleId><ArticleId IdType="pubmed">32345226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Green S: Cochrane handbook for systematic reviews of interventions, vol. 5: Wiley Online Library; 2008.</Citation></Reference><Reference><Citation>Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. doi: 10.1186/1471-2288-5-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-5-13</ArticleId><ArticleId IdType="pmc">PMC1097734</ArticleId><ArticleId IdType="pubmed">15840177</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539&#x2013;1558. doi: 10.1002/sim.1186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 2003;327(7414):557&#x2013;560. doi: 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;be S, Richter S, Seige M, Stehr S, Laufs U, Hagendorff A. Echocardiographic characteristics of patients with SARS-CoV-2 infection. Clin Res Cardiol. 2020;109(12):1549&#x2013;1566. doi: 10.1007/s00392-020-01727-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01727-5</ArticleId><ArticleId IdType="pmc">PMC7428201</ArticleId><ArticleId IdType="pubmed">32803387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Chen B, Liao H, Wang Z, Lyu M, Man S, Pu Q, Liu L. The comparable efficacy of lung donation after circulatory death and brain death: a systematic review and meta-analysis. Transplantation. 2019;103(12):2624&#x2013;2633. doi: 10.1097/TP.0000000000002888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000002888</ArticleId><ArticleId IdType="pubmed">31369516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2018;39:119&#x2013;177. doi: 10.1093/eurheartj/ehx393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx393</ArticleId><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation. 2020;141(6):e69&#x2013;e92. doi: 10.1161/CIR.0000000000000745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000745</ArticleId><ArticleId IdType="pubmed">31902242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gali&#xe8; N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J. 2016;37(1):67&#x2013;119. doi: 10.1093/eurheartj/ehv317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv317</ArticleId><ArticleId IdType="pubmed">26320113</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685&#x2013;713. doi: 10.1016/j.echo.2010.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2010.05.010</ArticleId><ArticleId IdType="pubmed">20620859</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan P, Desikan R, Dixit NM. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection. PLoS Comput Biol. 2020;16(12):e1008461. doi: 10.1371/journal.pcbi.1008461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1008461</ArticleId><ArticleId IdType="pmc">PMC7748278</ArticleId><ArticleId IdType="pubmed">33290397</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. Jama. 2020;324(15):1565&#x2013;1567. doi: 10.1001/jama.2020.17052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17052</ArticleId><ArticleId IdType="pmc">PMC7489366</ArticleId><ArticleId IdType="pubmed">32880615</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Matthay MA, Calfee CS. Is a &#x201c;cytokine storm&#x201d; relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152&#x2013;1154. doi: 10.1001/jamainternmed.2020.3313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3313</ArticleId><ArticleId IdType="pubmed">32602883</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction (2018) J Am Coll Cardiol. 2018;72(18):2231&#x2013;2264. doi: 10.1016/j.jacc.2018.08.1038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.08.1038</ArticleId><ArticleId IdType="pubmed">30153967</ArticleId></ArticleIdList></Reference><Reference><Citation>Delano MJ, Ward PA. The immune system&#x2019;s role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016;274(1):330&#x2013;353. doi: 10.1111/imr.12499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12499</ArticleId><ArticleId IdType="pmc">PMC5111634</ArticleId><ArticleId IdType="pubmed">27782333</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffer U, Wade RG, Gourlay T. Cytokines in the systemic inflammatory response syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth. 2010;2:161&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484588</ArticleId><ArticleId IdType="pubmed">23441054</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengl M, Bartak F, Sykora R, Chvojka J, Benes J, Krouzecky A, Novak I, Sviglerova J, Kuncova J, Matejovic M. Reduced L-type calcium current in ventricular myocytes from pigs with hyperdynamic septic shock. Crit Care Med. 2010;38(2):579&#x2013;587. doi: 10.1097/CCM.0b013e3181cb0f61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181cb0f61</ArticleId><ArticleId IdType="pubmed">20029342</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe H, Semba H, Takeda N. The roles of hypoxia signaling in the pathogenesis of cardiovascular diseases. J Atheroscler Thromb. 2017;24(9):884&#x2013;894. doi: 10.5551/jat.RV17009.</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.RV17009</ArticleId><ArticleId IdType="pmc">PMC5587513</ArticleId><ArticleId IdType="pubmed">28757538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaki A, Singh H, Cohen G, Schreiber T. A case report of a large intracardiac thrombus in a COVID-19 patient managed with percutaneous thrombectomy and right ventricular mechanical circulatory support. Eur Heart J Case Rep. 2020;4(6):1&#x2013;5. doi: 10.1093/ehjcr/ytaa308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytaa308</ArticleId><ArticleId IdType="pmc">PMC7665472</ArticleId><ArticleId IdType="pubmed">33437917</ArticleId></ArticleIdList></Reference><Reference><Citation>Urso C, Brucculeri S, Caimi G. Acid&#x2013;base and electrolyte abnormalities in heart failure: pathophysiology and implications. Heart Fail Rev. 2015;20:493&#x2013;503. doi: 10.1007/s10741-015-9482-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-015-9482-y</ArticleId><ArticleId IdType="pmc">PMC4464645</ArticleId><ArticleId IdType="pubmed">25820346</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho H, Richard MC, Chouihed T, Goffinet N, Le Bastard Q, Freund Y, Kratz A, Dubroux M, Masson D, Figueres L, et al. Electrolyte imbalance in COVID-19 patients admitted to the Emergency Department: a case&#x2013;control study. Intern Emerg Med. 2021;16:1&#x2013;6. doi: 10.1007/s11739-021-02632-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02632-z</ArticleId><ArticleId IdType="pmc">PMC7823192</ArticleId><ArticleId IdType="pubmed">33484453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honor&#xe9; S, Colson P, Chabri&#xe8;re E, la Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId><ArticleId IdType="pmc">PMC7102549</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Awortwe C, Cascorbi I. Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. Pharmacol Res. 2020;161:105250. doi: 10.1016/j.phrs.2020.105250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.105250</ArticleId><ArticleId IdType="pmc">PMC7550259</ArticleId><ArticleId IdType="pubmed">33059010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG, Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss HP, Tsch&#xf6;pe C, Cooper LT, Jr, Camici PG. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020;13(11):e007405. doi: 10.1161/CIRCHEARTFAILURE.120.007405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.120.007405</ArticleId><ArticleId IdType="pmc">PMC7673642</ArticleId><ArticleId IdType="pubmed">33176455</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32629772</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2051</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm9072051</ELocationID><Abstract><AbstractText>Vasopressors and inotropes are routinely used in acute myocardial infarction (AMI) related cardiogenic shock (CS) to improve hemodynamics. We aimed to investigate the effect of routinely used vasopressor and inotropes on mortality in AMI related CS. A systematic search of MEDLINE, EMBASE and CENTRAL was performed up to 20 February 2019. Randomized and observational studies reporting mortality of AMI related CS patients were included. At least one group should have received the vasopressor/inotrope compared with a control group not exposed to the vasopressor/inotrope. Exclusion criteria were case reports, correspondence and studies including only post-cardiac surgery patients. In total, 19 studies (6 RCTs) were included, comprising 2478 CS patients. The overall quality of evidence was graded low. Treatment with adrenaline, noradrenaline, vasopressin, milrinone, levosimendan, dobutamine or dopamine was not associated with a difference in mortality between therapy and control group. We found a trend toward better outcome with levosimendan, compared with control (RR 0.69, 95% CI 0.47-1.00). In conclusion, we found insufficient evidence that routinely used vasopressors and inotropes are associated with reduced mortality in patients with AMI related CS. Considering the limited evidence, this study emphasizes the need for randomized trials with appropriate endpoints and methodology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karami</LastName><ForeName>Mina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6514-5786</Identifier><AffiliationInfo><Affiliation>Heart Center, Department of Interventional Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemradj</LastName><ForeName>Veemal V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Isala, 8025 AB Zwolle, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouweneel</LastName><ForeName>Dagmar M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Heart Center, Department of Interventional Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>den Uil</LastName><ForeName>Corstiaan A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-0635-2843</Identifier><AffiliationInfo><Affiliation>Departments of Cardiology and Intensive Care Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limpens</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Library, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otterspoor</LastName><ForeName>Luuk C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Heart Center Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlaar</LastName><ForeName>Alexander P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagrand</LastName><ForeName>Wim K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Jos&#xe9; P S</ForeName><Initials>JPS</Initials><Identifier Source="ORCID">0000-0002-8969-7929</Identifier><AffiliationInfo><Affiliation>Heart Center, Department of Interventional Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">inotrope</Keyword><Keyword MajorTopicYN="N">low cardiac output</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">review</Keyword><Keyword MajorTopicYN="N">shock</Keyword><Keyword MajorTopicYN="N">vasopressor</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32629772</ArticleId><ArticleId IdType="pmc">PMC7408805</ArticleId><ArticleId IdType="doi">10.3390/jcm9072051</ArticleId><ArticleId IdType="pii">jcm9072051</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vallabhajosyula S., Dunlay S.M., Prasad A., Kashani K., Sakhuja A., Gersh B.J., Jaffe A.S., Holmes D.R., Jr., Barsness G.W. Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock. J. Am. Coll. Cardiol. 2019;73:1781&#x2013;1791. doi: 10.1016/j.jacc.2019.01.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.01.053</ArticleId><ArticleId IdType="pubmed">30975295</ArticleId></ArticleIdList></Reference><Reference><Citation>Wayangankar S.A., Bangalore S., McCoy L.A., Jneid H., Latif F., Karrowni W., Charitakis K., Feldman D.N., Dakik H.A., Mauri L., et al. Temporal trends and outcomes of patients undergoing percutaneous coronary interventions for cardiogenic shock in the setting of acute myocardial infarction: A report from the CathPCI registry. JACC Cardiovasc. Interv. 2016;9:341&#x2013;351. doi: 10.1016/j.jcin.2015.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2015.10.039</ArticleId><ArticleId IdType="pubmed">26803418</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds H.R., Hochman J.S. Cardiogenic shock: Current concepts and improving outcomes. Circulation. 2008;117:686&#x2013;697. doi: 10.1161/CIRCULATIONAHA.106.613596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.613596</ArticleId><ArticleId IdType="pubmed">18250279</ArticleId></ArticleIdList></Reference><Reference><Citation>van Diepen S., Katz J.N., Albert N.M., Henry T.D., Jacobs A.K., Kapur N.K., Kilic A., Menon V., Ohman E.M., Sweitzer N.K., et al. Contemporary management of cardiogenic shock: A scientific statement from the american heart association. Circulation. 2017;136:e232&#x2013;e268. doi: 10.1161/CIR.0000000000000525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000525</ArticleId><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur. Heart J. 2017;39:119&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D.D., Bohula E.A., Van Diepen S., Katz J.N., Alviar C.L., Baird-Zars V.M., Barnett C.F., Barsness G.W., Burke J.A., Cremer P.C., et al. Epidemiology of Shock in Contemporary Cardiac Intensive Care Units. Circ. Cardiovasc. Qual. Outcomes. 2019;12:e005618. doi: 10.1161/CIRCOUTCOMES.119.005618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.119.005618</ArticleId><ArticleId IdType="pmc">PMC11032172</ArticleId><ArticleId IdType="pubmed">30879324</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg R.J., Samad N.A., Yarzebski J., Gurwitz J., Bigelow C., Gore J.M. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N. Engl. J. Med. 1999;340:1162&#x2013;1168. doi: 10.1056/NEJM199904153401504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199904153401504</ArticleId><ArticleId IdType="pubmed">10202167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman J.S., Sleeper L.A., Webb J.G., Sanborn T.A.A., White H.D., Talley J.D., Buller C.E., Jacobs A.K., Slater J.N., Col J., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N. Engl. J. Med. 1999;341:625&#x2013;634. doi: 10.1056/NEJM199908263410901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199908263410901</ArticleId><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>Overgaard C.B., Dzavik V. Inotropes and vasopressors: Review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118:1047&#x2013;1056. doi: 10.1161/CIRCULATIONAHA.107.728840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.728840</ArticleId><ArticleId IdType="pubmed">18765387</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Altman D.G., Gotzsche P.C., Juni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A. The cochrane collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed) 2011;343:d5928. doi: 10.1136/bmj.d5928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010;25:603&#x2013;605. doi: 10.1007/s10654-010-9491-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-010-9491-z</ArticleId><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Balshem H., Helfand M., Sch&#xfc;nemann H.J., Oxman A.D., Kunz R., Brozek J., Vist G.E., Falck-Ytter Y., Meerpohl J., Norris S., et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 2011;64:401&#x2013;406. doi: 10.1016/j.jclinepi.2010.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.07.015</ArticleId><ArticleId IdType="pubmed">21208779</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy B., Clere-Jehl R., Legras A., Morichau-Beauchant T., Leone M., Frederique G., Quenot J.P., Kimmoun A., Cariou A., Lassus J., et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J. Am. Coll. Cardiol. 2018;72:173&#x2013;182. doi: 10.1016/j.jacc.2018.04.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.04.051</ArticleId><ArticleId IdType="pubmed">29976291</ArticleId></ArticleIdList></Reference><Reference><Citation>Myburgh J.A., Higgins A., Jovanovska A., Lipman J., Ramakrishnan N., Santamaria J. Investigators CATS: A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34:2226&#x2013;2234. doi: 10.1007/s00134-008-1219-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-008-1219-0</ArticleId><ArticleId IdType="pubmed">18654759</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D., Biston P., Devriendt J., Madl C., Chochrad D., Aldecoa C., Brasseur A., Defrance P., Gottignies P., Vincent J.L., et al. Comparison of dopamine and norepinephrine in the treatment of shock. N. Engl. J. Med. 2010;362:779&#x2013;789. doi: 10.1056/NEJMoa0907118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0907118</ArticleId><ArticleId IdType="pubmed">20200382</ArticleId></ArticleIdList></Reference><Reference><Citation>Samimi-Fard S., Garcia-Gonzalez M.J., Dominguez-Rodriguez A., Abreu-Gonzalez P. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int. J. Cardiol. 2008;127:284&#x2013;287. doi: 10.1016/j.ijcard.2007.04.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2007.04.143</ArticleId><ArticleId IdType="pubmed">17643519</ArticleId></ArticleIdList></Reference><Reference><Citation>Husebye T., Eritsland J., Muller C., Sandvik L., Arnesen H., Seljeflot I., Mangschau A., Bjornerheim R., Andersen G.O. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: A randomized, placebo-controlled study. Eur J. Heart Fail. 2013;15:565&#x2013;572. doi: 10.1093/eurjhf/hfs215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfs215</ArticleId><ArticleId IdType="pubmed">23288914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann J.T., Schmeisser A. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit. Care Med. 2009;37:2678&#x2013;2679. doi: 10.1097/CCM.0b013e3181b469f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181b469f7</ArticleId><ArticleId IdType="pubmed">19687655</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarvasmaki T., Lassus J., Varpula M., Sionis A., Sund R., Kober L., Spinar J., Parissis J., Banaszewski M., Silva Cardoso J., et al. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit. Care (London, England) 2016;20:208. doi: 10.1186/s13054-016-1387-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1387-1</ArticleId><ArticleId IdType="pmc">PMC4931696</ArticleId><ArticleId IdType="pubmed">27374027</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin R.F., Moore S., Marpole D.G. Shock following myocardial infarction: A clinical survey of 140 cases. Can. Med Assoc. J. 1965;93:57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1928521</ArticleId><ArticleId IdType="pubmed">20328285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T., Tachibana E., Ueki Y., Sakamoto K., Imamura H., Miyamoto T., Takahashi H., Hanada H., Yonemoto N., Nagao K., et al. The effect of vasopressor agents in the treatment of cardiovascular shock. Circulation. 2015;132(Suppl. 3):A13004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126606</ArticleId><ArticleId IdType="pubmed">34012971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis T.C., Aberle C., Altshuler D., Piper G.L., Papadopoulos J. Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock. J. Cardiovasc. Pharmacol. Ther. 2018 doi: 10.1177/1074248418797357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248418797357</ArticleId><ArticleId IdType="pubmed">30175599</ArticleId></ArticleIdList></Reference><Reference><Citation>Vally S., Ferdynus C., Persichini R., Bouchet B., Braunberger E., Lo Pinto H., Martinet O., Vandroux D., Aujoulat T., Allyn J., et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann. Intensive Care. 2019;9:24. doi: 10.1186/s13613-019-0503-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-019-0503-1</ArticleId><ArticleId IdType="pmc">PMC6358626</ArticleId><ArticleId IdType="pubmed">30707314</ArticleId></ArticleIdList></Reference><Reference><Citation>Affronti A., di Bella I., Carino D., Ragni T. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO J. 2013;59:554&#x2013;557. doi: 10.1097/MAT.0b013e3182a4b32e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0b013e3182a4b32e</ArticleId><ArticleId IdType="pubmed">24172260</ArticleId></ArticleIdList></Reference><Reference><Citation>Omerovic E., Ramunddal T., Albertsson P., Holmberg M., Hallgren P., Boren J., Grip L., Matejka G. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction. Vasc. Health Risk Manag. 2010;6:657&#x2013;663. doi: 10.2147/VHRM.S8856.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VHRM.S8856</ArticleId><ArticleId IdType="pmc">PMC2941779</ArticleId><ArticleId IdType="pubmed">20859537</ArticleId></ArticleIdList></Reference><Reference><Citation>Caetano F., Almeida I., Silva J., Botelho A., Mota P., Leitao Marques A. Cardiogenic shock in acute myocardial infarction: Still looking for the best inotrope. Eur. Heart J. Acute Cardiovasc. Care. 2012;1:28&#x2013;29.</Citation></Reference><Reference><Citation>Christoph A., Prondzinsky R., Russ M., Janusch M., Schlitt A., Lemm H., Reith S., Werdan K., Buerke M. Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card. Care. 2008;10:49&#x2013;57. doi: 10.1080/17482940701358564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482940701358564</ArticleId><ArticleId IdType="pubmed">17924229</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsytadze I., Amosova E., Prudkyi I., Bogomolets A.K.O. Long term effects of Levosimendan therapy in patients with cardiogenic shock. Resuscitation. 2013;84:S11. doi: 10.1016/j.resuscitation.2013.08.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2013.08.043</ArticleId></ArticleIdList></Reference><Reference><Citation>El Mokhtari N.E., Arlt A., Meissner A., Lins M. Inotropic therapy for cardiac low output syndrome: Comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine. Eur. J. Med Res. 2007;12:563&#x2013;567. doi: 10.1186/s40001-017-0256-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-017-0256-y</ArticleId><ArticleId IdType="pubmed">18024265</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulopoulos S.D., Stamateolopoulos S.F., Nanas J.N., Kontoyannis D.A., Nanas S.N. Effect of protracted dobutamine infusion on survival of patients in cardiogenic shock treated with intraaortic balloon pumping. Chest. 1993;103:248&#x2013;252. doi: 10.1378/chest.103.1.248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.103.1.248</ArticleId><ArticleId IdType="pubmed">8417888</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriange M., Calay G., Gach J., Lisin N. Shock states during myocardial infarct: Treatment of cardiogenic shock with dopamine. Acta Clinica Belgica. 1971;26:249&#x2013;261. doi: 10.1080/17843286.1971.11716793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17843286.1971.11716793</ArticleId><ArticleId IdType="pubmed">5161426</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann J., Henrich E.C., Strobl H., Prondzinsky R., Weiche S., Thiele H., Werdan K., Frantz S., Unverzagt S. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst. Rev. 2018 doi: 10.1002/14651858.CD009669.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009669.pub3</ArticleId><ArticleId IdType="pmc">PMC6491099</ArticleId><ArticleId IdType="pubmed">29376560</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamper G., Havel C., Arrich J., Losert H., Pace N.L., Mullner M., Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst. Rev. 2016 doi: 10.1002/14651858.CD003709.pub4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003709.pub4</ArticleId><ArticleId IdType="pmc">PMC6516856</ArticleId><ArticleId IdType="pubmed">26878401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamontagne F., Richards-Belle A., Thomas K., Harrison D.A., Sadique M.Z., Grieve R.D., Camsooksai J., Darnell R., Gordon A.C., Henry D., et al. Effect of reduced exposure to vasopressors on 90-Day mortality in older critically ill patients with Vasodilatory hypotension: A randomized clinical trial. JAMA. 2020;323:938&#x2013;949. doi: 10.1001/jama.2020.0930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.0930</ArticleId><ArticleId IdType="pmc">PMC7064880</ArticleId><ArticleId IdType="pubmed">32049269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong M.E.H., Tiah L., Leong B.S.-H., Tan E.C.C., Ong V.Y.K., Tan E.A.T., Poh B.Y., Pek P.P., Chen Y. A randomised, double-blind, multi-centre trial comparing vasopressin and adrenaline in patients with cardiac arrest presenting to or in the Emergency Department. Resuscitation. 2012;83:953&#x2013;960. doi: 10.1016/j.resuscitation.2012.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2012.02.005</ArticleId><ArticleId IdType="pubmed">22353644</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins G.D., Ji C., Deakin C.D., Quinn T., Nolan J.P., Scomparin C., Regan S., Long J., Slowther A., Pocock H., et al. A randomized trial of epinephrine in out-of-hospital cardiac arrest. N. Engl. J. Med. 2018;379:711&#x2013;721. doi: 10.1056/NEJMoa1806842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1806842</ArticleId><ArticleId IdType="pubmed">30021076</ArticleId></ArticleIdList></Reference><Reference><Citation>Olasveengen T.M., Sunde K., Brunborg C., Thowsen J., Steen P.A., Wik L. Intravenous drug administration during out-of-hospital cardiac arrest: A randomized trial. JAMA. 2009;302:2222&#x2013;2229. doi: 10.1001/jama.2009.1729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1729</ArticleId><ArticleId IdType="pubmed">19934423</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36413687</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8191</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of cardiac surgery</Title><ISOAbbreviation>J Card Surg</ISOAbbreviation></Journal><ArticleTitle>Prophylactic LVAD for high-risk patients undergoing cardiac surgery.</ArticleTitle><Pagination><StartPage>5120</StartPage><EndPage>5129</EndPage><MedlinePgn>5120-5129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.17222</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Postcardiotomy cardiogenic shock (PCS) is associated with poor prognosis. Medical therapy with afterload reduction, contractility optimization and systemic vasopressors often fails, and mechanical support is required. The aim of this study was to propose a strategy of prophylactic left ventricular assist device (LVAD) for high-risk patients undergoing cardiac surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between 2013 and 2019, 12 consecutive patients at high risk for PCS underwent cardiac surgery (valve surgery and/or coronary artery bypass grafting) with preplanned, prophylactic implantation of LVAD (CentriMag or Rotaflow). We reviewed patient characteristics and outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight patients underwent a valve corrective surgery and seven&#xa0;patients underwent coronary artery bypass grafting. Eleven of 12 patients had successful LVAD insertion, support and wean, and survival to hospital discharge. Left ventricular function was stable perioperatively and improved at follow-up. Patients required low doses of inotropic support and no patients required extracorporeal membranous oxygenation. Major complications included, prolonged mechanical ventilation (n&#x2009;=&#x2009;7), intra-aortic balloon pump (n&#x2009;=&#x2009;1), temporary dialysis (n&#x2009;=&#x2009;2), stroke (n&#x2009;=&#x2009;1), bleeding requiring reoperation (n&#x2009;=&#x2009;3), infection requiring mediastinal washout (n&#x2009;=&#x2009;1). At a mean follow-up of, 660&#x2009;&#xb1;&#x2009;460.6 days all patients had either NYHA Class 1 (n&#x2009;=&#x2009;6) or 2 (n&#x2009;=&#x2009;4). There were two late mortalities (after 1 year).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prophylactic LVAD is a viable technique in select cardiac surgery patients who are high-risk for postcardiotomy shock. Further prospective study is warranted.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaidka</LastName><ForeName>Atul K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-1246-7359</Identifier><AffiliationInfo><Affiliation>Department of Medicine, London Health Sciences Centre, Division of Cardiology, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De</LastName><ForeName>Sabe</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, London Health Sciences Centre, Division of Cardiology, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drullinsky</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, London Health Sciences Centre, Division of Cardiac Surgery, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagpal</LastName><ForeName>Atul Dave</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Surgery, London Health Sciences Centre, Division of Cardiac Surgery, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, London Health Sciences Centre, Division of Critical Care, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Michael W A</ForeName><Initials>MWA</Initials><AffiliationInfo><Affiliation>Department of Surgery, London Health Sciences Centre, Division of Cardiac Surgery, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Surg</MedlineTA><NlmUniqueID>8908809</NlmUniqueID><ISSNLinking>0886-0440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular research</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">valve repair/replacement</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>15</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36413687</ArticleId><ArticleId IdType="doi">10.1111/jocs.17222</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Akay MH, Gregoric ID, Radovancevic R, Cohn WE, Frazier OH. Timely use of a CentriMag heart assist device improves survival in postcardiotomy cardiogenic shock. J Card Surg. 2011;26:548-552.</Citation></Reference><Reference><Citation>Griffith BP, Anderson MB, Samuels LE, Pae WE, Naka Y, Frazier OH. The RECOVER I: a&#xa0;multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg. 2013;145:548-554.</Citation></Reference><Reference><Citation>Lorusso R, Gelsomino S, Carella R, et al. Impact of prophylactic intra-aortic balloon counter-pulsation on postoperative outcome in high-risk cardiac surgery patients: a multicentre, propensity-score analysis. Eur J Cardiothorac Surg. 2010;38:585-591. doi:10.1016/j.ejcts.2010.03.017</Citation></Reference><Reference><Citation>Nagpal AD, Singal RK, Arora RC, Lamarche Y. Temporary mechanical circulatory support in cardiac critical care:&#xa0;a&#xa0;state of the art review and algorithm for device selection. Can J Cardiol. 2017;33:110-118.</Citation></Reference><Reference><Citation>Lorusso R, Whitman G, Milojevic M, et al. 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. Ann Thorac Surg. 2021;111:327-369.</Citation></Reference><Reference><Citation>Jaidka A, De S, Nagpal AD, Chu MWA. Prophylactic right ventricular assist device for high-risk patients undergoing valve corrective surgery. CJC Open. 2019;1:19-27.</Citation></Reference><Reference><Citation>Fukuhara S, Takeda K, Garan AR, et al. Contemporary mechanical circulatory support therapy for postcardiotomy shock. Gen Thorac Cardiovasc Surg. 2016;64:183-191.</Citation></Reference><Reference><Citation>Pozzi M, Alvau F, Armoiry X, et al. Outcomes after extracorporeal life support for postcardiotomy cardiogenic shock. J Card Surg. 2019;34:74-81.</Citation></Reference><Reference><Citation>Lorusso R, Raffa GM, Alenizy K, et al. Structured review of post-cardiotomy extracorporeal membrane oxygenation: part 1-adult patients. J Heart Lung Transplant. 2019;38:1125-1143.</Citation></Reference><Reference><Citation>Raffa GM, Kowalewski M, Brodie D, et al. Meta-analysis of peripheral or central extracorporeal membrane oxygenation in postcardiotomy and non-postcardiotomy shock. Ann Thorac Surg. 2019;107:311-321.</Citation></Reference><Reference><Citation>Rastan AJ, Dege A, Mohr M, et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg. 2010;139:302-311.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32926537</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Percutaneous large-bore axillary access is a safe alternative to surgical approach: A systematic review.</ArticleTitle><Pagination><StartPage>1481</StartPage><EndPage>1488</EndPage><MedlinePgn>1481-1488</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.29273</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To systematically review relevant literature regarding cardiovascular outcomes of large-bore axillary arterial access via percutaneous and surgical approaches.</AbstractText><AbstractText Label="BACKGROUND">In patients with severe peripheral arterial disease (PAD) undergoing cardiac interventions, large-bore femoral access may be prohibitive. The axillary artery provides an alternative vascular access for transcatheter aortic valve replacement (TAVR) or mechanical circulatory support. There have been limited comparisons of percutaneous transaxillary (pTAX) approach with the more traditional surgical transaxillary (sTAX) approach.</AbstractText><AbstractText Label="METHODS">Pubmed and Medline databases were queried through January 2019 for studies describing pTAX or sTAX approaches with TAVR or Impella insertion. Primary outcomes were access-related mortality, 30-day mortality, stroke, major vascular complications, and major bleeding.</AbstractText><AbstractText Label="RESULTS">One hundred and fifty five studies were reviewed, with additional unpublished data from 1 institution. Twenty-two studies met the inclusion criteria. Patient data was heterogeneous, with 69% TAVR and 31% Impella use in the pTAX group, and 96% TAVR and 4% Impella use in the sTAX group. There was more cardiogenic shock in the pTAX group. When compared to surgical approach, the percutaneous approach had similar 30-day mortality for TAVR (5.6% vs 4.6%, OR non-significant) and Impella (43.4% vs 38.6%, OR non-significant), similar stroke rates (4.3% vs 4.2%, OR non-significant), similar major vascular complications (2.8% vs 2.3%, OR non-significant) and less major bleeding (2.7% vs 17.9%, OR significant).</AbstractText><AbstractText Label="CONCLUSIONS">Data suggests large-bore pTAX access has similar 30-day mortality, stroke rates, and major vascular complications as sTAX access, with less major bleeding. Additional studies are needed to validate results.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Southmayd</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoque</LastName><ForeName>Azizul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaki</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Ascension St. John Hospital, Detroit, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tayal</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Cardiology, RWJ Barnabas Health, Newark Beth Israel Medical Center, Newark, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rab</LastName><ForeName>S Tanveer</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0001-8258-1600</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Catheter Cardiovasc Interv. 2020 Dec;96(7):1489-1490. doi: 10.1002/ccd.29408.</RefSource><PMID Version="1">33306878</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001366" MajorTopicYN="Y">Axillary Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006328" MajorTopicYN="Y">Cardiac Catheterization</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002406" MajorTopicYN="Y">Catheterization, Peripheral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006350" MajorTopicYN="N">Heart Valve Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058729" MajorTopicYN="N">Peripheral Arterial Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011677" MajorTopicYN="N">Punctures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="Y">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">TAVR</Keyword><Keyword MajorTopicYN="N">Transaxillary access</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>15</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32926537</ArticleId><ArticleId IdType="doi">10.1002/ccd.29273</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kaki A, Blank N, Alraies MC, et al. Axillary artery access for mechanical circulatory support devices in patients with prohibitive peripheral arterial disease presenting with cardiogenic shock. Am J Cardiol. 2019;123:1715-1721.</Citation></Reference><Reference><Citation>Cheney AE, McCabe JM. Alternative percutaneous access for large bore devices. Circ Cardiovasc Interv. 2019;12:e007707-e007710.</Citation></Reference><Reference><Citation>Bangalore S, Bhatt DL. Femoral arterial access and closure. Circulation. 2011;124:e147-e156.</Citation></Reference><Reference><Citation>Rao SV, Ou F-S, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2008;1:379-386.</Citation></Reference><Reference><Citation>Di Mario C, Goodwin M, Ristalli F, Ravani M, Meucci F, et al. A prospective registry of intravascular lithotripsy-enabled vascular access for transfemoral transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(5):502-504.</Citation></Reference><Reference><Citation>Tayal R, Iftikhar H, LeSar B, et al. CT angiography analysis of axillary artery diameter versus common femoral artery diameter: implications for axillary approach for Transcatheter aortic valve replacement in patients with hostile Aortoiliac segment and advanced lung disease. J Vasc Med. 2016;2016:1-5.</Citation></Reference><Reference><Citation>AbuRahma AF, Robinson PA, Boland JP, Umstot RK, Clubb EA, et al. Complications of arteriography in a recent series of 707 cases: factors affecting outcome. Ann Vasc Surg. 1993;7:122-129.</Citation></Reference><Reference><Citation>Sandhu NS. The use of ultrasound for axillary artery catheterization through pectoral muscles: a new anterior approach. Anesth Analg. 2004;99:562-565.</Citation></Reference><Reference><Citation>Petronio AS, DE Carlo M, Bedogni F, Marzocchi A, Klugmann S, et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ Cardiovasc Interv. 2010;3:359-366.</Citation></Reference><Reference><Citation>Dahle TG, Kaneko T, McCabe JM. Outcomes following subclavian and axillary artery access for transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:662-669.</Citation></Reference><Reference><Citation>Sch&#xe4;fer U, Ho Y, Frerker C, et al. Direct percutaneous access technique for transaxillary transcatheter aortic valve implantation: "the Hamburg Sankt Georg approach". JACC Cardiovasc Interv. 2012;5:477-486.</Citation></Reference><Reference><Citation>Lotun K, Shetty R, Patel M, Arain SA. Percutaneous left axillary artery approach for Impella 2.5 liter circulatory support for patients with severe aortoiliac arterial disease undergoing high-risk percutaneous coronary intervention. J Interv Cardiol. 2012;25:210-213.</Citation></Reference><Reference><Citation>Truong HTD, Hunter G, Lotun K, et al. Insertion of the Impella via the axillary artery for high-risk percutaneous coronary intervention. Cardiovasc Revasc Med. 2018;19:540-544.</Citation></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1-9.</Citation></Reference><Reference><Citation>Sch&#xe4;fer U, Deuschl F, Schofer N, et al. Safety and efficacy of the percutaneous transaxillary access for transcatheter aortic valve implantation using various transcatheter heart valves in 100 consecutive patients. Int J Cardiol. 2017;232:247-254.</Citation></Reference><Reference><Citation>McCabe J, Khaki A, Nicholson W, Blank N, Grantham JA, et al. TCT-99 safety and efficacy of percutaneous axillary artery access for mechanical circulatory support with the Impella devices: an initial evaluation from the axillary access registry to monitor safety (ARMS) MultiCenter registry. J Am Coll Cardiol. 2017;70:B43.</Citation></Reference><Reference><Citation>Deuschl F, Schofer N, Seiffert M, et al. Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis. Catheter Cardiovasc Interv. 2017;90:1167-1174.</Citation></Reference><Reference><Citation>Van der Wulp K, Verkroost MWA, Van Wely MH, Gehlmann HR, Van Garsse LAFM, et al. Feasibility and outcomes of TAVI using the left axillary artery as primary access site. Ann Thorac Surg. 2018;107:546-552.</Citation></Reference><Reference><Citation>Fr&#xf6;hlich GM, Baxter PD, Malkin CJ, et al. Comparative survival after transapical, direct aortic, and subclavian transcatheter aortic valve implantation (data from the UKTAVI registry). Am J Cardiol. 2015;116:1555-1559.</Citation></Reference><Reference><Citation>Petronio AS, DE Carlo M, Bedogni F, Maisano F, Ettori F, et al. 2-year results of CoreValve implantation through the subclavian access: a propensity-matched comparison with the femoral access. J Am Coll Cardiol. 2012;60:502-507.</Citation></Reference><Reference><Citation>Hysi I, Gommeaux A, P&#xe9;cheux M, Hochart P, Hannebicque G, et al. Axillary transcatheter aortic valve replacement in patients with peripheral vascular disease. Semin Thorac Cardiovasc Surg. 2018;31:175-180.</Citation></Reference><Reference><Citation>Muensterer A, Mazzitelli D, Ruge H, et al. Safety and efficacy of the subclavian access route for TAVI in cases of missing transfemoral access. Clin Res Cardiol. 2013;102:627-636.</Citation></Reference><Reference><Citation>Moynagh AM, Scott DJA, Baumbach A, et al. CoreValve transcatheter aortic valve implantation via the subclavian artery: comparison with the transfemoral approach. J Am Coll Cardiol. 2011;57:634-635.</Citation></Reference><Reference><Citation>Adamo M, Fiorina C, Curello S, et al. Role of different vascular approaches on transcatheter aortic valve implantation outcome: a single-center study. J Cardiovasc Med (Hagerstown). 2015;16:279-285.</Citation></Reference><Reference><Citation>Cioni M, Taramasso M, Giacomini A, et al. Transaxillary approach: short- and mid-term results in a single-center experience. Innovations (Phila). 2011;6:361-365.</Citation></Reference><Reference><Citation>Bansal A, Bhama JK, Patel R, et al. Using the minimally invasive Impella 5.0 via the right subclavian artery cutdown for acute on chronic decompensated heart failure as a bridge to decision. Ochsner J. 2016;16:210-216.</Citation></Reference><Reference><Citation>Boll G, Fischer A, Kapur NK, Salehi P. Right axillary artery conduit is a safe and reliable access for implantation of Impella 5.0 microaxial pump. Ann Vasc Surg. 2018;54:54-59.</Citation></Reference><Reference><Citation>Guarracino F, Covello RD, Landoni G, et al. Anesthetic management of transcatheter aortic valve implantation with transaxillary approach. J Cardiothorac Vasc Anesth. 2011;25:437-443.</Citation></Reference><Reference><Citation>Laflamme M, Mazine A, Demers P, et al. Transcatheter aortic valve implantation by the left axillary approach: a single-center experience. Ann Thorac Surg. 2014;97:1549-1554.</Citation></Reference><Reference><Citation>Doersch KM, Tong CW, Gongora E, Konda S, Sareyyupoglu B. Temporary left ventricular assist device through an axillary access is a promising approach to improve outcomes in refractory cardiogenic shock patients. ASAIO J. 2015;61:253-258.</Citation></Reference><Reference><Citation>Mastroianni C, Bouabdallaoui N, Leprince P, Lebreton G. Short-term mechanical circulatory support with the Impella 5.0 device for cardiogenic shock at La Piti&#xe9;-Salp&#xea;tri&#xe8;re. Eur Heart J Acute Cardiovasc Care. 2017;6:87-92.</Citation></Reference><Reference><Citation>Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aortic valve implantation: early results of the France (FRench aortic national CoreValve and Edwards) registry. Eur Heart J. 2011;32:191-197.</Citation></Reference><Reference><Citation>Doshi SN, George S, Kwok CS, et al. A feasibility study of transaxillary TAVI with the lotus valve. Catheter Cardiovasc Interv. 2018;92:542-549.</Citation></Reference><Reference><Citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747.</Citation></Reference><Reference><Citation>Kappetein AP, Head SJ, G&#xe9;n&#xe9;reux P, Piazza N, van Mieghem NM, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013;145:6-23.</Citation></Reference><Reference><Citation>Greenbaum AB, Babaliaros VC, Chen MY, et al. Transcaval access and closure for transcatheter aortic valve replacement: a prospective investigation. J Am Coll Cardiol. 2017;69:511-521.</Citation></Reference><Reference><Citation>Bob-Manuel T, Almusawi H, Rezan T, Khaira H, Akingbola A, et al. Efficacy and safety of transcarotid transcatheter aortic valve replacement: a systematic review. Cardiovasc Revasc Med. 2019;21:917-926.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32239284</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1861-0692</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinical research in cardiology : official journal of the German Cardiac Society</Title><ISOAbbreviation>Clin Res Cardiol</ISOAbbreviation></Journal><ArticleTitle>Multivessel versus culprit-only PCI in STEMI patients with multivessel disease: meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>1381</StartPage><EndPage>1391</EndPage><MedlinePgn>1381-1391</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00392-020-01637-6</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To perform a pairwise meta-analysis of randomized controlled trials (RCTs) comparing multivessel percutaneous coronary intervention (PCI) and culprit vessel-only PCI in ST-elevation myocardial infarction (STEMI) patients without cardiogenic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched MEDLINE, Cochrane Central Register of Controlled Trials, and Embase for RCTs comparing multivessel PCI with culprit vessel-only PCI in STEMI patients without cardiogenic shock and multivessel coronary artery disease. Only RCTs reporting mortality or myocardial reinfarction after at least 6&#xa0;months following randomization were included. Hazard ratios (HRs) were pooled using random-effect models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine RCTs were included in the final analysis. In total, 523 (8.3%) of 6314 patients suffered the combined primary endpoint of death or non-fatal reinfarction. This primary endpoint was significantly reduced with multivessel PCI compared to culprit vessel-only PCI (HR 0.63, 95% confidence interval [CI] 0.43-0.93; p&#x2009;=&#x2009;0.03). This finding was driven by a reduction of non-fatal reinfarction (HR 0.64, 95% CI 0.52-0.79; p&#x2009;=&#x2009;0.001), whereas no significant reduction of all-cause death (HR 0.77, 95% CI 0.44-1.35; p&#x2009;=&#x2009;0.28) or cardiovascular death (HR 0.64, 95% CI 0.37-1.11; p&#x2009;=&#x2009;0.09) was observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In STEMI patients without cardiogenic shock multivessel PCI reduced the risk of death or non-fatal reinfarction compared to culprit vessel-only PCI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feistritzer</LastName><ForeName>Hans-Josef</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Str&#xfc;mpellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leipzig Heart Institute, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jobs</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Str&#xfc;mpellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leipzig Heart Institute, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center L&#xfc;beck, University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Waha-Thiele</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center L&#xfc;beck, University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center L&#xfc;beck, University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Str&#xfc;mpellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leipzig Heart Institute, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Wahab</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Str&#xfc;mpellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leipzig Heart Institute, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desch</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Str&#xfc;mpellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leipzig Heart Institute, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Str&#xfc;mpellstr. 39, 04289, Leipzig, Germany. Holger.Thiele@medizin.uni-leipzig.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leipzig Heart Institute, Leipzig, Germany. Holger.Thiele@medizin.uni-leipzig.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Res Cardiol</MedlineTA><NlmUniqueID>101264123</NlmUniqueID><ISSNLinking>1861-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="N">Coronary Vessels</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="N">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Culprit vessel</Keyword><Keyword MajorTopicYN="N">Multivessel coronary artery disease</Keyword><Keyword MajorTopicYN="N">Revascularization</Keyword><Keyword MajorTopicYN="N">ST-elevation myocardial infarction</Keyword></KeywordList><CoiStatement>All authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32239284</ArticleId><ArticleId IdType="pmc">PMC7588388</ArticleId><ArticleId IdType="doi">10.1007/s00392-020-01637-6</ArticleId><ArticleId IdType="pii">10.1007/s00392-020-01637-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Park DW, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014;312:2019&#x2013;2027. doi: 10.1001/jama.2014.15095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.15095</ArticleId><ArticleId IdType="pubmed">25399277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28:1709&#x2013;1716. doi: 10.1093/eurheartj/ehm184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehm184</ArticleId><ArticleId IdType="pubmed">17556348</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaaf RJ, Timmer JR, Ottervanger JP, et al. Long-term impact of multivessel disease on cause-specific mortality after ST elevation myocardial infarction treated with reperfusion therapy. Heart. 2006;92:1760&#x2013;1763. doi: 10.1136/hrt.2005.086058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.2005.086058</ArticleId><ArticleId IdType="pmc">PMC1861301</ArticleId><ArticleId IdType="pubmed">16644856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannan EL, Samadashvili Z, Walford G, et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv. 2010;3:22&#x2013;31. doi: 10.1016/j.jcin.2009.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2009.10.017</ArticleId><ArticleId IdType="pubmed">20129564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2011;58:704&#x2013;711. doi: 10.1016/j.jacc.2011.02.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.02.071</ArticleId><ArticleId IdType="pubmed">21816305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115&#x2013;1123. doi: 10.1056/NEJMoa1305520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1305520</ArticleId><ArticleId IdType="pubmed">23991625</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015;65:963&#x2013;972. doi: 10.1016/j.jacc.2014.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.12.038</ArticleId><ArticleId IdType="pmc">PMC4359051</ArticleId><ArticleId IdType="pubmed">25766941</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstrom T, Kelbaek H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386:665&#x2013;671. doi: 10.1016/S0140-6736(15)60648-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)60648-1</ArticleId><ArticleId IdType="pubmed">26347918</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits PC, Abdel-Wahab M, Neumann FJ, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017;376:1234&#x2013;1244. doi: 10.1056/NEJMoa1701067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1701067</ArticleId><ArticleId IdType="pubmed">28317428</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381:1411&#x2013;1421. doi: 10.1056/NEJMoa1907775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1907775</ArticleId><ArticleId IdType="pubmed">31475795</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. doi: 10.1136/bmj.d4002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d4002</ArticleId><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvino Santos RA, Estevez-Loureiro R, Bouzas-Mosquera A, et al. Complete revascularisation versus stress echocardiography-guided revascularisation in patients with ST-segment elevation myocardial infarction and multivessel disease (CROSS-AMI): a clinical trial. Eur Heart J. 2017;38(suppl_1):P2121. doi: 10.1093/eurheartj/ehx502.P2121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx502.P2121</ArticleId><ArticleId IdType="pubmed">31554422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mashhour K, Omar W, Mowafy A, et al. Complete revascularization versus culprit-vessel revascularization in acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016;5:61&#x2013;62. doi: 10.1177/2048872615590146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872615590146</ArticleId><ArticleId IdType="pubmed">26056392</ArticleId></ArticleIdList></Reference><Reference><Citation>Hlinomaz O (2015) Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy (PRAGUE 13 trial). In: Presented at: EuroPCR 2015; May 19, 2015; Paris, France 2015</Citation></Reference><Reference><Citation>Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart. 2010;96:662&#x2013;667. doi: 10.1136/hrt.2009.177162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.2009.177162</ArticleId><ArticleId IdType="pubmed">19778920</ArticleId></ArticleIdList></Reference><Reference><Citation>Backhaus SJ, Kowallick JT, Stiermaier T, et al. Culprit vessel-related myocardial mechanics and prognostic implications following acute myocardial infarction. Clin Res Cardiol. 2020;109:339&#x2013;349. doi: 10.1007/s00392-019-01514-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-019-01514-x</ArticleId><ArticleId IdType="pubmed">31278521</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ger B, Haller PM, Piackova E, et al. Predictors of transportation delay in patients with suspected ST-elevation-myocardial infarction in the VIENNA-STEMI network. Clin Res Cardiol. 2020;109:393&#x2013;399. doi: 10.1007/s00392-019-01520-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-019-01520-z</ArticleId><ArticleId IdType="pmc">PMC7042186</ArticleId><ArticleId IdType="pubmed">31256260</ArticleId></ArticleIdList></Reference><Reference><Citation>Corpus RA, House JA, Marso SP, et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J. 2004;148:493&#x2013;500. doi: 10.1016/j.ahj.2004.03.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2004.03.051</ArticleId><ArticleId IdType="pubmed">15389238</ArticleId></ArticleIdList></Reference><Reference><Citation>Meliga E, Fiorina C, Valgimigli M, et al. Early angio-guided complete revascularization versus culprit vessel PCI followed by ischemia-guided staged PCI in STEMI patients with multivessel disease. J Interv Cardiol. 2011;24:535&#x2013;541. doi: 10.1111/j.1540-8183.2011.00666.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1540-8183.2011.00666.x</ArticleId><ArticleId IdType="pubmed">22010970</ArticleId></ArticleIdList></Reference><Reference><Citation>Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC) Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569&#x2013;2619. doi: 10.1093/eurheartj/ehs215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs215</ArticleId><ArticleId IdType="pubmed">22922416</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavasini R, Biscaglia S, Barbato E, et al. Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2019 doi: 10.1093/eurheartj/ehz896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz896</ArticleId><ArticleId IdType="pubmed">31891653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangalore S, Toklu B, Stone GW. Meta-analysis of culprit-only versus multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction and multivessel coronary disease. Am J Cardiol. 2018;121:529&#x2013;536. doi: 10.1016/j.amjcard.2017.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2017.11.022</ArticleId><ArticleId IdType="pubmed">29304995</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasceri V, Patti G, Pelliccia F, et al. Complete revascularization during primary percutaneous coronary intervention reduces death and myocardial infarction in patients with multivessel disease: meta-analysis and meta-regression of randomized trials. JACC Cardiovasc Interv. 2018;11:833&#x2013;843. doi: 10.1016/j.jcin.2018.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2018.02.028</ArticleId><ArticleId IdType="pubmed">29747913</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman M, Khan SU, Farjo PD, et al. Meta-analysis comparing complete versus infarct-related artery revascularization in patients with ST-elevation myocardial infarction and multivessel coronary disease. Am J Cardiol. 2020;125:513&#x2013;520. doi: 10.1016/j.amjcard.2019.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.11.017</ArticleId><ArticleId IdType="pmc">PMC7453957</ArticleId><ArticleId IdType="pubmed">31812228</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner N, Nickenig G, Sinning JM. Complex PCI procedures: challenges for the interventional cardiologist. Clin Res Cardiol. 2018;107(Suppl 2):64&#x2013;73. doi: 10.1007/s00392-018-1316-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-018-1316-1</ArticleId><ArticleId IdType="pubmed">29978353</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Interv. 2004;6:128&#x2013;133. doi: 10.1080/14628840310030441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14628840310030441</ArticleId><ArticleId IdType="pubmed">16146905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghani A, Dambrink JH, van&#x2019;t Hof AW, et al. Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomised clinical trial. Neth Heart J. 2012;20:347&#x2013;353. doi: 10.1007/s12471-012-0281-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12471-012-0281-y</ArticleId><ArticleId IdType="pmc">PMC3430767</ArticleId><ArticleId IdType="pubmed">22622701</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamza M, Mahmoud N, Elgendy IY. A randomized trial of complete versus culprit-only revascularization during primary percutaneous coronary intervention in diabetic patients with acute ST elevation myocardial infarction and multi vessel disease. J Interv Cardiol. 2016;29:241&#x2013;247. doi: 10.1111/joic.12293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joic.12293</ArticleId><ArticleId IdType="pubmed">27245121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32598523</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8191</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of cardiac surgery</Title><ISOAbbreviation>J Card Surg</ISOAbbreviation></Journal><ArticleTitle>The use of extracorporeal membrane oxygenation postcardiotomy-A systematic review.</ArticleTitle><Pagination><StartPage>1941</StartPage><EndPage>1953</EndPage><MedlinePgn>1941-1953</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.14694</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The use of extracorporeal membrane oxygenation (ECMO) in cardiac surgery has been established in cases of postcardiotomy cardiogenic shock, which is refractory to conventional therapy with inotropes and intra-aortic balloon pulsation support. We sought to examine the literature in a systematic review manner on the outcomes of using ECMO postcardiac surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive electronic literature search was done to identify all the articles that have discussed the use of ECMO postcardiac surgery. The keywords and medical subject headings terms were used to identify the relevant articles. Studies have been screened according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The identified studies have been summarized in each relevant section of this study. Cardiogenic shock postcardiac surgery can benefit from ECMO to varying degrees and the survival for this; otherwise, fatal condition has been shown to be improving through the use of ECMO. However, the decision and timing to initiate ECMO therapy remains selective and is dependent on a range of factors such as patient factor, clinician's judgment, meaning there is no consistent and solid ground regarding the timing of ECMO initiation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Current evidence suggests that the circulatory support provided by ECMO improves survival rates for postcardiac surgery cardiogenic shock patients who are refractory to inotropic management, without such ECMO support patient mortality rates would be much greater.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harahwa</LastName><ForeName>Tinotenda</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6979-6655</Identifier><AffiliationInfo><Affiliation>School of Medicine, St George's, University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chor</LastName><ForeName>Cheryl Yan Ting</ForeName><Initials>CYT</Initials><Identifier Source="ORCID">0000-0003-3232-4491</Identifier><AffiliationInfo><Affiliation>School of Medicine, St George's, University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harky</LastName><ForeName>Amer</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5507-5841</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Surg</MedlineTA><NlmUniqueID>8908809</NlmUniqueID><ISSNLinking>0886-0440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">cardiac surgery</Keyword><Keyword MajorTopicYN="N">cardiotomy</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32598523</ArticleId><ArticleId IdType="doi">10.1111/jocs.14694</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Makdishi G, Wang I. Extra corporeal membrane oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015;7(7):E166-E174. https://doi.org/10.3978/j.issn.2072-1439.2015.07.17</Citation></Reference><Reference><Citation>Allen S, Holena D, McCunn M, et al. A review of the fundamental principles and evidence base in the use of extracorporeal membrane oxygenation (ECMO) in critically Ill adult patients. J Intensive Care Med. 2011;26(1):13-26. https://doi.org/10.1177/0885066610384061</Citation></Reference><Reference><Citation>Extracorporeal Life Support Organization. ECMO and ECLS &gt; Registry &gt; Statistics &gt; International Summary. 2020. https://www.elso.org/Registry/Statistics/InternationalSummary.aspx. Accessed March 20, 2020.</Citation></Reference><Reference><Citation>Frenckner B, Broman M, Broom&#xe9; M. Position of draining venous cannula in extracorporeal membrane oxygenation for respiratory and respiratory/circulatory support in adult patients. Crit Care. 2018;22:163. https://doi.org/10.1186/s13054-018-2083-0</Citation></Reference><Reference><Citation>Rao P, Khalpey Z, Smith R, et al. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. Circ Heart Fail. 2018;11:e004906. https://doi.org/10.1161/CIRCHEARTFAILURE.118.004905</Citation></Reference><Reference><Citation>Stulak JM, Dearani JA, Burkhart HM, et al. ECMO cannulation controversies and complications. Semin Cardiothorac Vasc Anesth. 2009;13(3):176-182. https://doi.org/10.1177/1089253209347943</Citation></Reference><Reference><Citation>Fl&#xe9;cher E, Anselmi A, Corbineau H, et al. Current aspects of extracorporeal membrane oxygenation in a tertiary referral centre: determinants of survival at follow-up. Eur J Cardio-Thoracic Surg. 2014;46(4):655-671. https://doi.org/10.1093/ejcts/ezu029</Citation></Reference><Reference><Citation>Ranney DN, Benrashid E, Meza JM, et al. Central cannulation as a viable alternative to peripheral cannulation in extracorporeal membrane oxygenation. Semin Thorac Cardiovasc Surg. 2017;29(2):188-195. https://doi.org/10.1053/j.semtcvs.2017.02.007</Citation></Reference><Reference><Citation>Jayaraman AL, Cormica D, Shah P, Ramakrishna H. Cannulation strategies in adult veno-arterial and veno-venous extracorporeal membrane oxygenation: techniques, limitations, and special considerations. Ann Card Anaesth. 2017;20(suppl 1):S11-S18. https://doi.org/10.4103/0971-9784.197791</Citation></Reference><Reference><Citation>Kanji HD, Schulze CJ, Oreopoulos A, et al. Peripheral versus central cannulation for extracorporeal membrane oxygenation: a comparison of limb ischaemia and transfusion requirements. Thorac Cardiovasc Surg. 2010;58(8):459-462. https://doi.org/10.1055/s-0030-1250005</Citation></Reference><Reference><Citation>Loforte A, Marinellie G, Musumeci F, et al. Extracorporeal membrane oxygenation support in refractory cardiogenic shock: treatment strategies and analysis of risk factors. Artif Organs. 2014;38(7):E129-E141. https://doi.org/10.1111/aor.12317</Citation></Reference><Reference><Citation>Rastan AJ, Dege A, Mohr M, et al. Early and late outcomes of 517 consecutive adults patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg. 2010;139(2):302-311. https://doi.org/10.1016/j.jtcvs.2009.10.043</Citation></Reference><Reference><Citation>Khorsandi M, Shaikhrezai K, Prasad S, et al. Advanced mechanical circulatory support for post-cardiotomy cardiogenic shock: a 20-year outcome analysis in a non-transplant unit. J Cardiothorac Surg. 2016;11:29. https://doi.org/10.1186/s13019-016-0430-2</Citation></Reference><Reference><Citation>Elsharkawy HA, Li L, Esa WA, et al. Outcome in patients who require venoarterial extracorporeal membrane oxygenation support after cardiac surgery. J Cardiothorac Vasc Anesth. 2010;24(6):946-951. https://doi.org/10.1053/j.jvca.2010.03.020</Citation></Reference><Reference><Citation>Wu MY, Lin PJ, Lee MY, et al. Using extracorporeal life support to resuscitate adult postcardiotomy cardiogenic shock: treatment strategies and predictors of short-term and mid-term survival. Resuscitation. 2010;81(9):1111-1116. https://doi.org/10.1016/j.resuscitation.2010.04.031</Citation></Reference><Reference><Citation>Hsu PS, Chen JL, Hong GH, et al. Extracorporeal membrane oxygenation for refractory cardiogenic shock after cardiac surgery: predictors of early mortality and outcome from 51 adult patients. Eur J Cardiothorac Surg. 2010;37(2):328-333. https://doi.org/10.1016/j.ejcts.2009.07.033</Citation></Reference><Reference><Citation>Yan X, Jia S, Meng X, et al. Acute kidney injury in adult postcardiotomy patients with extracorporeal membrane oxygenation: evaluation of the RIFLE classification and the Acute Kidney Injury Network criteria. Eur J Cardiothorac Surg. 2010;37(2):334-338. https://doi.org/10.1016/j.ejcts.2009.07.004</Citation></Reference><Reference><Citation>Slottosch I, Liakopoulos O, Kuhn E, et al. Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience. J Surg Res. 2013;181(2):e47-e55. https://doi.org/10.1016/j.jss.2012.07.030</Citation></Reference><Reference><Citation>Unosawa S, Sezai A, Hata M, et al. Long-term outcomes of patients undergoing extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. Surg Today. 2013;43(3):264-270. https://doi.org/10.1007/s00595-012-0322-6</Citation></Reference><Reference><Citation>Wang JG, Han J, Jia YX, et al. Outcome of veno-arterial extracorporeal membrane oxygenation for patients undergoing valvular surgery. PLoS One. 2013;8(5):e63924. https://doi.org/10.1371/journal.pone.0063924</Citation></Reference><Reference><Citation>Li CL, Wang H, Jia M, et al. The early dynamic behavior of lactate is linked to mortality in postcardiotomy patients with extracorporeal membrane oxygenation support: a retrospective observational study. J Thorac Cardiovasc Surg. 2015;149(5):1445-1450. https://doi.org/10.1016/j.jtcvs.2014.11.052</Citation></Reference><Reference><Citation>Saxena P, Neal J, Joyce LD, et al. Extracorporeal membrane oxygenation support in postcardiotomy elderly patients: the Mayo Clinic experience. Ann Thorac Surg. 2015;99(6):2053-2060. https://doi.org/10.1016/j.athoracsur.2014.11.075</Citation></Reference><Reference><Citation>Papadopoulos N, Marinos S, Ahmad AE, et al. Risk factors associated with adverse outcome following extracorporeal life support: analysis from 360 consecutive patients. Perfusion. 2015;30(4):284-290. https://doi.org/10.1177/0267659114542458</Citation></Reference><Reference><Citation>Biancari F, Dal&#xe9;n M, Perrotti A, et al. Venoarterial extracorporeal membrane oxygenation after coronary artery bypass grafting: Results of a multicenter study. Int J Cardiol. 2017;241:109-114. https://doi.org/10.1016/j.ijcard.2017.03.120</Citation></Reference><Reference><Citation>Rubino A, Costanzo D, Stanszus, et al. Central veno-arterial extracorporeal membrane oxygenation (C-VA-ECMO) after cardiothoracic surgery: a single-center experience. J Cardiothorac Vasc. 2018;32(3):1169-1174. https://doi.org/10.1053/j.jvca.2017.12.003</Citation></Reference><Reference><Citation>Xie H, Yang F, Hou D, et al. Risk factors of in-hospital mortality in adult postcardiotomy cardiogenic shock patients successfully weaned from venoarterial extracorporeal membrane oxygenation. Perfusion. 2019. https://doi.org/10.1177/0267659119890214</Citation></Reference><Reference><Citation>Hu RTC, Broad JD, Osawa EA, et al. 30-Day outcomes post veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) after cardiac surgery and predictors of survival. Heart Lung Circ. 2020;S1443-9506:30038-X. https://doi.org/10.1016/j.hlc.2020.01.009</Citation></Reference><Reference><Citation>Biancari F, Dal&#xe9;n M, Fiore A, et al. Multicenter study on postcardiotomy venoarterial extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2020, 159(5):1844-1854. https://doi.org/10.1016/j.jtcvs.2019.06.039</Citation></Reference><Reference><Citation>Pokersnik JA, Buda T, Bashour CA, et al. Have changes in ECMO technology impacted outcomes in adult patients developing postcardiotomy cardiogenic shock? J Card Surg. 2012;27(2):246-252. https://doi.org/10.1111/j.1540-8191.2011.01409.x</Citation></Reference><Reference><Citation>Millar JE, Fanning JP, McDonald CI, et al. The inflammatory response to extracorporeal membrane oxygenation (ECMO): A review of the pathophysiology. Crit Care. 2016;20(1):387. https://doi.org/10.1186/s13054-016-1570-4</Citation></Reference><Reference><Citation>Dieleman JM, van Paassen J, van Dijk D, et al. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database Syst Rev. 2011;5:CD005566. https://doi.org/10.1002/14651858.cd005566.pub3</Citation></Reference><Reference><Citation>Dieleman JM, Nierich AP, Rosseel PM, et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA. 2012;308(17):1761-1767. https://doi.org/10.1001/jama.2012.14144</Citation></Reference><Reference><Citation>Qiang Y, Liang G, Yu L. Human amniotic mesenchymal stem cells alleviate lung injury induced by ischemia and reperfusion after cardiopulmonary bypass in dogs. Lab Investig. 2016;96(5):537-546. https://doi.org/10.1038/labinvest.2016.37</Citation></Reference><Reference><Citation>Bruenger F, Kizner L, Weile J, et al. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs. 2015;38(2):113-116. https://doi.org/10.5301/ijao.5000382</Citation></Reference><Reference><Citation>Yang F, Hou D, Wang J, et al. Vascular complications in adult postcardiotomy cardiogenic shock patients receiving venoarterial extracorporeal membrane oxygenation. Ann Intensive Care. 2018;8(1):72. https://doi.org/10.1186/s13613-018-0417-3</Citation></Reference><Reference><Citation>Bonicolini E, Martucci G, Simons J, et al. Limb ischemia in peripheral veno-arterial extracorporeal membrane oxygenation: a narrative review of incidence, prevention, monitoring, and treatment. Crit Care. 2019;23:266. https://doi.org/10.1186/s13054-019-2541-3</Citation></Reference><Reference><Citation>Girn HRS, Ahilathirunayagam S, Mavor AID, et al. Basic science review: reperfusion syndrome: cellular mechanisms of microvascular dysfunction and potential therapeutic strategies. Vasc Endovasc Surg. 2007;41(4):277-293. https://doi.org/10.1177/1538574407304510</Citation></Reference><Reference><Citation>Choi MS, Sung K, Cho YH. Clinical pearls of venoarterial extracorporeal membrane oxygenation for cardiogenic shock. Korean Circ J. 2019;49(8):657-677. https://doi.org/10.4070/kcj.2019.0188</Citation></Reference><Reference><Citation>Badheka A, Stucker SE, Turek JW, et al. Efficacy of flow monitoring during ECMO. ASAIO J. 2017;63(4):496-500. https://doi.org/10.1097/MAT.0000000000000538</Citation></Reference><Reference><Citation>Doll N, Kiaii B, Borger M, et al. Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock. Ann Thorac Surgery. 2004;77(1):151-157. https://doi.org/10.1016/S0003-4975(03)01329-8</Citation></Reference><Reference><Citation>Kasirajan V, Smedira NG, McCarthy JF, et al. Risk factors for intracranial hemorrhage in adults on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg. 1999;15(4):508-514. https://doi.org/10.1016/S1010-7940(99)00061-5</Citation></Reference><Reference><Citation>Biffi S, di Bella S, Scaravilli V, et al. Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention. Int Antimicrob Agents. 2017;50(1):9-16. https://doi.org/10.1016/j.ijantimicag.2017.02.025</Citation></Reference><Reference><Citation>Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multi-centre randomised controlled trial. Lancet. 2009;372:1351-1363. https://doi.org/10.1016/S0140-6736(09)61069-2</Citation></Reference><Reference><Citation>Ziganshin BA, Elefteriades JA. Deep hypothermic circulatory arrest. Ann Cardiothorac Surg. 2013;2(3):303-315. https://doi.org/10.3978/j.issn.2225-319X.2013.01.05</Citation></Reference><Reference><Citation>Ge M, Pan T, Wang JX, et al. Outcomes of early versus delayed initiation of extracorporeal life support in cardiac surgery. J Cardiothorac Surg. 2019;14(1):129. https://doi.org/10.1186/s13019-019-0950-7</Citation></Reference><Reference><Citation>Madhani SP, Frankowski BJ, Burgreen GW, et al. In vitro and in vivo evaluation of a novel integrated wearable artificial lung. J Heart Lung Transplant. 2017;36(7):806-811. https://doi.org/10.1016/j.healun.2017.02.025</Citation></Reference><Reference><Citation>Cevasco M, Takayama H, Ando M, et al. Left ventricular distension and venting strategies for patients on venoarterial extracorporeal membrane oxygenation. J Thorac Dis. 2019;11(4):1276-1683. https://doi.org/10.21037/jtd.2019.03.29</Citation></Reference><Reference><Citation>Br&#xe9;chot N, Demondion P, Santi F, et al. Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. Eur Heart J Acute Cardiovasc Care. 2018;7(1):62-69. https://doi.org/10.1177/2048872617711169</Citation></Reference><Reference><Citation>Chen K, Hou J, Tang H, et al. Concurrent initiation of intra-aortic balloon pumping with extracorporeal membrane oxygenation reduced in-hospital mortality in postcardiotomy cardiogenic shock. Ann Intensive Care. 2019;9:16. https://doi.org/10.1186/s13613-019-0496-9</Citation></Reference><Reference><Citation>Donker DW, Brodie D, Henriques JS, Broom&#xe9; M. Left ventricular unloading during veno-arterial ECMO: a simulation study. ASAIO J. 2019;65(1):11-20. https://doi.org/10.1097/MAT.0000000000000755</Citation></Reference><Reference><Citation>Moazzami K, Dolmatova E, Cocke TP, et al. Left ventricular mechanical support with the Impella during extracorporeal membrane oxygenation. J Tehran Heart Cent. 2017;12(1):11-14.</Citation></Reference><Reference><Citation>Bain JC, Turner DA, Rehder KJ, et al. Economic outcomes of extracorporeal membrane oxygenation with and without ambulation as a bridge to lung transplantation. Respir Care. 2016;61(1):1-7. https://doi.org/10.4187/respcare.03729</Citation></Reference><Reference><Citation>Scottish Government Health Directorates. The Provision of Non-H1N1 Adult Respiratory Extra Corporeal Membrane Oxygenation (ECMO) in the Medium and Longer Term for Scotland. ECMO Expert Group Report and Recommendations. 2009.</Citation></Reference><Reference><Citation>Westaby S, Taggart D. Inappropriate restrictions on life saving technology. Heart. 2012;98(15):1117-1119. https://doi.org/10.1136/heartjnl-2011-301365</Citation></Reference><Reference><Citation>Sedgwick C, Gati S, Sharma S. Extra corporeal membrane oxygenation (ECMO) devices in all heart attack centres in the UK? Br J Cardiol. 2012;19:102-103. https://doi.org/10.5837/bjc.2012.021</Citation></Reference><Reference><Citation>Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection is Suspected. 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 20 March 2020.</Citation></Reference><Reference><Citation>MacLaren G, Fisher D, Brodie D. Preparing for the most critically Ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA. 2020;323:1245-1246. https://doi.org/10.1001/jama.2020.2342</Citation></Reference><Reference><Citation>Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020;8:E24. https://doi.org/10.1016/S2213-2600(20)30119-3</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40542431</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>The effects of extracorporeal blood purification (oXiris&#xae;) in patients with cardiogenic shock who require VA-ECMO (CLEAN ECMO): a prospective, open-label, randomized controlled pilot study.</ArticleTitle><Pagination><StartPage>255</StartPage><MedlinePgn>255</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">255</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-025-05495-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A systemic inflammatory response can contribute to poor outcomes in an advanced stage of cardiogenic shock (CS). We investigated the efficacy of extracorporeal endotoxin and cytokine adsorption using oXiris in patients with CS undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective, single-center, randomized, open-label pilot trial, 40 patients with CS who were undergoing VA-ECMO were randomly assigned to receive either oXiris for 24&#xa0;h (n&#x2009;=&#x2009;20) or usual care (n&#x2009;=&#x2009;20). The primary endpoint was endotoxin levels at 48&#xa0;h. Secondary endpoints included changes in inflammatory cytokines, vasoactive-inotropic score (VIS), ECMO weaning success, and in-hospital and 30-day mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median endotoxin levels at 48&#xa0;h were 0.5 (IQR 0.4-1.0) in the oXiris group and 0.4 (IQR 0.2-0.5) in the control group, with no significant difference between them (P&#x2009;=&#x2009;0.097). The oXiris group showed significant temporal reductions in GDF-15 and IL-6 levels, with IL-6 revealing significant reductions from baseline to 24&#xa0;h (P&#x2009;=&#x2009;0.020) and from baseline to 7 days (P&#x2009;=&#x2009;0.003). VIS decreased significantly from baseline to 48&#xa0;h (-13.63, 95% CI: -20.90 - -6.34, P&#x2009;&lt;&#x2009;0.001) and 7 days (-12.19, 95% CI: -21.0 - -3.31, P&#x2009;=&#x2009;0.007) in the oXiris group, but intergroup differences were insignificant. ECMO weaning success, duration of ECMO support, and mortality rates were similar between the groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this pilot study conducted on CS patients requiring VA-ECMO, oXiris treatment did not significantly reduce endotoxin levels or improve patient centered clinical outcomes.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT05642273, registered 8 December 2022.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Ryoung-Eun</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ki Hong</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyungho</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Junseok</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Hye Ryoun</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Chi Ryang</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Yang Hyun</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Taek Kyu</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joo Myung</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Young Bin</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Joo-Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Seung-Hyuk</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwon</LastName><ForeName>Hyeon-Cheol</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jeong Hoon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. jhysmc@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. jhysmc@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05642273</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>2022-01</GrantID><Agency>Korean Society of Interventional Cardiology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004731">Endotoxins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004731" MajorTopicYN="N">Endotoxins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Endotoxin</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Inflammatory marker</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The research was conducted according to the Declaration of Helsinki, and the study protocol was approved by the institutional review board of Samsung Medical Center (No. 2022-09-082) and registered at ClinicalTrials.gov (NCT05642273, registered 8 December 2022). All participants or their representatives provided written informed consent to participate. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>21</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>20</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40542431</ArticleId><ArticleId IdType="pmc">PMC12181899</ArticleId><ArticleId IdType="doi">10.1186/s13054-025-05495-4</ArticleId><ArticleId IdType="pii">10.1186/s13054-025-05495-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: A scientific statement from the American heart association. Circulation. 2017;136(16):e232&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rob D, Belohlavek J. The mechanical support of cardiogenic shock. Curr Opin Crit Care. 2021;27(4):440&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33929344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005;165(14):1643&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16043684</ArticleId></ArticleIdList></Reference><Reference><Citation>Adrie C, Adib-Conquy M, Laurent I, Monchi M, Vinsonneau C, Fitting C, et al. Successful cardiopulmonary resuscitation after cardiac arrest as a sepsis-like syndrome. Circulation. 2002;106(5):562&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12147537</ArticleId></ArticleIdList></Reference><Reference><Citation>Geppert A, Dorninger A, Delle-Karth G, Zorn G, Heinz G, Huber K. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2006;34(8):2035&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16775569</ArticleId></ArticleIdList></Reference><Reference><Citation>Krack A, Sharma R, Figulla HR, Anker SD. The importance of the Gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005;26(22):2368&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980032</ArticleId></ArticleIdList></Reference><Reference><Citation>Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321(5):280&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2664516</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care. 2016;20(1):387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5125043</ArticleId><ArticleId IdType="pubmed">27890016</ArticleId></ArticleIdList></Reference><Reference><Citation>Monard C, Rimmele T, Ronco C. Extracorporeal blood purification therapies for Sepsis. Blood Purif. 2019;47(Suppl 3):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">30974444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesbekov T, Nurmykhametova Z, Kaliyev R, Kuanyshbek A, Faizov L, Bekishev B, et al. Hemadsorption in patients requiring V-A ECMO support: comparison of cytosorb versus Jafron HA330. Artif Organs. 2023;47(4):721&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">36398369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovric D, Pasalic M, Krizanac S, Kovacic K, Skoric B, Jurin H, et al. The addition of cytosorb in patients on VA-ECMO improves urinary output and ICU survival. Ther Apher Dial. 2024;28(1):103&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">37697687</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W, Smits L, Kotz D, Bud&#xe9; L, Spigt M, Serroyen J, et al. A simple formula for the calculation of sample size in pilot studies. J Clin Epidemiol. 2015;68(11):1375&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26146089</ArticleId></ArticleIdList></Reference><Reference><Citation>Na SJ, Choi HJ, Chung CR, Cho YH, Jang HR, Suh GY, et al. Using additional pressure control lines when connecting a continuous renal replacement therapy device to an extracorporeal membrane oxygenation circuit. BMC Nephrol. 2018;19(1):369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6299989</ArticleId><ArticleId IdType="pubmed">30567509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong D, Choi KH, Cho YH, Cho SH, Park SJ, Kim D, et al. Multidisciplinary team approach in acute myocardial infarction patients undergoing veno-arterial extracorporeal membrane oxygenation. Ann Intensive Care. 2020;10(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296889</ArticleId><ArticleId IdType="pubmed">32548658</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W, Smits L, Kotz D, Bude L, Spigt M, Serroyen J, et al. A simple formula for the calculation of sample size in pilot studies. J Clin Epidemiol. 2015;68(11):1375&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26146089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez P, Villarreal E, Gordon M, Gomez MD, de Hevia L, Vacacela K, et al. Septic participation in cardiogenic shock: exposure to bacterial endotoxin. Shock. 2017;47(5):588&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">27861258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen M, Gautier T, Masson D, Bouhemad B, Guinot PG. Endotoxemia in acute heart failure and cardiogenic shock: evidence, mechanisms and therapeutic options. J Clin Med. 2023;12(7):2579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10094881</ArticleId><ArticleId IdType="pubmed">37048662</ArticleId></ArticleIdList></Reference><Reference><Citation>Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169(3):823&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2189288</ArticleId><ArticleId IdType="pubmed">2647895</ArticleId></ArticleIdList></Reference><Reference><Citation>Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, et al. Newly designed CRRT membranes for sepsis and SIRS&#x2013;a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013;59(2):99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">23438770</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman ME, Hansson F, Vincent JL, Bodelsson M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double-blind study. PLoS ONE. 2019;14(8):e0220444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675097</ArticleId><ArticleId IdType="pubmed">31369593</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan M, Wang H, Tang X, Zhao Y, Wang F, Zhang L, et al. Continuous renal replacement therapy with adsorbing filter oXiris in acute kidney injury with septic shock: A retrospective observational study. Front Med (Lausanne). 2022;9:789623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9024201</ArticleId><ArticleId IdType="pubmed">35463014</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-Day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233793</ArticleId><ArticleId IdType="pubmed">30304428</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280819</ArticleId><ArticleId IdType="pubmed">30470853</ArticleId></ArticleIdList></Reference><Reference><Citation>Prondzinsky R, Unverzagt S, Lemm H, Wegener N, Heinroth K, Buerke U, et al. Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-gamma, TNF-alpha, MIP-1beta, G-CSF, and MCP-1beta. Med Klin Intensivmed Notfmed. 2012;107(6):476&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">22810435</ArticleId></ArticleIdList></Reference><Reference><Citation>Geppert A, Steiner A, Zorn G, Delle-Karth G, Koreny M, Haumer M, et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med. 2002;30(9):1987&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">12352031</ArticleId></ArticleIdList></Reference><Reference><Citation>Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R, et al. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol. 2008;97(5):298&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">18491171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HS. Cardiogenic shock: failure of oxygen delivery and oxygen utilization. Clin Cardiol. 2016;39(8):477&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490770</ArticleId><ArticleId IdType="pubmed">27509355</ArticleId></ArticleIdList></Reference><Reference><Citation>Prondzinsky R, Unverzagt S, Lemm H, Wegener NA, Schlitt A, Heinroth KM, et al. Interleukin-6, -7, -8 and &#x2013;&#x2009;10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol. 2012;101(5):375&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">22212516</ArticleId></ArticleIdList></Reference><Reference><Citation>Monard C, Bianchi N, Poli E, Altarelli M, Debonneville A, Oddo M, et al. Cytokine hemoadsorption with CytoSorb((R)) in post-cardiac arrest syndrome, a pilot randomized controlled trial. Crit Care. 2023;27(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9869834</ArticleId><ArticleId IdType="pubmed">36691082</ArticleId></ArticleIdList></Reference><Reference><Citation>Diab M, Lehmann T, Bothe W, Akhyari P, Platzer S, Wendt D, et al. Cytokine hemoadsorption during cardiac surgery versus standard surgical care for infective endocarditis (REMOVE): results from a multicenter randomized controlled trial. Circulation. 2022;145(13):959&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">35213213</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker S, Lang H, Vollmer Barbosa C, Tian Z, Melk A, Schmidt BMW. Efficacy of CytoSorb(R): a systematic review and meta-analysis. Crit Care. 2023;27(1):215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230475</ArticleId><ArticleId IdType="pubmed">37259160</ArticleId></ArticleIdList></Reference><Reference><Citation>Honore PM, Matson JR. Extracorporeal removal for sepsis: acting at the tissue level&#x2013;the beginning of a new era for this treatment modality in septic shock. Crit Care Med. 2004;32(3):896&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15090989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29376560</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.</ArticleTitle><Pagination><StartPage>CD009669</StartPage><MedlinePgn>CD009669</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD009669</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD009669.pub3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) as complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery are life-threatening conditions. While there is a broad body of evidence for the treatment of people with acute coronary syndrome under stable haemodynamic conditions, the treatment strategies for people who become haemodynamically unstable or develop CS remain less clear. We have therefore summarised here the evidence on the treatment of people with CS or LCOS with different inotropic agents and vasodilative drugs. This is the first update of a Cochrane review originally published in 2014.</AbstractText><AbstractText Label="OBJECTIVES">To assess efficacy and safety of cardiac care with positive inotropic agents and vasodilator strategies in people with CS or LCOS due to AMI, HF or cardiac surgery.</AbstractText><AbstractText Label="SEARCH METHODS">We searched CENTRAL, MEDLINE, Embase and CPCI-S Web of Science in June 2017. We also searched four registers of ongoing trials and scanned reference lists and contacted experts in the field to obtain further information. No language restrictions were applied.</AbstractText><AbstractText Label="SELECTION CRITERIA">Randomised controlled trials in people with myocardial infarction, heart failure or cardiac surgery complicated by cardiogenic shock or LCOS.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS">We used standard methodological procedures expected by Cochrane.</AbstractText><AbstractText Label="MAIN RESULTS">We identified 13 eligible studies with 2001 participants (mean or median age range 58 to 73 years) and two ongoing studies. We categorised studies into eight comparisons, all against cardiac care and additional other active drugs or placebo. These comparisons investigated the efficacy of levosimendan versus dobutamine, enoximone or placebo, epinephrine versus norepinephrine-dobutamine, amrinone versus dobutamine, dopexamine versus dopamine, enoximone versus dopamine and nitric oxide versus placebo.All trials were published in peer-reviewed journals, and analysis was done by the intention-to-treat (ITT) principle. Twelve of 13 trials were small with few included participants. Acknowledgement of funding by the pharmaceutical industry or missing conflict of interest statements emerged in five of 13 trials. In general, confidence in the results of analysed studies was reduced due to serious study limitations, very serious imprecision or indirectness. Domains of concern, which show a high risk of more than 50%, include performance bias (blinding of participants and personnel) and bias affecting the quality of evidence on adverse events.Levosimendan may reduce short-term mortality compared to a therapy with dobutamine (RR 0.60, 95% CI 0.37 to 0.95; 6 studies; 1776 participants; low-quality evidence; NNT: 16 (patients with moderate risk), NNT: 5 (patients with CS)). This initial short-term survival benefit with levosimendan vs. dobutamine is not confirmed on long-term follow up. There is uncertainty (due to lack of statistical power) as to the effect of levosimendan compared to therapy with placebo (RR 0.48, 95% CI 0.12 to 1.94; 2 studies; 55 participants, very low-quality evidence) or enoximone (RR 0.50, 95% CI 0.22 to 1.14; 1 study; 32 participants, very low-quality evidence).All comparisons comparing other positive inotropic, inodilative or vasodilative drugs presented uncertainty on their effect on short-term mortality with very low-quality evidence and based on only one RCT. These single studies compared epinephrine with norepinephrine-dobutamine (RR 1.25, 95% CI 0.41 to 3.77; 30 participants), amrinone with dobutamine (RR 0.33, 95% CI 0.04 to 2.85; 30 participants), dopexamine with dopamine (no in-hospital deaths from 70 participants), enoximone with dobutamine (two deaths from 40 participants) and nitric oxide with placebo (one death from three participants).</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS">Apart from low quality of evidence data suggesting a short-term mortality benefit of levosimendan compared with dobutamine, at present there are no robust and convincing data to support a distinct inotropic or vasodilator drug-based therapy as a superior solution to reduce mortality in haemodynamically unstable people with cardiogenic shock or LCOS.Considering the limited evidence derived from the present data due to a generally high risk of bias and imprecision, it should be emphasised that there remains a great need for large, well-designed randomised trials on this topic to close the gap between daily practice in critical care medicine and the available evidence. It seems to be useful to apply the concept of 'early goal-directed therapy' in cardiogenic shock and LCOS with early haemodynamic stabilisation within predefined timelines. Future clinical trials should therefore investigate whether such a therapeutic concept would influence survival rates much more than looking for the 'best' drug for haemodynamic support.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schumann</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Surgical Intensive Care, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Eva C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Strobl</LastName><ForeName>Hellen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Prondzinsky</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Weiche</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Werdan</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Frantz</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Unverzagt</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000150</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006835">Hydrazones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical><Chemical><RegistryNumber>3S12J47372</RegistryNumber><NameOfSubstance UI="D004280">Dobutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>C7Z4ITI7L7</RegistryNumber><NameOfSubstance UI="D017335">Enoximone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2014 Jan 02;(1):CD009669. doi: 10.1002/14651858.CD009669.pub2.</RefSource><PMID Version="1">24385385</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Heart. 2019 Feb;105(3):178-179. doi: 10.1136/heartjnl-2018-313854.</RefSource><PMID Version="1">30228252</PMID></CommentsCorrections><CommentsCorrections RefType="UpdateIn"><RefSource>Cochrane Database Syst Rev. 2020 Nov 5;11:CD009669. doi: 10.1002/14651858.CD009669.pub4.</RefSource><PMID Version="1">33152122</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002303" MajorTopicYN="N">Cardiac Output, Low</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004280" MajorTopicYN="N">Dobutamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017335" MajorTopicYN="N">Enoximone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006835" MajorTopicYN="N">Hydrazones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Julia Schumann</b>: no relevant conflicts of interests&#x2028;
<b>Eva Henrich</b>: no relevant conflicts of interests&#x2028;
<b>Hellen Strobl</b>: no relevant conflicts of interests&#x2028;
<b>Roland Prondzinsky</b>: no relevant conflicts of interests&#x2028;
<b>Sophie Weiche</b>: no relevant conflicts of interests&#x2028;
<b>Holger Thiele</b> has received research funding (Maquet Cardiovascular, Teleflex Medical, Terumo, Lilly Germany, The Medicines Company), honoraria for advisory board activities (Lilly, Maquet Cardiovascular), honoraria for lectures (AstraZeneca, Lilly, Daiichi Sankyo, The Medicines Company, Terumo, Maquet Cardiovascular, Bayer, Boehringer Ingelheim).&#x2028;
<b>Karl Werdan</b> has received honoraria for lectures (Abbott, Biogen, Biotest, Boston scientific, Brahms, Datascope, Maquet, Novartis, Roche, Servier), honoraria for advisory board activities (Abbott, Baxter, Biotest, Datascope, Servier), took part in clinical trials (Arrows, Datascope, MSD, Novartis, Servier) and has received research funding from Biotest, Bayer, Datascope, Novartis Roche, Servier.&#x2028;
<b>Stefan Frantz</b> has received research funding (Charite Berlin, Covance Inc 210 Carnegie Center Princeton, Janssen&#x2010;Cilag GmbH, Mapi Life Sciences (Germany) GmbH, Medtronic Bakken Research Center, NOVARTIS PHARMA GMBH, Bayer, Boehringer, BMS, Astra), received honoraria for lectures (AMGEN Europe, AstraZeneca, Assistenz, Bayer Vital, Boehringer Ingelheim, Bristol&#x2010;Meyers Squibb GmbH, Daiichi Sankyo, Messe D&#xfc;sseldorf, MSD, Novartis, ORGASYMPOSIA, Pfizer, Servier) and honoraria for advisory board activities (Bayer, Boehringer, MSD, Pfizer).&#x2028;
<b>Susanne Unverzagt</b>: no relevant conflicts of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29376560</ArticleId><ArticleId IdType="pmc">PMC6491099</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD009669.pub3</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Adamopoulos 2006 {published data only}</Title><Reference><Citation>Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology 2006;98:102&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16784930</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Alvarez 2006 {published data only}</Title><Reference><Citation>Alvarez J, Baluja A, Selas S, Otero P, Rial M, Veiras S, et al. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study. Anaesthesia &amp; Intensive Care 2013;41(6):719&#x2010;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">24180712</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez J, Bouzada M, Fernandez AL, Caruezo V, Taboada M, Rodriguez J, et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia 2006;59(4):338&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709386</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Atallah 1990 {published data only}</Title><Reference><Citation>Atallah G, George M, Lehot JJ, Bastien O, Bejuit R, Durand PG, et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double&#x2010;blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux 1990;83(3):63&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2147837</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Baldassarre 2008 {published and unpublished data}</Title><Reference><Citation>Baldassare 2008. The effects of nitric oxide for inhalation in right ventricular infarction patients. clinicaltrials.gov/ct2/show/NCT00782652?term=NCT00782652 2008 (accessed 22 May 2012).</Citation></Reference></ReferenceList><ReferenceList><Title>Dupuis 1992 {published data only}</Title><Reference><Citation>Dupuis JY, Bondy R, Cattran C, Nathan HJ, Wynands JE. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. Journal of Cardiothoracic and Vascular Anesthesia 1992;6(5):542&#x2010;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">1421065</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Follath(LIDO) 2002 {published data only}</Title><Reference><Citation>Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low&#x2010;output heart failure (the LIDO study): a randomised double&#x2010;blind trial. Lancet 2002;360:196&#x2010;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">12133653</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fuhrmann 2008 {published data only}</Title><Reference><Citation>Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine 2008;36(8):2257&#x2010;66. [DOI: 10.1097/CCM.0b013e3181809846]</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181809846</ArticleId><ArticleId IdType="pubmed">18664782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Garc&#x3af;a&#x2010;Gonz&#xe1;lez 2006 {published data only}</Title><Reference><Citation>Dominguez&#x2010;Rodriguez A, Samimi&#x2010;Fard S, Garcia&#x2010;Gonzalez MJ, Abreu&#x2010;Gonzalez P. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. International Journal of Cardiology 2008;128:214&#x2010;7. [DOI: 10.1016/j.ijcard.2007.05.018]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2007.05.018</ArticleId><ArticleId IdType="pubmed">17643535</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a&#x2010;Gonz&#xe1;lez MJ, Dominguez&#x2010;Rodr&#xed;guez A, Ferrer&#x2010;Hita JJ, Abreu&#x2010;Gonz&#xe1;lez P, Mu&#x148;oz MB. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure 2006;8:723&#x2010;8. [DOI: 10.1016/j.ejheart.2006.01.007]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejheart.2006.01.007</ArticleId><ArticleId IdType="pubmed">16492404</ArticleId></ArticleIdList></Reference><Reference><Citation>Samini&#x2010;Fard S, Garc&#xed;a&#x2010;Gonz&#xe1;lez MJ, Dom&#xed;nguez&#x2010;Rodr&#xed;guez A, Abreu&#x2010;Gonz&#xe1;lez P. Effects of levosimendan versus dobutamine on long&#x2010;term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology 2008;127:284&#x2010;7. [DOI: 10.1016/j.ijcard.2007.04.143]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2007.04.143</ArticleId><ArticleId IdType="pubmed">17643519</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Husebye 2013 {published and unpublished data}</Title><Reference><Citation>Husebye T, Eritsland J, Muller C, Sandvik L, Arnesen H, Seljeflot I, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention&#x2010;treated acute ST&#x2010;elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo&#x2010;controlled study. European Journal of Heart Failure 2013;15(5):565&#x2010;72. [DOI: 10.1093/eurjhf/hfs215]</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfs215</ArticleId><ArticleId IdType="pubmed">23288914</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levin 2008 {published data only}</Title><Reference><Citation>Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espa&#x148;ola de Cardiolog&#xed;a 2008;61(5):471&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18462650</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levy 2011 {published data only}</Title><Reference><Citation>Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepinephrine&#x2010;dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine 2011;39(3):450&#x2010;5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181ffe0eb</ArticleId><ArticleId IdType="pubmed">21037469</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mebazaa (SURVIVE) 2007 {published data only}</Title><Reference><Citation>Mebazaa A, Nieminen MS, Packer M, Cohen&#x2010;Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. JAMA 2007;297(17):1883&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17473298</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rosseel 1997 {published data only}</Title><Reference><Citation>Rosseel PM, Santman FW, Bouter H, Dott CS. Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?. Intensive Care Medicine 1997;23:962&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9347368</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Affonti 2013 {published data only}</Title><Reference><Citation>Affronti A, Bella I, Carino D, Ragni T. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO Journal 2013;59(6):554&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24172260</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Al&#x2010;Shawaf 2006 {published data only}</Title><Reference><Citation>Al&#x2010;Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R. Levosimendan or milrinone in the type 2 diabetes patient with low ejection fraction undergoing elective coronary artery surgery. Journal of Cardiothoracic and Vascular Anesthesia 2006;20:353&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16750735</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Andriange 1971 {published data only}</Title><Reference><Citation>Andriange M, Calay G, Gach J, Lisin N. Shock states during myocardial infarct: treatment of cardiogenic shock with dopamine. Acta Clinica Belgica 1971;26(5):249&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">5161426</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Aronski 1978 {published data only}</Title><Reference><Citation>Aro&#x144;ski A, K&#xfc;bler A, Sliwinski M, Paszkowska A. The use of dopamin in shock and heart failure. Anaesthesist 1978 Apr;27(4):183&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">655365</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Avanzini 2002 {published data only}</Title><Reference><Citation>Avanzini F, Ferrario G, Santoro L, Peci P, Giani P, Santoro E, et al. Risks and benefits of early treatment of acute myocardial infarction with an angiotensin&#x2010;converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI&#x2010;3 database. American Heart Journal 2002;144(6):1018&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">12486426</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Barisin 2004 {published data only}</Title><Reference><Citation>Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D. Levosimendan in off&#x2010;pump coronary artery bypass: a four&#x2010;times masked controlled study. Journal of Cardiovascular Pharmacology 2004;44:703&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15550791</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Beller 1995 {published data only}</Title><Reference><Citation>Beller B, Bulle T, Bourge RC, Colfer H, Fowles RE, Giles TD, et al. Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group. Journal of Clinical Pharmacology 1995;35(7):673&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">7560247</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Belskii 1987 {published data only}</Title><Reference><Citation>Belskii NE, Pilipenko VA, Roshchin SI, Shira AI, Gilmar IS. Use of nitroglycerin in the treatment of acute heart failure and cardiogenic shock in patients with myocardial infarction. Cor et Vasa 1987;29(2):89&#x2010;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">3109805</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berger 2007 {published data only}</Title><Reference><Citation>Berger R, Moertl D, Huelsmann M, Bojic A, Ahmadi R, Heissenberger I, et al. Levosimendan and prostaglandin E1 for uptitration of beta&#x2010;blockade in patients with refractory, advanced chronic heart failure. European Journal of Heart Failure 2007;9(2):202&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859992</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bussmann 1983 {published data only}</Title><Reference><Citation>Bussmann WD. Nitroglycerin in the treatment of acute myocardial infarct. Clinica Terapeutica 1983;105(5):371&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">6409496</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Butterworth 1993 {published data only}</Title><Reference><Citation>Butterworth JF, Royster RL, Prielipp RC, Lawless ST, Wallenhaupt SL. Amrinone in cardiac surgical patients with left&#x2010;ventricular dysfunction. A prospective, randomized placebo&#x2010;controlled trial. Chest 1993;104(6):1660&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8252937</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Caimmi 2011 {published data only}</Title><Reference><Citation>Caimmi PP, Kapetanakis EI, Beggino C, Molinari C, Giustini G, Crosio E, et al. Management of acute cardiac failure by intracoronary administration of levosimendan. Journal of Cardiovascular Pharmacology 2011;58(3):246&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">21654504</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Canella 1981 {published data only}</Title><Reference><Citation>Coma Canella I, Lopez&#x2010;Sendon J. Hemodynamic effect of dobutamine in cardiogenic shock. Revista Espanola de Cardiologia 1981;34(6):483&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7339730</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Carmona 2010 {published data only}</Title><Reference><Citation>Carmona MJC, Martins LM, Vane MF, Longo BA, Paredes LS, S&#xe1; Malbouisson LM. Comparison of the effects of dobutamine and milrinone on hemodynamic parameters and oxygen supply in patients undergoing cardiac surgery with low cardiac output after anesthetic induction. Revista Brasileira de Anestesiologia 2010;60(3):237&#x2010;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">20682156</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Clark 1983 {published data only}</Title><Reference><Citation>Clark RE, Magovern GJ, Christlieb IY, Boe S. Nifedipine cardioplegia experience: results of a 3&#x2010;year cooperative clinical study. Annals of Thoracic Surgery 1983;36(6):654&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">6360055</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cotter 2003 {published data only}</Title><Reference><Citation>Cotter G, Kaluski E, Milo O, Blatt A, Salah A, Hendler A, et al. LINCS: L&#x2010;NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. European Heart Journal 2003;24:1287&#x2010;95. [DOI: 10.1016/S0195-668X(03)00193-3]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0195-668X(03)00193-3</ArticleId><ArticleId IdType="pubmed">12871685</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cuffe 2002 {published data only}</Title><Reference><Citation>Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, et al. Short&#x2010;term intravenous milrinone for acute exacerbation of chronic heart failure &#x2010; a randomized controlled trial. JAMA 2002;287(12):1541&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11911756</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>De Hert 2007 {published data only}</Title><Reference><Citation>Hert SG, Lorsomradee S, Cromheecke S, Linden P. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia 2007;104(6):1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">17377079</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Delle Karth 2003 {published data only}</Title><Reference><Citation>Delle Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, et al. Haemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiologia Scandinavica 2003;47:1251&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14616323</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>De Monte 1986 {published data only}</Title><Reference><Citation>Monte A, Nardi G, Giordano F, Bertolissi M. Comparison between dopamine and dobutamine in the treatment of low cardiac output syndrome. Minerva Cardioangiologica 1986;34:781&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">3574705</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dhainaut 1990 {published data only}</Title><Reference><Citation>Dhainaut JF, Ghannad E, Villemant D, Brunet F, Devaux JY, Schremmer B, et al. Role of tricuspid regurgitation and left ventricular damage in the treatment of right ventricular infarction&#x2010;induced low cardiac output syndrome. American Journal of Cardiology 1990;66(3):289&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">2368673</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dominguez&#x2010;Rodriguez 2007 {published data only}</Title><Reference><Citation>Dominguez&#x2010;Rodriguez A, Abreu&#x2010;Gonzalez P, Garcia&#x2010;Gonzalez MJ, Kaski JC, Reiter RJ, Jimenez&#x2010;Sosa A. A unicenter, randomized, double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled study of melatonin as an adjunct in patients with acute myocardial infarction undergoing primary angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemporary Clinical Trials 2007;28(4):532&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17123867</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Duygu 2008 {published data only}</Title><Reference><Citation>Duygu H, Ozerkan F, Zoghi M, Nalbantgil S, Yildiz A, Akilli A, et al. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. International Journal of Clinical Practice 2008;62(2):228&#x2010;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17949428</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Erb 2014 {published data only}</Title><Reference><Citation>Erb J, Beutlhauser T, Feldheiser A, Schuster B, Treskatsch S, Grubitzsch H, et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research 2014;42(3):750&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">24781725</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Estanove 1988 {published data only}</Title><Reference><Citation>Estanove S, Lehot JJ, Bastien O, Demorti&#xe8;re P, Bompard D, Clerc J, et al. Clinical and hemodynamic multicenter study of the effect of intravenous amrinone in the treatment of low cardiac output after valvular replacement. Annales de Cardiologie et d Ang&#xe9;iologie 1988;37(7):393&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">3064697</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Felker 2003 {published data only}</Title><Reference><Citation>Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, et al. Heart failure etiology and response to milrinone in decompensated heart failure &#x2010; results from the OPTIME&#x2010;CHF study. Journal of the American College of Cardiology 2003;41(6):997&#x2010;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">12651048</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Feneck 2001 {published data only}</Title><Reference><Citation>Feneck RO, Sherry KM, Withington PS, Oduro&#x2010;Dominah A, European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 2001;3:306&#x2010;15. [DOI: 10.1053/jcan.2001.23274]</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jcan.2001.23274</ArticleId><ArticleId IdType="pubmed">11426360</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ferrario 1994 {published data only}</Title><Reference><Citation>Ferrario M, Poli A, Previtali M, Lanzarini L, Fetiveau R, Diotallevi P, et al. Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarction. American Journal of Cardiology 1994;74:329&#x2010;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8059693</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fowler 1980 {published data only}</Title><Reference><Citation>Fowler MB, Timmis AD, Chamberlain DA. Synergistic effects of a combined salbutamol&#x2010;nitroprusside regimen in acute myocardial infarction and severe left ventricular failure. British Medical Journal 1980;280(6212):435&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1600444</ArticleId><ArticleId IdType="pubmed">7370524</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Friedle 1992 {published data only}</Title><Reference><Citation>Friedel N, Wenzel R, Matheis G, Hetzer R. The use of dopexamine after cardiac surgery: acute and long&#x2010;term effects in patients with impaired cardiac function. Thoracic and Cardiovascular Surgeon 1992;40(6):378&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">1363257</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Galinier 1990 {published data only}</Title><Reference><Citation>Galinier M, Rochiccioli JP, Edouard P, Fourcade J, Massabuau P, Puel J, et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Archives des Maladies du Coeur et des Vaisseaux 1990;83:27&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">2147831</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Genth&#x2010;Zotz 2000 {published data only}</Title><Reference><Citation>Genth&#x2010;Zotz S, Zotz RJ, Sigmund M, Hanrath P, Hartmann D, Bohm M, et al. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. European Journal of Heart Failure 2000;2(2):175&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">10856731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>George 1989 {published data only}</Title><Reference><Citation>George M, Lehot JJ, Bastien O, Durand PG, Estanove S. Comparison of cardiovascular effects of dobutamine and enoximone in treatment of low cardiac output syndrome after valvular surgery&#x2010;&#x2010;preliminary results. Journal of Cardiothoracic Anesthesia 1989;3(12):5 Suppl 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">2535301</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gray 1981 {published data only}</Title><Reference><Citation>Gray R, Shah PK, Singh B, Conklin C, Matloff JM. Low cardiac output states after open heart surgery. Comparative hemodynamic effects of dobutamine, dopamine, and norepinephrine plus phentolamine. Chest 1981;80(1):16&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">7249704</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gunnicker 1995 {published data only}</Title><Reference><Citation>Gunnicker M, Brinkmann M, Donovan TJ, Freund U, Schieffer M, Reidemeister JC. The efficacy of amrinone or adrenaline on low cardiac&#x2010;output following cardiopulmonary bypass in patients with coronary&#x2010;artery disease undergoing preoperative beta&#x2010;blockade. The Thoracic and Cardiovascular Surgeon 1995;43:153&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7570567</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hobbs 1998 {published data only}</Title><Reference><Citation>Hobbs RE. Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure?. Cleveland Clinic Journal of Medicine 1998;65(10):539&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9830787</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hoffman 2003 {published data only}</Title><Reference><Citation>Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang A, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107(7):996&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">12600913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jondeau 1994 {published data only}</Title><Reference><Citation>Jondeau G, Dubourg O, Delorme G, Arnal JF, Chikli F, Kamoun L, et al. Oral enoximone as a substitute for intravenous catecholamine support in end&#x2010;stage congestive heart failure. European Heart Journal 1994;15(2):242&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8005127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kaplan 1980 {published data only}</Title><Reference><Citation>Kaplan JA, Finlayson DC, Woodward S. Vasodilator therapy after cardiac surgery: a review of the efficacy and toxicity of nitroglycerin and nitroprusside. Canadian Anaesthetists' Society Journal 1980;27(3):254&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">6769567</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kieler&#x2010;Jensen 1995 {published data only}</Title><Reference><Citation>Kieler&#x2010;Jensen N, Houltz E, Ricksten SE. A comparison of prostacyclin and sodium nitroprusside for the treatment of heart failure after cardiac surgery. Journal of Cardiothoracic &amp; Vascular Anesthesia 1995;9(6):641&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8664453</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kikura 1997 {published data only}</Title><Reference><Citation>Kikura M, Levy JH, Michelsen LG, Shanewise JS, Bailey JM, Sadel SM, et al. The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. Anesthesia and Analgesia 1997;85:16&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212116</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kikura 2002 {published data only}</Title><Reference><Citation>Kikura M, Sato S. The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia 2002;94:22&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11772795</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kones 1972 {published data only}</Title><Reference><Citation>Kones RJ. Glucagon in the therapy of low cardiac output syndromes. Revista Medica de Chile 1972;100(9):1116&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">4644078</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lancon 1990 {published data only}</Title><Reference><Citation>Lancon JP, Caillard B, Volot F, Obadia JF, Bock F. Enoximone vs. dobutamine in the treatment of low cardiac output syndrome following cardiac surgery. Annales Francaises d&#x2019;Anesthesie et de Reanimation 1990;9:289&#x2010;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2142589</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Landoni 2017 {published data only}</Title><Reference><Citation>Landoni G, Lomivorotov VV, Alvaro R, Lobreglio R, Pisano A, Guarracino F, et al. Levosimendan for hemodynamic support after cardiac surgery. The New England Journal of Medicine 2017;376(21):2021&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28320259</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lanfear 2009 {published data only}</Title><Reference><Citation>Lanfear DE, Hasan R, Gupta RC, Williams C, Czerska B, Tita C, et al. Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. Journal of Translational Medicine 2009;7:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724498</ArticleId><ArticleId IdType="pubmed">19640280</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lechner 2012 {published data only}</Title><Reference><Citation>Lechner E, Hofer A, Leitner&#x2010;Peneder G, Freynschlag R, Mair R, Weinzettel R, et al. Levosimendan versus milrinone in neonates and infants after corrective open&#x2010;heart surgery: a pilot study. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2012;13(5):542&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22622649</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levin 2012 {published data only}</Title><Reference><Citation>Levin R, Degrange M, Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high&#x2010;risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology 2012;17(3):125&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628425</ArticleId><ArticleId IdType="pubmed">23620700</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lilleberg 1998 {published data only}</Title><Reference><Citation>Lilleberg J, Nieminem MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after CABG. European Heart Journal 1998;19:660&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9597417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lima 2010 {published data only}</Title><Reference><Citation>Lima MV, Cardoso JN, Ochiai ME, Grativvol KM, Grativvol PS, Brancalhao EC, et al. Is it necessary to suspend betablockers in decompensated heart failure with low output?. Arquivos Brasileiros de Cardiologia 2010;95(4):530&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20721517</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Loeb 1971 {published data only}</Title><Reference><Citation>Loeb HS, Winslow EB, Rahimtoola SH, Rosen KM, Gunnar RM. Acute hemodynamic effects of dopamine in patients with shock. Circulation 1971;44:163&#x2010;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">4935052</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lopez 1997 {published data only}</Title><Reference><Citation>Lopez SL, Leighton JO, Walther FJ. Supranormal cardiac output in the dopamine&#x2010; and dobutamine&#x2010;dependent preterm infant. Pediatric Cardiology 1997;18(4):292&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9175527</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lvoff 1972 {published data only}</Title><Reference><Citation>Lvoff R, Wilcken DE. Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients. Circulation 1972;45(3):534&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">4401050</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>MacGregor 1994 {published data only}</Title><Reference><Citation>MacGregor DA, Butterworth JF 4th, Zaloga CP, Prielipp RC, James R, Royster RL. Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 1994;106(3):835&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">7915979</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mavrogeni 2007 {published data only}</Title><Reference><Citation>Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, et al. A 6&#x2010;month follow&#x2010;up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. Journal of Cardiac Failure 2007;13(7):556&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17826646</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mehta 2017 {published data only}</Title><Reference><Citation>Mehta RH, Leimberger JD, Diepen S, Meza J, Wang A, Jankowich R, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine 2017;376(21):2032&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">28316276</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meissner 1996 {published data only}</Title><Reference><Citation>Meissner A, Schmelzle T, Simon R. Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine. Zeitschrift fur Kardiologie 1996;85(11):839&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9064946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meng 2016 {published data only}</Title><Reference><Citation>Meng A, Hu M, Lai Z, Ji C, Xu X, Zhang G, et al. Levosimendan versus dobutamine in myocardial injury patients with septic shock: a randomized controlled trial. Medical Science Monitor 2016;22:1486&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4861009</ArticleId><ArticleId IdType="pubmed">27138236</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nadjamabadi 1980 {published data only}</Title><Reference><Citation>Nadjmabadi MH, Aftandelian E, Kashani IA, Rastan H, Bastanfar M. Simultaneous dopamine and sodium nitroprusside therapy following open heart surgery. Japanese Heart Journal 1980;21(3):325&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">7401314</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nijhawan 1999 {published data only}</Title><Reference><Citation>Nijhawan N, Nicolosi A, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo&#x2010;controlled trial. Journal of Cardiovascular Pharmacology 1999;34:219&#x2010;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">10445673</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>O'Connor 1999 {published data only}</Title><Reference><Citation>O'Connor CM, Gattis WA, Uretsky BF, Adams KF, McNulty SE, Grossman SH, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients advanced heart failure. American Heart Journal 1999;138(1):78&#x2010;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">10385768</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ochiai 2014 {published data only}</Title><Reference><Citation>Ochiai ME, Brancalhao EC, Puig RS, Vieira KR, Cardoso JN, Oliveira&#x2010;Jr MT, et al. Short&#x2010;term add&#x2010;on therapy with angiotensin receptor blocker for end&#x2010;stage inotrope&#x2010;dependent heart failure patients: B&#x2010;type natriuretic peptide reduction in a randomized clinical trial. Clinics (Sao Paulo, Brazil) 2014;96(5):308&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012233</ArticleId><ArticleId IdType="pubmed">24838894</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Orellano 1991 {published data only}</Title><Reference><Citation>Orellano L, Darwisch M, Dieterich HA, Kollner V. Enoximone in postoperative "low&#x2010;output syndrome"&#x2010;&#x2010;comparison with dobutamine [Enoximon beim postoperativen "Low&#x2010;output&#x2010;Syndrom"&#x2010;&#x2010;Vergleich mit Dobutamin]. Zeitschrift fur Kardiologie 1991;Suppl 4:53&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1833898</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Packer 2013 {published data only}</Title><Reference><Citation>Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short&#x2010;term clinical course of patients with acutely decompensated heart failure. JACC. Heart Failure 2013;1(2):103&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">24621834</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Patel 1993 {published data only}</Title><Reference><Citation>Patel A, Caldicott LD, Skoyles JR, Das P, Sherry KM. Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia 1993;71:869&#x2010;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8280556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Perret 1978 {published data only}</Title><Reference><Citation>Perret C. The treatment for shock during myocardial infarction and its results. Annales de Cardiologie et d'Angeiologie 1878;27(6):455&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">749676</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pouleur 1992 {published data only}</Title><Reference><Citation>Pouleur H. Results of the treatment trial of the studies of left ventricular dysfunction (SOLVD). The SOLVD Investigators. The American Journal of Cardiology 1992;72(10):135c&#x2013;136c.</Citation><ArticleIdList><ArticleId IdType="pubmed">1414890</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Richard 1983 {published data only}</Title><Reference><Citation>Richard C, Ricome JL, Rimailho A, Bottineau G, Auzepy P. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 1983;67(3):620&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">6821904</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Russ 2009 {published data only}</Title><Reference><Citation>Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Critical Care Medicine 2009;37(12):3017&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661807</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Santman 1992 {published data only}</Title><Reference><Citation>Santman FW. Prolonged infusion of varied doses of dopexamine hydrochloride for low cardiac output after cardiac surgery. Journal of Cardiothoracic &amp; Vascular Anesthesia 1992;6(5):568&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">1358247</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Seino 1996 {published data only}</Title><Reference><Citation>Seino Y, Momomura S, Takano T, Hayakawa H, Katoh K. Multicenter, double&#x2010;blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. Intensive Care Medicine 1996;24(9):1490&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797620</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shah 2014 {published data only}</Title><Reference><Citation>Shah B, Sharma P, Brahmbhatt A, Shah R, Rathod B, Shastri N, et al. Study of levosimendan during off&#x2010;pump coronary artery bypass grafting in patients with LV dysfunction: a double&#x2010;blind randomized study. Indian Journal of Pharmacology 2014;46(1):29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912803</ArticleId><ArticleId IdType="pubmed">24550581</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sharma 2014 {published data only}</Title><Reference><Citation>Sharma P, Malhotra A, Gandhi S, Garg P, Bishnoi A, Gandhi H. Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular &amp; Thoracic Annals 2014;22(5):539&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24867027</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Slawsky 2000 {published data only}</Title><Reference><Citation>Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11056096</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stanek 1999 {published data only}</Title><Reference><Citation>Stanek B, Sturm B, Frey B, H&#xfc;lsmann M, Bojic A, Berger R, et al. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. Journal of Heart and Lung Transplantation 1999;18(4):358&#x2010;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">10226901</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sterling 1984 {published data only}</Title><Reference><Citation>Sterling RP, Taegtmeyer H, Turner SA, Walker WE, Cooley DA. Comparison of dopamine and dobutamine therapy during intraaortic balloon pumping for the treatment of postcardiotomy low&#x2010;output syndrome. Annals of Thoracic Surgery 1984;38(1):37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610395</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sunny 2016 {published data only}</Title><Reference><Citation>Sunny, Yunus M, Karim HM, Saikia MK, Bhattacharyya P, Dey S. Comparison of levosimendan, milrinone and dobutamine in treating low cardiac output syndrome following valve replacement surgeries with cardiopulmonary bypass. Journal of Clinical and Diagnostic Research 2016;10(12):UC05&#x2010;UC08.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5296550</ArticleId><ArticleId IdType="pubmed">28208977</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tacon 2012 {published data only}</Title><Reference><Citation>Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure. Intensive Care Medicine 2012;38(3):359&#x2010;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">22160239</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Timewell 1990 {published data only}</Title><Reference><Citation>Timewell RM, Stark RD, Marlow HF, and the European 'Crowin' Group. Xamoterol monotherapy in heart failure. European Heart Journal 1990;11(Supplement A):62&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1971596</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tritapepe 1999 {published data only}</Title><Reference><Citation>Tritapepe L, Voci P, Cogliati AA, Pasotti E, Papalia U, Menichetti A. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Critical Care Medicine 1999;27(10):2180&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">10548203</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tritapepe 2009 {published data only}</Title><Reference><Citation>Tritapepe L, Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, et al. Levosimendan pre&#x2010;treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia 2009;102:198&#x2010;204. [DOI: 10.1093/bja/aen367]</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aen367</ArticleId><ArticleId IdType="pubmed">19151048</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tzimas 2009 {published data only}</Title><Reference><Citation>Tzimas P, Arnaoutoglou H, Krikonis K, Papadopoulos G. Levosimendan improves haemodynamic stability in coronary artery bypass surgery patients with compromised left ventricular function. Journal of Cardiothoracic and Vascular Anesthesia 2009;1:S37.</Citation></Reference></ReferenceList><ReferenceList><Title>Verma 1992 {published data only}</Title><Reference><Citation>Verma SP, Silke B, Reynolds GW, Kelly JG, Richmond A, Taylor SH. Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha&#x2010;adrenoceptor blockade, and angiotensin&#x2010;converting enzyme inhibition. Journal of Cardiovascular Pharmacology 1992;20(2):274&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">1381019</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wimmer 1999 {published data only}</Title><Reference><Citation>Wimmer A, Stanek B, Kubecova L, Vitovec J, Spinar J, Yilmaz N, et al. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Japanese Heart Journal 1999;40(3):321&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10506854</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wright 1992 {published data only}</Title><Reference><Citation>Wright EM, Skoyles J, Sherry KM. Milrinone in the treatment of low output states following cardiac surgery. European Journal of Anaesthesiology &#x2010; Supplement 1992;5:21&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1600964</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zerkowski 1992 {published data only}</Title><Reference><Citation>Zerkowski HR, G&#xfc;nnicker M, Freund U, Dieterich HA, Dressler HT, Doetsch N, et al. Low&#x2010;output syndrome after heart surgery: is a monotherapy with phosphodiesterase&#x2010;III inhibitors feasible? A comparative study of amrinone and enoximone. Thoracic and Cardiovascular Surgeon 1992;40(6):371&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1290186</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zw&#xf6;lfer 1995 {published data only}</Title><Reference><Citation>Zw&#xf6;lfer W, Dressler HT, Keznickl P, Dieterich HA. Enoximone versus epinephrine/nitroglycerin in cardiac low&#x2010;output states following valve replacement. Clinical Cardiology 1995;18:145&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7743685</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to ongoing studies</Title><ReferenceList><Title>NCT02767024 {published data only}</Title><Reference><Citation>NCT02767024. Effect of levosimendan on the short&#x2010;term clinical course of patients with acutely decompensated heart failure. clinicaltrials.gov/ct2/show/NCT02767024 (first received 28 July 2017).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT03207165 {published data only}</Title><Reference><Citation>NCT03207165. Milrinone versus dobutamine in critically Ill patients. clinicaltrials.gov/ct2/show/NCT03207165 (first received 28 July 2017).</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Alexander 2001</Title><Reference><Citation>Alexander RW, Pratt CM, Ryan TJ, Roberts R. Diagnosis and management of patients with acute myocardial infarction. In: Fuster V, Alexander RW, O&#x2019;Rourke RA editor(s). Hurst&#x2019;s The Heart. 10th Edition. New York: McGraw&#x2010;Hill Company, 2001:1275&#x2013;359.</Citation></Reference></ReferenceList><ReferenceList><Title>Balshem 2011</Title><Reference><Citation>Balshem H, Helfand M, Sch&#xfc;nemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64(4):401&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208779</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Buerke 2011</Title><Reference><Citation>Buerke M, Lemm H, Dietz S, Werdan K. Pathophysiology, diagnosis, and treatment of infarction&#x2010;related cardiogenic shock. Herz 2011;36(2):73&#x2010;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21424345</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>CDC 2011</Title><Reference><Citation>Centers for Disease Control and Prevention. Heart Disease and Stroke Prevention. www.cdc.gov/chronicdisease/resources/publications/AAG/dhdsp.htm accessed 14 December 2011.</Citation></Reference></ReferenceList><ReferenceList><Title>De Backer 2010</Title><Reference><Citation>Backer D, Ortiz JA, Salgado D. Coupling microcirculation to systemic hemodynamics. Current Opinion in Critical Care 2010;16(3):250&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20179590</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>De Luca 2015</Title><Reference><Citation>Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Chiara A, et al. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. European Journal of Heart Failure 2015;17(11):1124&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26339723</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>De Waha 2012</Title><Reference><Citation>Waha S, Desch S, Eitel I, Fuernau G, Lurz P, Waha A, et al. What is the evidence for IABP in STEMI with and without cardiogenic shock?. Therapeutic Advances in Cardiovascular Disease 2012;6(3):123&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">22569335</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Delaney 2010</Title><Reference><Citation>Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: a meta&#x2010;analysis of randomised controlled trials. International Journal of Cardiology 2010;138:281&#x2010;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">18817994</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Den Uil 2009</Title><Reference><Citation>Uil CA, Caliskan K, Lagrand WK, Ent M, Jewbali LS, Kuijk JP, et al. Dose&#x2010;dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure. Intensive Care Medicine 2009;35(11):1893&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19639300</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dickstein 2008</Title><Reference><Citation>Dickstein K, Cohen&#x2010;Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole&#x2010;Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 2008;29:2388&#x2010;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">18799522</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gamper 2016</Title><Reference><Citation>Gamper G, Havel C, Arrich J, Losert H, Pace NL, M&#xfc;llner M, et al. Vasopressors for hypotensive shock. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD003709.pub4]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003709.pub4</ArticleId><ArticleId IdType="pmc">PMC6516856</ArticleId><ArticleId IdType="pubmed">26878401</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gaziano 2010</Title><Reference><Citation>Gaziano TA, Bitton A, Anand S, Abrahams&#x2010;Gessel S, Murphy A. Growing epidemic of coronary heart disease in low&#x2010; and middle&#x2010;income countries. Current Problems in Cardiology 2010;35(2):72&#x2010;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864143</ArticleId><ArticleId IdType="pubmed">20109979</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldberg 1999</Title><Reference><Citation>Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating myocardial infarction. New England Journal of Medicine 1999;340:1162&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202167</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>GRADEpro GDT 2015 [Computer program]</Title><Reference><Citation>McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.</Citation></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011a</Title><Reference><Citation>Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction&#x2010;GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383&#x2010;94. [DOI: 10.1016/j.jclinepi.2010.04.026]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.04.026</ArticleId><ArticleId IdType="pubmed">21195583</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011b</Title><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso&#x2010;Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence&#x2010;&#x2010;imprecision. Journal of Clinical Epidemiology 2011;64(12):1283&#x2010;93. [DOI: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">21839614</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011c</Title><Reference><Citation>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso&#x2010;Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence&#x2010;&#x2010;study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407&#x2010;15. [DOI: 10.1016/j.jclinepi.2010.07.017]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.07.017</ArticleId><ArticleId IdType="pubmed">21247734</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011d</Title><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence&#x2010;&#x2010;inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294&#x2010;302. [DOI: 10.1016/j.jclinepi.2011.03.017]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2011.03.017</ArticleId><ArticleId IdType="pubmed">21803546</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011e</Title><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence&#x2010;&#x2010;indirectness. Journal of Clinical Epidemiology 2011;64(12):1303&#x2010;10. [DOI: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">21802903</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2011f</Title><Reference><Citation>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence&#x2010;&#x2010;publication bias. Journal of Clinical Epidemiology 2011;64(12):1277&#x2010;82. [DOI: 10.1016/j.jclinepi.2010.01.011]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.01.011</ArticleId><ArticleId IdType="pubmed">21802904</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guyatt 2013</Title><Reference><Citation>Guyatt GH, Oxman AD, Santesso N, Hefland M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables&#x2010;binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158&#x2010;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609141</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harjola 2010</Title><Reference><Citation>Harjola VP, Costa S, Sund R, Ylikangas S, Siiril&#xe4;&#x2010;Waris K, Melin J, et al. FINN&#x2010;AKVA Study Group. The type of acute heart failure and the costs of hospitalization. International Journal of Cardiology 2010;145(1):103&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19560830</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harrison 2013</Title><Reference><Citation>Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta&#x2010;analysis. Journal of Cardiothoracic and Vascular Anesthesia 2013;27(6):1224&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">24050857</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hermansen 2011</Title><Reference><Citation>Hermansen SE, Kalstad T, How OJ, Myrmel T. Inflammation and reduced endothelial function in the course of severe acute heart failure. Translational Research 2011;157(3):117&#x2010;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">21316028</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>HFMA 2010</Title><Reference><Citation>Healthcare Financial Management Association. National average costs by department for heart failure and shock. Healthcare Financial Management 2010;64(3):122&#x2010;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">20214117</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2002</Title><Reference><Citation>Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta&#x2010;analysis. Statistics in Medicine 2002;21:1539&#x2010;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2011a</Title><Reference><Citation>Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Hochman 1999</Title><Reference><Citation>Hochmann JS, Sleeper LA, Webb JG, Sanborn TA, White HD, et al. Early revascularisation in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New England Journal of Medicine 1999;341:625&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hochman 2001</Title><Reference><Citation>Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. One&#x2010;year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190&#x2010;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176812</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hochman 2006</Title><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, et al. Early revascularization and long&#x2010;term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006;295:2511&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782030</ArticleId><ArticleId IdType="pubmed">16757723</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hochman 2007</Title><Reference><Citation>Hochman JS, Apolito R. The calm after the storm. Long&#x2010;term survival after cardiogenic shock. Journal of the American College of Cardiology 2007;50(18):1759&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">17964039</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hollenberg 2007</Title><Reference><Citation>Hollenberg SM. Vasodilators in acute heart failure. Heart Failure Reviews 2007;12(2):143&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17447137</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>How 2010</Title><Reference><Citation>How OJ, R&#xf8;sner A, Kildal AB, Stenberg TA, Gjessing PF, Hermansen SE, et al. Dobutamine&#x2010;norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock. Translational Research 2010;156(5):273&#x2010;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20970750</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Huang 2013</Title><Reference><Citation>Huang X, Lei S, Zhu M, Jiang R, Huang L, Xia G, et al. Levosimendan versus dobutamine in critically ill patients: a meta&#x2010;analysis of randomized controlled trials. Journal of Zhejiang University&#x2010;SCIENCE B 2013;14(5):400&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3650454</ArticleId><ArticleId IdType="pubmed">23645177</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Komamura 2008</Title><Reference><Citation>Komamura K, Matsuo H, Sasaki T. Comparison of the initial hospitalization costs between the patients treated with dobutamine and the patients treated with amrinone for acute decompensated heart failure in a Japanese institute. Value in Health 2008;11 Suppl 1:S39&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">18387066</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Koster 2015</Title><Reference><Citation>Koster G, Wetterslev J, Gluud C, Zijlstra JG, Scheeren TWL, Horst ICC, et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta&#x2010;analysis and trial sequential analysis. Intensive Care Medicine 2015;41:203&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25518953</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Landmesser 2007</Title><Reference><Citation>Landmesser U, Drexler H. Update on inotropic therapy in the management of acute heart failure. Current Treatment Options in Cardiovascular Medicine 2007;9(6):443&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18221596</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Landoni 2010a</Title><Reference><Citation>Landoni G, Mizzi A, Biondi&#x2010;Zoccai G, Bruno G, Bignami E, Corno L, et al. Reducing mortality in cardiac surgery with levosimendan: a meta&#x2010;analysis of randomized controlled trials. Journal of Cardiothoracic and Vascular Anesthesia 2010;24(1):51&#x2010;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19700350</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Landoni 2010b</Title><Reference><Citation>Landoni G, Mizzi A, Biondi&#x2010;Zoccai A, Bignami E, Prati P, Ajello V, et al. Levosimendan reduces mortality in critically ill patients. A meta&#x2010;analysis of randomized controlled studies. Minerva Anestesiologica 2010;76(4):276&#x2010;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">20332741</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Landoni 2012</Title><Reference><Citation>Landoni G, Biondi&#x2010;Zoccai G, Greco M, Greco T, Bignami E, Morelli A, et al. Effects of levosimendan on mortality and hospitalization. A meta&#x2010;analysis of randomized controlled studies. Critical Care Medicine 2012;40(2):634&#x2010;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">21963578</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lefebvre 2011</Title><Reference><Citation>Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. assessed 04.05.2016. The Cochrane Collaboration.</Citation></Reference></ReferenceList><ReferenceList><Title>Leone 2004</Title><Reference><Citation>Leone M, Vallet B, Teboul JL, Mateo J, Bastien O, Martin C. Survey of the use of catecholamines by French physicians. Intensive Care Medicine 2004;30(5):984&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14997293</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Loisance 1991</Title><Reference><Citation>Loisance D, Benvenuti C, Lebrun T, Leclerc A, Tarral A, Sailly JC. Cost and cost effectiveness of the mechanical and pharmacologic bridge to transplantation. ASAIO Transactions 1991;37(3):M125&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1836332</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Loisance 1993</Title><Reference><Citation>Loisance D, Sailly JC. Cost&#x2010;effectiveness in patients awaiting transplantation receiving intravenous inotropic support. European Journal of Anaesthesiology. Supplement 1993;8:9&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223355</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lozano 2012</Title><Reference><Citation>Lozano R, Naghavi M, Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2010;380(9859):2095&#x2010;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10790329</ArticleId><ArticleId IdType="pubmed">23245604</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Maharaj 2011</Title><Reference><Citation>Maharaj R, Metaxa V. Levosimendan and mortality after coronary revascularisation: a meta&#x2010;analysis of randomised controlled trials. Critical Care 2011;15:R140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219012</ArticleId><ArticleId IdType="pubmed">21651806</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mattera 2008</Title><Reference><Citation>Mattera GG, Vanoli E, Gagnol JP, Loi FM, Borsini F, Carminati P. Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta&#x2010;blocker&#x2010;treated ischaemic heart: comparison with a new agent. European Journal of Heart Failure 2008;10(10):990&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18693136</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>McGhie 1992</Title><Reference><Citation>McGhie AI, Golstein RA. Pathogenesis and management of acute heart failure and cardiogenic shock: role of inotropic therapy. Chest 1992;102(5 Suppl 2):626&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">1424938</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Menon 2000</Title><Reference><Citation>Menon V, Slater JN, White HD, Sleeper LA, Cocke T, Hochman JS. Acute myocardial infarction complicated&#xa0; by systemic hypoperfusion without hypotension: report of the SHOCK&#x2010;Trial registry. American Journal of Medicine 2000;108(5):374&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">10759093</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mentzer 2011</Title><Reference><Citation>Mentzer RM Jr. Myocardial protection in heart surgery. Journal of Cardiovascular Pharmacology and Therapeutics 2011;16(3&#x2010;4):290&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21821531</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Moher 2009</Title><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta&#x2010;Analyses: The PRISMA Statement. PLoS Medicine 2009;6(7):1&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Moran 2008</Title><Reference><Citation>Moran A, Zhao D, Gu D, Coxson P, Chen CS, Cheng J, et al. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model&#x2010;China. BMC Public Health 2008;27(8):394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631484</ArticleId><ArticleId IdType="pubmed">19036167</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Moscucci 2005</Title><Reference><Citation>Moscucci, M, Share D, Smith D, O&#x2019;Donnell MJ, Riba A, McNamara R, et al. Relationship between operator volume and adverse outcome in contemporary percutaneous coronary intervention practice: an analysis of a quality&#x2010;controlled multicenter percutaneous coronary intervention clinical database. Journal of the American College of Cardiology 2005;46(4):625&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098426</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mozaffarian 2016</Title><Reference><Citation>Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Executive Summary: Heart Disease and Stroke Statistics&#x2010;&#x2010;2016 Update: a report from the American Heart Association. Circulation 2016;133(4):447&#x2010;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26811276</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Murray 1996</Title><Reference><Citation>Murray CJL, Lopez AD. Evidence&#x2010;based health policy &#x2010; lessons from the global burden of disease study. Science 1996;274:740&#x2010;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8966556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nativi&#x2010;Nicolau 2014</Title><Reference><Citation>Nativi&#x2010;Nicolau J, Selzman CH, Fang JC, Stehlik J. Pharmacologic therapies for acute cardiogenic shock. Current Opinion in Cardiology 2014;29(3):250&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24686400</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nieminen 2006</Title><Reference><Citation>Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. European heart journal 2006;27(22):2725&#x2010;36. [PUBMED: 17000631]</Citation><ArticleIdList><ArticleId IdType="pubmed">17000631</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nieminen 2014</Title><Reference><Citation>Nieminen MS, Altenberger J, Ben&#x2010;Gal T, Boehmer A, Comin&#x2010;Colet J, Dickstein K, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure. International Journal of Cardiology 2014;174(2):360&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24780540</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>O'Gara 2013</Title><Reference><Citation>O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, Lemos JA, et al. 2013 ACCF/AHA Guideline for the management of ST&#x2010;elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127(4):e362&#x2013;e425. [DOI: 10.1161/CIR.0b013e3182742cf6]</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e3182742cf6</ArticleId><ArticleId IdType="pubmed">23247304</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pietrangelo 2010</Title><Reference><Citation>Pietrangelo T, Giampietro L, Filippis B, Rovere R, Fulle S, Amoroso R. Effect of milrinone analogues on intracellular calcium increase in single living H9C2 cardiac cells. European Journal of Medicinal Chemistry 2010;45(11):4928&#x2010;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">20801556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Prondzinsky 2010</Title><Reference><Citation>Prondzinsky R, Lemm H, Swyter M, Wegener N, Unverzagt S, Carter JM, et al. Intra&#x2010;aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Critical Care Medicine 2010;38(1):152&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19770739</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Reyentovich 2016</Title><Reference><Citation>Reyentovich A, Barghash MH, Hochman JS. Management of refractory cardiogenic shock. Nat Rev Cardiol 2016;13(8):481&#x2010;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">27356877</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ribeiro 2010</Title><Reference><Citation>Ribeiro RA, Rohde LEP, Polanczyk CA. Levosimendan in acute decompensated heart failure: systematic review and meta&#x2010;analysis. Arquivos Brasileiros de Cardiologia 2010;95(2):230&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20549133</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rivers 2001</Title><Reference><Citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. for the Early Goal&#x2010;Directed Therapy Collaborative Group. Early goal&#x2010;directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine 2001;345:1368&#x2010;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794169</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rognoni 2011</Title><Reference><Citation>Rognoni A, Lupi A, Lazzero M, Bongo AS, Rognoni G. Levosimendan: from basic science to clinical trials. Recent Patents on Cardiovascular Drug Discovery 2011;6(1):9&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208157</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>R&#xfc;cker 2008</Title><Reference><Citation>R&#xfc;cker G, Schwarzer G, Schumacher M. Heterogeneity in meta&#x2010;analysis: misconceiving I2. Evidenz, Fortbildung und Qualit&#xe4;t im Gesundheitswesen 2008;Supplement VI:20.</Citation></Reference></ReferenceList><ReferenceList><Title>Samimi&#x2010;Fard 2008</Title><Reference><Citation>Samimi&#x2010;Fard S, Garc&#xed;a&#x2010;Gonz&#xe1;lez MJ, Dom&#xed;nguez&#x2010;Rodr&#xed;guez A, Abreu&#x2010;Gonz&#xe1;lez P. Effects of levosimendan versus dobutamine on long&#x2010;term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology 2008;127(2):284&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17643519</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Santesso 2016</Title><Reference><Citation>Santesso N, Carrasco&#x2010;Labra A, Langendam M, Brignardello&#x2010;Petersen R, Mustafa RA, Heus P, et al. Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. J Clin Epidemiol 2016;74:28&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">26796947</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sehgal 2011</Title><Reference><Citation>Sehgal A, Francis JV, Lewis AI. Use of milrinone in the management of haemodynamic instability following duct ligation. European Journal of Pediatrics 2011;170(1):115&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20848128</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Severi 2011</Title><Reference><Citation>Severi L, Lappa A, Landoni G, Pirro L, Luzzi SJ, Caravetta P, et al. Levosimendan versus intra&#x2010;aortic balloon pump in high&#x2010;risk cardiac surgery patients. Journal of Cardiothoracic and Vascular Anesthesia 2011;25(4):632&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21546269</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shea 2009</Title><Reference><Citation>Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. Journal of Clinical Epidemiology 2009;62(10):1013&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19230606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shpektor 2010</Title><Reference><Citation>Shpektor A. Cardiogenic shock: the role of inflammation. Acute Cardiac Care 2010;12(4):115&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21039083</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Silvetti 2014</Title><Reference><Citation>Silvetti S, Greco T, Prima AL, Mucchetti M, Lurdes Castro M, Pasin L, et al. Intermittent levosimendan improves mid&#x2010;term survival in chronic heart failure patients. Clinical Research in Cardiology 2014;103(7):505&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">24368740</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Singh 2007</Title><Reference><Citation>Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, et al. Long&#x2010;term outcome and its predictors among patients with ST&#x2010;segment elevation myocardial infarction complicated by shock. Journal of the American College of Cardiology 2007;50(18):1752&#x2013;8. [DOI: 10.1016/j.jacc.2007.04.101]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2007.04.101</ArticleId><ArticleId IdType="pubmed">17964038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sleeper 2005</Title><Reference><Citation>Sleeper LA, Ramanathan K, Picard MH, Lejemtel TH, White HD, Dzavik V, et al. SHOCK Investigators. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. Journal of the American College of Cardiology 2005;46(2):266&#x2010;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16022953</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Steg 2012</Title><Reference><Citation>Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kaab S, et al. CLARIFY Registry Investigators. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. European Heart Journal 2012;33(22):2831&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498005</ArticleId><ArticleId IdType="pubmed">22922505</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thackray 2002</Title><Reference><Citation>Thackray S, Easthaugh J, Freemantle N, Cleland JGF. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure &#x2010; a meta&#x2010;regression analysis. European Journal of Heart Failure 2002;4(4):515&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">12167393</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thiele 2009</Title><Reference><Citation>Thiele H, Schuler G. Cardiogenic shock: to pump or not to pump?. European Heart Journal 2009;30:389&#x2010;90. [DOI: 10.1016/j.amjcard.2006.01.068]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2006.01.068</ArticleId><ArticleId IdType="pubmed">19181707</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thiele 2012</Title><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. IABP&#x2010;SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. New England Journal of Medicine 2012;367(14):1287&#x2010;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thiele 2013</Title><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra&#x2010;aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP&#x2010;SHOCK II): final 12 month results of a randomised, open&#x2010;label trial. Lancet 2013;382(9905):1638&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24011548</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Triposkiadis 2009</Title><Reference><Citation>Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. Journal of the American College of Cardiology 2009;54(19):1747&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">19874988</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Triumph 2007</Title><Reference><Citation>TRIUMPH Investigators, Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Werf F, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007;297(15):1657&#x2010;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">17387132</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Unverzagt 2011</Title><Reference><Citation>Unverzagt S, Machemer M&#x2010;T, Solms A, Thiele H, Burkhoff D, Seyfarth M, et al. Intra&#x2010;aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD007398.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD007398.pub2</ArticleId><ArticleId IdType="pubmed">21735410</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Werdan 2012</Title><Reference><Citation>Werdan K, Rus M, Buerke M, Delle&#x2010;Karth G, Geppert A, Sch&#xf6;ndube FA, et al. Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German&#x2010;Austrian S3 Guideline. Deutsches Arzteblatt International 2012;109(19):343&#x2010;51. [DOI: 10.3238/arztebl.2012.0343]</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2012.0343</ArticleId><ArticleId IdType="pmc">PMC3364528</ArticleId><ArticleId IdType="pubmed">22675405</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>WHO 2014</Title><Reference><Citation>WHO. The top 10 causes of death. Fact sheet 310 2014.</Citation></Reference></ReferenceList><ReferenceList><Title>Yusuf 2004</Title><Reference><Citation>Yusuf S, Hawken S, &#xd4;unpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case&#x2010;control study. Lancet 2004;364:937&#x2010;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364185</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zheng 2009</Title><Reference><Citation>Zheng J, Ma J, Zhang P, Hu L, Fan X, Tang Q. Milrinone inhibits hypoxia or hydrogen dioxide&#x2010;induced persistent sodium current in ventricular myocytes. European Journal of Pharmacology 2009;616(1&#x2010;3):206&#x2010;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19549513</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>Unverzagt 2014</Title><Reference><Citation>Unverzagt S, Wachsmuth L, Hirsch K, Thiele H, Buerke M, Haerting J, et al. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD009669.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009669.pub2</ArticleId><ArticleId IdType="pubmed">24385385</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28857849</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Advanced Percutaneous Mechanical Circulatory Support Devices for Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>1922</StartPage><EndPage>1929</EndPage><MedlinePgn>1922-1929</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0000000000002676</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To review temporary percutaneous mechanical circulatory support devices for the treatment of cardiogenic shock, including current evidence, contraindications, complications, and future directions.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">A MEDLINE search was conducted with MeSH terms: cardiogenic shock, percutaneous mechanical circulatory support, extracorporeal membrane oxygenation, Impella, and TandemHeart.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Selected publications included randomized controlled trial data and observational studies describing experience with percutaneous mechanical circulatory support in cardiogenic shock.</AbstractText><AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">Studies were chosen based on strength of association with and relevance to cardiogenic shock.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Until recently, there were few options if cardiogenic shock was refractory to vasopressors or intra-aortic balloon pump counterpulsation. Now, several percutaneous mechanical circulatory support devices, including Impella (Abiomed, Danvers, MA), TandemHeart (CardiacAssist, Pittsburgh, PA), and extracorporeal membrane oxygenation, are more accessible. Compared with intra-aortic balloon pump, Impella provides greater hemodynamic support but no reduction in mortality. Similarly, TandemHeart improves hemodynamic variables but not survival. Comparative studies have been underpowered for mortality because of small sample size. Veno-arterial extracorporeal membrane oxygenation offers the advantage of biventricular circulatory support and oxygenation, but there are significant vascular complications. Comparative studies with extracorporeal membrane oxygenation have not been completed. Despite lack of randomized controlled data, there has been a substantial increase in use of percutaneous mechanical circulatory support. Several ongoing prospective studies with larger sample sizes may provide answers, and newer devices may become smaller, easier to insert, and more effective.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mortality from cardiogenic shock remains unacceptably high despite early coronary revascularization or other therapies. Although evidence is lacking and complications rates are high, improvements and experience with percutaneous mechanical circulatory support may offer the prospect of better outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>P Elliott</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>1Critical Care Medicine, National Institutes of Health Clinical Center, Bethesda, MD. 2Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>McAreavey</LastName><ForeName>Dorothea</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 CL999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of Interest:</b> The authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28857849</ArticleId><ArticleId IdType="mid">NIHMS897493</ArticleId><ArticleId IdType="pmc">PMC5640487</ArticleId><ArticleId IdType="doi">10.1097/CCM.0000000000002676</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294(4):448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeger RV, Radovanovic D, Hunziker PR, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med. 2008;149(9):618&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">18981487</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117(5):686&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">18250279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjauw KD, Engstrom AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 2009;30(4):459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">19168529</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J. 2015;36(20):1223&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">25732762</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Unverzagt S, Buerke M, de Waha A, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev. 2015;(3):CD007398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8454261</ArticleId><ArticleId IdType="pubmed">25812932</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382(9905):1638&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">24011548</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor CM, Rogers JG. Evidence for overturning the guidelines in cardiogenic shock. N Engl J Med. 2012;367(14):1349&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920913</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">23247303</ArticleId></ArticleIdList></Reference><Reference><Citation>Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) Eur Heart J. 2016;37(3):267&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26320110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JM, den Uil CA, Hoeks SE, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30(17):2102&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pubmed">19617601</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Cram P, Lu X, et al. Trends in the use of percutaneous ventricular assist devices: analysis of national inpatient sample data, 2007 through 2012. JAMA Intern Med. 2015;175(6):941&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780323</ArticleId><ArticleId IdType="pubmed">25822170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandhu A, McCoy LA, Negi SI, et al. Use of mechanical circulatory support in patients undergoing percutaneous coronary intervention: insights from the National Cardiovascular Data Registry. Circulation. 2015;132(13):1243&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">26286905</ArticleId></ArticleIdList></Reference><Reference><Citation>Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d&#x2019;intervention) J Card Fail. 2015;21(6):499&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">26036425</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MB, Goldstein J, Milano C, et al. Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant. 2015;34(12):1549&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">26681124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol. 2017;69(3):278&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudard P, Mourad M, Eliet J, et al. Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock. Crit Care. 2015;19:363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4600310</ArticleId><ArticleId IdType="pubmed">26453047</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoli TM, Guerrero M, O&#x2019;Neill WW. Mechanical Circulatory Support With Impella to Facilitate Percutaneous Coronary Intervention for Post-TAVI Bilateral Coronary Obstruction. Catheter Cardio Inte. 2016;88(1):E34&#x2013;E37.</Citation><ArticleIdList><ArticleId IdType="pubmed">26104838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur NK, Qiao X, Paruchuri V, et al. Mechanical Pre-Conditioning With Acute Circulatory Support Before Reperfusion Limits Infarct Size in Acute Myocardial Infarction. JACC Heart Fail. 2015;3(11):873&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">26541785</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidu SS. Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support. Circulation. 2011;123(5):533&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">21300961</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Engstrom AE, Sjauw KD, et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. Int J Cardiol. 2016;202:894&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">26476989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Seyfarth M, Henriques JP. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock: Meta-Analysis. J Am Coll Cardiol. 2017;69(3):358&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">27810348</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill WW, Schreiber T, Wohns DH, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol. 2014;27(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238821</ArticleId><ArticleId IdType="pubmed">24329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstrom AE, Cocchieri R, Driessen AH, et al. The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: the Academic Medical Center intensive care unit experience. Crit Care Med. 2011;39(9):2072&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pubmed">21602670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemaire A, Anderson MB, Lee LY, et al. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg. 2014;97(1):133&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24090575</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith BP, Anderson MB, Samuels LE, Pae WE, Jr, Naka Y, Frazier OH. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg. 2013;145(2):548&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">22405676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011;57(6):688&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">20950980</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation. 2001;104(24):2917&#x2013;2922.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono S, Nishimura K, Nishina T, et al. Autosynchronized systolic unloading during left ventricular assist with a centrifugal pump. J Thorac Cardiovasc Surg. 2003;125(2):353&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">12579105</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26(13):1276&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff D, Cohen H, Brunckhorst C, O&#x2019;Neill WW. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152(3):469 e461&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">16923414</ArticleId></ArticleIdList></Reference><Reference><Citation>Paden ML, Conrad SA, Rycus PT, Thiagarajan RR, Registry E. Extracorporeal Life Support Organization Registry Report 2012. ASAIO J. 2013;59(3):202&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">23644605</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63(25 Pt A):2769&#x2013;2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">24814488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson WE, Koo M. Percutaneous Ventricular Assist Devices and ECMO in the Management of Acute Decompensated Heart Failure. Clinical Medicine Insights. Cardiology. 2015;9(Suppl 1):41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412014</ArticleId><ArticleId IdType="pubmed">25983563</ArticleId></ArticleIdList></Reference><Reference><Citation>Beurtheret S, Mordant P, Paoletti X, et al. Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program) Eur Heart J. 2013;34(2):112&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">22513777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Schulte C, Pieri M, et al. Concomitant implantation of Impella(R) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19(3):404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">27709750</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamogeorgakis T, Rafael A, Shafii AE, Nagpal D, Pokersnik JA, Gonzalez-Stawinski GV. Which is better: a miniaturized percutaneous ventricular assist device or extracorporeal membrane oxygenation for patients with cardiogenic shock? ASAIO J. 2013;59(6):607&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">24088905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Schotborgh JV, Limpens J, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016;42(12):1922&#x2013;1934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5106498</ArticleId><ArticleId IdType="pubmed">27647331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheu JJ, Tsai TH, Lee FY, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med. 2010;38(9):1810&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pubmed">20543669</ArticleId></ArticleIdList></Reference><Reference><Citation>Stub D, Bernard S, Pellegrino V, et al. Refractory cardiac arrest treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial) Resuscitation. 2015;86:88&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25281189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar B, Basra SS, Shah NR, Loyalka P. Percutaneous circulatory support in cardiogenic shock: interventional bridge to recovery. Circulation. 2012;125(14):1809&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pubmed">22492948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauten A, Engstrom AE, Jung C, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail. 2013;6(1):23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">23212552</ArticleId></ArticleIdList></Reference><Reference><Citation>Burzotta F, Trani C, Doshi SN, et al. Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. Int J Cardiol. 2015;201:684&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">26363632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Barili F, Mauro MD, et al. In-Hospital Neurologic Complications in Adult Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation: Results From the Extracorporeal Life Support Organization Registry. Crit Care Med. 2016;44(10):e964&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">27340754</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R, Hachamovitch R, Kittleson M, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014;97(2):610&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">24210621</ArticleId></ArticleIdList></Reference><Reference><Citation>Askenazi DJ, Selewski DT, Paden ML, et al. Renal replacement therapy in critically ill patients receiving extracorporeal membrane oxygenation. Clin J Am Soc Nephrol. 2012;7(8):1328&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5486859</ArticleId><ArticleId IdType="pubmed">22498496</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulate D, Luyt CE, Pozzi M, et al. Acute lung injury after mechanical circulatory support implantation in patients on extracorporeal life support: an unrecognized problem. Eur J Cardiothorac Surg. 2013;44(3):544&#x2013;549. discussion 549&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477925</ArticleId></ArticleIdList></Reference><Reference><Citation>Stretch R, Sauer CM, Yuh DD, Bonde P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol. 2014;64(14):1407&#x2013;1415.</Citation><ArticleIdList><ArticleId IdType="pubmed">25277608</ArticleId></ArticleIdList></Reference><Reference><Citation>Maini B, Gregory D, Scotti DJ, Buyantseva L. Percutaneous cardiac assist devices compared with surgical hemodynamic support alternatives: cost-effectiveness in the emergent setting. Catheter Cardiovasc Interv. 2014;83(6):E183&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">24130115</ArticleId></ArticleIdList></Reference><Reference><Citation>Briceno N, Kapur NK, Perera D. Percutaneous mechanical circulatory support: current concepts and future directions. Heart. 2016;102(18):1494&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pubmed">27503999</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques JP, Ouweneel DM, Naidu SS, et al. Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study. Am Heart J. 2014;167(4):472&#x2013;479. e475.</Citation><ArticleIdList><ArticleId IdType="pubmed">24655695</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39267391</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0879</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Innovations (Philadelphia, Pa.)</Title><ISOAbbreviation>Innovations (Phila)</ISOAbbreviation></Journal><ArticleTitle>Impella 5.5: A Systematic Review of the Current Literature.</ArticleTitle><Pagination><StartPage>380</StartPage><EndPage>389</EndPage><MedlinePgn>380-389</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/15569845241266527</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory support device used for patients in cardiogenic shock. This review provides a comprehensive overview of the device's clinical effectiveness, safety profile, patient outcomes, and relevant procedural considerations.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the PubMed/MEDLINE database. The search query included articles available from October 6, 2022, through January 13, 2023. Our initial search identified 75 studies. All records were screened by 2 independent reviewers using the Covidence software for adherence to our inclusion criteria, and 8 retrospective cohort studies were identified as appropriate for inclusion.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Across the included studies, the sample size ranged from 4 to 275, with predominantly male cohorts. Indications for Impella support varied, and the duration of support ranged from 9.8 to 70 days. Overall, Impella support appeared to be associated with favorable survival rates and manageable complications in various patient populations. Complications associated with Impella use included bleeding, stroke, and device malfunctions. Two studies compared prolonged and Food and Drug Administration-approved Impella support, showing similar outcomes and adverse events.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Impella 5.5 continues to be an attractive option for bridging patients to definitive therapy. Survival during and after Impella 5.5 was favorable for patients regardless of initial indication. However, device use was associated with several important complications, which calls for judicious use and a precontemplated exit strategy. Limitations of this literature review include biases inherent to the retrospective studies included, such as selection and publication bias.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valdes</LastName><ForeName>Carlos Alberto</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-6156-1165</Identifier><AffiliationInfo><Affiliation>College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilgili</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5449-2114</Identifier><AffiliationInfo><Affiliation>College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Akshay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharaf</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez-Contreras</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stinson</LastName><ForeName>Griffin</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5070-1022</Identifier><AffiliationInfo><Affiliation>College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilaro</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Alex M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Ani</LastName><ForeName>Mohammad Az</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demos</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aranda</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleiweis</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaver</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeng</LastName><ForeName>Eric I</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Innovations (Phila)</MedlineTA><NlmUniqueID>101257528</NlmUniqueID><ISSNLinking>1556-9845</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">bridge to therapy</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">left ventricular assist devices</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>15</Day><Hour>21</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>2</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39267391</ArticleId><ArticleId IdType="doi">10.1177/15569845241266527</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36750852</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data.</ArticleTitle><Pagination><StartPage>51</StartPage><MedlinePgn>51</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">51</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-023-04328-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Retrospective cohorts have suggested that levosimendan may facilitate the weaning of veno-arterial extracorporeal membrane oxygenation (VA-ECMO). We therefore studied this clinical question by emulating a randomized trial with observational data.</AbstractText><AbstractText Label="METHODS">All patients with refractory postcardiotomy cardiogenic shock and assisted with VA-ECMO, admitted to a surgical intensive care unit at La Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital between 2016 and 2019, were eligible. To avoid immortal-time bias, we emulated a target trial sequentially comparing levosimendan administration versus no levosimendan administration in patients treated with VA-ECMO. The primary outcome was time to successful ECMO weaning. The secondary outcomes were 30-day and 1-year mortality. We performed a multivariable analysis to adjust for confounding at baseline.</AbstractText><AbstractText Label="RESULTS">Two hundred and thirty-nine patients were included in the study allowing building a nested trials cohort of 1434 copies of patients. No association of levosimendan treatment and VA-ECMO weaning was found (HR&#x2009;=&#x2009;0.91, [0.57; 1.45], p&#x2009;=&#x2009;0.659 in multivariable analysis), or 30-day mortality (OR&#x2009;=&#x2009;1.03, [0.52; 2.03], p&#x2009;=&#x2009;0.940) and 1-year mortality (OR&#x2009;=&#x2009;1.00, [0.53; 1.89], p&#x2009;=&#x2009;0.999).</AbstractText><AbstractText Label="CONCLUSIONS">Using the emulated target trial framework, this study did not find any association of levosimendan treatment and ECMO weaning success after postcardiotomy cardiogenic shock. However, the population of interest remains heterogeneous and subgroups might benefit from levosimendan.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Massol</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Simon-Tillaux</LastName><ForeName>No&#xe9;mie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohme</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hariri</LastName><ForeName>Geoffroy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dureau</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duceau</LastName><ForeName>Baptiste</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajage</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Rycke</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charfeddine</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebreton</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Combes</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bougl&#xe9;</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, La Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, 47-83 Boulevard de L'H&#xf4;pital, 75013, Paris, France. adrien.bougle@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>0</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36750852</ArticleId><ArticleId IdType="pmc">PMC9906922</ArticleId><ArticleId IdType="doi">10.1186/s13054-023-04328-6</ArticleId><ArticleId IdType="pii">10.1186/s13054-023-04328-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lorusso R, Raffa GM, Alenizy K, Sluijpers N, Makhoul M, Brodie D, et al. Structured review of post-cardiotomy extracorporeal membrane oxygenation: part 1-Adult patients. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2019;38:1125&#x2013;1143. doi: 10.1016/j.healun.2019.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2019.08.014</ArticleId><ArticleId IdType="pmc">PMC8152367</ArticleId><ArticleId IdType="pubmed">31522913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalewski M, Zieli&#x144;ski K, Brodie D, MacLaren G, Whitman G, Raffa GM, et al. Venoarterial extracorporeal membrane oxygenation for postcardiotomy shock-analysis of the extracorporeal life support organization registry. Crit Care Med. 2021 doi: 10.1097/CCM.0000000000004922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004922</ArticleId><ArticleId IdType="pmc">PMC8217275</ArticleId><ArticleId IdType="pubmed">33729722</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2019;94:29&#x2013;37. doi: 10.1002/ccd.28329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28329</ArticleId><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorsandi M, Dougherty S, Bouamra O, Pai V, Curry P, Tsui S, et al. Extra-corporeal membrane oxygenation for refractory cardiogenic shock after adult cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Surg. 2017;12:55. doi: 10.1186/s13019-017-0618-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-017-0618-0</ArticleId><ArticleId IdType="pmc">PMC5512816</ArticleId><ArticleId IdType="pubmed">28716039</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancari F, Dal&#xe9;n M, Fiore A, Ruggieri VG, Saeed D, J&#xf3;nsson K, et al. Multicenter study on postcardiotomy venoarterial extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 2020;159:1844&#x2013;1854.e6. doi: 10.1016/j.jtcvs.2019.06.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2019.06.039</ArticleId><ArticleId IdType="pubmed">31358340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Hou D, Wang J, Cui Y, Wang X, Xing Z, et al. Vascular complications in adult postcardiotomy cardiogenic shock patients receiving venoarterial extracorporeal membrane oxygenation. Ann Intensive Care. 2018;8:72. doi: 10.1186/s13613-018-0417-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-018-0417-3</ArticleId><ArticleId IdType="pmc">PMC6006001</ArticleId><ArticleId IdType="pubmed">29916091</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia D, Yang IX, Ling RR, Syn N, Poon WH, Murughan K, et al. Vascular complications of extracorporeal membrane oxygenation: a systematic review and meta-regression analysis. Crit Care Med. 2020;48:e1269&#x2013;e1277. doi: 10.1097/CCM.0000000000004688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004688</ArticleId><ArticleId IdType="pubmed">33105148</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlagenhauf A, Kalbhenn J, Geisen U, Beyersdorf F, Zieger B. Acquired von Willebrand syndrome and platelet function defects during extracorporeal life support (mechanical circulatory support) Hamostaseologie. 2020;40:221&#x2013;225. doi: 10.1055/a-1150-2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1150-2016</ArticleId><ArticleId IdType="pubmed">32455462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariscalco G, El-Dean Z, Yusuff H, Fux T, Dell&#x2019;Aquila AM, J&#xf3;nsson K, et al. Duration of venoarterial extracorporeal membrane oxygenation and mortality in postcardiotomy cardiogenic shock. J Cardiothorac Vasc Anesth. 2021;35:2662&#x2013;2668. doi: 10.1053/j.jvca.2020.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.11.003</ArticleId><ArticleId IdType="pubmed">33250434</ArticleId></ArticleIdList></Reference><Reference><Citation>Distelmaier K, Wiedemann D, Binder C, Haberl T, Zimpfer D, Heinz G, et al. Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. J Thorac Cardiovasc Surg. 2018;155:2471&#x2013;2476. doi: 10.1016/j.jtcvs.2017.12.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2017.12.079</ArticleId><ArticleId IdType="pubmed">29395201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Whitman G, Milojevic M, Raffa G, McMullan DM, Boeken U, et al. 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. Ann Thorac Surg. 2021;111:327&#x2013;369. doi: 10.1016/j.athoracsur.2020.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2020.07.009</ArticleId><ArticleId IdType="pubmed">33036737</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013;38:341&#x2013;349. doi: 10.1111/jcpt.12067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.12067</ArticleId><ArticleId IdType="pubmed">23594161</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmakis D, Alvarez J, Gal TB, Brito D, Fedele F, Fonseca C, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016;222:303&#x2013;312. doi: 10.1016/j.ijcard.2016.07.202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.07.202</ArticleId><ArticleId IdType="pubmed">27498374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaddoura R, Omar AS, Ibrahim MIM, Alkhulaifi A, Lorusso R, Elsherbini H, et al. The effectiveness of Levosimendan on Veno-arterial extracorporeal membrane oxygenation management and outcome: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2021: 10.1053/j.jvca.2021.01.019.</Citation><ArticleIdList><ArticleId IdType="pubmed">33583718</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilherme E, Jacquet-Lagr&#xe8;ze M, Pozzi M, Achana F, Armoiry X, Fellahi J-L. Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis. Crit Care Lond Engl. 2020;24:442. doi: 10.1186/s13054-020-03122-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03122-y</ArticleId><ArticleId IdType="pmc">PMC7367381</ArticleId><ArticleId IdType="pubmed">32677985</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Fernandez-Gatta M, Merchan-Gomez S, Gonzalez-Cebrian M, Diego-Nieto A, Alzola E, Toranzo-Nieto I, et al. Levosimendan in veno-arterial extracorporeal membrane oxygenator supported patients: Impact on the success of weaning and survival. Artif Organs. 2020 doi: 10.1111/aor.13899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.13899</ArticleId><ArticleId IdType="pubmed">33377185</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;349. doi: 10.1016/j.jclinepi.2007.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2007.11.008</ArticleId><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohme J, Piat C, Aissat N, Lebreton G, Duceau B, Charfeddine A, et al. Weaning-related shock in patients with ecmo: incidence, mortality, and predisposing factors. J Cardiothorac Vasc Anesth. 2021;35:41&#x2013;47. doi: 10.1053/j.jvca.2020.07.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.07.069</ArticleId><ArticleId IdType="pubmed">32828655</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendon&#xe7;a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707&#x2013;10. doi: 10.1007/bf01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Oba K, Matsui Y, Morimoto Y. Vasoactive-inotropic score as a predictor of morbidity and mortality in adults after cardiac surgery with cardiopulmonary bypass. J Anesth. 2018;32:167&#x2013;173. doi: 10.1007/s00540-018-2447-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-018-2447-2</ArticleId><ArticleId IdType="pubmed">29332153</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerman BA, Garc&#xed;a-Alb&#xe9;niz X, Logan RW, Denaxas S, Hern&#xe1;n MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25:1601&#x2013;1606. doi: 10.1038/s41591-019-0597-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0597-x</ArticleId><ArticleId IdType="pmc">PMC7076561</ArticleId><ArticleId IdType="pubmed">31591592</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766&#x2013;779. doi: 10.1097/EDE.0b013e3181875e61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181875e61</ArticleId><ArticleId IdType="pmc">PMC3731075</ArticleId><ArticleId IdType="pubmed">18854702</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaefi S, Brenner SK, Gupta S, O&#x2019;Gara BP, Krajewski ML, Charytan DM, et al. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Med. 2021;47:208&#x2013;221. doi: 10.1007/s00134-020-06331-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06331-9</ArticleId><ArticleId IdType="pmc">PMC7851810</ArticleId><ArticleId IdType="pubmed">33528595</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Sauer BC, Hern&#xe1;ndez-D&#xed;az S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70&#x2013;75. doi: 10.1016/j.jclinepi.2016.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2016.04.014</ArticleId><ArticleId IdType="pmc">PMC5124536</ArticleId><ArticleId IdType="pubmed">27237061</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601&#x2013;609. doi: 10.1161/CIRCULATIONAHA.115.017719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.017719</ArticleId><ArticleId IdType="pmc">PMC4741409</ArticleId><ArticleId IdType="pubmed">26858290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377:1391&#x2013;1398. doi: 10.1056/NEJMsm1605385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsm1605385</ArticleId><ArticleId IdType="pubmed">28976864</ArticleId></ArticleIdList></Reference><Reference><Citation>Gran JM, R&#xf8;ysland K, Wolbers M, Didelez V, Sterne JAC, Ledergerber B, et al. A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. Stat Med. 2010;29:2757&#x2013;2768. doi: 10.1002/sim.4048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4048</ArticleId><ArticleId IdType="pubmed">20803557</ArticleId></ArticleIdList></Reference><Reference><Citation>Maringe C, Benitez Majano S, Exarchakou A, Smith M, Rachet B, Belot A, et al. Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. Int J Epidemiol. 2020;49:1719&#x2013;29. doi: 10.1093/ije/dyaa057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa057</ArticleId><ArticleId IdType="pmc">PMC7823243</ArticleId><ArticleId IdType="pubmed">32386426</ArticleId></ArticleIdList></Reference><Reference><Citation>Distelmaier K, Roth C, Schrutka L, Binder C, Steinlechner B, Heinz G, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016;117:52&#x2013;58. doi: 10.1093/bja/aew151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aew151</ArticleId><ArticleId IdType="pmc">PMC4913403</ArticleId><ArticleId IdType="pubmed">27317704</ArticleId></ArticleIdList></Reference><Reference><Citation>Vally S, Ferdynus C, Persichini R, Bouchet B, Braunberger E, Lo Pinto H, et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care. 2019;9:24. doi: 10.1186/s13613-019-0503-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-019-0503-1</ArticleId><ArticleId IdType="pmc">PMC6358626</ArticleId><ArticleId IdType="pubmed">30707314</ArticleId></ArticleIdList></Reference><Reference><Citation>Keebler ME, Haddad EV, Choi CW, McGrane S, Zalawadiya S, Schlendorf KH, et al. Venoarterial extracorporeal membrane oxygenation in cardiogenic shock. JACC Heart Fail. 2018;6:503&#x2013;516. doi: 10.1016/j.jchf.2017.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2017.11.017</ArticleId><ArticleId IdType="pubmed">29655828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496&#x2013;509. doi: 10.1080/01621459.1999.10474144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference><Reference><Citation>Murad H, Dankner R, Berlin A, Olmer L, Freedman LS. Imputing missing time-dependent covariate values for the discrete time Cox model. Stat Methods Med Res. 2020;29:2074&#x2013;2086. doi: 10.1177/0962280219881168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280219881168</ArticleId><ArticleId IdType="pubmed">31680633</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB, editor. Multiple imputation for nonresponse in surveys. Wiley, Hoboken, NJ, USA, 1987. 10.1002/9780470316696.</Citation></Reference><Reference><Citation>Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York, NY: Springer New York; 2000. 10.1007/978-1-4757-3294-8.</Citation></Reference><Reference><Citation>Buuren S van, Groothuis-Oudshoorn K. mice&#x202f;: Multivariate Imputation by Chained Equations in R. J Stat Softw 2011; 10.18637/jss.v045.i03.</Citation></Reference><Reference><Citation>Gray, Bob. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2&#x2013;10. 2020.</Citation></Reference><Reference><Citation>Burgos LM, Seoane L, Furmento JF, Costabel JP, Diez M, Vrancic M, et al. Effects of levosimendan on weaning and survival in adult cardiogenic shock patients with veno-arterial extracorporeal membrane oxygenation: systematic review and meta-analysis. Perfusion. 2020;35:484&#x2013;491. doi: 10.1177/0267659120918473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659120918473</ArticleId><ArticleId IdType="pubmed">32449494</ArticleId></ArticleIdList></Reference><Reference><Citation>Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66:648&#x2013;653. doi: 10.1016/j.jclinepi.2012.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2012.09.017</ArticleId><ArticleId IdType="pubmed">23415868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivikko M, Antila S, Eha J, Lehtonen L, Pentik&#xe4;inen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002;40:465&#x2013;471. doi: 10.5414/cpp40465.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/cpp40465</ArticleId><ArticleId IdType="pubmed">12395979</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller G, Flecher E, Lebreton G, Luyt C-E, Trouillet J-L, Br&#xe9;chot N, et al. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Med. 2016;42:370&#x2013;378. doi: 10.1007/s00134-016-4223-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4223-9</ArticleId><ArticleId IdType="pubmed">26825953</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffner G, Ajob G, Cristinar M, Marguerite S, Oulehri W, Heger B. Levosimendan for weaning veno-arterial ECMO. Crit Care. 2018;22(Suppl 1):128.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangalli F, Avalli L, Laratta M, Formica F, Maggioni E, Caruso R, et al. Effects of levosimendan on endothelial function and hemodynamics during weaning from veno-arterial extracorporeal life support. J Cardiothorac Vasc Anesth. 2016;30:1449&#x2013;1453. doi: 10.1053/j.jvca.2016.03.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2016.03.139</ArticleId><ArticleId IdType="pubmed">27495966</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF. The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol. 2013;13:7. doi: 10.1186/1471-2253-13-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2253-13-7</ArticleId><ArticleId IdType="pmc">PMC3643838</ArticleId><ArticleId IdType="pubmed">23517311</ArticleId></ArticleIdList></Reference><Reference><Citation>Immohr MB, Akhyari P, Boettger C, Erbel S, Westenfeld R, Scheiber D, et al. Levosimendan for treatment of primary graft dysfunction after heart transplantation: optimal timing of application. Exp Clin Transplant Off J Middle East Soc Organ Transplant. 2021 doi: 10.6002/ect.2020.0342.</Citation><ArticleIdList><ArticleId IdType="doi">10.6002/ect.2020.0342</ArticleId><ArticleId IdType="pubmed">33877035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28232854</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1915-7398</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Ontario health technology assessment series</Title><ISOAbbreviation>Ont Health Technol Assess Ser</ISOAbbreviation></Journal><ArticleTitle>Percutaneous Ventricular Assist Devices: A Health Technology Assessment.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>97</EndPage><MedlinePgn>1-97</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Percutaneous coronary intervention (PCI)-using a catheter to place a stent to keep blood vessels open-is increasingly used for high-risk patients who cannot undergo surgery. Cardiogenic shock (when the heart suddenly cannot pump enough blood) is associated with a high mortality rate. The percutaneous ventricular assist device can help control blood pressure and increase blood flow in these high-risk conditions. This health technology assessment examined the benefits, harms, and budget impact of the Impella percutaneous ventricular assist device in high-risk PCI and cardiogenic shock. We also analyzed cost-effectiveness of the Impella device in high-risk PCI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a systematic search of the literature for studies examining the effects of the Impella percutaneous ventricular assist device in high-risk PCI and cardiogenic shock, and appraised the evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria, focusing on hemodynamic stability, mortality, major adverse cardiac events, bleeding, and vascular complications. We developed a Markov decision-analytical model to assess the cost- effectiveness of Impella devices versus intra-aortic balloon pumps (IABPs), calculated incremental cost-effectiveness ratios (ICERs) using a 10-year time horizon, and conducted sensitivity analyses to examine the robustness of the estimates. The economic model was conducted from the perspective of the Ontario Ministry of Health and Long-Term Care.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen studies (one randomized controlled trial and 10 observational studies for high-risk PCI, and one randomized controlled trial and six observational studies for cardiogenic shock) were included in the clinical review. Compared with IABPs, Impella 2.5, one model of the device, improved hemodynamic parameters (GRADE low-very low) but showed no significant difference in mortality (GRADE low), major adverse cardiac events (GRADE low), bleeding (GRADE low), or vascular complications (GRADE low) in high-risk PCI and cardiogenic shock. No randomized controlled trials or prospective observational studies with a control group have studied Impella CP and Impella 5.0 (other models of the device) in patients undergoing high-risk PCI or patients with cardiogenic shock. The economic model predicted that treatment with the Impella device would have fewer quality-adjusted life-years (QALYs) and higher costs than IABP in high-risk PCI patients. These observations were consistent even when uncertainty in model inputs and parameters was considered. We estimated that adopting Impella would increase costs by $2.9 to $11.5 million per year.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">On the basis of evidence of low to very low quality, Impella 2.5 devices were associated with improved hemodynamic stability, but had mortality rates and safety profile similar to IABPs in high-risk PCI and cardiogenic shock. Our cost-effectiveness analysis indicated that Impella 2.5 is likely associated with greater costs and fewer quality-adjusted life years than IABP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>Health Quality Ontario </CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Ont Health Technol Assess Ser</MedlineTA><NlmUniqueID>101521610</NlmUniqueID><ISSNLinking>1915-7398</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054059" MajorTopicYN="N">Coronary Occlusion</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N">Ontario</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013673" MajorTopicYN="Y">Technology Assessment, Biomedical</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djalalov</LastName><ForeName>Sandjar</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xie</LastName><ForeName>Xuanqian</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holubowich</LastName><ForeName>Corinne</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28232854</ArticleId><ArticleId IdType="pmc">PMC5313122</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care (Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology - Association Canadienne de Cardiologie d'intervention). J Card Fail. 2015;21(6):499&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">26036425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar B, Basra SS, Shah NR, Loyalka P. Percutaneous circulatory support in cardiogenic shock: interventional bridge to recovery. Circulation. 2012;125(14):1809&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">22492948</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294(4):448&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046651</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999;340(15):1162&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202167</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon SR, Henriques JP, Mauri L, Sjauw K, Civitello A, Kar B, et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (the PROTECT I trial): initial U.S. experience. JACC Cardiovasc Interv. 2009;2(2):91&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19463408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011;57(6):688&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">20950980</ArticleId></ArticleIdList></Reference><Reference><Citation>Makdisi G, Wang IW. Extra corporeal membrane oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015;7(7):E166&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522501</ArticleId><ArticleId IdType="pubmed">26380745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacic JC, Nguyen HT, Karajgikar R, Sharma SK, Kini AS. The Impella Recover 2.5 and TandemHeart ventricular assist devices are safe and associated with equivalent clinical outcomes in patients undergoing high-risk percutaneous coronary intervention. Catheter Cardiovasc Interv. 2013;82(1):E28&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477303</ArticleId><ArticleId IdType="pubmed">21234916</ArticleId></ArticleIdList></Reference><Reference><Citation>Valgimigli M, Steendijk P, Sianos G, Onderwater E, Serruys PW. Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous Impella Recover LP 2.5 assist device during high-risk coronary intervention. Catheter Cardiovasc Interv. 2005;65(2):263&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895406</ArticleId></ArticleIdList></Reference><Reference><Citation>Remmelink M, Sjauw KD, Henriques JPS, De Winter RJ, Koch KT, Van Der Schaaf RJ, et al. Effects of left ventricular unloading by Impella Recover LP 2.5 on coronary hemodynamics. Catheter Cardiovasc Interv. 2007;70(4):532&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17896398</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudoulas KD, Pederzolli A, Saini U, Gumina RJ, Mazzaferri EL, Jr, Davis M, et al. Comparison of Impella and intra-aortic balloon pump in high-risk percutaneous coronary intervention: vascular complications and incidence of bleeding. Acute Card Care. 2012;14(4):120&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23215746</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. Impella 2.5 system - P140003 [Internet]. Silver Spring (MD): U.S. Department of Health and Human Resources; 2015.  [cited 2016 May 26]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=p140003</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. Premarket approval [Internet]. Silver Spring (MD): U.S. Department of Health and Human Services; 2016.  [cited 2016 June 7]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140003S005</Citation></Reference><Reference><Citation>Technology Assessment Unit of the McGill University Health Centre. The Impella&#xae; percutaneous ventricular assist device [Internet]. Montreal (QC): McGill University; 2009.  [cited 2015 Oct 13]. Available from: https://www.mcgill.ca/tau/files/tau/IMPELLA_FINAL_JUNE_2009.pdf</Citation></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan J, Sampson M, Salzwedel D, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27005575</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">21185693</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126(14):1717&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">22935569</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasnag MA, Gardi DO, Elder M, Kannam H, Ali F, Petrina M, et al. Use of the Impella 2.5 for prophylactic circulatory support during elective high-risk percutaneous coronary intervention. Cardiovasc Revasc Med. 2011;12(5):299&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">21454139</ArticleId></ArticleIdList></Reference><Reference><Citation>Anusionwu O, Fischman D, Cheriyath P. The duration of Impella 2.5 circulatory support and length of hospital stay of patients undergoing high-risk percutaneous coronary interventions. Cardiol Res. 2012;3(4):154&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358206</ArticleId><ArticleId IdType="pubmed">28348680</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MG, Matthews R, Maini B, Dixon S, Vetrovec G, Wohns D, et al. Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: real-world versus clinical trial experience. Am Heart J. 2015;170(5):872&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26542494</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliodromitis KE, Kahlert P, Plicht B, Hoffmann AC, Eggebrecht H, Erbel R, et al. High-risk PCI in acute coronary syndromes with Impella LP 2.5 device support. Int J Cardiol. 2011;153(1):59&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">20826017</ArticleId></ArticleIdList></Reference><Reference><Citation>Maini B, Naidu SS, Mulukutla S, Kleiman N, Schreiber T, Wohns D, et al. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USpella Registry. Catheter Cardiovasc Interv. 2012;80(5):717&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">22105829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjauw KD, Konorza T, Erbel R, Danna PL, Viecca M, Minden HH, et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device. The Europella registry. J Am Coll Cardiol. 2009;54(25):2430&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20082934</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz BG, Ludeman DJ, Mayeda GS, Kloner RA, Economides C, Burstein S. High-risk percutaneous coronary intervention with the TandemHeart and Impella devices: a single-center experience. J Invasive Cardiol. 2011;23(10):417&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">21972160</ArticleId></ArticleIdList></Reference><Reference><Citation>Venugopal V, Spiro J, Zaphiriou A, Khan S, Townend JN, Ludman PF, et al. Percutaneous mechanical ventricular support in acute cardiac care: a UK quaternary centre experience using 2.5L, 3.8L and 5.0L Impella catheters. Cardiol Ther. 2015;4(1):47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4472647</ArticleId><ArticleId IdType="pubmed">25515965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AP, Retzer EM, Nathan S, Paul JD, Friant J, Dill KE, et al. Clinical and economic effectiveness of percutaneous ventricular assist devices for high-risk patients undergoing percutaneous coronary intervention. J Invasive Cardiol. 2015;27(3):148&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">25740967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, et al. The efficacy and safety of mechanical hemodynamic support in patients undergoing high-risk percutaneous coronary intervention with or without cardiogenic shock: Bayesian approach network meta-analysis of 13 randomized controlled trials. Int J Cardiol. 2015;184(1):36&#x2013;46</Citation><ArticleIdList><ArticleId IdType="pubmed">25697869</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MG, Ghatak A, Kleiman NS, Naidu SS, Massaro JM, Kirtane AJ, et al. Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT II study. Catheter Cardiovasc Interv. 2014;83(7):1057&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">24174321</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill WW, Schreiber T, Wohns DH, Rihal C, Naidu SS, Civitello AB, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol. 2014;27(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238821</ArticleId><ArticleId IdType="pubmed">24329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauten A, Engstr&#xf6;m AE, Jung C, Empen K, Erne P, Cook S, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-Registry. Circ Heart Fail. 2013;6(1):23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">23212552</ArticleId></ArticleIdList></Reference><Reference><Citation>Casassus F, Corre J, Leroux L, Chevalereau P, Fresselinat A, Seguy B, et al. The use of Impella 2.5 in severe refractory cardiogenic shock complicating an acute myocardial infarction. J Interv Cardiol. 2015;28(1):41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">25689547</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith BP, Anderson MB, Samuels LE, Pae WE, Jr, Naka Y, Frazier OH. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg. 2013;145(2):548&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">22405676</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstr&#xf6;m AE, Granfeldt H, Seybold-Epting W, Dahm M, Cocchieri R, Driessen AHG, et al. Mechanical circulatory support with the Impella 5.0 device for postcardiotomy cardiogenic shock: a three-center experience. Minerva Cardioangiol. 2013;61(5):539&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">24096248</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo-Silberman S, Fichet J, Mathonnet A, Varenne O, Ricome S, Chaib A, et al. Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and Impella Recover LP 2.5. Resuscitation. 2013;84(5):609&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23069592</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J, Lamarche Y, Kaan A, Stevens LM, Cheung A. Microaxial devices for ventricular failure: a multicentre, population-based experience. Can J Cardiol. 2011;27(6):725&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">21983112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarche Y, Cheung A, Ignaszewski A, Higgins J, Kaan A, Griesdale DEG, et al. Comparative outcomes in cardiogenic shock patients managed with Impella microaxial pump or extracorporeal life support. J Thorac Cardiovasc Surg. 2011;142(1):60&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20880553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemaire A, Anderson MB, Lee LY, Scholz P, Prendergast T, Goodman A, et al. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg. 2014;97(1):133&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24090575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JM, Den Uil CA, Hoeks SE, Van Der Ent M, Jewbali LSD, Van Domburg RT, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30(17):2102&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19617601</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory D, Scotti DJ, de Lissovoy G, Palacios I, Dixon S, Maini B, et al. A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention. Am Health Drug Benefits. 2013;6(2):88&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4031707</ArticleId><ArticleId IdType="pubmed">24991349</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos JB, Doshi SN, Konorza T, Palacios I, Schreiber T, Borisenko OV, et al. The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: Mid-stage evaluation from the European perspective. J Med Econ. 2013;16(3):381&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">23301850</ArticleId></ArticleIdList></Reference><Reference><Citation>Maini B, Scotti DJ, Gregory D. Health economics of percutaneous hemodynamic support in the treatment of high-risk cardiac patients: A systematic appraisal of the literature. Expert Review of Pharmacoeconomics and Outcomes Research. 2014;14(3):403&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">24734930</ArticleId></ArticleIdList></Reference><Reference><Citation>Borisenko O, Wylie G, Payne J, Bjessmo S, Smith J, Firmin R, et al. The cost impact of short-term ventricular assist devices and extracorporeal life support systems therapies on the National Health Service in the UK. Interact Cardiovasc Thorac Surg. 2014;19(1):41&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24667583</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotti DJ, Gregory DA, Schreiber TL, Shroff A, Buck DR. Operational implications of utilizing 2 advanced technologies for rendering short-term hemodynamic support to patients presenting with cardiogenic shock: a view through the lens of hospital readmissions. Managed care (Langhorne, Pa). 2015;24(5):38&#x2013;44, 6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26117965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohns D, Muthusamy P, Davis AT, Khan M, Postma JK, Williams EE, et al. Economic and operational implications of a standardized approach to hemodynamic support therapy using percutaneous cardiac assist devices. Innovations (Phila). 2014;9(1):38&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">24562292</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory D, Scotti DJ. A Budget impact model to estimate the cost dynamics of treating high-risk heart failure patients with advanced percutaneous cardiac assist devices: The payer perspective. Journal of Managed Care Medicine. 2013;16(1):61&#x2013;9.</Citation></Reference><Reference><Citation>Esfandiari S, Erickson L, McGregor M. The Impella percutaneous ventricular assist device. Montreal (QC): McGill University; 2009.</Citation></Reference><Reference><Citation>Sjauw KD, Konorza T, Erbel R, Danna PL, Viecca M, Minden HH, et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J Am Coll Cardiol. 2009;54(25):2430&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20082934</ArticleId></ArticleIdList></Reference><Reference><Citation>Maini B, Naidu SS, Mulukutla S, Kleiman N, Schreiber T, Wohns D, et al. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USpella Registry. Catheter Cardiovasc Interv. 2012;80(5):717&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">22105829</ArticleId></ArticleIdList></Reference><Reference><Citation>Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23538200</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera D, Stables R, Clayton T, De Silva K, Lumley M, Clack L, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation. 2013;127(2):207&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23224207</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasnag MA, Gardi DO, Elder M, Kannam H, Ali F, Petrina M, et al. Use of the Impella 2.5 for prophylactic circulatory support during elective high-risk percutaneous coronary intervention. Cardiovasc Revasc Med. 2011;12(5):299&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">21454139</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudoulas KD, Pederzolli A, Saini U, Gumina RJ, Mazzaferri EL, Jr., Davis M, et al. Comparison of Impella and intra-aortic balloon pump in high-risk percutaneous coronary intervention: vascular complications and incidence of bleeding. Acute Card Care. 2012;14(4):120&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23215746</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliodromitis KE, Kahlert P, Plicht B, Hoffmann AC, Eggebrecht H, Erbel R, et al. High-risk PCI in acute coronary syndromes with Impella LP 2.5 device support. Int J Cardiol. 2011;153(1):59&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">20826017</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangas GD, Kini AS, Sharma SK, Henriques JP, Claessen BE, Dixon SR, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). Am J Cardiol. 2014;113(2):222&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24527505</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe MT, Li S, Thomas L, Wang TY, Alexander KP, Ohman EM, et al. Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2013;6(3):323&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">23652734</ArticleId></ArticleIdList></Reference><Reference><Citation>Littnerova S, Kala P, Jarkovsky J, Kubkova L, Prymusova K, Kubena P, et al. GRACE score among six risk scoring systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) demonstrated the best predictive value for prediction of long-term mortality in patients with ST-elevation myocardial infarction. PLoS One. 2015;10(4):e0123215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404322</ArticleId><ArticleId IdType="pubmed">25893501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakshminarayan K, Berger AK, Fuller CC, Jacobs DR, Jr., Anderson DC, Steffen LM, et al. Trends in 10-year survival of patients with stroke hospitalized between 1980 and 2000: the Minnesota stroke survey. Stroke. 2014;45(9):2575&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768867</ArticleId><ArticleId IdType="pubmed">25028450</ArticleId></ArticleIdList></Reference><Reference><Citation>Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107(8):1208&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072746</ArticleId><ArticleId IdType="pubmed">21296319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15(4):369&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">10537955</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P, Cohen DJ, Gaziano T, Mauri L. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol. 2008;51(19):1844&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18466798</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen DJ, Breall JA, Ho KK, Kuntz RE, Goldman L, Baim DS, et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. Circulation. 1994;89(4):1859&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">8149551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Henderson RA, Pocock SJ, Clayton T, Sculpher MJ, Fox KA, et al. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). J Am Coll Cardiol. 2005;45(2):221&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653019</ArticleId></ArticleIdList></Reference><Reference><Citation>Capomolla S, Febo O, Ceresa M, Caporotondi A, Guazzotti G, La Rovere M, et al. Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. J Am Coll Cardiol. 2002;40(7):1259&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">12383573</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsa GP, Matchar DB, Goldstein L, Bonito A, Duncan PW, Lipscomb J, et al. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J. 1998;136(4 Pt 1):703&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health and Long Term Care. Schedule of benefits physician services [Internet]. Toronto (ON): The Ministry; 2015.  [cited 2016 Jun 9]. Available from: http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/sob_master11062015.pdf</Citation></Reference><Reference><Citation>Ontario Case Costing Initiative [Internet]. Toronto (ON): Ministry of Health and Long-Term Care; 
2016.  [cited 2016 Jun 9]. Available from: https://hsimi.ca/occp/occpreports/</Citation></Reference><Reference><Citation>Cardiac Care Network. About us [Internet]. Toronto (ON): The Network; 2016.  [cited 2016 Jun 9]. Available from: http://www.ccn.on.ca/ccn_public/FormsAboutCCN/about.aspx</Citation></Reference><Reference><Citation>Singh SM, Micieli A, Wijeysundera HC. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation. 2013;127(24):2414&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23697908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeysundera HC, Tomlinson G, Ko DT, Dzavik V, Krahn MD. Medical therapy v. PCI in stable coronary artery disease: a cost-effectiveness analysis. Med Decis Making. 2013;33(7):891&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">23886676</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Country-specific unit costs [Internet]. Geneva, Switzerland: The Organization; 2016.  [cited 2016 Jun 9]. Available from: http://www.who.int/choice/country/country_specific/en/</Citation></Reference><Reference><Citation>Singh V, Patel SV, Savani C, Patel NJ, Patel N, Arora S, et al. Mechanical Circulatory Support Devices and Transcatheter Aortic Valve Implantation (from the National Inpatient Sample). Am J Cardiol. 2015;116(10):1574&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">26434512</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. 3rd ed. Ottawa (ON): Agency; 2006.</Citation></Reference><Reference><Citation>Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009;53(1):13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19118718</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt BJ, Ballman KV, Brown RD, Jr., Meverden RA, Jacobsen SJ, Roger VL. The incidence of stroke after myocardial infarction: a meta-analysis. Am J Med. 2006;119(4):354 e1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16564779</ArticleId></ArticleIdList></Reference><Reference><Citation>Fokkema ML, van der Vleuten PA, Vlaar PJ, Svilaas T, Zijlstra F. Incidence, predictors, and outcome of reinfarction and stent thrombosis within one year after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Catheter Cardiovasc Interv. 2009;73(5):627&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19309712</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond MF, Sculpher MJ, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes 3rd ed. Oxford, UK: Oxford University Press; 2005.</Citation></Reference><Reference><Citation>Dangas GD, Kini AS, Sharma SK, Henriques JPS, Claessen BE, Dixon SR, et al. Impact of hemodynamic support with impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). Am J Cardiol. 2014;113(2):222&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24527505</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34479456</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-111X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Perfusion</Title><ISOAbbreviation>Perfusion</ISOAbbreviation></Journal><ArticleTitle>Venoarterial extracorporeal membrane oxygenation with intra-aortic balloon pump for postcardiotomy cardiogenic shock: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>142</StartPage><EndPage>149</EndPage><MedlinePgn>142-149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/02676591211042568</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Intra-aortic balloon pump (IABP) is currently recommended as a strategy to address the increased afterload in patients who received venoarterial extracorporeal membrane oxygenation (VA-ECMO). The benefit of VA-ECMO with IABP in postcardiotomy cardiogenic shock is inconclusive. A systematic review and meta-analysis was conducted to assess the influence of VA-ECMO with IABP for postcardiotomy cardiogenic shock (PCS).</AbstractText><AbstractText Label="METHODS">The Cochrane Library, PubMed, and Embase were searched for all articles published from 1 January, 1964 to July 11, 2020. Retrospective cohort studies targeting the comparison of VA-ECMO with IABP and isolated VA-ECMO were included in this study.</AbstractText><AbstractText Label="RESULTS">We included 2251 patients in the present study (917 patients in the VA-ECMO with IABP group and 1334 patients in the isolated VA-ECMO group). Deaths occurred in 589 of 917 patients (64.2%) in the VA-ECMO with IABP group and occurred in 885 of 1334 patients (66.3%) in isolated VA-ECMO group. Pooling the results of all studies showed that VA-ECMO with IABP was not related to a reduced in-hospital mortality in patients who received VA-ECMO for PCS (RR, 0.95; 95% CI, 0.86-1.04; p&#x2009;=&#x2009;0.231). In addition, VA-ECMO with IABP was not related to an increased rate of VA-ECMO weaning in patients who received VA-ECMO for PCS (RR, 1.28; 95% CI, 0.99-1.66; p&#x2009;=&#x2009;0.058).</AbstractText><AbstractText Label="CONCLUSIONS">This study indicates that VA-ECMO with IABP did not improve either in-hospital survival or weaning for VA-ECMO in postcardiotomy cardiogenic shock patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Daochao</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Emergency Department, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, ZheJiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Anyi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Emergency Department, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, ZheJiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>QiongChan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Emergency Department, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, ZheJiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Emergency Department, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, ZheJiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chuang</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9463-5431</Identifier><AffiliationInfo><Affiliation>Emergency Department, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, ZheJiang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Perfusion</MedlineTA><NlmUniqueID>8700166</NlmUniqueID><ISSNLinking>0267-6591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">intra-aortic balloon pump</Keyword><Keyword MajorTopicYN="N">postcardiotomy cardiogenic shock</Keyword><Keyword MajorTopicYN="N">venoarterial extracorporeal membrane oxygenation mortality</Keyword><Keyword MajorTopicYN="N">weaning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>4</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34479456</ArticleId><ArticleId IdType="doi">10.1177/02676591211042568</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32334790</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1608</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Best practice &amp; research. Clinical anaesthesiology</Title><ISOAbbreviation>Best Pract Res Clin Anaesthesiol</ISOAbbreviation></Journal><ArticleTitle>Critical care management in patients with acute liver failure.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>99</EndPage><MedlinePgn>89-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bpa.2020.01.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1521-6896(20)30004-5</ELocationID><Abstract><AbstractText>Acute liver failure (ALF) is defined as severe hepatic dysfunction (marked transaminases elevation, detoxification disorder (jaundice and coagulopathy with international normal ratio (INR)&#xa0;&gt;&#xa0;1.5), the presence of hepatic encephalopathy, and exclusion of underlying chronic liver disease, and a secondary cause like sepsis or cardiogenic shock. Reasons for ALF include paracetamol and warfarin toxicity, autoimmune and viral (mainly hepatitis B and E) hepatitis, and herbal and dietary supplements. Even in terms of meticulous and careful review of the patient, around 20-30% of the reasons remains unknown. In order of its rarity, a randomized controlled trial could hardly be done. However, because of improved ICU treatment, the mortality, even in the advanced stage of ALF decreased. However, in 5-10% of the cases an emergency transplantation is required. This justifies the treatment of this patient cohort in institutions that can provide this kind of treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rifaie</LastName><ForeName>Nadja</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General, Visceral and Transplantation Surgery, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saner</LastName><ForeName>Fuat H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Department of General, Visceral and Transplantation Surgery, Germany. Electronic address: fuat.saner@uni-due.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Best Pract Res Clin Anaesthesiol</MedlineTA><NlmUniqueID>101121446</NlmUniqueID><ISSNLinking>1753-3740</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017114" MajorTopicYN="N">Liver Failure, Acute</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute liver failure</Keyword><Keyword MajorTopicYN="N">coagulopathy</Keyword><Keyword MajorTopicYN="N">hemodynamic</Keyword><Keyword MajorTopicYN="N">intracranial hypertension</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32334790</ArticleId><ArticleId IdType="doi">10.1016/j.bpa.2020.01.004</ArticleId><ArticleId IdType="pii">S1521-6896(20)30004-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31811556</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1568-5888</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation</Title><ISOAbbreviation>Neth Heart J</ISOAbbreviation></Journal><ArticleTitle>Haemodynamic efficacy of microaxial left ventricular assist device in cardiogenic shock: a&#xa0;systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>179</StartPage><EndPage>189</EndPage><MedlinePgn>179-189</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12471-019-01351-7</ELocationID><Abstract><AbstractText>The Impella percutaneous mechanical circulatory support device is designed to augment cardiac output and reduce left ventricular wall stress and aims to improve survival in cases of cardiogenic shock. In this meta-analysis we investigated the haemodynamic effects of the Impella device in a&#xa0;clinical setting. We systematically searched all articles in PubMed/Medline and Embase up to July 2019. The primary outcomes were cardiac power (CP) and cardiac power index (CPI). Survival rates and other haemodynamic data were included as secondary outcomes. For the critical appraisal, we used a&#xa0;modified version of the U.S.&#xa0;Department of Health and Human Services quality assessment form. The systematic review included 12&#xa0;studies with a&#xa0;total of 596 patients. In 258 patients the CP and/or CPI could be extracted. Our meta-analysis showed an increase of 0.39&#x202f;W [95% confidence interval (CI): 0.24, 0.54], (p&#x202f;=&#x2009;0.01) and 0.22&#x202f;W/m<sup>2</sup> (95% CI: 0.18, 0.26), (p&#x202f;&lt;&#x2009;0.01) for the CP and CPI, respectively. The overall survival rate was 56% (95% CI: 0.50, 0.62), (p&#x202f;=&#x2009;0.09). The quality of the studies was moderate, mostly due to the presence of confounders. Our study suggests that in patients with cardiogenic shock, Impella support seems effective in augmenting CP(I). This study merely investigates the haemodynamic effectiveness of the Impella device and does not reflect the complete clinical impact for the patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Dort</LastName><ForeName>D I M</ForeName><Initials>DIM</Initials><Identifier Source="ORCID">0000-0002-1032-7491</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands. d.vandort@radboudumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peij</LastName><ForeName>K R A H</ForeName><Initials>KRAH</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manintveld</LastName><ForeName>O C</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoeks</LastName><ForeName>S E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morshuis</LastName><ForeName>W J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Royen</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Cate</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geuzebroek</LastName><ForeName>G S C</ForeName><Initials>GSC</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Neth Heart J</MedlineTA><NlmUniqueID>101095458</NlmUniqueID><ISSNLinking>1568-5888</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Haemodynamic monitoring</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Left ventricular assist device</Keyword></KeywordList><CoiStatement>D.I.M.&#xa0;van Dort is a&#xa0;shareholder of and consultant to CardiacBooster B.V. and K.R.A.H.&#xa0;Peij Peij is an employee of CardiacBooster B.V. O.C.&#xa0;Manintveld, S.E.&#xa0;Hoeks, W.J.&#xa0;Morshuis, N.&#xa0;van Royen, T.&#xa0;Ten Cate and G.S.C.&#xa0;Geuzebroek declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31811556</ArticleId><ArticleId IdType="pmc">PMC7113339</ArticleId><ArticleId IdType="doi">10.1007/s12471-019-01351-7</ArticleId><ArticleId IdType="pii">10.1007/s12471-019-01351-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wei X, Li T, Hagen B, et al. Short-term mechanical unloading with left ventricular assist devices after acute myocardial infarction conserves calcium cycling and improves heart function. JACC Cardiovasc Interv. 2013;6:406&#x2013;415. doi: 10.1016/j.jcin.2012.12.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2012.12.122</ArticleId><ArticleId IdType="pmc">PMC3752892</ArticleId><ArticleId IdType="pubmed">23523452</ArticleId></ArticleIdList></Reference><Reference><Citation>Burzotta F, Trani C, Doshi SN, et al. Impella ventricular support in clinical practice: collaborative viewpoint from a&#xa0;European expert user group. Int J Cardiol. 2015;201:684&#x2013;691. doi: 10.1016/j.ijcard.2015.07.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.07.065</ArticleId><ArticleId IdType="pubmed">26363632</ArticleId></ArticleIdList></Reference><Reference><Citation>Rihal CS, Naidu SS, Givertz MM, et al. SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care (endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; affirmation of value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d&#x2019;intervention) J Card Fail. 2015;2015(21):499&#x2013;518. doi: 10.1016/j.cardfail.2015.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2015.03.002</ArticleId><ArticleId IdType="pubmed">26036425</ArticleId></ArticleIdList></Reference><Reference><Citation>Stretch R, Sauer CM, Yuh DD, Bonde P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol. 2014;64:1407&#x2013;1415. doi: 10.1016/j.jacc.2014.07.958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.07.958</ArticleId><ArticleId IdType="pubmed">25277608</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill WW, Schreiber T, Wohns DH, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol. 2014;27:1&#x2013;11. doi: 10.1111/joic.12080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joic.12080</ArticleId><ArticleId IdType="pmc">PMC4238821</ArticleId><ArticleId IdType="pubmed">24329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998&#x2013;3002. doi: 10.1161/01.CIR.0000075927.67673.F2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000075927.67673.F2</ArticleId><ArticleId IdType="pubmed">12821585</ArticleId></ArticleIdList></Reference><Reference><Citation>Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a&#xa0;report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44:340&#x2013;348. doi: 10.1016/j.jacc.2004.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2004.03.060</ArticleId><ArticleId IdType="pubmed">15261929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sionis A, Rivas-Lasarte M, Mebazaa A, et al. Current use and impact on 30-day mortality of pulmonary artery catheter in cardiogenic shock patients: results from the CardShock study. J Intensive Care Med. 2019 doi: 10.1177/0885066619828959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066619828959</ArticleId><ArticleId IdType="pubmed">30732522</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006&#x2013;1012. doi: 10.1016/j.jclinepi.2009.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2009.06.005</ArticleId><ArticleId IdType="pubmed">19631508</ArticleId></ArticleIdList></Reference><Reference><Citation>Quality assessment tool for before-after (pre-post) studies with no control group [available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools]. Accessed 12 January 2018.</Citation></Reference><Reference><Citation>Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a&#xa0;sample. BMC Med Res Methodol. 2005;5:13. doi: 10.1186/1471-2288-5-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-5-13</ArticleId><ArticleId IdType="pmc">PMC1097734</ArticleId><ArticleId IdType="pubmed">15840177</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyns B, Dens J, Sergeant P, et al. Initial experiences with the Impella device in patients with cardiogenic shock&#x2014;Impella support for cardiogenic shock. Thorac cardiovasc Surg. 2003;51:312&#x2013;317. doi: 10.1055/s-2003-45422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2003-45422</ArticleId><ArticleId IdType="pubmed">14669126</ArticleId></ArticleIdList></Reference><Reference><Citation>Dens J, Meyns B, Hilgers R-D, et al. First experience with the Impella Recover&#xae; LP 2.5 micro axial pump in patients with cardiogenic shock or undergoing high-risk revascularisation. EuroIntervention. 2006;2:84&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">19755241</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a&#xa0;percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584&#x2013;1588. doi: 10.1016/j.jacc.2008.05.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2008.05.065</ArticleId><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresson D, Sibellas F, Farhat F, et al. Preliminary experience with Impella Recover &#xae; LP5.0 in nine patients with cardiogenic shock: a&#xa0;new circulatory support system in the intensive cardiac care unit. Arch Cardiovasc Dis. 2011;104:458&#x2013;464. doi: 10.1016/j.acvd.2011.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2011.04.005</ArticleId><ArticleId IdType="pubmed">21944148</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith BP, Anderson MB, Samuels LE, et al. The RECOVER I: a&#xa0;multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiov Sur. 2013;145:548&#x2013;554. doi: 10.1016/j.jtcvs.2012.01.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2012.01.067</ArticleId><ArticleId IdType="pubmed">22405676</ArticleId></ArticleIdList></Reference><Reference><Citation>Casassus F, Corre J, Leroux L, et al. The use of Impella 2.5 in severe refractory cardiogenic shock complicating an acute myocardial infarction. J Interv Cardiol. 2015;28:41&#x2013;50. doi: 10.1111/joic.12172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joic.12172</ArticleId><ArticleId IdType="pubmed">25689547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima B, Kale P, Gonzalez-Stawinski GV, et al. Effectiveness and safety of the Impella 5.0 as a&#xa0;bridge to cardiac transplantation or durable left ventricular assist device. Am J Cardiol. 2016;117:1622&#x2013;1628. doi: 10.1016/j.amjcard.2016.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2016.02.038</ArticleId><ArticleId IdType="pubmed">27061705</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiller P, Vikholm P, The Impella HL. R) Recover mechanical assist device in acute cardiogenic shock: a&#xa0;single-centre experience of 66 patients. Interact CardioVasc Thorac Surg. 2016;22:452&#x2013;458. doi: 10.1093/icvts/ivv305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivv305</ArticleId><ArticleId IdType="pubmed">26763043</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph SM, Brisco MA, Colvin M, et al. Women with cardiogenic shock derive greater benefit from early mechanical circulatory support: an update from the cVAD registry. J Interv Cardiol. 2016;29:248&#x2013;256. doi: 10.1111/joic.12298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joic.12298</ArticleId><ArticleId IdType="pubmed">27229327</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastroianni C, Bouabdallaoui N, Leprince P, Lebreton G. Short-term mechanical circulatory support with the Impella 5.0 device for cardiogenic shock at La Pitie-Salpetriere. Eur Heart J Acute Cardiovasc Care. 2017;6:87&#x2013;92. doi: 10.1177/2048872616633877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872616633877</ArticleId><ArticleId IdType="pubmed">26873912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall SA, Uriel N, Carey SA, et al. Use of a&#xa0;percutaneous temporary circulatory support device as a&#xa0;bridge to decision during acute decompensation of advanced heart failure. J Heart Lung Transplant. 2018;37:100&#x2013;106. doi: 10.1016/j.healun.2017.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2017.09.020</ArticleId><ArticleId IdType="pubmed">29056460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69:278&#x2013;287. doi: 10.1016/j.jacc.2016.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.10.022</ArticleId><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139:1249&#x2013;1258. doi: 10.1161/CIRCULATIONAHA.118.036614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.036614</ArticleId><ArticleId IdType="pubmed">30586755</ArticleId></ArticleIdList></Reference><Reference><Citation>Annamalai SK, Esposito ML, Jorde L, et al. The Impella microaxial flow catheter is safe and effective for treatment of myocarditis complicated by cardiogenic shock: an analysis from the global cVAD registry. J Card Fail. 2018;24:706&#x2013;710. doi: 10.1016/j.cardfail.2018.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2018.09.007</ArticleId><ArticleId IdType="pubmed">30244180</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstrom AE, Granfeldt H, Seybold-Epting W, et al. Mechanical circulatory support with the Impella 5.0 device for postcardiotomy cardiogenic shock: a&#xa0;three-center experience. Minerva Cardioangiol. 2013;61:539&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">24096248</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegenthaler MP, Brehm K, Strecker T, et al. The Impella Recover microaxial left ventricular assist device reduces mortality for postcardiotomy failure: a&#xa0;three-center experience. J Thorac Cardiovasc Surg. 2004;127:812&#x2013;822. doi: 10.1016/j.jtcvs.2003.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2003.09.055</ArticleId><ArticleId IdType="pubmed">15001911</ArticleId></ArticleIdList></Reference><Reference><Citation>Nativi-Nicolau J, Selzman CH, Fang JC, Stehlik J. Pharmacologic therapies for acute cardiogenic shock. Curr Opin Cardiol. 2014;29:250&#x2013;257. doi: 10.1097/HCO.0000000000000057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HCO.0000000000000057</ArticleId><ArticleId IdType="pubmed">24686400</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitake I, Hata M, Sezai A, et al. The effect of combined treatment with Impella((R)) and landiolol in a&#xa0;swine model of acute myocardial infarction. J Artif Organs. 2012;15:231&#x2013;239. doi: 10.1007/s10047-012-0640-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10047-012-0640-x</ArticleId><ArticleId IdType="pubmed">22527977</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Schreiber TL, Grines CL, et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol. 2017;119:845&#x2013;851. doi: 10.1016/j.amjcard.2016.11.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2016.11.037</ArticleId><ArticleId IdType="pubmed">28040188</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazkani M, Murarka S, Kobayashi A, et al. A retrospective analysis of Impella use in all-comers: 1-year outcomes. J Interv Cardiol. 2017;30:577&#x2013;583. doi: 10.1111/joic.12409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joic.12409</ArticleId><ArticleId IdType="pubmed">28736903</ArticleId></ArticleIdList></Reference><Reference><Citation>Meraj PM, Editorial DR. Stop thinking and start acting: Early Impella placement associated with improved outcomes, again! J Interv Cardiol. 2017;30:584&#x2013;585. doi: 10.1111/joic.12434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joic.12434</ArticleId><ArticleId IdType="pubmed">29193318</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito ML, Zhang Y, Qiao X, et al. Left ventricular unloading before reperfusion promotes functional recovery after acute myocardial infarction. J Am Coll Cardiol. 2018;72:501&#x2013;514. doi: 10.1016/j.jacc.2018.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.05.034</ArticleId><ArticleId IdType="pmc">PMC6817809</ArticleId><ArticleId IdType="pubmed">30049311</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Schreiber T, Dixon S, et al. Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: the Detroit cardiogenic shock initiative. Catheter Cardiovasc Interv. 2018;91:454&#x2013;461. doi: 10.1002/ccd.27427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.27427</ArticleId><ArticleId IdType="pubmed">29266676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, de Brabander J, Karami M, et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. Eur Heart J Acute Cardiovasc Care. 2019;8:338&#x2013;349. doi: 10.1177/2048872618805486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872618805486</ArticleId><ArticleId IdType="pmc">PMC6616211</ArticleId><ArticleId IdType="pubmed">30403366</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28843328</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1916-7075</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Canadian journal of cardiology</Title><ISOAbbreviation>Can J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Transcatheter vs Surgical Aortic Valve Replacement for Aortic Stenosis in Low-Intermediate Risk Patients: A Meta-analysis.</ArticleTitle><Pagination><StartPage>1171</StartPage><EndPage>1179</EndPage><MedlinePgn>1171-1179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cjca.2017.06.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0828-282X(17)30311-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Transcatheter aortic valve replacement (TAVR) has emerged as the treatment of choice for patients with severe aortic stenosis at high surgical risk; the role of TAVR compared with surgical aortic valve replacement (SAVR) in the low-intermediate surgical risk population remains uncertain. Our primary objective was to determine differences in 30-day and late mortality in patients treated with TAVR compared with SAVR at low-intermediate risk (Society of Thoracic Surgeons Predicted Risk of Mortality &lt; 10%).</AbstractText><AbstractText Label="METHODS">Medline and Embase were searched from 2010 to March 2017 for studies that compared TAVR with SAVR in the low-intermediate surgical risk population, restricted to randomized clinical trials and matched observational studies. Two investigators independently abstracted the data and a random effects meta-analysis was performed.</AbstractText><AbstractText Label="RESULTS">Four randomized clinical trials (n&#xa0;= 4042) and 9 propensity score-matched observational studies (n&#xa0;= 4192) were included in the meta-analysis (n&#xa0;= 8234). There was no difference in 30-day mortality between TAVR and SAVR (3.2% vs 3.1%, pooled risk ratio: 1.02; 95% confidence interval, 0.80-1.30; P&#xa0;= 0.89; I<sup>2</sup>&#xa0;= 0%) or mortality at a median of 1.5-year follow-up (incident rate ratio: 1.01; 95% confidence interval, 0.90-1.15; P&#xa0;= 0.83; I<sup>2</sup>&#xa0;= 0%). There was a higher risk of pacemaker implantation and greater than trace aortic insufficiency in the TAVR group whereas the risk of early stroke, atrial fibrillation, acute kidney injury, cardiogenic shock, and major bleeding was higher in the SAVR group.</AbstractText><AbstractText Label="CONCLUSIONS">Although there was no difference in 30-day and late mortality, the rate of complications differed between TAVR and SAVR in the low-intermediate surgical risk population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Derrick Y</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vo</LastName><ForeName>Thin Xuan</ForeName><Initials>TX</Initials><AffiliationInfo><Affiliation>School of Medicine, Queen's University, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijeysundera</LastName><ForeName>Harindra C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Cardiology, Department of Medicine, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Dennis T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Cardiology, Department of Medicine, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Rodolfo Vigil</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedrich</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fremes</LastName><ForeName>Stephen E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Electronic address: Stephen.fremes@sunnybrook.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Cardiol</MedlineTA><NlmUniqueID>8510280</NlmUniqueID><ISSNLinking>0828-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="N">Aortic Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="N">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="Y">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="N">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28843328</ArticleId><ArticleId IdType="doi">10.1016/j.cjca.2017.06.005</ArticleId><ArticleId IdType="pii">S0828-282X(17)30311-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39209579</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0938</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>Cardiovascular revascularization medicine : including molecular interventions</Title><ISOAbbreviation>Cardiovasc Revasc Med</ISOAbbreviation></Journal><ArticleTitle>Outcomes following TAVR in patients with cardiogenic shock: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>8</StartPage><EndPage>13</EndPage><MedlinePgn>8-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.carrev.2024.08.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1553-8389(24)00622-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While transcatheter aortic valve replacement (TAVR) has broadened treatment options for critically ill patients, outcomes among those with concomitant cardiogenic shock (CS) are not well-explored.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a comprehensive search of major databases for studies comparing outcomes following TAVR in patients with and without CS since inception up to October 31, 2023. Our meta-analysis included five non-randomized observational. Dichotomous outcomes were assessed using the Mantel-Haenszel method (risk ratio, 95&#xa0;% CI), and continuous outcomes were evaluated using mean difference and 95&#xa0;% CI with the inverse variance method. Statistical heterogeneity was determined using the inconsistency test (I<sup>2</sup>).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 26,283 patients across five studies, 30-day mortality was higher in the CS group (7267 patients; 27.6&#xa0;%) compared to those without CS (OR 3.41, 95&#xa0;% CI [2.01, 5.76], p&#xa0;&lt;&#xa0;0.01), as well as 30-day major vascular complications (OR 1.72, 95&#xa0;% CI [1.54, 1.92], p&#xa0;&lt;&#xa0;0.01). At 1-year follow-up, there was no statistically significant difference in mortality rates between the compared groups (OR 2.68, 95&#xa0;% CI [0.53, 13.46], p&#xa0;=&#xa0;0.12). No significant between-group differences were observed in the likelihood of 30-day aortic valve reintervention (OR 3.20, 95&#xa0;% CI [0.63, 16.22], p&#xa0;=&#xa0;0.09) or post-TAVR aortic insufficiency (OR 0.91, 95&#xa0;% CI [0.33, 2.51], p&#xa0;=&#xa0;0.73). Furthermore, 30-day stroke, pacemaker implantation, and in-hospital major bleeding were comparable between both cohorts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among patients undergoing TAVR, short-term mortality is higher but one-year outcomes are similar when comparing those with, to those without, CS. Future studies should examine whether TAVR outcomes are improved when the procedure is delayed to optimize CS and when delay is not possible, whether particular management strategies lead to more favorable periprocedural outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jabri</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, William Beaumont University Hospital, Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayyad</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rutgers New Jersey Medical school, Newark, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albandak</LastName><ForeName>Maram</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hospital Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Abdouh</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hospital Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madanat</LastName><ForeName>Luai</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, William Beaumont University Hospital, Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalefa</LastName><ForeName>Basma Badrawy</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhuneafat</LastName><ForeName>Laith</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayyad</LastName><ForeName>Asem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemor</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mhanna</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Iowa, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Jebaje</LastName><ForeName>Zaid</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fadel</LastName><ForeName>Raef</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Pedro Engel</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagur</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, London Health Sciences Centre, Western University, Canada Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Ivan D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, William Beaumont University Hospital, Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbas</LastName><ForeName>Amr E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, William Beaumont University Hospital, Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoli</LastName><ForeName>Tiberio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dee Dee</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Vikas</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alaswad</LastName><ForeName>Khaldoon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronow</LastName><ForeName>Herbert D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlQarqaz</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villablanca</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University, College of Human Medicine, Detroit, MI, USA. Electronic address: pvillab1@hfhs.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Revasc Med</MedlineTA><NlmUniqueID>101238551</NlmUniqueID><ISSNLinking>1878-0938</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="Y">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="Y">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="Y">Aortic Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aortic stenosis</Keyword><Keyword MajorTopicYN="N">Aortic valvular disease</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">TAVR</Keyword><Keyword MajorTopicYN="N">Transcatheter aortic valve replacement</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>21</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39209579</ArticleId><ArticleId IdType="doi">10.1016/j.carrev.2024.08.002</ArticleId><ArticleId IdType="pii">S1553-8389(24)00622-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37161616</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1594</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Artificial organs</Title><ISOAbbreviation>Artif Organs</ISOAbbreviation></Journal><ArticleTitle>Percutaneous decannulation of venoarterial extracorporeal membrane oxygenation using the Manta vascular closure device: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1431</StartPage><EndPage>1441</EndPage><MedlinePgn>1431-1441</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/aor.14554</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To perform a systematic review and meta-analysis of the techniques and outcomes associated with percutaneous decannulation of venoarterial extracorporeal membrane oxygenation (VA-ECMO) using the Manta vascular closure device.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Peripheral VA-ECMO can be used to treat critically ill patients with conditions such as refractory cardiogenic shock. After percutaneous implantation of VA-ECMO, VA-ECMO can also be decannulated completely percutaneously by using a vascular closure device. The Manta vascular closure device is a dedicated device used in the closure of large-bore arteriotomies by sandwiching the arteriotomy with an intra-arterial toggle and an extraluminal collagen plug.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a thorough literature search using various electronic databases. We included studies that reported outcomes after peripheral femorofemoral VA-ECMO decannulation with the Manta vascular closure device. We performed a meta-analysis of proportions on outcome measures, including technical success, bleeding complications, vascular complications, wound complications, major amputation, and procedural-related deaths.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included seven studies with a total of 116 patients. The overall technical success of percutaneous decannulation of VA-ECMO with the Manta vascular closure device was 93.7%. The overall incidence of bleeding, vascular and wound complications was 1.7%, 13.8%, and 3.4%, respectively. No patient required lower limb amputation or died due to VA-ECMO decannulation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Percutaneous decannulation with the Manta vascular closure device is an effective and safe procedure that should be considered in suitable patients on VA-ECMO.</AbstractText><CopyrightInformation>&#xa9; 2023 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Jun Jie</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic and Vascular Surgery, National University Heart Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingVaSC, Singapore Vascular Surgical Collaborative, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Stefanie H T</ForeName><Initials>SHT</Initials><AffiliationInfo><Affiliation>SingVaSC, Singapore Vascular Surgical Collaborative, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Joseph K W</ForeName><Initials>JKW</Initials><Identifier Source="ORCID">0000-0002-2906-2550</Identifier><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic and Vascular Surgery, National University Heart Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingVaSC, Singapore Vascular Surgical Collaborative, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Karen K W</ForeName><Initials>KKW</Initials><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic and Vascular Surgery, National University Heart Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingVaSC, Singapore Vascular Surgical Collaborative, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Mark D S</ForeName><Initials>MDS</Initials><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic and Vascular Surgery, National University Heart Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingVaSC, Singapore Vascular Surgical Collaborative, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Mohamed A I</ForeName><Initials>MAI</Initials><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic and Vascular Surgery, National University Heart Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingVaSC, Singapore Vascular Surgical Collaborative, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loh</LastName><ForeName>Stanley E K</ForeName><Initials>SEK</Initials><AffiliationInfo><Affiliation>SingVaSC, Singapore Vascular Surgical Collaborative, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Woodlands Health Campus, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choong</LastName><ForeName>Andrew M T L</ForeName><Initials>AMTL</Initials><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic and Vascular Surgery, National University Heart Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingVaSC, Singapore Vascular Surgical Collaborative, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Artif Organs</MedlineTA><NlmUniqueID>7802778</NlmUniqueID><ISSNLinking>0160-564X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065506" MajorTopicYN="Y">Vascular Closure Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020878" MajorTopicYN="N">Device Removal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">decannulation</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">percutaneous</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37161616</ArticleId><ArticleId IdType="doi">10.1111/aor.14554</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Eckman PM, Katz JN, El Banayosy A, Bohula EA, Sun B, van Diepen S. Veno-arterial extracorporeal membrane oxygenation for cardiogenic shock: an introduction for the busy clinician. Circulation. 2019;140:2019-37.</Citation></Reference><Reference><Citation>Jayaraman AL, Cormican D, Shah P, Ramakrishna H. Cannulation strategies in adult veno-arterial and veno-venous extracorporeal membrane oxygenation: techniques, limitations, and special considerations. Ann Card Anaesth. 2017;20:S11-8.</Citation></Reference><Reference><Citation>Danial P, Hajage D, Nguyen LS, Mastroianni C, Demondion P, Schmidt M, et al. Percutaneous versus surgical femoro-femoral veno-arterial ECMO: a propensity score matched study. Intensive Care Med. 2018;44:2153-61.</Citation></Reference><Reference><Citation>van Gils L, De Jaegere PPT, Roubin G, Van Mieghem NM. The MANTA vascular closure device. J Am Coll Cardiol Intv. 2016;9:1195-6.</Citation></Reference><Reference><Citation>Krajcer Z, Wood DA, Strickman N, Bernardo N, Metzger C, Aziz M, et al. Pivotal clinical study to evaluate the safety and effectiveness of the MANTA vascular closure device during percutaneous EVAR and TEVAR procedures. J Endovasc Ther. 2020;27:414-20.</Citation></Reference><Reference><Citation>Kroon HG, Tonino PAL, Savontaus M, Amoroso G, Laine M, Christiansen EH, et al. Dedicated plug based closure for large bore access-the MARVEL prospective registry. Catheter Cardiovasc Interv. 2021;97:1270-8.</Citation></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3. Updated February 2022. Accessed March 15, 2022. http://www.training.cochrane.org/handbook</Citation></Reference><Reference><Citation>Page MJ, JE MK, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 2021(372):n71.</Citation></Reference><Reference><Citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardised bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736-47.</Citation></Reference><Reference><Citation>Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18:2127-33.</Citation></Reference><Reference><Citation>Au S-Y, Chan K-S, Fong K-M, Wong HMR, Fong YH, Chui SF, et al. Comparing the outcomes of bedside percutaneous VA-ECMO decannulation by ProGlide and manta in a high-ECMO-volume center in Hong Kong. Artif Organs. 2022;46(7):1382-8. https://doi.org/10.1111/aor.14198</Citation></Reference><Reference><Citation>Dal&#xe9;n M, Settergren M, Kastengren M, Ullstr&#xf6;m P, Fux T. Percutaneous decannulation of extracorporeal membrane oxygenation using a plug-based closure device. Catheter Cardiovasc Interv. 2022;99:1945-52. https://doi.org/10.1002/ccd.30096</Citation></Reference><Reference><Citation>Kalverkamp S, Hatam N, Kersten A, et al. Interventional closure of the femoral artery access site after percutaneous Venoarterial ECMO: the Aachen experience. 50th annual meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG; 2021. Epub ahead of print January 2021. https://doi.org/10.1055/s-0041-1725787</Citation></Reference><Reference><Citation>Pingpoh C, Kondov S, Schroefel H, Kreibich M, Puiu P, Kueri S, et al. Efficacy of vascular closure devices in closing large-bore sheath arterial sites after treatment with extracorporeal life support system. Thorac Cardiovasc Surg. 2021;69:537-41.</Citation></Reference><Reference><Citation>Bemtgen X, Heidt T, Zotzmann V, Rilinger J, Wengenmayer T, Biever PM, et al. Venoarterial extracorporeal membrane oxygenation decannulation using the novel manta vascular closure device. Eur Heart J Acute Cardiovasc Care. 2020;9:342-7.</Citation></Reference><Reference><Citation>Shah A, Ghoreishi M, Taylor BS, Toursavadkohi S, Kaczorowski DJ, Pasrija C, et al. Complete percutaneous decannulation from femoral venoarterial extracorporeal membrane oxygenation. JTCVS Tech. 2021;6:75-81.</Citation></Reference><Reference><Citation>Kmiec L, Philipp A, Holzamer A, et al. Decannulation after VA-ECMO with a new vascular closure device. Abstracts for the 8th EuroELSO congress on ECMO-ECLS, 10-13 April 2019. Volume 34. Barcelona, Spain: Perfusion; 2019. p. 82-251.</Citation></Reference><Reference><Citation>Wood DA, Krajcer Z, Sathananthan J, Strickman N, Metzger C, Fearon W, et al. Pivotal clinical study to evaluate the safety and effectiveness of the MANTA percutaneous vascular closure device. Circ Cardiovasc Interv. 2019;12:e007258.</Citation></Reference><Reference><Citation>D&#xed;ez-Delhoyo F, Elizaga J, Gutierrez-Iba&#xf1;es E, Fern&#xe1;ndez-Aviles F. Toggle malapposition and femoral subocclusion as a potential complication of manta closure device during TAVR. J Invasive Cardiol. 2019;31:E300.</Citation></Reference><Reference><Citation>Moccetti F, Brinkert M, Seelos R, Ockert S, Bossard M, Cuculi F, et al. Insights from a multidisciplinary introduction of the MANTA vascular closure device. JACC Cardiovasc Interv. 2019;12:1730-6.</Citation></Reference><Reference><Citation>Au S-Y, Fong K-M, Ng W-YG, Lee KYM, So SO, Leung KHA. Real-time ultrasound-guided bedside closure of arteriotomy wound using MANTA closure device during venoarterial extracorporeal membrane oxygenation decannulation. Perfusion. 2021;36:118-21.</Citation></Reference><Reference><Citation>Dahlbacka S, V&#xe4;h&#xe4;silta T, Moriyama N, Vainikka T, Aho P, Laine M. Ultrasound-navigated manta deployment after removal of extracorporeal membrane oxygenation cannula. Ann Thorac Surg. 2020;110:e307-9.</Citation></Reference><Reference><Citation>Sharma RK, Poulin M, Tamez-Aguilar H, Pinto DS. Post hoc closure of large bore vascular access using the MANTA closure device. Catheter Cardiovasc Interv. 2021;97:282-6.</Citation></Reference><Reference><Citation>Martin-Tuffreau A-S, Bagate F, Boukantar M, Saiydoun G, Mangiameli A, Rostain L, et al. Complete percutaneous angio-guided approach using preclosing for venoarterial extracorporeal membrane oxygenation implantation and explantation in patients with refractory cardiogenic shock or cardiac arrest. Crit Care. 2021;25:93.</Citation></Reference><Reference><Citation>Bechara CF, Barshes NR, Pisimisis G, Chen H, Pak T, Lin PH, et al. Predicting the learning curve and failures of total percutaneous endovascular aortic aneurysm repair. J Vasc Surg. 2013;57:72-6.</Citation></Reference><Reference><Citation>Gao H, Luo M, Fang K, Fan B, Zhao J, Xue Y, et al. Cumulative sum analysis of the learning curve for the preclosure technique using Proglide. Interact Cardiovasc Thorac Surg. 2020;30:280-6.</Citation></Reference><Reference><Citation>Miyashita H, Moriyama N, Laine M. Incidence and predictors of access site vascular complications following ultrasound-guided MANTA closure deployment. J Endovasc Ther. 2022;29(4):576-585.</Citation></Reference><Reference><Citation>Hwang J-W, Yang JH, Sung K, Song YB, Hahn JY, Choi JH, et al. Percutaneous removal using Perclose ProGlide closure devices versus surgical removal for weaning after percutaneous cannulation for venoarterial extracorporeal membrane oxygenation. J Vasc Surg. 2016;63:998-1003.e1.</Citation></Reference><Reference><Citation>Majunke N, Mangner N, Linke A, Boudriot E, Erbs S, Tietz F, et al. Comparison of percutaneous closure versus surgical femoral cutdown for decannulation of large-sized arterial and venous access sites in adults after successful weaning of veno-arterial extracorporeal membrane oxygenation. J Invasive Cardiol. 2016;28:415-9.</Citation></Reference><Reference><Citation>Pellenc Q, Girault A, Roussel A, Aguir S, Cerceau P, Longrois D, et al. Preclosing of the femoral artery allows total percutaneous venoarterial extracorporeal membrane oxygenation and prevents groin wound infection after lung transplantation. Eur J Cardiothorac Surg. 2020;58:371-8.</Citation></Reference><Reference><Citation>Perclose ProGlide Deployment. Abbott. Accessed April 9, 2022. https://www.cardiovascular.abbott/int/en/hcp/products/peripheral-intervention/vessel-closure/perclose-proglide-suture-mediated-closure-system/deployment.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34570351</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1496-8975</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Canadian journal of anaesthesia = Journal canadien d'anesthesie</Title><ISOAbbreviation>Can J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Anesthetic implications of perioperative Takotsubo syndrome: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>1747</StartPage><EndPage>1755</EndPage><MedlinePgn>1747-1755</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12630-021-02109-9</ELocationID><Abstract><AbstractText Label="PURPOSE">Takotsubo syndrome is a reversible cardiomyopathy triggered by emotional or physical stressors. Although surgeries could be physical triggers, this has been scantily investigated. We aimed to describe the baseline characteristics, surgical/anesthesia-related triggering events, clinical presentation, and in-hospital outcomes of a cohort of patients diagnosed with perioperative Takotsubo syndrome.</AbstractText><AbstractText Label="METHODS">In this retrospective study, we included all consecutive adult patients who were admitted to Hospital Italiano de Buenos Aires between 1 June 2008 and 30 November 2017 and diagnosed with Takotsubo syndrome according to the revised criteria of the European Society of Cardiology during hospitalization.</AbstractText><AbstractText Label="RESULTS">We diagnosed 21 patients with perioperative Takotsubo syndrome out of 305,906 patients undergoing procedures with anesthesia care. The median (interquartile range [IQR]) patient age was 75 (55-82) yr, and 16 (76%) were women. The median (IQR) left ventricular ejection fraction was 35 (35-42)% at diagnosis and 55 (46-55)% at discharge. Fifteen patients (71%) required inotropic/vasopressor support; however, this is a controversial treatment considering the physiopathology of the syndrome. Severe complications such as unexplained syncope/cardiac arrest, cardiogenic shock, and ventricular thrombus formation occurred in seven (33%) patients, and two (10%) patients died. These results were compared with 31 patients who experienced non-perioperative Takotsubo syndrome during the same period of time.</AbstractText><AbstractText Label="CONCLUSION">Perioperative Takotsubo syndrome is a reversible cardiomyopathy. Nevertheless, it seems to be associated with severe complications, the need for aggressive treatment, and non-negligible mortality.</AbstractText><CopyrightInformation>&#xa9; 2021. Canadian Anesthesiologists' Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garc&#xed;a Guzzo</LastName><ForeName>Mar&#xed;a Eugenia</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-7172-3367</Identifier><AffiliationInfo><Affiliation>Anesthesiology Department, Hospital Italiano de Buenos Aires, Autonomous City of Buenos Aires, Teniente General Juan Domingo Per&#xf3;n 4190, 1199, Buenos Aires, Argentina. mariae.garcia@hospitalitaliano.org.ar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez Novas</LastName><ForeName>Delfina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Hospital Italiano de Buenos Aires, Autonomous City of Buenos Aires, Teniente General Juan Domingo Per&#xf3;n 4190, 1199, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iglesias</LastName><ForeName>Federico &#xc1;ngel</ForeName><Initials>F&#xc1;</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Hospital Italiano de Buenos Aires, Autonomous City of Buenos Aires, Teniente General Juan Domingo Per&#xf3;n 4190, 1199, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deluca Bisurgi</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Hospital Italiano de Buenos Aires, Autonomous City of Buenos Aires, Teniente General Juan Domingo Per&#xf3;n 4190, 1199, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domenech</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Hospital Italiano de Buenos Aires, Autonomous City of Buenos Aires, Teniente General Juan Domingo Per&#xf3;n 4190, 1199, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terrasa</LastName><ForeName>Sergio Adri&#xe1;n</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Research Department, Hospital Italiano de Buenos Aires, Autonomous City de Buenos Aires, Teniente General Juan Domingo Per&#xf3;n 4190, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Implications anesth&#xe9;siques du syndrome p&#xe9;riop&#xe9;ratoire de Takotsubo : une &#xe9;tude de cohorte r&#xe9;trospective.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Anaesth</MedlineTA><NlmUniqueID>8701709</NlmUniqueID><ISSNLinking>0832-610X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Can J Anaesth. 2021 Dec;68(12):1738-1743. doi: 10.1007/s12630-021-02108-w.</RefSource><PMID Version="1">34580833</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000777" MajorTopicYN="Y">Anesthetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054549" MajorTopicYN="Y">Takotsubo Cardiomyopathy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>R&#xe9;SUM&#xe9;: OBJECTIF: Le syndrome de Takotsubo est une cardiomyopathie r&#xe9;versible d&#xe9;clench&#xe9;e par des facteurs de stress &#xe9;motionnels ou physiques. Bien que les chirurgies puissent constituer des d&#xe9;clencheurs physiques, cela n&#x2019;a &#xe9;t&#xe9; que peu &#xe9;tudi&#xe9;. Nous avons cherch&#xe9; &#xe0; d&#xe9;crire les caract&#xe9;ristiques de base, les &#xe9;v&#xe9;nements d&#xe9;clencheurs chirurgicaux / anesth&#xe9;siques, la pr&#xe9;sentation clinique et les devenirs hospitaliers d&#x2019;une cohorte de patients ayant re&#xe7;u un diagnostic de syndrome p&#xe9;riop&#xe9;ratoire de Takotsubo. M&#xe9;THODE: Dans cette &#xe9;tude r&#xe9;trospective, nous avons inclus tous les patients adultes cons&#xe9;cutifs qui ont &#xe9;t&#xe9; admis &#xe0; l&#x2019;H&#xf4;pital Italiano de Buenos Aires entre le 1<sup>er</sup> juin 2008 et le 30 novembre 2017 et qui ont re&#xe7;u un diagnostic de syndrome de Takotsubo selon les crit&#xe8;res r&#xe9;vis&#xe9;s de la Soci&#xe9;t&#xe9; europ&#xe9;enne de cardiologie pendant leur hospitalisation. R&#xe9;SULTATS: Nous avons diagnostiqu&#xe9; 21 patients atteints d&#x2019;un syndrome de Takotsubo p&#xe9;riop&#xe9;ratoire sur 305 906 patients subissant des interventions n&#xe9;cessitant des soins d&#x2019;anesth&#xe9;sie. L&#x2019;&#xe2;ge m&#xe9;dian des patients (&#xe9;cart interquartile [&#xc9;IQ]) &#xe9;tait de 75 ans (55-82 ans) et 16 (76 %) &#xe9;taient des femmes. La m&#xe9;diane de la fraction d&#x2019;&#xe9;jection ventriculaire gauche (&#xc9;IQ) &#xe9;tait de 35 (35 &#xe0; 42) % au moment du diagnostic et de 55 (46 &#xe0; 55 ) % au cong&#xe9;. Quinze patients (71 %) ont eu besoin d&#x2019;un soutien inotrope/vasopresseur; cependant, il s&#x2019;agit d&#x2019;un traitement controvers&#xe9; compte tenu de la physiopathologie du syndrome. Des complications graves telles qu&#x2019;une syncope / un arr&#xea;t cardiaque inexpliqu&#xe9;, un choc cardiog&#xe9;nique et la formation de thrombus ventriculaire, sont survenues chez sept patients (33&#xa0;%), et deux (10&#xa0;%) patients sont d&#xe9;c&#xe9;d&#xe9;s. Ces r&#xe9;sultats ont &#xe9;t&#xe9; compar&#xe9;s &#xe0; 31 patients ayant pr&#xe9;sent&#xe9; un syndrome de Takotsubo non p&#xe9;riop&#xe9;ratoire au cours de la m&#xea;me p&#xe9;riode. CONCLUSION: Le syndrome de Takotsubo p&#xe9;riop&#xe9;ratoire est une cardiomyopathie r&#xe9;versible. N&#xe9;anmoins, il semble &#xea;tre associ&#xe9; &#xe0; des complications graves, &#xe0; la n&#xe9;cessit&#xe9; d&#x2019;un traitement agressif et &#xe0; une mortalit&#xe9; non n&#xe9;gligeable.</AbstractText><CopyrightInformation>&#xa9; 2021. Canadian Anesthesiologists' Society.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Perioperative</Keyword><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34570351</ArticleId><ArticleId IdType="doi">10.1007/s12630-021-02109-9</ArticleId><ArticleId IdType="pii">10.1007/s12630-021-02109-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hessel EA 2nd. Takotsubo cardiomyopathy and its relevance to anesthesiology: a narrative review. Can J Anesth 2016; 63: 1059-74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-016-0680-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Helwani MA, Amin A, Lavigne P, et al. Etiology of acute coronary syndrome after noncardiac surgery. Anesthesiology 2018; 128: 1084-91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000002107</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, Bossone E, Schneider B, et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2016; 18: 8-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossone E, Savarese G, Ferrara F, et al. Takotsubo cardiomyopathy: overview. Heart Fail Clin 2013; 9: 249-66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hfc.2012.12.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Komamura K, Fukui M, Iwasaku T, Hirotani S, Masuyama T. Takotsubo cardiomyopathy: pathophysiology, diagnosis and treatment. World J Cardiol 2014; 6: 602-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.4330/wjc.v6.i7.602</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh K, Carson K, Shah R, et al. Meta-analysis of clinical correlates of acute mortality in takotsubo cardiomyopathy. Am J Cardiol 2014; 113: 1420-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2014.01.419</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina de Chazal H, Del Buono MG, Keyser-Marcus L, et al. Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72: 1955-71.</Citation></Reference><Reference><Citation>Dias A, N&#xfa;&#xf1;ez Gil IJ, Santoro F, et al. Takotsubo syndrome: state-of-the-art review by an expert panel - part 1. Cardiovasc Revasc Med 2019; 20: 70-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2018.11.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias A, N&#xfa;&#xf1;ez Gil IJ, Santoro F, et al. Takotsubo syndrome: state-of-the-art review by an expert panel - part 2. Cardiovasc Revasc Med 2019; 20: 153-66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2018.11.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria and pathophysiology. Eur Heart J 2018; 39: 2032-46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J 2018; 39: 2047-62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri JR, Kato K, Cammann VL, et al. Long-term prognosis of patients with Takotsubo syndrome. J Am Coll Cardiol 2018; 72: 874-82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.06.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 2015; 373: 929-38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1406761</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol 2010; 55: 333-41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.08.057</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 2011; 306: 277-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">21771988</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerasi C, Koifman E, Weissman G, et al. Impact of triggering event in outcomes of stress-induced (Takotsubo) cardiomyopathy. Eur Heart J Acute Cardiovasc Care 2017; 6: 280-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872616633881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PH, Song JK, Sun BJ, et al. Outcomes of patients with stress-induced cardiomyopathy diagnosed by echocardiography in a tertiary referral hospital. J Am Soc Echocardiogr 2010; 23: 766-71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2010.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Bean MG, Hata JS, Castresana MR. Perioperative takotsubo cardiomyopathy: a systematic review of published cases. Semin Cardiothorac Vasc Anesth 2017; 21: 277-90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1089253217700511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen SD, Knuuti J, Saraste A, et al.; Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2014; 31: 517-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000150</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients. Cardiooncology 2019; DOI: https://doi.org/10.1186/s40959-019-0042-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40959-019-0042-9</ArticleId><ArticleId IdType="pubmed">32154016</ArticleId><ArticleId IdType="pmc">7048097</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin KJ, Lee YJ, Yang YR, et al. Molecular mechanisms underlying psychological stress and cancer. Curr Pharm Des 2016; 22: 2389-402.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612822666160226144025</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunetti ND, Tarantino N, Guastafierro F, et al. Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy. Heart Fail Rev 2019; 24: 481-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-019-09773-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J 2008; 155: 408-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2007.11.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Sanghvi C, Odo N, Castresana MR. Perioperative takotsubo cardiomyopathy: implications for anesthesiologist. Ann Card Anaesth 2019; 22: 309-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/aca.ACA_71_18</ArticleId></ArticleIdList></Reference><Reference><Citation>Citro R, Rigo F, D&#x2019;Andrea A, et al.; Tako-Tsubo Italian Network Investigators. Echocardiographic correlates of acute heart failure, cardiogenic shock, and in-hospital mortality in tako-tsubo cardiomyopathy. JACC Cardiovasc Imaging 2014; 7: 119-29.</Citation></Reference><Reference><Citation>Wright PT, Tranter MH, Morley-Smith AC, Lyon AR. Pathophysiology of takotsubo syndrome: temporal phases of cardiovascular responses to extreme stress. Circ J 2014; 78: 1550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-14-0623</ArticleId></ArticleIdList></Reference><Reference><Citation>Paur H, Wright PT, Sikkel MB, et al. High levels of circulating epinephrine trigger apical cardiodepression in a &#x3b2;2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation 2012; 126: 697-706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.111591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy&#x2014;a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008; 5: 22-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpcardio1066</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandel M, Hetzer R. Deleterious effects of catecholamine administration in acute heart failure caused by unrecognized Takotsubo cardiomyopathy. BMC Cardiovasc Disord 2018; DOI: https://doi.org/10.1186/s12872-018-0882-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0882-5</ArticleId><ArticleId IdType="pubmed">29996761</ArticleId><ArticleId IdType="pmc">6042343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansari U, El-Battrawy I, Fastner C, et al. Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy. BMC Cardiovasc Disord 2018; DOI: https://doi.org/10.1186/s12872-018-0784-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0784-6</ArticleId><ArticleId IdType="pubmed">29554866</ArticleId><ArticleId IdType="pmc">5859783</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Vece D, Citro R, Cammann VL, et al. Outcomes associated with cardiogenic shock in takotsubo syndrome. Circulation 2019; 139: 413-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.036164</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider B, Athanasiadis A, Schwab J, et al. Complications in the clinical course of tako-tsubo cardiomyopathy. Int J Cardiol 2014; 176: 199-205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2014.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gili S, Cammann VL, Schlossbauer SA, et al. Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. Eur Heart J 2019; 40: 2142&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz170</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinjikji W, El-Sayed AM, Salka S. In-hospital mortality among patients with takotsubo cardiomyopathy: a study of the National Inpatient Sample 2008 to 2009. Am Heart J 2012; 164: 215-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2012.04.010</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28716039</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Extra-corporeal membrane oxygenation for refractory cardiogenic shock after adult cardiac surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>55</StartPage><MedlinePgn>55</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">55</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-017-0618-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Postcardiotomy cardiogenic shock (PCCS) refractory to inotropic support and intra-aortic balloon pump (IABP) occurs rarely but is almost universally fatal without mechanical circulatory support. In this systematic review and meta-analysis we looked at the evidence behind the use of veno-arterial extra-corporeal membrane oxygenation (VA ECMO) in refractory PCCS from a patient survival rate and determinants of outcome viewpoint.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review was performed in January 2017 using PubMed (with no defined time period) using the keywords "postcardiotomy", "cardiogenic shock", "extracorporeal membrane oxygenation" and "cardiac surgery". We excluded papers pertaining to ECMO following paediatric cardiac surgery, medical causes of cardiogenic shock, as well as case reports, review articles, expert opinions, and letters to the editor. Once the studies were collated, a meta-analysis was performed on the proportion of survivors in those papers that met the inclusion criteria. Meta-regression was performed for the most commonly reported adverse prognostic indicators (API).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 24 studies and a cumulative pool of 1926 patients from 1992 to 2016. We tabulated the demographic data, including the strengths and weaknesses for each of the studies, outcomes of VA ECMO for refractory PCCS, complications, and APIs. All the studies were retrospective cohort studies. Meta-analysis of the moderately heterogeneous data (95% CI 0.29 to 0.34, p&#xa0;&lt;&#xa0;0.01, I <sup>2</sup> &#xa0;=&#xa0;60%) revealed overall survival rate to hospital discharge of 30.8%. Some of the commonly reported APIs were advanced age (&gt;70&#xa0;years, 95% CI -0.057 to 0.001, P&#xa0;=&#xa0;0.058), and long ECMO support (95% CI -0.068 to 0.166, P&#xa0;=&#xa0;0.412). Postoperative renal failure, high EuroSCORE (&gt;20%), diabetes mellitus, obesity, rising lactate whilst on ECMO, gastrointestinal complications had also been reported.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Haemodynamic support with VA ECMO provides a survival benefit with reasonable intermediate and long-term outcomes. Many studies had reported advanced age, renal failure and prolonged VA ECMO support as the most likely APIs for VA ECMO in PCCS. EuroSCORE can be utilized to anticipate the need for prophylactic perioperative VA ECMO in the high-risk category. APIs can be used to aid decision-making regarding both the institution and weaning of ECMO for refractory PCCS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khorsandi</LastName><ForeName>Maziar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Transplantation, Golden Jubilee National Hospital, Glasgow, UK. maziarkhorsandi@doctors.org.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dougherty</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Ninewells hospital, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouamra</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Medical Statistics, Trauma, Audit &amp; Research Network, University of Manchester, Salford Royal NHS foundation trust, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pai</LastName><ForeName>Vasudev</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Thoracic Surgery, Kasturba Medical College, Manipal University, Manipal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curry</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Transplantation, Golden Jubilee National Hospital, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsui</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Transplantation, Papworth hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac surgery and Transplantation, Freeman hospital, Newcastle, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westaby</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Oxford Heart Center, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Attar</LastName><ForeName>Nawwar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Transplantation, Golden Jubilee National Hospital, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamvar</LastName><ForeName>Vipin</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Extra-corporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Postcardiotomy</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable as this is a meta-analysis. CONSENT FOR PUBLICATION: Not applicable as this is a meta-analysis. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28716039</ArticleId><ArticleId IdType="pmc">PMC5512816</ArticleId><ArticleId IdType="doi">10.1186/s13019-017-0618-0</ArticleId><ArticleId IdType="pii">10.1186/s13019-017-0618-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hernandez AF, Grab JD, Gammie JS, O&#x2019;Brien SM, Hammill BG, Rogers JG, et al. A decade of short-term outcomes in post&#x2013;cardiac surgery ventricular assist device implantation. Circulation. 2007;116:606&#x2013;612. doi: 10.1161/CIRCULATIONAHA.106.666289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.666289</ArticleId><ArticleId IdType="pubmed">17646586</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRose JJ, Umana JP, Argenziano M, Catanese KA, Levin HR, Sun BC, et al. Improved results for Postcardiotomy Cardiogenic shock with the use of implantable left ventricular assist devices. Ann Thorac Surg. 1997;64:1757&#x2013;1763. doi: 10.1016/S0003-4975(97)01107-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(97)01107-7</ArticleId><ArticleId IdType="pubmed">9436568</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehrcke DD, McCarthy PM, Stewart RW, Foster RC, Ogella DA, Borsh JA, et al. Extracorporeal membrane oxygenation for Postcardiotomy Cardiogenic shock. Ann Thorac Surg. 1996;61:684&#x2013;691. doi: 10.1016/0003-4975(95)01042-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-4975(95)01042-4</ArticleId><ArticleId IdType="pubmed">8572788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohite PN, Sabashnikov A, Patil NP, S&#xe1;ez DG, Zych B, Popov AF, et al. Short-term ventricular assist device in post-cardiotomy cardiogenic shock: factors influencing survival. J Artif Organs. 17(3):228&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">24880478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan AJ, Dege A, Mohr M, Doll N, Falk V, Walther T, et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg. 2010;139:302&#x2013;311. doi: 10.1016/j.jtcvs.2009.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.10.043</ArticleId><ArticleId IdType="pubmed">20106393</ArticleId></ArticleIdList></Reference><Reference><Citation>Fou AA, John H. Gibbon. The first 20 years of the heart-lung machine. Tex Heart Inst J. 1997;24(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC325389</ArticleId><ArticleId IdType="pubmed">9068131</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart GC, Giverts MM. Mechanical circulatory support for advanced heart failure: patients and technology in evolution. Circulation. 2012;125:1304&#x2013;1315. doi: 10.1161/CIRCULATIONAHA.111.060830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.060830</ArticleId><ArticleId IdType="pubmed">22412091</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll N, Fabricius A, Borger MA, Bucerius J, Doll S, Kr&#xe4;mer K, et al. Temporary extracorporeal membrane oxygenation in patients with refractory postoperative cardiogenic shock--a single center experience. J Card Surg. 2003;18(6):512&#x2013;518. doi: 10.1046/j.0886-0440.2003.02061.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0886-0440.2003.02061.x</ArticleId><ArticleId IdType="pubmed">14992102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy FB, Mueller DK, Geiss DM, Munns JR, Bond LM, Linett CE, et al. Bridge to recovery for postcardiotomy failure: is there still a role for centrifugal pumps? Ann Thorac Surg. 2000;70(4):1259&#x2013;1263. doi: 10.1016/S0003-4975(00)01715-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(00)01715-X</ArticleId><ArticleId IdType="pubmed">11081882</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousse N, Juthier F, Pin&#xe7;on C, Hysi I, Ban C, Robin E, et al. ECMO as a bridge to decision: recovery, VAD, or heart transplantation? Int J Cardiol. 2015;187:620&#x2013;627. doi: 10.1016/j.ijcard.2015.03.283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.03.283</ArticleId><ArticleId IdType="pubmed">25863737</ArticleId></ArticleIdList></Reference><Reference><Citation>Roussel A, Al-Attar N, Alkhoder S, Radu C, Raffoul R, Alshammari M, et al. Outcomes of percutaneous femoral cannulation for venoarterial extracorporeal membrane oxygenation support. Eur Heart J Acute Cardiovasc Care. 2012;1(2):111&#x2013;114. doi: 10.1177/2048872612449417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872612449417</ArticleId><ArticleId IdType="pmc">PMC3760531</ArticleId><ArticleId IdType="pubmed">24062897</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll N, Kiaii B, Borger M, Bucerius J, Kramer K, Schmitt D, et al. Five year results of 219 consecutive patients treated with extracorporeal membrane oxygenation after refractory postoperative cardiogenic shock. Ann Thorac Surg. 2004;77:151&#x2013;157. doi: 10.1016/S0003-4975(03)01329-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(03)01329-8</ArticleId><ArticleId IdType="pubmed">14726052</ArticleId></ArticleIdList></Reference><Reference><Citation>Santarpino G, Ruggieri VG, Mariscalco G, Bounader K, Beghi C, Fischlein T, et al. Outcome in patients having salvage coronary artery bypass grafting. Am J Cardiol. 2015;116(8):1193&#x2013;1198. doi: 10.1016/j.amjcard.2015.07.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2015.07.034</ArticleId><ArticleId IdType="pubmed">26303635</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CL, Wang H, Jia M, Ma N, Meng X, Hou XT. The early dynamic behavior of lactate is linked to mortality in postcardiotomy patients with extracorporeal membrane oxygenation support: a retrospective observational study. J Thorac Cardiovasc Surg. 2015;149(5):1445&#x2013;1450. doi: 10.1016/j.jtcvs.2014.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.11.052</ArticleId><ArticleId IdType="pubmed">25534305</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsharkawy HA, Li L, Esa WA, Sessler DI, Bashour CA. Outcome in patients who require venoarterial extracorporeal membrane oxygenation support after cardiac surgery. J Cardiothorac Vasc Anesth. 2010;24(6):946&#x2013;951. doi: 10.1053/j.jvca.2010.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2010.03.020</ArticleId><ArticleId IdType="pubmed">20599396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MY, Lin PJ, Lee MY, Tsai FC, Chu JJ, Chang YS, et al. Using extracorporeal life support to resuscitate adult postcardiotomy cardiogenic shock: treatment strategies and predictors of short-term and midterm survival. Resuscitation. 2010;81(9):1111&#x2013;1116. doi: 10.1016/j.resuscitation.2010.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2010.04.031</ArticleId><ArticleId IdType="pubmed">20627521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhtiary F, Keller H, Dogan S, Dzemali O, Oezaslan F, Meininger D, et al. Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock: clinical experiences in 45 adult patients. J Thorac Cardiovasc Surg. 2008;135(2):382&#x2013;388. doi: 10.1016/j.jtcvs.2007.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2007.08.007</ArticleId><ArticleId IdType="pubmed">18242273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko WJ, Lin CY, Chen RJ, Wang SS, Lin FY, Chen YS, et al. Extracorporeal membrane oxygenation support for adult Postcardiotomy Cardiogenic shock. Ann Thorac Surg. 2002;73:538&#x2013;545. doi: 10.1016/S0003-4975(01)03330-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(01)03330-6</ArticleId><ArticleId IdType="pubmed">11845871</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorsandi M, Dougherty S, Sinclair A, Buchan K, MacLennan F, Bouamra O, et al. A 20-year multicentre outcome analysis of salvage mechanical circulatory support for refractory cardiogenic shock after cardiac surgery. J Cardiothorac Surg. 2016;8(11):151. doi: 10.1186/s13019-016-0545-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-016-0545-5</ArticleId><ArticleId IdType="pmc">PMC5100311</ArticleId><ArticleId IdType="pubmed">27821152</ArticleId></ArticleIdList></Reference><Reference><Citation>Slottosch I, Liakopoulos O, Kuhn E, Deppe AC, Scherner M, Madershahian N, et al. Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience. J Surg Res. 2013;181(2):47&#x2013;55. doi: 10.1016/j.jss.2012.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2012.07.030</ArticleId><ArticleId IdType="pubmed">22878151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikus E, Tripodi A, Calvi S, Giglio D, Cavallucci A, Lamarra M, et al. CentriMag Venoarterial extracorporeal membrane oxygenation support as treatment for patients with refractory Postcardiotomy Cardiogenic shock. ASAIO J. 2013;59(1):18&#x2013;23. doi: 10.1097/MAT.0b013e3182768b68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0b013e3182768b68</ArticleId><ArticleId IdType="pubmed">23271391</ArticleId></ArticleIdList></Reference><Reference><Citation>Smedira NG, Moazami N, Golding CM, McCarthy PM, Apperson-Hansen C, Blackstone EH, et al. Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: survival at five years. J Thorac Cardiovasc Surg. 2001;122:92&#x2013;102. doi: 10.1067/mtc.2001.114351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mtc.2001.114351</ArticleId><ArticleId IdType="pubmed">11436041</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CY, Chen YC, Tsai FC, Tian YC, Jenq CC, Fang JT, et al. RIFLE classification is predictive of short-term prognosis in critically ill patients with acute renal failure supported by extracorporeal membrane oxygenation. Nephrol Dial Transplant. 2006;21:2867&#x2013;2873. doi: 10.1093/ndt/gfl326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfl326</ArticleId><ArticleId IdType="pubmed">16799171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kielstein JT, Heiden AM, Beutel G, Gottlieb J, Wiesner O, Hafer C, et al. Renal function and survival in 200 patients undergoing ECMO therapy. Nephrol Dial Transplant. 2013;28:86&#x2013;90. doi: 10.1093/ndt/gfs398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfs398</ArticleId><ArticleId IdType="pubmed">23136216</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Montisci A. Veno-arterial extracorporeal membrane oxygenation (VA ECMO) in postcardiotomy cardiogenic shock: how much pump flow is enough? J Thorac Dis. 2016;8(10):1444&#x2013;1448. doi: 10.21037/jtd.2016.10.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2016.10.01</ArticleId><ArticleId IdType="pmc">PMC5107499</ArticleId><ArticleId IdType="pubmed">27867655</ArticleId></ArticleIdList></Reference><Reference><Citation>Unosawa S, Sezai A, Hata M, Nakata K, Yoshitake I, Wakui S, et al. Long-term outcomes of patients undergoing extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. Surg Today. 2013;43(3):264&#x2013;270. doi: 10.1007/s00595-012-0322-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00595-012-0322-6</ArticleId><ArticleId IdType="pubmed">22945889</ArticleId></ArticleIdList></Reference><Reference><Citation>Acheampong B, Johnson JN, Stulak JM, Dearani JA, Kushwaha SS, Daly RC, et al. Postcardiotomy ECMO support after high-risk operations in adult congenital heart disease. Congenit Heart Dis. 2016;11(6):751&#x2013;755. doi: 10.1111/chd.12396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/chd.12396</ArticleId><ArticleId IdType="pubmed">27436116</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorsandi M, Shaikhrezai K, Prasad S, Pessotto R, Walker W, Berg G, et al. Advanced mechanical circulatory support for post-cardiotomy cardiogenic shock: a 20-year outcome analysis in a non-transplant unit. J Cardiothorac Surg. 2016;11(29). doi:10.1186/s13019-016-0430-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758144</ArticleId><ArticleId IdType="pubmed">26892226</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunning J. Post-cardiotomy mechanical support update. SCTS annual meeting Belfast: Society for Cardiothoracic Surgery in Great Britain &amp; Ireland. 2017.</Citation></Reference><Reference><Citation>Fl&#xe9;cher E. AA, Corbineau H, Langanay T, Verhoye JP, F&#xe9;lix C, et al. current aspects of extracorporeal membrane oxygenation in a tertiary referral centre: determinants of survival at follow-up. Eur J Cardio-Thoracic Surg. 2014;46(4):665&#x2013;671. doi: 10.1093/ejcts/ezu029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezu029</ArticleId><ArticleId IdType="pubmed">24574452</ArticleId></ArticleIdList></Reference><Reference><Citation>Annich GM, Lynch WR, MacLaren G, Wilson JM, Bartlett RH. Extracorporeal Cardiopulmonay support in critical care. 4. ELSO: Michigan; 2012.</Citation></Reference><Reference><Citation>Emin A, Rogers CA, Parameshwar J, MacGowan G, Taylor R, Yonan N, et al. Trends in long-term mechanical circulatory support for advanced heart failure in the UK. Eur J Heart Fail. 2013;15:1185&#x2013;1193. doi: 10.1093/eurjhf/hft127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hft127</ArticleId><ArticleId IdType="pubmed">23901056</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui S. Outcome of temporary MCS support for post- cardiotomy cardiogenic shock: is it worth the effort? In: meeting SA, editor. Society for Cardiothoracic Surgery in Great Britain &amp; Ireland: Belfast; 2017.</Citation></Reference><Reference><Citation>Westaby S, Taggart D. Inappropriate restrictions on life saving technology. Heart. 2012;98(15):1117&#x2013;1119. doi: 10.1136/heartjnl-2011-301365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2011-301365</ArticleId><ArticleId IdType="pmc">PMC3392688</ArticleId><ArticleId IdType="pubmed">22634172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashani A, Manganas C. Extracorporeal membrane oxygenation (ECMO) in post-cardiotomy cardiogenic shock (PCCS) in adults: a systematic review. Heart Lung Circ. 2015;24(1):e56. doi: 10.1016/j.hlc.2014.12.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2014.12.119</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Seco M, Forrest P, Jackson SA, Martinez G, Andvik S, Bannon PG, et al. Extracorporeal membrane oxygenation for very high-risk transcatheter aortic valve implantation. Heart Lung Circ. 2014;23(10):957&#x2013;962. doi: 10.1016/j.hlc.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2014.05.006</ArticleId><ArticleId IdType="pubmed">24954708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu PS, Chen JL, Hong GJ, Tsai YT, Lin CY, Lee CY, et al. Extracorporeal membrane oxygenation for refractory cardiogenic shock after cardiac surgery: predictors of early mortality and outcome from 51 adult patients. Eur J Cardiothorac Surg. 2010;37:328&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">19748279</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed D, Maxhera B, Westenfeld R, Lichtenberg A, Albert A, et al. An alternative approach for Perioperative extracorporeal life support implantation. Artif Organs. 2015;39(8):719&#x2013;723. doi: 10.1111/aor.12490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12490</ArticleId><ArticleId IdType="pubmed">25912873</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajjad M, Osman A, Mohsen S, Alanazi M, Ugurlucan M, Canver C, et al. Extracorporeal membrane oxygenation in adults: experience from the Middle East. Asian Cardiovasc Thorac Ann. 2012;2(5):521&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">24570552</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokersnik JA, Buda T, Bashour CA, Gonzalez-Stawinski GV. Have changes in ECMO technology impacted outcomes in adult patients developing postcardiotomy cardiogenic shock? J Card Surg. 2012;27(2):246&#x2013;252. doi: 10.1111/j.1540-8191.2011.01409.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1540-8191.2011.01409.x</ArticleId><ArticleId IdType="pubmed">22372761</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno I, Soria A, L&#xf3;pez G&#xf3;mez A, Vicente R, Porta J, Vicente JL, et al. Extracorporeal membrane oxygenation after cardiac surgery in 12 patients with cardiogenic shock. Rev Esp Anestesiol Reanim. 2011;58(3):156&#x2013;160. doi: 10.1016/S0034-9356(11)70023-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0034-9356(11)70023-8</ArticleId><ArticleId IdType="pubmed">21534290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SS, Chen YS, Ko WJ, Chu SH. Extracorporeal membrane oxygenation support for postcardiotomy cardiogenic shock. Artif Organs. 1996;20(12):1287&#x2013;1291. doi: 10.1111/j.1525-1594.1996.tb00676.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1594.1996.tb00676.x</ArticleId><ArticleId IdType="pubmed">8947449</ArticleId></ArticleIdList></Reference><Reference><Citation>Magovern GJ, Jr, Magovern JA, Benckart DH, Lazzara RR, Sakert T, Maher TD, Jr, et al. Extracorporeal membrane oxygenation: preliminary results in patients with postcardiotomy cardiogenic shock. Ann Thorac Surg. 1994;57(6):1469&#x2013;1471. doi: 10.1016/0003-4975(94)90101-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-4975(94)90101-5</ArticleId><ArticleId IdType="pubmed">8010788</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena P, Neal J, Joyce LD, Greason KL, Schaff HV, Guru P, et al. Extracorporeal membrane oxygenation support in Postcardiotomy elderly patients: the Mayo Clinic experience. Ann Thorac Surg. 2015;99(6):2053&#x2013;2060. doi: 10.1016/j.athoracsur.2014.11.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2014.11.075</ArticleId><ArticleId IdType="pubmed">25865760</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X, Jia S, Meng X, Dong P, Jia M, Wan J, et al. Acute kidney injury in adult postcardiotomy patients with extracorporeal membrane oxygenation: evaluation of the RIFLE classification and the acute kidney injury network criteria. European J Cardio-Thoracic Surg. 2010;37(2):334&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">19692267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37075941</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8414</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of cardiac failure</Title><ISOAbbreviation>J Card Fail</ISOAbbreviation></Journal><ArticleTitle>Safety and Efficacy of Istaroxime 1.0 and 1.5 &#xb5;g/kg/min for Patients With Pre-Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>1097</StartPage><EndPage>1103</EndPage><MedlinePgn>1097-1103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cardfail.2023.03.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1071-9164(23)00115-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Istaroxime was shown, in a small study, to increase systolic blood pressure (SBP) in patients with pre-cardiogenic shock (CS) due to acute heart failure (AHF).</AbstractText><AbstractText Label="OBJECTIVES">In the current analysis, we describe the effects of 2 doses of istaroxime 1.0 (Ista-1) and 1.5 &#xb5;g/kg/min (Ista-1.5).</AbstractText><AbstractText Label="METHODS">The target dose of istaroxime, administered in a double-blind, placebo-controlled fashion, was 1.5 &#xb5;g/kg/min in the first cohort (n&#x202f;=&#x202f;24), and it was reduced to 1.0 &#xb5;g/kg/min in subsequent patients (n&#x202f;=&#x202f;36).</AbstractText><AbstractText Label="RESULTS">Ista-1 was associated with numerically larger effects on SBP area under the curve, with a 93.6% relative increase from baseline during the first 6 hours with Ista-1 vs 39.5% for Ista-1.5, and with a 49.4% and 24.3% relative increase, respectively, at 24 hours. Compared to placebo, Ista-1.5 had more worsening HF events until day 5 and fewer days alive out of hospital (DAOH) through day 30. Ista-1 had no worsening HF events, and DAOH to day 30 were significantly increased. Effects on echocardiographic measures were similar, although decreases in left ventricular end systolic and diastolic volumes were numerically larger in the Ista-1 group. Ista-1, but not Ista-1.5, showed numerically smaller creatinine increases and larger decreases in natriuretic peptides as compared to placebo. There were 5 serious adverse events in Ista-1.5 (4 of which were cardiac) but only 1 in Ista-1.</AbstractText><AbstractText Label="CONCLUSIONS">In patients with pre-CS due to AHF, istaroxime 1.0 &#xb5;g/kg/min induced beneficial effects on SBP and DAOH. Clinical benefits appear to be reached at dosages less than 1.5 ug/kg/min.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Metra</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chioncel</LastName><ForeName>Ovidiu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Emergency Institute for Cardiovascular Diseases Prof. C.C. Iliescu, Bucharest, Romania; University of Medicine Carol Davila, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davison</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Momentum Research, Durham, NC, USA; Universit&#xe9; Paris Cit&#xe9;; Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippatos</LastName><ForeName>Gerasimos</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University of Cyprus, School of Medicine &amp; National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;; Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France; Department of Anesthesiology and Critical Care and Burn Unit, H&#xf4;pital Saint-Louis Lariboisi&#xe8;re, FHU PROMICE, DMU Parabol, APHP.Nord, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagnesi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamo</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novosadova</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Momentum Research, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponikowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Heart Diseases, Wroclaw Medical University, Wroc&#x142;aw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Phillip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Windtree Therapeutics, Warrington, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soffer</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Windtree Therapeutics, Warrington, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonson</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Windtree Therapeutics, Warrington, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Gad</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Momentum Research, Durham, NC, USA; Universit&#xe9; Paris Cit&#xe9;; Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France. Electronic address: gadcotter@momentum-research.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Fail</MedlineTA><NlmUniqueID>9442138</NlmUniqueID><ISSNLinking>1071-9164</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>W8I9H2TPPL</RegistryNumber><NameOfSubstance UI="C468128">Istaroxime</NameOfSubstance></Chemical><Chemical><RegistryNumber>97CGB1M48I</RegistryNumber><NameOfSubstance UI="D005043">Etiocholanolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005043" MajorTopicYN="N">Etiocholanolone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute heart failure</Keyword><Keyword MajorTopicYN="N">SERCA2a</Keyword><Keyword MajorTopicYN="N">blood pressure</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">istaroxime</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>Disclosures MM received personal fees of minimal amounts in the past 3 years from Amgen, Livanova, and Vifor pharma as a member of Executive or Data Monitoring Committees of sponsored clinical trials; from Astra-Zeneca, Abbott vascular, Bayer, Boheringer Ingelhelm, and Edwards Therapeutics for participation on advisory boards and/or speeches at sponsored meetings. OC is a member of Boehringer Ingelheim Advisory Board. GC, BD and MN are employees of Momentum Research, which has received grants from Abbott Laboratories, Amgen, Celyad, Cirius Therapeutics, Corteria Pharmaceuticals, Roche Diagnostics, Sanofi, Windtree Therapeutics, and XyloCor Therapeutics. GF is an executive committee member and consultant to Corthera (a Novartis company), Bayer, Amgen, Servier, Medtronic, Vifor, and Boehringer Ingelheim and has received research grants from the European Union. AM reports personal fees from Orion, Roche, Adrenomed, and Fire 1 and grants and personal fees from 4TEEN4, Abbott, Roche, and Sphyngotec. PP reports other income from Trevena during the conduct of the study, reports grants and personal fees from Amgen, grants and personal fees from Servier, Boehringer Ingelheim, Vifor Pharma, Novartis, Bayer, Cibiem, AstraZeneca, BMS, Renal Guard Solutions, Impulse Dynamics, and Abbott Vascular, personal fees from Berlin Chemie outside of the submitted work. PS, JS and SS are employees of Windtree Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37075941</ArticleId><ArticleId IdType="doi">10.1016/j.cardfail.2023.03.020</ArticleId><ArticleId IdType="pii">S1071-9164(23)00115-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25772369</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0938</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Season>Apr-May</Season></PubDate></JournalIssue><Title>Cardiovascular revascularization medicine : including molecular interventions</Title><ISOAbbreviation>Cardiovasc Revasc Med</ISOAbbreviation></Journal><ArticleTitle>Simultaneous multi-vessel coronary thrombosis in patients with ST-elevation myocardial infarction: a systematic review.</ArticleTitle><Pagination><StartPage>163</StartPage><EndPage>166</EndPage><MedlinePgn>163-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.carrev.2015.02.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1553-8389(15)00064-0</ELocationID><Abstract><AbstractText>Acute ST-elevation myocardial infarction (STEMI) with simultaneous multiple coronary thrombosis has been described, however; the available information about the clinical presentation and management of this condition is scarce. We searched the Medline and Web of Science databases from 1990 until August 2014 for all case reports, case series, and observational studies that reported simultaneous multi-vessel thrombosis at the time of the primary percutaneous coronary intervention (PCI). We excluded the articles that reported an identifiable cause for coronary thrombosis. A total of 29 articles were retrieved yielding 56 patients. Patients were predominantly males (88%) with a mean age of 59 years. Cardiogenic shock was the predominant presentation (41%). Simultaneous thrombosis of the left anterior descending and right coronary arteries was the commonest angiographic finding (50%). Primary PCI was the main treatment modality and an intra-aortic balloon pump was utilized in 38% of the cases. The in-hospital mortality was 5%. Simultaneous multi-vessel thrombosis at the time of STEMI presents a rare condition. The cases reported in the literature presented with a high incidence of cardiogenic shock. Larger studies are needed to address the proper management and evaluate the outcomes associated with this condition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahmoud</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Florida, Gainesville, FL, USA. Electronic address: ahmed.mahmoud@medicine.ufl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Marwan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Seton Hall University School of Health and Medical Sciences, Trinitas Regional Medical Center, Elizabeth, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elgendy</LastName><ForeName>Islam Y</ForeName><Initials>IY</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Revasc Med</MedlineTA><NlmUniqueID>101238551</NlmUniqueID><ISSNLinking>1878-0938</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003328" MajorTopicYN="N">Coronary Thrombosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="N">Coronary Vessels</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronary occlusion</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25772369</ArticleId><ArticleId IdType="doi">10.1016/j.carrev.2015.02.009</ArticleId><ArticleId IdType="pii">S1553-8389(15)00064-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">37652847</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8422</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>J Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>Pulmonary Vasodilator and Inodilator Drugs in Cardiac Surgery: A Systematic Review With Bayesian Network Meta-Analysis.</ArticleTitle><Pagination><StartPage>2261</StartPage><EndPage>2271</EndPage><MedlinePgn>2261-2271</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.jvca.2023.07.041</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-0770(23)00533-5</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors performed a systematic review to evaluate the effect of pharmacologic therapy on pulmonary hypertension in the perioperative setting of elective cardiac surgery (PROSPERO CRD42023321041).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Systematic review of randomized controlled trials with a Bayesian network meta-analysis.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The authors searched biomedical databases for randomized controlled trials on the perioperative use of inodilators and pulmonary vasodilators in adult cardiac surgery, with in-hospital mortality as the primary outcome and duration of ventilation, length of stay in the intensive care unit, stage 3 acute kidney injury, cardiogenic shock requiring mechanical support, and change in mean pulmonary artery pressure as secondary outcomes.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Twenty-eight studies randomizing 1,879 patients were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Catecholamines and noncatecholamine inodilators, arterial pulmonary vasodilators, vasodilators, or their combination were considered eligible interventions compared with placebo or standard care.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Ten studies reported in-hospital mortality and assigned 855 patients to 12 interventions. Only inhaled prostacyclin use was supported by a statistically discernible improvement in mortality, with a number-needed-to-treat estimate of at least 3.3, but a wide credible interval (relative risk 1.26&#xa0;&#xd7;&#xa0;10<sup>-17</sup> - 0.7). Inhaled prostacyclin and nitric oxide were associated with a reduction in intensive care unit stay, and none of the included interventions reached a statistically evident difference compared to usual care or placebo in the other secondary clinical outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Inhaled prostacyclin was the only pharmacologic intervention whose use is supported by a statistically discernible improvement in mortality in the perioperative cardiac surgery setting as treatment of pulmonary hypertension. However, available evidence has significant limitations, mainly the low number of events and imprecision.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sardo</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy. Electronic address: salvatore.sardo@unica.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripodi</LastName><ForeName>Vincenzo Francesco</ForeName><Initials>VF</Initials><AffiliationInfo><Affiliation>Department of Human Pathology, Unit of Anesthesia and Intensive Care, University Hospital of Messina, Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerzoni</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musu</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortegiani</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncological and Oral Science, University of Palermo, Palermo, Italy; Department of Anesthesia, Intensive Care, and Emergency, University Hospital "Policlinico Paolo Giaccone", Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finco</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9110208</NlmUniqueID><ISSNLinking>1053-0770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac</Keyword><Keyword MajorTopicYN="N">cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary hypertension</Keyword><Keyword MajorTopicYN="N">vasodilator</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>22</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37652847</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2023.07.041</ArticleId><ArticleId IdType="pii">S1053-0770(23)00533-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33993525</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8191</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of cardiac surgery</Title><ISOAbbreviation>J Card Surg</ISOAbbreviation></Journal><ArticleTitle>Risk factors for Takotsubo syndrome following cardiac surgery: A case-control study.</ArticleTitle><Pagination><StartPage>2767</StartPage><EndPage>2773</EndPage><MedlinePgn>2767-2773</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.15626</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Takotsubo syndrome following cardiac surgery is a rare occurrence. However, early diagnosis is essential to prevent treatment which could increase the left ventricular outflow tract pressure gradient in patients with Takotsubo syndrome, and lead to cardiogenic shock. Therefore, our study aimed to identify the incidence of Takotsubo syndrome after cardiopulmonary bypass and the associated risk factors and prognosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively studied 5773 patients who underwent cardiopulmonary bypass between February 2007 and July 2017. Among these, Takotsubo syndrome was diagnosed in 52 (0.9%). To evaluate the risk factors for Takotsubo syndrome, 104 of the remaining 5721 patient were randomly selected as the control group (1:2 ratio). Univariate and multivariate logistic regression analyses were used for risk factor analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Majority of patients (69.2%) in the Takotsubo syndrome group underwent mitral valve surgery, compared with 32.7% in the control group. The following risk factors of Takotsubo syndrome were identified: atrio-ventricular valve surgery (odds ratio (OR) 10.5; 95% confidence interval (CI), 2.6-42.5; p&#x2009;=&#x2009;0.001); and the immediate postoperative use of epinephrine (OR, 3.3; 95% CI, 1.0-10.7; p&#x2009;=&#x2009;0.05) and dobutamine (OR, 4.8; 95% CI, 1.72-13.3; p&#x2009;=&#x2009;0.003). Hypertension was a significant protective factor against Takotsubo syndrome following cardiac surgery (OR, 0.22; 95% CI, 0.06-0.73; p&#x2009;=&#x2009;0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Takotsubo syndrome following cardiac surgery is rare. Immediate postoperative use of epinephrine and doputamine, as well as atrio-ventricular valve surgery were factors associated with the development of Takotsubo syndrome.</AbstractText><CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yun Seok</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0002-2817-557X</Identifier><AffiliationInfo><Affiliation>Departments of Thoracic and Cardiovascular Surgery, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Ju Yong</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-2864-1630</Identifier><AffiliationInfo><Affiliation>Departments of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Surg</MedlineTA><NlmUniqueID>8908809</NlmUniqueID><ISSNLinking>0886-0440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054549" MajorTopicYN="Y">Takotsubo Cardiomyopathy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword><Keyword MajorTopicYN="N">cardiac surgery</Keyword><Keyword MajorTopicYN="N">postoperative management</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>16</Day><Hour>21</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33993525</ArticleId><ArticleId IdType="doi">10.1111/jocs.15626</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Dote K , Sato H , Tateishi H , Uchida T , Ishihara M. Myocardial stunning due to simultaneous multivessel spasm; review of five cases [in Japanese]. J Cardiol. 1991;21:203-214.</Citation></Reference><Reference><Citation>Chiariello GA , Bruno P , Colizzi C , Crea F , Massetti M. Takotsubo cardiomyopathy following cardiac surgery. J Card Surg. 2016;31:89-95.</Citation></Reference><Reference><Citation>Ohwada R , Hotta M , Kimura H , et al. Ampulla cardiomyopathy after hypoglycemia in three young female patients with anorexia nervosa. Intern Med. 2005;44:228-233.</Citation></Reference><Reference><Citation>Wittstein IS , Thiemann DR , Lima JA , et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352:539-548.</Citation></Reference><Reference><Citation>Elesber A , Lerman A , Bybee KA , et al. Myocardial perfusion in apical ballooning syndrome: correlate of myocardial injury. Am Heart J. 2006;152:469.e9-13.</Citation></Reference><Reference><Citation>Bybee KA , Kara T , Prasad A , et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med. 2004;141:858-865.</Citation></Reference><Reference><Citation>Itoh H , Miyake Y , Hioki I , Tanaka S , Okabe M. Report of Takotsubo cardiomyopathy occurring during cardiopulmonary bypass. J Extra Corpor Technol. 2007;39:109-111.</Citation></Reference><Reference><Citation>Kawaji T , Shiomi H , Morimoto T , et al. Clinical impact of left ventricular outflow tract obstruction in Takotsubo cardiomyopathy. Circ J. 2015;79:839-846.</Citation></Reference><Reference><Citation>Templin C , Ghadri JR , Diekmann J , et al. Clinical feature and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929-938.</Citation></Reference><Reference><Citation>Prasad A , Lerman A , Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155:408-417.</Citation></Reference><Reference><Citation>Wong CP , Jim MH , Chan AO , Chau EM , Chow WH . Iatrogenic Tako-Tsubo cardiomyopathy. Int J Cardiol. 2008;125:e16-e18.</Citation></Reference><Reference><Citation>Kogan A , Ghosh P , Schwammenthal E , Raanani E. Takotsubo syndrome after cardiac surgery. Ann Thorac Surg. 2008;85:1439-1441.</Citation></Reference><Reference><Citation>Ohata T , Ueda H , Kamata S , Sakagoshi N. Fulminant apical ballooning syndrome after replacement of a prosthetic aortic valve. Gen Thorac Cardiovas Surg. 2009;57:477-480.</Citation></Reference><Reference><Citation>Vernick WJ , Hargrove WC , Augoustides JG , Horak J. Takotsubo cardiomyopathy associated with cardiac arrest following cardiac surgery: new variants of an unusual syndrome. J Card Surg. 2010;25:679-683.</Citation></Reference><Reference><Citation>Blazquez JA , Gonzalez JM , Dalmau MJ , Lopez J. Takotsubo cardiomyopathy after elective mitral valve replacement. Interact Cardiovas Thorac Surg. 2010;11:117-119.</Citation></Reference><Reference><Citation>Gariboldi V , Jop B , Grisoli D , Jaussaud N , Kerbaul F , Collart F . Takotsubo syndrome after mitral valve replacement for acute endocarditis. Ann Thorac Surg. 2011;91:e31-e32.</Citation></Reference><Reference><Citation>F&#xe4;rber G , M&#xfc;hle A , Doenst T , Borger MA , Mohr FW . Late onset Takotsubo cardiomyopathy after mitral valve replacement. Thorac Cardiovasc Surg. 2011;59:500-503.</Citation></Reference><Reference><Citation>Yamane K , Hirose H , Reeves GR , Marhefka GD , Silvestry SC. Left ventricular dysfunction mimicking Takotsubo cardiomyopathy following cardiac surgery. J Heart Valve Dis. 2011;20:471-473.</Citation></Reference><Reference><Citation>Wang LW , Jansz PC , Baron DW. Delirium and Takotsubo cardiomyopathy following cardiac surgery. Anaesth Intensive Care. 2013;41:437-438.</Citation></Reference><Reference><Citation>Li S , Koerner MM , El-Banayosy A , Soleimani B , Pae WE , Leuenberger UA. Takotsubo's syndrome after mitral valve repair and rescue with extracorporeal membrane oxygenation. Ann Thorac Surg. 2014;97:1777-1778.</Citation></Reference><Reference><Citation>Choi JH , Oh ID , Shin E , et al. Extracorporeal membrane oxygenation for Takotsubo cardiomyopathy that developed after mitral valve replacement. Acute Crit Care. 2020;35:51-55.</Citation></Reference><Reference><Citation>Pergolini A , Zampi G , Casali G , et al. Takotsubo syndrome after mitral valve replacement: case report and brief review of the literature. J Cardiothorac Vasc Anesth. 2015;29:431-435.</Citation></Reference><Reference><Citation>Goldfine H , Aurigemma GP , Zile MR , Gaasch WH . Left ventricular length-force-shortening relations before and after surgical correction of chronic mitral regurgitation. J Am Coll Cardiol. 1998;31:180-185.</Citation></Reference><Reference><Citation>Abraham J , Mudd JO , Kapur N , Klein K , Champion HC , Wittstein IS. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol. 2009;53:1320-1325.</Citation></Reference><Reference><Citation>Donohue D , Movahed MR . Clinical characteristics, demographics and prognosis of transient left ventricular apical ballooning syndrome. Heart Fail Rev. 2005;10:311-316.</Citation></Reference><Reference><Citation>Ueyama T , Hano T , Kasamatsu K , Yamamoto K , Tsuruo Y , Nishio I . Estrogen attenuates the emotional stress-induced cardiac response in the animal model of Tako-Tsubo (ampulla) cardiomyopathy. J Cardiovasc Pharmacol. 2003;42(Suppl 1):117-119.</Citation></Reference><Reference><Citation>Lyon AR , Bossone E , Schneider B , et al. Current state of knowledge on Takotsubo syndrome: a position statement from the task force on Takotsubo syndrome of the Heart Failure Association on the European Society of Cardiology. Eur J Heart Fail. 2016;18:8-27.</Citation></Reference><Reference><Citation>Madias JE. Low prevalence of diabetes mellitus in patients with Takotsubo syndrome: a plausible 'protective' effect with pathophysiologic connotations. Eur Heart J Acute Cardiovasc Care. 2016;5:164-170.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37079182</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8261</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Cardiology and therapy</Title><ISOAbbreviation>Cardiol Ther</ISOAbbreviation></Journal><ArticleTitle>Transcatheter Aortic Valve Replacement for Aortic Valve Infective Endocarditis: A Systematic Review and Call for Action.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>306</EndPage><MedlinePgn>297-306</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40119-023-00314-9</ELocationID><Abstract><AbstractText>We aimed to systematically analyze the literature on the use of transcatheter aortic valve replacement (TAVR) to treat active aortic valve infective endocarditis (AV-IE). Surgery is declined in one-third of patients with IE who meet indications because of prohibitive surgical risk. TAVR might be an alternative for selected patients with AV-IE as a bridge-to-surgery or stand-alone therapy. PubMed/MEDLINE, Embase, and Cochrane databases were searched (2002-2022) for studies on TAVR use in active AV-IE. Of 450 identified reports, six met inclusion criteria (all men, mean age 71&#x2009;&#xb1;&#x2009;12&#xa0;years, median Society of Thoracic Surgeons (STS) score 27, EuroSCORE 56). All patients were prohibitive surgical risk candidates. Five out of six patients had severe, and one patient had moderate aortic regurgitation on presentation. Five out of six patients had prosthetic valve endocarditis after surgical valve replacement 13&#xa0;years before (median), and one patient had TAVR a year before hospitalization. All patients had cardiogenic shock as the indication for TAVR. Four patients received balloon-expanding, and two patients received self-expanding TAVR after a median of 19&#xa0;(IQR 9-25) days from diagnosis of IE. No death or myocardial infarction occurred, but one patient had a stroke within the first 30&#xa0;days. The median event-free time was 9 (IQR 6-14) months including no death, reinfection, relapse IE, or valve-related rehospitalization. Our review suggests that TAVR can be considered as an adjuvant therapy to medical treatment for selected patients in whom surgery is indicated for treatment of acute heart failure due to aortic valve destruction and incompetence caused by infective endocarditis, but who have a prohibitive surgical risk. Nonetheless, a well-designed prospective registry is urgently needed to investigate the outcomes of TAVR for this off-label indication. No evidence exists for using the TAVR to treat infection-related surgical indications such as uncontrolled infection or control of septic embolization.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brankovic</LastName><ForeName>Milos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transatlantic Cardiovascular Study Group, Bloomfield, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashemi</LastName><ForeName>Ashkan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, New Jersey Medical School, Newark, NJ, USA. abhisheksharma4mamc@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiol Ther</MedlineTA><NlmUniqueID>101634495</NlmUniqueID><ISSNLinking>2193-6544</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Infective endocarditis</Keyword><Keyword MajorTopicYN="N">Prosthetic valve endocarditis</Keyword><Keyword MajorTopicYN="N">Transcatheter aortic valve replacement</Keyword><Keyword MajorTopicYN="N">Valve-in-valve</Keyword></KeywordList><CoiStatement>Milos Brankovic, Ashkan Hashemi, Julia Ansari and Abhishek Sharma have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>13</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37079182</ArticleId><ArticleId IdType="pmc">PMC10209359</ArticleId><ArticleId IdType="doi">10.1007/s40119-023-00314-9</ArticleId><ArticleId IdType="pii">10.1007/s40119-023-00314-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang X, Chen H, Zhang D, Shen L, An G, Zhao S. Global magnitude and temporal trend of infective endocarditis, 1990&#x2013;2019: results from the Global Burden of Disease Study. Eur J Prev Cardiol. 2021;29:1277&#x2013;1286. doi: 10.1093/eurjpc/zwab184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwab184</ArticleId><ArticleId IdType="pubmed">34739047</ArticleId></ArticleIdList></Reference><Reference><Citation>See I, Gokhale RH, Geller A, et al. National public health burden estimates of endocarditis and skin and soft-tissue infections related to injection drug use: a review. J Infect Dis. 2020;222:S429&#x2013;s436. doi: 10.1093/infdis/jiaa149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa149</ArticleId><ArticleId IdType="pmc">PMC8112118</ArticleId><ArticleId IdType="pubmed">32877563</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG. Infective endocarditis. Nat Rev Dis Primers. 2016;2:16059. doi: 10.1038/nrdp.2016.59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.59</ArticleId><ArticleId IdType="pmc">PMC5240923</ArticleId><ArticleId IdType="pubmed">27582414</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu VH, Park LP, Athan E, et al. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. Circulation. 2015;131:131&#x2013;140. doi: 10.1161/CIRCULATIONAHA.114.012461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.012461</ArticleId><ArticleId IdType="pubmed">25480814</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021;143:e35&#x2013;e71.</Citation><ArticleIdList><ArticleId IdType="pubmed">33332149</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561&#x2013;632. doi: 10.1093/eurheartj/ehab395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab395</ArticleId><ArticleId IdType="pubmed">34453165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirabel M, Sonneville R, Hajage D, et al. Long-term outcomes and cardiac surgery in critically ill patients with infective endocarditis. Eur Heart J. 2014;35:1195&#x2013;1204. doi: 10.1093/eurheartj/eht303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht303</ArticleId><ArticleId IdType="pubmed">23964033</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Mart&#xed;nez S, Alkhodair A, Nombela-Franco L, et al. Transcatheter aortic valve replacement for residual lesion of the aortic valve following &#x201c;healed&#x201d; infective endocarditis. JACC Cardiovasc Interv. 2020;13:1983&#x2013;1996. doi: 10.1016/j.jcin.2020.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2020.05.033</ArticleId><ArticleId IdType="pubmed">32912458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz J, Reardon MJ, Pilgrim T, et al. Incidence and outcomes of infective endocarditis after transcatheter or surgical aortic valve replacement. J Am Heart Assoc. 2021;10:e020368. doi: 10.1161/JAHA.120.020368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.020368</ArticleId><ArticleId IdType="pmc">PMC8649131</ArticleId><ArticleId IdType="pubmed">34581194</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen CP, Munsayac MA, Robinson AA, Stinis CT. Transcatheter aortic valve replacement: a palliative approach to infective endocarditis. BMJ Case Rep. 2022;15:e248951. doi: 10.1136/bcr-2022-248951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2022-248951</ArticleId><ArticleId IdType="pmc">PMC9062781</ArticleId><ArticleId IdType="pubmed">35501070</ArticleId></ArticleIdList></Reference><Reference><Citation>Albu C, Swaans MJ, ten Berg JM. With the back against the wall: TAVI in a patient with endocarditis. Catheter Cardiovasc Interv. 2013;82:E595&#x2013;E597.</Citation><ArticleIdList><ArticleId IdType="pubmed">23225737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen C, Cheong AP, Himbert D. Valve-in-valve-in-valve: treating endocarditis of a transcatheter heart valve. Catheter Cardiovasc Interv. 2015;86:E200&#x2013;E204. doi: 10.1002/ccd.25899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.25899</ArticleId><ArticleId IdType="pubmed">25712243</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi SY, Salama IG, Narins C, Stuver T. Corynebacterium striatum prosthetic valve endocarditis with severe aortic regurgitation successfully treated with transcatheter aortic valve replacement. BMJ Case Rep. 2018;11:e226881. doi: 10.1136/bcr-2018-226881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2018-226881</ArticleId><ArticleId IdType="pmc">PMC6303625</ArticleId><ArticleId IdType="pubmed">30567113</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathi AS, Ali JM, Mann S, Taghavi J, Davies WR, Sudarshan C. Emergency valve-in-valve transcatheter aortic valve implantation for endocarditis degeneration. J Card Surg. 2020;35:713&#x2013;715. doi: 10.1111/jocs.14441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.14441</ArticleId><ArticleId IdType="pubmed">31999375</ArticleId></ArticleIdList></Reference><Reference><Citation>Brankovic M, Ansari J, Karanam R, Waxman S. Transcatheter aortic valve replacement as a rescue treatment for prosthetic valve endocarditis. JACC Case Rep. 2022;4:1306&#x2013;1310. doi: 10.1016/j.jaccas.2022.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccas.2022.04.022</ArticleId><ArticleId IdType="pmc">PMC9666743</ArticleId><ArticleId IdType="pubmed">36406906</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136/bmj.b2700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Dagher M, Ruffin F, et al. Risk factors for recurrent Staphylococcus aureus bacteremia. Clin Infect Dis. 2021;72:1891&#x2013;1899. doi: 10.1093/cid/ciaa801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa801</ArticleId><ArticleId IdType="pmc">PMC8315037</ArticleId><ArticleId IdType="pubmed">32564065</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu VH, Sexton DJ, Cabell CH, et al. Repeat infective endocarditis: differentiating relapse from reinfection. Clin Infect Dis. 2005;41:406&#x2013;409. doi: 10.1086/431590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/431590</ArticleId><ArticleId IdType="pubmed">16007540</ArticleId></ArticleIdList></Reference><Reference><Citation>Testa L, Agnifili M, Van Mieghem NM, et al. Transcatheter aortic valve replacement for degenerated transcatheter aortic valves: the TRANSIT international project. Circ Cardiovasc Interv. 2021;14:e010440. doi: 10.1161/CIRCINTERVENTIONS.120.010440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.120.010440</ArticleId><ArticleId IdType="pubmed">34092097</ArticleId></ArticleIdList></Reference><Reference><Citation>Landes U, Webb JG, De Backer O, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol. 2020;75:1882&#x2013;1893. doi: 10.1016/j.jacc.2020.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.02.051</ArticleId><ArticleId IdType="pubmed">32327098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawitz OK, Gulack BC, Grau-Sepulveda MV, et al. Reoperation after transcatheter aortic valve replacement: an analysis of the Society of Thoracic Surgeons Database. JACC Cardiovasc Interv. 2020;13:1515&#x2013;1525. doi: 10.1016/j.jcin.2020.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2020.04.029</ArticleId><ArticleId IdType="pmc">PMC7354233</ArticleId><ArticleId IdType="pubmed">32535005</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara S, Brescia AA, Shiomi S, et al. Surgical explantation of transcatheter aortic bioprostheses: results and clinical implications. J Thorac Cardiovasc Surg. 2021;162:539&#x2013;547.e1. doi: 10.1016/j.jtcvs.2019.11.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2019.11.139</ArticleId><ArticleId IdType="pmc">PMC7388726</ArticleId><ArticleId IdType="pubmed">32037245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangi AA, Ramchandani M, Reardon M. Surgical removal and replacement of chronically implanted transcatheter aortic prostheses: how I teach it. Ann Thorac Surg. 2018;105:12&#x2013;14. doi: 10.1016/j.athoracsur.2017.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.08.015</ArticleId><ArticleId IdType="pubmed">29233330</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31063466</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Incidence and complications of perioperative atrial fibrillation after non-cardiac surgery for malignancy.</ArticleTitle><Pagination><StartPage>e0216239</StartPage><MedlinePgn>e0216239</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0216239</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0216239</ELocationID><Abstract><AbstractText Label="BACKGROUND">Perioperative atrial fibrillation (POAF) is one of the common arrhythmias in the setting of non-cardiac surgeries for malignancy. As POAF may cause subsequent adverse events, it is important to confirm its characteristics and risk factors.</AbstractText><AbstractText Label="MATERIALS AND METHODS">The prospective cohort study of surveillance for perioperative atrial fibrillation recurrence (PREDICT AF RECURRENCE) is an ongoing prospective, single-center, observational study that aims to illustrate the clinical impact of POAF in major non-cardiac surgery for malignancy. Patients who planned to undergo non-cardiac surgery for definitive/suspected malignancy were registered. Those with a history of AF and atrial flutter were excluded. Any 30-day complications included acute myocardial infarction, congestive heart failure, bleeding, thrombosis, any infection, and acute kidney injury. The primary endpoint was an incidence of POAF.</AbstractText><AbstractText Label="RESULTS">The present study included 799 patients (age, 68 &#xb1; 11; male, 62%). Of these, 80 patients (10.0%) developed POAF. Notably, 66 patients (83%) had no symptoms. Any 30-day complications occurred in 180 patients (23%) (with POAF: 34 (43%); without POAF: 146 (20%); p &lt; 0.001). POAF in 17 patients (50%) was preceded by the development of complications. No patient developed cardiogenic shock and/or acute heart failure. The association between 30-day complications and POAF development were analyzed using the multivariate adjusted model (odds ratio: 2.84; 95% confidence interval: 1.74-4.62; p &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSION">Ten percent of patients who underwent non-cardiac surgery for malignancy developed POAF, which was strongly associated with perioperative complications. As a majority were asymptomatic, careful observation using electrocardiography monitoring is important to avoid oversights.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION">UMIN ID: UMIN000016146.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7914-8256</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabeya</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Internal Medicine, Tokai University, Kanagawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Home Care Medicine, Saiyu Clinic, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsushita</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Nobuaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Thoracic Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tachibana</LastName><ForeName>Keisei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Thoracic Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Ryota</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General Thoracic Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawachi</LastName><ForeName>Riken</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General Thoracic Surgery, Nihon University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takei</LastName><ForeName>Hidefumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Thoracic Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogure</LastName><ForeName>Masaharu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imanishi</LastName><ForeName>Yorihisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriyama</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yorozu</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Koichiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Nobutsugu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Haruhiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Thoracic Surgery, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshino</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>UMIN-CTR</DataBankName><AccessionNumberList><AccessionNumber>UMIN000016146</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059035" MajorTopicYN="N">Perioperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31063466</ArticleId><ArticleId IdType="pmc">PMC6504100</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0216239</ArticleId><ArticleId IdType="pii">PONE-D-18-37073</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. Jama. 2014;312(6):616&#x2013;22. Epub 2014/08/15. 10.1001/jama.2014.9143</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.9143</ArticleId><ArticleId IdType="pmc">PMC4277813</ArticleId><ArticleId IdType="pubmed">25117130</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH, et al. Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery. Journal of the American College of Cardiology. 2018;72(17):2027&#x2013;36. Epub 2018/10/20. 10.1016/j.jacc.2018.07.088 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.07.088</ArticleId><ArticleId IdType="pubmed">30336826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310&#x2013;7. Epub 2013/07/12. 10.1182/blood-2013-04-460162 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-04-460162</ArticleId><ArticleId IdType="pubmed">23843493</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Annals of palliative medicine. 2018;7(2):265&#x2013;73. Epub 2018/01/09. 10.21037/apm.2017.11.01 .</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm.2017.11.01</ArticleId><ArticleId IdType="pubmed">29307210</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi S, Kabeya Y, Matsushita K, Tachibana K, Kawachi R, Takei H, et al. The study protocol for PREDICT AF RECURRENCE: a PRospEctive cohort stuDy of surveIllanCe for perioperaTive Atrial Fibrillation RECURRENCE in major non-cardiac surgery for malignancy. BMC cardiovascular disorders. 2018;18(1):127 Epub 2018/06/27. 10.1186/s12872-018-0862-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0862-9</ArticleId><ArticleId IdType="pmc">PMC6019832</ArticleId><ArticleId IdType="pubmed">29940875</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology. 2018;72(18):2231&#x2013;64. Epub 2018/08/30. 10.1016/j.jacc.2018.08.1038 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.08.1038</ArticleId><ArticleId IdType="pubmed">30153967</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical care (London, England). 2007;11(2):R31 Epub 2007/03/03. 10.1186/cc5713</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc5713</ArticleId><ArticleId IdType="pmc">PMC2206446</ArticleId><ArticleId IdType="pubmed">17331245</ArticleId></ArticleIdList></Reference><Reference><Citation>Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500&#x2013;10. Epub 2012/01/17. 10.1093/eurheartj/ehr488 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehr488</ArticleId><ArticleId IdType="pubmed">22246443</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra GS, Molyneux J, Scott NA. Colorectal patients and cardiac arrhythmias detected on the surgical high dependency unit. Ann R Coll Surg Engl. 2001;83(3):174&#x2013;6. Epub 2001/07/04.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2503575</ArticleId><ArticleId IdType="pubmed">11432135</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neal WT, Lakoski SG, Qureshi W, Judd SE, Howard G, Howard VJ, et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol. 2015;115(8):1090&#x2013;4. Epub 2015/02/26. 10.1016/j.amjcard.2015.01.540</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2015.01.540</ArticleId><ArticleId IdType="pmc">PMC4380860</ArticleId><ArticleId IdType="pubmed">25711434</ArticleId></ArticleIdList></Reference><Reference><Citation>Erichsen R, Christiansen CF, Mehnert F, Weiss NS, Baron JA, Sorensen HT. Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study. Intern Emerg Med. 2012;7(5):431&#x2013;8. Epub 2011/10/05. 10.1007/s11739-011-0701-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-011-0701-9</ArticleId><ArticleId IdType="pubmed">21968511</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32(3):695&#x2013;703. Epub 1998/09/19. .</Citation><ArticleIdList><ArticleId IdType="pubmed">9741514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920&#x2013;5. Epub 2003/05/29. 10.1161/01.CIR.0000072767.89944.6E .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000072767.89944.6E</ArticleId><ArticleId IdType="pubmed">12771006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009;11(7):676&#x2013;83. Epub 2009/06/26. 10.1093/eurjhf/hfp085 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfp085</ArticleId><ArticleId IdType="pubmed">19553398</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. American heart journal. 2000;140(6):878&#x2013;85. Epub 2000/12/02. .</Citation><ArticleIdList><ArticleId IdType="pubmed">11099991</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart. 2001;86(5):527&#x2013;32. Epub 2001/10/17. 10.1136/heart.86.5.527</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.86.5.527</ArticleId><ArticleId IdType="pmc">PMC1729969</ArticleId><ArticleId IdType="pubmed">11602545</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J. 1999;20(10):748&#x2013;54. Epub 1999/05/18. .</Citation><ArticleIdList><ArticleId IdType="pubmed">10329066</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417&#x2013;27. Epub 2018/02/01. 10.1056/NEJMoa1707855 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707855</ArticleId><ArticleId IdType="pubmed">29385358</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992;20(3):527&#x2013;32. Epub 1992/09/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">1512329</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667&#x2013;77. Epub 2008/06/21. 10.1056/NEJMoa0708789 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0708789</ArticleId><ArticleId IdType="pubmed">18565859</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res. 2014;114(9):1500&#x2013;15. Epub 2014/04/26. 10.1161/CIRCRESAHA.114.303772</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.114.303772</ArticleId><ArticleId IdType="pmc">PMC4043633</ArticleId><ArticleId IdType="pubmed">24763467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37217802</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1861-0692</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical research in cardiology : official journal of the German Cardiac Society</Title><ISOAbbreviation>Clin Res Cardiol</ISOAbbreviation></Journal><ArticleTitle>Effects of levosimendan on the outcome of veno-arterial extracorporeal membrane oxygenation: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>509</StartPage><EndPage>521</EndPage><MedlinePgn>509-521</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00392-023-02208-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">For patients with severe cardiopulmonary failure, such as cardiogenic shock, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is primarily utilized to preserve their life by providing continuous extracorporeal respiration and circulation. However, because of the complexity of patients' underlying diseases and serious complications, successful weaning from ECMO is often difficult. At present, there have been limited studies on ECMO weaning strategies, so the principal purpose of this meta-analysis is to examine how levosimendan contributes to the weaning of extracorporeal membrane oxygenation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Cochrane Library, Embase, Web of Science, and PubMed were browsed for all potentially related research about clinical benefits of levosimendan in weaning patients receiving VA-ECMO and included 15 of them. The main outcome is success of weaning from extracorporeal membrane oxygenation, with the secondary outcomes of 1-month mortality (28 or 30&#xa0;days), ECMO duration, hospital or intensive care unit (ICU) length of stay, and use of vasoactive drugs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">1772 patients altogether from 15 publications were incorporated in our meta-analysis. We used fixed and random-effect models to combine odds ratio (OR) and 95% confidence interval (CI) for dichotomous outcomes and standardized mean difference (SMD) for continuous outcomes. The weaning success rate in the levosimendan group was considerably higher in contrast to the comparison (OR&#x2009;=&#x2009;2.78, 95% CI 1.80-4.30; P&#x2009;&lt;&#x2009;0.00001; I<sup>2</sup>&#x2009;=&#x2009;65%), and subgroup analysis showed that there was less heterogeneity in patients after cardiac surgery (OR&#x2009;=&#x2009;2.06, 95% CI, 1.35-3.12; P&#x2009;=&#x2009;0.0007; I<sup>2</sup>&#x2009;=&#x2009;17%). In addition, the effect of levosimendan on improving weaning success rate was statistically significant only at 0.2 mcg/kg/min (OR&#x2009;=&#x2009;2.45, 95% CI, 1.11-5.40; P&#x2009;=&#x2009;0.03; I<sup>2</sup>&#x2009;=&#x2009;38%). At the same time, the 28-day or 30-day proportion of deaths in the sample receiving levosimendan also decreased (OR&#x2009;=&#x2009;0.47, 95% CI, 0.28-0.79; P&#x2009;=&#x2009;0.004; I<sup>2</sup>&#x2009;=&#x2009;73%), and the difference was statistically significant. In terms of secondary outcomes, we found that individuals undergoing levosimendan treatment had a longer duration of VA-ECMO support.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients receiving VA-ECMO, levosimendan treatment considerably raised the weaning success rate and helped lower mortality. Since most of the evidence comes from retrospective studies, more randomized multicenter trials are required to verify the conclusion.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Yuliang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Lichen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yao</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yihui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Weidong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Wanlin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Pengyong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuguo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine and Chest Pain Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China. Chenxm008@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Chenxm008@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Chenxm008@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Haipeng</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0043-3976</Identifier><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China. Haipeng198334@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Haipeng198334@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Haipeng198334@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82172165</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>tsqn202103171</GrantID><Agency>Taishan Young Scholar Program of Shandong Province</Agency><Country/></Grant><Grant><GrantID>YXH2020ZX024</GrantID><Agency>Clinical Research Foundation of Shandong Province Medical Association</Agency><Country/></Grant><Grant><GrantID>2020T130072ZX</GrantID><Agency>China Postdoctoral Science Foundation</Agency><Country/></Grant><Grant><GrantID>2020SDUCRCC007</GrantID><Agency>Clinical Research Center of Shandong University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Res Cardiol</MedlineTA><NlmUniqueID>101264123</NlmUniqueID><ISSNLinking>1861-0684</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="Y">Simendan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="Y">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Cardiopulmonary support</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Levosimendan</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Weaning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37217802</ArticleId><ArticleId IdType="doi">10.1007/s00392-023-02208-1</ArticleId><ArticleId IdType="pii">10.1007/s00392-023-02208-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rao P, Khalpey Z, Smith R, Burkhoff D, Kociol RD (2018) Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. Circ Heart Fail 11(9):e004905. https://doi.org/10.1161/circheartfailure.118.004905</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circheartfailure.118.004905</ArticleId><ArticleId IdType="pubmed">30354364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstr&#xf6;m AE, Lagrand WK, Cherpanath TGV, Driessen AHG, de Mol B, Henriques JPS (2016) Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med 42(12):1922&#x2013;1934. https://doi.org/10.1007/s00134-016-4536-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4536-8</ArticleId><ArticleId IdType="pubmed">27647331</ArticleId><ArticleId IdType="pmc">5106498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostadal P, Rokyta R, Karasek J, Kruger A, Vondrakova D, Janotka M, Naar J, Smalcova J, Hubatova M, Hromadka M, Volovar S, Seyfrydova M, Jarkovsky J, Svoboda M, Linhart A, Belohlavek J (2023) Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: results of the ECMO-CS randomized clinical trial. Circulation 147(6):454&#x2013;464. https://doi.org/10.1161/circulationaha.122.062949</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.122.062949</ArticleId><ArticleId IdType="pubmed">36335478</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchal AR, Bartos JA, Caba&#xf1;as JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, O&#x2019;Neil BJ, Peberdy MA, Rittenberger JC, Rodriguez AJ, Sawyer KN, Berg KM (2020) Part 3: adult basic and advanced life support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 142(2):S366-s468. https://doi.org/10.1161/cir.0000000000000916</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000916</ArticleId><ArticleId IdType="pubmed">33081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Munshi L, Walkey A, Goligher E, Pham T, Uleryk EM, Fan E (2019) Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med 7(2):163&#x2013;172. https://doi.org/10.1016/s2213-2600(18)30452-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(18)30452-1</ArticleId><ArticleId IdType="pubmed">30642776</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglin M, Zucker MJ, Bazan VM, Bozkurt B, El Banayosy A, Estep JD, Gurley J, Nelson K, Malyala R, Panjrath GS, Zwischenberger JB, Pinney SP (2019) Venoarterial ECMO for adults: JACC scientific expert panel. J Am Coll Cardiol 73(6):698&#x2013;716. https://doi.org/10.1016/j.jacc.2018.11.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.11.038</ArticleId><ArticleId IdType="pubmed">30765037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsangaris A, Alexy T, Kalra R, Kosmopoulos M, Elliott A, Bartos JA, Yannopoulos D (2021) Overview of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support for the management of cardiogenic shock. Front Cardiovasc Med 8:686558. https://doi.org/10.3389/fcvm.2021.686558</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.686558</ArticleId><ArticleId IdType="pubmed">34307500</ArticleId><ArticleId IdType="pmc">8292640</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M, Vukomanovic A, Brodie D, Thiagarajan R, Rycus P, Buscher H (2017) Duration of veno-arterial extracorporeal life support (VA ECMO) and outcome: an analysis of the extracorporeal life support organization (ELSO) registry. Crit Care 21(1):45. https://doi.org/10.1186/s13054-017-1633-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-017-1633-1</ArticleId><ArticleId IdType="pubmed">28264702</ArticleId><ArticleId IdType="pmc">5339999</ArticleId></ArticleIdList></Reference><Reference><Citation>Toller WG, Stranz C (2006) Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 104(3):556&#x2013;569. https://doi.org/10.1097/00000542-200603000-00024</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200603000-00024</ArticleId><ArticleId IdType="pubmed">16508404</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997) Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333(2&#x2013;3):249&#x2013;259. https://doi.org/10.1016/s0014-2999(97)01108-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0014-2999(97)01108-4</ArticleId><ArticleId IdType="pubmed">9314042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaddoura R, Omar AS, Ibrahim MIM, Alkhulaifi A, Lorusso R, Elsherbini H, Soliman O, Caliskan K (2021) The effectiveness of levosimendan on veno-arterial extracorporeal membrane oxygenation management and outcome: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 35(8):2483&#x2013;2495. https://doi.org/10.1053/j.jvca.2021.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2021.01.019</ArticleId><ArticleId IdType="pubmed">33583718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivikko M, Antila S, Eha J, Lehtonen L, Pentik&#xe4;inen PJ (2002) Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40(10):465&#x2013;471. https://doi.org/10.5414/cpp40465</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/cpp40465</ArticleId><ArticleId IdType="pubmed">12395979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellouze O, Soudry Faure A, Radhouani M, Abou-Arab O, Besnier E, Moussa M, Cransac A, Ksiazek E, Fischer MO, Mertes PM, Bouhemad B, Guinot PG (2021) Levosimendan in venoarterial ECMO weaning rational and design of a randomized double blind multicentre trial. ESC Heart Fail 8(4):3339&#x2013;3347. https://doi.org/10.1002/ehf2.13427</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13427</ArticleId><ArticleId IdType="pubmed">34145993</ArticleId><ArticleId IdType="pmc">8318420</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#xf3;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:71. https://doi.org/10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern&#xe1;n MA, Hopewell S, Hr&#xf3;bjartsson A, Junqueira DR, J&#xfc;ni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy FH, McDermott KM, Kini V, Gutsche JT, Wald JW, Xie D, Szeto WY, Bermudez CA, Atluri P, Acker MA, Desai ND (2015) Trends in US extracorporeal membrane oxygenation use and outcomes: 2002&#x2013;2012. Semin Thorac Cardiovasc Surg 27(2):81&#x2013;88. https://doi.org/10.1053/j.semtcvs.2015.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semtcvs.2015.07.005</ArticleId><ArticleId IdType="pubmed">26686427</ArticleId><ArticleId IdType="pmc">4780346</ArticleId></ArticleIdList></Reference><Reference><Citation>Stub D, Bernard S, Pellegrino V, Smith K, Walker T, Sheldrake J, Hockings L, Shaw J, Duffy SJ, Burrell A, Cameron P (2015) Refractory cardiac arrest treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial). Resuscitation 86:88&#x2013;94. https://doi.org/10.1016/j.resuscitation.2014.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2014.09.010</ArticleId><ArticleId IdType="pubmed">25281189</ArticleId></ArticleIdList></Reference><Reference><Citation>Distelmaier K, Roth C, Schrutka L, Binder C, Steinlechner B, Heinz G, Lang IM, Maurer G, Koinig H, Niessner A et al (2016) Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth 117(1):52&#x2013;58. https://doi.org/10.1093/bja/aew151</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aew151</ArticleId><ArticleId IdType="pubmed">27317704</ArticleId><ArticleId IdType="pmc">4913403</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilherme E, Jacquet-Lagreze M, Pozzi M, Achana F, Armoiry X, Fellahi J-L (2020) Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis. Crit Care 24(1):2. https://doi.org/10.1186/s13054-020-03122-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03122-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacky A, Rudiger A, Kruger B, Wilhelm MJ, Paal S, Seifert B, Spahn DR, Bettex D (2018) Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery-a retrospective before-and-after study. J Cardiothorac Vasc Anesth 32(5):2112&#x2013;2119. https://doi.org/10.1053/j.jvca.2018.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2018.04.019</ArticleId><ArticleId IdType="pubmed">29748076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangalli F, Avalli L, Laratta M, Formica F, Maggioni E, Caruso R, Costa MC, Guazzi M, Fumagalli R (2016) Effects of levosimendan on endothelial function and hemodynamics during weaning from veno-arterial extracorporeal life support. J Cardiothorac Vasc Anesth 30(6):1449&#x2013;1453. https://doi.org/10.1053/j.jvca.2016.03.139</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2016.03.139</ArticleId><ArticleId IdType="pubmed">27495966</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschka H, Schafers B, Gottschalk A, Scherer M, Martens S, Welp H (2019) Effects of levosimendan therapy in patients undergoing extracorporeal membrane oxygenation after cardiac surgery. Thorac Cardiovasc Surg 67:2. https://doi.org/10.1055/s-0039-1679012</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1679012</ArticleId></ArticleIdList></Reference><Reference><Citation>Vally S, Ferdynus C, Persichini R, Bouchet B, Braunberger E, Lo Pinto H, Martinet O, Vandroux D, Aujoulat T, Allyn J, Allou N (2019) Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intens Care. 9(1):2. https://doi.org/10.1186/s13613-019-0503-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-019-0503-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng WS, Tang KB, Shum HP (2022) Impact of levosimendan use on survival of patients on veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. Crit Care 26(1):2. https://doi.org/10.1186/s13054-022-03927-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-03927-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipfel S, Reiter B, Sill B, Barten M, Rybczinski M, Kubik M, Kluge S, Reichenspurner H, Bernhardt A (2018) Levosimendan effects benefit weaning from veno-arterial extracorporeal life support. Thoracic and cardiovascular surgeon. Conference: 47th annual meeting of the german society for thoracic and cardiovascular surgery, DGTHG 2018. Germany, 2018. 66(Supplement 1) (no pagination). https://doi.org/10.1055/s-0038-1628090</Citation></Reference><Reference><Citation>Haffner G, Ajob G, Cristinar M, Marguerite S, Oulehri W, Heger B, Kindo M, Mertes PM, Steib A (2018) Levosimendan for weaning veno-arterial ECMO (VA ECMO). Crit Care 22:2. https://doi.org/10.1186/s13054-018-1973-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-1973-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Fernandez-Gatta M, Merchan-Gomez S, Gonzalez-Cebrian M, Diego-Nieto A, Alzola E, Toranzo-Nieto I, Barrio A, Martin-Herrero F, Sanchez PL (2021) Levosimendan in veno-arterial extracorporeal membrane oxygenator supported patients: Impact on the success of weaning and survival. Artif Organs 45(7):717&#x2013;725. https://doi.org/10.1111/aor.13899</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.13899</ArticleId><ArticleId IdType="pubmed">33377185</ArticleId></ArticleIdList></Reference><Reference><Citation>Affronti A, Di Bella I, Carino D, Ragni T (2013) Levosimendan may improve weaning outcomesin venoarterial ECMO patients. ASAIO J 59(6):554&#x2013;557. https://doi.org/10.1097/MAT.0b013e3182a4b32e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0b013e3182a4b32e</ArticleId><ArticleId IdType="pubmed">24172260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hau M, Fong KM, Au SY (2022) Levosimendan&#x2019;s effect on venoarterial extracorporeal membrane oxygenation weaning. Int J Artif Organs. https://doi.org/10.1177/03913988221098773</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03913988221098773</ArticleId><ArticleId IdType="pubmed">35570732</ArticleId></ArticleIdList></Reference><Reference><Citation>Florchinger B, Provaznik Z, Philipp A, Foltan M, Camboni D, Rupprecht L, Lunz D, Schmid C (2021) Use of levosimendan in adult patients with postcardiotomy extracorporeal life support: a single-center experience. Thorac Cardiovasc Surg 69(1):2. https://doi.org/10.1055/s-0041-1725792</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1725792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-W, Lee W-C, Wu P-J, Fang H-Y, Fang Y-N, Chen H-C, Tong M-S, Sung P-H, Lee C-H, Chung W-J (2022) Early levosimendan administration improved weaning success rate in extracorporeal membrane oxygenation in patients with cardiogenic shock. Front Cardiovasc Med 9:2. https://doi.org/10.3389/fcvm.2022.912321</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.912321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaisendrees C, Gerfer S, Ivanov B, Sabashnikov A, Eghbalzadeh K, Djordjevic I, Wahlers T (2022) Feasibility and safety of levosimendan in patients after cardiac arrest treated with eCPR. Perfusion 37(1 SUPPL):4. https://doi.org/10.1177/02676591221089240</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02676591221089240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz&#xe1;lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37(27):2129&#x2013;2200. https://doi.org/10.1093/eurheartj/ehw128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw128</ArticleId><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>Werdan K, Ru&#xdf; M, Buerke M, Delle-Karth G, Geppert A, Sch&#xf6;ndube FA (2012) Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German&#x2013;Austrian S3 guideline. Dtsch Arztebl Int 109(19):343&#x2013;351. https://doi.org/10.3238/arztebl.2012.0343</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2012.0343</ArticleId><ArticleId IdType="pubmed">22675405</ArticleId><ArticleId IdType="pmc">3364528</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J, Jia L, Hao Y, Huang S, Ma Y, Li X, Wang M, Mao Y (2017) Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci 184:30&#x2013;36. https://doi.org/10.1016/j.lfs.2017.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2017.07.001</ArticleId><ArticleId IdType="pubmed">28689804</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedele F, Bruno N, Brasolin B, Caira C, D&#x2019;Ambrosi A, Mancone M (2014) Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail 16(3):281&#x2013;288. https://doi.org/10.1002/ejhf.9</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.9</ArticleId><ArticleId IdType="pubmed">24464960</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieminen MS, Altenberger J, Ben-Gal T, B&#xf6;hmer A, Comin-Colet J, Dickstein K, Edes I, Fedele F, Fonseca C, Garc&#xed;a-Gonz&#xe1;lez MJ, Giannakoulas G, Iakobishvili Z, J&#xe4;&#xe4;skel&#xe4;inen P, Karavidas A, Kettner J, Kivikko M, Lund LH, Matskeplishvili ST, Metra M, Morandi F, Oliva F, Parkhomenko A, Parissis J, Pollesello P, P&#xf6;lzl G, Schwinger RH, Segovia J, Seidel M, Vrtovec B, Wikstr&#xf6;m G (2014) Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol 174(2):360&#x2013;367. https://doi.org/10.1016/j.ijcard.2014.04.111</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2014.04.111</ArticleId><ArticleId IdType="pubmed">24780540</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Dunlay SM, Prasad A, Kashani K, Sakhuja A, Gersh BJ, Jaffe AS, Holmes DR Jr, Barsness GW (2019) Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock. J Am Coll Cardiol 73(14):1781&#x2013;1791. https://doi.org/10.1016/j.jacc.2019.01.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.01.053</ArticleId><ArticleId IdType="pubmed">30975295</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholley B, Levy B, Fellahi JL, Longrois D, Amour J, Ouattara A, Mebazaa A (2019) Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care 23(1):385. https://doi.org/10.1186/s13054-019-2674-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2674-4</ArticleId><ArticleId IdType="pubmed">31783891</ArticleId><ArticleId IdType="pmc">6883606</ArticleId></ArticleIdList></Reference><Reference><Citation>Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, Kallikazaros I (2005) The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7(5):882&#x2013;887. https://doi.org/10.1016/j.ejheart.2005.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejheart.2005.02.002</ArticleId><ArticleId IdType="pubmed">15921958</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilherme E, Jacquet-Lagr&#xe8;ze M, Pozzi M, Achana F, Armoiry X, Fellahi JL (2020) Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis. Crit Care 24(1):442. https://doi.org/10.1186/s13054-020-03122-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03122-y</ArticleId><ArticleId IdType="pubmed">32677985</ArticleId><ArticleId IdType="pmc">7367381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hau M, Fong KM, Au SY (2022) Levosimendan&#x2019;s effect on venoarterial extracorporeal membrane oxygenation weaning. Int J Artif Organs. https://doi.org/10.1177/03913988221098773</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03913988221098773</ArticleId><ArticleId IdType="pubmed">35570732</ArticleId></ArticleIdList></Reference><Reference><Citation>Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A (2012) Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 40(2):634&#x2013;646. https://doi.org/10.1097/CCM.0b013e318232962a</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318232962a</ArticleId><ArticleId IdType="pubmed">21963578</ArticleId></ArticleIdList></Reference><Reference><Citation>Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360(9328):196&#x2013;202. https://doi.org/10.1016/s0140-6736(02)09455-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(02)09455-2</ArticleId><ArticleId IdType="pubmed">12133653</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng F, Chen Y, Li M, Yuan JJ, Chang XN, Dong CM (2019) Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis. Chin Med J (Engl) 132(10):1212&#x2013;1217. https://doi.org/10.1097/cm9.0000000000000197</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/cm9.0000000000000197</ArticleId><ArticleId IdType="pubmed">31140992</ArticleId></ArticleIdList></Reference><Reference><Citation>Van De Moortel L, De Mey N, De Decker K (2020) Levosimendan after cardiac surgery: a single-center case series. Chest 157(6):A137. https://doi.org/10.1016/j.chest.2020.05.155</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.05.155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholley B, Levy B, Fellahi JL, Longrois D, Amour J, Ouattara A, Mebazaa A (2019) Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care 23(1):2. https://doi.org/10.1186/s13054-019-2674-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2674-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Becher PM, Bernhardt A, Bezerra H, Blankenberg S, Brunner S, Colson P, CudemusDeseda G, Dabboura S, Eckner D, Eden M, Eitel I, Frank D, Frey N, Funamoto M, Go&#xdf;ling A, Graf T, Hagl C, Kirchhof P, Kupka D, Landmesser U, Lipinski J, Lopes M, Majunke N, Maniuc O, McGrath D, M&#xf6;bius-Winkler S, Morrow DA, Mourad M, Noel C, Nordbeck P, Orban M, Pappalardo F, Patel SM, Pauschinger M, Pazzanese V, Reichenspurner H, Sandri M, Schulze PC (2020) Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International Multicenter Cohort Study. Circulation 142(22):2095&#x2013;2106. https://doi.org/10.1161/circulationaha.120.048792</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.120.048792</ArticleId><ArticleId IdType="pubmed">33032450</ArticleId><ArticleId IdType="pmc">7688081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S, Ahsan MJ, Ikram S, Lateef N, Khan BA, Tabassum S, Naeem A, Qavi AH, Ardhanari S, Goldsweig AM (2023) Impella versus extracorporeal membranous oxygenation (ecmo) for cardiogenic shock: a systematic review and meta-analysis. Curr Probl Cardiol 48(1):101427. https://doi.org/10.1016/j.cpcardiol.2022.101427</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2022.101427</ArticleId><ArticleId IdType="pubmed">36174742</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24848410</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-7080</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Current opinion in cardiology</Title><ISOAbbreviation>Curr Opin Cardiol</ISOAbbreviation></Journal><ArticleTitle>Intra-aortic balloon pump: indications, efficacy, guidelines and future directions.</ArticleTitle><Pagination><StartPage>285</StartPage><EndPage>292</EndPage><MedlinePgn>285-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/HCO.0000000000000075</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">The intra-aortic balloon pump (IABP) has been used as a cardiac assist device in various clinical situations since 1968 on the basis of the physiological principles and observational data, with little randomized data until recently.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Recently published randomized controlled trials (RCTs) and meta-analyses have demonstrated acceptable safety for IABP but have raised doubt over efficacy in acute myocardial infarction (MI) both with and without cardiogenic shock. RCTs and meta-analyses have provided limited and qualified support for the efficacy of IABP in high-risk percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). There remains only observational data to support the efficacy of IABP in other niche indications, including mechanical complications of MI (acute severe mitral regurgitation and ventricular septal rupture) and refractory ventricular arrhythmia.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Current randomized trial data and meta-analyses support the safety of IABP, but provide limited or no support for its efficacy in the treatment of high-risk MI, MI complicated by cardiogenic shock or the use of prophylactic IABP in high-risk PCI and CABG. Further studies to inform optimal patient selection, timing and use of associated therapies are required to characterize the role of IABP in contemporary practice and optimize outcome in high-risk patient subsets.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ihdayhid</LastName><ForeName>Abdul R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Cardiology Department, Royal Perth Hospital, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chopra</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Cardiol</MedlineTA><NlmUniqueID>8608087</NlmUniqueID><ISSNLinking>0268-4705</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="N">Coronary Artery Bypass</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="Y">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24848410</ArticleId><ArticleId IdType="doi">10.1097/HCO.0000000000000075</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40436616</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0844</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>European journal of heart failure</Title><ISOAbbreviation>Eur J Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Kidney injury in patients with heart failure-related cardiogenic shock: Results from an international, multicentre cohort study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ejhf.3701</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Heart failure-related cardiogenic shock (HF-CS) accounts for about half of CS cases, with a paucity of data regarding the role of kidney injury in this subset. This study aims to evaluate patient characteristics and outcome associated with renal function in patients with HF-CS.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">In this multicentre, international, retrospective study, patients with HF-CS from 16 tertiary care centres in five countries were enrolled between 2010 and 2021. To investigate differences in clinical presentation, complications, and 30-day mortality, based on renal function, adjusted logistic and Cox regression models were fitted. Among 1010 HF-CS patients, the median age was 64 (interquartile range [IQR] 52-75) years, with 71.7% being male. Median baseline creatinine was 1.7 (IQR 1.2-2.5) mg/dl, corresponding to an estimated glomerular filtration rate (eGFR) of 41.0 (IQR 25.2-62.2) ml/min/1.73&#x2009;m<sup>2</sup>. In patients with acute kidney injury (AKI), 30-day mortality increased with AKI stages (no AKI 41.7%, AKI stage 1 43.3%, AKI stage 2 50.0%, AKI stage 3 63.7%; adjusted hazard ratio [HR] for AKI stage 3 1.97, 95% confidence interval [CI] 1.56-2.48, p&#x2009;&lt;&#x2009;0.001). Similarly, severe renal dysfunction (eGFR &#x2264; median) was associated with a 21% higher 30-day mortality risk (61.0% vs. 40.1%; adjusted HR 1.48, 95% CI 1.20-1.84, p&#x2009;&lt;&#x2009;0.001). Sepsis and bleeding were associated with both AKI and renal dysfunction, even after adjustment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In HF-CS, kidney injury is associated with higher 30-day mortality, potentially mediated by bleeding and sepsis. These findings support the consideration of kidney function as a prognostic marker and call for the development and evaluation of kidney-restoring adjunct interventions in HF-CS.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). European Journal of Heart Failure published by John Wiley &amp; Sons Ltd on behalf of European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sundermeyer</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0076-2211</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellner</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beer</LastName><ForeName>Benedikt N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besch</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dettling</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoldi</LastName><ForeName>Letizia Fausta</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Cardio Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blankenberg</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dauw</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckner</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Paracelsus Medical University N&#xfc;rnberg, N&#xfc;rnberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Heart Center L&#xfc;beck, University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graf</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Heart Center L&#xfc;beck, University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jozwiak-Nozdrzykowska</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchhof</LastName><ForeName>Paulus</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kluge</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linke</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department for Internal Medicine and Cardiology, Heart Center Dresden, Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landmesser</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9; (DHZC), Campus Benjamin Franklin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xfc;sebrink</LastName><ForeName>Enzo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majunke</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangner</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department for Internal Medicine and Cardiology, Heart Center Dresden, Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Sven M&#xf6;bius</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orban</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Anesthesia and Intensive Care, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pauschinger</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Paracelsus Medical University N&#xfc;rnberg, N&#xfc;rnberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazdernik</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, IKEM, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proudfoot</LastName><ForeName>Alastair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Perioperative Medicine, St. Bartholomew's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelham</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Perioperative Medicine, St. Bartholomew's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassaf</LastName><ForeName>Tienush</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichenspurner</LastName><ForeName>Hermann</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherer</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulze</LastName><ForeName>P Christian</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwinger</LastName><ForeName>Robert H G</ForeName><Initials>RHG</Initials><AffiliationInfo><Affiliation>Medizinische Klinik II, Kliniken Nordoberpfalz AG, Weiden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9; (DHZC), Campus Benjamin Franklin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sramko</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, IKEM, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavazzi</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical-Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villanova</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit&#xe0; di Cure Intensive Cardiologiche and De Gasperis Cardio-Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morici</LastName><ForeName>Nuccia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Gnocchi, ONLUS, Santa Maria Nascente, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winzer</LastName><ForeName>Ephraim B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department for Internal Medicine and Cardiology, Heart Center Dresden, Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westermann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schrage</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Heart Fail</MedlineTA><NlmUniqueID>100887595</NlmUniqueID><ISSNLinking>1388-9842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Kidney function</Keyword><Keyword MajorTopicYN="N">Kidney injury</Keyword><Keyword MajorTopicYN="N">Non&#x2010;AMI CS</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>29</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>29</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40436616</ArticleId><ArticleId IdType="doi">10.1002/ejhf.3701</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B&#xf6;hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599&#x2013;3726. https://doi.org/10.1093/eurheartj/ehab368</Citation></Reference><Reference><Citation>Naidu SS Baran DA Jentzer JC, Hollenberg SM, van Diepen S, Basir MB, et al. SCAI SHOCK stage classification expert consensus update: A review and incorporation of validation studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December&#x2009;2021. J Am Coll Cardiol 2022 79 933 946 https://doi.org/10.1016/j.jacc.2022.01.018</Citation></Reference><Reference><Citation>Van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: A scientific statement from the American Heart Association. Circulation 2017;136:e232&#x2013;e268. https://doi.org/10.1161/CIR.0000000000000525</Citation></Reference><Reference><Citation>Osman M, Syed M, Patibandla S, Sulaiman S, Kheiri B, Shah MK, et al. Fifteen&#x2010;year trends in incidence of cardiogenic shock hospitalization and in&#x2010;hospital mortality in the United States. J Am Heart Assoc 2021;10:e021061. https://doi.org/10.1161/JAHA.121.021061</Citation></Reference><Reference><Citation>Helgestad OKL, Josiassen J, Hassager C, Jensen LO, Holmvang L, S&#xf8;rensen A, et al. Temporal trends in incidence and patient characteristics in cardiogenic shock following acute myocardial infarction from 2010 to 2017: A Danish cohort study. Eur J Heart Fail 2019;21:1370&#x2013;1378. https://doi.org/10.1002/ejhf.1566</Citation></Reference><Reference><Citation>Schrage B, Becher PM, Go&#xdf;ling A, Savarese G, Dabboura S, Yan I, et al. Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. ESC Heart Fail 2021;8:1295&#x2013;1303. https://doi.org/10.1002/ehf2.13202</Citation></Reference><Reference><Citation>Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird&#x2010;Zars VM, et al. Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes 2019;12(3):e005618. https://doi.org/10.1161/CIRCOUTCOMES.119.005618</Citation></Reference><Reference><Citation>Shah M, Patnaik S, Patel B, Ram P, Garg L, Agarwal M, et al. Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non&#x2010;infarction related cardiogenic shock in the United States. Clin Res Cardiol 2017;107:287&#x2013;303. https://doi.org/10.1007/S00392&#x2010;017&#x2010;1182&#x2010;2</Citation></Reference><Reference><Citation>Thiele H, Ohman EM, De Waha&#x2010;Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: An update 2019. Eur Heart J 2019;40:2671&#x2013;2683. https://doi.org/10.1093/eurheartj/ehz363</Citation></Reference><Reference><Citation>Thayer KL, Zweck E, Ayouty M, Garan AR, Hernandez&#x2010;Montfort J, Mahr C, et al. Invasive hemodynamic assessment and classification of in&#x2010;hospital mortality risk among patients with cardiogenic shock. Circ Heart Fail 2020;13:e007099. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007099</Citation></Reference><Reference><Citation>Schrage B, Dabboura S, Yan I, Hilal R, Neumann JT, S&#xf6;rensen NA, et al. Application of the SCAI classification in a cohort of patients with cardiogenic shock. Catheter Cardiovasc Interv 2020;96:E213&#x2013;E219. https://doi.org/10.1002/ccd.28707</Citation></Reference><Reference><Citation>Sundermeyer J, Kellner C, Beer BN, Besch L, Dettling A, Bertoldi LF, et al. Clinical presentation, shock severity and mortality in patients with de novo versus acute&#x2010;on&#x2010;chronic heart failure&#x2010;related cardiogenic shock. Eur J Heart Fail 2024;26:432&#x2013;444. https://doi.org/10.1002/ejhf.3082</Citation></Reference><Reference><Citation>Jentzer JC, van Diepen S, Barsness GW, Henry TD, Menon V, Rihal CS, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol 2019;74(17):2117 2128. https://doi.org/10.1016/j.jacc.2019.07.077</Citation></Reference><Reference><Citation>Schrage B, Sundermeyer J, Beer BN, Bertoldi L, Bernhardt A, Blankenberg S, et al. Use of mechanical circulatory support in patients with non&#x2010;ischaemic cardiogenic shock. Eur J Heart Fail 2023;25:562&#x2013;572. https://doi.org/10.1002/ejhf.2796</Citation></Reference><Reference><Citation>Ghionzoli N, Sciaccaluga C, Mandoli G, Vergaro G, Gentile F, D'Ascenzi F, et al. Cardiogenic shock and acute kidney injury: The rule rather than the exception. Heart Fail Rev 2021;26:487&#x2013;496. https://doi.org/10.1007/s10741&#x2010;020&#x2010;10034&#x2010;0</Citation></Reference><Reference><Citation>Rewa O, Bagshaw SM. Acute kidney injury&#xa0;&#x2013;&#xa0;epidemiology, outcomes and economics. Nat Rev Nephrol 2014;10:193&#x2013;207. https://doi.org/10.1038/nrneph.2013.282</Citation></Reference><Reference><Citation>Zhang J, Bottiglieri T, McCullough PA. The central role of endothelial dysfunction in cardiorenal syndrome. Cardiorenal Med 2017;7:104&#x2013;117. https://doi.org/10.1159/000452283</Citation></Reference><Reference><Citation>Damman K, Testani JM. The kidney in heart failure: An update. Eur Heart J 2015;36:1437&#x2013;1444. https://doi.org/10.1093/eurheartj/ehv010</Citation></Reference><Reference><Citation>Tarvasm&#xe4;ki T, Haapio M, Mebazaa A, Sionis A, Silva&#x2010;Cardoso J, Tolppanen H, et al.; CardShock Study Investigators. Acute kidney injury in cardiogenic shock: Definitions, incidence, haemodynamic alterations, and mortality. Eur J Heart Fail 2018;20:572&#x2013;581. https://doi.org/10.1002/ejhf.958</Citation></Reference><Reference><Citation>Koreny M, Karth GD, Geppert A, Neunteufl T, Priglinger U, Heinz G, et al. Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 2002;112:115&#x2013;119. https://doi.org/10.1016/S0002&#x2010;9343(01)01070&#x2010;1</Citation></Reference><Reference><Citation>Pickering JW, Blunt IRH, Than MP. Acute kidney injury and mortality prognosis in acute coronary syndrome patients: A meta&#x2010;analysis. Nephrol Ther 2018;23:237&#x2013;246. https://doi.org/10.1111/NEP.12984</Citation></Reference><Reference><Citation>Uzendu A, Kennedy K, Chertow G, Amin AP, Giri JS, Rymer JA, et al. Contemporary methods for predicting acute kidney injury after coronary intervention. JACC Cardiovasc Interv 2023;16:2294&#x2013;2305. https://doi.org/10.1016/j.jcin.2023.07.041</Citation></Reference><Reference><Citation>Dalia T, Pothuru S, Chan WC, Mehta H, Goyal A, Farhoud H, et al. Trends and outcomes of cardiogenic shock in patients with end&#x2010;stage renal disease: Insights from USRDS database. Circ Heart Fail 2023;16:e010462. https://doi.org/10.1161/CIRCHEARTFAILURE.122.010462</Citation></Reference><Reference><Citation>Sheikh O, Nguyen T, Bansal S, Prasad A. Acute kidney injury in cardiogenic shock: A comprehensive review. Catheter Cardiovasc Interv 2021;98:E91&#x2013;E105. https://doi.org/10.1002/ccd.29141</Citation></Reference><Reference><Citation>Sundermeyer J, Kellner C, Beer BN, Besch L, Dettling A, Bertoldi LF, et al. Association between left ventricular ejection fraction, mortality and use of mechanical circulatory support in patients with non&#x2010;ischaemic cardiogenic shock. Clin Res Cardiol 2024;113:570&#x2013;580. https://doi.org/10.1007/s00392&#x2010;023&#x2010;02332&#x2010;y</Citation></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv, 2019; 94(1): 29&#x2013;37. https://doi.org/10.1002/ccd.28329</Citation></Reference><Reference><Citation>Kramer HJ, Jaar BG, Choi MJ, Palevsky PM, Vassalotti JA, Rocco MV. An endorsement of the removal of race from GFR estimation equations: A position statement from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis 2022;80:691&#x2013;696. https://doi.org/10.1053/j.ajkd.2022.08.004</Citation></Reference><Reference><Citation>Inker LA Eneanya ND Coresh J Tighiouart H Wang D Sang Y, et al.; Chronic Kidney Disease Epidemiology Collaboration. New creatinine&#x2010; and cystatin C&#x2010;based equations to estimate GFR without race N Engl J Med 2021 385 1737 1749 https://doi.org/10.1056/NEJMoa2102953</Citation></Reference><Reference><Citation>Zweck E, Thayer KL, Helgestad OKL, Kanwar M, Ayouty M, Garan AR, et al. Phenotyping cardiogenic shock. J Am Heart Assoc 2021;10:e020085. https://doi.org/10.1161/JAHA.120.020085</Citation></Reference><Reference><Citation>Kapur NK, Kanwar M, Sinha SS, Thayer KL, Garan AR, Hernandez&#x2010;Montfort J, et al. Criteria for defining stages of cardiogenic shock severity. J Am Coll Cardiol 2022;80:185&#x2013;198. https://doi.org/10.1016/j.jacc.2022.04.049</Citation></Reference><Reference><Citation>Beer BN, Jentzer JC, Weimann J, Dabboura S, Yan I, Sundermeyer J, et al. Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause&#xa0;&#x2013;&#xa0;the Cardiogenic Shock Score. Eur J Heart Fail 2022;24:657&#x2013;667. https://doi.org/10.1002/ejhf.2449</Citation></Reference><Reference><Citation>Kanwar MK, Billia F, Randhawa V, Cowger JA, Barnett CM, Chih S, et al. Heart failure related cardiogenic shock: An ISHLT consensus conference content summary. J Heart Lung Transplant 2024;43:189&#x2013;203. https://doi.org/10.1016/j.healun.2023.09.014</Citation></Reference><Reference><Citation>Padkins M, Breen T, Van Diepen S, Barsness G, Kashani K, Jentzer JC. Incidence and outcomes of acute kidney injury stratified by cardiogenic shock severity. Catheter Cardiovasc Interv 2021;98:330&#x2013;340. https://doi.org/10.1002/ccd.29692</Citation></Reference><Reference><Citation>Fuernau G, Poenisch C, Eitel I, Denks D, de Waha S, P&#xf6;ss J, et al. Prognostic impact of established and novel renal function biomarkers in myocardial infarction with cardiogenic shock: A biomarker substudy of the IABP&#x2010;SHOCK II&#x2010;trial. Int J Cardiol 2015;191:159&#x2013;166. https://doi.org/10.1016/j.ijcard.2015.04.242</Citation></Reference><Reference><Citation>Marenzi G, Assanelli E, Campodonico J, de Metrio M, Lauri G, Marana I, et al. Acute kidney injury in ST&#x2010;segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med 2010;38:438&#x2013;444. https://doi.org/10.1097/CCM.0B013E3181B9EB3B</Citation></Reference><Reference><Citation>Harjola VP, Lassus J, Sionis A, K&#xf8;ber L, Tarvasm&#xe4;ki T, Spinar J, et al.; CardShock Study Investigators; GREAT network. Clinical picture and risk prediction of short&#x2010;term mortality in cardiogenic shock. Eur J Heart Fail 2015;17:501&#x2013;509. https://doi.org/10.1002/ejhf.260</Citation></Reference><Reference><Citation>Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation 2019;139:E840&#x2013;E878. https://doi.org/10.1161/CIR.0000000000000664</Citation></Reference><Reference><Citation>Jentzer JC, Bihorac A, Brusca SB, del Rio&#x2010;Pertuz G, Kashani K, Kazory A, et al.; Critical Care Cardiology Working Group of the Heart Failure and Transplant Section Leadership Council. Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome: JACC Council perspectives. J Am Coll Cardiol 2020;76:1084&#x2013;1101. https://doi.org/10.1016/j.jacc.2020.06.070</Citation></Reference><Reference><Citation>Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, et al. Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance. Eur J Heart Fail 2008;10:188&#x2013;195. https://doi.org/10.1016/j.ejheart.2008.01.011</Citation></Reference><Reference><Citation>Patsalis N, Kreutz J, Chatzis G, Syntila S, Griewing S, Pirlet&#x2010;Grant C, et al. Renal protection and hemodynamic improvement by Impella&#xae; microaxial pump in patients with cardiogenic shock. J Clin Med 2022;11:6817. https://doi.org/10.3390/jcm11226817</Citation></Reference><Reference><Citation>Lauridsen MD, Gammelager H, Schmidt M, Rasmussen TB, Shaw RE, B&#xf8;tker HE, et al. Acute kidney injury treated with renal replacement therapy and 5&#x2010;year mortality after myocardial infarction&#x2010;related cardiogenic shock: A nationwide population&#x2010;based cohort study. Crit Care 2015;19:452. https://doi.org/10.1186/s13054&#x2010;015&#x2010;1170&#x2010;8</Citation></Reference><Reference><Citation>Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence&#x2010;based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007;3:138&#x2013;153. https://doi.org/10.1038/ncpneph0421</Citation></Reference><Reference><Citation>Prowle JR, Liu YL, Licari E, Bagshaw SM, Egi M, Haase M, et al. Oliguria as predictive biomarker of acute kidney injury in critically ill patients. Crit Care 2011;15:R172. https://doi.org/10.1186/cc10318</Citation></Reference><Reference><Citation>Hanberg JS, Sury K, Perry Wilson F, Wilson FP, Brisco MA, Ahmad T, et al. Reduced cardiac index is not the dominant driver of renal dysfunction in heart failure. J Am Coll Cardiol 2016;67:2199&#x2013;2208. https://doi.org/10.1016/j.jacc.2016.02.058</Citation></Reference><Reference><Citation>Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589&#x2013;596. https://doi.org/10.1016/j.jacc.2008.05.068</Citation></Reference><Reference><Citation>Roman&#x2010;Pognuz E, Elmer J, Rittenberger JC, Guyette FX, Berlot G, De Rosa S, et al. Markers of cardiogenic shock predict persistent acute kidney injury after out of hospital cardiac arrest. Heart Lung 2019;48:126&#x2013;130. https://doi.org/10.1016/j.hrtlng.2018.10.025</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37813286</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>396</Volume><PubDate><Year>2024</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Temporary mechanical circulatory support with Impella in cardiac surgery: A systematic review.</ArticleTitle><Pagination><StartPage>131418</StartPage><MedlinePgn>131418</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2023.131418</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(23)01447-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Perioperative cardiogenic shock (CS) in cardiac surgery is still burdened by a high mortality risk. The introduction of Impella pumps in the therapeutic armory of temporary mechanical circulatory support (tMCS) has potential implications to improve the management of complex cases, although it has never been systematically addressed. We performed a systematic review of the reported use of tMCS with Impella in cardiac surgery.</AbstractText><AbstractText Label="METHODS">We searched PubMed for all original studies on the Impella use in adult patients in cardiac surgery.</AbstractText><AbstractText Label="RESULTS">Nineteen studies (out of 151 identified by search string) were included. All studies were observational and all but one (95%) were retrospective. Seven studies focused on the implantation of Impella in the pre-operative setting (coronary or valvular surgery), either as a prophylactic device in high-risk cases (3 studies) or in patients with CS as stabilization tool prior to cardiac surgery procedure (4 studies). Three studies reported the use of Impella as periprocedural support for percutaneous valvular procedure, three as bridge to heart replacement, and six for postcardiotomy CS. Impella support had a low complication rate and was successful in supporting hemodynamics pre-, intra- and postoperatively. Most consistently reported data were left-ventricular ejection fraction at implant, short-term survival and weaning rate.</AbstractText><AbstractText Label="CONCLUSIONS">tMCS with Impella in cardiac surgery patients is feasible and successful. It can be applied in selected cardiac surgery patients and presents advantages over other types of support. Systematic prospective studies are needed to standardize indications for implant and management of surgical issues, and to identify which patients may benefit.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pieri</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy; Vita-Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy. Electronic address: pieri.marina@hsr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Andria Ursoleo</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardelli</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortalda</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajello</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delrio</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fominskiy</LastName><ForeName>Evgeny</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scandroglio</LastName><ForeName>Anna Mara</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bridge to surgery</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Low cardiac output syndrome</Keyword><Keyword MajorTopicYN="N">Postcardiotomy shock</Keyword><Keyword MajorTopicYN="N">Preoperative implant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>2</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37813286</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2023.131418</ArticleId><ArticleId IdType="pii">S0167-5273(23)01447-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35533755</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>362</Volume><PubDate><Year>2022</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Timing of impella placement in PCI for acute myocardial infarction complicated by cardiogenic shock: An updated meta-analysis.</ArticleTitle><Pagination><StartPage>47</StartPage><EndPage>54</EndPage><MedlinePgn>47-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2022.05.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(22)00662-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The timing of hemodynamic support in acute myocardial infarction complicated by cardiogenic shock (AMICS) has yet to be defined. The aim of this meta-analysis was to evaluate the impact of timing of Impella initiation on early and midterm mortality.</AbstractText><AbstractText Label="METHODS">A systematic literature review and meta-analysis was conducted using PubMed and Cochrane databases. All studies reporting short-term mortality rates and timing of Impella placement in AMICS were included. Meta-regression analysis and sensitivity analysis were performed on the primary endpoint, short-term mortality (&#x2264;30&#xa0;days), and secondary endpoints (midterm mortality, device-related bleeding, and limb ischemia).</AbstractText><AbstractText Label="RESULTS">Of 1289 studies identified, 13 studies (6810 patients; 2970 patients identified as receiving Impella pre-PCI and 3840 patients receiving Impella during/post-PCI) were included in this analysis. Median age was 63.8&#xa0;years (IQR 63-65.7); 76% of patients were male, and a high prevalence of cardiovascular risk factors was noted across the entire population. Short-term mortality was significantly reduced in those receiving pre-PCI vs. during/post-PCI Impella support (37.2% vs 53.6%, RR 0.7; CI 0.56-0.88). Midterm mortality was also lower in the pre-PCI Impella group (47.9% vs 73%, RR 0.81; CI 0.68-0.97). The rate of device-related bleeding (RR 1.05; CI 0.47-2.33) and limb ischemia (RR 1.6; CI 0.63-2.15) were similar between the two groups.</AbstractText><AbstractText Label="CONCLUSION">This analysis suggests that Impella placement prior to PCI in AMICS may have a positive impact on short- and midterm mortality compared with post-PCI, with similar safety outcomes. Due to the observational nature of the included studies, further studies are needed to confirm this hypothesis (CRD42022300372).</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iannaccone</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, San Giovanni Bosco Hospital, ASL Citt&#xe0; di Torino, Turin, Italy. Electronic address: mario.iannaccone@hotmail.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franchin</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Cardiology, San Giovanni Bosco Hospital, ASL Citt&#xe0; di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Ivan D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Beaumont Hospital Royal Oak, Royal Oak, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccuzzi</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiology, San Giovanni Bosco Hospital, ASL Citt&#xe0; di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basir</LastName><ForeName>Mir B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truesdell</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Virginia Heart/Inova Heart and Vascular Institute, Falls Church, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Door to support</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Primary PCI</Keyword><Keyword MajorTopicYN="N">Time to support</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>9</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35533755</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2022.05.011</ArticleId><ArticleId IdType="pii">S0167-5273(22)00662-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32496607</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Mechanical assist devices for acute cardiogenic shock.</ArticleTitle><Pagination><StartPage>CD013002</StartPage><MedlinePgn>CD013002</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD013002</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD013002.pub2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cardiogenic shock (CS) is a state of critical end-organ hypoperfusion due to a primary cardiac disorder. For people with refractory CS despite maximal vasopressors, inotropic support and intra-aortic balloon pump, mortality approaches 100%. Mechanical assist devices provide mechanical circulatory support (MCS) which has the ability to maintain vital organ perfusion, to unload the failing ventricle thus reduce intracardiac filling pressures which reduces pulmonary congestion, myocardial wall stress and myocardial oxygen consumption. This has been hypothesised to allow time for myocardial recovery (bridge to recovery) or allow time to come to a decision as to whether the person is a candidate for a longer-term ventricular assist device (VAD) either as a bridge to heart transplantation or as a destination therapy with a long-term VAD.</AbstractText><AbstractText Label="OBJECTIVES">To assess whether mechanical assist devices improve survival in people with acute cardiogenic shock.</AbstractText><AbstractText Label="SEARCH METHODS">We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid) and Web of Science Core Collection in November 2019. In addition, we searched three trials registers in August 2019. We scanned reference lists and contacted experts in the field to obtain further information. There were no language restrictions.</AbstractText><AbstractText Label="SELECTION CRITERIA">Randomised controlled trials on people with acute CS comparing mechanical assist devices with best current intensive care management, including intra-aortic balloon pump and inotropic support.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS">We performed data collection and analysis according to the published protocol. Primary outcomes were survival to discharge, 30 days, 1 year and secondary outcomes included, quality of life, major adverse cardiovascular events (30 days/end of follow-up), dialysis-dependent (30 days/end of follow-up), length of hospital stay and length of intensive care unit stay and major adverse events. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta-analyses for the prespecified outcomes Summary statistics for the primary endpoints were risk ratios (RR), hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs).</AbstractText><AbstractText Label="MAIN RESULTS">The search identified five studies from 4534&#xa0;original citations reviewed. Two studies included acute CS of all causes randomised to treatment using TandemHeart percutaneous VAD and three studies included people with&#xa0;CS secondary to acute myocardial infarction&#xa0;who&#xa0;were randomised to Impella CP or best medical management. Meta-analysis was performed only to assess the 30-day survival as there were insufficient data to perform any further meta-analyses. The results from the five studies with 162 participants showed mechanical assist devices may have little or no effect on 30-day survival (RR of 1.01 95% CI 0.76 to 1.35) but the evidence is very uncertain. Complications such as sepsis, thromboembolic phenomena, bleeding and major adverse cardiovascular events were not infrequent in both the MAD and control group across the studies, but these could not be pooled due to inconsistencies in adverse event definitions and reporting. We identified four randomised control trials assessing mechanical assist devices in acute CS that are currently ongoing.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS">There is no evidence from this review of a benefit from MCS in improving survival for people with acute CS. Further use of the technology, risk stratification and optimising the use protocols have been highlighted as potential reasons for lack of benefit and are being addressed in the current ongoing clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ni hIci</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, Morriston Hospital, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boardman</LastName><ForeName>Henry Mp</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baig</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stafford</LastName><ForeName>Jody L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Perfusion/Cardiothoracic Surgery, University Hospital of Wales, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cernei</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Swansea University Medical School, Swansea University, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodger</LastName><ForeName>Owen</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Swansea University Medical School, Swansea University, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westaby</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>doi: 10.1002/14651858.CD013002</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003325" MajorTopicYN="N">Coronary Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>TNH: none. HB: none. KB: none. JS: none. CC: none. OB: I have not received any payment (or benefits), either directly or indirectly, for my contribution to (or as a consequence of my involvement in) this project. SW: Professor Westaby is medical director of Cell Therapy Ltd, and founder and shareholder of Calon Cardiotechnology.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32496607</ArticleId><ArticleId IdType="pmc">PMC7271960</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD013002.pub2</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Bonnefoy&#x2010;Cudraz 2014 {published data only}</Title><Reference><Citation>Bonnefoy-Cudraz E, Huot L, Elbaz M, Cottin Y, Roux A, Bouchot O, et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal 2014;1:1063.</Citation></Reference></ReferenceList><ReferenceList><Title>Burkhoff 2006 {published data only}</Title><Reference><Citation>Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW, TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal 2006;152(3):469.e1-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16923414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ouweneel 2017 {published data only}</Title><Reference><Citation>NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012).</Citation></Reference><Reference><Citation>Ouweneel DM, Engstrom AE, Sjauw KD, Hirsch A, Hill JM, Gockel B, et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology 2016;202:894-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26476989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Sjauw KD, Dongen IM, Hirsch A, Packer EJ, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology 2017;69(3):278-87. [DOI: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Seyfarth 2008 {published data only}</Title><Reference><Citation>Seyfarth M, Bauer I, Sibbing D, Bott-Flugel L, Kastrati A, Schomig A. A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation 2007;116(16):929.</Citation></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology 2008;52(19):1584-8. [DOI: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfarth M, Sibbing D, Gloeck T, Bott-Fluegel L, Bauer I, Kastrati A, et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal 2009;1:157-8.</Citation></Reference></ReferenceList><ReferenceList><Title>Thiele 2005 {published data only}</Title><Reference><Citation>Thiele H, Boudriot E, Sick P, Niebauer J, Diederich KW, Hambrecht R, et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology 2004;43(5):234A.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Boudriot E, Sick R, Diederich KW, Niebauer J, Hambrecht R, et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal 2004;25:73.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal 2005;26(13):1276-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal 2003;24:25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Abraham 2012 {published data only}</Title><Reference><Citation>Abraham WT, Anand I, Aranda JM Jr, Boehmer J, Costanzo MR, DeMarco T, et al. Randomized controlled trial of ventricular elastic support therapy in the treatment of symptomatic heart failure: rationale and design. American Heart Journal 2012;164(5):638-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23137493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Abraham 2014 {published data only}</Title><Reference><Citation>Abraham W, Adamson P, Costa M, Nienaber C, Ince H, Erglis A, et al. Percutaneous ventricular restoration therapy using the parachute device in patients with ischemic dilated heart failure: pooled analysis of the first 100 patients treated for 1 year. European Journal of Heart Failure 2014;2:215.</Citation></Reference></ReferenceList><ReferenceList><Title>Agarwal 2015 {published data only}</Title><Reference><Citation>Agarwal S, Sud K, Martin J M, Menon V. Trends in the use of mechanical circulatory support devices in patients presenting with ST-segment elevation myocardial infarction. JACC. Cardiovascular Interventions 2015;8(13):1772-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26585627</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Agrawal 2016 {published data only}</Title><Reference><Citation>Agrawal H, Aggarwal K. Mechanical circulatory support in percutaneous coronary interventions: expanding the possibilities. Journal of Invasive Cardiology 2016;28(6):243-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27236008</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Almond 2017 {published data only}</Title><Reference><Citation>Almond C, Jaquiss J, Massicotte P, Ichord R, Kaltman J, Stylianou M, et al. The pumpkin trial study design and rationale. Cardiology in the Young 2017;27(4):S78-9.</Citation></Reference></ReferenceList><ReferenceList><Title>Alushi 2019 {published data only}</Title><Reference><Citation>Alushi B, Douedari A, Froehlig G, Knie W, Wurster TH, Leistner DM, et al. Impella versus IABP in acute myocardial infarction complicated by cardiogenic shock. Open Heart 2019;6(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546200</ArticleId><ArticleId IdType="pubmed">31218000</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Anderson 2006 {published data only}</Title><Reference><Citation>Anderson M, Madani M, Raess D, Samuels L, Sun B, Sleeper L. Ventricular assist devices improve recovery outcomes in acute myocardial infarction cardiogenic shock: benchmark of US multicenter experience against SHOCK trial. American Journal of Cardiology 2006;98(8A):88M.</Citation></Reference></ReferenceList><ReferenceList><Title>Basir 2019 {published data only}</Title><Reference><Citation>Basir MB, Kapur NK, Patel K, Salam MA, Schreiber T, Kaki A, et al. Improved outcomes associated with the use of shock protocols: updates from the National Cardiogenic Shock Initiative. Catheterization and Cardiovascular Interventions 2019;93(7):1173-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">31025538</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Birks 2009 {published data only}</Title><Reference><Citation>Birks EJ, Dulay M, O'Driscoll G, Jansz P, Wieselthaler G, Strueber M. Health-related QOL and neurocognitive status before and after implantation of the HeartWare left ventricular assist system. Journal of Cardiac Failure 2009;1:S46.</Citation></Reference></ReferenceList><ReferenceList><Title>Birks 2018 {published data only}</Title><Reference><Citation>Birks EJ, Drakos SG, Lowes BD, Patel SR, Selzman C, Slaughter MS, et al. Outcome and primary endpoint results from a prospective multicenter study of myocardial recovery using LVADs: remission from stage d heart failure (RESTAGE-HF). Journal of Heart and Lung Transplantation 2018;37 (4 Suppl 1):S142.</Citation></Reference></ReferenceList><ReferenceList><Title>Bluhm 2010 {published data only}</Title><Reference><Citation>Bluhm R. The epistemology and ethics of chronic disease research: further lessons from ECMO. Theoretical Medicine and Bioethics 2010;31(2):107-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20333473</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bol 2019 {published data only}</Title><Reference><Citation>Bol ME, Suverein MM, Lorusso R, Delnoij TS, Brandon Bravo Bruinsma GJ, Otterspoor L, et al. Early initiation of extracorporeal life support in refractory out-of-hospital cardiac arrest: design and rationale of the INCEPTION trial. American Heart Journal 2019;210:58-68.</Citation><ArticleIdList><ArticleId IdType="pubmed">30738245</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bronicki 2013 {published data only}</Title><Reference><Citation>Bronicki RA, Adachi I. The ventricular assist device: bridge to transplant. Bridge to recovery? Bridge to beyond? Pediatric Critical Care Medicine 2013;14(9):910-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">24226563</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brunner 2019 {published data only}</Title><Reference><Citation>Brunner S, Guenther SP, Lackermair K, Peterss S, Orban M, Boulesteix AL, et al. Extracorporeal life support in cardiogenic shock complicating acute myocardial infarction. Journal of the American College of Cardiology 2019;73(18):2355-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31072581</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kar 2012 {published data only}</Title><Reference><Citation>Kar B, Basra SS, Shah NR, Loyalka P. Percutaneous circulatory support in cardiogenic shock interventional bridge to recovery. Circulation 2012;125(14):1809-17.</Citation><ArticleIdList><ArticleId IdType="pubmed">22492948</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Liu 2012 {published data only}</Title><Reference><Citation>Liu W, Barbagelata NA, Fujise K. Percutaneous hemodynamic support (Impella) in patients with advanced heart failure and/or cardiogenic shock not eligible to protect ii trial. Journal of Cardiac Failure 2012;1:S101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830570</ArticleId><ArticleId IdType="pubmed">24436614</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Morici 2018 {published data only}</Title><Reference><Citation>Morici N, Oliva F, Ajello S, Stucchi M, Sacco A, Cipriani MG, et al. Management of cardiogenic shock in acute decompensated chronic heart failure: the ALTSHOCK phase II clinical trial. American Heart Journal 2018;204:196-201.</Citation><ArticleIdList><ArticleId IdType="pubmed">30100052</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>NCT03101787 {published data only}</Title><Reference><Citation>NCT03101787. Early initiation of extracorporeal life support in refractory OHCA. clinicaltrials.gov/show/NCT03101787 (first received 5 April 2017).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT03431467 {published data only}</Title><Reference><Citation>NCT03431467. Impella CP with VA ECMO for cardiogenic shock. clinicaltrials.gov/show/NCT03431467 (first received 13 February 2018).</Citation></Reference></ReferenceList><ReferenceList><Title>Patel 2011 {published data only}</Title><Reference><Citation>Patel MR, Thiele H, Smalling RW, Chandra P, Zhou Y, Cohen M, et al. A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial. American Heart Journal 2011;162(1):47-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">21742089</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Saeed 2013 {published data only}</Title><Reference><Citation>Saeed D, Arusoglu L, Gazzoli F, Hetzer R, Morshius M, Alloni A, et al. Results of the European clinical trial of Arrow CorAide left ventricular assist system. Artificial Organs 2013;37(2):121-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23043450</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Vallabhajosyula 2017 {published data only}</Title><Reference><Citation>Vallabhajosyula S, O'Horo JC, Antharam P, Ananthaneni S, Vallabhajosyula S, Stulak JM, et al. Concomitant intra-aortic balloon pump use in cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation. Circulation. Cardiovascular Interventions 2018;11(9):e006930.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354593</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, O'Horo JC, Antharam P, Ananthaneni S, Vallabhajosyula S, Stulak JM, et al. Venoarterial extracorporeal membrane oxygenation with concomitant Impella versus venoarterial extracorporeal membrane oxygenation for cardiogenic shock. ASAIO Journal 2017;17:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">31335363</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to ongoing studies</Title><ReferenceList><Title>DanGer Shock Trial {unpublished data only}</Title><Reference><Citation>NCT01633502. Danish cardiogenic shock trial (DanShock). clinicaltrials.gov/ct2/show/NCT01633502 (first received 4 July 2012).</Citation></Reference></ReferenceList><ReferenceList><Title>ECLS&#x2010;SHOCK {published data only}</Title><Reference><Citation>NCT02544594. Clinical study of extra-corporal life support in cardiogenic shock complicating acute myocardial infarction. clinicaltrials.gov/show/NCT02544594 (first received 9 September 2015).</Citation></Reference><Reference><Citation>NCT03637205. Extracorporeal life support in cardiogenic shock (ECLS-SHOCK). clinicaltrials.gov/ct2/show/NCT03637205 (first received 17 August 2018).</Citation></Reference></ReferenceList><ReferenceList><Title>ECMO&#x2010;CS {published data only}</Title><Reference><Citation>NCT02301819. Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS). clinicaltrials.gov/ct2/show/NCT02301819 (first received 26 November 2014).</Citation></Reference></ReferenceList><ReferenceList><Title>EuroShock {published data only}</Title><Reference><Citation>NCT03813134. Testing the value of novel strategy and its cost efficacy in order to improve the poor outcomes in cardiogenic shock. clinicaltrials.gov/show/NCT03813134 (first received 23 January 2019).</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>AHA 2012</Title><Reference><Citation>Peura JL, Colvin-Adams M, Francis GS, Grady KL, Hoffman TM, Jessup M, et al, on behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation 2012;126:2648-67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23109468</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>AHA 2017</Title><Reference><Citation>Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017;136(16):e232-68.</Citation><ArticleIdList><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Austin 2017</Title><Reference><Citation>Austin PC. A tutorial on multilevel survival analysis: methods, models and applications. International Statistical Review 2017;85(2):185-203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5756088</ArticleId><ArticleId IdType="pubmed">29307954</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Babaev 2005</Title><Reference><Citation>Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005;294:448-54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046651</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bartlett 2010</Title><Reference><Citation>Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiologica 2010;76:534-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20613694</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Basir 2016 USpella registry</Title><Reference><Citation>Basir MB, Schrieber TL, Grines CL, Dixon SR, Moses JW, Mani BS, et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. American Journal of Cardiology 2017;119:845-51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28040188</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chamogeorgakis 2013</Title><Reference><Citation>Chamogeorgakis T, Lima B, Shaffii AE, Nagpal D, Pokersnik JA, Navia JL, et al. Outcomes of axillary artery side graft cannulation for extracorporeal membrane oxygenation. Journal of Thoracic and Cardiovascular Surgery 2013;145:1088-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">22999514</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chung 2012</Title><Reference><Citation>Chung SY, Sheu JJ, Lin YJ, Sun CK, Chang LT, Chen YL, et al. Outcomes of patients with profound cardiogenic shock after cardiopulmonary resuscitation and prompt extracorporeal membrane oxygenation support. A single-centre observational study. Circulation 2012;6:1385-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">22447007</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Copeland 2004</Title><Reference><Citation>Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. New England Journal of Medicine 2004;351(9):859-67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15329423</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>DanGer Shock 2019</Title><Reference><Citation>Udesen NJ, Moller JE, Lindholm MG, Eiskjaer H, Schafer A, Werner N, et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. American Heart Journal 2019;214:69-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31176289</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Deeks 2011</Title><Reference><Citation>Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Emmert 2011</Title><Reference><Citation>Emmert MY, Pr&#xea;tre R, Ruschitzka F, Krhenmann F, Falk V, Wilhelm MJ. Peripartum cardiomyopathy with cardiogenic shock: recovery after prolactin inhibition and mechanical support. Annals of Thoracic Surgery 2011;91(1):274-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21172530</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>ESC 2019</Title><Reference><Citation>Thiele H, Ohman EM, deWaha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. European Heart Journal 2019;40:2671-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fox 2007</Title><Reference><Citation>Fox KA, Anderson FA Jr, Dabbous OH, Steg PG, Lopez-Sendon J, Vande Werf F, et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart 2007;93:177-82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861403</ArticleId><ArticleId IdType="pubmed">16757543</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Friedel 1992</Title><Reference><Citation>Friedel N, Viazis P, Schiessler A, Warnecke H, Hennig E, Trittin A, et al. Recovery of end-organ failure during mechanical circulatory support. European Journal of Cardiothoracic Surgery 1992;6(10):519-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">1389232</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldberg 2001</Title><Reference><Citation>Goldberg RJ, Gore JR, Thompson CA, Gurwitz JH. Recent magnitude of and temporal trends (1994&#x2013;1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second National Registry of Myocardial Infarction. American Heart Journal 2001;141:65-72.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136488</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>GRADEpro GDT [Computer program]</Title><Reference><Citation>McMaster University (developed by Evidence Prime) GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.Available at gradepro.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Hasdai 2000</Title><Reference><Citation>Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW, et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. Journal of American College of Cardiology 2000;36:685-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">10987585</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hendry 1999</Title><Reference><Citation>Hendry PJ, Masters RG, Mussivand TV, Smith S, Davies RA, Finlay S, et al. Circulatory support for cardiogenic shock due to acute myocardial infarction: a Canadian experience. Canadian Journal of Cardiology 1999;15(10):1090-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10523475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2011</Title><Reference><Citation>Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Hill 1986</Title><Reference><Citation>Hill JD, Farrar DJ, Hershon JJ, Compton PG, Avery GJ 2nd, Levin BS, et al. Use of a prosthetic ventricle as a bridge to cardiac transplantation for postinfarction cardiogenic shock. New England Journal of Medicine 1986;314:626-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3511373</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hochman 1999</Title><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New England Journal of Medicine 1999;341:625-34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hochman 2001</Title><Reference><Citation>Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. One year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176812</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Holman 1995</Title><Reference><Citation>Holman WL, Roye GD, Bourge RC, McGiffin DC, Iyer SS, Kirklin JK. Circulatory support for myocardial infarction with ventricular arrhythmias. Annals of Thoracic Surgery 1995;59(5):1230-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">7733732</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Howell 2016</Title><Reference><Citation>Howell E, Paivanas N, Stern J, Vidula H. Treatment of acute necrotizing eosinophilic myocarditis with immunosuppression and mechanical circulatory support. Circulation. Heart Failure 2016;9(12):e003665.</Citation><ArticleIdList><ArticleId IdType="pubmed">27940496</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>ISHLT 2013</Title><Reference><Citation>Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. Journal of Heart and Lung Transplantation 2013;32:157-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">23352391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kato 1999</Title><Reference><Citation>Kato S, Morimoto S, Hiramitsu S, Nomura M, Ito T, Hishida H. Use of percutaneous cardiopulmonary support of patients with fulminant myocarditis and cardiogenic shock for improving prognosis. American Journal of Cardiology 1999;83(4):623-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10073879</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lefebvre 2011</Title><Reference><Citation>Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Liberati 2009</Title><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707010</ArticleId><ArticleId IdType="pubmed">19621070</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>L&#xfc; 2016</Title><Reference><Citation>L&#xfc; TF. Prevention: some important steps forward, but many unmet needs in a world with cardiovascular disease as the leading cause of death. European Heart Journal 2016;37(42):3179-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">27856560</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mandawat 2017</Title><Reference><Citation>Mandawat A, Rao SV. Percutaneous mechanical circulatory support devices in cardiogenic shock. Circulation. Cardiovascular Interventions 2017;10:e004337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578718</ArticleId><ArticleId IdType="pubmed">28500136</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>NICE 2014</Title><Reference><Citation>National Institute for Health and Care Excellence. Acute heart failure: diagnosis and management. nice.org.uk/guidance/cg187 (accessed prior to 7 May 2020).</Citation></Reference></ReferenceList><ReferenceList><Title>Omerovic 2016</Title><Reference><Citation>Omerovic E. Takotsubo syndrome &#x2013; scientific basis for current treatment strategies. Heart Failure Clinics 2016;12(4):577-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">27638027</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ponikowski 2016</Title><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 2016;37(27):2129-200.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Review Manager 2014 [Computer program]</Title><Reference><Citation>Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.</Citation></Reference></ReferenceList><ReferenceList><Title>Reynolds 2008</Title><Reference><Citation>Reynolds H, Hochman S. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008;117:686-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">18250279</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rihal 2015</Title><Reference><Citation>Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. Journal of the American College of Cardiology 2015;65(19):e7-e26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25861963</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sellke 2010</Title><Reference><Citation>Sellke FW, Nido PH, Swanson SJ. Sabiston &amp; Spencer Surgery of the Chest. 8th edition. Vol. II. Philadelphia (PA): Saunders Elsevier, 2010.</Citation></Reference></ReferenceList><ReferenceList><Title>Shekar 2016</Title><Reference><Citation>Shekar K, Gregory SD, Fraser JF. Mechanical circulatory support in the new era: an overview. Critical Care (London, England) 2016;20(1):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4794944</ArticleId><ArticleId IdType="pubmed">26984504</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shemilt 2011</Title><Reference><Citation>Shemilt I, Mugford M, Byford S, Drummond M, Eisenstein E, Knapp M, et al. Chapter 15: Incorporating economics evidence In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Shemilt 2017</Title><Reference><Citation>Shemilt I, Mugford M, Vale L, Craig D, Campbell and Cochrane Economics Methods Group. Searching NHS EED and HEED to inform development of economic commentary for Cochrane intervention reviews. www.methods.cochrane.org/economics/workshops (accessed 13 July 2017).</Citation></Reference></ReferenceList><ReferenceList><Title>Simmonds 2005</Title><Reference><Citation>Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MI, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials 2005;2:209-17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16279144</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Squiers 2016</Title><Reference><Citation>Squiers JJ, Lima B, DiMaio JM. Contemporary extracorporeal membrane oxygenation therapy in adults: fundamental principles and systematic review of the evidence. Journal of Thoracic and Cardiovascular Surgery 2016;152(1):20-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">27060027</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thiele 2017</Title><Reference><Citation>Thiele H, Jobs A, Ouweneel DM, Henriques JP, Seyfarth M, Desch S, et al. Percutaneous short term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. European Heart Journal 2017;38:3523-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29020341</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thiele 2017 CULPRIT Shock Trial</Title><Reference><Citation>Thiele H, Kin I, Sandri M, Fuernau G, Waha S, Meyer-Saraei R, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. New England Journal of Medicine 2017;377:2419-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">29083953</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>WHO 2018</Title><Reference><Citation>World Health Organization. Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000&#x2013;2016. www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html (accessed prior to 7 May 2020).</Citation></Reference></ReferenceList><ReferenceList><Title>Zalewska&#x2010;Adamiec 2016</Title><Reference><Citation>Zalewska-Adamiec M, Bachorzewska-Gajewska H, Tomaszuk-Kazberuk A, Nowak K, Drozdowski P, Bychowski J, et al. Takotsubo cardiomyopathy: serious early complications and two-year mortality &#x2013; a 101 case study. Netherlands Heart Journal 2016;24(9):511-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5005189</ArticleId><ArticleId IdType="pubmed">27401602</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>Ni hlci 2018</Title><Reference><Citation>Ni hlci T, Boardman HM, Baig K, Aifesehi PE, Stafford JL, Cernei C, et al. Mechanical assist devices for acute cardiogenic shock. Cochrane Database of Systematic Reviews 2018, Issue 4. [DOI: 10.1002/14651858.CD013002]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013002</ArticleId><ArticleId IdType="pmc">PMC7271960</ArticleId><ArticleId IdType="pubmed">32496607</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32790536</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0377</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Vascular medicine (London, England)</Title><ISOAbbreviation>Vasc Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of extracorporeal membrane oxygenation for high-risk pulmonary embolism: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>460</StartPage><EndPage>467</EndPage><MedlinePgn>460-467</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1358863X20944469</ELocationID><Abstract><AbstractText>High-risk pulmonary embolism (PE) requires hemodynamic and respiratory support along with reperfusion strategies. Recently updated European guidelines assign a low class of recommendation to extracorporeal membrane oxygenation (ECMO) for high-risk PE. This systematic review assessed clinical outcomes after ECMO in high-risk PE. We searched electronic databases including PubMed, Embase and Web of Science from January 2000 to April 2020. Efficacy outcomes included in-hospital survival with good neurological outcome and survival at follow-up. Safety outcomes included lower limb ischemia and hemorrhagic and ischemic stroke. Where possible (absence of high heterogeneity), meta-analyses of outcomes were undertaken using a random-effects model. We included 16 uncontrolled case-series (533 participants). In-hospital survival with good neurological outcome ranged between 50% and 95% while overall survival at follow-up ranged from 35% to 95%, both with a major degree of heterogeneity (I<sup>2</sup> &gt; 70%). The prevalence of lower limb ischemia was 8% (95% CI 3% to 15%). The prevalence of stroke (either hemorrhagic or ischemic) was 11% (95% CI 3% to 23%), with notable heterogeneity (I&#xb2; = 63.35%). Based on currently available literature, it is not possible to draw definite conclusions on the usefulness of ECMO for high-risk PE. Prospective, multicenter, large-scale studies or nationwide registries are needed to best define the role of ECMO for high-risk PE. <b>PROSPERO registration ID: CRD42019136282</b>.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6550-0872</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metge</LastName><ForeName>Augustin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelin</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Devices Unit - Pharmacy Department, "Edouard Herriot" Hospital, - Lyon University Hospitals, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giroudon</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7947-9437</Identifier><AffiliationInfo><Affiliation>Central Documentation Department, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanier Demma</LastName><ForeName>Justine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koffel</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornier</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiari</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fellahi</LastName><ForeName>Jean Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obadia</LastName><ForeName>Jean Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armoiry</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>University of Lyon, School of Pharmacy - Pharmacy Department (ISPB)/UMR CNRS 5510 MATEIS/"Edouard Herriot" Hospital - Lyon University Hospitals, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vasc Med</MedlineTA><NlmUniqueID>9610930</NlmUniqueID><ISSNLinking>1358-863X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac arrest</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation (ECMO)</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism (PE)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32790536</ArticleId><ArticleId IdType="doi">10.1177/1358863X20944469</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35526506</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>Propofol versus midazolam sedation in patients with cardiogenic shock - an observational propensity-matched study.</ArticleTitle><Pagination><StartPage>154051</StartPage><MedlinePgn>154051</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2022.154051</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-9441(22)00080-6</ELocationID><Abstract><AbstractText Label="PURPOSE">Benzodiazepines are recommended as first line sedative agent in ventilated cardiogenic shock patients, although data regarding the optimal sedation strategy are sparse. The aim of this study was to investigate the hemodynamic effects of propofol versus midazolam sedation in our cardiogenic shock registry.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Mechanically ventilated patients suffering from cardiogenic shock were retrospectively enrolled from the cardiogenic shock registry of the university hospital of Munich. 174 patients treated predominantly with propofol were matched by propensity-score to 174 patients treated predominantly with midazolam.</AbstractText><AbstractText Label="RESULTS">Catecholamine doses were similar on admission but significantly lower in the propofol group on days 1-4 of ICU stay. Mortality rate was 38% in the propofol and 52% in the midazolam group after 30 days (p = 0.002). Rate of &#x2265;BARC3 bleeding was significantly lower in the propofol group compared to the midazolam group (p = 0.008). Sedation with midazolam was significantly associated with ICU mortality.</AbstractText><AbstractText Label="CONCLUSION">In this observational cohort study, sedation with propofol in comparison to midazolam was linked to a reduced dose of catecholamines, decreased mortality and bleeding rates for patients with cardiogenic shock. Based on this study and in contrast to current recommendations, propofol should be given consideration for sedation in cardiogenic shock patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scherer</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleeberger</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellnar</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binzenh&#xf6;fer</LastName><ForeName>Leonhard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xfc;sebrink</LastName><ForeName>Enzo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocker</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berghoff</LastName><ForeName>Stefan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keutner</LastName><ForeName>Alix</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thienel</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deseive</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stark</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braun</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orban</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petzold</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagl</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; Department of Cardiac Surgery, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausleiter</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massberg</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orban</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Department of Medicine I, University Hospital, LMU Munich, Munich, Germany. Electronic address: Martin.Orban@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>R60L0SM5BC</RegistryNumber><NameOfSubstance UI="D008874">Midazolam</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI7VU623SF</RegistryNumber><NameOfSubstance UI="D015742">Propofol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016292" MajorTopicYN="N">Conscious Sedation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008874" MajorTopicYN="Y">Midazolam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015742" MajorTopicYN="Y">Propofol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anesthetics</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Midazolam</Keyword><Keyword MajorTopicYN="N">Propofol</Keyword><Keyword MajorTopicYN="N">Sedation</Keyword><Keyword MajorTopicYN="N">VA-ECMO</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>8</Day><Hour>18</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35526506</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2022.154051</ArticleId><ArticleId IdType="pii">S0883-9441(22)00080-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25183512</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-742X</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of thrombosis and thrombolysis</Title><ISOAbbreviation>J Thromb Thrombolysis</ISOAbbreviation></Journal><ArticleTitle>Comparison of radial to femoral PCI in acute myocardial infarction and cardiogenic shock: a systematic review.</ArticleTitle><Pagination><StartPage>108</StartPage><EndPage>117</EndPage><MedlinePgn>108-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11239-014-1133-y</ELocationID><Abstract><AbstractText>In randomized control trials and meta-analyses in patients with acute MI undergoing PCI, the radial artery (RA) approach compared to the femoral artery (FA) approach has shown to safely reduce access site related bleeding, length of hospitalization, and major adverse cardiac event (MACE) rates. However, these studies have excluded patients with cardiogenic shock. A systematic search was conducted to retrieve studies that investigated the safety of RA to FA PCI in patients with AMI and cardiogenic shock. Primary outcomes of interest was the pooled relative risk ratio (RR) of access site related bleeding. Secondary outcomes included (i) 30-day all cause mortality, (ii) major bleeding, (iii) final TIMI 3 flow, (iv) fluoroscopy time, and (v) amount of contrast volume administered. 6 observational studies with 7,753 patients met inclusion; 5,347 (69 %) with STEMI, 2,406 (31 %) with non-STEMI. In comparison of RA to FA PCI, there was less access site related bleeding (relative risk (RR) 0.11, p = 0.001), less 30-day mortality (RR 0.65, p = 0.0 &lt; 0.001), and less major bleeding (RR of 0.46 p &lt; 0.0001). There was no significant difference in final TIMI 3 flow (p = 0.27), fluoroscopy time (p = 0.95), and contrast volume administered (p = 0.59). In conclution, despite its limitations, our analysis demonstrates an association towards lower adverse events in the RA PCI group. Although we believe that the choice of access site in a high-risk setting should be at the operator discretion, if technically feasible, the RA appears to be a reasonable vascular access approach in high-risk patients in cardiogenic shock.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Sumeet</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, McMaster University, Hamilton, ON, Canada, sumeet.gandhi@medportal.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakar</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Overgaard</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Thromb Thrombolysis</MedlineTA><NlmUniqueID>9502018</NlmUniqueID><ISSNLinking>0929-5305</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005263" MajorTopicYN="N">Femoral Artery</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017534" MajorTopicYN="N">Radial Artery</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25183512</ArticleId><ArticleId IdType="doi">10.1007/s11239-014-1133-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS Med. 2009 Jul 21;6(7):e1000097</Citation><ArticleIdList><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2011 Apr 23;377(9775):1409-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21470671</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart. 2008 Aug;94(8):1019-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18332059</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2009 Nov;158(5):814-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19853703</ArticleId></ArticleIdList></Reference><Reference><Citation>Catheter Cardiovasc Interv. 2014 Jan 1;83(1):E1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23441063</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invasive Cardiol. 2014 May;26(5):196-202</Citation><ArticleIdList><ArticleId IdType="pubmed">24791717</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2014 Jun;167(6):900-8.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">24890541</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2013 Mar;165(3):280-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23453093</ArticleId></ArticleIdList></Reference><Reference><Citation>JACC Cardiovasc Interv. 2013 Aug;6(8):814-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23968700</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2006 Aug 22;114(8):774-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16908769</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Aug 26;341(9):625-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 Jul 27;294(4):448-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16046651</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2013 Dec;166(6):1019-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24268216</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2013 Mar;165(3):338-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23453102</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart. 2012 Apr;98(7):552-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22337951</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Feb 10;342:d549</Citation><ArticleIdList><ArticleId IdType="pubmed">21310794</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2012 Dec 18;60(24):2490-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23103036</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invasive Cardiol. 2013 Mar;25(3):150-3</Citation><ArticleIdList><ArticleId IdType="pubmed">23468447</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2012 Dec 18;60(24):2481-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22858390</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2014 Mar 18;63(10):964-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24211309</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2011 Jun 14;123(23):2736-47</Citation><ArticleIdList><ArticleId IdType="pubmed">21670242</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32652713</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8191</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of cardiac surgery</Title><ISOAbbreviation>J Card Surg</ISOAbbreviation></Journal><ArticleTitle>Cardiac manifestations in COVID-19 patients-A systematic review.</ArticleTitle><Pagination><StartPage>1988</StartPage><EndPage>2008</EndPage><MedlinePgn>1988-2008</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.14808</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The coronavirus disease-2019 (COVID-19) pandemic has resulted in the worst global pandemic of our generation, affecting 215 countries with nearly 5.5 million cases. The association between COVID-19 and the cardiovascular system has been well described. We sought to systematically review the current published literature on the different cardiac manifestations and the use of cardiac-specific biomarkers in terms of their prognostic value in determining clinical outcomes and correlation to disease severity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature review across PubMed, Cochrane database, Embase, Google Scholar, and Ovid was performed according to PRISMA guidelines to identify relevant articles that discussed risk factors for cardiovascular manifestations, cardiac manifestations in COVID-19 patients, and cardiac-specific biomarkers with their clinical implications on COVID-19.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-one relevant articles were identified which described risk factors for cardiovascular manifestations, cardiac manifestations (including heart failure, cardiogenic shock, arrhythmia, and myocarditis among others) and cardiac-specific biomarkers (including CK-MB, CK, myoglobin, troponin, and NT-proBNP). Cardiovascular risk factors can play a crucial role in identifying patients vulnerable to developing cardiovascular manifestations of COVID-19 and thus help to save lives. A wide array of cardiac manifestations is associated with the interaction between COVID-19 and the cardiovascular system. Cardiac-specific biomarkers provide a useful prognostic tool in helping identify patients with the severe disease early and allowing for escalation of treatment in a timely fashion.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">COVID-19 is an evolving pandemic with predominate respiratory manifestations, however, due to the interaction with the cardiovascular system; cardiac manifestations/complications feature heavily in this disease, with cardiac biomarkers providing important prognostic information.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Journal of Cardiac Surgery published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shafi</LastName><ForeName>Ahmed M A</ForeName><Initials>AMA</Initials><Identifier Source="ORCID">0000-0002-8910-3713</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Barts Heart Centre, St Bartholomew's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaikh</LastName><ForeName>Safwan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirke</LastName><ForeName>Manasi M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iddawela</LastName><ForeName>Sashini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University Hospitals Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harky</LastName><ForeName>Amer</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5507-5841</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Surg</MedlineTA><NlmUniqueID>8908809</NlmUniqueID><ISSNLinking>0886-0440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009211">Myoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014336">Troponin</NameOfSubstance></Chemical><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D052279">Creatine Kinase, MB Form</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052279" MajorTopicYN="N">Creatine Kinase, MB Form</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009211" MajorTopicYN="N">Myoglobin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014336" MajorTopicYN="N">Troponin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cardiac biomarkers</Keyword><Keyword MajorTopicYN="N">cardiac manifestations</Keyword><Keyword MajorTopicYN="N">cardiovascular risk factors</Keyword><Keyword MajorTopicYN="N">clinical presentations</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32652713</ArticleId><ArticleId IdType="pmc">PMC7404674</ArticleId><ArticleId IdType="doi">10.1111/jocs.14808</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2010;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID&#x2010;19 and Multiorgan Response. Current Problems in Cardiology. 2020;45(8):100618 10.1016/j.cpcardiol.2020.100618</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100618</ArticleId><ArticleId IdType="pmc">PMC7187881</ArticleId><ArticleId IdType="pubmed">32439197</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed Abdel Shafi A, Hewage S, Harky A. The impact of COVID&#x2010;19 on the provision of cardiac surgical services. J Card Surg. 202035(6):1295&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276906</ArticleId><ArticleId IdType="pubmed">32419218</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy&#x2010;confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007;28:1205&#x2010;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108465</ArticleId><ArticleId IdType="pubmed">17440221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong JC, Schwartz KL, Campitelli MA. Acute myocardial infarction after laboratory&#x2010;confirmed influenza infection. N Engl J Med. 2018;378:2540&#x2010;2541.</Citation><ArticleIdList><ArticleId IdType="pubmed">29949484</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611&#x2010;2618.</Citation><ArticleIdList><ArticleId IdType="pubmed">15602021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x2010;infected pneumonia in Wuhan, China. JAMA. 2020;323:1061&#x2010;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta&#x2010;analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS&#x2010;CoV&#x2010;2 pneumonia in Wuhan, China: a single&#x2010;centered, retrospective, observational study. Lancet Respir Med. 2020;8:475&#x2010;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID&#x2010;19 based on an analysis of data of 150 patients from Wuhan, China. Intens Care Med. 2020;46:846&#x2010;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur heart J. 2020;41:2070&#x2010;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239100</ArticleId><ArticleId IdType="pubmed">32391877</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID&#x2010;19 in Wuhan, China. JAMA Cardiology. 2020. 10.1001/jamacardio.2020.0950</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID&#x2010;19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2010;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID&#x2010;19). JAMA Cardiol. 2020:e201017 10.1001/jamacardio.2020.1017</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS&#x2010;CoV&#x2010;2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574&#x2010;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease drug therapy, and mortality in Covid&#x2010;19. N Engl J Med. 2020382(25):e102&#x2013;e102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206931</ArticleId><ArticleId IdType="pubmed">32356626</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal S, Garcia&#x2010;Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID&#x2010;19): early report from the United States. Diagnosis. 2020;7:91&#x2010;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">32352401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Correction to: clinical predictors of mortality due to COVID&#x2010;19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(6):1294&#x2010;1297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131986</ArticleId><ArticleId IdType="pubmed">32253449</ArticleId></ArticleIdList></Reference><Reference><Citation>Du RH, Liu LM, Yin W. Hospitalization and critical care of 109 decedents with COVID&#x2010;19 pneumonia in Wuhan, China. Ann Am Thorac Soc. 2020. 10.1513/AnnalsATS.202003-225OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202003-225OC</ArticleId><ArticleId IdType="pmc">PMC7328178</ArticleId><ArticleId IdType="pubmed">32255382</ArticleId></ArticleIdList></Reference><Reference><Citation>Harikrishnan S, Mohanan PP, Chopra VK, et al. Cardiological society of India position statement on COVID&#x2010;19 and heart failure. Indian heart J. 2020;72:75&#x2010;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219407</ArticleId><ArticleId IdType="pubmed">32405088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried JA, Ramasubbu K, Bhatt R, et al. The variety of cardiovascular presentations of COVID&#x2010;19. Circulation. 2020;141:1930&#x2010;1936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314498</ArticleId><ArticleId IdType="pubmed">32243205</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID&#x2010;19 cardiogenic shock. Eur J Heart Fail. 2020;22:911&#x2010;915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262276</ArticleId><ArticleId IdType="pubmed">32275347</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez&#x2010;Recalde &#xc1;, Solano&#x2010;L&#xf3;pez J, Miguelena&#x2010;Hycka J, Mart&#xed;n&#x2010;Pinacho JJ, Sanmart&#xed;n M, Zamorano JL. COVID&#x2010;19 and cardiogenic shock. Different cardiovascular presentations with high mortality. Rev Esp Cardiol. 2020;4(18).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184000</ArticleId><ArticleId IdType="pubmed">32499016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemtgen X, Kr&#xfc;ger K, Supady A, et al. First successful treatment of COVID&#x2010;19 induced refractory cardiogenic plus vasoplegic shock by combination of pVAD and ECMO&#x2014;a case report. ASAIO J. 2020;66:607&#x2010;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217127</ArticleId><ArticleId IdType="pubmed">32472827</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari R, Bangalore S, Chang E, Shah B. COVID&#x2010;19 complicated by acute myocardial infarction with extensive thrombus burden and cardiogenic shock. Cathete Cardiovas Intervn. 2020. 10.1002/ccd.28992</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28992</ArticleId><ArticleId IdType="pmc">PMC7276857</ArticleId><ArticleId IdType="pubmed">32427416</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133:1025&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147277</ArticleId><ArticleId IdType="pubmed">32044814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Hu C, Luo L, et al. Clinical features and short&#x2010;term outcomes of 221 patients with COVID&#x2010;19 in Wuhan, China. J Clin Virol. 2020;127:104364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194884</ArticleId><ArticleId IdType="pubmed">32311650</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou W, Zhang W, Jin R, Liang L, Xu B, Hu Z. Risk factors for disease progression in hospitalized patients with COVID&#x2010;19: a retrospective cohort study. Infect Dis. 2020;52(7):498&#x2010;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212540</ArticleId><ArticleId IdType="pubmed">32370577</ArticleId></ArticleIdList></Reference><Reference><Citation>Seecheran R, Narayansingh R, Giddings S, et al. Atrial arrhythmias in a patient presenting with coronavirus disease&#x2010;2019 (COVID&#x2010;19) infection. J Investig Med High Impact Case Rep. 2020;8:2324709620925571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218462</ArticleId><ArticleId IdType="pubmed">32370558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahreyar M, Fahhoum R, Akinseye O, Bhandari S, Dang G, Khouzam RN. Severe sepsis and cardiac arrhythmias. Ann Transl Med. 2018;6:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787725</ArticleId><ArticleId IdType="pubmed">29404352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui H, Zhang Y, Yang X, et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. medRxiv. 2020.</Citation></Reference><Reference><Citation>Du Y, Tu L, Zhu P. Clinical features of 85 fatal cases of COVID&#x2010;19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med. 2020;201:1372&#x2010;1379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7258652</ArticleId><ArticleId IdType="pubmed">32242738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188&#x2010;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4093680</ArticleId><ArticleId IdType="pubmed">24876563</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;89:3659&#x2010;3670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4403411</ArticleId><ArticleId IdType="pubmed">25589660</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaecher SR, Stabenow J, Oberle C, et al. An immunosuppressed Syrian golden hamster model for SARS&#x2010;CoV infection. Virology. 2008;380:312&#x2010;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722600</ArticleId><ArticleId IdType="pubmed">18760437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine&#x2010;Weber H, Schroeder S, et al. SARS&#x2010;CoV&#x2010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2010;80.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation. 2020;141:e69&#x2010;e92.</Citation><ArticleIdList><ArticleId IdType="pubmed">31902242</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID&#x2010;19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020. 10.1111/jth.14850</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14850</ArticleId><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID&#x2010;19: evidence from front&#x2010;line clinical observation in Wuhan, China. Int J Cardiol. 2020;311;116&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141178</ArticleId><ArticleId IdType="pubmed">32291207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng JH, Liu YX, Yuan J, et al. First case of COVID&#x2010;19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020:1&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146072</ArticleId><ArticleId IdType="pubmed">32277408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim IC, Kim JY, Kim HA, Han S. COVID&#x2010;19&#x2010;related myocarditis in a 21&#x2010;year&#x2010;old female patient. Eur Heart J. 2020;41:1859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184491</ArticleId><ArticleId IdType="pubmed">32282027</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle J, Igbinomwanhia E, Sanchez&#x2010;Nadales A, Danciu S, Chu C, Shah N. A recovered case of COVID&#x2010;19 myocarditis and ARDS treated with corticosteroids, tocilizumab, and experimental AT&#x2010;001. JACC. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196388</ArticleId><ArticleId IdType="pubmed">32368755</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua A, O'Gallagher K, Sado D, Byrne J. Life&#x2010;threatening cardiac tamponade complicating myo&#x2010;pericarditis in COVID&#x2010;19. Eur Heart J. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184427</ArticleId><ArticleId IdType="pubmed">32227076</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez&#x2010;Erquicia P, Dobarro D, Raposeiras&#x2010;Roub&#xed;n G, I&#xf1;iguez&#x2010;Romo A. Multivessel coronary thrombosis in a patient with COVID&#x2010;19 pneumonia. Eur Heart J. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239221</ArticleId><ArticleId IdType="pubmed">32374373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangalore S, Sharma A, Slotwiner A, et al. ST&#x2010;segment elevation in patients with Covid&#x2010;19&#x2014;a case series. N Engl J Med. 2020382(25):2478&#x2013;2480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182015</ArticleId><ArticleId IdType="pubmed">32302081</ArticleId></ArticleIdList></Reference><Reference><Citation>Asif T, Ali Z. Transient ST segment elevation in two patients with COVID&#x2010;19 and a normal transthoracic echocardiogram. Eur J Case Rep Intern Med. 2020;7:001672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213832</ArticleId><ArticleId IdType="pubmed">32399454</ArticleId></ArticleIdList></Reference><Reference><Citation>Courand P&#x2010;Y, Harbaoui B, Bonnet M, Lantelme P. Spontaneous coronary artery dissection in a patient with COVID&#x2010;19. JACC Cardiovasc Interv. 2020;13(12):e107&#x2013;e108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142671</ArticleId><ArticleId IdType="pubmed">32553344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar K, Vogt JC, Divanji PH, Cigarroa JE. Spontaneous coronary artery dissection of the left anterior descending artery in a patient with COVID&#x2010;19 infection. Catheter Cardiovasc Interv. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267179</ArticleId><ArticleId IdType="pubmed">32383284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID&#x2010;19&#x2014;a systematic review. Life Sci. 2020;254:117788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219356</ArticleId><ArticleId IdType="pubmed">32475810</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long&#x2010;term implications. Eur Heart J. 2020;41:1798&#x2010;117800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454513</ArticleId><ArticleId IdType="pubmed">32186331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID&#x2010;19 patients in northeast Chongqing. J Med Virol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228368</ArticleId><ArticleId IdType="pubmed">32198776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YY, Ma YT, Zhang JY, Xie X. COVID&#x2010;19 and the cardiovascular system. Nat Review Cardiol. 2020;17:259&#x2010;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095524</ArticleId><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoganathan A, Sajjad MS, Harky A. Cardiovascular disease and the impact of COVID&#x2010;19. J Card Surg. 2020. 10.1111/jocs.14682</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.14682</ArticleId><ArticleId IdType="pmc">PMC7323179</ArticleId><ArticleId IdType="pubmed">32542799</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded "cardiovascular continuum". J Am Coll Cardiol. 2016;67:1091&#x2010;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779182</ArticleId><ArticleId IdType="pubmed">26940931</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095&#x2010;4103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403635</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M. Cardiovascular disease and COVID&#x2010;19. Diab Metab Syndrome. 2020;14:247&#x2010;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan IH, Zahra SA, Zaim S, Harky A. At the heart of COVID&#x2010;19. J Card Surg. 2020;35(6):1287&#x2013;1294. 10.1111/jocs.14596</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.14596</ArticleId><ArticleId IdType="pubmed">32369872</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan IH, Savarimuthu S, Leung MST, Harky A. The need to manage the risk of thromboembolism in COVID&#x2010;19 patients. J Vasc Surg. 2020. 10.1016/j.jvs.2020.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7224653</ArticleId><ArticleId IdType="pubmed">32417304</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016;1:274&#x2010;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5158013</ArticleId><ArticleId IdType="pubmed">27438105</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba MGS, Val FdA, Sampaio VS, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS&#x2010;CoV&#x2010;2) infection: preliminary safety results of a randomized, double&#x2010;blinded, phase IIb clinical trial (CloroCovid&#x2010;19 Study). medRxiv. 2020.</Citation></Reference><Reference><Citation>Li JW, Han TW, Woodward M, et al. The impact of 2019 novel coronavirus on heart injury: a systematic review and meta&#x2010;analysis. Prog Cardiovasc Dis. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160645</ArticleId><ArticleId IdType="pubmed">32305557</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2010;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Belhadjer Z, M&#xe9;ot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS&#x2010;C) in the context of global SARS&#x2010;CoV&#x2010;2 pandemic. Circulation. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32418446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah W, Saeed R, Sarwar U, Patel R, Fischman DL. COVID&#x2010;19 complicated by acute pulmonary embolism and right&#x2010;sided heart failure. JACC Case Rep. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164919</ArticleId><ArticleId IdType="pubmed">32313884</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshirian A, Heydari K, Alizadeh&#x2010;Navaei R, Moosazadeh M, Abrotan S, Hessami A. Cardiovascular diseases and COVID&#x2010;19 mortality and intensive care unit admission: a systematic review and meta&#x2010;analysis. medRxiv. 2020.</Citation></Reference><Reference><Citation>Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID&#x2010;19: a cause of raised troponin and ECG changes. Lancet. 2020;395:1516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180035</ArticleId><ArticleId IdType="pubmed">32334650</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako&#x2010;Tsubo syndrome in a patient with SARS&#x2010;CoV&#x2010;2 respiratory infection. Eur Heart J. 2020;41:1861&#x2010;1862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184339</ArticleId><ArticleId IdType="pubmed">32267502</ArticleId></ArticleIdList></Reference><Reference><Citation>Craver R, Huber S, Sandomirsky M, McKenna D, Schieffelin J, Finger L. Fatal eosinophilic myocarditis in a healthy 17&#x2010;year&#x2010;old male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS&#x2010;CoV&#x2010;2c). Fetal Pediatr Pathol. 2020;39:1&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232882</ArticleId><ArticleId IdType="pubmed">32401577</ArticleId></ArticleIdList></Reference><Reference><Citation>Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID&#x2010;19). JAMA Cardiol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364333</ArticleId><ArticleId IdType="pubmed">32219357</ArticleId></ArticleIdList></Reference><Reference><Citation>Luetkens JA, Isaak A, Zimmer S, et al. Diffuse myocardial inflammation in COVID&#x2010;19 associated myocarditis detected by multiparametric cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2020;13:e010897.</Citation><ArticleIdList><ArticleId IdType="pubmed">32397816</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberweis ML, Codreanu A, Boehm W, et al. Pediatric life&#x2010;threatening coronavirus disease 2019 with myocarditis. Pediatric Infect Dis J. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32427645</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez Gasso L, Maneiro Melon NM, Sarnago Cebada F, Solis J, Garcia Tejada J. Multivessel spontaneous coronary artery dissection presenting in a patient with severe acute SARS&#x2010;CoV&#x2010;2 respiratory infection. Eur Heart J. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239194</ArticleId><ArticleId IdType="pubmed">32379308</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID&#x2010;19 patients in one hospital in Wuhan, China. J Med Virol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228305</ArticleId><ArticleId IdType="pubmed">32232979</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao XY, Xu XX, Yin HS, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non&#x2010;Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020;20:311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188494</ArticleId><ArticleId IdType="pubmed">32345226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Xu H, Yang M, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID&#x2010;19 in Chengdu. J Clin Virol. 2020;127:104366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146675</ArticleId><ArticleId IdType="pubmed">32302954</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Jiang D, Wen XS, et al. Prognostic value of NT&#x2010;proBNP in patients with severe COVID&#x2010;19. Respir Res. 2020;21:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156898</ArticleId><ArticleId IdType="pubmed">32293449</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y, Yang Y. Clinical characteristics and outcomes of patients with severe covid&#x2010;19 with diabetes. BMJ Open Diab Res Care. 2020;8:e001343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222577</ArticleId><ArticleId IdType="pubmed">32345579</ArticleId></ArticleIdList></Reference><Reference><Citation>Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID&#x2010;19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41:1821&#x2010;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239204</ArticleId><ArticleId IdType="pubmed">32383763</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID&#x2010;19. J Med Virol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262332</ArticleId><ArticleId IdType="pubmed">32293741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. Analysis of myocardial injury in patients with COVID&#x2010;19 and association between concomitant cardiovascular diseases and severity of COVID&#x2010;19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E008.</Citation><ArticleIdList><ArticleId IdType="pubmed">32141280</ArticleId></ArticleIdList></Reference><Reference><Citation>Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID&#x2010;19 in Washington State. JAMA. 2020;323:1612&#x2010;1614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7082763</ArticleId><ArticleId IdType="pubmed">32191259</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019&#x2010;nCoV infected patients linked to viral loads and lung injury. Science China Life Sci. 2020;63:364&#x2010;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088566</ArticleId><ArticleId IdType="pubmed">32048163</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H, Chen J, Zhang L, et al. Retrospective analysis of clinical features in 101 death cases with COVID&#x2010;19. medRxiv. 2020. 10.1101/2020.03.09.20033068</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.09.20033068</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Hu X, Song J, et al. Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID&#x2010;19). medRxiv. 2020. 10.1101/2020.02.26.20028589</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.26.20028589</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37774926</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>395</Volume><PubDate><Year>2024</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Overview of SARS-CoV-2 infection and vaccine associated myocarditis compared to non-COVID-19-associated myocarditis: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>131401</StartPage><MedlinePgn>131401</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2023.131401</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(23)01394-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Previous literature suggests that both SARS-CoV-2 infection and COVID-19 mRNA vaccine are associated with myocarditis, in which the incidence is higher in the infection group. COVID-19 mRNA vaccine-related myocarditis is noted to have a more benign course. Despite these findings, there is a need for a larger population systematic review that compares the outcomes to pre-pandemic acute myocarditis to better understand the extent of the current post-COVID state.</AbstractText><AbstractText Label="METHODS">We performed a literature search with PubMed and EMBASE and identified studies investigating COVID-19 and its vaccinated population, and the population prior to the pandemic (control group) who had myocarditis. We performed a one-group meta-analysis of the incidence, baseline demographics, and outcomes of myocarditis for each group.</AbstractText><AbstractText Label="RESULTS">The incidence in the SARS-CoV-2 infection group was 2.76 per thousand (95% CI, 0.85-8.92), 19.7 per million (95% CI, 12.3-31.6) in the vaccine group, and 0.861 per million (95% CI, 0.04-16.7) in the control group. The majority of patients were male, with the highest proportion in the vaccine group. The mean age was the youngest in the vaccine group (24.8, 95% CI, 19.1-30.6). The vaccine group had the lowest mortality (2.0%, 95% CI, 1.3-2.7) followed by the control and the SARS-CoV-2 infection group. The vaccine group had the lowest proportion of immunoglobulin and glucocorticoid use, mechanical circulatory support, and cardiogenic shock.</AbstractText><AbstractText Label="CONCLUSION">Our study showed favorable outcomes of myocarditis in patients with COVID-19 mRNA vaccination, despite a higher incidence than pre-COVID controls. Further studies with standardized myocarditis diagnostic criteria assessing long-term outcomes are necessary.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishisaka</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, NY, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Atsuyuki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, NY, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aikawa</LastName><ForeName>Tadao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hokkaido Cardiovascular Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanaoka</LastName><ForeName>Koshiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Hisato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiley</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Cardiology, Department of Medicine, Tulane University School of Medicine, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasuhara</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Royal Children's Hospital, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, NY, New York, USA; Division of Cardiology, Jacobi Medical Center, Albert Einstein College of Medicine, NY, New York, USA. Electronic address: tkuno@montefiore.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37774926</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2023.131401</ArticleId><ArticleId IdType="pii">S0167-5273(23)01394-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37415183</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Risk factors for postoperative myocardial injury-related cardiogenic shock in patients undergoing cardiac surgery.</ArticleTitle><Pagination><StartPage>220</StartPage><MedlinePgn>220</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">220</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-023-02312-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myocardial injury-related cardiogenic shock (MICS) is significantly associated with poor outcomes in patients after cardiac surgery. Herein, we aimed to investigate the risk factor for postoperative MICS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a case-control study on 792 patients undergoing cardiac surgery from 2016 to 2019, including 172 patients with postoperative MICS and 620 age- and sex-matched controls. MICS was defined as composite criteria: a cardiac index of &lt;&#x2009;2.2&#xa0;L/m<sup>2</sup>/min, arterial lactate levels of &gt;&#x2009;5 mmol/L at the end of the surgery, a vasoactive-inotropic score of &gt;&#x2009;40 at the end of the surgery, and a cardiac troponin T (cTnT) level of &gt;&#x2009;0.8&#xa0;&#xb5;g/L on postoperative day 1 (POD1) with an increase of &gt;&#x2009;10% on POD 2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 4671 patients who underwent cardiac surgery in our hospital between 2016 and 2019 were included; of these, 172 (3.68%) had MICS and the remaining 4499 did not. For investigating the risk factors, we selected 620 age- and sex-matched controls. In the univariate analysis, MICS was significantly associated with death (P&#x2009;&lt;&#x2009;0.05), extracorporeal membrane oxygenation (P&#x2009;&lt;&#x2009;0.05), continuous renal replacement therapy (P&#x2009;&lt;&#x2009;0.01), and ventricular arrhythmias (P&#x2009;&lt;&#x2009;0.05). Multivariable logistic regression analysis revealed that diabetes mellitus (OR:8.11, 95% CI: 3.52-18.66, P&#x2009;&lt;&#x2009;0.05) and a cardiopulmonary bypass (CPB) time of &gt;&#x2009;2&#xa0;h (OR: 3.16, 95% CI: 1.94-5.15, P&#x2009;&lt;&#x2009;0.05) were associated with postoperative MICS. Moreover, long-time administration of preoperative calcium channel blocker (CCB) was associated with a less incidence of MICS (OR: 0.11, 95% CI: 0.05-0.27, P&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Postoperative MICS is significantly associated with poor outcomes. Diabetes mellitus and long CPB time are associated with MICS. Preoperative CCB administration is associated with less incidence of MICS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Xiao-Feng</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Number 321 Zhongshan Road, Nanjing, 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Number 321 Zhongshan Road, Nanjing, 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hai-Tao</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Number 321 Zhongshan Road, Nanjing, 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>He</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Number 321 Zhongshan Road, Nanjing, 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xin-Yi</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Number 321 Zhongshan Road, Nanjing, 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Li-Chong</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Cardio-thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Number 321 Zhongshan Road, Nanjing, 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardio-thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Number 321 Zhongshan Road, Nanjing, 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yong-Qing</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>Department of Cardio-thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Number 321 Zhongshan Road, Nanjing, 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dong-Jin</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Number 321 Zhongshan Road, Nanjing, 210008, China. dongjin_wang@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Number 321 Zhongshan Road, Nanjing, 210008, China. dongjin_wang@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Number 321 Zhongshan Road, Nanjing, 210008, China. dongjin_wang@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardio-thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Number 321 Zhongshan Road, Nanjing, 210008, China. dongjin_wang@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Number 321 Zhongshan Road, Nanjing, 210008, China. dongjin_wang@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardio-thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Number 321 Zhongshan Road, Nanjing, 210008, China. likai@njglyy.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">Myocardial injury</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37415183</ArticleId><ArticleId IdType="pmc">PMC10326937</ArticleId><ArticleId IdType="doi">10.1186/s13019-023-02312-3</ArticleId><ArticleId IdType="pii">10.1186/s13019-023-02312-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maganti MD, Rao V, Borger MA, Lvanov J, David TE. Predictors of low cardiac output syndrome after isolated aortic valve surgery. Circulation. 2005;112(9 Suppl):1448&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16159861</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg. 1996;112(1):38&#x2013;51. doi: 10.1016/S0022-5223(96)70176-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(96)70176-9</ArticleId><ArticleId IdType="pubmed">8691884</ArticleId></ArticleIdList></Reference><Reference><Citation>Maganti M, Badiwala M, Sheikh A, Scully H, Feindel C, David TE, et al. Predictors of low cardiac output syndrome after isolated aortic valve surgery. J Thorac Cardiovasc Surg. 2010;140(4):790&#x2013;6. doi: 10.1016/j.jtcvs.2009.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.11.022</ArticleId><ArticleId IdType="pubmed">20152992</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle EM, Jr, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg. 1997;63(1):277&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8993292</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997;11(3):355&#x2013;66. doi: 10.1016/S1053-0770(97)90106-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1053-0770(97)90106-3</ArticleId><ArticleId IdType="pubmed">9161905</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauermann E, Bolliger D, Fassl J, Grapow M, Seeberger EE, Seeberger MD, et al. Association of troponin trends and cardiac morbidity and mortality after on-pump cardiac surgery. Ann Thorac Surg. 2017;104(4):1289&#x2013;97. doi: 10.1016/j.athoracsur.2017.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.03.003</ArticleId><ArticleId IdType="pubmed">28935302</ArticleId></ArticleIdList></Reference><Reference><Citation>Montaigne D, Marechal X, Modine T, Coisne A, Mouton S, Fayad G, et al. Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erb&#x3b1; antagonism: a single-centre propensity-matched cohort study and a randomised study. Lancet. 2018;6(10115):59&#x2013;69. doi: 10.1016/S0140-6736(17)32132-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32132-3</ArticleId><ArticleId IdType="pubmed">29107324</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan T, Long GF, Chen C, Zhang HT, Wang JX, Ahaskar A, et al. Heparin-binding protein measurement improves the prediction of myocardial injury-related cardiogenic shock. BMC Cardiovasc Disord. 2020;11(20):124. doi: 10.1186/s12872-020-01406-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-020-01406-3</ArticleId><ArticleId IdType="pmc">PMC7065315</ArticleId><ArticleId IdType="pubmed">32156261</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Pan T, Ge M, Chen T, Ye J, Lu L, et al. Evaluation of vasopressin for vasoplegic shock in patients with preoperative left ventricular dysfunction after cardiac surgery: a propensity-score analysis. Shock. 2018;50(5):519&#x2013;24. doi: 10.1097/SHK.0000000000001114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001114</ArticleId><ArticleId IdType="pubmed">29424795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge M, Pan T, Wang JX, Chen ZJ, Wang DJ. Outcomes of early versus delayed initiation of extracorporeal life support in cardiac surgery. J Cardiothorac Surg. 2019;14(1):129&#x2013;37. doi: 10.1186/s13019-019-0950-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-019-0950-7</ArticleId><ArticleId IdType="pmc">PMC6610966</ArticleId><ArticleId IdType="pubmed">31272456</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Pan T, Luo X, Wang D. High central venous-to-arterial CO2 difference is associated with poor outcomes in patients after cardiac surgery:a propensity score analysis. Shock. 2019;52(6):583&#x2013;9. doi: 10.1097/SHK.0000000000001324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001324</ArticleId><ArticleId IdType="pubmed">30724815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtar AT, Begum J, Buth KJ, Legare JF. Cardiac troponin T is an important predictor of mortality after cardiac surgery. J Crit Care. 2017;38:41&#x2013;6. doi: 10.1016/j.jcrc.2016.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2016.10.011</ArticleId><ArticleId IdType="pubmed">27837691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrke S, Steen H, Sievers HH, Peters H, Opitz A, Muller-Bardorff M, et al. Cardiac troponin T for prediction of short-and long-term morbidity and mortality after elective open heart surgery. Clin Chem. 2014;50(9):1560&#x2013;7. doi: 10.1373/clinchem.2004.031468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2004.031468</ArticleId><ArticleId IdType="pubmed">15217992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurati Buse GA, Bolliger D, Seeberger E, Kasper J, Grapow M, Koller MT, et al. Troponin T and B-type natriuretic peptide after on-pump cardiac surgery: prognostic impact on 12-month mortality and major cardiac events after adjustment for postoperative complications. Circulation. 2014;130(12):948&#x2013;57. doi: 10.1161/CIRCULATIONAHA.113.007253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.007253</ArticleId><ArticleId IdType="pubmed">25098242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasdev S, Chauhan S, Choudhury M, Hote MP, Malik M, Kiran U. Arterial pressure waveform derived cardiac output FloTrac/Vigileo system (third generation software): comparison of two monitoring sites with the thermodilution cardiac output. J ClinMonit Comput. 2012;26:115&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22350311</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Herce J, Bustinza A, Sancho L, Menc&#xed;a S, Carrillo A, Moral R, Bell&#xf3;n JM. Cardiac output and blood volume parameters using femoral arterial thermodilution. Pediatr Int. 2009;51:59&#x2013;65. doi: 10.1111/j.1442-200X.2008.02654.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-200X.2008.02654.x</ArticleId><ArticleId IdType="pubmed">19371279</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010;11(2):234&#x2013;8. doi: 10.1097/PCC.0b013e3181b806fc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b806fc</ArticleId><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinning C, Makarova N, V&#xf6;lzke H, et al. Association of glycated hemoglobin A(1c) levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovasc Diabetol Nov. 2021;15(1):223. doi: 10.1186/s12933-021-01413-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01413-4</ArticleId><ArticleId IdType="pmc">PMC8594211</ArticleId><ArticleId IdType="pubmed">34781939</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med Mar. 2010;4(9):800&#x2013;11. doi: 10.1056/NEJMoa0908359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908359</ArticleId><ArticleId IdType="pmc">PMC2872990</ArticleId><ArticleId IdType="pubmed">20200384</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancks MP, Ning H, Allen NB, et al. Long-term Absolute Risk for Cardiovascular Disease stratified by fasting glucose level. Diabetes Care. 2019 Jan;7. 10.2337/dc18-1773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6385698</ArticleId><ArticleId IdType="pubmed">30617142</ArticleId></ArticleIdList></Reference><Reference><Citation>Stainsby D, MacLennanS, Thomas D, et al. Guidelines on the management of massive blood loss. Br Commit Stand Haematol. 2006;135(5):634&#x2013;41. doi: 10.1111/j.1365-2141.2006.06355.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2006.06355.x</ArticleId><ArticleId IdType="pubmed">17107347</ArticleId></ArticleIdList></Reference><Reference><Citation>Samama CM, Djoudi R, LecompteT. Perioperative platelet transfusion.recommendationsof the French Health Products Safety Agency (AFSSAPS)2003.Minerva Anestesiol, 2006;72(6):447&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation managementfresh frozen plasma. Best Pract Res Clin Anaesth. 2010;24(1):51&#x2013;64. doi: 10.1016/j.bpa.2009.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpa.2009.09.007</ArticleId><ArticleId IdType="pubmed">20402170</ArticleId></ArticleIdList></Reference><Reference><Citation>Riskin DJ, Tsai TC, Riskin L, et al. Massive transfusion protocols: the role of aggressive resuscitation versus product ratio in mortality reduction. J Am CollSurg. 2009;209:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">19632596</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993;55:552&#x2013;9. doi: 10.1016/0003-4975(93)91048-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-4975(93)91048-R</ArticleId><ArticleId IdType="pubmed">8431082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen C, Thiis JJ, Clemmensen P, et al. Significance and management of early graft failure after coronary artery bypass grafting: feasibility and results of acute angiography and re-re- vascularization. Eur J Cardiothorac Surg. 1997;12(6):847&#x2013;52. doi: 10.1016/S1010-7940(97)00268-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1010-7940(97)00268-6</ArticleId><ArticleId IdType="pubmed">9489868</ArticleId></ArticleIdList></Reference><Reference><Citation>Filomena D, Monosilio S, Cimino S, Maestrini V, Luongo F, Neccia M et al. Prognostic role of pre- and post-interventional myocardial injury in patients undergoing transcatheter aortic valve implantation. Minerva Cardiol Angiol. 2021; online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">33944532</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC, Brand A. Postoperative complications associ ated with transfusion of platelets and plasma in cardiac sur gery. Transfusion. 2011;51:2603&#x2013;10. doi: 10.1111/j.1537-2995.2011.03200.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2011.03200.x</ArticleId><ArticleId IdType="pubmed">21645007</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hout FM, Hogervorst EK, Rosseel PM, et al. Does a platelet transfusion independently affect bleeding and adverse outcomes in cardiac surgery?[J] Anesthesiology. 2017;126(3):1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28092320</ArticleId></ArticleIdList></Reference><Reference><Citation>Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. 2011;14(5):781&#x2013;90. doi: 10.1089/ars.2010.3343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2010.3343</ArticleId><ArticleId IdType="pmc">PMC3052273</ArticleId><ArticleId IdType="pubmed">20578962</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of akt phosphorylation. Diabetes. 2005;54(8):2360&#x2013;4. doi: 10.2337/diabetes.54.8.2360.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.54.8.2360</ArticleId><ArticleId IdType="pubmed">16046302</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ. The diabetic heart: too sweet for its own good? Cardiol Res Pract. 2012;2012:845698. doi: 10.1155/2012/845698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/845698</ArticleId><ArticleId IdType="pmc">PMC3296224</ArticleId><ArticleId IdType="pubmed">22462028</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittington HJ, Harding I, Stephenson CIM, Bell R, Hausenloy DJ, Mocanu MM, et al. Cardioprotection in the aging, diabetic heart: the loss of protective akt signalling. Cardiovasc Res. 2013;99:694&#x2013;704. doi: 10.1093/cvr/cvt140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvt140</ArticleId><ArticleId IdType="pmc">PMC3746954</ArticleId><ArticleId IdType="pubmed">23723063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes. 2007;56(1):127&#x2013;36. doi: 10.2337/db06-0907.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db06-0907</ArticleId><ArticleId IdType="pubmed">17192474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Raedschelders K, Shravah J, Hui Y, Safaei HG, Chen DDY, et al. Differences in myocardial PTEN expression and akt signalling in type 2 diabetic and nondiabetic patients undergoing coronary bypass surgery. Clin Endocrinol. 2011;74(6):705&#x2013;13. doi: 10.1111/j.1365-2265.2011.03979.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.2011.03979.x</ArticleId><ArticleId IdType="pmc">PMC3378665</ArticleId><ArticleId IdType="pubmed">21521253</ArticleId></ArticleIdList></Reference><Reference><Citation>Lejay A, Fang F, John R, Van JAD, Barr M, Thaveau F, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol. 2016;91:11&#x2013;22. doi: 10.1016/j.yjmcc.2015.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2015.12.020</ArticleId><ArticleId IdType="pubmed">26718721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59(4):418&#x2013;58. doi: 10.1124/pr.107.06002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.107.06002</ArticleId><ArticleId IdType="pubmed">18048761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouairi S, Carrie D, Puel J. Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. Eur Heart J. 1995;16(Suppl H):3&#x2013;8. doi: 10.1093/eurheartj/16.suppl_H.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/16.suppl_H.3</ArticleId><ArticleId IdType="pubmed">8846802</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen JB, Gislason GH, Charlot MG, Fosb&#xf8;l EL, Andersson C, Weeke P, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol. 2011;25(4):409&#x2013;17. doi: 10.1016/j.jacc.2010.08.640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.08.640</ArticleId><ArticleId IdType="pubmed">21251580</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M, Carrero JJ, Szummer K, &#xc5;kerblom A, Edfors R, Spaak J et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction. J Am Coll Cardiol. 2016; 12;67(14):1687-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">27056774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36802136</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>The impact of chronic total occlusions in patients undergoing transcatheter aortic valve replacement: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>806</StartPage><EndPage>812</EndPage><MedlinePgn>806-812</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.30601</ELocationID><Abstract><AbstractText>Coronary artery disease (CAD) is frequently encountered in patients evaluated for transcatheter aortic valve replacement (TAVR) due to severe aortic stenosis. The prognostic relevance of chronic total occlusions (CTOs) in this setting is poorly understood. We conducted a search of MEDLINE and EMBASE to identify studies evaluating patients who underwent TAVR and evaluated outcomes depending on the presence of coronary CTOs. Pooled analysis was performed to estimate the rate and risk ratio for mortality.&#xa0;Four studies involving 25,432 patients fulfilled the inclusion criteria. The follow up ranged from in-hospital outcomes to 8-years follow-up. Coronary artery disease was present in 67.8% to 75.5% of patients in 3 studies which reported this variable. The prevalence of CTOs varied between 2% and 12.6% in this cohort. The presence of CTOs was associated with increase in length of stay (8.1&#x2009;&#xb1;&#x2009;8.2 vs. 5.9&#x2009;&#xb1;&#x2009;6.5, p&#x2009;&lt;&#x2009;0.01), cardiogenic shock (5.1% vs. 1.7%, p&#x2009;&lt;&#x2009;0.01), acute myocardial infarction (5.8% vs. 2.8%, p&#x2009;=&#x2009;0.02) and acute kidney injury (18.6% vs. 13.9%, p&#x2009;=&#x2009;0.048). The pooled 1-year death rate revealed 41 deaths in 165 patients in the CTO group and 396 deaths in 1663 patients with no CTO ((24.8%) vs. (23.8%)). The meta-analysis of death with CTO versus no CTO showed a nonsignificant trend toward increased mortality with CTOs (risk ratio 1.11 95%&#xa0;CI 0.90-1.40, I<sup>2</sup> &#x2009;=&#x2009;0%). Our analysis suggests that concomitant CTO lesions in patients undergoing TAVR are common, and its presence was associated with increased in-hospital complications. However, CTO presence by itself was not associated with increased long-term mortality, only a nonsignificant trend toward an increased risk of death in patients with CTO was found. Further studies are warranted to assess the prognostic relevance of CTO lesion in TAVR patients.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Will</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9217-0191</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine 3, University Hospital St. P&#xf6;lten, Karl Landsteiner University of Health Sciences, Krems, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karl Landsteiner Institute for Cardiometabolics, Karl Landsteiner Society, St Poelten, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine 3, University Hospital St. P&#xf6;lten, Karl Landsteiner University of Health Sciences, Krems, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Karl Landsteiner Institute for Cardiometabolics, Karl Landsteiner Society, St Poelten, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, Sigmund-Freud University, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leibundgut</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0122-5397</Identifier><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kardiologie, Universit&#xe4;tsspital Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamm</LastName><ForeName>Gudrun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine 3, University Hospital St. P&#xf6;lten, Karl Landsteiner University of Health Sciences, Krems, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vock</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine 3, University Hospital St. P&#xf6;lten, Karl Landsteiner University of Health Sciences, Krems, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mascherbauer</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine 3, University Hospital St. P&#xf6;lten, Karl Landsteiner University of Health Sciences, Krems, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Chun Shing</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0001-7047-1586</Identifier><AffiliationInfo><Affiliation>Department of Post-Qualifying Healthcare Practice, School of Nursing and Midwifery, Birmingham City University, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Karl Landsteiner Privatuniversit&#xe4;t f&#xfc;r Gesundheitswissenschaften</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="Y">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="Y">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="N">Aortic Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054059" MajorTopicYN="Y">Coronary Occlusion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aortic stenosis (AS)</Keyword><Keyword MajorTopicYN="N">chronic total occlusion (CTO)</Keyword><Keyword MajorTopicYN="N">coronary artery disease (CAD)</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention (PCI)</Keyword><Keyword MajorTopicYN="N">trans aortic valve replacement (TAVR)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>21</Day><Hour>17</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36802136</ArticleId><ArticleId IdType="doi">10.1002/ccd.30601</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. doi:10.1056/NEJMOA1814052/SUPPL_FILE/NEJMOA1814052_DATA-SHARING.PDF</Citation></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632. doi:10.1093/EURHEARTJ/EHAB395</Citation></Reference><Reference><Citation>Reardon MJ, van Mieghem NM, Popma JJ, et al. Surgical or transcatheter&#xa0;aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321-1331. doi:10.1056/NEJMOA1700456</Citation></Reference><Reference><Citation>Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical&#xa0;aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620. doi:10.1056/NEJMOA1514616</Citation></Reference><Reference><Citation>Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790-1798. doi:10.1056/NEJMOA1400590</Citation></Reference><Reference><Citation>Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. JACC. 2020;76:2492-2516. doi:10.1016/J.JACC.2020.09.595</Citation></Reference><Reference><Citation>Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. JACC. 1997;29:630-634. doi:10.1016/S0735-1097(96)00563-3</Citation></Reference><Reference><Citation>Andersson C, Johnson AD, Benjamin EJ, Levy D, Vasan RS. 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol. 2019;16:687-698. doi:10.1038/S41569-019-0202-5</Citation></Reference><Reference><Citation>Goel SS, Ige M, Tuzcu EM, et al. Severe aortic stenosis and coronary artery&#xa0;disease-implications for management in the transcatheter aortic valve replacement era. JACC. 2013;62:1-10. doi:10.1016/J.JACC.2013.01.096</Citation></Reference><Reference><Citation>Abdel-Wahab M, Zahn R, Horack M, et al. Transcatheter aortic valve implantation in patients with and without concomitant coronary artery disease: comparison of characteristics and early outcome in the German multicenter TAVI registry. Clin&#xa0;Res&#xa0;Cardiol. 2012;101:973-981. doi:10.1007/S00392-012-0486-5</Citation></Reference><Reference><Citation>Stefanini GG, Stortecky S, Cao D, et al. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur Heart J. 2014;35:2530-2540. doi:10.1093/EURHEARTJ/EHU074</Citation></Reference><Reference><Citation>Cao D, Chiarito M, Pagnotta P, Reimers B, Stefanini GG. Coronary revascularisation in transcatheter aortic valve implantation candidates: why, who, when? Interv&#xa0;cardiol&#xa0;(London, England). 2018;13:69-76. doi:10.15420/ICR.2018:2:2</Citation></Reference><Reference><Citation>Kotronias RA, Bray JH, Scarsini R, et al. Transcatheter aortic valve replacement and percutaneous coronary intervention versus surgical aortic valve replacement and coronary artery bypass grafting in patients with severe aortic stenosis and concomitant coronary artery disease: a&#xa0;systematic review and meta-analysis. Catheter Cardiovasc Interv. 2020;96:1113-1125. doi:10.1002/CCD.29110</Citation></Reference><Reference><Citation>S&#xf8;ndergaard L, Popma JJ, Reardon MJ, et al. Comparison of a complete percutaneous versus surgical approach to aortic valve replacement and revascularization in patients at intermediate surgical risk: results from the randomized SURTAVI trial. Circulation. 2019;140:1296-1305. doi:10.1161/CIRCULATIONAHA.118.039564</Citation></Reference><Reference><Citation>Patterson T, Clayton T, Dodd M, et al. ACTIVATION (PercutAneous coronary intervention prIor to transcatheter aortic VAlve implantaTION). JACC&#xa0;Cardiovasc&#xa0;Interven. 2021;14:1965-1974. doi:10.1016/J.JCIN.2021.06.041</Citation></Reference><Reference><Citation>Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions. JACC. 2012;59:991-997. doi:10.1016/J.JACC.2011.12.007</Citation></Reference><Reference><Citation>Farooq V, Serruys PW, Garcia-Garcia HM, et al. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions. JACC. 2013;61:282-294. doi:10.1016/J.JACC.2012.10.017</Citation></Reference><Reference><Citation>George S, Cockburn J, Clayton TC, et al. Long-term follow-up of elective chronic total coronary occlusion angioplasty. JACC. 2014;64:235-243. doi:10.1016/J.JACC.2014.04.040</Citation></Reference><Reference><Citation>R&#xe5;munddal T, Hoebers LP, Henriques JPS, et al. Prognostic impact of chronic total occlusions. JACC&#xa0;Cardiovasc&#xa0;Interven. 2016;9:1535-1544. doi:10.1016/J.JCIN.2016.04.031</Citation></Reference><Reference><Citation>Godino C, Giannattasio A, Scotti A, et al. Risk of cardiac and sudden death with and without revascularisation of a coronary chronic total occlusion. Heart. 2019;105:1096-1102. doi:10.1136/heartjnl-2018-314076</Citation></Reference><Reference><Citation>van der Schaaf RJ, Vis MM, Sjauw KD, et al. Impact of multivessel coronary disease on long-term mortality in patients with ST-elevation myocardial infarction is due to the presence of a chronic total occlusion. Am J Cardiol. 2006;98:1165-1169. doi:10.1016/J.AMJCARD.2006.06.010</Citation></Reference><Reference><Citation>Park TK, Lee SH, Choi KH, et al. Late survival benefit of percutaneous coronary intervention compared with medical therapy in patients with coronary chronic total occlusion:&#xa0;a&#xa0;10-year follow-up study. J Am Heart Assoc. 2021;10:19022. doi:10.1161/JAHA.120.019022</Citation></Reference><Reference><Citation>Sankaramangalam K, Banerjee K, Kandregula K, et al. Impact of coronary artery disease on 30-day and 1-year mortality in patients undergoing transcatheter aortic valve replacement: a meta-analysis. J Am Heart Assoc. 2017;6. doi:10.1161/JAHA.117.006092</Citation></Reference><Reference><Citation>Kleczynski P, Dziewierz A, Bagienski M, et al. Impact of coronary artery disease burden on 12-month mortality of patients after transcatheter aortic valve implantation. J Interv Cardiol. 2016;29:375-381. doi:10.1111/JOIC.12308</Citation></Reference><Reference><Citation>Gifft K, Brilakis E, Kumar A, Omran J, Enezate T. Transcatheter aortic valve replacement in patients with coronary chronic total occlusion. Cardiovasc&#xa0;Revasc&#xa0;Med. 2020;21:741-744. doi:10.1016/J.CARREV.2019.10.025</Citation></Reference><Reference><Citation>Howard TM, Cantey EP, Abutaleb AA, et al. Transcatheter aortic valve replacement outcomes based on the presence of chronic total occlusion. Cardiovasc&#xa0;Revasc&#xa0;Med. 2020;21:1305-1310. doi:10.1016/J.CARREV.2020.03.014</Citation></Reference><Reference><Citation>Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surgery. 2021;156:787-788. doi:10.1001/JAMASURG.2021.0522</Citation></Reference><Reference><Citation>George W, Beverley S, O'Connell D, Peterson J, Vivian W. The newcastle-ottawa scale (NOS) for assessing the quality of case-control studies in meta-analyses. Eur J Epidemiol. 2011;25:603-605.</Citation></Reference><Reference><Citation>Millan-Iturbe O, Sawaya FJ, L&#xf8;nborg J, et al. Coronary artery disease, revascularization, and clinical outcomes in transcatheter aortic valve replacement: real-world results from the east Denmark heart registry. Catheter Cardiovasc Interv. 2018;92:818-826. doi:10.1002/CCD.27440</Citation></Reference><Reference><Citation>Nombela-Franco L, Mitroi CD, Fern&#xe1;ndez-Lozano I, et al. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study). Circ&#xa0;Arrhythm&#xa0;Electrophysiol. 2012;5:147-154. doi:10.1161/CIRCEP.111.968008</Citation></Reference><Reference><Citation>Iannaccone M, Nombela-Franco L, Gallone G, et al. Impact of successful chronic coronary total occlusion recanalization on recurrence of ventricular arrhythmias in implantable cardioverter-defibrillator recipients for ischemic cardiomyopathy (VACTO PCI study). Cardiovasc&#xa0;Revasc&#xa0;Med. 2022;43:104-111. doi:10.1016/J.CARREV.2022.03.029</Citation></Reference><Reference><Citation>Nombela-Franco L, Iannaccone M, Anguera I, et al. Impact of chronic total coronary occlusion on recurrence of ventricular arrhythmias in ischemic secondary prevention implantable&#xa0;cardioverter-defibrillator recipients (VACTO secondary study). JACC Cardiovasc&#xa0;Interven. 2017;10:879-888. doi:10.1016/j.jcin.2017.02.008</Citation></Reference><Reference><Citation>Khan MF, Wendel CS, Thai HM, Movahed MR. Effects of percutaneous revascularization of chronic total occlusions on clinical outcomes: a meta-analysis comparing successful versus failed percutaneous intervention for chronic total occlusion. Catheter Cardiovasc Interv. 2013;82:95-107. doi:10.1002/CCD.24863</Citation></Reference><Reference><Citation>Fujii T, Sakai K, Nakano M, et al. Impact of the origin of the collateral feeding donor artery on short-term mortality in ST-elevation myocardial infarction with comorbid chronic total occlusion. Int J Cardiol. 2016;218:158-163. doi:10.1016/J.IJCARD.2016.05.023</Citation></Reference><Reference><Citation>Scotti A, Godino C, Munaf&#xf2; A, et al. Cardiac and sudden death after chronic total occlusion percutaneous coronary intervention: prognostic role of the target vessel. Catheter Cardiovasc Interv. 2021;97:E789-E800. doi:10.1002/CCD.29425</Citation></Reference><Reference><Citation>Yap SC, Sakhi R, Theuns DAMJ, et al. Increased risk of ventricular arrhythmias in survivors of out-of-hospital cardiac arrest with chronic total coronary occlusion. Heart Rhythm. 2018;15:124-129. doi:10.1016/J.HRTHM.2017.09.004</Citation></Reference><Reference><Citation>Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012;52:857-864. doi:10.1016/J.YJMCC.2011.08.028</Citation></Reference><Reference><Citation>J K, Y van der G, PP de J, DE G. Coronary collaterals: an important and underexposed aspect of coronary artery disease. Circulation. 2003;107:59-70. doi:10.1161/01.CIR.0000065118.99409.5F</Citation></Reference><Reference><Citation>Regieli JJ, Jukema JW, Nathoe HM, et al. Coronary collaterals improve prognosis in patients with ischemic heart disease. Int J Cardiol. 2009;132:257-262. doi:10.1016/J.IJCARD.2007.11.100</Citation></Reference><Reference><Citation>Kumar A, Sammour Y, Reginauld S, et al. Adverse clinical outcomes in patients undergoing both PCI and TAVR: analysis from a pooled multi-center registry. Catheter Cardiovasc Interv. 2021;97:529-539. doi:10.1002/CCD.29233</Citation></Reference><Reference><Citation>Kotronias RA, Kwok CS, George S, et al. Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy:&#xa0;a&#xa0;systematic review and meta-analysis. J Am Heart Assoc. 2017;6. doi:10.1161/JAHA.117.005960</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35680428</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2048-8734</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>European heart journal. Acute cardiovascular care</Title><ISOAbbreviation>Eur Heart J Acute Cardiovasc Care</ISOAbbreviation></Journal><ArticleTitle>Multivessel vs. culprit-vessel only percutaneous coronary interventions in acute myocardial infarction and cardiogenic shock: a systematic review and meta-analysis of prospective randomized and retrospective studies.</ArticleTitle><Pagination><StartPage>558</StartPage><EndPage>569</EndPage><MedlinePgn>558-569</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjacc/zuac072</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Studies comparing outcomes of multivessel (MV) vs. culprit-vessel (CV) only percutaneous coronary intervention (PCI) during index cardiac catheterization in patients presenting with acute myocardial infarction (MI) and cardiogenic shock (CS) have reported conflicting results. In this systematic review we aim to investigate outcomes with MV vs. CV-only revascularization strategies in patients with acute MI and CS.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">PubMed, Google Scholar, CINAHL and Cochrane databases were queried for studies comparing MV vs. CV PCI in patients with acute MI and CS. Data were extracted and pooled by means of random effects model. Primary outcome was early all-cause mortality (up to 30 days), while the secondary outcomes included late all-cause mortality (mean, 11.4 months), stroke, new renal replacement therapy, reinfarction, repeat revascularization, and bleeding. Pooled odds ratio (OR), 95% confidence intervals (CIs), and number needed to harm (NNH) were calculated. A total of 16 studies enrolling 75 &#x2009;431 patients were included. The MV PCI was associated with higher risk of early mortality [OR 1.17, 95% CI (1.00-1.35); P&#x2009;=&#x2009;0.04; NNH&#x2009;=&#x2009;62], stroke [1.15 (1.03-1.29); P&#x2009;=&#x2009;0.01; NNH&#x2009;=&#x2009;351], and new renal replacement therapy [1.33 (1.06-1.67); P&#x2009;=&#x2009;0.01; NNH&#x2009;=&#x2009;61]; and with lower risk of repeat revascularization [0.61 (0.41-0.89); P&#x2009;=&#x2009;0.01] when compared with CV PCI. No significant difference was observed in late-term mortality [1.02 (0.84-1.25); P&#x2009;=&#x2009;0.84], risk of reinfarction [1.13 (0.94-1.35); P&#x2009;=&#x2009;0.18], or bleeding [1.21 (0.94-1.55); P&#x2009;=&#x2009;0.13] between groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among patients with acute MI and CS, MV PCI during index cardiac catheterization was associated with higher risk of early mortality, stroke, and renal replacement therapy.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Gauravpal S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0002-4806-6418</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, Creighton University School of Medicine, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez</LastName><ForeName>Jorge Sanz</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Hospital Universitari i Politecnic La Fe, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biomedica en Red (CIBERCV), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thandra</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, Creighton University School of Medicine, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanmanthareddy</LastName><ForeName>Arun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, Creighton University School of Medicine, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alla</LastName><ForeName>Venkata Mahesh</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, Creighton University School of Medicine, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Garcia</LastName><ForeName>Hector M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Georgetown University, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Acute Cardiovasc Care</MedlineTA><NlmUniqueID>101591369</NlmUniqueID><ISSNLinking>2048-8726</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Culprit vessel</Keyword><Keyword MajorTopicYN="N">Multivessel</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>21</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35680428</ArticleId><ArticleId IdType="doi">10.1093/ehjacc/zuac072</ArticleId><ArticleId IdType="pii">6605048</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35940444</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6795</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</Title><ISOAbbreviation>J Am Soc Echocardiogr</ISOAbbreviation></Journal><ArticleTitle>Comparison of Pre- and Postnatally Diagnosed Coronary Artery Fistulae: Echocardiographic Features and Clinical Outcomes.</ArticleTitle><Pagination><StartPage>1322</StartPage><EndPage>1335</EndPage><MedlinePgn>1322-1335</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.echo.2022.07.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0894-7317(22)00390-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Coronary artery fistulae (CAFs) are abnormal connections of a coronary artery to a cardiac chamber or vessel. There is a paucity of data regarding clinical outcomes, especially when detected prenatally.</AbstractText><AbstractText Label="METHODS">This was a multicenter retrospective cohort study of all CAF cases from 2002 to 2016. Clinical characteristics and outcomes were compared between the prenatal and postnatal cohorts. A scoping literature review of prenatal CAFs was completed.</AbstractText><AbstractText Label="RESULTS">CAFs were diagnosed prenatally in 12 (median, 23&#xa0;weeks' gestation; interquartile range, 17-36&#xa0;weeks' gestation) and postnatally in 94 (median, 2.8&#xa0;years; interquartile range, 0-15&#xa0;years) cases. Structural heart defects were present in five (42%) prenatal and 19 (20%) postnatal cases (P&#xa0;=&#xa0;.011) and genetic conditions in five (42%) and 14 (15%), respectively (P&#xa0;=&#xa0;.001). CAFs were considered large in 12 (100%) prenatal versus 14 (15%) postnatal cases (P&#xa0;&lt;&#xa0;.001). The CAF distribution was similar between cohorts: 39 (67%) from the left and 19 (33%) from the right coronary artery, with the most common exit sites being the main pulmonary artery 54 (51%), right ventricle 30 (28%), and right atrium 12 (11%). Of prenatal cases, all large at presentation, none progressed, six (50%) resolved by birth, and one (8%) underwent elective neonatal ligation. Of postnatal cases, one presented in cardiogenic shock, and no other case had ventricular dysfunction, arrhythmias, or ischemic changes. Nine (10%) with large shunts underwent intervention (seven percutaneous, two surgical), of whom three were symptomatic. Two (17%) prenatal and two (2%) postnatal cases had coronary abnormalities, two with normal results on stress perfusion imaging. Postnatal death occurred in two (17%) prenatal and four (4%) postnatal cases (P&#xa0;=&#xa0;.05). Of the total 36 prenatal cases reported in the literature, including the 12 cases in the present series, 10 (28%) had clinical symptoms at birth, including three (8%) with cardiogenic shock, and 19 (53%) underwent intervention.</AbstractText><AbstractText Label="CONCLUSIONS">Prenatally and postnatally encountered CAFs are associated with a good prognosis for most, with many not requiring intervention. Although half of the prenatal CAFs resolved prenatally, given the risk for cardiogenic shock at birth and heart failure in early infancy, appropriate perinatal planning and postnatal surveillance is warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pisesky</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Labatt Family Heart Center, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nield</LastName><ForeName>Lynne E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Labatt Family Heart Center, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address: lynne.nield@sickkids.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fetal and Neonatal Cardiology Program, Division of Cardiology, Department of Pediatrics, Stollery Children's Hospital, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaeggi</LastName><ForeName>Edgar T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Labatt Family Heart Center, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornberger</LastName><ForeName>Lisa K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Fetal and Neonatal Cardiology Program, Division of Cardiology, Department of Pediatrics, Stollery Children's Hospital, Edmonton, Alberta, Canada; Department of Obstetrics &amp; Gynecology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Soc Echocardiogr</MedlineTA><NlmUniqueID>8801388</NlmUniqueID><ISSNLinking>0894-7317</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006330" MajorTopicYN="Y">Heart Defects, Congenital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005402" MajorTopicYN="Y">Fistula</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016216" MajorTopicYN="N">Ultrasonography, Prenatal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aneuploidy</Keyword><Keyword MajorTopicYN="N">Coronary artery fistula</Keyword><Keyword MajorTopicYN="N">Fetal echocardiography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>8</Day><Hour>19</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35940444</ArticleId><ArticleId IdType="doi">10.1016/j.echo.2022.07.015</ArticleId><ArticleId IdType="pii">S0894-7317(22)00390-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37552372</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2110-5820</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Annals of intensive care</Title><ISOAbbreviation>Ann Intensive Care</ISOAbbreviation></Journal><ArticleTitle>Overview of the current use of levosimendan in France: a prospective observational cohort study.</ArticleTitle><Pagination><StartPage>69</StartPage><MedlinePgn>69</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">69</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13613-023-01164-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Following the results of randomized controlled trials on levosimendan, French health authorities requested an update of the current use and side-effects of this medication on a national scale.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The France-LEVO registry was a prospective observational cohort study reflecting the indications, dosing regimens, and side-effects of levosimendan, as well as patient outcomes over a year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patients included (n&#x2009;=&#x2009;602) represented 29.6% of the national yearly use of levosimendan in France. They were treated for cardiogenic shock (n&#x2009;=&#x2009;250, 41.5%), decompensated heart failure (n&#x2009;=&#x2009;127, 21.1%), cardiac surgery-related low cardiac output prophylaxis and/or treatment (n&#x2009;=&#x2009;86, 14.3%), and weaning from veno-arterial extracorporeal membrane oxygenation (n&#x2009;=&#x2009;82, 13.6%). They received 0.18&#x2009;&#xb1;&#x2009;0.07&#xa0;&#xb5;g/kg/min levosimendan over 26&#x2009;&#xb1;&#x2009;8&#xa0;h. An initial bolus was administered in 45 patients (7.5%), 103 (17.1%) received repeated infusions, and 461 (76.6%) received inotropes and or vasoactive agents concomitantly. Hypotension was reported in 218 patients (36.2%), atrial fibrillation in 85 (14.1%), and serious adverse events in 17 (2.8%). 136 patients (22.6%) died in hospital, and 26 (4.3%) during the 90-day follow-up.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observed that levosimendan was used in accordance with recent recommendations by French physicians. Hypotension and atrial fibrillation remained the most frequent side-effects, while serious adverse event potentially attributable to levosimendan were infrequent. The results suggest that this medication was safe and potentially associated with some benefit in the population studied.</AbstractText><CopyrightInformation>&#xa9; 2023. La Soci&#xe9;t&#xe9; de R&#xe9;animation de Langue Francaise = The French Society of Intensive Care (SRLF).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cholley</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6388-6011</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care Medicine, H&#xf4;pital Europ&#xe9;en Georges Pompidou, AP-HP, 75015, Paris, France. bernard.cholley@aphp.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, INSERM, UMR_S 1140 "Innovations Th&#xe9;rapeutiques en H&#xe9;mostase", 75006, Paris, France. bernard.cholley@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bojan</LastName><ForeName>Mirela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>P&#xf4;le Cardiopathies Cong&#xe9;nitales, H&#xf4;pital Marie Lannelongue, Groupe Hospitalier Paris-Saint Joseph, 92350, Le Plessis-Robinson, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillon</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Besancon, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besnier</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, Normandie Univ, UNIROUEN, INSERM U1096, CHU Rouen, 76000, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattei</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Cardiac Surgery, CHRU de Nancy, H&#xf4;pital de Brabois, Vandoeuvre-les Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CHRU Nancy, Critical Care, CHRU de Nancy, H&#xf4;pital de Brabois, Vandoeuvre-Les Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouattara</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anesthesia and Critical Care, CHU Bordeaux, CHU de Bordeaux, 33000, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology of Cardiovascular Diseases, Universit&#xe9; de Bordeaux, INSERM, U1034, 33600, Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tafer</LastName><ForeName>Nadir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anesthesia and Critical Care, CHU Bordeaux, CHU de Bordeaux, 33000, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology of Cardiovascular Diseases, Universit&#xe9; de Bordeaux, INSERM, U1034, 33600, Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmas</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiology Department, Rangueil University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, AP-HM, Aix-Marseille University, 13385, Marseille CEDEX 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozec</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, Institut du Thorax, Laennec Hospital, CHU de Nantes, and Nantes Universit&#xe9;, CHU Nantes*, CNRS, INSERM, 44000, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fellahi</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Anaesthesiology and Critical Care, Louis Pradel University Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiology department, Henri-Mondor University Hospital, AP-HP, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labaste</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, Rangueil University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roubille</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiology Department INI-CRT PhyMedExp INSERM, CNRS CHU de Montpellier, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caruba</LastName><ForeName>Thibaut</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, H&#xf4;pital Europ&#xe9;en Georges Pompidou, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauriat</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anesthesia and Critical Care, CHU Bordeaux, CHU de Bordeaux, 33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ARCOTHOVA study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Intensive Care</MedlineTA><NlmUniqueID>101562873</NlmUniqueID><ISSNLinking>2110-5820</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Ann Intensive Care. 2023 Sep 29;13(1):94. doi: 10.1186/s13613-023-01193-y.</RefSource><PMID Version="1">37770809</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Inotropes</Keyword><Keyword MajorTopicYN="N">Levosimendan</Keyword><Keyword MajorTopicYN="N">Repetitive infusions</Keyword><Keyword MajorTopicYN="N">VA-ECMO weaning</Keyword></KeywordList><CoiStatement>Bernard Cholley, Bruno Levy, Alexandre Ouattara, Jean-Luc Fellahi, and Thibaut Caruba are part of an advisory board for Orion Pharma in charge of designing and coordinating the FRANCE LEVO registry, at the request of the French Haute Autorit&#xe9; de Sant&#xe9;. Philippe Mauriat is a consultant for Orion Pharma.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Barbot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laurent</LastName><ForeName>Berthomieu</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Besselat</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katrien</LastName><ForeName>Blanchart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bougle</LastName><ForeName>Adrien</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgoin</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnaud</LastName><ForeName>Causeret</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charbonneau</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cristinar</LastName><ForeName>Mircea</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desebbe</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eljezi</LastName><ForeName>Veldat</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genet</LastName><ForeName>Thibaud</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grenier</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guinot</LastName><ForeName>Pierre Gr&#xe9;goire</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebel</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>Yael</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lion</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mansourati</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marli&#xe8;re</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Anne-C&#xe9;line</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohammad</LastName><ForeName>Usman</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monsegu</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nessler</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orsel</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puymirat</LastName><ForeName>Etienne</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Recher</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soussi</LastName><ForeName>Sabri</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troussard</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uhry</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zirphile</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>11</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37552372</ArticleId><ArticleId IdType="pmc">PMC10409690</ArticleId><ArticleId IdType="doi">10.1186/s13613-023-01164-3</ArticleId><ArticleId IdType="pii">10.1186/s13613-023-01164-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cholley B, Caruba T, Grosjean S, Amour J, Ouattara A, Villacorta J, et al. Effect of Levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA. 2017;318(6):548&#x2013;556. doi: 10.1001/jama.2017.9973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.9973</ArticleId><ArticleId IdType="pmc">PMC5817482</ArticleId><ArticleId IdType="pubmed">28787507</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. New Engl J Med. 2016;375(17):1638&#x2013;1648. doi: 10.1056/NEJMoa1609409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1609409</ArticleId><ArticleId IdType="pubmed">27705084</ArticleId></ArticleIdList></Reference><Reference><Citation>Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, et al. Levosimendan for hemodynamic support after cardiac surgery. New Engl J Med. 2017;376(21):2021&#x2013;2031. doi: 10.1056/NEJMoa1616325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1616325</ArticleId><ArticleId IdType="pubmed">28320259</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New Engl J Med. 2017;376(25):2032&#x2013;2042. doi: 10.1056/NEJMoa1616218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1616218</ArticleId><ArticleId IdType="pubmed">28316276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129&#x2013;2200. doi: 10.1093/eurheartj/ehw128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw128</ArticleId><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobarro D, Donoso-Trenado V, Sole-Gonzalez E, Moliner-Abos C, Garcia-Pinilla JM, Lopez-Fernandez S, et al. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. ESC Heart Fail. 2023 doi: 10.1002/ehf2.14278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.14278</ArticleId><ArticleId IdType="pmc">PMC10053278</ArticleId><ArticleId IdType="pubmed">36655614</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsherbini H, Soliman O, Zijderhand C, Lenzen M, Hoeks SE, Kaddoura R, et al. Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure: a systematic review and meta-analysis of 984 patients. Heart Fail Rev. 2022;27(2):493&#x2013;505. doi: 10.1007/s10741-021-10101-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-021-10101-0</ArticleId><ArticleId IdType="pmc">PMC8898255</ArticleId><ArticleId IdType="pubmed">33839989</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelshafy M, Elsherbini H, Elkoumy A, Simpkin AJ, Elzomor H, Caliskan K, et al. Perioperative levosimendan infusion in patients with end-stage heart failure undergoing left ventricular assist device implantation. Front Cardiovasc Med. 2022;9:888136. doi: 10.3389/fcvm.2022.888136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.888136</ArticleId><ArticleId IdType="pmc">PMC9095918</ArticleId><ArticleId IdType="pubmed">35571194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholley B, Levy B, Fellahi J-L, Longrois D, Amour J, Ouattara A, et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care. 2019;23(1):385&#x2013;385. doi: 10.1186/s13054-019-2674-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2674-4</ArticleId><ArticleId IdType="pmc">PMC6883606</ArticleId><ArticleId IdType="pubmed">31783891</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmakis D, Agostoni P, Baholli L, Bautin A, Comin-Colet J, Crespo-Leiro MG, et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: an expert panel consensus. Int J Cardiol. 2019;297:83&#x2013;90. doi: 10.1016/j.ijcard.2019.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2019.09.005</ArticleId><ArticleId IdType="pubmed">31615650</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Ped Crit Care Med. 2010;11(2):234&#x2013;238. doi: 10.1097/PCC.0b013e3181b806fc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b806fc</ArticleId><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann J, Henrich EC, Strobl H, Prondzinsky R, Weiche S, Thiele H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1(1):CD009669. doi: 10.1002/14651858.CD009669.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009669.pub3</ArticleId><ArticleId IdType="pmc">PMC6491099</ArticleId><ArticleId IdType="pubmed">29376560</ArticleId></ArticleIdList></Reference><Reference><Citation>Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2005;2005(1):CD002230. doi: 10.1002/14651858.CD002230.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002230.pub2</ArticleId><ArticleId IdType="pmc">PMC8407097</ArticleId><ArticleId IdType="pubmed">15674893</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37(2):290&#x2013;301. doi: 10.1007/s00134-010-2073-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-2073-4</ArticleId><ArticleId IdType="pubmed">21086112</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology. 2008;108(6):979&#x2013;987. doi: 10.1097/ALN.0b013e318173026f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e318173026f</ArticleId><ArticleId IdType="pubmed">18497597</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen DV, Hansen MK, Johnsen SP, Hansen M, Hindsholm K, Jakobsen CJ. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology. 2014;120(5):1098&#x2013;1108. doi: 10.1097/ALN.0000000000000224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000000224</ArticleId><ArticleId IdType="pubmed">24614322</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellahi JL, Fischer MO, Daccache G, Gerard JL, Hanouz JL. Positive inotropic agents in myocardial ischemia-reperfusion injury: a benefit/risk analysis. Anesthesiology. 2013;118(6):1460&#x2013;1465. doi: 10.1097/ALN.0b013e31828f4fc3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e31828f4fc3</ArticleId><ArticleId IdType="pubmed">23511607</ArticleId></ArticleIdList></Reference><Reference><Citation>Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196&#x2013;202. doi: 10.1016/S0140-6736(02)09455-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)09455-2</ArticleId><ArticleId IdType="pubmed">12133653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11(3):304&#x2013;311. doi: 10.1093/eurjhf/hfn045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfn045</ArticleId><ArticleId IdType="pmc">PMC2645051</ArticleId><ArticleId IdType="pubmed">19158152</ArticleId></ArticleIdList></Reference><Reference><Citation>Comin-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garcia Pinilla JM, Almenar L, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20(7):1128&#x2013;1136. doi: 10.1002/ejhf.1145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1145</ArticleId><ArticleId IdType="pubmed">29405611</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gonzalez MJ, Aldea Perona A, Lara Padron A, Morales Rull JL, Martinez-Selles M, de Mora MM, et al. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC Heart Fail. 2021;8(6):4820&#x2013;4831. doi: 10.1002/ehf2.13670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13670</ArticleId><ArticleId IdType="pmc">PMC8712777</ArticleId><ArticleId IdType="pubmed">34716753</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis. Int J Cardiol. 2016;202:138&#x2013;143. doi: 10.1016/j.ijcard.2015.08.188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.08.188</ArticleId><ArticleId IdType="pubmed">26386941</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo JC, Zheng WH, Meng C, Zhou H, Xu Y, Tu GW, et al. Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: a meta-analysis. Front Med. 2021;8:741108. doi: 10.3389/fmed.2021.741108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.741108</ArticleId><ArticleId IdType="pmc">PMC8546177</ArticleId><ArticleId IdType="pubmed">34712681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaddoura R, Omar AS, Ibrahim MIM, Alkhulaifi A, Lorusso R, Elsherbini H, et al. The effectiveness of levosimendan on veno-arterial extracorporeal membrane oxygenation management and outcome: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2021;35(8):2483&#x2013;2495. doi: 10.1053/j.jvca.2021.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2021.01.019</ArticleId><ArticleId IdType="pubmed">33583718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellouze O, Faure AS, Radhouani M, Abou-Arab O, Besnier E, Moussa M, et al. Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial. ESC Heart Fail. 2021;8(4):3339&#x2013;3347. doi: 10.1002/ehf2.13427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13427</ArticleId><ArticleId IdType="pmc">PMC8318420</ArticleId><ArticleId IdType="pubmed">34145993</ArticleId></ArticleIdList></Reference><Reference><Citation>Terbeck S, Heinisch PP, Lenz A, Friess JO, Guensch D, Carrel T, et al. Levosimendan and systemic vascular resistance in cardiac surgery patients: a systematic review and meta-analysis. Sci Rep. 2019;9(1):20343. doi: 10.1038/s41598-019-56831-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56831-y</ArticleId><ArticleId IdType="pmc">PMC6937247</ArticleId><ArticleId IdType="pubmed">31889123</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103&#x2013;111. doi: 10.1016/j.jchf.2012.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2012.12.004</ArticleId><ArticleId IdType="pubmed">24621834</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, Li Z, Yat Wong PC. Levosimendan treatment for heart failure: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1415&#x2013;1425. doi: 10.1053/j.jvca.2015.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2015.03.023</ArticleId><ArticleId IdType="pubmed">26275522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40448257</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2253</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC anesthesiology</Title><ISOAbbreviation>BMC Anesthesiol</ISOAbbreviation></Journal><ArticleTitle>Ivabradine use in critical care: a systematic review and metanalysis of cardiogenic and septic shock patients.</ArticleTitle><Pagination><StartPage>276</StartPage><MedlinePgn>276</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">276</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12871-025-03121-y</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In patients with acute illness, compensatory tachycardia initially serves to maintain adequate cardiac output, oxygen delivery and tissue oxygenation but may persist despite appropriate fluid and vasopressor resuscitation or may be secondary to inotropic therapy. Sustained tachycardia is a predictor of adverse outcomes in critical illness. Ivabradine, a highly selective inhibitor of the sinoatrial node's pacemaker current (I<sub>f</sub> or "funny" current), mitigates tachycardia by modulating diastolic depolarization slope without affecting contractility.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To report the existing evidence on the use of ivabradine in critically ill patients and assess its effect on rate control.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search was performed up to May 2024 in the MEDLINE/PubMed&#xae;, Cochrane Controlled Clinical Trial register, EMBASE&#xae; and Scopus&#xae; databases. The search included: P- only original studies conducted in humans admitted to the Intensive Care Unit (ICU); I - when ivabradine administration was tested; C - in presence or absence of a control group; O - for any outcome; S - including case reports, randomized and observational trials, published in English in peer-reviewed journals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After the first screening, 39 studies were assessed for eligibility on a total of 682 records identified. Among those, 29 were excluded; 10 studies (4 randomized controlled trial, 5 case report/series, 1 prospective observational), including a total of 243 patients, were included in the qualitative analysis, 6 studies were included in the quantitative analysis. The use of ivabradine resulted in a pooled mean heart rate reduction of 18.70 [12.70-24.80] bpm (p&#x2009;&lt;&#x2009;0.01) without a significant decrease in cardiac index (p&#x2009;=&#x2009;0.59). A significant reduction of noradrenaline dose was reported in one study (-0.134 mcg/kg/min; 95% CI -0.172 to -0.012; p&#x2009;=&#x2009;0.027). In addition, the combination of dobutamine with ivabradine has been reported to optimize dobutamine inotropic action, while mitigating its positive chronotropic effects, resulting in a more efficient cardiac cycle and improved hemodynamics.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ivabradine may be a useful alternative to beta-blocker in the management of inappropriate sinus tachycardia. Yet, evidence is limited and inconsistent. Larger randomized trials are needed to investigate the potential benefits or hazards of ivabradine use on hemodynamics and long-term outcomes.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calabr&#xf2;</LastName><ForeName>Lorenzo Antonino</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, H&#xf4;pital Erasme, Route de Lennik 808, Brussels, BE, 1070, Belgium. l.calabro@hubruxelles.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasetto</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anesthesia and Intensive Care Unit B, Integrated University Hospital of Verona, Verona, 37134, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Intensive Care Unit, Hospital and University Trust of Verona, P. le A.Stefani, Verona, 37124, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scolletta</LastName><ForeName>Sabino</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anestesia E Rianimazione - Azienda Ospedaliera Universitaria Senese, Siena, 53100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annoni</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, H&#xf4;pital Erasme, Route de Lennik 808, Brussels, BE, 1070, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demailly</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>CHU Rouen: Centre Hospitalier Universitaire de Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halenarova</LastName><ForeName>Katarina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, H&#xf4;pital Erasme, Route de Lennik 808, Brussels, BE, 1070, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donadello</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Anesthesia and Intensive Care Unit B, Integrated University Hospital of Verona, Verona, 37134, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Dentistry, Ginaecology and Paediatrics, University of Verona, Verona, 337129, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taccone</LastName><ForeName>Fabio Silvio</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, H&#xf4;pital Erasme, Route de Lennik 808, Brussels, BE, 1070, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Anesthesiol</MedlineTA><NlmUniqueID>100968535</NlmUniqueID><ISSNLinking>1471-2253</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3H48L0LPZQ</RegistryNumber><NameOfSubstance UI="D000077550">Ivabradine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002317">Cardiovascular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077550" MajorTopicYN="Y">Ivabradine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="Y">Critical Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="Y">Shock, Septic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002317" MajorTopicYN="Y">Cardiovascular Agents</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical studies</Keyword><Keyword MajorTopicYN="N">Critically illness</Keyword><Keyword MajorTopicYN="N">Ivabradine</Keyword><Keyword MajorTopicYN="N">Shock</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>31</Day><Hour>22</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>31</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40448257</ArticleId><ArticleId IdType="pmc">PMC12125779</ArticleId><ArticleId IdType="doi">10.1186/s12871-025-03121-y</ArticleId><ArticleId IdType="pii">10.1186/s12871-025-03121-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369:1726&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24171518</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Trabold F, Sharshar T, et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med. 1999;160:458&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430714</ArticleId></ArticleIdList></Reference><Reference><Citation>Domizi R, Calcinaro S, Harris S, et al. Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation. J Crit Care. 2020;57:185&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171905</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse T, Hossain A, Perkins GD, et al. Landiolol and organ failure in patients with septic shock: the STRESS-L randomized clinical trial. JAMA. 2023;330:1641&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10600724</ArticleId><ArticleId IdType="pubmed">37877587</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1:CD009669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491099</ArticleId><ArticleId IdType="pubmed">29376560</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015;20:249&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">25432872</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">35363499</ArticleId></ArticleIdList></Reference><Reference><Citation>Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of Ivabradine. J Am Coll Cardiol. 2017;70:1777&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">28958335</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardiner SM, Kemp PA, March JE, Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol. 1995;115:579&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1908496</ArticleId><ArticleId IdType="pubmed">7582475</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale D, De Santis V, Guarracino F, Fontana A, Pellegrini F, Tritapepe L. Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol. 2010;99:853&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20821020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Barilla F, Pannarale G, Torromeo C, et al. Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study. Clin Drug Investig. 2016;36:849&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">27312076</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo CNJ, Dammassa V, Klersy C, et al. Heart rate control and haemodynamic improvement with ivabradine in cardiogenic shock patient on mechanical circulatory support. Eur Heart J Acute Cardiovasc Care. 2022;11:916&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">36222185</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta PK, Rewari V, Ramachandran R, et al. Effectiveness of enteral ivabradine for heart rate control in septic shock: a randomised controlled trial. Anaesth Intensive Care. 2021;49:366&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">34407620</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallet R, Ternacle J, Damy T, et al. Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction. Int J Cardiol. 2014;176:450&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25129291</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LS, Squara P, Amour J, et al. Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial. Crit Care. 2018;22:193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097391</ArticleId><ArticleId IdType="pubmed">30115103</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuding S, Schroder J, Presek P, et al. Reducing elevated heart rates in patients with multiple organ dysfunction syndrome with the If (Funny Channel Current) inhibitor Ivabradine. Shock. 2018;49:402&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">28930912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwicker C, Becker M, Lepper W, Koch KC, Westenfeld R. Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine. Cardiology. 2010;116:174&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20628253</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke J, Schmahl D, Lehrke S, et al. Adjuvant use of ivabradine in acute heart failure due to myocarditis. Case Rep Med. 2011;2011:203690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3180827</ArticleId><ArticleId IdType="pubmed">21966292</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis V, Frati G, Greco E, Tritapepe L. Ivabradine: a preliminary observation for a new terapeutic role in patients with multiple organ dysfunction syndrome. Clin Res Cardiol. 2014;103:831&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159564</ArticleId><ArticleId IdType="pubmed">24805930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009;24:293&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">19703817</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreis DT, Singer M. Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med. 2016;42:1387&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">26873833</ArticleId></ArticleIdList></Reference><Reference><Citation>Belletti A, Landoni G, Lomivorotov VV, Oriani A, Ajello S. Adrenergic downregulation in critical care: molecular mechanisms and therapeutic evidence. J Cardiothorac Vasc Anesth. 2020;34:1023&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">31839459</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">24108526</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D, Arias Ortiz J, Levy B. The medical treatment of cardiogenic shock: cardiovascular drugs. Curr Opin Crit Care. 2021;27:426&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">33797431</ArticleId></ArticleIdList></Reference><Reference><Citation>Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">20801500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bin Sumarni MN, Chiew AL, Isbister GK, Wylie CJ, Isoardi KZ. Ivabradine poisoning: a retrospective observational case series. Toxicol Commun. 2025;9:2464274.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40132104</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2048-8734</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>European heart journal. Acute cardiovascular care</Title><ISOAbbreviation>Eur Heart J Acute Cardiovasc Care</ISOAbbreviation></Journal><ArticleTitle>Development and validation of a risk score in acute myocardial infarction-related cardiogenic shock.</ArticleTitle><Pagination><StartPage>327</StartPage><EndPage>341</EndPage><MedlinePgn>327-341</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjacc/zuaf043</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Mortality in patients with acute myocardial infarction-related cardiogenic shock (AMICS) is high, but a widely accepted tool for individual risk assessment is lacking. A reliable prediction model could assist in clinical decision-making, patient selection for clinical trials, and comparison of AMICS populations. Therefore, the aim of this study was to develop and externally validate a prediction model for 30-day mortality in AMICS patients.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">This retrospective cohort study included patients from 2017 to 2021 (development cohort) and 2010-2017 (validation cohort). Patients with AMICS undergoing percutaneous coronary intervention in The Netherlands were identified using the Netherlands Heart Registration. International validation was performed in the Danish Retroshock registry. The main outcome was 30-day mortality. Among 2261 patients, the median age was 67 years [interquartile range (IQR) 58-75], and 1649 (73%) were male. The mortality rate at 30 days was 39% (n = 886). Significant predictors for mortality were: initial lactate, glucose, renal function, haemoglobin, age, blood pressure, heart rate, intubation prior to PCI, intervention in the left main coronary artery, and successful revascularization. The AUC of the initial model was 0.81 (0.79-0.83). The external validation cohort included 1393 patients with 1050 (75%) male and a median age of 67 years (IQR 59-75). The 30-day mortality rate was 49% (n = 680). The model showed good performance on the external validation with an AUC of 0.73 (0.70-0.76).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A prediction model was developed and externally validated using data from two large national registries. The model demonstrated good performance and is suitable for clinical decision-making and quality purposes in AMICS.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Elma J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0003-4851-1320</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Heart Center, Amsterdam University Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunkel</LastName><ForeName>Joakim B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogerd</LastName><ForeName>Margriet</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0002-2554-6352</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Heart Center, Amsterdam University Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Berg</LastName><ForeName>Sanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0008-0029-4391</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Heart Center, Amsterdam University Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmermans</LastName><ForeName>Marijke J C</ForeName><Initials>MJC</Initials><AffiliationInfo><Affiliation>Netherlands Heart Registration, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helgestad</LastName><ForeName>Ole K L</ForeName><Initials>OKL</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravn</LastName><ForeName>Hanne B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Anesthesia, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraaijeveld</LastName><ForeName>Adriaan O</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Utrecht University Medical Center, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otterspoor</LastName><ForeName>Luuk C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-8510-8648</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Catharina Hospital, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sjauw</LastName><ForeName>Krischan D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lip&#x161;ic</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engstr&#xf6;m</LastName><ForeName>Annemarie E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Amsterdam University Medical Centers, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlaar</LastName><ForeName>Alexander P J</ForeName><Initials>APJ</Initials><Identifier Source="ORCID">0000-0002-3453-7186</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care, Amsterdam University Medical Centers, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassager</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Jos&#xe9; P S</ForeName><Initials>JPS</Initials><Identifier Source="ORCID">0000-0002-8969-7929</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Heart Center, Amsterdam University Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Acute Cardiovasc Care</MedlineTA><NlmUniqueID>101591369</NlmUniqueID><ISSNLinking>2048-8726</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Prediction model</Keyword><Keyword MajorTopicYN="N">Risk prediction</Keyword></KeywordList><CoiStatement>Conflict of interest: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare: no support from any organization for the submitted work; O.K.L.H. has received a consultant fee from Abiomed, H.B.R. has received honoraria from Abiomed, A.O.K. declares an institutional research grant from Xenios AG, institutional lecture fees from Novartis and Inari, and travel support from Edwards, E.L. has received an educational institutional grant from Abbott Medical Nederland and a consulting fee from Dekra Certification BV and is a board member of the Interventional Cardiology Working group of the NVVC (Nederlandse Vereniging Voor Cardiologie), J.E.M. has received speakers fees from Abbott Vascular, Orion Corporation, and Boehringer Ingelheim and declares institutional research fees from Abiomed and Roche, J.P.S.H. reports receiving research grants from Health&#x223c;Holland, B. Braun, Infraredx/Nipro, ZonMw, Astra Zeneca, and Abbott Vascular and is a board member of the NVVC; no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>3</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>25</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>25</Day><Hour>15</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40132104</ArticleId><ArticleId IdType="pmc">PMC12365599</ArticleId><ArticleId IdType="doi">10.1093/ehjacc/zuaf043</ArticleId><ArticleId IdType="pii">8093447</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med 1999;131:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391815</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J 2019;40:2671&#x2013;2683.</Citation><ArticleIdList><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference><Reference><Citation>van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017;136:e232&#x2013;e268.</Citation><ArticleIdList><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathod KS, Koganti S, Iqbal MB, Jain AK, Kalra SS, Astroulakis Z, et al. Contemporary trends in cardiogenic shock: incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group. Eur Heart J Acute Cardiovasc Care 2018;7:16&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">29111770</ArticleId></ArticleIdList></Reference><Reference><Citation>Karami M, Peters EJ, Lagrand WK, Houterman S, den Uil CA, Engstr&#xf6;m AE, et al. Outcome and predictors for mortality in patients with cardiogenic shock: a Dutch nationwide registry-based study of 75,407 patients with acute coronary syndrome treated by PCI. J Clin Med 2021;10:2047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8151113</ArticleId><ArticleId IdType="pubmed">34064638</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Schreiber T, Dixon S, Alaswad K, Patel K, Almany S, et al. Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: the Detroit cardiogenic shock initiative. Catheter Cardiovasc Interv 2018;91:454&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">29266676</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund A, Desch S, Thiele H. Challenges in the conduct of randomised controlled trials in cardiogenic shock complicating acute myocardial infarction. J Geriatr Cardiol 2022;19:125&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8915423</ArticleId><ArticleId IdType="pubmed">35317398</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleeper LA, Reynolds HR, White HD, Webb JG, Dzav&#xed;k V, Hochman JS. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry. Am Heart J 2010;160:443&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229030</ArticleId><ArticleId IdType="pubmed">20826251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Burrell A, Roberts L, Bailey M, Sheldrake J, Rycus PT, et al. Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J 2015;36:2246&#x2013;2256.</Citation><ArticleIdList><ArticleId IdType="pubmed">26033984</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf6;ss J, K&#xf6;ster J, Fuernau G, Eitel I, de Waha S, Ouarrak T, et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 2017;69:1913&#x2013;1920.</Citation><ArticleIdList><ArticleId IdType="pubmed">28408020</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller G, Flecher E, Lebreton G, Luyt C-E, Trouillet J-L, Br&#xe9;chot N, et al. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Med 2016;42:370&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">26825953</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein LW, Shaw RE, Krone RJ, Brindis RG, Anderson HV, Block PC, et al. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. Am J Cardiol 2005;96:35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15979429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasdai D, Holmes DR Jr, Califf RM, Thompson TD, Hochman JS, Pfisterer M, et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Am Heart J 1999;138:21&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10385759</ArticleId></ArticleIdList></Reference><Reference><Citation>Harjola VP, Lassus J, Sionis A, K&#xf8;ber L, Tarvasm&#xe4;ki T, Spinar J, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015;17:501&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">25820680</ArticleId></ArticleIdList></Reference><Reference><Citation>Champion S. Toward catecholamine responsiveness in cardiogenic shock: insights from the CRASH score. Int J Artif Organs 2016;39:94&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">26953902</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy O, Rouanet S, Brugier D, Vignolles N, Bertin B, Zeitouni M, et al. Predictive value of the residual SYNTAX score in patients with cardiogenic shock. J Am Coll Cardiol 2021;77:144&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">33446307</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias FG, Alonso-Fernandez-Gatta M, Dominguez MP, Mart&#xed;nez JM, Veloso PR, Bermejo RMA, et al. Predictive model and risk score for in-hospital mortality in patients with all-cause cardiogenic shock. Int Heart J 2022;63:1034&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">36372409</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer BN, Jentzer JC, Weimann J, Dabboura S, Yan I, Sundermeyer J, et al. Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause&#x2014;the Cardiogenic Shock Score. Eur J Heart Fail 2022;24:657&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">35119176</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat AG, van Diepen S, Katz JN, Islam A, Tehrani BN, Truesdell AG, et al. A comprehensive appraisal of risk prediction models for cardiogenic shock. Shock 2022;57:617&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">35583910</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters EJ, Berg ST, Bogerd M, Timmermans MJC, Kraaijeveld AO, Bunge JJH, et al. Characteristics, treatment strategies and outcome in cardiogenic shock complicating acute myocardial infarction: a contemporary Dutch cohort. J Clin Med 2023;12:5221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10455258</ArticleId><ArticleId IdType="pubmed">37629263</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmermans MJC, Houterman S, Daeter ED, Danse PW, Li WW, Lipsic E, et al. Using real-world data to monitor and improve quality of care in coronary artery disease: results from The Netherlands Heart Registration. Neth Heart J 2022;30:546&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988537</ArticleId><ArticleId IdType="pubmed">35389133</ArticleId></ArticleIdList></Reference><Reference><Citation>Helgestad OKL, Josiassen J, Hassager C, Jensen LO, Holmvang L, S&#xf8;rensen A, et al. Temporal trends in incidence and patient characteristics in cardiogenic shock following acute myocardial infarction from 2010 to 2017: a Danish cohort study. Eur J Heart Fail 2019;21:1370&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pubmed">31339222</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster NA, Rijnhart JJM, Twisk JWR, Heymans MW. Modeling non-linear relationships in epidemiological data: the application and interpretation of spline models. Front Epidemiol 2022;2:975380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10910897</ArticleId><ArticleId IdType="pubmed">38455295</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer International Publishing AG; 2015.</Citation></Reference><Reference><Citation>Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009;9:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727536</ArticleId><ArticleId IdType="pubmed">19638200</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, Snell KIE, Ensor J, Burke DL, Harrell FE, Moons KG, et al. Minimum sample size for developing a multivariable prediction model: part II&#x2014;binary and time-to-event outcomes. Stat Med 2019;38:1276&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6519266</ArticleId><ArticleId IdType="pubmed">30357870</ArticleId></ArticleIdList></Reference><Reference><Citation>Alviar CL, Li BK, Keller NM, Bohula-May E, Barnett C, Berg DD, et al. Prognostic performance of the IABP-SHOCK II Risk Score among cardiogenic shock subtypes in the critical care cardiology trials network registry. Am Heart J 2024;270:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11032171</ArticleId><ArticleId IdType="pubmed">38190931</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer JC, van Diepen S, Barsness GW, Henry TD, Menon V, Rihal CS, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol 2019;74:2117&#x2013;2128.</Citation><ArticleIdList><ArticleId IdType="pubmed">31548097</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 2019;94:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidu SS, Baran DA, Jentzer JC, Hollenberg SM, van Diepen S, Basir MB, et al. SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies: this statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. J Am Coll Cardiol 2022;79:933&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">35115207</ArticleId></ArticleIdList></Reference><Reference><Citation>Helgestad OKL, Povlsen AL, Josiassen J, M&#xf6;ller S, Hassager C, Jensen LO, et al. Data-driven point-of-care risk model in patients with acute myocardial infarction and cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2021;10:668&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">34151353</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataja A, Tarvasm&#xe4;ki T, Lassus J, Cardoso J, Mebazaa A, K&#xf8;ber L, et al. The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock&#x2014;results from the CardShock Study. Int J Cardiol 2017;226:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">27788389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Ferrer JJ, Garcia-Rubira JC, Balcones DV, Gil IN, Barrio RC, Fuentes-Ferrer M, et al. Influence of hemoglobin level on in-hospital prognosis in patients with acute coronary syndrome. Rev Esp Cardiol 2008;61:945&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">18775236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostenfeld S, Lindholm MG, Kjaergaard J, Bro-Jeppesen J, M&#xf8;ller JE, Wanscher M, et al. Prognostic implication of out-of-hospital cardiac arrest in patients with cardiogenic shock and acute myocardial infarction. Resuscitation 2015;87:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">25475249</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C, Chen F, Liu L, Ge Z, Feng C, Chen Y. Impact of diabetes on outcomes of cardiogenic shock: a systematic review and meta-analysis. Diab Vasc Dis Res 2022;19:14791641221132242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9580099</ArticleId><ArticleId IdType="pubmed">36250870</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49:907&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">8699212</ArticleId></ArticleIdList></Reference><Reference><Citation>Naggara O, Raymond J, Guilbert F, Roy D, Weill A, Altman DG. Analysis by categorizing or dichotomizing continuous variables is inadvisable: an example from the natural history of unruptured aneurysms. Am J Neuroradiol 2011;32:437&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013096</ArticleId><ArticleId IdType="pubmed">21330400</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittle R, Royle KL, Jordan KP, Riley RD, Mallen CD, Peat G. Prognosis research ideally should measure time-varying predictors at their intended moment of use. Diagn Progn Res 2017;1:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457137</ArticleId><ArticleId IdType="pubmed">31093533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer JC, Wiley BM, Anavekar NS, Pislaru SV, Mankad SV, Bennett CE, et al. Noninvasive hemodynamic assessment of shock severity and mortality risk prediction in the cardiac intensive care unit. JACC Cardiovasc Imaging 2021;14:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">32828777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33583718</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8422</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>J Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>The Effectiveness of Levosimendan on Veno-Arterial Extracorporeal Membrane Oxygenation Management and Outcome: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>2483</StartPage><EndPage>2495</EndPage><MedlinePgn>2483-2495</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.jvca.2021.01.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-0770(21)00054-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides a temporary support system for patients with cardiogenic shock refractory to conventional medical therapies. It has been reported that levosimendan may facilitate VA-ECMO weaning and improve survival. The primary objective of this review was to examine the effect of levosimendan use on VA-ECMO weaning and mortality in critically ill patients on VA-ECMO.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">MEDLINE, EMBASE, and CENTRAL were searched. A pair of reviewers identified eligible clinical trials. Two reviewers extracted data and independently assessed the risk of bias. A random-effect model was used to combine data. The primary outcome was the success of weaning from VA-ECMO.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Seven studies of observational design, including a total of 630 patients, were selected in the final analysis. The sample size ranged from ten-to-240 patients, with a mean age between 53 and 65 years, and more than half of them underwent cardiac surgeries. The VA-ECMO durations varied between four and 11.6 days. Overall, levosimendan use was significantly associated with successful weaning compared with control (odds ratio [OR] 2.89, 95% CI, 1.53-5.46; p<sub>overall effect</sub>&#x2009;=&#x2009;0.001); I<sup>2</sup>&#x202f;=&#x202f;49%). For survival, six studies (n&#x202f;=&#x202f;617) were included in the meta-analysis involving 326 patients in the levosimendan group and 291 in the comparator group. Pooled results showed a significantly higher survival rate in the levosimendan group (OR&#x2009;0.46, 95% CI, 0.30-0.71; p<sub>overall effect</sub>&#x2009;=&#x2009;0.0004; I<sup>2</sup>&#x202f;=&#x202f;20%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Levosimendan therapy was significantly associated with successful weaning and survival benefit in patients with cardiogenic or postcardiotomy shock needing VA-ECMO support for severe cardiocirculatory compromise. To date, there is limited literature and absence of evidence from randomized trials addressing the use of levosimendan in VA-ECMO weaning. This study may be considered a hypothesis-generating research for randomized controlled trials to confirm its findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaddoura</LastName><ForeName>Rasha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. Electronic address: rkaddoura@hamad.qa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omar</LastName><ForeName>Amr S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery/Cardiac Anesthesia &amp; ICU, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Mohamed Izham Mohamed</ForeName><Initials>MIM</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alkhulaifi</LastName><ForeName>Abdulaziz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery/Cardiac Anesthesia &amp; ICU, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Maastricht University Medical Centre (MUMC) Cardiovascular Research Institute, Maastricht (CARIM) Maastricht University, Roterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elsherbini</LastName><ForeName>Hagar</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiology, Erasmus University Medical Center, Roterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soliman</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>National University of Ireland Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caliskan</LastName><ForeName>Kadir</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiology, Erasmus University Medical Center, Roterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9110208</NlmUniqueID><ISSNLinking>1053-0770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Cardiothorac Vasc Anesth. 2021 Aug;35(8):2496-2498. doi: 10.1053/j.jvca.2021.03.052.</RefSource><PMID Version="1">34006467</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="Y">Shock</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECLS</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal life support</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">levosimendan</Keyword><Keyword MajorTopicYN="N">weaning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>15</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33583718</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2021.01.019</ArticleId><ArticleId IdType="pii">S1053-0770(21)00054-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34301817</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-3624</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Open heart</Title><ISOAbbreviation>Open Heart</ISOAbbreviation></Journal><ArticleTitle>Mechanical circulatory support in CS: device or patient?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e001733</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/openhrt-2021-001733</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morici</LastName><ForeName>Nuccia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>SS UTIC/ SC Cardiologia 1-Emodinamica, ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondazione IRCCS Policlinico S. Matteo, Department of Anesthesia and Intensive Care Unit, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavazzi</LastName><ForeName>Guido</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9560-5138</Identifier><AffiliationInfo><Affiliation>Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy guido.tavazzi@unipv.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Open Heart</MedlineTA><NlmUniqueID>101631219</NlmUniqueID><ISSNLinking>2053-3624</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Open Heart. 2021 Jun;8(1):e001662. doi: 10.1136/openhrt-2021-001662.</RefSource><PMID Version="1">34127531</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathies</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>24</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34301817</ArticleId><ArticleId IdType="pmc">PMC8728356</ArticleId><ArticleId IdType="doi">10.1136/openhrt-2021-001733</ArticleId><ArticleId IdType="pii">openhrt-2021-001733</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lawler PR, Mehra MR. Advancing from a "hemodynamic model" to a "mechanistic disease-modifying model" of cardiogenic shock. J Heart Lung Transplant 2018;37:1285&#x2013;8. 10.1016/j.healun.2018.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2018.07.009</ArticleId><ArticleId IdType="pubmed">30197209</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Kapur NK, Patel K, et al. . Improved outcomes associated with the use of shock protocols: updates from the National cardiogenic shock initiative. Catheter Cardiovasc Interv 2019;93:1173&#x2013;83. 10.1002/ccd.28307</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28307</ArticleId><ArticleId IdType="pubmed">31025538</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Ibrahim K, Loehn T, et al. . Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation 2019;139:1249&#x2013;58. 10.1161/CIRCULATIONAHA.118.036614</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.036614</ArticleId><ArticleId IdType="pubmed">30586755</ArticleId></ArticleIdList></Reference><Reference><Citation>Alushi B, Douedari A, Froehlig G, et al. . Impella versus IABP in acute myocardial infarction complicated by cardiogenic shock. Open Heart 2019;6:e000987. 10.1136/openhrt-2018-000987</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2018-000987</ArticleId><ArticleId IdType="pmc">PMC6546200</ArticleId><ArticleId IdType="pubmed">31218000</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo JJ, Aleksova N, Pitcher I, et al. . Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol 2019;73:654&#x2013;62. 10.1016/j.jacc.2018.10.085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.10.085</ArticleId><ArticleId IdType="pubmed">30765031</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Becher PM, Bernhardt A, et al. . Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with Venoarterial extracorporeal membrane oxygenation: results from an international, multicenter cohort study. Circulation 2020;142:2095&#x2013;106. 10.1161/CIRCULATIONAHA.120.048792</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048792</ArticleId><ArticleId IdType="pmc">PMC7688081</ArticleId><ArticleId IdType="pubmed">33032450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah W, Zghouzi M, Mukhtar M, et al. . Comparative safety of percutaneous ventricular assist device and intra-aortic balloon pump in acute myocardial infarction-induced cardiogenic shock. Open Heart 2021;8:e001662. 10.1136/openhrt-2021-001662</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2021-001662</ArticleId><ArticleId IdType="pmc">PMC8204163</ArticleId><ArticleId IdType="pubmed">34127531</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehrani BN, Truesdell AG, Psotka MA, et al. . A standardized and comprehensive approach to the management of cardiogenic shock. JACC Heart Fail 2020;8:879&#x2013;91. 10.1016/j.jchf.2020.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2020.09.005</ArticleId><ArticleId IdType="pmc">PMC8167900</ArticleId><ArticleId IdType="pubmed">33121700</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg DD, Bohula EA, van Diepen S, et al. . Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes 2019;12:e005618. 10.1161/CIRCOUTCOMES.119.005618</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.119.005618</ArticleId><ArticleId IdType="pmc">PMC11032172</ArticleId><ArticleId IdType="pubmed">30879324</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M, Patnaik S, Patel B, et al. . Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. Clin Res Cardiol 2018;107:287&#x2013;303. 10.1007/s00392-017-1182-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-017-1182-2</ArticleId><ArticleId IdType="pubmed">29134345</ArticleId></ArticleIdList></Reference><Reference><Citation>van Diepen S, Katz JN, Albert NM, et al. . Contemporary management of cardiogenic shock: a scientific statement from the American heart association. Circulation 2017;136:e232&#x2013;68. 10.1161/CIR.0000000000000525</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000525</ArticleId><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Garan AR, Kanwar M, Thayer KL, et al. . Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in-hospital mortality. JACC Heart Fail 2020;8:903&#x2013;13. 10.1016/j.jchf.2020.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2020.08.012</ArticleId><ArticleId IdType="pubmed">33121702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35460230</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2058-1742</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>European heart journal. Quality of care &amp; clinical outcomes</Title><ISOAbbreviation>Eur Heart J Qual Care Clin Outcomes</ISOAbbreviation></Journal><ArticleTitle>Transradial versus transfemoral approach for percutaneous coronary intervention in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>640</StartPage><EndPage>650</EndPage><MedlinePgn>640-650</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjqcco/qcac018</ELocationID><Abstract><AbstractText Label="BACKGROUND">In ST-elevation myocardial infarction (STEMI), transradial access (TRA) for percutaneous coronary intervention (PCI) is associated with less bleeding and mortality than transfemoral access (TFA). However, patients in cardiogenic shock (CS) are more often treated via TFA. The aim of this meta-analysis is to compare the safety and efficacy of TRA vs. TFA in CS.</AbstractText><AbstractText Label="METHODS">Systematic review was performed querying PubMed, Google Scholar, Cochrane, and clinicaltrials.gov for studies comparing TRA to TFA in PCI for CS. Outcomes included in-hospital, 30-day and&#xa0;&#x2265;1-year mortality, major and access site bleeding, TIMI3 (thrombolytics in myocardial infarction) flow, procedural success, fluoroscopy time, and contrast volume. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using random effects models.</AbstractText><AbstractText Label="RESULTS">Six prospective and eight retrospective studies (TRA, n&#xa0;=&#xa0;8032; TFA, n&#xa0;=&#xa0;23&#xa0;031) were identified. TRA was associated with lower in-hospital (RR 0.59, 95% CI 0.52-0.66, P&#xa0;&amp;lt;&#xa0;0.0001), 30-day and&#xa0;&#x2265;1-year mortality, as well as less in-hospital major (RR 0.41, 0.31-0.56, P&#xa0;&amp;lt;&#xa0;0.001) and access site bleeding (RR 0.42, 0.23-0.77, P&#xa0;=&#xa0;0.005). There were no statistically significant differences in post-PCI coronary flow grade, procedural success, fluoroscopy time, and contrast volume between TRA vs. TFA.</AbstractText><AbstractText Label="CONCLUSIONS">In PCI for STEMI with CS, TRA is associated with significantly lower mortality and bleeding complications than TFA while achieving similar TIMI3 flow and procedural success rates.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahsan</LastName><ForeName>Muhammad Junaid</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-2472-9379</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Iowa Heart Center, Des Moines, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Soban</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, East Carolina University, Greenville, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latif</LastName><ForeName>Azka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Creighton University, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lateef</LastName><ForeName>Noman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahsan</LastName><ForeName>Mohammad Zoraiz</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Fatima Memorial Hospital, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abusnina</LastName><ForeName>Waiel</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Creighton University, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathan</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altin</LastName><ForeName>S Elissa</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolte</LastName><ForeName>Dhaval S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messenger</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Cardiology Medicine, University of Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tannenbaum</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Iowa Heart Center, Des Moines, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldsweig</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-2952-7837</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Qual Care Clin Outcomes</MedlineTA><NlmUniqueID>101677796</NlmUniqueID><ISSNLinking>2058-1742</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Heart J Qual Care Clin Outcomes. 2022 Sep 05;8(6):600-601. doi: 10.1093/ehjqcco/qcac034.</RefSource><PMID Version="1">35700130</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002406" MajorTopicYN="Y">Catheterization, Peripheral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005263" MajorTopicYN="N">Femoral Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017534" MajorTopicYN="N">Radial Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35460230</ArticleId><ArticleId IdType="pmc">PMC9442849</ArticleId><ArticleId IdType="doi">10.1093/ehjqcco/qcac018</ArticleId><ArticleId IdType="pii">6572835</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JPet al. . Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2020;323:734&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042879</ArticleId><ArticleId IdType="pubmed">32040163</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009;119:1211&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730832</ArticleId><ArticleId IdType="pubmed">19237658</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BRet al. ; HORIZONS-AMI Trial Investigators . Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">19717185</ArticleId></ArticleIdList></Reference><Reference><Citation>Romagnoli E, Biondi-Zoccai, G, Sciahbasi, A, Politi, L, Rigattieri, S, Pendenza, Get al. . Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol 2012;60:2481&#x2013;2489.</Citation><ArticleIdList><ArticleId IdType="pubmed">22858390</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobcsuk A, K&#xf3;nyi A, Aradi D, Horv&#xe1;th IG, Ungi I, Louvard Yet al. . Transradial versus transfemoral percutaneous coronary intervention in acute myocardial infarction Systematic overview and meta-analysis. Am Heart J 2009;158:814&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">19853703</ArticleId></ArticleIdList></Reference><Reference><Citation>Pancholy SB, Palamaner Subash Shantha G, Romagnoli E, Kedev S, Bernat I, Rao SVet al. . Impact of access site choice on outcomes of patients with cardiogenic shock undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Am Heart J 2015;170:353&#x2013;361.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26299234</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">19631508</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">10877304</ArticleId></ArticleIdList></Reference><Reference><Citation>Romagnoli E, De Vita M, Burzotta F, Cortese B, Biondi-Zoccai G, Summaria Fet al. . Radial versus femoral approach comparison in percutaneous coronary intervention with intraaortic balloon pump support: the Radial Pump Up registry. Am Heart J 2013;166:1019&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pubmed">24268216</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernat I, Abdelaal E, Plourde G, Bataille Y, Cech J, Pesek Jet al. . Early and late outcomes after primary percutaneous coronary intervention by radial or femoral approach in patients presenting in acute ST-elevation myocardial infarction and cardiogenic shock. Am Heart J 2013;165:338&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">23453102</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii T, Masuda N, Ijichi T, Kamiyama Y, Tanaka S, Nakazawa Get al. . Transradial intervention for patients with ST elevation myocardial infarction with or without cardiogenic shock. Catheter Cardiovasc Interv 2014;83:E1&#x2013;E7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23441063</ArticleId></ArticleIdList></Reference><Reference><Citation>Iga A, Wagatsuma K, Yamazaki J, Ikeda T. Transradial versus transfemoral coronary intervention for acute myocardial infarction complicated by cardiogenic shock: is transradial coronary intervention suitable for emergency PCI in high-risk acute myocardial infarction? J Invasive Cardiol 2014;26:196&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">24791717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedev S, Kalpak O, Dharma S, Antov S, Kostov J, Pejkov Het al. . Complete transitioning to the radial approach for primary percutaneous coronary intervention: a real-world single-center registry of 1808 consecutive patients with acute ST-elevation myocardial infarction. J Invasive Cardiol 2014;26:475&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">25198492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamas MA, Anderson SG, Ratib K, Routledge H, Neyses L, Fraser DGet al. ; British Cardiovascular Intervention Society; National Institute for Cardiovascular Outcomes Research . Arterial access site utilization in cardiogenic shock in the United Kingdom: is radial access feasible? Am Heart J 2014;167:900&#x2013;908.e1e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">24890541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Leor O, Fernandez-Nofrerias E, Carrillo X, Mauri J, Oliete C, Rivas Mdel Cet al. . Transradial percutaneous coronary intervention in cardiogenic shock: a single-center experience. Am Heart J 2013;165:280&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">23453093</ArticleId></ArticleIdList></Reference><Reference><Citation>Roule V, Lemaitre A, Sabatier R, Lognon&#xe9; T, Dahdouh Z, Berger Let al. . Transradial versus transfemoral approach for percutaneous coronary intervention in cardiogenic shock: a radial-first centre experience and meta-analysis of published studies. Arch Cardiovasc Dis 2015;108:563&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">26365478</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedeney P, Thiele H, Kerneis M, Barth&#xe9;l&#xe9;my O, Baumann S, Sandri Met al. ; CULPRIT-SHOCK Investigators . Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: subanalysis from the CULPRIT-SHOCK trial. Am Heart J 2020;225:60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">32497906</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehrani BN, Damluji AA, Sherwood MW, Rosner C, Truesdell AG, Epps KCet al. . Transradial access in acute myocardial infarction complicated by cardiogenic shock: stratified analysis by shock severity. Catheter Cardiovasc Interv 2021;97:1354&#x2013;1366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8165635</ArticleId><ArticleId IdType="pubmed">32744434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo S, Yamaji K, Inohara T, Kohsaka S, Tanaka H, Ishii Het al. . In-hospital outcomes after percutaneous coronary intervention for acute coronary syndrome with cardiogenic shock [from a Japanese nationwide registry (J-PCI Registry)]. Am J Cardiol 2019;123:1595&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">30846213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahn R, Hochadel M, Schumacher B, Pauschinger M, Stellbrink C, Schaechinger Vet al. . Cardiogenic shock and radial access in patients with an acute ST elevation myocardial infarction. Eur Heart J 2020;41.</Citation></Reference><Reference><Citation>Tokarek T, Dziewierz A, Plens K, Rakowski T, Dudek D, Siudak Z. Radial approach reduces mortality in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Pol Arch Intern Med 2021;131:421&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">33739779</ArticleId></ArticleIdList></Reference><Reference><Citation>Karrowni W, Vyas A, Giacomino B, Schweizer M, Blevins A, Girotra Set al. . Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2013;6:814&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">23968700</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Singh M, Grewal N, Khosla S. Transradial vs transfemoral percutaneous coronary intervention in ST-segment elevation myocardial infarction: a systemic review and meta-analysis. Can J Cardiol 2016;32:777&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">27233893</ArticleId></ArticleIdList></Reference><Reference><Citation>Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenb&#xfc;hler M, Tebaldi Met al. ; MATRIX Investigators . Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet 2018;392:835&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">30153988</ArticleId></ArticleIdList></Reference><Reference><Citation>Le May M, Wells G, So D, Chong AY, Dick A, Froeschl Met al. . Safety and efficacy of femoral access vs radial access in ST-segment elevation myocardial infarction: The SAFARI-STEMI randomized clinical trial. JAMA Cardiol 2020;5:126&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990931</ArticleId><ArticleId IdType="pubmed">31895439</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle JA, Kaltenbach LA, Bradley SM, Yeh RW, Rao SV, Gurm HSet al. . Variation in the adoption of transradial access for ST-segment elevation myocardial infarction: insights from the NCDR CathPCI registry. JACC Cardiovasc Interv 2017;10:2242&#x2013;2254.</Citation><ArticleIdList><ArticleId IdType="pubmed">29102582</ArticleId></ArticleIdList></Reference><Reference><Citation>Baklanov DV, Kaltenbach LA, Marso SP, Subherwal SS, Feldman DN, Garratt KNet al. . The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). J Am Coll Cardiol 2013;61:420&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883049</ArticleId><ArticleId IdType="pubmed">23265340</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira K, Honda S, Takegami M, Kojima S, Asaumi Y, Suzuki Met al. . Impact of bleeding on mortality in patients with acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2021;10:388&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">34037718</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeger RV, Assmann SF, Yehudai L, Ramanathan K, Farkouh ME, Hochman JS. Causes of death and re-hospitalization in cardiogenic shock. Acute Card Care 2007;9:25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17453536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenfeld MS, Kassas I, Shah B. Transradial artery access in percutaneous coronary intervention for ST-segment elevation myocardial infarction and cardiogenic shock. Curr Treat Options Cardiovasc Med 2018;20:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8476228</ArticleId><ArticleId IdType="pubmed">29478085</ArticleId></ArticleIdList></Reference><Reference><Citation>Seto AH, Roberts JS, Abu-Fadel MS, Czak SJ, Latif F, Jain SPet al. . Real-time ultrasound guidance facilitates transradial access: RAUST (Radial Artery Access with Ultrasound Trial). JACC Cardiovasc Interv 2015;8:283&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">25596790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirker A, Kwok CS, Kotronias R, Bagur R, Bertrand O, Butler Ret al. . Influence of access site choice for cardiac catheterization on risk of adverse neurological events: a systematic review and meta-analysis. Am Heart J 2016;181:107&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">27823682</ArticleId></ArticleIdList></Reference><Reference><Citation>Nwaejike N, Son AY, Patel CB, Schroder JN, Milano CA, Daneshmand MA. The axillary intra-aortic balloon pump as a bridge to recovery allows early ambulation in long-term use: case series and literature review. Innovations (Phila) 2017;12:472&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">29232299</ArticleId></ArticleIdList></Reference><Reference><Citation>Estep JD, Cordero-Reyes AM, Bhimaraj A, Trachtenberg B, Khalil N, Loebe Met al. . Percutaneous placement of an intra-aortic balloon pump in the left axillary/subclavian position provides safe, ambulatory long-term support as bridge to heart transplantation. JACC Heart Fail 2013;1:382&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">24621970</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Singh M, Grewal N, Khosla S. The fluoroscopy time, door to balloon time, contrast volume use and prevalence of vascular access site failure with transradial versus transfemoral approach in ST segment elevation myocardial infarction: a systematic review &amp; meta-analysis. Cardiovasc Revasc Med 2015;16:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">26563537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciahbasi A, Romagnoli E, Burzotta F, Trani C, Sarandrea A, Summaria Fet al. . Transradial approach (left vs right) and procedural times during percutaneous coronary procedures: TALENT study. Am Heart J 2011;161:172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">21167351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YH, Lee Y, Shin J, Yoon J, Lee SH, Rha SWet al. . Comparisons of clinical and procedural outcomes between transradial and transfemoral approaches in percutaneous coronary intervention (from the Korean Transradial Intervention Prospective Registry). Am J Cardiol 2016;117:1272&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">26899492</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper CJ, El-Shiekh RA, Cohen DJ, Blaesing L, Burket MW, Basu Aet al. . Effect of transradial access on quality of life and cost of cardiac catheterization: a randomized comparison. Am Heart J 1999;138:430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">10467191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell MD, Hong JA, Lee BY, Umscheid CA, Bartsch SM, Don CW. Systematic review and cost&#x2013;benefit analysis of radial artery access for coronary angiography and intervention. Circ Cardiovasc Qual Outcomes 2012;5:454&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3430729</ArticleId><ArticleId IdType="pubmed">22740010</ArticleId></ArticleIdList></Reference><Reference><Citation>Safley DM, Amin AP, House JA, Baklanov D, Mills R, Giersiefen Het al. . Comparison of costs between transradial and transfemoral percutaneous coronary intervention: a cohort analysis from the Premier research database. Am Heart J 2013;165:303&#x2013;309e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23453097</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulme W, Sperrin M, Rushton H, Ludman PF, De Belder M, Curzen Net al. . Is there a relationship of operator and center volume with access site-related outcomes? An analysis from the British Cardiovascular Intervention Society. Circ Cardiovasc Interv 2016;9:e003333.</Citation><ArticleIdList><ArticleId IdType="pubmed">27162213</ArticleId></ArticleIdList></Reference><Reference><Citation>Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti Fet al. ; ESC Scientific Document Group . [2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. G Ital Cardiol (Rome) 2016;17:831&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">27869901</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SV, Tremmel JA, Gilchrist IC, Shah PB, Gulati R, Shroff ARet al. ; Society for Cardiovascular Angiography and Intervention's Transradial Working Group . Best practices for transradial angiography and intervention: a consensus statement from the Society for Cardiovascular Angiography and Intervention's Transradial Working Group. Catheter Cardiovasc Interv 2014;83:228&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">24123781</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TDet al. . SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 2019;94:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Kakar R, Overgaard CB, Comparison of radial to femoral PCI in acute myocardial infarction and cardiogenic shock: a systematic review. J Thromb Thrombolysis 2015;40:108&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">25183512</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio-Pertuz G, Mekraksakit P, Ansari MM. Meta-analysis comparing vascular access site on mortality in patients undergoing primary percutaneous coronary intervention with ST-elevation myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2022;168:173&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">35090699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37064794</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1735-1995</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences</Title><ISOAbbreviation>J Res Med Sci</ISOAbbreviation></Journal><ArticleTitle>Prevalence and associated factors of mortality after percutaneous coronary intervention for adult patients with ST-elevation myocardial infarction: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>17</StartPage><MedlinePgn>17</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4103/jrms.jrms_781_21</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">There is a paucity of systematic reviews on the associated factors of mortality among ST-elevation myocardial infarction (STEMI) patients after percutaneous coronary intervention (PCI). This meta-analysis was designed to synthesize available evidence on the prevalence and associated factors of mortality after PCI for adult patients with STEMI.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">Databases including the Cochrane Library, PubMed, Web of Science, Embase, Ovid, Scopus, ProQuest, MEDLINE, and CINAHL Complete were searched systematically to identify relevant articles published from January 2008 to March 2020 on factors affecting mortality after PCI in STEMI patients. Meta-analysis was conducted using Stata 12.0 software package.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our search yielded 91 cohort studies involving a total of 199, 339 participants. The pooled mortality rate for STEMI patients after PCI was 10%. After controlling for grouping criteria or follow-up time, the following 17 risk factors were significantly associated with mortality for STEMI patients after PCI: advanced age (odds ratio [OR] = 3.89), female (OR = 2.01), out-of-hospital cardiac arrest (OR = 5.55), cardiogenic shock (OR = 4.83), renal dysfunction (OR = 3.50), admission anemia (OR = 3.28), hyperuricemia (OR = 2.71), elevated blood glucose level (OR = 2.00), diabetes mellitus (OR = 1.8), chronic total occlusion (OR = 2.56), Q wave (OR = 2.18), without prodromal angina (OR = 2.12), delay in door-to-balloon time (OR = 1.72), delay in symptom onset-to-balloon time (OR = 1.43), anterior infarction (OR = 1.66), ST-segment resolution (OR = 1.40), and delay in symptom onset-to-door time (OR = 1.29).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The pooled prevalence of mortality after PCI for STEMI patients was 10%, and 17 risk factors were significantly associated with mortality for STEMI patients after PCI.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Journal of Research in Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Fanghong</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TheFirst School of Clinical Medicine, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Yayan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Sijun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of New Technology Development, SceneRay, Suzhou, 215000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Mengqi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yutan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanru</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Wenli</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yuxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TheFirst School of Clinical Medicine, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, Gansu Provincial Hospital, Lanzhou, Gansu Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Res Med Sci</MedlineTA><NlmUniqueID>101235599</NlmUniqueID><ISSNLinking>1735-1995</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">ST-elevation myocardial infarction</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>3</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37064794</ArticleId><ArticleId IdType="pmc">PMC10098139</ArticleId><ArticleId IdType="doi">10.4103/jrms.jrms_781_21</ArticleId><ArticleId IdType="pii">JRMS-28-17</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li J, Li X, Wang Q, Hu S, Wang Y, Masoudi FA, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-retrospective acute myocardial infarction study): A retrospective analysis of hospital data. Lancet. 2015;385:441&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4415374</ArticleId><ArticleId IdType="pubmed">24969506</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanik VO, Cinar T, Arugaslan E, Karabag Y, Hayiroglu MI, Cagdas M, et al. The predictive value of PRECISE-DAPT score for in-hospital mortality in patients with st-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2019;70:440&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30322265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341:1413&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10547403</ArticleId></ArticleIdList></Reference><Reference><Citation>Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: Description of the current situation in 30 countries. Eur Heart J. 2010;31:943&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854523</ArticleId><ArticleId IdType="pubmed">19933242</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med. 2011;124:40&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011975</ArticleId><ArticleId IdType="pubmed">21187184</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernberg T, Johanson P, Held C, Svennblad B, Lindb&#xe4;ck J, Wallentin L, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA. 2011;305:1677&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">21521849</ArticleId></ArticleIdList></Reference><Reference><Citation>Casella G, Ottani F, Ortolani P, Guastaroba P, Santarelli A, Balducelli M, et al. Off-hour primary percutaneous coronary angioplasty does not affect outcome of patients with ST-segment elevation acute myocardial infarction treated within a regional network for reperfusion: The REAL (registro regionale angioplastiche dell&#x2019;emilia-romagna) registry. JACC Cardiovasc Interv. 2011;4:270&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21435603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Jiang DM, Sun YJ, Ren LN, Zhang ZH, Gao Y, et al. The role of gender difference on the prognosis of ST-segment elevation myocardial infarction (STEMI) in patients treated with primary percutaneous coronary intervention. Zhonghua Liu Xing Bing Xue Za Zhi. 2012;33:92&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22575120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Zhao W, Zhang Z, Qin L, Zhang W, Zheng Y. Clinical characteristics and outcomes in young patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Am J Med Sci. 2018;355:544&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">29891037</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamfiloff K, Vassilev D, Staneva M, Vladimirova L, Stoykova J. Influence of gender on mortality in patients with st-elevation acute myocardial infarction treated with primary percutaneous coronary intervention &#x2013; Single high volume centre experience. C R Acad Bulg Sci. 2015;68:795&#x2013;800.</Citation></Reference><Reference><Citation>Ekmekci A, Uluganyan M, Tufan F, Uyarel H, Karaca G, Kul S, et al. Impact of admission blood glucose levels on prognosis of elderly patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention. J Geriatr Cardiol. 2013;10:310&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888911</ArticleId><ArticleId IdType="pubmed">24454322</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen FC, Lin YR, Kung CT, Cheng CI, Li CJ. The association between door-to-balloon time of less than 60 minutes and prognosis of patients developing ST segment elevation myocardial infarction and undergoing primary percutaneous coronary intervention. Biomed Res Int. 2017;2017:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5394347</ArticleId><ArticleId IdType="pubmed">28473978</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen F, Butrymovich V, Kelb&#xe6;k H, Wachtell K, Helqvist S, Kastrup J, et al. Short and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol. 2014;64:2101&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25457398</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair NS, Lewis LE, Lakiang T, Godinho M, Murthy S, Venkatesh BT. Factors associated with mortality due to neonatal pneumonia in India: A protocol for systematic review and planned meta-analysis. BMJ Open. 2017;7:e017616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589018</ArticleId><ArticleId IdType="pubmed">28882924</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting.Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan F, Liu H, Jiang W. Prevalence and associated factors of mortality after percutaneous coronary intervention for adult patients with ST elevation myocardial infarction: A systematic review and meta-analysis protocol. Medicine (Baltimore) 2019;98:e16226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6617472</ArticleId><ArticleId IdType="pubmed">31261578</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaszuk-Kazberuk A, Ko&#x17c;uch M, Ma&#x142;yszko J, Bach&#xf3;rzewska-Gajewska H, Kosacka U, Dobrzycki S, et al. Do overweight patients have a better five years prognosis after an acute myocardial infarction treated with coronary intervention? Kardiol Pol. 2012;70:686&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">22825942</ArticleId></ArticleIdList></Reference><Reference><Citation>Her AY, Shin ES, Kim YH, Garg S, Jeong MH. The contribution of gender and age on early and late mortality following ST-segment elevation myocardial infarction: Results from the Korean acute myocardial infarction national registry with registries. J Geriatr Cardiol. 2018;15:205&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919808</ArticleId><ArticleId IdType="pubmed">29720999</ArticleId></ArticleIdList></Reference><Reference><Citation>Noman A, Balasubramaniam K, Das R, Ang D, Kunadian V, Ivanauskiene T, et al. Admission heart rate predicts mortality following primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational study. Cardiovasc Ther. 2013;31:363&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23517545</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo F, Wang X, Li G, Chen X, Fan J. Primary percutaneous coronary intervention on older patients with acute ST-segment elevation myocardial infarction: Analysis of its risk factors. J Med Coll PLA. 2010;25:29&#x2013;37.</Citation></Reference><Reference><Citation>Zhou Z. Analysis of related factors influencing the short-term prognosis of direct PCI in elderly STEMI patients. Zhejiang Clin Med. 2017;19:1225&#x2013;7.</Citation></Reference><Reference><Citation>Claessen BE, Kikkert WJ, Engstrom AE, Hoebers LP, Damman P, Vis MM, et al. Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: Trends and outcomes. Heart. 2010;96:843&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19966111</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): A randomised non-inferiority trial. Lancet. 2013;381:661&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23374649</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone SG, Serrao GW, Mehran R, Tomey MI, Witzenbichler B, Guagliumi G, et al. Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: The harmonizing outcomes with revascularization and stents in acute myocardial infarction trial. Circ Cardiovasc Interv. 2014;7:543&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">24939928</ArticleId></ArticleIdList></Reference><Reference><Citation>Sederholm Lawesson S, Isaksson RM, Ericsson M, &#xc4;ngerud K, Thyl&#xe9;n I, SymTime Study Group. Gender disparities in first medical contact and delay in ST-elevation myocardial infarction: A prospective multicentre Swedish survey study. BMJ Open. 2018;8:e020211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942442</ArticleId><ArticleId IdType="pubmed">29724738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchberger I, Heier M, Kuch B, Wende R, Meisinger C. Sex differences in patient-reported symptoms associated with myocardial infarction (from the population-based MONICA/KORA myocardial infarction registry) Am J Cardiol. 2011;107:1585&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21420056</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtman JH, Leifheit EC, Safdar B, Bao H, Krumholz HM, Lorenze NP, et al. Sex differences in the presentation and perception of symptoms among young patients with myocardial infarction: Evidence from the VIRGO study (variation in recovery: Role of gender on outcomes of young AMI patients) Circulation. 2018;137:781&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822747</ArticleId><ArticleId IdType="pubmed">29459463</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathi RB, Gurm HS, Chew DP, Gupta R, Bhatt DL, Ellis SG. The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. Am Heart J. 2005;150:1190&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16338257</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007;116:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17606856</ArticleId></ArticleIdList></Reference><Reference><Citation>Stub D, Bernard S, Duffy SJ, Kaye DM. Post cardiac arrest syndrome: A review of therapeutic strategies. Circulation. 2011;123:1428&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">21464058</ArticleId></ArticleIdList></Reference><Reference><Citation>Myat A, Song KJ, Rea T. Out-of-hospital cardiac arrest: Current concepts. Lancet. 2018;391:970&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29536861</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai TH, Chai HT, Sun CK, Leu S, Fan CQ, Zhang ZH, et al. Comparison of 30-day mortality between anterior-wall versus inferior-wall ST-segment elevation myocardial infarction complicated by cardiogenic shock in patients undergoing primary coronary angioplasty. Cardiology. 2010;116:144&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">20606428</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb JG, Lowe AM, Sanborn TA, White HD, Sleeper LA, Carere RG, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol. 2003;42:1380&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14563578</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RH, Ou FS, Peterson ED, Shaw RE, Hillegass WB, Jr, Rumsfeld JS, et al. Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2009;2:56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">19463399</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19608025</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabroe JE, Thayssen P, Antonsen L, Hougaard M, Hansen KN, Jensen LO. Impact of renal insufficiency on mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. BMC Cardiovasc Disord. 2014;14:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922030</ArticleId><ArticleId IdType="pubmed">24506974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra PR, Greenlaw N, Ferrari R, Ford I, Tardif JC, Tendera M, et al. Hemoglobin and change in hemoglobin status predict mortality, cardiovascular events, and bleeding in stable coronary artery disease. Am J Med. 2017;130:720&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">28109968</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JY, Choi BG, Rha SW, Kang TS. Five-year outcomes in patients with anemia on admission undergoing a coronary intervention for acute myocardial infarction in Koreans: Propensity score matching analysis. Coron Artery Dis. 2018;29:647&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">30074518</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CW, Liao PC, Chen KC, Chiu YW, Liu YH, Ke SR, et al. Relationship of serum uric acid and Killip class on mortality after acute ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. Int J Cardiol. 2017;226:26&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27780079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandurino-Mirizzi A, Crimi G, Raineri C, Pica S, Ruffinazzi M, Gianni U, et al. Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Cardiovasc Med (Hagerstown) 2018;19:240&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29470249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Guo L, Guan Q. Analysis of the relationship between hyperglycemia and prognosis in elderly patients with high-risk acute myocardial infarction. PLA Med J. 2013;38:496&#x2013;500.</Citation></Reference><Reference><Citation>Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16609090</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, et al. Abnormal glucose regulation in patients with acute ST &#x2013; Elevation myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabetol. 2009;8:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646717</ArticleId><ArticleId IdType="pubmed">19183453</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajstra M, Gasior M, Gierlotka M, Pres D, Hawranek M, Trzeciak P, et al. Comparison of five-year outcomes of patients with and without chronic total occlusion of noninfarct coronary artery after primary coronary intervention for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2012;109:208&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">21996144</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Wang X, Shi Y, Zhao X, Han Y. Prognostic value of the age, creatinine, and ejection fraction score for non-infarct-related chronic total occlusion revascularization after primary percutaneous intervention in acute ST-elevation myocardial infarction patients: A retrospective study. J Interv Cardiol. 2018;31:33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28940388</ArticleId></ArticleIdList></Reference><Reference><Citation>Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams P, Westerhout CM, et al. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation. 2008;118:1335&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">18779444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Behnes M, Mashayekhi K, Bufe A, Meyer-Gessner M, El-Battrawy I, et al. Prognostic impact of percutaneous coronary intervention of chronic total occlusion in acute and periprocedural myocardial infarction. J Clin Med. 2021;10:258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7828144</ArticleId><ArticleId IdType="pubmed">33445664</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor SA, Garot P, Sanguineti F, Hoebers LP, Unterseeh T, Benamer H, et al. Meta-analysis of the impact on mortality of noninfarct-related artery coronary chronic total occlusion in patients presenting with ST-segment elevation myocardial infarction. Am J Cardiol. 2015;116:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">26068700</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitel I, Franke A, Schuler G, Thiele H. ST-segment resolution and prognosis after facilitated versus primary percutaneous coronary intervention in acute myocardial infarction: A meta-analysis. Clin Res Cardiol. 2010;99:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">19727894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndrepepa G, Alger P, Kufner S, Mehilli J, Sch&#xf6;mig A, Kastrati A. ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Cardiol J. 2012;19:61&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22298169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Hsieh C, Sivagangabalan G, Chan H, Ryding AD, Narayan A, et al. Prognostic impact of Q waves on presentation and ST resolution in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol. 2009;104:780&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19733711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Zhang RY, Zhu TQ, Hu J, Yang ZK, Ding FH, et al. Impact of angina prior to acute ST-elevation myocardial infarction on short-term outcomes after primary percutaneous coronary intervention: Results from the Shanghai Registry of Acute Coronary Syndrome (SRACE) Chin Med J (Engl) 2012;125:977&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">22613517</ArticleId></ArticleIdList></Reference><Reference><Citation>Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">3769170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahler D, Lee-Rozenfeld K, Ravid D, Rozenbaum Z, Banai S, Keren G, et al. Relation of lowering door-to-balloon time and mortality in ST segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. Clin Res Cardiol. 2019;108:1053&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30778668</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Choi KH, Lee JM, Kim HK, Hwang D, Rhee TM, et al. Prognostic Implications of door-to-balloon time and onset-to-door time on mortality in patients with ST segment-elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Heart Assoc. 2019;8:e012188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512115</ArticleId><ArticleId IdType="pubmed">31041869</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekhar J, Marley P, Allada C, McGill D, O&#x2019;Connor S, Rahman M, et al. Symptom-to-balloon time is a strong predictor of adverse events following primary percutaneous coronary intervention: Results from the Australian Capital territory PCI registry. Heart Lung Circ. 2017;26:41&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27451348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2018;39:119&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley EH, Nallamothu BK, Herrin J, Ting HH, Stern AF, Nembhard IM, et al. National efforts to improve door-to-balloon time results from the door-to-balloon alliance. J Am Coll Cardiol. 2009;54:2423&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20082933</ArticleId></ArticleIdList></Reference><Reference><Citation>Trzeciak P, Gierlotka M, G&#x105;sior M, Lekston A, Wilczek K, S&#x142;onka G, et al. Mortality of patients with ST-segment elevation myocardial infarction and cardiogenic shock treated by PCI is correlated to the infarct-related artery &#x2013; Results from the PL-ACS registry. Int J Cardiol. 2013;166:193&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22088222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervellin G, Rastelli G. The clinics of acute coronary syndrome. Ann Transl Med. 2016;4:191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4885904</ArticleId><ArticleId IdType="pubmed">27294087</ArticleId></ArticleIdList></Reference><Reference><Citation>Vis M M, Sjauw K D, Schaaf R, et al. In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes. ACC Cardiosource Review J. 2007;154:1184&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Zhang R-y, Shen J, et al. Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation. Chinese Medi J. 2008;121:2379&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19102952</ArticleId></ArticleIdList></Reference><Reference><Citation>Nienhuis MB, Ottervanger JP, Dambrink J-HE, et al. Comparative predictive value of infarct location, peak CK, and ejection fraction after primary PCI for ST elevation myocardial infarction. Coronary Artery Disease. 2009;20:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19050596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann S, Ruthrof S, Nowak K, et al. Short-term prognosis of contemporary interventional therapy of ST-elevation myocardial infarction: does gender matter? Clinical Research in Cardiology. 2009;98:709&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">19690904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann S, Ruthrof S, Nowak K, et al. Outcomes of Contemporary Interventional Therapy of ST Elevation Infarction in Patients Older than 75 Years. Clinical Cardiology. 2009;32:87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6652950</ArticleId><ArticleId IdType="pubmed">19215008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bufe A, Wolfertz J, Dinh W, et al. Gender-Based Differences in Long-Term Outcome After ST-Elevation Myocardial Infarction in Patients Treated with Percutaneous Coronary Intervention. Journal of Womens Health. 2010;19:471&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20136522</ArticleId></ArticleIdList></Reference><Reference><Citation>Lekston A, Slonka G, Gasior M, et al. Comparison of early and long-term results of percutaneous coronary interventions in patients with ST elevation myocardial infarction, complicated or not by cardiogenic shock. Coronary Artery Disease. 2010;21:13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19940765</ArticleId></ArticleIdList></Reference><Reference><Citation>Claessen BEPM, Peter Damman MMV, Karel T Koch, Jan Baan, Jr, Martijn Meuwissen, Rene&#xb4; J van der Schaaf RJdW, et al. Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians:trends and outcomes. Acute coronary syndromes. 2010;96:843e847.</Citation><ArticleIdList><ArticleId IdType="pubmed">19966111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pres D, Gasior M, Strojek K, et al. Blood glucose level on admission determines in-hospital and long-term mortality in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock treated with percutaneous coronary intervention. Kardiologia Polska. 2010;68:743&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20648428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannan EL, Zhong Y, Jacobs AK, et al. Effect of onset-to-door time and door-to-balloon time on mortality in patients undergoing percutaneous coronary interventions for st-segment elevation myocardial infarction. The American journal of cardiology. 2010;106:143&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20598994</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodi G, Bellandi B, Valenti R, et al. Heart rate as an independent prognostic risk factor in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Atherosclerosis. 2010;211:255&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20226462</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zwaan HB, Stoel MG, Roos-Hesselink JW, Veen G, Boersma E, von Birgelen C. Early versus late ST-segment resolution and clinical outcomes after percutaneous coronary intervention for acute myocardial infarction. Netherlands Heart Journal. 2010;18:416&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941127</ArticleId><ArticleId IdType="pubmed">20862236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoebers LPC, Kikkert W, Damman P, et al. Predictive value of plasma glucose level at admission for short and long term mortality in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. European Heart Journal. 2010;31:896&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21944676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang WY, Jeong MH, Ahn YK, et al. Obesity paradox in Korean patients undergoing primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Journal of Cardiology. 2010;55:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">20122553</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Li J-j, Yuan J-q, et al. Coronary intervention in patients &gt;= 75 years old with ST-elevation myocardial infarction: in-hospital and 6-month clinical outcomes. Chinese Medical Journal. 2010;123:2171&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20819659</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell MC, Henry JT, Henry TD, et al. Impact of age on treatment and outcomes in ST-elevation myocardial infarction. American Heart Journal. 2011;161:664&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21473964</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson MP, Armstrong PW, O&#x2019;Neil WW, et al. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. Circulation Cardiovascular quality and outcomes. 2011;4:183&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">21304097</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkemeyer R, Rillig A, Treusch F, et al. Outcome and treatment quality of transfer primary percutaneous intervention in older patients with acute ST-elevation myocardial infarction (STEMI) Archives of gerontology and geriatrics. 2011;53:e259&#x2013;e262.</Citation><ArticleIdList><ArticleId IdType="pubmed">21146233</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharacholou SM, Lopes RD, Alexander KP, et al. Age and Outcomes in ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Findings From the APEX-AMI Trial. Archives of Internal Medicine. 2011;171:559&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">21444846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawesson SS, Todt T, Alfredsson J, Janzon M, Stenestrand U, Swahn E. Gender difference in prevalence and prognostic impact of renal insufficiency in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2011;97:308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21212134</ArticleId></ArticleIdList></Reference><Reference><Citation>Siudak Z, Rakowski T, Dziewierz A, et al. Primary percutaneous coronary intervention during on- vs off-hours in patients with ST-elevation myocardial infarction.Results from EUROTRANSFER Registry. Kardiologia Polska. 2011;69:1017&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">22006600</ArticleId></ArticleIdList></Reference><Reference><Citation>Planer D, Witzenbichler B, Guagliumi G, et al. Impact of Hyperglycemia in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: The HORIZONS-AMI Trial. Journal of the American College of Cardiology. 2012;58:B27&#x2013;B27.</Citation><ArticleIdList><ArticleId IdType="pubmed">22795245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul P, Fu Y, Westerhout CM, Granger CB, Armstrong PW. Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. American journal of cardiology. 2012;110:1555&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920928</ArticleId></ArticleIdList></Reference><Reference><Citation>Siudak Z, Birkemeyer R, Dziewierz A, et al. Out-of-hospital cardiac arrest in patients treated with primary PCI for STEMI. Long-term follow up data from EUROTRANSFER registry. Resuscitation. 2012;83:303&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21958931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzeri C, Valente S, Chiostri M, et al. Impact of Age on the Prognostic Value of Body Mass Index in ST-Elevation Myocardial Infarction. Nutrition Metabolism and Cardiovascular Diseases. 2013;23:205&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">22901842</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiansen EC, Wickstrom KK, Henry TD, et al. Comparison of functional recovery following percutaneous coronary intervention for ST elevation myocardial infarction in three age groups (&lt;70, 70 to 79, and &#x2265;80 years) The American journal of cardiology. 2013;112:330&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23642505</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y-C, Yang T-H, Kim D-I, et al. Neutrophil to Lymphocyte Ratio Predicts Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Korean Circulation Journal. 2013;43:93&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596670</ArticleId><ArticleId IdType="pubmed">23508782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnbergen I, Tijssen J, van&#x2019;t Veer M, Michels R, Pijls NH. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction. Catheterization and cardiovascular interventions. 2013;82:379&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23553888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaya MG, Akpek M, Lam YY, et al. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: A prospective, multicenter study. International Journal of Cardiology. 2013;168:1154&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23219132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ki-Woon Kang, Seong-Kyu Lee, Hyeon Soo Yoon et al. Influence of the Obesity on Clinical Outcomes in the Young Korean Patients with Acute ST-Elevation Myocardial Infarction. The Korean Journal of Obesity. 2013;22:215&#x2013;21.</Citation></Reference><Reference><Citation>Antonsen L, Jensen LO, Terkelsen CJ, et al. Outcomes after primary percutaneous coronary intervention in octogenarians and nonagenarians with ST-segment elevation myocardial infarction: From the Western Denmark heart registry. Catheterization and Cardiovascular Interventions. 2013;81:912&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22887706</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkouh ME, Reiffel J, Dressler O, et al. Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report. Circulation Cardiovascular interventions. 2013;6:216&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23652600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cubeddu RJ, Palacios IF, Blankenship JC, et al. Outcome of Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.During On- Versus Off-hours (A Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction HORIZONS-AMI Trial Substudy) American Journal of Cardiology. 2013;111:946&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23340031</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai T-H, Yeh K-H, Sun C-K, et al. Estimated Glomerular Filtration Rate as a Useful Predictor of Mortality in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. American Journal of the Medical Sciences. 2013;345:104&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23276890</ArticleId></ArticleIdList></Reference><Reference><Citation>Allahwala UK, Murphy JC, Nelson GIC, Bhindi R. Absence of a &#x2018;smoker's paradox&#x2019; in field triaged ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. Cardiovascular revascularization medicine : including molecular interventions. 2013;14:213&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23856073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann S, Flachskampf FA, Alff A, et al. Out-of-hospital cardiac arrest and percutaneous coronary intervention for ST-elevation myocardial infarction: Long-term survival and neurological outcome. International Journal of Cardiology. 2013;166:236&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22204846</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaszuk-Kazberuk A, Bolinska S, Mlodawska E, Lopatowska P, Sobkowicz B, Musial W. Does admission anaemia still predict mortality six years after myocardial infarction? Kardiologia Polska. 2014;72:488&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24526561</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusuroglu H, Akgul O, Cakmak HA, et al. Long-term prognostic value of admission haemoglobin A1c (HbA1c) levels in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology. 2014;10:166&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252307</ArticleId><ArticleId IdType="pubmed">25489302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J-w, He L-j, Cao S-j, Yang Q, Yang S-w, Zhou Y-j. Effect of glycemic variability on short term prognosis in acute myocardial infarction subjects undergoing primary percutaneous coronary interventions. Diabetology &amp; Metabolic Syndrome. 2014:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4091650</ArticleId><ArticleId IdType="pubmed">25013458</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathod KS, Jones DA, Rathod VS, et al. Prognostic impact of anaemia on patients with ST-elevation myocardial infarction treated by primary PCI. Coronary artery disease. 2014;25:52&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24051679</ArticleId></ArticleIdList></Reference><Reference><Citation>David RB, Almeida ED, Cruz LV, et al. Diabetes mellitus and glucose as predictors of mortality in primary coronary percutaneous intervention. Arquivos brasileiros de cardiologia. 2014;103:323&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206363</ArticleId><ArticleId IdType="pubmed">25352506</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi T, Shiomi H, Toyota T, et al. Effect of Preinfarction Angina Pectoris on Long-term Survival in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention. American Journal of Cardiology. 2014;114:1179&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">25159235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho Y-C, Tsai T-H, Sung P-H, et al. Minimizing door-to-balloon time is not the most critical factor in improving clinical outcome of ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.Critical care medicine. 2014;42(8):1788&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pubmed">24717469</ArticleId></ArticleIdList></Reference><Reference><Citation>Claessen BEPM, Kikkert WJ, Hoebers LP, et al. Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly. Netherlands Heart Journal. 2015;23:477&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4580666</ArticleId><ArticleId IdType="pubmed">26259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CH, Zhang SY, Fang Q, et al. Renal dysfunction and hsCRP predict long-term outcomes of percutaneous coronary intervention in acute myocardial infarction. American journal of the medical sciences. 2015;349:413&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25782335</ArticleId></ArticleIdList></Reference><Reference><Citation>Laufer-Perl M, Shacham Y, Letourneau-Shesaf S, et al. Gender-related mortality and in-hospital complications following ST-segment elevation myocardial infarction: data from a primary percutaneous coronary intervention cohort. Clinical cardiology. 2015;38:145&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6711103</ArticleId><ArticleId IdType="pubmed">25728563</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal MB, Khamis R, Ilsley C, et al. Time-Trend Analyses of Bleeding and Mortality After Primary Percutaneous Coronary Intervention During Out of Working Hours Versus In-Working Hours An Observational Study of 11 466 Patients. Circulation-Cardiovascular Interventions. 2015;8:6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26038482</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy O, Degrell P, Berman E, et al. Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Archives of Cardiovascular Diseases. 2015;108:428&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">25937358</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan W, Zhao D, Zhang C, et al. Application of neutrophil/lymphocyte ratio in predicting coronary blood flow and mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. Journal of Cardiology. 2015;66:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25560801</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-W, Liao P-C, Chen K-C, et al. Baseline Hemoglobin Levels Associated with One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients. Acta Cardiologica Sinica. 2016;32:656&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5126443</ArticleId><ArticleId IdType="pubmed">27899852</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicek G, Korkmaz A. Two-year prognosis of admission hemoglobin A1c following a primary percutaneous coronary intervention. Coronary Artery Disease. 2016;27:673&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">27433996</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J, Ye X, Liu C, et al. Outcomes of off- and on-hours admission in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention A retrospective observational cohort study. Medicine. 2016;95:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058832</ArticleId><ArticleId IdType="pubmed">27399103</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathod KS, Jones DA, Gallagher S, et al. Atypical risk factor profile and excellent long-term outcomes of young patients treated with primary percutaneous coronary intervention for ST-elevation myocardial infarction. European heart journal Acute cardiovascular care. 2016;5:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">25589633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W-f, Liang Y, Zhu J, et al. Comparison of 4 Admission Blood Pressure Indexes for Predicting 30-Day Mortality in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Hypertension. 2016;29:332&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26158853</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemradj VV, Ottervanger JP, van&#x2019;t Hof AW, et al. Cardiogenic Shock Predicts Long-term Mortality in Hospital Survivors of STEMI Treated with Primary Percutaneous Coronary Intervention. Clinical cardiology. 2016;39:665&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490725</ArticleId><ArticleId IdType="pubmed">27775864</ArticleId></ArticleIdList></Reference><Reference><Citation>Topaz G, Finkelstein A, Flint N, et al. Comparison of 30-Day and Long-Term Outcomes and Hospital Complications Among Patients Aged &lt; 75 Versus &gt;= 75 Years With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology. 2017;119:1897&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">28460740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanic V, Suran D, Vollrath M, Tapajner A, Kompara G. Influence of minor deterioration of renal function after PCI on outcome in patients with ST-elevation myocardial infarction. Journal of Interventional Cardiology. 2017;30:473&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28730745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertelt K, Brener SJ, Mehran R, Ben-Yehuda O, McAndrew T, Stone GW. Comparison of Outcomes and Prognosis of Patients With Versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (the HORIZONS-AMI Study) American journal of cardiology (no pagination), 2017. 2017 Date of Publication: February 08.</Citation><ArticleIdList><ArticleId IdType="pubmed">28427734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmidou I, Redfors B, Crowley A, et al. Prognostic implications of Q waves at presentation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: an analysis of the HORIZONS-AMI study. Clinical cardiology. 2017;40:982&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490428</ArticleId><ArticleId IdType="pubmed">28696573</ArticleId></ArticleIdList></Reference><Reference><Citation>Yudi MB, Hamilton G, Farouque O, et al. Trends and Impact of Door-to-Balloon Time on Clinical Outcomes in Patients Aged &lt;75, 75 to 84, and &gt;/=85 Years With ST-Elevation Myocardial Infarction. The American journal of cardiology. 2017;120:1245&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu PJ, Wang HT, Sung PH, et al. No correlation between body mass index and 30-day prognostic outcome in Asians with acute ST-elevation myocardial infarction undergoing primary coronary intervention. Biomedical journal. 2017;40:169&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6136285</ArticleId><ArticleId IdType="pubmed">28651739</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M, Rigatelli G, Picariello C, et al. Correlation and prognostic role of neutrophil to lymphocyte ratio and SYNTAX score in patients with acute myocardial infarction treated with percutaneous coronary intervention: A six-year experience. Cardiovascular revascularization medicine : including molecular interventions. 2017;18:565&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">28529092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumiz E, Berenguer A, Vicente Vilar J, et al. Long-term outcomes and predictors of morbi-mortality according to age in stemi patients with multivessel disease: Impact of an incomplete revascularization. Catheterization and Cardiovascular Interventions. 2018;92:E512&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30019820</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu WX, Zhou TN, Wang XZ, Zhang L, Jing QM, Han YL. Sex-Related Differences in Short- and Long-Term Outcome among Young and Middle-Aged Patients for ST-Segment Elevation Myocardial Infarction Underwent Percutaneous Coronary Intervention. Chinese medical journal. 2018;131:1420&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6006816</ArticleId><ArticleId IdType="pubmed">29893358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti G, Bacchi Reggiani ML, Rosetti C, et al. Prodromal angina and risk of 2-year cardiac mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Medicine. 2018;97:e12332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6156056</ArticleId><ArticleId IdType="pubmed">30212983</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitaleri G, Brugaletta S, Scalone G, et al. Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial) The American journal of cardiology. 2018;121:1039&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">29544865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanic V, Kompara G, Vollrath M, Suran D, Kanic Z. Sex-Related Anemia Contributes to Disparities in Outcome of Patients Younger Than 60 Years with ST-Elevation Myocardial Infarction. Journal of Womens Health. 2018;27:755&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">29377747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenko E, van der Schaar M, Yoon J, et al. Sex-Specific Treatment Effects After Primary Percutaneous Intervention: A Study on Coronary Blood Flow and Delay to Hospital Presentation. Journal of the American Heart Association. 2019;8:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6405653</ArticleId><ArticleId IdType="pubmed">30764687</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Choi KH, Lee JM, et al. Prognostic Implications of Door-to-Balloon Time and Onset-to-Door Time on Mortality in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Journal of the American Heart Association. 2019;8:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512115</ArticleId><ArticleId IdType="pubmed">31041869</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy A, Keeble C, Burton-Wood N, et al. Clinical outcomes following primary percutaneous coronary intervention for ST-elevation myocardial infarction according to sex and race. European heart journal Acute cardiovascular care. 2019;8:264&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980483</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele L, Palmer J, Lloyd A, Fotheringham J, Iqbal J, Grech ED. The impact of smoking on mortality after acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a retrospective cohort outcome study at 3years. Journal of Thrombosis and Thrombolysis. 2019;47:520&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30666553</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy AC, Yudi MB, Farouque O, et al. Impact of Gender and Door-to-Balloon Times on Long-Term Mortality in Patients Presenting With ST-Elevation Myocardial Infarction. The American journal of cardiology. 2019;124:833&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">31327488</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehli J, Martin C, Brennan A, Dinh DT, Lefkovits J, Zaman S. Sex Differences Persist in Time to Presentation, Revascularization, and Mortality in Myocardial Infarction Treated With Percutaneous Coronary Intervention. Journal of the American Heart Association. 2019;8:e012161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585344</ArticleId><ArticleId IdType="pubmed">31092091</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke P. Dawson a DDb, Stephen Duffy b,c,d, Angela Brennan b, David Clark e,Christopher M. Reid b, David Blusztein a, Dion Stub b,c,d, Nick Andrianopoulos b,Melanie Freeman f, Ernesto Oqueli g,h, Andrew E. Ajani a,b,*,. Short- and long-term outcomes of out-of-hospital cardiac arrest following ST-elevation myocardial infarction managed with percutaneous coronary intervention. RESUSCITATION. 2020;150:121&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32209377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, Shea B, O&#x2019;Connell D, et al.  The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta analyses [EB/OL] 2017-11.  [Accessed April 10, 2019].  Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.html. 
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39560531</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>46</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of percutaneous mechanical circulatory support in patients with cardiogenic shock following acute myocardial infarction: A meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>e40595</StartPage><MedlinePgn>e40595</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e40595</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000040595</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI) with high mortality rates. While mechanical circulatory support devices like intra-aortic balloon pump (IABP) and Impella are used to manage CS, their comparative effectiveness remains unclear. This meta-analysis aims to evaluate the safety and efficacy of Impella in the treatment of AMI-associated CS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive literature search was performed across PubMed, EMBASE, Google Scholar, SCOPUS, and Web of Science. The primary efficacy endpoint was 6-month all-cause mortality. Secondary efficacy endpoints included 30-day mortality, major bleeding, limb ischemia, sepsis, and left ventricular ejection fraction. Pooled odds ratios (OR) and standardized mean difference (SMD) with 95% confidence intervals (CIs) were calculated using the random-effects model via Revman version 5.4. Statistical significance was determined at P&#x2005;&lt;&#x2005;.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four RCTs with a total of 442 patients were included in this meta-analysis. The pooled analysis showed that the odds of 6-month all-cause mortality were significantly lower with Impella compared to standard of care (OR: 0.64, 95% CI: 0.43-0.95; P value: .03). However, 30-day mortality reported no statistically significant difference between the 2 groups (OR: 1.03; 95% CI: 0.43-2.48; P&#x2005;=&#x2005;.95). Our analysis found that the use of impella is associated with a statistically significant increase in the odds of major bleeding (OR: 3.61; 95% CI: 1.14-11.40; P&#x2005;=&#x2005;.03), limb ischemia (OR: 4.91; 95% CI: 1.37-17.59; P&#x2005;=&#x2005;.01), and sepsis (OR: 2.75; 95% CI: 1.25-6.08; P&#x2005;=&#x2005;.01). No statistical significance was found in left ventricular ejection fraction at follow-up between the 2 groups (SMD: -0.35; 95% CI: -0.78 to 0.07; P&#x2005;=&#x2005;.11).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Impella significantly reduces 6-month all-cause mortality in patients with CS following AMI compared to standard of care. However, this survival benefit is offset by a substantial increase in major bleeding, limb ischemia, and sepsis risks associated with Impella. Future large scale trials are needed to validate these findings and refine clinical guidelines for the optimal use of Impella in treating CS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tariq</LastName><ForeName>Muhammad Daoud</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0009-0003-7769-5592</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Hritvik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, All India Institute of Medical Sciences-Jodhpur, Jodhpur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Abdul Moiz</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ayub Medical College, Abbottabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahnoor</LastName><ForeName>Syeda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dayanand Medical College and Hospital, Punajb, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zulfiqar</LastName><ForeName>Eeshal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahsan</LastName><ForeName>Areeba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaiswal</LastName><ForeName>Vikash</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Larkin Community Hospital, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daoud</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0005-7705-6883</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Bogomolets National Medical University, Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohail</LastName><ForeName>Amir Humza</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of New Mexico Health Sciences, Albuquerque, NM.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="Y">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>15</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>15</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39560531</ArticleId><ArticleId IdType="pmc">PMC11576003</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000040595</ArticleId><ArticleId IdType="pii">00005792-202411150-00024</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pepe M, Bortone AS, Giordano A, et al. . Cardiogenic shock following acute myocardial infarction: what&#x2019;s new? Shock. 2020;53:391&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31090679</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Qadir HM, Ivanov J, Austin PC, Tu JV, D&#x17e;av&#xed;k V. Sex differences in the management and outcomes of Ontario patients with cardiogenic shock complicating acute myocardial infarction. Can J Cardiol. 2013;29:691&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23265097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D, Khera S, Aronow WS, et al. . Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014;3:e000590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959706</ArticleId><ArticleId IdType="pubmed">24419737</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabel KM, Quazi MA, Leyba K, et al. . Cardiac arrest mortality and disposition patterns in United States Emergency Departments. J Clin Med. 2024;13:5585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11433634</ArticleId><ArticleId IdType="pubmed">39337071</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgendy IY, Van Spall HGC, Mamas MA. Cardiogenic shock in the setting of acute myocardial infarction: history repeating itself? Circ Cardiovasc Interv. 2020;13:e009034.</Citation><ArticleIdList><ArticleId IdType="pubmed">32151160</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal A, Maheshwari S, Shahbaz H, et al. . The presence of chronic total occlusion in non infarct-related arteries is associated with higher mortality and worse patient outcomes following percutaneous coronary intervention for STEMI: a systematic review, meta-analysis and meta-regression. Cardiol Rev. 2024. doi: 10.1097/CRD.0000000000000683.</Citation><ArticleIdList><ArticleId IdType="pubmed">38456689</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, et al. .; IABP-SHOCK II Trial Investigators. IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine GN, Bates ER, Blankenship JC, et al. . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">22064601</ArticleId></ArticleIdList></Reference><Reference><Citation>Windecker S, Kolh P, Alfonso F, et al. .; Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">25173339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjauw KD, Engstr&#xf6;m AE, Vis MM, et al. . A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 2009;30:459&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">19168529</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, et al. .; Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) Trial Investigators. Intraaortic balloon pump in cardiogenic shock II (IABP-SHOCK II) trial investigators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382:1638&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24011548</ArticleId></ArticleIdList></Reference><Reference><Citation>Glazier JJ, Kaki A. The Impella device: historical background, clinical applications and future directions. Int J Angiol. 2019;28:118&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679960</ArticleId><ArticleId IdType="pubmed">31384109</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstr&#xf6;m AE, Cocchieri R, Driessen AH, et al. . The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: the Academic Medical Center intensive care unit experience. Crit Care Med. 2011;39:2072&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21602670</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjauw KD, Remmelink M, Baan J, Jr, et al. . Left ventricular unloading in acute ST-segment elevation myocardial infarction patients is safe and feasible and provides acute and sustained left ventricular recovery. J Am Coll Cardiol. 2008;51:1044&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18325447</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, et al. . A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Engstrom AE, Sjauw KD, et al. . Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. Int J Cardiol. 2016;202:894&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26476989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Sjauw KD, et al. . Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69:278&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahuja M, Hernandez-Montfort J, Whitehead EH, Kawabori M, Kapur NK. Device profile of the Impella 5.0 and 5.5 system for mechanical circulatory support for patients with cardiogenic shock: overview of its safety and efficacy. Expert Rev Med Devices. 2022;19:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">34894975</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, et al. ., eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. Cochrane; 2019.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264&#x2013;9, W64.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622511</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, et al. . The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochaton T, Huot L, Elbaz M, et al. .; IMPELLA-STIC investigators. Mechanical circulatory support with the Impella&#xae; LP5.0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: the IMPELLA-STIC randomized study. Arch Cardiovasc Dis. 2020;113:237&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31740272</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller JE, Engstr&#xf8;m T, Jensen LO, et al. .; DanGer Shock Investigators. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390:1382&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">38587239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Shapero K, Ahn SS, Goldsweig AM, Desai N, Altin SE. Outcomes of mechanical circulatory support for acute myocardial infarction complicated by cardiogenic shock. Catheter Cardiovasc Interv. 2022;99:658&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10877703</ArticleId><ArticleId IdType="pubmed">34156755</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughman KL, Jarcho JA. Bridge to life--cardiac mechanical support. N Engl J Med. 2007;357:846&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehrani B, Truesdell A, Singh R, Murphy C, Saulino P. Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry): observational and retrospective study. JMIR Res Protoc. 2018;7:e160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043735</ArticleId><ArticleId IdType="pubmed">29954728</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatzis G, Markus B, Luesebrink U, et al. . Early Impella support in post cardiac arrest cardiogenic shock complicating acute myocardial infarction improves short- and long-term survival. Crit Care Med. 2021;49:943&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">33729726</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Schreiber T, Dixon S, et al. . Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: the Detroit cardiogenic shock initiative. Catheter Cardiovasc Interv. 2018;91:454&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">29266676</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal A, Shahbaz H, Jain H, et al. . The impact of chronic total occlusion in non-infarct related arteries on patient outcomes following percutaneous coronary intervention for STEMI superimposed with cardiogenic shock: a pilot systematic review and meta-analysis. Curr Probl Cardiol. 2024;49:102237.</Citation><ArticleIdList><ArticleId IdType="pubmed">38042227</ArticleId></ArticleIdList></Reference><Reference><Citation>Panuccio G, Neri G, Macr&#xec; LM, Salerno N, De Rosa S, Torella D. Use of Impella device in cardiogenic shock and its clinical outcomes: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2022;40:101007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8961185</ArticleId><ArticleId IdType="pubmed">35360892</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyns B, Stolinski J, Leunens V, Verbeken E, Flameng W. Left ventricular support by catheter-mounted axial flow pump reduces infarct size. J Am Coll Cardiol. 2003;41:1087&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679206</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal A, Abbasi FQ, Tariq MD, et al. . Efficacy and outcomes of antiplatelet therapy versus oral anticoagulants in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Ann Med Surg (Lond). 2024;86:2911&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11060210</ArticleId><ArticleId IdType="pubmed">38694361</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty MP, Khan AR, O&#x2019;Neill WW. Early initiation of Impella in acute myocardial infarction complicated by cardiogenic shock improves survival: a meta-analysis. JACC Cardiovasc Interv. 2017;10:1805&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">28882288</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill WW, Schreiber T, Wohns DH, et al. . The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol. 2014;27:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238821</ArticleId><ArticleId IdType="pubmed">24329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Kapur NK, Patel K, et al. .; National Cardiogenic Shock Initiative Investigators. Improved outcomes associated with the use of shock protocols: updates from the national cardiogenic shock initiative. Catheter Cardiovasc Interv. 2019;93:1173&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">31025538</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Schreiber TL, Grines CL, et al. . Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol. 2017;119:845&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28040188</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain H, Marsool MDM, Odat RM, et al. . Emergence of artificial intelligence and machine learning models in sudden cardiac arrest: a comprehensive review of predictive performance and clinical decision support. Cardiol Rev. 2024. doi: 10.1097/CRD.0000000000000708.</Citation><ArticleIdList><ArticleId IdType="pubmed">38836621</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo-Silberman S, Fichet J, Mathonnet A, et al. . Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5. Resuscitation. 2013;84:609&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23069592</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios SA, Bravo CA, Weinreich M, et al. . Meta-analysis and trial sequential analysis comparing percutaneous ventricular assist devices versus intra-aortic balloon pump during high-risk percutaneous coronary intervention or cardiogenic shock. Am J Cardiol. 2018;122:1330&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30146099</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Ibrahim K, Loehn T, et al. . Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139:1249&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">30586755</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid N, Rogers T, Shlofmitz E, et al. . Adverse events and modes of failure related to the Impella percutaneous left ventricular assist devices: a retrospective analysis of the MAUDE database. EuroIntervention. 2019;15:44&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30803939</ArticleId></ArticleIdList></Reference><Reference><Citation>Damluji AA, Tehrani B, Sinha SS, et al. . Position statement on vascular access safety for percutaneous devices in AMI complicated by cardiogenic shock. JACC Cardiovasc Interv. 2022;15:2003&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10312149</ArticleId><ArticleId IdType="pubmed">36265932</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam AV, Barsness GW, Vallabhajosyula S, Vallabhajosyula S. Complications of temporary percutaneous mechanical circulatory support for cardiogenic shock: an appraisal of contemporary literature. Cardiol Ther. 2019;8:211&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6828896</ArticleId><ArticleId IdType="pubmed">31646440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok CS, Khan MA, Rao SV, et al. . Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Interv. 2015;8:e001645.</Citation><ArticleIdList><ArticleId IdType="pubmed">25825007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zein R, Patel C, Mercado-Alamo A, Schreiber T, Kaki A. A review of the Impella devices. Interv Cardiol. 2022;17:e05.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9026144</ArticleId><ArticleId IdType="pubmed">35474971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollmuth J, Korngold E, Croce K, Pinto DS. The single-access for hi-risk PCI (SHiP) technique. Catheter Cardiovasc Interv. 2020;96:114&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383894</ArticleId><ArticleId IdType="pubmed">31654483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrovec GW, Kaki A, Dahle TG. A review of bleeding risk with Impella-supported high-risk percutaneous coronary intervention. Heart Int. 2020;14:92&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9524743</ArticleId><ArticleId IdType="pubmed">36276510</ArticleId></ArticleIdList></Reference><Reference><Citation>Haertel F, Lenk K, Fritzenwanger M, et al. . Rationale and design of JenaMACS-acute hemodynamic impact of ventricular unloading using the Impella CP assist device in patients with cardiogenic shock. J Clin Med. 2022;11:4623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9369529</ArticleId><ArticleId IdType="pubmed">35956238</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin C, Yandrapalli S, Yang Y, Liu B, Aronow WS, Naidu SS. A comparison of in-hospital outcomes between the use of Impella and IABP in acute myocardial infarction cardiogenic shock undergoing percutaneous coronary intervention. J Invasive Cardiol. 2022;34:E98&#x2013;E103.</Citation><ArticleIdList><ArticleId IdType="pubmed">35100554</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo I, Axman R, Lu DY, et al. . Impella versus intra-aortic balloon pump in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: an observational study. J Am Heart Assoc. 2024;13:e032607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11056174</ArticleId><ArticleId IdType="pubmed">38240236</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin AP, Spertus JA, Curtis JP, et al. . The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. 2020;141:273&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">31735078</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson JA, Hajduk A, Curtis J, et al. . Acute kidney injury among older patients undergoing coronary angiography for acute myocardial infarction: the SILVER-AMI study. Am J Med. 2019;132:e817&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6891160</ArticleId><ArticleId IdType="pubmed">31170374</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott L, Cook G, Park J, Yang Q, Hirose H. Save the leg: utilization of distal perfusion catheter with Impella CP&#xae; may prevent morbidity of limb. Cureus. 2022;14:e29916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9633060</ArticleId><ArticleId IdType="pubmed">36348905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur NK, Whitehead EH, Thayer KL, Pahuja M. The science of safety: complications associated with the use of mechanical circulatory support in cardiogenic shock and best practices to maximize safety. F1000Res. 2020;9:F1000 Faculty Rev-794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391013</ArticleId><ArticleId IdType="pubmed">32765837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M, Sorrentino T, Oppizzi M, et al. . The role of different mechanical circulatory support devices and their timing of implantation on myocardial damage and mid-term recovery in acute myocardial infarction related cardiogenic shock. J Interv Cardiol. 2018;31:717&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30460719</ArticleId></ArticleIdList></Reference><Reference><Citation>Abaunza M, Kabbani LS, Nypaver T, et al. . Incidence and prognosis of vascular complications after percutaneous placement of left ventricular assist device. J Vasc Surg. 2015;62:417&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26054591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichaa H. The &#x201c;lend a hand&#x201d; external bypass technique: external radial to femoral bypass for antegrade perfusion of an ischemic limb with occlusive large bore sheath &#x2013; a novel and favorable approach. Catheter Cardiovasc Interv. 2020;96:E614&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754488</ArticleId><ArticleId IdType="pubmed">32757357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallikethi-Reddy S, Khan MR, Khan H, Munir A, Moza A. Novel modification of Impella sheath to prevent limb Ischemia. ASAIO J. 2022;68:e93&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34619696</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed H, Abdullah MBBS, Naeem I, et al. . Demographic trends and disparities in mortality related to coexisting heart failure and diabetes mellitus among older adults in the United States between 1999 and 2020: a retrospective population-based cohort study from the CDC WONDER database. Int J Cardiol Cardiovasc Risk Prev. 2024;23:200326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11395761</ArticleId><ArticleId IdType="pubmed">39282605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38955117</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>The effect of high-dose selenium on mortality and postoperative organ dysfunction in post-cardiotomy cardiogenic shock patients supported with mechanical circulatory support - A post-hoc analysis of the SUSTAIN CSX trial.</ArticleTitle><Pagination><StartPage>154853</StartPage><MedlinePgn>154853</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2024.154853</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-9441(24)00340-X</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Cardiac surgery, post-cardiotomy cardiogenic shock (PCCS), and temporary mechanical circulatory support (tMCS) provoke substantial inflammation. We therefore investigated whether a selenium-based, anti-inflammatory strategy would benefit PCCS patients treated with tMCS in a post-hoc analysis of the sustain CSX trial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Post-hoc analysis of patients receiving tMCS for PCCS in the Sustain CSX trial, which investigated the effects of high-dose selenium on postoperative organ dysfunction in cardiac surgery patients.</AbstractText><AbstractText Label="PRIMARY OUTCOME" NlmCategory="METHODS">duration of tMCS therapy.</AbstractText><AbstractText Label="SECONDARY OUTCOMES" NlmCategory="RESULTS">postoperative organ dysfunction and 30-day mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-nine patients were treated with tMCS for PCCS. There was no difference in the median duration of tMCS between the selenium and the placebo group (3&#xa0;days [IQR: 1-6] vs. 2&#xa0;days [IQR: 1-7], p&#xa0;=&#xa0;0.52). Median dialysis duration was longer in the selenium group (1.5&#xa0;days [0-21.8] vs. 0&#xa0;days [0-1.8], p&#xa0;=&#xa0;0.048). There was no difference in 30-day mortality (53% vs. 41%, OR 1.44, 95% CI 0.32-6.47, p&#xa0;=&#xa0;0.62).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this explorative study, a perioperative high-dose selenium-supplementation did not show beneficial effects on organ dysfunctions and mortality rates in patients with PCCS receiving tMCS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ott</LastName><ForeName>Sascha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiac Anaesthesiology and Intensive Care Medicine, Berlin, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; Outcomes Research Consortium, Department of Anesthesiology, Cleveland Clinic, OH, USA. Electronic address: Sascha.ott@dhzc-charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dresen</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University Hospital W&#xfc;rzburg, Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, W&#xfc;rzburg, Germany. Electronic address: Dresen_E@ukw.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Zheng Yii</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiac Anaesthesiology and Intensive Care Medicine, Berlin, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Germany; Department of Anaesthesiology, Faculty of Medicine, University of Malaysia, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller-Wirtz</LastName><ForeName>Lukas M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Outcomes Research Consortium, Department of Anesthesiology, Cleveland Clinic, OH, USA; Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Medical Center and Saarland University Faculty of Medicine, 66424 Homburg, Saarland, Germany. Electronic address: lukas@muellerwirtz.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Procopiuc</LastName><ForeName>Livia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiac Anaesthesiology and Intensive Care Medicine, Berlin, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Germany. Electronic address: livia.procopiuc@dhzc-charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekrami</LastName><ForeName>Elyad</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Outcomes Research Consortium, Department of Anesthesiology, Cleveland Clinic, OH, USA. Electronic address: ekramie@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pitts</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Germany; Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9; (DHZC), 13353 Berlin, Germany; Berlin Institute of Health, 10117 Berlin, Germany. Electronic address: Leonard.pitts@dhzc-charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellner</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiac Anaesthesiology and Intensive Care Medicine, Berlin, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Germany. Electronic address: nicolas.hellner@charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catena</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiac Anaesthesiology and Intensive Care Medicine, Berlin, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Germany. Electronic address: Daniel.catena@charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duerr</LastName><ForeName>Georg Daniel</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Medical Center Mainz (Johannes Gutenberg-University Mainz), 55131 Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wittmann</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, University Hospital Bonn, Bonn, Germany. Electronic address: Maria.Wittmann@ukbonn.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waeschle</LastName><ForeName>Reiner M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site G&#xf6;ttingen, G&#xf6;ttingen, Germany. Electronic address: rwaeschle@med.uni-goettingen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elke</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Medical Center Schleswig-Holstein, Campus Kiel, D-24105 Kiel, Germany. Electronic address: gunnar.elke@uksh.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiac Anaesthesiology and Intensive Care Medicine, Berlin, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; St Bartholomew's Hospital and Barts Heart Centre, Department of Perioperative Medicine, London, EC1A 7BE, UK. Electronic address: Ben.obrien@dhzc-charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyland</LastName><ForeName>Daren K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Queen's University, Kingston, ON, Canada. Electronic address: dkh2@queensu.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoppe</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiac Anaesthesiology and Intensive Care Medicine, Berlin, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Germany; University Hospital W&#xfc;rzburg, Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, W&#xfc;rzburg, Germany. Electronic address: Stoppe_c@ukw.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CS/18/3/34063</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>H6241UJ22B</RegistryNumber><NameOfSubstance UI="D012643">Selenium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012643" MajorTopicYN="Y">Selenium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antioxidants</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">Post-cardiotomy cardiogenic shock</Keyword></KeywordList><CoiStatement>Declaration of competing interest S.O. received institutional research and study funds from Novartis Pharma GmbH and institutional research, study and educational grants, speaker fees, and advisory board fees from Abiomed outside this work. E. D. received speaker honoraria from Baxter outside this work. G.E. declares speaker honoraria from Baxter and Fresenius Kabi outside this work. B.O&#xb7;B declares: British Heart Foundation for Tight K, The role of Potassium in AFACS prevention (Grant number CS/18/3/34063); National Institute for Health Research (NIHR) for Predicting AF after Cardiac Surgery - the PARADISE Scores: A Clinical Prediction Rule for AFACS (Grant number NIHR131227). All outside this work. All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>3</Day><Hour>10</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>2</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38955117</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2024.154853</ArticleId><ArticleId IdType="pii">S0883-9441(24)00340-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40055145</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Transcatheter Edge-to-Edge Repair for Severe Mitral Regurgitation in Patients With Cardiogenic Shock: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>e034932</StartPage><MedlinePgn>e034932</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e034932</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.124.034932</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with severe mitral regurgitation and cardiogenic shock demonstrate a poor prognosis. Mitral transcatheter edge-to-edge repair could alter patient management.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We systematically reviewed PubMed/Medline, Scopus, and Cochrane Library until January 2023, including studies assessing transcatheter edge-to-edge repair in patients with severe mitral regurgitation and cardiogenic shock. Studies with &lt;5 patients were excluded. The primary outcome was device success and all-cause death, while secondary outcomes included myocardial infarction, stroke, and heart failure hospitalization rates at 30-day and intermediate-term follow-up. A fixed-effects meta-analysis was used to estimate pooled rates. Risk of bias was assessed with the Newcastle-Ottawa Scale. A total of 24 studies and 5428 patients were included, with a mean age of 71.2&#xb1;3.3&#x2009;years and a high mean Society of Thoracic Surgery score (15.2&#xb1;8.9). Device success was achieved in 86% (95% CI, 85%-87%) and mitral regurgitation &#x2264;2+ in 89% (95% CI: 88%-90%). The 30-day all-cause mortality rate was 14% (95% CI, 13%-15%). Stroke, myocardial infarction, and heart failure hospitalization rates were 2% (95% CI, 1%-2%), 15% (95% CI, 13%-18%), and 9% (95% CI, 8%-10%), respectively. Patients with acute myocardial infarction had similar device success (81% [95% CI, 74%-87%]), a 30-day mortality rate of 20% (95% CI, 16%-25%), and intermediate-term mortality rate of 14% (95% CI, 9%-19%). In non-myocardial infarction populations, the 30-day mortality rate was 13% (95% CI, 13%-14%), and the intermediate-term mortality rate was 35% (95% CI, 34%-36%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with mitral regurgitation and cardiogenic shock, transcatheter edge-to-edge repair is associated with favorable 30-day and intermediate-term outcomes. Limitations, including the observational design of included studies and considerable heterogeneity, necessitate further research in this setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dimitriadis</LastName><ForeName>Kyriakos</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3186-8905</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soulaidopoulos</LastName><ForeName>Stergios</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pyrpyris</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0401-9473</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagris</LastName><ForeName>&#x39c;arios</ForeName><Initials>&#x39c;</Initials><Identifier Source="ORCID">0000-0002-3473-1368</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aznaouridis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beneki</LastName><ForeName>Eirini</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0464-3607</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theofilis</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9260-6306</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsioufis</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1100-7430</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatakis</LastName><ForeName>Fotis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fragkoulis</LastName><ForeName>Christos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5598-9950</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuvy</LastName><ForeName>Mony</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Jesselson Integrated Heart Centre, Shaare Zedek Medical Center and Faculty of Medicine Hebrew University Jerusalem Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrysohoou</LastName><ForeName>Christina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6340-3996</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggeli</LastName><ForeName>Konstantina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsioufis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7636-6725</Identifier><AffiliationInfo><Affiliation>First Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="Y">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006328" MajorTopicYN="Y">Cardiac Catheterization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008943" MajorTopicYN="Y">Mitral Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="Y">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MitraClip</Keyword><Keyword MajorTopicYN="N">TEER</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mitral regurgitation</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">transcatheter edge&#x2010;to&#x2010;edge repair</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>18</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40055145</ArticleId><ArticleId IdType="pmc">PMC12132604</ArticleId><ArticleId IdType="doi">10.1161/JAHA.124.034932</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, et&#xa0;al. Transcatheter mitral&#x2010;valve repair in patients with heart failure. N Engl J Med. 2018;379:2307&#x2013;2318.</Citation><ArticleIdList><ArticleId IdType="pubmed">30280640</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, et&#xa0;al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">34453165</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, et&#xa0;al. ACC/AHA guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021;143;5:e72&#x2013;e227. doi: 10.1161/CIR.0000000000000923</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000923</ArticleId><ArticleId IdType="pubmed">33332150</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson CR, Buller CE, Sleeper LA, Antonelli TA, Webb JG, Jaber WA, Abel JG, Hochman JS. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1104&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985712</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigioni F, Enriquez&#x2010;Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation. Circulation. 2001;103:1759&#x2013;1764.</Citation><ArticleIdList><ArticleId IdType="pubmed">11282907</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstr&#xf6;m AE, Vis MM, Bouma BJ, Claessen BEPM, Sjauw KD, Baan J, Meuwissen M, Koch KT, de Winter RJ, Tijssen JGP, et&#xa0;al. Mitral regurgitation is an independent predictor of 1&#x2010;year mortality in ST&#x2010;elevation myocardial infarction patients presenting in cardiogenic shock on admission. Acute Card Care. 2010;12:51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">20482326</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Sivaraj K, Hendrickson M, Chang PP, Weickert T, Qamar A, Vaduganathan M, Caughey MC, Pandey A, Cavender MA, et&#xa0;al. Prevalence and prognostic significance of mitral regurgitation in acute decompensated heart failure. JACC Heart Fail. 2021;9:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075289</ArticleId><ArticleId IdType="pubmed">33309575</ArticleId></ArticleIdList></Reference><Reference><Citation>Parlow S, Weng W, Di Santo P, Jung RG, Lepage&#x2010;Ratte MF, Motazedian P, Prosperi&#x2010;Porta G, Abdel&#x2010;Razek O, Simard T, Chan V, et&#xa0;al. Significant valvular dysfunction and outcomes in cardiogenic shock: insights from the randomized DOREMI trial. Can J Cardiol. 2022;38:1211&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pubmed">35430192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X&#x2010;C, Zhu D&#x2010;M, Shan Y&#x2010;X. Dobutamine therapy is associated with worse clinical outcomes compared with Nesiritide therapy for acute decompensated heart failure: a systematic review and meta&#x2010;analysis. Am J Cardiovasc Drugs. 2015;15:429&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">26123415</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann F&#x2010;J, Ferenc M, Olbrich H&#x2010;G, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, et&#xa0;al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et&#xa0;al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008539</ArticleId><ArticleId IdType="pubmed">33781348</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta&#x2010;analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>
Cochrane Training
. Chapter&#xa0;3: defining the criteria for including studies and how they will be grouped for the synthesis. https://training.cochrane.org/handbook/current/chapter&#x2010;03.</Citation></Reference><Reference><Citation>Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, et&#xa0;al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">29483172</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle&#x2010;Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta&#x2010;Analyses. Ottawa Hospital Research Institute. 2013. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
</Citation></Reference><Reference><Citation>Tang GHL, Estevez&#x2010;Loureiro R, Yu Y, Prillinger JB, Zaid S, Psotka MA. Survival following edge&#x2010;to&#x2010;edge transcatheter mitral valve repair in patients with cardiogenic shock: a Nationwide analysis. J Am Heart Assoc. 2021;10; 8: e019882. doi: 10.1161/JAHA.120.019882</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.019882</ArticleId><ArticleId IdType="pmc">PMC8174169</ArticleId><ArticleId IdType="pubmed">33821669</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard T, Vemulapalli S, Jung RG, Vekstein A, Stebbins A, Holmes DR, Czarnecki A, Hibbert B, Alkhouli M. Transcatheter edge&#x2010;to&#x2010;edge mitral valve repair in patients with severe mitral regurgitation and cardiogenic shock. J Am Coll Cardiol. 2022;80:2072&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pubmed">36126766</ArticleId></ArticleIdList></Reference><Reference><Citation>So C, Kang G, Lee JC, Frisoli TM, O'Neill B, Wang DD, Eng MH, O'Neill W, Villablanca PA. Transcatheter edge&#x2010;to&#x2010;edge repair for acute mitral regurgitation with cardiogenic shock secondary to mechanical complication. Cardiovasc Revasc Med. 2022;45:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">35882600</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia S, Alsidawi S, Bae R, Cavalcante J, Eckman P, G&#xf6;ssl M, Steffen R, Sun B, Schmidt CW, Sorajja P. Percutaneous mitral valve repair with MitraClip in inoperable patients with severe mitral regurgitation complicated by cardiogenic shock. J Invasive Cardiol. 2020;32:228&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">32385191</ArticleId></ArticleIdList></Reference><Reference><Citation>Falasconi G, Melillo F, Pannone L, Adamo M, Ronco F, Latib A, Rahgozar K, Carrabba N, Valenti R, Citro R, et&#xa0;al. Use of edge&#x2010;to&#x2010;edge percutaneous mitral valve repair for severe mitral regurgitation in cardiogenic shock: a multicenter observational experience (MITRA&#x2010;SHOCK study). Catheter Cardiovasc Interv. 2021;98;1:E163&#x2013;E170. doi: 10.1002/ccd.29683</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29683</ArticleId><ArticleId IdType="pubmed">33797142</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint K, Brieke A, Wiktor D, Carroll J. Percutaneous edge&#x2010;to&#x2010;edge mitral valve repair may rescue select patients in cardiogenic shock: findings from a single center case series. Catheter Cardiovasc Interv. 2019;94;2:E82&#x2013;E87. doi: 10.1002/ccd.28089</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28089</ArticleId><ArticleId IdType="pubmed">30677212</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo M, Curello S, Chiari E, Fiorina C, Chizzola G, Magatelli M, Locantore E, Cuminetti G, Lombardi C, Manzato A, et&#xa0;al. Percutaneous edge&#x2010;to&#x2010;edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: a single centre experience. Int J Cardiol. 2017;234:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258847</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo M, Barbanti M, Curello S, Fiorina C, Chiari E, Chizzola G, Capodanno D, Tamburino C, Metra M, Ettori F. Effectiveness of MitraClip therapy in patients with refractory heart failure. J Interv Cardiol. 2015;28:61&#x2013;68. doi: 10.1111/joic.12179</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joic.12179</ArticleId><ArticleId IdType="pubmed">25689549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovach CP, Bell S, Kataruka A, Reisman M, Don C. Outcomes of urgent/emergent transcatheter mitral valve repair (MitraClip): a single center experience. Catheter Cardiovasc Interv. 2021;97;3:E402&#x2013;E410. doi: 10.1002/ccd.29084</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29084</ArticleId><ArticleId IdType="pubmed">32588956</ArticleId></ArticleIdList></Reference><Reference><Citation>Perel N, Asher E, Taha L, Levy N, Steinmetz Y, Karameh H, Karmi M, Maller T, Harari E, Dvir D, et&#xa0;al. Urgent transcatheter edge&#x2010;to&#x2010;edge repair for severe mitral regurgitation in patients with refractory cardiogenic shock. J Clin Med. 2022;11:5617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9573095</ArticleId><ArticleId IdType="pubmed">36233485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C&#x2010;W, Huang W&#x2010;M, Tsai Y&#x2010;L, Lu D&#x2010;Y, Sung S&#x2010;H, Yu W&#x2010;C, Guo C&#x2010;Y, Chen C&#x2010;H. Feasibility of the transcatheter mitral valve repair for patients with severe mitral regurgitation and endangered heart failure. J Formos Med Assoc. 2021;120:452&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">32620461</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzzatti N, Taramasso M, Cioni M, Denti P, Colombo A, La Canna G, Alfieri O, Maisano F. TCT&#x2010;699 MitraClip therapy in idiopathic vs ischemic dilated cardiomyopathy, a single center experience. J Am Coll Cardiol. 2013;62:B213.</Citation></Reference><Reference><Citation>Benito&#x2010;Gonz&#xe1;lez T, Est&#xe9;vez&#x2010;Loureiro R, del Castillo S, Minguito&#x2010;Carazo C, Garrote&#x2010;Coloma C, Alonso&#x2010;Rodr&#xed;guez D, Tundidor&#x2010;Sanz E, Rodr&#xed;guez&#x2010;Santamarta M, P&#xe9;rez de Prado A, Ram&#xf3;n CC, et&#xa0;al. Clinical outcomes following urgent vs. elective percutaneous mitral valve repair. Cardiovasc Revasc Med. 2021;26:6&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">33199248</ArticleId></ArticleIdList></Reference><Reference><Citation>Turyan Medvedovsky A, Tonchev I, Tahiroglu I, Lotan C, Gilon D, Planer D, Danenberg HD, Beeri R, Shuvy M. MitraClip therapy in critically ill patients with severe functional mitral regurgitation and refractory heart failure. Struct Heart. 2019;3:296&#x2013;301.</Citation></Reference><Reference><Citation>Est&#xe9;vez&#x2010;Loureiro R, Shuvy M, Taramasso M, Benito&#x2010;Gonzalez T, Denti P, Arzamendi D, Adamo M, Freixa X, Villablanca P, Krivoshei L, et&#xa0;al. Use of MitraClip for mitral valve repair in patients with acute mitral regurgitation following acute myocardial infarction: effect of cardiogenic shock on outcomes (IREMMI registry). Catheter Cardiovasc Interv. 2021;97:1259&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pubmed">33600072</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbriele C, Balthazar T, Wilson J, Adriaenssens T, Davies S, Droogne W, Dubois C, Caetano AF, Goetschalckx K, Jacobs S, et&#xa0;al. Left Impella&#xae;&#x2010;device as bridge from cardiogenic shock with acute, severe mitral regurgitation to MitraClip&#xae;&#x2010;procedure: a new option for critically ill patients. Eur Heart J Acute Cardiovasc Care. 2021;10:415&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">33620436</ArticleId></ArticleIdList></Reference><Reference><Citation>Farwati M, Saad AM, Abushouk AI, Bansal A, Gad MM, Krishnaswamy A, Yun J, Kapadia S. Short&#x2010;term outcomes following urgent transcatheter edge&#x2010;to&#x2010;edge repair with MitraClip in cardiogenic shock. JACC Cardiovasc Interv. 2021;14:2077&#x2013;2078.</Citation><ArticleIdList><ArticleId IdType="pubmed">34332943</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R, Dawkins S, Hamilton MA, Makar M, Hussaini A, Azarbal B, Patel JK, Kobashigawa JA, Trento A, Makkar RR, et&#xa0;al. Percutaneous mitral repair for patients in cardiogenic shock requiring inotropes and temporary mechanical circulatory support. JACC Cardiovasc Interv. 2019;12:2440&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pubmed">31806229</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman D, Taramasso M, Czarnecki A, Kerner A, Chrissoheris M, Spargias K, Poles L, Agmon Y, Scianna S, Beeri R, et&#xa0;al. Salvage MitraClip in severe secondary mitral regurgitation complicating acute myocardial infarction: data from a multicentre international study. Eur J Heart Fail. 2019;21:1161&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pubmed">31380580</ArticleId></ArticleIdList></Reference><Reference><Citation>Estevez&#x2010;Loureiro R, Adamo M, Arzamendi D, Denti P, Freixa X, Nombela&#x2010;Franco L, Pascual I, Melica B, Attias D, Serrador A, et&#xa0;al. Transcatheter mitral valve repair in patients with acute myocardial infarction: insights from the European registry of MitraClip in acute mitral regurgitation following an acute myocardial infarction (EREMMI). EuroIntervention. 2020;15:1248&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">31738168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleger ST, Chorianopoulos E, Krumsdorf U, Katus HA, Bekeredjian R. Percutaneous edge&#x2010;to&#x2010;edge repair of mitral regurgitation as a bail&#x2010;out strategy in critically ill patients. J Invasive Cardiol. 2013;25:69&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">23388223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan V, Messika&#x2010;Zeitoun D, Labinaz M, Hynes M, Nicholson D, Dryden A, Mesana T, Hibbert B. Percutaneous mitral repair as salvage therapy in patients with mitral regurgitation and refractory cardiogenic shock. Circ Cardiovasc Interv. 2019;12;11:e008435. doi: 10.1161/CIRCINTERVENTIONS.119.008435</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.119.008435</ArticleId><ArticleId IdType="pubmed">31694413</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;vez&#x2010;Loureiro R, Arzamendi D, Freixa X, Cardenal R, Carrasco&#x2010;Chinchilla F, Serrador&#x2010;Frutos A, Pan M, Sabat&#xe9; M, Diaz J, Hern&#xe1;ndez JM, et&#xa0;al. Percutaneous mitral valve repair for acute mitral regurgitation after an acute myocardial infarction. J Am Coll Cardiol. 2015;66:91&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">26139064</ArticleId></ArticleIdList></Reference><Reference><Citation>Turyan Medvedovsky A, Haberman D, Ibrahimli M, Tonchev I, Rashi Y, Peretz A, Shimoni S, Tuvali O, Danenberg H, Beeri R, et&#xa0;al. Percutaneous mitral valve repair in patients with severe mitral regurgitation and acute decompensated heart failure. J Clin Med. 2021;10:5849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8704045</ArticleId><ArticleId IdType="pubmed">34945146</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung RG, Simard T, Kovach C, Flint K, Don C, Di Santo P, Adamo M, Branca L, Valentini F, Benito&#x2010;Gonz&#xe1;lez T, et&#xa0;al. Transcatheter mitral valve repair in cardiogenic shock and mitral regurgitation. JACC Cardiovasc Interv. 2021;14:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">33069653</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, et&#xa0;al. ACC/AHA guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021:143;5:e35&#x2013;e71. doi: 10.1161/CIR.0000000000000932</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000932</ArticleId><ArticleId IdType="pubmed">33332149</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli&#x2010;Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et&#xa0;al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST&#x2010;segment elevation. Eur Heart J. 2018;39:119&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">29198432</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmon L, Boccalandro F. Cardiogenic shock secondary to severe acute ischemic mitral regurgitation managed with an impella 2.5 percutaneous left ventricular assist device. Catheter Cardiovasc Interv. 2012;79:1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">21805597</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, et&#xa0;al. 2021 ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio&#x2010;Thoracic Surgery (EACTS). Rev Esp Cardiol. 2022;75:524.</Citation><ArticleIdList><ArticleId IdType="pubmed">35636831</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman D, Est&#xe9;vez&#x2010;Loureiro R, Benito&#x2010;Gonzalez T, Denti P, Arzamendi D, Adamo M, Freixa X, Nombela&#x2010;Franco L, Villablanca P, Krivoshei L, et&#xa0;al. Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. Eur Heart J. 2022;43:641&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">34463727</ArticleId></ArticleIdList></Reference><Reference><Citation>Tcheng JE, Jackman JD, Nelson CL, Gardner LH, Smith LR, Rankin JS, Califf RM, Stack RS. Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. Ann Intern Med. 1992;117:18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">1596043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, Godfrey E, White HD, Lim J, LeJemtel T. Cardiogenic shock complicating acute myocardial infarction&#x2014;etiologies, management and outcome: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985706</ArticleId></ArticleIdList></Reference><Reference><Citation>Jogani S, Van de Heyning CM, Paelinck BP, De Bock D, Mertens P, Heidbuchel H, Claeys MJ. Afterload mismatch after MitraClip implantation: intraoperative assessment and prognostic implications. J Invasive Cardiol. 2020;32:88&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">32024805</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwald AB, Meyer T, Scholz K, Unterberg C, Schorn B. Efficacy of balloon valvuloplasty in patients with critical aortic stenosis and cardiogenic shock&#x2014;the role of shock duration. Clin Cardiol. 2001;24:214&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655224</ArticleId><ArticleId IdType="pubmed">11288967</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno PR, Jang I&#x2010;K, Newell JB, Block PC, Palacios IF. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol. 1994;23:1071&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">8144770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongiovanni D, K&#xfc;hl C, Bleiziffer S, Stecher L, Poch F, Greif M, Mehilli J, Massberg S, Frey N, Lange R, et&#xa0;al. Emergency treatment of decompensated aortic stenosis. Heart. 2018;104:23&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">28566471</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel K, Shah P, Jones BM, Korngold E, Bhardwaj A, Kar B, Barker C, Szerlip M, Smalling R, Dhoble A. Outcomes of transcatheter aortic valve replacement in patients with cardiogenic shock. Eur Heart J. 2023;44:3181&#x2013;3195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10471523</ArticleId><ArticleId IdType="pubmed">37350747</ArticleId></ArticleIdList></Reference><Reference><Citation>Masha L, Vemulapalli S, Manandhar P, Balan P, Shah P, Kosinski AS, Stewart G. Demographics, procedural characteristics, and clinical outcomes when cardiogenic shock precedes TAVR in the United States. JACC Cardiovasc Interv. 2020;13:1314&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">32499022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, Aronow HD, Elmariah S, Inglessis I, Palacios IF, et&#xa0;al. Outcomes following urgent/emergent transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:1175&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">29929641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay D, Chakraborty S, Amgai B, Patel N, Hajra A, Ghosh RK, Kolte D, Fonarow GC, Ramee SR, Lavie CJ, et&#xa0;al. Urgent balloon aortic valvuloplasty or urgent TAVR in patients with severe aortic stenosis. JACC Cardiovasc Interv. 2020;13:274&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">31973805</ArticleId></ArticleIdList></Reference><Reference><Citation>Chioncel O, Adamo M, Nikolaou M, Parissis J, Mebazaa A, Yilmaz MB, Hassager C, Moura B, Bauersachs J, Harjola V, et&#xa0;al. Acute heart failure and valvular heart disease: a scientific statement of the heart failure association, the Association for Acute CardioVascular care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. Eur J Heart Fail. 2023;25:1025&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">37312239</ArticleId></ArticleIdList></Reference><Reference><Citation>Parlow S, Di Santo P, Jung RG, Fam N, Czarnecki A, Horlick E, Abdel&#x2010;Razek O, Chan V, Hynes M, Nicholson D, et&#xa0;al. Transcatheter mitral valve repair for inotrope dependent cardiogenic shock&#x2014;design and rationale of the CAPITAL MINOS trial. Am Heart J. 2022;254:81&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">36002047</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29258529</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Postcardiotomy VA-ECMO for refractory cardiogenic shock.</ArticleTitle><Pagination><StartPage>116</StartPage><MedlinePgn>116</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-017-0674-5</ELocationID><Abstract><AbstractText>Postcardiotomy cardiogenic shock (PCCS) is a rare but catastrophic syndrome that can occur following separation from cardiopulmonary bypass or at any time during the immediate postoperative course. The management of PCCS varies between clinicians, institutions and countries. The available evidence to guide this practice is limited. In their systematic review and meta-analysis, Khorsandi and colleagues report a synthesis of case-series pertinent to the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for PCCS. Whilst we acknowledge the potential survival benefit for carefully selected patients for what is ordinarily a condition with high mortality, we wish to comment on several aspects of the study in the context of its application to clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charlesworth</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7389-4955</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Anaesthesia, University Hospital South Manchester, Southmoor Road, Manchester, M23 9LT, UK. mda05mc@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkateswaran</LastName><ForeName>Rajamiyer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiac and Transplant Surgeon, University Hospital South Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Julian M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Cardiothoracic Anaesthesia, Critical Care and ECMO, University Hospital South Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feddy</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiothoracic Anaesthesia, Critical Care and ECMO, University Hospital South Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Postcardiotomy</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">VA-EMO</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable as this is a meta-analysis CONSENT FOR PUBLICATION: Not applicable as this is a meta-analysis COMPETING INTERESTS: Professor Vipin Zamvar is the Editor-in-Chief of the Journal of Cardiothoracic Surgery. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29258529</ArticleId><ArticleId IdType="pmc">PMC5764222</ArticleId><ArticleId IdType="doi">10.1186/s13019-017-0674-5</ArticleId><ArticleId IdType="pii">10.1186/s13019-017-0674-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>MEDLINE, PubMed, and PMC (PubMed Central) How are they different? Maryland: National Library of Medicine; 2017.</Citation></Reference><Reference><Citation>Khorsandi M, Dougherty S, Bouamra O, Pai V, Curry P, Tsui S, et al. Extra-corporeal membrane oxygenation for refractory cardiogenic shock after adult cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Surg. 2017;12:55. doi: 10.1186/s13019-017-0618-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-017-0618-0</ArticleId><ArticleId IdType="pmc">PMC5512816</ArticleId><ArticleId IdType="pubmed">28716039</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35662424</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1942-5546</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Mayo Clinic proceedings</Title><ISOAbbreviation>Mayo Clin Proc</ISOAbbreviation></Journal><ArticleTitle>Newer P2Y<sub>12</sub> Inhibitors vs Clopidogrel in Acute Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>1074</StartPage><EndPage>1085</EndPage><MedlinePgn>1074-1085</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mayocp.2022.02.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-6196(22)00120-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate the outcomes, safety, and efficacy of dual antiplatelet therapy (DAPT) with newer P2Y<sub>12</sub> inhibitors compared with clopidogrel in patients with acute myocardial infarction (AMI) complicated by cardiac arrest (CA) or cardiogenic shock (CS).</AbstractText><AbstractText Label="PATIENTS AND METHODS">MEDLINE, EMBASE, and the Cochrane Library were queried systematically from inception to January 2021 for comparative studies of adults (&#x2265;18 years) with AMI-CA/CS receiving DAPT with newer P2Y<sub>12</sub> inhibitors as opposed to clopidogrel. We compared outcomes (30-day or in-hospital and 1-year all-cause mortality, major bleeding, and definite stent thrombosis) of newer P2Y<sub>12</sub> inhibitors and clopidogrel in patients with AMI-CA/CS.</AbstractText><AbstractText Label="RESULTS">Eight studies (1 randomized trial and 7 cohort studies) comprising 1100 patients (695 [63.2%] receiving clopidogrel and 405 [36.8%] receiving ticagrelor or prasugrel) were included. The population was mostly male (68.5%-86.7%). Risk of bias was low for these studies, with between-study heterogeneity and subgroup differences not statistically significant. Compared with the clopidogrel cohort, the newer P2Y<sub>12</sub> cohort had lower rates of early mortality (odds ratio [OR], 0.60; 95% CI, 0.45 to 0.81; P=.001) (7 studies) and 1-year mortality (OR, 0.51; 95% CI, 0.36 to 0.71; P&lt;.001) (3 studies). We did not find a significant difference in major bleeding (OR, 1.21; 95% CI, 0.71 to 2.06; P=.48) (6 studies) or definite stent thrombosis (OR, 2.01; 95% CI, 0.63 to 6.45; P=.24) (7 studies).</AbstractText><AbstractText Label="CONCLUSION">In patients with AMI-CA/CS receiving DAPT, compared with clopidogrel, newer P2Y<sub>12</sub> inhibitors were associated with lower rates of early and 1-year mortality. Data on major bleeding and stent thrombosis were inconclusive.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patlolla</LastName><ForeName>Sri Harsha</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN; Center for Clinical and Translational Science, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandlakunta</LastName><ForeName>Harika</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, Staten Island University Hospital, Staten Island, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuchkuntla</LastName><ForeName>Aravind R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Rosalind Franklin University Hospital, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Colin P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Mayo Clinic, Rochester, MN; Department of Medicine, Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murad</LastName><ForeName>M Hassan</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Division of Preventive, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, MN; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Center for Clinical and Translational Science, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kochar</LastName><ForeName>Ajar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rab</LastName><ForeName>S Tanveer</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Emory University School of Medicine, Atlanta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gersh</LastName><ForeName>Bernard J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>David X</ForeName><Initials>DX</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saraschandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC. Electronic address: svallabh@wakehealth.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mayo Clin Proc</MedlineTA><NlmUniqueID>0405543</NlmUniqueID><ISSNLinking>0025-6196</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058921">Purinergic P2Y Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>A74586SNO7</RegistryNumber><NameOfSubstance UI="D000077144">Clopidogrel</NameOfSubstance></Chemical><Chemical><RegistryNumber>G89JQ59I13</RegistryNumber><NameOfSubstance UI="D000068799">Prasugrel Hydrochloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mayo Clin Proc. 2022 Jun;97(6):1041-1043. doi: 10.1016/j.mayocp.2022.04.012.</RefSource><PMID Version="1">35662420</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000077144" MajorTopicYN="N">Clopidogrel</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="Y">Heart Arrest</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068799" MajorTopicYN="N">Prasugrel Hydrochloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058921" MajorTopicYN="N">Purinergic P2Y Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>6</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35662424</ArticleId><ArticleId IdType="doi">10.1016/j.mayocp.2022.02.016</ArticleId><ArticleId IdType="pii">S0025-6196(22)00120-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39832942</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2053-3624</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>Open heart</Title><ISOAbbreviation>Open Heart</ISOAbbreviation></Journal><ArticleTitle>Emergency interventions for cardiogenic shock due to decompensated aortic stenosis: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003110</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/openhrt-2024-003110</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">This study aimed to systematically review and analyse the existing evidence on outcomes of emergency transcatheter aortic valve implantation (eTAVI) and emergency balloon aortic valvuloplasty (eBAV) in CS patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature review and meta-analysis was performed. The primary endpoint was mortality at 30 days. Secondary endpoints were in-hospital mortality, 1-year mortality, bleeding, major vascular complications, myocardial infarction, stroke, incidence of pacemaker implantation, acute kidney injury and aortic regurgitation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventeen studies were included, totalling 2811 patients. The analysis revealed a 30-day mortality pooled estimated rate for eTAVI of 19% (CI 0.17 - 0.20) and for eBAV 39% (CI 0.32 - 0.46). In-hospital mortality pooled estimated rates were 11% for eTAVI (CI 0.06 - 0.18) and for eBAV 40% (CI 0.28 - 0.54). One-year mortality pooled estimated rates for eTAVI were 29% (CI 0.20 - 0.40) and for eBAV 67% (CI 0.58 - 0.74). Pooled estimated rates of any bleeding were 12% for eTAVI (CI 0.06 - 0.20) and 15% for eBAV (CI 0.10 - 0.21). The rate of major vascular complications for eTAVI was 8% (CI 0.07 - 0.10) and 3% for eBAV (CI 0.0 - 0.23).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This meta-analysis indicates that mortality in CS due to AS remains high despite emergency interventional treatment. These findings offer critical insights for clinical decision-making optimising patient care in this critically ill population.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>K&#xfc;hne</LastName><ForeName>Stephanie Gladys</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, University Hospital Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patrignani</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-7807-8772</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elvinger</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, University Hospital Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wein</LastName><ForeName>Bastian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, University Hospital Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmel</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, University Hospital Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penev</LastName><ForeName>Damyan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, University Hospital Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owais</LastName><ForeName>Tamer</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Thoracic Surgery, University Hospital Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girdauskas</LastName><ForeName>Evaldas</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1571-4244</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular and Thoracic Surgery, University Hospital Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raake</LastName><ForeName>Philip W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, University Hospital Augsburg, Augsburg, Germany dario.bongiovanni@med.uni-augsburg.de philip.raake@uk-augsburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiarito</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bongiovanni</LastName><ForeName>Dario</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4162-1482</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, University Hospital Augsburg, Augsburg, Germany dario.bongiovanni@med.uni-augsburg.de philip.raake@uk-augsburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Open Heart</MedlineTA><NlmUniqueID>101631219</NlmUniqueID><ISSNLinking>2053-3624</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="Y">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="Y">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063126" MajorTopicYN="Y">Balloon Valvuloplasty</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004630" MajorTopicYN="N">Emergencies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aortic Valve Stenosis</Keyword><Keyword MajorTopicYN="N">Heart Valve Prosthesis Implantation</Keyword><Keyword MajorTopicYN="N">Meta-Analysis</Keyword><Keyword MajorTopicYN="N">Systematic Reviews as Topic</Keyword><Keyword MajorTopicYN="N">Transcatheter Aortic Valve Replacement</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>21</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>20</Day><Hour>21</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39832942</ArticleId><ArticleId IdType="pmc">PMC11751810</ArticleId><ArticleId IdType="doi">10.1136/openhrt-2024-003110</ArticleId><ArticleId IdType="pii">openhrt-2024-003110</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Osnabrugge RLJ, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62:1002&#x2013;12. doi: 10.1016/j.jacc.2013.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.05.015</ArticleId><ArticleId IdType="pubmed">23727214</ArticleId></ArticleIdList></Reference><Reference><Citation>Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005&#x2013;11. doi: 10.1016/S0140-6736(06)69208-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69208-8</ArticleId><ArticleId IdType="pubmed">16980116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006&#x2013;8. doi: 10.1161/01.cir.0000047200.36165.b8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.0000047200.36165.b8</ArticleId><ArticleId IdType="pubmed">12473543</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597&#x2013;607. doi: 10.1056/NEJMoa1008232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1008232</ArticleId><ArticleId IdType="pubmed">20961243</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187&#x2013;98. doi: 10.1056/NEJMoa1103510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1103510</ArticleId><ArticleId IdType="pubmed">21639811</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker CM, Reardon MJ. The CoreValve US pivotal trial. Semin Thorac Cardiovasc Surg. 2014;26:179&#x2013;86. doi: 10.1053/j.semtcvs.2014.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semtcvs.2014.10.001</ArticleId><ArticleId IdType="pubmed">25527011</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention. 2021;17:e1126&#x2013;96. doi: 10.4244/EIJ-E-21-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-E-21-00009</ArticleId><ArticleId IdType="pmc">PMC9725093</ArticleId><ArticleId IdType="pubmed">34931612</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwald AB, Meyer T, Scholz K, et al. Efficacy of balloon valvuloplasty in patients with critical aortic stenosis and cardiogenic shock--the role of shock duration. Clin Cardiol. 2001;24:214&#x2013;8. doi: 10.1002/clc.4960240308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.4960240308</ArticleId><ArticleId IdType="pmc">PMC6655224</ArticleId><ArticleId IdType="pubmed">11288967</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Kidney E, Bem D, et al. Transcatheter aortic valve implantation for aortic stenosis in high surgical risk patients: A systematic review and meta-analysis. PLoS ONE. 2018;13:e0196877. doi: 10.1371/journal.pone.0196877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0196877</ArticleId><ArticleId IdType="pmc">PMC5944928</ArticleId><ArticleId IdType="pubmed">29746546</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res . 2018;27:1785&#x2013;805. doi: 10.1177/0962280216669183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280216669183</ArticleId><ArticleId IdType="pubmed">27683581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol . 2014;14:135. doi: 10.1186/1471-2288-14-135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Chu H. Meta-analysis of Proportions Using Generalized Linear Mixed Models. Epidemiology. 2020;31:713&#x2013;7. doi: 10.1097/EDE.0000000000001232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001232</ArticleId><ArticleId IdType="pmc">PMC7398826</ArticleId><ArticleId IdType="pubmed">32657954</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol . 2021;21:189. doi: 10.1186/s12874-021-01381-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01381-z</ArticleId><ArticleId IdType="pmc">PMC8451728</ArticleId><ArticleId IdType="pubmed">34544368</ArticleId></ArticleIdList></Reference><Reference><Citation>Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry. Circulation. 1991;84:2383&#x2013;97. doi: 10.1161/01.CIR.84.6.2383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.84.6.2383</ArticleId><ArticleId IdType="pubmed">1959194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribier A, Remadi F, Koning R, et al. Emergency balloon valvuloplasty as initial treatment of patients with aortic stenosis and cardiogenic shock. N Engl J Med. 1992;326:646. doi: 10.1056/NEJM199202273260916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199202273260916</ArticleId><ArticleId IdType="pubmed">1734262</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno PR, Jang IK, Newell JB, et al. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol. 1994;23:1071&#x2013;5. doi: 10.1016/0735-1097(94)90592-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(94)90592-4</ArticleId><ArticleId IdType="pubmed">8144770</ArticleId></ArticleIdList></Reference><Reference><Citation>Saia F, Marrozzini C, Ciuca C, et al. Emerging indications, in-hospital and long-term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era. EuroIntervention. 2013;8:1388&#x2013;97. doi: 10.4244/EIJV8I12A212.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJV8I12A212</ArticleId><ArticleId IdType="pubmed">23680956</ArticleId></ArticleIdList></Reference><Reference><Citation>Theiss HD, Greif M, Steinbeck G, et al. Balloon valvuloplasty for treatment of cardiogenic shock in the era of surgical valve replacement and TAVI. Intern Emerg Med. 2014;9:345&#x2013;7. doi: 10.1007/s11739-013-0972-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-013-0972-4</ArticleId><ArticleId IdType="pubmed">23824445</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongiovanni D, K&#xfc;hl C, Bleiziffer S, et al. Emergency treatment of decompensated aortic stenosis. Heart. 2018;104:23&#x2013;9. doi: 10.1136/heartjnl-2016-311037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2016-311037</ArticleId><ArticleId IdType="pubmed">28566471</ArticleId></ArticleIdList></Reference><Reference><Citation>Debry N, Kone P, Vincent F, et al. Urgent balloon aortic valvuloplasty in patients with cardiogenic shock related to severe aortic stenosis: time matters. EuroIntervention. 2018;14:e519&#x2013;25. doi: 10.4244/EIJ-D-18-00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-D-18-00029</ArticleId><ArticleId IdType="pubmed">29741481</ArticleId></ArticleIdList></Reference><Reference><Citation>Eug&#xe8;ne M, Urena M, Abtan J, et al. Effectiveness of Rescue Percutaneous Balloon Aortic Valvuloplasty in Patients With Severe Aortic Stenosis and Acute Heart Failure. Am J Cardiol. 2018;121:746&#x2013;50. doi: 10.1016/j.amjcard.2017.11.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2017.11.048</ArticleId><ArticleId IdType="pubmed">29397882</ArticleId></ArticleIdList></Reference><Reference><Citation>Varela ML, Teixeira P, Ponte M, et al. Balloon Aortic Valvuloplasty in Patients Admitted for Cardiogenic Shock with Severe Aortic Stenosis: A Retrospective Analysis of 14 Cases. Cureus. 2019;11:e5407. doi: 10.7759/cureus.5407.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.5407</ArticleId><ArticleId IdType="pmc">PMC6795346</ArticleId><ArticleId IdType="pubmed">31632861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilias A, Stefanou M-I, Steeg M, et al. Rescue aortic valvuloplasty for severe aortic stenosis is simple and effective in severely hemodynamically compromised patients presenting to centers without on-site heart surgery or TAVI facilities. Heart Vessels. 2023;38:957&#x2013;63. doi: 10.1007/s00380-023-02243-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-023-02243-y</ArticleId><ArticleId IdType="pubmed">36781429</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair RM, Chawla S, Abdelghaffar B, et al. Comparison of Contemporary Treatment Strategies in Patients With Cardiogenic Shock Due to Severe Aortic Stenosis. J Am Heart Assoc. 2024;13:e033601. doi: 10.1161/JAHA.123.033601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.033601</ArticleId><ArticleId IdType="pmc">PMC11179830</ArticleId><ArticleId IdType="pubmed">38761069</ArticleId></ArticleIdList></Reference><Reference><Citation>Frerker C, Schewel J, Schl&#xfc;ter M, et al. Emergency transcatheter aortic valve replacement in patients with cardiogenic shock due to acutely decompensated aortic stenosis. EuroIntervention. 2016;11:1530&#x2013;6. doi: 10.4244/EIJY15M03_03.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJY15M03_03</ArticleId><ArticleId IdType="pubmed">25751886</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraccaro C, Campante Teles R, Tch&#xe9;tch&#xe9; D, et al. Transcatheter aortic valve implantation (TAVI) in cardiogenic shock: TAVI-shock registry results. Catheter Cardiovasc Interv. 2020;96:1128&#x2013;35. doi: 10.1002/ccd.29112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29112</ArticleId><ArticleId IdType="pubmed">32627924</ArticleId></ArticleIdList></Reference><Reference><Citation>Masha L, Vemulapalli S, Manandhar P, et al. Demographics, Procedural Characteristics, and Clinical Outcomes When Cardiogenic Shock Precedes TAVR in the United States. JACC Cardiovasc Interv. 2020;13:1314&#x2013;25. doi: 10.1016/j.jcin.2020.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2020.02.033</ArticleId><ArticleId IdType="pubmed">32499022</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffen J, Stocker A, Scherer C, et al. Emergency transcatheter aortic valve implantation for acute heart failure due to severe aortic stenosis in critically ill patients with or without cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2022;11:877&#x2013;86. doi: 10.1093/ehjacc/zuac131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuac131</ArticleId><ArticleId IdType="pubmed">36210517</ArticleId></ArticleIdList></Reference><Reference><Citation>Piriou P-G, Manigold T, Letocart V, et al. Outcomes of emergency transcatheter aortic valve replacement in patients with cardiogenic shock: A multicenter retrospective study. Catheter Cardiovasc Interv. 2022;99:2117&#x2013;24. doi: 10.1002/ccd.30194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.30194</ArticleId><ArticleId IdType="pubmed">35395142</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72&#x2013;227. doi: 10.1161/CIR.0000000000000923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000923</ArticleId><ArticleId IdType="pubmed">33332150</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelo A, Teixeira B, Grazina A, et al. Urgent versus Non-Urgent Transcatheter Aortic Valve Implantation Outcomes. Cardiology. 2023;148:469&#x2013;77. doi: 10.1159/000531815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000531815</ArticleId><ArticleId IdType="pubmed">37429257</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Wei S, Zhu L, et al. Effectiveness and safety of emergency transcatheter aortic valve replacement in patients with severe aortic stenosis complicated by cardiogenic shock: A systematic review and meta-analysis. H L. 2025;69:62&#x2013;70. doi: 10.1016/j.hrtlng.2024.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2024.09.011</ArticleId><ArticleId IdType="pubmed">39321747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernly B, Jirak P, Lichtenauer M, et al. Systematic Review and Meta-Analysis of Interventional Emergency Treatment of Decompensated Severe Aortic Stenosis. J Invasive Cardiol. 2020;32:30&#x2013;6. doi: 10.25270/jic/19.00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.25270/jic/19.00003</ArticleId><ArticleId IdType="pubmed">31611428</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty S, Patel N, Bandyopadhyay D, et al. Readmission following urgent transcatheter aortic valve implantation versus urgent balloon aortic valvuloplasty in patients with decompensated heart failure or cardiogenic shock. Catheter Cardiovasc Interv. 2021;98:607&#x2013;12. doi: 10.1002/ccd.29690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29690</ArticleId><ArticleId IdType="pubmed">33817969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichibori Y, Mizote I, Tsuda M, et al. Long-Term Outcomes of High-Risk or Inoperable Patients Who Underwent Transcatheter Aortic Valve Implantation. Am J Cardiol. 2019;124:573&#x2013;9. doi: 10.1016/j.amjcard.2019.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.05.025</ArticleId><ArticleId IdType="pubmed">31255236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaewkes D, Ochiai T, Flint N, et al. Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis Hospitalized With Acute Heart Failure. Am J Cardiol. 2021;144:100&#x2013;10. doi: 10.1016/j.amjcard.2020.12.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.12.046</ArticleId><ArticleId IdType="pubmed">33383005</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan N, Borlaug BA, Bailey AL, et al. Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure. JACC: Heart Failure . 2024;12:1141&#x2013;56. doi: 10.1016/j.jchf.2024.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2024.03.020</ArticleId><ArticleId IdType="pubmed">38960519</ArticleId></ArticleIdList></Reference><Reference><Citation>Urena M, Himbert D. Cardiogenic Shock in Aortic Stenosis: Is It the Time for &#x201c;Primary&#x201d; TAVR? JACC Cardiovasc Interv. 2020;13:1326&#x2013;8. doi: 10.1016/j.jcin.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2020.04.005</ArticleId><ArticleId IdType="pubmed">32499023</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraccaro C, Karam N, M&#xf6;llmann H, et al. Transcatheter interventions for left-sided valvular heart disease complicated by cardiogenic shock: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the Association for Acute Cardiovascular Care (ACVC) and the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2023;19:634&#x2013;51. doi: 10.4244/EIJ-D-23-00473.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-D-23-00473</ArticleId><ArticleId IdType="pmc">PMC10587846</ArticleId><ArticleId IdType="pubmed">37624587</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedeney P, Chevrot G, Collet J-P. VARC-3 Criteria: Adding Prognosis to Injury. JACC Cardiovasc Interv. 2023;16:1233&#x2013;5. doi: 10.1016/j.jcin.2023.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2023.04.012</ArticleId><ArticleId IdType="pubmed">37225295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Lee J-H. Emergency transcatheter aortic valve replacement for a patient with decompensated severe aortic stenosis accompanied by cardiorenal syndrome: a case report. BMC Cardiovasc Disord. 2018;18:55. doi: 10.1186/s12872-018-0791-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0791-7</ArticleId><ArticleId IdType="pmc">PMC5859714</ArticleId><ArticleId IdType="pubmed">29558902</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38936467</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1885-5857</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Revista espanola de cardiologia (English ed.)</Title><ISOAbbreviation>Rev Esp Cardiol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Timing of multivessel revascularization in stable patients with STEMI: a systematic review and network meta-analysis.</ArticleTitle><Pagination><StartPage>127</StartPage><EndPage>137</EndPage><MedlinePgn>127-137</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rec.2024.06.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1885-5857(24)00193-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">Multivessel percutaneous coronary intervention (MV-PCI) is recommended in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (CAD) without cardiogenic shock. The present network meta-analysis investigated the optimal timing of MV-PCI in this context.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We pooled the aggregated data from randomized trials investigating stable STEMI patients with multivessel CAD treated with a strategy of either MV-PCI or culprit vessel-only PCI. The primary outcome was all-cause death. The main secondary outcomes were cardiovascular death, myocardial infarction, and unplanned ischemia-driven revascularization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 11 trials, a total of 10 507 patients were randomly assigned to MV-PCI (same sitting, n=1683; staged during the index hospitalization, n=3460; staged during a subsequent hospitalization within 45 days, n=3275) or to culprit vessel-only PCI (n=2089). The median follow-up was 18.6 months. In comparison with culprit vessel-only PCI, MV-PCI staged during the index hospitalization significantly reduced all-cause death (risk ratio, 0.73; 95%CI, 0.56-0.92; P=.008) and ranked as possibly the best treatment option for this outcome compared with all other strategies. In comparison with culprit vessel-only PCI, a MV-PCI reduced cardiovascular mortality without differences dependent on the timing of revascularization. MV-PCI within the index hospitalization, either in a single procedure or staged, significantly reduced myocardial infarction and unplanned ischemia-driven revascularization, with no significant difference between each other.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with STEMI and multivessel CAD without cardiogenic shock, multivessel PCI within the index hospitalization, either in a single procedure or staged, represents the safest and most efficacious approach. The different timings of multivessel PCI did not result in any significant differences in all-cause death. This study is registered at PROSPERO (CRD42023457794).</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Sociedad Espa&#xf1;ola de Cardiolog&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voll</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuna</LastName><ForeName>Constantin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scalamogna</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany; Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessler</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany; Deutsches Zentrum f&#xfc;r Herz-Kreislauf-Forschung (DZHK), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kufner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rheude</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sager</LastName><ForeName>Hendrik B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany; Deutsches Zentrum f&#xfc;r Herz-Kreislauf-Forschung (DZHK), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xhepa</LastName><ForeName>Erion</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiebe</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany; Deutsches Zentrum f&#xfc;r Herz-Kreislauf-Forschung (DZHK), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute Dublin and Department of Cardiology, Mater Private Network, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons of Ireland University of Medicine and Health Sciences, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schunkert</LastName><ForeName>Heribert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany; Deutsches Zentrum f&#xfc;r Herz-Kreislauf-Forschung (DZHK), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ndrepepa</LastName><ForeName>Gjin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xe4;hli</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastrati</LastName><ForeName>Adnan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany; Deutsches Zentrum f&#xfc;r Herz-Kreislauf-Forschung (DZHK), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassese</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany. Electronic address: cassese@dhm.mhn.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Cardiol (Engl Ed)</MedlineTA><NlmUniqueID>101587954</NlmUniqueID><ISSNLinking>1885-5857</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009204" MajorTopicYN="Y">Myocardial Revascularization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronary artery disease</Keyword><Keyword MajorTopicYN="N">Enfermedad coronaria</Keyword><Keyword MajorTopicYN="N">Infarto de miocardio</Keyword><Keyword MajorTopicYN="N">Intervenci&#xf3;n coronaria percut&#xe1;nea</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Metan&#xe1;lisis</Keyword><Keyword MajorTopicYN="N">Multivaso</Keyword><Keyword MajorTopicYN="N">Multivessel</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>30</Day><Hour>0</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38936467</ArticleId><ArticleId IdType="doi">10.1016/j.rec.2024.06.002</ArticleId><ArticleId IdType="pii">S1885-5857(24)00193-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32458216</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-7322</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Heart failure reviews</Title><ISOAbbreviation>Heart Fail Rev</ISOAbbreviation></Journal><ArticleTitle>Outcomes of percutaneous temporary biventricular mechanical support: a systematic review.</ArticleTitle><Pagination><StartPage>879</StartPage><EndPage>890</EndPage><MedlinePgn>879-890</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10741-020-09971-7</ELocationID><Abstract><AbstractText>Percutaneous biventricular assist devices (BiVAD) are a recently developed treatment option for severe cardiogenic shock. This systematic review sought to identify indications and outcomes of patients placed on percutaneous BiVAD support. An electronic search was performed to identify all appropriate studies utilizing a percutaneous BiVAD configuration. Fifteen studies comprising of 20 patients were identified. Individual patient survival and outcomes data were combined for statistical analysis. All 20 patients were supported with a microaxial LVAD, 12/20 (60%) of those patients were supported with a microaxial (RMA) right ventricular assist device (RVAD), and the remaining 8/20 (40%) patients were supported with a centrifugal extracorporeal RVAD (RCF). All patients presented with cardiogenic shock, and of these, 12/20 (60%) presented with a non-ischemic etiology vs 8/20 (40%) with ischemic disease. For the RMA group, RVAD support was significantly longer [RMA 5 (IQR 4-7) days vs RCF 1 (IQR 1-2) days, p&#x2009;=&#x2009;0.03]. Intravascular hemolysis post-BiVAD occurred in three patients (27.3%) [RMA 3 (33.3%) vs RCF 0 (0%), p&#x2009;=&#x2009;0.94]. Five patients received a durable left ventricular assist device, one patient received a total artificial heart, and one patient underwent a heart transplantation. Estimated 30-day mortality was 15.0%, and 78.6% were discharged alive. Both strategies for percutaneous BiVAD support appear to be viable options for severe cardiogenic shock.</AbstractText><CopyrightInformation>&#xa9; 2020. Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-9128-1084</Identifier><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jae H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maynes</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prochno</LastName><ForeName>Kyle W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Chelsey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Sinal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Rohinton J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massey</LastName><ForeName>H Todd</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchantchaleishvili</LastName><ForeName>Vakhtang</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA, 19107, USA. tchantchaleishvili@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Fail Rev</MedlineTA><NlmUniqueID>9612481</NlmUniqueID><ISSNLinking>1382-4147</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biventricular assist device</Keyword><Keyword MajorTopicYN="N">Biventricular heart failure</Keyword><Keyword MajorTopicYN="N">Centrifugal devices</Keyword><Keyword MajorTopicYN="N">Microaxial devices</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32458216</ArticleId><ArticleId IdType="doi">10.1007/s10741-020-09971-7</ArticleId><ArticleId IdType="pii">10.1007/s10741-020-09971-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiu C-Y, H&#xe4;ttasch R, Praeger D, Knebel F, Stangl K, Ramirez ID, Dreger H (2018) Percutaneous biventricular Impella support in therapy-refractory cardiogenic shock. Heart Lung 47:250&#x2013;252. https://doi.org/10.1016/j.hrtlng.2018.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2018.03.009</ArticleId><ArticleId IdType="pubmed">29628145</ArticleId></ArticleIdList></Reference><Reference><Citation>Goda A, Takayama H, Koeckert M, Pak SW, Sutton EM, Cohen S, Uriel N, Jorde U, Mancini D, Naka Y (2011) Use of ventricular assist devices in patients with mitral valve prostheses. J Card Surg 26:334&#x2013;337. https://doi.org/10.1111/j.1540-8191.2011.01248.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1540-8191.2011.01248.x</ArticleId><ArticleId IdType="pubmed">21480991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaparro SV, Badheka A, Marzouka GR, Tanawuttiwat T, Ahmed F, Sacher V, Pham SM (2012) Combined use of Impella left ventricular assist device and extracorporeal membrane oxygenation as a bridge to recovery in fulminant myocarditis. ASAIO J 58:285&#x2013;287. https://doi.org/10.1097/MAT.0b013e31824b1f70</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0b013e31824b1f70</ArticleId><ArticleId IdType="pubmed">22395121</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumean M, Pham DT, Kapur NK (2015) Percutaneous bi-atrial extracorporeal membrane oxygenation for acute circulatory support in advanced heart failure. Catheter Cardiovasc Interv 85:1097&#x2013;1099. https://doi.org/10.1002/ccd.25791</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.25791</ArticleId><ArticleId IdType="pubmed">25529821</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghili N, Bader Y, Vest AR et al (2016) Biventricular circulatory support using 2 axial flow catheters for cardiogenic shock without the need for surgical vascular access. Circ Cardiovasc Interv 9. https://doi.org/10.1161/CIRCINTERVENTIONS.116.003636</Citation></Reference><Reference><Citation>Gaudard P, Mourad M, Eliet J et al (2015) Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock. Crit Care 19:363. https://doi.org/10.1186/s13054-015-1073-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-1073-8</ArticleId><ArticleId IdType="pubmed">26453047</ArticleId><ArticleId IdType="pmc">4600310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshi H, Shinshi T, Takatani S (2006) Third-generation blood pumps with mechanical noncontact magnetic bearings. Artif Organs 30:324&#x2013;338. https://doi.org/10.1111/j.1525-1594.2006.00222.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1594.2006.00222.x</ArticleId><ArticleId IdType="pubmed">16683949</ArticleId></ArticleIdList></Reference><Reference><Citation>De Robertis F, Birks EJ, Rogers P et al (2006) Clinical performance with the Levitronix Centrimag short-term ventricular assist device. J Heart Lung Transplant 25:181&#x2013;186. https://doi.org/10.1016/j.healun.2005.08.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2005.08.019</ArticleId><ArticleId IdType="pubmed">16446218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar B, Adkins LE, Civitello AB et al (2006) Clinical experience with the TandemHeart percutaneous ventricular assist device. Tex Heart Inst J 33:111&#x2013;115</Citation><ArticleIdList><ArticleId IdType="pubmed">16878609</ArticleId><ArticleId IdType="pmc">1524679</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Scandroglio AM, Latib A (2018) Full percutaneous biventricular support with two Impella pumps: the bi-Pella approach. ESC Heart Fail 5:368&#x2013;371. https://doi.org/10.1002/ehf2.12274</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12274</ArticleId><ArticleId IdType="pubmed">29465166</ArticleId><ArticleId IdType="pmc">5933967</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum EC, Martz CR, Selektor Y, Nemeh H, Smith ZR, To L (2018) Anticoagulation of percutaneous ventricular assist device using Argatroban-based purge solution: a case series. J Pharm Pract 31:514&#x2013;518. https://doi.org/10.1177/0897190017727191</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0897190017727191</ArticleId><ArticleId IdType="pubmed">28830286</ArticleId></ArticleIdList></Reference><Reference><Citation>Stulak JM, Lim JY, Maltais S (2014) Ventricular assist device selection: which one and when? Croat Med J 55:596&#x2013;599. https://doi.org/10.3325/cmj.2014.55.596</Citation><ArticleIdList><ArticleId IdType="doi">10.3325/cmj.2014.55.596</ArticleId><ArticleId IdType="pubmed">25559830</ArticleId><ArticleId IdType="pmc">4295068</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama H, Soni L, Kalesan B, Truby LK, Ota T, Cedola S, Khalpey Z, Uriel N, Colombo P, Mancini DM, Jorde UP, Naka Y (2014) Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. Circ Heart Fail 7:799&#x2013;806. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000271</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.113.000271</ArticleId><ArticleId IdType="pubmed">25027874</ArticleId><ArticleId IdType="pmc">4369383</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopal V, Steahr G, Wilmer CI, Raval NY (2010) A novel percutaneous mechanical biventricular bridge to recovery in severe cardiac allograft rejection. J Heart Lung Transplant 29:93&#x2013;95. https://doi.org/10.1016/j.healun.2009.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2009.09.015</ArticleId><ArticleId IdType="pubmed">20123247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellert J, Jensen MJ, Jensen LO, M&#xf8;ller JE (2018) Percutaneous biventricular cardiac assist device in cardiogenic shock and refractory cardiac arrest. EuroIntervention 13:e2114&#x2013;e2115. https://doi.org/10.4244/eij-d-17-00637</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/eij-d-17-00637</ArticleId><ArticleId IdType="pubmed">29039311</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunziker P, Hunziker L (2013) Percutaneous biventricular cardiac assist device in cardiogenic shock. Eur Heart J 34:1620. https://doi.org/10.1093/eurheartj/eht020</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht020</ArticleId><ArticleId IdType="pubmed">23594594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamioka N, Patel A, Burke MA, Greenbaum A, Babaliaros V (2019) Biventricular Impella placement via complete venous access. Catheter Cardiovasc Interv 93:E343&#x2013;e345. https://doi.org/10.1002/ccd.27103</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.27103</ArticleId><ArticleId IdType="pubmed">28544381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur NK, Jumean M, Ghuloom A, Aghili N, Vassallo C, Kiernan MS, DeNofrio D, Pham DT (2015) First successful use of 2 axial flow catheters for percutaneous biventricular circulatory support as a bridge to a durable left ventricular assist device. Circ Heart Fail 8:1006&#x2013;1008. https://doi.org/10.1161/circheartfailure.115.002374</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circheartfailure.115.002374</ArticleId><ArticleId IdType="pubmed">26374919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasa JJ, Castellanos DA, Denfield SW (2018) First report of biventricular percutaneous Impella ventricular assist device use in pediatric patients. ASAIO J 64:e134&#x2013;e137. https://doi.org/10.1097/mat.0000000000000732</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mat.0000000000000732</ArticleId><ArticleId IdType="pubmed">29240626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy CD, Jumean MF, Pham DT, Kiernan MS, Denofrio D, Kapur NK (2013) Percutaneous circulatory support for biventricular failure. Circ Cardiovasc Interv 6:e12&#x2013;e14. https://doi.org/10.1161/circinterventions.112.000018</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circinterventions.112.000018</ArticleId><ArticleId IdType="pubmed">23591421</ArticleId></ArticleIdList></Reference><Reference><Citation>Renard BM, Hanson ID, Goldstein JA et al (2017) Severe mitral regurgitation and biventricular heart failure successfully treated with biventricular percutaneous axial flow pumps as a bridge to mitral valve surgery. Catheter Cardiovasc Interv 89:159&#x2013;162. https://doi.org/10.1002/ccd.26496</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.26496</ArticleId><ArticleId IdType="pubmed">27015603</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokr M, Rashed A, Yassin AS, Kaki A, Schreiber T (2018) Use of percutaneous biventricular mechanical support in post infarction ventricular septal rupture: mechanical support for a mechanical catastrophe. J Am Coll Cardiol 71:A2186. https://doi.org/10.1016/S0735-1097(18)32727-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(18)32727-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirabel M, Luyt C-E, Leprince P, Trouillet JL, L&#xe9;ger P, Pavie A, Chastre J, Combes A (2011) Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support*. Crit Care Med 39:1029&#x2013;1035. https://doi.org/10.1097/CCM.0b013e31820ead45</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31820ead45</ArticleId><ArticleId IdType="pubmed">21336134</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulate D, Luyt C-E, Pozzi M, Niculescu M, Combes A, Leprince P, Kirsch M (2013) Acute lung injury after mechanical circulatory support implantation in patients on extracorporeal life support: an unrecognized problem&#x2020;. Eur J Cardiothorac Surg 44:544&#x2013;550. https://doi.org/10.1093/ejcts/ezt125</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezt125</ArticleId><ArticleId IdType="pubmed">23477925</ArticleId></ArticleIdList></Reference><Reference><Citation>Donker DW, Brodie D, Henriques JPS, Broom&#xe9; M (2019) Left ventricular unloading during veno-arterial ECMO: a review of percutaneous and surgical unloading interventions. Perfusion 34:98&#x2013;105. https://doi.org/10.1177/0267659118794112</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659118794112</ArticleId><ArticleId IdType="pubmed">30112975</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M, Pappalardo F (2018) Impella RP in the treatment of right ventricular failure: what we know and where we go. J Cardiothorac Vasc Anesth 32:2339&#x2013;2343. https://doi.org/10.1053/j.jvca.2018.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2018.06.007</ArticleId><ArticleId IdType="pubmed">30093192</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MB, Goldstein J, Milano C, Morris LD, Kormos RL, Bhama J, Kapur NK, Bansal A, Garcia J, Baker JN, Silvestry S, Holman WL, Douglas PS, O&#x2019;Neill W (2015) Benefits of a novel percutaneous ventricular assist device for right heart failure: the prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant 34:1549&#x2013;1560. https://doi.org/10.1016/j.healun.2015.08.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2015.08.018</ArticleId><ArticleId IdType="pubmed">26681124</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MB, O&#x2019;Brien M (2013) Use of the Impella 2.5 microaxial pump for right ventricular support after insertion of Heartmate II left ventricular assist device. Ann Thorac Surg 95:e109&#x2013;e110. https://doi.org/10.1016/j.athoracsur.2012.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2012.10.013</ArticleId><ArticleId IdType="pubmed">23608288</ArticleId></ArticleIdList></Reference><Reference><Citation>John R, Long JW, Massey HT, Griffith BP, Sun BC, Tector AJ, Frazier OH, Joyce LD (2011) Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg 141:932&#x2013;939. https://doi.org/10.1016/j.jtcvs.2010.03.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2010.03.046</ArticleId><ArticleId IdType="pubmed">20605026</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Heldman A (2015) Emergent percutaneous biventricular support during transcatheter aortic valve replacement. J Heart Valve Dis 24:313&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pubmed">26901902</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmack B, Weymann A, Popov A-F, Patil NP, Sabashnikov A, Kremer J, Farag M, Brcic A, Lichtenstern C, Karck M, Ruhparwar A (2016) Concurrent left ventricular assist device (LVAD) implantation and percutaneous temporary RVAD support via CardiacAssist Protek-Duo TandemHeart to preempt right heart failure. Med Sci Monit Basic Res 22:53&#x2013;57. https://doi.org/10.12659/MSMBR.898897</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSMBR.898897</ArticleId><ArticleId IdType="pubmed">27145697</ArticleId><ArticleId IdType="pmc">4913730</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey HT, Choi JH, Maynes EJ, Tchantchaleishvili V (2019) Temporary support strategies for cardiogenic shock: extracorporeal membrane oxygenation, percutaneous ventricular assist devices and surgically placed extracorporeal ventricular assist devices. Ann Cardiothorac Surg 8:32&#x2013;43. https://doi.org/10.21037/acs.2018.11.05</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs.2018.11.05</ArticleId><ArticleId IdType="pubmed">30854310</ArticleId><ArticleId IdType="pmc">6379194</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, Ngufor C, Girotra S, Amin AP, Shah ND, Desai NR (2020) Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. Jama. 323:734. https://doi.org/10.1001/jama.2020.0254</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.0254</ArticleId><ArticleId IdType="pubmed">32040163</ArticleId><ArticleId IdType="pmc">7042879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla S, Esposito ML, Breton C, Pedicini R, Mullin A, O'Kelly R, Anderson M, Morris DL, Batsides G, Ramzy D, Grise M, Pham DT, Kapur NK (2017) Acute biventricular mechanical circulatory support for cardiogenic shock. J Am Heart Assoc 6. https://doi.org/10.1161/JAHA.117.006670</Citation></Reference><Reference><Citation>Tchantchaleishvili V, Wood KL, Carlson LA, Barrus B, Swartz MF, Vidula H, Lehoux JM, Todd Massey H, Chen L (2017) Temporary mechanical circulatory support after orthotopic heart transplantation: a single-centre experience. Interact Cardiovasc Thorac Surg 25:41&#x2013;46. https://doi.org/10.1093/icvts/ivx077</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivx077</ArticleId><ArticleId IdType="pubmed">28387838</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan K, Luc JGY, Xu J, Maltais S, Stulak JM, Yan TD, Tchantchaleishvili V (2017) Utilization and outcomes of temporary mechanical circulatory support for graft dysfunction after heart transplantation. ASAIO J 63:695&#x2013;703. https://doi.org/10.1097/MAT.0000000000000599</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000599</ArticleId><ArticleId IdType="pubmed">28906273</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrovec GW, Anderson M, Schreiber T, Popma J, Lombardi W, Maini B, Moller JE, Sch&#xe4;fer A, Dixon SR, Hall S, Ohman EM, Mindrescu C, Moses J, O'Neill W (2018) The cVAD registry for percutaneous temporary hemodynamic support: a prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. Am Heart J 199:115&#x2013;121. https://doi.org/10.1016/j.ahj.2017.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2017.09.007</ArticleId><ArticleId IdType="pubmed">29754648</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39748537</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Transcatheter Aortic Valve Replacement in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>754</StartPage><EndPage>760</EndPage><MedlinePgn>754-760</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.31367</ELocationID><Abstract><AbstractText Label="BACKGROUND">The co-existence of severe aortic stenosis (AS) and hypertrophic cardiomyopathy (HCM) is not uncommon. Surgical intervention is the gold standard management. Patients with high surgical risk might undergo transcatheter aortic valve replacement (TAVR). However, TAVR outcomes are unclear in this population. We aimed to investigate the impact of HCM on the outcomes of TAVR.</AbstractText><AbstractText Label="AIM">We aim to investigate the outcomes of TAVR in patients with HCM.</AbstractText><AbstractText Label="METHODS">We systematically searched PubMed, EMBASE, and Scopus for studies that compared outcomes of TAVR procedure between patients with HCM and those without it. Using the random-effects model, the odds ratios (OR) with 95% confidence interval (CI) were reported.</AbstractText><AbstractText Label="RESULTS">We screened 102 articles and identified three observational cohort studies. Compared to patients who underwent TAVR without underlying HCM, TAVR for AS co-existed with HCM was associated with higher rates of mortality (OR 5.79; 95% CI: 3.38; 9.91, p&#x2009;&lt;&#x2009;0.0001), cardiogenic shock (OR 4.55; 95% CI: 3.40; 6.08, p&#x2009;&lt;&#x2009;0.0001), aortic dissection (OR 4.95; 95% CI: 3.17; 7.74, p&#x2009;&lt;&#x2009;0.0001), vascular complications (OR 2.10; 95% CI: 1.27; 3.47, p&#x2009;=&#x2009;0.004), and renal impairment (OR 1.80; 95% CI: 1.36; 2.40, p&#x2009;&lt;&#x2009;0.0001). There was no difference between the comparison groups in terms of complete heart block, new permanent pacemaker implantation, or bleeding.</AbstractText><AbstractText Label="CONCLUSION">In patients with severe AS and HCM, TAVR was associated with significantly higher occurrence of mortality, cardiogenic shock, aortic dissection, vascular complications, and renal impairment as well as the need for mechanical ventilation than patients who did not have HCM.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Ashraf</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1029-2559</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaddoura</LastName><ForeName>Rasha</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2613-9759</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Abhinav</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinyandu</LastName><ForeName>Tawanda</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webber</LastName><ForeName>Fabricio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davila</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Diseases, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarich</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Diseases, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>The authors received no specific funding for this work.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002312" MajorTopicYN="Y">Cardiomyopathy, Hypertrophic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="Y">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="Y">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="Y">Aortic Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HCM</Keyword><Keyword MajorTopicYN="N">TAVI</Keyword><Keyword MajorTopicYN="N">TAVR</Keyword><Keyword MajorTopicYN="N">aortic stenosis</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">heart block</Keyword><Keyword MajorTopicYN="N">pacemaker</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>3</Day><Hour>1</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39748537</ArticleId><ArticleId IdType="doi">10.1002/ccd.31367</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. Roberta and S. Comenale, 2023, Epidemiology of Aortic Valve Stenosis (AS) and of&#xa0;Aortic Valve Incompetence (AI): Is the Prevalence of AS/AI Similar in Different Parts of the World? Vol. 18, http://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-18/epidemiology-of-aortic-valve-stenosis-as-and-of-aortic-valve-incompetence-ai.</Citation></Reference><Reference><Citation>S. H. Pujari and P. Agasthi, &#x201c;Aortic Stenosis.&#x201d; StatPearls [Internet], ed. P. Agasthi (Treasure Island (FL): StatPearls Publishing, 2023). [cited 2023 Nov 28], http://www.ncbi.nlm.nih.gov/books/NBK557628/.</Citation></Reference><Reference><Citation>C. Vanichsarn and R. J. Siegel, &#x201c;Fool Me Once, Fool Me Twice: Hypertrophic Cardiomyopathy With Aortic Stenosis,&#x201d; American Journal of Medicine 128, no. 10 (October 2015): 1076&#x2013;1079.</Citation></Reference><Reference><Citation>M. Y. Desai, A. Alashi, Z. B. Popovic, et al., &#x201c;Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy and Concomitant Aortic Stenosis Undergoing Surgical Myectomy and Aortic Valve Replacement,&#x201d; Journal of the American Heart Association 10, no. 18 (September 2021): e018435.</Citation></Reference><Reference><Citation>C. M. Otto, R. A. Nishimura, R. O. Bonow, et al., &#x201c;2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,&#x201d; Circulation 143, no. 5 (February 2021): e72&#x2013;e227.</Citation></Reference><Reference><Citation>M. J. Reardon, N. M. Van Mieghem, J. J. Popma, et al., &#x201c;Surgical or Transcatheter Aortic&#x2010;Valve Replacement in Intermediate&#x2010;Risk Patients,&#x201d; New England Journal of Medicine 376, no. 14 (April 2017): 1321&#x2013;1331.</Citation></Reference><Reference><Citation>M. B. Leon, C. R. Smith, M. Mack, et al., &#x201c;Transcatheter Aortic&#x2010;Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery,&#x201d; New England Journal of Medicine 363, no. 17 (October 2010): 1597&#x2013;1607.</Citation></Reference><Reference><Citation>M. B. Leon, C. R. Smith, M. J. Mack, et al., &#x201c;Transcatheter or Surgical Aortic&#x2010;Valve Replacement in Intermediate&#x2010;Risk Patients,&#x201d; New England Journal of Medicine 374, no. 17 (April 2016): 1609&#x2013;1620.</Citation></Reference><Reference><Citation>C. R. Smith, M. B. Leon, M. J. Mack, et al., &#x201c;Transcatheter Versus Surgical Aortic&#x2010;Valve Replacement in High&#x2010;Risk Patients,&#x201d; New England Journal of Medicine 364, no. 23 (June 2011): 2187&#x2013;2198.</Citation></Reference><Reference><Citation>M. Mhanna, A. M. K. Minhas, R. W. Ariss, et al., &#x201c;Transcatheter Versus Surgical Aortic Valve Replacement in Hypertrophic Cardiomyopathy Patients With Aortic Stenosis,&#x201d; Current Problems in Cardiology 48, no. 8 (August 2023): 101180.</Citation></Reference><Reference><Citation>J. P. T. Higgins, J. Thomas, J. Chandler, et al., eds., Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024) (Cochrane, 2024), www.training.cochrane.org/handbook.</Citation></Reference><Reference><Citation>D. Bandyopadhyay, S. Chakraborty, B. Amgai, et al., &#x201c;Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement,&#x201d; JAMA Network Open 3, no. 2 (2020): e1921669.</Citation></Reference><Reference><Citation>R. Vyas, S. Nazir, K. R. Ahuja, et al., &#x201c;Endovascular Transcatheter Aortic Valve Replacement Outcomes in Hypertrophic Cardiomyopathy: Insights From The National Inpatient Sample (2014&#x2013;2018),&#x201d; Cardiology 148, no. 3 (July 2023): 289&#x2013;292.</Citation></Reference><Reference><Citation>N. J. Kiefer, G. C. Salber, G. M. Burke, et al., &#x201c;The Impact of Basal Septal Hypertrophy on Outcomes After Transcatheter Aortic Valve Replacement,&#x201d; Journal of the American Society of Echocardiography 32, no. 11 (November 2019): 1416&#x2013;1425.</Citation></Reference><Reference><Citation>B. J. Maron, M. Y. Desai, R. A. Nishimura, et al., &#x201c;Diagnosis and Evaluation of Hypertrophic Cardiomyopathy,&#x201d; Journal of the American College of Cardiology 79, no. 4 (February 2022): 372&#x2013;389.</Citation></Reference><Reference><Citation>M. S. Maron, B. J. Maron, C. Harrigan, et al., &#x201c;Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance,&#x201d; Journal of the American College of Cardiology 54, no. 3 (July 2009): 220&#x2013;228.</Citation></Reference><Reference><Citation>J. Bogaert and I. Olivotto, &#x201c;MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside,&#x201d; Radiology 273, no. 2 (November 2014): 329&#x2013;348.</Citation></Reference><Reference><Citation>A. J. Baxi, C. S. Restrepo, D. Vargas, A. Marmol&#x2010;Velez, D. Ocazionez, and H. Murillo, &#x201c;Hypertrophic Cardiomyopathy From A to Z: Genetics, Pathophysiology, Imaging, and Management,&#x201d; Radiographics 36, no. 2 (2016): 335&#x2013;354.</Citation></Reference><Reference><Citation>S. R. Ommen, S. Mital, M. A. Burke, et al., &#x201c;2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy,&#x201d; Circulation 142, no. 25 (December 2020): e558&#x2013;e631.</Citation></Reference><Reference><Citation>B. J. Maron, M. Y. Desai, R. A. Nishimura, et al., &#x201c;Diagnosis and Evaluation of Hypertrophic Cardiomyopathy : JACC State&#x2010;of&#x2010;the&#x2010;Art Review,&#x201d; Journal of the American College of Cardiology 79, no. 4 (2022): 372&#x2013;389, https://doi.org/10.1016/j.jacc.2021.12.002.</Citation></Reference><Reference><Citation>R. Rubinshtein, J. F. Glockner, S. R. Ommen, et al., &#x201c;Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast&#x2010;Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy,&#x201d; Circulation: Heart Failure 3 (2010): 51&#x2013;58, https://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.109.854026.</Citation></Reference><Reference><Citation>T. F. Ismail, A. Jabbour, A. Gulati, et al., &#x201c;Role of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in the Risk Stratification of Hypertrophic Cardiomyopathy,&#x201d; Heart 100 (2014): 1851&#x2013;1858, https://heart-bmj-com.qulib.idm.oclc.org/content/100/23/1851.short.</Citation></Reference><Reference><Citation>B. J. Gersh, B. J. Maron, R. O. Bonow, et al., &#x201c;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy,&#x201d; Circulation 124, no. 24 (December 2011): e783&#x2013;e831.</Citation></Reference><Reference><Citation>A. F. Members and H. Bundgaard, &#x201c;2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC),&#x201d; European Heart Journal 35, no. 39 (2014 Oct 14): 2733&#x2013;2779.</Citation></Reference><Reference><Citation>M. A. Raj, S. Ranka, and A. Goyal, &#x201c;Hypertrophic Obstructive Cardiomyopathy.&#x201d; StatPearls [Internet]. Treasure Island (FL) (StatPearls Publishing, 2023, http://www.ncbi.nlm.nih.gov/books/NBK430820/.</Citation></Reference><Reference><Citation>M. Qintar, P. Villablanca, J. Lee, et al., &#x201c;Emergency Alcohol Septal Ablation for Shock After TAVR: One More Option in the Toolbox,&#x201d; JACC. Case reports 3, no. 6 (2021): 853&#x2013;858.</Citation></Reference><Reference><Citation>K. R. Olsen, J. E. LaGrew, C. A. Awoniyi, and J. C. Goldstein, &#x201c;Undiagnosed Hypertrophic Obstructive Cardiomyopathy During Transcatheter Aortic Valve Replacement: A Case Report,&#x201d; Journal of Medical Case Reports 12 (2018): 372, https://jmedicalcasereports-biomedcentral-com.qulib.idm.oclc.org/articles/10.1186/s13256-018-1904-8.</Citation></Reference><Reference><Citation>W. M. Suh, C. F. Witzke, and I. F. Palacios, &#x201c;Suicide Left Ventricle Following Transcatheter Aortic Valve Implantation,&#x201d; Catheterization and Cardiovascular Interventions 76 (2010): 616&#x2013;620, https://onlinelibrary-wiley-com.qulib.idm.oclc.org/doi/10.1002/ccd.22609.</Citation></Reference><Reference><Citation>T. Hamana, H. Yamamoto, N. Takahashi, et al., &#x201c;Non&#x2010;Surgical Management of an Acute Decompensated Heart Failure Patient With Severe Aortic Stenosis and Concomitant Left Ventricular Outflow Tract Obstruction,&#x201d; Journal of Cardiology Cases 25, no. 3 (March 2022): 188&#x2013;192.</Citation></Reference><Reference><Citation>C. Pollick, H. Shmueli, N. Maalouf, and R. H. Zadikany, &#x201c;Left Ventricular Cavity Obliteration: Mechanism of the Intracavitary Gradient and Differentiation From Hypertrophic Obstructive Cardiomyopathy,&#x201d; Echocardiography 37, no. 6 (2020): 822&#x2013;831.</Citation></Reference><Reference><Citation>A. Khurana, A. Khalif, S. A. Al&#x2010;Adwan, and R. Khalil, &#x201c;The Suicide Left Ventricle: A Dreaded Complication of Post Aortic Valve Replacement,&#x201d; Journal of the American College of Cardiology 81, no. 8_Suppl (March 2023): 2911.</Citation></Reference><Reference><Citation>E. Monda, M. Lioncino, G. Palmiero, et al., &#x201c;Bisoprolol for Treatment of Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. The Basic (Bisoprolol as Therapy in Hypertrophic Cardiomyopathy) Study,&#x201d; International Journal of Cardiology 354 (May 2022): 22&#x2013;28.</Citation></Reference><Reference><Citation>A. R. Fath, C. E. Jokerst, A. Aglan, N. Mihyawi, and F. Mookadam, &#x201c;Multimodality Imaging Demonstrating an Apical Variant Hypertrophic Cardiomyopathy in an Uncommon Pentad,&#x201d; Journal of Investigative Medicine High Impact Case Reports 8 (2020), https://doi.org/10.1177/2324709620934324.</Citation></Reference><Reference><Citation>Y. Li, Y. Feng, X. Li, et al., &#x201c;Case Report: Minimally Invasive Therapy by Transcatheter Aortic Valve Replacement and Percutaneous Intramyocardial Septal Radiofrequency Ablation for a Patient With Aortic Stenosis Combined With Hypertrophic Obstructive Cardiomyopathy: Two&#x2010;Year Follow&#x2010;Up Results,&#x201d; Frontiers in Cardiovascular Medicine 8 (2021): 735219.</Citation></Reference><Reference><Citation>M. Marchel, E. Szczerba, E. P&#x119;dzich&#x2010;Placha, et al., &#x201c;Left Ventricular Outflow Obstruction After TAVR Due to Systolic Anterior Motion Successfully Treated With Cardiac Pacing,&#x201d; Journal of Cardiothoracic and Vascular Anesthesia 34, no. 10 (October 2020): 2718&#x2013;2721.</Citation></Reference><Reference><Citation>A. A. Ayouby, M. Gilard, T. Hebert, and R. Didier, &#x201c;Case Report: Iatrogenic Left Ventricular Outflow Tract to Right Atrium Fistula After Trans&#x2010;Femoral Transcatheter Aortic Valve Implantation Associated With Asymmetric Septal Hypertrophy,&#x201d; European Heart Journal&#x2014;Case Reports 5 (2021): ytab020, https://academic-oup-com.qulib.idm.oclc.org/ehjcr/article/5/3/ytab020/6167943.</Citation></Reference><Reference><Citation>M. C. Saccheri, T. F. Cianciulli, F. L. Blanco, And R. I. Blanco, &#x201c;Rapidly Progressive Aortic Stenosis Treated With Transcatheter Aortic Valve Implantation in a Patient With Fabry Disease: A Case Report,&#x201d; European Heart Journal&#x2014;Case Reports 5 (2021): ytab124, https://academic-oup-com.qulib.idm.oclc.org/ehjcr/article/5/6/ytab124/6301260.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35182020</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Timing of mechanical circulatory support during primary angioplasty in acute myocardial infarction and cardiogenic shock: Systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>998</StartPage><EndPage>1005</EndPage><MedlinePgn>998-1005</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.30137</ELocationID><Abstract><AbstractText Label="OBJECTIVES">We aim to define whether the timing of microaxial left ventricular assist device (IMLVAD) implantation might impact on mortality in acute myocardial infarction (AMI) cardiogenic shock (CS) patients who underwent primary percutaneous coronary intervention (PPCI).</AbstractText><AbstractText Label="BACKGROUND">Despite the widespread use of PPCI, mortality in patients with AMI and CS remains high. Mechanical circulatory support is a promising bridge to recovery strategy, but evidence on its benefit is still inconclusive and the optimal timing of its utilization remains poorly explored.</AbstractText><AbstractText Label="METHODS">We compared clinical outcomes of upstream IMLVAD use before PPCI versus bailout use after PPCI in patients with AMI CS. A systematic review and meta-analysis of studies comparing the two strategies were performed. Effect size was reported as odds ratio (OR) using bailout as reference group and a random effect model was used. Study-level risk estimates were pooled through the generic inverse variance method (random effect model).</AbstractText><AbstractText Label="RESULTS">A total of 11 observational studies were identified, including a pooled population of 6759 AMI-CS patients. Compared with a bailout approach, upstream IMLVAD was associated with significant reduction of 30-day (OR&#x2009;=&#x2009;0.65; 95% confidence interval [CI]&#x2009;=&#x2009;0.51-0.82; I<sup>2</sup> &#x2009;=&#x2009;43%, adjusted OR&#x2009;=&#x2009;0.54; 95% CI&#x2009;=&#x2009;0.37-0.59; I<sup>2</sup> &#x2009;=&#x2009;3%, test for subgroup difference p&#x2009;=&#x2009;0.30), 6-month (OR&#x2009;=&#x2009;0.51; 95% CI&#x2009;=&#x2009;0.27-0.96; I<sup>2</sup> &#x2009;=&#x2009;66%), and 1-year (OR&#x2009;=&#x2009;0.56; 95% CI&#x2009;=&#x2009;0.39-0.79; I<sup>2</sup> &#x2009;=&#x2009;0%) all-cause mortality. Incidence of access-related bleeding, acute limb ischemia and transfusion outcomes were similar between the two strategies.</AbstractText><AbstractText Label="CONCLUSION">In patients with AMI-CS undergoing PPCI, upstream IMLVAD was associated with reduced early and midterm all-cause mortality when compared with a bailout strategy.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Archilletti</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1478-3408</Identifier><AffiliationInfo><Affiliation>Department of Innovative Technologies in Medicine &amp; Odontology, Institute of Cardiology, "G. d'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giuliani</LastName><ForeName>Livio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Interventional Cardiology Department, Cath Lab, Ospedale SS. Annunziata, ASL 2 Abruzzo, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dangas</LastName><ForeName>George D</ForeName><Initials>GD</Initials><Identifier Source="ORCID">0000-0001-7502-8049</Identifier><AffiliationInfo><Affiliation>The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Casa di Cura Villa Serena, Citt&#xe0; Sant'Angelo, Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedetto</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "G D'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radico</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Innovative Technologies in Medicine &amp; Odontology, Institute of Cardiology, "G. d'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallina</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Interventional Cardiology Department, Cath Lab, Ospedale SS. Annunziata, ASL 2 Abruzzo, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maddestra</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Interventional Cardiology Department, Cath Lab, Ospedale SS. Annunziata, ASL 2 Abruzzo, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimarino</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5455-6010</Identifier><AffiliationInfo><Affiliation>Department of Innovative Technologies in Medicine &amp; Odontology, Institute of Cardiology, "G. d'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interventional Cardiology Department, Cath Lab, Ospedale SS. Annunziata, ASL 2 Abruzzo, Chieti, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017130" MajorTopicYN="N">Angioplasty</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMI - acute myocardial infarction/STEMI</Keyword><Keyword MajorTopicYN="N">CS - shock</Keyword><Keyword MajorTopicYN="N">ECMO/IABP/Tandem/Impella</Keyword><Keyword MajorTopicYN="N">MCS - mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">META - meta-analysis</Keyword><Keyword MajorTopicYN="N">PCIC - percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">PPCI - primary PCI</Keyword><Keyword MajorTopicYN="N">cardiogenic</Keyword><Keyword MajorTopicYN="N">complex PCI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35182020</ArticleId><ArticleId IdType="doi">10.1002/ccd.30137</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341:625-634.</Citation></Reference><Reference><Citation>Thiele H, Akin I, Sandri M, et al. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018;379(18):1699-1710.</Citation></Reference><Reference><Citation>Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177.</Citation></Reference><Reference><Citation>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-e425.</Citation></Reference><Reference><Citation>Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165.</Citation></Reference><Reference><Citation>Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(8):1315-1341.</Citation></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42(36):3599-3726.</Citation></Reference><Reference><Citation>Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69(3):278-287.</Citation></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584-1588.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.</Citation></Reference><Reference><Citation>Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280-286.</Citation></Reference><Reference><Citation>Dhruva SS, Ross JS, Mortazavi BJ, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. J Am Med Assoc. 2020;323(8):734-745.</Citation></Reference><Reference><Citation>Davidsen C, Packer EJ, L&#xf8;land KH, et al. Impella use in acute myocardial infarction complicated by cardiogenic shock and cardiac arrest: analysis of 10 years registry data. Resuscitation. 2019;140:178-184.</Citation></Reference><Reference><Citation>Hemradj VV, Karami M, Sjauw KD, et al. Pre-PCI versus immediate post-PCI Impella initiation in acute myocardial infarction complicated by cardiogenic shock. PLOS One. 2020;15(7):1-13.</Citation></Reference><Reference><Citation>Tarantini G, Masiero G, Burzotta F, et al. Timing of Impella implantation and outcomes in cardiogenic shock or high-risk percutaneous coronary revascularization. Catheter Cardiovasc Interv. 2021;98.</Citation></Reference><Reference><Citation>Jensen PB, Kann SH, Veien KT, et al. Single-centre experience with the Impella CP, 5.0 and RP in 109 consecutive patients with profound cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2018;7(1):53-61.</Citation></Reference><Reference><Citation>Loehn T, Neill WWO, Lange B, et al. Long term survival after early unloading with Impella CP&#xae; in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2020;9(2):149-157.</Citation></Reference><Reference><Citation>O'Neill WW, Schreiber T, Wohns DHW, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol. 2014;27(1):1-11.</Citation></Reference><Reference><Citation>O'Neill WW, Grines C, Schreiber T, et al. Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. Am Heart J. 2018;202:33-38.</Citation></Reference><Reference><Citation>Ouweneel DM, de Brabander J, Karami M, et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. Eur Heart J Acute Cardiovasc Care. 2019;8(4):338-349.</Citation></Reference><Reference><Citation>Sch&#xe4;fer A, Werner N, Burkhoff D, et al. Influence of timing and predicted risk on mortality in Impella-treated infarct-related cardiogenic shock patients. Front Cardiovasc Med. 2020;14(7):74.</Citation></Reference><Reference><Citation>Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;5(10):1249-1258.</Citation></Reference><Reference><Citation>Schroeter MR, K&#xf6;hler H, Wachter A, et al. Use of the Impella device for acute coronary syndrome complicated by Cardiogenic shock - experience from a single heart center with analysis of long-term mortality. J Invasive Cardiol. 2016;28(12):467-472.</Citation></Reference><Reference><Citation>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction: executive summary. J Am Coll Cardiol. 2013;61(4):485-510.</Citation></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200.</Citation></Reference><Reference><Citation>Basir MB, Kapur NK, Patel K, et al. Improved outcomes associated with the use of shock protocols: updates from the National Cardiogenic Shock Initiative. Catheter Cardiovasc Interv. 2019;93(7):1173-1183.</Citation></Reference><Reference><Citation>Iannaccone M, Albani S, Giannini F, et al. Short term outcomes of Impella in cardiogenic shock: a review and meta-analysis of observational studies. Int J Cardiol. 2021;324:44-51.</Citation></Reference><Reference><Citation>Kapur NK, Paruchuri V, Urbano-Morales JA, et al. Mechanically unloading the left ventricle before coronary reperfusion reduces left ventricular wall stress and myocardial infarct size. Circulation. 2013;128(4):328-336.</Citation></Reference><Reference><Citation>Esposito ML, Zhang Y, Qiao X, et al. Left ventricular unloading before reperfusion promotes functional recovery after acute myocardial infarction. J Am Coll Cardiol. 2018;72(5):501-514.</Citation></Reference><Reference><Citation>Tehrani BN, Truesdell AG, Sherwood MW, et al. Standardized team-based care for cardiogenic shock. J Am Coll Cardiol. 2019;73(13):1659-1669.</Citation></Reference><Reference><Citation>Antman EM. Time is muscle. Translation into practice. J Am Coll Cardiol. 2008;52(15):1216-1221.</Citation></Reference><Reference><Citation>Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107(24):2998-3002.</Citation></Reference><Reference><Citation>Udesen NJ, M&#xf8;ller JE, Lindholm MG, et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J. 2019;214:60-68.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38256608</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Mechanical Circulatory Support Strategies in Takotsubo Syndrome with Cardiogenic Shock: A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">473</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13020473</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Takotsubo syndrome is, by definition, a reversible form of acute heart failure. If cardiac output is severely reduced, Takotsubo syndrome can cause cardiogenic shock, and mechanical circulatory support can serve as a bridge to recovery. To date, there are no recommendations on when to use mechanical circulatory support and on which device is particularly effective in this context. Our aim was to determine the best treatment strategy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature research and analysis of individual patient data was performed in MEDLINE/PubMed according to PRISMA guidelines. Our research considered original works published until 31 July 2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 93 publications that met the inclusion criteria were identified, providing individual data from 124 patients. Of these, 62 (50%) were treated with veno-arterial extracorporeal life support (va-ECLS), and 44 (35.5%) received a microaxial left ventricular assist device (Impella). Eighteen patients received an Impella CP and twenty-one an Impella 2.5. An intra-aortic balloon pump (IABP) without other devices was used in only 13 patients (10.5%), while other devices (BiVAD or Tandem Heart) were used in 5 patients (4%). The median initial left ventricular ejection fraction was 20%, with no difference between the four device groups except for the IABP group, which was less affected by cardiac output failure (<i>p</i> = 0.015). The overall survival was 86.3%. Compared to the other groups, the time to cardiac recovery was shorter with Impella (<i>p</i> &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Though the Impella treatment is new, our analysis may show a significant benefit of Impella compared to other MCS strategies for cardiogenic shock in Takotsubo syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Mackensen</LastName><ForeName>Johanna K R</ForeName><Initials>JKR</Initials><Identifier Source="ORCID">0009-0002-7335-4769</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwaans</LastName><ForeName>Vanessa I T</ForeName><Initials>VIT</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Shazly</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Praet</LastName><ForeName>Karel M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, ASZ Hospital Aalst, 9300 Aalst, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Surgery Department, Hartcentrum OLV Aalst, 9300 Aalst, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heck</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starck</LastName><ForeName>Christoph T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), Partner Site, 10785 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoenrath</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), Partner Site, 10785 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potapov</LastName><ForeName>Evgenij V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), Partner Site, 10785 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kempfert</LastName><ForeName>Joerg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), Partner Site, 10785 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), Partner Site, 10785 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falk</LastName><ForeName>Volkmar</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), Partner Site, 10785 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Charit&#xe9;, Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences and Technology, ETH Z&#xfc;rich, 8093 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wert</LastName><ForeName>Leonhard</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2840-8724</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9;-Medical Heart Center of Charit&#xe9; and German Heart Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECLS</Keyword><Keyword MajorTopicYN="N">IABP</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Takotsubo</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">stress cardiomyopathy</Keyword></KeywordList><CoiStatement>The work presented received no financial support, the following table contains the conflict of interest statement of each author.
 [Table: see text] </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38256608</ArticleId><ArticleId IdType="pmc">PMC10816930</ArticleId><ArticleId IdType="doi">10.3390/jcm13020473</ArticleId><ArticleId IdType="pii">jcm13020473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lyon A.R., Bossone E., Schneider B., Sechtem U., Citro R., Underwood S.R., Sheppard M.N., Figtree G.A., Parodi G., Akashi Y.J., et al. Current state of knowledge on Takotsubo syndrome: A Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2016;18:8&#x2013;27. doi: 10.1002/ejhf.424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.424</ArticleId><ArticleId IdType="pubmed">26548803</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiermaier T., Eitel C., Desch S., Fuernau G., Schuler G., Thiele H., Eitel I. Incidence, determinants and prognostic relevance of cardiogenic shock in patients with Takotsubo cardiomyopathy. Eur. Heart J. Acute Cardiovasc. Care. 2016;5:489&#x2013;496. doi: 10.1177/2048872615612456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872615612456</ArticleId><ArticleId IdType="pubmed">26474843</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta A.G., Carrie D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med. Sci. Monit. 2023;29:e939020. doi: 10.12659/MSM.939020.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.939020</ArticleId><ArticleId IdType="pmc">PMC9999670</ArticleId><ArticleId IdType="pubmed">36872594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabri A., Kalra A., Kumar A., Alameh A., Adroja S., Bashir H., Nowacki A.S., Shah R., Khubber S., Kanaa N.A., et al. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020;3:e2014780. doi: 10.1001/jamanetworkopen.2020.14780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.14780</ArticleId><ArticleId IdType="pmc">PMC7348683</ArticleId><ArticleId IdType="pubmed">32644140</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider B., Athanasiadis A., Schwab J., Pistner W., Gottwald U., Schoeller R., Toepel W., Winter K.D., Stellbrink C., M&#xfc;ller-Honold T., et al. Complications in the clinical course of tako-tsubo cardiomyopathy. Int. J. Cardiol. 2014;176:199&#x2013;205. doi: 10.1016/j.ijcard.2014.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2014.07.002</ArticleId><ArticleId IdType="pubmed">25049018</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S., Dunlay S.M., Murphree D.H., Barsness G.W., Jr., Sandhu G.S., Lerman A., Prasad A. Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction: An 8-Year National Perspective on Clinical Characteristics, Management, and Outcomes. JACC Heart Fail. 2019;7:469&#x2013;476. doi: 10.1016/j.jchf.2018.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2018.12.007</ArticleId><ArticleId IdType="pubmed">31078481</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhavan M., Rihal C.S., Lerman A., Prasad A. Acute heart failure in apical ballooning syndrome (TakoTsubo/stress cardiomyopathy): Clinical correlates and Mayo Clinic risk score. J. Am. Coll. Cardiol. 2011;57:1400&#x2013;1401. doi: 10.1016/j.jacc.2010.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.10.038</ArticleId><ArticleId IdType="pubmed">21414539</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri J.R., Cammann V.L., Jurisic S., Seifert B., Napp L.C., Diekmann J., Bataiosu D.R., D&#x2019;Ascenzo F., Ding K.J., Sarcon A., et al. A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: Results from the International Takotsubo Registry. Eur. J. Heart Fail. 2017;19:1036&#x2013;1042. doi: 10.1002/ejhf.683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.683</ArticleId><ArticleId IdType="pubmed">27928880</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran D.A., Grines C.L., Bailey S., Burkhoff D., Hall S.A., Henry T.D., Hollenberg S.M., Kapur N.K., O&#x2019;Neill W., Ornato J.P., et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter. Cardiovasc. Interv. 2019;94:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Napierkowski S., Banerjee U., Anderson H.V., Charitakis K., Madjid M., Smalling R.W., Dhoble A. Trends and Impact of the Use of Mechanical Circulatory Support for Cardiogenic Shock Secondary to Takotsubo Cardiomyopathy. Am. J. Cardiol. 2021;139:28&#x2013;33. doi: 10.1016/j.amjcard.2020.09.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.09.047</ArticleId><ArticleId IdType="pubmed">33035466</ArticleId></ArticleIdList></Reference><Reference><Citation>Terasaki S., Kanaoka K., Nakai M., Sumita Y., Onoue K., Soeda T., Watanabe M., Miyamoto Y., Saito Y. Outcomes of catecholamine and/or mechanical support in Takotsubo syndrome. Heart. 2022;108:1467&#x2013;1473. doi: 10.1136/heartjnl-2021-319904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2021-319904</ArticleId><ArticleId IdType="pubmed">35046103</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Vece D., Citro R., Cammann V.L., Kato K., Gili S., Szawan K.A., Micek J., Jurisic S., Ding K.J., Bacchi B., et al. Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation. 2019;139:413&#x2013;415. doi: 10.1161/CIRCULATIONAHA.118.036164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.036164</ArticleId><ArticleId IdType="pubmed">30586690</ArticleId></ArticleIdList></Reference><Reference><Citation>Elapavaluru S., Gologorsky A., Thai N., Uemura T., Khalil R., Mareddy C., Dishart M., Gologorsky E. Perioperative Stress Cardiomyopathy in Simultaneous Liver and Kidney Transplantation: A Call for Early Consideration of Mechanical Circulatory Support. J. Cardiothorac. Vasc. Anesth. 2017;31:248&#x2013;253. doi: 10.1053/j.jvca.2016.04.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2016.04.030</ArticleId><ArticleId IdType="pubmed">27542899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri J.R., Wittstein I.S., Prasad A., Sharkey S., Dote K., Akashi Y.J., Cammann V.L., Crea F., Galiuto L., Desmet W., et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur. Heart J. 2018;39:2032&#x2013;2046. doi: 10.1093/eurheartj/ehy076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy076</ArticleId><ArticleId IdType="pmc">PMC5991216</ArticleId><ArticleId IdType="pubmed">29850871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittstein I.S., Thiemann D.R., Lima J.A., Baughman K.L., Schulman S.P., Gerstenblith G., Wu K.C., Rade J.J., Bivalacqua T.J., Champion H.C. Neurohumoral features of myocardial stunning due to sudden emotional stress. N. Engl. J. Med. 2005;352:539&#x2013;548. doi: 10.1056/NEJMoa043046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043046</ArticleId><ArticleId IdType="pubmed">15703419</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro F., Nunez Gil I.J., Stiermaier T., El-Battrawy I., Moeller C., Guerra F., Novo G., Arcari L., Musumeci B., Cacciotti L., et al. Impact of intra-aortic balloon counterpulsation on all-cause mortality among patients with Takotsubo syndrome complicated by cardiogenic shock: Results from the German-Italian-Spanish (GEIST) registry. Eur. Heart J. Open. 2023;3:oead003. doi: 10.1093/ehjopen/oead003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjopen/oead003</ArticleId><ArticleId IdType="pmc">PMC9921723</ArticleId><ArticleId IdType="pubmed">36789137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani S., Richter J., Pappalardo F., B&#x11b;lohl&#xe1;vek J., Lorusso R., Schmitto J.D., Bauersachs J., Napp L.C. Mechanical circulatory support for Takotsubo syndrome: A systematic review and meta-analysis. Int. J. Cardiol. 2020;316:31&#x2013;39. doi: 10.1016/j.ijcard.2020.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.05.033</ArticleId><ArticleId IdType="pubmed">32473281</ArticleId></ArticleIdList></Reference><Reference><Citation>Nersesian G., Hennig F., Muller M., Mulzer J., Tsyganenko D., Starck C., Gromann T., Falk V., Potapov E., Schoenrath F. Temporary mechanical circulatory support for refractory heart failure: The German Heart Center Berlin experience. Ann. Cardiothorac. Surg. 2019;8:76&#x2013;83. doi: 10.21037/acs.2018.12.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs.2018.12.01</ArticleId><ArticleId IdType="pmc">PMC6379195</ArticleId><ArticleId IdType="pubmed">30854315</ArticleId></ArticleIdList></Reference><Reference><Citation>Eulert-Grehn J.J., Starck C., Kempfert J., Falk V., Potapov E. ECMELLA 2.0: Single Arterial Access Technique for a Staged Approach in Cardiogenic Shock. Ann. Thorac. Surg. 2021;111:e135&#x2013;e137. doi: 10.1016/j.athoracsur.2020.06.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2020.06.084</ArticleId><ArticleId IdType="pubmed">32918864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wert L., Kempfert J., Falk V., Potapov E.V. Transaxillary implantation of a temporary microaxial left ventricular assist device in a patient with a rectangular kinked subclavian artery. Interdiscip. Cardiovasc. Thorac. Surg. 2023;36:ivad088. doi: 10.1093/icvts/ivad088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivad088</ArticleId><ArticleId IdType="pmc">PMC10371038</ArticleId><ArticleId IdType="pubmed">37279727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B., Becher P.M., Bernhardt A., Bezerra H., Blankenberg S., Brunner S., Colson P., Cudemus Deseda G., Dabboura S., Eckner D., et al. Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study. Circulation. 2020;142:2095&#x2013;2106. doi: 10.1161/CIRCULATIONAHA.120.048792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048792</ArticleId><ArticleId IdType="pmc">PMC7688081</ArticleId><ArticleId IdType="pubmed">33032450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bairashevskaia A.V., Belogubova S.Y., Kondratiuk M.R., Rudnova D.S., Sologova S.S., Tereshkina O.I., Avakyan E.I. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int. J. Cardiol. Heart Vasc. 2022;39:100990. doi: 10.1016/j.ijcha.2022.100990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2022.100990</ArticleId><ArticleId IdType="pmc">PMC8913320</ArticleId><ArticleId IdType="pubmed">35281752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa R., Nagano N., Kokubu N., Hashimoto K., Nakata J., Kishiue N., Takahashi R., Otomo S., Tsuchihashi K., Yano T. Favorable Effects of Impella on Takotsubo Syndrome Complicated with Cardiogenic Shock. Int. Heart J. 2021;62:1430&#x2013;1435. doi: 10.1536/ihj.21-299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1536/ihj.21-299</ArticleId><ArticleId IdType="pubmed">34789645</ArticleId></ArticleIdList></Reference><Reference><Citation>Napp L.C., Westenfeld R., M&#xf8;ller J.E., Pappalardo F., Ibrahim K., Bonello L., Wilkins C., Pershad A., Mannino S.F., Schreiber T.L., et al. Impella Mechanical Circulatory Support for Takotsubo Syndrome With Shock: A Retrospective Multicenter Analysis. Cardiovasc. Revasc. Med. 2022;40:113&#x2013;119. doi: 10.1016/j.carrev.2021.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2021.11.018</ArticleId><ArticleId IdType="pubmed">34916157</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsoum E., Elhosseiny S., Patel B., Pathak S., Patel A., Vaidya P. Successful use of the impella ventricular assist device for management of reverse Takotsubo Cardiomyopathy in the setting of acute intracranial hemorrhage. Heart Lung. 2021;50:313&#x2013;315. doi: 10.1016/j.hrtlng.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2021.01.007</ArticleId><ArticleId IdType="pubmed">33482434</ArticleId></ArticleIdList></Reference><Reference><Citation>Laliberte B., Reed B.N. Use of an argatroban-based purge solution in a percutaneous ventricular assist device. Am. J. Health Syst. Pharm. 2017;74:e163&#x2013;e169. doi: 10.2146/ajhp160212.</Citation><ArticleIdList><ArticleId IdType="doi">10.2146/ajhp160212</ArticleId><ArticleId IdType="pubmed">28438820</ArticleId></ArticleIdList></Reference><Reference><Citation>Attisano T., Silverio A., Prota C., Briguori C., Galasso G., Citro R. Impella in Takotsubo syndrome complicated by left ventricular outflow tract obstruction and severe mitral regurgitation. ESC Heart Fail. 2020;7:306&#x2013;310. doi: 10.1002/ehf2.12546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12546</ArticleId><ArticleId IdType="pmc">PMC7083498</ArticleId><ArticleId IdType="pubmed">31898420</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonacchi M., Maiani M., Harmelin G., Sani G. Intractable cardiogenic shock in stress cardiomyopathy with left ventricular outflow tract obstruction: Is extra-corporeal life support the best treatment? Eur. J. Heart Fail. 2009;11:721&#x2013;727. doi: 10.1093/eurjhf/hfp068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfp068</ArticleId><ArticleId IdType="pubmed">19468019</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonacchi M., Valente S., Harmelin G., Gensini G.F., Sani G. Extracorporeal life support as ultimate strategy for refractory severe cardiogenic shock induced by Tako-tsubo cardiomyopathy: A new effective therapeutic option. Artif. Organs. 2009;33:866&#x2013;870. doi: 10.1111/j.1525-1594.2009.00825.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1594.2009.00825.x</ArticleId><ArticleId IdType="pubmed">19681838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazcano-Diaz E.A., Gonzalez-Ruiz F.J., Sarre-Alvarez D., Alvarez-Alvarez R.J., Bucio-Reta E., Garcia-Cruz E., Rojas-Velazco G., Ramos-Enriquez A., Melano-Carranza E., Santos-Martinez L.E., et al. Circulatory support with venoarterial ECMO in a patient with biventricular Takotsubo cardiomyopathy. Arch. Cardiol. Mex. 2020;91:100&#x2013;104. doi: 10.24875/ACME.M21000178.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/ACME.M21000178</ArticleId><ArticleId IdType="pmc">PMC8258904</ArticleId><ArticleId IdType="pubmed">33008148</ArticleId></ArticleIdList></Reference><Reference><Citation>Redfors B., Shao Y., Omerovic E. &#x201c;Primum nil nocere&#x201d; first choice in Takotsubo cardiomyopathy. Mechanical support as a bridge to recovery should be tested in severe cases. Lakartidningen. 2014;111:1366&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pubmed">25221833</ArticleId></ArticleIdList></Reference><Reference><Citation>Besnier E., Hubscher C., Doguet F., Bessou J.P., Dureuil B. Extracorporeal membrane oxygenation support for tako-tsubo syndrome after urgent caesarean section. Ann. Fr. Anesth. Reanim. 2013;32:704&#x2013;706. doi: 10.1016/j.annfar.2013.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annfar.2013.06.002</ArticleId><ArticleId IdType="pubmed">23993158</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Villen L., Corcia-Palomo Y., Escalona-Rodriguez S., Roldan-Reina A., Acosta-Delgado D., Martin-Bermudez R. Extracorporeal membrane oxygenation support in a patient with pheochromocytoma stress myocardyopathy. Med. Intensiv. (Engl. Ed.) 2018;42:566&#x2013;568. doi: 10.1016/j.medin.2018.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medin.2018.04.004</ArticleId><ArticleId IdType="pubmed">29764675</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Delgado M., Garcia-Huertas D., Navarrete-Sanchez I., Olivencia-Pena L., Garrido J.M. Extracorporeal membrane oxygenation support for Takotsubo syndrome and long QT after cardiac surgery. Med. Intensiv. 2017;41:441&#x2013;443. doi: 10.1016/j.medine.2017.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medine.2017.06.006</ArticleId><ArticleId IdType="pubmed">27650460</ArticleId></ArticleIdList></Reference><Reference><Citation>Esnault P., Nee L., Signouret T., Jaussaud N., Kerbaul F. Reverse Takotsubo cardiomyopathy after iatrogenic epinephrine injection requiring percutaneous extracorporeal membrane oxygenation. Can. J. Anaesth. 2014;61:1093&#x2013;1097. doi: 10.1007/s12630-014-0230-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-014-0230-x</ArticleId><ArticleId IdType="pubmed">25187250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagao T., Ohwada T., Hashimoto M., Aoki K., Shimizu H., Katayama M. Intra-aortic balloon pumping is effective for hemodynamic management of catecholamine resistant ampulla (Takotsubo) cardiomyopathy. Masui. 2004;53:799&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">15298251</ArticleId></ArticleIdList></Reference><Reference><Citation>Vachiat A., McCutcheon K., Mahomed A., Schleicher G., Brand L., Botha J., Sussman M., Manga P. Takotsubo cardiomyopathy post liver transplantation. Cardiovasc. J. Afr. 2016;27:e1&#x2013;e3. doi: 10.5830/CVJA-2016-032.</Citation><ArticleIdList><ArticleId IdType="doi">10.5830/CVJA-2016-032</ArticleId><ArticleId IdType="pmc">PMC5370358</ArticleId><ArticleId IdType="pubmed">27805244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassid B., Azmoon S., Aronow W.S., Palaniswamy C., Cohen M., Gass A. Hemodynamic support with TandemHeart in tako-tsubo cardiomyopathy&#x2014;A case report. Arch. Med. Sci. 2010;6:971&#x2013;975. doi: 10.5114/aoms.2010.19311.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2010.19311</ArticleId><ArticleId IdType="pmc">PMC3302713</ArticleId><ArticleId IdType="pubmed">22427775</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalberts J.J.J., Klinkenberg T.J., Mariani M.A., van der Harst P. Mechanical circulatory support for refractory cardiogenic shock in Takotsubo syndrome: A case report and review of the literature. Eur. Heart J. Case Rep. 2017;1:ytx005. doi: 10.1093/ehjcr/ytx005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytx005</ArticleId><ArticleId IdType="pmc">PMC6176877</ArticleId><ArticleId IdType="pubmed">31020064</ArticleId></ArticleIdList></Reference><Reference><Citation>Moguilevitch M., Rufino M., Leff J., Delphin E. Novel approach for heart failure treatment after liver transplantation. Liver Transplant. 2015;21:1103&#x2013;1104. doi: 10.1002/lt.24162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.24162</ArticleId><ArticleId IdType="pubmed">26069158</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo T.K., Lee J.Y., Sung K.C., Oh S.S., Song Y.S., Lee S.J., Ko K.J. Stress-Induced Cardiomyopathy Presenting as Shock. J. Cardiovasc. Ultrasound. 2016;24:79&#x2013;83. doi: 10.4250/jcu.2016.24.1.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.4250/jcu.2016.24.1.79</ArticleId><ArticleId IdType="pmc">PMC4828422</ArticleId><ArticleId IdType="pubmed">27081451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanim D., Adler Z., Qarawani D., Kusniec F., Amir O., Carasso S. Takotsubo cardiomyopathy caused by epinephrine-treated bee sting anaphylaxis: A case report. J. Med. Case Rep. 2015;9:247. doi: 10.1186/s13256-015-0722-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-015-0722-5</ArticleId><ArticleId IdType="pmc">PMC4628238</ArticleId><ArticleId IdType="pubmed">26518383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamid T.E.f.J., Fraser D., Fath-Ordoubadi F. Use of the Impella Left Ventricular Assist Device as a Bridge to Recovery in a Patient with Cardiogenic Shock Related to Takotsubo Cardiomyopathy. J. Clin. Exp. Cardiol. 2013;4:246. doi: 10.4172/2155-9880.1000246.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-9880.1000246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Zhang L., Ruan X., He K., Yu C., Shen L. Case Report: Takotsubo Syndrome Induced by Severe Anaphylactic Reaction During Anesthesia Induction and Subsequent High-Dose Epinephrine Resuscitation. Front. Cardiovasc. Med. 2022;9:842440. doi: 10.3389/fcvm.2022.842440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.842440</ArticleId><ArticleId IdType="pmc">PMC8968145</ArticleId><ArticleId IdType="pubmed">35369310</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson T.E., Frizzola M.A., Priest M.A., Rochman M.F., Froehlich C.D. Pediatric Extracorporeal Cardiopulmonary Resuscitation Patient With Traumatic Subarachnoid Hemorrhage and Takotsubo Syndrome. Air Med. J. 2018;37:64&#x2013;66. doi: 10.1016/j.amj.2017.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amj.2017.09.002</ArticleId><ArticleId IdType="pubmed">29332781</ArticleId></ArticleIdList></Reference><Reference><Citation>Flam B., Broome M., Frenckner B., Branstrom R., Bell M. Pheochromocytoma-Induced Inverted Takotsubo-Like Cardiomyopathy Leading to Cardiogenic Shock Successfully Treated With Extracorporeal Membrane Oxygenation. J. Intensive Care Med. 2015;30:365&#x2013;372. doi: 10.1177/0885066614552992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066614552992</ArticleId><ArticleId IdType="pubmed">25286918</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria B.M.M., Portugues J., Roncon-Albuquerque R., Pimentel R., Jr. Inverted takotsubo syndrome complicated with cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation in a patient with bilateral pheochromocytoma: A case report. Eur. Heart J. Case Rep. 2020;4:1&#x2013;5. doi: 10.1093/ehjcr/ytaa055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytaa055</ArticleId><ArticleId IdType="pmc">PMC7180540</ArticleId><ArticleId IdType="pubmed">32352062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominedo C., D&#x2019;Avino E., Martinotti A., Cingolani E. A rare pheochromocytoma complicated by cardiogenic shock and posterior reversible encephalopathy syndrome: Case report. Eur. Heart J. Case Rep. 2021;5:ytaa513. doi: 10.1093/ehjcr/ytaa513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytaa513</ArticleId><ArticleId IdType="pmc">PMC7873792</ArticleId><ArticleId IdType="pubmed">33598609</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zwet C.J., Rist A., Haeussler A., Graves K., Zollinger A., Blumenthal S. Extracorporeal Membrane Oxygenation for Treatment of Acute Inverted Takotsubo-Like Cardiomyopathy From Hemorrhagic Pheochromocytoma in Late Pregnancy. A A Case Rep. 2016;7:196&#x2013;199. doi: 10.1213/XAA.0000000000000383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/XAA.0000000000000383</ArticleId><ArticleId IdType="pubmed">27607406</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilio F., Muraglia S., Bonmassari R. Cardiac arrest complicating cardiogenic shock: From pathophysiological insights to Impella-assisted cardiopulmonary resuscitation in a pheochromocytoma-induced Takotsubo cardiomyopathy-a case report. Eur. Heart J. Case Rep. 2021;5:ytab092. doi: 10.1093/ehjcr/ytab092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytab092</ArticleId><ArticleId IdType="pmc">PMC8186919</ArticleId><ArticleId IdType="pubmed">34113770</ArticleId></ArticleIdList></Reference><Reference><Citation>Mierke J., Loehn T., Linke A., Ibrahim K. Reverse takotsubo cardiomyopathy- life-threatening symptom of an incidental pheochromocytoma: A case report. Eur. Heart J. Case Rep. 2019;3:1&#x2013;6. doi: 10.1093/ehjcr/ytz195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytz195</ArticleId><ArticleId IdType="pmc">PMC7026602</ArticleId><ArticleId IdType="pubmed">32099962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiamanesh O., Vu E.N., Webber D.L., Lau E., Kapeluto J.E., Stuart H., Wood D.A., Wong G.C. Pheochromocytoma-Induced Takotsubo Syndrome Treated With Extracorporeal Membrane Oxygenation: Beware of the Apical Sparing Pattern. JACC Case Rep. 2019;1:85&#x2013;90. doi: 10.1016/j.jaccas.2019.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccas.2019.06.001</ArticleId><ArticleId IdType="pmc">PMC8301256</ArticleId><ArticleId IdType="pubmed">34316755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaese S., Schulke C., Fischer D., Lebiedz P. Pheochromocytoma-induced takotsubo-like cardiomyopathy and global heart failure with need for extracorporal life support. Intensive Care Med. 2013;39:1473&#x2013;1474. doi: 10.1007/s00134-013-2942-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-013-2942-8</ArticleId><ArticleId IdType="pubmed">23670051</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S., Kim M., Lee D.I., Lee J.H., Kim S., Lee S.Y., Bae J.W., Hwang K.K., Kim D.W., Cho M.C., et al. Successful extracorporeal membrane oxygenation treatment of catecholamine-induced cardiomyopathy-associated pheochromocytoma. Acute Crit. Care. 2022 ahead-of-print .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11002611</ArticleId><ArticleId IdType="pubmed">35545235</ArticleId></ArticleIdList></Reference><Reference><Citation>Garla V.V., Gosi S., Kanduri S., Lien L. A case of catecholamine-induced cardiomyopathy treated with extracorporeal membrane oxygenation. BMJ Case Rep. 2019;12:e230196. doi: 10.1136/bcr-2019-230196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2019-230196</ArticleId><ArticleId IdType="pmc">PMC6768387</ArticleId><ArticleId IdType="pubmed">31570347</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z., Wang Y., Fei H. Takotsubo-Like Cardiomyopathy in Pheochromocytoma. CASE. 2019;3:157&#x2013;161. doi: 10.1016/j.case.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.case.2019.04.006</ArticleId><ArticleId IdType="pmc">PMC6710850</ArticleId><ArticleId IdType="pubmed">31468018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu T., Niu J., Liu Z., Li T. Case Report: Early Resection of Pheochromocytoma in a Patient With Cardiogenic Shock Due to Pheochromocytoma-Induced Cardiomyopathy With Extracorporeal Life Support. Front. Cardiovasc. Med. 2022;9:788644. doi: 10.3389/fcvm.2022.788644.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.788644</ArticleId><ArticleId IdType="pmc">PMC8982527</ArticleId><ArticleId IdType="pubmed">35391844</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Zhang A., Qi M., Xiong B., Zhang S., Zhou J., Cao Y. Pheochromocytoma crisis with refractory Acute Respiratory Distress Syndrome (ARDS), Takotsubo syndrome, emergency adrenalectomy, and need for Extracorporeal Membrane Oxygenation (ECMO) in a previously undiagnosed and asymptomatic patient, due to the use of metoclopramide. BMC Endocr. Disord. 2023;23:145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10332044</ArticleId><ArticleId IdType="pubmed">37430225</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari A.K., D&#x2019;Attellis N. Intraoperative left ventricular apical ballooning: Transient Takotsubo cardiomyopathy during orthotopic liver transplantation. J. Cardiothorac. Vasc. Anesth. 2008;22:442&#x2013;445. doi: 10.1053/j.jvca.2007.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2007.11.015</ArticleId><ArticleId IdType="pubmed">18503938</ArticleId></ArticleIdList></Reference><Reference><Citation>Caturegli G., Crane M.A., Etchill E., Giuliano K., Nguyen M., Philosophe B., Cho S.M., Wittstein I.S., Whitman G.J.R. Stress-Induced (Takotsubo) Cardiomyopathy After Liver Transplant Rescued with Venoarterial Extracorporeal Membrane Oxygenation. ASAIO J. 2022;68:e66&#x2013;e68. doi: 10.1097/MAT.0000000000001453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001453</ArticleId><ArticleId IdType="pubmed">35349528</ArticleId></ArticleIdList></Reference><Reference><Citation>Omosule A., Malik M.F., Cisneros L., Guruswamy J. Takotsubo Cardiomyopathy After Double-Lung Transplantation: Role of Early Extracorporeal Membrane Oxygenation Support. J. Cardiothorac. Vasc. Anesth. 2019;33:2503&#x2013;2507. doi: 10.1053/j.jvca.2018.10.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2018.10.042</ArticleId><ArticleId IdType="pubmed">30579661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirigaya J., Iwahashi N., Tanaka R., Inayama Y., Takeuchi I. A Fatal Case of Takotsubo Cardiomyopathy Secondary to Refractory Hypoglycemia in Severe Starvation: An Autopsy Case Report. Cureus. 2022;14:e23287. doi: 10.7759/cureus.23287.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.23287</ArticleId><ArticleId IdType="pmc">PMC9012600</ArticleId><ArticleId IdType="pubmed">35449611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hekimian G., Kharcha F., Brechot N., Schmidt M., Ghander C., Lebreton G., Girerd X., Tresallet C., Trouillet J.L., Leprince P., et al. Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock. Ann. Intensive Care. 2016;6:117. doi: 10.1186/s13613-016-0219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-016-0219-4</ArticleId><ArticleId IdType="pmc">PMC5126035</ArticleId><ArticleId IdType="pubmed">27896787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonacchi M., Vannini A., Harmelin G., Batacchi S., Bugetti M., Sani G., Peris A. Inverted-Takotsubo cardiomyopathy: Severe refractory heart failure in poly-trauma patients saved by emergency extracorporeal life support. Interact. Cardiovasc. Thorac. Surg. 2015;20:365&#x2013;371. doi: 10.1093/icvts/ivu421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivu421</ArticleId><ArticleId IdType="pubmed">25535176</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster K.T., Apridonidze T., Mopala P.R., Sherman A.E., Potakamuri L.N., Storms D.R., Kono A.T., Mohanty B.D. Stress-Induced Cardiomyopathy Complicated by Dynamic Left Ventricular Outflow Obstruction, Cardiogenic Shock, and Ventricular Septal Rupture. Can. J. Cardiol. 2019;35:229.e7&#x2013;229.e9. doi: 10.1016/j.cjca.2018.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2018.12.005</ArticleId><ArticleId IdType="pubmed">30760435</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi S., Ramsdale D. Tako-tsubo, hypertrophic obstructive cardiomyopathy &amp; muscle bridging--separate disease entities or a single condition? Int. J. Cardiol. 2011;147:133&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">19428131</ArticleId></ArticleIdList></Reference><Reference><Citation>Laghlam D., Touboul O., Herry M., Estagnasie P., Dib J.C., Baccouche M., Brusset A., Nguyen L.S., Squara P. Takotsubo cardiomyopathy after cardiac surgery: A case-series and systematic review of literature. Front. Cardiovasc. Med. 2022;9:1067444. doi: 10.3389/fcvm.2022.1067444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1067444</ArticleId><ArticleId IdType="pmc">PMC9871635</ArticleId><ArticleId IdType="pubmed">36704455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri J.R., Kato K., Cammann V.L., Gili S., Jurisic S., Di Vece D., Candreva A., Ding K.J., Micek J., Szawan K.A., et al. Long-Term Prognosis of Patients With Takotsubo Syndrome. J. Am. Coll. Cardiol. 2018;72:874&#x2013;882. doi: 10.1016/j.jacc.2018.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.06.016</ArticleId><ArticleId IdType="pubmed">30115226</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida Junior G.L.G., Mansur Filho J., Albuquerque D.C., Xavier S.S., Pontes A., Gouvea E.P., Martins A.B.B., Nunes N.S.V., Carestiato L.V., Petriz J.L.F., et al. Takotsubo Multicenter Registry (REMUTA)&#x2014;Clinical Aspects, In-Hospital Outcomes, and Long-Term Mortality. Arq. Bras. Cardiol. 2020;115:207&#x2013;216. doi: 10.36660/abc.20190166.</Citation><ArticleIdList><ArticleId IdType="doi">10.36660/abc.20190166</ArticleId><ArticleId IdType="pmc">PMC8384277</ArticleId><ArticleId IdType="pubmed">32876186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangen H., Imori Y., Tara S., Yamamoto T., Takano H., Shimizu W. Haemodynamic deterioration due to intra-aortic balloon counterpulsation in takotsubo cardiomyopathy. Eur. Heart J. 2018;39:2118. doi: 10.1093/eurheartj/ehx812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx812</ArticleId><ArticleId IdType="pubmed">29351617</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M., Nakagaito M., Hori M., Ueno H., Kinugawa K. A case of Takotsubo cardiomyopathy with cardiogenic shock after influenza infection successfully recovered by IMPELLA support. J. Artif. Organs. 2019;22:330&#x2013;333. doi: 10.1007/s10047-019-01112-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10047-019-01112-8</ArticleId><ArticleId IdType="pubmed">31228028</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J.H., Oh I.D., Shin E., Lee S., Jeon J.M., Kim H.T., Youn H.C. Extracorporeal membrane oxygenation for takotsubo cardiomyopathy that developed after mitral valve replacement. Acute Crit. Care. 2020;35:51&#x2013;55. doi: 10.4266/acc.2018.00304.</Citation><ArticleIdList><ArticleId IdType="doi">10.4266/acc.2018.00304</ArticleId><ArticleId IdType="pmc">PMC7056952</ArticleId><ArticleId IdType="pubmed">31743637</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo Y.Y., Park S., Choi Y.S. Extracorporeal membrane oxygenation in a patient with stress-induced cardiomyopathy after caesarean section. Anaesth. Intensive Care. 2011;39:954&#x2013;957. doi: 10.1177/0310057X1103900524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0310057X1103900524</ArticleId><ArticleId IdType="pubmed">21970146</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashed A., Won S., Saad M., Schreiber T. Use of the Impella 2.5 left ventricular assist device in a patient with cardiogenic shock secondary to takotsubo cardiomyopathy. BMJ Case Rep. 2015;2015:bcr2014208354. doi: 10.1136/bcr-2014-208354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2014-208354</ArticleId><ArticleId IdType="pmc">PMC4434270</ArticleId><ArticleId IdType="pubmed">25953675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammedzein A., Taha A., Salwan A., Nambiar R. Impella Use in Cardiogenic Shock Due to Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction. JACC Case Rep. 2019;1:161&#x2013;165. doi: 10.1016/j.jaccas.2019.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccas.2019.06.022</ArticleId><ArticleId IdType="pmc">PMC8301524</ArticleId><ArticleId IdType="pubmed">34316775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28341358</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1913</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>The American journal of cardiology</Title><ISOAbbreviation>Am J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Meta-Analysis of the Optimal Percutaneous Revascularization Strategy in Patients With Acute Myocardial Infarction, Cardiogenic Shock, and Multivessel Coronary Artery Disease.</ArticleTitle><Pagination><StartPage>1525</StartPage><EndPage>1531</EndPage><MedlinePgn>1525-1531</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjcard.2017.02.028</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9149(17)30214-X</ELocationID><Abstract><AbstractText>The optimal percutaneous coronary intervention (PCI) revascularization strategy in patients with multivessel (MV) coronary artery disease (CAD) who present with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) has not been systematically addressed. Accordingly, we performed a study-level meta-analysis comparing 2 PCI strategies in these patients-infarct-related artery (IRA) only versus MV revascularization. Studies including patients with AMI and MV CAD complicated with CS who received primary PCI were searched from 2000 to 2016. The primary end points were in-hospital/30-day and mid- to long-term (&#x2265;6 month) mortality. Fixed and random effects models were used for analysis. Ten studies (9 prospective and 1 retrospective) involving 6,068 patients met our inclusion criteria. IRA-only PCI was the most frequently used revascularization strategy (4,872 patients, 80%), while MV PCI was performed in 1,196 patients (20%). The MV PCI strategy was associated with higher short-term mortality compared with the IRA-only PCI strategy (odds ratio 1.41, 95% confidence interval 1.15 to 1.71, p&#xa0;= 0.008). There was no difference in mid- to long-term mortality between MV PCI and IRA-only strategies (odds ratio 1.02, 95% confidence interval 0.65 to 1.58, p&#xa0;= 0.94). In conclusion, in patients with AMI and MV CAD complicated by CS, the IRA-only PCI strategy seems to be associated with lower short-term, but not mid- to long-term mortality compared with MV&#xa0;PCI. This finding is different from the revascularization strategy recommended by current professional guidelines and suggests the need for dedicated randomized clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tarantini</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. Electronic address: giuseppe.tarantini.1@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amico</LastName><ForeName>Gianpiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tellaroli</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Epidemiology and Public Health Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brener</LastName><ForeName>Sorin J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Cardiac Catheterization Laboratory, New York Methodist Hospital, Brooklyn, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Cardiol</MedlineTA><NlmUniqueID>0207277</NlmUniqueID><ISSNLinking>0002-9149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28341358</ArticleId><ArticleId IdType="doi">10.1016/j.amjcard.2017.02.028</ArticleId><ArticleId IdType="pii">S0002-9149(17)30214-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36388905</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Methylene blue dosing strategies in critically ill adults with shock-A retrospective cohort study.</ArticleTitle><Pagination><StartPage>1014276</StartPage><MedlinePgn>1014276</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1014276</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.1014276</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Shock increases mortality in the critically ill and the mainstay of therapy is the administration of vasopressor agents to achieve hemodynamic targets. In the past, studies have found that the NO-pathway antagonist methylene blue improves hemodynamics. However, the optimal dosing strategy remains elusive. Therefore, we investigated the hemodynamic and ICU outcome parameters of three different dosing strategies for methylene blue.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a retrospective cohort study of patients in shock treated with methylene blue. Shock was defined as norepinephrine dose &gt;0.1 &#x3bc;g/kg/min and serum lactate level &gt;2 mmol/l at the start of methylene blue administration. Different demographic variables, ICU treatment, and outcome parameters were evaluated. To compare the differences in the administration of vasopressors or inotropes, the vasoactive inotropic score (VIS) was calculated at different time points after starting the administration of methylene blue. Response to methylene blue or mortality at 28 days were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">262 patients from July 2014 to October 2019 received methylene blue. 209 patients met the inclusion criteria. Three different dosing strategies were identified: bolus injection followed by continuous infusion (<i>n</i> = 111), bolus injection only (no continuous infusion; <i>n</i> = 59) or continuous infusion only (no bolus prior; <i>n</i> = 39). The groups did not differ in demographics, ICU scoring system, or comorbidities. In all groups, VIS decreased over time, indicating improved hemodynamics. Cardiogenic shock and higher doses of norepinephrine increased the chance of responding to methylene blue, while bolus only decreased the chance of responding to methylene blue treatment. 28-day mortality increased with higher SAPSII scores and higher serum lactate levels, while bolus injection followed by continuous infusion decreased 28-day mortality. No severe side effects were noted.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In this cohort, methylene blue as a bolus injection followed by continuous infusion was associated with a reduced 28-day mortality in patients with shock. Prospective studies are needed to systematically evaluate the role of methylene blue in the treatment of shock.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sari-Yavuz, Heck-Swain, Keller, Magunia, Feng, Haeberle, Wied, Schlensak, Rosenberger and Koeppen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sari-Yavuz</LastName><ForeName>Sibel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heck-Swain</LastName><ForeName>Ka-Lin</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magunia</LastName><ForeName>Harry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>You-Shan</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Institute for Clinical Epidemiology and Applied Biostatistics (IKEaB), Eberhard-Karls-University T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haeberle</LastName><ForeName>Helene A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wied</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlensak</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberger</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeppen</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Med (Lausanne). 2022 Nov 23;9:1094735. doi: 10.3389/fmed.2022.1094735.</RefSource><PMID Version="1">36507519</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">methylene blue</Keyword><Keyword MajorTopicYN="N">retrospective study</Keyword><Keyword MajorTopicYN="N">shock</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36388905</ArticleId><ArticleId IdType="pmc">PMC9650001</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.1014276</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kimmoun A, Levy B. Pathophysiology of Shock Oxford Textbook of Critical Care. Oxford, UK: Oxford University Press; (2016). 10.1093/med/9780199600830.003.0149</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/med/9780199600830.003.0149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. . Consensus on circulatory shock and hemodynamic monitoring. Task force of the European society of intensive care medicine. Intens Care Med. (2014) 40:1795&#x2013;815. 10.1007/s00134-014-3525-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-014-3525-z</ArticleId><ArticleId IdType="pmc">PMC4239778</ArticleId><ArticleId IdType="pubmed">25392034</ArticleId></ArticleIdList></Reference><Reference><Citation>Koeppen M, Feil R, Siegl D, Feil S, Hofmann F, Pohl U, et al. . cGMP-dependent protein kinase mediates NO- but not acetylcholine-induced dilations in resistance vessels in vivo. Hypertension. (2004) 44:952&#x2013;5. 10.1161/01.HYP.0000147661.80059.ca</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000147661.80059.ca</ArticleId><ArticleId IdType="pubmed">15505114</ArticleId></ArticleIdList></Reference><Reference><Citation>Joffre J, Hellman J, Ince C, Ait-Oufella H. Endothelial responses in sepsis. Am J Respir Crit Care Med. (2020) 202:361&#x2013;70. 10.1164/rccm.201910-1911TR</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201910-1911TR</ArticleId><ArticleId IdType="pubmed">32101446</ArticleId></ArticleIdList></Reference><Reference><Citation>Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res. (1994) 28:34&#x2013;9. 10.1093/cvr/28.1.34</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/28.1.34</ArticleId><ArticleId IdType="pubmed">7509259</ArticleId></ArticleIdList></Reference><Reference><Citation>Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intens Care Med. (2008) 34:2226&#x2013;34. 10.1007/s00134-008-1219-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-008-1219-0</ArticleId><ArticleId IdType="pubmed">18654759</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, et al. . Norepinephrine plus dobutamine vs. epinephrine alone for management of septic shock: a randomised trial. Lancet. (2007) 370:676&#x2013;84. 10.1016/S0140-6736(07)61344-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61344-0</ArticleId><ArticleId IdType="pubmed">17720019</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. . Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. (2010) 362:779&#x2013;89. 10.1056/NEJMoa0907118</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0907118</ArticleId><ArticleId IdType="pubmed">20200382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey A, Pope TW, Moore SA, Campbell CL. The Tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock. Am J Cardiovascular Drugs. (2007) 7:337&#x2013;45. 10.2165/00129784-200707050-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00129784-200707050-00003</ArticleId><ArticleId IdType="pubmed">17953472</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland RH. Methylene blue: the long and winding road from stain to brain: part 1. J Psychosoc Nurs Ment Health Serv. (2016) 54:21&#x2013;4. 10.3928/02793695-20160818-01</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/02793695-20160818-01</ArticleId><ArticleId IdType="pubmed">27576224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbj&#xf8;rnsson B, et al. . Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. (2001) 29:1860&#x2013;7. 10.1097/00003246-200110000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200110000-00002</ArticleId><ArticleId IdType="pubmed">11588440</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, et al. . Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. (2004) 77:496&#x2013;9. 10.1016/S0003-4975(03)01510-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(03)01510-8</ArticleId><ArticleId IdType="pubmed">14759425</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohlfelder B, Douglas A, Wang L, Wanek M, Bauer SR. Association of methylene blue dosing with hemodynamic response for the treatment of vasoplegia. J Cardiothorac Vasc Anesth. (2022) 36:3543&#x2013;50. 10.1053/j.jvca.2022.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2022.04.003</ArticleId><ArticleId IdType="pubmed">35697643</ArticleId></ArticleIdList></Reference><Reference><Citation>Porizka M, Kopecky P, Dvorakova H, Kunstyr J, Lips M, Michalek P, et al. . Methylene blue administration in patients with refractory distributive shock&#x2014;a retrospective study. Sci Rep. (2020) 10:1828. 10.1038/s41598-020-58828-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-58828-4</ArticleId><ArticleId IdType="pmc">PMC7000741</ArticleId><ArticleId IdType="pubmed">32020043</ArticleId></ArticleIdList></Reference><Reference><Citation>Belletti A, Lerose CC, Zangrillo A, Landoni G. Vasoactive-inotropic score: evolution, clinical utility, and pitfalls. J Cardiothorac Vasc Anesth. (2021) 35:3067&#x2013;77. 10.1053/j.jvca.2020.09.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.09.117</ArticleId><ArticleId IdType="pubmed">33069558</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Levy M, Andrews PJ, Chastre J, Hudson LD. International consensus conference p. France, 27&#x2013;28 April 2006. Intensive Care Med. (2007) 33:575&#x2013;90. 10.1007/s00134-007-0531-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-007-0531-4</ArticleId><ArticleId IdType="pubmed">17285286</ArticleId></ArticleIdList></Reference><Reference><Citation>Koeppen M, Gravlee GP, Nasrallah F, Eckle T. Transesophageal echocardiography in the diagnosis of acute pericardial tamponade during hiatal hernia repair. J Cardiothorac Vasc Anesth. (2014) 28:112&#x2013;4. 10.1053/j.jvca.2012.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2012.09.015</ArticleId><ArticleId IdType="pubmed">23157738</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildhirt SM, Dudek RR, Suzuki H, Bing RJ. Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Int J Cardiol. (1995) 50:253&#x2013;61. 10.1016/0167-5273(95)02385-A</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-5273(95)02385-A</ArticleId><ArticleId IdType="pubmed">8537149</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider F, Lutun P, Hasselmann M, Stoclet JC, Temp&#xe9; JD. Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Med. (1992) 18:309&#x2013;11. 10.1007/BF01706481</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01706481</ArticleId><ArticleId IdType="pubmed">1527264</ArticleId></ArticleIdList></Reference><Reference><Citation>Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, et al. . Methylene blue administration in septic shock: a clinical trial. Crit Care Med. (1995) 23:259&#x2013;64. 10.1097/00003246-199502000-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199502000-00010</ArticleId><ArticleId IdType="pubmed">7532559</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode HF, Cowley HC, Walker BE, Howdle PD, Webster NR. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit Care Med. (1995) 23:646&#x2013;51. 10.1097/00003246-199504000-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199504000-00011</ArticleId><ArticleId IdType="pubmed">7712754</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennington CR. Disease-associated malnutrition in the year 2000. Postgrad Med J. (1998) 74:65&#x2013;71. 10.1136/pgmj.74.868.65</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.74.868.65</ArticleId><ArticleId IdType="pmc">PMC2360805</ArticleId><ArticleId IdType="pubmed">9616486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowes DA, Webster NR, Murphy MP, Galley HF. Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesth. (2013) 110:472&#x2013;80. 10.1093/bja/aes577</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aes577</ArticleId><ArticleId IdType="pmc">PMC3570068</ArticleId><ArticleId IdType="pubmed">23381720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. (1993) 45:367&#x2013;74. 10.1016/0006-2952(93)90072-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-2952(93)90072-5</ArticleId><ArticleId IdType="pubmed">7679577</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther. (1985) 232:708&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">2983068</ArticleId></ArticleIdList></Reference><Reference><Citation>Oz M, Lorke DE, Hasan M, Petroianu GA. Cellular and molecular actions of methylene blue in the nervous system. Med Res Rev. (2011) 31:93&#x2013;117. 10.1002/med.20177</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20177</ArticleId><ArticleId IdType="pmc">PMC3005530</ArticleId><ArticleId IdType="pubmed">19760660</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, et al. . Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. (2007) 297:1657&#x2013;66. 10.1001/jama.297.15.joc70035</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.297.15.joc70035</ArticleId><ArticleId IdType="pubmed">17387132</ArticleId></ArticleIdList></Reference><Reference><Citation>Moilanen E, Vapaatalo H. Nitric oxide in inflammation and immune response. Ann Med. (1995) 27:359&#x2013;67. 10.3109/07853899509002589</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07853899509002589</ArticleId><ArticleId IdType="pubmed">7546626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkeb&#xf8;en KA, Strand OA. The role of nitric oxide in sepsis&#x2014;an overview. Acta Anaesthesiol Scand. (1999) 43:275&#x2013;88. 10.1034/j.1399-6576.1999.430307.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-6576.1999.430307.x</ArticleId><ArticleId IdType="pubmed">10081533</ArticleId></ArticleIdList></Reference><Reference><Citation>Keaney JF, Hare JM, Balligand JL, Loscalzo J, Smith TW, Colucci WS. Inhibition of nitric oxide synthase augments myocardial contractile responses to beta-adrenergic stimulation. Am J Physiol. (1996) 271:H2646&#x2013;2652. 10.1152/ajpheart.1996.271.6.H2646</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.1996.271.6.H2646</ArticleId><ArticleId IdType="pubmed">8997327</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama K, Kimura A, Suzuki H, Takeyama Y, Gluckman TL, Terhakopian A, et al. . Production of oxidative products ofnitric oxide in infarcted human heart. J Am Coll Cardiol. (1998) 32:373&#x2013;9. 10.1016/S0735-1097(98)00270-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(98)00270-8</ArticleId><ArticleId IdType="pubmed">9708463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. . Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. (2005) 165:1643&#x2013;50. 10.1001/archinte.165.14.1643</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.165.14.1643</ArticleId><ArticleId IdType="pubmed">16043684</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuttall Gregory A, Houle Timothy T. Liars, damn liars, and propensity scores. Anesthesiology. (2008) 108:3&#x2013;4. 10.1097/01.anes.0000296718.35703.20</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.anes.0000296718.35703.20</ArticleId><ArticleId IdType="pubmed">18156873</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24514033</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6500</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Current opinion in anaesthesiology</Title><ISOAbbreviation>Curr Opin Anaesthesiol</ISOAbbreviation></Journal><ArticleTitle>Management of perioperative heart failure.</ArticleTitle><Pagination><StartPage>140</StartPage><EndPage>145</EndPage><MedlinePgn>140-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/ACO.0000000000000056</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">In the perioperative period, acute heart failure can result from a variety of conditions, and treatment may vary considerably depending on its mechanism. This review aims to provide conceptual framework by selectively presenting recent knowledge and advances in acute heart failure therapies including drugs (inotropes, diuretics) and devices (mechanical assistance, biventricular pacing, ultrafiltration).</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">The calcium sensitizer levosimendan, showed a mortality benefit in cardiac surgery patients in a recent meta-analysis. A study involving patients with cardiogenic shock complicating myocardial infarction for which early revascularization was planned, intra-aortic balloon support did not reduce 30-day mortality. A novel study showed that ultrafiltration was inferior to pharmacologic therapy in acute heart failure in nonsurgical patients. Biventricular pacing provided a significant clinical benefit over right ventricular pacing in nonsurgical patients with left ventricular dysfunction and atrioventricular block. Two recently published meta-analyses confirmed the prognostic role of natriuretic peptides in the perioperative setting.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Poor data exist in the perioperative setting concerning acute heart failure therapies. Large trials are needed to support the use of levosimendan, mechanical assistance, utrafiltration and biventricular pacing in the perioperative setting. The prognostic role of natriuretic peptides was confirmed in the perioperative period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soussi</LastName><ForeName>Sabri</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Unit, Assistance Publique H&#xf4;pitaux de Paris, Groupe H&#xf4;spitalier Saint-Louis-Lariboisiere. Paris-Diderot University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatti</LastName><ForeName>Kais</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Anaesthesiol</MedlineTA><NlmUniqueID>8813436</NlmUniqueID><ISSNLinking>0952-7907</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059035" MajorTopicYN="N">Perioperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014462" MajorTopicYN="N">Ultrafiltration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24514033</ArticleId><ArticleId IdType="doi">10.1097/ACO.0000000000000056</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27584567</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>223</Volume><PubDate><Year>2016</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Intravenous &#x3b2;-blockers for patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials.</ArticleTitle><Pagination><StartPage>891</StartPage><EndPage>897</EndPage><MedlinePgn>891-897</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2016.08.293</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(16)32012-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The efficacy and safety of intravenous &#x3b2;-blockers in patients with ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) are not well known.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Electronic databases were searched for randomized trials that compared intravenous &#x3b2;-blocker use with routine care or placebo in patients with STEMI undergoing primary PCI. Summary estimates risk ratios (RR) were constructed using DerSimonian and Laird model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four randomized trials with 1149 Killip class I or II STEMI patients were included. Intravenous &#x3b2;-blockers were associated with a reduction in the risk of ventricular arrhythmias during hospitalization (RR 0.42, 95% confidence interval [CI] 0.26-0.69, P=0.001). The risk of cardiogenic shock (RR 0.78, 95% CI 0.31-1.97, P=0.61), bradycardia (RR 1.54, 95% CI 0.35-6.81, P=0.57), all-cause mortality (RR 0.71, 95% CI 0.19-3.17, P=0.72), and cardiovascular mortality (RR 0.93, 95% CI 0.35-2.48, P=0.88) during hospitalization was similar in both groups. There was a trend towards a lower risk of future heart failure hospitalizations with intravenous &#x3b2;-blockers (RR 0.32, 95% CI 0.10-1.05, P=0.06).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Intravenous &#x3b2;-blockers, in STEMI patients (Killip class I or II) undergoing primary PCI, appear to be safe. Intravenous &#x3b2;-blockers were associated with a reduced risk of ventricular arrhythmias. Due to the small number of patients, the impact on other outcomes could not be determined. Therefore, future trials are recommended to establish the efficacy of intravenous &#x3b2;-blockers in primary PCI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elgendy</LastName><ForeName>Islam Y</ForeName><Initials>IY</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Florida, Gainesville, FL, USA. Electronic address: Islam.elgendy@medicine.ufl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elgendy</LastName><ForeName>Akram Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahmoud</LastName><ForeName>Ahmed N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansoor</LastName><ForeName>Hend</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mojadidi</LastName><ForeName>Mohammad K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bavry</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Florida, Gainesville, FL, USA; North Florida/South, Georgia Veterans Health System, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adrenergic beta-antagonists</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27584567</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2016.08.293</ArticleId><ArticleId IdType="pii">S0167-5273(16)32012-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31384109</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1061-1711</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The International journal of angiology : official publication of the International College of Angiology, Inc</Title><ISOAbbreviation>Int J Angiol</ISOAbbreviation></Journal><ArticleTitle>The Impella Device: Historical Background, Clinical Applications and Future Directions.</ArticleTitle><Pagination><StartPage>118</StartPage><EndPage>123</EndPage><MedlinePgn>118-123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0038-1676369</ELocationID><Abstract><AbstractText>The Impella device is a catheter-based miniaturized ventricular assist device. Using a retrograde femoral artery access, it is placed in the left ventricle across the aortic valve. The device pumps blood from left ventricle into ascending aorta and helps to maintain a systemic circulation at an upper rate between 2.5 and 5.0 L/min. This results in almost immediate and sustained unloading of the left ventricle, while increasing overall systemic cardiac output. The most common indications for using the Impella device are in the treatment of acute myocardial infarction complicated by cardiogenic shock and to facilitate high risk coronary angioplasty. Other indications include the treatment of cardiomyopathy with acute decompensation, postcardiotomy shock, and off-pump coronary bypass surgery. A growing body of observational and registry data suggest a potentially valuable role for the Impella system in reducing the mortality associated with cardiogenic shock. However, there are, as of yet, no randomized controlled trial data supporting this observation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glazier</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaki</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Angiol</MedlineTA><NlmUniqueID>9504821</NlmUniqueID><ISSNLinking>1061-1711</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Archimedes' screw</Keyword><Keyword MajorTopicYN="N">Impella device</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">high risk coronary angioplasty</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">postcardiotomy shock</Keyword><Keyword MajorTopicYN="N">ventricular assist device</Keyword></KeywordList><CoiStatement><b>Conflicts of Interest</b> Dr. A.K. serves as a proctor and speaker for Abiomed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31384109</ArticleId><ArticleId IdType="pmc">PMC6679960</ArticleId><ArticleId IdType="doi">10.1055/s-0038-1676369</ArticleId><ArticleId IdType="pii">180065</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kantrowitz A, Tjonneland S, Freed P S, Phillips S J, Butner A N, Sherman J L., Jr Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA. 1968;203(02):113&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">5694059</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub R M, Aroesty J M, Paulin S et al.Medically refractory unstable angina pectoris. I. Long-term follow-up of patients undergoing intraaortic balloon counterpulsation and operation. Am J Cardiol. 1979;43(05):877&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">312004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bregman D, Casarella W J. Percutaneous intraaortic balloon pumping: initial clinical experience. Ann Thorac Surg. 1980;29(02):153&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">7356366</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson T M, Ohman E M, O'Neill W W, Rab T, Cigarroa J E; Interventional Scientific Council of the American College of Cardiology.A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention: an interventional perspective JACC Cardiovasc Interv 2016909871&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">27151604</ArticleId></ArticleIdList></Reference><Reference><Citation>Rihal C S, Naidu S S, Givertz M M et al.2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; affirmation of value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. J Am Coll Cardiol. 2015;65(19):e7&#x2013;e26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25861963</ArticleId></ArticleIdList></Reference><Reference><Citation>Myat A, Patel N, Tehrani S, Banning A P, Redwood S R, Bhatt D L. Percutaneous circulatory assist devices for high-risk coronary intervention. JACC Cardiovasc Interv. 2015;8(02):229&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">25700745</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann F J et al.Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera D, Stables R, Thomas M et al.Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA. 2010;304(08):867&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">20736470</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff D, Moscucci M, Henriques J PS. Philadelphia, PA: Lippincott Williams &amp;Wilkins; 2014. Percutaneous circulatory support: intra-aortic balloon counterpulsation, Impella, TandemHeart, and extracorporeal bypass; pp. 601&#x2013;625.</Citation></Reference><Reference><Citation>Oleson J P. Dordrecht, Holland: D. Reidel Publishing Company; 1984. Greek and Roman Mechanical Water-Lifting Devices: The History of a Technology.</Citation></Reference><Reference><Citation>Phillips S.Project bionics pioneer interview Richard K. Wampler, MD: interviewed by Steven Phillips, MD 2011. Available from:https://www.asaio.com/wp-content/uploads/2015/04/Richard-Wampler-interview-2011-transcript-final.pdf. Accessed July 26, 2018</Citation></Reference><Reference><Citation>Sweeney M S. The Hemopump in 1997: a clinical, political, and marketing evolution. Ann Thorac Surg. 1999;68(02):761&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">10475484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wampler R K, Moise J C, Frazier O H, Olsen D B. In vivo evaluation of a peripheral vascular access axial flow blood pump. ASAIO Trans. 1988;34(03):450&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">3196544</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman L K.A tiny heart pump saves its first life, researchers reportNew York Times;1988. Available from:https://www.nytimes.com/1988/05/05/us/a-tiny-heart-pump-saves-its-first-life-researchers-report.html. Accessed November 16, 2018.</Citation></Reference><Reference><Citation>Siess T, Nix C, Menzler F. From a lab type to a product: a retrospective view on Impella's assist technology. Artif Organs. 2001;25(05):414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403675</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyns B, Sergeant P, Nishida T, Perek B, Zietkiewicz M, Flameng W. Micropumps to support the heart during CABG. Eur J Cardiothorac Surg. 2000;17(02):169&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">10731653</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyns B, Stolinski J, Leunens V, Verbeken E, Flameng W. Left ventricular support by catheter-mounted axial flow pump reduces infarct size. J Am Coll Cardiol. 2003;41(07):1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679206</ArticleId></ArticleIdList></Reference><Reference><Citation>Abiomed surpasses 50,000 Impella patients treated in the United States. DAIC,2017. Available from:https://www.dicardiology.com/content/abiomed-surpasses-50000-impella-patients-treated-united-states. Accessed July 14, 2018</Citation></Reference><Reference><Citation>Abiomed Impella Quality (IQ) Database AbiomedDanvers, Massachusetts</Citation></Reference><Reference><Citation>TCT feature: Impella comes in under $100k threshold 2011. Available from:www.cardiovascularbusiness.com/topics/coronary-intervention-surgery/tct-feature-impella-comes-under-100k-threshold. Accessed April 14, 2018</Citation></Reference><Reference><Citation>Burzotta F, Trani C, Doshi S N et al.Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. Int J Cardiol. 2015;201:684&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">26363632</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D, Khera S, Aronow W S et al.Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014;3(01):e000590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959706</ArticleId><ArticleId IdType="pubmed">24419737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangalore S, Gupta N, Guo Y et al.Outcomes with invasive vs conservative management of cardiogenic shock complicating acute myocardial infarction. Am J Med. 2015;128(06):601&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">25554376</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill W W, Schreiber T, Wohns D H et al.The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol. 2014;27(01):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238821</ArticleId><ArticleId IdType="pubmed">24329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith B P, Anderson M B, Samuels L E, Pae W E, Jr., Naka Y, Frazier O H. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg. 2013;145(02):548&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">22405676</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorsandi M, Dougherty S, Bouamra O et al.Extra-corporeal membrane oxygenation for refractory cardiogenic shock after adult cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Surg. 2017;12(01):55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512816</ArticleId><ArticleId IdType="pubmed">28716039</ArticleId></ArticleIdList></Reference><Reference><Citation>Glazier J J, Kaki A. Improving survival in cardiogenic shock: is Impella the answer? Am J Med. 2018;131(10):e403&#x2013;e404.</Citation><ArticleIdList><ArticleId IdType="pubmed">29859134</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemaire A, Anderson M B, Lee L Y et al.The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg. 2014;97(01):133&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24090575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel D M, Engstrom A E, Sjauw K D et al.Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. Int J Cardiol. 2016;202:894&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">26476989</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I et al.A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel D M, Eriksen E, Sjauw K D et al.Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69(03):278&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel D M, Eriksen E, Seyfarth M, Henriques J P. Percutaneous mechanical circulatory support versus intra-aortic balloon pump for treating cardiogenic shock: meta-analysis. J Am Coll Cardiol. 2017;69(03):358&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">27810348</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J M, den Uil C A, Hoeks S E et al.Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30(17):2102&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pubmed">19617601</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandhu A, McCoy L A, Negi S I et al.Use of mechanical circulatory support in patients undergoing percutaneous coronary intervention: insights from the National Cardiovascular Data Registry. Circulation. 2015;132(13):1243&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">26286905</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill W W, Grines C, Schreiber T et al.Analysis of outcomes for 15,259 U.S. patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. Am Heart J. 2018;202:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803984</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty M P, Khan A R, O'Neill W W. Early initiation of Impella in acute myocardial infarction complicated by cardiogenic shock improves survival: a meta-analysis. JACC Cardiovasc Interv. 2017;10(17):1805&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pubmed">28882288</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir M B, Schreiber T, Dixon S et al.Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: the Detroit cardiogenic shock initiative. Catheter Cardiovasc Interv. 2018;91(03):454&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">29266676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon S R, Henriques J P, Mauri L et al.A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (the PROTECT I trial): initial U.S. experience. JACC Cardiovasc Interv. 2009;2(02):91&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">19463408</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques J P, Remmelink M, Baan J, Jr et al.Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella recover LP 2.5. Am J Cardiol. 2006;97(07):990&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">16563902</ArticleId></ArticleIdList></Reference><Reference><Citation>Burzotta F, Paloscia L, Trani C et al.Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study. J Cardiovasc Med (Hagerstown) 2008;9(10):1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">18799962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjauw K D, Konorza T, Erbel R et al.Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J Am Coll Cardiol. 2009;54(25):2430&#x2013;2434.</Citation><ArticleIdList><ArticleId IdType="pubmed">20082934</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill W W, Kleiman N S, Moses J et al.A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126(14):1717&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pubmed">22935569</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy Y M, Chinitz L, Mansour M et al.Percutaneous left ventricular assist devices in ventricular tachycardia ablation: multicenter experience. Circ Arrhythm Electrophysiol. 2014;7(02):244&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329420</ArticleId><ArticleId IdType="pubmed">24532564</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller M A, Dukkipati S R, Chinitz J S et al.Percutaneous hemodynamic support with Impella 2.5 during scar-related ventricular tachycardia ablation (PERMIT 1) Circ Arrhythm Electrophysiol. 2013;6(01):151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">23255277</ArticleId></ArticleIdList></Reference><Reference><Citation>Suradi H, Breall J A. Successful use of the Impella device in giant cell myocarditis as a bridge to permanent left ventricular mechanical support. Tex Heart Inst J. 2011;38(04):437&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147205</ArticleId><ArticleId IdType="pubmed">21841879</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter M R, Uns&#xf6;ld B, Holke K, Schillinger W. Pro-thrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an Impella LP 2.5 heart pump. Clin Res Cardiol. 2013;102(02):155&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555232</ArticleId><ArticleId IdType="pubmed">22829017</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineton de Chambrun M, Br&#xe9;chot N, Combes A. Mechanical circulatory devices in acute heart failure. Curr Opin Crit Care. 2018;24(04):286&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">29901460</ArticleId></ArticleIdList></Reference><Reference><Citation>Cena M, Karam F, Ramineni R, Khalife W, Barbagelata A. New Impella cardiac power device used in patient with cardiogenic shock due to nonischemic cardiomyopathy. Int J Angiol. 2016;25(04):258&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114131</ArticleId><ArticleId IdType="pubmed">27867292</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez C A, Singh V, Londo&#xf1;o J C et al.Percutaneous retrograde left ventricular assist support for interventions in patients with aortic stenosis and left ventricular dysfunction. Catheter Cardiovasc Interv. 2012;80(07):1201&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pubmed">22511541</ArticleId></ArticleIdList></Reference><Reference><Citation>Londo&#xf1;o J C, Martinez C A, Singh V, O'Neill W W. Hemodynamic support with impella 2.5 during balloon aortic valvuloplasty in a high-risk patient. J Interv Cardiol. 2011;24(02):193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">21223375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludeman D J, Schwartz B G, Burstein S. Impella-assisted balloon aortic valvuloplasty. J Invasive Cardiol. 2012;24(01):E19&#x2013;E20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22210593</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiro J, Venugopal V, Raja Y, Ludman P F, Townend J N, Doshi S N. Feasibility and efficacy of the 2.5&#x2009;L and 3.8&#x2009;L impella percutaneous left ventricular support device during high-risk, percutaneous coronary intervention in patients with severe aortic stenosis. Catheter Cardiovasc Interv. 2015;85(06):981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">24408882</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez C A, Singh V, Heldman A W, O'Neill W W. Emergent use of retrograde left ventricular support in patients after transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2013;82(02):E128&#x2013;E132.</Citation><ArticleIdList><ArticleId IdType="pubmed">22888042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotun K, Shetty R, Patel M, Arain S A. Percutaneous left axillary artery approach for Impella 2.5 liter circulatory support for patients with severe aortoiliac arterial disease undergoing high-risk percutaneous coronary intervention. J Interv Cardiol. 2012;25(02):210&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">22348689</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39291476</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Surgery Versus Thrombolytic Therapy for the Management of Left-Sided Prosthetic Valve Thrombosis Without Hemodynamic Compromise: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>e035143</StartPage><MedlinePgn>e035143</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e035143</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.124.035143</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal strategy in prosthetic heart valve thrombosis (PVT) remains controversial, with no randomized trials and conflicting observational data. We performed a systematic review and meta-analysis of evidence comparing systemic thrombolysis and cardiac surgery in PVT.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We searched PubMed, the Cochrane Library, and Embase for studies on treatment strategies in patients with left-sided PVT since 2000. The primary outcome was death, and the secondary outcomes were major bleeding and thromboembolism during follow-up (International Prospective Register of Systematic Reviews No. CRD42022384092). We identified 2298 studies, of which 16 were included, comprising 1389 patients with PVT (mean age, 50.4&#xb1;9.3&#x2009;years; 60.0% women). Among them, 67.2% were New York Heart Association stage III/IV at admission. Overall, 48.1% were treated with systemic thrombolysis and 51.9% with cardiac surgery. The mortality rate was 10.8% in the thrombolysis group and 15.3% in the surgery group. The pooled risk difference for death with systemic thrombolysis was 1.13 (exact CI, 0.74-1.79; <i>&#x3b6;</i><sup>2</sup>=0.89; <i>P</i>&lt;0.001) versus cardiac surgery. Rates of both transient ischemic attack and non-central nervous system embolism were higher in the thrombolysis group (<i>P</i>=0.002 and <i>P</i>=0.02, respectively). Treatment success, major bleeding, and stroke were similar between groups. Sensitivity analysis including studies that used low-dose or slow-infusion thrombolysis showed that the mortality rate was lower, and treatment success was higher, in patients referred to systemic thrombolysis, with similar rates of other secondary outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is evidence to suggest that thrombolysis might be the preferred option for the management of PVT without cardiogenic shock, pending future randomized controlled trials or larger observational studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chopard</LastName><ForeName>Romain</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8358-515X</Identifier><AffiliationInfo><Affiliation>Department of Cardiology University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SINERGIES University of Franche-Comt&#xe9; Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidoni</LastName><ForeName>Charles</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0003-4695-3077</Identifier><AffiliationInfo><Affiliation>Department of Cardiology University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besutti</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0008-3729-2007</Identifier><AffiliationInfo><Affiliation>Department of Thoracic and Cardio-Vascular Surgery University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ecarnot</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4224-9731</Identifier><AffiliationInfo><Affiliation>Department of Cardiology University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SINERGIES University of Franche-Comt&#xe9; Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Favoulet</LastName><ForeName>Baptiste</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badoz</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SINERGIES University of Franche-Comt&#xe9; Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiele</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-4974-6551</Identifier><AffiliationInfo><Affiliation>Department of Cardiology University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SINERGIES University of Franche-Comt&#xe9; Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrotti</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardio-Vascular Surgery University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meneveau</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1017-0463</Identifier><AffiliationInfo><Affiliation>Department of Cardiology University Hospital Besan&#xe7;on France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SINERGIES University of Franche-Comt&#xe9; Besan&#xe7;on France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006350" MajorTopicYN="Y">Heart Valve Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="Y">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">meta&#x2010;analysis</Keyword><Keyword MajorTopicYN="N">prosthetic valve thrombosis</Keyword><Keyword MajorTopicYN="N">surgery</Keyword><Keyword MajorTopicYN="N">thrombolysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39291476</ArticleId><ArticleId IdType="pmc">PMC11681445</ArticleId><ArticleId IdType="doi">10.1161/JAHA.124.035143</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68:2670&#x2013;2689. doi: 10.1016/j.jacc.2016.09.958</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.09.958</ArticleId><ArticleId IdType="pubmed">27978952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15&#x2009;years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36:1152&#x2013;1158. doi: 10.1016/s0735-1097(00)00834-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(00)00834-2</ArticleId><ArticleId IdType="pubmed">11028464</ArticleId></ArticleIdList></Reference><Reference><Citation>Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart. 2007;93:137&#x2013;142. doi: 10.1136/hrt.2005.071183</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.2005.071183</ArticleId><ArticleId IdType="pmc">PMC1861363</ArticleId><ArticleId IdType="pubmed">17170355</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemulapalli S, Patel MR. Prosthetic valve thrombosis: when and how should we lyse? JACC Cardiovasc Imaging. 2013;6:217&#x2013;219. doi: 10.1016/j.jcmg.2012.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2012.12.003</ArticleId><ArticleId IdType="pubmed">23489535</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilho FM, de Sousa MR, Mendonca AL, Ribeiro AL, Caceres&#x2010;Loriga FM. Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta&#x2010;analysis. J Thromb Haemost. 2014;12:1218&#x2013;1228. doi: 10.1111/jth.12577</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12577</ArticleId><ArticleId IdType="pubmed">24698327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour P, Saedi S, Saneei L, Rafiee F, Yoosefi S, Parsaee M, Siami R, Saberi M, Pouraliakbar H, Ghadrdoost B, et&#xa0;al. Fast vs. ultraslow thrombolytic infusion regimens in patients with obstructive mechanical prosthetic valve thrombosis: a pilot randomized clinical trial. Eur Heart J Cardiovasc Pharmacother. 2022;8:668&#x2013;676. doi: 10.1093/ehjcvp/pvab083</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvab083</ArticleId><ArticleId IdType="pubmed">34864978</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zkan M, Gunduz S, Gursoy OM, Karakoyun S, Astarcioglu MA, Kalcik M, Aykan AC, Cakal B, Bayram Z, Oguz AE, et&#xa0;al. Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve thrombosis and the prEdictors of outcomE: the ultra&#x2010;slow PROMETEE trial. Am Heart J. 2015;170:409&#x2013;418. doi: 10.1016/j.ahj.2015.04.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2015.04.025</ArticleId><ArticleId IdType="pubmed">26299240</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zkan M, Gunduz S, Biteker M, Astarcioglu MA, Cevik C, Kaynak E, Yildiz M, Oguz E, Aykan AC, Erturk E, et&#xa0;al. Comparison of different TEE&#x2010;guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. JACC Cardiovasc Imaging. 2013;6:206&#x2013;216. doi: 10.1016/j.jcmg.2012.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2012.10.016</ArticleId><ArticleId IdType="pubmed">23489534</ArticleId></ArticleIdList></Reference><Reference><Citation>Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N, Bahl VK, Airan B. Urgent surgery compared with fibrinolytic therapy for the treatment of left&#x2010;sided prosthetic heart valve thrombosis: a systematic review and meta&#x2010;analysis of observational studies. Eur Heart J. 2013;34:1557&#x2013;1566. doi: 10.1093/eurheartj/ehs486</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs486</ArticleId><ArticleId IdType="pubmed">23329151</ArticleId></ArticleIdList></Reference><Reference><Citation>Correction to: 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e185. doi: 10.1161/CIR.0000000000001190</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001190</ArticleId><ArticleId IdType="pubmed">37956227</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, de Bonis M, de Paulis R, et&#xa0;al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561&#x2013;632. doi: 10.1093/eurheartj/ehab395</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab395</ArticleId><ArticleId IdType="pubmed">34453165</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, et&#xa0;al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72&#x2013;e227. doi: 10.1161/CIR.0000000000000923</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000923</ArticleId><ArticleId IdType="pubmed">33332150</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG; Group P . Preferred reporting items for systematic reviews and meta&#x2010;analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancellotti P, Pibarot P, Chambers J, Edvardsen T, Delgado V, Dulgheru R, Pepi M, Cosyns B, Dweck MR, Garbi M, et&#xa0;al. Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter&#x2010;American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:589&#x2013;590. doi: 10.1093/ehjci/jew025jew025</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jew025jew025</ArticleId><ArticleId IdType="pubmed">27143783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd CJ, Li D. Computing highly accurate confidence limits from discrete data using importance sampling. Stat Comput. 2014;24:663&#x2013;673. doi: 10.1007/s11222-013-9409-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11222-013-9409-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabaila P, Lloyd CJ. Theory &amp; methods: profile upper confidence limits from discrete data. Aust N Z J Stat. 2000;42:67&#x2013;79. doi: 10.1111/1467-842X.00108</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1467-842X.00108</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzer G, Carpenter JR, R&#xfc;cker G. Meta&#x2010;Analysis with R. 1st ed. Heidelberg, New York, Dordrecht, London: Springer Cham; 2015. doi: 10.1007/978-3-319-21416-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-21416-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez Islas C, Rice KM. Addressing the estimation of standard errors in fixed effects meta&#x2010;analysis. Stat Med. 2018;37:1788&#x2013;1809. doi: 10.1002/sim.7625</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7625</ArticleId><ArticleId IdType="pmc">PMC6001579</ArticleId><ArticleId IdType="pubmed">29574827</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpitarte J, Sanchez&#x2010;Ramos J, Urda T, Vivancos R, Oyonarte JM, Malpartida F. Prosthetic valve thrombosis: which is the most appropriate initial therapy? Rev Esp Cardiol. 2001;54:1367&#x2013;1376. doi: 10.1016/s0300-8932(01)76519-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0300-8932(01)76519-0</ArticleId><ArticleId IdType="pubmed">11754805</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollag L, Attenhofer Jost CH, Vogt PR, Linka AZ, Rickli H, Oechslin E, Pretre R, Dubach P, Turina F, Jenni R. Symptomatic mechanical heart valve thrombosis: high morbidity and mortality despite successful treatment options. Swiss Med Wkly. 2001;131:109&#x2013;116. doi: 10.4414/smw.2001.09685</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2001.09685</ArticleId><ArticleId IdType="pubmed">11416965</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;rrleman N, Pellerin M, Bouchard D, Hebert Y, Cartier R, Perrault LP, Basmadjian A, Carrier M. Prosthetic valve thrombosis: twenty&#x2010;year experience at the Montreal Heart Institute. J Thorac Cardiovasc Surg. 2004;127:1388&#x2013;1392. doi: 10.1016/j.jtcvs.2003.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2003.12.013</ArticleId><ArticleId IdType="pubmed">15115997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermis N, Atalay H, Altay H, Bilgi M, Binici S, Sezgin AT. Comparison of fibrinolytic versus surgical therapy in the treatment of obstructive prosthetic valve thrombosis: a single&#x2010;center experience. Heart Surg Forum. 2011;14:e87&#x2013;e92. doi: 10.1532/HSF98.20101062</Citation><ArticleIdList><ArticleId IdType="doi">10.1532/HSF98.20101062</ArticleId><ArticleId IdType="pubmed">21521682</ArticleId></ArticleIdList></Reference><Reference><Citation>Keuleers S, Herijgers P, Herregods MC, Budts W, Dubois C, Meuris B, Verhamme P, Flameng W, van de Werf F, Adriaenssens T. Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. Am J Cardiol. 2011;107:275&#x2013;279. doi: 10.1016/j.amjcard.2010.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2010.09.013</ArticleId><ArticleId IdType="pubmed">21211605</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AA, Shah AA, Dilbahar Ali Shah S, Aslam M, Ahsan RS. A prospective study on treatment of prosthetic valve thrombosis and its clinical presentation. Pak J Med Health Sci. 2022;16:871&#x2013;873. doi: 10.53350/pjmhs22166871</Citation><ArticleIdList><ArticleId IdType="doi">10.53350/pjmhs22166871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lengyel M, Vandor L. The role of thrombolysis in the management of left&#x2010;sided prosthetic valve thrombosis: a study of 85 cases diagnosed by transesophageal echocardiography. J Heart Valve Dis. 2001;10:636&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603604</ArticleId></ArticleIdList></Reference><Reference><Citation>Manandhar R, Prajapati D, Tamrakar R, Bogati A, Roka M, Sherpa K, Shrestha S, Bhandari S, Chaudhary T, Yadav S, et&#xa0;al. Clinical profile and management of prosthetic valve thrombosis in Tertiary cardiac Centre of Nepal, a prospective study. Nepal Heart J. 2022;19:1&#x2013;15. doi: 10.3126/njh.v19i1.45276</Citation><ArticleIdList><ArticleId IdType="doi">10.3126/njh.v19i1.45276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansuri Z, Sharma V, Jain S, Prajapati J, Bhatia S, Patel K. Clinical profile of prosthetic heart valve thrombosis and outcome analysis of fibrinolytic therapy versus surgical management: a single&#x2010;center experience. Heart India. 2020;8:74&#x2013;79. doi: 10.4103/heartindia.heartindia_5_20</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/heartindia.heartindia_5_20</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zkan M, Gunduz S, Guner A, Kalcik M, Gursoy MO, Uygur B, Keles N, Kaya H, Kilicgedik A, Bayam E, et&#xa0;al. Thrombolysis or surgery in patients with obstructive mechanical valve thrombosis: the multicenter HATTUSHA study. J Am Coll Cardiol. 2022;79:977&#x2013;989. doi: 10.1016/j.jacc.2021.12.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.12.027</ArticleId><ArticleId IdType="pubmed">35272803</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman K, Mohanraj A, Palanisamy V, Ganesh J, Rawal S, Kurian VM, Sethuratnam R. Thrombolysis and surgery for mitral prosthetic valve thrombosis: 11&#x2010;year outcomes. Asian Cardiovasc Thorac Ann. 2019;27:633&#x2013;640. doi: 10.1177/0218492319878015</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0218492319878015</ArticleId><ArticleId IdType="pubmed">31522516</ArticleId></ArticleIdList></Reference><Reference><Citation>Renzulli A, Onorati F, de Feo M, Vitale N, Esposito S, Agozzino L, Santarpino G, Mastroroberto P, Marchese AR, de Luca L, et&#xa0;al. Mechanical valve thrombosis: a tailored approach for a multiplex disease. J Heart Valve Dis. 2004;13(Suppl 1):S37&#x2013;S42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15224999</ArticleId></ArticleIdList></Reference><Reference><Citation>Roudaut R, Lafitte S, Roudaut MF, Reant P, Pillois X, Durrieu&#x2010;Jais C, Coste P, Deville C, Roques X. Management of prosthetic heart valve obstruction: fibrinolysis versus surgery. Early results and long&#x2010;term follow&#x2010;up in a single&#x2010;centre study of 263 cases. Arch Cardiovasc Dis. 2009;102:269&#x2013;277. doi: 10.1016/j.acvd.2009.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2009.01.007</ArticleId><ArticleId IdType="pubmed">19427604</ArticleId></ArticleIdList></Reference><Reference><Citation>Separham A, Ghaffari S, Aslanabadi N, Sohrabi B, Ghojazadeh M, Anamzadeh E, Hajizadeh R, Davarmoin G. Prosthetic valve thrombosis. J Card Surg. 2015;30:246&#x2013;250. doi: 10.1111/jocs.12510</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.12510</ArticleId><ArticleId IdType="pubmed">25581399</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif Khan H, Ijaz Z, Ali M, Saif M, Ishaq U, Kamal A, Ikram U, Abdul Sattar R, Malik J. Clinical outcomes of mechanical prosthetic valve thrombosis. Cureus. 2020;12:e8760. doi: 10.7759/cureus.8760</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.8760</ArticleId><ArticleId IdType="pmc">PMC7377662</ArticleId><ArticleId IdType="pubmed">32714698</ArticleId></ArticleIdList></Reference><Reference><Citation>Yay K, Boysan E, Irdem A, Cetin E, Altinay L, Tutun U, Cicekcioglu F, Katircioglu SF. Treatment of mechanical aortic valve thrombosis: fibrinolytic treatment versus surgical intervention: result of eight cases. Innovations (Phila). 2010;5:439&#x2013;443. doi: 10.1177/155698451000500610</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/155698451000500610</ArticleId><ArticleId IdType="pubmed">22437640</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, Khandheria BK, Levine RA, Marx GR, Miller FA Jr, et&#xa0;al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2009;22:975&#x2013;1014; quiz 1082&#x2013;1014. doi: 10.1016/j.echo.2009.07.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2009.07.013</ArticleId><ArticleId IdType="pubmed">19733789</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik C, Izgi C, Dechyapirom W, Nugent K. Treatment of prosthetic valve thrombosis: rationale for a prospective randomized clinical trial. J Heart Valve Dis. 2010;19:161&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">20369498</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25543217</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8422</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Journal of cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>J Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest: a meta-analysis.</ArticleTitle><Pagination><StartPage>637</StartPage><EndPage>645</EndPage><MedlinePgn>637-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.jvca.2014.09.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-0770(14)00427-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effect of extracorporeal membrane oxygenation (ECMO) on survival and complication rates in adults with refractory cardiogenic shock or cardiac arrest.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Meta-analysis.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">University hospitals.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">One thousand one hundred ninety-nine patients from 22 observational studies.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">None.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Observational studies published from the year 2000 onwards, examining at least 10 adult patients who received ECMO for refractory cardiogenic shock or cardiac arrest were included. Pooled estimates with 95% confidence intervals were calculated based on the Freeman-Tukey double-arcsine transformation and DerSimonian-Laird random-effect model. Survival to discharge was 40.2% (95% confidence intervals [CI], 33.9-46.7), while survival at 3, 6, and 12 months was 55.9% (95% CI, 41.5-69.8), 47.6% (95% CI, 25.4-70.2), and 54.4% (95% CI, 36.6-71.7), respectively. Survival up to 30 days was higher in cardiogenic shock patients (52.5%, 95% CI, 43.7%-61.2%) compared to cardiac arrest (36.2%, 95% CI, 23.1%-50.4%). Concurrently, complication rates were particularly substantial for neurologic deficits (13.3%, 95% CI, 8.3-19.3), infection (25.1%, 95%CI, 15.9-35.5), and renal impairment (47.4%, 95% CI, 30.2-64.9). Significant heterogeneity was detected, although its levels were similar to previous meta-analyses that only examined short-term survival to discharge.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Venoarterial ECMO can improve short-term survival in adults with refractory cardiogenic shock or cardiac arrest. It also may provide favorable long-term survival at up to 3 years postdischarge. However, ECMO also is associated with significant complication rates, which must be incorporated into the risk-benefit analysis when considering treatment. These findings require confirmation by large, adequately controlled and standardized trials with long-term follow-up.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Ashleigh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Yi-Chin</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Prince Charles Hospital, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Tristan D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; Department of Cardiothoracic Surgery; University of Sydney, Sydney, Australia. Electronic address: tristanyan@annalscts.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiothoracic Anesthesia and Perfusion, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9110208</NlmUniqueID><ISSNLinking>1053-0770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="N">Heart Arrest</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult</Keyword><Keyword MajorTopicYN="N">cardiac arrest</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal circulation</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25543217</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2014.09.005</ArticleId><ArticleId IdType="pii">S1053-0770(14)00427-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29987125</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>14</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Periprocedural Cardiopulmonary Bypass or Venoarterial Extracorporeal Membrane Oxygenation During Transcatheter Aortic Valve Replacement: A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e009608</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.118.009608</ELocationID><Abstract><AbstractText Label="BACKGROUND">There are limited data on the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) or cardiopulmonary bypass (CPB) to provide hemodynamic support periprocedurally during transcatheter aortic valve replacement. This study sought to evaluate patients receiving transcatheter aortic valve replacement with concomitant use of CPB/VA-ECMO.</AbstractText><AbstractText Label="METHODS AND RESULTS">We systematically reviewed the published literature from 2000 to 2018 for studies evaluating adult patients requiring CPB/VA-ECMO periprocedurally during transcatheter aortic valve replacement. Studies reporting short-term and long-term mortality were included. Given the significant methodological and statistical differences between published studies, meta-analysis of the association of CPB/VA-ECMO with mortality was not performed. Of the 537 studies identified, 9 studies representing 5191 patients met our inclusion criteria. Median ages were between 75 and 87&#xa0;years with 33% to 75% male patients. Where reported, the Edwards SAPIEN&#x2122; transcatheter heart valve was the most frequently used. A total of 203 (3.9%) patients received periprocedural hemodynamic support with CPB/VA-ECMO. Common indications for CPB/VA-ECMO included left ventricular or aortic annular rupture, rapid hemodynamic deterioration, aortic regurgitation, cardiac arrest, and left main coronary artery obstruction. The use of CPB/VA-ECMO was predominantly an emergent strategy and was used for durations of 1 to 2&#xa0;hours. Short-term mortality (in-hospital and 30-day) was 29.8%, and 1-year mortality was 52.4%. Major complications such as bleeding, vascular injury, tamponade, stroke, and renal failure were noted in 10% to 50% of patients.</AbstractText><AbstractText Label="CONCLUSIONS">CPB/VA-ECMO was used in 4% in the early experience of patients undergoing transcatheter aortic valve replacement, most commonly for periprocedural complications. There are limited data on preprocedural planned use of VA-ECMO, and the characteristics of this population remain poorly defined.</AbstractText><CopyrightInformation>&#xa9; 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saraschandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patlolla</LastName><ForeName>Sri Harsha</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandhyavenu</LastName><ForeName>Harigopal</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saarwaani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barsness</LastName><ForeName>Gregory W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunlay</LastName><ForeName>Shannon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greason</LastName><ForeName>Kevin L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eleid</LastName><ForeName>Mackram F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN eleid.mackram@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="N">Aortic Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="N">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="N">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="N">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">transcatheter valve implantation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29987125</ArticleId><ArticleId IdType="pmc">PMC6064861</ArticleId><ArticleId IdType="doi">10.1161/JAHA.118.009608</ArticleId><ArticleId IdType="pii">JAHA.118.009608</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S. Transcatheter aortic&#x2010;valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961243</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG. Transcatheter or surgical aortic&#x2010;valve replacement in intermediate&#x2010;risk patients. N Engl J Med. 2016;374:1609&#x2013;1620.</Citation><ArticleIdList><ArticleId IdType="pubmed">27040324</ArticleId></ArticleIdList></Reference><Reference><Citation>Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, Smalling R, Lim S, Malaisrie SC, Kapadia S, Szeto WY, Greason KL, Kereiakes D, Ailawadi G, Whisenant BK, Devireddy C, Leipsic J, Hahn RT, Pibarot P, Weissman NJ, Jaber WA, Cohen DJ, Suri R, Tuzcu EM, Svensson LG, Webb JG, Moses JW, Mack MJ, Miller DC, Smith CR, Alu MC, Parvataneni R, D'Agostino RB Jr, Leon MB. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate&#x2010;risk patients: a propensity score analysis. Lancet. 2016;387:2218&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pubmed">27053442</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes DR Jr, Nishimura RA, Grover FL, Brindis RG, Carroll JD, Edwards FH, Peterson ED, Rumsfeld JS, Shahian DM, Thourani VH, Tuzcu EM, Vemulapalli S, Hewitt K, Michaels J, Fitzgerald S, Mack MJ. Annual outcomes with transcatheter valve therapy: from the STS/ACC TVT registry. Ann Thorac Surg. 2016;101:789&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">27175453</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Tsai J, Hsu TY, Lai WY, Chen WK, Muo CH, Kao CH. ECMO used in a refractory ventricular tachycardia and ventricular fibrillation patient: a national case&#x2010;control study. Medicine (Baltimore). 2016;95:e3204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4998545</ArticleId><ArticleId IdType="pubmed">27043684</ArticleId></ArticleIdList></Reference><Reference><Citation>Yannopoulos D, Bartos JA, Raveendran G, Conterato M, Frascone RJ, Trembley A, John R, Connett J, Benditt DG, Lurie KG, Wilson RF, Aufderheide TP. Coronary artery disease in patients with out&#x2010;of&#x2010;hospital refractory ventricular fibrillation cardiac arrest. J Am Coll Cardiol. 2017;70:1109&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">28838358</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Damluji AA, Mendirichaga R, Alfonso CE, Martinez CA, Williams D, Heldman AW, de Marchena EJ, O'Neill WW, Cohen MG. Elective or emergency use of mechanical circulatory support devices during transcatheter aortic valve replacement. J Interv Cardiol. 2016;29:513&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">27550213</ArticleId></ArticleIdList></Reference><Reference><Citation>Shreenivas SS, Lilly SM, Szeto WY, Desai N, Anwaruddin S, Bavaria JE, Hudock KM, Thourani VH, Makkar R, Pichard A, Webb J, Dewey T, Kapadia S, Suri RM, Xu K, Leon MB, Herrmann HC. Cardiopulmonary bypass and intra&#x2010;aortic balloon pump use is associated with higher short and long term mortality after transcatheter aortic valve replacement: a PARTNER trial substudy. Catheter Cardiovasc Interv. 2015;86:316&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">25546704</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2020496</ArticleId><ArticleId IdType="pubmed">17941715</ArticleId></ArticleIdList></Reference><Reference><Citation>Arlt M, Philipp A, Voelkel S, Schopka S, Husser O, Hengstenberg C, Schmid C, Hilker M. Early experiences with miniaturized extracorporeal life&#x2010;support in the catheterization laboratory. Eur J Cardiothorac Surg. 2012;42:858&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">22555310</ArticleId></ArticleIdList></Reference><Reference><Citation>Banjac I, Petrovic M, Akay MH, Janowiak LM, Radovancevic R, Nathan S, Patel M, Loyalka P, Kar B, Gregoric ID. Extracorporeal membrane oxygenation as a procedural rescue strategy for transcatheter aortic valve replacement cardiac complications. ASAIO J. 2016;62:e1&#x2013;e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26309098</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolmatova E, Moazzami K, Cocke TP, Elmann E, Vaidya P, Ng AF, Satya K, Narayan RL. Extracorporeal membrane oxygenation in transcatheter aortic valve replacement. Asian Cardiovasc Thorac Ann. 2017;25:31&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">27913738</ArticleId></ArticleIdList></Reference><Reference><Citation>Husser O, Holzamer A, Philipp A, Nunez J, Bodi V, Muller T, Lubnow M, Luchner A, Lunz D, Riegger GA, Schmid C, Hengstenberg C, Hilker M. Emergency and prophylactic use of miniaturized veno&#x2010;arterial extracorporeal membrane oxygenation in transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2013;82:E542&#x2013;E551.</Citation><ArticleIdList><ArticleId IdType="pubmed">23554044</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontailler M, Demondion P, Lebreton G, Golmard JL, Leprince P. Experience with extracorporeal life support for cardiogenic shock in the older population more than 70&#xa0;years of age. ASAIO J. 2017;63:279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">27922888</ArticleId></ArticleIdList></Reference><Reference><Citation>Seco M, Forrest P, Jackson SA, Martinez G, Andvik S, Bannon PG, Ng M, Fraser JF, Wilson MK, Vallely MP. Extracorporeal membrane oxygenation for very high&#x2010;risk transcatheter aortic valve implantation. Heart Lung Circ. 2014;23:957&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">24954708</ArticleId></ArticleIdList></Reference><Reference><Citation>
Trenkwalder T, Pellegrini C, Holzamer A, Philipp A, Rheude T, Michel J, Reinhard W, Joner M, Kasel AM, Kastrati A, Schunkert H, Endemann D, Debl K, Mayr NP, Hilker M, Hengstenberg C, Husser O. Emergency extracorporeal membrane oxygenation in transcatheter aortic valve implantation: a two&#x2010;center experience of incidence, outcome and temporal trends from 2010 to 2015. Catheter Cardiovasc Interv. 2017.  Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/ccd.27385. Accessed July 2, 2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.27385</ArticleId><ArticleId IdType="pubmed">29130616</ArticleId></ArticleIdList></Reference><Reference><Citation>Uehara K, Minakata K, Saito N, Imai M, Daijo H, Nakatsu T, Sakamoto K, Yamazaki K, Kimura T, Sakata R. Use of extracorporeal membrane oxygenation in complicated transcatheter aortic valve replacement. Gen Thorac Cardiovasc Surg. 2017;65:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">28236098</ArticleId></ArticleIdList></Reference><Reference><Citation>Afilalo J, Lauck S, Kim DH, Lefevre T, Piazza N, Lachapelle K, Martucci G, Lamy A, Labinaz M, Peterson MD, Arora RC, Noiseux N, Rassi A, Palacios IF, Genereux P, Lindman BR, Asgar AW, Kim CA, Trnkus A, Morais JA, Langlois Y, Rudski LG, Morin JF, Popma JJ, Webb JG, Perrault LP. Frailty in older adults undergoing aortic valve replacement: the FRAILTY&#x2010;AVR study. J Am Coll Cardiol. 2017;70:689&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">28693934</ArticleId></ArticleIdList></Reference><Reference><Citation>Toutouzas K, Synetos A, Latsios G, Mastrokostopoulos A, Stathogiannis K, Drakopoulou M, Trantalis G, Tsiamis E, Tousoulis D. The requirement of extracorporeal circulation system for transluminal aortic valve replacement: do we really need it in the catheterization laboratory? Catheter Cardiovasc Interv. 2018;91:E43&#x2013;E48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25945931</ArticleId></ArticleIdList></Reference><Reference><Citation>Frerker C, Schewel J, Schluter M, Schewel D, Ramadan H, Schmidt T, Thielsen T, Kreidel F, Schlingloff F, Bader R, Wohlmuth P, Schafer U, Kuck KH. Emergency transcatheter aortic valve replacement in patients with cardiogenic shock due to acutely decompensated aortic stenosis. EuroIntervention. 2016;11:1530&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pubmed">25751886</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Patel SV, Savani C, Patel NJ, Patel N, Arora S, Panaich SS, Deshmukh A, Cleman M, Mangi A, Forrest JK, Badheka AO. Mechanical circulatory support devices and transcatheter aortic valve implantation (from the National Inpatient Sample). Am J Cardiol. 2015;116:1574&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">26434512</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther T, Hamm CW, Schuler G, Berkowitsch A, Kotting J, Mangner N, Mudra H, Beckmann A, Cremer J, Welz A, Lange R, Kuck KH, Mohr FW, Mollmann H. Perioperative results and complications in 15,964 transcatheter aortic valve replacements: prospective data from the GARY registry. J Am Coll Cardiol. 2015;65:2173&#x2013;2180.</Citation><ArticleIdList><ArticleId IdType="pubmed">25787198</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A, Hardison D, Bridges B, Pietsch J. Red blood cell transfusion volume and mortality among patients receiving extracorporeal membrane oxygenation. Perfusion. 2013;28:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">22892295</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffert M, Conradi L, Terstesse AC, Koschyk D, Schirmer J, Schnabel RB, Wilde S, Ojeda FM, Reichenspurner H, Blankenberg S, Schafer U, Treede H, Diemert P. Blood transfusion is associated with impaired outcome after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2015;85:460&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">25292388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka D, Hirose H, Cavarocchi N, Entwistle JW. The impact of vascular complications on survival of patients on venoarterial extracorporeal membrane oxygenation. Ann Thorac Surg. 2016;101:1729&#x2013;1734.</Citation><ArticleIdList><ArticleId IdType="pubmed">26872734</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoon JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD, Harrington RA, Bhatt DL, Ferrari VA, Fisher JD, Garcia MJ, Gardner TJ, Gentile F, Gilson MF, Hernandez AF, Jacobs AK, Kaul S, Linderbaum JA, Moliterno DJ, Weitz HH. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio&#x2010;Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Catheter Cardiovasc Interv. 2012;79:1023&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">22294439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindman BR, Alexander KP, O'Gara PT, Afilalo J. Futility, benefit, and transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2014;7:707&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322002</ArticleId><ArticleId IdType="pubmed">24954571</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH, Davis MM, Annich GM. Association of hospital&#x2010;level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med. 2015;191:894&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435456</ArticleId><ArticleId IdType="pubmed">25695688</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera S, Kolte D, Gupta T, Goldsweig A, Velagapudi P, Kalra A, Tang GHL, Aronow WS, Fonarow GC, Bhatt DL, Aronow HD, Kleiman NS, Reardon M, Gordon PC, Sharaf B, Abbott JD. Association between hospital volume and 30&#x2010;day readmissions following transcatheter aortic valve replacement. JAMA Cardiol. 2017;2:732&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710612</ArticleId><ArticleId IdType="pubmed">28494061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35566450</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Impact of SARS-CoV-2 Outbreak on Emergency Department Presentation and Prognosis of Patients with Acute Myocardial Infarction: A Systematic Review and Updated Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2323</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm11092323</ELocationID><Abstract><AbstractText>We performed an updated meta-analysis to robustly quantify admission trends of patients with ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI) during the first wave of the pandemic and to characterize on a large basis the risk profile and early prognosis. Studies having the same observation period for the comparison between SARS-CoV-2 outbreak in 2020 versus control period in 2019 were included. Primary endpoints were the relative variation of hospital admissions, the difference of in-hospital mortality for STEMI and NSTEMI. Secondary were: mortality according to countries, income levels and data quality; cardiogenic shock, mechanical complications, door-to-balloon time, time from symptom onset to first medical contact, left ventricular ejection fraction (LVEF) and troponin. In total, 61 observational studies with 125,346 patients were included. Compared with 2019, during the pandemic for STEMI were observed: a 24% reduction of hospitalizations with an impact on early survival (OR = 1.33 in-hospital mortality); the time from symptom onset to first medical contact was 91.31 min longer, whereas door-to-balloon time was increased (+5.44 min); after STEMI, the rate of cardiogenic shock was 33% higher; LVEF at discharge was decreased (-3.46); elevated high-sensitivity troponin levels (1.52) on admission. For NSTEMI, in the COVID-19 period, we observed a 31% reduction of hospitalizations and higher in-hospital deaths (OR = 1.34). The highest mortality rates among countries were: Italy OR = 3.71 (high income), Serbia OR = 2.15 (upper middle) and Pakistan OR = 1.69 (lower middle). Later hospital presentation was associated with larger infarctions, as well as with increased cardiogenic shock and in-hospital mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altobelli</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Life, Public Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angeletti</LastName><ForeName>Paolo Matteo</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Life, Public Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Surgical Intensive Care Unit, Giuseppe Mazzini Hospital, 64100 Teramo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Life, Public Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ascenzo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiovascular and Thoracic Department, Division of Cardiology, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrocelli</LastName><ForeName>Reimondo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>San Timoteo Hospital, ASREM Molise, 86039 Termoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patti</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5404-3968</Identifier><AffiliationInfo><Affiliation>Department of Translational Medicine, Maggiore della Carit&#xe0; Hospital, University of Eastern Piedmont, 28100 Novara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NSTEMI</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">STEMI</Keyword><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">geographical areas</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35566450</ArticleId><ArticleId IdType="pmc">PMC9102296</ArticleId><ArticleId IdType="doi">10.3390/jcm11092323</ArticleId><ArticleId IdType="pii">jcm11092323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;273. doi: 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Virtual Press Conference on COVID-19-11 March 2020.  [(accessed on 11 March 2020)].  Available online:  https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audioemergen-cies-coronavirus-press-conference-full-and-final11mar2020.pdf?sfvrsn=cb432bb3_2.</Citation></Reference><Reference><Citation>Livingston E., Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323:1335. doi: 10.1001/jama.2020.4344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4344</ArticleId><ArticleId IdType="pubmed">32181795</ArticleId></ArticleIdList></Reference><Reference><Citation>De Filippo O., D&#x2019;Ascenzo F., Angelini F., Bocchino P.P., Conrotto F., Saglietto A., Secco G.G., Campo G., Gallone G., Verardi R., et al. Reduced rate of hospital admissions for ACS during COVID-19 outbreak in Northern Italy. N. Engl. J. Med. 2020;383:88&#x2013;89. doi: 10.1056/NEJMc2009166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2009166</ArticleId><ArticleId IdType="pmc">PMC7224608</ArticleId><ArticleId IdType="pubmed">32343497</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzler B., Siostrzonek P., Binder R.K., Bauer A., Reinstadler S.J. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: The pandemic response causes cardiac collateral damage. Eur. Hearth J. 2020;41:1852&#x2013;1853. doi: 10.1093/eurheartj/ehaa314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa314</ArticleId><ArticleId IdType="pmc">PMC7184486</ArticleId><ArticleId IdType="pubmed">32297932</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia S., Albaghdadi M.S., Meraj P.M., Schmidt C., Garberich R., Jaffer F.A., Dixon S., Rade J.J., Tannenbaum M., Chambers J., et al. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic. J. Am. Coll. Cardiol. 2020;75:2871&#x2013;2872. doi: 10.1016/j.jacc.2020.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.011</ArticleId><ArticleId IdType="pmc">PMC7151384</ArticleId><ArticleId IdType="pubmed">32283124</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S., Spaccarotella C., Basso C., Calabr&#xf2; M.P., Curcio A., Filardi P.P., Mancone M., Mercuro G., Muscoli S., Nodari S., et al. Societ&#xe0; Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitali-zations for myocardial infarction in Italy in the COVID-19 era. Eur. Heart J. 2020;41:2083&#x2013;2088. doi: 10.1093/eurheartj/ehaa409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa409</ArticleId><ArticleId IdType="pmc">PMC7239145</ArticleId><ArticleId IdType="pubmed">32412631</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadri G., Rognoni A., Cerrato E., Baralis G., Boccuzzi G., Brscic E., Conrotto F., De Benedictis M., De Martino L., Di Leo A., et al. Catheterization laboratory activity before and during COVID-19 spread: A comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE) Int. J. Cardiol. 2021;323:288&#x2013;291. doi: 10.1016/j.ijcard.2020.08.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.08.072</ArticleId><ArticleId IdType="pmc">PMC7446645</ArticleId><ArticleId IdType="pubmed">32858138</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew N.W., Ow Z.G.W., Teo V.X.Y., Heng R.R.Y., Ng C.H., Lee C.-H., Low A.F., Chan M.Y.-Y., Yeo T.-C., Tan H.-C., et al. The Global Effect of the COVID-19 Pandemic on STEMI Care: A Systematic Review and Meta-analysis. Can. J. Cardiol. 2021;37:1450&#x2013;1459. doi: 10.1016/j.cjca.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8056787</ArticleId><ArticleId IdType="pubmed">33848599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dell&#x2019;era G., Colombo C., Forleo G.B., Curnis A., Marcantoni L., Racheli M., Sartori P., Notarstefano P., De Salvia A., Guerra F., et al. Reduction of admissions for urgent and elective pacemaker implant during the COVID-19 outbreak in Northern Italy. J. Cardiovasc. Med. 2022;23:22&#x2013;27. doi: 10.2459/JCM.0000000000001189.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001189</ArticleId><ArticleId IdType="pubmed">34545009</ArticleId></ArticleIdList></Reference><Reference><Citation>Severino P., D&#x2019;Amato A., Saglietto A., D&#x2019;Ascenzo F., Marini C., Schiavone M., Ghionzoli N., Pirrotta F., Troiano F., Cannillo M., et al. Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. ESC Heart Fail. 2020;7:4182&#x2013;4188. doi: 10.1002/ehf2.13043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13043</ArticleId><ArticleId IdType="pmc">PMC7754919</ArticleId><ArticleId IdType="pubmed">33094929</ArticleId></ArticleIdList></Reference><Reference><Citation>Rognoni A., D&#x2019;Ascenzo F., Solli M., Mennuni M.G., Galiffa V., Rosso R., Cavallino C., Ugo F., De Filippo O., Borin A., et al. Return towards normality in admissions for myocardial infarction after the lockdown removal for COVID-19 outbreak in Italy. Int. J. Cardiol. 2021;332:235&#x2013;237. doi: 10.1016/j.ijcard.2021.03.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2021.03.046</ArticleId><ArticleId IdType="pmc">PMC7983363</ArticleId><ArticleId IdType="pubmed">33766626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nef H.M., Els&#xe4;sser A., M&#xf6;llmann H., Abdel-Hadi M., Bauer T., Br&#xfc;ck M., Eggebrecht H., Ehrlich J.R., Ferrari M.W., Fichtlscherer S., et al. Impact of the COVID-19 pandemic on cardiovascular mortality and catherization activity during the lockdown in central Germany: An observational study. Clin. Res. Cardiol. 2021;110:292&#x2013;301. doi: 10.1007/s00392-020-01780-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01780-0</ArticleId><ArticleId IdType="pmc">PMC7680078</ArticleId><ArticleId IdType="pubmed">33219854</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Belle E., Manigold T., Pi&#xe9;rache A., Furber A., Debry N., Luycx-Bore A., Bauchart J.-J., Nugue O., Huchet F., Bic M., et al. Myocardial Infarction incidence during national lockdown in two French provinces unevenly affected by COVID-19 outbreak: An observational study. Lancet Reg. Health Eur. 2021;2:100030. doi: 10.1016/j.lanepe.2021.100030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100030</ArticleId><ArticleId IdType="pmc">PMC7938895</ArticleId><ArticleId IdType="pubmed">34173627</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ascenzo F., De Filippo O., Borin A., Barbieri L., Adamo M., Morici N., Truffa Giachet A., Iannaccone M., Crimi G., Gaido L., et al. Impact of COVID-19 pandemic and infection on in-hospital survival for patients presenting with acute coronary syndromes: A multicenter registry. Int. J. Cardiol. 2021;332:227&#x2013;234. doi: 10.1016/j.ijcard.2021.03.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2021.03.063</ArticleId><ArticleId IdType="pmc">PMC8006512</ArticleId><ArticleId IdType="pubmed">33794235</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Boutron I., Hoffmann T.C., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G.A., Shea B., O&#x2019;Connell D., Peterson J., Welch V., Losos M., Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute.  [(accessed on 6 January 2022)].  Available online:  https://www.ohri.ca.</Citation></Reference><Reference><Citation>Cancer Incidence and Mortality Data: Sources and Methods by Country.  [(accessed on 6 January 2022)].  Available online:  https://gco.iarc.fr/today/data/methods/GLOBOCAN2020_Annex_A.XLSX.</Citation></Reference><Reference><Citation>World Bank Country and Lending Groups.  [(accessed on 6 January 2022)].  Available online:  https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.</Citation></Reference><Reference><Citation>Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863. doi: 10.3389/fpsyg.2013.00863.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2013.00863</ArticleId><ArticleId IdType="pmc">PMC3840331</ArticleId><ArticleId IdType="pubmed">24324449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 2005;5:13. doi: 10.1186/1471-2288-5-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-5-13</ArticleId><ArticleId IdType="pmc">PMC1097734</ArticleId><ArticleId IdType="pubmed">15840177</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanile A., Verdecchia P., Ravera A., Coiro S., Mattei C., Scavelli F., Bearzot L., Cutolo A., Centola M., Carugo S., et al. Intensive cardiac care unit admission trends during the COVID-19 outbreak in Italy: A multi-center study. Intern. Emerg. Med. 2021;16:2077&#x2013;2086. doi: 10.1007/s11739-021-02718-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02718-8</ArticleId><ArticleId IdType="pmc">PMC7993896</ArticleId><ArticleId IdType="pubmed">33768468</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreger H., Bruch L., Maier B., Sch&#xfc;hlen H. Acute Myocardial Infarction Admissions in Berlin During the COVID-19 Pandemic. Dtsch. Arztebl. Int. 2020;117:597&#x2013;598. doi: 10.3238/arztebl.2020.0597.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2020.0597</ArticleId><ArticleId IdType="pubmed">33161944</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardman A., Zahger D., Orvin K., Oren D., Kofman N., Mohsen J., Tsafrir O., Asher E., Rubinshtein R., Jamal J., et al. Acute myocardial infarction in the COVID-19 era: Incidence, clinical characteristics and in-hospital outcomes-A multicenter registry. PLoS ONE. 2021;16:e0253524. doi: 10.1371/journal.pone.0253524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253524</ArticleId><ArticleId IdType="pmc">PMC8213163</ArticleId><ArticleId IdType="pubmed">34143840</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesnier J., Cottin Y., Coste P., Ferrari E., Schiele F., Lemesle G., Thuaire C., Angoulvant D., Cayla G., Bouleti C., et al. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: A registry study. Lancet Public Health. 2020;5:e536&#x2013;e542. doi: 10.1016/S2468-2667(20)30188-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30188-2</ArticleId><ArticleId IdType="pmc">PMC7498416</ArticleId><ArticleId IdType="pubmed">32950075</ArticleId></ArticleIdList></Reference><Reference><Citation>Papafaklis M.I., Katsouras C.S., Tsigkas G., Toutouzas K., Davlouros P., Hahalis G.N., Kousta M.S., Styliadis I.G., Triantafyllou K., Pappas L., et al. &#x201c;Missing&#x201d; acute coronary syndrome hospitalizations during the COVID-19 era in Greece: Medical care avoidance combined with a true reduction in incidence? Clin. Cardiol. 2020;43:1142&#x2013;1149. doi: 10.1002/clc.23424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23424</ArticleId><ArticleId IdType="pmc">PMC7404667</ArticleId><ArticleId IdType="pubmed">32691901</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccolo R., Bruzzese D., Mauro C., Aloia A., Baldi C., Boccalatte M., Bottiglieri G., Briguori C., Caiazzo G., Calabr&#xf2; P., et al. Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syn-dromes Associated with the COVID-19 Outbreak. Circulation. 2020;141:2035&#x2013;2037. doi: 10.1161/CIRCULATIONAHA.120.047457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047457</ArticleId><ArticleId IdType="pmc">PMC7294593</ArticleId><ArticleId IdType="pubmed">32352318</ArticleId></ArticleIdList></Reference><Reference><Citation>Romaguera R., Ribera A., G&#xfc;ell-Viaplana F., Tom&#xe1;s-Querol C., Mu&#xf1;oz-Camacho J.F., Agudelo V. Decrease in ST-segment elevation myocardial infarction admissions in Catalonia during the COVID-19 pandemic. Rev. Esp. Cardiol. 2020;73:778&#x2013;780. doi: 10.1016/j.recesp.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7274622</ArticleId><ArticleId IdType="pubmed">32565077</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz T., Meisinger C., Kirchberger I., Thilo C., Amann U., Baumeister S.E., Linseisen J. Impact of COVID-19 pandemic lockdown on myocardial infarction care. Eur. J. Epidemiol. 2021;36:619&#x2013;627. doi: 10.1007/s10654-021-00764-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-021-00764-2</ArticleId><ArticleId IdType="pmc">PMC8179954</ArticleId><ArticleId IdType="pubmed">34091769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayad S., Shenouda R., Henein M. The Impact of COVID-19 on In-Hospital Outcomes of ST-Segment Elevation Myocardial Infarction Patients. J. Clin. Med. 2021;10:278. doi: 10.3390/jcm10020278.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10020278</ArticleId><ArticleId IdType="pmc">PMC7828690</ArticleId><ArticleId IdType="pubmed">33466588</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;inier G., Hay&#x131;ro&#x11f;lu M., Pay L., Yumurta&#x15f; A., Tezen O., Parsova K.E., Tekkesin I. Effect of the COVID-19 pandemic on access to primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Turk. Kardiyol. Dern. Ars. 2020;48:640&#x2013;645. doi: 10.5543/tkda.2020.95845.</Citation><ArticleIdList><ArticleId IdType="doi">10.5543/tkda.2020.95845</ArticleId><ArticleId IdType="pubmed">33034585</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan J.J., Chongprasertpon N., Arockiam S., Arnous S., Kiernan T.J. COVID-19 and STEMI: A snapshot analysis of presentation patterns during a pandemic. IJC Hearth Vasc. 2020;30:100546. doi: 10.1016/j.ijcha.2020.100546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2020.100546</ArticleId><ArticleId IdType="pmc">PMC7247988</ArticleId><ArticleId IdType="pubmed">32838018</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoulah A., Hersi A.S., Al-Faifi S.M., Alasmari A., Aljohar A., Balghith M., Alshehri M., Youssef A.A., ElSayed O., Alama M.N., et al. STEMI and COVID-19 Pandemic in Saudi Arabia. Curr. Probl. Cardiol. 2021;46:100656. doi: 10.1016/j.cpcardiol.2020.100656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100656</ArticleId><ArticleId IdType="pmc">PMC7374127</ArticleId><ArticleId IdType="pubmed">32839042</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca G., Verdoia M., Cercek M., Jensen L.O., Vavlukis M., Calmac L., Johnson T., Ferrer G.R., Ganyukov V., Wojakowski W., et al. Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. J. Am. Coll. Cardiol. 2020;76:2321&#x2013;2330. doi: 10.1016/j.jacc.2020.09.546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.09.546</ArticleId><ArticleId IdType="pmc">PMC7834750</ArticleId><ArticleId IdType="pubmed">33183506</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Liberto I.A., Pilato G., Geraci S., Milazzo D., Vaccaro G., Buccheri S., Caramanno G. Impact on hospital admission of ST-elevation myocardial infarction patients during coronavirus disease 2019 pandemic in an Italian Hospital. J. Cardiovasc. Med. 2020;21:722&#x2013;724. doi: 10.2459/JCM.0000000000001053.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001053</ArticleId><ArticleId IdType="pubmed">32658006</ArticleId></ArticleIdList></Reference><Reference><Citation>Erol M.K., Kay&#x131;k&#xe7;&#x131;o&#x11f;lu M., K&#x131;l&#x131;&#xe7;kap M., G&#xfc;ler A., Y&#x131;ld&#x131;r&#x131;m A., Kahraman F., Can V., Inci S., Baysal S.S., Er O., et al. Treatment delays and in-hospital outcomes in acute myocardial infarction during the COVID-19 pandemic: A nationwide study. Anatol J. Cardiol. 2020;24:334&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724394</ArticleId><ArticleId IdType="pubmed">33122486</ArticleId></ArticleIdList></Reference><Reference><Citation>Fileti L., Vecchio S., Moretti C., Reggi A., Aquilina M., Balducelli M., Santarelli A., Grosseto D., Piovaccari G., Rubboli A. Impact of the COVID-19 pandemic on coronary invasive procedures at two Italian high-volume referral centers. J. Cardiovasc. Med. 2020;21:869&#x2013;873. doi: 10.2459/JCM.0000000000001101.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001101</ArticleId><ArticleId IdType="pubmed">33009170</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas A., Baptista R., Gon&#xe7;alves V., Ferreira C., Milner J., Louren&#xe7;o C., Costa S., Franco F., Monteiro S., Gon&#xe7;alves F., et al. Impact of SARS-CoV-2 pandemic on ST-elevation myocardial infarction admissions and outcomes in a Portuguese primary percutaneous coronary intervention center: Preliminary Data. Rev. Port. Cardiol. 2021;40:465&#x2013;471. doi: 10.1016/j.repc.2020.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.repc.2020.10.012</ArticleId><ArticleId IdType="pmc">PMC8278193</ArticleId><ArticleId IdType="pubmed">34274091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X.-Y., Shen X.-F., Cheng Y.-R., Zhou M.-Y., Ye L., Feng Z.-H., Xu Z., Chen J., Wang M.-W., Zhang X.-W. Effect of COVID-19 outbreak on the treatment time of patients with acute ST-segment elevation myocardial infarction. Am. J. Emerg. Med. 2021;44:192&#x2013;197. doi: 10.1016/j.ajem.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494496</ArticleId><ArticleId IdType="pubmed">33039221</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad K., Potter B.J., Matteau A., Gobeil F., Mansour S. Implications of COVID-19 on Time-Sensitive STEMI Care: A Report From a North American Epicenter. Cardiovasc. Revasc. Med. 2020;30:33&#x2013;37. doi: 10.1016/j.carrev.2020.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2020.09.024</ArticleId><ArticleId IdType="pmc">PMC7501080</ArticleId><ArticleId IdType="pubmed">32988743</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiris T., Avci E., Ekin T., Akg&#xfc;n D.E., Tiryaki M., Yidirim A., Hazir K., Murat B., Yeni M., Altindag R., et al. Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial &#x131;nfarction (STEMI) in Turkey: Results from TURSER study (TURKISH St-segment elevation myocardial &#x131;nfarction registry) J. Thromb. Thrombolysis. 2021;53:321&#x2013;334. doi: 10.1007/s11239-021-02487-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02487-3</ArticleId><ArticleId IdType="pmc">PMC8164077</ArticleId><ArticleId IdType="pubmed">34050883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobo O., Efraim R., Saada M., Kofman N., Abu Dogosh A., Abramowitz Y., Aronson D., Minha S., Roguin A., Meisel S.R. The impact of lockdown enforcement during the SARSCoV-2 pandemic on the timing of presentation and early outcomes of patients with ST-elevation myocardial infarction. PLoS ONE. 2020;15:e0241149. doi: 10.1371/journal.pone.0241149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241149</ArticleId><ArticleId IdType="pmc">PMC7584161</ArticleId><ArticleId IdType="pubmed">33095801</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng W.-X., Yang J.-G., Li X.-D., Jiang W.-Y., Gao L.-J., Wu Y., Yang Y.-M., Yuan J.-Q., Yang W.-X., Qiao S.-B., et al. Impact of the shift to a fibrinolysis-first strategy on care and outcomes of patients with ST-segment&#x2013;elevation myocardial infarction during the COVID-19 pandemic&#x2014;The experience from the largest cardiovascular-specific centre in China. Int. J. Cardiol. 2021;329:260&#x2013;265. doi: 10.1016/j.ijcard.2020.11.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.11.074</ArticleId><ArticleId IdType="pmc">PMC7723441</ArticleId><ArticleId IdType="pubmed">33307137</ArticleId></ArticleIdList></Reference><Reference><Citation>Little C.D., Kotecha T., Candilio L., Jabbour R.J., Collins G.B., Ahmed A., Connolly M., Kanyal R., Demir O.M., Lawson L.O., et al. COVID-19 pandemic and STEMI: Pathway activation and outcomes from the pan-London heart attack group. Open Heart. 2020;7:e001432. doi: 10.1136/openhrt-2020-001432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2020-001432</ArticleId><ArticleId IdType="pmc">PMC7592245</ArticleId><ArticleId IdType="pubmed">33106441</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita K., Hess S., Marchandot B., Sato C., Truong D.P., Kim N.T., Weiss A., Jesel L., Ohlmann P., Morel O. Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic. J. Thromb. Thrombolysis. 2021;52:95&#x2013;104. doi: 10.1007/s11239-020-02340-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02340-z</ArticleId><ArticleId IdType="pmc">PMC7668406</ArticleId><ArticleId IdType="pubmed">33200333</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengal N., Saghir T., Hassan Rizvi S.N., Khan N., Qamar N., Masood S., Badini A. Acute ST-Elevation Myocardial Infarction Before and During the COVID-19 Pandemic: What is the Clinically Significant Difference? Cureus. 2020;12:e10523. doi: 10.7759/cureus.10523.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.10523</ArticleId><ArticleId IdType="pmc">PMC7574816</ArticleId><ArticleId IdType="pubmed">33094064</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovi&#x107; M., Milovan&#x10d;ev A., Kova&#x10d;evi&#x107; M., Miljkovi&#x107; T., Ili&#x107; A., Stoj&#x161;i&#x107;-Milosavljevi&#x107; A., Golubovi&#x107; M. Impact of COVID-19 outbreak on hospital admissions and outcome of acute coronary syndromes in a single high-volume centre in southeastern Europe. Neth. Heart J. 2021;29:230&#x2013;236. doi: 10.1007/s12471-021-01554-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12471-021-01554-x</ArticleId><ArticleId IdType="pmc">PMC7950419</ArticleId><ArticleId IdType="pubmed">33704668</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Leor O., Cid-&#xc1;lvarez B., P&#xe9;rez de Prado A., Rossello X., Ojeda S., Serrador A., L&#xf3;pez-Palop R., Mart&#xed;n-Moreiras J., Rumoroso J.R., Cequier &#xc1;., et al. Impact of COVID-19 on ST-segment elevation myocardial infarction care. Span. Exp. Rev. Esp. Cardiol. 2020;73:994&#x2013;1002. doi: 10.1016/j.recesp.2020.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2020.07.033</ArticleId><ArticleId IdType="pmc">PMC7834732</ArticleId><ArticleId IdType="pubmed">32917566</ArticleId></ArticleIdList></Reference><Reference><Citation>Salarifar M., Ghavami M., Poorhosseini H., Masoudkabir F., Jenab Y., Amirzadegan A., Alidoosti M., Aghajani H., Bozorgi A., Hosseini K., et al. The impact of a dedicated coronavirus disease 2019 primary angioplasty protocol on time components related to ST segment elevation myocardial infarction management in a 24/7 primary percutaneous coronary intervention-capable hospital. Kardiol Pol. 2020;78:1227&#x2013;1234. doi: 10.33963/KP.15607.</Citation><ArticleIdList><ArticleId IdType="doi">10.33963/KP.15607</ArticleId><ArticleId IdType="pubmed">32955819</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C., Liu S., Yin D., Wang Y., Zhao Y., Yang W., Qiao S., Dou K., Xu B. Impact of Public Health Emergency Response to COVID-19 on Management and Outcome for STEMI Patients in Beijing&#x2014;A Single-Center Historic Control Study. Curr. Probl. Cardiol. 2021;46:100693. doi: 10.1016/j.cpcardiol.2020.100693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100693</ArticleId><ArticleId IdType="pmc">PMC7462598</ArticleId><ArticleId IdType="pubmed">33032817</ArticleId></ArticleIdList></Reference><Reference><Citation>Soylu K., Coksevim M., Yan&#x131;k A., Bugra Cerik I., Aksan G. Effect of COVID-19 pandemic process on STEMI patients timeline. Int. J. Clin. Pr. 2021;75:e14005. doi: 10.1111/ijcp.14005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14005</ArticleId><ArticleId IdType="pmc">PMC7883118</ArticleId><ArticleId IdType="pubmed">33400345</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasoni D., Adamo M., Italia L., Branca L., Chizzola G., Fiorina C., Lupi L., Inciardi R.M., Cani D.S., Lombardi C.M., et al. Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction. J. Cardiovasc. Med. 2020;21:874&#x2013;881. doi: 10.2459/JCM.0000000000001098.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001098</ArticleId><ArticleId IdType="pubmed">32941325</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang D., Xiang X., Zhang W., Yi S., Zhang J., Gu X., Xu Y., Huang K., Su X., Yu B., et al. Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China. J. Am. Coll. Cardiol. 2020;76:1318&#x2013;1324. doi: 10.1016/j.jacc.2020.06.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.06.039</ArticleId><ArticleId IdType="pmc">PMC7438071</ArticleId><ArticleId IdType="pubmed">32828614</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachariah G., Ramakrishnan S., Das M.K., Jabir A., Jayagopal P.B., Venugopal K., Mani K., Khan A.K., Malviya A., Gupta A., et al. Changing pattern of admissions for acute myocardial infarction in India during the COVID-19 pandemic. Indian Heart J. 2021;73:413&#x2013;423. doi: 10.1016/j.ihj.2021.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ihj.2021.06.003</ArticleId><ArticleId IdType="pmc">PMC8424286</ArticleId><ArticleId IdType="pubmed">34474751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Song X., Dang Y. Experience of ST Segment Elevation Myocardial Infarction Management During COVID-19 Pandemic From the Mainland of China. Cardiovasc. Revasc. Med. 2021;28:92&#x2013;94. doi: 10.1016/j.carrev.2020.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2020.07.027</ArticleId><ArticleId IdType="pmc">PMC7381921</ArticleId><ArticleId IdType="pubmed">32855085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryndza M.A., Litwinowicz R., Bartu&#x15b; S., Nosal M., Godlewski J., Orzechowska A., Wi&#x15b;niewski A., Korpak-Wysocka R., Rzeszutko &#x141;., Kocik P., et al. Incidence of mechanical complications following myocardial infarction during the first two months of the COVID-19 pandemic in the Southern Poland region: A multicenter study. Kardiol. Polska. 2021;79:66&#x2013;68. doi: 10.33963/KP.15653.</Citation><ArticleIdList><ArticleId IdType="doi">10.33963/KP.15653</ArticleId><ArticleId IdType="pubmed">33094570</ArticleId></ArticleIdList></Reference><Reference><Citation>Clifford C.R., Le May M., Chow A., Boudreau R., Fu A.Y., Barry Q., Chong A.Y., So D.Y. Delays in ST-Elevation Myocardial Infarction Care During the COVID-19 Lockdown: An Observational Study. CJC Open. 2020;3:565&#x2013;573. doi: 10.1016/j.cjco.2020.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjco.2020.12.009</ArticleId><ArticleId IdType="pmc">PMC7834324</ArticleId><ArticleId IdType="pubmed">33521615</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin N., Iglesias J.F., Rey F., Benzakour L., Cimci M., Noble S., Degrauwe S., Tessitore E., Mach F., Roffi M. Impact of the COVID-19 pandemic on acute coronary syndromes. Swiss Med. Wkly. 2020;150:w20448. doi: 10.4414/smw.2020.20448.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2020.20448</ArticleId><ArticleId IdType="pubmed">33382905</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelaziz H.K., Abdelrahman A., Nabi A., D&#x119;bski M., Mentias A., Choudhury T., Patel B., Saad M. Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: Insights from a British cardiac center. Am. Heart J. 2020;226:45&#x2013;48. doi: 10.1016/j.ahj.2020.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.04.022</ArticleId><ArticleId IdType="pmc">PMC7211651</ArticleId><ArticleId IdType="pubmed">32497914</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeddinghaus J., Nestelberger T., Kaiser C., Twerenbold R., Fahrni G., Bingisser R., Khanna N., Tschudin-Sutter S., Widmer A., Jeger R., et al. Effect of COVID-19 on acute treatment of ST-segment elevation and Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland. IJC Heart Vasc. 2020;32:100686. doi: 10.1016/j.ijcha.2020.100686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2020.100686</ArticleId><ArticleId IdType="pmc">PMC7734221</ArticleId><ArticleId IdType="pubmed">33335974</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammalleri V., Muscoli S., Benedetto D., Stifano G., Macrini M., Di Landro A., Di Luozzo M., Marchei M., Mariano E.G., Cota L., et al. Who Has Seen Patients With ST-Segment-Elevation Myocardial Infarction? First Results From Italian Real-World Coronavirus Disease 2019. J. Am. Heart Assoc. 2020;9:e017126. doi: 10.1161/JAHA.120.017126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.017126</ArticleId><ArticleId IdType="pmc">PMC7792389</ArticleId><ArticleId IdType="pubmed">32901560</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.-H., Huang W.-C., Hwang J.-J. No Reduction of ST-segment Elevation Myocardial Infarction Admission in Taiwan During Coronavirus Pandemic. Am. J. Cardiol. 2020;131:133&#x2013;134. doi: 10.1016/j.amjcard.2020.06.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.06.030</ArticleId><ArticleId IdType="pmc">PMC7319917</ArticleId><ArticleId IdType="pubmed">32713656</ArticleId></ArticleIdList></Reference><Reference><Citation>Secco G.G., Zocchi C., Parisi R., Roveta A., Mirabella F., Vercellino M., Pistis G., Reale M., Maggio S., Audo A., et al. Decrease and Delay in Hospitalization for Acute Coronary Syndromes During the 2020 SARS-CoV-2 Pandemic. Can. J. Cardiol. 2020;36:1152&#x2013;1155. doi: 10.1016/j.cjca.2020.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2020.05.023</ArticleId><ArticleId IdType="pmc">PMC7242185</ArticleId><ArticleId IdType="pubmed">32447060</ArticleId></ArticleIdList></Reference><Reference><Citation>Siudak Z., Grygier M., Wojakowski W., Msc K.P.M., Witkowski A., G&#x105;sior M., Dudek D., Bartu&#x15b; S. Clinical and procedural characteristics of COVID-19 patients treated with percutaneous coronary interventions. Catheter. Cardiovasc. Interv. 2020;96:E568&#x2013;E575. doi: 10.1002/ccd.29134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29134</ArticleId><ArticleId IdType="pmc">PMC7405230</ArticleId><ArticleId IdType="pubmed">32686899</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabattoni D., Montorsi P., Merlino L. Late STEMI and NSTEMI Patients&#x2019; Emergency Calling in COVID-19 Outbreak. Can. J. Cardiol. 2020;36:1161.e7&#x2013;1161.e8. doi: 10.1016/j.cjca.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2020.05.003</ArticleId><ArticleId IdType="pmc">PMC7206418</ArticleId><ArticleId IdType="pubmed">32437729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiessman M., Abitbol M., Perl L., Bental T., Levy S., Agmon I.N., Gurevitz C., Porter A., Eisen A., Kornowski R., et al. Hospital admissions for acute coronary syndrome during the first wave of COVID-19 pandemic in Israel: A single tertiary center experience. Coron. Artery Dis. 2021;32:658&#x2013;660. doi: 10.1097/MCA.0000000000001016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCA.0000000000001016</ArticleId><ArticleId IdType="pmc">PMC8492076</ArticleId><ArticleId IdType="pubmed">33471474</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangashamaiah S., Hayagreev V., Krishnan S., Prabhavathi B., Manjunath C.N. The impact of COVID19 nationwide lock-down on STEMI hospitalization and outcomes in South India. Indian Heart J. 2021;73:379&#x2013;381. doi: 10.1016/j.ihj.2021.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ihj.2021.03.008</ArticleId><ArticleId IdType="pmc">PMC7989664</ArticleId><ArticleId IdType="pubmed">34154762</ArticleId></ArticleIdList></Reference><Reference><Citation>Flori M., Marinucci L., Gabrielli G., Baiocco E., Accardi R., Scalone G., Grossi P., Guerra F. Reduction in acute coronary syndromes during coronavirus disease 2019 global pandemic: Data from the Marche region of Italy. J. Cardiovasc. Med. 2021;22:350&#x2013;356. doi: 10.2459/JCM.0000000000001130.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001130</ArticleId><ArticleId IdType="pubmed">33136811</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Song C., Yin D., Wang Y., Zhao Y., Yang W., Qiao S., Dou K., Xu B. Impact of public health emergency response to COVID-19 on management and outcome for NSTEMI patients in Beijing: A single-center historic control. Catheter. Cardiovasc. Interv. 2021;97:E475&#x2013;E483. doi: 10.1002/ccd.29145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29145</ArticleId><ArticleId IdType="pubmed">32725858</ArticleId></ArticleIdList></Reference><Reference><Citation>Braiteh N., Rehman W.U., Alom M., Skovira V., Breiteh N., Rehman I., Yarkoni A., Kahsou H., Rehman A. Decrease in acute coronary syndrome presentations during the COVID-19 pandemic in upstate New York. Am. Heart J. 2020;226:147&#x2013;151. doi: 10.1016/j.ahj.2020.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7244433</ArticleId><ArticleId IdType="pubmed">32569892</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeymer U., Gitt A., Thiele H. COVID-19-Pandemie: Effekte auf die klinische Versorgung von Herz-Kreislauf-Patienten im Fr&#xfc;hling 2020 [COVID-19 pandemic: Effects on clinical care of cardiovascular patients in spring 2020] Herz. 2021;46:115&#x2013;119. doi: 10.1007/s00059-020-05015-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00059-020-05015-w</ArticleId><ArticleId IdType="pmc">PMC7884099</ArticleId><ArticleId IdType="pubmed">33590283</ArticleId></ArticleIdList></Reference><Reference><Citation>Primessnig U., Pieske B.M., Sherif M. Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID-19 pandemic. ESC Heart Fail. 2021;8:333&#x2013;343. doi: 10.1002/ehf2.13075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13075</ArticleId><ArticleId IdType="pmc">PMC7835606</ArticleId><ArticleId IdType="pubmed">33283476</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoni L., Alimehmeti I., Ceka A., Tafaj E., Gina M., Dibra A., Goda A. Impact of coronavirus disease 19 (COVID 19) pandemic on acute coronary syndrome (ACS) hospitalizations, and related invasive procedures. Eur. Heart J. Acute Cardiovasc. Care. 2021;10((Suppl. 1)):593&#x2013;599. doi: 10.1093/ehjacc/zuab020.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuab020.079</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon M.D., McNulty E.J., Rana J.S., Leong T.K., Lee C., Sung S.-H., Ambrosy A.P., Sidney S., Go A.S. The COVID-19 Pandemic and the Incidence of Acute Myocardial Infarction. N. Engl. J. Med. 2020;383:691&#x2013;693. doi: 10.1056/NEJMc2015630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2015630</ArticleId><ArticleId IdType="pubmed">32427432</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren-Gash C., Blackburn R., Whitaker H., McMenamin J., Hayward A.C. Laboratory-confirmed respiratory in-fections as triggers for acute myocardial infarction and stroke: A self-controlled case series analysis of national linked datasets from Scotland. Eur. Respir. J. 2018;51:3. doi: 10.1183/13993003.01794-2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01794-2017</ArticleId><ArticleId IdType="pmc">PMC5898931</ArticleId><ArticleId IdType="pubmed">29563170</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldeira D., Rodrigues B.S., David C., Costa J., Pinto F.J., Ferreira J.J. The association of influenza infection and vaccine with myocardial infarction: Systematic review and meta-analysis of self-controlled case series. Expert Rev. Vaccines. 2019;18:1211&#x2013;1217. doi: 10.1080/14760584.2019.1690459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2019.1690459</ArticleId><ArticleId IdType="pubmed">31693865</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong T.-Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: Acute and long-term implications. Eur. Heart J. 2020;41:1798&#x2013;1800. doi: 10.1093/eurheartj/ehaa231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa231</ArticleId><ArticleId IdType="pmc">PMC7454513</ArticleId><ArticleId IdType="pubmed">32186331</ArticleId></ArticleIdList></Reference><Reference><Citation>Masi P., H&#xe9;kimian G., Lejeune M., Chommeloux J., Desnos C., Pineton De Chambrun M., Martin-Toutain I., Nieszkowska A., Lebreton G., Br&#xe9;chot N., et al. Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study. Circulation. 2020;142:611&#x2013;614. doi: 10.1161/CIRCULATIONAHA.120.048925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048925</ArticleId><ArticleId IdType="pmc">PMC7418760</ArticleId><ArticleId IdType="pubmed">32776849</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudry F.A., Hamshere S.M., Rathod K.S., Akhtar M.M., Archbold R.A., Guttmann O.P., Woldman S., Jain A.K., Knight C.J., Baumbach A., et al. High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction. J. Am. Coll. Cardiol. 2020;76:1168&#x2013;1176. doi: 10.1016/j.jacc.2020.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.07.022</ArticleId><ArticleId IdType="pmc">PMC7833185</ArticleId><ArticleId IdType="pubmed">32679155</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldi E., Sechi G.M., Mare C., Canevari F., Brancaglione A., Primi R., Klersy C., Palo A., Contri E., Ronchi V., et al. Out-of-Hospital Cardiac Arrest during the COVID-19 Outbreak in Italy. N. Engl. J. Med. 2020;383:496&#x2013;498. doi: 10.1056/NEJMc2010418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2010418</ArticleId><ArticleId IdType="pmc">PMC7204428</ArticleId><ArticleId IdType="pubmed">32348640</ArticleId></ArticleIdList></Reference><Reference><Citation>Boersma E., Maas A.C., Deckers J.W., Simoons M.L. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet. 1996;348:771&#x2013;775. doi: 10.1016/S0140-6736(96)02514-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)02514-7</ArticleId><ArticleId IdType="pubmed">8813982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman J.S., Buller C.E., Sleeper L.A., Boland J., Dzavik V., Sanborn T.A., Godfrey E., White H.D., Lim J., LeJemtel T. Cardiogenic shock complicating acute myocardial infarction--etiologies, management, and outcome: A report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? J. Am. Coll. Cardiol. 2000;36((Suppl. 3A)):1063&#x2013;1070. doi: 10.1016/S0735-1097(00)00879-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(00)00879-2</ArticleId><ArticleId IdType="pubmed">10985706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">29083610</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK459378</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2025</Year><Month>01</Month></PubDate><BeginningDate><Year>2025</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-22569">Hantavirus Cardiopulmonary Syndrome (Archived)</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Akram</LastName><ForeName>Sami M.</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>University of Florida, Gainesville</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangat</LastName><ForeName>Rupinder</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Rochester Medical Center</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Marian Un College of Osteopathic Med</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Hantaviruses are single-stranded, negative-sense RNA viruses in the Bunyavirales order. Infection occurs via inhalation of aerosolized excretions from infected rodents. These viruses are associated with both hantavirus cardiopulmonary syndrome (HCPS) caused by hantaviruses of the New World and hemorrhagic fever with renal syndrome (HFRS) caused by hantaviruses of the Old World. HCPS, also known as hantavirus pulmonary syndrome (HPS),&#xa0;is a febrile illness&#xa0;characterized by respiratory failure&#xa0;with diffuse interstitial edema. The illness has three distinct phases: the prodrome, cardiopulmonary phase, and the convalescent phase.&#xa0;After a non-specific prodromal phase, patients have significant respiratory symptoms as their lungs fill with fluid. This is often associated with hemodynamic compromise with a clinical picture resembling cardiogenic shock. Treatment remains largely supportive and includes ventilator support and even extracorporeal membrane oxygenation if necessary.&#xa0; The etiologic agent causing HFRS was first described in 1978 and named after the Hantan river in South Korea. This virus caused Korean hemorrhagic fever among United Nations troops during the Korean War between 1951 and 1953.&#xa0; HCPS was first described in 1993 after several people from the Navajo tribe developed an acute respiratory illness in the Four Corners region in the US. Patients initially presented with symptoms of fevers, chills, cough, and myalgias, however, progressed to significant respiratory distress and hemodynamic compromise. An early case-control study identified exposure to rodents as a risk factor for disease, thus a&#xa0;rodent-trapping operation was initiated. A genetic detection assay was used to determine that patients were infected with a novel hantavirus which was termed the Sin Nombre virus (SNV). The clinical illness became known as hantavirus cardiopulmonary syndrome.&#xa0;</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s1">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s2">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s3">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s4">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s5">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s6">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s7">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s8">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s9">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s10">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s11">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s12">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s13">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-22569" sec="article-22569.s14">References</SectionTitle></Section></Sections><ContributionDate><Year>2023</Year><Month>2</Month><Day>25</Day></ContributionDate><ReferenceList><Reference><Citation>Llah ST, Mir S, Sharif S, Khan S, Mir MA. Hantavirus induced cardiopulmonary syndrome: A public health concern. J Med Virol. 2018 Jun;90(6):1003-1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">29446472</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir MA. Hantaviruses. Clin Lab Med. 2010 Mar;30(1):67-91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880890</ArticleId><ArticleId IdType="pubmed">20513542</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Outbreak of acute illness--southwestern United States, 1993. MMWR Morb Mortal Wkly Rep. 1993 Jun 11;42(22):421-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8502213</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenison S, Hjelle B, Simpson S, Hallin G, Feddersen R, Koster F. Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects. Semin Respir Infect. 1995 Dec;10(4):259-269.</Citation><ArticleIdList><ArticleId IdType="pubmed">8668854</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral CD, Costa GB, de Souza WM, Alves PA, Borges IA, Tolardo AL, Romeiro MF, Drumond BP, Abrah&#xe3;o JS, Kroon EG, Paglia AP, Figueiredo LTM, de Souza Trindade G. Silent Orthohantavirus Circulation Among Humans and Small Mammals from Central Minas Gerais, Brazil. Ecohealth. 2018 Sep;15(3):577-589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30105563</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuenzli AB, Marschall J, Schefold JC, Schafer M, Engler OB, Ackermann-G&#xe4;umann R, Reineke DC, Suter-Riniker F, Staehelin C. Hantavirus Cardiopulmonary Syndrome Due to Imported Andes Hantavirus Infection in Switzerland: A Multidisciplinary Challenge, Two Cases and a Literature Review. Clin Infect Dis. 2018 Nov 13;67(11):1788-1795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233683</ArticleId><ArticleId IdType="pubmed">30084955</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipley LC, Taylor ST, Grimsley C, Stoffer K, Goldstein J. Rats! Hantavirus: A Case Report of a Suspected Case in Eastern Tennessee. Perm J. 2018 Jul 19;22:17-222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6047851</ArticleId><ArticleId IdType="pubmed">30010530</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, United States, 1993-2009. Emerg Infect Dis. 2011 Jul;17(7):1195-201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321561</ArticleId><ArticleId IdType="pubmed">21762572</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters CJ, Khan AS. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin Infect Dis. 2002 May 01;34(9):1224-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941549</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Hantavirus pulmonary syndrome in visitors to a national park--Yosemite Valley, California, 2012. MMWR Morb Mortal Wkly Rep. 2012 Nov 23;61(46):952.</Citation><ArticleIdList><ArticleId IdType="pubmed">23169317</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy H, Simpson SQ. Hantavirus pulmonary syndrome. Am J Respir Crit Care Med. 1994 Jun;149(6):1710-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8004332</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallin GW, Simpson SQ, Crowell RE, James DS, Koster FT, Mertz GJ, Levy H. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med. 1996 Feb;24(2):252-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8605797</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandy S, Mathai D. Globally emerging hantaviruses: An overview. Indian J Med Microbiol. 2017 Apr-Jun;35(2):165-175.</Citation><ArticleIdList><ArticleId IdType="pubmed">28681802</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29083610</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29858926</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1238</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Intensive care medicine</Title><ISOAbbreviation>Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients.</ArticleTitle><Pagination><StartPage>847</StartPage><EndPage>856</EndPage><MedlinePgn>847-856</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00134-018-5222-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Catecholamines have been the mainstay of pharmacological treatment of cardiogenic shock (CS). Recently, use of epinephrine has been associated with detrimental outcomes. In the present study we aimed to evaluate the association between epinephrine use and short-term mortality in all-cause CS patients.</AbstractText><AbstractText Label="DESIGN">We performed a meta-analysis of individual data with prespecified inclusion criteria: (1) patients in non-surgical CS treated with inotropes and/or vasopressors and (2) at least 15% of patients treated with epinephrine administrated alone or in association with other inotropes/vasopressors. The primary outcome was short-term mortality.</AbstractText><AbstractText Label="MEASUREMENTS AND RESULTS">Fourteen published cohorts and two unpublished data sets were included. We studied 2583 patients. Across all cohorts of patients, the incidence of epinephrine use was 37% (17-76%) and short-term mortality rate was 49% (21-69%). A positive correlation was found between percentages of epinephrine use and short-term mortality in the CS cohort. The risk of death was higher in epinephrine-treated CS patients (OR [CI]&#x2009;=&#x2009;3.3 [2.8-3.9]) compared to patients treated with other drug regimens. Adjusted mortality risk remained striking in epinephrine-treated patients (n&#x2009;=&#x2009;1227) (adjusted OR&#x2009;=&#x2009;4.7 [3.4-6.4]). After propensity score matching, two sets of 338 matched patients were identified and epinephrine use remained associated with a strong detrimental impact on short-term mortality (OR&#x2009;=&#x2009;4.2 [3.0-6.0]).</AbstractText><AbstractText Label="CONCLUSIONS">In this very large cohort, epinephrine use for hemodynamic management of CS patients is associated with a threefold increase of risk of death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xe9;opold</LastName><ForeName>Valentine</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, APHP - Saint Louis Lariboisi&#xe8;re University Hospitals, University Paris Diderot and INSERM UMR-S 942, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gayat</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, APHP - Saint Louis Lariboisi&#xe8;re University Hospitals, University Paris Diderot and INSERM UMR-S 942, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirracchio</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, H&#xf4;pital Europ&#xe9;en Georges Pompidou, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinar</LastName><ForeName>Jindrich</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology Department, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parenica</LastName><ForeName>Jiri</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology Department, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarvasm&#xe4;ki</LastName><ForeName>Tuukka</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassus</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harjola</LastName><ForeName>Veli-Pekka</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Champion</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital F&#xe9;lix Guyon, Saint Denis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zannad</LastName><ForeName>Faiez</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CIC-Plurith&#xe9;matique, INSERM, University Hospital of Nancy, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Serafina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit, Florence University Hospital, Careggi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urban</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, H&#xf4;pital de la Tour, Meyrin-Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Horng-Ruey</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Austin Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian and New Zealand Intensive Care Research Centre (ANZIC RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nephrology, National University Health System, University Medicine Cluster, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellomo</LastName><ForeName>Rinaldo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Austin Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian and New Zealand Intensive Care Research Centre (ANZIC RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popovic</LastName><ForeName>Batric</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiology Department, University Hospital of Nancy, Vandoeuvre-l&#xe8;s-Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouweneel</LastName><ForeName>Dagmar M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>AMC Heart Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Jos&#xe9; P S</ForeName><Initials>JPS</Initials><AffiliationInfo><Affiliation>AMC Heart Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonis</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine/Cardiology, Heart Center Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Praxisklinik Herz und Gefaesse, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe9;vy</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Faculty of Medicine, University Hospital of Nancy, France, and U1116, Vandoeuvre-l&#xe8;s-Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmoun</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Faculty of Medicine, University Hospital of Nancy, France, and U1116, Vandoeuvre-l&#xe8;s-Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaudard</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basir</LastName><ForeName>Mir Babar</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Henry Ford Hospital, 2799W. Grand Blvd - K14, Detroit, MI, 48202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markota</LastName><ForeName>Andrej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, University Medical Centre Maribor, Ljubljanska, Maribor, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reuter</LastName><ForeName>Hannes</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, APHP - Saint Louis Lariboisi&#xe8;re University Hospitals, University Paris Diderot and INSERM UMR-S 942, Paris, France. alexandre.mebazaa@aphp.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Investigation Network Initiative - Cardiovascular and Renal Clinical Trialists, INI-CRCT, Nancy, France. alexandre.mebazaa@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chouihed</LastName><ForeName>Tahar</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, APHP - Saint Louis Lariboisi&#xe8;re University Hospitals, University Paris Diderot and INSERM UMR-S 942, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIC-Plurith&#xe9;matique, INSERM, University Hospital of Nancy, Nancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emergency Department, University Hospital of Nancy, Nancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1116, University of Lorraine, Nancy, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Intensive Care Med</MedlineTA><NlmUniqueID>7704851</NlmUniqueID><ISSNLinking>0342-4642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>YKH834O4BH</RegistryNumber><NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Med Klin Intensivmed Notfmed. 2018 Nov;113(8):681-684. doi: 10.1007/s00063-018-0471-5.</RefSource><PMID Version="1">30074054</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Intensive Care Med. 2018 Nov;44(11):2022-2023. doi: 10.1007/s00134-018-5372-9.</RefSource><PMID Version="1">30215188</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004837" MajorTopicYN="Y">Epinephrine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="Y">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Epinephrine</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29858926</ArticleId><ArticleId IdType="doi">10.1007/s00134-018-5222-9</ArticleId><ArticleId IdType="pii">10.1007/s00134-018-5222-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Heart J. 1999 Jul;20(14):1030-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10383377</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2015 Apr 28;313(16):1657-65</Citation><ArticleIdList><ArticleId IdType="pubmed">25919529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12 ):1167</Citation><ArticleIdList><ArticleId IdType="pubmed">27894487</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Heart Fail. 2018 Feb;20(2):332-341</Citation><ArticleIdList><ArticleId IdType="pubmed">28990358</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2014 Jul;42(1):22-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24827392</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2006 Dec;34(12 Suppl):S483-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17114981</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1995 Nov 15;92(10):3089-93</Citation><ArticleIdList><ArticleId IdType="pubmed">7586280</ArticleId></ArticleIdList></Reference><Reference><Citation>Resuscitation. 2002 Dec;55(3):269-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12458064</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cardiol. 2012 Apr;35(4):200-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22147681</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz. 2017 Feb;42(1):27-44</Citation><ArticleIdList><ArticleId IdType="pubmed">28127638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2018 Jan 29;1:CD009669</Citation><ArticleIdList><ArticleId IdType="pubmed">29376560</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2017 Jan 24;69(3):278-287</Citation><ArticleIdList><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2012 Jun;40(6):1715-23</Citation><ArticleIdList><ArticleId IdType="pubmed">22487996</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2012 Apr;37(4):378-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22266974</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Res Cardiol. 2012 Dec;101(12):955-62</Citation><ArticleIdList><ArticleId IdType="pubmed">22729756</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 2008 Aug;34(2):262-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18457961</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2011;15(6):R291</Citation><ArticleIdList><ArticleId IdType="pubmed">22152228</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2015 Oct 09;19:363</Citation><ArticleIdList><ArticleId IdType="pubmed">26453047</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Oct 31;369(18):1726-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24171518</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2011 Mar;39(3):450-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21037469</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2017 Oct 17;136(16):e232-e268</Citation><ArticleIdList><ArticleId IdType="pubmed">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Heart Fail. 2006 Nov;8(7):697-705</Citation><ArticleIdList><ArticleId IdType="pubmed">16516552</ArticleId></ArticleIdList></Reference><Reference><Citation>Catheter Cardiovasc Interv. 2018 Feb 15;91(3):454-461</Citation><ArticleIdList><ArticleId IdType="pubmed">29266676</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2016 Jul 04;20(1):208</Citation><ArticleIdList><ArticleId IdType="pubmed">27374027</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2015 May 21;36(20):1223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">25732762</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2011 Feb;37(2):290-301</Citation><ArticleIdList><ArticleId IdType="pubmed">21086112</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 1990;277:851-60</Citation><ArticleIdList><ArticleId IdType="pubmed">2096685</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2009 Apr;37(4):1408-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19242339</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2010 Dec;36(12):1993-2003</Citation><ArticleIdList><ArticleId IdType="pubmed">20689924</ArticleId></ArticleIdList></Reference><Reference><Citation>Resuscitation. 2012 Jun;83(6):721-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22155699</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2008 Feb 5;117(5):686-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18250279</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33046363</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8422</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>J Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>Blood Transfusion Threshold in Patients Receiving Extracorporeal Membrane Oxygenation Support for Cardiac and Respiratory Failure-A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>1192</StartPage><EndPage>1202</EndPage><MedlinePgn>1192-1202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.jvca.2020.08.068</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-0770(20)30863-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review studies that have evaluated the effects of liberal or restrictive red cell transfusion thresholds on clinical outcomes in patients requiring extracorporeal membrane oxygenation (ECMO) support for cardiac or respiratory failure.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A systematic review and meta-analysis.</AbstractText><AbstractText Label="SETTING AND PARTICIPANTS" NlmCategory="METHODS">The study comprised 1,070 patients from observational studies and randomized controlled trials analyzing transfusion policies in venoarterial (VA) and venovenous (VV) ECMO adult populations.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Eligible studies were identified by searching the Cochrane Central Register of Controlled Trials, Medline, and EMBASE until March 4, 2020, using a combination of subject headings and text words. Risk of bias assessment was performed to assess study quality according to the ROBINS-I tool and the case series studies appraisal checklist. There was high risk of bias in the studies analyzed, and none had methodologic adequacy. Three studies analyzed VA ECMO and VV ECMO patients separately. Five datasets were related exclusively or mostly to VA ECMO. Four were retrospective analyses, and one was conducted as a prospective observational study; the median transfusion threshold reported was 8 g/dL, with a mean mortality of 52%. Eight datasets were related either exclusively or mostly to VV ECMO. Six were retrospective and two were prospective observational studies; the median transfusion threshold was 8 g/dL, and the mean mortality rate was 33%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study did not resolve uncertainty as to transfusion management in ECMO, although several studies (most of them in VV ECMO) demonstrated that a restrictive threshold has acceptable outcomes in single-center cohorts.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abbasciano</LastName><ForeName>Riccardo Giuseppe</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Leicester, United Kingdom. Electronic address: rga8@leicester.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusuff</LastName><ForeName>Hakeem</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, Glenfield Hospital, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlaar</LastName><ForeName>Alexander P J</ForeName><Initials>APJ</Initials><AffiliationInfo><Affiliation>Adult Intensive Care Unit, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Gavin James</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AA/18/3/34220</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>CH/12/1/29419</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RG/17/9/32812</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9110208</NlmUniqueID><ISSNLinking>1053-0770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Cardiothorac Vasc Anesth. 2021 Apr;35(4):1203-1204. doi: 10.1053/j.jvca.2020.11.019.</RefSource><PMID Version="1">33293218</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">blood transfusion</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>13</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33046363</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2020.08.068</ArticleId><ArticleId IdType="pii">S1053-0770(20)30863-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26152708</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4539</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Circulation</Title><ISOAbbreviation>Circulation</ISOAbbreviation></Journal><ArticleTitle>Percutaneous Coronary Intervention at Centers With and Without On-Site Surgical Backup: An Updated Meta-Analysis of 23 Studies.</ArticleTitle><Pagination><StartPage>388</StartPage><EndPage>401</EndPage><MedlinePgn>388-401</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCULATIONAHA.115.016137</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Emergency coronary artery bypass grafting for unsuccessful percutaneous coronary intervention (PCI) is now rare. We aimed to evaluate the current safety and outcomes of primary PCI and nonprimary PCI at centers with and without on-site surgical backup.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We performed an updated systematic review and meta-analysis by using mixed-effects models. We included 23 high-quality studies that compared clinical outcomes and complication rates of 1 101 123 patients after PCI at centers with or without on-site surgery. For primary PCI for ST-segment-elevation myocardial infarction (133 574 patients), all-cause mortality (without on-site surgery versus with on-site surgery: observed rates, 4.8% versus 7.2%; pooled odds ratio [OR], 0.99; 95% confidence interval, 0.91-1.07; P=0.729; I(2)=3.4%) or emergency coronary artery bypass grafting rates (observed rates, 1.5% versus 2.4%; pooled OR, 0.76; 95% confidence interval, 0.56-1.01; P=0.062; I(2)=42.5%) did not differ by presence of on-site surgery. For nonprimary PCI (967 549 patients), all-cause mortality (observed rates, 1.6% versus 2.1%; pooled OR, 1.15; 95% confidence interval, 0.94-1.41; P=0.172; I(2)=67.5%) and emergency coronary artery bypass grafting rates (observed rates, 0.5% versus 0.8%; pooled OR, 1.14; 95% confidence interval, 0.62-2.13; P=0.669; I(2)=81.7%) were not significantly different. PCI complication rates (cardiogenic shock, stroke, aortic dissection, tamponade, recurrent infarction) also did not differ by on-site surgical capability. Cumulative meta-analysis of nonprimary PCI showed a temporal decrease of the effect size (OR) for all-cause mortality after 2007.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical outcomes and complication rates of PCI at centers without on-site surgery did not differ from those with on-site surgery, for both primary and nonprimary PCI. Temporal trends indicated improving clinical outcomes in nonprimary PCI at centers without on-site surgery.</AbstractText><CopyrightInformation>&#xa9; 2015 American Heart Association, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joo Myung</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>From Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Korea (J.M.L., D.H., J.P., K.-J.K., B.-K.K.); Division of Biostatistics, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD (C.A.); and Institute of Aging, Seoul National University, Korea (B.-K.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Doyeon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Korea (J.M.L., D.H., J.P., K.-J.K., B.-K.K.); Division of Biostatistics, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD (C.A.); and Institute of Aging, Seoul National University, Korea (B.-K.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jonghanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Korea (J.M.L., D.H., J.P., K.-J.K., B.-K.K.); Division of Biostatistics, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD (C.A.); and Institute of Aging, Seoul National University, Korea (B.-K.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyung-Jin</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>From Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Korea (J.M.L., D.H., J.P., K.-J.K., B.-K.K.); Division of Biostatistics, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD (C.A.); and Institute of Aging, Seoul National University, Korea (B.-K.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Chul</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Korea (J.M.L., D.H., J.P., K.-J.K., B.-K.K.); Division of Biostatistics, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD (C.A.); and Institute of Aging, Seoul National University, Korea (B.-K.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Bon-Kwon</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>From Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Korea (J.M.L., D.H., J.P., K.-J.K., B.-K.K.); Division of Biostatistics, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD (C.A.); and Institute of Aging, Seoul National University, Korea (B.-K.K.). bkkoo@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circulation</MedlineTA><NlmUniqueID>0147763</NlmUniqueID><ISSNLinking>0009-7322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2015 Aug 4;132(5):365-7. doi: 10.1161/CIRCULATIONAHA.115.017848.</RefSource><PMID Version="1">26152707</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Cardiol. 2015 Oct;12(10):563-4. doi: 10.1038/nrcardio.2015.131.</RefSource><PMID Version="1">26346732</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2016 Feb 16;133(7):e406. doi: 10.1161/CIRCULATIONAHA.115.019476.</RefSource><PMID Version="1">26884631</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2016 Feb 16;133(7):e407. doi: 10.1161/CIRCULATIONAHA.115.020201.</RefSource><PMID Version="1">26884632</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Catheter Cardiovasc Interv. 2022 Feb;99(3):607-608. doi: 10.1002/ccd.30127.</RefSource><PMID Version="1">35235696</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013531" MajorTopicYN="N">Surgicenters</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013903" MajorTopicYN="N">Thoracic Surgery</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">STEMI</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">onsite coronary artery bypass graft (CABG)</Keyword><Keyword MajorTopicYN="N">outcome assessment (health care)</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">thoracic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26152708</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.016137</ArticleId><ArticleId IdType="pii">CIRCULATIONAHA.115.016137</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39957274</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0844</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of heart failure</Title><ISOAbbreviation>Eur J Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Organ perfusion pressure predicts outcomes in cardiogenic shock patients.</ArticleTitle><Pagination><StartPage>659</StartPage><EndPage>668</EndPage><MedlinePgn>659-668</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ejhf.3627</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The diagnosis of cardiogenic shock (CS) relies upon signs and/or symptoms of end-organ hypoperfusion. The combination of hypoperfusion and systemic congestion identifies patients at particularly high risk. This study evaluated organ perfusion pressure (OPP), calculated as mean arterial pressure minus invasive central venous pressure, as a predictor of outcomes in CS.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">All consecutive patients with acute myocardial infarction-related CS (AMI-CS) or acutely decompensated heart failure-related CS (ADHF-CS) enrolled in the multicentre Altshock-2 registry between January 2020 and November 2023 were included. The primary outcome was in-hospital all-cause mortality. Overall, 316 patients were included (mean age: 64&#x2009;&#xb1;&#x2009;13&#x2009;years, 62 [20%] female, median left ventricular ejection fraction: 22% [interquartile range, IQR 15-30%], 261 [85.9%] SCAI stage C or worse, median OPP at presentation: 57.0&#x2009;mmHg [IQR 47.0-69.8&#x2009;mmHg]). A total of 117 (37%) patients died during the hospitalization. Low OPP (i.e. &lt;57.0&#x2009;mmHg) was associated with significantly higher in-hospital all-cause mortality (hazard ratio [HR] 1.757, 95% confidence interval [CI] 1.208-2.556, p&#x2009;=&#x2009;0.003), whereas low mean arterial pressure alone was not (HR 1.323, 95% CI 0.901-1.941, p&#x2009;=&#x2009;0.153). After multivariable adjustment for significant clinical data available at first bedside assessment (age and Sequential Organ Failure Assessment score), low OPP still predicted significantly higher in-hospital all-cause mortality (HR per mmHg decrease: 1.016, 95% CI 1.004-1.029, p&#x2009;=&#x2009;0.010). Low OPP appeared particularly powerful in predicting higher in-hospital all-cause mortality among ADHF-CS patients (HR 3.172, p&#x2009;=&#x2009;0.002).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this multicentre, observational, prospective study on patients hospitalized for CS, lower OPP on admission was associated with significantly higher in-hospital all-cause mortality.</AbstractText><CopyrightInformation>&#xa9; 2025 European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bocchino</LastName><ForeName>Pier Paolo</ForeName><Initials>PP</Initials><Identifier Source="ORCID">0000-0001-7868-1852</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, 'Citt&#xe0; della Salute e della Scienza' Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frea</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, 'Citt&#xe0; della Salute e della Scienza' Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertaina</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, San Giovanni Bosco Hospital, ASL Citt&#xe0; di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Kore University, Enna and Policlinico Centro Cuore G.B. Morgani, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavazzi</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical-Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anesthesia and Intensive Care, Fondazione IRCCS Policlinico San Matteo Hospital, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morici</LastName><ForeName>Nuccia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Gnocchi, ONLUS, Santa Maria Nascente, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelini</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, 'Citt&#xe0; della Salute e della Scienza' Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garatti</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briani</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Humanitas Research Hospital, IRCCS Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorini Dini</LastName><ForeName>Carlotta</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villanova</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallone</LastName><ForeName>Guglielmo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, 'Citt&#xe0; della Salute e della Scienza' Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravera</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Cardiology Department, S. Giovanni Di Dio e Ruggi d'Aragona Hospital, Salerno, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoldi</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Humanitas Research Hospital, IRCCS Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corsini</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic and Vascular Department, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maj</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Anesthesia and Intensive Care, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potena</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic and Vascular Department, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camporotondo</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit, Fondazione IRCCS Policlinico San Matteo Hospital, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Costanza Natalia Julia</ForeName><Initials>CNJ</Initials><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit, Fondazione IRCCS Policlinico San Matteo Hospital, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montisci</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiothoracic Intensive Care, ASST Spedali Civili, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliva</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iannaccone</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, San Giovanni Bosco Hospital, ASL Citt&#xe0; di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ettore</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Anesthesia and Intensive Care, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Serafina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagnesi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metra</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marini</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology and ICCU, Department of Cardiovascular Sciences, Ospedali Riuniti, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Ferrari</LastName><ForeName>Gaetano Maria</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, 'Citt&#xe0; della Salute e della Scienza' Hospital, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Heart Fail</MedlineTA><NlmUniqueID>100887595</NlmUniqueID><ISSNLinking>1388-9842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute heart failure</Keyword><Keyword MajorTopicYN="N">Blood pressure</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Central venous pressure</Keyword><Keyword MajorTopicYN="N">Organ perfusion pressure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>17</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>17</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39957274</ArticleId><ArticleId IdType="doi">10.1002/ejhf.3627</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Vahdatpour C, Collins D, Goldberg S. Cardiogenic shock. J Am Heart Assoc 2019;8:e011991. https://doi.org/10.1161/JAHA.119.011991</Citation></Reference><Reference><Citation>Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock&#x2014;A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;22:1315&#x2013;1341. https://doi.org/10.1002/ejhf.1922</Citation></Reference><Reference><Citation>Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589&#x2013;596. https://doi.org/10.1016/j.jacc.2008.05.068</Citation></Reference><Reference><Citation>Shinagawa H, Inomata T, Koitabashi T, Nakano H, Takeuchi I, Osaka T, et al. Increased serum bilirubin levels coincident with heart failure decompensation indicate the need for intravenous inotropic agents. Int Heart J 2007;48:195&#x2013;204. https://doi.org/10.1536/ihj.48.195</Citation></Reference><Reference><Citation>Bocchino PP, Cingolani M, Frea S, Angelini F, Gallone G, Garatti L, et al. Organ perfusion pressure at admission and clinical outcomes in patients hospitalized for acute heart failure. Eur Heart J Acute Cardiovasc Care 2024;13:215&#x2013;224. https://doi.org/10.1093/ehjacc/zuad133</Citation></Reference><Reference><Citation>Wong BT, Chan MJ, Glassford NJ, M&#xe5;rtensson J, Bion V, Chai SY, et al. Mean arterial pressure and mean perfusion pressure deficit in septic acute kidney injury. J Crit Care 2015;30:975&#x2013;981. https://doi.org/10.1016/j.jcrc.2015.05.003</Citation></Reference><Reference><Citation>Bertaina M, Morici N, Frea S, Garatti L, Briani M, Sorini C, et al. Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction. ESC Heart Fail 2023;10:3472&#x2013;3482. https://doi.org/10.1002/ehf2.14510</Citation></Reference><Reference><Citation>Sacco A, Montisci A, Tavecchia G, Frea S, Bernasconi D, Colombo CNJ, et al.; AltShock&#x2010;2 Investigators. Ventilation strategies in cardiogenic shock: Insights from the AltShock&#x2010;2 registry. Eur J Heart Fail 2024;26:2412&#x2013;2420. https://doi.org/10.1002/ejhf.3409</Citation></Reference><Reference><Citation>Kapur NK, Kanwar M, Sinha SS, Thayer KL, Garan AR, Hernandez&#x2010;Montfort J, et al. Criteria for defining stages of cardiogenic shock severity. J Am Coll Cardiol 2022;80:185&#x2013;198. https://doi.org/10.1016/j.jacc.2022.04.049</Citation></Reference><Reference><Citation>Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457&#x2013;481. https://doi.org/10.2307/2281868</Citation></Reference><Reference><Citation>Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685&#x2013;713. https://doi.org/10.1016/j.echo.2010.05.010</Citation></Reference><Reference><Citation>Sarma D, Jentzer JC. Cardiogenic shock: Pathogenesis, classification, and management. Crit Care Clin 2024;40:37&#x2013;56. https://doi.org/10.1016/j.ccc.2023.05.001</Citation></Reference><Reference><Citation>Monge Garc&#xed;a MI, Santos Oviedo A. Why should we continue measuring central venous pressure? Med Intensiva 2017;41:483&#x2013;486. https://doi.org/10.1016/j.medin.2016.12.006</Citation></Reference><Reference><Citation>Hrymak C, Strumpher J, Jacobsohn E. Acute right ventricle failure in the intensive care unit: Assessment and management. Can J Cardiol 2017;33:61&#x2013;71. https://doi.org/10.1016/j.cjca.2016.10.030</Citation></Reference><Reference><Citation>Ostermann M, Hall A, Crichton S. Low mean perfusion pressure is a risk factor for progression of acute kidney injury in critically ill patients&#xa0;&#x2013;&#xa0;a retrospective analysis. BMC Nephrol 2017;18:151. https://doi.org/10.1186/s12882&#x2010;017&#x2010;0568&#x2010;8</Citation></Reference><Reference><Citation>Hu R, Kalam Y, Broad J, Ho T, Parker F, Lee M, et al. Decreased mean perfusion pressure as an independent predictor of acute kidney injury after cardiac surgery. Heart Vessels 2020;35:1154&#x2013;1163. https://doi.org/10.1007/s00380&#x2010;020&#x2010;01578&#x2010;0</Citation></Reference><Reference><Citation>Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short&#x2010;term mortality in cardiogenic shock. Eur J Heart Fail 2015;17:501&#x2013;509. https://doi.org/10.1002/ejhf.260</Citation></Reference><Reference><Citation>Malick W, Fried JA, Masoumi A, Nair A, Zuver A, Huang A, et al. Comparison of the hemodynamic response to intra&#x2010;aortic balloon counterpulsation in patients with cardiogenic shock resulting from acute myocardial infarction versus acute decompensated heart failure. Am J Cardiol 2019;124:1947&#x2013;1953. https://doi.org/10.1016/j.amjcard.2019.09.016</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28703046</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2048-8734</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European heart journal. Acute cardiovascular care</Title><ISOAbbreviation>Eur Heart J Acute Cardiovasc Care</ISOAbbreviation></Journal><ArticleTitle>Multivessel versus culprit lesion only percutaneous coronary intervention in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>28</StartPage><EndPage>37</EndPage><MedlinePgn>28-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/2048872617719640</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early revascularisation of the culprit lesion is the therapeutic cornerstone in cardiogenic shock complicating acute myocardial infarction. The optimal management of additional non-culprit lesions is unclear. This systematic review and meta-analysis aims to summarise current evidence on the comparison of immediate multivessel percutaneous coronary intervention (MV-PCI) or culprit lesion only PCI with possible staged revascularisation (C-PCI) in patients with cardiogenic shock complicating acute myocardial infarction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Medical literature databases were screened to identify analyses comparing MV-PCI with C-PCI in patients with cardiogenic shock complicating acute myocardial infarction and multivessel coronary artery disease. In absence of randomised trials, 10 cohort studies were included in the current meta-analysis. The primary outcome of short-term mortality was assessed at hospital discharge or 30 days after hospital admission. Secondary outcomes were long-term mortality as well as myocardial re-infarction, stroke, acute renal failure, and bleeding at short-term follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 6051 patients, 1194 (19.7%) received MV-PCI and 4857 (80.3%) C-PCI. Short-term mortality was 37.5% in patients undergoing MV-PCI compared with 28.8% in C-PCI patients (risk ratio 1.26, 95% confidence interval 1.12-1.41, p=0.001). Long-term mortality ( p=0.77), myocardial re-infarction ( p=0.77), stroke ( p=0.12), acute renal failure ( p=0.17) and bleeding ( p=0.53) did not differ significantly between the two revascularisation groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results of this first meta-analysis on the interventional management of patients with cardiogenic shock complicating acute myocardial infarction and multivessel coronary artery disease do not support MV-PCI over C-PCI. However, possible treatment selection bias in the individual studies must be taken into account.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Waha</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jobs</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xf6;ss</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stiermaier</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Saraei</LastName><ForeName>Roza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuernau</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeymer</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>3 Klinikum Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desch</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1 University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4 Heart Centre Leipzig, Department of Internal Medicine/Cardiology, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Acute Cardiovasc Care</MedlineTA><NlmUniqueID>101591369</NlmUniqueID><ISSNLinking>2048-8726</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Multivessel coronary artery disease</Keyword><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">reperfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28703046</ArticleId><ArticleId IdType="doi">10.1177/2048872617719640</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35911539</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Gender Differences in Cardiogenic Shock Patients: Clinical Features, Risk Prediction, and Outcomes in a Hub Center.</ArticleTitle><Pagination><StartPage>912802</StartPage><MedlinePgn>912802</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">912802</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2022.912802</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">There is scarce knowledge about gender differences in clinical presentation, management, use of risk stratification tools and prognosis in cardiogenic shock (CS) patients.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">The primary endpoint was to investigate the differences in characteristics, management, and in-hospital mortality according to gender in a cohort of CS patients admitted to a tertiary hub center. The secondary endpoint was to evaluate the prognostic performance of the Society of Cardiovascular Angiography and Interventions (SCAI) classification in predicting in-hospital mortality according to sex.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This is a retrospective single-Center cohort study of CS patients treated by a multidisciplinary shock team between September 2014 and December 2020. Baseline characteristics and clinical outcomes according to gender were registered. Discrimination of SCAI classification was assessed using the area under the receiver operating characteristic curve (AUC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, 163 patients were included, 39 of them female (24%). Mean age of the overall cohort was 55 years (44-62), similar between groups. Compared with men, women were less likely to be smokers and the prevalence of COPD and diabetes mellitus was significantly lower in this group (<i>p</i> &lt; 0.05). Postcardiotomy (44 vs. 31%) and fulminant myocarditis (13 vs. 2%) were more frequent etiologies in females than in males (<i>p</i> = 0.01), whereas acute myocardial infarction was less common among females (13 vs. 33%). Regarding management, the use of temporary mechanical circulatory support, mechanical ventilation, or renal replacement therapy was frequent and no different between the groups (88, 87, and 49%, respectively, in females vs. 42, 91, and 41% in males, <i>p</i> &gt; 0.05). In-hospital survival in the overall cohort was 53%, without differences between groups (52% in females vs. 55% in males, <i>p</i> = 0.76). Most of the patients (60.7%) were in SCAIE at presentation without differences between sexes. The SCAI classification showed a moderate ability for predicting in-hospital mortality (overall, AUC: 0.653, 95% CI 0.582-0.725). The AUC was 0.636 for women (95% CI 0.491-0.780) and 0.658 for men (95% CI 0.575-0.740).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Only one in four of patients treated at a dedicated CS team were female. This may reflect differences in prevalence of severe heart disease at young (&lt;65) ages, although a patient-selection bias cannot be ruled out. In this very high-risk CS population of multiple etiologies, overall, in-hospital survival was slightly above 50% and showed no differences between sexes. Treatment approaches, procedures, and SCAI risk stratification performance did not show gender disparities among treated patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Lozano-Jim&#xe9;nez, Iranzo-Valero, Segovia-Cubero, G&#xf3;mez-Bueno, Rivas-Lasarte, Mitroi, Escudier-Villa, Oteo-Dominguez, Vieitez-Florez, Villar-Garc&#xed;a and Hern&#xe1;ndez-P&#xe9;rez.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lozano-Jim&#xe9;nez</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Biomedical Research in Cardiovascular Diseases (CIBERCV), Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iranzo-Valero</LastName><ForeName>Reyes</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segovia-Cubero</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Bueno</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivas-Lasarte</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitroi</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escudier-Villa</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oteo-Dominguez</LastName><ForeName>Juan Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieitez-Florez</LastName><ForeName>Jose Mar&#xed;a</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villar-Garc&#xed;a</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-P&#xe9;rez</LastName><ForeName>Francisco Jos&#xe9;</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SCAI classification</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">gender</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>1</Day><Hour>3</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35911539</ArticleId><ArticleId IdType="pmc">PMC9326060</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.912802</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL-, Baird-Zars V, et al. Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes. (2019) 12:e005618. 10.1161/CIRCOUTCOMES.119.005618</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.119.005618</ArticleId><ArticleId IdType="pmc">PMC11032172</ArticleId><ArticleId IdType="pubmed">30879324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, Sanborn T, Harvey MD, White DS, et al. Early revascularization in acute myocardial infarction complicate by cardiogenic shock. SHOCK investigators should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. (1999) 341:625&#x2013;34. 10.1056/NEJM199908263410901</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199908263410901</ArticleId><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubini Gimenez M, Zeymer U, Desch S, Waha-Thiele S, Ouarrak T, Poess J, et al. Sex-specific management in patients with acute myocardial infarction and cardiogenic shock: a substudy of the CULPRIT-SHOCK trial. Circulation. (2020) 13:e008537. 10.1161/CIRCINTERVENTIONS.119.008537</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.119.008537</ArticleId><ArticleId IdType="pubmed">32151161</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Qadir HM, Ivanov J, Austin PC, Tu J, D&#x17e;av&#xed;k V. Sex differences in the management and outcomes of Ontario patients with cardiogenic shock complicating acute myocardial infarction. Can J Cardiol. (2013) 29:691&#x2013;6. 10.1016/j.cjca.2012.09.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2012.09.020</ArticleId><ArticleId IdType="pubmed">23265097</ArticleId></ArticleIdList></Reference><Reference><Citation>Holger Thiele MD, Uwe Zeymer MD, Franz-Josef Neumann MD, Miroslaw Ferenc MD, Hans-Georg Olbrich MD, J&#xf6;rg Hausleiter MD, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. (2012) 367:1287&#x2013;96. 10.1056/NEJMoa1208410</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208410</ArticleId><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Isorni MA, Aissaoui N, Angoulvant D, Bonello L, Lemesle G, Delmas C, et al. Temporal trends in clinical characteristics and management according to sex in patients with cardiogenic shock after acute myocardial infarction: the FAST-MI programme. Arch Cardiovasc Dis. (2018) 111:555&#x2013;63. 10.1016/j.acvd.2018.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2018.01.002</ArticleId><ArticleId IdType="pubmed">29478810</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran DA, Grines GL, Bailey S, Burkhoff D, A Hall S, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheter Cardiovasc Interv. (2019) 94:29&#x2013;37. 10.1002/ccd.28329</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28329</ArticleId><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-P&#xe9;rez FJ, &#xc1;lvarez-Avell&#xf3; JM, Forteza A, G&#xf3;mez-Bueno M, Gonz&#xe1;lez A, et al. Resultados iniciales de un programa multidisciplinario de atenci&#xf3;n a pacientes en shock cardiog&#xe9;nico en red. Rev Espa&#xf1;ola de Cardiol. (2020) 74:33&#x2013;43. 10.1016/j.recesp.2020.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2020.01.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Collado-Lled&#xf3; E, Lla&#xf3; I, Rivas-Lasarte M, Gonz&#xe1;lez-Fern&#xe1;ndez V, Noriega FJ, Hern&#xe1;ndez-Perez FJ, et al. Clinical picture, management and risk stratification in patients with cardiogenic shock: does gender matter? BMC Cardiovasc Disord. (2020) 20:189. 10.1186/s12872-020-01467-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-020-01467-4</ArticleId><ArticleId IdType="pmc">PMC7362401</ArticleId><ArticleId IdType="pubmed">32664921</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan I, Schrage B, Weimann J, Dabboura S, Hilal R, Beer BN, et al. Sex differences in patients with cardiogenic shock. ESC Heart Fail. (2021) 8:1775&#x2013;83. 10.1002/ehf2.13303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13303</ArticleId><ArticleId IdType="pmc">PMC8120358</ArticleId><ArticleId IdType="pubmed">33763997</ArticleId></ArticleIdList></Reference><Reference><Citation>Fengler K, Fuernau G, Desch S, Eitel I, Neumann FJ, Olbrichet HG, et al. Gender differences in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial. Clin Res Cardiol. (2015) 104:71&#x2013;8. 10.1007/s00392-014-0767-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-014-0767-2</ArticleId><ArticleId IdType="pubmed">25287767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud AN, Elgendy IY. Gender impact on 30-day readmissions after hospitalization with acute myocardial infarction complicated by cardiogenic shock (from the 2013 to 2014 National Readmissions Database). Am J Cardiol. (2018) 121:523&#x2013;8. 10.1016/j.amjcard.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2017.11.023</ArticleId><ArticleId IdType="pubmed">29289360</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Ya'Qoub L, Singh M, Bell MR, Gulati R, Cheungpasitporn W, et al. Sex disparities in the management and outcomes of cardiogenic shock complicating acute myocardial infarction in the young. Circ Heart Fail. (2020) 13:e007154. 10.1161/CIRCHEARTFAILURE.120.007154</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.120.007154</ArticleId><ArticleId IdType="pmc">PMC7578068</ArticleId><ArticleId IdType="pubmed">32988218</ArticleId></ArticleIdList></Reference><Reference><Citation>Redfors B, Anger&#xe5;s O, R&#xe5;munddal T, Petursson P, Haraldsson I, Dworeck C, et al. Trends in gender differences in cardiac care and outcome after acute myocardial infarction in Western Sweden: a report from the Swedish web system for enhancement of evidence-based Care in Heart Disease Evaluated According to recommended therapies (SWEDEHEART). J Am Heart Assoc. (2015) 4:e001995. 10.1161/JAHA.115.001995</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.115.001995</ArticleId><ArticleId IdType="pmc">PMC4608084</ArticleId><ArticleId IdType="pubmed">26175358</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph SM, Brisco MA, Colvin M, Grady KL, Walsh MN, Cook JL, et al. Women with cardiogenic shock derive greater benefit from early mechanical circulatory support: an update from the cVAD registry. J Interv Cardiol. (2016) 29:248&#x2013;56. 10.1111/joic.12298</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joic.12298</ArticleId><ArticleId IdType="pubmed">27229327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24385385</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.</ArticleTitle><Pagination><StartPage>CD009669</StartPage><MedlinePgn>CD009669</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD009669.pub2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The recently published German-Austrian S3 Guideline for the treatment of infarct related cardiogenic shock (CS) revealed a lack of evidence for all recommended therapeutic measures.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the effects in terms of efficacy, efficiency and safety of cardiac care with inotropic agents and vasodilator strategies versus placebo or against each other for haemodynamic stabilisation following surgical treatment, interventional therapy (angioplasty, stent implantation) and conservative treatment (that is no revascularization) on mortality and morbidity in patients with acute myocardial infarction (AMI) complicated by CS or low cardiac output syndrome (LCOS).</AbstractText><AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We searched CENTRAL, MEDLINE (Ovid), EMBASE (Ovid) and ISI Web of Science, registers of ongoing trials and proceedings of conferences in January 2013. Reference lists were scanned and experts in the field were contacted to obtain further information. No language restrictions were applied.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised controlled trials in patients with AMI complicated by CS or LCOS.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Data collection and analysis were performed according to the published protocol. All trials were analysed individually. Hazard ratios (HRs) and odds ratios with 95% confidence intervals (CI) were extracted but not pooled because of high heterogeneity between the control group interventions.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Four eligible, very small studies were identified from a total of 4065 references. Three trials with high overall risk of bias compared levosimendan to standard treatment (enoximone or dobutamine) or placebo. Data from a total of 63 participants were included in our comparisons, 31 were treated with levosimendan and 32 served as controls. Levosimendan showed an imprecise survival benefit in comparison with enoximone based on a very small trial with 32 participants (HR 0.33; 95% CI 0.11 to 0.97). Results from the other similarly small trials were too imprecise to provide any meaningful information about the effect of levosimendan in comparison with dobutamine or placebo. Only small differences in haemodynamics, length of hospital stay and the frequency of major adverse cardiac events or adverse events overall were found between study groups.Only one small randomised controlled trial with three participants was found for vasodilator strategies (nitric oxide gas versus placebo) in AMI complicated by CS or LCOS. This study was too small to draw any conclusions on the effects on our key outcomes.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">At present there are no robust and convincing data to support a distinct inotropic or vasodilator drug based therapy as a superior solution to reduce mortality in haemodynamically unstable patients with CS or low cardiac output complicating AMI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Unverzagt</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle-Wittenberg, Magdeburge Stra&#xdf;e 8, Halle/Saale, Germany, 06097.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wachsmuth</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Buerke</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Haerting</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Werdan</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Prondzinsky</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006835">Hydrazones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical><Chemical><RegistryNumber>3S12J47372</RegistryNumber><NameOfSubstance UI="D004280">Dobutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>C7Z4ITI7L7</RegistryNumber><NameOfSubstance UI="D017335">Enoximone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Cochrane Database Syst Rev. 2018 Jan 29;1:CD009669. doi: 10.1002/14651858.CD009669.pub3.</RefSource><PMID Version="1">29376560</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002303" MajorTopicYN="N">Cardiac Output, Low</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004280" MajorTopicYN="N">Dobutamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017335" MajorTopicYN="N">Enoximone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006835" MajorTopicYN="N">Hydrazones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24385385</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD009669.pub2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33512605</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-8595</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing</Title><ISOAbbreviation>J Interv Card Electrophysiol</ISOAbbreviation></Journal><ArticleTitle>Complication rates following ventricular tachycardia ablation in ischaemic and non-ischaemic cardiomyopathies: a systematic review.</ArticleTitle><Pagination><StartPage>59</StartPage><EndPage>67</EndPage><MedlinePgn>59-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10840-021-00948-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Catheter ablation of ventricular tachycardia (VT) is associated with potential major complications, including mortality. The risk of acute complications in patients with ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy (NICM) has not been systematically evaluated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed was searched for studies of catheter ablation of VT published between September 2009 and September 2019. Pre-specified primary outcomes were (1) rate of major acute complications, including death, and (2) mortality rate.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 7395 references were evaluated for relevance. From this, 50 studies with a total of 3833 patients undergoing 4319 VT ablation procedures fulfilled the inclusion criteria (mean age 59&#xa0;years; male 82%; 2363 [62%] ICM; 1470 [38%] NICM). The overall major complication rate in ICM cohorts was 9.4% (95% CI, 8.1-10.7) and NICM cohorts was 7.1% (95% CI, 6.0-8.3). Reported complication rates were highly variable between studies (ICM I<sup>2</sup>&#xa0;=&#x2009;90%; NICM I<sup>2</sup>&#xa0;=&#x2009;89%). Vascular complications (ICM 2.5% [95% CI, 1.9-3.1]; NICM 1.2% [95% CI, 0.7-1.7]) and cerebrovascular events (ICM 0.5% [95% CI, 0.2-0.7]; NICM, 0.1% [95% CI, 0-0.2]) were significantly higher in ICM cohorts. Acute mortality rates in the ICM and NICM cohorts were low (ICM 0.9% [95% CI, 0.5-1.3]; NICM 0.6% [95% CI, 0.3-1.0]) with the majority of overall deaths (ICM 75%; NICM 80%) due to either recurrent VT or cardiogenic shock.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall acute complication rates of VT ablation are comparable between ICM and NICM patients. However, the pattern and predictors of complications vary depending on the underlying cardiomyopathy.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Wern Yew</ForeName><Initials>WY</Initials><Identifier Source="ORCID">0000-0003-3596-6545</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology, Liverpool Heart and Chest Hospital, Liverpool, UK. dwyew@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Science, Liverpool, UK. dwyew@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearman</LastName><ForeName>Charles M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Cardiac Physiology, Institute of Cardiovascular Sciences, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnett</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adlan</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Shui Hao</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denham</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Unit of Cardiac Physiology, Institute of Cardiovascular Sciences, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modi</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Derick</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark C S</ForeName><Initials>MCS</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahida</LastName><ForeName>Saagar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology, Liverpool Heart and Chest Hospital, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Science, Liverpool, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Interv Card Electrophysiol</MedlineTA><NlmUniqueID>9708966</NlmUniqueID><ISSNLinking>1383-875X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017115" MajorTopicYN="Y">Catheter Ablation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017202" MajorTopicYN="Y">Myocardial Ischemia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017180" MajorTopicYN="Y">Tachycardia, Ventricular</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Catheter ablation</Keyword><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Death</Keyword><Keyword MajorTopicYN="N">Ischaemic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Non-ischaemic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Structural heart disease</Keyword><Keyword MajorTopicYN="N">Ventricular tachycardia</Keyword></KeywordList><CoiStatement>The author declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>29</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33512605</ArticleId><ArticleId IdType="pmc">PMC8755671</ArticleId><ArticleId IdType="doi">10.1007/s10840-021-00948-6</ArticleId><ArticleId IdType="pii">10.1007/s10840-021-00948-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877&#x2013;883. doi: 10.1056/NEJMoa013474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa013474</ArticleId><ArticleId IdType="pubmed">11907286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225&#x2013;237. doi: 10.1056/NEJMoa043399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043399</ArticleId><ArticleId IdType="pubmed">15659722</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietti R, Labos C, Davis M, Thanassoulis G, Santangeli P, Russo V, di Biase L, Roux JF, Verma A, Natale A, Essebag V. A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality. Can J Cardiol. 2015;31(3):270&#x2013;277. doi: 10.1016/j.cjca.2014.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2014.11.023</ArticleId><ArticleId IdType="pubmed">25746019</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Armenta J, Andreu D, Penela D, Trucco E, Cipolletta L, Arbelo E, et al. Sinus rhythm detection of conducting channels and ventricular tachycardia isthmus in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2014;11(5):747&#x2013;754. doi: 10.1016/j.hrthm.2014.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2014.02.016</ArticleId><ArticleId IdType="pubmed">24561159</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuck K-H, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375(9708):31&#x2013;40. doi: 10.1016/S0140-6736(09)61755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61755-4</ArticleId><ArticleId IdType="pubmed">20109864</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin J-F, Thibault B, Rivard L, Gula L, Leong-Sit P, Essebag V, Nery PB, Tung SK, Raymond JM, Sterns LD, Veenhuyzen GD, Healey JS, Redfearn D, Roux JF, Tang AS. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111&#x2013;121. doi: 10.1056/NEJMoa1513614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1513614</ArticleId><ArticleId IdType="pubmed">27149033</ArticleId></ArticleIdList></Reference><Reference><Citation>Barra S, Begley D, Heck P, Turner I, Agarwal S. Ablation of ventricular tachycardia in the very elderly patient with cardiomyopathy: how old is too old? Can J Cardiol. 2015;31(6):717&#x2013;722. doi: 10.1016/j.cjca.2014.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2014.12.016</ArticleId><ArticleId IdType="pubmed">25869352</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahapatra S, Tucker-Schwartz J, Wiggins D, Gillies GT, Mason PK, McDaniel G, LaPar DJ, Stemland C, Sosa E, Ferguson JD, Bunch TJ, Ailawadi G, Scanavacca M. Pressure frequency characteristics of the pericardial space and thorax during subxiphoid access for epicardial ventricular tachycardia ablation. Heart Rhythm. 2010;7(5):604&#x2013;609. doi: 10.1016/j.hrthm.2010.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2010.01.011</ArticleId><ArticleId IdType="pmc">PMC3047445</ArticleId><ArticleId IdType="pubmed">20156612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunch TJ, Darby A, May HT, Ragosta M, Lim DS, Taylor AM, DiMarco JP, Ailawadi G, Revenaugh JR, Weiss JP, Mahapatra S. Efficacy and safety of ventricular tachycardia ablation with mechanical circulatory support compared with substrate-based ablation techniques. Europace. 2012;14(5):709&#x2013;714. doi: 10.1093/europace/eur347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eur347</ArticleId><ArticleId IdType="pmc">PMC3598428</ArticleId><ArticleId IdType="pubmed">22080473</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008&#x2013;2012. doi: 10.1001/jama.283.15.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson KC, Brooks AG, Sanders P. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm Electrophysiol. 2013;6(6):1082&#x2013;1088. doi: 10.1161/CIRCEP.113.000768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.113.000768</ArticleId><ArticleId IdType="pubmed">24243785</ArticleId></ArticleIdList></Reference><Reference><Citation>Core Team R. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019.</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177&#x2013;188. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539&#x2013;1558. doi: 10.1002/sim.1186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046&#x2013;1055. doi: 10.1016/s0895-4356(01)00377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0895-4356(01)00377-8</ArticleId><ArticleId IdType="pubmed">11576817</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Armenta J, Soto-Iglesias D, Silva E, Penela D, J&#xe1;uregui B, Linhart M, Bisbal F, Acosta J, Fernandez M, Borras R, Villuendas R, Cano L, Guasch E, Mont L, Berruezo A. Safety and outcomes of ventricular tachycardia substrate ablation during sinus rhythm: a prospective multicenter registry. JACC Clin Electrophysiol. 2020;6(11):1435&#x2013;1448. doi: 10.1016/j.jacep.2020.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2020.07.028</ArticleId><ArticleId IdType="pubmed">33121673</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein K, Dalziel K, Garside R, Castelnuovo E, Round A. Association between methodological characteristics and outcome in health technology assessments which included case series. Int J Technol Assess Health Care. 2005;21(3):277&#x2013;287. doi: 10.1017/S0266462305050373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266462305050373</ArticleId><ArticleId IdType="pubmed">16110706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25529851</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><PubDate><Year>2014</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Low-dose intramuscular dexmedetomidine as premedication: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>2714</StartPage><EndPage>2719</EndPage><MedlinePgn>2714-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/MSM.891051</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dexmedetomidine-induced bradycardia or hypotension has recently attracted considerable attention because of potentially grave consequences, including sinus arrest and refractory cardiogenic shock. A route other than intravenous injection or a low dose may help minimize cardiovascular risks associated with dexmedetomidine. However, few studies have addressed the clinical effects of low-dose intramuscular dexmedetomidine as premedication.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Forty American Society of Anesthesiologists physical status I adult patients undergoing suspension laryngoscopic surgery were randomized to receive intramuscular dexmedetomidine (1 &#xb5;g&#xb7;kg-1) or midazolam (0.02 mg&#xb7;kg-1) 30 minutes prior to anaesthesia induction. The sedative, hemodynamic, and adjuvant anaesthetic effects of both premedications were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The levels of sedation (Observer's Assessment of Alertness/Sedation scales) and anxiety (visual analog score) at pre-induction, and the times to eye-opening and extubation, were not different between the groups. The heart rate response following tracheal intubation and extubation, and mean arterial pressure responses after extubation, were attenuated in the dexmedetomidine group compared to the midazolam group. No bradycardia or hypotension was noted in any patients. Propofol target concentrations at intubation and at start and completion of surgery were decreased in the dexmedetomidine group, whereas no difference in respective remifentanil levels was detected.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides further evidence that dexmedetomidine premedication in low dose (1 &#x3bc;g&#xb7;kg-1) by intramuscular route can induce preoperative sedation and adjuvant anaesthetic effects without clinically significant bradycardia or hypotension.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Guangzhou First People's Hospital, Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chaolei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Second Affiliated Hospital, Hebei Medical University, Guangzhou, Guangdong, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuehong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Guangzhou First People's Hospital, Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Guangzhou First People's Hospital, Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>She</LastName><ForeName>Shouzhang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Guangzhou First People's Hospital, Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lixin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Guangzhou First People's Hospital, Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Xiangcai</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Guangzhou First People's Hospital, Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (mainland).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01937611</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>67VB76HONO</RegistryNumber><NameOfSubstance UI="D020927">Dexmedetomidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>R60L0SM5BC</RegistryNumber><NameOfSubstance UI="D008874">Midazolam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018686" MajorTopicYN="N">Anesthetics, Intravenous</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020927" MajorTopicYN="N">Dexmedetomidine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008874" MajorTopicYN="N">Midazolam</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011292" MajorTopicYN="Y">Premedication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25529851</ArticleId><ArticleId IdType="pmc">PMC4278696</ArticleId><ArticleId IdType="doi">10.12659/MSM.891051</ArticleId><ArticleId IdType="pii">891051</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Strom S. Preoperative evaluation, premedication, and induction of anesthesia in infants and children. Curr Opin Anaesthesiol. 2012;25:321&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">22488124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kain ZN, Mayes LC, Bell C, et al. Premedication in the United States: a status report. Anesth Analg. 1997;84:427&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9024042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10910487</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamibayashi T, Maze M. Clinical uses of alpha2 -adrenergic agonists. Anesthesiology. 2000;93:1345&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">11046225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyck JB, Maze M, Haack C, et al. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology. 1993;78:813&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8098190</ArticleId></ArticleIdList></Reference><Reference><Citation>Taittonen MT, Kirvela OA, Aantaa R, Kanto JH. Effect of clonidine and dexmedetomidine premedication on perioperative oxygen consumption and haemodynamic state. Br J Anaesth. 1997;78:400&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9135361</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinin H, Aantaa R, Anttila M, et al. Reversal of the Sedative and Sympatholytic Effects of Dexmedetomidine with a Specific &#x3b1;2-Adrenoceptor Antagonist Atipamezole: A Pharmacodynamic and Kinetic Study in Healthy Volunteers. Anesthesiology. 1998;89:574&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743392</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaaslan D, Peker TT, Alaca A, et al. Comparison of buccal and intramuscular dexmedetomidine premedication for arthroscopic knee surgery. J Clin Anesth. 2006;18:589&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">17175428</ArticleId></ArticleIdList></Reference><Reference><Citation>Mowafi HA, Aldossary N, Ismail SA, Alqahtani J. Effect of dexmedetomidine premedication on the intraocular pressure changes after succinylcholine and intubation. Br J Anaesth. 2008;100:485&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">18285392</ArticleId></ArticleIdList></Reference><Reference><Citation>Eren G, Cukurova Z, Demir G, et al. Comparison of dexmedetomidine and three different doses of midazolam in preoperative sedation. J Anaesthesiol Clin Pharmacol. 2011;27:367&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3161464</ArticleId><ArticleId IdType="pubmed">21897510</ArticleId></ArticleIdList></Reference><Reference><Citation>Anttila M, Penttila J, Helminen A, et al. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol. 2003;56:691&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1884292</ArticleId><ArticleId IdType="pubmed">14616431</ArticleId></ArticleIdList></Reference><Reference><Citation>Menda F, Koner O, Sayin M, et al. Dexmedetomidine as an adjunct to anesthetic induction to attenuate hemodynamic response to endotracheal intubation in patients undergoing fast-track CABG. Ann Card Anaesth. 2010;13:16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20075530</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhang Y, She S, et al. A randomised controlled trial of dexmedetomidine for suspension laryngoscopy. Anaesthesia. 2013;68:60&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">23106186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sichrovsky TC, Mittal S, Steinberg JS. Dexmedetomidine sedation leading to refractory cardiogenic shock. Anesth Analg. 2008;106:1784&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">18499610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlach AT, Murphy CV. Dexmedetomidine-associated bradycardia progressing to pulseless electrical activity: case report and review of the literature. Pharmacotherapy. 2009;29:1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">19947809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato J, Ogawa Y, Kojima W, et al. Cardiovascular reflex responses to temporal reduction in arterial pressure during dexmedetomidine infusion: a double-blind, randomized, and placebo-controlled study. Br J Anaesth. 2009;103:561&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">19679580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Schmidt U, Wain JC, Bigatello L. Bradycardia leading to asystole during dexmedetomidine infusion in an 18 year-old double-lung transplant recipient. J Clin Anesth. 2010;22:45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">20206851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J, Steil GM, Curtis M, et al. Cardiovascular effects of dexmedetomidine sedation in children. Anesth Analg. 2012;114:193&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">21965374</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinin H, Karhuvaara S, Olkkola KT, et al. Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clin Pharmacol Ther. 1992;52:537&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">1358496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuer S, Biedler A, Larsen R, et al. Narcotrend monitoring allows faster emergence and a reduction of drug consumption in propofol-remifentanil anesthesia. Anesthesiology. 2003;99:34&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12826839</ArticleId></ArticleIdList></Reference><Reference><Citation>Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997;86:10&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9009935</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer&#x2019;s Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990;10:244&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">2286697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason KP, Robinson F, Fontaine P, Prescilla R. Dexmedetomidine offers an option for safe and effective sedation for nuclear medicine imaging in children. Radiology. 2013;267:911&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449958</ArticleId></ArticleIdList></Reference><Reference><Citation>Virkkila M, Ali-Melkkila T, Kanto J, et al. Dexmedetomidine as intramuscular premedication in outpatient cataract surgery. A placebo-controlled dose-ranging study. Anaesthesia. 1993;48:482&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">8100688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattila MJ, Mattila ME, Olkkola KT, Scheinin H. Effect of dexmedetomidine and midazolam on human performance and mood. Eur J Clin Pharmacol. 1991;41:217&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">1684154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuso A, Luis M, Sala X, et al. Effects of anesthetic technique on the hemodynamic response to microlaryngeal surgery. Ann Otol Rhinol Laryngol. 1997;106:863&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9342984</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussofara M, Bracco D, Ravussin P. Comparison of the effects of clonidine and hydroxyzine on haemodynamic and catecholamine reactions to microlaryngoscopy. Eur J Anaesthesiol. 2001;18:75&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11270028</ArticleId></ArticleIdList></Reference><Reference><Citation>Matot I, Sichel JY, Yofe V, Gozal Y. The effect of clonidine premedication on hemodynamic responses to microlaryngoscopy and rigid bronchoscopy. Anesth Analg. 2000;91:828&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11004033</ArticleId></ArticleIdList></Reference><Reference><Citation>Seybold JL, Ramamurthi RJ, Hammer GB. The use of dexmedetomidine during laryngoscopy, bronchoscopy, and tracheal extubation following tracheal reconstruction. Paediatr Anaesth. 2007;17:1212&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulka PJ, Tryba M, Zenz M. Dose-response effects of intravenous clonidine on stress response during induction of anesthesia in coronary artery bypass graft patients. Anesth Analg. 1995;80:263&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">7818111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology. 1992;77:1134&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">1361311</ArticleId></ArticleIdList></Reference><Reference><Citation>Uyar AS, Yagmurdur H, Fidan Y, et al. Dexmedetomidine attenuates the hemodynamic and neuroendocrinal responses to skull-pin head-holder application during craniotomy. J Neurosurg Anesthesiol. 2008;20:174&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">18580347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravipati P, Reddy PN, Kumar C, et al. Dexmedetomidine decreases the requirement of ketamine and propofol during burns debridement and dressings. Indian J Anaesth. 2014;58:138&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050928</ArticleId><ArticleId IdType="pubmed">24963176</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28472406</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>14</StartPage><EndPage>25</EndPage><MedlinePgn>14-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ejcts/ezx088</ELocationID><Abstract><AbstractText>Short-term mechanical circulatory support (MCS) is increasingly used as a bridge to decision in patients with refractory cardiogenic shock. Subsequently, these patients might be bridged to durable MCS either as a bridge to candidacy/transplantation, or as destination therapy. The aim of this study was to review support duration and clinical outcome of short-term MCS in cardiogenic shock, and to analyse application of this technology as a bridge to long-term cardiac support (left ventricular assist device, LVAD) from 2006 till June 2016. Using Cochrane Register of Trials, Embase and Medline, a systematic review was performed on patients with cardiogenic shock from acute myocardial infarction, end-stage cardiomyopathy, or acute myocarditis, receiving short-term MCS. Studies on periprocedural, post-cardiotomy and cardiopulmonary resuscitation support were excluded. Thirty-nine studies, mainly registries of heterogeneous patient populations (n&#x2009;=&#x2009;4151 patients), were identified. Depending on the device used (intra-aortic balloon pump, TandemHeart, Impella 2.5, Impella 5.0, CentriMag and peripheral veno-arterial extracorporeal membrane oxygenation), mean support duration was (range) 1.6-25 days and the mean proportion of short-term MCS patients discharged was (range) 45-66%. The mean proportion of bridge to durable LVAD was (range) 3-30%. Bridge to durable LVAD was most frequently performed in patients with end-stage cardiomyopathy (22 [12-35]%). We conclude that temporary MCS can be used to bridge patients with cardiogenic shock towards durable LVAD. Clinicians are encouraged to share their results in a large multicentre registry in order to investigate optimal device selection and best duration of support.</AbstractText><CopyrightInformation>&#xa9; The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>den Uil</LastName><ForeName>Corstiaan A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akin</LastName><ForeName>Sakir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jewbali</LastName><ForeName>Lucia S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Reis Miranda</LastName><ForeName>Dinis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brugts</LastName><ForeName>Jasper J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constantinescu</LastName><ForeName>Alina A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kappetein</LastName><ForeName>Arie Pieter</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caliskan</LastName><ForeName>Kadir</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001243" MajorTopicYN="N">Assisted Circulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Left ventricular assist device</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28472406</ArticleId><ArticleId IdType="doi">10.1093/ejcts/ezx088</ArticleId><ArticleId IdType="pii">3793752</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28941078</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>The effectiveness and safety of the Impella ventricular assist device for high-risk percutaneous coronary interventions: A systematic review.</ArticleTitle><Pagination><StartPage>1250</StartPage><EndPage>1260</EndPage><MedlinePgn>1250-1260</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.27316</ELocationID><Abstract><AbstractText Label="BACKGROUND">Small randomized controlled trials (RCTs) and observational studies have examined the effectiveness and safety of the Impella device, a percutaneous left ventricular assist device, in the setting of high-risk percutaneous coronary intervention (PCI). However, data are sparse and results are conflicting. Our objective was to evaluate the effectiveness and safety of the Impella device in high-risk patients undergoing PCI via a systematic review of the literature.</AbstractText><AbstractText Label="METHODS">We searched Medline, EMBASE, and the Cochrane Library for RCTs and observational studies that evaluated the Impella device in high-risk patients undergoing PCI. Inclusion was restricted to studies in which &#x2265;10 patients received the Impella device; both uncontrolled and controlled (versus intra-aortic-balloon pump [IABP]) studies were included.</AbstractText><AbstractText Label="RESULTS">A total of 20 studies (4 RCTs, 2 controlled observational studies, and 14 uncontrolled observational studies; 1,287 patients) were included, with follow-up ranging from 1 to 42 months. The use of Impella resulted in improved procedural and hemodynamic characteristics in controlled and uncontrolled studies. In controlled studies, the 30-day rates of all-cause mortality and MACE were similar across groups. In most uncontrolled studies, the 30-day rates of all-cause mortality were generally low (range: 3.7%-10%), though rates of MACE were slightly higher (range: 5%-20%).</AbstractText><AbstractText Label="CONCLUSION">The Impella device was found to improve procedural and hemodynamic parameters, but only limited randomized data are available regarding clinical outcomes associated with its use. Large, multicenter RCTs are needed to definitively establish the effectiveness of the Impella device among high-risk PCI patients.</AbstractText><CopyrightInformation>&#xa9; 2017 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ait Ichou</LastName><ForeName>Jamal</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lariv&#xe9;e</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Jewish General Hospital/McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suissa</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filion</LastName><ForeName>Kristian B</ForeName><Initials>KB</Initials><Identifier Source="ORCID">0000-0001-6055-0088</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Catheter Cardiovasc Interv. 2018 Jun;91(7):1261-1262. doi: 10.1002/ccd.27664.</RefSource><PMID Version="1">29894595</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003327" MajorTopicYN="N">Coronary Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28941078</ArticleId><ArticleId IdType="doi">10.1002/ccd.27316</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30354593</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1941-7632</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Circulation. Cardiovascular interventions</Title><ISOAbbreviation>Circ Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Concomitant Intra-Aortic Balloon Pump Use in Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation.</ArticleTitle><Pagination><StartPage>e006930</StartPage><MedlinePgn>e006930</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCINTERVENTIONS.118.006930</ELocationID><Abstract><AbstractText Label="BACKGROUND">There are contrasting reports on the effectiveness of a concomitant intra-aortic balloon pump (IABP) in cardiogenic shock patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO). This study sought to compare short-term mortality in patients with cardiogenic shock treated with VA-ECMO with and without IABP.</AbstractText><AbstractText Label="METHODS AND RESULTS">We reviewed the published literature from 2000 to 2018 for studies evaluating adult patients requiring VA-ECMO for cardiogenic shock with concomitant IABP. Studies reporting short-term mortality were included. Meta-analysis of the association of IABP with mortality was performed using Mantel-Haenszel models. Subgroup analyses were performed in patients with cardiogenic shock complicating acute myocardial infarction (AMI) and postcardiotomy cardiogenic shock. Twenty-two observational studies with 4653 patients were included. These studies showed high heterogeneity for the total and postcardiotomy cardiogenic shock cohorts and low heterogeneity for the AMI cohort. Short-term mortality was not significantly different in patients with and without IABP 42.1% versus 57.8%; risk ratio, 0.80; 95% CI, 0.52-1.22; P=0.30. However, concomitant IABP with VA-ECMO was associated with lower mortality in patients with AMI (50.8% versus 62.4%; risk ratio, 0.56; 95% CI, 0.46-0.67; P&lt;0.001). There was no difference in mortality in postcardiotomy cardiogenic shock and mixed causes for cardiogenic shock.</AbstractText><AbstractText Label="CONCLUSIONS">In cardiogenic shock patients requiring VA-ECMO support, the use of IABP did not influence mortality in the total cohort. In patients with AMI, use of IABP with VA-ECMO was associated with 18.5% lower mortality in comparison to patients on VA-ECMO alone. Further randomized studies are warranted to corroborate these observational data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saraschandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine (Saraschandra Vallabhajosyula, S.A., Saarwaani Vallabhajosyula, M.F.E., S.M.D., B.J.G., C.S.R., G.W.B.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine (Saraschandra Vallabhajosyula, J.C.O.H., P.A.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Horo</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine (Saraschandra Vallabhajosyula, J.C.O.H., P.A.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine (J.C.O.H.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antharam</LastName><ForeName>Phanindra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine (Saraschandra Vallabhajosyula, J.C.O.H., P.A.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ananthaneni</LastName><ForeName>Sindhura</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine (Saraschandra Vallabhajosyula, S.A., Saarwaani Vallabhajosyula, M.F.E., S.M.D., B.J.G., C.S.R., G.W.B.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saarwaani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine (Saraschandra Vallabhajosyula, S.A., Saarwaani Vallabhajosyula, M.F.E., S.M.D., B.J.G., C.S.R., G.W.B.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stulak</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery (J.M.S.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eleid</LastName><ForeName>Mackram F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine (Saraschandra Vallabhajosyula, S.A., Saarwaani Vallabhajosyula, M.F.E., S.M.D., B.J.G., C.S.R., G.W.B.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunlay</LastName><ForeName>Shannon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine (Saraschandra Vallabhajosyula, S.A., Saarwaani Vallabhajosyula, M.F.E., S.M.D., B.J.G., C.S.R., G.W.B.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gersh</LastName><ForeName>Bernard J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine (Saraschandra Vallabhajosyula, S.A., Saarwaani Vallabhajosyula, M.F.E., S.M.D., B.J.G., C.S.R., G.W.B.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rihal</LastName><ForeName>Charanjit S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine (Saraschandra Vallabhajosyula, S.A., Saarwaani Vallabhajosyula, M.F.E., S.M.D., B.J.G., C.S.R., G.W.B.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barsness</LastName><ForeName>Gregory W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine (Saraschandra Vallabhajosyula, S.A., Saarwaani Vallabhajosyula, M.F.E., S.M.D., B.J.G., C.S.R., G.W.B.), Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Cardiovasc Interv</MedlineTA><NlmUniqueID>101499602</NlmUniqueID><ISSNLinking>1941-7640</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Circ Cardiovasc Interv. 2018 Sep;11(9):e007214. doi: 10.1161/CIRCINTERVENTIONS.118.007214.</RefSource><PMID Version="1">30354607</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="Y">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">intra-aortic balloon pumping</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">patients</Keyword><Keyword MajorTopicYN="N">risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30354593</ArticleId><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.118.006930</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38471248</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>Bleeding complications, coagulation disorders, and their management in acute myocardial infarction-related cardiogenic shock rescued by veno-arterial ECMO: A retrospective cohort study.</ArticleTitle><Pagination><StartPage>154771</StartPage><MedlinePgn>154771</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2024.154771</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-9441(24)00258-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Management of dual antiplatelet therapy (DAPT) in patients on venoarterial-extracorporeal membrane (VA-ECMO) after acute myocardial infarction (AMI) is challenging. Our objective was to describe the frequency, management and outcomes of severe bleeding complications and determine their occurrence risk factors.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">We conducted a retrospective observational cohort study including post-AMI cardiogenic shock patients requiring VA-ECMO. Severe bleeding was defined based on the Bleeding Academic Research Consortium classification. We calculated multivariable Fine-Gray models to assess factors associated with risk of severe bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From January 2015 to July 2019, 176 patients received VA-ECMO after AMI and 132 patients were included. Sixty-five (49%) patients died. Severe bleeding occurred in 39% of cases. Severe thrombocytopenia (&lt; 50&#xa0;G/L) and hypofibrinogenemia (&lt;1,5&#xa0;g/L) occurred in respectively 31% and 19% of patients. DAPT was stopped in 32% of patients with a 6% rate of stent thrombosis. Anticoagulation was stopped in 39% of patients. Using a multivariate competing risk model, female sex, time on ECMO, troponin at admission and Impella&#xae; implantation were independently associated with severe bleeding.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bleeding complications and coagulation disorders were frequent and severe in patients on VA-ECMO after AMI, leading of antiplatelet therapy withdrawal in one third of patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masi</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; AP-HP, H&#xf4;pitaux Universitaires Henri-Mondor, Service de M&#xe9;decine Intensive R&#xe9;animation, F-94010 Cr&#xe9;teil, France. Electronic address: paul.masi@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendreau</LastName><ForeName>S&#xe9;gol&#xe8;ne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AP-HP, H&#xf4;pitaux Universitaires Henri-Mondor, Service de M&#xe9;decine Intensive R&#xe9;animation, F-94010 Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moyon</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leguyader</LastName><ForeName>Maxence</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebreton</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France; Cardiothoracic surgery department, Assistance Publique-H&#xf4;pitaux de Paris, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ropers</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Paris, Unit&#xe9; de Recherche Clinique des H&#xf4;pitaux Universitaires Piti&#xe9; Salp&#xea;tri&#xe8;re -H&#xf4;pitaux Universitaires Piti&#xe9; Salp&#xea;tri&#xe8;re - Charles Foix, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dangers</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>R&#xe9;animation Polyvalente, Centre Hospitalier Universitaire F&#xe9;lix Guyon, Saint-Denis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sitruk</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Paris, Unit&#xe9; de Recherche Clinique des H&#xf4;pitaux Universitaires Piti&#xe9; Salp&#xea;tri&#xe8;re -H&#xf4;pitaux Universitaires Piti&#xe9; Salp&#xea;tri&#xe8;re - Charles Foix, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe9;chot</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineton de Chambrun</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chommeloux</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luyt</LastName><ForeName>Charles Edouard</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leprince</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France; Cardiothoracic surgery department, Assistance Publique-H&#xf4;pitaux de Paris, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Combes</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frere</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France; Department of Hematology, Assistance Publique-H&#xf4;pitaux de Paris, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe9;kimian</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France; Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="Y">Hemorrhage</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001778" MajorTopicYN="N">Blood Coagulation Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bleeding</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Stent thrombosis</Keyword><Keyword MajorTopicYN="N">Venoarterial-extracorporeal membrane oxygenation</Keyword></KeywordList><CoiStatement>Declaration of competing interest Matthieu Schmidt reports lecture fees from Getinge, Drager and Xenios outside the submitted work. Alain Combes reports grants from Getinge, personal fees from Getinge, Baxter and Xenios outside the submitted work. Charles Edouard Luyt reported personal fees from Bayer Healthcare, Carmat, Faron, Merck Sharp &amp; Dohme, ThermoFischer Brahms, and Biom&#xe9;rieux; and grants from Bayer Healthcare outside the submitted work. Guillaume Lebreton reports lecture fees from Livanova and Abiomed, outside of the submitted work. The other authors declare that they have no conflicts of interest related to the purpose of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>31</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>13</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>12</Day><Hour>19</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38471248</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2024.154771</ArticleId><ArticleId IdType="pii">S0883-9441(24)00258-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32726215</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1522-6662</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>The heart surgery forum</Title><ISOAbbreviation>Heart Surg Forum</ISOAbbreviation></Journal><ArticleTitle>The Effect of Different Types of Mechanical Circulatory Support on Mortality of Patients after Adult Cardiac Surgery: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>E537</StartPage><EndPage>E545</EndPage><MedlinePgn>E537-E545</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1532/hsf.2979</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Sample size may limit the ability of individual studies to detect differences in clinical outcomes between extracorporeal membrane oxygenation (ECMO) alone and ECMO plus intra-aortic balloon pump (IABP) after adult cardiac surgery. Therefore, we undertook a meta-analysis of the best evidence available on the comparison of clinical outcomes of ECMO alone and ECMO plus IABP after adult cardiac surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, EMBASE, Web of Science, and Cochrane Center Registry of Controlled Trials were searched for studies comparing the use of ECMO alone and ECMO plus IABP after adult cardiac surgery. A meta-analysis and a sensitivity analysis were conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 472 screened articles, 24 studies (1302 cases of ECMO plus IABP and 1603 cases of ECMO) were included. A significant relationship between patient risk profile and benefits from IABP plus ECMO was found in terms of the 30-day mortality (odds ratio [OR] 0.75; 95% confidence interval [CI] 0.62 to 0.91; P = .004) with postcardiotomy shock (PCS). However, ECMO alone was associated with lower in-hospital mortality (OR 1.75; 95% CI 1.06 to 3.01; Z = 2.19; P = .03) compared with ECMO plus IABP without PCS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pooled data show that patients receiving IABP plus ECMO with PCS have lower 30-day mortality than those receiving ECMO also, which in turn show higher 30-day mortality in patients with IABP plus ECMO without PCS. Further randomized studies are warranted to corroborate these observational data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Zhiyuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Peking University Third Hospital, Haidian District, Beijing, China. gzy__2008@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Peking University, Beijing, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Kaiyun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Peking University Third Hospital, Haidian District, Beijing, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yanqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing University of Technology, Beijing, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Peking University Third Hospital, Haidian District, Beijing, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Peking University Third Hospital, Haidian District, Beijing, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University Third Hospital, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Chunli</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Peking University Third Hospital, Beijing, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Peking University Third Hospital, Haidian District, Beijing, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Shanghai East Hospital, Tongji University, Pudong District, Shanghai, China. schl@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Surg Forum</MedlineTA><NlmUniqueID>100891112</NlmUniqueID><ISSNLinking>1098-3511</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32726215</ArticleId><ArticleId IdType="doi">10.1532/hsf.2979</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38929524</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal Life Support in Myocardial Infarction: New Highlights.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">907</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina60060907</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>: Cardiogenic shock (CS) is a potentially severe complication following acute myocardial infarction (AMI). The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in these patients has risen significantly over the past two decades, especially when conventional treatments fail. Our aim is to provide an overview of the role of VA-ECMO in CS complicating AMI, with the most recent literature highlights. <i>Materials and Methods</i>: We have reviewed the current VA-ECMO practices with a particular focus on CS complicating AMI. The largest studies reporting the most significant results, i.e., overall clinical outcomes and management of the weaning process, were identified in the PubMed database from 2019 to 2024. <i>Results:</i> The literature about the use of VA-ECMO in CS complicating AMI primarily has consisted of observational studies until 2019, generating the need for randomized controlled trials. The EURO-SHOCK trial showed a lower 30-day all-cause mortality rate in patients receiving VA-ECMO compared to those receiving standard therapy. The ECMO-CS trial compared immediate VA-ECMO implementation with early conservative therapy, with a similar mortality rate between the two groups. The ECLS-SHOCK trial, the largest randomized controlled trial in this field, found no significant difference in mortality at 30 days between the ECMO group and the control group. Recent studies suggest the potential benefits of combining left ventricular unloading devices with VA-ECMO, but they also highlight the increased complication rate, such as bleeding and vascular issues. The routine use of VA-ECMO in AMI complicated by CS cannot be universally supported due to limited evidence and associated risks. Ongoing trials like the Danger Shock, Anchor, and Recover IV trials aim to provide further insights into the management of AMI complicated by CS. <i>Conclusions</i>: Standardizing the timing and indications for initiating mechanical circulatory support (MCS) is crucial and should guide future trials. Multidisciplinary approaches tailored to individual patient needs are essential to minimize complications from unnecessary MCS device initiation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piccone</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Intensive Care Unit, Hospital and University Trust of Verona, P. le A. Stefani, 37124 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiavoni</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2168-9017</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, Fondazione Policlinico Universitario Campus-Bio-Medico, Via Alvaro del Portillo 200, 00127 Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattei</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, Fondazione Policlinico Universitario Campus-Bio-Medico, Via Alvaro del Portillo 200, 00127 Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedetto</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7357-7180</Identifier><AffiliationInfo><Affiliation>Cardio-thoracic and Vascular Anesthesia and Intensive Care Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">intra-aortic balloon pump</Keyword><Keyword MajorTopicYN="N">left ventricular unloading</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">veno-arterial extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">weaning</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38929524</ArticleId><ArticleId IdType="pmc">PMC11205984</ArticleId><ArticleId IdType="doi">10.3390/medicina60060907</ArticleId><ArticleId IdType="pii">medicina60060907</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hochman J.S., Sleeper L.A., Webb J.G., Sanborn T.A., White H.D., Talley J.D., Buller C.E., Jacobs A.K., Slater J.N., Col J., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N. Engl. J. Med. 1999;341:625&#x2013;634. doi: 10.1056/NEJM199908263410901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199908263410901</ArticleId><ArticleId IdType="pubmed">10460813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeymer U., Bueno H., Granger B.C., Hochman J., Huber K., Lettino M., Price S., Schiele F., Tubaro M., Vranckx P., et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. Eur. Heart J. Acute Cardiovasc. Care. 2020;9:183&#x2013;197. doi: 10.1177/2048872619894254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872619894254</ArticleId><ArticleId IdType="pubmed">32114774</ArticleId></ArticleIdList></Reference><Reference><Citation>Brener M.I., Rosenblum H.R., Burkhoff D. Pathophysiology and Advanced Hemodynamic Assessment of Cardiogenic Shock. Methodist DeBakey Cardiovasc. J. 2020;16:7&#x2013;15. doi: 10.14797/mdcj-16-1-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.14797/mdcj-16-1-7</ArticleId><ArticleId IdType="pmc">PMC7137617</ArticleId><ArticleId IdType="pubmed">32280412</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Neumann F.J., Ferenc M., Olbrich H.G., Hausleiter J., Richardt G., Hennersdorf M., Empen K., Fuernau G., et al. IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N. Engl. J. Med. 2012;367:1287&#x2013;1296. doi: 10.1056/NEJMoa1208410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208410</ArticleId><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglin M., Zucker M.J., Bazan V.M., Bozkurt B., El Banayosy A., Estep J.D., Gurley J., Nelson K., Malyala R., Panjrath G.S., et al. Venoarterial ECMO for Adults: JACC Scientific Expert Panel. J. Am. Coll. Cardiol. 2019;73:698&#x2013;716. doi: 10.1016/j.jacc.2018.11.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.11.038</ArticleId><ArticleId IdType="pubmed">30765037</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed M., Khan M.Z., Osman M., Sulaiman S., Agrawal P., Raina S., Patel B., Bianco C., Balla S., Daggubati R. Sixteen-Year National Trends in Use and Outcomes of VA-ECMO in Cardiogenic Shock. Cardiovasc. Revasc. Med. 2022;44:1&#x2013;7. doi: 10.1016/j.carrev.2022.06.267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2022.06.267</ArticleId><ArticleId IdType="pubmed">35853815</ArticleId></ArticleIdList></Reference><Reference><Citation>Alba A.C., Foroutan F., Buchan T.A., Alvarez J., Kinsella A., Clark K., Zhu A., Lau K., McGuinty C., Aleksova N., et al. Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients. J. Heart Lung Transplant. 2021;40:260&#x2013;268. doi: 10.1016/j.healun.2021.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2021.01.009</ArticleId><ArticleId IdType="pubmed">33551227</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R., Shekar K., MacLaren G., Schmidt M.P.V., Meyns B., Haft J., Vercaemst L., Pappalardo F., Bermudez C., Belohlavek J., et al. ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients. ASAIO J. 2021;67:827&#x2013;844. doi: 10.1097/MAT.0000000000001510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001510</ArticleId><ArticleId IdType="pubmed">34339398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur. Heart J. 2018;39:119&#x2013;177. doi: 10.1093/eurheartj/ehx393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx393</ArticleId><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo M., Gardner R.S., McDonagh T.A., Metra M. The &#x2018;Ten Commandments&#x2019; of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2022;43:440&#x2013;441. doi: 10.1093/eurheartj/ehab853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab853</ArticleId><ArticleId IdType="pubmed">34922348</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchal A.R., Bartos J.A., Caba&#xf1;as J.G., Donnino M.W., Drennan I.R., Hirsch K.G., Kudenchuk P.J., Kurz M.C., Lavonas E.J., Morley P.T., et al. Adult Basic and Advanced Life Support Writing Group. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142((Suppl. S2)):S366&#x2013;S468. doi: 10.1161/CIR.0000000000000916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000916</ArticleId><ArticleId IdType="pubmed">33081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson A.S.C., Tonna J.E., Nanjayya V., Nixon P., Abrams D.C., Raman L., Bernard S., Finney S.J., Grunau B., Youngquist S.T., et al. Extracorporeal Cardiopulmonary Resuscitation in Adults. Interim Guideline Consensus Statement From the Extracorporeal Life Support Organization. ASAIO J. 2021;67:221&#x2013;228. doi: 10.1097/MAT.0000000000001344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001344</ArticleId><ArticleId IdType="pmc">PMC7984716</ArticleId><ArticleId IdType="pubmed">33627592</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlushkov E., Berman M., Valchanov K. Cannulation techniques for extracorporeal life support. Ann. Transl. Med. 2017;5:70. doi: 10.21037/atm.2016.11.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2016.11.47</ArticleId><ArticleId IdType="pmc">PMC5337209</ArticleId><ArticleId IdType="pubmed">28275615</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Liu K., Zheng J.L., Li X., Zhu D.M., Zhang Y., Zhang Y.J., Wang C.S., Shi T.T., Luo Z., et al. Hemodynamic monitoring in patients with venoarterial extracorporeal membrane oxygenation. Ann. Transl. Med. 2020;8:792. doi: 10.21037/atm.2020.03.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2020.03.186</ArticleId><ArticleId IdType="pmc">PMC7333156</ArticleId><ArticleId IdType="pubmed">32647717</ArticleId></ArticleIdList></Reference><Reference><Citation>Willers A., Swol J., Buscher H., McQuilten Z., van Kuijk S.M.J., Ten Cate H., Rycus P.T., McKellar S., Lorusso R., Tonna J.E. Longitudinal Trends in Bleeding Complications on Extracorporeal Life Support Over the Past Two Decades-Extracorporeal Life Support Organization Registry Analysis. Crit. Care Med. 2022;50:e569&#x2013;e580. doi: 10.1097/CCM.0000000000005466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005466</ArticleId><ArticleId IdType="pmc">PMC9210715</ArticleId><ArticleId IdType="pubmed">35167502</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya D., Torabi M., Borgstrom M., Rajapreyar I., Lee K., Kern K., Rycus P., Tonna J.E., Alexander P., Lotun K. Extracorporeal Membrane Oxygenation in Myocardial Infarction Complicated by Cardiogenic Shock: Analysis of the ELSO Registry. J. Am. Coll. Cardiol. 2020;76:1001&#x2013;1002. doi: 10.1016/j.jacc.2020.06.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.06.062</ArticleId><ArticleId IdType="pubmed">32819457</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler S., Khaladj N., Zaruba M.M., Fischer M., Hausleiter J., Mehilli J., K&#xe4;&#xe4;b S., Hagl C., Massberg S., Theiss H.D. Extracorporal life support (ECLS) in acute ischaemic cardiogenic shock. Int. J. Clin. Pract. 2014;68:529&#x2013;531. doi: 10.1111/ijcp.12380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.12380</ArticleId><ArticleId IdType="pubmed">24674706</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheu J.-J., Tsai T.-H., Lee F.-Y., Fang H.-Y., Sun C.-K., Leu S., Yang C.-H., Chen S.-M., Hang C.-L., Hsieh Y.-K., et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit. Care Med. 2010;38:1810&#x2013;1817. doi: 10.1097/CCM.0b013e3181e8acf7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181e8acf7</ArticleId><ArticleId IdType="pubmed">20543669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel D.M., Eriksen E., Sjauw K.D., van Dongen I.M., Hirsch A., Packer E.J., Vis M.M., Wykrzykowska J.J., Koch K.T., Baan J., et al. Percutaneous Mechanical Circulatory Support versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2017;69:278&#x2013;287. doi: 10.1016/j.jacc.2016.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.10.022</ArticleId><ArticleId IdType="pubmed">27810347</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner S., Guenther S.P.W., Lackermair K., Peterss S., Orban M., Boulesteix A.L., Michel S., Hausleiter J., Massberg S., Hagl C. Extracorporeal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2019;73:2355&#x2013;2357. doi: 10.1016/j.jacc.2019.02.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.02.044</ArticleId><ArticleId IdType="pubmed">31072581</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund A., Desch S., P&#xf6;ss J., Sulimov D., Sandri M., Majunke N., Thiele H. Extracorporeal Membrane Oxygenation in Infarct-Related Cardiogenic Shock. J. Clin. Med. 2022;11:1256. doi: 10.3390/jcm11051256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11051256</ArticleId><ArticleId IdType="pmc">PMC8910965</ArticleId><ArticleId IdType="pubmed">35268347</ArticleId></ArticleIdList></Reference><Reference><Citation>Banning A.S., Sabat&#xe9; M., Orban M., Gracey J., L&#xf3;pez-Sobrino T., Massberg S., Kastrati A., Bogaerts K., Adriaenssens T., Berry C., et al. Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: The multicentre, randomised EURO SHOCK trial. EuroIntervention. 2023;19:482&#x2013;492. doi: 10.4244/EIJ-D-23-00204.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-D-23-00204</ArticleId><ArticleId IdType="pmc">PMC10436068</ArticleId><ArticleId IdType="pubmed">37334659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostadal P., Rokyta R., Karasek J., Kruger A., Vondrakova D., Janotka M., Naar J., Smalcova J., Hubatova M., Hromadka M., et al. ECMO-CS Investigators. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. Circulation. 2023;147:454&#x2013;464. doi: 10.1161/CIRCULATIONAHA.122.062949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.062949</ArticleId><ArticleId IdType="pubmed">36335478</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Akin I., Behnes M., Rassaf T., Mahabadi A.A., Lehmann R., Eitel I., Graf T., Seidler T., et al. ECLS-SHOCK Investigators. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N. Engl. J. Med. 2023;389:1286&#x2013;1297. doi: 10.1056/NEJMoa2307227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2307227</ArticleId><ArticleId IdType="pubmed">37634145</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B., Becher P.M., Bernhardt A., Bezerra H., Blankenberg S., Brunner S., Colson P., Cudemus Deseda G., Dabboura S., Eckner D., et al. Left Ventricular Unloading Is Associated with Lower Mortality in Patients with Cardiogenic Shock Treated with Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study. Circulation. 2020;142:2095&#x2013;2106. doi: 10.1161/CIRCULATIONAHA.120.048792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048792</ArticleId><ArticleId IdType="pmc">PMC7688081</ArticleId><ArticleId IdType="pubmed">33032450</ArticleId></ArticleIdList></Reference><Reference><Citation>Meertens M.M., Tichelb&#xe4;cker T., Macherey-Meyer S., Heyne S., Braumann S., Nie&#xdf;en S.F., Baldus S., Adler C., Lee S. Meta-analysis of extracorporeal membrane oxygenation in combination with intra-aortic balloon pump vs. extracorporeal membrane oxygenation only in patients with cardiogenic shock due to acute myocardial infarction. Front. Cardiovasc. Med. 2023;9:1104357. doi: 10.3389/fcvm.2022.1104357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1104357</ArticleId><ArticleId IdType="pmc">PMC9889933</ArticleId><ArticleId IdType="pubmed">36741852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zein R., Patel C., Mercado-Alamo A., Schreiber T., Kak A. A Review of the Impella Devices. Interv. Cardiol. 2022;17:e05. doi: 10.15420/icr.2021.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/icr.2021.11</ArticleId><ArticleId IdType="pmc">PMC9026144</ArticleId><ArticleId IdType="pubmed">35474971</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsch&#xf6;pe C., Van Linthout S., Klein O., Mairinger T., Krackhardt F., Potapov E.V., Schmidt G., Burkhoff D., Pieske B., Spillmann F. Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts. J. Cardiovasc. Transl. Res. 2019;12:116&#x2013;123. doi: 10.1007/s12265-018-9820-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12265-018-9820-2</ArticleId><ArticleId IdType="pmc">PMC6497621</ArticleId><ArticleId IdType="pubmed">30084076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoldi L.F., Montisci A., Delmas C., Pappalardo F. Weaning from Impella and mobilization of Impella patients. Eur. Heart J. Suppl. 2021;23((Suppl. A)):A41&#x2013;A45. doi: 10.1093/eurheartj/suab008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/suab008</ArticleId><ArticleId IdType="pmc">PMC8005888</ArticleId><ArticleId IdType="pubmed">33815014</ArticleId></ArticleIdList></Reference><Reference><Citation>Marabotti A., Bertini P., Paternoster G., Landoni G., Guarracino F. Levosimendan&#x2019;s ability on veno-arterial extracorporeal membrane oxygenation weaning: Evidence says yes! Int. J. Artif. Organs. 2023;46:193&#x2013;194. doi: 10.1177/03913988221145502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03913988221145502</ArticleId><ArticleId IdType="pubmed">36726212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Jang W.J., Park T.K., Cho Y.H., Choi J.O., Jeon E.S., Yang J.H. Echocardiographic Predictors of Successful Extracorporeal Membrane Oxygenation Weaning After Refractory Cardiogenic Shock. J. Am. Soc. Echocardiogr. 2021;34:414&#x2013;422.e4. doi: 10.1016/j.echo.2020.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2020.12.002</ArticleId><ArticleId IdType="pubmed">33321165</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried J.A., Masoumi A., Takeda K., Brodie D. How I approach weaning from venoarterial ECMO. Crit. Care. 2020;24:307. doi: 10.1186/s13054-020-03010-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03010-5</ArticleId><ArticleId IdType="pmc">PMC7278069</ArticleId><ArticleId IdType="pubmed">32513218</ArticleId></ArticleIdList></Reference><Reference><Citation>Matassini M.V., Marini M., Angelozzi A., Angelini L., Shkoza M., Compagnucci P., Falanga U., Battistoni I., Pongetti G., Francioni M., et al. Clinical outcomes and predictors of success with Impella weaning in cardiogenic shock: A single-center experience. Front. Cardiovasc. Med. 2023;10:1171956. doi: 10.3389/fcvm.2023.1171956.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1171956</ArticleId><ArticleId IdType="pmc">PMC10321515</ArticleId><ArticleId IdType="pubmed">37416919</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoldi L., Pappalardo F., Lubos E., Grahn H., Rybczinski M., Barten M.J., Legros T., Bertoglio L., Schrage B., Westermann D., et al. Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. J. Crit. Care. 2020;57:259&#x2013;263. doi: 10.1016/j.jcrc.2019.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2019.12.028</ArticleId><ArticleId IdType="pubmed">32061461</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry T.D., Yannopoulos D., van Diepen S. Extracorporeal Membrane Oxygenation for Cardiogenic Shock: When to Open the Parachute? Circulation. 2023;147:465&#x2013;468. doi: 10.1161/CIRCULATIONAHA.122.063190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.063190</ArticleId><ArticleId IdType="pubmed">36745696</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller J.E., Engstr&#xf8;m T., Jensen L.O., Eiskj&#xe6;r H., Mangner N., Polzin A., Schulze P.C., Skurk C., Nordbeck P., Clemmensen P., et al. DanGer Shock Investigators. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N. Engl. J. Med. 2024;390:1382&#x2013;1393. doi: 10.1056/NEJMoa2312572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2312572</ArticleId><ArticleId IdType="pubmed">38587239</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoki T., Nakayama T., Tsurusaki Y., Inamori T., Toyofuku T., Konami Y., Suzuyama H., Inoue M., Horio E., Kodama E., et al. Combined use of VA-ECMO and Impella (ECPELLA) improves short- and long-term mortality in patients with cardiogenic shock who received VA-ECMO. Eur. Heart J. 2023;44((Suppl. S2)):ehad655.1596. doi: 10.1093/eurheartj/ehad655.1596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad655.1596</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32449494</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-111X</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Perfusion</Title><ISOAbbreviation>Perfusion</ISOAbbreviation></Journal><ArticleTitle>Effects of levosimendan on weaning and survival in adult cardiogenic shock patients with veno-arterial extracorporeal membrane oxygenation: systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>484</StartPage><EndPage>491</EndPage><MedlinePgn>484-491</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0267659120918473</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Veno-arterial extracorporeal membrane oxygenation may be used to support patients with refractory cardiogenic shock. Many patients can be successfully weaned, the ability of some medications to facilitate weaning from veno-arterial extracorporeal membrane oxygenation were reported. To date, there are limited studies investigating the impact of levosimendan on veno-arterial extracorporeal membrane oxygenation weaning. The objective of this systematic review and meta-analysis was to assess the effects of levosimendan on successful weaning from veno-arterial extracorporeal membrane oxygenation and survival in adult patients with cardiogenic shock.</AbstractText><AbstractText Label="METHODS">We performed a systematic review and meta-analysis (PubMed, the Cochrane Library, and the International Clinical Trials Registry Platform published from the year 2000 onwards) investigating whether levosimendan offers advantages compared to standard therapy or placebo, in cardiogenic shock adult patients treated with veno-arterial extracorporeal membrane oxygenation. The primary outcome was veno-arterial extracorporeal membrane oxygenation successful weaning, whereas secondary outcome was all-cause mortality at the longest follow-up available. We pooled risk ratio and 95% confidence interval using fixed and random effects models according to the heterogeneity.</AbstractText><AbstractText Label="RESULTS">A total of five non-randomized clinical trials comprising 557 patients were included, 299 patients for levosimendan and 258 patients for control groups. The pooled prevalence of veno-arterial extracorporeal membrane oxygenation successful weaning was 61.4% (95% confidence interval 39.8-82.9%), and all-cause mortality was 36% (95% confidence interval 29.6-48.8%). There was a significant increase in veno-arterial extracorporeal membrane oxygenation successful weaning with levosimendan compared to the controls (risk ratio&#x2009;=&#x2009;1.42 (95% confidence interval 1.12-1.8), p for effect&#x2009;=&#x2009;0.004, I<sup>2</sup>&#x2009;=&#x2009;71%). A decrease risk of all-cause mortality in the levosimendan group was also observed, risk ratio&#x2009;=&#x2009;0.62 (95% confidence interval 0.44-0.88), p for effect&#x2009;=&#x2009;0.007, I<sup>2</sup>&#x2009;=&#x2009;36%.</AbstractText><AbstractText Label="CONCLUSION">The use of levosimendan on adult patients with cardiogenic shock may facilitate the veno-arterial extracorporeal membrane oxygenation weaning and reduce all-cause mortality. Few articles of this topic are available, and prospective, randomized multi-center trials are warranted to conclude decisively on the benefits of levosimendan in this setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burgos</LastName><ForeName>Lucrecia Mar&#xed;a</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-3999-1265</Identifier><AffiliationInfo><Affiliation>Heart Failure, Pulmonary Hypertension and Transplant Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seoane</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Critical Care Cardiology Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furmento</LastName><ForeName>Juan Francisco</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-6818-9634</Identifier><AffiliationInfo><Affiliation>Critical Care Cardiology Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costabel</LastName><ForeName>Juan Pablo</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Critical Care Cardiology Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez</LastName><ForeName>Mirta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Heart Failure, Pulmonary Hypertension and Transplant Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrancic</LastName><ForeName>Mariano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aissaoui</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Penn State Heart and Vascular Institute (HVI), Critical Care Unit, Penn State Health Milton S. Hershey Medical Center (HMC), The Pennsylvania State University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzad&#xf3;n</LastName><ForeName>Mariano Noel</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Critical Care Cardiology Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navia</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Department, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Perfusion</MedlineTA><NlmUniqueID>8700166</NlmUniqueID><ISSNLinking>0267-6591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">levosimendan</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">weaning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32449494</ArticleId><ArticleId IdType="doi">10.1177/0267659120918473</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23756410</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-2035</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of cardiovascular medicine (Hagerstown, Md.)</Title><ISOAbbreviation>J Cardiovasc Med (Hagerstown)</ISOAbbreviation></Journal><ArticleTitle>Percutaneous coronary intervention in nonagenarian: a meta-analysis of observational studies.</ArticleTitle><Pagination><StartPage>773</StartPage><EndPage>779</EndPage><MedlinePgn>773-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2459/JCM.0b013e3283619410</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Developed countries are facing a sustained increase in life expectancy. Along with all social and cultural implications of increase lifespan, very elderly patients are undergoing percutaneous coronary intervention (PCI) with increasing frequency. However, there is limited evidence to guide clinicians in evaluating pros and cons of PCI in this very frail patient population. We, thus, aimed to perform a systematic review and meta-analysis of clinical studies reporting on PCI with stenting in nonagenarians.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Studies reporting on five or more nonagenarians undergoing PCI were systematically searched in PubMed (last updated on November 2011). Baseline and clinical characteristics, in-hospital and long-term outcomes were systematically appraised. End points of interest were in-hospital and long-term follow-up incidence of death and Major Adverse Cardiac Events (MACE; i.e. the composite of death from all causes, myocardial infarction or repeat revascularization). Events were pooled with a random-effect model, generating summary estimates of incidence rates [95% confidence intervals (CI)].</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 10 studies were included, reporting on a total of 575 nonagenarians undergoing PCI with stenting who represented 1.99% (1.34-2.5) of those undergoing revascularization in the cath lab in a mean period of 5 (3-7) years. Twenty-three percent (13-45) of patients presented with STEMI (ST Segment Elevation Myocardial Infarction), 10% (7-12) with cardiogenic shock and in 78% (64-88) of cases a multivessel disease was diagnosed. Meta-analytic pooling of event rates showed an in-hospital death risk of 12.61% (9.71-15.50) with MACE in 16.41% (13.36-19.47). After a follow-up ranging from 6 to 29 months (median 12), the risk of long-term death was 31.00% (17.10-45.52), with MACE in 37.00% (19.56-55.95; all CI 95%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our meta-analysis, pooling the largest cohort ever of nonagenarians undergoing PCI with stents, confirms the feasibility of percutaneous coronary stenting even in this very frail patient subset, despite the expected severe event attrition during follow-up. Thus, nonagenarians with an acceptable risk profile, recent clinical instability and/or disabling symptoms should not be denied the possibility of percutaneous coronary revascularization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Presutti</LastName><ForeName>Davide G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>aDivision of Cardiology, Department of Internal Medicine, Turin, Italy bDepartment of Cardiology, St.Joseph's Regional Medical Center, Paterson, New Jersey cDivision of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, California, USA dDivision of Interventional Cardiology, Instituto Cardiovascular, Hospital La Paz, Paseo La Castellana, Madrid, Spain eDepartment of Medico-Surgical Sciences, Biotechnologies Sapienza University of Rome, Italy fInvasive Cardiology, Campus Middelheim, Antwerpen, Belgium gMeta-analysis and Evidence based medicine Training in Cardiology, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ascenzo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Omed&#xe8;</LastName><ForeName>Pierluigi</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Biondi-Zoccai</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Moretti</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bollati</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sciuto</LastName><ForeName>Filippo</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Raul</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bikkina</LastName><ForeName>Mahesh</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Di Cuia</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Resmini</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gaita</LastName><ForeName>Fiorenzo</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sheiban</LastName><ForeName>Imad</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Med (Hagerstown)</MedlineTA><NlmUniqueID>101259752</NlmUniqueID><ISSNLinking>1558-2027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003327" MajorTopicYN="N">Coronary Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010043" MajorTopicYN="N">Outcome and Process Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23756410</ArticleId><ArticleId IdType="doi">10.2459/JCM.0b013e3283619410</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29678433</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8422</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>J Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>Clinical Outcomes of Adult Patients Who Receive Extracorporeal Membrane Oxygenation for Postcardiotomy Cardiogenic Shock: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>2087</StartPage><EndPage>2093</EndPage><MedlinePgn>2087-2093</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.jvca.2018.03.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-0770(18)30206-4</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To investigate the clinical outcomes of adult patients receiving extracorporeal membrane oxygenation (ECMO) for postcardiotomy cardiogenic shock (PCS).</AbstractText><AbstractText Label="DESIGN">Meta-analysis of 20 observational studies.</AbstractText><AbstractText Label="SETTING">Hospitals that perform cardiac surgery.</AbstractText><AbstractText Label="PARTICIPANTS">The study included 2,877 PCS patients undergoing ECMO from 20 observational studies.</AbstractText><AbstractText Label="INTERVENTIONS">ECMO use.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">Twenty observational studies were selected for final analysis. The pooled survival rate to hospital discharge was 34.0% (30.0%-38.0%) in PCS patients receiving ECMO. The pooled 1-year survival rate was 24.0% (19.05%-30.0%). The pooled midterm survival rate was 18.0% (11.0%-27.0%). The pooled rate of leg ischemia was 14.0% (10.0%-20.0%). The pooled rate of redo surgery was 50.0% (32.0%-68.0%). The pooled rate of renal failure was 57.0% (47.0%-66.0%). The pooled rate of neurologic complications was 16.0% (13.0%-20.0%). The pooled rate of infection was 31.0% (22.0%-41.0%). Most of the included studies commonly revealed that age &gt;65 years, pre-ECMO or post-ECMO blood lactate, renal insufficiency, a longer duration of ECMO, and neurologic complications were risk factors of in-hospital mortality in PCS patients undergoing ECMO.</AbstractText><AbstractText Label="CONCLUSIONS">The short-term and midterm survival rates of PCS patients treated with ECMO were disappointingly low, and post-ECMO complication rates were relatively high.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liangshan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Cardiac Intensive Care, Capital Medical University Affiliated Anzhen Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Cardiac Intensive Care, Capital Medical University Affiliated Anzhen Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Xiaotong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Cardiac Intensive Care, Capital Medical University Affiliated Anzhen Hospital, Beijing, People's Republic of China. Electronic address: xt.hou@ccmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9110208</NlmUniqueID><ISSNLinking>1053-0770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Cardiothorac Vasc Anesth. 2018 Oct;32(5):2094-2095. doi: 10.1053/j.jvca.2018.05.029.</RefSource><PMID Version="1">30049522</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Cardiothorac Vasc Anesth. 2019 Aug;33(8):2360-2361. doi: 10.1053/j.jvca.2019.01.053.</RefSource><PMID Version="1">30770178</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">complication</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">postcardiotomy cardiogenic shock</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword><Keyword MajorTopicYN="N">survival outcome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29678433</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2018.03.016</ArticleId><ArticleId IdType="pii">S1053-0770(18)30206-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21335478</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1940-4034</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of cardiovascular pharmacology and therapeutics</Title><ISOAbbreviation>J Cardiovasc Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular outcomes using intra-aortic balloon pump in high-risk acute myocardial infarction with or without cardiogenic shock: a meta-analysis.</ArticleTitle><Pagination><StartPage>44</StartPage><EndPage>56</EndPage><MedlinePgn>44-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1074248410395019</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Intra-aortic balloon pump (IABP) has been widely used ever since it was first developed in 1962 and became part of clinical practice in 1968. It is used to treat patients with complications of acute myocardial infarction (AMI) such as cardiogenic shock, refractory left ventricular failure, and for high-risk patients undergoing angioplasty and coronary artery bypass grafting. However, current literature demonstrates a significant variance in terms of indications for using IABP and its outcomes. The aim of this study is to review the existing literature to analyze whether the use of IABP offers any cardiovascular benefit to the patients with AMI and the complications associated with the use of IABP. Material and</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review of literature identified 16 studies. We analyzed the primary endpoint (in-hospital mortality, reinfarction, recurrent ischemia) and secondary endpoint (incidence of moderate and severe bleeding during hospitalization at 7 days). We estimated the proportion of between-study inconsistency (heterogeneity) due to true differences between studies (rather than differences due to random error or chance) using the I2 statistic. Mantel-Haenszel fixed-effect model was used to calculate the combined relative risks (RRs) when studies were homogenous, and the random effect model was used when studies were heterogenic. A 2-sided &#x3b1; error &lt;.05 was considered statistically significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Meta-analysis revealed that in-hospital mortality of patients with AMI with and without cardiogenic shock did not differ between IABP group as compared to no IABP group (RR: 1.11; confidence interval [CI]: 0.69-1.78; P = .67). However, analysis of patients with AMI with cardiogenic shock showed statistically significant improvement in mortality (RR: 0.72; CI: 0.60-0.86; P &lt; .0004). There was no significant reduction in the rate of reinfarction (RR: 0.81; CI: 0.30-2.17; P = .67) or recurrent ischemia (RR: 0.78; CI: 0.34-1.78; P = .55) using IABP. Intra-aortic balloon pump was found to significantly increase the risk of moderate bleeding (RR: 1.71; CI: 1.03-2.85; P = .04) and major bleeding (RR: 4.01; CI: 2.66-6.06; P &lt; .0001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present meta-analysis suggests that patients with high-risk AMI without cardiogenic shock do not seem to benefit from the use of IABP as measured by in-hospital mortality, rate of reinfarction, and recurrent angina. However, in patients with AMI with cardiogenic shock (systolic blood pressure [SBP] &lt; 90), there was significant reduction in mortality using IABP. The use of IABP is associated with increase in the rate of both moderate and severe bleeding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bahekar</LastName><ForeName>Amol</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chicago Medical School, Rosalind Franklin University of Medicine &amp; Science, North Chicago, IL, USA. abahekar@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Mukesh</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Sarabjeet</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bhuriya</LastName><ForeName>Rohit</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Khraisat</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Khosla</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Rohit</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Pharmacol Ther</MedlineTA><NlmUniqueID>9602617</NlmUniqueID><ISSNLinking>1074-2484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="Y">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21335478</ArticleId><ArticleId IdType="doi">10.1177/1074248410395019</ArticleId><ArticleId IdType="pii">1074248410395019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39064166</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>14</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Novel Techniques and Technologies for Surgical Aortic Valve Replacement: A Large Retrospective Cohort Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4126</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13144126</ELocationID><Abstract><AbstractText><b>Background/Objectives</b>: In an era of growing evidence for transaortic valve implantation (TAVI), our research topic was the evaluation of how surgical aortic valve replacements (SAVRs) are performing in terms of short- and long-term outcomes in different risk categories. <b>Methods</b>: This was a single centre, prospective, and observational cohort study of consecutive patients with aortic valve stenosis, undergoing isolated aortic valve replacement using a biological or mechanical prosthesis, Freestyle&#x2122; (Medtronic, Minneapolis, MN, USA) graft, homograft, or Ross procedure. The participant data were collected by review of an internal database. The primary endpoints were all-cause operative mortality (in hospital and at 30 days) and late mortality at the follow-up date. The secondary composite endpoint was the incidence of postoperative complications. <b>Results</b>: 1501 patients underwent SAVR; the mean age was 67 years (SD: 12.6). The in-hospital mortality was 1% (<i>n</i> = 16). At a median follow-up of 60 months, the survival rate was 98.7%. The main predictors for mortality were operative urgency and cardiogenic shock. The overall incidence of PPM was 2.3% (<i>n</i> = 34). Patients who underwent Ross procedure were younger (mean age: 20 years (SD: 1.7)), had a lower incidence of postoperative complications, and were all alive at follow-up. <b>Conclusions</b>: SAVR shows an excellent survival rate and a low rate of postoperative complications despite an increasing surgical risk. Recent advancements in technology, like sutureless/rapid deployment prostheses and minimally invasive techniques, are shown to have favourable effects on outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, St. Thomas' Hospital, London SE1 7EH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilkhu</LastName><ForeName>Rajdeep</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5866-9001</Identifier><AffiliationInfo><Affiliation>Cardiovascular Department, St. Thomas' Hospital, London SE1 7EH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, St. Thomas' Hospital, London SE1 7EH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roxburgh</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, St. Thomas' Hospital, London SE1 7EH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, St. Thomas' Hospital, London SE1 7EH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucchese</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8444-6840</Identifier><AffiliationInfo><Affiliation>Cardiovascular Department, St. Thomas' Hospital, London SE1 7EH, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aortic valve replacement</Keyword><Keyword MajorTopicYN="N">minimally invasive surgery</Keyword><Keyword MajorTopicYN="N">ross operation</Keyword><Keyword MajorTopicYN="N">sutureless aortic valves</Keyword><Keyword MajorTopicYN="N">trans-aortic valve implantation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39064166</ArticleId><ArticleId IdType="pmc">PMC11278247</ArticleId><ArticleId IdType="doi">10.3390/jcm13144126</ArticleId><ArticleId IdType="pii">jcm13144126</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P., III, Guyton R.A., O&#x2019;Gara P.T., Ruiz C.E., Skubas N.J., Sorajja P., et al. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2014;63:e57&#x2013;e185. doi: 10.1016/j.jacc.2014.02.536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.02.536</ArticleId><ArticleId IdType="pubmed">24603191</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyregod H.G., Ihlemann N., J&#xf8;rgensen T.H., Nissen H., Kjeldsen B.J., Petursson P., Chang Y., Franzen O.W., Engstr&#xf8;m T., Clemmensen P., et al. Five-year clinical and echocardiographic outcomes from the NOTION randomized clinical trial in patients at lower surgical risk. Circulation. 2019;139:2714&#x2013;2723. doi: 10.1161/CIRCULATIONAHA.118.036606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.036606</ArticleId><ArticleId IdType="pubmed">30704298</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon M.J., Van Mieghem N.M., Popma J.J., Kleiman N.S., S&#xf8;ndergaard L., Mumtaz M., Adams D.H., Deeb G.M., Maini B., Gada H., et al. SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N. Engl. J. Med. 2017;376:1321&#x2013;1331. doi: 10.1056/NEJMoa1700456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1700456</ArticleId><ArticleId IdType="pubmed">28304219</ArticleId></ArticleIdList></Reference><Reference><Citation>Popma J.J., Deeb G.M., Yakubov S.J., Mumtaz M., Gada H., O&#x2019;Hair D., Bajwa T., Heiser J.C., Merhi W., Kleiman N.S., et al. Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N. Engl. J. Med. 2019;380:1706&#x2013;1715. doi: 10.1056/NEJMoa1816885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1816885</ArticleId><ArticleId IdType="pubmed">30883053</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack M.J., Leon M.B., Thourani V.H., Makkar R., Kodali S.K., Russo M., Kapadia S.R., Malaisrie S.C., Cohen D.J., Pibarot P., et al. PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N. Engl. J. Med. 2019;380:1695&#x2013;1705. doi: 10.1056/NEJMoa1814052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1814052</ArticleId><ArticleId IdType="pubmed">30883058</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto C.M., Nishimura R.A., Bonow R.O., Carabello B.A., Erwin J.P., III, Gentile F., Jneid H., Krieger E.V., Mack M., McLeod C., et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35&#x2013;e71.</Citation><ArticleIdList><ArticleId IdType="pubmed">33332149</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyersdorf F., Vahanian A., Milojevic M., Praz F., Baldus S., Bauersachs J., Capodanno D., Conradi L., De Bonis M., De Paulis R., et al. ESC/EACTS Scientific Document Group, 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur. Heart J. 2022;43:561&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondergaard L. Transcatheter aortic valve implantation in patients with longer life expectancy: What measures are needed? Eur. Heart J. 2019;40:1331&#x2013;1333. doi: 10.1093/eurheartj/ehy774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy774</ArticleId><ArticleId IdType="pubmed">30508084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D., Vlahakes G.J., Palacios I.F., Sakhuja R., Passeri J.J., Inglessis I., Elmariah S. Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. J. Am. Coll. Cardiol. 2019;74:1532&#x2013;1540. doi: 10.1016/j.jacc.2019.06.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.06.076</ArticleId><ArticleId IdType="pubmed">31537261</ArticleId></ArticleIdList></Reference><Reference><Citation>Vipparthy S.C., Ravi V., Avula S., Kambhatla S., Mahmood M., Kabour A., Ali S.S., Barzallo M., Mungee S. Meta-Analysis of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients with Low Surgical Risk. Am. J. Cardiol. 2020;125:459&#x2013;468. doi: 10.1016/j.amjcard.2019.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.10.036</ArticleId><ArticleId IdType="pubmed">31784051</ArticleId></ArticleIdList></Reference><Reference><Citation>Meco M., Miceli A., Montisci A., Donatelli F., Cirri S., Ferrarini M., Lio A., Glauber M. Sutureless aortic valve replacement versus transcatheter aortic valve implantation: A meta-analysis of comparative matched studies using propensity score matching. Interact. Cardiovasc. Thorac. Surg. 2018;26:202&#x2013;209. doi: 10.1093/icvts/ivx294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivx294</ArticleId><ArticleId IdType="pubmed">29049787</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischlein T., Folliguet T., Meuris B., Shrestha M.L., Roselli E.E., McGlothlin A., Kappert U., Pfeiffer S., Corbi P., Lorusso R., et al. Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement Investigators. Sutureless versus conventional bioprostheses for aortic valve replacement in severe symptomatic aortic valve stenosis. J. Thorac. Cardiovasc. Surg. 2021;161:920&#x2013;932. doi: 10.1016/j.jtcvs.2020.11.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2020.11.162</ArticleId><ArticleId IdType="pubmed">33478837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R., Folliguet T., Shrestha M., Meuris B., Kappetein A.P., Roselli E., Klersy C., Nozza M., Verhees L., Larracas C., et al. Sutureless versus Stented Bioprostheses for Aortic Valve Replacement: The Randomized PERSIST-AVR Study Design. Thorac. Cardiovasc. Surg. 2020;68:114&#x2013;123. doi: 10.1055/s-0038-1675847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1675847</ArticleId><ArticleId IdType="pubmed">30497085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousuf Salmasi M., Hamilton H., Rahman I., Chien L., Rival P., Benedetto U., Young C., Caputo M., Angelini G.D., Vohra H.A. Mini-sternotomy vs. right anterior thoracotomy for aortic valve replacement. J. Card. Surg. 2020;35:1570&#x2013;1582. doi: 10.1111/jocs.14607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.14607</ArticleId><ArticleId IdType="pubmed">32652784</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C., Raza S., Altarabsheh S.E., Delozier S., Sharma U.M., Zia A., Khan M.S., Neudecker M., Markowitz A.H., Sabik J.F., III, et al. Minimally Invasive Approaches to Surgical Aortic Valve Replacement: A Meta-Analysis. Ann. Thorac. Surg. 2018;106:1881&#x2013;1889. doi: 10.1016/j.athoracsur.2018.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2018.07.018</ArticleId><ArticleId IdType="pubmed">30189193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda Y., Yamamoto H., Miyata H., Usui A., Motomura N. Japan Cardiovascular Surgery Database Organization. Contemporary Outcomes of Surgical Aortic Valve Replacement in Japan. Circ. J. 2020;84:277&#x2013;282. doi: 10.1253/circj.CJ-19-0674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-19-0674</ArticleId><ArticleId IdType="pubmed">31932559</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Caulo E.A., Guijarro-Contreras A., Guz&#xf3;n A., Otero-Forero J., Matar&#xf3; M.J., S&#xe1;nchez-Esp&#xed;n G., Porras C., Villaescusa J.M., Melero-Tejedor J.M., Jim&#xe9;nez-Navarro M. Quality of Life After Ministernotomy Versus Full Sternotomy Aortic Valve Replacement. Semin. Thorac. Cardiovasc. Surg. 2021;33:328&#x2013;334. doi: 10.1053/j.semtcvs.2020.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semtcvs.2020.07.013</ArticleId><ArticleId IdType="pubmed">32853740</ArticleId></ArticleIdList></Reference><Reference><Citation>Micali L.R., Algargoosh S., Parise O., Parise G., Matteucci F., de Jong M., Ioanna Moula A., Tetta C., Gelsomino S. Patient survival in severe low-flow, low-gradient aortic stenosis after aortic valve replacement or conservative management. J. Card. Surg. 2021;36:1030&#x2013;1039. doi: 10.1111/jocs.15209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.15209</ArticleId><ArticleId IdType="pmc">PMC7898507</ArticleId><ArticleId IdType="pubmed">33336497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilkhu R., Jahangiri M., Otto C.M. Patient-prosthesis mismatch following aortic valve replacement. Heart. 2019;105((Suppl. S2)):s28&#x2013;s33. doi: 10.1136/heartjnl-2018-313515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2018-313515</ArticleId><ArticleId IdType="pubmed">30846522</ArticleId></ArticleIdList></Reference><Reference><Citation>Horstkotte D., Loogen F. The natural history of aortic valve stenosis. Eur. Heart J. 1988;9((Suppl. E)):57&#x2013;64. doi: 10.1093/eurheartj/9.suppl_E.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/9.suppl_E.57</ArticleId><ArticleId IdType="pubmed">3042404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim W.Y., Ramasamy A., Lloyd G., Bhattacharyya S. Meta-analysis of the impact of intervention versus symptom-driven management in asymptomatic severe aortic stenosis. Heart (Br. Card. Soc.) 2017;103:268&#x2013;272. doi: 10.1136/heartjnl-2016-309830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2016-309830</ArticleId><ArticleId IdType="pubmed">27540178</ArticleId></ArticleIdList></Reference><Reference><Citation>Movahed M.R., Hepner A.D., Ahmadi-Kashani M. Echocardiographic prevalence of bicuspid aortic valve in the population. Heart Lung Circ. 2006;15:297&#x2013;299. doi: 10.1016/j.hlc.2006.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2006.06.001</ArticleId><ArticleId IdType="pubmed">16914375</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornhill M.H., Dayer M.J., Nicholl J., Prendergast B.D., Lockhart P.B., Baddour L.M. An alarming rise in incidence of infective endocarditis in England since 2009: Why? Lancet. 2020;395:1325&#x2013;1327. doi: 10.1016/S0140-6736(20)30530-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30530-4</ArticleId><ArticleId IdType="pubmed">32334690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvaslerud A.B., Santic K., Hussain A.I., Auensen A., Fiane A., Skulstad H., Aaberge L., Gullestad L., Broch K. Outcomes in asymptomatic, severe aortic stenosis. PLoS ONE. 2021;16:e0249610. doi: 10.1371/journal.pone.0249610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0249610</ArticleId><ArticleId IdType="pmc">PMC8026050</ArticleId><ArticleId IdType="pubmed">33826652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdemir E., Esin F.K., Tuluce S.Y., Karaca M. Emergent Transcatheter Aortic Valve Implantation as a Life-saving Procedure: A Primary Treatment Approach. J. Coll. Physicians Surg. Pak. 2019;29:996&#x2013;999. doi: 10.29271/jcpsp.2019.10.996.</Citation><ArticleIdList><ArticleId IdType="doi">10.29271/jcpsp.2019.10.996</ArticleId><ArticleId IdType="pubmed">31564277</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos K., Chrissoheris M., Halapas A., Kourkoveli P., Ozden Tok O., Spargias K. Emergency TAVI in a critically ill patient: A case report. Clin. Case Rep. 2020;9:1024&#x2013;1026. doi: 10.1002/ccr3.3732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.3732</ArticleId><ArticleId IdType="pmc">PMC7869389</ArticleId><ArticleId IdType="pubmed">33598290</ArticleId></ArticleIdList></Reference><Reference><Citation>Enta Y., Miyasaka M., Taguri M., Tada N., Hata M., Watanabe Y., Naganuma T., Yamawaki M., Yamanaka F., Shirai S., et al. Patients&#x2019; characteristics and mortality in urgent/emergent/salvage transcatheter aortic valve replacement: Insight from the OCEAN-TAVI registry. Open Heart. 2020;7:e001467. doi: 10.1136/openhrt-2020-001467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2020-001467</ArticleId><ArticleId IdType="pmc">PMC7737081</ArticleId><ArticleId IdType="pubmed">33318151</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth K., Clark S. Pacemaker implantation rate post suture- less aortic valve replacement: 23% is just too high. Ann. Thorac. Surg. 2017;104:1761&#x2013;1762. doi: 10.1016/j.athoracsur.2016.12.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.12.050</ArticleId><ArticleId IdType="pubmed">29054226</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischlein T., Gersak B., Pfeiffer S. How to prevent a pace- maker implantation after sutureless bioprosthesis. J. Thorac. Cardiovasc. Surg. 2016;152:635&#x2013;636. doi: 10.1016/j.jtcvs.2016.03.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2016.03.055</ArticleId><ArticleId IdType="pubmed">27423841</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt F., Dell&#x2019;Aquila A.M., Santarpino G. How to prevent pacemaker implantation after sutureless aortic valve replacement: Tips and tricks. Ann. Thorac. Surg. 2017;104:720&#x2013;721. doi: 10.1016/j.athoracsur.2016.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.11.013</ArticleId><ArticleId IdType="pubmed">28734415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamamsy I., Poirier N.C. What is the role of the Ross procedure in today&#x2019;s armamentarium? Can. J. Cardiol. 2013;29:1569&#x2013;1576. doi: 10.1016/j.cjca.2013.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2013.08.009</ArticleId><ArticleId IdType="pubmed">24267802</ArticleId></ArticleIdList></Reference><Reference><Citation>McClure G.R., Belley-Cote E.P., Um K., Gupta S., Bouhout I., Lortie H., Alraddadi H., Alsagheir A., McIntyre W.F., Dorobantu D.M., et al. The Ross procedure versus prosthetic and homograft aortic valve replacement: A systematic review and meta-analysis. Eur. J. Cardiothorac. Surg. 2019;55:247&#x2013;255. doi: 10.1093/ejcts/ezy247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezy247</ArticleId><ArticleId IdType="pubmed">30084899</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38327179</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2058-1742</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>European heart journal. Quality of care &amp; clinical outcomes</Title><ISOAbbreviation>Eur Heart J Qual Care Clin Outcomes</ISOAbbreviation></Journal><ArticleTitle>Long-term survival after surgical treatment for post-infarction mechanical complications: results from the Caution study.</ArticleTitle><Pagination><StartPage>737</StartPage><EndPage>749</EndPage><MedlinePgn>737-749</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjqcco/qcae010</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Mechanical complications (MCs) are rare but potentially fatal sequelae of acute myocardial infarction (AMI). Surgery, though challenging, is considered the treatment of choice. The authors sought to study the early and long-term results of patients undergoing surgical treatment for post-AMI MCs.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Patients who underwent surgical treatment for post-infarction MCs between 2001 through 2019 in 27 centres worldwide were retrieved from the database of the CAUTION study. In-hospital and long-term mortality were the primary outcomes. Cox proportional hazards regression models were used to determine independent factors associated with overall mortality. The study included 720 patients. The median age was 70.0 [62.0-77.0] years, with a male predominance (64.6%). The most common MC encountered was ventricular septal rupture (VSR) (59.4%). Cardiogenic shock was seen on presentation in 56.1% of patients. In-hospital mortality rate was 37.4%; in more than 50% of cases, the cause of death was low cardiac output syndrome (LCOS). Late mortality occurred in 133 patients, with a median follow-up of 4.4 [1.0-8.6] years. Overall survival at 1, 5, and 10 years was 54.0, 48.1, and 41.0%, respectively. Older age (P&#xa0;&lt;&#xa0;0.001) and post-operative LCOS (P&#xa0;&lt;&#xa0;0.001) were independent predictors of overall mortality. For hospital survivors, 10-year survival was 65.7% and was significantly higher for patients with VSR than those with papillary muscle rupture (long-rank P&#xa0;=&#xa0;0.022).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Contemporary data from a multicentre cohort study show that surgical treatment for post-AMI MCs continues to be associated with high in-hospital mortality rates. However, long-term survival in patients surviving the immediate post-operative period is encouraging.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matteucci</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0694-2747</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Circolo Hospital, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronco</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5250-1796</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalewski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massimi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Bonis</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9329-7437</Identifier><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, San Raffaele University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formica</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3989-6134</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Parma, Cardiac Surgery Unit, University Hospital of Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiritano</LastName><ForeName>Federica</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6889-5686</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folliguet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0009-6543</Identifier><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, University Hospital Henri-Mondor, Cr&#xe9;teil, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonaros</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7656-5812</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sponga</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic Department, University Hospital of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwalski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2670-4164</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Martino</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2889-4918</Identifier><AffiliationInfo><Affiliation>Section of Cardiac Surgery, University Hospital, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischlein</LastName><ForeName>Theodor</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9781-3590</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Cardiovascular Center, Klinikum N&#xfc;rnberg, Paracelsus Medical University, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troise</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Poliambulanza Foundation Hospital, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dato</LastName><ForeName>Guglielmo Actis</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0003-4209-2866</Identifier><AffiliationInfo><Affiliation>Cardiac Surgery Department, Mauriziano Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serraino</LastName><ForeName>Filiberto Giuseppe</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Shabir Hussain</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Cardiovascular and Thoracic Surgery Department, King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scrofani</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Fondazione Ospedale Maggiore Policlinico IRCCS C&#xe0; Granda, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalisnik</LastName><ForeName>Jurij Matija</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Cardiovascular Center, Klinikum N&#xfc;rnberg, Paracelsus Medical University, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2724-3961</Identifier><AffiliationInfo><Affiliation>Section of Cardiac Surgery, University Hospital, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Claudio Francesco</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranucci</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4915-3572</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettinari</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Ziekenhuis Oost-Limburg, Genk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalowka</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thielmann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West-German Heart Center, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyns</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khouqeer</LastName><ForeName>Fareed</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obadia</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Louis Pradel Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeken</LastName><ForeName>Udo</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-8128-9659</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Hospital D&#xfc;sseldorf, Heinrich Heine University, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular and Transplant Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naito</LastName><ForeName>Shiho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Heart &amp; Vascular Center Hamburg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musazzi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Circolo Hospital, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1777-2045</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Qual Care Clin Outcomes</MedlineTA><NlmUniqueID>101677796</NlmUniqueID><ISSNLinking>2058-1742</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018658" MajorTopicYN="N">Ventricular Septal Rupture</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Free-wall rupture</Keyword><Keyword MajorTopicYN="N">Mechanical complications</Keyword><Keyword MajorTopicYN="N">Papillary muscle rupture</Keyword><Keyword MajorTopicYN="N">Surgical treatment</Keyword><Keyword MajorTopicYN="N">Ventricular septal rupture</Keyword></KeywordList><CoiStatement>M.D.B. reported consulting for Abbott and Medtronic until 2020. T.F. reported consulting for LivaNova outside the submitted work. N.B. reported receiving grants and personal fees from Edwards Lifesciences, personal fees from Medtronic, and grants from LivaNova outside the submitted work. M.R. reported consulting for LivaNova and Medtronic outside the submitted work. P.S. reported receiving speakers&#x2019; fees from Atricure outside the submitted work. T.F. reported consulting for LivaNova and BioStable outside the submitted work. B.M. reported receiving grants from Abiomed outside the submitted work. J.-F.O. reported receiving grants from Abbott and Carmat and receiving personal fees from Delacroix Chevalier, Landanger, and Medtronic during the conduct of the study. R.L. reported being the principal investigator of the Perceval Sutureless Implant vs. Standard Aortic Valve Replacement (PERSIST-AVR) Study, sponsored by LivaNova, and consulting for Medtronic, LivaNova, and Eurosets with all honoraria paid to the University. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>19</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>3</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38327179</ArticleId><ArticleId IdType="pmc">PMC11656062</ArticleId><ArticleId IdType="doi">10.1093/ehjqcco/qcae010</ArticleId><ArticleId IdType="pii">7603375</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>French &#xa0;JK, Hellkamp &#xa0;AS, Armstrong &#xa0;PW, Cohen &#xa0;E, Kleiman &#xa0;NS, O'Connor &#xa0;CM &#xa0;et al. &#xa0;Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). Am J Cardiol &#xa0;2010;105:59&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">20102891</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbadawi &#xa0;A, Elgendy &#xa0;IY, Mahmoud &#xa0;K, Barakat &#xa0;AF, Mentias &#xa0;A, Mohamed &#xa0;AH &#xa0;et al. &#xa0;Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. JACC Cardiovasc Interv &#xa0;2019;12:1825&#x2013;1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">31537282</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueras &#xa0;J, Alcalde &#xa0;O, Barrab&#xe9;s &#xa0;JA, Serra &#xa0;V, Alguersuari &#xa0;J, Cortadellas &#xa0;J &#xa0;et al. &#xa0;Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation &#xa0;2008;118:2783&#x2013;2789</Citation><ArticleIdList><ArticleId IdType="pubmed">19064683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitahara &#xa0;S, Fujino &#xa0;M, Honda &#xa0;S, Asaumi &#xa0;Y, Kataoka &#xa0;Y, Otsuka &#xa0;F &#xa0;et al. &#xa0;COVID-19 pandemic is associated with mechanical complications in patients with ST-elevation myocardial infarction. Open Heart &#xa0;2021;8:e001497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7871043</ArticleId><ArticleId IdType="pubmed">33547221</ArticleId></ArticleIdList></Reference><Reference><Citation>Damluji &#xa0;AA, van Diepen &#xa0;S, Katz &#xa0;JN, Menon &#xa0;V, Tamis-Holland &#xa0;JE, Bakitas &#xa0;M &#xa0;et al. &#xa0;American Heart Association Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Surgery and Anesthesia; and Council on Cardiovascular and Stroke Nursing. Mechanical complications of acute myocardial infarction: a scientific statement from the American Heart Association. Circulation &#xa0;2021;144:e16&#x2013;e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9364424</ArticleId><ArticleId IdType="pubmed">34126755</ArticleId></ArticleIdList></Reference><Reference><Citation>Puerto &#xa0;E, Viana-Tejedor &#xa0;A, Mart&#xed;nez-Sell&#xe9;s &#xa0;M, Dom&#xed;nguez-P&#xe9;rez &#xa0;L, Moreno &#xa0;G, Mart&#xed;n-Asenjo &#xa0;R &#xa0;et al. &#xa0;Temporal trends in mechanical complications of acute myocardial infarction in the elderly. J Am Coll Cardiol &#xa0;2018;72:959&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">30139440</ArticleId></ArticleIdList></Reference><Reference><Citation>Giblett &#xa0;JP, Matetic &#xa0;A, Jenkins &#xa0;D, Ng &#xa0;CY, Venuraju &#xa0;S, MacCarthy &#xa0;T &#xa0;et al. &#xa0;Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry. Eur Heart J &#xa0;2022;43:5020&#x2013;5032.</Citation><ArticleIdList><ArticleId IdType="pubmed">36124729</ArticleId></ArticleIdList></Reference><Reference><Citation>Matteucci &#xa0;M, Ronco &#xa0;D, Ravaux &#xa0;JM, Massimi &#xa0;G, Di Mauro &#xa0;M, Houterman &#xa0;S &#xa0;et al. &#xa0;Surgical repair of post-infarction ventricular free-wall rupture in the Netherlands: data from a nationwide registry. Ann Cardiothorac Surg &#xa0;2022;11:310&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9207691</ArticleId><ArticleId IdType="pubmed">35733708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilic &#xa0;A, Sultan &#xa0;I, Chu &#xa0;D, Wang &#xa0;Y, Gleason &#xa0;TG. Mitral valve surgery for papillary muscle rupture: outcomes in 1342 patients from the society of thoracic surgeons database. Ann Thorac Surg &#xa0;2020;110:1975&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pubmed">32376352</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong &#xa0;FF, Vaitenas &#xa0;I, Malaisrie &#xa0;SC, Maganti &#xa0;K. Mechanical complications of acute myocardial infarction: a review. JAMA Cardiol &#xa0;2021;6:341&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">33295949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco &#xa0;D, Matteucci &#xa0;M, Ravaux &#xa0;JM, Marra &#xa0;S, Torchio &#xa0;F, Corazzari &#xa0;C &#xa0;et al. &#xa0;Mechanical circulatory support as a bridge to definitive treatment in post-infarction ventricular septal rupture. JACC Cardiovasc Interv &#xa0;2021;14:1053&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">34016403</ArticleId></ArticleIdList></Reference><Reference><Citation>Matteucci &#xa0;M, Fina &#xa0;D, Jiritano &#xa0;F, Meani &#xa0;P, Raffa &#xa0;GM, Kowalewski &#xa0;M &#xa0;et al. &#xa0;The use of extracorporeal membrane oxygenation in the setting of postinfarction mechanical complications: outcome analysis of the Extracorporeal Life Support Organization Registry. Interact Cardiovasc Thorac Surg &#xa0;2020;31:369&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">32728712</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef &#xa0;S, Sultan &#xa0;I, VonVille &#xa0;HM, Kahru &#xa0;K, Arnaoutakis &#xa0;GJ. Surgical management for mechanical complications of acute myocardial infarction: a systematic review of long-term outcomes. Ann Cardiothorac Surg &#xa0;2022;11:239&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9207694</ArticleId><ArticleId IdType="pubmed">35733723</ArticleId></ArticleIdList></Reference><Reference><Citation>Formica &#xa0;F, Mariani &#xa0;S, Singh &#xa0;G, D'Alessandro &#xa0;S, Messina &#xa0;LA, Jones &#xa0;N &#xa0;et al. &#xa0;Postinfarction left ventricular free wall rupture: a 17-year single-centre experience. Eur J Cardiothorac Surg &#xa0;2018;53:150&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">28977576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouma &#xa0;W, Wijdh-den Hamer &#xa0;IJ, Koene &#xa0;BM, Kuijpers &#xa0;M, Natour &#xa0;E, Erasmus &#xa0;ME &#xa0;et al. &#xa0;Long-term survival after mitral valve surgery for post-myocardial infarction papillary muscle rupture. J Cardiothorac Surg &#xa0;2015;10:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320582</ArticleId><ArticleId IdType="pubmed">25622516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzgruber &#xa0;P, El-Hamid &#xa0;F, Koller &#xa0;L, Forster &#xa0;S, Goliasch &#xa0;G, Wojta &#xa0;J &#xa0;et al. &#xa0;Long-term outcome and risk prediction in patients suffering acute myocardial infarction complicated by post-infarction cardiac rupture. Int J Cardiol &#xa0;2017;227:399&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">27847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez &#xa0;EJ, Lee &#xa0;KL, Jones &#xa0;RH, Al-Khalidi &#xa0;HR, Hill &#xa0;JA, Panza &#xa0;JA &#xa0;et al. &#xa0;Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med &#xa0;2016;374:1511&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4938005</ArticleId><ArticleId IdType="pubmed">27040723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco &#xa0;D, Corazzari &#xa0;C, Matteucci &#xa0;M, Massimi &#xa0;G, Di Mauro &#xa0;M, Ravaux &#xa0;JM &#xa0;et al. &#xa0;Effects of concomitant coronary artery bypass grafting on early and late mortality in the treatment of post-infarction mechanical complications: a systematic review and meta-analysis. Ann Cardiothorac Surg &#xa0;2022;11:210&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9207702</ArticleId><ArticleId IdType="pubmed">35733718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouma &#xa0;W, Wijdh-den Hamer &#xa0;IJ, Klinkenberg &#xa0;TJ, Kuijpers &#xa0;M, Bijleveld &#xa0;A, van der Horst &#xa0;IC &#xa0;et al. &#xa0;Mitral valve repair for post-myocardial infarction papillary muscle rupture. Eur J Cardiothorac Surg &#xa0;2013;44:1063&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858020</ArticleId><ArticleId IdType="pubmed">23520228</ArticleId></ArticleIdList></Reference><Reference><Citation>Athanasiou &#xa0;T, Chow &#xa0;A, Rao &#xa0;C, Aziz &#xa0;O, Siannis &#xa0;F, Ali &#xa0;A &#xa0;et al. &#xa0;Preservation of the mitral valve apparatus: evidence synthesis and critical reappraisal of surgical techniques. Eur J Cardiothorac Surg &#xa0;2008;33:391&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">18249001</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelvecchio &#xa0;S, Parolari &#xa0;A, Garatti &#xa0;A, Gagliardotto &#xa0;P, Mossuto &#xa0;E, Canziani &#xa0;A &#xa0;et al. &#xa0;Surgical ventricular restoration plus mitral valve repair in patients with ischaemic heart failure: risk factors for early and mid-term outcomes. Eur J Cardiothorac Surg &#xa0;2016;49:e72&#x2013;e78.</Citation><ArticleIdList><ArticleId IdType="pubmed">26819293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25698226</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><JournalIssue CitedMedium="Internet"><Volume>125</Volume><Issue>3</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Polskie Archiwum Medycyny Wewnetrznej</Title><ISOAbbreviation>Pol Arch Med Wewn</ISOAbbreviation></Journal><ArticleTitle>Intraaortic balloon pump in patients with cardiogenic shock complicating myocardial infarction: a systematic review and meta-analysis of randomized trials.</ArticleTitle><Pagination><StartPage>181</StartPage><EndPage>190</EndPage><MedlinePgn>181-90</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">AOP_15_019</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cardiogenic shock is associated with significant mortality, particularly when caused by myocardial infarction. Intraaortic balloon pump (IABP) is the primary hemodynamic adjunct in patients with cardiogenic shock; however, evidence suggests that IABP may not improve mortality in this population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted an electronic search of the Medline, EMBASE, and Cochrane trial registry databases. Two reviewers independently screened citations and identified eligible trials. The same reviewers abstracted data independently. We pooled the data using a fixed effect model and reported dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CIs). Subsequently, we used the GRADE approach to judge the quality of evidence.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 4 randomized trials with 735 patients. The use of IABP did not reduce the risk of death in patients with cardiogenic shock secondary to cardiac ischemia when compared with usual care (RR, 0.94; 95% CI, 0.79-1.13; P = 0.52; I&#xb2; = 0%; moderate confidence). The use of IABP was not associated with an increased risk of stroke (RR, 0.77; 95% CI 0.22-2.69; P = 0.68; I&#xb2; = 48%; very low confidence), limb ischemia (RR, 1.24; 95% CI, 0.59-2.59; P = 0.58; I&#xb2; = 0%; low confidence), or major bleeding (RR, 0.76; 95% CI, 0.34-1.72; P = 0.52; I&#xb2; = 0%; low confidence).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of IABP in patients with cardiogenic shock complicating myocardial ischemia does not reduce mortality (moderate confidence) and is not associated with a higher risk of complications (very low to low confidence). The results should be interpreted with caution owing to limitations such as imprecision, risk of bias, and clinical heterogeneity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altayyar</LastName><ForeName>Sultan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Al-Omari</LastName><ForeName>Awad</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Alqahtani</LastName><ForeName>Abdulrahman M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Rochwerg</LastName><ForeName>Bram</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Alnasser</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Alqahtani</LastName><ForeName>Zuhoor</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Fox-Robichaud</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Alhazzani</LastName><ForeName>Waleed</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Pol Arch Med Wewn</MedlineTA><NlmUniqueID>0401225</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25698226</ArticleId><ArticleId IdType="doi">10.20452/pamw.2713</ArticleId><ArticleId IdType="pii">AOP_15_019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37642192</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0844</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European journal of heart failure</Title><ISOAbbreviation>Eur J Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Early left atrial venting versus conventional treatment for left ventricular decompression during venoarterial extracorporeal membrane oxygenation support: The EVOLVE-ECMO randomized clinical trial.</ArticleTitle><Pagination><StartPage>2037</StartPage><EndPage>2046</EndPage><MedlinePgn>2037-2046</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ejhf.3014</ELocationID><Abstract><AbstractText Label="AIMS">Few studies have reported data on the optimal timing of left ventricular (LV) unloading during venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiac arrest or shock. This study evaluated the feasibility of an early LV unloading strategy compared with a conventional strategy in VA-ECMO.</AbstractText><AbstractText Label="METHODS AND RESULTS">Between December 2018 and August 2022, 60 patients at two institutions were randomized in a 1:1 ratio to receive early (n&#x2009;=&#x2009;30) or conventional (n&#x2009;=&#x2009;30) LV unloading strategies. The early LV unloading strategy was defined as LV unloading performed at the time of VA-ECMO insertion. LV unloading was performed using a percutaneous transseptal left atrial cannulation via the femoral vein incorporated into the ECMO venous circuit. The early and conventional LV unloading groups included 29 (96.7%) and 23 (76.7%) patients, respectively (median time from VA-ECMO insertion to LV unloading: 48.4&#x2009;h, interquartile range 47.8-96.5&#x2009;h). The groups showed no significant differences in the rate of VA-ECMO weaning as the primary endpoint (70.0% vs. 76.7%; relative risk 0.91; 95% confidence interval 0.67-1.24; p&#x2009;=&#x2009;0.386) and survival to discharge (53.3% vs. 50.0%, p&#x2009;=&#x2009;0.796). However, the pulmonary congestion score index at 48&#x2009;h after LV unloading was significantly improved only in the early LV unloading group (2.0&#x2009;&#xb1;&#x2009;0.7 vs. 1.7&#x2009;&#xb1;&#x2009;0.6 at baseline vs. at 48&#x2009;h; p&#x2009;=&#x2009;0.008).</AbstractText><AbstractText Label="CONCLUSIONS">Compared with the conventional approach, early LV unloading did not improve the VA-ECMO weaning rate, despite the rapid improvement in pulmonary congestion. Therefore, the results of this study do not support the application of this strategy after VA-ECMO insertion.</AbstractText><CopyrightInformation>&#xa9; 2023 European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hanbit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jeong Hoon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Jung-Min</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Do-Yoon</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Pil Hyung</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae Oh</ForeName><Initials>TO</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ki Hong</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Pil Je</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Sung-Ho</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Sung-Cheol</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Duk-Woo</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Whan</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seung-Jung</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min-Seok</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-0860-3650</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2018IT0646</GrantID><Agency>Asan Institute for Life Sciences, Asan Medical Center</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Heart Fail</MedlineTA><NlmUniqueID>100887595</NlmUniqueID><ISSNLinking>1388-9842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Heart Fail. 2023 Nov;25(11):2047-2049. doi: 10.1002/ejhf.3045.</RefSource><PMID Version="1">37771278</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006325" MajorTopicYN="N">Heart Atria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011654" MajorTopicYN="Y">Pulmonary Edema</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003664" MajorTopicYN="N">Decompression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Catheters</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Heart transplantation</Keyword><Keyword MajorTopicYN="N">Pulmonary oedema</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37642192</ArticleId><ArticleId IdType="doi">10.1002/ejhf.3014</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in cardiogenic shock. Eur Heart J 2013;35:156-167. https://doi.org/10.1093/eurheartj/eht248</Citation></Reference><Reference><Citation>Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, et al.; Society for Cardiovascular Angiography and Interventions (SCAI); Heart Failure Society of America (HFSA); Society of Thoracic Surgeons (STS); American Heart Association (AHA), and American College of Cardiology (ACC). 2015 SCAI/ACC/HFSA/STS Clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; affirmation of value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'Intervention. J Am Coll Cardiol 2015;65:e7-e26. https://doi.org/10.1016/j.jacc.2015.03.036</Citation></Reference><Reference><Citation>Chen YS, Lin JW, Yu HY, Ko WJ, Jerng JS, Chang WT, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: An observational study and propensity analysis. Lancet 2008;372:554-561. https://doi.org/10.1016/s0140-6736(08)60958-7</Citation></Reference><Reference><Citation>Lim JH, Lee SY, Ju MH, Kim SH, Choi JH, Chon MK, et al. Direct extracorporeal membrane oxygenation bridged heart transplantation: The importance of multi-organ failure. Int J Heart Fail 2023;5:91-99. https://doi.org/10.36628/ijhf.2023.0013</Citation></Reference><Reference><Citation>Wayangankar SA, Bangalore S, McCoy LA, Jneid H, Latif F, Karrowni W, et al. Temporal trends and outcomes of patients undergoing percutaneous coronary interventions for cardiogenic shock in the setting of acute myocardial infarction: A report from the CathPCI Registry. JACC Cardiovasc Interv 2016;9:341-351. https://doi.org/10.1016/j.jcin.2015.10.039</Citation></Reference><Reference><Citation>Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: A meta-analysis of 1,866 adult patients. Ann Thorac Surg 2014;97:610-616. https://doi.org/10.1016/j.athoracsur.2013.09.008</Citation></Reference><Reference><Citation>Truby LK, Takeda K, Mauro C, Yuzefpolskaya M, Garan AR, Kirtane AJ, et al. Incidence and implications of left ventricular distention during venoarterial extracorporeal membrane oxygenation support. ASAIO J 2017;63:257-265. https://doi.org/10.1097/mat.0000000000000553</Citation></Reference><Reference><Citation>Hlavacek AM, Atz AM, Bradley SM, Bandisode VM. Left atrial decompression by percutaneous cannula placement while on extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2005;130:595-596. https://doi.org/10.1016/j.jtcvs.2004.12.029</Citation></Reference><Reference><Citation>Guirgis M, Kumar K, Menkis AH, Freed DH. Minimally invasive left-heart decompression during venoarterial extracorporeal membrane oxygenation: An alternative to a percutaneous approach. Interact Cardiovasc Thorac Surg 2010;10:672-674. https://doi.org/10.1510/icvts.2009.228346</Citation></Reference><Reference><Citation>Aso S, Matsui H, Fushimi K, Yasunaga H. The effect of intraaortic balloon pumping under venoarterial extracorporeal membrane oxygenation on mortality of cardiogenic patients: An analysis using a nationwide inpatient database. Crit Care Med 2016;44:1974-1979. https://doi.org/10.1097/ccm.0000000000001828</Citation></Reference><Reference><Citation>Schrage B, Burkhoff D, R&#xfc;bsamen N, Becher PM, Schwarzl M, Bernhardt A, et al. Unloading of the left ventricle during venoarterial extracorporeal membrane oxygenation therapy in cardiogenic shock. JACC Heart Fail 2018;6:1035-1043. https://doi.org/10.1016/j.jchf.2018.09.009</Citation></Reference><Reference><Citation>Russo JJ, Aleksova N, Pitcher I, Couture E, Parlow S, Faraz M, et al. Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol 2019;73:654-662. https://doi.org/10.1016/j.jacc.2018.10.085</Citation></Reference><Reference><Citation>Schrage B, Becher PM, Bernhardt A, Bezerra H, Blankenberg S, Brunner S, et al. Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: Results from an international, multicenter cohort study. Circulation 2020;142:2095-2106. https://doi.org/10.1161/circulationaha.120.048792</Citation></Reference><Reference><Citation>Na SJ, Yang JH, Yang JH, Sung K, Choi JO, Hahn JY, et al. Left heart decompression at venoarterial extracorporeal membrane oxygenation initiation in cardiogenic shock: Prophylactic versus therapeutic strategy. J Thorac Dis 2019;11:3746-3756. https://doi.org/10.21037/jtd.2019.09.35</Citation></Reference><Reference><Citation>Grandin EW, Nunez JI, Willar B, Kennedy K, Rycus P, Tonna JE, et al. Mechanical left ventricular unloading in patients undergoing venoarterial extracorporeal membrane oxygenation. J Am Coll Cardiol 2022;79:1239-1250. https://doi.org/10.1016/j.jacc.2022.01.032</Citation></Reference><Reference><Citation>Kobayashi M, Bercker M, Huttin O, Pierre S, Sadoul N, Bozec E, et al. Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study. Int J Cardiol 2020;299:192-198. https://doi.org/10.1016/j.ijcard.2019.06.062</Citation></Reference><Reference><Citation>Kobayashi M, Douair A, Duarte K, Jaeger D, Giacomin G, Bassand A, et al. Diagnostic performance of congestion score index evaluated from chest radiography for acute heart failure in the emergency department: A retrospective analysis from the PARADISE cohort. PLoS Med 2020;17:e1003419. https://doi.org/10.1371/journal.pmed.1003419</Citation></Reference><Reference><Citation>Kobayashi M, Watanabe M, Coiro S, Bercker M, Paku Y, Iwasaki Y, et al. Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. Int J Cardiol 2019;289:91-98. https://doi.org/10.1016/j.ijcard.2019.01.091</Citation></Reference><Reference><Citation>Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol 2012;65:301-308. https://doi.org/10.1016/j.jclinepi.2011.07.011</Citation></Reference><Reference><Citation>Kowalewski M, Malvindi PG, Zieli&#x144;ski K, Martucci G, S&#x142;omka A, Suwalski P, et al. Left ventricle unloading with veno-arterial extracorporeal membrane oxygenation for cardiogenic shock. Systematic review and meta-analysis. J Clin Med 2020;9:1039. https://doi.org/10.3390/jcm9041039</Citation></Reference><Reference><Citation>Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, et al. Concomitant implantation of Impella&#xae; on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 2017;19:404-412. https://doi.org/10.1002/ejhf.668</Citation></Reference><Reference><Citation>Kim AR, Park H, Lee SE, Ahn JM, Park DW, Lee SW, et al. Outcomes of left ventricular unloading with a transseptal cannula during extracorporeal membrane oxygenation in adults. Artif Organs 2021;45:390-398. https://doi.org/10.1111/aor.13838</Citation></Reference><Reference><Citation>Schrage B, Sundermeyer J, Blankenberg S, Colson P, Eckner D, Eden M, et al. Timing of active left ventricular unloading in patients on venoarterial extracorporeal membrane oxygenation therapy. JACC Heart Fail 2023;11:321-330. https://doi.org/10.1016/j.jchf.2022.11.005</Citation></Reference><Reference><Citation>Abrams D, MacLaren G, Lorusso R, Price S, Yannopoulos D, Vercaemst L, et al. Extracorporeal cardiopulmonary resuscitation in adults: Evidence and implications. Intensive Care Med 2022;48:1-15. https://doi.org/10.1007/s00134-021-06514-y</Citation></Reference><Reference><Citation>Roumy A, Liaudet L, Rusca M, Marcucci C, Kirsch M. Pulmonary complications associated with veno-arterial extra-corporeal membrane oxygenation: A comprehensive review. Crit Care 2020;24:212. https://doi.org/10.1186/s13054-020-02937-z</Citation></Reference><Reference><Citation>Klompas M. Complications of mechanical ventilation&#xa0;-&#xa0;The CDC's new surveillance paradigm. N Engl J Med 2013;368:1472-1475. https://doi.org/10.1056/NEJMp1300633</Citation></Reference><Reference><Citation>Klompas M. Potential strategies to prevent ventilator-associated events. Am J Respir Crit Care Med 2015;192:1420-1430. https://doi.org/10.1164/rccm.201506-1161CI</Citation></Reference><Reference><Citation>Bertaina M, Galluzzo A, Rossello X, Sbarra P, Petitti E, Prever SB, et al. Prognostic implications of pulmonary artery catheter monitoring in patients with cardiogenic shock: A systematic review and meta-analysis of observational studies. J Crit Care 2022;69:154024. https://doi.org/10.1016/j.jcrc.2022.154024</Citation></Reference><Reference><Citation>Chow JY, Vadakken ME, Whitlock RP, Koziarz A, Ainsworth C, Amin F, et al. Pulmonary artery catheterization in patients with cardiogenic shock: A systematic review and meta-analysis. Can J Anaesth 2021;68:1611-1629. https://doi.org/10.1007/s12630-021-02083-2</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35360892</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of cardiology. Heart &amp; vasculature</Title><ISOAbbreviation>Int J Cardiol Heart Vasc</ISOAbbreviation></Journal><ArticleTitle>Use of Impella device in cardiogenic shock and its clinical outcomes: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>101007</StartPage><MedlinePgn>101007</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101007</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcha.2022.101007</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Cardiogenic shock (CS) is a life-threatening condition and mechanical circulatory support (MCS) might exert a relevant impact on its clinical course. Among MCS devices, Impella is very promising. Yet, its usefulness is still debated. We performed a meta-analysis of all studies evaluating the clinical impact of Impella in CS.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">All studies including patients with CS and treated with Impella were included. The primary endpoint was short-term mortality. Secondary endpoints were vascular access complications and major bleeding. Data synthesis was obtained using random-effects metanalysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Thirty-three studies and 5204 patients were included. Short-term mortality was 47%. Meta-regression analysis showed that patients age (p&#xa0;=&#xa0;0.01), higher support level (p&#xa0;=&#xa0;0.004) and pre-PCI insertion (p&#xa0;&lt;&#xa0;0.001) were significant moderators for the primary endpoint. Vascular access complications were registered in 6.4% of cases, whereas age (p&#xa0;=&#xa0;0.05) and diabetes (p&#xa0;=&#xa0;0.007) were significant predictors. Major bleeding occurred in 16.4% of patients. Meta-analysis of the subgroup of studies comparing Impella to IABP showed no significant difference in short-term mortality (RR&#xa0;=&#xa0;1.08, p&#xa0;=&#xa0;0.45), while rates of vascular access complications (p&#xa0;&lt;&#xa0;0.001) or major bleeding (p&#xa0;&lt;&#xa0;0.001) were significantly higher with Impella. Subgroup and metaregression analyses showed that these results were influenced by lower adoption rates of higher degree of MCS support (p&#xa0;=&#xa0;0.003), and by higher vascular complications rates (p&#xa0;=&#xa0;0.014).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our results suggest that the choice of adequate device size, careful patients selection and optimal timing of MCS initiation are key to clinical success with Impella in CS. Large prospective studies are mandatory to confirm these results deriving from retrospective studies.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panuccio</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neri</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macr&#xec;</LastName><ForeName>Lucrezia Maria</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salerno</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Rosa</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torella</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Cardiol Heart Vasc</MedlineTA><NlmUniqueID>101649525</NlmUniqueID><ISSNLinking>2352-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Hemodynamic support</Keyword><Keyword MajorTopicYN="N">IABP</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword></KeywordList><CoiStatement>The authors report no relationships that could be construed as a conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35360892</ArticleId><ArticleId IdType="pmc">PMC8961185</ArticleId><ArticleId IdType="doi">10.1016/j.ijcha.2022.101007</ArticleId><ArticleId IdType="pii">S2352-9067(22)00056-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chioncel O., et al. Epidemiology, patophysiology and contemporary management of cardiogenic shock- a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2020;22:1315&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">32469155</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahdatpour C., et al. Cardiogenic Shock. J. Am. Heart Assoc. 2019;8(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6507212</ArticleId><ArticleId IdType="pubmed">30947630</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., et al. Management of cardiogenic shock. EuroIntervention. 2021;17(6):451&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9724885</ArticleId><ArticleId IdType="pubmed">34413010</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., et al. Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock. N. Engl. J. Med. 2012;367(14):1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N. Engl. J. Med. 2017;377(25):2419&#x2013;2432.</Citation><ArticleIdList><ArticleId IdType="pubmed">29083953</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazdernik M., et al. Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub. 2021;165(3):291&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">34421120</ArticleId></ArticleIdList></Reference><Reference><Citation>Redfors B., et al. 17-year trends in incidence and prognosis of cardiogenic shock in patients with acute myocardial infarction in western Sweden. Int. J. Cardiol. 2015;185:256&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">25814213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wayangankar S.A., et al. Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry. JACC: Cardiovas. Intervent. 2016;9(4):341&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">26803418</ArticleId></ArticleIdList></Reference><Reference><Citation>Werdan K., et al. Mechanical circulatory support in cardiogenic shock. Eur. Heart J. 2014;35(3):156&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">24014384</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahuja M., Hernandez-Montfort J., Whitehead E.H., Kawabori M., Kapur N.K. Device profile of the Impella 5.0 and 5.5 system for mechanical circulatory support for patients with cardiogenic shock: overview of its safety and efficacy. Expert Rev. Med. Devices. 2021:1&#x2013;10. doi: 10.1080/17434440.2022.2015323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17434440.2022.2015323</ArticleId><ArticleId IdType="pubmed">34894975</ArticleId></ArticleIdList></Reference><Reference><Citation>Glazier J.J., Kaki A. The Impella Device: Historical Background, Clinical Applications and Future Directions. Int. J. Angiol. 2019;28(2):118&#x2013;123. doi: 10.1055/s-0038-1676369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1676369</ArticleId><ArticleId IdType="pmc">PMC6679960</ArticleId><ArticleId IdType="pubmed">31384109</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill W.W., et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126(14):1717&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pubmed">22935569</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill W.W., et al. Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. Am. Heart J. 2018;202:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803984</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., et al. Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement. Lancet. 1999;354:1896&#x2013;1900.</Citation><ArticleIdList><ArticleId IdType="pubmed">10584742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Hern&#xe1;n M.A., Reeves B.C., Savovi&#x107; J., Berkman N.D., Viswanathan M., Henry D., Altman D.G., Ansari M.T., Boutron I., Carpenter J.R., Chan A.W., Churchill R., Deeks J.J., Hr&#xf3;bjartsson A., Kirkham J., J&#xfc;ni P., Loke Y.K., Pigott T.D., Ramsay C.R., Regidor D., Rothstein H.R., Sandhu L., Santaguida P.L., Sch&#xfc;nemann H.J., Shea B., Shrier I., Tugwell P., Turner L., Valentine J.C., Waddington H., Waters E., Wells G.A., Whiting P.F., Higgins J.P.T. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355 doi: 10.1136/bmj.i4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S., Polimeni A., Petraco R., Davies J.E., Indolfi C. Diagnostic performance of the instantaneous wave-free ratio: comparison with fractional flow reserve. Circ. Cardiovasc. Interv. 2018;11(1) doi: 10.1161/CIRCINTERVENTIONS.116.004613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.116.004613</ArticleId><ArticleId IdType="pubmed">29326150</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S., Polimeni A., Sabatino J., Indolfi C. Long-term outcomes of coronary artery bypass grafting versus stent-PCI for unprotected left main disease: a meta-analysis. BMC Cardiovasc. Disord. 2017;17(1):240. doi: 10.1186/s12872-017-0664-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-017-0664-5</ArticleId><ArticleId IdType="pmc">PMC5588710</ArticleId><ArticleId IdType="pubmed">28877676</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran D.A., Grines C.L., Bailey S., Burkhoff D., Hall S.A., Henry T.D., Hollenberg S.M., Kapur N.K., O'Neill W., Ornato J.P., Stelling K., Thiele H., Diepen S., Naidu S.S. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter. Cardiovasc. Interv. 2019 doi: 10.1002/ccd.28329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28329</ArticleId><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B., Becher P.M., Go&#xdf;ling A., Savarese G., Dabboura S., Yan I., Beer B., S&#xf6;ffker G., Seiffert M., Kluge S., Kirchhof P., Blankenberg S., Westermann D. Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. ESC Heart Fail. 2021;8(2):1295&#x2013;1303. doi: 10.1002/ehf2.13202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13202</ArticleId><ArticleId IdType="pmc">PMC8006704</ArticleId><ArticleId IdType="pubmed">33605565</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S., Ya'Qoub L., Kumar V., Verghese D., Subramaniam A.V., Patlolla S.H., Desai V.K., Sundaragiri P.R., Cheungpasitporn W., Deshmukh A.J., Kashani K., Barsness G.W. Contemporary National Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Patients with Prior Chronic Kidney Disease and End-Stage Renal Disease. J. Clin. Med. 2020;9(11):3702. doi: 10.3390/jcm9113702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113702</ArticleId><ArticleId IdType="pmc">PMC7698908</ArticleId><ArticleId IdType="pubmed">33218121</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh M.J., et al. Door-to-unload: left ventricular unloading before reperfusion in ST-elevation myocardial infarction. Future Cardiol. 2021;17(4):549&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">33599135</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahdatpour C., Collins D., Goldberg S. Cardiogenic Shock. J. Am. Heart Assoc. 2019;8(8) doi: 10.1161/JAHA.119.011991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.011991</ArticleId><ArticleId IdType="pmc">PMC6507212</ArticleId><ArticleId IdType="pubmed">30947630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno T., Takagi H., Ando T., Kodaira M., Numasawa Y., Fox J., Bangalore S. Safety and efficacy of mechanical circulatory support with Impella or intra-aortic balloon pump for high-risk percutaneous coronary intervention and/or cardiogenic shock: Insights from a network meta-analysis of randomized trials. Catheter. Cardiovasc. Interv. 2021;97(5):E636&#x2013;E645. doi: 10.1002/ccd.29236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29236</ArticleId><ArticleId IdType="pubmed">32894797</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia E., Iannaccone M., D'Ascenzo F., Gallone G., Colombo F., Albani S., Attisani M., Rinaldi M., Boccuzzi G., Conrotto F., Noussan P., De Ferrari G.M. Short term outcomes of Impella circulatory support for high-risk percutaneous coronary intervention a systematic review and meta-analysis. Catheter. Cardiovasc. Interv. 2022;99(1):27&#x2013;36. doi: 10.1002/ccd.29757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29757</ArticleId><ArticleId IdType="pubmed">34028964</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone M., Albani S., Giannini F., Colangelo S., Boccuzzi G.G., Garbo R., Brilakis E.S., D'ascenzo F., de Ferrari G.M., Colombo A. Short term outcomes of Impella in cardiogenic shock: A review and meta-analysis of observational studies. Int. J. Cardiol. 2021;1(324):44&#x2013;51. doi: 10.1016/j.ijcard.2020.09.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.09.044</ArticleId><ArticleId IdType="pubmed">32971148</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32926456</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-8737</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Clinical cardiology</Title><ISOAbbreviation>Clin Cardiol</ISOAbbreviation></Journal><ArticleTitle>Transcatheter vs surgical aortic valve replacement in low to intermediate surgical risk aortic stenosis patients: A systematic review and meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>1414</StartPage><EndPage>1422</EndPage><MedlinePgn>1414-1422</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/clc.23454</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Transcatheter aortic valve replacement (TAVR) is regarded as the most superior alternative treatment approach for patients with aortic stenosis (AS) who are associated with high surgical risk, whereas the effectiveness of TAVR vs surgical aortic valve replacement (SAVR) in low to intermediate surgical risk patients remained inconclusive. This study aimed to determine the best treatment strategies for AS with low to intermediate surgical risk based on published randomized controlled trials (RCTs).</AbstractText><AbstractText Label="HYPOTHESIS AND METHODS" NlmCategory="OBJECTIVE">RCTs that compared TAVR vs SAVR in AS patients with low to intermediate surgical risk were identified by PubMed, EmBase, and the Cochrane library from inception till April 2019. The pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated for the data collected using random-effects models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven RCTs with a total of 6929 AS patients were enrolled. We noted that TAVR significantly increased the risk of transient ischemic attack (TIA) (RR: 1.43; 95%CI: 1.04-1.96; P = .029), and permanent pacemaker implantation (RR: 3.00; 95%CI: 1.70-5.30; P&#x2009;&lt;&#x2009;.001). However, TAVR was associated with lower risk of post-procedural bleeding (RR: 0.57; 95%CI: 0.33-0.98; P = .042), new-onset or worsening of atrial fibrillation (RR: 0.32; 95%CI: 0.23-0.45; P&#x2009;&lt;&#x2009;.001), acute kidney injury (RR: 0.40; 95%CI: 0.25-0.63; P&#x2009;&lt;&#x2009;.001), and cardiogenic shock (RR: 0.34; 95%CI: 0.19-0.59; P&#x2009;&lt;&#x2009;.001). The risk of aortic-valve reintervention at 1- (RR: 2.63; 95%CI: 1.34-5.15; P = .005), and 2&#x2009;years (RR: 3.19; 95%CI: 1.63-6.24; P = .001) in low to intermediate surgical risk patients who received TAVR was significantly increased than those who received SAVR.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings indicated that low to intermediate surgical risk patients who received TAVR had low risk of complications, whereas the risk of TIA, permanent pacemaker implantation, and aortic-valve reintervention was increased.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dengshen</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Daxing</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8288-5911</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Liangliang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cardiol</MedlineTA><NlmUniqueID>7903272</NlmUniqueID><ISSNLinking>0160-9289</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="N">Aortic Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="N">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="N">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aortic stenosis</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">surgical aortic valve replacement</Keyword><Keyword MajorTopicYN="N">surgical risk</Keyword><Keyword MajorTopicYN="N">transcatheter aortic valve replacement</Keyword></KeywordList><CoiStatement>All authors declare that they have no any conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>15</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32926456</ArticleId><ArticleId IdType="pmc">PMC7724228</ArticleId><ArticleId IdType="doi">10.1002/clc.23454</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez&#x2010;Sarano M. Burden of valvular heart diseases: a population&#x2010;based study. Lancet. 2006;368:1005&#x2010;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindroos M, Kupari M, Heikkila J, et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21:1220&#x2010;1225.</Citation><ArticleIdList><ArticleId IdType="pubmed">8459080</ArticleId></ArticleIdList></Reference><Reference><Citation>Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta&#x2010;analysis and modeling study. J Am Coll Cardiol. 2013;62:1002&#x2010;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">23727214</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373:956&#x2010;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">19232707</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2017;135:e1159&#x2010;e1195.</Citation><ArticleIdList><ArticleId IdType="pubmed">28298458</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451&#x2010;2496.</Citation><ArticleIdList><ArticleId IdType="pubmed">22922415</ArticleId></ArticleIdList></Reference><Reference><Citation>Oguri A, Yamamoto M, Mouillet G, et al. Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia: subanalysis of the French aortic national CoreValve and Edwards 2 registry. Circ Cardiovasc Interv. 2014;7:602&#x2010;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006175</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees CM, Eric HO. Should patients with low&#x2010;moderate surgical risk be offered TAVI instead of conventional aortic valve replacement in the management of symptomatic aortic stenosis? Res Medica. 2015;23:15&#x2010;21.</Citation></Reference><Reference><Citation>Liu Z, Kidney E, Bem D, et al. Transcatheter aortic valve implantation for aortic stenosis in high surgical risk patients: a systematic review and meta&#x2010;analysis. PLoS One. 2018;13:e0196877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5944928</ArticleId><ArticleId IdType="pubmed">29746546</ArticleId></ArticleIdList></Reference><Reference><Citation>Villablanca PA, Mathew V, Thourani VH, et al. A meta&#x2010;analysis and meta&#x2010;regression of long&#x2010;term outcomes of transcatheter versus surgical aortic valve replacement for severe aortic stenosis. Int J Cardiol. 2016;225:234&#x2010;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">27732927</ArticleId></ArticleIdList></Reference><Reference><Citation>Siontis GC, Praz F, Pilgrim T, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta&#x2010;analysis of randomized trials. Eur Heart J. 2016;37:3503&#x2010;3512.</Citation><ArticleIdList><ArticleId IdType="pubmed">27389906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo G, Sannino A, Capodanno D, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement: a systematic review and meta&#x2010;analysis. Ann Intern Med. 2016;165:334&#x2010;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">27272666</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T, All&#x2010;Literature Investigation of Cardiovascular Evidence (ALICE) Group . A meta&#x2010;analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement. Ann Thorac Surg. 2013;96:513&#x2010;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">23816417</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group . Preferred reporting items for systematic reviews and meta&#x2010;analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1&#x2010;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta&#x2010;analysis in clinical trials. Control Clin Trials. 1986;7:177&#x2010;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ades AE, Lu G, Higgins JP. The interpretation of random&#x2010;effects meta&#x2010;analysis in decision models. Med Decis Making. 2005;25:646&#x2010;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282215</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta&#x2010;analyses. Oxford, UK: The Cochrane Collaboration; 2008.</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta&#x2010;analyses. BMJ. 2003;327:557&#x2010;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobias A. Assessing the influence of a single study in meta&#x2010;analysis. Stata Tech Bull. 1999;47:15&#x2010;17.</Citation></Reference><Reference><Citation>Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1125071</ArticleId><ArticleId IdType="pubmed">12543843</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, et al. Bias in meta&#x2010;analysis detected by a simple, graphical test. BMJ. 1997;315:629&#x2010;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088&#x2010;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">7786990</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondergaard L, Steinbruchel DA, Ihlemann N, et al. Two&#x2010;year outcomes in patients with severe aortic valve stenosis randomized to Transcatheter versus surgical aortic valve replacement: the all&#x2010;comers Nordic aortic valve intervention randomized clinical trial. Circ Cardiovasc Interv. 2016;9(6):e003665.</Citation><ArticleIdList><ArticleId IdType="pubmed">27296202</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ, Kleiman NS, Adams DH, et al. Outcomes in the randomized CoreValve US pivotal high risk trial in patients with a Society of Thoracic Surgeons risk score of 7% or less. JAMA Cardiol. 2016;1:945&#x2010;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">27541162</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic&#x2010;valve replacement in intermediate&#x2010;risk patients. N Engl J Med. 2016;374:1609&#x2010;1620.</Citation><ArticleIdList><ArticleId IdType="pubmed">27040324</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter aortic&#x2010;valve replacement in intermediate&#x2010;risk patients. N Engl J Med. 2017;376:1321&#x2010;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">28304219</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW, Modolo R, Reardon M, et al. One&#x2010;year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. EuroIntervention. 2018;14:877&#x2010;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">29992904</ArticleId></ArticleIdList></Reference><Reference><Citation>Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic&#x2010;valve replacement with a self&#x2010;expanding valve in low&#x2010;risk patients. N Engl J Med. 2019;380:1706&#x2010;1715.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883053</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic&#x2010;valve replacement with a balloon&#x2010;expandable valve in low&#x2010;risk patients. N Engl J Med. 2019;380:1695&#x2010;1705.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883058</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Strassle PD, Ramm CJ, et al. Transcatheter versus surgical aortic valve replacement in patients with lower surgical risk scores: a systematic review and meta&#x2010;analysis of early outcomes. Heart Lung Circ. 2017;26:840&#x2010;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">28169084</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh K, Carson K, Rashid MK, et al. Transcatheter aortic valve implantation in intermediate surgical risk patients with severe aortic stenosis: a systematic review and meta&#x2010;analysis. Heart Lung Circ. 2018;27:227&#x2010;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">28473216</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AR, Khan S, Riaz H, et al. Efficacy and safety of transcatheter aortic valve replacement in intermediate surgical risk patients: a systematic review and meta&#x2010;analysis. Catheter Cardiovasc Interv. 2016;88:934&#x2010;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">26946091</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SU, Lone AN, Saleem MA, Kaluski E. Transcatheter vs surgical aortic&#x2010;valve replacement in low&#x2010; to intermediate&#x2010;surgical&#x2010;risk candidates: a meta&#x2010;analysis and systematic review. Clin Cardiol. 2017;40:974&#x2010;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490337</ArticleId><ArticleId IdType="pubmed">29168984</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam DY, Vo TX, Wijeysundera HC, et al. Transcatheter vs surgical aortic valve replacement for aortic stenosis in low&#x2010;intermediate risk patients: a meta&#x2010;analysis. Can J Cardiol. 2017;33:1171&#x2010;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">28843328</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmaraezy A, Ismail A, Abushouk AI, et al. Efficacy and safety of transcatheter aortic valve replacement in aortic stenosis patients at low to moderate surgical risk: a comprehensive meta&#x2010;analysis. BMC Cardiovasc Disord. 2017;17:234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5571502</ArticleId><ArticleId IdType="pubmed">28836953</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Rao SV, Visveswaran G, et al. Transcatheter aortic valve replacement versus surgical valve replacement in low&#x2010;intermediate surgical risk patients: a systematic review and meta&#x2010;analysis. J Invasive Cardiol. 2017;29:209&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">28570236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Wang Y, Wu Y, Zhu J. Transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: a meta&#x2010;analysis of randomized and observational studies. Int J Cardiol. 2017;228:723&#x2010;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">27886617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando T, Ashraf S, Villablanca P, et al. Meta&#x2010;analysis of effectiveness and safety of Transcatheter aortic valve implantation versus surgical aortic valve replacement in low&#x2010;to&#x2010;intermediate surgical risk cohort. Am J Cardiol. 2019;124:580&#x2010;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">31200922</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TKM, Wang MTM, Gamble GD, Webster M, Ruygrok PN. Performance of contemporary surgical risk scores for transcatheter aortic valve implantation: a meta&#x2010;analysis. Int J Cardiol. 2017;236:350&#x2010;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">28111053</ArticleId></ArticleIdList></Reference><Reference><Citation>Siontis GC, Juni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta&#x2010;analysis. J Am Coll Cardiol. 2014;64:129&#x2010;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">25011716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34260547</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>28</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Comparison of postprocedural new-onset atrial fibrillation between transcatheter and surgical aortic valve replacement: A systematic review and meta-analysis based on 16 randomized controlled trials.</ArticleTitle><Pagination><StartPage>e26613</StartPage><MedlinePgn>e26613</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e26613</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000026613</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Presently, transcatheter aortic valve replacement (TAVR) as an effective and convenient intervention has been adopted extensively for patients with severe aortic disease. However, after surgical aortic valve replacement (SAVR) and TAVR, the incidence of new-onset atrial fibrillation (NOAF) is prevalently found. This meta-analysis was designed to comprehensively compare the incidence of NOAF at different times after TAVR and SAVR for patients with severe aortic disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search of PubMed, Embase, Cochrane Library, and Web of Science up to October 1, 2020 was conducted for relevant studies that comparing TAVR and SAVR in the treatment of severe aortic disease. The primary outcomes were the incidence of NOAF with early, midterm and long term follow-up. The secondary outcomes included permanent pacemaker (PM) implantation, myocardial infarction (MI), cardiogenic shock, as well as mortality and other complications. Two reviewers assessed trial quality and extracted the data independently. All statistical analyses were performed using the standard statistical procedures provided in Review Manager 5.2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 16 studies including 13,310 patients were identified. The pooled results indicated that, compared with SAVR, TAVR experienced a significantly lower incidence of 30-day/in-hospital, 1-year, 2-year, and 5-year NOAF, with pooled risk ratios (RRs) of 0.31 (95% confidence interval [CI] 0.23-0.41; 5725 pts), 0.30 (95% CI 0.24-0.39; 6321 pts), 0.48 (95% CI 0.38-0.61; 3441 pts), and 0.45 (95% CI 0.37-0.55; 2268 pts) respectively. In addition, TAVR showed lower incidence of MI (RR 0.62; 95% CI 0.40-0.97) and cardiogenic shock (RR 0.34; 95% CI 0.19-0.59), but higher incidence of permanent PM (RR 3.16; 95% CI 1.61-6.21) and major vascular complications (RR 2.22; 95% CI 1.14-4.32) at 30-day/in-hospital. At 1- and 2-year after procedure, compared with SAVR, TAVR experienced a significantly higher incidence of neurological events, transient ischemic attacks (TIA), permanent PM, and major vascular complications, respectively. At 5-year after procedure, compared with SAVR, TAVR experienced a significantly higher incidence of TIA and re-intervention respectively. There was no difference in 30-day, 1-year, 2-year, and 5-year all-cause or cardiovascular mortality as well as stroke between TAVR and SAVR.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our analysis showed that TAVR was superior to SAVR in decreasing the both short and long term postprocedural NOAF. TAVR was equal to SAVR in early, midterm and long term mortality. In addition, TAVR showed lower incidence of 30-day/in-hospital MI and cardiogenic shock after procedure. However, pooled results showed that TAVR was inferior to SAVR in reducing permanent pacemaker implantation, neurological events, TIA, major vascular complications, and re-intervention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Yongmin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Department.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Minmin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Outpatient Department, Zhebei Mingzhou hospital, Huzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hemei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Department.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chunyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Department.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Zhuoyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Medical Department.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="N">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>17</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34260547</ArticleId><ArticleId IdType="pmc">PMC8284731</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000026613</ArticleId><ArticleId IdType="pii">00005792-202107160-00030</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart 2016;102:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">26541169</ArticleId></ArticleIdList></Reference><Reference><Citation>Osnabrugge RL, Mylotte D, Head SJ, et al. . Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 2013;62:1002&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23727214</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner H, Falk V, Bax JJ, et al. . 2017&#x200a;ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura RA, Otto CM, Bonow RO, et al. . 2014&#x200a;AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e57&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">24603191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleason TG, Reardon MJ, Popma JJ, et al. . 5-Year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol 2018;72:2687&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">30249462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D, Vlahakes JJ, Palacios IF, et al. . Transcatheter versus surgical aortic valve replacement in low-risk patients. J Am Coll Cardiol 2019;74:1532&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">31537261</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon MB, Smith CR, Mack MJ, et al. . Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">27040324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack MJ, Leon MB, Thourani VH, et al. . Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura RA, Otto CM, Bonow RO, et al. . 2017&#x200a;AHA/ACC focused update of the 2014&#x200a;AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2017;135:e1159&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">28298458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks D, Baxter B, Campbell BCV, et al. . Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke 2018;13:612&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">29786478</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ, Van Miegham NM, Popma JJ, et al. . Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017;376:1321&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28304219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarantini G, Mojoli M, Urena M, Vahanian A. Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. Eur Heart J 2017;38:1285&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">27744287</ArticleId></ArticleIdList></Reference><Reference><Citation>Vavuranakis M, Kolokathis AM, Vrachatis DA, et al. . Atrial fibrillation during or after TAVI: incidence, implications and therapeutical considerations. Curr Pharm Des 2016;22:1896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">26642773</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen TH, Thygesen JB, Thyregod HG, Svendsen JH, Sondergaard L. New-onset atrial fibrillation after surgical aortic valve replacement and transcatheter aortic valve implantation: a concise review. J Invasive Cardiol 2015;27:41&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25589700</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark HD, Hu&#xeb;t WG, McAlister C, Salmi FA, Fergusson LRD. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999;20:448&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10503804</ArticleId></ArticleIdList></Reference><Reference><Citation>Review Manager (RevMan) [Computer Program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.</Citation></Reference><Reference><Citation>Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382404</ArticleId></ArticleIdList></Reference><Reference><Citation>University of York Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: CRD, University of York, 2009.</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45(pt A):139&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639420</ArticleId><ArticleId IdType="pubmed">26343745</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">13655060</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea BJ, Reeves BC, Wells G, et al. . AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference><Reference><Citation>Popma JJ, Deeb GM, Yakubov SJ, et al. . Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883053</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen TH, Thyregod HGH, Tarp JB, Svendsen JH, Sondergaard L. Temporal changes of new-onset atrial fibrillation in patients randomized to surgical or transcatheter aortic valve replacement. Int J Cardiol 2017;234:16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258844</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyregod HGH, Ihlemann N, Jorgensen TH, et al. . Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">30704298</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen HH, Charitos EI, Charitos EI, et al. . A prospective, randomised trial of transapical transcatheter aortic valve implantation vs. surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trial. EuroIntervention 2012;8:383&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22581299</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DC, Blackstone EH, Mack MJ, et al. . Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg 2012;143:832&#x2013;43. e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424519</ArticleId></ArticleIdList></Reference><Reference><Citation>Motloch LJ, Reda S, Rottlaender D, et al. . Postprocedural atrial fibrillation after transcatheter aortic valve implantation versus surgical aortic valve replacement. Ann Thorac Surg 2012;93:124&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">22115334</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack MJ, Leon MB, Smith CR, et al. . 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015;385:2477&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25788234</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW, Modolo R, Reardon M, et al. . One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. EuroIntervention 2018;14:877&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">29992904</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;ndergaard L, Steinbruchel DA, Ihlemann N, et al. . Two-year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: the all-comers Nordic Aortic Valve Intervention randomized clinical trial. Circ Cardiovasc Interv 2016;9:06.</Citation><ArticleIdList><ArticleId IdType="pubmed">27296202</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ, Adams DH, Kleiman NS, et al. . 2-Year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol 2015;66:113&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26055947</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkar RR, Charitos EI, Charitos EI, et al. . Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382:799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">31995682</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ, Leon MB, Smith CR, et al. . Outcomes in the randomized corevalve US pivotal high risk trial in patients with a society of thoracic surgeons risk score of 7% or less. JAMA Cardiol 2016;1:945&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27541162</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyregod HG, Steinbruchel DA, Ihlemann N, et al. . Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 2015;65:2184&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25787196</ArticleId></ArticleIdList></Reference><Reference><Citation>Pibarot P, Salaun E, Dahou A, et al. . Echocardiographic results of transcatheter versus surgical aortic valve replacement in low-risk patients: The PARTNER 3 Trial. Circulation 2020;141:1527&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">32272848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan GH, Zidar DA, Josephson RA, Al-Kindi SG. Mortality due to aortic stenosis in the United States, 2008-2017. JAMA 2019;321:2236&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563552</ArticleId><ArticleId IdType="pubmed">31184728</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart BF, Siscovick S, Lind BK, et al. . Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9060903</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SU, Riaz H, Khan MU, et al. . Meta-analysis of temporal and surgical risk dependent associations with outcomes after transcatheter versus surgical aortic valve implantation. Am J Cardiol 2019;124:1608&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453964</ArticleId><ArticleId IdType="pubmed">31521258</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves A, Nyman C, Okada DR, et al. . Transthoracic echocardiography to assess aortic regurgitation after TAVR: a comparison with periprocedural transesophageal echocardiography. Cardiology 2017;137:01&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27925612</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker CM, Reardon MJ. Should TAVR replace surgery for aortic stenosis in low- to intermediate-risk patients? Can J Cardiol 2017;33:1124&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28843323</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Abdouh A, Upadhrasta S, Fashanu O, et al. . Transcatheter aortic valve replacement in low-risk patients: a meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 2020;21:461&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31447314</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J, Popal MS, Li Y, et al. . Transcatheter versus surgical aortic valve replacement in low and intermediate risk patients with severe aortic stenosis: systematic review and meta-analysis of randomized controlled trials and propensity score matching observational studies. J Thorac Dis 2019;11:1945&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588740</ArticleId><ArticleId IdType="pubmed">31285888</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Rao SV, Visveswaran G, et al. . Transcatheter aortic valve replacement versus surgical valve replacement in low-intermediate surgical risk patients: a systematic review and meta-analysis. J Invasive Cardiol 2017;29:209&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">28570236</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SU, Lone AN, Saleem MA, Kaluski E. Transcatheter vs surgical aortic-valve replacement in low- to intermediate-surgical-risk candidates: A meta-analysis and systematic review. Clin Cardiol 2017;40:974&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490337</ArticleId><ArticleId IdType="pubmed">29168984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheiri B, Osman M, Abubakar H, et al. . Transcatheter versus surgical aortic valve replacement in low-risk surgical patients: A meta-analysis of randomized clinical trials. Cardiovasc Revasc Med 2019;20:838&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638890</ArticleId></ArticleIdList></Reference><Reference><Citation>Polimeni A, Sorrentino S, De Rosa S, et al. . Transcatheter versus surgical aortic valve replacement in low-risk patients for the treatment of severe aortic stenosis. J Clin Med 2020;9:02.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7074202</ArticleId><ArticleId IdType="pubmed">32041189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardar P, Kundu A, Chatterjee S, et al. . Transcatheter versus surgical aortic valve replacement in intermediate-risk patients: Evidence from a meta-analysis. Catheter Cardiovasc Interv 2017;90:504&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">28398671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhou Y, Zhang L, Zhu J. Midterm outcome of transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: A meta-analysis of randomized controlled trials. J Cardiol 2018;71:534&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29655505</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CR, Leon MB, Mack MJ, et al. . Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">21639811</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams DH, Popma JJ, Reardon MJ, et al. . Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;370:1790&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24678937</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann M, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975993</ArticleId></ArticleIdList></Reference><Reference><Citation>Jong GP, Chen HY, Li SY, Liou YS. Long-term effect of antihypertensive drugs on the risk of new-onset atrial fibrillation: a longitudinal cohort study. Hypertens Res 2014;37:950&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">24965171</ArticleId></ArticleIdList></Reference><Reference><Citation>Amat-Santos IJ, Rodes-Cabau J, Urena M, et al. . Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 2012;59:178&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">22177537</ArticleId></ArticleIdList></Reference><Reference><Citation>Charitos EI, Stierle U, Ziegler PD, et al. . A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions. Circulation 2012;126:806&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">22824434</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindricks G, Pokushalov E, Urban L, et al. . Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3:141&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160169</ArticleId></ArticleIdList></Reference><Reference><Citation>Pecha S, Schafer T, Hartel F, et al. . Concomitant surgical atrial fibrillation ablation and event recorder implantation: better monitoring, better outcome? Interact Cardiovasc Thorac Surg 2013;16:465&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598051</ArticleId><ArticleId IdType="pubmed">23325063</ArticleId></ArticleIdList></Reference><Reference><Citation>Onorati F, D&#x2019;Errigo P, Barbanti M, et al. . Different impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: Results of the multicenter Italian OBSERVANT Registry. J Thorac Cardiovasc Surg 2014;147:1529&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">23856202</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter MP, Bartko P, Hofer F, et al. . Evolution of outcome and complications in TAVR: a meta-analysis of observational and randomized studies. Sci Rep 2020;10:15568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511292</ArticleId><ArticleId IdType="pubmed">32968104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31509267</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-8737</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinical cardiology</Title><ISOAbbreviation>Clin Cardiol</ISOAbbreviation></Journal><ArticleTitle>Timing of initiation of intra-aortic balloon pump in patients with acute myocardial infarction complicated by cardiogenic shock: A meta-analysis.</ArticleTitle><Pagination><StartPage>1126</StartPage><EndPage>1134</EndPage><MedlinePgn>1126-1134</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/clc.23264</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">For patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) undergoing primary percutaneous coronary intervention (PCI), the optimal timing of the initiation of intra-aortic balloon pump (IABP) therapy remains unclear. Therefore, we performed the first meta-analysis to compare the outcomes of IABP insertion before vs after primary PCI in this population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Electronic databases of PubMed, EMBASE, and Cochrane Library were comprehensively searched from inception to April 1, 2019, to identify the eligible studies. The main outcomes were short-term (in-hospital or 30&#x2009;days) and long-term (&#x2265;&#x2009;6 months) mortality. In addition, pooled analysis of risk-adjusted data were also performed to control for confounding factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven observational studies and two sub-analysis of randomized controlled trials involving 1348 patients were included. Compared to patients inserted IABP after PCI, patients who received IABP therapy before primary PCI had similar risks of short-term (odds ratio [OR] 0.88, 95% CI 0.49 to 1.59) and long-term (OR 0.99, 95% CI 0.58 to 1.68) all-cause mortality. Moreover, a pooled analysis of risk-adjusted data also found similar effects of the two therapies on short-term (OR 0.65, 95% CI 0.34 to 1.25) and long-term (OR 0.68, 95% CI 0.17 to 2.72) mortality. Besides, no significant difference was found between the two groups with respect to reinfarction, repeat revascularization, stroke, renal failure, and major bleeding.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The timing of the initiation of IABP therapy does not appear to impact short-term and long-term survival in patients with AMI complicated by CS undergoing primary PCI.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Kongyong</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyu</LastName><ForeName>Shuzheng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4243-2341</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xiantao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mingduo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dongfeng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Jinfan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yunfeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Kuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lingxiao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PXM2019_014226_000023</GrantID><Agency>Beijing Lab for Cardiovascular Precision Medicine, Beijing, China</Agency><Country/></Grant><Grant><GrantID>2011BAI11B05</GrantID><Agency>Ministry of Science and Technology of the People's Republic of China, State Science and Technology Support Program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cardiol</MedlineTA><NlmUniqueID>7903272</NlmUniqueID><ISSNLinking>0160-9289</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">intra-aortic balloon pump</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">timing</Keyword></KeywordList><CoiStatement>The authors declare no potential conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31509267</ArticleId><ArticleId IdType="pmc">PMC6837021</ArticleId><ArticleId IdType="doi">10.1002/clc.23264</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294(4):448&#x2010;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long&#x2010;term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295(21):2511&#x2010;2515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782030</ArticleId><ArticleId IdType="pubmed">16757723</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1:CD009669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491099</ArticleId><ArticleId IdType="pubmed">29376560</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AH, Puri R, Kalra A. Management of cardiogenic shock complicating acute myocardial infarction: a review. Clin Cardiol. 2019;42(4):484&#x2010;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712338</ArticleId><ArticleId IdType="pubmed">30815887</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheidt S, Wilner G, Mueller H, et al. Intra&#x2010;aortic balloon counterpulsation in cardiogenic shock. Report of a co&#x2010;operative clinical trial. N Engl J Med. 1973;288(19):979&#x2010;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">4696253</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Cram P, Lu X, et al. Trends in the use of percutaneous ventricular assist devices: analysis of national inpatient sample data, 2007 through 2012. JAMA Intern Med. 2015;175(6):941&#x2010;950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780323</ArticleId><ArticleId IdType="pubmed">25822170</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios SA, Bravo CA, Weinreich M, et al. Meta&#x2010;analysis and trial sequential analysis comparing percutaneous ventricular assist devices versus intra&#x2010;aortic balloon pump during high&#x2010;risk percutaneous coronary intervention or cardiogenic shock. Am J Cardiol. 2018;122(8):1330&#x2010;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">30146099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad Y, Sen S, Shun&#x2010;Shin MJ, et al. Intra&#x2010;aortic balloon pump therapy for acute myocardial infarction: a meta&#x2010;analysis. JAMA Intern Med. 2015;175(6):931&#x2010;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">25822657</ArticleId></ArticleIdList></Reference><Reference><Citation>Unverzagt S, Buerke M, de Waha A, et al. Intra&#x2010;aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev. 2015;3:CD007398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8454261</ArticleId><ArticleId IdType="pubmed">25812932</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Thelemann N, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long&#x2010;term 6&#x2010;year outcome of the randomized IABP&#x2010;SHOCK II trial. Circulation. 2018;139:395&#x2010;403. 10.1161/CIRCULATIONAHA.118.038201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.038201</ArticleId><ArticleId IdType="pubmed">30586721</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287&#x2010;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann FJ, Sousa&#x2010;Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87&#x2010;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">30615155</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST&#x2010;elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;127(4):e362&#x2010;e425.</Citation><ArticleIdList><ArticleId IdType="pubmed">23247304</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. Meta&#x2010;analysis of observational studies in epidemiology: a proposal for reporting. Meta&#x2010;analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008&#x2010;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, Group P . Preferred reporting items for systematic reviews and meta&#x2010;analyses: the PRISMA statement. BMJ. 2009;339:b2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle&#x2010;Ottawa scale for the assessment of the quality of nonrandomized studies in meta&#x2010;analyses. Eur J Epidemiol. 2010;25(9):603&#x2010;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088&#x2010;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">7786990</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta&#x2010;analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629&#x2010;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra&#x2010;aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26(13):1276&#x2010;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734771</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel&#x2010;Wahab M, Saad M, Kynast J, et al. Comparison of hospital mortality with intra&#x2010;aortic balloon counterpulsation insertion before versus after primary percutaneous coronary intervention for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2010;105(7):967&#x2010;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">20346314</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjauw KD, Engstrom AE, Vis MM, et al. Efficacy and timing of intra&#x2010;aortic counterpulsation in patients with ST&#x2010;elevation myocardial infarction complicated by cardiogenic shock. Neth Hear J. 2012;20(10):402&#x2010;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439539</ArticleId><ArticleId IdType="pubmed">22847042</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JM, van Leeuwen MA, de Boer SP, et al. Impact of intra&#x2010;aortic balloon pump support initiated before versus after primary percutaneous coronary intervention in patients with cardiogenic shock from acute myocardial infarction. Int J Cardiol. 2013;168(4):3758&#x2010;3763.</Citation><ArticleIdList><ArticleId IdType="pubmed">23830073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergh N, Anger&#xe5;s O, Albertsson P, et al. Does the timing of treatment with intra&#x2010;aortic balloon counterpulsation in cardiogenic shock due to ST&#x2010;elevation myocardial infarction affect survival? Acute Card Care. 2014;16(2):57&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24670205</ArticleId></ArticleIdList></Reference><Reference><Citation>Negi SI, Anand A, Briceno&#x2010;Gomez D, et al. Timing of intra&#x2010;aortic balloon therapy in ST elevation myocardial infarction. J Am Coll Cardiol. 2014;64(11):B21&#x2010;B22.</Citation></Reference><Reference><Citation>Schwarz B, Abdel&#x2010;Wahab M, Robinson DR, Richardt G. Predictors of mortality in patients with cardiogenic shock treated with primary percutaneous coronary intervention and intra&#x2010;aortic balloon counterpulsation. Med Klin Intensivmed Notfmed. 2016;111(8):715&#x2010;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">26596273</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan L, Nie SP. Efficacy of intra&#x2010;aortic balloon pump before versus after primary percutaneous coronary intervention in patients with cardiogenic Shock from ST&#x2010;elevation myocardial infarction. Chin Med J. 2016;129(12):1400&#x2010;1405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910361</ArticleId><ArticleId IdType="pubmed">27270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuernau G, Ledwoch J, Eitel I, et al. Impact of timing of intra&#x2010;aortic balloon counterpulsation on mortality in cardiogenic shock: a sub&#x2010;analysis of the IABP&#x2010;shock II&#x2010;trial. J Am Coll Cardiol. 2017;69(11):1182.</Citation></Reference><Reference><Citation>Kantrowitz A, Tjonneland S, Freed PS, Phillips SJ, Butner AN, Sherman JL Jr. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA. 1968;203(2):113&#x2010;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">5694059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohman EM, Nanas J, Stomel RJ, et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS trial. J Thromb Thrombolysis. 2005;19(1):33&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">15976965</ArticleId></ArticleIdList></Reference><Reference><Citation>Achour H, Boccalandro F, Felli P, et al. Mechanical left ventricular unloading prior to reperfusion reduces infarct size in a canine infarction model. Catheter Cardiovasc Interv. 2005;64(2):182&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">15678467</ArticleId></ArticleIdList></Reference><Reference><Citation>LeDoux JF, Tamareille S, Felli PR, Amirian J, Smalling RW. Left ventricular unloading with intra&#x2010;aortic counter pulsation prior to reperfusion reduces myocardial release of endothelin&#x2010;1 and decreases infarction size in a porcine ischemia&#x2010;reperfusion model. Catheter Cardiovasc Interv. 2008;72(4):513&#x2010;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">18814226</ArticleId></ArticleIdList></Reference><Reference><Citation>Smalling RW, Cassidy DB, Barrett R, Lachterman B, Felli P, Amirian J. Improved regional myocardial blood flow, left ventricular unloading, and infarct salvage using an axial&#x2010;flow, transvalvular left ventricular assist device. A comparison with intra&#x2010;aortic balloon counterpulsation and reperfusion alone in a canine infarction model. Circulation. 1992;85(3):1152&#x2010;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">1537113</ArticleId></ArticleIdList></Reference><Reference><Citation>Prondzinsky R, Lemm H, Swyter M, et al. Intra&#x2010;aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med. 2010;38(1):152&#x2010;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">19770739</ArticleId></ArticleIdList></Reference><Reference><Citation>Francone M, Bucciarelli&#x2010;Ducci C, Carbone I, et al. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST&#x2010;segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(23):2145&#x2010;2153.</Citation><ArticleIdList><ArticleId IdType="pubmed">19942086</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Gersh BJ, Mehran R, et al. Effect of ischemia duration and door&#x2010;to&#x2010;balloon time on myocardial perfusion in ST&#x2010;segment elevation myocardial infarction: an analysis from HORIZONS&#x2010;AMI trial (harmonizing outcomes with revascularization and stents in acute myocardial infarction). JACC Cardiovasc Interv. 2015;8(15):1966&#x2010;1974.</Citation><ArticleIdList><ArticleId IdType="pubmed">26738667</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37852913</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8422</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>J Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>Temporary Mechanical Circulatory Support in Sepsis-Associated Cardiogenic Shock With and Without Acute Myocardial Infarction.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>213</EndPage><MedlinePgn>207-213</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.jvca.2023.09.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-0770(23)00792-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To describe the current use and outcomes of temporary mechanical circulatory support (MCS) in patients with sepsis-associated cardiogenic shocks with and without acute myocardial infarction (AMI) in the United States.</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING">The National Inpatient Sample database from 2017 to 2019.</AbstractText><AbstractText Label="PARTICIPANTS">Adult patients with sepsis-associated cardiogenic shock with and without AMI.</AbstractText><AbstractText Label="INTERVENTIONS">Temporary MCSs, including intra-aortic balloon pump (IABP), percutaneous left ventricular assist device (pLVAD), and extracorporeal membrane oxygenation (ECMO).</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">Multivariate logistic regression analyses adjusting for patient characteristics, organ failures, and socioeconomic status. Although the uses of IABP and pLVAD were associated with significantly lower odds of in-hospital mortality in patients with sepsis-associated cardiogenic shock (IABP: adjusted odds ratio [aOR] 0.57, 95% CI 0.44-0.73, p &lt; .001; pLVAD: aOR 0.66, 95% CI 0.45-0.98, p&#xa0;=&#xa0;.037), ECMO was not (aOR 1.51, 95% CI 0.93-2.45, p&#xa0;=&#xa0;0.096). In the subgroup with AMI, temporary MCSs were not associated with significantly lower or higher odds of in-hospital mortality. In the subgroup without AMI, IABP was associated with significantly lower odds of in-hospital mortality (aOR 0.43, 95% CI 0.28-0.65, p &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS">Although temporary MCS is deemed to be a feasible option in sepsis-associated cardiogenic shock, the selection of the right patients whose shock is driven mainly by cardiogenic shock rather than septic shock, as represented by low cardiac output and high systemic vascular resistance, plays a critical role in the feasibility of this approach in the absence of clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Ryota</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Department of Medicine, The Queen's Medical Center, Honolulu, HI. Electronic address: st051035@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Mount Sinai Beth Israel, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Stephanie C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Department of Medicine, The Queen's Medical Center, Honolulu, HI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishida</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Graduate School of Medicine, Nagoya University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugar</LastName><ForeName>Siddharth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Lerner College of Medicine, Cleveland, OH.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9110208</NlmUniqueID><ISSNLinking>1053-0770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword><Keyword MajorTopicYN="N">septic shock</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>19</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>22</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37852913</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2023.09.026</ArticleId><ArticleId IdType="pii">S1053-0770(23)00792-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30252028</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Effect of an intra-aortic balloon pump with venoarterial extracorporeal membrane oxygenation on mortality of patients with cardiogenic shock: a systematic review and meta-analysis&#x2020;.</ArticleTitle><Pagination><StartPage>395</StartPage><EndPage>404</EndPage><MedlinePgn>395-404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ejcts/ezy304</ELocationID><Abstract><AbstractText>An intra-aortic balloon pump (IABP) concomitant with venoarterial extracorporeal membrane oxygenation (VA-ECMO) is frequently used to support patients with refractory cardiogenic shock (CS). Because of the lack of evidence of the adjunctive benefit, the goal of the study was to compare the effect of VA-ECMO plus IABP with that of VA-ECMO alone. Systematic searches were conducted to identify studies using PubMed, Embase, the Cochrane Library and the International Clinical Trials Registry Platform. Studies reporting on patients with adult CS treated with VA-ECMO plus IABP or VA-ECMO alone were identified and included. The primary outcome was in-hospital death. The secondary outcomes included neurological, gastrointestinal and limb-related complications. The study protocol was registered at PROSPERO (CRD42017069259). A total of 29 studies comprising 4576 patients were included. The pooled in-hospital deaths of patients on VA-ECMO were 1441/2285 (63.1%) compared with 1339/2291 (58.4%) for patients with adjunctive IABP. VA-ECMO plus IABP was associated with decreased in-hospital deaths [risk ratio (RR) 0.90; 95% confidence interval (CI) 0.85-0.95; P&#x2009;&lt;&#x2009;0.0001]. Moreover, IABP was related to decreased in-hospital deaths of patients with extracorporeal cardiopulmonary resuscitation, postcardiotomy CS and ischaemic heart disease (RR 0.78; 95% CI 0.64-0.95; P&#x2009;=&#x2009;0.01; RR 0.91; 95% CI: 0.85-0.98; P&#x2009;=&#x2009;0.008; RR 0.83; 95% CI 0.73-0.96, P&#x2009;=&#x2009;0.009). Neurological, gastrointestinal and limb-related complications did not differ significantly between patients on ECMO with and without concurrent IABP. VA-ECMO plus IABP was associated with decreased in-hospital deaths in patients with CS.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yongnan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiopulmonary Bypass, State Key Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Shujie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiopulmonary Bypass, State Key Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Sizhe</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiopulmonary Bypass, State Key Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mingyue</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiopulmonary Bypass, State Key Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiopulmonary Bypass, State Key Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiopulmonary Bypass, State Key Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Bingyang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiopulmonary Bypass, State Key Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Bingren</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Intra-aortic balloon pumping</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Venoarterial extracorporeal membrane oxygenation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30252028</ArticleId><ArticleId IdType="doi">10.1093/ejcts/ezy304</ArticleId><ArticleId IdType="pii">5106356</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25010916</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-943X</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>ASAIO journal (American Society for Artificial Internal Organs : 1992)</Title><ISOAbbreviation>ASAIO J</ISOAbbreviation></Journal><ArticleTitle>Thoratec CentriMag for temporary treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency: a systematic literature review and meta-analysis of observational studies.</ArticleTitle><Pagination><StartPage>487</StartPage><EndPage>497</EndPage><MedlinePgn>487-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MAT.0000000000000117</ELocationID><Abstract><AbstractText>The aim of the study was to systematically evaluate effect of CentriMag heart pump (Thoratec Corporation) as temporary ventricular assist device (VAD) and part of extracorporeal membrane oxygenation (ECMO) system on outcomes in patients with cardiac or cardiac-respiratory failure. A systematic search was conducted in five databases for the period 2003 to 2012. Fifty-three publications with data for 999 patients, supported with CentriMag, were included. In 72% studies, CentriMag was used as a VAD and in 25% as part of ECMO circuit. Mean duration of VAD support was 25.0 days in precardiotomy group, 10.9 days in postcardiac surgery cardiogenic shock group, 8.8 days in post-transplant graft failure and rejection group, and 16.0 days in post-LVAD placement right ventricular failure group. Survival on support was 82% (95% CI 70-92) for VAD support in precardiotomy cardiogenic shock indication, 63% (95% CI 46-78) in VAD support in postcardiac surgery cardiogenic shock indication, 62% (95% CI 46-76) in VAD support in post-transplant graft rejection or failure indication, and 83% (95% CI 73-92) in VAD support in post-LVAD placement right ventricular failure indication. CentriMag is an effective technology for temporary support of patients with cardiac and cardiorespiratory failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borisenko</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the *Synergus AB, Danderyd, Sweden; &#x2020;Scottish Extracorporeal Life Support Service, Royal Hospital for Sick Children, Glasgow, United Kingdom; &#x2021;Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Clydebank, United Kingdom; &#xa7;Medical Management Centre, Department of Learning Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; &#xb6;Paediatric and Neonatal ECMO Service, Freeman Hospital, Newcastle upon Tyne, United Kingdom; &#x2016;Department of Cardiothoracic Transplant, Wythenshawe Hospital, Manchester, United Kingdom; and #Emeritus Cardiothoracic Surgeon, Glenfield General Hospital, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wylie</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Payne</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bjessmo</LastName><ForeName>Staffan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yonan</LastName><ForeName>Nizar</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Firmin</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ASAIO J</MedlineTA><NlmUniqueID>9204109</NlmUniqueID><ISSNLinking>1058-2916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: O.B. and S.B. are employees of Synergus AB, which was commissioned by Thoratec Corp. to perform the study. G.W. has no conflict of interest to disclose. J.P. has received two travel grants from Thoratec Corp. J.S. is an expert witness in litigation and has received two travel grants from Chalice Medical. N.Y. received honorarium from Synergus AB for support related to design and collection of cost information for cost analysis of VAD and ECMO in the United Kingdom. R.F. is providing consulting support to Thoratec Corp. The study was funded by Thoratec Corporation (Pleasanton, CA).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25010916</ArticleId><ArticleId IdType="pmc">PMC4154791</ArticleId><ArticleId IdType="doi">10.1097/MAT.0000000000000117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Institute for Health and Clinical Excellence. Short-Term Circulatory Support with Left Ventricular Assist Devices as a Bridge to Cardiac Transplantation or Recovery. IPG177. London: National Institute for Health and Care Excellence; 2006.</Citation></Reference><Reference><Citation>ECMO. Extracorporeal Cardiopulmonary Support in Critical Care. 4th ed. 2005. p. pp. 625.</Citation></Reference><Reference><Citation>NHS England. Service Specification. Ventricular Assist Devices (VADs) for adults as a bridge to heart transplantation or myocardial recovery. 2011.</Citation></Reference><Reference><Citation>NHS England. Service Specification. Ventricular Assist Devices (VADs) for children as a bridge to heart transplantation. 2011.</Citation></Reference><Reference><Citation>Chuang-Stein C, Beltangady M. Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies. Pharm Stat. 2011;10:3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20073040</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S Cochrane Handbook for Systematic Reviews of Interventions. 2011. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration.</Citation></Reference><Reference><Citation>Extracorporeal Membrane Oxygenation: An Evaluation of Current Treatment Approaches in the United Kingdom (Service Evaluation) 2013. p. pp. 43.</Citation></Reference><Reference><Citation>Thomas HL, Dronavalli VB, Parameshwar J, Bonser RS, Banner NR Audit obotSGotUCT. Incidence and outcome of Levitronix CentriMag support as rescue therapy for early cardiac allograft failure: A United Kingdom national study. Eur J Cardiothorac Surg. 2011;40:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">21493083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosmane S, Venkateswaran R, Salaie J, Williams S, Yonan N. Joint Annual Meeting of ACTA-SCTC. Manchester: United Kingdom; 2012. Outcome of extracorporeal membrane oxygenation as short term mechanical support following heart transplantation: a single centre experience. p. pp. 139.</Citation></Reference><Reference><Citation>De Robertis F, Birks EJ, Rogers P, Dreyfus G, Pepper JR, Khaghani A. Clinical performance with the Levitronix Centrimag short-term ventricular assist device. J Heart Lung Transplant. 2006;25:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">16446218</ArticleId></ArticleIdList></Reference><Reference><Citation>De Robertis F, Rogers P, Amrani M, et al. Bridge to decision using the Levitronix CentriMag short-term ventricular assist device. J Heart Lung Transplant. 2008;27:474&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">18442711</ArticleId></ArticleIdList></Reference><Reference><Citation>Akay MH, Gregoric ID, Radovancevic R, Cohn WE, Frazier OH. Timely use of a CentriMag heart assist device improves survival in postcardiotomy cardiogenic shock. J Card Surg. 2011;26:548&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">21951040</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz TA, Singh G, Popjes E, et al. Initial experience with CentriMag extracorporal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock. J Heart Lung Transplant. 2010;29:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">19837609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhama JK, Kormos RL, Toyoda Y, Teuteberg JJ, McCurry KR, Siegenthaler MP. Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support. J Heart Lung Transplant. 2009;28:971&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">19716053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindoff C, Dean R, Bashford A, et al. Mobilization and physiotherapy of patients with Levitronix CentriMag short-term mechanical circulatory support device. J Heart Lung Transplant. 2009;28:S281.</Citation></Reference><Reference><Citation>Bruschi G, Cannata A, Russo CF, et al. Single center experience with the Levitronix CentriMag circulation support system as short term cardiac assist in different clinical scenarios. J Heart Lung Transplant. 2008;27:S154&#x2013;S155.</Citation></Reference><Reference><Citation>Byrnes J, McKamie W, Swearingen C, et al. Hemolysis during cardiac extracorporeal membrane oxygenation: A case-control comparison of roller pumps and centrifugal pumps in a pediatric population. ASAIO J. 2011;57:456&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">21822124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy J, Haynes S, Kirk R, et al. Changing patterns of bridging to heart transplantation in children. J Heart Lung Transplant. 2009;28:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">19285616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JM, Richmond ME, Charette K, et al. A decade of pediatric mechanical circulatory support before and after cardiac transplantation. J Thorac Cardiovasc Surg. 2012;143:344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">22143101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung DA, Kizner L, Al-Deiri M, et al. Clinical utility of the Levitronix CentriMag in extracorporeal membrane oxygenation for severe cardiogenic shock. J Heart Lung Transplant. 2007;26:S87.</Citation></Reference><Reference><Citation>Clough RE, Vallely MP, Henein MY, Pepper JR. Levitronix ventricular assist device as a bridge-to-recovery for post-cardiotomy cardiogenic shock. Int J Cardiol. 2009;134:408&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">18378019</ArticleId></ArticleIdList></Reference><Reference><Citation>den Uil CA, Maat AP, Lagrand WK, et al. Mechanical circulatory support devices improve tissue perfusion in patients with end-stage heart failure or cardiogenic shock. J Heart Lung Transplant. 2009;28:906&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">19716043</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Bella I, Ramoni E, Da Col U, et al. Is lower limb venous drainage during peripheral extracorporeal membrane oxygenation necessary? ASAIO J. 2010;56:35&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">20051830</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaloro RR, Bertolotti A, Diez M, et al. Adequate systemic perfusion maintained by a CentriMag during acute heart failure. Tex Heart Inst J. 2008;35:334&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2565526</ArticleId><ArticleId IdType="pubmed">18941648</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia JP, Kon ZN, Evans C, Wu Z, IA M, cCormick B, Griffith BP. Ambulatory veno-venous extracorporeal membrane oxygenation: Innovation and pitfalls. J Thorac Cardiovasc Surg. 2011;142:755&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">21924145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ga&#x161;parovi&#x107; H, Petri&#x10d;evi&#x107; M, Ivan&#x10d;an V, Mili&#x10d;i&#x107; C, Bio&#x10d;ina B. Initial clinical results with the Levitronix CentriMag Mechanical Assist Device at the University Hospital Rebro Zagreb. Rad Med Fak Zagrebu. 2011;36:47&#x2013;53.</Citation></Reference><Reference><Citation>Haj-Yahia S, Birks EJ, Amrani M, et al. Bridging patients after salvage from bridge to decision directly to transplant by means of prolonged support with the CentriMag short-term centrifugal pump. J Thorac Cardiovasc Surg. 2009;138:227&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">19577084</ArticleId></ArticleIdList></Reference><Reference><Citation>Horv&#xe1;th V, N&#x11b;mec P, Ondr&#xe1;&#x161;ek J, et al. Short-term mechanical support with the Levitronix CentriMag centrifugal pump. Cor Vasa. 2011;53:144&#x2013;147.</Citation></Reference><Reference><Citation>John R, Liao K, Lietz K, et al. Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg. 2007;134:351&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">17662772</ArticleId></ArticleIdList></Reference><Reference><Citation>John R, Long JW, Massey HT, et al. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg. 2011;141:932&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">20605026</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N, Al-alouo M, Shad DL. Early experience with the Levitronix CentriMag device for extra corporeal membrane oxygenation following lung transplantation. Eur J Cardiothorac Surg. 2008;34:1262&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">18951034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouretas PC, Kaza AK, Burch PT, et al. Experience with the Levitronix CentriMag in the pediatric population as a bridge to decision and recovery. Artif Organs. 2009;33:1002&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">19874281</ArticleId></ArticleIdList></Reference><Reference><Citation>Loforte A, Montalto A, Ranocchi F, et al. Temporary mechanical circulatory support for acute cardiogenic shock. Eur J Heart Fail. 2010;9:S193&#x2013;S194.</Citation></Reference><Reference><Citation>Loforte A, Potapov E, Krabatsch T, et al. Levitronix CentriMag to Berlin Heart Excor: A &#x201c;bridge to bridge&#x201d; solution in refractory cardiogenic shock. ASAIO J. 2009;55:465&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">19672191</ArticleId></ArticleIdList></Reference><Reference><Citation>Loforte A, Montalto A, Ranocchi F, et al. Levitronix CentriMag third-generation magnetically levitated continuous flow pump as bridge to solution. ASAIO J. 2011;57:247&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">21701270</ArticleId></ArticleIdList></Reference><Reference><Citation>Loforte A, Montalto A, Lilla Della Monica P, Musumeci F. Simultaneous temporary CentriMag right ventricular assist device placement in HeartMate II left ventricular assist system recipients at high risk of right ventricular failure. Interact Cardiovasc Thorac Surg. 2010;10:847&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">20231307</ArticleId></ArticleIdList></Reference><Reference><Citation>Maat AP, van Thiel RJ, Dalinghaus M, Bogers AJ. Connecting the Centrimag Levitronix pump to Berlin Heart Excor cannulae; a new approach to bridge to bridge. J Heart Lung Transplant. 2008;27:112&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">18187096</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquez TT, D&#x2019;Cunha J, John R, Liao K, Joyce L. Mechanical support for acute right ventricular failure: Evolving surgical paradigms. J Thorac Cardiovasc Surg. 2009;137:e39&#x2013;e40.</Citation><ArticleIdList><ArticleId IdType="pubmed">19154879</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick AJ, Reid BB, Budge D, et al. Versatility and patient outcomes with the levitronix centrimag temporary ventricular assist device. J Heart Lung Transplant. 2010;29:S100.</Citation></Reference><Reference><Citation>Meyer AL, Strueber M, Tomaszek S, et al. Temporary cardiac support with a mini-circuit system consisting of a centrifugal pump and a membrane ventilator. Interact Cardiovasc Thorac Surg. 2009;9:780&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">19671580</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan JA, Naseem TM, Cheema FH, et al. Improvement in survival with implantation of levitronix centrimag biventricular circulatory support in patients with acute st-elevation myocardial infarction (STEMI) and refractory cardiogenic shock. J Heart Lung Transplant. 2009;28:S143.</Citation></Reference><Reference><Citation>Nelson KM, Marks JD, Eidson M, et al. Initial pilot study of the Levitronix CentriMag VAS for RVAD support following LVAD implementation. ASAIO J. 2006;52:36A.</Citation></Reference><Reference><Citation>Netuka I, Mal&#xfd; J, Szarszoi O, et al. [Technique of implantation and experience with temporary mechanical cardiac support in right ventricular failure]. Rozhl Chir. 2011;90:88&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">21638844</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlak S, Sliwka J, Przybylski R, et al. Peirwsze doswiadczenia w kiniczynm zastosowaniu system wsopmagania serca pompa rotacynja Levitronix. (Early experience in clinical use of mechanical ventricular assist Levitronix device). Kardiochirugia I Torakochirugia i Polska. 2009;6:171&#x2013;175.</Citation></Reference><Reference><Citation>Reckers J, Asfour B, Fink C. Goodbye Hemolysis! Experience with Levitronix CentriMag in 33 Newborns, Infants and Children. 54th Annual Conference of ASAIO. San Francisco, United States; 2008.</Citation></Reference><Reference><Citation>Russo CF, Cannata A, Lanfranconi M, et al. Veno-arterial extracorporeal membrane oxygenation using Levitronix centrifugal pump as bridge to decision for refractory cardiogenic shock. J Thorac Cardiovasc Surg. 2010;140:1416&#x2013;1421.</Citation><ArticleIdList><ArticleId IdType="pubmed">20933244</ArticleId></ArticleIdList></Reference><Reference><Citation>Santise G, Petrou M, Pepper JR, Dreyfus G, Khaghani A, Birks EJ. Levitronix as a short-term salvage treatment for primary graft failure after heart transplantation. J Heart Lung Transplant. 2006;25:495&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678025</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuhaiber JH, Jenkins D, Berman M, et al. The Papworth experience with the Levitronix CentriMag ventricular assist device. J Heart Lung Transplant. 2008;27:158&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18267221</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RK, Addonizio LJ, Richmond M, Vincent J, Torres A, Williams M. A novel approach to management of acute rejection with percutaneous ventricular assist device insertion in two adolescent heart transplant patients. J Card Fail. 2009;15:S55.</Citation></Reference><Reference><Citation>Soleimani B, Brehm C, Wallace S, et al. Application of new generation rotary pumps and oxygenators for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock (RCS). J Heart Lung Transplant. 2011;30:S211.</Citation></Reference><Reference><Citation>Stepanenko A, Pappalardo F, Scandroglio AM, Potapov EV, Krabatsch T, Hetzer R. Anticoagulation management during CentriMag right ventricular assist device support after heartmate II implantation. Heart Surg Forum. 2010;13:S113.</Citation></Reference><Reference><Citation>Takayama H, Chen JM, Jorde UP, Naka Y. Implantation technique of the CentriMag biventricular assist device allowing ambulatory rehabilitation. Interact Cardiovasc Thorac Surg. 2011;12:110&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047827</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama H, Naka Y, Kodali SK, et al. A novel approach to percutaneous right-ventricular mechanical support. Eur J Cardiothorac Surg. 2012;41:423&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">21737292</ArticleId></ArticleIdList></Reference><Reference><Citation>Westaby S, Balacumaraswami L, Evans BJ, et al. Elective transfer from cardiopulmonary bypass to centrifugal blood pump support in very high-risk cardiac surgery. J Thorac Cardiovasc Surg. 2007;133:577&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">17258609</ArticleId></ArticleIdList></Reference><Reference><Citation>Worku B, Naka Y PS, Cheema FH, et al. Predictors of mortality after short-term ventricular assist device placement. Ann Thorac Surg. 2011;92:1608&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">22051257</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JA, Takayama H, Kim H, Cohen SA, Naka Y. Feasibility of BiVAD support with membrane oxygenation. J Heart Lung Transplant. 2010;29:S181&#x2013;S182.</Citation></Reference><Reference><Citation>Zych B, Popov AF, Barsan A, et al. Treatment of refractory right heart failure after implantation of a left ventricular assist device. Is the levitronix centrimag right heart support a solution? Heart. 2011;97:A49.</Citation></Reference><Reference><Citation>Velik-Salchner C, Hoermann C, Hoefer D, Margreiter J, Mair P. Thromboembolic complications during weaning from right ventricular assist device support. Anesth Analg. 2009;109:354&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">19608801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims DB, Takayama H, Uriel N, Gillam LD, Naka Y, Jorde UP. Ventricular assist device-associated thrombus. Circulation. 2011;124:e197&#x2013;e198.</Citation><ArticleIdList><ArticleId IdType="pubmed">21844083</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: A population-based perspective. Circulation. 2009;119:1211&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730832</ArticleId><ArticleId IdType="pubmed">19237658</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnendran L, Abboud R, Sleeper LA, et al. Trends in cardiogenic shock: report from the SHOCK Study. The SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? Eur Heart J. 2001;22:472&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy J, Dominguez T, Haynes S, et al. A longer waiting game: bridging children to heart transplant with the Berlin Heart EXCOR device&#x2014;The United Kingdom experience. J Heart Lung Transplant. 2013;32:1101&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pubmed">24060499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohite PN, Zych B, Popov AF, et al. CentriMag short-term ventricular assist as a bridge to solution in patients with advanced heart failure: Use beyond 30 days. Eur J Cardiothorac Surg. 2013;44:e310&#x2013;e315.</Citation><ArticleIdList><ArticleId IdType="pubmed">23990618</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35344825</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>Prognostic implications of pulmonary artery catheter monitoring in patients with cardiogenic shock: A systematic review and meta-analysis of observational studies.</ArticleTitle><Pagination><StartPage>154024</StartPage><MedlinePgn>154024</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2022.154024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-9441(22)00052-1</ELocationID><Abstract><AbstractText Label="PURPOSE">To investigate the impact of pulmonary artery catheter (PAC) monitoring on survival of cardiogenic shock(CS), in the light of the controversies in available evidence.</AbstractText><AbstractText Label="MATERIALS AND METHODS">MEDLINE, EMBASE, Cochrane library and Web of Science were systematically screened to identify most relevant studies on patients with CS comparing PAC use to non-use during hospital stay. Short-term mortality was the primary endpoint and the use of Mechanical Circulatory Support (MCS) devices was the secondary one.</AbstractText><AbstractText Label="RESULTS">Six observational studies including 1,166,762 patients were selected. The most frequent etiology of CS was post-myocardial infarction (75% [95% CI 55-89%] in PAC-group and 81%[95% CI 47-95%] in non-PAC group). Overall, PAC was used in 33%(95% CI 24-44%) of cases. Pooling data adjusted for confounders, a significant association between the PAC-group and a reduction in short-term mortality emerged when compared to the non-PAC group (36%[95% CI 27-45%] vs 47%[95% CI 35-59%];AdjustedOR 0.71, 95% CI 0.59-0.87, p &lt; 0.01). MCS use was significantly higher in PAC vs non-PAC group (59% [95% CI 54-65%]) vs 48% [95% CI 43-53%]);OR 1.60 [95% CI 1.27-2.02, p &lt; 0.01]).</AbstractText><AbstractText Label="CONCLUSIONS">PAC was associated with lower incidence of short-term mortality in CS pooling adjusted observational studies. Prospective studies are needed to confirm our hypothesis and better clarify the mechanisms of this potential prognostic benefit.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertaina</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy. Electronic address: maurizio.bertaina@aslcittaditorino.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galluzzo</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sant'Andrea Hospital, Vercelli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossello</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cardiology Department, Institut d'Investigaci&#xf3; Sanit&#xe0;ria Illes Balears, Hospital Universitari Son Espases, Palma, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbarra</LastName><ForeName>Pierluigi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petitti</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prever</LastName><ForeName>Silvia Brach</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccuzzi</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ascenzo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frea</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pidello</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morici</LastName><ForeName>Nuccia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; IRCCS S. Maria Nascente, Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy. Electronic address: nuccia.morici77@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliva</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Serafina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Diseases, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Ferrari</LastName><ForeName>Gaetano Maria</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Cardiovascular and Thoracic Department, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, University of Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ugo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sant'Andrea Hospital, Vercelli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rametta</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sant'Andrea Hospital, Vercelli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attisani</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Thoracic Surgery, Citt&#xe0; della Salute e della Scienza, Molinette Hospital, University of Turin, Italy; Department of cardiovascular surgery, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanini</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noussan</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iannaccone</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002407" MajorTopicYN="N">Catheterization, Swan-Ganz</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057785" MajorTopicYN="N">Catheters</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011651" MajorTopicYN="Y">Pulmonary Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Invasive monitoring</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">Pulmonary artery catheter</Keyword><Keyword MajorTopicYN="N">Swan-Ganz catheter</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>28</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35344825</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2022.154024</ArticleId><ArticleId IdType="pii">S0883-9441(22)00052-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40208153</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-7605</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>28</Day></PubDate></JournalIssue><Title>JACC. Cardiovascular interventions</Title><ISOAbbreviation>JACC Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Left Main Spontaneous Coronary Artery&#xa0;Dissection: Clinical Features, Management, and Outcomes.</ArticleTitle><Pagination><StartPage>975</StartPage><EndPage>983</EndPage><MedlinePgn>975-983</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcin.2025.01.427</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1936-8798(25)00498-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Spontaneous coronary artery dissection (SCAD) is an uncommon cause of acute myocardial infarction (MI) and is associated with substantial adverse events. SCAD involving the left main coronary artery (LM) is a rare but potentially life-threatening condition. Currently, minimal data on LM SCAD have been reported.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to investigate clinical features, contemporary management, and clinical outcomes of patients with LM SCAD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review and pooled analysis of published case reports was conducted using "left main" and "dissection" as keywords. The authors screened 1,106 papers in MEDLINE and Embase published between 1990 and&#xa0;2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The final analysis included 132 patients (mean age 40 &#xb1; 11 years, 80% women) diagnosed with LM SCAD. Remarkably, 36% of cases occurred during pregnancy, and 95% presented with acute coronary syndrome, 22% with cardiogenic shock, and 8% with ventricular arrhythmias. At 120-day median follow-up, all-cause death occurred in 9%, left ventricular assist device implantation or heart transplantation in 4%, recurrent MI in 13%, and urgent myocardial revascularization (MR) in 21%. Compared with conservative management, early revascularization by percutaneous coronary intervention or coronary artery bypass grafting significantly reduced the composite endpoint of all-cause death, left ventricular assist device implantation or heart transplantation, recurrent MI, and urgent MR (adjusted HR: 0.37; 95%&#xa0;CI: 0.20-0.69; P&#xa0;&lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LM SCAD carried significant acute morbidity and mortality. Early revascularization (percutaneous coronary intervention or coronary artery bypass graft) was associated with a lower incidence of early adverse outcomes&#xa0;compared with conservative management, driven largely by reduction in recurrent MI and urgent MR. These&#xa0;hypothesis-generating data should be confirmed in future prospective registries and clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morosato</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaspardone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romagnolo</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagnesi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldetti</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dormio</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Federico</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scandroglio</LastName><ForeName>Anna Mara</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chieffo</LastName><ForeName>Alaide</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy; Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godino</LastName><ForeName>Cosmo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margonato</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy; Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamo</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metra</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchetche</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Groupe Cardio-Vasculaire lnterventionnel, Cinique Pasteur, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumonteil</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Groupe Cardio-Vasculaire lnterventionnel, Cinique Pasteur, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tweet</LastName><ForeName>Marysia S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saw</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Vancouver General Hospital, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beneduce</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Groupe Cardio-Vasculaire lnterventionnel, Cinique Pasteur, Toulouse, France; Heart Valve Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: beneduce.alessandro@hsr.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 HL155506</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Cardiovasc Interv</MedlineTA><NlmUniqueID>101467004</NlmUniqueID><ISSNLinking>1936-8798</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C565153">Coronary Artery Dissection, Spontaneous</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003330" MajorTopicYN="Y">Coronary Vessel Anomalies</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="Y">Vascular Diseases</DescriptorName><QualifierName UI="Q000151" MajorTopicYN="N">congenital</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="Y">Coronary Artery Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072700" MajorTopicYN="Y">Conservative Treatment</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011249" MajorTopicYN="Y">Pregnancy Complications, Cardiovascular</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute coronary syndrome(s)</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">ischemic heart disease</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">spontaneous coronary artery dissection</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures Dr Beneduce has received speaker fees from Abiomed, Boston Scientific, and Medtronic, all outside the submitted work. Dr Baldetti has received speaker fees from Abiomed, outside the submitted work. Dr Pagnesi has received personal fees from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics, and Vifor Pharma, all outside the submitted work. Dr Tweet is supported by National Heart, Lung, and Blood Institute award K23HL155506. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>10</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40208153</ArticleId><ArticleId IdType="mid">NIHMS2094466</ArticleId><ArticleId IdType="pmc">PMC12290918</ArticleId><ArticleId IdType="doi">10.1016/j.jcin.2025.01.427</ArticleId><ArticleId IdType="pii">S1936-8798(25)00498-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saw J, Mancini GBJ, Humphries KH. Contemporary review on spontaneous coronary artery dissection. J Am Coll Cardiol. 2016;68:297&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">27417009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. Circulation. 2018;137(19):e523&#x2013;e557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5957087</ArticleId><ArticleId IdType="pubmed">29472380</ArticleId></ArticleIdList></Reference><Reference><Citation>Tweet MS, Hayes SN, Pitta SR, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. 2012;126:579&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">22800851</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiguchi T, Tanaka A, Ozaki Y, et al. Prevalence of spontaneous coronary artery dissection in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2016;5:263&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">24585938</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima T, Noguchi T, Haruta S, et al. Prognostic impact of spontaneous coronary artery dissection in young female patients with acute myocardial infarction: a report from the Angina Pectoris&#x2013;Myocardial Infarction Multicenter Investigators in Japan. Int J Cardiol. 2016;207:341&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">26820364</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold JR, West NE, van Gaal WJ, Karamitsos TD, Banning AP. The role of Intravascular Ultrasound in the management of spontaneous coronary artery dissection. Cardiovasc Ultrasound. 2008;6:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2429898</ArticleId><ArticleId IdType="pubmed">18513437</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfonso F, Paulo M, Gonzalo N, et al. Diagnosis of spontaneous coronary artery dissection by optical coherence tomography. J Am Coll Cardiol. 2012;59:1073&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">22421300</ArticleId></ArticleIdList></Reference><Reference><Citation>Saw J, Starovoytov A, Aymong E, et al. Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-year outcomes. J Am Coll Cardiol. 2022;80:1585&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">36265953</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014;129:1048&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">24548843</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel R, Alfadhel M, McAlister C, et al. De novo left main spontaneous coronary artery dissection. JACC Cardiovasc Interv. 2022;15:2349&#x2013;2351.</Citation><ArticleIdList><ArticleId IdType="pubmed">36423986</ArticleId></ArticleIdList></Reference><Reference><Citation>Benenati S, Giacobbe F, Zingarelli A, et al. Interventional versus conservative strategy in patients with spontaneous coronary artery dissections: insights from DISCO Registry. Circ Cardiovasc Interv. 2023;16(6):e012780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10810347</ArticleId><ArticleId IdType="pubmed">37259861</ArticleId></ArticleIdList></Reference><Reference><Citation>Clare R, Duan L, Phan D, et al. Characteristics and clinical outcomes of patients with spontaneous coronary artery dissection. J Am Heart Assoc. 2019;8:e012570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585323</ArticleId><ArticleId IdType="pubmed">31084345</ArticleId></ArticleIdList></Reference><Reference><Citation>Tweet MS, Lewey J, Smilowitz NR, Rose CH, Best PJM. Pregnancy-associated myocardial infarction. Circ Cardiovasc Interv. 2020;13:e008687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854968</ArticleId><ArticleId IdType="pubmed">32862672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tweet MS, Hayes SN, Codsi E, Gulati R, Rose CH, Best PJM. Spontaneous coronary artery dissection associated with pregnancy. J Am Coll Cardiol. 2017;70:426&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">28728686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cade JR, Szarf G, de Siqueira MEM, et al. Pregnancy-associated spontaneous coronary artery dissection: insights from a case series of 13 patients. Eur Heart J Cardiovasc Imaging. 2017;18:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26928981</ArticleId></ArticleIdList></Reference><Reference><Citation>Combaret N, Gerbaud E, D&#xe9;rimay F, et al. National French registry of spontaneous coronary artery dissections: prevalence of fibromuscular dysplasia and genetic analyses. EuroIntervention. 2021;17:508&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9725012</ArticleId><ArticleId IdType="pubmed">33319763</ArticleId></ArticleIdList></Reference><Reference><Citation>Adlam D, Alfonso F, Maas AHEM, et al. European Society of Cardiology, Acute Cardiovascular Care Association, SCAD Study Group: a position paper on spontaneous coronary artery dissection. Eur Heart J. 2018;39:3353&#x2013;3368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6148526</ArticleId><ArticleId IdType="pubmed">29481627</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterbury TM, Tweet MS, Hayes SN, et al. Early natural history of spontaneous coronary artery dissection. Circ Cardiovasc Interv. 2018;11:e006772.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354594</ArticleId></ArticleIdList></Reference><Reference><Citation>Tweet MS, Eleid MF, Best PJM, et al. Spontaneous coronary artery dissection revascularization versus conservative therapy. Circ Cardiovasc Interv. 2014;7:777&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">25406203</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlister C, Alfadhel M, Samuel R, et al. Differences in demographics and outcomes between men and women with spontaneous coronary artery dissection. JACC Cardiovasc Interv. 2022;15:2052&#x2013;2061.</Citation><ArticleIdList><ArticleId IdType="pubmed">36265936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chieffo A, Buchanan GL, Mauri F, et al. ACS and STEMI treatment: gender-related issues. EuroIntervention. 2012;8(suppl P):P27&#x2013;P35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22917787</ArticleId></ArticleIdList></Reference><Reference><Citation>Smilowitz NR, Mohananey D, Razzouk L, Weisz G, Slater JN. Impact and trends of intravascular imaging in diagnostic coronary angiography and percutaneous coronary intervention in inpatients in the United States. Catheter Cardiovasc Interv. 2018;92:E410&#x2013;E415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6258336</ArticleId><ArticleId IdType="pubmed">30019831</ArticleId></ArticleIdList></Reference><Reference><Citation>Koskinas KC, Nakamura M, R&#xe4;ber L, et al. Current use of intracoronary imaging in interventional practice&#x2014;results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) clinical practice survey. EuroIntervention. 2018;14:e475&#x2013;e484.</Citation><ArticleIdList><ArticleId IdType="pubmed">29537966</ArticleId></ArticleIdList></Reference><Reference><Citation>Krittanawong C, Gulati R, Eitzman D, Jneid H. Revascularization in patients with spontaneous coronary artery dissection: where are we now? J Am Heart Assoc. 2021;10:e018551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8403332</ArticleId><ArticleId IdType="pubmed">34187166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lettieri C, Zavalloni D, Rossini R, et al. Management and long-term prognosis of spontaneous coronary artery dissection. Am J Cardiol. 2015;116:66&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">25937347</ArticleId></ArticleIdList></Reference><Reference><Citation>Saw J, Starovoytov A, Humphries KH, et al. Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes. Eur Heart J. 2019;40:1188&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6462308</ArticleId><ArticleId IdType="pubmed">30698711</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720&#x2013;3826.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:197&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">34895951</ArticleId></ArticleIdList></Reference><Reference><Citation>Saw J, Humphries KH, Aymong E, et al. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol. 2017;70:1148&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">28838364</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfonso F, de la Torre Hern&#xe1;ndez JM, Ib&#xe1;&#xf1;ez B, et al. Rationale and design of the BA-SCAD (Beta-Blockers and Antiplatelet Agents in Patients With Spontaneous Coronary Artery Dissection) randomized clinical trial. Rev Esp Cardiol (Engl Ed). 2022;75:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">34561195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16215376</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0090-3493</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>10</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Lactate and glucose metabolism in severe sepsis and cardiogenic shock.</ArticleTitle><Pagination><StartPage>2235</StartPage><EndPage>2240</EndPage><MedlinePgn>2235-40</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the relative importance of increased lactate production as opposed to decreased utilization in hyperlactatemic patients, as well as their relation to glucose metabolism.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective observational study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Surgical intensive care unit of a university hospital.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Seven patients with severe sepsis or septic shock, seven patients with cardiogenic shock, and seven healthy volunteers.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">C-labeled sodium lactate was infused at 10 micromol/kg/min and then at 20 micromol/kg/min over 120 mins each. H-labeled glucose was infused throughout.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Baseline arterial lactate was higher in septic (3.2 +/- 2.6) and cardiogenic shock patients (2.8 +/- 0.4) than in healthy volunteers (0.9 +/- 0.20 mmol/L, p &lt; .05). Lactate clearance, computed using pharmacokinetic calculations, was similar in septic, cardiogenic shock, and controls, respectively: 10.8 +/- 5.4, 9.6 +/- 2.1, and 12.0 +/- 2.6 mL/kg/min. Endogenous lactate production was determined as the initial lactate concentration multiplied by lactate clearance. It was markedly enhanced in the patients (septic 26.2 +/- 10.5; cardiogenic shock 26.6 +/- 5.1) compared with controls (11.2 +/- 2.7 micromol/kg/min, p &lt; .01). C-lactate oxidation (septic 54 +/- 25; cardiogenic shock 43 +/- 16; controls 65 +/- 15% of a lactate load of 10 micromol/kg/min) and transformation of C-lactate into C-glucose were not different (respectively, 15 +/- 15, 9 +/- 18, and 10 +/- 7%). Endogenous glucose production was markedly increased in the patients (septic 14.8 +/- 1.8; cardiogenic shock 15.0 +/- 1.5) compared with controls (7.2 +/- 1.1 micromol/kg/min, p &lt; .01) and was not influenced by lactate infusion.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients suffering from septic or cardiogenic shock, hyperlactatemia was mainly related to increased production, whereas lactate clearance was similar to healthy subjects. Increased lactate production was concomitant to hyperglycemia and increased glucose turnover, suggesting that the latter substantially influences lactate metabolism during critical illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Revelly</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit, University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tappy</LastName><ForeName>Luc</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Alexandro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bollmann</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cayeux</LastName><ForeName>Marie-Christine</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Mette M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Chiol&#xe9;ro</LastName><ForeName>Ren&#xe9; L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>TU7HW0W0QT</RegistryNumber><NameOfSubstance UI="D019354">Sodium Lactate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2005 Oct;33(10):2420-2. doi: 10.1097/01.ccm.0000183003.65144.c7.</RefSource><PMID Version="1">16215407</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019354" MajorTopicYN="N">Sodium Lactate</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16215376</ArticleId><ArticleId IdType="doi">10.1097/01.ccm.0000181525.99295.8f</ArticleId><ArticleId IdType="pii">00003246-200510000-00013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34145993</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2055-5822</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>ESC heart failure</Title><ISOAbbreviation>ESC Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial.</ArticleTitle><Pagination><StartPage>3339</StartPage><EndPage>3347</EndPage><MedlinePgn>3339-3347</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ehf2.13427</ELocationID><Abstract><AbstractText Label="AIMS">Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used in circulatory failure. The main indications are cardiogenic shock, post-cardiotomy cardiac failure, and refractory cardiac arrest. However, VA-ECMO weaning is particularly challenging, and weaning failure is reported to be as high as 50%, with increased related mortality. Levosimendan is a novel long acting effect inodilator used in cardiogenic shock and terminal heart failure decompensation. Levosimendan use in VA-ECMO patients seems to reduce weaning failure regardless of the initial aetiology and to reduce mortality when administrated early after VA-ECMO initiation. However, studies are limited to retrospective analyses and reported case series. The aim of the WEANILEVO trial is to evaluate whether administration of levosimendan before VA-ECMO weaning is associated with a reduced rates of weaning failure and recourse to other temporary circulatory support.</AbstractText><AbstractText Label="METHODS AND RESULTS">WEANILEVO is a randomized, prospective, multicentre, double-blind, parallel-group, controlled trial. One hundred eighty patients will be enrolled if they had acute circulatory heart failure treated with VA-ECMO and for whom weaning is expected within 48&#xa0;h. The study drugs are either levosimendan (0.2&#xa0;&#x3bc;g/kg/min for 24&#xa0;h) or a placebo. The primary endpoint of the trial is the absence of VA-ECMO weaning, recourse to another VA-ECMO, or other temporary circulatory assistance or death within 7&#xa0;days of VA-ECMO weaning.</AbstractText><AbstractText Label="CONCLUSIONS">Levosimendan use in VA-ECMO appears to be beneficial for reducing weaning failure and mortality. The results of WEANILEVO should significantly influence decisions regarding the use of levosimendan for VA-ECMO weaning.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. ESC Heart Failure published by John Wiley &amp; Sons Ltd on behalf of European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ellouze</LastName><ForeName>Omar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-8003-5697</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soudry Faure</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Direction of Clinical Research, University Hospital of Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radhouani</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou-Arab</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Amiens, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besnier</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moussa</LastName><ForeName>Mouhamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cransac</LastName><ForeName>Am&#xe9;lie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University Hospital of Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ksiazek</LastName><ForeName>Elea</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Direction of Clinical Research, University Hospital of Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Marc-Olivier</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Caen, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mertes</LastName><ForeName>Paul Michel</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouhemad</LastName><ForeName>Belaid</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guinot</LastName><ForeName>Pierre Gr&#xe9;goire</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>ESC Heart Fail</MedlineTA><NlmUniqueID>101669191</NlmUniqueID><ISSNLinking>2055-5822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>ESC Heart Fail. 2022 Feb;9(1):236-240. doi: 10.1002/ehf2.13751.</RefSource><PMID Version="1">34873878</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Levosimendan</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Weaning</Keyword></KeywordList><CoiStatement>The authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>19</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34145993</ArticleId><ArticleId IdType="pmc">PMC8318420</ArticleId><ArticleId IdType="doi">10.1002/ehf2.13427</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Becher PM, Schrage B, Sinning CR, Schmack B, Fluschnik N, Schwarzl M, Waldeyer C, Lindner D, Seiffert M, Neumann JT, Bernhardt AM, Zeymer U, Thiele H, Reichenspurner H, Blankenberg S, Twerenbold R, Westermann D. Venoarterial extracorporeal membrane oxygenation for cardiopulmonary support. Circulation 2018; 138: 2298&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pubmed">30571518</ArticleId></ArticleIdList></Reference><Reference><Citation>Keebler ME, Haddad EV, Choi CW, McGrane S, Zalawadiya S, Schlendorf KH, Brinkley DM, Danter MR, Wigger M, Menachem JN, Shah A, Lindenfeld J. Venoarterial extracorporeal membrane oxygenation in cardiogenic shock. JACC Heart Fail 2018; 6: 503&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">29655828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellouze O, Vuillet M, Perrot J, Grosjean S, Missaoui A, Aho S, Malapert G, Bouhemad B, Bouchot O, Girard C. Comparable outcome of out&#x2010;of&#x2010;hospital cardiac arrest and in&#x2010;hospital cardiac arrest treated with extracorporeal life support. Artif Organs 2018; 42: 15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">28877346</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso S, Matsui H, Fushimi K, Yasunaga H. In&#x2010;hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a national inpatient database in Japan. Crit Care 2016; 20: 80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820970</ArticleId><ArticleId IdType="pubmed">27044572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellouze O, Abbad X, Constandache T, Missaoui A, Berthoud V, Daily T, Aho S, Bouchot O, Bouhemad B, Guinot PG. Risk factors of bleeding in patients undergoing venoarterial extracorporeal membrane oxygenation. Ann Thorac Surg 2020; S0003&#x2013;4975: 30362&#x2013;30363.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171730</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehron J, Schuster M, Rindler F, Bongert M, B&#xf6;ning A, Krombach G, Fiebich M, Grieshaber P, EMPACS (Exploration of the mixing phenomena during interaction of internal and external circulations) study group . Watershed phenomena during extracorporeal life support and their clinical impact: a systematic in vitro investigation. ESC Heart Fail 2020; 7: 1850&#x2013;1861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7373893</ArticleId><ArticleId IdType="pubmed">32530129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Pieri M, Arnaez Corada B, Ajello S, Melisurgo G, De Bonis M, Zangrillo A. Timing and strategy for weaning from venoarterial ECMO are complex issues. J Cardiothorac Vasc Anesth 2015; 29: 906&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">25836952</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiura A, Abe R, Nakayama T, Hattori N, Fujimoto Y, Himi T, Sano K, Oda S, Kobayashi Y. Predictors of successful weaning from veno&#x2010;arterial extracorporeal membrane oxygenation after coronary revascularization for acute myocardial infarction complicated by cardiac arrest: a retrospective multicenter study. Shock 2019; 51: 690&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">30080744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson F, Guarracino F, Schwinger RHG. The inodilator levosimendan as a treatment for acute heart failure in various settings. Eur Heart J Suppl 2017; 19: C2&#x2013;C7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932561</ArticleId><ArticleId IdType="pubmed">29249904</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieminen MS, Buerke M, Cohen&#x2010;Sol&#xe1;l A, Costa S, &#xc9;des I, Erlikh A, Franco F, Gibson C, Gorjup V, Guarracino F, Gustafsson F, Harjola VP, Husebye T, Karason K, Katsytadze I, Kaul S, Kivikko M, Marenzi G, Masip J, Matskeplishvili S, Mebazaa A, M&#xf8;ller JE, Nessler J, Nessler B, Ntalianis A, Oliva F, Pichler&#x2010;Cetin E, P&#xf5;der P, Recio&#x2010;Mayoral A, Rex S, Rokyta R, Strasser RH, Zima E, Pollesello P. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. Int J Cardiol 2016; 218: 150&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">27232927</ArticleId></ArticleIdList></Reference><Reference><Citation>Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006; 104: 556&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">16508404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholley B, Caruba T, Grosjean S, Amour J, Ouattara A, Villacorta J, Miguet B, Guinet P, L&#xe9;vy F, Squara P, A&#xef;t Hamou N, Carillion A, Boyer J, Boughenou MF, Rosier S, Robin E, Radutoiu M, Durand M, Guidon C, Desebbe O, Charles&#x2010;Nelson A, Menasch&#xe9; P, Rozec B, Girard C, Fellahi JL, Pirracchio R, Chatellier G. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA 2017; 318: 548&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5817482</ArticleId><ArticleId IdType="pubmed">28787507</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Fremes S, Duncan A, Soltesz EG, Luber J, Park S, Argenziano M, Murphy E, Marcel R, Kalavrouziotis D, Nagpal D, Bozinovski J, Toller W, Heringlake M, Goodman SG, Levy JH, Harrington RA, Anstrom KJ, Alexander JH. LEVO&#x2010;CTS Investigators. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 2017; 376: 2032&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">28316276</ArticleId></ArticleIdList></Reference><Reference><Citation>Distelmaier K, Roth C, Schrutka L, Binder C, Steinlechner B, Heinz G, Lang IM, Maurer G, Koinig H, Niessner A, H&#xfc;lsmann M, Speidl W, Goliasch G. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth 2016; 117: 52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913403</ArticleId><ArticleId IdType="pubmed">27317704</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos LM, Seoane L, Furmento JF, Costabel JP, Diez M, Vrancic M, Aissaoui N, Benzad&#xf3;n MN, Navia D. Effects of levosimendan on weaning and survival in adult cardiogenic shock patients with veno&#x2010;arterial extracorporeal membrane oxygenation: systematic review and meta&#x2010;analysis. Perfusion 2020; 35: 484&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">32449494</ArticleId></ArticleIdList></Reference><Reference><Citation>Vally S, Ferdynus C, Persichini R, Bouchet B, Braunberger E, Lo Pinto H, Martinet O, Vandroux D, Aujoulat T, Allyn J, Allou N. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care 2019; 9: 24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358626</ArticleId><ArticleId IdType="pubmed">30707314</ArticleId></ArticleIdList></Reference><Reference><Citation>Affronti A, di Bella I, Carino D, Ragni T. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO J 2013; 59: 554&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">24172260</ArticleId></ArticleIdList></Reference><Reference><Citation>Toller W, Algotsson L, Guarracino F, H&#xf6;rmann C, Knotzer J, Lehmann A, Rajek A, Salmenper&#xe4; M, Schirmer U, Tritapepe L, Weis F, Landoni G. Perioperative use of levosimendan: best practice in operative settings. J Cardiothorac Vasc Anesth 2013; 27: 361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">22658687</ArticleId></ArticleIdList></Reference><Reference><Citation>Toller W, Heringlake M, Guarracino F, Algotsson L, Alvarez J, Argyriadou H, Ben&#x2010;Gal T, &#x10c;ern&#xfd; V, Cholley B, Eremenko A, Guerrero&#x2010;Orriach JL, J&#xe4;rvel&#xe4; K, Karanovic N, Kivikko M, Lahtinen P, Lomivorotov V, Mehta RH, Mu&#x161;i&#x10d; &#x160;, Pollesello P, Rex S, Riha H, Rudiger A, Salmenper&#xe4; M, Szudi L, Tritapepe L, Wyncoll D, &#xd6;wall A. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol 2015; 184: 323&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">25734940</ArticleId></ArticleIdList></Reference><Reference><Citation>Belletti A, Lerose CC, Zangrillo A, Landoni G. Vasoactive&#x2010;inotropic score: evolution, clinical utility, and pitfalls. J Cardiothorac Vasc Anesth 2020; S1053&#x2013;0770: 31035&#x2013;31031.</Citation><ArticleIdList><ArticleId IdType="pubmed">33069558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohme J, Piat C, Aissat N, Lebreton G, Duceau B, Charfeddine A, Baptiste A, Bougl&#xe9; A. Weaning&#x2010;related shock in patients with ECMO: incidence, mortality, and predisposing factors. J Cardiothorac Vasc Anesth 2020; S1053&#x2013;0770: 30742&#x2013;30744.</Citation><ArticleIdList><ArticleId IdType="pubmed">32828655</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N, Luyt CE, Leprince P, Trouillet JL, L&#xe9;ger P, Pavie A, Diebold B, Chastre J, Combes A. Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med 2011; 37: 1738&#x2013;1745.</Citation><ArticleIdList><ArticleId IdType="pubmed">21965097</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KC, Lin LY, Chen YS, Lai CH, Hwang JJ, Lin LC. Three&#x2010;dimensional echocardiography&#x2010;derived right ventricular ejection fraction correlates with success of decannulation and prognosis in patients stabilized by venoarterial extracorporeal life support. J Am Soc Echocardiogr 2018; 31: 169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">29079045</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancari F, Fiore A, J&#xf3;nsson K, Gatti G, Zipfel S, Ruggieri VG, Perrotti A, Bounader K, Loforte A, Lechiancole A, Saeed D, Lichtenberg A, Pol M, Spadaccio C, Pettinari M, Mogianos K, Alkhamees K, Mariscalco G, El Dean Z, Settembre N, Welp H, Dell'Aquila AM, Fux T, Juvonen T, Dal&#xe9;n M. Prognostic significance of arterial lactate levels at weaning from postcardiotomy venoarterial extracorporeal membrane oxygenation. J Clin Med 2019; 8: 2218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6947236</ArticleId><ArticleId IdType="pubmed">31847464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A, Nieminen MS, Packer M, Cohen&#x2010;Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, P&#xf5;der P, Kivikko M, SURVIVE Investigators . Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297: 1883&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pubmed">17473298</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann J, Henrich EC, Strobl H, Prondzinsky R, Weiche S, Thiele H, Werdan K, Frantz S, Unverzagt S. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 2018; 1: CD009669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491099</ArticleId><ArticleId IdType="pubmed">29376560</ArticleId></ArticleIdList></Reference><Reference><Citation>Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, Calabr&#xf2; MG, Grigoryev EV, Likhvantsev VV, Salgado&#x2010;Filho MF, Bianchi A, Pasyuga VV, Baiocchi M, Pappalardo F, Monaco F, Boboshko VA, Abubakirov MN, Amantea B, Lembo R, Brazzi L, Verniero L, Bertini P, Scandroglio AM, Bove T, Belletti A, Michienzi MG, Shukevich DL, Zabelina TS, Bellomo R, Zangrillo A, CHEETAH Study Group . Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med 2017; 376: 2021&#x2013;2031.</Citation><ArticleIdList><ArticleId IdType="pubmed">28320259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen QH, Zheng RQ, Lin H, Shao J, Yu JQ, Wang HL. Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta&#x2010;analysis of randomized controlled trials. Crit Care 2017; 21: 253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645931</ArticleId><ArticleId IdType="pubmed">29041948</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacky A, Rudiger A, Kr&#xfc;ger B, Wilhelm MJ, Paal S, Seifert B, Spahn DR, Bettex D. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery&#x2014;a retrospective before&#x2010;and&#x2010;after study. J Cardiothorac Vasc Anesth 2018; 32: 2112&#x2013;2119.</Citation><ArticleIdList><ArticleId IdType="pubmed">29748076</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilherme E, Jacquet&#x2010;Lagr&#xe8;ze M, Pozzi M, Achana F, Armoiry X, Fellahi JL. Correction to: can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis. Crit Care 2020; 24: 487 Erratum for: Crit Care. 2020;24(1):442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7367381</ArticleId><ArticleId IdType="pubmed">32677985</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie H, Yang F, Hou D, Wang X, Wang L, Wang H, Hou X. Risk factors of in&#x2010;hospital mortality in adult postcardiotomy cardiogenic shock patients successfully weaned from venoarterial extracorporeal membrane oxygenation. Perfusion 2020; 35: 417&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">31854226</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33019394</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>40</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Impact of atrial fibrillation on outcomes of patients treated by transcatheter mitral valve repair: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e22195</StartPage><MedlinePgn>e22195</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e22195</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000022195</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Conflicting data have been reported related to the impact of atrial fibrillation (AF) on outcomes after transcatheter mitral valve repair with MitraClip (MC) implantation. In this study, we assessed the prognosis of MC-treated patients according to the presence of pre-existing AF.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Randomized and observational studies reporting outcomes of pre-existing AF or sinus rhythm in patients undergoing MC treatment were identified with an electronic search. Outcomes of interest were short-and long-term mortality, stroke, bleeding, rehospitalization, myocardial infarction (MI), cardiogenic shock, acute procedure success, the hospital stay, and the number of Clips implanted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight studies (8466 individuals) were eligible. Compared to sinus rhythm, long-term mortality, the risk of bleeding, rehospitalization, and longer hospital stay were significantly higher in AF groups, whereas similar correlations were found in the analysis of other outcomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AF may be related with worse outcomes in patients undergoing MC implantation, including long-term mortality, major bleeding, and rehospitalization. AF should be taken into account when referring a patient for MC treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Fuqiang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Honghao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Endovascular Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Fanfan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Haibo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiawei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="N">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>This study was supported by the grant from the National Natural Science Foundation of China (No. 31601139) and the Scientific Research Initiation Foundation for Youth of the First Affiliated Hospital of Zhengzhou University. The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33019394</ArticleId><ArticleId IdType="pmc">PMC7535682</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000022195</ArticleId><ArticleId IdType="pii">00005792-202010020-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980116</ArticleId></ArticleIdList></Reference><Reference><Citation>Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15745978</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Zoppini G, Benfari G, et al. Mitral regurgitation and increased risk of all-cause and cardiovascular mortality in patients with type 2 diabetes. Am J Med 2017;130:70&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27555095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamorano JL, Badano LP, Bruce C, et al. EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. Eur Heart J 2011;32:2189&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">21885465</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Vahanian AS, Adams DH, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: Part 1: clinical trial design principles: a consensus document from the mitral valve academic research consortium. J Am Coll Cardiol 2015;66:278&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">26184622</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886619</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SV, Chinnakondepalli KM, Spertus JA, et al. Health status after transcatheter mitral-valve repair in heart failure and secondary mitral regurgitation: COAPT trial. J Am Coll Cardiol 2019;73:2123&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499691</ArticleId><ArticleId IdType="pubmed">30894288</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol 2014;64:182&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24184254</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol 2014;64:875&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25169171</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeburger J, Borger MA, Doll N, et al. Comparison of outcomes of minimally invasive mitral valve surgery for posterior, anterior and bileaflet prolapse. Eur J Cardiothorac Surg 2009;36:532&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19464911</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutinho GF, Garcia AL, Correia PM, et al. Negative impact of atrial fibrillation and pulmonary hypertension after mitral valve surgery in asymptomatic patients with severe mitral regurgitation: a 20-year follow-up. Eur J Cardiothorac Surg 2015;48:548&#x2013;55. 555-556.</Citation><ArticleIdList><ArticleId IdType="pubmed">25564214</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls M, Lubos E, Boekstegers P, et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J 2016;37:703&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761401</ArticleId><ArticleId IdType="pubmed">26614824</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol 2015;66:2844&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26718672</ArticleId></ArticleIdList></Reference><Reference><Citation>Velu JF, Kortlandt FA, Hendriks T, et al. Comparison of outcome after percutaneous mitral valve repair with the mitraclip in patients with versus without atrial fibrillation. Am J Cardiol 2017;120:2035&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">29033048</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabs A, von Bardeleben RS, Boekstegers P, et al. Effects of atrial fibrillation and heart rate on percutaneous mitral valve repair with MitraClip: results from the TRAnscatheter Mitral valve Interventions (TRAMI) registry. Eurointervention 2017;12:1697&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">28216472</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann HC, Gertz ZM, Silvestry FE, et al. Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular valve edge-to-edge repair study) randomized trial. J Am Coll Cardiol 2012;59:1312&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22464260</ArticleId></ArticleIdList></Reference><Reference><Citation>Mojoli M, Gersh BJ, Barioli A, et al. Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: a systematic review and meta-analysis. Am Heart J 2017;192:64&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">28938965</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating s ummary time-to-event data into meta-analysis. Trials 2007;8:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1920534</ArticleId><ArticleId IdType="pubmed">17555582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler M, Pott A, Mammadova E, et al. Atrial fibrillation predicts long-term outcome after transcatheter edge-to-edge mitral valve repair by mitraclip implantation. Biomolecules 2018;8:152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6316291</ArticleId><ArticleId IdType="pubmed">30463247</ArticleId></ArticleIdList></Reference><Reference><Citation>Spieker M, Hellhammer K, Spiesshofer J, et al. Effect of atrial fibrillation and mitral valve gradients on response to percutaneous mitral valve repair with the mitraclip system. Am J Cardiol 2018;122:1371&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30103906</ArticleId></ArticleIdList></Reference><Reference><Citation>Subahi A, Munir A, Abubakar H, et al. The impact of atrial fibrillation on transcatheter mitral valve repair outcomes: a propensity-matched analysis. J Interv Cardiol 2018;31:925&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30456770</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Vemulapalli S, Stebbins A, et al. The prevalence and impact of atrial fibrillation on 1-year outcomes in patients undergoing transcatheter mitral valve repair: results from the society of thoracic surgeons/american college of cardiology transcatheter valve therapy registry. JACC Cardiovasc Interv 2019;12:569&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">30898255</ArticleId></ArticleIdList></Reference><Reference><Citation>Caggegi AM, Scandura S, Capranzano P, et al. Effects of atrial fibrillation in patients undergoing mitral valve repair with the mitraclip system: one-year outcomes from the GRASP registry. Eur Heart J Cardiovasc Imaging 2016;17: Supplement 2:</Citation></Reference><Reference><Citation>De Rosa R, Silverio A, Baldi C, et al. Transcatheter repair of functional mitral regurgitation in heart failure patients- a meta-analysis of 23 studies on MitraClip implantation. Circ J 2018;82:2800&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30210070</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigioni F, Benfari G, Vanoverschelde JL, et al. Long-term implications of atrial fibrillation in patients with degenerative mitral regurgitation. J Am Coll Cardiol 2019;73:264&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">30678755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bum KJ, Suk MJ, Yun SC, et al. Long-term outcomes of mechanical valve replacement in patients with atrial fibrillation: impact of the maze procedure. Circulation 2012;125:2071&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22456472</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertz ZM, Raina A, Saghy L, et al. Evidence of atrial functional mitral regurgitation due to atrial f ibrillation: reversal with arrhythmia control. J Am Coll Cardiol 2011;58:1474&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">21939832</ArticleId></ArticleIdList></Reference><Reference><Citation>Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 2015;65:1231&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25814231</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover FL, Vemulapalli S, Carroll JD, et al. 2016 Annual report of the society of thoracic surgeons/American College of cardiology transcatheter valve therapy registry. J Am Coll Cardiol 2017;69:1215&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">27956264</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013;62:1052&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23747789</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexiou C, Doukas G, Oc M, et al. The effect of preoperative atrial fibrillation on survival following mitral valve repair for degenerative mitral regurgitation. Eur J Cardiothorac Surg 2007;31:586&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17280837</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarito M, Pagnesi M, Martino EA, et al. Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart 2018;104:306&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28663365</ArticleId></ArticleIdList></Reference><Reference><Citation>Allessie MA. Atrial electrophysiologic remodeling: another vicious circle? J Cardiovasc Electrophysiol 1998;9:1378&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869538</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1866765</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeger J, Markovic S, Kessler M, et al. Apixaban after percutaneous edge-to-edge mitral valve repair in patients with maintained sinus rhythm. JACC Cardiovasc Interv 2019;12:214&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30678801</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi R, Patel K, Desai R, et al. Incidence and impact of new-onset atrial fibrillation on transcatheter mitral valve repair. Eur J Intern Med 2019;60:e18&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30268573</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber MI, Silwedel J, Friedrichs K, et al. Bleeding complications after percutaneous mitral valve repair with the MitraClip. Am J Cardiol 2018;121:94&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29122275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler M, Seeger J, Muche R, et al. Predictors of rehospitalization after percutaneous edge-to-edge mitral valve repair by MitraClip implantation. Eur J Heart Fail 2019;21:182&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">30178493</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Vemulapalli S, Stebbins A, et al. Atrial fibrillation is associated with higher rates of death and heart failure hospitalizations in patients undergoing mitraclip: outcomes from the TVT registry. J Am Coll Cardiol 2018;71: 11 Supplement 1:</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40042826</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2048-8734</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>European heart journal. Acute cardiovascular care</Title><ISOAbbreviation>Eur Heart J Acute Cardiovasc Care</ISOAbbreviation></Journal><ArticleTitle>Femoral vs. radial approach for primary percutaneous intervention in cardiogenic shock: a subanalysis from the ECLS-SHOCK trial.</ArticleTitle><Pagination><StartPage>351</StartPage><EndPage>358</EndPage><MedlinePgn>351-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjacc/zuaf035</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Cardiogenic shock (CS) is a life-threatening complication of acute coronary syndromes. Early revascularization with treating the culprit lesion improves survival. Nevertheless, the impact of access site (femoral vs. radial) on outcomes in infarct-related CS also in conjunction with extracorporeal life support (ECLS) remains unclear.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">This subanalysis of the ECLS-SHOCK trial included patients with infarct-related CS treated with or without ECLS, divided into femoral and radial access groups. The primary endpoint was 30-day mortality. Secondary endpoints included renal replacement therapy, repeat revascularization, reinfarction, rehospitalization for congestive heart failure, and poor neurological outcome (Cerebral Performance Categories 3-5) within 30 days. Safety outcomes included bleeding and peripheral vascular complications. Among 415 patients, percutaneous coronary intervention was initially intended through femoral (n = 304; 72.9%) or radial (n = 111; 26.6%) access. In the intended access site analysis, 25 patients (22.5%) in the radial group switched to femoral access, while 3 patients (1%) in the femoral group switched to radial access prior to or after coronary angiography. At 30 days, the overall mortality rate was higher in the femoral group compared with the radial group (52.0 vs. 37.8%) with a relative risk (RR) of 1.37, a 95% confidence interval (CI) of 1.06-1.78, and a P-value of 0.011 with no significant differences in the crude rates of secondary and safety endpoints. In the analysis based on the actual access site (as opposed to intended access site used), 7.8% of patients in the ECLS arm switched from radial to femoral, while 7.5% of patients in the conservative arm switched from radial to femoral for or after coronary angiography. Mortality rates were higher in the femoral group for both ECLS arm (52.7 vs. 26.8%; P = 0.003; RR, 1.96; 95% CI, 1.16-3.32) and conservative arm (52.2 vs. 37.5%; P = 0.074; RR, 1.39; 95% CI, 0.94-2.06). In a multivariate analysis, femoral access was associated with a trend for predicting adjusted 30-day mortality (RR, 1.22; 95% CI, 0.95-1.55; P = 0.11).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In myocardial infarction-related CS, nearly one-fifth of patients with intended radial access switched to femoral. In multivariate analysis, femoral access was associated with a trend to adversely affect 30-day mortality.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abumayyaleh</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4766-5523</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Angiology, Hemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4495-4597</Identifier><AffiliationInfo><Affiliation>Heart Center Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassaf</LastName><ForeName>Tienush</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8001-0265</Identifier><AffiliationInfo><Affiliation>The West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahabadi</LastName><ForeName>Amir Abbas</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>The West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Asklepios Clinic Langen, Langen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6442-246X</Identifier><AffiliationInfo><Affiliation>University Heart Center L&#xfc;beck and German Center for Cardiovascular Research, Partner Site Hamburg-Kiel-L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4953-601X</Identifier><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Benjamin Franklin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemmensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Heart and Vascular Center Hamburg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennersdorf</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>SLK Kliniken Heilbronn, Heilbronn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voigt</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-6820-3005</Identifier><AffiliationInfo><Affiliation>Contilia Elisabeth-Krankenhaus, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linke</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Technische Universit&#xe4;t Dresden, Heart Center, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tigges</LastName><ForeName>Eike</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Asklepios Clinic St. Georg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2560-4068</Identifier><AffiliationInfo><Affiliation>University Hospital W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8325-250X</Identifier><AffiliationInfo><Affiliation>University Hospital D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauten</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Zentralklinik Bad Berka, Bad Berka, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feistritzer</LastName><ForeName>Hans-Josef</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Heart Center Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xf6;ss</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Heart Center Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouarrak</LastName><ForeName>Taoufik</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7742-4408</Identifier><AffiliationInfo><Affiliation>Institut f&#xfc;r Herzinfarktforschung, Ludwigshafen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9375-4861</Identifier><AffiliationInfo><Affiliation>Institut f&#xfc;r Herzinfarktforschung, Ludwigshafen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behnes</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology, Hemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duerschmied</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology, Hemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desch</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Heart Center Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4999-6238</Identifier><AffiliationInfo><Affiliation>Heart Center Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeymer</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-7077-283X</Identifier><AffiliationInfo><Affiliation>Institut f&#xfc;r Herzinfarktforschung, Ludwigshafen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akin</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4387-7115</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Angiology, Hemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Acute Cardiovasc Care</MedlineTA><NlmUniqueID>101591369</NlmUniqueID><ISSNLinking>2048-8726</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017534" MajorTopicYN="Y">Radial Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005263" MajorTopicYN="Y">Femoral Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">ECLS-SCHOCK</Keyword><Keyword MajorTopicYN="N">Femoral access</Keyword><Keyword MajorTopicYN="N">Neurological outcome</Keyword><Keyword MajorTopicYN="N">Radial access</Keyword><Keyword MajorTopicYN="N">Rehospitalization</Keyword><Keyword MajorTopicYN="N">Reinfarction</Keyword><Keyword MajorTopicYN="N">Revascularization</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList><CoiStatement>Conflict of interest: The authors declare that they have no relevant or material financial interests that relate to the research described in this paper. T.R. has received honoraria, lecture fees, and grant support from Edwards Lifesciences, AstraZeneca, Bayer, Novartis, Berlin Chemie, Daiicho-Sankyo, Boehringer Ingelheim, Novo Nordisk, Cardiac Dimensions, and Pfizer, all unrelated to this work. He is co-founder of Bimyo GmbH, a company that develops cardioprotective peptides, co-founder of MyCor GmbH, a company focusing on AI-based EKG-algorithms, and co-founder of Yes2NO, developing nitric oxide-based treatments.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>3</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>5</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>5</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40042826</ArticleId><ArticleId IdType="doi">10.1093/ehjacc/zuaf035</ArticleId><ArticleId IdType="pii">8052709</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31718322</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-3297</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Circulation. Heart failure</Title><ISOAbbreviation>Circ Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Optimal Strategy and Timing of Left Ventricular Venting During Veno-Arterial Extracorporeal Life Support for Adults in Cardiogenic Shock: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>e006486</StartPage><MedlinePgn>e006486</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCHEARTFAILURE.119.006486</ELocationID><Abstract><AbstractText Label="BACKGROUND">Veno-arterial extracorporeal life support (VA-ECLS) is widely used to treat refractory cardiogenic shock. However, increased left ventricular (LV) afterload in VA-ECLS can worsen pulmonary congestion and compromise myocardial recovery. Our objectives were to explore the efficacy, safety, and optimal timing of adjunctive LV venting strategies.</AbstractText><AbstractText Label="METHODS">A systematic search was performed on Medline, EMBASE, PubMed, CDSR, CCRCT, CINAHL, ClinicalTrials.Gov, and WHO ICTRP from inception until January 2019 for all relevant studies, including LV venting. Data were analyzed for mortality and weaning from VA-ECLS on the basis of timing of LV venting, along with adverse complications.</AbstractText><AbstractText Label="RESULTS">A total of 7995 patients were included from 62 observational studies, wherein 3458 patients had LV venting during VA-ECLS. LV venting significantly improved weaning from VA-ECLS (odds ratio, 0.62 [95% CI, 0.47-0.83]; <i>P</i>=0.001) and reduced short-term (30 day; risk ratio [RR], 0.86 [95% CI, 0.77-0.96]; <i>P</i>=0.008) but not in-hospital (RR, 0.92 [95% CI, 0.83-1.01] <i>P</i>=0.09) or long-term (6 months; RR, 0.96 [95% CI, 0.90-1.03]; <i>P</i>=0.27) mortality. Early (&lt;12 hours; RR, 0.86 [95% CI, 0.75-0.99]; <i>P</i>=0.03) but not late (&#x2265;12 hours; RR, 0.99 [95% CI, 0.71-1.38]; <i>P</i>=0.93) LV venting significantly reduced short-term mortality. Patients with LV venting spent more time on VA-ECLS (3.6 versus 2.8 days, <i>P</i>&lt;0.001), and mechanical ventilation (7.1 versus 4.6 days, <i>P</i>=0.013). With the exception of hemolysis (RR, 2.18 [95% CI, 1.58-3.01]; <i>P</i>&lt;0.00001), overall adverse events did not differ.</AbstractText><AbstractText Label="CONCLUSIONS">LV venting, especially if done early (&lt;12 hours), appears to be associated with an increased success of weaning and reduced short-term mortality. Future studies are required to delineate the importance of any or early LV venting adjuncts on mortality and morbidity outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Fares</LastName><ForeName>Abdulrahman A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Interdepartmental Division of Critical Care Medicine (A.A.A.-F., E.F.), Toronto General Hospital, University of Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Extracorporeal Life Support Program (A.A.A.-F., E.F.), Toronto General Hospital, University of Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Al-Amiri Hospital, Ministry of Health, Kuwait (A.A.A.-F.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randhawa</LastName><ForeName>Varinder K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Departments of Cardiovascular Medicine (V.K.R., J.D.E.), Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Englesakis</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Library and Information Services (M.E.), Toronto General Hospital, University of Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Peter Munk Cardiac Centre (M.A.M.), Toronto General Hospital, University of Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagpal</LastName><ForeName>A Dave</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Divisions of Cardiac Surgery and Critical Care, London Health Sciences Center, ON, Canada (A.D.N.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estep</LastName><ForeName>Jerry D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Departments of Cardiovascular Medicine (V.K.R., J.D.E.), Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltesz</LastName><ForeName>Edward G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Thoracic and Cardiovascular Surgery (E.G.S.), Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Eddy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Interdepartmental Division of Critical Care Medicine (A.A.A.-F., E.F.), Toronto General Hospital, University of Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Extracorporeal Life Support Program (A.A.A.-F., E.F.), Toronto General Hospital, University of Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Heart Fail</MedlineTA><NlmUniqueID>101479941</NlmUniqueID><ISSNLinking>1941-3289</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Circ Heart Fail. 2019 Nov;12(11):e006581. doi: 10.1161/CIRCHEARTFAILURE.119.006581.</RefSource><PMID Version="1">31718318</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="Y">Time-to-Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">morbidity</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31718322</ArticleId><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.119.006486</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35197104</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Preoperative patient factors associated with blood product use in cardiac surgery, a retrospective cohort study.</ArticleTitle><Pagination><StartPage>23</StartPage><MedlinePgn>23</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-022-01770-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiac surgery is associated with a high rate of blood use. The aim of this study is to identify preoperative patient factors associated with allogeneic Red Blood Cell (RBC) or non-Red Blood Cell (NRBC) use in cardiac surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All adult cardiac surgical procedures conducted at a single Western Australian institution were retrospectively analysed. Data was collected from the Australia and New Zealand Cardiac Surgery Database from 2015 to 2018. A number of preoperative factors were identified, relating to past medical history or preoperative cardiac status. Outcome 1 was defined as the use of one or more RBC products intra or post-operatively. Outcome 2 was defined as the use of one or more NRBC products intra or post-operatively. Multivariate logistical regression analysis was done to assess for the association between preoperative factors and allogeneic blood product use.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1595 patients were included in this study, of which 1488 underwent a Coronary Artery Bypass Graft, Valve or a combined procedure. Patients on dialysis preoperatively and those who had preoperative cardiogenic shock demonstrated the greatest risk of requiring RBC transfusion with an odds ratio of 5.643 (95% CI 1.305-24.40) and 3.257 (95% 1.801-5.882) respectively. Patients who had preoperative cardiogenic shock demonstrated the greatest risk of requiring NRBC transfusion with an odds ratio of 3.473 (95% CI 1.970-6.135). Patients who have had a previous cardiothoracic intervention are at increased risk of both RBC and NRBC transfusion, with adjusted odds ratios of 1.774 (95% CI 1.353-2.325) and 2.370 (95% CI 1.748-3.215) respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A number of factors relating to past medical history or preoperative cardiac status are implicated with increased allogeneic blood product use in cardiac surgery. Identifying high-risk patients in a preoperative setting can enable us enrol them in a blood conservation program, therefore minimizing the risk of exposure to blood transfusion.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eranki</LastName><ForeName>Aditya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4484-3304</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, John Hunter Hospital, Newcastle, Australia. adit.eranki@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson-Smith</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, John Hunter Hospital, Newcastle, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Umar</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Fiona Stanley Hospital, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merry</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Fiona Stanley Hospital, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Notre Dame, Perth, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood product use</Keyword><Keyword MajorTopicYN="N">Blood transfusion</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Coronary artery bypass graft</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Valvular heart surgery</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35197104</ArticleId><ArticleId IdType="pmc">PMC8867771</ArticleId><ArticleId IdType="doi">10.1186/s13019-022-01770-5</ArticleId><ArticleId IdType="pii">10.1186/s13019-022-01770-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McQuilten Z, Andrianopoulos N, Wood E, Cole-Sinclair M, McNeil J, Cameron P, et al. Transfusion practice varies widely in cardiac surgery: results from a national registry. J Thorac Cardiovasc Surg. 2014;147:1684&#x2013;1690. doi: 10.1016/j.jtcvs.2013.10.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2013.10.051</ArticleId><ArticleId IdType="pubmed">24332109</ArticleId></ArticleIdList></Reference><Reference><Citation>Shortt J, Polizzotto M, Waters N, Borosak M, Comande M, Devine A, et al. Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use. Transfusion. 2009;49:2296&#x2013;2303. doi: 10.1111/j.1537-2995.2009.02305.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2009.02305.x</ArticleId><ArticleId IdType="pubmed">19624492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedele P, Polizotto M, Grigoriadis G, Waters N, Comande M, Borosak M, et al. Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study. Transfusion. 2016;56:2455&#x2013;2465. doi: 10.1111/trf.13778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.13778</ArticleId><ArticleId IdType="pubmed">27600298</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald M, McMillian J. Predicting blood usage in cardiac surgery&#x2014;the transfusion predictor product. J Extra Corpor Technol. 2005;37:157&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682531</ArticleId><ArticleId IdType="pubmed">16117452</ArticleId></ArticleIdList></Reference><Reference><Citation>Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002;74:1180&#x2013;1186. doi: 10.1016/S0003-4975(02)03766-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(02)03766-9</ArticleId><ArticleId IdType="pubmed">12400765</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116:2544&#x2013;2552. doi: 10.1161/CIRCULATIONAHA.107.698977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.698977</ArticleId><ArticleId IdType="pubmed">17998460</ArticleId></ArticleIdList></Reference><Reference><Citation>LaPar D, Hawkins R, McMurry T, Isbell J, Rich J, Speir A, et al. Preoperative anemia versus blood transfusion: Which is the culprit for worse outcomes in cardiac surgery? J Thorac Cardiovasc Surg. 2018;156:66&#x2013;74. doi: 10.1016/j.jtcvs.2018.03.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2018.03.109</ArticleId><ArticleId IdType="pmc">PMC6093299</ArticleId><ArticleId IdType="pubmed">29706372</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudie R, Sterne J, Verheyden V, Bharbra M, Ranucci M, Murphy G. Risk scores to facilitate preoperative prediction of transfusion and large volume blood transfusion associated with adult cardiac surgery. Br J Anaesth. 2015;114:757&#x2013;766. doi: 10.1093/bja/aeu483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeu483</ArticleId><ArticleId IdType="pubmed">25904607</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuylsteke A, Pagel C, Gerrard C, Reddy B, Nashef S, Aldam P, et al. The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardiothorac Surg. 2011;39:924&#x2013;930. doi: 10.1016/j.ejcts.2010.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2010.10.003</ArticleId><ArticleId IdType="pubmed">21094051</ArticleId></ArticleIdList></Reference><Reference><Citation>Karkouti K, O&#x2019;Farrell R, Yau TM, Beattie WS. Reducing bleeding in cardiac surgery research group: prediction of massive blood transfusion in cardiac surgery. Can J Anesth. 2006;53:781&#x2013;794. doi: 10.1007/BF03022795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03022795</ArticleId><ArticleId IdType="pubmed">16873345</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancari F, Brasica D, Onorati F, Reichard D, Perrotti A, Ruggieri V, et al. Prediction of severe bleeding after coronary surgery: the WILLBLEED Risk Score. Thromb Haemost. 2017;117:445&#x2013;456. doi: 10.1160/TH16-09-0721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH16-09-0721</ArticleId><ArticleId IdType="pubmed">27904903</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskowitz D, Klein SA, Cousineau K, Goldweit R, Bodain C, et al. Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation centre. Ann Thorac Surg. 2004;77:626&#x2013;634. doi: 10.1016/S0003-4975(03)01345-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(03)01345-6</ArticleId><ArticleId IdType="pubmed">14759450</ArticleId></ArticleIdList></Reference><Reference><Citation>Parr K, Patel M, Dekker R, Levin R, Glynn R, Avorn J, et al. Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth. 2003;17:176&#x2013;181. doi: 10.1053/jcan.2003.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jcan.2003.44</ArticleId><ArticleId IdType="pubmed">12698398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes C, Brunori E, Cavalcante A, Moorhead S, Lopes J, Barros A. Predictors of red blood cell transfusion after cardiac surgery: a prospective cohort study. J School of Nurs. 2015;49:914&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">27419674</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv AD, Massimiano P, Burton N, Pritchard G. Effect of patient age on blood product transfusion after cardiac surgery. J Thorac Cardiovasc Surg. 2015;150:209&#x2013;214. doi: 10.1016/j.jtcvs.2015.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2015.03.022</ArticleId><ArticleId IdType="pubmed">25896463</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoughdaran S, Sarzaeem M, Bagheri J, Jebelli M, Mandager M. Predictors of blood transfusion in patients undergoing coronary artery bypass grafting surgery. Int Cardiovasc Res J. 2013;7(1):25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3987423</ArticleId><ArticleId IdType="pubmed">24757615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazlan A, Ayob Y, Hussein A, Namasiwayam T, Mohammad W. Factors influencing transfusion requirement in patients undergoing first-time, elective coronary artery bypass graft surgery. Asian J Transfus Sci. 2017;11(2):95&#x2013;101. doi: 10.4103/ajts.AJTS_51_16.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ajts.AJTS_51_16</ArticleId><ArticleId IdType="pmc">PMC5613444</ArticleId><ArticleId IdType="pubmed">28970674</ArticleId></ArticleIdList></Reference><Reference><Citation>Billah B, Reid CM, Shardey GC, Smith JAA. preoperative risk prediction model for 30 day mortality following cardiac surgery in an Australian cohort. Eur J Cardiothorac Surg. 2010;37:P1086&#x2013;1092. doi: 10.1016/j.ejcts.2009.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2009.11.021</ArticleId><ArticleId IdType="pubmed">20117015</ArticleId></ArticleIdList></Reference><Reference><Citation>Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004;44:1453&#x2013;1462. doi: 10.1111/j.1537-2995.2004.04144.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2004.04144.x</ArticleId><ArticleId IdType="pubmed">15383018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazer C, Whitlock R, Fergusson D, Hall J, Belley-Cote E, Connolly K, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med. 2017;77:2133&#x2013;2144. doi: 10.1056/NEJMoa1711818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1711818</ArticleId><ArticleId IdType="pubmed">29130845</ArticleId></ArticleIdList></Reference><Reference><Citation>Galas F, Almeida J, Fukushima J, Osawa E, Nakamura R, Silva C, et al. Blood transfusion in cardiac surgery is a risk factor for increased hospital length of stay in adult patients. J Cardiothorac Surg. 2013;8:54. doi: 10.1186/1749-8090-8-54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1749-8090-8-54</ArticleId><ArticleId IdType="pmc">PMC3639844</ArticleId><ArticleId IdType="pubmed">23531208</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers MA, Blumberg N, Saint S, Langa KM, Nallamothu BK. Hospital variation in transfusion and infection after cardiac surgery: a cohort study. BMC Med. 2009;7:37. doi: 10.1186/1741-7015-7-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-7-37</ArticleId><ArticleId IdType="pmc">PMC2727532</ArticleId><ArticleId IdType="pubmed">19646221</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder-Ramos SA, Mohnle P, Weng YS, Bottiger BW, Kulier A, Levin J, et al. The ongoing variability in blood transfusion practices in cardiac surgery. Transfusion. 2008;48(7):1284&#x2013;1299. doi: 10.1111/j.1537-2995.2008.01666.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2008.01666.x</ArticleId><ArticleId IdType="pubmed">18422857</ArticleId></ArticleIdList></Reference><Reference><Citation>Greiff G, Pleym H, Berg K, Wahba A, Videm V. Prediction of bleeding after cardiac surgery: comparison of model performances: a prospective observational study. J Cardiothorac Vasc Anesth. 2015;29(2):311&#x2013;319. doi: 10.1053/j.jvca.2014.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2014.08.002</ArticleId><ArticleId IdType="pubmed">25529438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gombotz H, Schreier G, Neubauer S, Kastner P, Hofman A. Gender disparities in red blood cell transfusion in elective surgery: a post hoc multicentre cohort study. BMJ Open. 2016;6:e012210. doi: 10.1136/bmjopen-2016-012210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012210</ArticleId><ArticleId IdType="pmc">PMC5168603</ArticleId><ArticleId IdType="pubmed">27965248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nashef S, Sharples F, Nilsson J, Smith C, Goldstone A, Lockowandt U. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41:734&#x2013;744. doi: 10.1093/ejcts/ezs043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezs043</ArticleId><ArticleId IdType="pubmed">22378855</ArticleId></ArticleIdList></Reference><Reference><Citation>Roques F, Nashef S, Michel P, Gauducheau E, De Vincentiis C, Cortina J, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15:816&#x2013;822. doi: 10.1016/S1010-7940(99)00106-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1010-7940(99)00106-2</ArticleId><ArticleId IdType="pubmed">10431864</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernadi M, Schmidlin D, Schiferer A, Ristl R, Neugebauer T, Hiesmayr M, et al. Impact of preoperative serum creatinine on short- and long-term mortality after cardiac surgery: a cohort study. Br J Anaesth. 2014;114(11):53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">25240162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29(1):29&#x2013;40. doi: 10.1093/ndt/gft209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gft209</ArticleId><ArticleId IdType="pubmed">24132242</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D, Chen C, Ming Y, Liu J, Zhou L, Zhang F, et al. Risk of massive blood product requirement in&#xa0;cardiac surgery: a large retrospective study from 2 heart centers. Medicine. 2019;98(5):e14219. doi: 10.1097/MD.0000000000014219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000014219</ArticleId><ArticleId IdType="pmc">PMC6380710</ArticleId><ArticleId IdType="pubmed">30702577</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boer WJ, Visser C, Ganushchak YM. Preoperative hemoglobin level: the best predictor of transfusion of packed red cells. Perfusion. 2016;31:691&#x2013;698. doi: 10.1177/0267659116657864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659116657864</ArticleId><ArticleId IdType="pubmed">27484973</ArticleId></ArticleIdList></Reference><Reference><Citation>Boer C, Meesters M, Milojevic M, Benedetto U, Bolliger D, Von Heymann C, et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anaesth. 2018;32:88&#x2013;120. doi: 10.1053/j.jvca.2017.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2017.06.026</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gherli R, Mariscalco G, Dalen M, Onorati F, Perrotti A, Chocron S, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol. 2016;1:921&#x2013;928. doi: 10.1001/jamacardio.2016.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2016.3028</ArticleId><ArticleId IdType="pubmed">27653165</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudie R, Sterne J, Verheyden V, Bhabra M, Ranucci M, Murphy G. Risk scores to facilitate preoperative prediction of transfusion and large volume blood transfusion associated with adult cardiac surgery. Br J Anaesth. 2015;114:757&#x2013;766. doi: 10.1093/bja/aeu483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeu483</ArticleId><ArticleId IdType="pubmed">25904607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M, Castelvecchio S, Frigiola A, Scolletta S, Giomarelli P, Biagioli B. Predicting transfusions in cardiac surgery: the easier, the better: the Transfusion Risk and Clinical Knowledge score. Vox Sang. 2009;96:324&#x2013;332. doi: 10.1111/j.1423-0410.2009.01160.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1423-0410.2009.01160.x</ArticleId><ArticleId IdType="pubmed">19192264</ArticleId></ArticleIdList></Reference><Reference><Citation>Karkouti Km O&#x2019;Farrell R, Yau T, Beatie S. Prediction of massive blood transfusion in cardiac surgery. Can J Anesth. 2006;53(8):781&#x2013;794. doi: 10.1007/BF03022795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03022795</ArticleId><ArticleId IdType="pubmed">16873345</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraf N, Thalib L, Hughes A, Tolan M, Young V, McGovern E. Effect of smoking on short-term outcome of patients undergoing coronary artery bypass surgery. Ann Thorac Surg. 2008;86:517&#x2013;523. doi: 10.1016/j.athoracsur.2008.03.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2008.03.070</ArticleId><ArticleId IdType="pubmed">18640326</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone A. Smoking, haemostatic factors, and cardiovascular risk. Curr Pharm Des. 2007;13:1661&#x2013;1667. doi: 10.2174/138161207780831347.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161207780831347</ArticleId><ArticleId IdType="pubmed">17584096</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39194234</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-0514</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>MECHANICAL LEFT VENTRICULAR UNLOADING IN CARDIOGENIC SHOCK TREATED WITH VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION: A SYSTEMATIC REVIEW AND META-ANALYSIS.</ArticleTitle><Pagination><StartPage>182</StartPage><EndPage>188</EndPage><MedlinePgn>182-188</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SHK.0000000000002463</ELocationID><Abstract><AbstractText>Objective : To evaluate if mechanical left ventricular unloading could reduce mortality in patients with cardiogenic shock undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO). Methods : We searched MEDLINE, Embase, and the Cochrane Library for randomized controlled trials and propensity score-matched studies published until December 20, 2023. The primary outcome was mortality at the longest follow-up. We used a Mantel-Haenszel random effects meta-analysis and reported the pooled results with a risk ratio (RR) and 95% confidence interval (CI). The review protocol was registered on PROSPERO International prospective register of systematic review (CRD42024498665). Results : We identified two randomized controlled trials and 11 propensity score-matched studies, totaling 9,858 patients. Mechanical left ventricular unloading was significantly associated with reduced mortality at the longest follow-up (RR, 0.89; 95% CI, 0.84-0.94; P = 0.0001; moderate certainty of evidence), which was confirmed in studies using intra-aortic balloon pump. Benefits of mechanical unloading were also observed in terms of successful VA-ECMO weaning (RR, 1.15; 95% CI, 1.02-1.29; P = 0.02; low certainty of evidence) and favorable neurological outcome (two studies; RR, 2.45; 95% CI, 1.62-3.69; P &lt; 0.0001; low certainty of evidence), although we observed an increased incidence of major bleeding (RR, 1.27; 95% CI, 1.02-1.59; P = 0.03; low certainty of evidence) and hemolysis (RR, 1.49; 95% CI, 1.10-2.02; P = 0.01; moderate certainty of evidence). Conclusions : Among adult patients with cardiogenic shock treated with VA-ECMO, mechanical left ventricular unloading was associated with reduced mortality, which was confirmed in studies using intra-aortic balloon pump as an unloading device.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 by the Shock Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kotani</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9532-2859</Identifier></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Taihei</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koroki</LastName><ForeName>Takatoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaguchi</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonai</LastName><ForeName>Mayuko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karumai</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardelli</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Yoshiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39194234</ArticleId><ArticleId IdType="doi">10.1097/SHK.0000000000002463</ArticleId><ArticleId IdType="pii">00024382-990000000-00508</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berg DD, Bohula EA, van Diepen S, et al. Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes . 2019;12(3):e005618.</Citation></Reference><Reference><Citation>Becher PM, Schrage B, Sinning CR, et al. Venoarterial extracorporeal membrane oxygenation for cardiopulmonary support. Circulation . 2018;138(20):2298&#x2013;2300.</Citation></Reference><Reference><Citation>Lorusso R, Shekar K, MacLaren G, et al. ELSO interim guidelines for venoarterial extracorporeal membrane oxygenation in adult cardiac patients. ASAIO J . 2021;67(8):827&#x2013;844.</Citation></Reference><Reference><Citation>Rajsic S, Treml B, Jadzic D, et al. Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications. Ann Intensive Care . 2022;12(1):93.</Citation></Reference><Reference><Citation>Cevasco M, Takayama H, Ando M, et al. Left ventricular distension and venting strategies for patients on venoarterial extracorporeal membrane oxygenation. J Thorac Dis . 2019;11(4):1676&#x2013;1683.</Citation></Reference><Reference><Citation>Truby LK, Takeda K, Mauro C, et al. Incidence and implications of left ventricular distention during venoarterial extracorporeal membrane oxygenation support. ASAIO J . 2017;63(3):257&#x2013;265.</Citation></Reference><Reference><Citation>Combes A, Price S, Slutsky AS, et al. Temporary circulatory support for cardiogenic shock. Lancet . 2020;396(10245):199&#x2013;212.</Citation></Reference><Reference><Citation>Rao P, Khalpey Z, Smith R, et al. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. Circ Heart Fail . 2018;11(9):e004905.</Citation></Reference><Reference><Citation>Ezad SM, Ryan M, Donker DW, et al. Unloading the left ventricle in venoarterial ECMO: in whom, when, and how? Circulation . 2023;147(16):1237&#x2013;1250.</Citation></Reference><Reference><Citation>Russo JJ, Aleksova N, Pitcher I, et al. Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol . 2019;73(6):654&#x2013;662.</Citation></Reference><Reference><Citation>Grandin EW, Nunez JI, Willar B, et al. Mechanical left ventricular unloading in patients undergoing venoarterial extracorporeal membrane oxygenation. J Am Coll Cardiol . 2022;79(13):1239&#x2013;1250.</Citation></Reference><Reference><Citation>M&#xf8;ller JE, Engstr&#xf8;m T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med . 2024;390(15):1382&#x2013;1393.</Citation></Reference><Reference><Citation>Schrage B, Becher PM, Bernhardt A, et al. Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: results from an international, multicenter cohort study. Circulation . 2020;142(22):2095&#x2013;2106.</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ . 2021;372:n71.</Citation></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ . 2019;366:l4898.</Citation></Reference><Reference><Citation>Sterne JAC, Hern&#xe1;n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ . 2016;355:i4919.</Citation></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ . 2008;336(7650):924&#x2013;926.</Citation></Reference><Reference><Citation>GRADEpro GDT: GRADEpro Guideline Development Tool [Software].&#xa0;Developed by Evidence Prime, Inc. McMaster University, 2023. Available from: https://www.gradepro.org .</Citation></Reference><Reference><Citation>Suverein MM, Delnoij TSR, Lorusso R, et al. Early extracorporeal CPR for refractory out-of-hospital cardiac arrest. N Engl J Med . 2023;388(4):299&#x2013;309.</Citation></Reference><Reference><Citation>The Cochrane Collaboration: Review Manager (RevMan) version 5.4. 2020.</Citation></Reference><Reference><Citation>Brok J, Thorlund K, Gluud C, et al. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol . 2008;61(8):763&#x2013;769.</Citation></Reference><Reference><Citation>Ro SK, Kim JB, Jung SH, et al. Extracorporeal life support for cardiogenic shock: influence of concomitant intra-aortic balloon counterpulsation. Eur J Cardiothorac Surg . 2014;46(2):186&#x2013;192; discussion 192.</Citation></Reference><Reference><Citation>Aso S, Matsui H, Fushimi K, et al. The effect of intraaortic balloon pumping under venoarterial extracorporeal membrane oxygenation on mortality of cardiogenic patients: an analysis using a nationwide inpatient database. Crit Care Med . 2016;44(11):1974&#x2013;1979.</Citation></Reference><Reference><Citation>Pappalardo F, Schulte C, Pieri M, et al. Concomitant implantation of Impella&#xae; on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail . 2017;19(3):404&#x2013;412.</Citation></Reference><Reference><Citation>Br&#xe9;chot N, Demondion P, Santi F, et al. Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. Eur Heart J Acute Cardiovasc Care . 2018;7(1):62&#x2013;69.</Citation></Reference><Reference><Citation>Kuroki N, Nagao K, Otsuka T, et al. Combined use of venoarterial extracorporeal membrane oxygenation and intra-aortic balloon pump after cardiac arrest. Resuscitation . 2021;167:345&#x2013;354.</Citation></Reference><Reference><Citation>Bj&#xf6;rnsd&#xf3;ttir B, Biancari F, Dal&#xe9;n M, et al. Postcardiotomy venoarterial extracorporeal membrane oxygenation with and without intra-aortic balloon pump. J Cardiothorac Vasc Anesth . 2022;36(8 Pt B):2876&#x2013;2883.</Citation></Reference><Reference><Citation>Radakovic D, Penov K, Hamouda K, et al. Benefits of intra-aortic balloon pump support in patients with postcardiotomy shock requiring venoarterial extracorporeal membrane oxygenation. Life . 2022;12(8):1195.</Citation></Reference><Reference><Citation>Kashiura M, Kishihara Y, Ozawa H, et al. Intra-aortic balloon pump use in out-of-hospital cardiac arrest patients who underwent extracorporeal cardiopulmonary resuscitation. Resuscitation . 2023;182:109660.</Citation></Reference><Reference><Citation>Kim MC, Lim Y, Lee SH, et al. Early left ventricular unloading or conventional approach after Venoarterial extracorporeal membrane oxygenation: the EARLY-UNLOAD randomized clinical trial. Circulation . 2023;148(20):1570&#x2013;1581.</Citation></Reference><Reference><Citation>Park H, Yang JH, Ahn J-M, et al. Early left atrial venting versus conventional treatment for left ventricular decompression during venoarterial extracorporeal membrane oxygenation support: the EVOLVE-ECMO randomized clinical trial. Eur J Heart Fail . 2023;25(11):2037&#x2013;2046.</Citation></Reference><Reference><Citation>Thevathasan T, Kenny MA, Krause FJ, et al. Left-ventricular unloading in extracorporeal cardiopulmonary resuscitation due to acute myocardial infarction - a multicenter study. Resuscitation . 2023;186:109775.</Citation></Reference><Reference><Citation>Brunner S, Guenther SPW, Lackermair K, et al. Extracorporeal life support in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol . 2019;73(18):2355&#x2013;2357.</Citation></Reference><Reference><Citation>Ostadal P, Rokyta R, Karasek J, et al. ECMO-CS investigators: extracorporeal membrane oxygenation in the therapy of cardiogenic shock: results of the ECMO-CS randomized clinical trial. Circulation . 2023;147(6):454&#x2013;464.</Citation></Reference><Reference><Citation>Banning AS, Sabat&#xe9; M, Orban M, et al. Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial. EuroIntervention . 2023;19(6):482&#x2013;492.</Citation></Reference><Reference><Citation>Thiele H, Zeymer U, Akin I, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med . 2023;389(14):1286&#x2013;1297.</Citation></Reference><Reference><Citation>Dhruva SS, Ross JS, Mortazavi BJ, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA . 2020;323(8):734&#x2013;745.</Citation></Reference><Reference><Citation>Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol . 2008;52(19):1584&#x2013;1588.</Citation></Reference><Reference><Citation>Low CJW, Ling RR, Lau MPXL, et al. Mechanical circulatory support for cardiogenic shock: a network meta-analysis of randomized controlled trials and propensity score-matched studies. Intensive Care Med . 2024;50:209&#x2013;221.</Citation></Reference><Reference><Citation>Basir MB, Kapur NK, Patel K, et al; National Cardiogenic Shock Initiative Investigators. Improved outcomes associated with the use of shock protocols: updates from the National Cardiogenic Shock Initiative. Catheter Cardiovasc Interv . 2019;93(7):1173&#x2013;1183.</Citation></Reference><Reference><Citation>Ikeda Y, Ako J, Toda K, et al. J-PVAD investigators: short-term outcomes of Impella support in Japanese patients with cardiogenic shock due to acute myocardial infarction - Japanese registry for Percutaneous Ventricular Assist Device (J-PVAD). Circ J . 2023;87(5):588&#x2013;597.</Citation></Reference><Reference><Citation>Masi P, Gendreau S, Moyon Q, et al. Bleeding complications, coagulation disorders, and their management in acute myocardial infarction-related cardiogenic shock rescued by veno-arterial ECMO: a retrospective cohort study. J Crit Care . 2024;82(154771):154771.</Citation></Reference><Reference><Citation>Tamura T, Horiuchi H, Obayashi Y, et al. Acquired von Willebrand syndrome in patients treated with veno-arterial extracorporeal membrane oxygenation. Cardiovasc Interv Ther . 2019;34(4):358&#x2013;363.</Citation></Reference><Reference><Citation>Vandenbriele C, Vanassche T, Price S. Why we need safer anticoagulant strategies for patients on short-term percutaneous mechanical circulatory support. Intensive Care Med . 2020;46(4):771&#x2013;774.</Citation></Reference><Reference><Citation>Navaei A, Kostousov V, Teruya J. Is it time to switch to bivalirudin for ECMO anticoagulation? Front Med (Lausanne) . 2023;10:1237601.</Citation></Reference><Reference><Citation>Staudacher DL, Biever PM, Benk C, et al. Dual antiplatelet therapy (DAPT) versus no antiplatelet therapy and incidence of major bleeding in patients on venoarterial extracorporeal membrane oxygenation. PloS One . 2016;11(7):e0159973.</Citation></Reference><Reference><Citation>Baldetti L, Nardelli P, Ajello S, et al. Anti-thrombotic therapy with cangrelor and bivalirudin in venoarterial extracorporeal membrane oxygenation patients undergoing percutaneous coronary intervention: a single-center experience. ASAIO J . 2023;69(7):e346&#x2013;e350.</Citation></Reference><Reference><Citation>Van Edom CJ, Gramegna M, Baldetti L, et al. Management of bleeding and hemolysis during percutaneous microaxial flow pump support: a practical approach. JACC Cardiovasc Interv . 2023;16(14):1707&#x2013;1720.</Citation></Reference><Reference><Citation>Landoni G, Monaco F, Ti LK, et al; PROTECTION Study Group. A randomized trial of intravenous amino acids for kidney protection. N Engl J Med . 2024;391(8):687&#x2013;698.</Citation></Reference><Reference><Citation>Losiggio R, Redaelli MB, Pruna A, et al. The renal effects of amino acids infusion. Signa Vitae . 2024;20(7):1&#x2013;4.</Citation></Reference><Reference><Citation>Laimoud M, Qureshi R. The value of clinical scores in predicting mortality of adult patients on veno-arterial extracorporeal membrane oxygenation. Signa Vitae . 2022;18(4):5&#x2013;7.</Citation></Reference><Reference><Citation>Mazzeffi M, Greenwood J, Tanaka K, et al. Bleeding, transfusion, and mortality on extracorporeal life support: ECLS working group on thrombosis and hemostasis. Ann Thorac Surg . 2016;101(2):682&#x2013;689.</Citation></Reference><Reference><Citation>Dufour N, Radjou A, Thuong M. Hemolysis and plasma free hemoglobin during extracorporeal membrane oxygenation support: from clinical implications to laboratory details. ASAIO J . 2020;66(3):239&#x2013;246.</Citation></Reference><Reference><Citation>Zeymer U, Freund A, Hochadel M, et al. Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials. Lancet . 2023;402(10410):1338&#x2013;1346.</Citation></Reference><Reference><Citation>NCT03431467. Available at: https://clinicaltrials.gov/study/NCT03431467 . March 31, 2024.</Citation></Reference><Reference><Citation>ISRCTN82431978. Available at: https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN82431978 . January 24, 2024.</Citation></Reference><Reference><Citation>Roth D, Heidinger B, Havel C, et al. Different mortality time points in critical care trials: current practice and influence on effect estimates in meta-analyses. Crit Care Med . 2016;44(8):e737&#x2013;e741.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33337072</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2055-5822</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>ESC heart failure</Title><ISOAbbreviation>ESC Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Veno-Arterial Extracorporeal Life Support in Heart Transplant and Ventricle Assist Device Centres. Meta-analysis.</ArticleTitle><Pagination><StartPage>1064</StartPage><EndPage>1075</EndPage><MedlinePgn>1064-1075</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ehf2.13080</ELocationID><Abstract><AbstractText Label="AIMS">Because reported mortality on veno-arterial (V-A) extracorporeal life support (ECLS) substantially varies between centres, the aim of the current analysis was to assess the outcomes between units performing heart transplantation and/or implanting ventricular assist device (HTx/VAD) vs. non-HTx/VAD units in patients undergoing V-A ECLS for cardiogenic shock.</AbstractText><AbstractText Label="METHODS AND RESULTS">Systematic search according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses was performed using PubMed/MEDLINE databases until 30 November 2019. Articles reporting in-hospital/30-day mortality and centre's HTx/VAD status were included. In-hospital outcomes and long-term survival were analysed in subgroup meta-analysis. A total of 174 studies enrolling n&#xa0;=&#xa0;13&#xa0;308 patients were included with 20 series performed in non-HTx/VAD centres (1016 patients, 7.8%). Majority of patients underwent V-A ECLS for post-cardiotomy shock (44.2%) and acute myocardial infarction (20.7%). Estimated overall in-hospital mortality was 57.2% (54.9-59.4%). Mortality rates were higher in non-HTx/VAD [65.5% (59.8-70.8%)] as compared with HTx/VAD centres [55.8% (53.3-58.2%)], P&#xa0;&lt;&#xa0;0.001. Estimated late survival was 61.8% (55.7-67.9%) without differences between non-HTx/VAD and HTx/VAD centres: 66.5% (30.3-1.02%) vs. 61.7% (55.5-67.8%), respectively (P&#xa0;=&#xa0;0.797). No differences were seen with respect to ECLS duration, limb complications, and reoperations for bleeding, kidney injury, and sepsis. Yet, weaning rates were higher in HTx/VAD vs. non-HTx/VAD centres: 58.7% (56.2-61.1%) vs. 48.9% (42.0-55.9%), P&#xa0;=&#xa0;0.010. Estimated rate of bridge to heart transplant was 6.6% (5.2-8.3%) with numerical, yet not statistically significant, difference between non-HTx/VAD [2.7% (0.8-8.3%)] as compared with HTx/VAD [6.7% (5.3-8.6%)] (P&#xa0;=&#xa0;0.131).</AbstractText><AbstractText Label="CONCLUSIONS">Survival after V-A ECLS differed according to centre's HTx/VAD status. Potentially different risk profiles of patients must be taken account for before definite conclusions are drawn.</AbstractText><CopyrightInformation>&#xa9;&#xa0;2020 The Authors. ESC Heart Failure published by John Wiley &amp; Sons Ltd on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kowalewski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior, Centre of Postgraduate Medical Education, Wo&#x142;oska 137 Str, Warsaw, 02-507, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zieli&#x144;ski</LastName><ForeName>Kamil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gozdek</LastName><ForeName>Miros&#x142;aw</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raffa</LastName><ForeName>Giuseppe Maria</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, ISMETT-IRCCS, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilato</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, ISMETT-IRCCS, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alanazi</LastName><ForeName>Musab</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbers</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuts</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natour</LastName><ForeName>Ehsan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bidar</LastName><ForeName>Elham</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreurs</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delnoij</LastName><ForeName>Thijs</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driessen</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sels</LastName><ForeName>Jan Willem</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Cardiology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Poll</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roekaerts</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasierski</LastName><ForeName>Micha&#x142;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior, Centre of Postgraduate Medical Education, Wo&#x142;oska 137 Str, Warsaw, 02-507, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meani</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maessen</LastName><ForeName>Jos</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwalski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior, Centre of Postgraduate Medical Education, Wo&#x142;oska 137 Str, Warsaw, 02-507, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>ESC Heart Fail</MedlineTA><NlmUniqueID>101669191</NlmUniqueID><ISSNLinking>2055-5822</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016027" MajorTopicYN="Y">Heart Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute heart failure</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Extracorporeal life support</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword></KeywordList><CoiStatement>Dr Lorusso is consultant and conducts clinical trial for LivaNova (London, UK), is consultant for Medtronic (Minneapolis, MN), and an Advisory Board member of PulseCath (Arnhem, The Netherlands). The other authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>8</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33337072</ArticleId><ArticleId IdType="pmc">PMC8006654</ArticleId><ArticleId IdType="doi">10.1002/ehf2.13080</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harjola VP, Lassus J, Sionis A, K&#xf8;ber L, Tarvasm&#xe4;ki T, Spinar J, Parissis J, Banaszewski M, Silva&#x2010;Cardoso J, Carubelli V, di Somma S, Tolppanen H, Zeymer U, Thiele H, Nieminen MS, Mebazaa A, CardShock Study Investigators , GREAT network . Clinical picture and risk prediction of short&#x2010;term mortality in cardiogenic shock. Eur J Heart Fail 2015; 17: 501&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">25820680</ArticleId></ArticleIdList></Reference><Reference><Citation>Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in cardiogenic shock. Eur Heart J 2014; 35: 156&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">24014384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Raffa GM, Alenizy K, Sluijpers N, Makhoul M, Brodie D, McMullan M, Wang IW, Meani P, MacLaren G, Kowalewski M, Dalton H, Barbaro R, Hou X, Cavarocchi N, Chen YS, Thiagarajan R, Alexander P, Alsoufi B, Bermudez CA, Shah AS, Haft J, D'Alessandro DA, Boeken U, Whitman GJR. Structured review of post&#x2010;cardiotomy extracorporeal membrane oxygenation: part 1&#x2014;adult patients. J Heart Lung Transplant 2019; 38: 1125&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8152367</ArticleId><ArticleId IdType="pubmed">31522913</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitman GJ. Extracorporeal membrane oxygenation for the treatment of postcardiotomy shock. J Thorac Cardiovasc Surg 2017; 153: 95&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">27666787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Gelsomino S, Parise O, Mendiratta P, Prodhan P, Rycus P, MacLaren G, Brogan TV, Chen YS, Maessen J, Hou X, Thiagarajan RR. Venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock in elderly patients: trends in application and outcome from the extracorporeal life support organization (elso) registry. Ann Thorac Surg 2017; 104: 62&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">28131429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler PR, Silver DA, Scirica BM, Couper GS, Weinhouse GL, Camp PC Jr. Extracorporeal membrane oxygenation in adults with cardiogenic shock. Circulation 2015; 131: 676&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">25691703</ArticleId></ArticleIdList></Reference><Reference><Citation>Stretch R, Sauer CM, Yuh DD, Bonde P. National trends in the utilization of short&#x2010;term mechanical circulatory support: incidence, outcomes, and cost analysis. Journal of the American College of Cardiology 2014; 64: 1407&#x2013;1415.</Citation><ArticleIdList><ArticleId IdType="pubmed">25277608</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy FH, McDermott KM, Kini V, Gutsche JT, Wald JW, Xie D, Szeto WY, Bermudez CA, Atluri P, Acker MA, Desai ND. Trends in U.S. extracorporeal membrane oxygenation use and outcomes: 2002&#x2013;2012. Semin Thorac Cardiovasc Surg 2015; 27: 81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780346</ArticleId><ArticleId IdType="pubmed">26686427</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis C, Brodie D, Strassmann S, Stoelben E, Philipp A, Bein T, M&#xfc;ller T, Windisch W. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med 2016; 42: 889&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">26942446</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell BG, Powers AJ, Sheikh AY, Lee PH, Lobato RL, Wong JK. Resource use trends in extracorporeal membrane oxygenation in adults: an analysis of the nationwide inpatient sample 1998&#x2013;2009. J Thorac Cardiovasc Surg 2014; 148: 416&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">24183903</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH, Davis MM, Annich GM. Association of hospital&#x2010;level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med 2015; 191: 894&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435456</ArticleId><ArticleId IdType="pubmed">25695688</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta&#x2010;analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Hernan MA, Reeves BC, Savovi&#x107; J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan A&#x2010;W, Churchill R, Deeks JJ, Hr&#xf3;bjartsson A, Kirkham J, J&#xfc;ni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch&#xfc;nemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JPT. ROBINS&#x2010;I: a tool for assessing risk of bias in non&#x2010;randomised studies of interventions. BMJ 2016; 355: i4919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackman NJ, Koval JJ. Interval estimation for Cohen's kappa as a measure of agreement. Stat Med 2000; 19: 723&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10700742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published kaplan&#x2010;meier survival curves. BMC Med Res Methodol 2012; 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3313891</ArticleId><ArticleId IdType="pubmed">22297116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JPT. Recommendations for examining and interpreting funnel plot asymmetry in meta&#x2010;analyses of randomised controlled trials. BMJ 2011; 343: d4002.</Citation><ArticleIdList><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo JJ, Aleksova N, Pitcher I, Couture E, Parlow S, Faraz M, Visintini S, Simard T, di Santo P, Mathew R, So DY, Takeda K, Garan AR, Karmpaliotis D, Takayama H, Kirtane AJ, Hibbert B. Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol 2019; 73: 654&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">30765031</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffa GM, Kowalewski M, Brodie D, Ogino M, Whitman G, Meani P, Pilato M, Arcadipane A, Delnoij T, Natour E, Gelsomino S, Maessen J, Lorusso R. Meta&#x2010;analysis of peripheral or central extracorporeal membrane oxygenation in postcardiotomy and non&#x2010;postcardiotomy shock. Ann Thorac Surg 2019; 107: 311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">29959943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalewski M, Raffa G, Zieli&#x144;ski K, Meani P, Alanazi M, Gilbers M, Heuts S, Natour E, Bidar E, Schreurs R, Delnoij T, Driessen R, Sels JW, van de Poll M, Roekaerts P, Maessen J, Suwalski P, Lorusso R. Baseline surgical status and short&#x2010;term mortality after extracorporeal membrane oxygenation for post&#x2010;cardiotomy shock: a meta&#x2010;analysis. Perfusion 2019: 267659119865122.</Citation><ArticleIdList><ArticleId IdType="pubmed">31469037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsyganenko D, Gromann TW, Schoenrath F, Mueller M, Mulzer J, Starck C, Krabatsch T, Stein J, Falk V, Potapov E. Predictors of mid&#x2010;term outcomes in patients undergoing implantation of a ventricular assist device directly after extracorporeal life support. Eur J Cardiothorac Surg 2019; 55: 773&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">30445489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalewski M, Raffa GM, Zieli&#x144;ski K, Alanazi M, Gilbers M, Heuts S, Natour E, Bidar E, Schreurs R, Delnoij T, Driessen R, Sels J&#x2010;W, van de Poll M, Roekaerts P, Meani P, Maessen J, Suwalski P, Lorusso R. The impact of centre's heart transplant status and volume on in&#x2010;hospital outcomes following extracorporeal membrane oxygenation for refractory post&#x2010;cardiotomy cardiogenic shock: a meta&#x2010;analysis. BMC Cardiovasc Disord 2020; 20: 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6950870</ArticleId><ArticleId IdType="pubmed">31918663</ArticleId></ArticleIdList></Reference><Reference><Citation>Meani P, Matteucci M, Jiritano F, Fina D, Panzeri F, Raffa GM, Kowalewski M, Morici N, Viola G, Sacco A, Oliva F, Alyousif A, Heuts S, Gilbers M, Schreurs R, Maessen J, Lorusso R. Long&#x2010;term survival and major outcomes in post&#x2010;cardiotomy extracorporeal membrane oxygenation for adult patients in cardiogenic shock. Ann Cardiothorac Surg 2019; 8: 116&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379181</ArticleId><ArticleId IdType="pubmed">30854320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34260533</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>28</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>The noninferiority of transcatheter aortic valve implantation compared to surgical aortic valve replacement for severe aortic disease: Evidence based on 16 randomized controlled trials.</ArticleTitle><Pagination><StartPage>e26556</StartPage><MedlinePgn>e26556</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e26556</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000026556</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Currently, transcatheter aortic valve implantation (TAVI) as an effective and convenient intervention has been adopted extensively for patients with severe aortic disease. However, the efficacy and safety of TAVI have not yet been well evaluated and its noninferiority compared with traditional surgical aortic valve replacement (sAVR) still lack sufficient evidence. This meta-analysis was designed to comprehensively compare the noninferiority of TAVI with sAVR for patients with severe aortic disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search of PubMed, Embase, Cochrane Library, and Web of Science up to October 1, 2020 was conducted for relevant studies that comparing TAVI and sAVR in the treatment of severe aortic disease. The primary outcomes were early, midterm and long term mortality. The secondary outcomes included early complications and other late outcomes. Two reviewers assessed trial quality and extracted the data independently. All statistical analyzes were performed using the standard statistical procedures provided in Review Manager 5.2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 16 studies including 14394 patients were identified. There was no difference in 30-day, 1-year, 2-year, and 5-year all-cause or cardiovascular mortality as well as stroke between TAVI and sAVR. Regarding to the 30-day outcomes, compared with sAVR, TAVI experienced a significantly lower incidence of myocardial infarction (risk ratio [RR] 0.62; 95% confidence interval [CI] 0.40-0.97; 5441 pts), cardiogenic shock (RR 0.34; 95% CI 0.19-0.59; 1936 pts), acute kidney injury (AKI) &gt; stage 2 (RR 0.37; 95% CI 0.25-0.54; 5371 pts), and new-onset atrial fibrillation (NOAF) (RR 0.29; 95% CI 0.24-0.35; 5371 pts) respectively, but higher incidence of permanent pacemaker implantation (RR 3.16; 95% CI 1.61-6.21; 5441 pts) and major vascular complications (RR 2.22; 95% CI 1.14-4.32; 5371 pts). Regarding to the 1- and 2-year outcomes, compared with sAVR, TAVI experienced a significantly lower incidence of NOAF, but higher incidence of neurological events, transient ischemic attacks (TIA), permanent pacemaker and major vascular complications respectively. Regarding to the 5-year outcomes, compared with sAVR, TAVI experienced a significantly lower incidence of NOAF, but higher incidence of TIA and reintervention respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our analysis shows that TAVI was equal to sAVR in early, midterm and long term mortality for patients with severe aortic disease. In addition, TAVI may be favorable in reducing the incidence of both early, midterm and long term NOAF. However, pooled results showed superiority of sAVR in reducing permanent pacemaker implantation, neurological events, TIA, major vascular complications and reintervention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Peng-Ying</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Lanzhou University First Affiliated Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yong-Hong</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Qinghai University Affiliated Hospital, Xi'ning, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical College of Qinghai University, Qinghai University, Xi'ning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Rui-Sheng</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Lanzhou University First Affiliated Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ji-Hai</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Qinghai University Affiliated Hospital, Xi'ning, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical College of Qinghai University, Qinghai University, Xi'ning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jian-Ying</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Qinghai University Affiliated Hospital, Xi'ning, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical College of Qinghai University, Qinghai University, Xi'ning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Bing</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2046-2718</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Lanzhou University First Affiliated Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001018" MajorTopicYN="N">Aortic Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010138" MajorTopicYN="N">Pacemaker, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="N">Transcatheter Aortic Valve Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>17</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34260533</ArticleId><ArticleId IdType="pmc">PMC8284753</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000026556</ArticleId><ArticleId IdType="pii">00005792-202107160-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart 2016;102:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">26541169</ArticleId></ArticleIdList></Reference><Reference><Citation>Osnabrugge RL. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 2013;62:1002&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23727214</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner H. 2017&#x200a;ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura RA. 2014&#x200a;AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e57&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">24603191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleason TG. 5-year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol 2018;72:2687&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">30249462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D. Transcatheter versus surgical aortic valve replacement in low-risk patients. J Am Coll Cardiol 2019;74:1532&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">31537261</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon MB. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">27040324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack MJ. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura RA. 2017&#x200a;AHA/ACC Focused Update of the 2014&#x200a;AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017;135:e1159&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">28298458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks D. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke 2018;13:612&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">29786478</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017;376:1321&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28304219</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark HD, WF G, Hu&#xeb;t C, McAlister FA, Salmi LR, Fergusson D. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999;20:448&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10503804</ArticleId></ArticleIdList></Reference><Reference><Citation>Review Manager (RevMan) [Computer Program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.</Citation></Reference><Reference><Citation>Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382404</ArticleId></ArticleIdList></Reference><Reference><Citation>University of York Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: CRD, University of York; 2009.</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45(Pt A):139&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639420</ArticleId><ArticleId IdType="pubmed">26343745</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">13655060</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea BJ. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia SR. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015;385:2485&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">25788231</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack MJ. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015;385:2477&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25788234</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkar RR. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382:799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">31995682</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DC. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg 2012;143:832&#x2013;43. e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424519</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen HH. A prospective, randomised trial of transapical transcatheter aortic valve implantation vs surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trial. Euro Intervention 2012;8:383&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22581299</ArticleId></ArticleIdList></Reference><Reference><Citation>Pibarot P. Echocardiographic results of transcatheter versus surgical aortic valve replacement in low-risk patients: the PARTNER 3 trial. Circulation 2020;141:1527&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">32272848</ArticleId></ArticleIdList></Reference><Reference><Citation>Popma JJ. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883053</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ. 2-year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol 2015;66:113&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26055947</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ. Outcomes in the randomized corevalve us pivotal high risk trial in patients with a society of thoracic surgeons risk score of 7% or less. JAMA Cardiol 2016;1:945&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27541162</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW. One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. Euro Intervention 2018;14:877&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">29992904</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;ndergaard L. Two-year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: the all-comers nordic aortic valve intervention randomized clinical trial. Circ Cardiovasc Interv 2016;9:</Citation><ArticleIdList><ArticleId IdType="pubmed">27296202</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyregod HG. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 2015;65:2184&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25787196</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyregod HGH. Five-year clinical and echocardiographic outcomes from the nordic aortic valve intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation 2019;Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">30704298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan GH. Mortality due to aortic stenosis in the United States, 2008&#x2013;2017. JAMA 2019;321:2236&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563552</ArticleId><ArticleId IdType="pubmed">31184728</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart BF. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9060903</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SU. Meta-analysis of temporal and surgical risk dependent associations with outcomes after transcatheter versus surgical aortic valve implantation. Am J Cardiol 2019;124:1608&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453964</ArticleId><ArticleId IdType="pubmed">31521258</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves A. Transthoracic echocardiography to assess aortic regurgitation after TAVR: a comparison with periprocedural transesophageal echocardiography. Cardiology 2017;137:01&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27925612</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker CM, Reardon MJ. Should TAVR replace surgery for aortic stenosis in low- to intermediate-risk patients? Can J Cardiol 2017;33:1124&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28843323</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Abdouh A. Transcatheter aortic valve replacement in low-risk patients: a meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 2020;21:461&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31447314</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J. Transcatheter versus surgical aortic valve replacement in low and intermediate risk patients with severe aortic stenosis: systematic review and meta-analysis of randomized controlled trials and propensity score matching observational studies. J Thorac Dis 2019;11:1945&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588740</ArticleId><ArticleId IdType="pubmed">31285888</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A. Transcatheter aortic valve replacement versus surgical valve replacement in low-intermediate surgical risk patients: a systematic review and meta-analysis. J Invasive Cardiol 2017;29:209&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">28570236</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SU. Transcatheter vs surgical aortic-valve replacement in low- to intermediate-surgical-risk candidates: a meta-analysis and systematic review. Clin Cardiol 2017;40:974&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490337</ArticleId><ArticleId IdType="pubmed">29168984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheiri B. Transcatheter versus surgical aortic valve replacement in low-risk surgical patients: a meta-analysis of randomized clinical trials. Cardiovasc Revasc Med 2019;20:838&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638890</ArticleId></ArticleIdList></Reference><Reference><Citation>Polimeni A. Transcatheter versus surgical aortic valve replacement in low-risk patients for the treatment of severe aortic stenosis. J Clin Med 2020;9:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7074202</ArticleId><ArticleId IdType="pubmed">32041189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardar P. Transcatheter versus surgical aortic valve replacement in intermediate-risk patients: evidence from a meta-analysis. Catheter Cardiovasc Interv 2017;90:504&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">28398671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. Midterm outcome of transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: a meta-analysis of randomized controlled trials. J Cardiol 2018;71:534&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29655505</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams DH. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;370:1790&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24678937</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrodeza J. Propensity score matched comparison of transcatheter aortic valve implantation versus conventional surgery in intermediate and low risk aortic stenosis patients: A hint of real-world. Cardiol J 2016;23:541&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">27439368</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Errigo P. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis: results from an intermediate risk propensity-matched population of the Italian OBSERVANT study. Int J Cardiol 2013;167:1945&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">22633667</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraccaro C. Early and midterm outcome of propensity-matched intermediate-risk patients aged &#x2265;80 years with aortic stenosis undergoing surgical or transcatheter aortic valve replacement (from the italian multicenter OBSERVANT Study). Am J Cardiol 2016;117:1494&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">26993427</ArticleId></ArticleIdList></Reference><Reference><Citation>Frerker C, Bestehorn K, Schl&#xfc;ter M. In-hospital mortality in propensity-score matched low-risk patients undergoing routine isolated surgical or transfemoral transcatheter aortic valve replacement in 2014 in Germany 2017;106:610&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28283745</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa N. Minimally invasive versus transapical versus transfemoral aortic valve implantation: a one-to-one-to-one propensity score-matched analysis. J Thorac Cardiovasc Surg 2018;156:1825&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29861110</ArticleId></ArticleIdList></Reference><Reference><Citation>Muneretto C. Treating the patients in the &#x2019;grey-zone&#x2019; with aortic valve disease: a comparison among conventional surgery, sutureless valves and transcatheter aortic valve replacement. Interact Cardiovasc Thorac Surg 2015;20:90&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25320140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia SR. Stroke after surgical versus transfemoral transcatheter aortic valve replacement in the PARTNER trial. J Am Coll Cardiol 2018;72:2415&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">30442284</ArticleId></ArticleIdList></Reference><Reference><Citation>Onorati F. Different impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: results of the multicenter Italian OBSERVANT registry. J Thorac Cardiovasc Surg 2014;147:1529&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">23856202</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter MP. Evolution of outcome and complications in TAVR: a meta-analysis of observational and randomized studies. Sci Rep 2020;10:15568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511292</ArticleId><ArticleId IdType="pubmed">32968104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33856097</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Percutaneous mitral valve repair with MitraClip device in hemodynamically unstable patients: A systematic review.</ArticleTitle><Pagination><StartPage>E617</StartPage><EndPage>E625</EndPage><MedlinePgn>E617-E625</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.29703</ELocationID><Abstract><AbstractText Label="BACKGROUND">Very few data exist on percutaneous mitral valve repair (PMVr) in unstable patients with concomitant moderate-severe mitral regurgitation (MR). The purpose of this systematic review was to evaluate baseline characteristics, management and clinical outcomes of critically ill patients undergoing PMVr with MitraClip.</AbstractText><AbstractText Label="METHODS">We conducted a systematic review of the published data on MitraClip from its first use in 2003 to December 2020. Studies referring to critically ill patients in cardiogenic shock or acute refractory pulmonary edema were included. A total of 40 publications including 254 patients with significant MR (Grade 4 in 91%) were included.</AbstractText><AbstractText Label="RESULTS">Mean age was 70&#x2009;&#xb1;&#x2009;12&#x2009;years with mean Euroscore II and STS of 21&#x2009;&#xb1;&#x2009;13 and 20.5&#x2009;&#xb1;&#x2009;16, respectively. Clinical presentation was with cardiogenic shock and acute myocardial infarction in 72.8 and 60.0% of patients, respectively. Device success was achieved in 238 (93.7%) patients with a significant reduction in MR (Grade&#x2009;&#x2264;&#x2009;2 in 91.8%, p&#x2009;&lt;&#x2009;.001). The median weaning time from the procedure, to discontinuation of mechanical circulatory or respiratory support, was 2&#x2009;days (IQR 1-4), with an in-hospital mortality and non-fatal complication rate of 12.6 and 9.1%, respectively. Kaplan-Meier curves estimated an overall mortality rate of 39.1% at 12-month follow-up, with persistent reduction in MR severity for survivors (Grade&#x2009;&#x2264;&#x2009;2 in 81.3%) and one case of mitral valve reintervention.</AbstractText><AbstractText Label="CONCLUSIONS">Percutaneous mitral valve repair with MitraClip device is a technically feasible and potentially viable management option in high-risk patients with cardiogenic shock or refractory pulmonary edema and concomitant moderate-severe MR. Prospective trials are required to confirm these findings, and definitively determine the value of MitraClip in hemodynamically unstable patients.</AbstractText><CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez-Gomez</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McInerney</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1160-7735</Identifier><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirado-Conte</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Agustin</LastName><ForeName>Jose Alberto</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-4444-9622</Identifier><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez-Quevedo</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7562-8677</Identifier><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escudero</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozo Osinalde</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viana-Tejedor</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goirigolzarri</LastName><ForeName>Josebe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marroquin</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivas</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrera</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noriega</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Restrepo-Cordoba</LastName><ForeName>Maria Alejandra</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalo</LastName><ForeName>Nieves</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3827-945X</Identifier><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escaned</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ortiz</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amat-Santos</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2311-4129</Identifier><AffiliationInfo><Affiliation>Cardiology Department, CIBERCV, Hospital Cl&#xed;nico Universitario, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estevez-Loureiro</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5841-5514</Identifier><AffiliationInfo><Affiliation>Interventional Cardiology Unit, University Hospital Alvaro Cunqueiro, Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macaya</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nombela-Franco</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3438-8907</Identifier><AffiliationInfo><Affiliation>Cardiology Department, Cardiovascular Institute, Hospital Cl&#xed;nico San Carlos, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="Y">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008943" MajorTopicYN="N">Mitral Valve</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="Y">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MitraClip</Keyword><Keyword MajorTopicYN="N">acute mitral regurgitation</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mitral edge-to-edge repair</Keyword><Keyword MajorTopicYN="N">mortality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>8</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33856097</ArticleId><ArticleId IdType="doi">10.1002/ccd.29703</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66:2844-2854.</Citation></Reference><Reference><Citation>Baumgartner H, Falk V, Bax J, et al. 2017 ESC/EACTS guidelines or the management of valvular heart disease. Eur Heart J. 2017;38:2739-2791.</Citation></Reference><Reference><Citation>Nishimura R, Otto C, Bonow R, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;70:252-289.</Citation></Reference><Reference><Citation>Stone GW, Lindenfeld J, Abraham W, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307-2318.</Citation></Reference><Reference><Citation>Monteagudo JM, Galderisi M, Buonauro A, et al. Overview of mitral regurgitation in Europe: results from the European registry of mitral regurgitation (EuMiClip). Eur Heart J Cardiovasc Imaging. 2018;9:503-507.</Citation></Reference><Reference><Citation>Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol. 2017;70:2315-2327.</Citation></Reference><Reference><Citation>Nishino S, Watanabe N, Kimura T, et al. The course of ischemic mitral regurgitation in acute myocardial infarction after primary percutaneous coronary intervention: from emergency room to long-term follow-up. Circ Cardiovasc Imaging. 2016;9:e004841.</Citation></Reference><Reference><Citation>Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK trial registry. SHould we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol. 2000;36:1063-1070.</Citation></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, et al. PRISMA-P group. Preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.</Citation></Reference><Reference><Citation>Stone GW, Adams DH, Abraham WT, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium. J Am Coll Cardiol. 2015;66:308-321.</Citation></Reference><Reference><Citation>Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both randomized and non-randomized studies of health care interventions. J Epidemiol Community Health. 1998;52:377-384.</Citation></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.</Citation></Reference><Reference><Citation>Est&#xe9;vez-Loureiro R, Arzamendi D, Freixa X, et al. Percutaneous mitral valve repair for acute mitral regurgitation after an acute myocardial infarction. J Am Coll Cardiol. 2015;66:91-92.</Citation></Reference><Reference><Citation>Adamo M, Barbanti M, Curello S, et al. Effectiveness of Mitraclip therapy in patients with refractory heart failure. J Interv Cardiol. 2015;28:61-68.</Citation></Reference><Reference><Citation>Adamo M, Curello S, Chiari E, et al. Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: a single center experience. Int J Cardiol. 2017;234:53-57.</Citation></Reference><Reference><Citation>Pleger S, Chorianopoulus E, Krumsdorf U, Katus H, Bekeredjian R. Percutaneous edge-to-edge repair of mitral regurgitation as a bail-out strategy in critically ill patients. J Invasive Cardiol. 2013;25:69-72.</Citation></Reference><Reference><Citation>Haberman D, Taramasso M, Czarnecki A, et al. Salvage Mitraclip in severe secondary mitral regurgitation complicating acute myocardial infarction: data from a multicenter international study. Eur J Heart Fail. 2019;21:1161-1164.</Citation></Reference><Reference><Citation>Flint K, Brieke A, Wiktor D, Carroll J. Percutaneous edge-to-edge mitral valve repair may rescue select patients in cardiogenic shock: findings from a single center case series. Catheter Cardiovasc Interv. 2019;94:e82-e87.</Citation></Reference><Reference><Citation>Cheng R, Dawkins S, Hamilton M, et al. Percutaneous mitral repair for patients in cardiogenic shock requiring inotropes and temporary mechanical circulatory support. JACC Cardiovasc Interv. 2019;12:2440-2441.</Citation></Reference><Reference><Citation>Estevez-Loureiro R, Adamo M, Arzamendi D, et al. The European registry of Mitraclip in acute mitral regurgitation following an acute myocardial infarction (EREMII). EuroIntervention. 2020;15:1248-1250.</Citation></Reference><Reference><Citation>Yasin M, Nanjundappa A, Annie FH, et al. Use of Mitraclip for postmyocardial infarction mitral regurgitation secondary to papillary muscle dysfunction. Cureus. 2018;10:e3065.</Citation></Reference><Reference><Citation>Bahlmann E, Frerker C, Kreidel F, et al. MitraClip implantation after acute ischemic papillary muscle rupture in a patient with prolonged cardiogenic shock. Ann Thorac Surg. 2015;99:e41-e42.</Citation></Reference><Reference><Citation>Bilge M, Alemdar R, Saatci-Yasar A. Successful percutaneous mitral valve repair with the Mitraclip system of acute mitral regurgitation due to papillary muscle rupture as complication of acute myocardial infarction. Catheter Cardiovasc Interv. 2014;83:e137-e140.</Citation></Reference><Reference><Citation>Buckert D, Markovic S, Zunze M, W&#xf6;hrle J, Rotbauer W, Walcher D. Percutaneous mitral valve repair with the Mitraclip NT system in a patient presenting with prolonged cardiogenic shock. Clin Case Rep. 2017;5:1807-1810.</Citation></Reference><Reference><Citation>Valle J, Miyasaka R, Carroll J. Acute mitral regurgitation secondary to papillary muscle tear. Is transcatheter edge-to-edge mitral valve repair a new paradigm? Circ Cardiovasc Interv. 2017;10:e005050.</Citation></Reference><Reference><Citation>Couture P, Cloutier-Gil LA, Ducharme A, Bonan R, Asgar AW. Mitraclip intervention as rescue therapy in cardiogenic shock: one-year follow-up. Can J Cardiol. 2014;30:1108-1106.</Citation></Reference><Reference><Citation>Chandrashekar P, Fender E, Al-Hijii M, et al. Novel use of Mitraclip for severe mitral regurgitation due to infective endocarditis. J Invasive Cardiol. 2017;29:e21-e22.</Citation></Reference><Reference><Citation>Leurent G, Corbineau H, Donal E. Uncontrolled daily pulmonary oedema due to severe mitral regurgitation emergently and effectively corrected by Mitraclip implantation. Eur Heart J Acute Cardiovasc Care. 2016;5:150-151.</Citation></Reference><Reference><Citation>Kane B, Calfon M. Successful transcatheter mitral valve repair in acute cardiogenic shock due to flail posterior leaflet. Paper presented at: UCLA Healthcare. 2017;21.</Citation></Reference><Reference><Citation>Tarsia G, Smaldone C, Constantino M. Effective percutaneous &#x201c;edge-to-edge&#x201d; mitral valve repair with Mitraclip in a patient with acute post-MI regurgitation not related to papillary muscle rupture. Catheter Cardiovasc Interv. 2016;88:1177-1180.</Citation></Reference><Reference><Citation>Wolff R, Cohen G, Peterson C, et al. Mitraclip for papillary muscle rupture in patient with cardiogenic shock. Can J Cardiol. 2014;30:1461-1464.</Citation></Reference><Reference><Citation>Zuern CS, Schreieck J, Weig HJ, Gawaz M, May AE. Percutaneous mitral valve repair using the Mitraclip in acute cardiogenic shock. Clin Res Cardiol. 2011;100:719-721.</Citation></Reference><Reference><Citation>Komatsu I, Cohen E, Cohen G, Czarnecki A. Transcatheter mitral valve edge-to-edge repair with the new Mitraclip XTR system for acute mitral regurgitation caused by papillary muscle rupture. Can J Cardiol. 2019;35:1604-1604.e7.</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Santamarta M, Est&#xe9;vez-Loureiro R, Gualis J, Alonso D, P&#xe9;rez de Prado A, Fern&#xe1;ndez-V&#xe1;zquez F. Percutaneous mitral valve repair with Mitraclip system in a patient with acute mitral regurgitation after myocardial infarction. Rev Esp Cardiol (Engl Ed). 2015;68:259-261.</Citation></Reference><Reference><Citation>Eliaz R, Turyan A, Beeri R, Shuvy M. Utilization of intra-aortic balloon pump to allow Mitraclip procedure in patients with non-coapting mitral valve leaflets: a case series. Eur Heart J Case Rep. 2019;3:1-4.</Citation></Reference><Reference><Citation>Papadopoulus K, Chrissoheris M, Nikolau I, Spargias K. Edge-to-edge mitral valve regurgitation due to papillary muscle rupture: a case report. Eur Heart J Case Rep. 2019;3(1):1-4.</Citation></Reference><Reference><Citation>Staudacher DL, Bode C, Wengenmayer T. Severe mitral regurgitation requiring ECMO therapy treated by interventional valve reconstruction using the Mitraclip. Catheter Cardiovasc Interv. 2015;85:170-175.</Citation></Reference><Reference><Citation>Tang G, Cohen M, Dutta T, Undemir C. Afterload mismatch after transcatheter mitral valve repair with Mitraclip for degenerative mitral regurgitation in acute cardiogenic shock. Catheter Cardiovasc Interv. 2018;92:e168-e171.</Citation></Reference><Reference><Citation>Hern&#xe1;ndez-Enr&#xed;quez M, Freixa X, Sanch&#xed;s L. Mitraclip repair in cardiogenic shock due to acute mitral regurgitation: from near-death to walking. J Heart Valve Dis. 2018;27:114-116.</Citation></Reference><Reference><Citation>Chan V, Messika-Zeiton D, Labinaz M, et al. Percutaneous mitral repair as salvage therapy in patients with mitral regurgitation and refractory cardiogenic shock. Circ Cardiovasc Interv. 2019;12:e008435.</Citation></Reference><Reference><Citation>Turyan Medvedovsky A, Tonchev I, Tahiroglu I, et al. MitraClip therapy in critically Ill patients with severe functional mitral regurgitation and refractory heart failure. Struct Heart. 2019;3(4):296-301. https://doi.org/10.1080/24748706.2019.1618514.</Citation></Reference><Reference><Citation>Kovach CP, Bell S, Kataruka A, Reisman M, Don C. Outcomes of urgent/emergent transcatheter mitral valve repair (MitraClip): A single center experience. Cathether Cardiovasc Interv. 2021;97(3):E402-E410. https://doi.org/10.1002/ccd.29084.</Citation></Reference><Reference><Citation>Chitturi KR, Faza NN, Little SH, Kleiman NS, Reardon MJ, Goel SS. Transcatheter mitral valve repair with MitraClip for severe mitral regurgitation and cardiogenic shock during the COVID-19 pandemic. Cardiovasc Revasc Med. 2020;21:950-953.</Citation></Reference><Reference><Citation>Garc&#xed;a S, Alsidawi S, Bae R, et al. Percutaneous mitral valve repair with MitraClip in inoperable patients with severe mitral regurgitation complicated by cardiogenic shock. J Invasive Cardiol. 2020;32(6):228-231.</Citation></Reference><Reference><Citation>Lee CW, Huang WM, Tsai YL, et al. Feasibility of the transcatheter mitral valve repair for patients with severe mitral regurgitation and endangered heart failure. J Formos Med Assoc. 2021;120:452-459.</Citation></Reference><Reference><Citation>Perrin N, Frei A, M&#xfc;ller H, Noble S. Five-year follou-up after percutaneous management of a 40-year-old man in shock treated by percutaneous coronary intervention and MitraClip. CJC Open. 2020;2:691-694.</Citation></Reference><Reference><Citation>Tyler J, Narbutas R, Oakley L, Ebinger J, Nakamura M. Percutaneous mitral valve repair with MitraClip XTR for acute mitral regurgitation due to papillary muscle rupture. J Cardiol Cases. 2020;22:246-248.</Citation></Reference><Reference><Citation>Rizik DG, Burke RF, Goldstein JA. Urgent mechanical circulatory support and transcatheter mitral valve repair for refractory hemodynamic compromise. Catheter Cardiovasc Interv. 2019;94:886-892.</Citation></Reference><Reference><Citation>Benito-Gonzalez T, Est&#xe9;vez-Loureiro R, Del Castillo S, et al. Clinical outcomes following urgent vs. elective percutaneous mitral valve repair. Cardiovasc Revasc Med. 2020. https://doi.org/10.1016/j.carrev.2020.10.025. [Epub ahead of print].</Citation></Reference><Reference><Citation>Cannata F, Sanz-S&#xe1;nchez J, Chiarito M, et al. Percutaneous mitral valve repair in acute mitral regurgitation: case report and review of the literature. Mini-Invasive Surg. 2020;4:53.</Citation></Reference><Reference><Citation>Horstkotte JC, Horstkotte M, Beucher H, Felderhoff T, Boekstegers P. Percutaneous mitral valve repair as rescue procedure after post myocardial infarction papillary muscle rupture and acute cardiogenic shock. Clin Res Cardiol. 2015;104:275-278.</Citation></Reference><Reference><Citation>Alkhouli M, Wolfe S, Alqahtani F, et al. The feasibility of transcatheter edge-to-edge repair in the management of acute severe ischemic mitral regurgitation. JACC Cardiovasc Interv. 2017;10(5):529-531.</Citation></Reference><Reference><Citation>Von Bardeleben RS, Hobohm L, Kreidel F, et al. Incidence and in-hospital safety outcomes of patients undergoing percutaneous mitral valve edge-to-edge repair using Mitraclip: five-year German national patient sample including 13575 implants. EuroIntervention. 2019;14:1725-1732.</Citation></Reference><Reference><Citation>Armijo G, Estevez-Loureiro R, Carrasco-Chinchilla F, et al. Acute kidney injury after percutaneous edge-to-edge mitral repair. J Am Coll Cardiol. 2020;76:2463-2473.</Citation></Reference><Reference><Citation>Van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232-e268.</Citation></Reference><Reference><Citation>Engstrom A, Vis M, Bouma B, et al. Mitral regurgitation is an independent predictor of 1-year mortality in ST-elevation myocardial infarction patients presenting in cardiogenic shock on admission. Acute Card Care. 2010;12:51-57.</Citation></Reference><Reference><Citation>Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK trial registry. SHould we use emergently revascularize occluded coronaries in cardiogenic shocK? J Am Coll Cardiol. 2000;36(3 Suppl A):1104-1109.</Citation></Reference><Reference><Citation>Jung RG, Simard T, Kovach C, et al. Transcatheter mitral valve repair in cardiogenic shock and mitral regurgitation: a patient-level, multicenter analysis. JACC Cardiovasc Interv. 2021;14:1-11.</Citation></Reference><Reference><Citation>Nashef S, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41:734-744.</Citation></Reference><Reference><Citation>Frerker C, Shl&#xfc;ter M, Sanchez OD, et al. Cerebral protection during Mitraclip implantation: initial experience at 2 centers. JACC Cardiovasc Interv. 2016;9:171-179.</Citation></Reference><Reference><Citation>Freixa X, Hern&#xe1;ndez M, Farrero M, et al. Levosimendan as an adjunctive therapy to MitraClip implantation in patients with severe mitral regurgitation and left ventricular dysfunction. Int J Cardiol. 2016;202:517-518.</Citation></Reference><Reference><Citation>P&#xe9;rez de Isla L, Zamorano JL, Quezada M, et al. Prognostic significance of functional mitral regurgitation after a first non-ST-segment elevation acute coronary syndrome. Eur Heart J. 2006;27:2655-2660.</Citation></Reference><Reference><Citation>Grigioni F, Enriquez-Sarano F, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative doppler assessment. Circulation. 2001;103:1759-1764.</Citation></Reference><Reference><Citation>Picard MH, Davidoff R, Sleeper LA, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation. 2003;107:279-284.</Citation></Reference><Reference><Citation>Godino C, Munaf&#xf2; A, Scotti A, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the international MitraBridge registry. J Heart Lung Transplant. 2020;39:1353-1362.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32650950</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-6280</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Current problems in cardiology</Title><ISOAbbreviation>Curr Probl Cardiol</ISOAbbreviation></Journal><ArticleTitle>Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials for Multivessel PCI Versus Culprit Artery Only PCI in STEMI Without Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>100646</StartPage><MedlinePgn>100646</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cpcardiol.2020.100646</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0146-2806(20)30123-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traditionally ST-elevation myocardial infarction (STEMI) with multivessel coronary artery disease is treated with percutaneous coronary intervention (PCI) to culprit lesion only. The benefit of multivessel (MV) PCI among STEMI patients without cardiogenic shock is unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, EMBASE, and Cochrane Database were searched from 1996 to 2019, for studies of patients with STEMI without cardiogenic shock, who underwent PCI. Only randomized controlled trials comparing culprit PCI to MV PCI vs culprit vessel PCI were included for pairwise meta-analysis. All-cause mortality, cardiac mortality, reinfarction, revascularization and major adverse cardiovascular events (MACE) were compared. Trial sequential analysis (TSA) was performed for outcome variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine randomized controlled trials contributed 6930 patients meeting inclusion criteria. Three thousand three hundred seventy-six underwent MV PCI, and 3554 underwent culprit PCI. Our analysis demonstrated no significant difference in all-cause mortality. MV PCI had a lower risk of cardiac mortality, reinfarction, MACE and repeat revascularization compared to culprit PCI (P values &lt;0.05). TSA showed futility for further trials to detect all-cause mortality benefit and lack of firm evidence of benefit in cardiac mortality and re-infarction, but firm evidence of benefit in revascularization and MACE.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, MV PCI strategy was beneficial in reducing cardiac mortality, reinfarction, repeat revascularization, and MACE but there was no all-cause mortality benefit when compared to culprit only PCI strategy. Evidence for benefit in cardiac mortality and re-infarction is not robust per TSA.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Devesh</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tahir</LastName><ForeName>Muhammad Waqas</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Dhrubajyoti</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Medhat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kharsa</LastName><ForeName>Adnan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pendala</LastName><ForeName>Venkata Satish</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Hammad</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>Srihari S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Baibhav</LastName><ForeName>Bipul</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Probl Cardiol</MedlineTA><NlmUniqueID>7701802</NlmUniqueID><ISSNLinking>0146-2806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32650950</ArticleId><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100646</ArticleId><ArticleId IdType="pii">S0146-2806(20)30123-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40455778</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>5</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Effect of low-dose esketamine on cardio-biliary reflex and postoperative pain during laparoscopic cholecystectomy surgery: A randomized, controlled trail.</ArticleTitle><Pagination><StartPage>e0321892</StartPage><MedlinePgn>e0321892</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0321892</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0321892</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardio-biliary reflex can lead to cardiac arrest, brady-arrhythmia, cardiogenic shock, and other severe complications. NMDA receptor antagonists have been shown to have the effect of anti-vagal reflex. However, the regulation of vagus reflex by esketamine, an NMDA receptor antagonist, remains unclear. Our study aims to investigate intravenous low-dose esketamine on cardio-biliary reflex.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this randomized controlled trial, adult patients undergoing laparoscopic cholecystectomy were allocated in a 1:1 ratio to esketamine group or control group. 5 minutes before surgical incision, participants in the esketamine group received 0.3&#x2009;mg/kg of esketamine, while the control group received an equivalent volume of normal saline. The primary outcome was the occurrence of cardio-biliary reflex. Postoperative pain was assessed using the Visual Analogue Scale (VAS) on days 1, 2, and 3 post-surgery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our final analysis included 140 participants. The incidence of the cardio-biliary reflex occurred in 15 patients (21.4%) in the control group compared with 6 patients (8.6%) in the esketamine group (relative risk 0.34; 95%confidence interval (95% CI): 0.125-0.947; P&#x2009;&lt;&#x2009;0.05). Patients in the esketamine group reported lower pain intensity with movement on postoperative days (POD)1, 2, and 3 with mean differences (MD) of 0.59, 0.70, and 0.47 points respectively (all P&#x2009;&lt;&#x2009;0.05). Additionally, pain intensity at rest was also lower in the esketamine group at all observation time points (POD1: MD 0.51, POD2: MD 0.40, POD3: MD 0.30, all P&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Therapeutic use of low-dose esketamine significantly reduces the occurrence of cardio-biliary reflex and postoperative pain in patients undergoing laparoscopic cholecystectomy.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yingjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0009-0003-9455-4652</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>50LFG02TXD</RegistryNumber><NameOfSubstance UI="C000629870">Esketamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017081" MajorTopicYN="Y">Cholecystectomy, Laparoscopic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="Y">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="Y">Ketamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012018" MajorTopicYN="Y">Reflex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40455778</ArticleId><ArticleId IdType="pmc">PMC12129155</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0321892</ArticleId><ArticleId IdType="pii">PONE-D-24-35359</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gutt C, Schl&#xe4;fer S, Lammert F. The Treatment of Gallstone Disease. Dtsch Arztebl Int. 2020;117(9):148&#x2013;58. doi: 10.3238/arztebl.2020.0148</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2020.0148</ArticleId><ArticleId IdType="pmc">PMC7132079</ArticleId><ArticleId IdType="pubmed">32234195</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallaher JR, Charles A. Acute Cholecystitis: A Review. JAMA. 2022;327(10):965&#x2013;75. doi: 10.1001/jama.2022.2350</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.2350</ArticleId><ArticleId IdType="pubmed">35258527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz Leija MA, Alem&#xe1;n-Jim&#xe9;nez MC, Plata-&#xc1;lvarez H, C&#xe1;rdenas-Salas VD, Valdez-L&#xf3;pez R. Laparoscopic Management of Cholecystoduodenal and Cholecystocolic Fistula: A Clinical Case Report. Cureus. 2023;15(6):e40657. doi: 10.7759/cureus.40657</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.40657</ArticleId><ArticleId IdType="pmc">PMC10356180</ArticleId><ArticleId IdType="pubmed">37476135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez KV, M&#xe1;rquez-Gonz&#xe1;lez H, Aguirre I, Orellana JC. Prognostic risk factors for conversion in laparoscopic cholecystectomy. Updates Surg. 2018;70(1):67&#x2013;72. doi: 10.1007/s13304-017-0494-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13304-017-0494-0</ArticleId><ArticleId IdType="pubmed">28980164</ArticleId></ArticleIdList></Reference><Reference><Citation>Barazanchi AWH, MacFater WS, Rahiri J-L, Tutone S, Hill AG, Joshi GP, et al.. Evidence-based management of pain after laparoscopic cholecystectomy: a PROSPECT review update. Br J Anaesth. 2018;121(4):787&#x2013;803. doi: 10.1016/j.bja.2018.06.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2018.06.023</ArticleId><ArticleId IdType="pubmed">30236241</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang Y, Zhang X. Effect of pre-emptive pregabalin on pain management in patients undergoing laparoscopic cholecystectomy: A systematic review and meta-analysis. Int J Surg. 2017;44:122&#x2013;7. doi: 10.1016/j.ijsu.2017.06.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2017.06.047</ArticleId><ArticleId IdType="pubmed">28642088</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Diaz-Cort&#xe9;s G, Brancaccio-P&#xe9;rez IV, Esparza-Estrada I, Barbosa-Camacho FJ, Fuentes-Orozco C, Gonz&#xe1;lez-Hern&#xe1;ndez PG, et al.. Differences in Postoperative Pain, Nausea, and Vomiting After Elective Laparoscopic Cholecystectomy in Premenopausal and Postmenopausal Mexican Women. World J Surg. 2022;46(2):356&#x2013;61. doi: 10.1007/s00268-021-06367-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-021-06367-y</ArticleId><ArticleId IdType="pubmed">34731260</ArticleId></ArticleIdList></Reference><Reference><Citation>Tochie JN, Bengono Bengono RS, Metogo JM, Ndikontar R, Ngouatna S, Ntock FN, et al.. The efficacy and safety of an adapted opioid-free anesthesia regimen versus conventional general anesthesia in gynecological surgery for low-resource settings: a randomized pilot study. BMC Anesthesiol. 2022;22(1):325. doi: 10.1186/s12871-022-01856-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12871-022-01856-6</ArticleId><ArticleId IdType="pmc">PMC9589676</ArticleId><ArticleId IdType="pubmed">36280804</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu D, Wang X-M, Yang J-J, Chen S, Yue C-B, Hashimoto K, et al.. Effect of Intraoperative Esketamine Infusion on Postoperative Sleep Disturbance After Gynecological Laparoscopy: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(12):e2244514. doi: 10.1001/jamanetworkopen.2022.44514</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.44514</ArticleId><ArticleId IdType="pmc">PMC9716381</ArticleId><ArticleId IdType="pubmed">36454569</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin H-J, Na H-S, Do S-H. Magnesium and Pain. Nutrients. 2020;12(8):2184. doi: 10.3390/nu12082184</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12082184</ArticleId><ArticleId IdType="pmc">PMC7468697</ArticleId><ArticleId IdType="pubmed">32718032</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippot A, Dubois V, Lambrechts K, Grogna D, Robert A, Jonckheer U, et al.. Impact of physical exercise on depression and anxiety in adolescent inpatients: A randomized controlled trial. J Affect Disord. 2022;301:145&#x2013;53. doi: 10.1016/j.jad.2022.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2022.01.011</ArticleId><ArticleId IdType="pubmed">35007642</ArticleId></ArticleIdList></Reference><Reference><Citation>Klotz R, Seide SE, Knebel P, Probst P, Bruckner T, Motsch J, et al.. Continuous wound infiltration versus epidural analgesia for midline abdominal incisions - a randomized-controlled pilot trial (Painless-Pilot trial; DRKS Number: DRKS00008023). PLoS One. 2020;15(3):e0229898. doi: 10.1371/journal.pone.0229898</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0229898</ArticleId><ArticleId IdType="pmc">PMC7059935</ArticleId><ArticleId IdType="pubmed">32142529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cope Z. A sign of gall-bladder disease. Br Med J. 1970;3(5715):147&#x2013;8. doi: 10.1136/bmj.3.5715.147</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.3.5715.147</ArticleId><ArticleId IdType="pmc">PMC1702308</ArticleId><ArticleId IdType="pubmed">5431086</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly MV, Krauthamer MJ. &#x201c;Cope&#x2019;s sign&#x201d; and reflex bradycardia in two patients with cholecystitis. Br Med J. 1971;2(5754):146. doi: 10.1136/bmj.2.5754.146</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.2.5754.146</ArticleId><ArticleId IdType="pmc">PMC1795584</ArticleId><ArticleId IdType="pubmed">5581494</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang S, Gao L, Yang F, Gong Y-J. Delayed reversibility of complete atrioventricular block: cardio-biliary reflex after alcohol septal ablation in a patient with hypertrophic obstructive cardiomyopathy. BMC Cardiovasc Disord. 2021;21(1):372. doi: 10.1186/s12872-021-02165-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-021-02165-5</ArticleId><ArticleId IdType="pmc">PMC8330103</ArticleId><ArticleId IdType="pubmed">34344308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mainali A, Adhikari S, Chowdhury T, Shankar M, Gousy N, Dufresne A. Symptomatic Sinus Bradycardia in a Patient With Acute Calculous Cholecystitis Due to the Cardio-Biliary Reflex (Cope&#x2019;s Sign): A Case Report. Cureus. 2022;14(6):e25585. doi: 10.7759/cureus.25585</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.25585</ArticleId><ArticleId IdType="pmc">PMC9249057</ArticleId><ArticleId IdType="pubmed">35785008</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance KM, Rogers RC, Hermann GE. NMDA receptors control vagal afferent excitability in the nucleus of the solitary tract. Brain Res. 2015;1595:84&#x2013;91. doi: 10.1016/j.brainres.2014.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.11.010</ArticleId><ArticleId IdType="pmc">PMC4330085</ArticleId><ArticleId IdType="pubmed">25446446</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh JN, Lee SY, Lee JH, Choi SR, Chin YJ. Effect of ketamine and midazolam on oculocardiac reflex in pediatric strabismus surgery. Korean J Anesthesiol. 2013;64(6):500&#x2013;4. doi: 10.4097/kjae.2013.64.6.500</Citation><ArticleIdList><ArticleId IdType="doi">10.4097/kjae.2013.64.6.500</ArticleId><ArticleId IdType="pmc">PMC3695246</ArticleId><ArticleId IdType="pubmed">23814649</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Song Z, Zhang C, Chen P. Bispectral index monitoring of the clinical effects of propofol closed-loop target-controlled infusion: Systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(4):e23930. doi: 10.1097/MD.0000000000023930</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023930</ArticleId><ArticleId IdType="pmc">PMC7850716</ArticleId><ArticleId IdType="pubmed">33530193</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L-L, Wang C, Deng C-M, Dai S-B, Zhou Q, Peng Y-B, et al.. Efficacy and Safety of Esketamine for Supplemental Analgesia During Elective Cesarean Delivery: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(4):e239321. doi: 10.1001/jamanetworkopen.2023.9321</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.9321</ArticleId><ArticleId IdType="pmc">PMC10122167</ArticleId><ArticleId IdType="pubmed">37083664</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams HA, Meyer P, Stoppa A, M&#xfc;ller-Goch A, Bayer P, Hecker H. Anaesthesia for caesarean section. Comparison of two general anaesthetic regimens and spinal anaesthesia. Anaesthesist. 2003;52(1):23&#x2013;32. doi: 10.1007/s00101-002-0440-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00101-002-0440-4</ArticleId><ArticleId IdType="pubmed">12577162</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang J, An X-H, Chao Y-C, Bian Y, Xu Z, et al.. Optimum dose of spinal ropivacaine with or without single intravenous bolus of S-ketamine during elective cesarean delivery: a randomized, double-blind, sequential dose-finding study. BMC Pregnancy Childbirth. 2021;21(1):746. doi: 10.1186/s12884-021-04229-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12884-021-04229-y</ArticleId><ArticleId IdType="pmc">PMC8567718</ArticleId><ArticleId IdType="pubmed">34736438</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian XL, Li P, Chen YJ, Xu SQ, Wang X, Feng SW. Opioid Free Total Intravenous Anesthesia With Dexmedetomidine-Esketamine-Lidocaine for Patients Undergoing Lumpectomy. J Clin Med Res. 2023;15(8&#x2013;9):415&#x2013;22. doi: 10.14740/jocmr5000</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr5000</ArticleId><ArticleId IdType="pmc">PMC10563822</ArticleId><ArticleId IdType="pubmed">37822850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J-S, Peng G-F, Liang W-D, Chen Z, Liu Y-Y, Wang B-Y, et al.. Recent advances in the study of anesthesia-and analgesia-related mechanisms of S-ketamine. Front Pharmacol. 2023;14:1228895. doi: 10.3389/fphar.2023.1228895</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1228895</ArticleId><ArticleId IdType="pmc">PMC10539608</ArticleId><ArticleId IdType="pubmed">37781698</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas-Arroyave FD, Osorno-Upegui SC, Zamudio-Burbano MA. Therapeutic efficacy of intravenous lidocaine infusion compared with thoracic epidural analgesia in major abdominal surgery: a noninferiority randomised clinical trial. Br J Anaesth. 2023;131(5):947&#x2013;54. doi: 10.1016/j.bja.2023.07.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2023.07.032</ArticleId><ArticleId IdType="pubmed">37758623</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Zhang Y, Chen Y, Xu M, Lei X, Fu Q. Analgesic effect of erector spinae plane block in adults undergoing laparoscopic cholecystectomy: a systematic review and meta-analysis of randomized controlled trials. BMC Anesthesiol. 2023;23(1):7. doi: 10.1186/s12871-023-01969-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12871-023-01969-6</ArticleId><ArticleId IdType="pmc">PMC9817294</ArticleId><ArticleId IdType="pubmed">36609244</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cui F, Ma J-H, Wang D-X. Mini-dose esketamine-dexmedetomidine combination to supplement analgesia for patients after scoliosis correction surgery: a double-blind randomised trial. Br J Anaesth. 2023;131(2):385&#x2013;96. doi: 10.1016/j.bja.2023.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2023.05.001</ArticleId><ArticleId IdType="pubmed">37302963</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Lin C, Lan L, Liu J. Perioperative intravenous S-ketamine for acute postoperative pain in adults: A systematic review and meta-analysis. J Clin Anesth. 2021;68:110071. doi: 10.1016/j.jclinane.2020.110071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2020.110071</ArticleId><ArticleId IdType="pubmed">33007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Boenigk K, Echevarria GC, Nisimov E, von Bergen Granell AE, Cuff GE, Wang J, et al.. Low-dose ketamine infusion reduces postoperative hydromorphone requirements in opioid-tolerant patients following spinal fusion: A randomised controlled trial. Eur J Anaesthesiol. 2019;36(1):8&#x2013;15. doi: 10.1097/EJA.0000000000000877</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000877</ArticleId><ArticleId IdType="pubmed">30113350</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Yang H, Hai Y, Cheng Y. Perioperative Low-Dose Ketamine for Postoperative Pain Management in Spine Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Res Manag. 2022;2022:1507097. doi: 10.1155/2022/1507097</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/1507097</ArticleId><ArticleId IdType="pmc">PMC8989618</ArticleId><ArticleId IdType="pubmed">35401887</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Song C, Lu X, Wen Y, Song S, Yu J, et al.. The effect of low-dose esketamine on pain and post-partum depression after cesarean section: A prospective, randomized, double-blind clinical trial. Front Psychiatry. 2022;13:1038379. doi: 10.3389/fpsyt.2022.1038379</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2022.1038379</ArticleId><ArticleId IdType="pmc">PMC9845877</ArticleId><ArticleId IdType="pubmed">36683972</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Wang F, Dong R, Zhu K, Wang C. Efficacy and Safety of Remimazolam Tosilate Combined With Esketamine for Analgesic Sedation in Mechanically Ventilated ICU Patients: A Single-Arm Clinical Study Protocol. Front Med (Lausanne). 2022;9:832105. doi: 10.3389/fmed.2022.832105</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.832105</ArticleId><ArticleId IdType="pmc">PMC8968316</ArticleId><ArticleId IdType="pubmed">35372406</ArticleId></ArticleIdList></Reference><Reference><Citation>Launo C, Bassi C, Spagnolo L, Badano S, Ricci C, Lizzi A, et al.. Preemptive ketamine during general anesthesia for postoperative analgesia in patients undergoing laparoscopic cholecystectomy. Minerva Anestesiol. 2004;70(10):727&#x2013;34; 734&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirani SH, Areja D, Gilani SS, Tahir A, Pathan M, Bhatti S. Frequency of Depression and Anxiety Symptoms in Surgical Hospitalized Patients. Cureus. 2019;11(2):e4141. doi: 10.7759/cureus.4141</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.4141</ArticleId><ArticleId IdType="pmc">PMC6485537</ArticleId><ArticleId IdType="pubmed">31058024</ArticleId></ArticleIdList></Reference><Reference><Citation>Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu D-J, et al.. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N Engl J Med. 2023;389(14):1298&#x2013;309. doi: 10.1056/NEJMoa2304145</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2304145</ArticleId><ArticleId IdType="pubmed">37792613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahji A, Zarate CA, Vazquez GH. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21(6):853&#x2013;66. doi: 10.1080/14740338.2022.2047928</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2022.2047928</ArticleId><ArticleId IdType="pmc">PMC9949988</ArticleId><ArticleId IdType="pubmed">35231204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Song T, Zhang Y, Guo N, Zhao P. Intraoperative ketamine for reduction in postpartum depressive symptoms after cesarean delivery: A double-blind, randomized clinical trial. Brain Behav. 2020;10(9):e01715. doi: 10.1002/brb3.1715</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1715</ArticleId><ArticleId IdType="pmc">PMC7507540</ArticleId><ArticleId IdType="pubmed">32812388</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, et al.. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456&#x2013;66. doi: 10.1097/AAP.0000000000000806</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AAP.0000000000000806</ArticleId><ArticleId IdType="pmc">PMC6023582</ArticleId><ArticleId IdType="pubmed">29870457</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil LV, Mazzeffi MA, Cai Y, McLeod WW, Porter SB. Reasons for discontinuation of acute postoperative pain ketamine infusions: A retrospective case-control study. Pain Pract. 2021;21(7):759&#x2013;65. doi: 10.1111/papr.13012</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/papr.13012</ArticleId><ArticleId IdType="pubmed">33811788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y-L, Yuan J-J, Xing F, Zhu L-N, Zhang W. Effects of Different Doses of Esketamine on Pain Sensitivity of Patients Undergoing Thyroidectomy: A Randomized Controlled Trial. Pain Ther. 2023;12(3):739&#x2013;50. doi: 10.1007/s40122-023-00488-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-023-00488-z</ArticleId><ArticleId IdType="pmc">PMC10199971</ArticleId><ArticleId IdType="pubmed">36933139</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39825250</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2253</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>BMC anesthesiology</Title><ISOAbbreviation>BMC Anesthesiol</ISOAbbreviation></Journal><ArticleTitle>Outcome and complications in postcardiotomy cardiogenic shock treated with extracorporeal life support - a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>29</StartPage><MedlinePgn>29</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">29</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12871-025-02898-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Postcardiotomy cardiogenic shock (PCCS) in cardiac surgery is associated with a high rate of morbidity and mortality. Beside other therapeutic measures (e.g. intraaortic balloon pump (IABP)), extracorporeal life support is being increasingly used in this particular form of shock. Objectives of this meta-analysis were to determine mortality and complications of extracorporeal life support treatment (ECLS) in cardiac surgery patients, and if outcomes were influenced by a preexisting cardiovascular risk profile.</AbstractText><AbstractText Label="METHODS">MEDLINE and EMBASE were searched for studies in English, published between January 1<sup>st</sup> 2000 and January 16<sup>th</sup> 2023, reporting mortality and morbidity in patients aged&#x2009;&#x2265;&#x2009;18 treated with ECLS for PCCS. Supplementary data were requested from the respective corresponding authors. Outcomes were weaning from extracorporeal life support, hospital survival and complications.</AbstractText><AbstractText Label="RESULTS">Two thousand, seven hundred seventy-four papers were screened, of which 132 full text articles were assessed for suitability. 70 remaining studies were included for further evaluation and data analysis. Five studies could be included in the final analysis since the corresponding authors provided additional necessary information. Successful weaning from extracorporeal life support was accomplished in 52.8% (30.8%-57.4%) and 31.1% were discharged alive (mortality of 25.0 - 56.2% after weaning). 95.1% of all treated patients suffered from at least one complication. Diabetes mellitus and obesity seem to be independent risk factors for poor outcome.</AbstractText><AbstractText Label="CONCLUSIONS">Extracorporeal life support for PCCS is associated with a substantial mortality and complication rate. Diabetes mellitus and obesity seem to be independent risk factors. Therefore, until future work has elucidated which patients benefit at all, the risks of ECLS-treatment must be critically weighed up against a possible benefit.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kienlein</LastName><ForeName>Romana Maria</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Department of Anesthesiology and Intensive Care Medicine, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Trauzeddel</LastName><ForeName>Ralf Felix</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Department of Anesthesiology and Intensive Care Medicine, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Nilufar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Institute of Biometry and Clinical Epidemiology, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avalli</LastName><ForeName>Leonello</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Centro Cardiologico Monzino, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biancari</LastName><ForeName>Fausto</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Centro Cardiologico Monzino IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dini</LastName><ForeName>Carlotta Sorini</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intensive Cardiac Care Unit, Azienda Ospedaliera-Universitaria Senese, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guenther</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University Hospital Munich, Ludwig-Maximilian-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagl</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University Hospital Munich, Ludwig-Maximilian-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heringlake</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Heart- and Diabetes Center Mecklenburg - Western Pomerania, Karlsburg Hospital, Karlsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruppa</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hochschule Osnabr&#xfc;ck, University of Applied Sciences, Osnabr&#xfc;ck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe4;kikallio</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, South Karelia Central Hospital, University of Helsinki, Lappeenranta, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1CHU Rennes, Service de Cardiologie Et Maladies Vasculaires, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Chambrun</LastName><ForeName>Marc Pineton</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), H&#xf4;pital La Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Intensive R&#xe9;animation, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, UMRS_1166-ICAN, Institut de Cardiom&#xe9;tabolisme Et Nutrition (ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rastan</LastName><ForeName>Ardawan Julian</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Cardiac and Thoracic Vascular Surgery, Marburg University Hospital, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubino</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care, Royal Papworth Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Brink</LastName><ForeName>Floris</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Leids Universitair Medisch Centrum, Albinusdreef 2, Leiden, 2333ZA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordine</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Intensive Care Medicine, and Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treskatsch</LastName><ForeName>Sascha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Department of Anesthesiology and Intensive Care Medicine, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany. sascha.treskatsch@charite.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Anesthesiol</MedlineTA><NlmUniqueID>100968535</NlmUniqueID><ISSNLinking>1471-2253</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Extracorporeal life support</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Postcardiotomy cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Veno-arterial extracorporeal membrane oxygenation</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This meta-analysis was approved by the local ethics committee at Charit&#xe9; &#x2013; Universit&#xe4;tsmedizin Berlin (EA4/239/19) as well as the local data protection authority. Consent to participate was not applicable. Consent for publication: Not applicable. Competing interests: RFT, RMK, LA, CSD, RM, NA, JK, JAR, MN, MPdC, FB, TM, AR, FvdB have nothing to declare. SPWG received funding for the ECLS-SHOCK Trial (NCT02544594, Registration Date 02.09.2015) from the Sorin Group, Italy. MH reports honoraria for lectures and scientific advice by Orion Pharma, Amomed Pharma, Edwards Lifesciences, and CSL Behring. ST received funding for experimental research as well as honoraria for lectures from Edwards, OrionPharma, Amomed and Smith &amp; Nephews outside this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>18</Day><Hour>15</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>18</Day><Hour>15</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39825250</ArticleId><ArticleId IdType="pmc">PMC11740342</ArticleId><ArticleId IdType="doi">10.1186/s12871-025-02898-2</ArticleId><ArticleId IdType="pii">10.1186/s12871-025-02898-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg. 2001;93(1):7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11429329</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirose H, Gupta S, Pitcher H, Miessau J, Yang Q, Yang J, et al. Feasibility of diagnosis of postcardiotomy tamponade by miniaturized transesophageal echocardiography. J Surg Res. 2014;190(1):276&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24703223</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen S, Mayer E, Hake U, Schmiedt W, Jakob H, Oelert H. Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock. Scand J Thorac Cardiovasc Surg. 1992;26(2):143&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1439645</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller BJ, Sinha SS, Kapur NK, Bakitas M, Balsam LB, Chikwe J, et al. Escalating and de-escalating temporary mechanical circulatory support in cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2022;146(6):e50&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">35862152</ArticleId></ArticleIdList></Reference><Reference><Citation>Corujo Rodriguez A, Richter E, Ibekwe SO, Shah T, Faloye AO. Postcardiotomy shock syndrome: a narrative review of perioperative diagnosis and management. J Cardiothorac Vasc Anesth. 2023;37(12):2621&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">37806929</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbik B, Chou LP, Gorthi J. Extracorporeal membrane oxygenation in postcardiotomy cardiogenic shock. Methodist Debakey Cardiovasc J. 2023;19(4):66&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10402824</ArticleId><ArticleId IdType="pubmed">37547900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni T, Sharma NS, Diaz-Guzman E. Extracorporeal membrane oxygenation in adults: a practical guide for internists. Cleve Clin J Med. 2016;83(5):373&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27168514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Raffa GM, Alenizy K, Sluijpers N, Makhoul M, Brodie D, et al. Structured review of post-cardiotomy extracorporeal membrane oxygenation: part 1-adult patients. J Heart Lung Transplant. 2019;38(11):1125&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8152367</ArticleId><ArticleId IdType="pubmed">31522913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Shekar K, MacLaren G, Schmidt M, Pellegrino V, Meyns B, et al. ELSO interim guidelines for venoarterial extracorporeal membrane oxygenation in adult cardiac patients. ASAIO J. 2021;67(8):827&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">34339398</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman LM, Taccone FS, Lorusso R, Malfertheiner MV, Pappalardo F, Di Nardo M, et al. The ELSO Maastricht Treaty for ECLS nomenclature: abbreviations for cannulation configuration in extracorporeal life support - a position paper of the extracorporeal life support organization. Crit Care. 2019;23(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367794</ArticleId><ArticleId IdType="pubmed">30736845</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmann A, Beckmann A, Schmid C, Werdan K, Michels G, Miera O, et al. Use of extracorporeal Circulation (ECLS/ECMO) for cardiac and circulatory failure &#x2013;a clinical practice guideline level 3. ESC Heart Failure. 2021;9(1):506&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8788014</ArticleId><ArticleId IdType="pubmed">34811959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Whitman G, Milojevic M, Raffa G, McMullan DM, Boeken U, et al. 2020 EACTS/ELSO/STS/AATS Expert Consensus On Post-Cardiotomy Extracorporeal Life Support In Adult Patients. J Thorac Cardiovasc Surg. 2021;161(4):1287&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">33039139</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariscalco G, Salsano A, Fiore A, Dalen M, Ruggieri VG, Saeed D, et al. Peripheral versus central extracorporeal membrane oxygenation for postcardiotomy shock: multicenter registry, systematic review, and meta-analysis. J Thorac Cardiovasc Surg. 2020;160(5):1207&#x2013;16 e44.</Citation><ArticleIdList><ArticleId IdType="pubmed">31864699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang H, Hou X. Clinical outcomes of adult patients who receive extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2018;32(5):2087&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">29678433</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Yan S, Gao S, Liu M, Lou S, Liu G, et al. Effect of an intra-aortic balloon pump with venoarterial extracorporeal membrane oxygenation on mortality of patients with cardiogenic shock: a systematic review and meta-analysisdagger. Eur J Cardiothorac Surg. 2019;55(3):395&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">30252028</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D, Xu A, Guan Q, Qin J, Zhang C. Venoarterial extracorporeal membrane oxygenation with intra-aortic balloon pump for postcardiotomy cardiogenic shock: a systematic review and meta-analysis. Perfusion. 2023;38(1):142&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34479456</ArticleId></ArticleIdList></Reference><Reference><Citation>Harahwa T, Chor CYT, Harky A. The use of extracorporeal membrane oxygenation postcardiotomy-a systematic review. J Card Surg. 2020;35(8):1941&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">32598523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalewski M, Raffa G, Zielinski K, Meani P, Alanazi M, Gilbers M, et al. Baseline surgical status and short-term mortality after extracorporeal membrane oxygenation for post-cardiotomy shock: a meta-analysis. Perfusion. 2020;35(3):246&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">31469037</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J. 2017;38(47):3523&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29020341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackermair K, Brunner S, Orban M, Peterss S, Orban M, Theiss HD, et al. Outcome of patients treated with extracorporeal life support in cardiogenic shock complicating acute myocardial infarction: 1-year result from the ECLS-Shock study. Clin Res Cardiol. 2021;110(9):1412&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33180150</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner S, Guenther SPW, Lackermair K, Peterss S, Orban M, Boulesteix AL, et al. Extracorporeal life support in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 2019;73(18):2355&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31072581</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N Engl J Med. 2023;389(14):1286&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">37634145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstrom AE, Lagrand WK, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016;42(12):1922&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5106498</ArticleId><ArticleId IdType="pubmed">27647331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson-Smith AR, Bogdanova Y, Roydhouse S, Phan K, Tian DH, Yan TD, et al. Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: systematic review and meta-analysis. Ann Cardiothorac Surg. 2019;8(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379189</ArticleId><ArticleId IdType="pubmed">30854307</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Avalli L, Sangalli F, Migliari M, Maggioni E, Gallieri S, Segramora V, et al. Early vascular complications after percutaneous cannulation for extracorporeal membrane oxygenation for cardiac assist. Minerva Anestesiol. 2016;82(1):36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">25907578</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancari F, Dalen M, Fiore A, Ruggieri VG, Saeed D, Jonsson K, et al. Multicenter study on postcardiotomy venoarterial extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 2020;159(5):1844&#x2013;54 e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31358340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan AJ, Dege A, Mohr M, Doll N, Falk V, Walther T, et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg. 2010;139(2):302&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">20106393</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino A, Costanzo D, Szanszus D, Valchanov K, Jenkins D, Sertic F, et al. Central Veno-Arterial Extracorporeal Membrane Oxygenation (C-VA-ECMO) after cardiothoracic surgery: a single-center experience. J Cardiothorac Vasc Anesth. 2018;32(3):1169&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">29428358</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Brink FS, van Tooren R, Sonker U, Klein P, Waanders F, Zivelonghi C, et al. Veno arterial-extra corporal membrane oxygenation for the treatment of cardiac failure in patients with infective endocarditis. Perfusion. 2019;34(7):613&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31027458</ArticleId></ArticleIdList></Reference><Reference><Citation>de Pineton Chambrun M, Brechot N, Lebreton G, Schmidt M, Hekimian G, Demondion P, et al. Venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock post-cardiac arrest. Intensive Care Med. 2016;42(12):1999&#x2013;2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">27681706</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitman GJ. Extracorporeal membrane oxygenation for the treatment of postcardiotomy shock. J Thorac Cardiovasc Surg. 2017;153(1):95&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">27666787</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara S, Takeda K, Garan AR, Kurlansky P, Hastie J, Naka Y, et al. Contemporary mechanical circulatory support therapy for postcardiotomy shock. Gen Thorac Cardiovasc Surg. 2016;64(4):183&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">26874519</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmann A, Beckmann A, Schmid C, Werdan K, Michels G, Miera O, et al. Use of extracorporeal circulation (ECLS/ECMO) for cardiac and circulatory failure -a clinical practice Guideline Level 3. ESC Heart Fail. 2022;9(1):506&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8788014</ArticleId><ArticleId IdType="pubmed">34811959</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan K, Shekar K, Ling RR, Barbaro RP, Wong SN, Tan CS, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care. 2021;25(1):211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8201440</ArticleId><ArticleId IdType="pubmed">34127027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CN, Kaier K, Zotzmann V, Stachon P, Pottgiesser T, von Zur MC, et al. Cardiogenic shock: incidence, survival and mechanical circulatory support usage 2007&#x2013;2017-insights from a national registry. Clin Res Cardiol. 2021;110(9):1421&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8405485</ArticleId><ArticleId IdType="pubmed">33258007</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain P, Salama M, Everett K, Reyelt L, Kapur NK. To vent or not to vent: a loaded question during venoarterial extracorporeal membrane oxygenation support for cardiogenic shock. Circ Cardiovasc Interv. 2021;14(5):e010537.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003669</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodoo SN, Kwapong YA, Agyemang-Sarpong A, Amoran E, Egolum UO, Ghasemzadeh N, et al. Comparative healthcare resource utilization of percutaneous mechanical circulatory support using impella versus intra-aortic balloon pump use for patients with acute coronary syndrome and cardiogenic shock undergoing percutaneous coronary interventions: insights from national inpatient sample. Curr Probl Cardiol. 2023;49(1):102053.</Citation><ArticleIdList><ArticleId IdType="pubmed">37640173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Yang C, Chen J, Fan Z, Cai W, Huang Y, et al. Comparison of the efficacy of ECMO with or without IABP in patients with cardiogenic shock: a meta-analysis. Front Cardiovasc Med. 2022;9:917610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9300857</ArticleId><ArticleId IdType="pubmed">35872892</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M, D&#x2019;Andria Ursoleo J, Nardelli P, Ortalda A, Ajello S, Delrio S, et al. Temporary mechanical circulatory support with Impella in cardiac surgery: a systematic review. Int J Cardiol. 2024;396:131418.</Citation><ArticleIdList><ArticleId IdType="pubmed">37813286</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevathasan T, Fureder L, Fechtner M, Mork SR, Schrage B, Westermann D, et al. Left-ventricular unloading with Impella during refractory cardiac arrest treated with extracorporeal cardiopulmonary resuscitation: a systematic review and meta-analysis. Crit Care Med. 2024;52(3):464&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10876179</ArticleId><ArticleId IdType="pubmed">38180032</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>de Waha S, Fuernau G, Eitel I, Desch S, Thiele H. Long-term prognosis after extracorporeal life support in refractory cardiogenic shock - results from a real-world cohort. EuroIntervention. 2016;12(3):414.</Citation><ArticleIdList><ArticleId IdType="pubmed">27320436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostadal P, Rokyta R, Karasek J, Kruger A, Vondrakova D, Janotka M, et al. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: results of the ECMO-CS randomized clinical trial. Circulation. 2023;147(6):454&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">36335478</ArticleId></ArticleIdList></Reference><Reference><Citation>Banning AS, Sabat&#xe9; M, Orban M, Gracey J, L&#xf3;pez-Sobrino T, Massberg S, et al. Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial. EuroIntervention. 2023;19(6):482&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10436068</ArticleId><ArticleId IdType="pubmed">37334659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeymer U, Freund A, Hochadel M, Ostadal P, Belohlavek J, Rokyta R, et al. Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials. Lancet. 2023;402(10410):1338&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">37643628</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancari F, M&#xe4;kikallio T, Loforte A, Kaserer A, Ruggieri VG, Cho S, et al. Inter-institutional analysis of the outcome after postcardiotomy veno-arterial extracorporeal membrane oxygenation. Int J Artif Organs. 2024;47(1):25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">38053227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani S, Heuts S, van Bussel BCT, Di Mauro M, Wiedemann D, Saeed D, et al. Patient and management variables associated with survival after postcardiotomy extracorporeal membrane oxygenation in adults: The PELS-1 multicenter cohort study. J Am Heart Assoc. 2023;12(14):e029609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10382118</ArticleId><ArticleId IdType="pubmed">37421269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando SM, MacLaren G, Barbaro RP, Mathew R, Munshi L, Madahar P, et al. Age and associated outcomes among patients receiving venoarterial extracorporeal membrane oxygenation-analysis of the extracorporeal life support organization registry. Intensive Care Med. 2023;49(12):1456&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">37792052</ArticleId></ArticleIdList></Reference><Reference><Citation>Alba AC, Foroutan F, Buchan TA, Alvarez J, Kinsella A, Clark K, et al. Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients. J Heart Lung Transplant. 2021;40(4):260&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33551227</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorsandi M, Dougherty S, Bouamra O, Pai V, Curry P, Tsui S, et al. Extra-corporeal membrane oxygenation for refractory cardiogenic shock after adult cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Surg. 2017;12(1):55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512816</ArticleId><ArticleId IdType="pubmed">28716039</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39621097</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1861-0692</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical research in cardiology : official journal of the German Cardiac Society</Title><ISOAbbreviation>Clin Res Cardiol</ISOAbbreviation></Journal><ArticleTitle>Long-term outcomes with medical therapy, transcatheter repair, or surgery for isolated tricuspid regurgitation: a systematic review and network meta-analysis.</ArticleTitle><Pagination><StartPage>272</StartPage><EndPage>280</EndPage><MedlinePgn>272-280</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00392-024-02579-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several transcatheter tricuspid valve (TV) repair devices for tricuspid regurgitation (TR) have emerged. However, few studies have compared transcatheter TV repair with medical therapy (MT) alone or isolated TV surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed and EMBASE were searched in February 2024. Studies comparing at least any of the following 2 were included: MT, surgical TV repair, surgical TV replacement, or transcatheter TV repair. The primary outcome was long-term mortality (&#x2267; 1&#xa0;year). The secondary outcomes were short-term mortality (30-day or in-hospital mortality) and periprocedural complications. We performed a network meta-analysis using a random effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 25,831 patients from 22 studies (one randomized trial and 21 observational studies) were included. MT alone was associated with higher long-term mortality compared to surgical TV repair (HR [95% CI] 1.72 [1.34-2.23]), surgical TV replacement (HR [95% CI] 1.49 [1.14-1.96]), and transcatheter TV repair (HR [95% CI] 1.52 [1.30-1.78]). Long-term mortality was comparable between transcatheter and surgical interventions. Transcatheter TV repair had a lower risk of short-term mortality (versus surgical TV repair; RR [95% CI] 0.40 [0.22-0.72], versus surgical TV replacement; RR [95% CI] 0.35 [0.19-0.66]) and lower rates of periprocedural complications, including new pacemaker implantation, renal complications, cardiogenic shock than surgical interventions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MT alone for TR was associated with higher long-term mortality compared to surgical or transcatheter TV interventions. Transcatheter TV repair had better periprocedural outcomes compared to surgical interventions with similar long-term mortality. Despite the possibility of selection bias, transcatheter TV repair appears to be an attractive option for TR treatment.</AbstractText><CopyrightInformation>&#xa9; 2024. Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Edogawa Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2487-8366</Identifier><AffiliationInfo><Affiliation>Cardiology Division, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, GRB 800, Boston, MA, 02114, USA. kuno-toshiki@hotmail.co.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. kuno-toshiki@hotmail.co.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aikawa</LastName><ForeName>Tadao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueyama</LastName><ForeName>Hiroki A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampaktsis</LastName><ForeName>Polydoros N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Structural and Congenital Center, Hackensack Medical Center, Hackensack, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolte</LastName><ForeName>Dhaval</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misumida</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Hisato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Yousif</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Cardiology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Division, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zajarias</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Latib</LastName><ForeName>Azeem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Res Cardiol</MedlineTA><NlmUniqueID>101264123</NlmUniqueID><ISSNLinking>1861-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014262" MajorTopicYN="Y">Tricuspid Valve Insufficiency</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="Y">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006328" MajorTopicYN="Y">Cardiac Catheterization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014261" MajorTopicYN="Y">Tricuspid Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Surgical tricuspid valve repair</Keyword><Keyword MajorTopicYN="N">Surgical tricuspid valve replacement</Keyword><Keyword MajorTopicYN="N">Transcatheter tricuspid valve repair</Keyword><Keyword MajorTopicYN="N">Tricuspid regurgitation</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: Dr Ahmad is a consultant for Cardiovascular Systems Inc and Shockwave and serves on the Medical Advisory Board of Boston Scientific. Dr Latib has served on advisory boards or as a consultant for Medtronic, Abbott Vascular, Boston Scientific, Supira, Edwards Lifesciences, Shifamed, NeoChord Inc, V-dyne, and Philips. Nothing to disclose for other authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>19</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39621097</ArticleId><ArticleId IdType="doi">10.1007/s00392-024-02579-z</ArticleId><ArticleId IdType="pii">10.1007/s00392-024-02579-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hahn RT, Brener MI, Cox ZL, Pinney S, Lindenfeld JA (2023) Tricuspid regurgitation management for heart failure. JACC Hear Fail 11:1084&#x2013;1102. https://doi.org/10.1016/j.jchf.2023.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2023.07.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C et al (2021) 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2(143):e72&#x2013;e227. https://doi.org/10.1161/CIR.0000000000000923</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000923</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R et al (2022Feb) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 12(43):561&#x2013;632. https://doi.org/10.1093/eurheartj/ehab395</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab395</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotti A, Sturla M, Granada JF, Kodali SK, Coisne A, Mangieri A, Godino C, Ho E, Goldberg Y, Chau M et al (2022) Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5316 patients from 35 studies. EuroIntervention 18:840&#x2013;851. https://doi.org/10.4244/EIJ-D-22-00442</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-D-22-00442</ArticleId><ArticleId IdType="pubmed">36197445</ArticleId><ArticleId IdType="pmc">10167545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chick W, Alkhalil M, Egred M, Gorog DA, Edwards R, Das R, Abdeldayem T, Ibrahim O, Malik I, Mikhail G et al (2023) A systematic review and meta-analysis of the clinical outcomes of isolated tricuspid valve surgery. Am J Cardiol 203:414&#x2013;426. https://doi.org/10.1016/j.amjcard.2023.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2023.07.006</ArticleId><ArticleId IdType="pubmed">37531685</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehan ST, Eqbal F, Ul Hussain H, Ali E, Ali A, Ullah I, Ullah W, Ahmed J, Brailovsky Y, Rajapreyar IN et al (2024) Transcatheter edge-to-edge repair for tricuspid regurgitation&#x2014;A systematic review and meta-analysis. Curr Probl Cardiol 49:102055. https://doi.org/10.1016/j.cpcardiol.2023.102055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2023.102055</ArticleId><ArticleId IdType="pubmed">37652111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, Price MJ, Singh G, Fam N, Kar S et al (2023) Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 388(20):1833&#x2013;1842. https://doi.org/10.1056/NEJMoa2300525</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2300525</ArticleId><ArticleId IdType="pubmed">36876753</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, The PRISMA et al (2020) statement: An updated guideline for reporting systematic reviews. BMJ 2021:372. https://doi.org/10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008&#x2013;12. https://doi.org/10.1001/jama.283.15.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366:1&#x2013;8. https://doi.org/10.1136/bmj.l4898</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R (2012) Assessing risk of bias in prevalence studies: Modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 65:934&#x2013;939. https://doi.org/10.1016/j.jclinepi.2011.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2011.11.014</ArticleId><ArticleId IdType="pubmed">22742910</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;cker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:1&#x2013;9. https://doi.org/10.1186/s12874-015-0060-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-015-0060-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraca RJ, Moon MR, Lawton JS, Guthrie TJ, Aubuchon KA, Moazami N, Pasque MK, Damiano RJ Jr (2009) Outcomes of tricuspid valve repair and replacement: a propensity analysis. Ann Thorac Surg 87:83&#x2013;89. https://doi.org/10.1016/j.athoracsur.2008.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2008.10.003</ArticleId><ArticleId IdType="pubmed">19101275</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh TH, Wang TK, Sidhu K, Haydock DA (2014) Isolated tricuspid valve surgery at a single centre: The 47-year Auckland experience, 1965&#x2013;2011. Interact Cardiovasc Thorac Surg 18:27&#x2013;32. https://doi.org/10.1093/icvts/ivt452</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivt452</ArticleId><ArticleId IdType="pubmed">24144804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW (2013) Clinical and echocardiographic outcomes after surgery for severe isolated tricuspid regurgitation. J Thorac Cardiovasc Surg 146:278&#x2013;284. https://doi.org/10.1016/j.jtcvs.2012.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2012.04.019</ArticleId><ArticleId IdType="pubmed">22871566</ArticleId></ArticleIdList></Reference><Reference><Citation>Raikhelkar J, Lin HM, Neckman D, Afonso A, Scurlock C (2013) Isolated tricuspid valve surgery: predictors of adverse outcome and survival. Hear Lung Circ 22:211&#x2013;220. https://doi.org/10.1016/j.hlc.2012.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2012.09.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Farag M, Arif R, Sabashnikov A, Zeriouh M, Popov AF, Ruhparwar A, Schmack B, Dohmen PM, Szab&#xf3; G, Karck M et al (2017) Repair or replacement for isolated tricuspid valve pathology? Insights from a surgical analysis on long-term survival. Med Sci Monit 23:1017&#x2013;1025. https://doi.org/10.12659/msm.900841</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/msm.900841</ArticleId><ArticleId IdType="pubmed">28236633</ArticleId><ArticleId IdType="pmc">5338566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejiofor JI, Neely RC, Yammine M, McGurk S, Kaneko T, Leacche M, Cohn LH, Shekar PS (2017) Surgical outcomes of isolated tricuspid valve procedures: Repair versus replacement. Ann Cardiothorac Surg 6:214&#x2013;222. https://doi.org/10.21037/acs.2017.05.02</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs.2017.05.02</ArticleId><ArticleId IdType="pubmed">28706864</ArticleId><ArticleId IdType="pmc">5494421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundi H, Popma JJ, Cohen DJ, Liu DC, Laham RJ, Pinto DS, Chu LM, Strom JB, Shen C, Yeh RW (2019) Prevalence and outcomes of isolated tricuspid valve surgery among medicare beneficiaries. Am J Cardiol 123(1):132&#x2013;138. https://doi.org/10.1016/j.amjcard.2018.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2018.09.016</ArticleId><ArticleId IdType="pubmed">30442362</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutakiallah Y, Aithoussa M, Atmani N, Seghrouchni A, Moujahid A, Hatim A, Asfalou I, Lakhal Z, Boulahya A (2018) Reoperation for isolated rheumatic tricuspid regurgitation. J Cardiothorac Surg 13:1&#x2013;10. https://doi.org/10.1186/s13019-018-0793-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-018-0793-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhouli M, Berzingi C, Kowatli A, Alqahtani F, Badhwar V (2018) Comparative early outcomes of tricuspid Valve repair versus replacement for secondary tricuspid regurgitation. Open Hear 5(2):1&#x2013;8. https://doi.org/10.1136/openhrt-2018-000878</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2018-000878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamandi M, Smith RL, Ryan WH, Grayburn PA, Vasudevan A, George TJ, DiMaio JM, Hutcheson KA, Brinkman W, Szerlip M et al (2019) Outcomes of isolated tricuspid valve surgery have improved in the modern era. Ann Thorac Surg 108:11&#x2013;15. https://doi.org/10.1016/j.athoracsur.2019.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2019.03.004</ArticleId><ArticleId IdType="pubmed">30951698</ArticleId></ArticleIdList></Reference><Reference><Citation>Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, Lurz P, Braun D, Brochet E, Connelly KA et al (2019) Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 74:2998&#x2013;3008. https://doi.org/10.1016/j.jacc.2019.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.09.028</ArticleId><ArticleId IdType="pubmed">31568868</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai S, Bowers N, Dhoot A, Ho EC, Ong G, Eckstein J, Edwards J, Fam N, Connelly KA (2020) Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy. Int J Cardiol 320:49&#x2013;54. https://doi.org/10.1016/j.ijcard.2020.07.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.07.018</ArticleId><ArticleId IdType="pubmed">32682962</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Esp&#xed;n G, Rodr&#xed;guez-Capit&#xe1;n J, Otero Forero JJ, Becerra Mu&#xf1;oz VM, Rodr&#xed;guez Caulo EA, Such-Mart&#xed;nez M, Porras-Mart&#xed;n C, Villaescusa-Catal&#xe1;n JM, Matar&#xf3;-L&#xf3;pez MJ, Guz&#xf3;n-Rementer&#xed;a A et al (2020) Outcomes of isolated tricuspid valve surgery. Heart Surg Forum 23:E763&#x2013;E769. https://doi.org/10.1532/hsf.3093</Citation><ArticleIdList><ArticleId IdType="doi">10.1532/hsf.3093</ArticleId><ArticleId IdType="pubmed">33234222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyfus J, Flagiello M, Bazire B, Eggenspieler F, Viau F, Riant E, Mbaki Y, Bohbot Y, Eyharts D, Senage T et al (2020) Isolated tricuspid valve surgery: Impact of aetiology and clinical presentation on outcomes. Eur Heart J 41:4304&#x2013;4317. https://doi.org/10.1093/eurheartj/ehaa643</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa643</ArticleId><ArticleId IdType="pubmed">32974668</ArticleId></ArticleIdList></Reference><Reference><Citation>Patlolla SH, Schaff HV, Greason KL, Pochettino A, Daly RC, Frye RL, Nishimura RA, Dearani JA (2021) Early right ventricular reverse remodeling predicts survival after isolated tricuspid valve surgery. Ann Thorac Surg 112:1402&#x2013;1409. https://doi.org/10.1016/j.athoracsur.2021.02.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2021.02.051</ArticleId><ArticleId IdType="pubmed">33711306</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, Oh JK, Kim SO, Lee SA, Kim HJ, Lee S, Jung SH, Song JM, Choo SJ, Kang DH et al (2021) Determinants of clinical outcomes of surgery for isolated severe tricuspid regurgitation. Heart 107:403&#x2013;410. https://doi.org/10.1136/heartjnl-2020-317715</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2020-317715</ArticleId><ArticleId IdType="pubmed">33139325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TKM, Mentias A, Akyuz K, Kirincich J, Crane AD, Popovic ZB, Xu B, Gillinov AM, Pettersson GB, Griffin BP, Desai MY (2022) Effect of tricuspid valve repair or replacement on survival in patients with isolated severe tricuspid regurgitation. Am J Cardiol 162:163&#x2013;169. https://doi.org/10.1016/j.amjcard.2021.08.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2021.08.069</ArticleId><ArticleId IdType="pubmed">34903339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawsara A, Alqahtani F, Nkomo VT, Eleid MF, Pislaru SV, Rihal CS, Nishimura RA, Schaff HV, Crestanello JA, Alkhouli M (2021) Determinants of morbidity and mortality associated with isolated tricuspid valve surgery. J Am Heart Assoc 10:1&#x2013;18. https://doi.org/10.1161/JAHA.120.018417</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.018417</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyfus J, Galloo X, Taramasso M, Heitzinger G, Benfari G, Kresoja KP, Juarez-Casso F, Omran H, Bohbot Y, Iliadis C et al (2024) TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation. Eur Heart J 45:586&#x2013;597. https://doi.org/10.1093/eurheartj/ehad585</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad585</ArticleId><ArticleId IdType="pubmed">37624856</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Ma Y, Liu Z, Fan X, Guan G, Pan S, Wang J, Zhang Y (2023) Comparison of outcomes between transcatheter tricuspid valve repair and surgical tricuspid valve replacement or repair in patients with tricuspid insufficiency. J Cardiothorac Surg 18:1&#x2013;9. https://doi.org/10.1186/s13019-023-02271-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-023-02271-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed MS, Al Ali O, Hashem A, Abdelhay A, Khalouf A, Mahmoud A, Shehadah A, Ahmed A, Elkhapery A, Alwifati N et al (2023) Trends and outcomes of transcatheter tricuspid valve repair and surgical tricuspid valve repair in patients with tricuspid valve regurgitation; a population based study. Curr Probl Cardiol 48:101714. https://doi.org/10.1016/j.cpcardiol.2023.101714</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2023.101714</ArticleId><ArticleId IdType="pubmed">36967066</ArticleId></ArticleIdList></Reference><Reference><Citation>Fender EA, Zack CJ, Nishimura RA (2018) Isolated tricuspid regurgitation: outcomes and therapeutic interventions. Heart 104(10):798&#x2013;806. https://doi.org/10.1136/heartjnl-2017-311586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2017-311586</ArticleId><ArticleId IdType="pubmed">29229649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha MJ, Lee SA, Cho MS, Nam GB, Choi KJ, Kim J (2023) Reduction of moderate to severe tricuspid regurgitation after catheter ablation for atrial fibrillation. Heart. https://doi.org/10.1136/heartjnl-2023-323244</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2023-323244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchino PP, Angelini F, Vairo A et al (2021) Clinical outcomes following isolated transcatheter tricuspid valve repair: a meta-analysis and meta-regression study. JACC Cardiovasc Interv 14(20):2285&#x2013;2295. https://doi.org/10.1016/j.jcin.2021.08.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2021.08.050</ArticleId><ArticleId IdType="pubmed">34674867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, Zahr F, Chadderdon S, Fam N, Ong G et al (2023) Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J 44:4862&#x2013;4873. https://doi.org/10.1093/eurheartj/ehad667</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad667</ArticleId><ArticleId IdType="pubmed">37930776</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39977357</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Intravenous amino acids for renal protection in patients receiving temporary mechanical circulatory support: a secondary subgroup analysis of the PROTECTION study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ezaf035</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ejcts/ezaf035</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">In cardiac surgery patients, acute kidney injury (AKI) frequently occurs in the setting of haemodynamic instability and treatment with temporary mechanical circulatory support (tMCS). Recent evidence suggests amino acids (AA) infusion may reduce AKI rate. However, the effect of AA infusion in patients requiring tMCS may be less effective.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a secondary analysis of the PROTECTION multicentre randomized controlled trial including all patients treated with tMCS. Patients undergoing elective cardiac surgery with cardiopulmonary bypass were randomized to receive 2&#x2009;g/kg ideal body weight/day of intravenous AA to a maximum of 100&#x2009;g/day or matching placebo from operating room admission until up to 3&#x2009;days, receipt of renal-replacement therapy, discharge from ICU or death. The primary outcome of the PROTECTION study was the rate of AKI, as in this secondary analysis. A total of 3511 patients were randomized in the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We studied 232 patients who received tMCS, 112 randomized to AA infusion and 120 to placebo. The median preoperative serum creatinine value was significantly higher among AA group patients (AA: 1.08, interquartile range 0.90-1.26; placebo: 0.98, interquartile range 0.85-1.15; P&#x2009;=&#x2009;0.02). The rate of AKI, however, was lower in patients randomized to AA (44.6% vs 60.8%; relative risk 0.73; 95% confidence interval (0.57-0.94); P&#x2009;=&#x2009;0.01; number needed to treat&#x2009;=&#x2009;6). We found no significant differences in secondary outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Short-term AA infusion appears to reduce rate of AKI among patients requiring tMCS. Use of AA in this population at high-risk for renal failure appears justified.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT03709264.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Belletti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3131-0565</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisano</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiac Anesthesia and ICU, AORN "Dei Colli," Monaldi Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scandroglio</LastName><ForeName>Anna Mara</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-0639-8227</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garofalo</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Anesthesia and Intensive Care, Department of Medical and Surgical Sciences, Magna Gr&#xe6;cia University of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabr&#xf2;</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrod</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>S.C. Anestesia e Rianimazione Cardiovascolare, A.O. Ordine Mauriziano Umberto I di Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monaco</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5186-1976</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brambillasca</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dipartimento di Chirurgia Cardiovascolare, Unit&#xe0; Operativa di Anestesia e Terapia Intensiva, IRCCS Centro Cadiologico Monzino, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baiardo Redaelli</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meroi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Universitaria Friuli Centrale, Department of Emergency "Santa Maria Della Misericordia", University Hospital of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fominskiy</LastName><ForeName>Evgeny</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vignale</LastName><ForeName>Rosaria</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiovascular Anesthesia and ICU, San Carlo Hospital, Potenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajello</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venditto</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiac Anesthesia and ICU, AORN "Dei Colli," Monaldi Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scquizzato</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1394-8402</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porta</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>S.C. Anestesia e Rianimazione Cardiovascolare, A.O. Ordine Mauriziano Umberto I di Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losiggio</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0001-6181-7976</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suriano</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Chirurgia Cardiovascolare, Unit&#xe0; Operativa di Anestesia e Terapia Intensiva, IRCCS Centro Cadiologico Monzino, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontillo</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orso</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Universitaria Friuli Centrale, Department of Emergency "Santa Maria Della Misericordia", University Hospital of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomasi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital Pharmacy, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paternoster</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Health Science Anesthesia and ICU, School of Medicine, University of Basilicata, San Carlo Hospital, Potenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomivorotov</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longhini</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Anesthesia and Intensive Care, Department of Medical and Surgical Sciences, Magna Gr&#xe6;cia University of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8594-5980</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zangrillo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7687-7648</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maisano</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellomo</LastName><ForeName>Rinaldo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1650-8939</Identifier><AffiliationInfo><Affiliation>Department of Critical Care, The University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Analytics Research and Evaluation Centre, Austin Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Austin Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieri</LastName><ForeName>Marina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4101-800X</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PROTECTION Study Group Collaborators
</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03709264</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>RF-2016-02363260</GrantID><Agency>Italian Ministry of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="Y">Amino Acids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="Y">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute heart failure</Keyword><Keyword MajorTopicYN="N">Acute kidney injury</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Micro-axial flow pump</Keyword><Keyword MajorTopicYN="N">Renal-replacement therapy</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>D'Amico</LastName><ForeName>Filippo</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manazza</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marmiere</LastName><ForeName>Marilena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marzaroli</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monti</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliva</LastName><ForeName>Federico Mattia</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pruna</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turi</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veneziano</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vietri</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaraca</LastName><ForeName>Luisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fraja</LastName><ForeName>Diana Di</ForeName><Initials>DD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verniero</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruni</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perrelli</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prezzi</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massaro</LastName><ForeName>Cristiano</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrante</LastName><ForeName>Palma</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arangino</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Angelini</LastName><ForeName>Filippo</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bacchetti</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vitielli</LastName><ForeName>Michelangelo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallicchio</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bradic</LastName><ForeName>Nikola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ti</LastName><ForeName>Lian Kah</ForeName><Initials>LK</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>24</Day><Hour>23</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>13</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39977357</ArticleId><ArticleId IdType="doi">10.1093/ejcts/ezaf035</ArticleId><ArticleId IdType="pii">8026694</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29784591</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1008-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Chinese journal of traumatology = Zhonghua chuang shang za zhi</Title><ISOAbbreviation>Chin J Traumatol</ISOAbbreviation></Journal><ArticleTitle>Accuracy and outcome of rapid ultrasound in shock and hypotension (RUSH) in&#xa0;Egyptian polytrauma patients.</ArticleTitle><Pagination><StartPage>156</StartPage><EndPage>162</EndPage><MedlinePgn>156-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cjtee.2017.06.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1008-1275(17)30103-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">"Polytrauma" patients are of a higher risk of complications and death than the summation of expected mortality and morbidity of their individual injuries. The ideal goal in trauma resuscitation care is to identify and treat all injuries. With clinical and technological advanced imaging available for diagnosis and treatment of traumatic patients, point of care-rapid ultrasound in shock and hypotension (RUSH) significantly affects modern trauma services and patient outcomes. This study aims to evaluate the accuracy of RUSH and patient outcomes by early detection of the causes of unstable polytrauma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional, prospective study included 100 unstable polytrauma patients admitted in Suez Canal University Hospital. Clinical exam, RUSH and pan-computed tomography (pan-CT) were conducted. The result of CT was taken as the standard. Patients were managed according to the advanced trauma life support (ATLS) guidelines and treated of life threatening conditions if present. Patients were followed up for 28 days for a short outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The most diagnostic causes of unstability in polytrauma patients by RUSH are hypovolemic shock (64%), followed by obstructive shock (14%), distributive shock (12%) and cardiogenic shock (10%) respectively. RUSH had 94.2% sensitivity in the diagnosis of unstable polytrauma patients; the accuracy of RUSH in shock patients was 95.2%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">RUSH is accurate in the diagnosis of unstable polytrauma patients; and 4% of patients were diagnosed during follow-up after admission by RUSH and pan-CT.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Production and hosting by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elbaih</LastName><ForeName>Adel Hamed</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Faculty of Medicine, Suez Canal University, Egypt. Electronic address: elbaihzico@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Housseini</LastName><ForeName>Ahmed Mohamed</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Radiology, Faculty of Medicine, Suez Canal University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalifa</LastName><ForeName>Mohamed E M</ForeName><Initials>MEM</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, Faculty of Medicine, Suez Canal University, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin J Traumatol</MedlineTA><NlmUniqueID>100886162</NlmUniqueID><ISSNLinking>1008-1275</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007022" MajorTopicYN="N">Hypotension</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019095" MajorTopicYN="N">Point-of-Care Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Polytrauma</Keyword><Keyword MajorTopicYN="N">Rapid ultrasound in shock and hypotension</Keyword><Keyword MajorTopicYN="N">Shock</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29784591</ArticleId><ArticleId IdType="pmc">PMC6033727</ArticleId><ArticleId IdType="doi">10.1016/j.cjtee.2017.06.009</ArticleId><ArticleId IdType="pii">S1008-1275(17)30103-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amin N.H., Jakoi A., Katsman A. Incidence of orthopedic surgery intervention in a level I urban trauma center with motorcycle trauma. J&#xa0;Trauma. 2011;71:948&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">21768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldemir M., Ta&#xe7;yildiz I., Girgin S. Predicting factors for mortality in the penetrating abdominal trauma. Acta Chir Belg. 2004;104:429&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">15469156</ArticleId></ArticleIdList></Reference><Reference><Citation>Butcher N., Balogh Z.J. The definition of polytrauma: the need for international consensus. Injury. 2009;40:S12&#x2013;S22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19895948</ArticleId></ArticleIdList></Reference><Reference><Citation>Betz M., Li G. Injury prevention and control. Emerg Med Clin North Am. 2007;25:901&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">17826223</ArticleId></ArticleIdList></Reference><Reference><Citation>King R.W., Plewa M.C., Buderer N.M. Shock index as a marker for significant injury in trauma patients. Acad Emerg Med. 1996;3:1041&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">8922013</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;reide K. Epidemiology of major trauma. Br J Surg. 2009;96:697&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">19526611</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateer J., Plummer D., Heller M. Model curriculum for physician training in emergency ultrasonography. Ann Emerg Med. 1994;23:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8273966</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnbaum S., Brateman L., Hevezi J. American College of Radiology white paper on radiation dose in medicine. J&#xa0;Am Coll Radiol. 2007;4:272&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">17467608</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson B., Trapp R.G. 4th ed. Lange Basic Science; USA: 2004. Basic &amp; clinical biostatistics.</Citation></Reference><Reference><Citation>Seif D., Perera P., Mailhot T. Bedside ultrasound in resuscitation and the rapid ultrasound in shock protocol. Crit Care Res Pract. 2012;2012:503254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3485910</ArticleId><ArticleId IdType="pubmed">23133747</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalya P.L., Mchembe M., Gilyoma J.M. Missed injuries in multiple trauma patients: a tertiary care experience in Tanzania. East Central African J Surg. 2010;15:39&#x2013;46.</Citation></Reference><Reference><Citation>Tham K.Y., Seow E., Lau G. Pattern of injuries in helmeted motorcyclists in Singapore. Emerg Med J. 2004;21:478&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1726370</ArticleId><ArticleId IdType="pubmed">15208235</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha M., Elbaih A. Pathophysiology and management of different types of shock. Narayana Med J. 2017;6:14&#x2013;39.</Citation></Reference><Reference><Citation>Elbaih A., Ali M., Attia Y. Accuracy of predictive factors and focused assessment with sonography for trauma (FAST) in management of adult blunt abdominal trauma and its outcome. Int J Surg Med. 2016;2:58&#x2013;63.</Citation></Reference><Reference><Citation>Stawicki S.P., Braslow B.M., Panebianco N.L. Intensivist use of hand-carried ultrasonography to measure IVC collapsibility in estimating intravascular volume status: correlations with CVP. J&#xa0;Am Coll Surg. 2009;209:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19651063</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson P.R., McAuley D.J., Kendall R.J. Abdominal and cardiac evaluation with sonography in shock (ACES): an approach by emergency physicians for the use of ultrasound in patients with undifferentiated hypotension. Emerg Med J. 2009;26:87&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">19164614</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaih A.H., Abu-Elela S.T. Patterns and outcome of missed injuries in Egyptians polytrauma patients. Int J Surg Med. 2018;4:13&#x2013;21.</Citation></Reference><Reference><Citation>Kauvar D.D., Lefering R., Wade C.E. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations and therapeutic considerations. J&#xa0;Trauma. 2006;60:S3&#x2013;S11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16763478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31335363</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-943X</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>ASAIO journal (American Society for Artificial Internal Organs : 1992)</Title><ISOAbbreviation>ASAIO J</ISOAbbreviation></Journal><ArticleTitle>Venoarterial Extracorporeal Membrane Oxygenation With Concomitant Impella Versus Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>497</StartPage><EndPage>503</EndPage><MedlinePgn>497-503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MAT.0000000000001039</ELocationID><Abstract><AbstractText>There are contrasting data on concomitant Impella device in cardiogenic shock patients treated with venoarterial extracorporeal membrane oxygenation (VA ECMO) (ECPELLA). This study sought to compare early mortality in patients with cardiogenic shock treated with ECPELLA in comparison to VA ECMO alone. We reviewed the published literature from 2000 to 2018 for randomized, cohort, case-control, and case series studies evaluating adult patients requiring VA ECMO for cardiogenic shock. Five retrospective observational studies, representing 425 patients, were included. Venoarterial extracorporeal membrane oxygenation with concomitant Impella strategy was used in 27% of the patients. Median age across studies varied between 51 and 63 years with 59-88% patients being male. Use of ECPELLA was associated with higher weaning from VA ECMO and bridging to permanent ventricular assist device or cardiac transplant in three and four studies, respectively. The studies showed moderate heterogeneity with possible publication bias. The two studies that accounted for differences in baseline characteristics between treatment groups reported lower 30 day mortality with ECPELLA versus VA ECMO. The remaining three studies did not adjust for potential confounding and were at high risk for selection bias. In conclusion, ECPELLA is being increasingly used as a strategy in patients with cardiogenic shock. Additional large, high-quality studies are needed to evaluate clinical outcomes with ECPELLA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saraschandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Horo</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antharam</LastName><ForeName>Phanindra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ananthaneni</LastName><ForeName>Sindhura</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saarwaani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stulak</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunlay</LastName><ForeName>Shannon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>From the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Science Research, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>From the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barsness</LastName><ForeName>Gregory W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>From the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ASAIO J</MedlineTA><NlmUniqueID>9204109</NlmUniqueID><ISSNLinking>1058-2916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>ASAIO J. 2020 May;66(5):504-506. doi: 10.1097/MAT.0000000000001171.</RefSource><PMID Version="1">32341269</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31335363</ArticleId><ArticleId IdType="doi">10.1097/MAT.0000000000001039</ArticleId><ArticleId IdType="pii">00002480-202005000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Diepen S, Katz JN, Albert NM, et al.; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline: Contemporary management of cardiogenic shock: A scientific statement from the American Heart Association. Circulation 2017.136: e232&#x2013;e268.</Citation></Reference><Reference><Citation>Vallabhajosyula S, Dunlay SM, Prasad A, et al. Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock. J Am Coll Cardiol 2019.73: 1781&#x2013;1791.</Citation></Reference><Reference><Citation>Rihal CS, Naidu SS, Givertz MM, et al.; Society for Cardiovascular Angiography and Interventions (SCAI); Heart Failure Society of America (HFSA); Society of Thoracic Surgeons (STS); American Heart Association (AHA), and American College of Cardiology (ACC): 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d&#x2019;intervention. J Am Coll Cardiol 2015.65: e7&#x2013;e26.</Citation></Reference><Reference><Citation>Vallabhajosyula S, Arora S, Lahewala S, et al. Temporary mechanical circulatory support for refractory cardiogenic shock before left ventricular assist device surgery. J Am Heart Assoc 2018.7: e010193.</Citation></Reference><Reference><Citation>Vallabhajosyula S, Arora S, Sakhuja A, et al. Trends, predictors, and outcomes of temporary mechanical circulatory support for postcardiac surgery cardiogenic shock. Am J Cardiol 2019.123: 489&#x2013;497.</Citation></Reference><Reference><Citation>Vallabhajosyula S, Patlolla SH, Sandhyavenu H, et al. Periprocedural cardiopulmonary bypass or venoarterial extracorporeal membrane oxygenation during transcatheter aortic valve replacement: A systematic review. J Am Heart Assoc. 2018.7: e009608.</Citation></Reference><Reference><Citation>Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J 2015.36: 1223&#x2013;1230.</Citation></Reference><Reference><Citation>Br&#xe9;chot N, Demondion P, Santi F, et al. Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. Eur Heart J Acute Cardiovasc Care 2018.7: 62&#x2013;69.</Citation></Reference><Reference><Citation>Rao P, Khalpey Z, Smith R, Burkhoff D, Kociol RD. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. Circ Heart Fail 2018.11: e004905.</Citation></Reference><Reference><Citation>Cheng R, Hachamovitch R, Makkar R, et al. Lack of survival benefit found with use of intraaortic balloon pump in extracorporeal membrane oxygenation: A pooled experience of 1517 patients. J Invasive Cardiol 2015.27: 453&#x2013;458.</Citation></Reference><Reference><Citation>Akanni OJ, Takeda K, Truby LK, et al. EC-VAD: Combined use of extracorporeal membrane oxygenation and percutaneous microaxial pump left ventricular assist device. ASAIO J 2019.65: 219&#x2013;226.</Citation></Reference><Reference><Citation>Mourad M, Gaudard P, De La Arena P, et al. Circulatory support with extracorporeal membrane oxygenation and/or Impella for cardiogenic shock during myocardial infarction. ASAIO J 2018.64: 708&#x2013;714.</Citation></Reference><Reference><Citation>Pappalardo F, Schulte C, Pieri M, et al. Concomitant implantation of Impella&#xae; on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 2017.19: 404&#x2013;412.</Citation></Reference><Reference><Citation>Patel SM, Lipinski J, Al-Kindi SG, et al. Simultaneous venoarterial extracorporeal membrane oxygenation and percutaneous left ventricular decompression therapy with Impella is associated with improved outcomes in refractory cardiogenic shock. ASAIO J 2019.65: 21&#x2013;28.</Citation></Reference><Reference><Citation>Tepper S, Masood MF, Baltazar Garcia M, et al. Left ventricular unloading by Impella device versus surgical vent during extracorporeal life support. Ann Thorac Surg 2017.104: 861&#x2013;867.</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003.327: 557&#x2013;560.</Citation></Reference><Reference><Citation>Truby LK, Takeda K, Mauro C, et al. Incidence and implications of left ventricular distention during venoarterial extracorporeal membrane oxygenation support. ASAIO J 2017.63: 257&#x2013;265.</Citation></Reference><Reference><Citation>Vallabhajosyula S, O&#x2019;Horo JC, Antharam P, et al. Concomitant intra-aortic balloon pump use in cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation. Circ Cardiovasc Interv 2018.11: e006930.</Citation></Reference><Reference><Citation>Esposito ML, Kapur NK. Acute mechanical circulatory support for cardiogenic shock: The &#x201c;door to support&#x201d; time. F1000Res 2017.6: 737.</Citation></Reference><Reference><Citation>Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: A systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017.38: 3523&#x2013;3531.</Citation></Reference><Reference><Citation>Jentzer JC, Vallabhajosyula S, Khanna AK, et al. Management of refractory vasodilatory shock. Chest 2018.154: 416&#x2013;426.</Citation></Reference><Reference><Citation>Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for refractory cardiogenic shock: The survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J 2015.36: 2246&#x2013;2256.</Citation></Reference><Reference><Citation>Nalluri N, Patel NJ, Atti V, Kumar V, Basir MB, O&#x2019;Neill WW. Temporal trends in utilization of right-sided heart catheterization among percutaneous ventricular assist device recipients in acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2018.122: 2014&#x2013;2017.</Citation></Reference><Reference><Citation>Meani P, Gelsomino S, Natour E, et al. Modalities and effects of left ventricle unloading on extracorporeal life support: A review of the current literature. Eur J Heart Fail 2017.19(suppl 2): 84&#x2013;91.</Citation></Reference><Reference><Citation>Kotecha A, Vallabhajosyula S, Coville HH, Kashani K. Cardiorenal syndrome in sepsis: A narrative review. J Crit Care 2018.43: 122&#x2013;127.</Citation></Reference><Reference><Citation>Vallabhajosyula S, Sakhuja A, Geske JB, et al. Clinical profile and outcomes of acute cardiorenal syndrome type-5 in sepsis: An eight-year cohort study. PLoS One 2018.13: e0190965.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34668946</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Surgical Treatment of Postinfarction Ventricular Septal Rupture.</ArticleTitle><Pagination><StartPage>e2128309</StartPage><MedlinePgn>e2128309</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2128309</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2021.28309</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Ventricular septal rupture (VSR) is a rare but life-threatening mechanical complication of acute myocardial infarction associated with high mortality despite prompt treatment. Surgery represents the standard of care; however, only small single-center series or national registries are usually available in literature, whereas international multicenter investigations have been poorly carried out, therefore limiting the evidence on this topic.</AbstractText><AbstractText Label="OBJECTIVES">To assess the clinical characteristics and early outcomes for patients who received surgery for postinfarction VSR and to identify factors independently associated with mortality.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Mechanical Complications of Acute Myocardial Infarction: an International Multicenter Cohort (CAUTION) Study is a retrospective multicenter international cohort study that includes patients who were treated surgically for mechanical complications of acute myocardial infarction. The study was conducted from January 2001 to December 2019 at 26 different centers worldwide among 475 consecutive patients who underwent surgery for postinfarction VSR.</AbstractText><AbstractText Label="EXPOSURES">Surgical treatment of postinfarction VSR, independent of the technique, alone or combined with other procedures (eg, coronary artery bypass grafting).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was early mortality; secondary outcomes were postoperative complications.</AbstractText><AbstractText Label="RESULTS">Of the 475 patients included in the study, 290 (61.1%) were men, with a mean (SD) age of 68.5 (10.1) years. Cardiogenic shock was present in 213 patients (44.8%). Emergent or salvage surgery was performed in 212 cases (44.6%). The early mortality rate was 40.4% (192 patients), and it did not improve during the nearly 20 years considered for the study (median [IQR] yearly mortality, 41.7% [32.6%-50.0%]). Low cardiac output syndrome and multiorgan failure were the most common causes of death (low cardiac output syndrome, 70 [36.5%]; multiorgan failure, 53 [27.6%]). Recurrent VSR occurred in 59 participants (12.4%) but was not associated with mortality. Cardiogenic shock (survived: 95 [33.6%]; died, 118 [61.5%]; P&#x2009;&lt;&#x2009;.001) and early surgery (time to surgery &#x2265;7 days, survived: 105 [57.4%]; died, 47 [35.1%]; P&#x2009;&lt;&#x2009;.001) were associated with lower survival. At multivariate analysis, older age (odds ratio [OR], 1.05; 95% CI, 1.02-1.08; P&#x2009;=&#x2009;.001), preoperative cardiac arrest (OR, 2.71; 95% CI, 1.18-6.27; P&#x2009;=&#x2009;.02) and percutaneous revascularization (OR, 1.63; 95% CI, 1.003-2.65; P&#x2009;=&#x2009;.048), and postoperative need for intra-aortic balloon pump (OR, 2.98; 95% CI, 1.46-6.09; P&#x2009;=&#x2009;.003) and extracorporeal membrane oxygenation (OR, 3.19; 95% CI, 1.30-7.38; P&#x2009;=&#x2009;.01) were independently associated with mortality.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, surgical repair of postinfarction VSR was associated with a high risk of early mortality; this risk has remained unchanged during the last 2 decades. Delayed surgery seemed associated with better survival. Age, preoperative cardiac arrest and percutaneous revascularization, and postoperative need for intra-aortic balloon pump and extracorporeal membrane oxygenation were independently associated with early mortality. Further prospective studies addressing preoperative and perioperative patient management are warranted to hopefully improve the currently suboptimal outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ronco</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Circolo Hospital, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matteucci</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Circolo Hospital, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalewski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Bonis</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, San Raffaele University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formica</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Cardiac Surgery Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Parma, Cardiac Surgery Unit, University Hospital of Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiritano</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fina</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Anesthesia and Intensive Care, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Donato, San Donato Milanese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folliguet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, University Hospital Henri-Mondor, Assistance Publique-Hopitaux de Paris Cr&#xe9;teil, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonaros</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Claudio Francesco</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sponga</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic Department, University Hospital of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vendramin</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiothoracic Department, University Hospital of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vincentiis</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranucci</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anesthesia and Intensive Care, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Donato, San Donato Milanese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwalski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcetta</LastName><ForeName>Giosu&#xe8;</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Section of Cardiac Surgery, University Hospital, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischlein</LastName><ForeName>Theodor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Cardiovascular Center, Klinikum N&#xfc;rnberg, Paracelsus Medical University, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troise</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Poliambulanza Foundation Hospital, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Poliambulanza Foundation Hospital, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dato</LastName><ForeName>Guglielmo Actis</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Department, Mauriziano Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrozzini</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serraino</LastName><ForeName>Giuseppe Filiberto</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Shabir Hussain</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Cardiovascular and Thoracic Surgery Department, King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scrofani</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Luigi Sacco Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiore</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, University Hospital Henri-Mondor, Assistance Publique-Hopitaux de Paris Cr&#xe9;teil, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalisnik</LastName><ForeName>Jurij Matija</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Cardiovascular Center, Klinikum N&#xfc;rnberg, Paracelsus Medical University, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Alessandro</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Cardiac Surgery Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lodo</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Department, Mauriziano Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowal&#xf3;wka</LastName><ForeName>Adam R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Silesia, School of Medicine in Katowice, Katowice, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Upper-Silesian Heart Center, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deja</LastName><ForeName>Marek A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Silesia, School of Medicine in Katowice, Katowice, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Upper-Silesian Heart Center, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almobayedh</LastName><ForeName>Salman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massimi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thielmann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West-German Heart Center, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyns</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khouqeer</LastName><ForeName>Fareed A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Attar</LastName><ForeName>Nawwar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Louis Pradel Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obadia</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Louis Pradel Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeken</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Hospital D&#xfc;sseldorf, Heinrich Heine University, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalampokas</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Hospital D&#xfc;sseldorf, Heinrich Heine University, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fino</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular and Transplant Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular and Transplant Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naito</LastName><ForeName>Shiho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University Heart &amp; Vascular Center Hamburg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beghi</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Circolo Hospital, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="N">Coronary Artery Bypass</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018658" MajorTopicYN="N">Ventricular Septal Rupture</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr De Bonis reported consulting for Abbott and Medtronic until 2020. Dr Folliguet reported consulting for LivaNova outside the submitted work. Dr Bonaros reported receiving grants and personal fees from Edwards Lifesciences, personal fees from Medtronic, and grants from LivaNova outside the submitted work. Dr Ranucci reported consulting for LivaNova and Medtronic outside the submitted work. Dr Suwalski reported receiving speakers&#x2019; fees from Atricure outside the submitted work. Dr Fischlein reported consulting for LivaNova and BioStable outside the submitted work. Dr Meyns reported receiving grants from Abiomed outside the submitted work. Dr Al-Attar reported serving as a member of the advisory board of Medtronic outside the submitted work. Dr Obadia reported receiving grants from Abbott and Carmat and receiving personal fees from Delacroix Chevalier, Landanger, and Medtronic during the conduct of the study. Dr Lorusso reported being the principal investigator of the Perceval Sutureless Implant versus Standard Aortic Valve Replacement (PERSIST-AVR) Study, sponsored by LivaNova, and consulting for Medtronic, LivaNova, and Eurosets with all honoraria paid to the University. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>20</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34668946</ArticleId><ArticleId IdType="pmc">PMC8529403</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28309</ArticleId><ArticleId IdType="pii">2785311</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnaoutakis GJ, Zhao Y, George TJ, Sciortino CM, McCarthy PM, Conte JV. Surgical repair of ventricular septal defect after myocardial infarction: outcomes from the Society of Thoracic Surgeons National Database. Ann Thorac Surg. 2012;94(2):436-443. doi:10.1016/j.athoracsur.2012.04.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2012.04.020</ArticleId><ArticleId IdType="pmc">PMC3608099</ArticleId><ArticleId IdType="pubmed">22626761</ArticleId></ArticleIdList></Reference><Reference><Citation>Crenshaw BS, Granger CB, Birnbaum Y, et al. ; GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators . Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation. 2000;101(1):27-32. doi:10.1161/01.CIR.101.1.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.101.1.27</ArticleId><ArticleId IdType="pubmed">10618300</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbadawi A, Elgendy IY, Mahmoud K, et al. . Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2019;12(18):1825-1836. doi:10.1016/j.jcin.2019.04.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2019.04.039</ArticleId><ArticleId IdType="pubmed">31537282</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueras J, Alcalde O, Barrab&#xe9;s JA, et al. . Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation. 2008;118(25):2783-2789. doi:10.1161/CIRCULATIONAHA.108.776690</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.776690</ArticleId><ArticleId IdType="pubmed">19064683</ArticleId></ArticleIdList></Reference><Reference><Citation>French JK, Hellkamp AS, Armstrong PW, et al. . Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). Am J Cardiol. 2010;105(1):59-63. doi:10.1016/j.amjcard.2009.08.653</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2009.08.653</ArticleId><ArticleId IdType="pubmed">20102891</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BM, Kapadia SR, Smedira NG, et al. . Ventricular septal rupture complicating acute myocardial infarction: a contemporary review. Eur Heart J. 2014;35(31):2060-2068. doi:10.1093/eurheartj/ehu248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu248</ArticleId><ArticleId IdType="pubmed">24970335</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambaro A, Rosenberg A, Galiatsou E, Stock UA. Pros and cons of different types of mechanical circulatory support device in case of postinfarction ventricular septal defect. ASAIO J. 2021;67(6):e110-e113. doi:10.1097/MAT.0000000000001290</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001290</ArticleId><ArticleId IdType="pubmed">33060409</ArticleId></ArticleIdList></Reference><Reference><Citation>Giblett JP, Jenkins DP, Calvert PA. Transcatheter treatment of postinfarct ventricular septal defects. Heart. 2020;106(12):878-884. doi:10.1136/heartjnl-2019-315751</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2019-315751</ArticleId><ArticleId IdType="pubmed">32111641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez B, James S, Agewall S, et al. ; ESC Scientific Document Group . 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx393</ArticleId><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Gara PT, Kushner FG, Ascheim DD, et al. . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.11.019</ArticleId><ArticleId IdType="pubmed">23256914</ArticleId></ArticleIdList></Reference><Reference><Citation>David TE, Dale L, Sun Z. Postinfarction ventricular septal rupture: repair by endocardial patch with infarct exclusion. J Thorac Cardiovasc Surg. 1995;110(5):1315-1322. doi:10.1016/S0022-5223(95)70054-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(95)70054-4</ArticleId><ArticleId IdType="pubmed">7475183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cinq-Mars A, Voisine P, Dagenais F, et al. . Risk factors of mortality after surgical correction of ventricular septal defect following myocardial infarction: retrospective analysis and review of the literature. Int J Cardiol. 2016;206:27-36. doi:10.1016/j.ijcard.2015.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.12.011</ArticleId><ArticleId IdType="pubmed">26773765</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra A, Patel K, Sharma P, et al. . Techniques, timing and prognosis of post infarct ventricular septal repair: a re-look at old dogmas. Braz J Cardiovasc Surg. 2017;32(3):147-155. doi:10.21470/1678-9741-2016-0032</Citation><ArticleIdList><ArticleId IdType="doi">10.21470/1678-9741-2016-0032</ArticleId><ArticleId IdType="pmc">PMC5570397</ArticleId><ArticleId IdType="pubmed">28832791</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto Y, Yamamoto K, Asami F, et al. . Early and midterm outcomes of triple patch technique for postinfarction ventricular septal defects. J Thorac Cardiovasc Surg. 2016;151(6):1711-1716. doi:10.1016/j.jtcvs.2016.01.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2016.01.056</ArticleId><ArticleId IdType="pubmed">27045043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani V, Mariscalco G, Leva C, Blanzola C, Sala A. Surgical repair of post-infarction ventricular septal defect: 19 years of experience. Int J Cardiol. 2006;108(2):202-206. doi:10.1016/j.ijcard.2005.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2005.05.007</ArticleId><ArticleId IdType="pubmed">15950300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi G, Miyata H, Motomura N, et al. . Surgical repair of post-infarction ventricular septal defect&#x2014;findings from a Japanese national database. Circ J. 2019;83(11):2229-2235. doi:10.1253/circj.CJ-19-0593</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-19-0593</ArticleId><ArticleId IdType="pubmed">31511450</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CA, Nygaard TW, Kaiser DL, Cooper AA, Gibson RS. Postinfarction ventricular septal rupture: the importance of location of infarction and right ventricular function in determining survival. Circulation. 1986;74(1):45-55. doi:10.1161/01.CIR.74.1.45</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.74.1.45</ArticleId><ArticleId IdType="pubmed">3708777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pojar M, Harrer J, Omran N, Turek Z, Striteska J, Vojacek J. Surgical treatment of postinfarction ventricular septal defect: risk factors and outcome analysis. Interact Cardiovasc Thorac Surg. 2018;26(1):41-46. doi:10.1093/icvts/ivx230</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivx230</ArticleId><ArticleId IdType="pubmed">29049690</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC, Gore JM, Lambrew C, et al. . A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol. 1996;27(6):1321-1326. doi:10.1016/0735-1097(96)00008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(96)00008-3</ArticleId><ArticleId IdType="pubmed">8626938</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreyra AE, Huang MS, Wilson AC, Deng Y, Cosgrove NM, Kostis JB; MIDAS Study Group (MIDAS 13) . Trends in incidence and mortality rates of ventricular septal rupture during acute myocardial infarction. Am J Cardiol. 2010;106(8):1095-1100. doi:10.1016/j.amjcard.2010.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2010.06.013</ArticleId><ArticleId IdType="pubmed">20920645</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Send&#xf3;n J, Gurfinkel EP, Lopez de Sa E, et al. ; Global Registry of Acute Coronary Events (GRACE) Investigators . Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J. 2010;31(12):1449-1456. doi:10.1093/eurheartj/ehq061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehq061</ArticleId><ArticleId IdType="pubmed">20231153</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MY, Waqar T, Qaisrani PG, et al. . Surgical repair of post-infarction ventricular septal rupture: determinants of operative mortality and survival outcome analysis. Pak J Med Sci. 2018;34(1):20-26. doi:10.12669/pjms.341.13906</Citation><ArticleIdList><ArticleId IdType="doi">10.12669/pjms.341.13906</ArticleId><ArticleId IdType="pmc">PMC5857013</ArticleId><ArticleId IdType="pubmed">29643872</ArticleId></ArticleIdList></Reference><Reference><Citation>Matteucci M, Ronco D, Corazzari C, et al. . Surgical repair of postinfarction ventricular septal rupture: systematic review and meta-analysis. Ann Thorac Surg. 2021;112(1):326-337. doi:10.1016/j.athoracsur.2020.08.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2020.08.050</ArticleId><ArticleId IdType="pubmed">33157063</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker TA, Ramnarine IR, Woo EB, et al. . Repair of post-infarct ventricular septal defect with or without coronary artery bypass grafting in the northwest of England: a 5-year multi-institutional experience. Eur J Cardiothorac Surg. 2003;24(6):940-946. doi:10.1016/S1010-7940(03)00465-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1010-7940(03)00465-2</ArticleId><ArticleId IdType="pubmed">14643812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs R, Korutla V, Suzuki Y, Acker M, Vallabhajosyula P. Mechanical circulatory support as a bridge to definitive surgical repair after post-myocardial infarct ventricular septal defect. J Card Surg. 2015;30(6):535-540. doi:10.1111/jocs.12561</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.12561</ArticleId><ArticleId IdType="pubmed">25940559</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S, Patel MJ, Lima B, et al. . Using extracorporeal membrane oxygenation support preoperatively and postoperatively as a successful bridge to recovery in a patient with a large infarct-induced ventricular septal defect. Proc (Bayl Univ Med Cent). 2016;29(3):301-304. doi:10.1080/08998280.2016.11929443</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08998280.2016.11929443</ArticleId><ArticleId IdType="pmc">PMC4900776</ArticleId><ArticleId IdType="pubmed">27365878</ArticleId></ArticleIdList></Reference><Reference><Citation>Coskun KO, Coskun ST, Popov AF, et al. . Experiences with surgical treatment of ventricle septal defect as a post infarction complication. J Cardiothorac Surg. 2009;4(3):3. doi:10.1186/1749-8090-4-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1749-8090-4-3</ArticleId><ArticleId IdType="pmc">PMC2631454</ArticleId><ArticleId IdType="pubmed">19126196</ArticleId></ArticleIdList></Reference><Reference><Citation>Rob D, &#x160;punda R, Lindner J, et al. . A rationale for early extracorporeal membrane oxygenation in patients with postinfarction ventricular septal rupture complicated by cardiogenic shock. Eur J Heart Fail. 2017;19(suppl 2):97-103. doi:10.1002/ejhf.852</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.852</ArticleId><ArticleId IdType="pubmed">28470920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza-Sol&#xe9; A, S&#xe1;nchez-Salado JC, Sbraga F, et al. . The role of perioperative cardiorespiratory support in post infarction ventricular septal rupture-related cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2020;9(2):128-137. doi:10.1177/2048872618817485</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872618817485</ArticleId><ArticleId IdType="pubmed">30525871</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins AC, Maassel NL, Ghoreishi M, et al. . Preoperative venoarterial extracorporeal membrane oxygenation slashes risk score in advanced structural heart disease. Ann Thorac Surg. 2018;106(6):1709-1715. doi:10.1016/j.athoracsur.2018.07.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2018.07.038</ArticleId><ArticleId IdType="pubmed">30236527</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimura H, Tabata M. Delayed surgery after mechanical circulatory support for ventricular septal rupture with cardiogenic shock. Interact Cardiovasc Thorac Surg. 2020;31(6):868-873. doi:10.1093/icvts/ivaa185</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivaa185</ArticleId><ArticleId IdType="pubmed">33118011</ArticleId></ArticleIdList></Reference><Reference><Citation>Matteucci M, Fina D, Jiritano F, et al. . The use of extracorporeal membrane oxygenation in the setting of postinfarction mechanical complications: outcome analysis of the Extracorporeal Life Support Organization Registry. Interact Cardiovasc Thorac Surg. 2020;31(3):369-374. doi:10.1093/icvts/ivaa108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivaa108</ArticleId><ArticleId IdType="pubmed">32728712</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahuja M, Schrage B, Westermann D, Basir MB, Garan AR, Burkhoff D. Hemodynamic effects of mechanical circulatory support devices in ventricular septal defect: results from a computer simulation model. Circ Heart Failure. 2019;12(7):e005981. doi:10.1161/CIRCHEARTFAILURE.119.005981</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.119.005981</ArticleId><ArticleId IdType="pubmed">31296094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco D, Matteucci M, Ravaux JM, et al. . Mechanical circulatory support as a bridge to definitive treatment in post-infarction ventricular septal rupture. JACC Cardiovasc Interv. 2021;14(10):1053-1066. doi:10.1016/j.jcin.2021.02.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2021.02.046</ArticleId><ArticleId IdType="pubmed">34016403</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregoric ID, Kar B, Mesar T, et al. . Perioperative use of TandemHeart percutaneous ventricular assist device in surgical repair of postinfarction ventricular septal defect. ASAIO J. 2014;60(5):529-532. doi:10.1097/MAT.0000000000000108</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000108</ArticleId><ArticleId IdType="pubmed">25010911</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeppsson A, Liden H, Johnsson P, Hartford M, R&#xe5;degran K. Surgical repair of post infarction ventricular septal defects: a national experience. Eur J Cardiothorac Surg. 2005;27(2):216-221. doi:10.1016/j.ejcts.2004.10.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2004.10.037</ArticleId><ArticleId IdType="pubmed">15691673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39673774</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2753-670X</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>25</Day></PubDate></JournalIssue><Title>Interdisciplinary cardiovascular and thoracic surgery</Title><ISOAbbreviation>Interdiscip Cardiovasc Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>The role of Impella in the pre-procedural management of post-infarct ventricular septal defect: a systematic review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ivae212</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/icvts/ivae212</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Post-infarct ventricular septal defect is a rare but devastating complication. Delayed treatment offers better outcomes than emergency surgery, but when acute cardiogenic shock or unstable haemodynamics occur, temporary mechanical circulatory support may be needed to stabilize patients until treatment. The aim of our systematic review was to assess the outcomes of using Impella in this setting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search was performed in the Medline and EMBASE databases, and all the papers about the use of Impella in this setting were assessed. The study followed the PRISMA criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 20 papers encompassing 68 patients with an Impella implanted after the diagnosis of post-infarct ventricular septal defect and before its treatment were included. More than 95% were in cardiogenic shock when Impella was implanted, and half had another mechanical circulatory support device. Most of the patients (62%) had a posterior defect, and 72% underwent surgical or percutaneous repair. Total in-hospital mortality was 47%, and a total of 29 Impella-related complications were observed. Patients with surgical Impella had a numerically lower in-hospital mortality (35% vs. 58%) and a lower rate of complications compared to percutaneous device.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Impella represents an effective device for diminishing low output syndrome, improving peripheral perfusion, and unloading both the ventricles. It can be used as an upgrade from another mechanical circulatory support or as an addition to extracorporeal membrane oxygenation to provide adequate left ventricular or biventricular support. Despite this, Impella-related complications can occur after its implantation and must be considered.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gemelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2902-7947</Identifier><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular and Public Health Sciences, University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronco</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5250-1796</Identifier><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Surgery Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Mauro</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2611-5626</Identifier><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meani</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Anesthesia and Intensive Care Unit, IRCCS Policlinico San Donato Milanese, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalewski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Baylor University Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Rakesh C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Surgery, Harrington Heart and Vascular Institute, University Hospitals, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitman</LastName><ForeName>Glenn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potapov</LastName><ForeName>Evgenij</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9; (DHZC), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiedemann</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2055-8293</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimpfer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2185-4895</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milojevic</LastName><ForeName>Milan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0984-9011</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nersesian</LastName><ForeName>Gaik</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9524-7705</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charit&#xe9; (DHZC), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Fundaci&#xf3;n Cardiovascular de Colombia, Bucaramanga, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelsomino</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7746-989X</Identifier><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerosa</LastName><ForeName>Gino</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6261-699X</Identifier><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular and Public Health Sciences, University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1777-2045</Identifier><AffiliationInfo><Affiliation>Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Interdiscip Cardiovasc Thorac Surg</MedlineTA><NlmUniqueID>9918540787006676</NlmUniqueID><ISSNLinking>2753-670X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMI</Keyword><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">MCS</Keyword><Keyword MajorTopicYN="N">VSD</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>14</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>14</Day><Hour>20</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>14</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39673774</ArticleId><ArticleId IdType="pmc">PMC11684336</ArticleId><ArticleId IdType="doi">10.1093/icvts/ivae212</ArticleId><ArticleId IdType="pii">7924157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Elbadawi A, Elgendy IY, Mahmoud K. et al. Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. JACC Cardiovasc Interv 2019;12:1825&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">31537282</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaoutakis GJ, Zhao Y, George TJ, Sciortino CM, McCarthy PM, Conte JV.. Surgical repair of ventricular septal defect after myocardial infarction: outcomes from the Society of Thoracic Surgeons National Database. Ann Thorac Surg 2012;94:436&#x2013;43; discussion 43&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608099</ArticleId><ArticleId IdType="pubmed">22626761</ArticleId></ArticleIdList></Reference><Reference><Citation>Matteucci M, Ronco D, Corazzari C. et al. Surgical repair of postinfarction ventricular septal rupture: systematic review and meta-analysis. Ann Thorac Surg 2021;112:326&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">33157063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco D, Matteucci M, Kowalewski M. et al. Surgical treatment of postinfarction ventricular septal rupture. JAMA Netw Open 2021;4:e2128309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8529403</ArticleId><ArticleId IdType="pubmed">34668946</ArticleId></ArticleIdList></Reference><Reference><Citation>Giblett JP, Matetic A, Jenkins D. et al. Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry. Eur Heart J 2022;43:5020&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">36124729</ArticleId></ArticleIdList></Reference><Reference><Citation>Crenshaw BS, Granger CB, Birnbaum Y. et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation 2000;101:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10618300</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon V, Webb JG, Hillis LD. et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000;36:1110&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985713</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimagli A, Guida G, Sinha S. et al. Surgical outcomes of post-infarct ventricular septal defect repair: insights from the UK national adult cardiac surgery audit database. J Card Surg 2022;37:843&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">34910324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco D, Matteucci M, Ravaux JM. et al. Impact of COVID-19 on incidence and outcomes of post-infarction mechanical complications in Europe. Interdiscip Cardiovasc Thorac Surg 2023;37:ivad198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10749759</ArticleId><ArticleId IdType="pubmed">38109676</ArticleId></ArticleIdList></Reference><Reference><Citation>Pojar M, Harrer J, Omran N, Turek Z, Striteska J, Vojacek J.. Surgical treatment of postinfarction ventricular septal defect: risk factors and outcome analysis. Interact CardioVasc Thorac Surg 2018;26:41&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29049690</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425.</Citation><ArticleIdList><ArticleId IdType="pubmed">23247304</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, ESC Scientific Document Group et al.2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BM, Kapadia SR, Smedira NG. et al. Ventricular septal rupture complicating acute myocardial infarction: a contemporary review. Eur Heart J 2014;35:2060&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24970335</ArticleId></ArticleIdList></Reference><Reference><Citation>Rob D, &#x160;punda R, Lindner J. et al. A rationale for early extracorporeal membrane oxygenation in patients with postinfarction ventricular septal rupture complicated by cardiogenic shock. Eur J Heart Fail 2017;19 Suppl 2:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">28470920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco D, Matteucci M, Ravaux JM. et al. Mechanical circulatory support as a bridge to definitive treatment in post-infarction ventricular septal rupture. JACC Cardiovasc Interv 2021;14:1053&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">34016403</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller JE, Engstr&#xf8;m T, Jensen LO, DanGer Shock Investigators et al.Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med 2024;390:1382&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">38587239</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda K, Yoshioka I, Saiki Y.. Emergence of right to left shunt via postmyocardial infarction ventricular septal defect under Impella support. Artif Organs 2021;45:316&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33079396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraoka A, Saku K, Nishikawa T, Sunagawa K.. A case report of unexpected right-to-left shunt under mechanical support for post-infarction ventricular septal defect: evaluation with haemodynamic simulator. Eur Heart J Case Rep 2021;5:ytab209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422329</ArticleId><ArticleId IdType="pubmed">34514298</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmas C, Barbosa H, David C-H. et al. Impella for the management of ventricular septal defect complicating acute myocardial infarction: a European Multicenter Registry. ASAIO J 2023;69:e491&#x2013;e99.</Citation><ArticleIdList><ArticleId IdType="pubmed">37935014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalli S, Spinelli KJ, Kirker EB, Venkataraman A, Abraham J.. Impella as a bridge-to-closure in post-infarction ventricular septal defect: a case series. Eur Heart J Case Rep 2023;7:ytad500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10588615</ArticleId><ArticleId IdType="pubmed">37869741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz Duque E, Hohenwarter MR, Isom NR, Singhal AK.. Impella support for surgical ventricular septal defect repair. ASAIO J 2023;69:e278&#x2013;e83.</Citation><ArticleIdList><ArticleId IdType="pubmed">36574463</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S, Shibasaki I, Matsuoka T. et al. Impella support as a bridge to heart surgery in patients with cardiogenic shock. Interact CardioVasc Thorac Surg 2022;35:ivac088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9297506</ArticleId><ArticleId IdType="pubmed">35373286</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimahara Y, Fukushima S, Yajima S. et al. Emergency sandwich patch repair. Eur Heart J Case Rep 2021;5:ytab141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276610</ArticleId><ArticleId IdType="pubmed">34268476</ArticleId></ArticleIdList></Reference><Reference><Citation>Via G, Buson S, Tavazzi G. et al. Early cardiac unloading with ImpellaCP in acute myocardial infarction with ventricular septal defect. ESC Heart Fail 2020;7:708&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160491</ArticleId><ArticleId IdType="pubmed">32043814</ArticleId></ArticleIdList></Reference><Reference><Citation>La Torre MW, Centofanti P, Attisani M, Patan&#xe8; F, Rinaldi M.. Posterior ventricular septal defect in presence of cardiogenic shock: early implantation of the impella recover LP 5.0 as a bridge to surgery. Tex Heart Inst J 2011;38:42&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060738</ArticleId><ArticleId IdType="pubmed">21423467</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimarakis I, Adcox M, Pal JD, Khorsandi M.. Impella 5.5 support before, during, and after surgical ventricular septal defect repair: a bridge continuum. Perfusion 2024;39:1270&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">37295776</ArticleId></ArticleIdList></Reference><Reference><Citation>Giudicatti L, Silbert B, Xu X-F. et al. Post-myocardial infarction ventricular septal defect successfully treated with Impella as bridge to cardiac transplantation. Case Rep Cardiol 2022;2022:5690844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9357800</ArticleId><ArticleId IdType="pubmed">35958101</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyan G, Anand N, Imran M. et al. ECMO and Impella support strategies as a bridge to surgical repair of post-infarction ventricular septal rupture. Medicina (Kaunas) 2022;58:611. doi: 10.3390/medicina58050611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58050611</ArticleId><ArticleId IdType="pmc">PMC9146080</ArticleId><ArticleId IdType="pubmed">35630028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowatari R, Kondo N, Watanabe S, Daitoku K, Minakawa M.. Urgent repair of postinfarct ventricular septal rupture with ECPELLA support: a case report. J Card Surg 2021;36:3933&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34291837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JA, Montgomery RA, Zmaili MA. et al. Post-myocardial infarction ventricular septal rupture bridged to heartmate 3 with an Impella 5.5. Ann Thorac Surg 2021;112:e161&#x2013;e63.</Citation><ArticleIdList><ArticleId IdType="pubmed">33482161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M, Imamura T, Fukui T. et al. Impella support as a bridge to scheduled surgical repair of ventricular septal rupture. J Artif Organs 2020;23:278&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">32219577</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida M, Uchiyama M, Shimokawa T.. A successful case of percutaneous left ventricular assist device &#x201c;Impella&#x201d; to postmyocardial infarction ventricular septal perforation in Japan. Artif Organs 2019;43:806&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30788851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancona MB, Regazzoli D, Mangieri A, Monaco F, De Bonis M, Latib A.. Post-infarct ventricular septal rupture: early Impella implantation to delay surgery and reduce surgical risk. Cardiovasc Interv Ther 2017;32:381&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27604391</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibebuogu UN, Bolorunduro O, Hwang I.. Impella-assisted transcatheter closure of an acute postinfarction ventricular septal defect. BMJ Case Rep 2016;2016:bcr2015213887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823526</ArticleId><ArticleId IdType="pubmed">27030453</ArticleId></ArticleIdList></Reference><Reference><Citation>Patan&#xe8; F, Grassi R, Zucchetti MC. et al. The use of Impella Recover in the treatment of post-infarction ventricular septal defect: a new case report. Int J Cardiol 2010;144:313&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19346016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Hiraoka A, Toki M, Chikazawa G, Yoshitaka H.. Right-to-left shunt depending on the support level of Impella for post-infarction ventricular septal defect. Eur Heart J Cardiovasc Imaging 2022;23:e296.</Citation><ArticleIdList><ArticleId IdType="pubmed">35511606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeppsson A, Liden H, Johnsson P, Hartford M, R&#xe5;degran K.. Surgical repair of post infarction ventricular septal defects: a national experience. Eur J Cardiothorac Surg 2005;27:216&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15691673</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson WJ, Clarke SA, Quinn TA, Holmes JW.. Physiological implications of myocardial scar structure. Compr Physiol 2015;5:1877&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4727398</ArticleId><ArticleId IdType="pubmed">26426470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancona MB, Montorfano M, Masiero G. et al. Device-related complications after Impella mechanical circulatory support implantation: an IMP-IT observational multicentre registry substudy. Eur Heart J Acute Cardiovasc Care 2021;10:999&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">34389852</ArticleId></ArticleIdList></Reference><Reference><Citation>Toggweiler S, Jamshidi P, Erne P.. Functional mitral stenosis: a rare complication of the Impella assist device. Eur J Echocardiogr 2008;9:412&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">18490340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutallimov M, Er F, Gassanov N.. Device fracture as a potential complication of a left ventricular microaxial pump catheter: a case report. Eur Heart J Case Rep 2022;6:ytac335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9397508</ArticleId><ArticleId IdType="pubmed">36004047</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38920325</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Predictors of renal replacement therapy following isolated coronary artery surgery: a retrospective case-controlled study.</ArticleTitle><Pagination><StartPage>6684</StartPage><EndPage>6690</EndPage><MedlinePgn>6684-6690</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JS9.0000000000001772</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Severe acute kidney injury (AKI) requiring postoperative renal replacement therapy (RRT) is associated with increased morbidity and mortality rates following cardiac surgery. Our study aimed to analyze patients requiring postoperative RRT in a population undergoing isolated coronary artery surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following exclusions, we analyzed 124&#xa0;944 consecutive patients in the Polish National Registry of Cardiac Surgical Procedures (KROK Registry), scheduled for isolated coronary artery surgery between January 2010 and December 2019. Patients who underwent preoperative chronic dialysis were excluded from the study. Data of patients requiring postoperative RRT and patients without postoperative RRT were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the analyzed population, 1668 patients (1.3%) developed AKI requiring RRT. In-hospital mortality among patients with and without postoperative RRT was 40.1 and 1.6%, respectively ( P &lt;0.001). Patients requiring postoperative RRT had significantly more preoperative co-morbidities and more frequent postoperative complications. Preoperative chronic renal failure and cardiogenic shock were the two most prominent independent risk factors for postoperative RRT in these patients (OR: 5.0, 95% CI: 3.9-6.4, P &lt;0.001 and OR: 3.9, 95% CI: 2.8-5.6, P &lt;0.001, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Severe AKI requiring postoperative RRT dramatically increases in-hospital mortality and is associated with the development of serious postoperative complications. The need for postoperative RRT is clearly associated with the presence of preoperative co-morbidities. Preoperative chronic renal failure and cardiogenic shock were particularly related to the development of this complication.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krauchuk</LastName><ForeName>Alena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Therapy, Silesian Centre for Heart Diseases, Medical University of Silesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrapkowicz</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwalski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw and Centre of Postgraduate Medical Education, Warsaw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perek</LastName><ForeName>Bart&#x142;omiej</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Pozna&#x144;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jasi&#x144;ski</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department and Clinic of Cardiac Surgery, Wroclaw Medical University, Wroclaw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirnle</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiosurgery, Medical University of Bialystok, Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadziakiewicz</LastName><ForeName>Pawe&#x142;</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Therapy, Silesian Centre for Heart Diseases, Medical University of Silesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knapik</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Therapy, Silesian Centre for Heart Diseases, Medical University of Silesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="Y">Renal Replacement Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>26</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>26</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38920325</ArticleId><ArticleId IdType="pmc">PMC11487009</ArticleId><ArticleId IdType="doi">10.1097/JS9.0000000000001772</ArticleId><ArticleId IdType="pii">01279778-202410000-00062</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swaminathan M, Shaw AD, Phillips-Bute BG, et al. . Trends in acute renal failure associated with coronary artery bypass graft surgery in the United States. Crit Care Med 2007;35:2286&#x2013;2291.</Citation><ArticleIdList><ArticleId IdType="pubmed">17944016</ArticleId></ArticleIdList></Reference><Reference><Citation>Loef BG, Epema AH, Smilde TD, et al. . Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol 2005;16:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow GM, Lazarus JM, Christiansen CL, et al. . Preoperative renal risk stratification. Circulation 1997;95:878&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">9054745</ArticleId></ArticleIdList></Reference><Reference><Citation>Huckaby LV, Seese LM, Hess N, et al. . Fate of the kidneys in patients with post-operative renal failure after cardiac surgery. J Surg Res 2022;272:166&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">34979472</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoara A, Patel UD, Phillips-Bute BG, et al. . Mortality trends associated with acute renal failure requiring dialysis after CABG surgery in the United States. Blood Purif 2009;28:359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">19729906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenihan CR, Montez-Rath ME, Mora Mangano CT, et al. . Trends in acute kidney injury, associated use of dialysis, and mortality after cardiac surgery, 1999 to 2008. Ann Thorac Surg 2013;95:20&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115367</ArticleId><ArticleId IdType="pubmed">23272825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004;66:480&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">15253693</ArticleId></ArticleIdList></Reference><Reference><Citation>Karkouti K, Wijeysundera DN, Yau TM, et al. . Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 2009;119:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">19153273</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafford-Smith M, Shaw A, Swaminathan M. Cardiac surgery, and acute kidney injury: emerging concepts. Curr Opin Crit Care 2009;15:498&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">19812485</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakar CV, Arrigain S, Worley S, et al. . A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005;16:162&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563569</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SY, Chen JY, Yang WC, et al. . Acute kidney injury network classification predicts in-hospital and long-term mortality in patients undergoing elective coronary artery bypass grafting surgery. Eur J Cardiothorac Surg 2011;39:323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumbert SD, Kork F, Jackson ML, et al. . Perioperative acute kidney injury. Anesthesiology 2020;132:180&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10924686</ArticleId><ArticleId IdType="pubmed">31687986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon JT, Jung TE, Lee DH. Predictive risk factors of acute kidney injury after on-pump coronary artery bypass grafting. Ann Transl Med 2019;7:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389572</ArticleId><ArticleId IdType="pubmed">30906748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato TS, Machida Y, Kuwaki K, et al. . Factors associated with postoperative requirement of renal replacement therapy following off-pump coronary bypass surgery. Heart Vessels 2017;32:134&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">27272895</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapik P, Knapik M, Zembala MO, et al. . In-hospital and mid-term outcomes in patients reoperated on due to bleeding following coronary artery surgery (from the KROK Registry). Interact Cardiovasc Thorac Surg 2019;29:237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">30968119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew G, Agha R, for the STROCSS Group . STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg 2021;96:106165.</Citation><ArticleIdList><ArticleId IdType="pubmed">34774726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease Improving Global Outcomes . KDIGO clinical practice guidelines on acute kidney injury. Kidney Int Suppl 2012;2:8&#x2013;12.</Citation></Reference><Reference><Citation>Knapik P, Hirnle G, Kowalczuk-Wieteska A, et al. . Off-pump versus on-pump coronary artery surgery in octogenarians (from the KROK Registry). PLoS One 2020;15:e0238880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7482977</ArticleId><ArticleId IdType="pubmed">32913359</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RH, Honeycutt E, Patel UD, et al. . Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting. Am J Cardiol 2010;106:1728&#x2013;1734.</Citation><ArticleIdList><ArticleId IdType="pubmed">21126617</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakeri R, Freemantle N, Barnett V, et al. . Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting. Circulation 2005;112(9 suppl):I270&#x2013;I275.</Citation><ArticleIdList><ArticleId IdType="pubmed">16159830</ArticleId></ArticleIdList></Reference><Reference><Citation>Corredor C, Thomson R, Al-Subaie N. Long-term consequences of acute kidney injury after cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2016;30:69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">26482483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis MR, Naik BI, Freundlich RE, et al. . Preoperative risk and the association between hypotension and postoperative acute kidney injury. Anesthesiology 2020;132:461&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7015776</ArticleId><ArticleId IdType="pubmed">31794513</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper WA, O&#x2019;Brien SM, Thourani VH, et al. . Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006;113:1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490821</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong B, St, Onge J, Korkola S, et al. . Validating a scoring tool to predict acute kidney injury (AKI) following cardiac surgery. Can J Kidney Heal Dis 2015;2:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4349478</ArticleId><ArticleId IdType="pubmed">25780626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Chen R, Liu S, et al. . Global incidence and outcomes of adult patients with acute kidney injury after cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2016;30:82&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">26482484</ArticleId></ArticleIdList></Reference><Reference><Citation>Axtell AL, Fiedler AG, Melnitchouk S, et al. . Correlation of cardiopulmonary bypass duration with acute renal failure after cardiac surgery. J Thorac Cardiovasc Surg 2020;159:170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">30826102</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabra VF, Alobaidi S, Balk EM, et al. . Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 2010;5:1734&#x2013;1744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2974371</ArticleId><ArticleId IdType="pubmed">20671222</ArticleId></ArticleIdList></Reference><Reference><Citation>Reents W, Hilker M, B&#xf6;rgermann J, et al. . Acute kidney injury after on-pump or off-pump coronary artery bypass grafting in elderly patients. Ann Thorac Surg 2014;98:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">24881861</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a Fuster R, Paredes F, Garc&#xed;a Pel&#xe1;ez A, et al. . Impact of increasing degrees of renal impairment on outcomes of coronary artery bypass grafting: the off-pump advantage. Eur J Cardiothorac Surg 2013;44:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">23425679</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeysundera DN, Karkouti K, Dupuis JY, et al. . Derivation and validation of a simplified predictive index for renal replacement therapy after cardiac surgery. JAMA 2007;297:1801&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">17456822</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neal JB, Shaw AD, Billings FT, IV. Acute kidney injury following cardiac surgery: current understanding and future directions. Crit Care 2016;20:187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931708</ArticleId><ArticleId IdType="pubmed">27373799</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnie K, Verheyden V, Pagano D, et al. . Predictive models for kidney disease: Improving global outcomes (KDIGO) defined acute kidney injury in UK cardiacsurgery. Crit Care 2014;18:606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4258283</ArticleId><ArticleId IdType="pubmed">25673427</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34582413</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Clinical Benefit of Extubation in Patients on Venoarterial Extracorporeal Membrane Oxygenation.</ArticleTitle><Pagination><StartPage>760</StartPage><EndPage>769</EndPage><MedlinePgn>760-769</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0000000000005304</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Although patients on venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock are usually supported with mechanical ventilation, it is not clear whether sedation cessation and extubation might improve outcomes.</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study with propensity score overlap weighting analysis.</AbstractText><AbstractText Label="SETTING">Three ICUs in a 1,500-bed tertiary university hospital.</AbstractText><AbstractText Label="PATIENTS">From an overall cohort of 641 patients with venoarterial-extracorporeal membrane oxygenation support, the primary analysis was performed in 344 patients who had been successfully decannulated in order to reduce immortal time bias.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">Seventy-five patients (22%) were extubated during extracorporeal membrane oxygenation support and were subsequently decannulated alive. Forty-nine percent received noninvasive ventilation, and 25% had emergency reintubation for respiratory, neurologic, or hemodynamic reasons. Higher Simplified Acute Physiology Score II at admission (odds ratio, 0.97; 95% CI [0.95-0.99]; p = 0.008) was associated with a lower probability of extubation, whereas cannulation in cardiac surgery ICU (odds ratio, 3.14; 95% CI [1.21-8.14]; p = 0.018) was associated with an increased probability. Baseline characteristics were well balanced after propensity score overlap weighting. The number of ICU-free days within 30 days of extracorporeal membrane oxygenation decannulation was significantly higher among extubated patients compared with nonextubated patients (22 d [11-26 d] vs 18 d [7-25 d], respectively; p = 0.036). There were no differences in other outcomes including ventilator-associated pneumonia (odds ratio, 0.96; 95% CI [0.51-1.82]; p = 0.90) and all-cause mortality within 30 days of extracorporeal membrane oxygenation decannulation (5% vs 17%; hazard ratio, 0.54; 95% CI [0.19-1.59]; p = 0.27).As a secondary analysis, outcomes were compared in the overall cohort of 641 venoarterial extracorporeal membrane oxygenation-supported patients. Results were consistent with the primary analysis as extubated patients had a higher number of ICU-free days (18 d [0-24 d] vs 0 d [0-18 d], respectively; &lt; 0.001) and a lower risk of death within 30 days of extracorporeal membrane oxygenation cannulation (hazard ratio, 0.45; 95% CI [0.29-0.71]; p = 0.001).</AbstractText><AbstractText Label="CONCLUSIONS">Extubation during venoarterial-extracorporeal membrane oxygenation support is safe, feasible, and associated with greater ICU-free days.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Massart</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Intensive-care Unit, Centre Hospitalier Yves Le Foll, Saint-Brieuc, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, Rennes University Hospital, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansour</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Intensive-care Unit, Centre Hospitalier Yves Le Foll, Saint-Brieuc, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flecher</LastName><ForeName>Erwan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Intensive-care Unit, Centre Hospitalier Yves Le Foll, Saint-Brieuc, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Intensive-care Unit, Centre Hospitalier Yves Le Foll, Saint-Brieuc, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ecoffey</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, Rennes University Hospital, Rennes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhoye</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Intensive-care Unit, Centre Hospitalier Yves Le Foll, Saint-Brieuc, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launey</LastName><ForeName>Yoann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intensive-care Unit, Centre Hospitalier Yves Le Foll, Saint-Brieuc, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auffret</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Intensive-care Unit, Centre Hospitalier Yves Le Foll, Saint-Brieuc, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nesseler</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, Rennes University Hospital, Rennes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ Rennes, CHU de Rennes, Inra, Inserm, Institut NUMECAN - UMR_A 1341, UMR_S 1241, Rennes, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2022 Jun 1;50(6):e606-e607. doi: 10.1097/CCM.0000000000005510.</RefSource><PMID Version="1">35612455</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D060666" MajorTopicYN="N">Airway Extubation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>17</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34582413</ArticleId><ArticleId IdType="doi">10.1097/CCM.0000000000005304</ArticleId><ArticleId IdType="pii">00003246-202205000-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt M, Burrell A, Roberts L, et al.: Predicting survival after ECMO for refractory cardiogenic shock: The survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J. 2015; 36:2246&#x2013;2256</Citation></Reference><Reference><Citation>Slutsky AS, Ranieri VM: Ventilator-induced lung injury. N Engl J Med. 2013; 369:2126&#x2013;2136</Citation></Reference><Reference><Citation>Kollef MH, Levy NT, Ahrens TS, et al.: The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest. 1998; 114:541&#x2013;548</Citation></Reference><Reference><Citation>Kress JP, Pohlman AS, O&#x2019;Connor MF, et al.: Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000; 342:1471&#x2013;1477</Citation></Reference><Reference><Citation>Abrams D, Garan AR, Brodie D: Awake and fully mobile patients on cardiac extracorporeal life support. Ann Cardiothorac Surg. 2019; 8:44&#x2013;53</Citation></Reference><Reference><Citation>Mohite PN, Kaul S, Sabashnikov A, et al.: Extracorporeal life support in patients with refractory cardiogenic shock: Keep them awake. Interact Cardiovasc Thorac Surg. 2015; 20:755&#x2013;760</Citation></Reference><Reference><Citation>Bataillard A, Hebrard A, Gaide-Chevronnay L, et al.: Extubation in patients undergoing extracorporeal life support. Int J Artif Organs. 2017; 40:696&#x2013;700</Citation></Reference><Reference><Citation>Ellouze O, Lamirel J, Perrot J, et al.: Extubation of patients undergoing extracorporeal life support. A retrospective study. Perfusion. 2019; 34:50&#x2013;57</Citation></Reference><Reference><Citation>Vail EA, Gershengorn HB, Wunsch H, et al.: Attention to immortal time bias in critical care research. Am J Respir Crit Care Med. 2021; 203:1222&#x2013;1229</Citation></Reference><Reference><Citation>Fl&#xe9;cher E, Anselmi A, Corbineau H, et al.: Current aspects of extracorporeal membrane oxygenation in a tertiary referral centre: Determinants of survival at follow-up. Eur J Cardiothorac Surg. 2014; 46:665&#x2013;671</Citation></Reference><Reference><Citation>Chanques G, Jaber S, Barbotte E, et al.: Impact of systematic evaluation of pain and agitation in an intensive care unit. Crit Care Med. 2006; 34:1691&#x2013;1699</Citation></Reference><Reference><Citation>Sessler CN, Gosnell MS, Grap MJ, et al.: The Richmond Agitation&#x2013;Sedation Scale. Am J Resp Crit Care. 2002; 166:1338&#x2013;1344</Citation></Reference><Reference><Citation>Payen JF, Bru O, Bosson JL, et al.: Assessing pain in critically ill sedated patients by using a Behavioral Pain Scale. Crit Care Med. 2001; 29:2258&#x2013;2263</Citation></Reference><Reference><Citation>Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70:41</Citation></Reference><Reference><Citation>Thomas LE, Li F, Pencina MJ: Overlap weighting: A propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020; 323:2417&#x2013;2418</Citation></Reference><Reference><Citation>Winck JC, Azevedo LF, Costa-Pereira A, et al.: Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema&#x2013;a systematic review and meta-analysis. Crit Care. 2006; 10:R69</Citation></Reference><Reference><Citation>Br&#xe9;chot N, Demondion P, Santi F, et al.: Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. Eur Heart J Acute Cardiovasc Care. 2018; 7:62&#x2013;69</Citation></Reference><Reference><Citation>Nash G, Blennerhassett JB, Pontoppidan H: Pulmonary lesions associated with oxygen therapy and artificial ventilation. New Engl J Medicine. 1967; 276:368&#x2013;374</Citation></Reference><Reference><Citation>Sprung J, Ogletree-Hughes ML, McConnell BK, et al.: The effects of propofol on the contractility of failing and nonfailing human heart muscles. Anesth Analg. 2001; 93:550&#x2013;559</Citation></Reference><Reference><Citation>Patel SB, Poston JT, Pohlman A, et al.: Rapidly reversible, sedation-related delirium versus persistent delirium in the intensive care unit. Am J Respir Crit Care Med. 2014; 189:658&#x2013;665</Citation></Reference><Reference><Citation>Schweickert WD, Pohlman MC, Pohlman AS, et al.: Early physical and occupational therapy in mechanically ventilated, critically ill patients: A randomised controlled trial. Lancet. 2009; 373:1874&#x2013;1882</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38584083</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0938</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cardiovascular revascularization medicine : including molecular interventions</Title><ISOAbbreviation>Cardiovasc Revasc Med</ISOAbbreviation></Journal><ArticleTitle>Outcomes of mitral valve transcatheter edge-to-edge repair for patients with hemodynamic instability: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>19</StartPage><EndPage>28</EndPage><MedlinePgn>19-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.carrev.2024.04.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1553-8389(24)00149-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) for the patients with severe mitral regurgitation (MR) in hemodynamically unstable conditions, such as cardiogenic shock, still remain unclear. We aimed to integrate previous publications regarding M-TEER indicated for life-threatening conditions and indirectly particularly compared the short-term outcomes thereof, with that of other treatments.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched the PubMed, Cochrane, and MEDLINE databases for studies from inception to June 2023, regarding M-TEER in patients with hemodynamic instability and severe MR. The primary outcomes analyzed included the in-hospital and 30-day mortality rates, and peri-procedural complications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the initial 820 publications, we conducted a meta-analysis of a total of 25 studies. The relative risk of moderate-to-severe or severe MR was 0.13 (95&#xa0;% confidence interval [CI]: 0.10-0.18, I<sup>2</sup>&#xa0;=&#xa0;45.2&#xa0;%). The pooled in-hospital and 30-day mortality rates were 11.8&#xa0;% (95&#xa0;% CI: 8.7-15.9, I<sup>2</sup>&#xa0;=&#xa0;96.4&#xa0;%) and 14.1&#xa0;% (95&#xa0;% CI: 10.9-18.3, I<sup>2</sup>&#xa0;=&#xa0;35.5&#xa0;%), respectively. The 30-day mortality rate was statistically significantly correlated with the residual moderate-to-severe or severe MR, as per the meta-regression analysis (coefficient &#x3b2;&#xa0;=&#xa0;3.48 [95&#xa0;% CI: 0.99-5.97], p&#xa0;=&#xa0;0.006). Regarding peri-procedural complications, the pooled rates of a stroke or transient ischemic attack, life-threatening or major bleeding, acute kidney injury, and peri-procedural mitral valve surgery were 2.3&#xa0;% (95&#xa0;% CI: 1.9-2.6), 7.6&#xa0;% (95&#xa0;% CI: 6.8-8.5), 32.9&#xa0;% (95&#xa0;% CI: 31.6-34.3), and 1.0&#xa0;% (95&#xa0;% CI: 0.8-1.3), respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This meta-analysis demonstrates that the relatively higher rates of procedural complications were observed, nevertheless, M-TEER can potentially provide favorable short-term outcomes even in hemodynamically unstable patients.</AbstractText><AbstractText Label="PROSPERO REGISTRATION NUMBER" NlmCategory="UNASSIGNED">CRD42023468946.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tokushima Red Cross Hospital, Tokushima, Japan. Electronic address: hyokoyama1986@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokawa</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Tokushima Red Cross Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shigekiyo</LastName><ForeName>Saori</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tokushima Red Cross Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seno</LastName><ForeName>Akiho</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tokushima Red Cross Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Tokushima Red Cross Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogura</LastName><ForeName>Riyo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Tokushima Red Cross Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahara</LastName><ForeName>Keitaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tokushima Red Cross Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosokawa</LastName><ForeName>Shinobu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tokushima Red Cross Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Revasc Med</MedlineTA><NlmUniqueID>101238551</NlmUniqueID><ISSNLinking>1878-0938</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006328" MajorTopicYN="Y">Cardiac Catheterization</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="Y">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="Y">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008943" MajorTopicYN="Y">Mitral Valve</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="Y">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support device</Keyword><Keyword MajorTopicYN="N">Mitral regurgitation</Keyword><Keyword MajorTopicYN="N">Mitral valve transcatheter edge-to-edge repair</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>7</Day><Hour>21</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38584083</ArticleId><ArticleId IdType="doi">10.1016/j.carrev.2024.04.006</ArticleId><ArticleId IdType="pii">S1553-8389(24)00149-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37713615</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2048-8734</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>European heart journal. Acute cardiovascular care</Title><ISOAbbreviation>Eur Heart J Acute Cardiovasc Care</ISOAbbreviation></Journal><ArticleTitle>Multidisciplinary cardiogenic shock team approach improves the long-term outcomes of patients suffering from refractory cardiogenic shock treated with short-term mechanical circulatory support.</ArticleTitle><Pagination><StartPage>821</StartPage><EndPage>830</EndPage><MedlinePgn>821-830</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjacc/zuad108</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Short-term mechanical circulatory support (STMCS) may be used as an intentional escalation strategy to treat refractory cardiogenic shock (rCS). However, with growing technical possibilities, making the right choice at the right time can be challenging. We established a shock team in January 2013 comprising a cardiac anaesthetist-intensivist, an interventional cardiologist, and a cardiac surgeon. Since then, a diagnosis of rCS has triggered a multidisciplinary team meeting based on a common algorithm. This study aimed to compare the decision-making process for STMCS for rCS before (2007-2013) and after (2013-2019) the creation of the shock team.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">This before-and-after cohort study was conducted over a 156-month period. Post-cardiotomy rCS were excluded. The primary outcome was a 1-year survival rate. In total, 250 consecutive adult patients were included in the analysis (84 in the control group and 166 in the shock team group). At baseline, the CardShock score was not different between the two groups (5[3-5] vs. 5[4-6], P = 0.323). The 1-year survival rate was significantly higher in the shock team group compared with the control group (59% vs. 45%, P = 0.043). After a Cox regression analysis, the shock team intervention was independently associated with a significantly improved 1-year survival rate (HR: 0.592, 95% CI: 0.398-0.880, P = 0.010).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A multidisciplinary shock team-based decision for STMCS device implantation in rCS is associated with better 1-year survival rates.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xe9;rion</LastName><ForeName>Fran&#xe7;ois-Xavier</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beurton</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3708-4653</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oddos</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nubret</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Heart Failure Unit, Cardiology Department, H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguerreche</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quessard</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faure</LastName><ForeName>Maxime</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Heart Failure Unit, Cardiology Department, H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerbaud</LastName><ForeName>Edouard</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4669-3562</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Intensive Care Unit and Interventional Cardiology, H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bordeaux Cardio-Thoracic Research Centre, U1045, University Hospital of Bordeaux, Plateforme Technologique d'Innovation Biom&#xe9;dicale, Avenue du Haut L&#xe9;v&#xea;que, 33600 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pernot</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5882-8925</Identifier><AffiliationInfo><Affiliation>University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, H&#xf4;pital Cardiologique du Haut L&#xe9;v&#xea;que, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imbault</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouattara</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut L&#xe9;v&#xea;que, 33604 Pessac, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Acute Cardiovasc Care</MedlineTA><NlmUniqueID>101591369</NlmUniqueID><ISSNLinking>2048-8726</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Extracorporeal life support</Keyword><Keyword MajorTopicYN="N">Hospital rapid response team</Keyword><Keyword MajorTopicYN="N">Multidisciplinary care team</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Ventricular assist device</Keyword></KeywordList><CoiStatement>Conflict of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>15</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37713615</ArticleId><ArticleId IdType="doi">10.1093/ehjacc/zuad108</ArticleId><ArticleId IdType="pii">7274996</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38597975</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2110-5820</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Annals of intensive care</Title><ISOAbbreviation>Ann Intensive Care</ISOAbbreviation></Journal><ArticleTitle>Oxygenation management during veno-arterial ECMO support for cardiogenic shock: a multicentric retrospective cohort study.</ArticleTitle><Pagination><StartPage>56</StartPage><MedlinePgn>56</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">56</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13613-024-01286-2</ELocationID><Abstract><AbstractText Label="BACKGOUND" NlmCategory="BACKGROUND">Hyperoxemia is common and associated with poor outcome during veno-arterial extracorporeal membrane oxygenation (VA ECMO) support for cardiogenic shock. However, little is known about practical daily management of oxygenation. Then, we aim to describe sweep gas oxygen fraction (F<sub>S</sub>O<sub>2</sub>), postoxygenator oxygen partial pressure (P<sub>POST</sub>O<sub>2</sub>), inspired oxygen fraction (F<sub>I</sub>O<sub>2</sub>), and right radial arterial oxygen partial pressure (P<sub>a</sub>O<sub>2</sub>) between day 1 and day 7 of peripheral VA ECMO support. We also aim to evaluate the association between oxygenation parameters and outcome. In this retrospective multicentric study, each participating center had to report data on the last 10 eligible patients for whom the ICU stay was terminated. Patients with extracorporeal cardiopulmonary resuscitation were excluded. Primary endpoint was individual mean F<sub>S</sub>O<sub>2</sub> during the seven first days of ECMO support (F<sub>S</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-7)</sub>).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between August 2019 and March 2022, 139 patients were enrolled in 14 ECMO centers in France, and one in Switzerland. Among them, the median value for F<sub>S</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-7)</sub> was 70 [57; 79] % but varied according to center case volume. Compared to high volume centers, centers with less than 30 VA-ECMO runs per year were more likely to maintain F<sub>S</sub>O<sub>2</sub> &#x2265; 70% (OR 5.04, CI 95% [1.39; 20.4], p&#x2009;=&#x2009;0.017). Median value for right radial P<sub>a</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-7)</sub> was 114 [92; 145] mmHg, and decreased from 125 [86; 207] mmHg at day 1, to 97 [81; 133] mmHg at day 3 (p&#x2009;&lt;&#x2009;0.01). Severe hyperoxemia (i.e. right radial P<sub>a</sub>O<sub>2</sub> &#x2265; 300 mmHg) occurred in 16 patients (12%). P<sub>POST</sub>O<sub>2</sub>, a surrogate of the lower body oxygenation, was measured in only 39 patients (28%) among four centers. The median value of P<sub>POST</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-7)</sub> value was 198 [169; 231] mmHg. By multivariate analysis, age (OR 1.07, CI95% [1.03-1.11], p&#x2009;&lt;&#x2009;0.001), F<sub>S</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-3)</sub>(OR 1.03 [1.00-1.06], p&#x2009;=&#x2009;0.039), and right radial P<sub>a</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-3)</sub> (OR 1.03, CI95% [1.00-1.02], p&#x2009;=&#x2009;0.023) were associated with in-ICU mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In a multicentric cohort of cardiogenic shock supported by VA ECMO, the median value for F<sub>S</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-7)</sub> was 70 [57; 79] %. P<sub>POST</sub>O<sub>2</sub> monitoring was infrequent and revealed significant hyperoxemia. Higher F<sub>S</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-3)</sub> and right radial P<sub>a</sub>O<sub>2</sub>&#xa0;<sub>mean (day 1-3)</sub> were independently associated with in-ICU mortality.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winiszewski</LastName><ForeName>Hadrien</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3728-2334</Identifier><AffiliationInfo><Affiliation>Service de r&#xe9;animation m&#xe9;dicale, CHU Besan&#xe7;on, Besan&#xe7;on, France. hwiniszewski@chu-besancon.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit EA 3920 and SFR FED 4234, University of Franche Comt&#xe9;, Besancon, France. hwiniszewski@chu-besancon.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieille</LastName><ForeName>Thibault</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Service de r&#xe9;animation m&#xe9;dicale, CHU Besan&#xe7;on, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guinot</LastName><ForeName>Pierre-Gr&#xe9;goire</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Service d'anesth&#xe9;sie-r&#xe9;animation chirurgicale, CHU Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nesseler</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University Hospital of Rennes, Pontchaillou, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Berre</LastName><ForeName>Mael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de r&#xe9;animation m&#xe9;dicale, CHU Besan&#xe7;on, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crognier</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Anesthesia and Critical Care Department, Rangueil University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roche</LastName><ForeName>Anne-Claude</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Anesthesia, Intensive Care and Perioperative Medicine, Nouvel H&#xf4;pital Civil, Strasbourg University Hospital, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fellahi</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Service d'Anesth&#xe9;sie-R&#xe9;animation, H&#xf4;pital Louis Pradel, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ostrevy</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Department, Montpied Hospital, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ltaief</LastName><ForeName>Zied</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Adult Intensive Care Medicine, Lausanne University Hospital and Lausanne University, Lausanne, 1011, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didier</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service de m&#xe9;decine intensive r&#xe9;animation, CHU Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arab</LastName><ForeName>Osama Abou</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Critical Care Medicine, Amiens University Medical Center, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meslin</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anesthesiology and Critical Care Medicine Department, H&#xf4;pital Europ&#xe9;en Georges Pompidou, APHP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherrer</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, CHU Rouen, Rouen, F-76000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besch</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>D&#xe9;partement d'Anesth&#xe9;sie R&#xe9;animation Chirurgicale, Universit&#xe9; de Franche-Comt&#xe9;, CHU Besan&#xe7;on, CIC Inserm 1431, Besan&#xe7;on, EA3920, F-25000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monnier</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation M&#xe9;dicale, CHU Strasbourg, Nouvel H&#xf4;pital Civil, Universit&#xe9; de Strasbourg, Strasbourg, 67000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piton</LastName><ForeName>Gael</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de r&#xe9;animation m&#xe9;dicale, CHU Besan&#xe7;on, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmoun</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de m&#xe9;decine intensive r&#xe9;animation, CHU Nancy, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capellier</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de r&#xe9;animation m&#xe9;dicale, CHU Besan&#xe7;on, Besan&#xe7;on, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Clayton, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Intensive Care</MedlineTA><NlmUniqueID>101562873</NlmUniqueID><ISSNLinking>2110-5820</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Hyperoxia</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Sweep gas oxygen fraction</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>10</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>10</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>10</Day><Hour>11</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38597975</ArticleId><ArticleId IdType="pmc">PMC11006645</ArticleId><ArticleId IdType="doi">10.1186/s13613-024-01286-2</ArticleId><ArticleId IdType="pii">10.1186/s13613-024-01286-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ross P, Miller C, Sheldrake J, McGuiness W, Udy A, Burrell A. Hyperoxia in patients with cardiogenic shock after myocardial infarction supported with venoarterial extracorporeal membrane oxygenation. Aust Crit Care off J Confed Aust Crit Care Nurses 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32620254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W-T, Wang C-H, Lai C-H, et al. Optimal arterial blood oxygen tension in the early postresuscitation phase of extracorporeal cardiopulmonary resuscitation: a 15-Year retrospective observational study. Crit Care Med; 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31356478</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kawaz MN, Canner J, Caturegli G et al. Duration of Hyperoxia and neurologic outcomes in patients undergoing extracorporeal membrane oxygenation. Crit Care Med 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33935164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnemain J, Rusca M, Ltaief Z, et al. Hyperoxia during extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest is associated with severe circulatory failure and increased mortality. BMC Cardiovasc Disord. 2021;21(1):542. doi: 10.1186/s12872-021-02361-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-021-02361-3</ArticleId><ArticleId IdType="pmc">PMC8591834</ArticleId><ArticleId IdType="pubmed">34775951</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll SE, Paul E, Pilcher D, Udy A, Burrell A. Hyperoxia and mortality in conventional versus extracorporeal cardiopulmonary resuscitation. J Crit Care. 2022;69:154001. doi: 10.1016/j.jcrc.2022.154001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2022.154001</ArticleId><ArticleId IdType="pubmed">35217372</ArticleId></ArticleIdList></Reference><Reference><Citation>Halter M, Jouffroy R, Saade A, Philippe P, Carli P, Vivien B. Association between hyperoxemia and mortality in patients treated by eCPR after out-of-hospital cardiac arrest. Am J Emerg Med 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31303537</ArticleId></ArticleIdList></Reference><Reference><Citation>Munshi L, Kiss A, Cypel M, Keshavjee S, Ferguson ND, Fan E. Oxygen thresholds and mortality during extracorporeal life support in adult patients. Crit Care Med 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28787294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer JC, Miller PE, Alviar C, Yalamuri S, Bohman JK, Tonna JE. Exposure to arterial hyperoxia during extracorporeal membrane oxygenator support and mortality in patients with cardiogenic shock. Circ Heart Fail. 2023;16(4):e010328. doi: 10.1161/CIRCHEARTFAILURE.122.010328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.122.010328</ArticleId><ArticleId IdType="pmc">PMC10121893</ArticleId><ArticleId IdType="pubmed">36871240</ArticleId></ArticleIdList></Reference><Reference><Citation>Shou BL, Ong CS, Premraj L, et al. Arterial oxygen and carbon dioxide tension and acute brain injury in extracorporeal cardiopulmonary resuscitation patients: analysis of the extracorporeal life support organization registry. J Heart Lung Transpl off Publ Int Soc Heart Transpl. 2023;42(4):503&#x2013;11. doi: 10.1016/j.healun.2022.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2022.10.019</ArticleId><ArticleId IdType="pmc">PMC10050131</ArticleId><ArticleId IdType="pubmed">36435686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashiura M, Yasuda H, Kishihara Y, et al. Association between short-term neurological outcomes and extreme hyperoxia in patients with out-of-hospital cardiac arrest who underwent extracorporeal cardiopulmonary resuscitation: a retrospective observational study from a multicenter registry. BMC Cardiovasc Disord. 2022;22(1):163. doi: 10.1186/s12872-022-02598-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-022-02598-6</ArticleId><ArticleId IdType="pmc">PMC9003952</ArticleId><ArticleId IdType="pubmed">35410132</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonna JE, Selzman CH, Bartos JA et al. The association of modifiable mechanical ventilation settings, blood gas changes and survival on extracorporeal membrane oxygenation for cardiac arrest. Resuscitation 2022;S0300-9572(22)00083&#x2009;&#x2013;&#x2009;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050917</ArticleId><ArticleId IdType="pubmed">35331803</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa MD, Beyls C, Lamer A, et al. Early hyperoxia and 28-day mortality in patients on venoarterial ECMO support for refractory cardiogenic shock: a bicenter retrospective propensity score-weighted analysis. Crit Care Lond Engl. 2022;26(1):257. doi: 10.1186/s13054-022-04133-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04133-7</ArticleId><ArticleId IdType="pmc">PMC9414410</ArticleId><ArticleId IdType="pubmed">36028883</ArticleId></ArticleIdList></Reference><Reference><Citation>Celi&#x144;ska-Spodar M, Za&#x142;&#x119;ska-Koci&#x119;cka M, Bana&#x15b; S, ARTERIAL HYPEROXIA AND MORTALITY IN PATIENTS UNDERGOING VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION et al. Shock Augusta Ga. 2023;59(1):20&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">36703274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Shekar K, MacLaren G et al. ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients. ASAIO J Am Soc Artif Intern Organs 1992 2021;67(8):827&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">34339398</ArticleId></ArticleIdList></Reference><Reference><Citation>Winiszewski H, Guinot P-G, Schmidt M, et al. Optimizing PO2 during peripheral veno-arterial ECMO: a narrative review. Crit Care Lond Engl. 2022;26(1):226. doi: 10.1186/s13054-022-04102-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04102-0</ArticleId><ArticleId IdType="pmc">PMC9316319</ArticleId><ArticleId IdType="pubmed">35883117</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L, Brown A, Fraser JF, Pellegrino V, Pilcher D, Burrell A. Oxygenation during venoarterial extracorporeal membrane oxygenation: physiology, current evidence, and a pragmatic Approach to Oxygen Titration. Crit Care Med; 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">38059745</ArticleId></ArticleIdList></Reference><Reference><Citation>Distelmaier K, Roth C, Schrutka L, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016;117(1):52&#x2013;8. doi: 10.1093/bja/aew151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aew151</ArticleId><ArticleId IdType="pmc">PMC4913403</ArticleId><ArticleId IdType="pubmed">27317704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellouze O, Lamirel J, Perrot J, et al. Extubation of patients undergoing extracorporeal life support. A retrospective study. Perfusion. 2019;34(1):50&#x2013;7. doi: 10.1177/0267659118791072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659118791072</ArticleId><ArticleId IdType="pubmed">30044174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamhaut L, Hutin A, Puymirat E, et al. A pre-hospital extracorporeal Cardio Pulmonary Resuscitation (ECPR) strategy for treatment of refractory out hospital cardiac arrest: an observational study and propensity analysis. Resuscitation. 2017;117:109&#x2013;17. doi: 10.1016/j.resuscitation.2017.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2017.04.014</ArticleId><ArticleId IdType="pubmed">28414164</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrei S, Nguyen M, Berthoud V, et al. Determinants of arterial pressure of Oxygen and Carbon Dioxide in patients supported by veno-arterial ECMO. J Clin Med. 2022;11(17):5228. doi: 10.3390/jcm11175228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11175228</ArticleId><ArticleId IdType="pmc">PMC9457238</ArticleId><ArticleId IdType="pubmed">36079158</ArticleId></ArticleIdList></Reference><Reference><Citation>Justus A, Burrell A, Anstey C, Cornmell G, Brodie D, Shekar K. The Association of Oxygenation, Carbon Dioxide removal, and Mechanical Ventilation practices on Survival during Venoarterial extracorporeal membrane oxygenation. Front Med. 2021;8:756280. doi: 10.3389/fmed.2021.756280.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.756280</ArticleId><ArticleId IdType="pmc">PMC8636903</ArticleId><ArticleId IdType="pubmed">34869455</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L, Brown A, Burrell A, Fraser JF, Pilcher D. Hyperoxia during venoarterial ECMO: culprit or co-variate? A comment from the BLENDER investigators. Crit Care Lond Engl. 2022;26(1):345. doi: 10.1186/s13054-022-04213-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04213-8</ArticleId><ArticleId IdType="pmc">PMC9644601</ArticleId><ArticleId IdType="pubmed">36348428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Jang JH, Yang JH, Cho YH, Ahn J, Ryu J-A. Optimal arterial blood gas tensions for the prognosis of favorable neurological outcomes in survivors after extracorporeal cardiopulmonary resuscitation. J Clin Med. 2022;11(14):4211. doi: 10.3390/jcm11144211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11144211</ArticleId><ArticleId IdType="pmc">PMC9323021</ArticleId><ArticleId IdType="pubmed">35887974</ArticleId></ArticleIdList></Reference><Reference><Citation>Falk L, Sallisalmi M, Lindholm JA, et al. Differential hypoxemia during venoarterial extracorporeal membrane oxygenation. Perfusion. 2019;34(1suppl):22&#x2013;9. doi: 10.1177/0267659119830513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659119830513</ArticleId><ArticleId IdType="pubmed">30966908</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourad M, Eliet J, Zeroual N, et al. Pulse pressure and end-tidal carbon dioxide for monitoring low native cardiac output during veno-arterial ECLS: a prospective observational study. Crit Care Lond Engl. 2020;24(1):569. doi: 10.1186/s13054-020-03280-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03280-z</ArticleId><ArticleId IdType="pmc">PMC7507590</ArticleId><ArticleId IdType="pubmed">32962727</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce CJ, Anderson C, Shekar K. Hyperoxia on Venoarterial extracorporeal membrane oxygenation: a modifiable risk? Crit Care Med. 2022;50(1):e99&#x2013;100. doi: 10.1097/CCM.0000000000005252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005252</ArticleId><ArticleId IdType="pubmed">34914658</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Tao Y, Xu J, et al. Hyperoxia provokes Time- and dose-dependent gut Injury and Endotoxemia and alters gut microbiome and transcriptome in mice. Front Med. 2021;8:732039. doi: 10.3389/fmed.2021.732039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.732039</ArticleId><ArticleId IdType="pmc">PMC8635731</ArticleId><ArticleId IdType="pubmed">34869425</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaro RP, Odetola FO, Kidwell KM, et al. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med. 2015;191(8):894&#x2013;901. doi: 10.1164/rccm.201409-1634OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201409-1634OC</ArticleId><ArticleId IdType="pmc">PMC4435456</ArticleId><ArticleId IdType="pubmed">25695688</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34479465</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-111X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Perfusion</Title><ISOAbbreviation>Perfusion</ISOAbbreviation></Journal><ArticleTitle>Intra-aortic balloon pump versus percutaneous Impella<sup>&#xa9;</sup> in emergency revascularisation for myocardial infarction and cardiogenic shock: systematic review.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>59</EndPage><MedlinePgn>45-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/02676591211037026</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Mortality rates in patients with acute myocardial infarction and cardiogenic shock (AMI-CS) remain persistently high despite advances over the past decade in percutaneous mechanical circulatory support. This systematic review aims to analyse the existing literature to compare mortality outcomes in patients mechanically supported by intra-aortic balloon pump or percutaneous Impella 2.5/CP<sup>&#xa9;</sup> for AMI-CS undergoing emergency revascularisation.</AbstractText><AbstractText Label="METHODS">The following MeSH terms were applied to the databases Ovid Medline, Ovid Embase, Cochrane and Web of Science: 'Intra-aortic balloon pump', 'Impella', 'Cardiogenic shock', 'Myocardial Infarction' and 'Mortality'. This yielded 2643 studies. Using predefined inclusion and exclusion criteria, the studies were initially screened by title and abstract before full text analysis.</AbstractText><AbstractText Label="RESULTS">Fourteen studies met eligibility criteria: two randomised controlled trials (RCTs) and 12 observational studies. Data from a total of 21,006 patients were included across the studies. Notably, one study claimed reduced mortality with IABP versus control, and one study concluded that Impella<sup>&#xa9;</sup> improved survival rates over the IABP. The average 30-day all-cause mortality in patients supported by IABP was 38.1%, 54.3% in Impella<sup>&#xa9;</sup> groups and 39.4% in control groups.</AbstractText><AbstractText Label="CONCLUSION">AMI-CS presents an important cohort of patients in whom conducting RCTs is difficult. As a result, the literature is limited. Analysis of the available literature suggests that there is insufficient evidence to support superior survival in those supported by IABP or Impella<sup>&#xa9;</sup> when compared to control despite suggestions that the Impella<sup>&#xa9;</sup> offers superior haemodynamic support. Limitations of the studies have been discussed to outline suggestions for future research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frain</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5690-4098</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of St Andrews, St Andrews, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Academic Department of Military Medicine, Barts Heart Centre, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Perfusion</MedlineTA><NlmUniqueID>8700166</NlmUniqueID><ISSNLinking>0267-6591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">coronary artery bypass graft</Keyword><Keyword MajorTopicYN="N">intra-aortic balloon pump</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>4</Day><Hour>5</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34479465</ArticleId><ArticleId IdType="doi">10.1177/02676591211037026</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35262574</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1678-4170</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Arquivos brasileiros de cardiologia</Title><ISOAbbreviation>Arq Bras Cardiol</ISOAbbreviation></Journal><ArticleTitle>Impact of Preoperative Functional Capacity on Postoperative Outcomes in Congenital Heart Surgery: An Observational and Prospective Study.</ArticleTitle><Pagination><StartPage>411</StartPage><EndPage>419</EndPage><MedlinePgn>411-419</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.36660/abc.20201137</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0066-782X2022000200411</ELocationID><Abstract><AbstractText Label="BACKGROUND">Despite advances in surgical technique and postoperative care in congenital heart disease, cardiovascular morbidity is still high.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the association between preoperative cardiovascular fitness of children and adolescents, measured by the 6-minute walk test (6MWT) and Heart Rate Variability (HRV), and the occurrence of cardiogenic, septic shock and death in the postoperative period.</AbstractText><AbstractText Label="METHODS">Prospective, observational clinic study including 81 patients aged from 8 to 18 years. In the preoperative period, the 6MWT (distance walked and SpO2) and HRV were performed. The adjusted risk score for surgeries for congenital heart disease (RACHS-1) was applied to predict the surgical risk factor for mortality. The occurrence of at least one of the listed complications was considered as a combined event. P values &lt; 0.05 were considered as significant.</AbstractText><AbstractText Label="RESULTS">Of the patients, 59% were male, with mean age of 12 years; 33% were cyanotic; and 72% had undergone previous cardiac surgery. Cardiogenic shock was the most common complication, and 31% had a combined event. Prior to surgery, type of current heart disease, RACHS-1, SpO2at rest, during the 6MWT and recovery were selected for the multivariate analysis. The SpO2at recovery by the 6MWT remained as an independent risk factor (OR 0.93, 95%CI [0.88 - 0.99], p=0.02) for the increasing occurrence of combined events.</AbstractText><AbstractText Label="CONCLUSION">SpO2after the application of the 6MWT in the preoperative period was an independent predictor of prognosis in children and adolescents undergoing surgical correction; the walked distance and the HRV did not present this association.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Angela Sachiko</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0003-1251-8723</Identifier><AffiliationInfo><Affiliation>Universidade de S&#xe3;o Paulo Hospital das Cl&#xed;nicas,S&#xe3;o Paulo, SP - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Ant&#xf4;nio Augusto Barbosa</ForeName><Initials>AAB</Initials><AffiliationInfo><Affiliation>Universidade de S&#xe3;o Paulo Hospital das Cl&#xed;nicas,S&#xe3;o Paulo, SP - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Ana Cristina Sayuri</ForeName><Initials>ACS</Initials><AffiliationInfo><Affiliation>Universidade de S&#xe3;o Paulo Hospital das Cl&#xed;nicas,S&#xe3;o Paulo, SP - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feltrim</LastName><ForeName>Maria Ign&#xea;z Zanetti</ForeName><Initials>MIZ</Initials><AffiliationInfo><Affiliation>Universidade de S&#xe3;o Paulo Hospital das Cl&#xed;nicas,S&#xe3;o Paulo, SP - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galas</LastName><ForeName>Filomena R B G</ForeName><Initials>FRBG</Initials><AffiliationInfo><Affiliation>Universidade de S&#xe3;o Paulo Hospital das Cl&#xed;nicas,S&#xe3;o Paulo, SP - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Juliano Pinheiro</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Universidade de S&#xe3;o Paulo Hospital das Cl&#xed;nicas,S&#xe3;o Paulo, SP - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajjar</LastName><ForeName>Ludhmila Abrah&#xe3;o</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Universidade de S&#xe3;o Paulo Hospital das Cl&#xed;nicas,S&#xe3;o Paulo, SP - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nozawa</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Universidade de S&#xe3;o Paulo Hospital das Cl&#xed;nicas,S&#xe3;o Paulo, SP - Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Impacto da Capacidade Funcional Pr&#xe9;-operat&#xf3;ria nos Resultados P&#xf3;s-Operat&#xf3;rios de Cirurgia de Cardiopatia Cong&#xea;nita: Estudo Observacional e Prospectivo.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Bras Cardiol</MedlineTA><NlmUniqueID>0421031</NlmUniqueID><ISSNLinking>0066-782X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arq Bras Cardiol. 2022 Feb;118(2):420-421. doi: 10.36660/abc.20220020.</RefSource><PMID Version="1">35262575</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="Y">Exercise Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070857" MajorTopicYN="N">Walk Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="Y">Walking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="FUNDAMENTO">Apesar de avan&#xe7;os em t&#xe9;cnicas cir&#xfa;rgicas e cuidados p&#xf3;s-operat&#xf3;rios em cardiopatia cong&#xea;nita, a morbidade cardiovascular permanece elevada.</AbstractText><AbstractText Label="OBJETIVO">Avaliar a associa&#xe7;&#xe3;o do condicionamento pr&#xe9;-operat&#xf3;rio de crian&#xe7;as e adolescentes com cardiopatias, mensurado por teste de caminhada de 6-minutos (TC6M) e variabilidade da frequ&#xea;ncia card&#xed;aca (VFC), com a ocorr&#xea;ncia de choque cardiog&#xea;nico, s&#xe9;ptico e morte no per&#xed;odo p&#xf3;s-operat&#xf3;rio.</AbstractText><AbstractText Label="M&#xc9;TODOS">Estudo cl&#xed;nico prospectivo e observacional de 81 pacientes de 8 a 18 anos. No per&#xed;odo pr&#xe9;-operat&#xf3;rio foram realizados o TC6M (dist&#xe2;ncia caminhada e SpO2) e a VFC. O escore de risco ajustado para cirurgia de cardiopatia cong&#xea;nita ( RACHS-1 ) foi aplicado para predizer o fator de risco cir&#xfa;rgico para mortalidade. A ocorr&#xea;ncia de pelo menos uma das complica&#xe7;&#xf5;es citadas foi considerada como evento combinado. Valores de p&lt;0,05 foram considerados significantes.</AbstractText><AbstractText Label="RESULTADOS">Dos 81 pacientes, 59% eram do sexo masculino, com idade m&#xe9;dia de 12 anos; 33% eram cian&#xf3;ticos; e 72% j&#xe1; tinham realizado cirurgias pr&#xe9;vias. O choque cardiog&#xea;nico foi a complica&#xe7;&#xe3;o mais comum, e 31% apresentaram evento combinado. Cirurgia pr&#xe9;via, tipo de cardiopatia atual, RACHS-1 , SpO2 em repouso, durante e ap&#xf3;s recupera&#xe7;&#xe3;o do TC6M foram selecionados para o estudo multivariado. A SpO2 ap&#xf3;s o TC6M permaneceu como fator de risco independente para aumentar a ocorr&#xea;ncia de evento combinado no p&#xf3;s-operat&#xf3;rio (OR: 0,93, IC95% [0,88 &#x2013; 0,99], p=0,02).</AbstractText><AbstractText Label="CONCLUS&#xc3;O">O SpO2 ap&#xf3;s o TC6M no per&#xed;odo pr&#xe9;-operat&#xf3;rio foi o fator independente preditor de progn&#xf3;stico no p&#xf3;s-operat&#xf3;rio em crian&#xe7;as e adolescentes submetidos &#xe0; corre&#xe7;&#xe3;o cir&#xfa;rgica; a dist&#xe2;ncia caminhada e as vari&#xe1;veis da VFC n&#xe3;o tiveram a mesma associa&#xe7;&#xe3;o.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="eng"><AbstractText Label="BACKGROUND">Despite advances in surgical technique and postoperative care in congenital heart disease, cardiovascular morbidity is still high.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the association between preoperative cardiovascular fitness of children and adolescents, measured by the 6-minute walk test (6MWT) and Heart Rate Variability (HRV), and the occurrence of cardiogenic, septic shock and death in the postoperative period.</AbstractText><AbstractText Label="METHODS">Prospective, observational clinic study including 81 patients aged from 8 to 18 years. In the preoperative period, the 6MWT (distance walked and SpO<sub>2</sub>) and HRV were performed. The adjusted risk score for surgeries for congenital heart disease (RACHS-1) was applied to predict the surgical risk factor for mortality. The occurrence of at least one of the listed complications was considered as a combined event. P values &lt; 0.05 were considered as significant.</AbstractText><AbstractText Label="RESULTS">Of the patients, 59% were male, with mean age of 12 years; 33% were cyanotic; and 72% had undergone previous cardiac surgery. Cardiogenic shock was the most common complication, and 31% had a combined event. Prior to surgery, type of current heart disease, RACHS-1, SpO<sub>2</sub>at rest, during the 6MWT and recovery were selected for the multivariate analysis. The SpO<sub>2</sub>at recovery by the 6MWT remained as an independent risk factor (OR 0.93, 95%CI [0.88 - 0.99], p=0.02) for the increasing occurrence of combined events.</AbstractText><AbstractText Label="CONCLUSION">SpO<sub>2</sub>after the application of the 6MWT in the preoperative period was an independent predictor of prognosis in children and adolescents undergoing surgical correction; the walked distance and the HRV did not present this association.</AbstractText></OtherAbstract><CoiStatement>Potencial conflito de interesse. N&#xe3;o h&#xe1; conflito com o presente artigo</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35262574</ArticleId><ArticleId IdType="pmc">PMC8856681</ArticleId><ArticleId IdType="doi">10.36660/abc.20201137</ArticleId><ArticleId IdType="pii">S0066-782X2022000200411</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nixon PA, Joswiak ML, Fricker FJ. A Six-Minute Walk Test for Assessing Exercise Tolerance in Severely ill Children. J Pediatr. 1996;129(3):362-6. doi: 10.1016/s0022-3476(96)70067-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8804324</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrindle BW, Williams RV, Mitchell PD, Hsu DT, Paridon SM, Atz AM, et al. Relationship of Patient and Medical Characteristics to Health Status in Children and Adolescents after the Fontan Procedure. Circulation. 2006;113(8):1123-9. doi: 10.1161/CIRCULATIONAHA.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490823</ArticleId></ArticleIdList></Reference><Reference><Citation>Norozi K, Gravenhorst V, Hobbiebrunken E, Wessel A. Normality of Cardiopulmonary Capacity in Children Operated on to Correct Congenital Heart Defects. Arch Pediatr Adolesc Med. 2005;159(11):1063-8. doi: 10.1001/archpedi.159.11.1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275798</ArticleId></ArticleIdList></Reference><Reference><Citation>Golpe R, P&#xe9;rez-de-Llano LA, M&#xe9;ndez-Marote L, Veres-Racamonde A. Prognostic Value of Walk Distance, Work, Oxygen Saturation, and Dyspnea during 6-Minute Walk Test in COPD Patients. Respir Care. 2013;58(8):1329-34. doi: 10.4187/respcare.02290.</Citation><ArticleIdList><ArticleId IdType="pubmed">23322886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubim VS, Drumond Neto C, Romeo JL, Montera MW. Prognostic value of the Six-Minute Walk Test in heart failure. Arq Bras Cardiol. 2006;86(2):120-5. doi: 10.1590/s0066-782x2006000200007.</Citation><ArticleIdList><ArticleId IdType="pubmed">16501803</ArticleId></ArticleIdList></Reference><Reference><Citation>Moalla W, Gauthier R, Maingourd Y, Ahmaidi S. Six-Minute Walking Test to Assess Exercise Tolerance and Cardiorespiratory Responses During Training Program in Children with Congenital Heart Disease. Int J Sports Med. 2005;26(9):756-62. doi: 10.1055/s-2004-830558.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237621</ArticleId></ArticleIdList></Reference><Reference><Citation>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med. 2002;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehmeier ES, Sommer MH, Galonska A, Zeus T, Verde P, Kelm M. Diagnostic Value of the Six-Minute Walk Test (6MWT) in Grown-up Congenital Heart Disease (GUCH): Comparison with Clinical Status and Functional Exercise Capacity. Int J Cardiol. 2016;203:90-7. doi: 10.1016/j.ijcard.2015.10.074.</Citation><ArticleIdList><ArticleId IdType="pubmed">26498869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohuchi H, Watanabe K, Kishiki K, Wakisaka Y, Echigo S. Heart Rate Dynamics During and After Exercise in Postoperative Congenital Heart Disease Patients. Their Relation to Cardiac Autonomic Nervous Activity and Intrinsic Sinus Node Dysfunction. Am Heart J. 2007;154(1):165-71. doi: 10.1016/j.ahj.2007.03.031.</Citation><ArticleIdList><ArticleId IdType="pubmed">17584572</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-Based Method for Risk Adjustment for Surgery for Congenital Heart Disease. J Thorac Cardiovasc Surg. 2002;123(1):110-8. doi: 10.1067/mtc.2002.119064.</Citation><ArticleIdList><ArticleId IdType="pubmed">11782764</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg GA. Psychophysical Bases of Perceived Exertion. Med Sci Sports Exerc. 1982;14(5):377-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">7154893</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamelin FX, Baquet G, Berthoin S, Bosquet L. Validity of the Polar S810 to Measure R-R Intervals in Children. Int J Sports Med. 2008;29(2):134-8. doi: 10.1055/s-2007-964995.</Citation><ArticleIdList><ArticleId IdType="pubmed">17614016</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Rate Variability: Standards of Measurement, Physiological Interpretation and Clinical Use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043-65.</Citation><ArticleIdList><ArticleId IdType="pubmed">8598068</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-Minute Walk Test in Children and Adolescents. J Pediatr. 2007;150(4):395-9. doi: 10.1016/j.jpeds.2006.12.052.</Citation><ArticleIdList><ArticleId IdType="pubmed">17382117</ArticleId></ArticleIdList></Reference><Reference><Citation>Priesnitz CV, Rodrigues GH, Stumpf CS, Viapiana G, Cabral CP, Stein RT, et al. Reference Values for the 6-min Walk Test in Healthy Children Aged 6-12 years. Pediatr Pulmonol. 2009;44(12):1174-9. doi: 10.1002/ppul.21062.</Citation><ArticleIdList><ArticleId IdType="pubmed">19911357</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts MM, Cho JG, Sandoz JS, Wheatley JR. Oxygen Desaturation and Adverse Events During 6-min walk Testing in Patients with COPD. Respirology. 2015;20(3):419-25. doi: 10.1111/resp.12471.</Citation><ArticleIdList><ArticleId IdType="pubmed">25601398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, et al. A 6MWT Index to Predict O2 Flow Correcting Exercise Induced SpO2 Desaturation in ILD. Respir Med. 2013;107(12):2014-21. doi: 10.1016/j.rmed.2013.10.002.</Citation><ArticleIdList><ArticleId IdType="pubmed">24161677</ArticleId></ArticleIdList></Reference><Reference><Citation>Briand J, Behal H, Chenivesse C, W&#xe9;meau-Stervinou L, Wallaert B. The 1-minute Sit-to-Stand Test to Detect Exercise-Induced Oxygen Desaturation in Patients with Interstitial Lung Disease. Ther Adv Respir Dis. 2018;12:1753466618793028. doi: 10.1177/1753466618793028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088463</ArticleId><ArticleId IdType="pubmed">30091679</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaan CW, Macedo ACP, Sbruzzi G, Umpierre D, Schaan BD, Pellanda LC. Functional Capacity in Congenital Heart Disease: A Systematic Review and Meta-Analysis. Arq Bras Cardiol. 2017;109(4):357-67. doi: 10.5935/abc.20170125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5644216</ArticleId><ArticleId IdType="pubmed">28876372</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Bandyopadhyay B, Eriksson P, Chattopadhyay A. Functional Capacity Following Univentricular Repair-Midterm Outcome. Congenit Heart Dis. 2012;7(5):423-32. doi: 10.1111/j.1747-0803.2012.00640.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">22471644</ArticleId></ArticleIdList></Reference><Reference><Citation>Hami, K, Corcia MCG. Heart Rate Variability Modifications after Surgery for Congenital Heart Disease in Young Patients. Evid Based Med Pract, 2017;3(1):1-3. doi: 10.4172/2471-9919.1000113</Citation></Reference><Reference><Citation>Elder RW, McCabe NM, Veledar E, Kogon BE, Jokhadar M, Rodriguez FH 3rd, et al. Risk Factors for Major Adverse Events Late After Fontan Palliation. Congenit Heart Dis. 2015;10(2):159-68. doi: 10.1111/chd.12212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4512755</ArticleId><ArticleId IdType="pubmed">25130602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gewillig M, Goldberg DJ. Failure of the Fontan Circulation. Heart Fail Clin. 2014;10(1):105-16. doi: 10.1016/j.hfc.2013.09.010.</Citation><ArticleIdList><ArticleId IdType="pubmed">24275298</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamberti A, Chessa M, Abella R, Butera G, Carlucci C, Nuri H, et al. Morbidity and Mortality Risk Factors in Adults with Congenital Heart Disease Undergoing Cardiac Reoperations. Ann Thorac Surg. 2009;88(4):1284-9. doi: 10.1016/j.athoracsur.2009.05.060.</Citation><ArticleIdList><ArticleId IdType="pubmed">19766822</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36608781</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-6280</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Current problems in cardiology</Title><ISOAbbreviation>Curr Probl Cardiol</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Outcomes of Redo-coronary Artery Bypass Graft Versus Percutaneous Coronary Intervention of Index Bypass Grafts Among Acute Coronary Syndrome: Regression Matched National Cohort Study.</ArticleTitle><Pagination><StartPage>101580</StartPage><MedlinePgn>101580</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cpcardiol.2022.101580</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0146-2806(22)00476-5</ELocationID><Abstract><AbstractText>Procedural and hospital outcomes of Percutaneous coronary intervention (PCI) versus Coronary artery bypass grafting (CABG) among ACS patients with prior history of CABG remains understudied. PCI and CABG formed the 2 comparison cohorts. Nationwide Inpatient Sample (NIS) from 2015 to 2020 were analyzed using the ICD-10 coding system. Demographic characteristics, baseline comorbidities, and outcomes such as inpatient mortality, cardiogenic shock, mechanical circulatory support, length of stay (LOS), and cost of hospitalization were compared between the two cohorts. A total of 503,900 ACS hospitalizations with prior history of CABG were identified who underwent PCI and CABG (141650 vs 7715, respectively). Median age was 71 vs 67, with male predominance (74.6% vs 75.4%), Caucasian had the most hospitalizations (79.3% vs 75.1%) in the PCI group compared to patients who underwent CABG. A higher burden of smoking (57.1% vs 52.6%, P &lt; 0.0001)&#xa0;was noted in the CABG group. On adjusted analysis, ACS patients undergoing Redo- CABG had a higher risk of in-hospital mortality (aOR 1.69, CI 1.53-1.87, P &lt; 0.0001) compared to those undergoing PCI. In addition, Redo-CABG group were more likely to have CS (aOR 1.37, CI 1.26-1.48, P &lt; 0.0001), MCS devices use (aOR 2.61, CI 2.43-2.80, P &lt; 0.0001), AKI (aOR 1.42, CI 1.34-1.50, P &lt; 0.0001) and respiratory failure (aOR 1.39, CI 1.29-1.47, P &lt; 0.0001) as compared to PCI group. CABG in acute myocardial infarction with prior history of CABG is associated with higher cardiovascular complications compared to PCI. Further exploration and individual-patient level risk assessment is crucial.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faisaluddin</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rochester General Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattar</LastName><ForeName>Yasar</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, West Virginia University, Morgantown, WV.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manasrah</LastName><ForeName>Nouraldeen</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Detroit Medical Center/ Wayne State University, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Neel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taha</LastName><ForeName>Amro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takla</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rochester General Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Asmaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rochester General Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osama</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rochester General Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Titus</LastName><ForeName>Anoop</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Saint Vincent Hospital, Worcestor, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamza</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Albany Medical Center Hospital, Albany, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Harsh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Southern Illinois University, Springfield, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakkar</LastName><ForeName>Samarth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Houston Methodist Hospital, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syed</LastName><ForeName>Moinuddin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Boston University, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almas</LastName><ForeName>Talal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mayo University Hospital, Mayo, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daggubati</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, West Virginia University, Morgantown, WV. Electronic address: ramesh.daggubati@wvumedicine.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Probl Cardiol</MedlineTA><NlmUniqueID>7701802</NlmUniqueID><ISSNLinking>0146-2806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054058" MajorTopicYN="Y">Acute Coronary Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="N">Coronary Artery Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36608781</ArticleId><ArticleId IdType="doi">10.1016/j.cpcardiol.2022.101580</ArticleId><ArticleId IdType="pii">S0146-2806(22)00476-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30854307</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2225-319X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of cardiothoracic surgery</Title><ISOAbbreviation>Ann Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>8</EndPage><MedlinePgn>1-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/acs.2018.11.09</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite advances in management techniques and medical therapy, refractory cardiogenic shock remains a life-threatening condition with high mortality rates. The present systematic review and meta-analysis aims to explore the outcomes associated with venoarterial extracorporeal membrane oxygenation (VA-ECMO) use in the setting of refractory cardiogenic shock, stratified per survivorship.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A literature search was performed using three electronic databases from the date of their inception up to June 2018. The literature search and subsequent data extraction were performed by two independent reviewers. Digitized survival data were extracted from Kaplan-Meier curves in order to re-create the original patient data using an iterative algorithm and were subsequently aggregated for analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-two studies were included, with 44 undergoing quantitative analysis. A total of 17,515 patients were identified, with a mean age of 58.4&#xb1;9.4 years and a mean duration of ECMO support of 5.1&#xb1;2.6 days; 68.7% of the patients were male. Aggregated survival rates at 1, 2, 3 and 5 years were 36.7%, 34.8%, 33.8% and 29.9%, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present systematic review illustrates the expected survival results for VA-ECMO in the intermediate- to long-term. Extended follow-up and standardized reporting measures are urgently needed in order to carry out more definitive subgroup analyses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilson-Smith</LastName><ForeName>Ashley R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>The Collaborative Research Group (CORE), Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of New South Wales, Faculty of Medicine, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanova</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The University of New South Wales, Faculty of Medicine, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roydhouse</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of New South Wales, Faculty of Medicine, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Collaborative Research Group (CORE), Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>The Collaborative Research Group (CORE), Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal North Shore Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Tristan D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>The Collaborative Research Group (CORE), Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital (RPA), Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loforte</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery and Transplantation, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Ann Cardiothorac Surg</MedlineTA><NlmUniqueID>101605877</NlmUniqueID><ISSNLinking>2225-319X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECLS</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation (ECMO)</Keyword><Keyword MajorTopicYN="N">refractory cardiogenic shock</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30854307</ArticleId><ArticleId IdType="pmc">PMC6379189</ArticleId><ArticleId IdType="doi">10.21037/acs.2018.11.09</ArticleId><ArticleId IdType="pii">acs-08-01-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Napp LC, K&#xfc;hn C, Bauersachs J. ECMO in cardiac arrest and cardiogenic shock. Herz 2017;42:27-44. 10.1007/s00059-016-4523-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00059-016-4523-4</ArticleId><ArticleId IdType="pmc">PMC5306351</ArticleId><ArticleId IdType="pubmed">28127638</ArticleId></ArticleIdList></Reference><Reference><Citation>Brissaud O, Botte A, Cambonie G, et al. Experts&#x2019; recommendations for the management of cardiogenic shock in children. Ann Intensive Care 2016;6:14. 10.1186/s13613-016-0111-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-016-0111-2</ArticleId><ArticleId IdType="pmc">PMC4754230</ArticleId><ArticleId IdType="pubmed">26879087</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorson W, Jr, Baker E, Cohen ML, et al. A perfusion system for infants. Trans Am Soc Artif Intern Organs 1969;15:155-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">5819378</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy JH. The role of assisted circulation in cardiac resuscitation. JAMA 1966;197:615-8. 10.1001/jama.1966.03110080055017</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1966.03110080055017</ArticleId><ArticleId IdType="pubmed">5953090</ArticleId></ArticleIdList></Reference><Reference><Citation>Makdisi G, Wang I. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis 2015;7:E166-76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522501</ArticleId><ArticleId IdType="pubmed">26380745</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris AH, Wallace CJ, Menlove RL, et al. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med 1994;149:295-305. 10.1164/ajrccm.149.2.8306022</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.149.2.8306022</ArticleId><ArticleId IdType="pubmed">8306022</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill JD, O'Brien TG, Murray JJ, et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. N Engl J Med 1972;286:629-34. 10.1056/NEJM197203232861204</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197203232861204</ArticleId><ArticleId IdType="pubmed">5060491</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbon JH., Jr Artificial maintenance of circulation during experimental occlusion of pulmonary artery. Arch Surg 1937;34:1105-31. 10.1001/archsurg.1937.01190120131008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1937.01190120131008</ArticleId></ArticleIdList></Reference><Reference><Citation>Loforte A, Marinelli G, Musumeci F, et al. Extracorporeal membrane oxygenation support in refractory cardiogenic shock: treatment strategies and analysis of risk factors. Artif Organs 2014;38:E129-41. 10.1111/aor.12317</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12317</ArticleId><ArticleId IdType="pubmed">24841637</ArticleId></ArticleIdList></Reference><Reference><Citation>Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009;374:1351-63. 10.1016/S0140-6736(09)61069-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61069-2</ArticleId><ArticleId IdType="pubmed">19762075</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. 10.1136/bmj.b2700</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9. 10.1186/1471-2288-12-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-12-9</ArticleId><ArticleId IdType="pmc">PMC3313891</ArticleId><ArticleId IdType="pubmed">22297116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J 2015;36:2246-56. 10.1093/eurheartj/ehv194</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv194</ArticleId><ArticleId IdType="pubmed">26033984</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma AS, Weerwind PW, Ganushchak YM, et al. Towards a proactive therapy utilizing the modern spectrum of extracorporeal life support: a single-centre experience. Perfusion 2015;30:113-8. 10.1177/0267659114530455</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659114530455</ArticleId><ArticleId IdType="pubmed">24759930</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller G, Flecher E, Lebreton G, et al. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Med 2016;42:370-8. 10.1007/s00134-016-4223-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4223-9</ArticleId><ArticleId IdType="pubmed">26825953</ArticleId></ArticleIdList></Reference><Reference><Citation>Schopka S, Philipp A, Hilker M, et al. Clinical course and long-term outcome following venoarterial extracorporeal life support-facilitated interhospital transfer of patients with circulatory failure. Resuscitation 2015;93:53-7. 10.1016/j.resuscitation.2015.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2015.05.021</ArticleId><ArticleId IdType="pubmed">26051810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JG, Han J, Jia YX, et al. Outcome of veno-arterial extracorporeal membrane oxygenation for patients undergoing valvular surgery. PLoS One 2013;8:e63924. 10.1371/journal.pone.0063924</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0063924</ArticleId><ArticleId IdType="pmc">PMC3662767</ArticleId><ArticleId IdType="pubmed">23717509</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Jiang C, Yang F, et al. Veno-Arterial Extracorporeal Membrane Oxygenation Support in Patients Undergoing Aortic Surgery. Artif Organs 2017;41:1113-20. 10.1111/aor.12951</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12951</ArticleId><ArticleId IdType="pubmed">28718889</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai TY, Tsai FC, Fan PC, et al. Application of the Age, Creatinine, and Left Ventricular Ejection Fraction Score for Patients on Extracorporeal Membrane Oxygenation. Artif Organs 2017;41:146-52. 10.1111/aor.12765</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12765</ArticleId><ArticleId IdType="pubmed">27580634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh TC, Chang HH, Ger LP, et al. Clinical risk factors of extracorporeal membrane oxygenation support in older adults. PLoS One 2018;13:e0195445. 10.1371/journal.pone.0195445</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0195445</ArticleId><ArticleId IdType="pmc">PMC5889174</ArticleId><ArticleId IdType="pubmed">29624620</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena P, Neal J, Joyce LD, et al. Extracorporeal Membrane Oxygenation Support in Postcardiotomy Elderly Patients: The Mayo Clinic Experience. Ann Thorac Surg 2015;99:2053-60. 10.1016/j.athoracsur.2014.11.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2014.11.075</ArticleId><ArticleId IdType="pubmed">25865760</ArticleId></ArticleIdList></Reference><Reference><Citation>Loforte A, Montalto A, Ranocchi F, et al. Peripheral extracorporeal membrane oxygenation system as salvage treatment of patients with refractory cardiogenic shock: preliminary outcome evaluation. Artif Organs 2012;36:E53-61. 10.1111/j.1525-1594.2011.01423.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1594.2011.01423.x</ArticleId><ArticleId IdType="pubmed">22352417</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso S, Matsui H, Fushimi K, et al. In-hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a national inpatient database in Japan. Crit Care 2016;20:80. 10.1186/s13054-016-1261-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1261-1</ArticleId><ArticleId IdType="pmc">PMC4820970</ArticleId><ArticleId IdType="pubmed">27044572</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubin H, Petrov G, Dalyanoglu H, et al. Four-year experience of providing mobile extracorporeal life support to out-of-center patients within a suprainstitutional network&#x2014;Outcome of 160 consecutively treated patients. Resuscitation 2017;121:151-7. 10.1016/j.resuscitation.2017.08.237</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2017.08.237</ArticleId><ArticleId IdType="pubmed">28870718</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama H, Truby L, Koekort M, et al. Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era. J Heart Lung Transplant 2013;32:106-11. 10.1016/j.healun.2012.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2012.10.005</ArticleId><ArticleId IdType="pubmed">23260710</ArticleId></ArticleIdList></Reference><Reference><Citation>Liden H, Wiklund L, Haraldsson A, et al. Temporary circulatory support with extra corporeal membrane oxygenation in adults with refractory cardiogenic shock. Scand Cardiovasc J 2009;43:226-32. 10.1080/14017430802596420</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14017430802596420</ArticleId><ArticleId IdType="pubmed">19089752</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehrcke DD, McCarthy PM, Stewart RW, et al. Extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock. Ann Thorac Surg 1996;61:684-91. 10.1016/0003-4975(95)01042-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-4975(95)01042-4</ArticleId><ArticleId IdType="pubmed">8572788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranney DN, Benrashid E, Meza JM, et al. Central Cannulation as a Viable Alternative to Peripheral Cannulation in Extracorporeal Membrane Oxygenation. Semin Thorac Cardiovasc Surg 2017;29:188-95. 10.1053/j.semtcvs.2017.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semtcvs.2017.02.007</ArticleId><ArticleId IdType="pubmed">28823327</ArticleId></ArticleIdList></Reference><Reference><Citation>Musial R, Moncznik P, Smialek P, et al. Veno-arterial extracorporeal membrane oxygenation for short-term mechanical circulation support in adults with cardiogenic shock: a single centre experience. Kardiol Pol 2016;74:1477-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27221960</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo CF, Cannata A, Lanfranconi M, et al. Veno-arterial extracorporeal membrane oxygenation using Levitronix centrifugal pump as bridge to decision for refractory cardiogenic shock. J Thorac Cardiovasc Surg 2010;140:1416-21. 10.1016/j.jtcvs.2010.07.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2010.07.083</ArticleId><ArticleId IdType="pubmed">20933244</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40469854</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1755-5922</ISSN><JournalIssue CitedMedium="Internet"><Volume>2025</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Cardiovascular therapeutics</Title><ISOAbbreviation>Cardiovasc Ther</ISOAbbreviation></Journal><ArticleTitle>The Effect of Vasopressin on 90-Day Mortality in Patients With Cardiogenic Shock: A Retrospective Cohort Study Using Propensity Score-Weighted Analysis.</ArticleTitle><Pagination><StartPage>9920490</StartPage><MedlinePgn>9920490</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9920490</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/cdr/9920490</ELocationID><Abstract><AbstractText><b>Background:</b> Cardiogenic shock (CS) may lead to a refractory vasoplegic state that requires vasopressin on top of norepinephrine. Vasopressin has been available in France since January 2022. However, data assessing the clinical impact of vasopressin in CS are very scarce. <b>Objective:</b> In this study, we aimed to assess the association between vasopressin and 90-day mortality in a cohort of CS. <b>Method:</b> We conducted a retrospective, single-center study at Amiens University Hospital comparing two cohorts of patients experiencing at least Stage C of CS: one historical cohort from 2018 to 2019 without vasopressin and a contemporary cohort from 2022 to 2023 treated with vasopressin. The primary outcome was 90-day mortality. The secondary outcome was the occurrence of serious adverse events (SAEs) during ICU stay. Inverse probability of treatment weighting (IPTW) derived from propensity score was used to reduce imbalances in baseline characteristics. <b>Results:</b> We included 201 patients in the study: 59 in the vasopressin group and 142 in the no vasopressin group. The SOFA score and norepinephrine equivalent were higher in the vasopressin group (13 [10-16] vs. 12 [9-15]; <i>p</i> = 0.02 and 0.72 [0.21-1.51] vs. 0.13 [0.07-0.34]; <i>p</i> &lt; 0.001, respectively). There was no significant difference between the two groups for the 90-day mortality (<i>n</i> = 31/59 vs. 75/142; <i>p</i> = 0.97). Before adjustment, vasopressin was not associated with 90-day mortality (OR = 0.98 [95% CI 0.50-1.78]; <i>p</i> = 0.87). After weighting, vasopressin remained not associated with 90-day mortality (OR = 1.10 [95% CI 0.56-2.17]; <i>p</i> = 0.77). There was no significant difference for SAEs between the two groups (<i>n</i> = 57/142 [40%] vs. <i>n</i> = 23/59 [39%]; <i>p</i> = 0.88). <b>Conclusion:</b> Vasopressin was not associated with 30-day mortality and SAEs in patients with CS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Christophe Beyls et al. Cardiovascular Therapeutics published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beyls</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8949-7348</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UR UPJV 7518 SSPC (Simplification of Care of Complex Surgical Patients) Research Unit, University of Picardie Jules Verne, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanquiez</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollet</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarfati</LastName><ForeName>Yoni</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerima</LastName><ForeName>Adel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chafiki</LastName><ForeName>Souheil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besserve</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupont</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diouf</LastName><ForeName>Momar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Statistics, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou-Arab</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahjoub</LastName><ForeName>Yazine</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UR UPJV 7518 SSPC (Simplification of Care of Complex Surgical Patients) Research Unit, University of Picardie Jules Verne, Amiens, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Ther</MedlineTA><NlmUniqueID>101319630</NlmUniqueID><ISSNLinking>1755-5914</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>11000-17-2</RegistryNumber><NameOfSubstance UI="D014667">Vasopressins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014667" MajorTopicYN="Y">Vasopressins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="Y">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">norepinephrine</Keyword><Keyword MajorTopicYN="N">vasopressin</Keyword><Keyword MajorTopicYN="N">vasopressor</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40469854</ArticleId><ArticleId IdType="pmc">PMC12136860</ArticleId><ArticleId IdType="doi">10.1155/cdr/9920490</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vahdatpour C., Collins D., Goldberg S. Cardiogenic Shock. Journal of the American Heart Association . 2019;8(8) doi: 10.1161/JAHA.119.011991.e011991</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.011991</ArticleId><ArticleId IdType="pmc">PMC6507212</ArticleId><ArticleId IdType="pubmed">30947630</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling L. H., Fernando S. M., Talarico R., et al. Long-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction. Journal of the American College of Cardiology . 2023;82(10):985&#x2013;995. doi: 10.1016/j.jacc.2023.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.06.026</ArticleId><ArticleId IdType="pubmed">37648357</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostadal P., Rokyta R., Karasek J., et al. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. Circulation . 2023;147(6):454&#x2013;464. doi: 10.1161/CIRCULATIONAHA.122.062949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.062949</ArticleId><ArticleId IdType="pubmed">36335478</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweck E., Thayer K. L., Helgestad O. K. L., et al. Phenotyping Cardiogenic Shock. Journal of the American Heart Association . 2021;10(14) doi: 10.1161/JAHA.120.020085.e020085</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.020085</ArticleId><ArticleId IdType="pmc">PMC8483502</ArticleId><ArticleId IdType="pubmed">34227396</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Ohman E. M., de Waha-Thiele S., Zeymer U., Desch S. Management of Cardiogenic Shock Complicating Myocardial Infarction: An Update 2019. European Heart Journal . 2019;40(32):2671&#x2013;2683. doi: 10.1093/eurheartj/ehz363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz363</ArticleId><ArticleId IdType="pubmed">31274157</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones T. L., Nakamura K., McCabe J. M. Cardiogenic Shock: Evolving Definitions and Future Directions in Management. Open Heart . 2019;6(1) doi: 10.1136/openhrt-2018-000960.e000960</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2018-000960</ArticleId><ArticleId IdType="pmc">PMC6519403</ArticleId><ArticleId IdType="pubmed">31168376</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran D. A., Grines C. L., Bailey S., et al. SCAI Clinical Expert Consensus Statement on the Classification of Cardiogenic Shock: This Document Was Endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheterization and Cardiovascular Interventions . 2019;94(1):29&#x2013;37. doi: 10.1002/ccd.28329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28329</ArticleId><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom J. E., Chan W., Kaye D. M., Stub D. State of Shock: Contemporary Vasopressor and Inotrope Use in Cardiogenic Shock. Journal of the American Heart Association . 2023;12(15) doi: 10.1161/JAHA.123.029787.e029787</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.029787</ArticleId><ArticleId IdType="pmc">PMC10492962</ArticleId><ArticleId IdType="pubmed">37489740</ArticleId></ArticleIdList></Reference><Reference><Citation>Demiselle J., Fage N., Radermacher P., Asfar P. Vasopressin and Its Analogues in Shock States: A Review. Annals of Intensive Care . 2020;10(1):p. 9. doi: 10.1186/s13613-020-0628-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-0628-2</ArticleId><ArticleId IdType="pmc">PMC6975768</ArticleId><ArticleId IdType="pubmed">31970567</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry D. W., Oliver J. A. The ATP-Sensitive K+ Channel Mediates Hypotension in Endotoxemia and Hypoxic Lactic Acidosis in Dog. Journal of Clinical Investigation . 1992;89(6):2071&#x2013;2074. doi: 10.1172/JCI115820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI115820</ArticleId><ArticleId IdType="pmc">PMC295927</ArticleId><ArticleId IdType="pubmed">1602014</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry D. W., Levin H. R., Gallant E. M., et al. Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock. Circulation . 1997;95(5):1122&#x2013;1125. doi: 10.1161/01.CIR.95.5.1122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.95.5.1122</ArticleId><ArticleId IdType="pubmed">9054839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon A. C., Mason A. J., Thirunavukkarasu N., et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA . 2016;316(5):509&#x2013;518. doi: 10.1001/jama.2016.10485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.10485</ArticleId><ArticleId IdType="pubmed">27483065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar L. A., Vincent J. L., Barbosa Gomes Galas F. R., et al. Vasopressin Versus Norepinephrine in Patients With Vasoplegic Shock After Cardiac Surgery: The VANCS Randomized Controlled Trial. Anesthesiology . 2017;126(1):85&#x2013;93. doi: 10.1097/ALN.0000000000001434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000001434</ArticleId><ArticleId IdType="pubmed">27841822</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L., Rhodes A., Alhazzani W., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Medicine . 2021;49(11):e1063&#x2013;e1143. doi: 10.1097/CCM.0000000000005337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005337</ArticleId><ArticleId IdType="pubmed">34605781</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid I. A. Role of Vasopressin Deficiency in the Vasodilation of Septic Shock. Circulation . 1997;95(5):1108&#x2013;1110. doi: 10.1161/01.CIR.95.5.1108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.95.5.1108</ArticleId><ArticleId IdType="pubmed">9054835</ArticleId></ArticleIdList></Reference><Reference><Citation>Toulouse E. French Legal Approach to Clinical Research. Anaesthesia Critical Care &amp; Pain Medicine . 2018;37(6):607&#x2013;614. doi: 10.1016/j.accpm.2018.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.accpm.2018.10.013</ArticleId><ArticleId IdType="pubmed">30580775</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X. I., Wang X., Speicher P. J., et al. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. Journal of the National Cancer Institute . 2017;109(8):djw323. doi: 10.1093/jnci/djw323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djw323</ArticleId><ArticleId IdType="pmc">PMC6059208</ArticleId><ArticleId IdType="pubmed">28376195</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D. G., Egger M., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. Lancet . 2007;370(9596):1453&#x2013;1457. doi: 10.1016/S0140-6736(07)61602-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotani Y., Di Gioia A., Landoni G., Belletti A., Khanna A. K. An Updated &#x201c;Norepinephrine Equivalent&#x201d; Score in Intensive Care as a Marker of Shock Severity. Critical Care . 2023;27(1):p. 29. doi: 10.1186/s13054-023-04322-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04322-y</ArticleId><ArticleId IdType="pmc">PMC9854213</ArticleId><ArticleId IdType="pubmed">36670410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongardon N., de Roux Q., Leone M., Guerci P. Norepinephrine Formulation for Equivalent Vasopressive Score. Critical Care . 2023;27(1):p. 62. doi: 10.1186/s13054-023-04354-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04354-4</ArticleId><ArticleId IdType="pmc">PMC9933252</ArticleId><ArticleId IdType="pubmed">36797766</ArticleId></ArticleIdList></Reference><Reference><Citation>Na S. J., Chung C. R., Cho Y. H., et al. Vasoactive Inotropic Score as a Predictor of Mortality in Adult Patients With Cardiogenic Shock: Medical Therapy Versus ECMO. Revista Espa&#xf1;ola de Cardiolog&#xed;a . 2019;72(1):40&#x2013;47. doi: 10.1016/j.recesp.2017.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2017.12.020</ArticleId><ArticleId IdType="pubmed">29463462</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. L., Moreno R., Takala J., et al. The SOFA (Sepsis-Related Organ Failure Assessment) Score to Describe Organ Dysfunction/Failure. On Behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Medicine . 1996;22(7):707&#x2013;710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Chang C., Ido M. S., Long Q. Multiple Imputation for General Missing Data Patterns in the Presence of High-dimensional Data. Scientific Reports . 2016;6(1) doi: 10.1038/srep21689.21689</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep21689</ArticleId><ArticleId IdType="pmc">PMC4751511</ArticleId><ArticleId IdType="pubmed">26868061</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P. C., Stuart E. A. Moving Towards Best Practice When Using Inverse Probability of Treatment Weighting (IPTW) Using the Propensity Score to Estimate Causal Treatment Effects in Observational Studies. Statistics in Medicine . 2015;34(28):3661&#x2013;3679. doi: 10.1002/sim.6607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6607</ArticleId><ArticleId IdType="pmc">PMC4626409</ArticleId><ArticleId IdType="pubmed">26238958</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell J. A., Walley K. R., Singer J., et al. Vasopressin Versus Norepinephrine Infusion in Patients With Septic Shock. New England Journal of Medicine . 2008;358(9):877&#x2013;887. doi: 10.1056/NEJMoa067373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa067373</ArticleId><ArticleId IdType="pubmed">18305265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang C. N., Kaier K., Zotzmann V., et al. Cardiogenic Shock: Incidence, Survival and Mechanical Circulatory Support Usage 2007&#x2013;2017-Insights From a National Registry. Clinical Research in Cardiology . 2021;110(9):1421&#x2013;1430. doi: 10.1007/s00392-020-01781-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01781-z</ArticleId><ArticleId IdType="pmc">PMC8405485</ArticleId><ArticleId IdType="pubmed">33258007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen M., Berthoud V., Rizk A., Bouhemad B., Guinot P.-G. Real Life Use of Vasopressin in Patients With Cardiogenic Shock: A Retrospective Cohort Analysis. Critical Care . 2023;27(1):p. 291. doi: 10.1186/s13054-023-04574-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04574-8</ArticleId><ArticleId IdType="pmc">PMC10357707</ArticleId><ArticleId IdType="pubmed">37468928</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley M. S., Barletta J. F., Smithburger P. L., Radosevich J. J., Kane-Gill S. L. Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock. Pharmacotherapy . 2019;39(3):382&#x2013;398. doi: 10.1002/phar.2199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.2199</ArticleId><ArticleId IdType="pubmed">30506565</ArticleId></ArticleIdList></Reference><Reference><Citation>Guinot P.-G., Martin A., Berthoud V., et al. Vasopressor-Sparing Strategies in Patients With Shock: A Scoping-Review and an Evidence-Based Strategy Proposition. Journal of Clinical Medicine . 2021;10(14):p. 3164. doi: 10.3390/jcm10143164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10143164</ArticleId><ArticleId IdType="pmc">PMC8306396</ArticleId><ArticleId IdType="pubmed">34300330</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy B., Clere-Jehl R., Legras A., et al. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. Journal of the American College of Cardiology . 2018;72(2):173&#x2013;182. doi: 10.1016/j.jacc.2018.04.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.04.051</ArticleId><ArticleId IdType="pubmed">29976291</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20940381</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>304</Volume><Issue>14</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial.</ArticleTitle><Pagination><StartPage>1559</StartPage><EndPage>1567</EndPage><MedlinePgn>1559-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2010.1446</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Perioperative red blood cell transfusion is commonly used to address anemia, an independent risk factor for morbidity and mortality after cardiac operations; however, evidence regarding optimal blood transfusion practice in patients undergoing cardiac surgery is lacking.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To define whether a restrictive perioperative red blood cell transfusion strategy is as safe as a liberal strategy in patients undergoing elective cardiac surgery.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">The Transfusion Requirements After Cardiac Surgery (TRACS) study, a prospective, randomized, controlled clinical noninferiority trial conducted between February 2009 and February 2010 in an intensive care unit at a university hospital cardiac surgery referral center in Brazil. Consecutive adult patients (n = 502) who underwent cardiac surgery with cardiopulmonary bypass were eligible; analysis was by intention-to-treat.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were randomly assigned to a liberal strategy of blood transfusion (to maintain a hematocrit &#x2265;30%) or to a restrictive strategy (hematocrit &#x2265;24%).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Composite end point of 30-day all-cause mortality and severe morbidity (cardiogenic shock, acute respiratory distress syndrome, or acute renal injury requiring dialysis or hemofiltration) occurring during the hospital stay. The noninferiority margin was predefined at -8% (ie, 8% minimal clinically important increase in occurrence of the composite end point).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Hemoglobin concentrations were maintained at a mean of 10.5 g/dL (95% confidence interval [CI], 10.4-10.6) in the liberal-strategy group and 9.1 g/dL (95% CI, 9.0-9.2) in the restrictive-strategy group (P &lt; .001). A total of 198 of 253 patients (78%) in the liberal-strategy group and 118 of 249 (47%) in the restrictive-strategy group received a blood transfusion (P &lt; .001). Occurrence of the primary end point was similar between groups (10% liberal vs 11% restrictive; between-group difference, 1% [95% CI, -6% to 4%]; P = .85). Independent of transfusion strategy, the number of transfused red blood cell units was an independent risk factor for clinical complications or death at 30 days (hazard ratio for each additional unit transfused, 1.2 [95% CI, 1.1-1.4]; P = .002).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among patients undergoing cardiac surgery, the use of a restrictive perioperative transfusion strategy compared with a more liberal strategy resulted in noninferior rates of the combined outcome of 30-day all-cause mortality and severe morbidity.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT01021631.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hajjar</LastName><ForeName>Ludhmila A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit and Department of Anesthesiology, Heart Institute (InCor), Hospital das Clinicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Galas</LastName><ForeName>Filomena R B G</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Rosana E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Carolina M P</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Marilia H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kalil Filho</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sierra</LastName><ForeName>Denise B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Neuza H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Mauad</LastName><ForeName>Thais</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Roquim</LastName><ForeName>Aretusa C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Sundin</LastName><ForeName>Marcia R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Le&#xe3;o</LastName><ForeName>Wanderson C</ForeName><Initials>WC</Initials></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Juliano P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Pomerantzeff</LastName><ForeName>Pablo M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Dallan</LastName><ForeName>Luis O</ForeName><Initials>LO</Initials></Author><Author ValidYN="Y"><LastName>Jatene</LastName><ForeName>Fabio B</ForeName><Initials>FB</Initials></Author><Author ValidYN="Y"><LastName>Stolf</LastName><ForeName>Noedir A G</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Auler</LastName><ForeName>Jose O C</ForeName><Initials>JO</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01021631</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2010 Oct 13;304(14):1610-1. doi: 10.1001/jama.2010.1483.</RefSource><PMID Version="1">20940390</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2011 Jan 26;305(4):357-8; author reply 358-9. doi: 10.1001/jama.2011.14.</RefSource><PMID Version="1">21266679</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2011 Jan 26;305(4):357; author reply 358-9. doi: 10.1001/jama.2011.13.</RefSource><PMID Version="1">21266680</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2011 Aug;16(4):107-8. doi: 10.1136/ebm1186.</RefSource><PMID Version="1">21354982</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Surg. 2011 Apr;146(4):481-2. doi: 10.1001/archsurg.2011.48.</RefSource><PMID Version="1">21502460</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006400" MajorTopicYN="N">Hematocrit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019990" MajorTopicYN="N">Perioperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20940381</ArticleId><ArticleId IdType="doi">10.1001/jama.2010.1446</ArticleId><ArticleId IdType="pii">304/14/1559</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39509080</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1827-1898</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Panminerva medica</Title><ISOAbbreviation>Panminerva Med</ISOAbbreviation></Journal><ArticleTitle>Complete versus culprit-only coronary revascularization in patients with myocardial infarction and multivessel disease undergoing percutaneous coronary intervention: an updated meta-analysis.</ArticleTitle><Pagination><StartPage>408</StartPage><EndPage>416</EndPage><MedlinePgn>408-416</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.23736/S0031-0808.24.05267-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Recently, the FFR-Guidance for Complete Nonculprit Revascularization (FULL REVASC) trial in ST elevation myocardial infarction (STEMI) patients with multiple vessel disease (MVD) did not show differences in the composite endpoint of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only percutaneous coronary intervention (PCI) at 4.8 years, although complete revascularization is a recommendation IA in current guidelines. We want to determine through an updated meta-analysis whether complete revascularization is associated with decreased mortality and hard clinical endpoints compared to culprit lesion only PCI.</AbstractText><AbstractText Label="EVIDENCE ACQUISITION" NlmCategory="METHODS">We searched MEDLINE, Embase, ISI Web of Science, and Cochrane Central Register of Controlled Trials) from January 1990 to April 2024 using the terms "percutaneous coronary intervention" combined with "non culprit lesions" or "culprit lesion" or "complete revascularization" or "incomplete revascularization." Additionally, a "snowball search" was conducted. Only randomized clinical trials (RCT) reporting mortality, re-infarction or new revascularization after at least 12 months and using predominantly drug eluting stents were included. The summary effect of different revascularization strategies on cardiovascular endpoints was estimated and measures of effect size were expressed as odds ratios (ORs).</AbstractText><AbstractText Label="EVIDENCE SYNTHESIS" NlmCategory="RESULTS">Eight RCT involving 9515 patients were included, with a follow-up range between 12 months and 4.8 years. Main findings show that culprit lesion revascularization was associated with an increased risk of MI (OR: 1.38; 95% CI: 1.05 to 1.81, I2 42%) and ischemia-guided revascularization (OR: 2.81; 95% CI: 1.86 to 4.26, I2 80%) compared to complete revascularization, without differences in overall mortality (OR: 1.15; 95% CI: 0.98 to 1.36, I2 2%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with STEMI and MVD without cardiogenic shock, our metanalysis showed that complete revascularization with PCI significantly reduced the risk of non-fatal myocardial reinfarction and ischemic-driven revascularization compared to culprit vessel-only revascularization, without differences in overall mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodriguez-Granillo</LastName><ForeName>Alfredo M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Centro de Estudios en Cardiolog&#xed;a Intervencionista (CECI), Buenos Aires, Argentina - Mrodriguezgranillo@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Sanatorio Otamendi, Buenos Aires, Argentina - Mrodriguezgranillo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masson</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobo</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Campo de Mayo Military Hospital, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mieres</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Sanatorio Otamendi, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Valega</LastName><ForeName>Lisandro</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Monte Grande Clinic, Canning, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbagelata</LastName><ForeName>Leandro</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waisten</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zavala Clinic, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Pereira</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Estudios en Cardiolog&#xed;a Intervencionista (CECI), Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Sanatorio Otamendi, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Alfredo E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Centro de Estudios en Cardiolog&#xed;a Intervencionista (CECI), Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Sanatorio Otamendi, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Panminerva Med</MedlineTA><NlmUniqueID>0421110</NlmUniqueID><ISSNLinking>0031-0808</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009204" MajorTopicYN="Y">Myocardial Revascularization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054855" MajorTopicYN="N">Drug-Eluting Stents</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>13</Day><Hour>12</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39509080</ArticleId><ArticleId IdType="doi">10.23736/S0031-0808.24.05267-4</ArticleId><ArticleId IdType="pii">S0031-0808.24.05267-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40627256</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2110-5820</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Annals of intensive care</Title><ISOAbbreviation>Ann Intensive Care</ISOAbbreviation></Journal><ArticleTitle>Endotoxin removal by the OXIRIS filter for cardiogenic shock requiring veno-arterial extra-corporeal life support: the ECMORIX randomized controlled trial.</ArticleTitle><Pagination><StartPage>92</StartPage><MedlinePgn>92</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">92</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13613-025-01499-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Most severe cardiogenic shock requires veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The OXIRIS filter, has shown potential in reducing lipopolysaccharide (LPS) levels. Our objective was to compare the efficacy of the OXIRIS filter versus the ST-150 filter in reducing LPS plasma concentration. We hypothesized that the OXIRIS filter would reduce the endotoxin burden.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted an open-label randomized prospective study in the cardiac intensive care unit of Dijon University Hospital. Forty patients with refractory cardiogenic shock requiring VA-ECMO and renal replacement therapy (RRT) were randomized to receive either OXIRIS filter or ST-150 filter. Blood samples were collected at multiple time points. The primary outcome was LPS mass (measured 24&#xa0;h after the initiation of treatment). Secondary outcomes included LPS activity, cytokine levels, and clinical outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">20 patients were allocated to each group and analyzed. LPS plasma concentrations were not different between the OXIRIS filter and ST-150 filter groups at H24 (599&#xa0;pmol/ml of esterified 3-OH fatty acids [450;734] vs 520 [456;835], p&#x2009;=&#x2009;0.983) or when analyzing all time-points by linear mixed modelling (538 [469;723] vs 507 [434;671] at H26, 576 [513;614] vs 624 [503;724] at H48 and 632 [513;660] vs 586 [538;776] at H72, p&#x2009;=&#x2009;0.882). No significant between groups differences were found in LPS activity, inflammation markers (IL-6, TNF-&#x3b1;, IL-10, MCP-1), SOFA scores, VIS scores, or 28-day mortality (13 (65%) vs 9 (45%) p&#x2009;=&#x2009;0.21). There was high variability in LPS concentrations, suggesting heterogeneity in endotoxemia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with cardiogenic shock supported by VA-ECMO and requiring renal replacement therapy, we could not evidence any reduction in LPS blood concentration in patients treated with treatment with OXIRIS filter in comparison to ST-150 filter. Further research is required to confirm these findings and optimize endotoxin removal in this population.</AbstractText><AbstractText Label="TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT04886180. Registered 10 May 2021.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Maxime</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2334-1487</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Dijon University Hospital, Dijon, France. maxime.nguyen-soenen@chu-dijon.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Burgundy, Dijon, France. maxime.nguyen-soenen@chu-dijon.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Molecular Medicine (CTM), Lipness Team, INSERM UMR1231, Dijon, France. maxime.nguyen-soenen@chu-dijon.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Marvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Translational and Molecular Medicine (CTM), Lipness Team, INSERM UMR1231, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evezard</LastName><ForeName>Corentin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berthoud</LastName><ForeName>Vivien</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leleu</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Translational and Molecular Medicine (CTM), Lipness Team, INSERM UMR1231, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Clinical Chemistry, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pais-De-Barros</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Center for Translational and Molecular Medicine (CTM), Lipness Team, INSERM UMR1231, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lipidomic Facility, Universit&#xe9; de Bourgogne, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouchot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou-Arab</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouhemad</LastName><ForeName>Belaid</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Burgundy, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Molecular Medicine (CTM), Lipness Team, INSERM UMR1231, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masson</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Burgundy, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Molecular Medicine (CTM), Lipness Team, INSERM UMR1231, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Clinical Chemistry, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gautier</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Translational and Molecular Medicine (CTM), Lipness Team, INSERM UMR1231, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guinot</LastName><ForeName>Pierre-Gr&#xe9;goire</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Burgundy, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Molecular Medicine (CTM), Lipness Team, INSERM UMR1231, Dijon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04886180</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Intensive Care</MedlineTA><NlmUniqueID>101562873</NlmUniqueID><ISSNLinking>2110-5820</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic-shock</Keyword><Keyword MajorTopicYN="N">Critical care</Keyword><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">Endotoxemia</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Translocation</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This research was approved by the institutional review board (CPP Sud-ouest et Outre-mer II, France; ref. 2021-A00097-34). Informed consent was obtained from all patients or their next of kin prior to inclusion. Competing interests: MN: consulting honoraria and research grand from BAXTER, MN: formation fee Fresenius, MN: Congress fee Pfizer. PGG receive fees for lecture from Aguettant, AOP, BAXTER, Medtronic, Edwards and Vygon. PGG is consultant for ABBOT. VB received fees for lecture from AOP and LFB. OAA: research grand from BAXTER. Baxter, Oxiris, Prismaflex and PrisMax are trademarks of Baxter International Inc. or its subsidiaries.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>12</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40627256</ArticleId><ArticleId IdType="pmc">PMC12238705</ArticleId><ArticleId IdType="doi">10.1186/s13613-025-01499-z</ArticleId><ArticleId IdType="pii">10.1186/s13613-025-01499-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med. 1994;330:1724&#x2013;30. 10.1056/NEJM199406163302406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8190135</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H, Ohman EM, Desch S, Eitel I, De Waha S. Management of cardiogenic shock. Eur Heart J. 2015;36:1223&#x2013;30. 10.1093/eurheartj/ehv051.</Citation><ArticleIdList><ArticleId IdType="pubmed">25732762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogerd M, ten Berg S, Peters EJ, Vlaar APJ, Engstr&#xf6;m AE, Otterspoor LC, et al. Impella and venoarterial extracorporeal membrane oxygenation in cardiogenic shock complicating acute myocardial infarction. Eur J Heart Fail. 2023;25:2021&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">37671582</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed M, Khan MZ, Osman M, Sulaiman S, Agrawal P, Raina S, et al. Sixteen-year national trends in use and outcomes of VA-ECMO in cardiogenic Shock. Cardiovasc Revasc Med. 2022;44:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35853815</ArticleId></ArticleIdList></Reference><Reference><Citation>Krychtiuk KA, Vrints C, Wojta J, Huber K, Speidl WS. Basic mechanisms in cardiogenic shock: part 1&#x2014;definition and pathophysiology. Eur Heart J Acute Cardiovasc Care. 2022;11:356&#x2013;65. 10.1093/ehjacc/zuac021.</Citation><ArticleIdList><ArticleId IdType="pubmed">35218350</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo T, Takeuchi T, Inoue N, Cama-Olivares A, Chandramohan D, Tolwani AJ, et al. Impact of early initiation of renal replacement therapy in patients on venoarterial ECMO using target trial emulation with Japanese nationwide data. www.nature.com/scientificreports. Accessed 23 May 2025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11707199</ArticleId><ArticleId IdType="pubmed">39774191</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinclair C, De Montmollin E, Sonneville R, Reuter J, Lebut J, Cally R, et al. Factors associated with major adverse kidney events in patients who underwent veno-arterial extracorporeal membrane oxygenation. Ann Intensive Care. 2020;10:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167383</ArticleId><ArticleId IdType="pubmed">32307616</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowled P, Fitridge R. Pathophysiology of Reperfusion Injury. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. 2011; 331&#x2013;50. https://www.ncbi.nlm.nih.gov/books/NBK534267/. Accessed 11 Apr 2024.</Citation></Reference><Reference><Citation>Reintam Blaser A, Preiser JC, Fruhwald S, Wilmer A, Wernerman J, Benstoem C, et al. Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the section of metabolism, endocrinology and nutrition of the European Society of Intensive Care Medicine. Crit Care. 2020;24:224. 10.1186/s13054-020-02889-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7226709</ArticleId><ArticleId IdType="pubmed">32414423</ArticleId></ArticleIdList></Reference><Reference><Citation>Piton G, Capellier G. Biomarkers of gut barrier failure in the ICU. Curr Opin Crit Care. 2016. http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&amp;an=00075198-900000000-99379. Accessed 27 Feb 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">26808138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebrun LJ, Lenaerts K, Kiers D, Pais de Barros JP, Le Guern N, Plesnik J, et al. Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion. Cell Rep. 2017;21:1160&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebrun LJ, Grober J. Could glucagon-like peptide-1 be a potential biomarker of early-stage intestinal ischemia? Biochimie. 2018;159:107&#x2013;111. https://linkinghub.elsevier.com/retrieve/pii/S0300908418303250.
</Citation><ArticleIdList><ArticleId IdType="pubmed">30447282</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol. 2003;3:169&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12563300</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong PR, Gonz&#xe1;lez-Navajas JM, Jansen NJG. The digestive tract as the origin of systemic inflammation. Crit Care. 2016;20:279. 10.1186/s13054-016-1458-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5067918</ArticleId><ArticleId IdType="pubmed">27751165</ArticleId></ArticleIdList></Reference><Reference><Citation>Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018;6:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935601</ArticleId><ArticleId IdType="pubmed">29728790</ArticleId></ArticleIdList></Reference><Reference><Citation>Pais de Barros J-P, Gautier T, Sali W, Adrie C, Choubley H, Charron E, et al. Quantitative lipopolysaccharide analysis using HPLC/MS/MS and its combination with the limulus amebocyte lysate assay. J Lipid Res. 2015;56:1363&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479340</ArticleId><ArticleId IdType="pubmed">26023073</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Online). 2010;340:698&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrei S, Nguyen M, Berthoud V, Morgant M-C, Bouhemad B, Guinot P-G, et al. Evaluation of the oxiris membrane in cardiogenic shock requiring extracorporeal membrane oxygenation support: study protocol for a single center, single-blind, randomized controlled trial. Front Cardiovasc Med. 2021. 10.3389/fcvm.2021.738496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8544809</ArticleId><ArticleId IdType="pubmed">34708091</ArticleId></ArticleIdList></Reference><Reference><Citation>Belletti A, Lerose CC, Zangrillo A, Landoni G. Vasoactive-inotropic score: evolution, clinical utility, and pitfalls. J Cardiothorac Vasc Anesth. 2021;35:3067&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">33069558</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen M, Tavernier A, Gautier T, Aho S, Morgant MC, Bouhemad B, et al. Glucagon-like peptide-1 is associated with poor clinical outcome, lipopolysaccharide translocation and inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass. Cytokine. 2020;133:155182.</Citation><ArticleIdList><ArticleId IdType="pubmed">32593118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalenka A, Arens P, M&#xfc;llenbach RM, Weigand MA, Brune M, Fiedler-Kalenka MO. Effects of Oxiris&#xae; therapy on cytokine elimination after a lps infusion-an experimental animal study. Int J Mol Sci. 2024;25. https://pubmed.ncbi.nlm.nih.gov/39273234/. Accessed 8 Oct 2024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11394842</ArticleId><ArticleId IdType="pubmed">39273234</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier T, Lagrost L. Plasma PLTP (phospholipid-transfer protein): an emerging role in &#x201c;reverse lipopolysaccharide transport&#x201d; and innate immunity. Biochem Soc Trans. 2011;39:984&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21787334</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier T, Deckert V, Nguyen M, Desrumaux C, Masson D, Lagrost L. New therapeutic horizons for plasma phospholipid transfer protein (PLTP): targeting endotoxemia, infection and sepsis. Pharmacol Ther. 2022;236:108105.</Citation><ArticleIdList><ArticleId IdType="pubmed">34974028</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen M, Gautier T, Masson D, Bouhemad B, Guinot P-G. Endotoxemia in acute heart failure and cardiogenic shock: evidence, mechanisms and therapeutic options. J Clin Med. 2023;12:2579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10094881</ArticleId><ArticleId IdType="pubmed">37048662</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44:2205&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280819</ArticleId><ArticleId IdType="pubmed">30470853</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv. 2019;94:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">31104355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CT, Wang CH, Chan WS, Tsai YY, Wei TJ, Lai CH, et al. Endotoxin activity in patients with extracorporeal membrane oxygenation life support: an observational pilot study. Front Med (Lausanne). 2021;8:772413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667219</ArticleId><ArticleId IdType="pubmed">34912829</ArticleId></ArticleIdList></Reference><Reference><Citation>Antman EM, Loscalzo J. Precision medicine in cardiology. Nat Rev Cardiol. 2016;13:591&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">27356875</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckel M, Maclean P, Knight JC, Lawler PR, Proudfoot AG. Extending the &#x201c;host response&#x201d; paradigm from sepsis to cardiogenic shock: evidence, limitations and opportunities. Crit Care. 2023;27. https://pubmed.ncbi.nlm.nih.gov/38012789/. Accessed 22 May 2024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10683227</ArticleId><ArticleId IdType="pubmed">38012789</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano-Gamez E, Burnham KL, Goh C, Allcock A, Malick ZH, Overend L, et al. An immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expression. Sci Transl Med. 2022;14. https://pubmed.ncbi.nlm.nih.gov/36322631/. Accessed 3 Nov 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613832</ArticleId><ArticleId IdType="pubmed">36322631</ArticleId></ArticleIdList></Reference><Reference><Citation>Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4:259&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820667</ArticleId><ArticleId IdType="pubmed">26917434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashbrook MJ, Mcdonough KL, Pituch JJ, Christopherson PL, Cornell TT, Selewski DT, et al. Citrate modulates lipopolysaccharide-induced monocyte inflammatory responses. Clin Exp Immunol. 2015;180:520&#x2013;30. 10.1111/cei.12591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449780</ArticleId><ArticleId IdType="pubmed">25619261</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>